<SEC-DOCUMENT>0001731122-25-001316.txt : 20250929
<SEC-HEADER>0001731122-25-001316.hdr.sgml : 20250929
<ACCEPTANCE-DATETIME>20250929155612
ACCESSION NUMBER:		0001731122-25-001316
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		93
CONFORMED PERIOD OF REPORT:	20250630
FILED AS OF DATE:		20250929
DATE AS OF CHANGE:		20250929

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lunai Bioworks Inc.
		CENTRAL INDEX KEY:			0001527728
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				452259340
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38758
		FILM NUMBER:		251355936

	BUSINESS ADDRESS:	
		STREET 1:		CENTURY CITY MEDICAL PLAZA
		STREET 2:		2080 CENTURY CITY EAST
		CITY:			SUITE 906 LOS ANGELES
		STATE:			CA
		ZIP:			90067
		BUSINESS PHONE:		45 39179840

	MAIL ADDRESS:	
		STREET 1:		CENTURY CITY MEDICAL PLAZA
		STREET 2:		2080 CENTURY CITY EAST
		CITY:			SUITE 906 LOS ANGELES
		STATE:			CA
		ZIP:			90067

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RENOVARO INC.
		DATE OF NAME CHANGE:	20240213

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RENOVARO BIOSCIENCES INC.
		DATE OF NAME CHANGE:	20230807

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Enochian Biosciences Inc.
		DATE OF NAME CHANGE:	20230804
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>e6882_10-k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:RENB="http://renovarobio.com/20250630">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_029_US%2DGAAP%2D2024%2D(with%2DECD%2Dand%2DCYD) -->
<!-- Field: Set; Name: xdx; ID: xdx_036_RENB_renovarobio.com_20250630 -->
<!-- Field: Set; Name: xdx; ID: xdx_044_20240701_20250630 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05C_edei%2D%2DDocumentFiscalYearFocus_2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DEntityCentralIndexKey_0001527728 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_065_Ratio_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2024-07-01to2025-06-30" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-07-01to2025-06-30" id="Fact000004" name="dei:DocumentFiscalYearFocus">2025</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-07-01to2025-06-30" id="Fact000005" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-07-01to2025-06-30" id="Fact000006" name="dei:EntityCentralIndexKey">0001527728</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:EquitySecuritiesFvNi" contextRef="AsOf2024-06-30" id="xdx2ixbrl0081" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CapitalizedComputerSoftwareGross" contextRef="AsOf2024-06-30" id="xdx2ixbrl0099" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FiniteLivedTrademarksGross" contextRef="AsOf2024-06-30" id="xdx2ixbrl0102" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DepositsAssetsNoncurrent" contextRef="AsOf2025-06-30" id="xdx2ixbrl0107" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2024-06-30" id="xdx2ixbrl0144" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="From2024-07-01to2025-06-30" id="xdx2ixbrl0229" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EquitySecuritiesFvNiRealizedLoss" contextRef="From2023-07-012024-06-30" id="xdx2ixbrl0254" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0296" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-06-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0303" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RENB:IssuanceOfPreferredStockAndWarrantsInPrivatePlacement" contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0308" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RENB:IssuanceOfPreferredStockAndWarrantsInPrivatePlacement" contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0310" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RENB:IssuanceOfPreferredStockAndWarrantsInPrivatePlacement" contextRef="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0311" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RENB:IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable" contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0317" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RENB:IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable" contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0319" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RENB:IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable" contextRef="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0320" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RENB:RestrictedSharesIssuedForServicesRenderedValue" contextRef="From2023-07-012024-06-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0325" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RENB:RestrictedSharesIssuedForServicesRenderedValue" contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0328" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RENB:RestrictedSharesIssuedForServicesRenderedValue" contextRef="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0329" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RENB:StockIssuedDuringPeriodValueExerciseOfWarrants" contextRef="From2023-07-012024-06-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0334" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RENB:StockIssuedDuringPeriodValueExerciseOfWarrants" contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0337" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RENB:StockIssuedDuringPeriodValueExerciseOfWarrants" contextRef="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0338" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RENB:IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue" contextRef="From2023-07-012024-06-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0343" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RENB:IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue" contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0346" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RENB:IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue" contextRef="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0347" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RENB:SharesIssuableForSettlementOfContingentConsiderationValue" contextRef="From2023-07-012024-06-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0352" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RENB:SharesIssuableForSettlementOfContingentConsiderationValue" contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0355" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RENB:SharesIssuableForSettlementOfContingentConsiderationValue" contextRef="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0356" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RENB:IssuanceOfCommonStockPursuantToAcquisitionOfGediCube" contextRef="From2023-07-012024-06-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0361" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RENB:IssuanceOfCommonStockPursuantToAcquisitionOfGediCube" contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0364" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RENB:IssuanceOfCommonStockPursuantToAcquisitionOfGediCube" contextRef="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0365" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RENB:PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube" contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0373" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RENB:PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube" contextRef="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0374" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RENB:PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube" contextRef="From2023-07-012024-06-30" id="xdx2ixbrl0375" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-07-012024-06-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0381" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0382" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0384" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0385" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-07-012024-06-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0388" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0389" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0391" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0392" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012024-06-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0395" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0396" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0397" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0399" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2023-07-012024-06-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0402" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0403" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0404" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0405" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0409" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-06-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0416" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RENB:IssuanceOfCommonStockUnderPrivatePlacementOfferingValue" contextRef="From2024-07-012025-06-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0420" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RENB:IssuanceOfCommonStockUnderPrivatePlacementOfferingValue" contextRef="From2024-07-012025-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0423" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RENB:IssuanceOfCommonStockUnderPrivatePlacementOfferingValue" contextRef="From2024-07-012025-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0424" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RENB:RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationValue" contextRef="From2024-07-012025-06-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0429" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RENB:RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationValue" contextRef="From2024-07-012025-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0432" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RENB:RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationValue" contextRef="From2024-07-012025-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0433" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" contextRef="From2024-07-012025-06-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0438" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" contextRef="From2024-07-012025-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0441" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" contextRef="From2024-07-012025-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0442" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" contextRef="From2024-07-01to2025-06-30" id="xdx2ixbrl0443" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RENB:IssuanceOfCommonStockPursuantToAcquisitionValue" contextRef="From2024-07-012025-06-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0447" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RENB:IssuanceOfCommonStockPursuantToAcquisitionValue" contextRef="From2024-07-012025-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0450" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RENB:IssuanceOfCommonStockPursuantToAcquisitionValue" contextRef="From2024-07-012025-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0451" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-07-012025-06-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0456" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-07-012025-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0457" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-07-012025-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0459" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-07-012025-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0460" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-07-012025-06-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0463" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-07-012025-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0464" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-07-012025-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0465" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-07-012025-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0467" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2024-07-012025-06-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0470" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2024-07-012025-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0471" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2024-07-012025-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0472" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2024-07-012025-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0473" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0477" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-06-30_us-gaap_PreferredStockMember" id="xdx2ixbrl0484" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EquitySecuritiesFvNiRealizedLoss" contextRef="From2023-07-012024-06-30" id="xdx2ixbrl0504" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RENB:LossOnExtinguishmentOfDebt" contextRef="From2024-07-01to2025-06-30" id="xdx2ixbrl0506" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="From2024-07-01to2025-06-30" id="xdx2ixbrl0515" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2024-07-01to2025-06-30" id="xdx2ixbrl0560" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2024-07-01to2025-06-30" id="xdx2ixbrl0572" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RENB:CancellationOfRestrictedStockAwards" contextRef="From2023-07-012024-06-30" id="xdx2ixbrl0618" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EquitySecuritiesFvNi" contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0772" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EquitySecuritiesFvNi" contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0773" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AccruedLiabilitiesFairValueDisclosure" contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0776" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AccruedLiabilitiesFairValueDisclosure" contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0777" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure" contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl0779" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure" contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0780" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl0783" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0784" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RENB:NetDefinitelifeIntangibleAssets" contextRef="AsOf2024-06-30_custom_SoftwarePlatformMember" id="xdx2ixbrl0909" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" contextRef="From2024-07-012025-06-30_custom_SoftwarePlatformMember" id="xdx2ixbrl0917" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RENB:NetDefinitelifeIntangibleAssets" contextRef="AsOf2024-06-30_custom_TrademarkMember" id="xdx2ixbrl0923" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" contextRef="From2024-07-012025-06-30_custom_TrademarkMember" id="xdx2ixbrl0931" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RENB:DeferredTaxAssetExcessTaxOverDepreciationPatents" contextRef="AsOf2025-06-30" id="xdx2ixbrl1220" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RENB:DepreciationAndAmortizations" contextRef="AsOf2025-06-30" id="xdx2ixbrl1226" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AccumulatedAmortizationOfOtherDeferredCosts" contextRef="AsOf2024-06-30" id="xdx2ixbrl1239" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RENB:Section174ReCapitalization" contextRef="AsOf2024-06-30" id="xdx2ixbrl1242" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RENB:OperatingLeaseRightOfUseAssets" contextRef="AsOf2024-06-30" id="xdx2ixbrl1245" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="RENB:Section481aAdjustment" contextRef="AsOf2024-06-30" id="xdx2ixbrl1248" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2024-06-30" id="xdx2ixbrl1251" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" contextRef="AsOf2025-06-30" id="xdx2ixbrl1259" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" contextRef="AsOf2024-06-30" id="xdx2ixbrl1260" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" contextRef="From2024-07-01to2025-06-30" id="xdx2ixbrl1303" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" contextRef="From2023-07-012024-06-30" id="xdx2ixbrl1304" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange2Member" id="xdx2ixbrl1573" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange2Member" id="xdx2ixbrl1575" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2025-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange2Member" id="xdx2ixbrl1577" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2025-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange2Member" id="xdx2ixbrl1579" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange3Member" id="xdx2ixbrl1585" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange3Member" id="xdx2ixbrl1587" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2025-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange3Member" id="xdx2ixbrl1589" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2025-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange3Member" id="xdx2ixbrl1591" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2025-06-30_custom_EmployeeStockOptionsMember" id="xdx2ixbrl1645" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantMember" id="xdx2ixbrl1738" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantMember" id="xdx2ixbrl1740" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="renb-20250630.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2024-07-01to2025-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-26">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-13_custom_RenovaroCubeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">RENB:RenovaroCubeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_EmployeesOfficersDirectorsAndConsultantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">RENB:EmployeesOfficersDirectorsAndConsultantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_EmployeesOfficersDirectorsAndConsultantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">RENB:EmployeesOfficersDirectorsAndConsultantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_CommonStocksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">RENB:CommonStocksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_CommonStocksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">RENB:CommonStocksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-02-122025-02-13_custom_RenovaroCubeMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">RENB:RenovaroCubeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-02-12</xbrli:startDate>
        <xbrli:endDate>2025-02-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-02-122025-02-13_custom_RenovaroCubeMember_custom_ConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">RENB:RenovaroCubeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">RENB:ConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-02-12</xbrli:startDate>
        <xbrli:endDate>2025-02-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-02-13_custom_RenovaroCubeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">RENB:RenovaroCubeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-02-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_RenovaroCubeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">RENB:RenovaroCubeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_BlackScholesOptionPricingModelMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">RENB:BlackScholesOptionPricingModelMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_srt_MinimumMember_custom_BlackScholesOptionPricingModelMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">RENB:BlackScholesOptionPricingModelMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_srt_MaximumMember_custom_BlackScholesOptionPricingModelMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">RENB:BlackScholesOptionPricingModelMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_srt_MinimumMember_custom_BlackScholesOptionPricingModelMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">RENB:BlackScholesOptionPricingModelMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_srt_MaximumMember_custom_BlackScholesOptionPricingModelMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">RENB:BlackScholesOptionPricingModelMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_BlackScholesOptionPricingModelMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">RENB:BlackScholesOptionPricingModelMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_InitialRecognitionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">RENB:InitialRecognitionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_srt_MinimumMember_custom_InitialRecognitionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">RENB:InitialRecognitionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_srt_MaximumMember_custom_InitialRecognitionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">RENB:InitialRecognitionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_srt_MinimumMember_custom_InitialRecognitionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">RENB:InitialRecognitionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_srt_MaximumMember_custom_InitialRecognitionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">RENB:InitialRecognitionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_InitialRecognitionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">RENB:InitialRecognitionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_srt_MinimumMember_custom_LabEquipmentAndInstrumentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">RENB:LabEquipmentAndInstrumentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_srt_MaximumMember_custom_LabEquipmentAndInstrumentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">RENB:LabEquipmentAndInstrumentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_LabEquipmentAndInstrumentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">RENB:LabEquipmentAndInstrumentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_LabEquipmentAndInstrumentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">RENB:LabEquipmentAndInstrumentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_srt_MinimumMember_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_srt_MaximumMember_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_SoftwarePlatformMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">RENB:SoftwarePlatformMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_TrademarkMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">RENB:TrademarkMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-13_custom_RenovaroCubeMember1126484703">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">RENB:RenovaroCubeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-04-08_custom_BioSymetricsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">RENB:BioSymetricsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-04-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-04-08">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-04-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_SoftwarePlatformMember1126485421">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">RENB:SoftwarePlatformMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_SoftwarePlatformMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">RENB:SoftwarePlatformMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_SoftwarePlatformMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">RENB:SoftwarePlatformMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_TrademarkMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">RENB:TrademarkMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_TrademarkMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">RENB:TrademarkMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_PatentsMember1126485515">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_us-gaap_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_LessAccumulatedAmortizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">RENB:LessAccumulatedAmortizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_LessAccumulatedAmortizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">RENB:LessAccumulatedAmortizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_LessAccumulatedAmortizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">RENB:LessAccumulatedAmortizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_GoodwillMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_us-gaap_GoodwillMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_GoodwillMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_us-gaap_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_LessAccumulatedAmortizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">RENB:LessAccumulatedAmortizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_LessAccumulatedAmortizationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">RENB:LessAccumulatedAmortizationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_GoodwillMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_us-gaap_GoodwillMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_InProcessResearchAndDevelopmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_us-gaap_InProcessResearchAndDevelopmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_InProcessResearchAndDevelopmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-06-182018-06-19">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-06-18</xbrli:startDate>
        <xbrli:endDate>2018-06-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-12_custom_JanuaryNote2024Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:JanuaryNote2024Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-092024-01-12_custom_JanuaryNote2024Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:JanuaryNote2024Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-09</xbrli:startDate>
        <xbrli:endDate>2024-01-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-20_custom_DecemberNote2023Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:DecemberNote2023Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-12-192023-12-20_us-gaap_PrivatePlacementMember_custom_DecemberNote2023Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:DecemberNote2023Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-12-19</xbrli:startDate>
        <xbrli:endDate>2023-12-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-04_custom_PasecoApSMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RENB:PasecoApSMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_PasecoApSMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RENB:PasecoApSMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-04_custom_TheNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:TheNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_TheNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:TheNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_PasecoApSMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RENB:PasecoApSMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-21_custom_JanuaryNote2024Member_custom_PasecoApSMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:JanuaryNote2024Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RENB:PasecoApSMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-01-24_custom_JanuaryNote2024Member_custom_PasecoApSMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:JanuaryNote2024Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RENB:PasecoApSMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-01-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-21_custom_TheNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:TheNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-122024-12-03_custom_PromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:PromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-12</xbrli:startDate>
        <xbrli:endDate>2024-12-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-02-232025-02-24_custom_PromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:PromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-02-23</xbrli:startDate>
        <xbrli:endDate>2025-02-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-09-152024-09-16_custom_PromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:PromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-09-15</xbrli:startDate>
        <xbrli:endDate>2024-09-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-09-052024-09-06_custom_PromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:PromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-09-05</xbrli:startDate>
        <xbrli:endDate>2024-09-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-042024-02-05_custom_PromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:PromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-04</xbrli:startDate>
        <xbrli:endDate>2024-02-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-01-02_custom_PromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:PromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-01-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-022024-11-03_custom_PromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:PromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-02</xbrli:startDate>
        <xbrli:endDate>2024-11-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-30_custom_PromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:PromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-03-292020-03-30_custom_PromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:PromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-03-29</xbrli:startDate>
        <xbrli:endDate>2020-03-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-06-30_custom_PromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:PromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-30_us-gaap_OtherCurrentLiabilitiesMember_custom_FinanceAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RENB:FinanceAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-292024-11-30_custom_FinanceAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RENB:FinanceAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-29</xbrli:startDate>
        <xbrli:endDate>2024-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_FinanceAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RENB:FinanceAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_FinanceAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RENB:FinanceAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_UnitedStatesTaxMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">RENB:UnitedStatesTaxMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_UnitedStatesTaxMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">RENB:UnitedStatesTaxMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">RENB:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">RENB:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-20">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-20_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">RENB:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">RENB:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">RENB:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-072025-04-08_custom_CommonStockIssuancesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">RENB:CommonStockIssuancesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-07</xbrli:startDate>
        <xbrli:endDate>2025-04-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-122025-01-21_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-12</xbrli:startDate>
        <xbrli:endDate>2025-01-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-122025-01-22_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-12</xbrli:startDate>
        <xbrli:endDate>2025-01-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-162024-10-17">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-16</xbrli:startDate>
        <xbrli:endDate>2024-10-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-162024-10-17_custom_CommonStockIssuancesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">RENB:CommonStockIssuancesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-16</xbrli:startDate>
        <xbrli:endDate>2024-10-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-132024-10-14">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-13</xbrli:startDate>
        <xbrli:endDate>2024-10-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-132024-10-14_custom_CommonStockIssuancesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">RENB:CommonStockIssuancesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-13</xbrli:startDate>
        <xbrli:endDate>2024-10-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-132024-10-14_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-13</xbrli:startDate>
        <xbrli:endDate>2024-10-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-08-022024-08-23_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-02</xbrli:startDate>
        <xbrli:endDate>2024-08-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-08-022024-08-23_us-gaap_CommonStockMember_custom_MrMillerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">RENB:MrMillerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-02</xbrli:startDate>
        <xbrli:endDate>2024-08-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-08-23_custom_BoardOfDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">RENB:BoardOfDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-08-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-192024-08-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-19</xbrli:startDate>
        <xbrli:endDate>2024-08-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-292024-08-01_custom_CommonStockConsultingServicesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">RENB:CommonStockConsultingServicesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-29</xbrli:startDate>
        <xbrli:endDate>2024-08-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-06-132024-06-14">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-13</xbrli:startDate>
        <xbrli:endDate>2024-06-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-14_srt_MinimumMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-14_srt_MaximumMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_us-gaap_InvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_us-gaap_InvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_Investor1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:Investor1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-032024-10-02">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-03</xbrli:startDate>
        <xbrli:endDate>2024-10-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-02">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-042024-04-05_custom_CommonStockIssuancesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">RENB:CommonStockIssuancesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-04</xbrli:startDate>
        <xbrli:endDate>2024-04-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-20_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-20_srt_MinimumMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-20_srt_MaximumMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-192024-02-20_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-19</xbrli:startDate>
        <xbrli:endDate>2024-02-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-20_us-gaap_WarrantMember_custom_SingleRangeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RENB:SingleRangeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-192024-02-20_us-gaap_WarrantMember_custom_SingleRangeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RENB:SingleRangeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-19</xbrli:startDate>
        <xbrli:endDate>2024-02-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-142024-02-15">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-14</xbrli:startDate>
        <xbrli:endDate>2024-02-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-142024-02-15_custom_CommonStockIssuancesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">RENB:CommonStockIssuancesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-14</xbrli:startDate>
        <xbrli:endDate>2024-02-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-16_custom_GEDiCubeIntlLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:GEDiCubeIntlLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-122024-02-13_custom_StockPurchaseAgreementOfRenovaroCubeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RENB:StockPurchaseAgreementOfRenovaroCubeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-12</xbrli:startDate>
        <xbrli:endDate>2024-02-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-12-032023-12-04">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-12-03</xbrli:startDate>
        <xbrli:endDate>2023-12-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-10-23_us-gaap_CommonStockMember_custom_AvramMillerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:AvramMillerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-10-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-222023-10-23_custom_CommonStockIssuancesMember_custom_AvramMillerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">RENB:CommonStockIssuancesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:AvramMillerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-22</xbrli:startDate>
        <xbrli:endDate>2023-10-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-07-28_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-07-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-272023-07-28_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-27</xbrli:startDate>
        <xbrli:endDate>2023-07-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-132022-07-14_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-13</xbrli:startDate>
        <xbrli:endDate>2022-07-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-14_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_EBIAndWeirdScienceLLCMember_custom_AgreementAndPlanOfMergerAgreementAxisMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">RENB:EBIAndWeirdScienceLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RENB:AgreementAndPlanOfMergerAgreementAxisMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-02-06_custom_EquityIncentivePlan2014Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">RENB:EquityIncentivePlan2014Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-02-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_EmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:EmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_EmployeesThreeYearMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:EmployeesThreeYearMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_EmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:EmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_ShareBasedCompensationAwardAdvisoryBoardMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">RENB:ShareBasedCompensationAwardAdvisoryBoardMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_ShareBasedCompensationAwardBoardofDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">RENB:ShareBasedCompensationAwardBoardofDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_ShareBasedCompensationAwardBoardofDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">RENB:ShareBasedCompensationAwardBoardofDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_ShareBasedCompensationAwardConsultingServicesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">RENB:ShareBasedCompensationAwardConsultingServicesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_ShareBasedCompensationAwardConsultingServicesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">RENB:ShareBasedCompensationAwardConsultingServicesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-04_custom_PlanOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">RENB:PlanOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-012024-11-04">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-01</xbrli:startDate>
        <xbrli:endDate>2024-11-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-04">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_PlanOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">RENB:PlanOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_PlanOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">RENB:PlanOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_RestrictedStockAwardsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">RENB:RestrictedStockAwardsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_RestrictedStockAwardsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">RENB:RestrictedStockAwardsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_AdvisoryServicesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">RENB:AdvisoryServicesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_RenovaroMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">RENB:RenovaroMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_srt_MinimumMember_custom_RenovaroMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">RENB:RenovaroMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_srt_MaximumMember_custom_RenovaroMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">RENB:RenovaroMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_EmployeeStockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:EmployeeStockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_EmployeeStockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:EmployeeStockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_EmployeeStockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:EmployeeStockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_EmployeeStockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:EmployeeStockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange5Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange5Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange5Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange5Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange6Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange6Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange6Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange6Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_CommonStockPurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_CommonStockPurchaseWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_CommonStockPurchaseWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-302021-01-31_custom_GTechMember_custom_LicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:GTechMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RENB:LicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-30</xbrli:startDate>
        <xbrli:endDate>2021-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-302020-01-31_custom_GTechMember_custom_LicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:GTechMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RENB:LicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-30</xbrli:startDate>
        <xbrli:endDate>2020-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-02-052020-02-06_custom_GTechMember_custom_LicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:GTechMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RENB:LicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-02-05</xbrli:startDate>
        <xbrli:endDate>2020-02-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-11-142019-11-15">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-11-14</xbrli:startDate>
        <xbrli:endDate>2019-11-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-08-242022-08-25">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-08-24</xbrli:startDate>
        <xbrli:endDate>2022-08-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-09-092022-09-10">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-09-09</xbrli:startDate>
        <xbrli:endDate>2022-09-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_MarkDybulMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RENB:MarkDybulMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-08-022024-08-23">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-02</xbrli:startDate>
        <xbrli:endDate>2024-08-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-08-23">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-08-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-08-222025-08-23">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-22</xbrli:startDate>
        <xbrli:endDate>2025-08-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-02-16_custom_RSBioMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RENB:RSBioMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-02-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_BioSymetricsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">RENB:BioSymetricsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-03_custom_GEDiCubeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">RENB:GEDiCubeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_GEDiCubeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">RENB:GEDiCubeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_BioSymetricsncAcquisitionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">RENB:BioSymetricsncAcquisitionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_GEDiCubeIntlLtdAcquisitionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">RENB:GEDiCubeIntlLtdAcquisitionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-02-26_custom_BioSymetricsncAcquisitionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">RENB:BioSymetricsncAcquisitionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-02-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-02-122025-02-26_custom_BioSymetricsncAcquisitionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">RENB:BioSymetricsncAcquisitionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-02-12</xbrli:startDate>
        <xbrli:endDate>2025-02-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_BioSymetricsncAcquisitionMember1126504281">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">RENB:BioSymetricsncAcquisitionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-02-26_custom_GEDiCubeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">RENB:GEDiCubeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-02-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-02-122025-02-26_custom_GEDiCubeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">RENB:GEDiCubeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-02-12</xbrli:startDate>
        <xbrli:endDate>2025-02-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_GEDiCubeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">RENB:GEDiCubeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_BioSymetricsMember1126506984">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">RENB:BioSymetricsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_custom_BioSymetricsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">RENB:BioSymetricsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_country_NL">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:NL</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-30_country_NL">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:NL</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_RENBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">RENB:RENBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_BioSymetricsMember1126507484">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">RENB:BioSymetricsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012025-06-30_custom_RENCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">RENB:RENCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2025-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-08-18_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-08-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-07-03_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-07-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-08-19_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-08-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-07-07_us-gaap_SubsequentEventMember_custom_ExchangeAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">RENB:ExchangeAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-07-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-07-07_us-gaap_SubsequentEventMember_custom_ConvertiblePromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">RENB:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-07-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-07-07_us-gaap_SubsequentEventMember_custom_ConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">RENB:ConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-07-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-07-07_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-07-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Ratio">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 10pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 14pt; text-transform: uppercase"><b>United
states</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 14pt; text-transform: uppercase"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 14pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_905_edei--DocumentType_c20240701__20250630_zyBRhFQsBkS4"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" id="Fact000012" name="dei:DocumentType">10-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><span id="xdx_90D_edei--DocumentAnnualReport_c20240701__20250630_z2CZmEGPG1W8" title="Document Annual Report"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" format="ixt:booleantrue" id="Fact000014" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric></span><span style="text-transform: uppercase"><b>&#160;ANNUAL
report under section 13 Or 15(</b></span><b>d<span style="text-transform: uppercase">) of the securities exchange act of 1934</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">For the fiscal year ended <b><span style="text-decoration: underline"><span id="xdx_90E_edei--DocumentPeriodEndDate_c20240701__20250630_zJdnZOkqpPt2"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" format="ixt:datemonthdayyearen" id="Fact000015" name="dei:DocumentPeriodEndDate"><span id="xdx_902_edei--CurrentFiscalYearEndDate_c20240701__20250630_zbfZO9Pu0ew8" title="Current Fiscal Year End Date"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" format="ixt:datemonthdayen" id="Fact000017" name="dei:CurrentFiscalYearEndDate">June 30</ix:nonNumeric></span>, 2025</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><span id="xdx_901_edei--DocumentTransitionReport_c20240701__20250630_zOVlf6fGtqEg" title="Document Transition Report"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" format="ixt:booleanfalse" id="Fact000019" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span><span style="text-transform: uppercase"><b>&#160;TRANSITION
report under section 13 Or 15(</b></span><b>d<span style="text-transform: uppercase">) of the securities exchange act of 1934</span></b></span><b></b>
<span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">For the transition period from</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Commission file number <b><span style="text-decoration: underline"><span id="xdx_904_edei--EntityFileNumber_c20240701__20250630_zhgAISI6lby9"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" id="Fact000020" name="dei:EntityFileNumber">001-38758</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 24pt"><b><span id="xdx_902_edei--EntityRegistrantName_c20240701__20250630_zycvTu6Gt1g1" title="Entity Registrant Name"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" id="Fact000022" name="dei:EntityRegistrantName">LUNAI BIOWORKS INC</ix:nonNumeric></span>.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">(Name of registrant in its charter) </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 51%; text-align: center"><span style="font-size: 10pt"><span id="xdx_908_edei--EntityIncorporationStateCountryCode_c20240701__20250630_zJSOS7fMdKme"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" format="ixt-sec:stateprovnameen" id="Fact000023" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span> </span></td>
    <td style="vertical-align: top; width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 48%; text-align: center"><span style="font-size: 10pt"><span id="xdx_90C_edei--EntityTaxIdentificationNumber_c20240701__20250630_znxPIRWmXsBa"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" id="Fact000024" name="dei:EntityTaxIdentificationNumber">45-2259340</ix:nonNumeric></span> </span></td></tr>
  <tr>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">(State or other jurisdiction of <br/>
incorporation or organization) </span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">(I.R.S. Employer <br/>
Identification No.) </span></td></tr>
  <tr>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt"><span id="xdx_905_edei--EntityAddressAddressLine1_c20240701__20250630_zYEPBIK7NnKb"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" id="Fact000025" name="dei:EntityAddressAddressLine1">2080 Century Park East</ix:nonNumeric></span>, <span id="xdx_900_edei--EntityAddressAddressLine2_c20240701__20250630_zTCtWWCZsEvl"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" id="Fact000026" name="dei:EntityAddressAddressLine2">Suite 906</ix:nonNumeric> </span><br/>
<span id="xdx_90D_edei--EntityAddressCityOrTown_c20240701__20250630_zusRPEjt9vX"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" id="Fact000027" name="dei:EntityAddressCityOrTown">Los Angeles</ix:nonNumeric></span>, <span id="xdx_905_edei--EntityAddressStateOrProvince_c20240701__20250630_zRFUzV0NsyEi"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" id="Fact000028" name="dei:EntityAddressStateOrProvince">CA</ix:nonNumeric></span></span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt"><span id="xdx_906_edei--EntityAddressPostalZipCode_c20240701__20250630_zEZR5QvObAze"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" id="Fact000029" name="dei:EntityAddressPostalZipCode">90067</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">(Address of principal executive offices) </span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">(Zip Code) </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">+1<span id="xdx_909_edei--CityAreaCode_c20240701__20250630_zIUDqm0OLowc"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" id="Fact000030" name="dei:CityAreaCode">(305)</ix:nonNumeric></span> <span id="xdx_90E_edei--LocalPhoneNumber_c20240701__20250630_zXP2D6Kp3etj"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" id="Fact000031" name="dei:LocalPhoneNumber">918-1980</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Registrant&#8217;s telephone number, including area
code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Securities registered pursuant to Section 12(b) of
the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 1pt solid; width: 34%; text-align: center"><span style="font-size: 10pt"><b>Title of Each Class</b></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 31%; text-align: center"><span style="font-size: 10pt"><b>Trading Symbol</b></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 33%; text-align: center"><span style="font-size: 10pt"><b>Name of Each Exchange on Which Registered</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_90E_edei--Security12bTitle_c20240701__20250630_z7qr6Zj9xtrc"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" id="Fact000032" name="dei:Security12bTitle">Common Stock, par value $0.0001 per share</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_903_edei--TradingSymbol_c20240701__20250630_z2bW0Z3y70Fk"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" id="Fact000033" name="dei:TradingSymbol">RENB</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">The <span id="xdx_90A_edei--SecurityExchangeName_c20240701__20250630_zcLZOemNh47l"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" format="ixt-sec:exchnameen" id="Fact000034" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Stock Market LLC</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Securities registered pursuant to Section 12(g) of the Act: Common Stock,
$0.0001 par value</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark if the registrant is a well-known
seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;<span style="font-family: Segoe UI Symbol,sans-serif">&#9744;</span>
Yes <span style="font-family: Segoe UI Symbol,sans-serif">&#9746;</span> <span id="xdx_90F_edei--EntityWellKnownSeasonedIssuer_c20240701__20250630_zQDE7A55JEb9"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" id="Fact000035" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark if the registrant is not required
to file reports pursuant to Section 13 or Section 15(d) of the Act.&#160;<span style="font-family: Segoe UI Symbol,sans-serif">&#9744;</span>
Yes <span style="font-family: Segoe UI Symbol,sans-serif">&#9746;</span>&#160;<span id="xdx_900_edei--EntityVoluntaryFilers_c20240701__20250630_zofMgzgo6ng6"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" id="Fact000036" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant (1)
has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the last 12 months (or for such shorter period
that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <span id="xdx_909_edei--EntityCurrentReportingStatus_c20240701__20250630_zvghlllSt8Sh"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" id="Fact000037" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span>
<span style="font-family: Segoe UI Symbol,sans-serif">&#9746;</span> No&#160;<span style="font-family: Segoe UI Symbol,sans-serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark whether the registrant has submitted electronically,
if any, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during
the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&#160;<span id="xdx_900_edei--EntityInteractiveDataCurrent_c20240701__20250630_zLvGxScJp9s7"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" id="Fact000038" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span>&#160;<span style="font-family: Segoe UI Symbol,sans-serif">&#9746;</span>
No&#160;<span style="font-family: Segoe UI Symbol,sans-serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant is a
large-accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See
the definitions of &#8220;large-accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and
&#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 30%"><span style="font-size: 10pt">Large accelerated filer </span></td>
    <td style="width: 20%"><span style="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt">&#9744;</span></td>
    <td style="width: 30%"><span style="font-size: 10pt">Accelerated filer </span></td>
    <td style="width: 20%"><span style="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt">&#9744;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><span id="xdx_908_edei--EntityFilerCategory_c20240701__20250630_zQEzKBP5edpk" title="Entity Filer Category"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" format="ixt-sec:entityfilercategoryen" id="Fact000040" name="dei:EntityFilerCategory">Non-accelerated filer</ix:nonNumeric></span> </span></td>
    <td><span style="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt">&#9746;</span></td>
    <td><span style="font-size: 10pt">Smaller reporting company </span></td>
    <td><span style="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt"><span id="xdx_90A_edei--EntitySmallBusiness_c20240701__20250630_zKzDckSgzPec" title="Entity Small Business"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" format="ixt:booleantrue" id="Fact000042" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Emerging growth company</span></td>
    <td><span style="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt"><span id="xdx_902_edei--EntityEmergingGrowthCompany_c20240701__20250630_znmKrT9o2mC4" title="Entity Emerging Growth Company"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" format="ixt:booleanfalse" id="Fact000044" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If an emerging growth company, indicate by check mark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Segoe UI Symbol,sans-serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant has
filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting
under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its
audit report. <span style="font-family: Segoe UI Symbol,sans-serif"><span id="xdx_909_edei--IcfrAuditorAttestationFlag_dbF_c20240701__20250630_z3uy3UNlXf1i"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" format="ixt:booleanfalse" id="Fact000045" name="dei:IcfrAuditorAttestationFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If securities are registered pursuant to Section 12(b)
of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of
an error to previously issued financial statements. <span style="font-family: Segoe UI Symbol,sans-serif"><span id="xdx_901_edei--DocumentFinStmtErrorCorrectionFlag_dbF_c20240701__20250630_z9FsipfJJTC6"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" format="ixt:booleanfalse" id="Fact000046" name="dei:DocumentFinStmtErrorCorrectionFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether any of those error
corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s
executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). <span style="font-family: Segoe UI Symbol,sans-serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant is a
shell company (as defined in Rule 12b-2 of the Act). <span style="font-family: Segoe UI Symbol,sans-serif">&#9744;</span> Yes <span style="font-family: Segoe UI Symbol,sans-serif">&#9746;</span>
<span id="xdx_904_edei--EntityShellCompany_c20240701__20250630_zjPcWEafi0Yl"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" format="ixt:booleanfalse" id="Fact000047" name="dei:EntityShellCompany">No</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 31, 2024, the aggregate market value of
the voting and non-voting common equity held by non-affiliates was $<span id="xdx_90C_edei--EntityPublicFloat_iI_c20241231_z7b5IkcJmUcj"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2024-12-31" id="Fact000048" format="ixt:numdotdecimal" decimals="0" unitRef="USD">111,903,627</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 26, 2025, the number of shares outstanding
of the registrant&#8217;s common stock, par value $0.0001 per share (the &#8220;Common Stock&#8221;) was <span id="xdx_90E_edei--EntityCommonStockSharesOutstanding_iI_c20250926_zwBR6rbqunz3" title="Entity Common Stock, Shares Outstanding"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2025-09-26" id="Fact000050" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">231,802,470</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CONTENTS</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 7%"/>
    <td style="vertical-align: bottom; width: 83%"/>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Page</i></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_001">Forward-Looking
    Statements</a></span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_002"><b>Part
    I</b></a></span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1 </span></td>
    <td style="vertical-align: bottom"><a href="#c_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business</span></a></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1A </span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_003">Risk
    Factors</a></span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1B</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_004">Unresolved
    Staff Comments</a></span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1C</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_005">Cybersecurity
    Risk Management and Strategy&#160;</a></span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;50</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 2 </span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_006">Properties</a></span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 3 </span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_007">Legal
    Proceedings</a></span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 4 </span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_008">Mine
    Safety Disclosures</a></span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_009"><b>Part
    II</b></a></span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 5 </span></td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_010">Market
    for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 6 </span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_011">Selected
    Financial Data</a></span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 7 </span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_012">Management&#8217;s
    Discussion and Analysis of Financial Condition and Results Of Operations</a></span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 7A </span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_013">Quantitative
    and Qualitative Disclosures About Market Risk</a></span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 8 </span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_014">Financial
    Statements and Supplementary Data</a></span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9 </span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_015">Changes
    In and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9A </span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_016">Controls
    and Procedures</a></span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9B </span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_017">Other
    Information</a></span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_018"><b>Part
    III</b></a></span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 10 </span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_019">Directors,
    Executive Officers and Corporate Governance</a></span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 11 </span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_020">Executive
    Compensation</a></span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 12 </span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_021">Security
    Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 13 </span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_022">Certain
    Relationships and Related Transactions and Director Independence</a></span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 14 </span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_023">Principal
    Accountant Fees and Services</a></span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_024"><b>Part
    IV</b></a></span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 15</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_025">Exhibits,
    Financial Statement Schedules</a></span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_026">Signatures
    and Certifications</a></span></td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 3; Options: NewSection -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_001"></span>Cautionary Language Regarding Forward-Looking Statements and Industry
Data</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This Annual Report on Form 10-K
contains &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995 regarding
the plans and objectives of management for future operations and market trends and expectations. Forward-looking statements can be identified
by the fact that they do not relate strictly to historical or current facts. Forward-looking statements are based upon our current assumptions,
expectations and beliefs concerning future developments and their potential effect on our business. In some cases, you can identify forward-looking
statements by the following words: &#8220;may,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221;
&#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;approximately,&#8221; &#8220;estimate,&#8221;
&#8220;predict,&#8221; &#8220;project,&#8221; &#8220;potential&#8221; or the negative of these terms or other comparable terminology,
although the absence of these words does not necessarily mean that a statement is not forward-looking.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Forward-looking statements include,
but are not limited to, statements concerning:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 20px">&#160;</td>
    <td style="width: 20px"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">Our ability to continue as a going concern and ability to raise additional capital;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Our continuous incurrence of losses as a pre-clinical-stage biotechnology company with no products that have achieved regulatory approval;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">Our ability to generate revenue if we fail to develop marketable product;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Our dependence on substantial additional financing to support the research, development, licensing, manufacture, and marketing of product candidates and products, and the possibility that unforeseen operational costs will arise;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The dilutive effect on stockholders&#8217; ownership interests of the Company raising capital through an equity issuance in connection with future equity financing or equity debt agreements;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Our dependence on the services of experts, including third parties to research and develop product candidates in cooperation with our employees and officers;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The difficulty or impossibility of predicting future clinical trial results and regulatory outcomes of our products based upon our pre-clinical or earlier clinical trial performance;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The application of heightened regulatory and commercial scrutiny to our AI-based technology, gene, cell, and immunotherapy products given their novel nature and concomitant potential for actual or perceived safety issues;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Our ability to compete in rapidly developing fields, and the potential impact to our financial condition, product marketability, and operational capacities of a competitor receiving regulatory approval before us, or a competitor developing more advanced or efficacious products;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Potential delays or total failures of third parties, such as universities, non-profits, and clinical research centers, to perform obligations on which our product research and development rely;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The impact on our competitive position, business operations, and financial condition of implementation of amended healthcare laws and regulations;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The dependence of certain of our pipelines on intellectual property licensed from licensors, and the severe adverse impact to our business operations of a disruption of one of our licensing relationships;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The potential monetary costs of defending our intellectual property rights in a dispute, and the possibility that an intellectual property dispute will not be settled in our favor;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The possibility that our patents and patent applications, even if unchallenged, will not sufficiently protect or provide exclusive use of our intellectual property, which could jeopardize our ability to commercialize our products and dissuade companies from subsequently collaborating with us;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 20px">&#160;</td>
    <td style="width: 20px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The negative impact to our competitive position and the value of our technology of our failure to protect trade secrets through the use of non-disclosure and confidentiality agreements, or the unavailability of adequate recourse for breach of such agreements;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The fluctuation and volatility of the market price of our Common Stock due to its limited public market, and the possibility that these issues will compound and strain our stockholders&#8217; ability to resell their Common Stock;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Our significant dependence on sophisticated management with highly technical expertise to oversee business operations, and our ability to attract and retain qualified personnel to sustain growth;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Our ability to adapt to future growth by training an expanding employee base and shifting away from reliance on third-party contractors;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The risk of liability arising from claims of environmental damage, personal injury, and property damages in connection with our research and development activities, including those that involve the use of hazardous materials;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The possibility that enforcement actions to suspend or severely restrict our business operations will be brought against the Company for our failure to comply with laws or regulations and the potential costs of defending against such actions;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Our reliance on adequate maintenance of the security and integrity of our information technology systems to effectively operate our business; and </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Such other factors as discussed throughout Part II, Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations and in Part I, Item 1A. Risk Factors herein.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A forward-looking statement is
neither a prediction nor a guarantee of future events or circumstances, and those future events or circumstances may not occur. You should
not place undue reliance on forward-looking statements, which speak only as of the date of this Annual Report. Forward-looking statements
involve known and unknown risks, uncertainties, and other factors, including without limitation the risks and uncertainties described
below the heading &#8220;Item 1.A. Risk Factors&#8221; in this report, that may cause our actual results, performance, or achievements
to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.
The forward-looking statements included herein are based on current expectations and assumptions that involve numerous risks and uncertainties.
Our plans and objectives are based, in part, on assumptions involving the continued expansion of our business. Assumptions relating to
the foregoing involve judgments with respect to, among other things, future economic, competitive and market conditions and future business
decisions, all of which are difficult or impossible to predict accurately and many of which are beyond our control. Although we believe
that our assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove inaccurate and, therefore,
there can be no assurance that the forward-looking statements included in this Annual Report will prove to be accurate. Given these risks
and uncertainties, you should not rely on forward-looking statements as a prediction of actual results. Any or all of the forward-looking
statements contained in this Annual Report and any other public statement made by us, including by our management, may turn out to be
incorrect. We are including this cautionary note to make applicable and take advantage of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995 for forward-looking statements. We expressly disclaim any obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Information regarding market and
industry statistics contained in this report is included based on information available to us that we believe is accurate. It is generally
based on academic and other publications that are not produced for purposes of securities offerings or economic analysis. Forecasts and
other forward-looking information obtained from these sources are subject to the same qualifications and the additional uncertainties
accompanying any estimates of future market size, revenue and market acceptance of products and services. Except as required by U.S. federal
securities laws, we have no obligation to update forward-looking information to reflect actual results or changes in assumptions or other
factors that could affect those statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In February 2024, the Company
changed its corporate name from Renovaro BioSciences Inc. to Renovaro Inc. and then again in August 2025 to <span style="background-color: white">Lunai
Bioworks Inc.</span> The Company will not distinguish between its prior and current corporate name and will refer to the Company&#8217;s
current corporate name throughout this Annual Report on Form 10-K. <span style="background-color: white">As such, unless expressly indicated
or the context requires otherwise, the terms &#8220;Lunai,&#8221; &#8220;company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221;
in this document refer to Lunai Bioworks Inc., a Delaware corporation, and, where appropriate, its subsidiaries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 5 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_002"></span>PART I</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i>Unless otherwise indicated
or the context otherwise requires, all references in this prospectus to &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Lunai&#8221;
or the &#8220;Company&#8221; are to </i>Lunai Bioworks Inc.<i>, a Delaware corporation together with its wholly owned subsidiaries, Renovaro
Biosciences, Inc., a Delaware corporation (&#8220;Renovaro Biosciences&#8221;), GEDi Cube Intl Ltd, a private limited company incorporated
under the laws of England and Wales (&#8220;GEDi Cube UK&#8221;), GEDi Cube B.V., a Dutch private limited company, Grace Systems B.V.,
a Dutch private limited company, Renovaro Biosciences Denmark ApS, a Danish limited company, organized under the Danish Act on Limited
Companies of the Kingdom of Denmark, BioSymetrics Inc., a Delaware Corporation, BioSymetrics Corp., an unlimited company registered under
the laws of Nova Scotia.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="c_001"></span>Our Business</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Lunai
Bioworks Inc. operates through three subsidiaries, Renovaro Biosciences, Renovaro Cube and BioSymetrics. Renovaro Cube refers to GediCube
Intl. Ltd. and its wholly owned subsidiaries GediCube, B.V. and Grace Systems B.V., which were acquired on February 13, 2024. BioSymetrics
refers to BioSymetrics Inc. and its wholly owned subsidiary BioSymetrics Corp., which were acquired on April 8, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline">Renovaro Biosciences Overview</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Renovaro
Biosciences is a biotechnology company intending, if the necessary funding is obtained, to develop advanced allogeneic cell and gene therapies
to promote stronger immune system responses potentially for long-term or life-long cancer remission in some of the deadliest cancers.
As a result of our acquisition of GEDi Cube Intl on February 13, 2024, we have shifted the Company&#8217;s primary focus and resources
to the development of the GEDi Cube Intl technologies. This transition to focus more strongly on molecular diagnostics and oncology allows
us to better align with market trends and streamline our efforts to indication areas where we see strong market fit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Therapeutic Technologies</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Renovaro Bioscience aims to train
the immune system to allow a person to better fight diseases through allogeneic cell and/or gene therapy. Our vision is for a world with
healthy longevity, and free from toxic chemotherapy, for those with cancer and other serious diseases. Renovaro Biosciences will seek
to leverage general principles and advances in the knowledge of the immune response to engineer cells with enhanced attributes to promote
the recognition and elimination of disease cells.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="text-decoration: underline">Allogeneic Cell Therapy </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The strategic benefit of the allogeneic
cell therapy technologies is to potentially allow for the manufacture of large, &#8220;off-the-shelf&#8221; banks of therapeutic cells
that are readily available on demand by healthcare professionals, to potentially decrease the time between diagnosis and treatment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In certain treatments (e.g., cancer),
cells taken from healthy donors are engineered to introduce signaling molecules that are designed to enhance the ability of specific immune
cells to recognize diseased cells, and to help recruit other cells that will destroy cancer or virus infected cells.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline">Renovaro Biosciences Focus Areas:</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span style="text-decoration: underline">Oncology:</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span style="text-decoration: underline">RENB-DC11: Genetically modified
Allogeneic Dendritic Cell Therapeutic Vaccine as Potential Product for Long-term Remission of Solid Tumors; specifically Pancreatic tumors</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i>Allogeneic Cell Therapy Platform
&#8211; Completed pre-IND, IND-enabling phase.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 6; Options: NewSection -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Based
on learnings from our internal research, literature reviews of ongoing clinical development for solid tumors, and recent advances in immune
modulation, we have designed an innovative therapeutic vaccination platform that could potentially be used to induce life-long remission
from some of the deadliest solid tumors such as pancreatic, liver, triple negative breast and head &amp; neck cancers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The platform
may one day enable broad immune enhancements that are combined with cancer specific antigens that could be applicable to a wide range
of solid tumors. This approach allows us to quickly adapt our approach to any patient solid tumor using the same banked allogenic drug
substance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><b><span style="text-decoration: underline">RENB-DC20: Genetically modified Allogeneic Dendritic
Cell Therapeutic Vaccine as Potential Treatment Product for Long-term Remission of Triple Negative Breast Cancer</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Triple Negative Breast Cancer
(TNBC) is a subtype of breast cancer that is negative for estrogens receptor (ER) negative, progesterone receptor (PR) negative and human
epidermal growth factor receptor 2 (HER2). TNBC is characterized by its unique molecular profile, aggressive nature, and distinct metastatic
patterns that lack targeted therapies. TNBC is well known for its aggressive behavior and is characterized by onset at a younger age,
high mean tumor size, and higher-grade tumors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Based upon our internal research,
literature reviews of ongoing clinical development for solid tumors, and recent advances in immune modulation, we believe we may have
the ability to design an innovative therapeutic vaccination platform that could potentially be used to treat some of the deadliest and
hard-to-treat solid tumors that include triple negative breast cancer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline">Renovaro Cube Overview</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Renovaro Cube is an AI-driven
healthcare technology company focusing on the earliest possible detection of cancer and its recurrence. Renovaro Cube has developed a
proprietary AI platform that analyzes genetics using Explainable AI (as defined below) to provide earlier and more accurate cancer diagnosis.
This platform uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients. This approach
is combined with differential molecular capabilities that are designed to identify, differentiate and pinpoint the exact source. Renovaro
Cube&#8217;s process also involves the mining of biomarker panels, which are integrated into a machine learning library referred to as
&#8220;RenovaroCube&#8221; to further enhance diagnosis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Renovaro Cube also aims to utilize
its proprietary AI platform in the development of commercial products to support clinical, research and pharmaceutical organizations that
are trying to improve patient care through precision diagnosis, prediction of success of therapy, new drug discovery, treatment protocols
or clinical trials. Specifically, Renovaro Cube is focused on developing products and services aimed at (i) early cancer characterization,
(ii) personalized treatment selection, (iii) prediction and tracking response to therapies, (iv) recurrence detection and efficacy monitoring,
and (v) ultimately, drug discovery.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Renovaro Cube was initially incorporated
as Grace Systems B.V. (&#8220;Grace Systems&#8221;) in 2013 under the laws of the Netherlands to develop unique data mining algorithms
to enable banking, finance and government entities to extract business insights from data. Grace Systems began applying its algorithms
to biological data in 2018 to uncover cancer-associated patterns. Beginning in 2018, Grace Systems pivoted its platform to focus only
on healthcare. Renovaro Cube has focused on developing its AI technology for early cancer detection.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Renovaro Cube has now focused
on commercialization of its AI technology. Renovaro Cube believes that it has developed a unique approach to the early detection and diagnosis
of cancer and its recurrence and, in time, other rare diseases through the systematic analysis of data using AI technologies, data mining
procedures and algorithms for health technology.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28pt">Renovaro Cube&#8217;s technology
has been trained on complex heterogeneous cancer data and appears to find patterns associated with cancer in public and private data resources.
With the help of Renovaro Cube&#8217;s algorithms, discovered patterns may be translated into biomarkers that can be used in a clinical
setting to target various aspects of cancer diagnosis and treatment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28pt"></p>

<!-- Field: Page; Sequence: 7 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Renovaro Cube&#8217;s Strategy</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28pt">Renovaro Cube&#8217;s product development
focuses on four core areas:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Early Detection. </b>Multi-cancer early detection (&#8220;MCED&#8221;) blood tests are advanced diagnostic tools that analyze cell-derived molecules present in the bloodstream. These tests specifically look for abnormal genetic, epigenetic or proteomic patterns of these cell-derived molecules, which can indicate the presence of cancer cells. By examining the molecules shed from various cells, including cancer cells, MCED tests aim to detect cancer at an early stage. This approach holds promise for improving cancer detection and potentially saving lives.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Recurrence of cancer</b>. A recurrence refers to the return of cancer after a period of remission. A cancer recurrence happens because, in spite of the efforts to kill the cancer, some cells may remain, which grow and eventually cause symptoms. In rare instances, a patient may develop a new cancer that&#8217;s completely unrelated to the originally diagnosed cancer, which is referred to as a second primary cancer. An early warning system could help to identify a recurrence as early as possible, thereby helping to accelerate any treatment and diagnosis. The different types of recurrence include:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">o</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Local recurrence,</b>&#160;meaning that the cancer has returned in the same place it first started;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">o</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Regional recurrence</b>, meaning that the cancer has returned to the lymph nodes near the place it first started; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">o</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Distant recurrence</b>, meaning the cancer has returned in another part of the body.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Response to treatment. </b>At Renovaro Cube we aim to develop a new array of diagnostic products that can accurately identify patients that are going to respond or fail to a certain drug. In highly toxic therapies it will not only increase survival but it will also reduce unnecessary exposure to chemotherapy. Furthermore, the costs for cancer drugs are usually very high. Providing the right therapy to the right patient will therefore significantly reduce the costs of medicine in cancer. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Clinical trials</b>. Clinical trials involve a type of research that studies new tests and treatments and evaluates their effects on human health outcomes. People volunteer to take part in clinical trials to test medical interventions including drugs, cells and other biological products, surgical procedures, radiological procedures, devices, behavioral treatments and preventive care. Clinical trials are carefully designed, reviewed and completed, and need to be approved before they can start.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">In response to these four core
areas, the key components of Renovaro Cube&#8217;s product development are to build a software and hardware platform that:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Uses data science to develop novel insights into the characterization of diseases such as cancer. Renovaro Cube intends to apply its proprietary technology to biological data from multiple sources to enable the typification (or classification) of disease entities and sub-entities to provide insights about the nature and behavior of diseases to payers, providers, pharmaceutical companies and patients.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Enables more accurate diagnosis and earlier detection of cancer and other diseases with the goal of maximizing outcomes and minimizing the costs of treatment. Renovaro Cube intends to develop a system to understand the smallest fragments of cancer in the blood of the patient. Presently, Renovaro Cube is developing a product to analyze results from liquid biopsy run through an Oxford Nanopore Sequencer. We expect the Renovaro Cube product will subsequently identify, train and validate explainable biomarkers, panels and models on different molecular layers. Multiple models will be individually trained for optimal stratification through the entire health journey, ensuring the right accuracy for a therapeutic decision in every stage. Renovaro Cube will integrate different modalities and molecular data sources into a differential diagnostic report. Diagnostics and prognosis will be explainable with quality control reports and biomarker insights for different disciplines ensuring maximum trust and insight in medical decision making.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"></p>

<!-- Field: Page; Sequence: 8 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Assists in clinical trials with patient cohort selection and response tracking, to be used by companies like Renovaro Biosciences in their patient cohort selection for their clinical trials, by looking at which patients are reacting positively, negatively and have no reaction. This data becomes more important through the progression of the different phases of drug development, as more and more patients are added. Renovaro Cube will provide multi-omic data analysis, looking for specific changes in the patients that might indicate a change in their molecular make-up. This can then be used for the next phase of a clinical trial to look for the specific molecular data that has showed a positive reaction in the previous phase. It also provides insights for more effective response tracking, which Renovaro Cube believes is important to the providers of care as well as the development and evaluation of new pharmaceuticals and immune therapies in clinical trials. Patient response to treatment can be used to focus the target audience for drugs in development and in subsequent clinical practice. As Renovaro Cube collects more data, longitudinal about treatment and response, it will have the ability to train prognostic models to give an insight in disease progression and treatment response, both critical for enrolling in clinical trials and eventually every treatment. Because Renovaro Cube consists of many independently trained and validated models, it will have the ability to assist in virtually every therapeutic decision, for different subtypes and groups (stratifications). The multi-omics and multi-modal pipelines could allow the use of multiple combinations of tissue samples and diagnostic platforms. The detailed diagnostic reports will allow and support insights for multiple disciplines such as cancer biology, genomics and pathology to look at underpinning biomarkers, pathways and clinical annotations.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Provides insight into patients who have had cancer previously. These insights will provide for more effective recurrence monitoring, which Renovaro Cube believes is important to the providers of care and patients during follow-up monitoring of remissions. Renovaro Cube anticipates that payers want to detect and re-treat recurrences at the earliest possible stage to maximize patients&#8217; outcomes in terms of time and cost and that, similarly, patients with a recurrence are keen to re-engage with effective treatment at the earliest opportunity. A key aspect of this will be taking blood from the patients, sequencing this blood and running it through the Renovaro Cube platform which will identify if the patient has any indication of the recurrence of the same or a new cancer. For recurrence monitoring, Renovaro Cube will focus on a highly sensitive combination of lab and information technology. Lab protocols, sequence post processing and machine learning are all designed, trained and validated to get the best signal with the highest sensitivity to catch early signals of recurrence. This will be done on a regular basis allowing surveillance analysis over time.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Includes biomarker panels that will be extended to include as many layers of genetic information (multi-omics) as possible including mutation, gene expression, methylation status, fragmentomics, nucleosome mapping, collectively named multi-omics, with the goal to reach the highest accuracy possible, both in terms of sensitivity and specificity of each individual biomarker panel. This provides a non-invasive alternative for the current complex, expensive and cumbersome procedures.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Create value through advancing more sophisticated typification of diseases in an effort to address some of the pressing problems faced by modern healthcare, including healthcare costs, an aging population and developments in medical technology that produce a stream of increasingly sophisticated treatments requiring more precise targeting.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">One additional key focus of Renovaro
Cube is its multi-modal, data analysis. Multi-modal data encompasses the whole aspect of data from a patient perspective, whether genomics,
imaging, phenotypic or even wearable data, which can be cross analyzed to produce data that could not be previously produced. Renovaro
Cube intends to use multi-modal data to bring new insights to the clinical and research teams trying to understand what to do next with
the patient.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Renovaro Cube&#8217;s Technology
and Techniques </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Renovaro Cube is dedicated to
the development of early cancer detection blood tests and expects to develop partnerships with third-party laboratories across the United
Kingdom, the Netherlands and the rest of Europe and will also expand to the United States. Renovaro Cube is focused on developing diagnostic
tests and test kits that would analyze samples derived from non-invasive liquid biopsy samples and intends to perform these tests from
a Renovaro&#8217;s dedicated fully certified service laboratory and engage third-party laboratories to perform these tests for end-users.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 9 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For this purpose, Renovaro Cube
has developed an AI platform that aims to leverage expertise in both biological and computational sciences and to go beyond traditional
tumor signals by detecting the body&#8217;s early warning signs of cancer. Renovaro Cube&#8217;s goal is to provide accurate and reliable
tests that can aid in the early diagnosis and treatment of cancer. Renovaro Cube&#8217;s AI technology is created to detect a wide range
of biological signs to enhance the accuracy and sensitivity of early cancer detection and, thereby, enable earlier intervention and potentially
improved patient outcomes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Renovaro Cube&#8217;s AI technology
aims to address three critical facets of medical needs within the domain of cancer diagnosis (as illustrated below):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">type-specific cancer detection;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">pan-cancer detection; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">patient stratification.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><img src="image_001.jpg" alt="" style="height: 235.5pt; width: 415.5pt"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Moreover, the versatility of Renovaro
Cube&#8217;s AI technology extends to encompass the realm of rare cancers, including cases such as cancer of unknown primary.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Leveraging DNA methylation data,
Renovaro Cube has identified and validated biomarker panels tailored for the detection of a wide range of cancers, including bladder,
breast, colon, prostate, thyroid, head and neck, liver, kidney and lung cancer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The foundational architecture
of Renovaro Cube&#8217;s AI technology is engineered to facilitate comprehensive pan-cancer analysis through its extensive record of informative
biomarkers discovered across a diverse array of cancer types. This comprehensive repository empowers Renovaro Cube&#8217;s AI technology
to swiftly cross-reference biomarkers and explore molecular commonalities and distinctions that span multiple tumor categories.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For example, the capabilities
of Renovaro Cube&#8217;s AI technology have unearthed biomarkers capable of pinpointing a specific subgroup of thyroid cancer patients
characterized by a distinct genomic alteration, the neurotrophic tyrosine receptor kinase (&#8220;NTRK&#8221;) gene fusion. Identification
of these NTRK-positive patients provides an actionable therapeutic target.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 10 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Uses of Renovaro Cube&#8217;s AI Technology</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">Renovaro Cube has developed its AI platform to support:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">AI-assisted patient diagnostics;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">multi-omic data analysis;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">genome-wide or targeted analysis;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">pan-cancer analysis;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">different technology platforms (sequence or array);</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">tracking of each sample;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">AI-guided biomarker discovery for single or multiple cancer types; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">logs of analysis steps and outcomes (data preparation, discovery, validation).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Renovaro Cube&#8217;s AI platform
is an enterprise software platform that is distinguished from its competitors&#8217; technology by its core attributes encompassing AI-guided
analysis and meticulous record-keeping of data handling procedures within audit trails, logs, and data discoveries. Renovaro Cube designed
this technology to support and validate every phase of the process, from the initial handling of raw data to the creation of essential
biomarker panels. Renovaro Cube&#8217;s AI platform also facilitates the integration of data originating from diverse sources, including
public databases and collaborative partnership data.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Illustrated below is the three-phase
workflow behind Renovaro Cube&#8217;s AI platform for biomarker discovery using DNA methylation data. This workflow commences with the
identification of pertinent single- and multi-omic data best suited to address the specific inquiries of Renovaro Cube&#8217;s clients,
and the subsequent stages involve the meticulous pre-processing and loading of this data into the platform. This process culminates in
the availability of a dashboard offering the client insights into the data&#8217;s characteristics, such as data quality, the technology
employed, and associated metadata.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><img src="image_002.jpg" alt="" style="height: 276pt; width: 426.75pt"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<!-- Field: Page; Sequence: 11 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Phase I of the workflow behind Renovaro Cube&#8217;s AI platform primarily centers on the pivotal process of biomarker discovery. This intricate procedure unfolds through the application of data mining algorithms and statistical methodologies integrated into the AI platform. The paramount objective of Phase I is to reduce the plethora of genomic features displaying variations across samples, which is accomplished by systematically eliminating extraneous or inconsequential features while preserving those features that exhibit the greatest potential for accurately detecting cancer.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Phase II of the workflow builds upon the foundation of selected biomarkers by focusing on understanding the dynamic interplay among these chosen biomarkers, culminating in the creation of composite panels. The goal of Phase II is to pinpoint biomarker combinations that not only demonstrate robustness in detecting cancer but also maintain their efficacy across diverse contexts. Renovaro Cube believes that its AI algorithms are adept at uncovering multiple combinations across a spectrum of panels, which is supported by Renovaro Cube&#8217;s AI-guided panel mining, a proprietary combinatorial optimization technique used by Renovaro Cube&#8217;s AI technology. This approach, coupled with the capacity to explore numerous panels, significantly enhances the likelihood of discovering panels that align with specific metric criteria, such as sensitivity, specificity, precision, and recall and allows for tailoring criteria to align with clients&#8217; unique needs, such as the number of biomarkers included per panel, or the inclusion of biomarkers associated with the expression of specific genes. The performance of the top-tier panels is further fine-tuned through the application of machine learning models. Subsequently, the efficacy of these biomarker panels in detecting cancer is validated through independent data sets.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Phase III of the workflow involves Renovaro Cube&#8217;s collaboration with its clinical partners to validate the performance of the biomarker panels. Through this collaboration, Renovaro Cube can confirm the utility and accuracy of its biomarker panels in real-world clinical contexts. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>AI-Assisted Diagnostics</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The process of biomarker discovery
facilitated by Renovaro Cube&#8217;s AI technology has yielded a set of data that enables scrutiny of the genomic distinctions and commonalities
inherent in diverse cancer types. This data set can support the diagnosis of cancers when their type or origin remains unidentified.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition to this role in biomarker
discovery and the development of diagnostic tests, Renovaro Cube&#8217;s AI technology also integrates AI-guided molecular profiling of
patient samples and furnishes diagnostic patient reports. These diagnostic reports reflect the outcomes of molecular profiling, coupled
with interpretations provided by Renovaro Cube&#8217;s team, to facilitate the process of cancer diagnostics by a qualified healthcare
provider, who can consider these reports in the context of a patient&#8217;s medical history, clinical signs, and symptoms, among other
factors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><b>Quality Control Process</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Renovaro Cube undertakes post-processing
of data generated from sequence and arrays to ensure accurate and meaningful results. These post-processing steps for omic data include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><span style="text-decoration: underline">Quality Control</span>: Quality control is performed to assess the overall data quality and to identify any technical issues or anomalies.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><span style="text-decoration: underline">Normalization</span>: arrays can introduce various sources of technical variation, such as batch effects, intensity variations, and probe-specific biases.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><span style="text-decoration: underline">Quality Filtering</span>: After genotype calling, additional quality filtering may be performed to remove low-quality SNPs based on criteria like call rates, minor allele frequency, Hardy-Weinberg equilibrium p-values, and linkage disequilibrium.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Other post-processing steps may
include genotype calling, population stratification and association analysis. Specific post-processing steps may vary depending on the
type of array used, the study design, and the analytical goals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 12 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Planning for Commercialization</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="text-decoration: underline">Partnerships in Development</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">To enhance multi-omic and multi-modal
capacity, and to work to validate those capabilities with human samples including liquid-biopsy-based tests/test kits, Renovaro Cube is
actively pursuing relationships with leading academic cancer centers, pathology and imagery centers in Europe, the USA and the Middle
East. In certain cases, scopes of work are in process. This is a very attractive model for partners to be involved with Renovaro Cube
to perform multi-omics genetic analysis using liquid biopsies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Resources</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of the year ended June 30,
2025, Renovaro Cube intends to hire additional staff to increase the speed and velocity of its organization, including the development
of the AI platform and the opportunities to deploy the AI platform for research perspective and ultimately for clinical practice and into
clinical trials. In addition, Renovaro Cube intends to build out its infrastructure by leasing space for storage, networking and hosting
facilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Target Market</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Renovaro Cube&#8217;s intended
customers will be hospitals, clinics, insurance companies, pharmaceutical companies, biotech companies, research centers, physicians and
individual patients.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Renovaro Cube aims to utilize
its AI technology to commercialize products and test kits for healthcare providers, hospitals, clinics and doctors that will expedite
diagnosis and the selection of appropriate treatment for various types of cancer. Renovaro Cube intends to differentiate its products
based on the following factors:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">Proprietary and unique panel mining algorithms to create multiple biomarker stratifications per cancer;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">Explainable AI, offering traceability between the prediction and the exact biomarkers, panels and genes;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">Differential diagnosis, inclusion and exclusion of cancer types based on facts; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">Precision diagnosis, with a high accuracy percentage with machine-learning tuning.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The multi-omic design of Renovaro
Cube&#8217;s AI platform enables the use of different molecular layers, such as epigenomics, transcriptomics, and metabolomics, together
with genomics and clinical data.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Panel Mining </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The unique panel mining technique
in Renovaro Cube&#8217;s technology repeatedly investigates genes to identify relevant biomarkers. The proprietary technique in Renovaro
Cube&#8217;s technology not only searches for individual biomarkers, but also integrates validated panels for different cancer types into
the &#8220;RenovaroCube&#8221; machine learning library. This process enables precision diagnosis, by including one cancer and excluding
others based on statistically, scientifically and clinically validated machine-learning panels.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Panel mining is designed to combine
biomarkers into panels in such a way that the final panel meets:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">performance metric criteria;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">technical criteria, such as a minimum or maximum number of biomarkers for the selected assay;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">biological criteria, non-annotated genes inclusion; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">stratification criteria.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"></p>

<!-- Field: Page; Sequence: 13 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Explainable AI</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The term &#8220;Explainable AI&#8221;
refers to the ability of an AI system or model to provide human-understandable explanations for its decision-making process or predictions.
This feature aims to bridge the gap between the &#8220;black box&#8221; nature of many AI algorithms and the need for transparency, interpretability,
and accountability in AI applications.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In traditional machine learning
approaches, such as deep neural networks, the internal workings of the model can be complex and difficult to interpret. This lack of interpretability
poses challenges in critical domains where decisions have significant implications, such as healthcare.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Renovaro Cube believes that Explainable
AI is crucial for ensuring transparency, fairness, and accountability in AI systems. Renovaro Cube&#8217;s AI platform includes Explainable
AI by design. All data points, calculations and results are traceable, and all calculations are verifiable and reproducible with the same
result.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Disease prognosis is one of the
diagnostic capabilities of the Explainable AI feature of Renovaro Cube&#8217;s technology. Disease prognosis gives more insight for a
specific patient that empowers healthcare providers, patients, and their families to make well-informed decisions about treatment, care,
and future planning, thereby enhancing patient-centered care, optimizing resource utilization, and contributing to improved patient outcomes
and quality of life.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Differential Diagnosis</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Renovaro Cube&#8217;s AI platform
offers differential diagnosis by design due to its approach with a multitude of models for different diseases and the ability to include
and exclude diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Diseases like cancer are very
homogenous, meaning that markers like TP53 or BRCA are expressed with multiple cancers. To address this homogeneity, differential diagnosis
distinguishes between two or more conditions or diseases that share similar signs, symptoms or characteristics. The goal of differential
diagnosis is to consider and evaluate all possible diagnoses for the patient&#8217;s symptoms to determine the most likely cause. Differential
diagnosis therefore aims to identify the underlying condition accurately and guide appropriate treatment and management strategies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Differential diagnosis is important for several reasons:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><span style="text-decoration: underline">Accurate Diagnosis</span>: Differential diagnosis helps healthcare professionals arrive at the correct diagnosis by systematically considering all possible explanations for the patient&#8217;s symptoms. This ensures that the appropriate treatment and interventions are provided, leading to better patient outcomes.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><span style="text-decoration: underline">Avoiding Misdiagnosis</span>: Many medical conditions have similar or overlapping symptoms, and misdiagnosis can have serious consequences. Differential diagnosis helps to avoid misdiagnosing one condition as another, preventing unnecessary treatments, delays in appropriate care or potential harm to the patient.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><span style="text-decoration: underline">Tailored Treatment</span>: Different conditions require different treatments. Identifying the correct diagnosis through differential diagnosis allows healthcare professionals to develop a targeted treatment plan based on the specific condition, improving the chances of successful management and recovery.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">4.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><span style="text-decoration: underline">Avoiding Overtreatment or Undertreatment</span>: Some conditions may require aggressive interventions, while others may resolve with minimal treatment or simply require symptomatic management. Differential diagnosis helps prevent overtreating or undertreating patients by ensuring that interventions are appropriate for the specific condition.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">5.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><span style="text-decoration: underline">Identifying Underlying Causes</span>: In some cases, multiple conditions may present with similar symptoms, but the underlying causes may be distinct. Differential diagnosis helps identify the root cause of the symptoms, which is crucial for implementing effective long-term management strategies and preventing complications.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In summary, differential diagnosis
is a critical process in healthcare that supports accurate identification of the underlying condition, tailored treatment plans, and improved
patient outcomes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 14 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Precision Diagnostics</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Precision diagnostics and personalized
care is about focusing on what is required for a specific patient, what are their individual needs, how can we understand more about them
to be more precise when delivering care and identifying the right clinical pathway to move them through treatment. Renovaro Cube technology
will bring a high level of detail with multi-omic data, allowing individual genes and different possible cancers under suspicion to be
identified. Due to the structure of the data produced, Renovaro Cube can bring it into any format of user interface, documentation, or
database. We expect to provide the flexibility to respond to the different requirements for delivering data to the right person at the
right place at the right time. We will comply to user interface guidance and usability regulations (WC3C) to ensure that they meet the
correct standards to enable the data to be displayed, read and understood. Personalized care is what we all in the healthcare system are
striving for, we are one component that can make a huge difference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Future Development </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In driving towards future commercialization,
Renovaro Cube intends to undertake or continue the following activities to enable the development of its AI platform, bolster the credibility
of this platform and open up revenue opportunities:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Increase in-kind contribution projects with hospitals, research centers and pharmaceutical companies, focusing on rare disease, cancer diagnosis and other opportunities for clinical trials; it is expected that the investments required for these activities will be leveraged by non-dilutive funding instruments to de-risk individual projects and product development routes,</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Work to develop long-term strategic partnerships with clinical organizations, research centers and pharmaceutical companies to advance existing research in multi-modal analysis and open potential revenue streams;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Develop Renovaro Cube&#8217;s multi-modal, multi-omics platform architecture and first prototypes, with the goal of providing integrated multi-modal solutions that would be sold as a fully deployed and fully supported solution, subject to compliance with regulatory standards for hosting and support and for production of algorithms being deployed in a clinical environment;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Build Renovaro Cube&#8217;s service and support models for its AI platform;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Build or lease a &#8220;supercomputer&#8221; that will be utilized for processing genomic data, the training of algorithms and the development of Renovaro Cube&#8217;s solutions;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Continue business development across key territories in the Europe, Middle East, and Africa (&#8220;EMEA&#8221;) region, starting in the United Kingdom, the Netherlands and Germany, under the management of in-country managers supported by centralized teams in Amsterdam and London and progress to rolling out in the US leveraging the Lunai US based staff;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Deploy a sequencing lab in the EMEA region that will allow Renovaro Cube to control the sample preparation and medical device, thereby enabling faster commercialization analysis and quality control; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Expand its team to include biomedical scientists,
    data scientists, machine-learning engineers, specialized medical doctors (oncologist, geneticist), high-performance-computer engineers
    and software engineers.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#9679;&#160;Renovaro
    Cube plans to establish a state-of-the-art fully certified (CLIA and ISO standards) service laboratories to perform liquid biopsies in
    a multi-omic approach for third parties (primarily research and academic institutes) and provide data analysis at the same time. This
    activity serves two important goals:</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.25in"> &#9679; It
    provides immediate revenues for the company providing a superior service for multi-omic sequencing servicing using Oxford Nanopore
    Technologies for an attractive pricing and high-end services also applicable for liquid biopsies.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.25in">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.25in">&#9679; The Cube
    needs data to expand the indications, application and improve the capabilities of the system. Acquiring this data is a lengthy and
    expensive. We anticipate a significant number of clients will provide data sharing for a reduced price. The outcomes can be
    published collaboratively, and the potential products will be commercialized by Renovaro Cube. The partner will receive
    royalties.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.25in">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"> &#9679; A
    first service laboratory will be established in the Netherlands and rapidly expanded to other sites in the EU, US and rest of the world.</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"></p>

<!-- Field: Page; Sequence: 15 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Business Overview (BioSymetrics)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">BioSymetrics is a biomedical artificial
intelligence company focused on integrating multimodal data sources, including genomics, imaging, electronic health records, and other
real-world evidence, to advance biomarker discovery, therapeutic development, and precision medicine. BioSymetrics has developed proprietary
machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. These
insights are designed to support pharmaceutical research, early disease detection, and personalized treatment strategies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">BioSymetrics collaborates with
pharmaceutical companies, healthcare providers, and academic institutions to co-develop analytical tools and translational research programs.
Application areas of the BioSymetrics platform include: (i) multi-omics integration for target identification and validation; (ii) predictive
modeling of therapeutic efficacy and safety; (iii) clinical trial optimization, including patient stratification and response monitoring;
and (iv) experimental screening of gene and small molecule effects for the purpose of identifying novel drug targets and therapeutics.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The key to the BioSymetrics approach
is Contingent AI. In Contingent AI, any &#8220;settable&#8221; parameter for data processing, data integration, or feature selection is
permuted and the corresponding effects on the downstream predictive model measured. This process is similar in nature to hyperparameter
tuning in machine learning, however instead of optimizing only the machine learning model, the entire data science pipeline (including
model selection) is subject to optimization. We have applied this method extensively in drug discovery, producing marked improvements
in experiment interpretation and lead generation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><img src="image_003.jpg" alt="" style="height: 195pt; width: 347.25pt"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><img src="image_004.jpg" alt="" style="height: 123.95pt; width: 106.9pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Another
major component of BioSymetrics&#8217; platform is the Phenograph. The Phenograph<sup>TM</sup> is BioSymetrics&#8217; proprietary knowledge
graph. The purpose of the Phenograph<sup>TM</sup> is to map human genes and phenotypes to those of model systems, allowing <b>virtual
phenotypic screening</b>, target nomination, and active learning feedback. The Phenograph<sup>TM</sup> contains 5,856 diseases associated
with one or more phenotypes in humans, and 16,676 human genes with one or more orthologous zebrafish genes. Zebrafish genes are mapped
to phenotypic terms using over 300 individually-trained machine learning models, that fill in the gaps of known gene-phenotype associations.
Leveraging this platform, we can prioritize human genes on the basis of predicted experimental phenotype, reducing the number of required
experiments to produce human-informed <i>in vivo</i> disease models.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 16 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<p style="margin: 0; font-size: 10pt">Finally, one important component of the BioSymetrics platform is that it couples AI-based prediction
with experimental validation. BioSymetrics has designed deep learning-based computer vision software that automatically identifies and
characterizes organ systems relevant to neurological, cardiovascular, and muscle development (<b>Figure below</b>). Additionally, BioSymetrics
has developed a proprietary light stimulus battery and characterized a small number of known CNS therapeutics and unknown compounds, providing
an initial basis for evaluation of chemical effects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><img src="image_006.jpg" alt=""/>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>A large-scale behavioral profiling platform for identification of neurotherapeutics.</b> (A) 96-well plate containing 8 zebrafish larvae per well, as used for behavioral profiling. (B-C) Line plots showing activity over time for 48 replicate wells focusing in on a small (5 min) part of the behavioral profile. Unlike control wells (B), drug-treated wells (C) show much higher activity levels. (D-H) Example profiles for 5 different reference compounds showing the average behavioral profiles for control and compound-treated wells (n= 4 wells; orange and blue lines, respectively). Note that each of the 5 compounds causes a distinct behavioral profile. (I) Examples of morphological segmentation. Colored micrographs of laterally oriented zebrafish larvae show computer-vision-based organ segmentation using trained ML classifiers. &#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In prior work, we leveraged our
motion profiling capabilities to identify novel neuroactive compounds capable of resolving epilepsy-related phenotypes. Specifically,
we screened 1400 compounds from a proprietary small molecule library both with and without addition of a chemical convulsant. The experimental
component of this screen was completed by one technician in 10 days, giving us an approximate pace of 1,000 compounds screened per technician
per week. This study resulted in identification of a hit compound that later showed efficacy in a mouse seizure model, now being further
progressed as a potential therapeutic by BioSymetrics. Additionally, during the course of this study we screened approximately 100 known
neuroactives, including clinical anticonvulsants, antidepressants, antipsychotics, and dopaminergic signaling activators and inhibitors.
This study produced two key observations that are critical for this application. The result is both an experimental platform and coupled
computational model that can identify both neurotherapeutics and neurotoxins, the former through direct experimental screening, and the
latter through machine-learning based prediction based on chemical structure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 17 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We next we examined the ability
of one of these compounds (BioS_831) to resolve seizures in a murine model using a previously established electroshock seizure assay.
Briefly, after dosing each mouse with either BioS_831, negative control (vehicle), or positive control (Sodium Valproate), electroshock
is delivered transauricularly using stimulation at 50 Hz and 50 mA for 0.8 seconds with a pulse width of 10 milliseconds. The total number
of hind limb flexes, hind limb extensions, and mortality rate is monitored for 60 seconds following electroshock, as are other adverse
events. We screened BioS_831 at both a low and high dose and found that at 40 mg/kg of BioS_831 significantly increased latency time to
tonic seizure induction and significantly reduced the number of observed tonic extension seizures, as compared to vehicle control. Notably,
unlike the ASM Sodium Valproate, BioS_831 did not cause sedation or ataxia. Sodium Valproate (VPA) while effective in this model at this
concentration, results in high levels of neurotoxicity, and has been associated with multi-organ failure, underscoring the importance
of not observing negative neurological effects with our novel compound. Post-study PK analysis showed good distribution of BioS_831 into
the brains of the test animals (average brain to plasma ratio 0.68). Since the electroshock seizure model is not based on seizure induction
through hypofunction of KCC2, these findings suggest that our zebrafish epilepsy primary screening model is capable of identifying novel
compounds that show translation to mammalian generalized epilepsy models and suggest that BioS_831 could further be optimized as a potential
anti-epileptic therapeutic.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Additionally, during the course
of this study we screened approximately 100 known neuroactives in our zebrafish model including clinical anticonvulsants, antidepressants,
antipsychotics, and dopaminergic signaling activators and inhibitors. The result is both an experimental platform and coupled computational
model that can identify both neurotherapeutics and neurotoxins, the former through direct experimental screening, and the latter through
machine-learning based prediction based on chemical structure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">BioSymetrics intends to expand the use of its platform
across the biopharmaceutical and healthcare markets. The company is developing its technology in compliance with applicable healthcare
data privacy regulations, including HIPAA and GDPR, and is focused on building AI solutions that address the growing demand for robust,
transparent, and reliable applications of artificial intelligence in life sciences.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Our Intellectual Property</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Patents and licenses are key to
our business. Our strategy is to file patent applications to protect technology, inventions, and improvements to inventions that we consider
important for the development of our business. We rely on a combination of patent, copyright, trademark, and trade secret laws, as well
as continuing technological innovations, proprietary knowledge, and various third-party agreements, including, without limitation, confidentiality
agreements, materials transfer agreements, research agreements, and licensing agreements, to establish and protect our proprietary rights.
We aim to take advantage of all of the intellectual property rights that are available to us and seek the protection of those rights so
that we can fully exploit our innovations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We also protect our proprietary
information by requiring our employees, consultants, contractors, and other advisors to execute nondisclosure and assignment of invention
agreements upon commencement of their respective employment or engagement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Assigned Intellectual Property</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On August 16, 2022, the USPTO
issued U.S. Patent No. 11,413,338 B2, &#8220;Methods and Compositions Using Recombinant Dendritic Cells for Cancer Therapy&#8221;, pertaining
to methods and compositions for treating cancer by eliciting an immune response by administering dendritic cells expressing heterologous
proteins. This patent protects <b>RENB-DC11: </b><i>Genetically modified Allogeneic Dendritic Cells as Potential Product for Long-term
Remission of Solid Tumors &#8211; Starting with Pancreatic Cancer</i> and potential future products <b>RENB-DC-12XX: </b><i>Genetically
modified Allogeneic Dendritic Cells as Potential Product for Long-term Remission of Additional Indications</i> for twenty years. The Company
owns this patent application, through assignment as of July 15, 2019.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On July 5, 2022, the USPTO issued
Patent No. US-11379757-B2, &#8220;Methods, systems, and frameworks for data analytics using machine learning&#8221;, pertaining to methods
for pre-processing multi-modal data for biomedical applications. This patent protects our core Contingent AI technology, which allows
us to simultaneously process multiple types of biomedical and experimental data, resulting in a unique method for the application of AI
across therapeutic development. This method is applied in multiple components of the BioSymetrics platform and has been applied in projects
with pharmaceutical partners.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On June 17, 2020, a patent titled
&#8220;Allogeneic T-Cell-Based HIV Vaccine to Induce Cellular and Humoral Immunity&#8221;, US 2021/0030795 A1 for the composition and
method of use concepts for RENB-HV-12. was filed. The Company owns this patent application, through assignment as of September 28, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>In-Licensed Technology</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><b>Trade Secrets and Proprietary Know-How</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition to intellectual property
protected by patents and copyrights, we have trade secrets and proprietary know-how relating to our products, production processes, and
future strategies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Competition</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Renovaro Cube operates in a highly
competitive market with several companies developing AI-driven diagnostic platforms for early disease detection and personalized medicine.
Key competitors include Grail, Freenome, and Owkin, each utilizing advanced AI and machine learning to analyze multi-omic data for cancer
detection. While these companies focus primarily on specific diagnostic approaches, Renovaro Cube differentiates itself through its unique,
disease-agnostic AI platform that integrates various molecular data sources for differential diagnosis. Our platform&#8217;s explainable
AI system, capable of providing actionable insights and personalized treatment options, offers a distinct advantage. Despite the crowded
landscape, Renovaro Cube&#8217;s scalable technology, multi-omics capabilities, and ability to process diverse biopsy sources position
it as a versatile leader in precision diagnostics, allowing us to address a broader range of clinical and research needs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">BioSymetrics similarly operates
in a highly competitive market with companies including Recursion Pharma and insitro also focused on phenotype-based profiling using <i>in
vitro</i> cellular profiling and AI. While similar in concept, Recursion and insitro&#8217;s models provide evidence on cellular, but
not multicellular or multi-organ phenotypes, so we feel our platform is differentiated, specifically when investigating behavioral and
neurological diseases. Similarly, while murine models are broadly accepted as being relevant for the study of neurological disorders,
their experimental throughput is highly limited, and turnaround times for experimentation can be on the scale of months, resulting in
a substantial experimental cost. The biggest difference is scale &#8212; mice cannot be used in large-scale chemical screens using multi-well
plates. Therefore, BioSymetrics is targeting a market further upstream, for testing larger groups of candidate compounds in libraries
too large for mice.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Government Regulation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;<b><i>FDA Review and Approval
</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Government authorities in the
United States, at the federal, state, and local levels, and in other countries extensively regulate, among other things, the research,
development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution,
post-approval monitoring and reporting, marketing and export and import of therapeutic products such as those we are developing. Any products
we develop are likely to require regulatory review and allowance to proceed prior to conducting clinical trials and additional regulatory
approvals prior to commercialization. In the United States, the FDA regulates drugs under the Federal Food, Drug and Cosmetic Act (FDCA)
and the Public Health Service Act (PHSA) and their implementing regulations govern, among other things, biopharmaceutical testing, manufacturing,
safety, efficacy, labeling, storage, recordkeeping, advertising, and other promotional practices.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Obtaining FDA approval is a costly
and time-consuming process. FDA approval requires that preclinical studies be conducted in the laboratory and in animal model systems
to gain preliminary information on efficacy and to identify any major safety concerns. The results of these studies are then submitted
as a part of an IND, which the FDA must review and allow before human clinical trials can start. The IND includes a detailed description
of the proposed clinical investigations. An independent Institutional Review Board (&#8220;IRB&#8221;) must also review and approve the
clinical protocol and each clinical site.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A company must submit an IND for
each investigational medical product and specific indication(s) and must conduct clinical studies to demonstrate the safety and efficacy
of the product necessary to obtain FDA approval. The FDA receives reports on the progress of each phase of clinical testing and may require
the modification, suspension, or termination of clinical trials if an unwarranted risk is observed in participants including patients.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 19 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Obtaining FDA approval prior to
marketing a biopharmaceutical product in the United States typically requires multiple phases of clinical trials to demonstrate the safety
and efficacy of the product candidate. Clinical trials are how experimental treatments are evaluated in humans and are conducted following
preclinical testing. Clinical trials may be conducted within the United States or in foreign countries. If clinical trials are conducted
in foreign countries, the products under development as well as the trials are subject to regulations of the FDA and/or its regulatory
counterparts in the other countries. Upon successful completion of clinical trials, approval to market the treatment for a particular
patient population may be requested from the FDA in the United States and/or its counterparts in other countries.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Applications submitted to the
FDA are subject to an unpredictable and potentially prolonged approval process. Despite good-faith communication and collaboration between
the applicant and the FDA during the development process, the FDA may decide, upon final review of the data, that the application does
not satisfy its criteria for approval or requires additional product development or further preclinical or clinical studies. Even if FDA
regulatory approval(s) are obtained, a marketed product is subject to continual review, and later discovery of previously unknown problems
or failure to comply with the applicable regulatory requirements may result in restrictions on the marketing of a product or withdrawal
of the product from the market as well as possible civil or criminal sanctions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Sponsors of clinical trials are
required to register, and report results for, all controlled, clinical investigations, other than Phase 1 investigations, of a product
subject to FDA regulation. Trial registration may require public disclosure of certain confidential commercial development data.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The process of obtaining regulatory
approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure
of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development
process, approval process or after approval, may subject an applicant to administrative or judicial sanctions. FDA sanctions could include,
among other actions, refusal to approve pending applications, withdrawal of an approval, a clinical hold, warning letters, product recalls
or withdrawals from the market, product seizures, total or partial suspension of production or distribution injunctions, fines, refusals
of government contracts, restitution, disgorgement or civil or criminal penalties. Any agency or judicial enforcement action could have
a material adverse effect on our business, financial condition, results of operations and cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 8.2pt 0 0; text-align: justify; text-indent: 0.5in"><b><i>Other Healthcare
Laws and Compliance Regulations</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 8.2pt 0 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Although we currently do not have
any products on the market, we may also be subject to additional healthcare regulations and enforcement by the federal government and
by authorities in the states and foreign jurisdictions in which we conduct our business. In the United States, among other things, the
research, manufacturing, distribution, sale and promotion of pharmaceutical and biological products are potentially subject to regulation
and enforcement by various federal, state and local authorities in addition to the FDA, including the Centers for Medicare and Medicaid
Services (&#8220;CMS&#8221;), other divisions of the United States Department of Health and Human Services (e.g., the Office of Inspector
General), the Drug Enforcement Administration, the Consumer Product Safety Commission, the Federal Trade Commission, the Occupational
Safety and Health Administration, the Environmental Protection Agency, state Attorneys General and other state and local government agencies.
Our current and future business activities, including for example, sales, marketing, and scientific/educational grant programs, must comply
with health care regulatory laws, as applicable, including, without limitation:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 20px">&#160;</td>
    <td style="width: 20px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the federal anti-kickback statute, which is a criminal statute that makes it a felony for individuals or entities to knowingly and willfully offer or pay, or to solicit or receive, direct or indirect remuneration, in order to induce the purchase, order, lease, or recommending of items or services, or the referral of patients for services, that are reimbursed under a federal health care program, including Medicare and Medicaid; </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the federal False Claims Act, which prohibits, among other things, individuals and entities from knowingly submitting, or causing to be submitted, false or fraudulent claims for payment of government funds, with penalties that include three times the government&#8217;s damages plus civil penalties for each false claim; in addition, the False Claims Act permits a person with knowledge of fraud, referred to as a qui tam plaintiff, to file a lawsuit on behalf of the government against the person or business that committed the fraud, and, if the action is successful, the qui tam plaintiff is rewarded with a percentage of the recovery; </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 20 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 20px">&#160;</td>
    <td style="width: 20px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the Health Insurance Portability and Accountability Act of 1996, or HIPAA, which governs the conduct of certain electronic healthcare transactions and protects the security and privacy of protected health information; </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical suppliers to report annually to CMS information related to payments and other transfers of value to physicians, other healthcare professionals and teaching hospitals, and ownership and investment interests held by physicians and other healthcare professionals and their immediate family members; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 20px">&#160;</td>
    <td style="width: 20px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">state and foreign law equivalents of each of the above federal laws, such as state anti-kickback and false claims laws which may impose stricter requirements than federal law and may apply to items or services reimbursed by any payor (including commercial insurers and cash-paying patients); state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare professionals and other potential referral sources; state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare professionals or marketing expenditures; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If our operations are found to
be in violation of any of such laws or any other governmental laws or regulations that apply, they may be subject to penalties, including,
without limitation, civil and criminal penalties, damages, fines, disgorgement, the curtailment or restructuring of operations, exclusion
from participation in federal and state healthcare programs, additional program integrity obligations, individual imprisonment, injunctions,
recall or seizure of products, total or partial suspension of production, denial or withdrawal of product approvals, refusal to permit
us to enter into supply contracts, including government contracts, contractual damages, reputational harm, administrative burdens, diminished
profits, and future earnings, any of which could have a material adverse effect on our business, financial condition, result of operations,
and cash flows. These additional healthcare regulations could affect our current and future arrangements with healthcare professionals,
principal investigators, consultants, customers and third-party payors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Moreover, the introduction of
legislation, implementation of new regulations, or enforcement of existing regulations that have a negative impact on the commercial prospects
for the types of products we are developing could negatively impact our share price and our ability to raise capital.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 8.2pt 0 0; text-align: justify; text-indent: 0.5in"><b><i>Coverage and Reimbursement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 8.2pt 0 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In the United States, third-party
payors include federal and state healthcare programs, government authorities, private managed care providers, private health insurers
and other organizations. Third-party payors are increasingly challenging the price, examining the medical necessity and reviewing the
cost-effectiveness of medical drug products and medical services, in addition to questioning their safety and efficacy. Such payors may
limit coverage to specific drug products on an approved list, also known as a formulary, which might not include all the FDA-approved
drugs for a particular indication. Third-party payor coverage may be more limited than the purposes for which the FDA or foreign regulatory
authorities approve the product. Further, one payor&#8217;s determination to provide coverage for a drug product does not assure that
other payors will also provide coverage for the drug product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Further, third-party payers are
increasingly challenging the price of medical products and services, and there is increasing pressure on biotechnology companies to reduce
healthcare costs. If purchasers or users of our products are not able to obtain adequate reimbursement for the cost of using our products,
they may forgo or reduce their use. Significant uncertainty exists as to the reimbursement status of newly approved healthcare products,
and whether adequate third-party coverage will be available. Our inability to promptly obtain coverage and profitable payment rates from
both government funded and private payors for future products we develop could have a material adverse effect on our operating results,
our ability to raise capital needed to commercialize potential products, and our overall financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 21 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 8.2pt 0 0; text-align: justify; text-indent: 0.5in"><b><i>Healthcare Reform</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 8.2pt 0 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In March 2010, former President
Obama signed into law The Patient Protection and Affordable Care Act and the Health Care and Education Affordability Reconciliation Act
of 2010 (collectively, the &#8220;Affordable Care Act&#8221;), which substantially changed the way healthcare is financed by both governmental
and private insurers in the United States, and significantly affected the pharmaceutical industry. The Affordable Care Act contains a
number of provisions, including those governing enrollments in federal healthcare programs, reimbursement adjustments and fraud and abuse
changes. Additionally, the Affordable Care Act increases the minimum level of Medicaid rebates payable by manufacturers of brand name
drugs; requires collection of rebates for drugs paid by Medicaid managed care organizations; requires manufacturers to participate in
a coverage gap discount program, under which they must agree to offer point-of-sale discounts off negotiated prices of applicable brand
drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered
under Medicare Part&#160;D; and imposes a non-deductible annual fee on pharmaceutical manufacturers or importers who sell &#8220;branded
prescription drugs&#8221; to specified federal government programs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Since its enactment, there have
been judicial and Congressional challenges to certain aspects of the Affordable Care Act, and we expect there will be additional challenges
and amendments to the Affordable Care Act in the future. Other legislative changes have been proposed and adopted since the Affordable
Care Act was enacted, including aggregate reductions of Medicare payments to providers and reduced payments to several types of Medicare
providers. Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their
marketed products, which has resulted in several Congressional inquiries and proposed bills designed to, among other things, bring more
transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program
reimbursement methodologies for drug products. Individual states in the United States have also become increasingly active in implementing
regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions
on certain product access and marketing&#160;cost disclosure and transparency measures, and, in some cases, proposing to encourage importation
from other countries and bulk purchasing.&#160;We cannot predict what healthcare reform initiatives may be adopted in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We also are subject to various
federal, state, and local laws, regulations, and recommendations relating to safe working conditions, laboratory and manufacturing practices,
the experimental use of animals, and the use and disposal of hazardous or potentially hazardous substances, including radioactive compounds
and infectious disease agents, used in connection with our research. The extent of government regulation that might result from any future
legislation or administrative action cannot be accurately predicted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Renovaro Cube&#8217;s <i>AI</i>-guided
diagnostic platform operates within a highly regulated environment, particularly as it involves health data and medical diagnostics. As
a Software as a Medical Device (SaMD), the platform will require compliance with various regional regulations, including but not limited
to the U.S. Food and Drug Administration (FDA) guidelines and European Union Medical Device Regulation (MDR). Our regulatory strategy
involves a meticulous development process, adhering to international standards such as for quality management systems. Key elements include
rigorous clinical validation, cybersecurity, data privacy (in compliance with HIPAA and GDPR), and quality control to ensure patient safety
and diagnostic accuracy. Post-market surveillance and continuous improvement will be integral to maintaining compliance and effectiveness
as we aim for global commercialization. Given the rapidly evolving regulatory landscape for AI-driven diagnostics, Renovaro Cube remains
committed to working closely with regulatory bodies to navigate the approval processes and to address ethical considerations, ensuring
that our products meet the highest standards of safety and efficacy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Foreign Corrupt Practices
Act</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our business activities may be
subject to the Foreign Corrupt Practices Act, or FCPA, and similar anti-bribery or anti-corruption laws, regulations, or rules of other
countries in which we operate. The FCPA generally prohibits offering, promising, giving, or authorizing others to give anything of value,
either directly or indirectly, to a non-U.S. government official to influence official action, or otherwise obtain or retain business.
The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the
corporation and to devise and maintain an adequate system of internal accounting controls. Our business is heavily regulated and therefore
involves significant interaction with public officials, including officials of non-U.S. governments. Additionally, in many other countries,
the health care providers who prescribe pharmaceuticals are employed by their government, and the purchasers of pharmaceuticals are government
entities; therefore, our dealings with these prescribers and purchasers are subject to regulation under the FCPA. There is no certainty
that all of our employees,</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 22 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">agents, suppliers, manufacturers, contractors, or collaborators, or those of our affiliates, will comply with
all applicable laws and regulations, particularly given the high level of complexity of these laws. Violations of these laws and regulations
could result in fines, criminal sanctions against us, our officers, or our employees, the closing down of facilities, including those
of our suppliers and manufacturers, requirements to obtain export licenses, cessation of business activities in sanctioned countries,
implementation of compliance programs, and prohibitions on the conduct of our business. Any such violations could include prohibitions
on our ability to offer our products in one or more countries as well as difficulties in manufacturing or continuing to develop our products,
and could materially damage our reputation, our brand, our international expansion efforts, our ability to attract and retain employees,
and our business, prospects, operating results, and financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Employees</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of June 30, 2025, we had 29
full-time employees. The Company has streamlined the organization to focus on its oncology therapeutic vaccine and artificial intelligence
driven healthcare technology. The Company has tailored its workforce to focus on these therapies and technology. We believe that we have
good relations with our employees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Corporate Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">On February 13, 2024, Lunai Bioworks Inc. acquired
Renovaro Cube Intl Ltd and its subsidiaries (&#8220;Renovaro Cube&#8221;), as a wholly owned subsidiary pursuant to a stock purchase agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">On April 8, 2025 Lunai Bioworks Inc. acquired BioSymetrics
Inc. and its subsidiary BioSymetrics Corp., as a wholly owned subsidiary pursuant to a stock purchase agreement. The merger with BioSymetrics
is designed to enhance Lunai&#8217;s data repository and biomarker discovery capabilities, as well as add in vivo validation and drug
discovery to Lunai&#8217;s AI powered biomarker and diagnostic platform.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We trade on the NASDAQ Capital
Market under the ticker &#8220;RENB.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our website is http://www.renovarogroup.com.
We make available free of charge, on or through our website, our annual, quarterly, and current reports and any amendments to those reports
filed or furnished pursuant to Section 13(a) of the Exchange Act as soon as reasonably practicable after we electronically file such material
with, or furnish it to, the SEC. Information contained in our website is not part of, nor incorporated by reference into, this report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_003"></span>Item 1A. Risk Factors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>RISK FACTORS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Risk Factor Summary</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following is a summary of the risks and uncertainties
that could cause our business, financial condition or operating results to be harmed. We encourage you to carefully review the full risk
factors contained in this report in their entirety for additional information regarding these risks and uncertainties. These risk factors
should be considered applicable across all subsidiaries.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">We have incurred substantial losses since our inception and anticipate that we will continue to incur substantial and increasing losses for the foreseeable future.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">There is substantial doubt about our ability to continue as a going concern, which may hinder our ability to obtain future financing.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our product development or commercialization efforts. Similarly, we have submitted multiple applications for non-dilutive (i.e., grant) funding from sources both in the US and Canada, and while we do not necessarily depend on the success of these applications to sustain operations, changing government policy may alter our capacity to obtain these grants, which may result in changes to company strategy.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 23 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Raising additional capital may cause dilution to our existing stockholders or restrict our operations.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">From time to time, we may be subject to legal proceedings, regulatory investigations or disputes, and governmental inquiries that could cause us to incur significant expenses, divert our management&#8217;s attention, and materially harm our business, financial condition, and operating results.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Negative publicity has had and may continue to have a negative impact on our business and may have a long-term effect on our relationships with our customers, partners and collaborators.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Lunai Bioworks is a pre-clinical biotechnology company and may never be able to successfully develop marketable products or generate any revenue. We have a very limited relevant operating history upon which an evaluation of our performance and prospects can be made. There is no assurance that our future operations will result in profits. If we cannot generate sufficient revenues, we may suspend or cease operations.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The market for artificial intelligence -based (&#8220;AI&#8221;) healthcare solutions is new and unproven and may decline or experience limited growth, and concerns over the use of AI may hinder the adoption of AI technologies.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Regulators and legislators may limit our ability to develop or implement our AI algorithms and may eliminate or restrict the confidentiality of our proprietary technology, which could have an adverse effect on our business, results of operations, reputation, and financial condition. Similarly, while yet there is no substantial regulation influencing the adoption and inclusion of large language models (LLMs) as part of a commercial offering, that may be subject to change, resulting in alterations to our platform offering and/or company productivity.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The results of pre-clinical studies or earlier clinical studies are not necessarily predictive of future results, and if we fail to demonstrate efficacy in our pre-clinical studies and/or clinical trials in the future our future business prospects, financial condition and operating results will be materially adversely affected.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Our reliance on third parties, such as university laboratories, contract manufacturing organizations and contract or clinical research organizations, may result in delays in completing, or a failure to complete, non-clinical testing or clinical trials if they fail to perform under our agreements with them.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">We have limited experience in drug development and may not be able to successfully develop any drugs, which would cause us to cease our therapeutic development activities.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">We have licensed a portion of our intellectual property from our licensors. If we breach any of our license agreements with these licensors, or otherwise experience disruptions to our business relationships with our licensors, we could lose intellectual property rights that are important to our business.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">If we are unable to obtain and maintain sufficient intellectual property protection for our product candidates, or if the scope of the intellectual property protection is not sufficiently broad, our ability to commercialize our product candidates successfully and to compete effectively may be adversely affected</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Third-party claims of intellectual property infringement
may prevent or delay our development and commercialization efforts.</p></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">We use AI in our business, and challenges relating to the development and use of AI, including generative AI, could result in competitive harm, reputational harm, and legal liability, and adversely affect our results of operations.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">We have limited corporate infrastructure and may experience difficulties in managing growth.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">We have experienced and may continue to experience significant turnover in our management and executive leadership, which creates uncertainty and could harm our ability to operate our business effectively.</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If serious adverse events or other undesirable
side effects or safety concerns attributable to our product candidates occur, they may adversely affect or delay our clinical development
and commercialization of some or all of our product candidates.</p></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Our stock price has been and will likely continue to be volatile and may decline regardless of our operating performance.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Sales of a substantial number of shares of our Common Stock in the public market could cause our stock price to fall.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Future sales and issuances of our Common Stock or rights to purchase Common Stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Investing in our Common Stock involves a high degree
of risk. Investors should carefully consider all of the risk factors and uncertainties described below, in addition to the other information
contained in this Annual Report on Form 10-K, including the section of this report titled &#8220;Management&#8217;s Discussion and Analysis
of Financial Condition and Results of Operations&#8221; and our consolidated financial statements and related notes, before investing
in our Common Stock. </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>The risks described below may not be the only ones
relating to our Company and additional risks that we currently believe are immaterial may also affect us. If any of these risks, including
those described below, materialize, our business, competitive position, reputation, financial condition, results of operations, cash flows
and future prospects could be seriously harmed. In these circumstances, the market price of our Common Stock could decline, and investors
may lose all or a part of their investment.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Risks Related to Our Financial Position and Capital
Requirements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>We have incurred substantial
losses since our inception and anticipate that we will continue to incur substantial and increasing losses for the foreseeable future.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Lunai is a pre-clinical-stage
biotechnology company and AI-driven healthcare technology company. Investment in biotechnology related to genetically modified cells is
highly speculative because it entails substantial upfront capital expenditures and significant risk that a product candidate will fail
to prove effective, gain regulatory approval or become commercially viable. We do not have any products approved by regulatory authorities
and have not generated any revenues from product sales or otherwise to date, and have incurred significant research, development and other
expenses related to our ongoing operations and expect to continue to incur such expenses. As a result, we have not been profitable and
have incurred significant operating losses in every reporting period since our inception. For the years ended June 30, 2025, and 2024,
respectively, we reported a net loss of $178,007,489 and $88,425,828. We had an accumulated deficit of $510 million and $332 million as
of June 30, 2025 and 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We do not expect to generate revenues
for the foreseeable future. We expect to continue to incur significant expenses and operating losses for the foreseeable future. We anticipate
these losses to increase as we continue to research, develop, and seek regulatory approvals for our product candidates and any additional
product candidates we may acquire, in-license or develop, and potentially begin to commercialize product candidates that may achieve regulatory
approval. We may encounter unforeseen expenses, difficulties, complications, delays, and other unknown factors that may adversely affect
our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to
generate revenues. If any of our product candidates fails in clinical studies or does not gain regulatory approval, or if approved, fails
to achieve market acceptance, we may never become profitable. Even if we achieve profitability in the future, we may not be able to sustain
profitability in subsequent periods. We anticipate that our expenses will increase in the future as we continue to invest in research
and development of our existing product candidates, investigate and potentially acquire new product candidates and expand our manufacturing
and commercialization activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 25 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;<b><i>There is substantial
doubt about our ability to continue as a going concern, which may hinder our ability to obtain future financing.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our consolidated financial statements
as of June 30, 2025, have been prepared under the assumption that we will continue as a going concern for the next twelve months. As of
June 30, 2025, we had cash and cash equivalents of $92,700 and an accumulated deficit of $510 million. We do not believe that our cash
and cash equivalents are sufficient for the next twelve months. As a result of our financial condition and other factors described herein,
there is substantial doubt about our ability to continue as a going concern. Our ability to continue as a going concern will depend on
our ability to obtain additional funding, as to which no assurances can be given. We continue to analyze various alternatives, including
potentially obtaining debt or equity financings or other arrangements. Our future success depends on our ability to raise capital. We
cannot be certain that raising additional capital, whether through selling additional debt or equity securities or obtaining a line of
credit or other loan, will be available to us or, if available, will be on terms acceptable to us. If we issue additional securities to
raise funds, these securities may have rights, preferences, or privileges senior to those of our Common Stock, and our current shareholders
may experience dilution. If we are unable to obtain funds when needed or on acceptable terms, we may be required to curtail our current
development programs, cut operating costs, forgo future development and other opportunities, or even terminate our operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>We will require substantial
additional financing to achieve our goals, and a failure to obtain this necessary capital when needed could force us to delay, limit,
reduce or terminate our product development or commercialization efforts.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We expect to expend substantial
resources for the foreseeable future to continue the pre-clinical development of our cell, gene and immunotherapy product candidates,
and the advancement and potential expansion of our pre-clinical research pipeline. We also expect to continue to expend resources for
the development and manufacturing of product candidates and the technology we have licensed or have a right to license from our licensors.&#160;These
expenditures will include costs associated with research and development, potentially acquiring or licensing new product candidates or
technologies, conducting pre-clinical and clinical studies and potentially obtaining regulatory approvals and manufacturing products,
as well as marketing and selling products approved for sale, if any. Under the terms of certain of our license agreements, we are obligated
to make payments upon the achievement of certain development, regulatory and commercial milestones.&#160;We will also need to make significant
expenditures to develop a commercial organization capable of sales, marketing, and distribution for any products, if any, that we intend
to sell ourselves in the markets in which we choose to commercialize on our own. In addition, other unanticipated costs may arise. Because
the design and outcome of our ongoing, planned and anticipated pre-clinical and clinical studies is highly uncertain, we cannot reasonably
estimate the actual amounts necessary to successfully complete the development and commercialization of our product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our future capital requirements
depend on many factors, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 20px; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; width: 20px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the costs and payments associated with license agreements for our potential products and technologies;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the costs of conducting pre-clinical and clinical studies and the costs of manufacturing our product candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the timing of, and the costs involved in, obtaining regulatory approvals for our product candidates, if clinical studies are successful, including any costs from post-market requirements;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the cost of commercialization activities for our product candidates, if any of these product candidates is approved for sale, including marketing, sales and distribution costs;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our ability to establish and maintain strategic licensing or other arrangements and the financial terms of such agreements;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the costs involved in preparing, filing, prosecuting, maintaining, expanding, defending and enforcing patent claims, including litigation costs and the outcome of such litigation; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the timing, receipt and amount of sales of, or royalties on, our future products, if any.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 26 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Additional funds may not be available
when we need them on terms that are acceptable to us, or at all. If adequate funds are not available to us on a timely basis, we may be
required to delay, limit, reduce or terminate preclinical studies, clinical studies, or other development activities for one or more of
our product candidates or delay, limit, reduce or terminate our establishment of sales, marketing and distribution capabilities or other
activities that may be necessary to commercialize our product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Raising additional capital
may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies. </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Until such time as we can generate
substantial product revenues, we may attempt to finance our cash needs through equity offerings, debt financings, government and/or other
third-party grants or other third-party funding, marketing and distribution arrangements and other collaborations, strategic alliances,
and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities,
our investors&#8217; ownership interest will be diluted. Debt financing, if available, may involve agreements that include covenants limiting
or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.
If we are unable to obtain funding on a timely basis, we may be required to significantly curtail one or more clinical research or development
programs, which would adversely impact our potential revenues, future results of operations and financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>From time to time, we may
be subject to legal proceedings, regulatory investigations or disputes, and governmental inquiries that could cause us to incur significant
expenses, divert our management&#8217;s attention, and materially harm our business, financial condition, and operating results.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">From time to time, we may be subject
to claims, lawsuits, government investigations, and other proceedings involving intellectual property, privacy, securities, tax, labor
and employment, and other matters that could adversely affect our business operations and financial condition. Recently, we have seen
a rise in the number and significance of these disputes and inquiries. The arrest, indictment and conviction of Serhat G&#252;mr&#252;kc&#252;,
a co-founder of the Company, has, and could in the future, subject us to regulatory proceedings and litigation by governance agencies
and private litigants brought against us, that regardless of their merits, could harm our reputation, divert management&#8217;s attention
from our operations and result in substantial legal fees and other costs. Additionally, we have in the past been subject to intense media
scrutiny, which exposes us to increasing regulation, government investigations, legal actions, and penalties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have also been named in several
lawsuits related to Mr. G&#252;mr&#252;kc&#252;. For example, the Company and certain of its current and former officers have been named
in securities class actions by purported stockholders of ours, alleging defendants violated Sections 10(b) and 20(a) of the Securities
Exchange Act of 1934, as amended, and Rule 10b-5 thereunder, by making false and misleading statements and omissions of material fact
in connection with the Company&#8217;s relationship with Mr. G&#252;mr&#252;kc&#252; and its commercial prospects. In addition, two stockholders
filed stockholder&#160;derivative&#160;action lawsuits purportedly on behalf of the Company against certain of our executive officers
and the members of our Board of Directors alleging violations of Sections 14(a) and 20(a) of the Securities Exchange Act of 1934 and also
setting out claims for breach of fiduciary duty, contribution and indemnification, aiding and abetting, and gross mismanagement. Additionally,
from time to time, we may be, and currently are, subject to inquiries from regulators in which they seek information about us. Such further
inquiries could result in more formal investigations or allegations, which could adversely impact our business, financial condition, and
operating results.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Litigation, regulatory proceedings,
such as the investigations described above, as well as the related class action claims and lawsuits, and securities matters that we are
currently facing or could face, can be protracted and expensive, and have results that are difficult to predict. Certain of these matters
include speculative claims for substantial or indeterminate amounts of damages and include claims for injunctive relief. Additionally,
our legal costs for any of these matters, either alone or in the aggregate, could be significant. Adverse outcomes with respect to any
of these legal or regulatory proceedings may result in significant settlement costs or judgments, penalties, and fines. Even if these
proceedings are resolved in our favor, the time and resources necessary to resolve them could divert the resources of our management and
require significant expenditures. See&#160;<i>Note 11 - Commitments and Contingencies</i>&#160;in the Notes to our Consolidated Financial
Statements in Part II, Item 8 of this Annual Report on Form 10-K and the section titled &#8220;Legal Proceedings&#8221; in Part I, Item
3 of this Annual Report on Form 10-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 27 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The results of litigation, investigations,
claims, and regulatory proceedings cannot be predicted with certainty, and determining reserves for pending litigation and other legal
and regulatory matters requires significant judgment. There can be no assurance that our expectations will prove correct, and even if
these matters are resolved in our favor or without significant cash settlements, these matters, and the time and resources necessary to
litigate or resolve them, could harm our business, financial condition, and operating results.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Negative publicity has had
and may continue to have a negative impact on our business and may have a long-term effect on our relationships with our customers, partners
and collaborators.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our business and reputation have
been negatively affected by negative publicity resulting from the arrest, indictment and conviction of Serhat G&#252;mr&#252;kc&#252;,
a co-founder of the Company and an inventor of some of the Company&#8217;s intellectual property. If we are unable to rebuild the trust
of our collaborators, research institutions and investors, and if further negative publicity continues, we could experience a substantial
negative impact on our business. We have experienced claims and litigation as a consequence of these matters, including stockholder class
actions in connection with a decline in our stock price and litigation with Mr. G&#252;mr&#252;kc&#252;. Related legal expenses of defending
these claims have negatively impacted our operating results. Continuing higher legal fees, potential new claims, liabilities from existing
cases and continuing negative publicity could continue to have a negative impact on our operating results.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Risks Related to Our Limited Operating History</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Lunai Bioworks is a pre-clinical
biotechnology company and may never be able to successfully develop marketable products or generate any revenue. We have a very limited
relevant operating history upon which an evaluation of our performance and prospects can be made. There is no assurance that our future
operations will result in profits. If we cannot generate sufficient revenues, we may suspend or cease operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Lunai Bioworks is an early-stage
biotechnology company and has not generated any revenues to date. All of our product candidates are in the discovery stage or pre-clinical
development stage. Moreover, we cannot be certain that our research and development efforts will be successful or, if successful, that
our potential treatments will ever be approved for sale to generate commercial revenues. Our therapeutic pipeline includes cell, gene
and immunotherapy involving genetically modified cells targeted to treat cancer, and we rely on third parties under contract in the development
of product candidates in our pipeline. There is no guarantee that we will be able to manage and fund the development of a pipeline with
multiple target conditions, nor that third parties will meet their obligations to us in connection with our research and development.
We and certain third parties, on which we rely, have no relevant operating history upon which an evaluation of our performance and prospects
can be made. We are subject to all of the business risks associated with a new enterprise, including, but not limited to, risks of unforeseen
capital requirements, failure of treatments either in non-clinical testing or in clinical trials, failure to establish business relationships,
failure of our third parties to meet their obligations to us and competitive disadvantages against larger and more established companies.
If we fail to become profitable, we may suspend or cease operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>Renovaro
Cube and BioSymetrics are artificial intelligence (&#8220;AI&#8221;)-driven healthcare technology companies operating in a rapidly evolving
field with a limited operating history, which makes it difficult to evaluate their current business and predict Renovaro Cube&#8217;s
future performance.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Renovaro
Cube and BioSymetrics are AI-driven healthcare technology companies operating in a rapidly evolving field and, having commenced operations
in&#160;2013 and 2017, respectively, have a limited operating history. Renovaro Cube shifted its business from the financial technology
(or FinTech) industry to cancer diagnostics in 2018 and does not have a commercial product for sale. It has never generated any revenue
relating to its cancer diagnostics AI platform. Renovaro Cube&#8217;s short operating history makes any assessment of its current business
or future success and viability subject to significant uncertainty. BioSymetrics does have a history of deployment of a commercial AI-based
biotechnology platform and has had previous revenue generation, however the same risk regarding future performance applies. We expect
to encounter risks and difficulties, including those frequently experienced by&#160;early-stage&#160;companies in rapidly evolving fields.
If we do not address these risks and difficulties successfully, our business will suffer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"></p>

<!-- Field: Page; Sequence: 28 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>Renovaro
Cube and BioSymetrics have a history of net losses and anticipates that they may continue to incur net losses for the foreseeable future.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Grace
Systems (Renovaro Cube&#8217;s predecessor) has primarily incurred net losses since its inception in 2013 and has never generated any
revenue relating to its cancer diagnostics AI platform. Renovaro Cube anticipates that it may continue to incur primarily net losses in
the foreseeable future. Similarly, while BioSymetrics has a history of revenue generation since its inception in 2017, these revenues
have been inconsistent. Both Renovaro Cube and BioSymetrics have invested significant financial resources in research and development
activities, including to develop their technologies and investigational products. The amount of each company&#8217;s future net losses
will depend, in part, on the level of future expenditures and their ability to generate revenue following the commercialization of their
AI platform. Moreover, net losses may fluctuate significantly from quarter to quarter and year to year, such that a&#160;period-to-period&#160;comparison
of results of operations may not be a good indication of future performance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Renovaro
Cube and BioSymetrics expect to continue to incur significant expenses and operating losses for the foreseeable future if, and as, they:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr>
    <td style="width: 48px">&#160;</td>
    <td style="vertical-align: top; width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">attract, hire, and retain qualified personnel;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">continue their research and development activities;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">initiate and conduct additional clinical validation to support the development and commercialization of products;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">expands their technological and operating capabilities and introduce laboratory capacity;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">seek regulatory approvals and any other marketing authorizations or clearances that may be necessary or desired for their products;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">establish sales, marketing and distribution infrastructure to commercialize products;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">acquire or&#160;in-license&#160;additional intellectual property and technologies;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">make milestone, royalty, or other payments due under any license or collaboration agreements;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">obtain, maintain, protect and enforce their intellectual property portfolio, including intellectual property obtained through license agreements;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">provide additional infrastructure to support continued research and development operations and any planned commercialization efforts in the future;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">as part of the combined company, meets the requirements and demands of being a public company; and</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">defends against any product liability claims or other lawsuits related to its products.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>Renovaro
Cube has never generated revenue from its cancer diagnostics AI platform, and does not expect any&#160;near-term&#160;revenue to offset
Renovaro Cube&#8217;s ongoing operating expenses, and may never be able to maintain profitability.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Renovaro
Cube&#8217;s ability to generate revenue from product sales and maintain profitability in the future depends on its ability to commercialize
its products. Renovaro Cube cannot be certain that it will be able to do so successfully as planned, if at all, and Renovaro Cube&#8217;s
failure to do so would prevent Renovaro Cube from generating revenue. Furthermore, even if Renovaro Cube is able to launch its AI platform
or other products in a timely manner, Renovaro Cube may not be able to generate sufficient revenue to offset its costs and maintain profitability.
Renovaro Cube&#8217;s ability to generate future revenue from product sales depends heavily on its success in:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"></p>

<!-- Field: Page; Sequence: 29 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr>
    <td style="width: 48px">&#160;</td>
    <td style="vertical-align: top; width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">completing clinical development and additional validation of Renovaro Cube&#8217;s products and continuing to improve product performance and expand product features over time;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">seeking, obtaining and maintaining marketing approvals, clearances, licenses, or exemptions that may be necessary or desired for any future products that Renovaro Cube develops;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">establishing a sales force, marketing, medical affairs and distribution infrastructure or, alternatively, collaborating with a commercialization partner sufficient to launch and commercialize its products;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">obtaining market acceptance by consumers, including&#160;self-insured&#160;employers, integrated health systems, healthcare providers, patients and&#160;third-party&#160;payors;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr>
    <td style="width: 48px">&#160;</td>
    <td style="vertical-align: top; width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">establishing and maintaining supply and manufacturing relationships with third parties that can timely and consistently provide adequate, in both amount and quality, products and services to support clinical development and the market demand for Renovaro Cube&#8217;s future products;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">achieving adequate coverage or reimbursement recognition from governments, health insurance organizations and other&#160;third-party&#160;payors for products that Renovaro Cube launches;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">addressing any technological and market developments, including competing products;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">negotiating favorable terms in any collaboration, licensing, or other arrangements into which Renovaro Cube may enter, and maintaining such existing or future arrangements;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">achieving general adoption and acceptance of Renovaro Cube&#8217;s products by the medical community;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">maintaining, protecting and expanding Renovaro Cube&#8217;s portfolio of intellectual property rights, including patents, trade secrets,&#160;know-how&#160;and trademarks;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">defending against&#160;third-party&#160;interference or infringement claims, if any; and</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">attracting, hiring and retaining qualified personnel.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Renovaro
Cube anticipates incurring substantial costs to commercialize Renovaro Cube&#8217;s products. Renovaro Cube&#8217;s expenses could increase
beyond expectations if it is required by the U.S. Food and Drug Administration (the &#8220;FDA&#8221;), the European Medicines Agency
(the &#8220;EMA&#8221;), the Medicines and Healthcare products Regulatory Agency (&#8220;MHRA&#8221;) or other regulatory agencies to
delay its launch, narrow or change its intended use or product claims, modify or expand its clinical validation, perform future additional
clinical validation, either&#160;pre-&#160;or&#160;post-approval, or conduct clinical trials. Even if Renovaro Cube is able to generate
revenue from the sale of any products, Renovaro Cube may not become profitable and may need to continue to obtain additional funding to
continue its operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>Even
if we commercially launch Renovaro Cube&#8217;s or BioSymetrics&#8217; AI platforms and other products, they may fail to achieve the degree
of market acceptance necessary for commercial success.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The commercial
success of Renovaro Cube&#8217;s or BioSymetrics&#8217; AI platform and other future products will depend upon the degree of market acceptance
by consumers, including&#160;self-insured&#160;employers, integrated health systems, healthcare providers, patients and, over the&#160;long-term,&#160;third-party&#160;payors.
The degree of market acceptance of these products will depend on a number of factors, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr>
    <td style="width: 48px">&#160;</td>
    <td style="vertical-align: top; width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">the performance and clinical utility of its products as demonstrated in clinical validation and published in&#160;peer-reviewed&#160;journals;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">Renovaro Cube&#8217;s and BioSymetrics&#8217; ability to demonstrate the clinical utility of its products and their potential advantages to the medical community;</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 30 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr>
    <td style="width: 48px">&#160;</td>
    <td style="vertical-align: top; text-align: justify; width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">the ability of Renovaro Cube&#8217;s and BioSymetrics&#8217; products to demonstrate the same performance in&#160;real-world&#160;intended use populations as in clinical validation;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">the willingness of consumers, including&#160;self-insured&#160;employers, integrated health systems, healthcare providers, patients and others in the medical community to utilize Renovaro Cube&#8217;s and BioSymetrics&#8217; products;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">the willingness of commercial&#160;third-party&#160;payors and government payors to cover and reimburse for Renovaro Cube&#8217;s or BioSymetrics&#8217; products, the scope and amount of which will likely affect an individual&#8217;s willingness or ability to pay for these products and likely heavily influence healthcare providers&#8217; decisions to recommend these products;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr>
    <td style="width: 48px">&#160;</td>
    <td style="vertical-align: top; width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">with respect to products under development that Renovaro Cube or BioSymetrics intends to launch for use in a broad asymptomatic population, the concern that such products could lead to&#160;over-diagnosis&#160;or a high&#160;false-positive&#160;rate and unnecessary medical procedures and costs;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">the introduction of competing products, including the expansion of the capabilities of existing products;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">the market acceptance of existing competitive products, including tests that are currently reimbursed;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">publicity concerning Renovaro Cube&#8217;s or BioSymetrics&#8217; products or competing products; and</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">the strength of Renovaro Cube&#8217;s and BioSymetrics&#8217; marketing and distribution support.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The failure
of Renovaro Cube&#8217;s or BioSymetrics&#8217; AI platform, once introduced, to be listed in physician guidelines or any future clinical
validation to produce favorable results or to be published in&#160;peer-reviewed&#160;journals could limit the adoption of its AI platform.
In addition, healthcare providers and&#160;third-party&#160;payors, including Medicare, may rely on physician guidelines issued by industry
groups, medical societies and other key organizations, such as the U.S. Preventive Services Task Force, before utilizing or reimbursing
the cost of any diagnostic or screening test. Although Renovaro Cube has conducted prior clinical validation of its AI platform, this
platform is not yet, and may never be, listed in any such guidelines.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Further,
if Renovaro Cube&#8217;s or BioSymetrics&#8217; products and the technology underlying them do not receive sufficient favorable exposure
in&#160;peer-reviewed&#160;publications, the rate of physician and market acceptance of these products and positive reimbursement or coverage
decisions for these products could be negatively affected. The publication of clinical data in&#160;peer-reviewed&#160;journals is a crucial
step in commercializing and obtaining reimbursement or coverage for Renovaro Cube&#8217;s or BioSymetrics&#8217; products, and Renovaro
Cube&#8217;s and BioSymetrics&#8217; inability to control when, if ever, results are published may delay or limit our ability to derive
sufficient revenues from any of its products that are developed using data from a clinical study.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Failure
to achieve broad market acceptance of Renovaro Cube&#8217;s or BioSymetrics&#8217; products, once launched, would materially harm Renovaro
Cube&#8217;s and BioSymetrics&#8217; business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>Renovaro
Cube and BioSymetrics may be unable to develop and commercialize new products.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Renovaro
Cube and BioSymetrics continue to expand their research and development efforts to use their proprietary AI platforms to develop new products,
including in disease areas beyond cancer and neurology. The commercialization of any new products will require the completion of certain
clinical development activities, regulatory activities and the expenditure of additional cash resources. Renovaro Cube and BioSymetrics
cannot assure you that it can successfully complete the clinical development of any such products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Renovaro
Cube and BioSymetrics also cannot assure you that they will be able to reduce their expenditures sufficiently, generate sufficient revenue
from products that they successfully commercialize or otherwise mitigate the risks associated with their business to raise enough capital
to develop and commercialize new products. In addition, once Renovaro Cube&#8217;s and BioSymetrics&#8217; development efforts for a product
are completed, commercialization efforts, including allocation of resources necessary to comply with applicable laws and regulations,
will require significant expenditures. Any failure by Renovaro Cube or BioSymetrics to develop and commercialize new products could have
a material adverse effect on their ability to implement their strategy and grow their business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"></p>

<!-- Field: Page; Sequence: 31 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>One
of the key elements of Renovaro Cube&#8217;s strategy is to expand access to its tests by pursuing reimbursement and/or coverage from&#160;third-party&#160;payors.
If Renovaro Cube&#8217;s products do not receive adequate coverage or reimbursement from&#160;third-party&#160;payors, its ability to
expand access to its tests beyond its initial sales channels and its overall commercial success will be limited.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Renovaro
Cube anticipates that it will not have&#160;broad-based&#160;coverage or reimbursement at the initial commercial launch. However, a key
element to Renovaro Cube&#8217;s strategy is to expand access to its tests by pursuing coverage and/or reimbursement by&#160;third-party&#160;payors,
including government payors. Coverage and reimbursement by&#160;third-party&#160;payors, including managed care organizations, private
health insurers and government healthcare programs, such as Medicare and Medicaid in the United States and similar programs in other countries,
for the types of early detection and post-diagnosis service tests that Renovaro Cube provides can be limited and uncertain. Healthcare
providers may not order Renovaro Cube&#8217;s products unless&#160;third-party&#160;payors cover or provide adequate reimbursement for
a substantial portion of the price of Renovaro Cube&#8217;s products. If Renovaro Cube is not able to obtain adequate coverage or an acceptable
level of reimbursement for its products from&#160;third-party&#160;payors, there could be a greater&#160;co-insurance&#160;or&#160;co-payment&#160;obligation
for any individual for whom a test is ordered. The individual may be forced to pay the entire cost of a test&#160;out-of-pocket,&#160;which
could dissuade physicians from ordering Renovaro Cube&#8217;s products and, if ordered, could result in delay in, or decreased likelihood
of, Renovaro Cube&#8217;s collection of payment. Renovaro Cube believes its revenue and revenue growth will depend on its success in achieving
broad coverage and adequate reimbursement for its products from&#160;third-party&#160;payors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Coverage
and reimbursement by a&#160;third-party&#160;payor may depend on a number of factors, including a payor&#8217;s determination that a product
is appropriate, medically necessary and&#160;cost-effective.&#160;Each payor will make its own decision as to whether to establish a policy
or enter into a contract to cover Renovaro Cube&#8217;s products and the amount it will reimburse for such products. Any determination
by a payor to cover and the amount it will reimburse for Renovaro Cube&#8217;s products would likely be made on an&#160;indication-by-indication&#160;basis.
For example, because Renovaro Cube intends to cover a broad asymptomatic population with its future products which could potentially generate
a significant number of&#160;false-positive&#160;results on an absolute basis, Renovaro Cube may face additional scrutiny in obtaining
reimbursement from&#160;third-party&#160;payors given the additional costs of further diagnostic workup. As a result, obtaining approvals
from&#160;third-party&#160;payors to cover Renovaro Cube&#8217;s products and establishing adequate coding recognition and reimbursement
levels is an unpredictable, challenging,&#160;time-consuming&#160;and costly process and Renovaro Cube may never be successful. If&#160;third-party&#160;payors
do not provide adequate coverage or reimbursement for Renovaro Cube&#8217;s products, Renovaro Cube&#8217;s ability to succeed commercially
will be limited.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Even
if Renovaro Cube establishes relationships with payors to provide its products at negotiated rates, such agreements would not obligate
any healthcare providers to order its products or guarantee that it would receive reimbursement for its products from these or any other
payors at adequate levels. Thus, these payor relationships, or any similar relationships, may not result in acceptable levels of coverage
or reimbursement for Renovaro Cube&#8217;s products or meaningful increases in the number of billable tests it sells to healthcare providers.
Renovaro Cube believes it may take several years to achieve coverage or adequate reimbursement with a majority of&#160;third-party&#160;payors,
including with those payors offering negotiated rates. In addition, Renovaro Cube cannot predict whether, under what circumstances, or
at what payment levels payors will cover or reimburse for its products. If Renovaro Cube fails to establish and maintain&#160;broad-based&#160;coverage
or reimbursement for its products, its ability to expand access to its products, generate increased revenue and grow its test volume and
customer base will be limited and its overall commercial success will be limited.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>If
Renovaro Cube&#8217;s or BioSymetrics&#8217; products, or the products of its competitors, directly or indirectly result in harm or injury
to patients, Renovaro Cube or BioSymetrics could be subject to significant reputational and liability risks, and its operating results,
reputation and business could suffer.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Renovaro
Cube&#8217;s and BioSymetrics&#8217; success will depend on the market&#8217;s confidence that their developed products can provide reliable,&#160;high-quality&#160;results,
once such products are launched. Renovaro Cube and BioSymetrics believe that patients, physicians and regulators are likely to be particularly
sensitive to errors in the use of their products or failure of their products to perform as described, and there can be no guarantee that
their products will meet expectations. Renovaro Cube&#8217;s initial product is intended to be used to detect a cancer signal in patients,
but its results are not diagnostic. If a cancer signal is detected, the product would be used to localize the origin of the cancer signal.
A &#8220;cancer signal detected&#8221; test result would need to be followed up by appropriate diagnostic methods. Because this product
cannot detect all cancer signals, and may not detect signals for all cancer types,</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"></p>

<!-- Field: Page; Sequence: 32 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white">a negative test would not rule out the presence of
cancer. Additionally, a patient undergoing unnecessary diagnostic tests on the basis of a&#160;false-positive&#160;result or an erroneous
location of cancer signal result could expose Renovaro Cube to significant liability and reputational risks notwithstanding the emotional
and mental health effects to which the patient may be exposed. Similarly, a patient who receives a cancer diagnosis shortly following
a &#8220;no cancer signal detected&#8221; test result may create negative publicity about Renovaro Cube&#8217;s product, which would discourage
adoption. Performance failures could establish a negative perception of Renovaro Cube&#8217;s products among physicians, patients and
regulators, jeopardize Renovaro Cube&#8217;s ability to successfully commercialize its products, impair Renovaro Cube&#8217;s ability
to obtain regulatory approvals or secure favorable coverage or reimbursement, or otherwise result in reputational harm. In addition, Renovaro
Cube may be subject to legal claims arising from any errors in the use, manufacture, design, labelling or performance of its products,
including any&#160;false-positive&#160;or&#160;false-negative&#160;results.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">In addition,
other companies are developing competing cancer detection tests and technologies focused on improving cancer care with cancer detection
tests and&#160;post-diagnostic&#160;products. If any tests marketed or being developed by Renovaro Cube&#8217;s competitors that are similar
to its products do not perform in accordance with expectations or cause harm or injury to patients, such failure to perform, harm or injury
may result in lower confidence in early disease detection and&#160;post-diagnosis&#160;tests in general, which could potentially adversely
affect confidence in Renovaro Cube&#8217;s products and result in an adverse impact on its operating results and reputation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">BioSymetrics
does not currently have a similar diagnostic product, but if developing a similar product the same risks would apply.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>If Renovaro Cube&#8217;s
or BioSymetrics&#8217; facilities or those of its&#160;third-party&#160;collaborators become inoperable, their ability to provide its
products will be significantly impaired and its business will be harmed.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Renovaro
Cube and BioSymetrics rely on&#160;third-party&#160;collaborators, consultants, contractors, vendors, suppliers and service providers.
The facilities of these partners could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods,
tornadoes, hurricanes, fires, extreme weather conditions, medical epidemics, pandemics, global conflict, war and other natural or&#160;man-made&#160;disasters
or business interruptions. In addition, they may be affected by government shutdowns, changes to applicable laws, regulations and policies,
or withdrawn funding. The occurrence of any of these business disruptions could seriously harm their ability to complete their contracted
services to Renovaro Cube or BioSymetrics, which may adversely impact their operations and financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>Renovaro
Cube&#8217;s and BioSymetrics&#8217; business and results of operations will suffer if it fails to compete effectively.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The testing
and diagnostic products industry is intensely competitive. Renovaro Cube has competitors both in Europe and abroad, including Grail, Inc.,
Exact Sciences Corporation, Freenome, Inc. and Thrive Earlier Detection Corp., that have stated that they are developing tests designed
to detect cancer. Similarly, there are companies with comparable and possibly competing offerings to BioSymetrics, including Recursion
Pharma, insitro, and In Silico Medicine. Each of these potential competitors have, or may have, substantially greater financial, technical
and other resources, such as larger research and development staff and&#160;well-established&#160;marketing and sales forces, and they
may operate in jurisdictions where lower standards of evidence are required to bring products to market. These competitors may succeed
in developing, acquiring, or licensing, on an exclusive basis or otherwise, tests or services that are more effective or less costly than
Renovaro Cube&#8217;s or BioSymetrics&#8217; products. In addition, established medical technology, biotechnology, or pharmaceutical companies
may invest heavily to accelerate the discovery and development of tests that could make Renovaro Cube&#8217;s or BioSymetrics&#8217; products
less competitive than Renovaro anticipated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Renovaro
Cube&#8217;s and BioSymetrics&#8217; ability to compete successfully will depend largely on the ability of each to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr>
    <td style="width: 48px">&#160;</td>
    <td style="vertical-align: top; width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">successfully commercialize its products;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">demonstrate compelling advantages in the performance and convenience of its products, including on a cost-competitive basis;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">achieve market acceptance of its products by consumers, including&#160;self-insured&#160;employers, integrated health systems, healthcare providers and patients;</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 33 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr>
    <td style="width: 48px">&#160;</td>
    <td style="vertical-align: top; text-align: justify; width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">achieve adequate coverage or reimbursement by&#160;third-party&#160;payors for its products;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">differentiate its product from the other tests and products of current and potential competitors;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">attract qualified scientific, data science, clinical development, product development and commercial personnel;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">obtain, maintain, defend and enforce patents and other intellectual property rights and claims as necessary for its products;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">obtain and maintain any necessary or desirable clearance or approval from regulators in Europe, the United Kingdom, the United States and other jurisdictions;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">successfully collaborate with institutions in the discovery, development and commercialization of its products; and</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">successfully expand its operations and implement a successful sales and marketing strategy to support commercialization.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Renovaro
Cube and BioSymetrics may not be able to compete effectively if they are unable to accomplish one or more of these or similar objectives.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>If
Renovaro Cube or BioSymetrics cannot enter new collaborations in a timely manner and on acceptable terms, their efforts to develop and
commercialize their products could be delayed or adversely affected.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">From
time to time, Renovaro Cube and BioSymetrics expect to engage in discussions with potential development and/or commercial collaborators
that may or may not lead to collaborations. However, Renovaro Cube and BioSymetrics cannot guarantee that any discussions will result
in development or commercial collaborations. Further, once news of discussions regarding possible collaborations are known in the general
public, regardless of whether the news is accurate, failure to announce a collaboration agreement, or the entity&#8217;s announcement
of a collaboration with an entity other than Renovaro Cube or BioSymetrics, could result in adverse speculation about either, their products
or technology, resulting in harm to their reputation and business. In addition, establishing collaborations is difficult and&#160;time-consuming&#160;and
may require significant financial investment. Potential collaborators may elect not to work with Renovaro Cube or BioSymetrics based on
their assessment of their financial, regulatory, or intellectual property position. Even if Renovaro Cube or BioSymetrics establishes
new collaborations, they may not result in the successful development or commercialization of their products or technology.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>If
Renovaro Cube or BioSymetrics is unable to establish sales and marketing capabilities, they may not be successful in commercializing their
products.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Renovaro
Cube and BioSymetrics have only limited sales and marketing infrastructures and no experience as a company in the sale, marketing and
distribution of screening or diagnostic tests. In preparation of a commercial launch, Renovaro Cube and BioSymetrics are rapidly hiring
additional personnel in sales and marketing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Factors that may inhibit
Renovaro Cube&#8217;s or BioSymetrics&#8217; efforts to each commercialize any of their respective products include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr>
    <td style="width: 48px">&#160;</td>
    <td style="vertical-align: top; width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">its inability to recruit and retain adequate numbers of effective sales, marketing, reimbursement, customer service, medical affairs and other support personnel;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">the inability of sales personnel to persuade adequate numbers of customers, including healthcare systems and healthcare providers, to use its products;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">the inability to price its products at a sufficient price point to ensure an adequate and attractive level of profitability;</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 34 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr>
    <td style="width: 48px">&#160;</td>
    <td style="vertical-align: top; text-align: justify; width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">its inability to effectively market to, collaborate with, and secure coverage or reimbursement from&#160;third-party&#160;payors;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">its failure to comply with applicable regulatory requirements governing the sale, marketing, reimbursement and commercialization of its products; and</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">unforeseen costs and expenses associated with creating an independent commercialization organization.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Risks Related to the Development of Our Product
Candidates</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Renovaro
Cube&#8217;s and BioSymetrics&#8217; products are not subject to FDA or other government regulatory clearance or approval if they are
not intended to be used for the diagnosis, treatment or prevention of disease. However, as Renovaro Cube and BioSymetrics expands their
product line to encompass products that are intended to be used for the diagnosis of disease, certain of its products will become subject
to regulation by the FDA, or comparable international agencies, including requirements for regulatory clearance or approval of such products
before they can be marketed. Such regulatory approval processes or clearances may be expensive, time-consuming, and uncertain, and failure
to obtain or comply with such approvals and clearances could have an adverse effect on its business, financial condition, and operating
results. In addition, changes to the current regulatory framework, including the imposition of additional or new regulations, could arise
at any time during the development or marketing of future products, which may negatively affect its ability to obtain or maintain FDA
or comparable regulatory approval of its products, if required.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Diagnostic
products are regulated as medical devices by the FDA and comparable international agencies and may require either clearance from the FDA
or such other comparable agencies following the 510(k) pre-market notification process or pre-market approval from the FDA, in each case
prior to marketing. Obtaining the requisite regulatory approvals can be expensive and may involve considerable delay. If Renovaro Cube
or BioSymetrics fails to obtain, or experiences significant delays in obtaining, regulatory approvals for diagnostic products that it
develops in the future, Renovaro Cube and BioSymetrics may not be able to launch or successfully commercialize such products in a timely
manner, or at all.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">In addition,
if Renovaro Cube&#8217;s and BioSymetrics&#8217; products labelled as &#8220;For Research Use Only. Not for use in diagnostic procedures,&#8221;
or RUO, are used, or could be used, for the diagnosis of disease, the regulatory requirements related to marketing, selling, and supporting
such products could change or be uncertain, even if such use by Renovaro Cube&#8217;s or BioSymetrics&#8217; customers is without its
consent. If the FDA or other regulatory agencies assert that any of Renovaro Cube&#8217;s or BioSymetrics&#8217; RUO products are subject
to regulatory clearance or approval, Renovaro Cube&#8217;s or BioSymetrics&#8217; business, financial condition, and results of operations
could be adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white"><b><i>Regulatory and legislative
developments on the use of AI and machine learning could adversely affect Renovaro Cube&#8217;s or BioSymetrics&#8217; use of such technologies
in its platform and other products.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">As with
many technological innovations, artificial intelligence presents risks and challenges that could affect its adoption, and therefore our
business. Uncertainty in the legal regulatory regime relating to AI may require significant resources to modify and maintain business
practices to comply with U.S. and non-U.S. laws, the nature of which cannot be determined at this time. It is possible that new laws and
regulations will be adopted in the United Kingdom, the European Union, the United States and/or other foreign jurisdictions, or that existing
laws and regulations may be interpreted in ways that would affect the operation of Renovaro Cube&#8217;s or BioSymetrics&#8217; AI platform
and data analytics and the way in which Renovaro Cube or BioSymetrics uses AI and machine learning technology. Further, the cost to comply
with such laws or regulations could be significant and would increase operating expenses, which could adversely affect either&#8217;s
business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">For example,
in Europe, on April 21, 2021, the European Commission proposed a regulation seeking to establish a comprehensive, risk-based governance
framework for AI in the European Union market. The proposed legislation is intended to apply to companies that develop, use and/ or provide
AI in the European Union and includes requirements around transparency, conformity assessments and monitoring, risk assessments, human
oversight, security and accuracy, and proposes fines for breach of up to 6% of worldwide annual turnover. In addition, on September 28,
2022, the European Commission proposed the AI Liability Directive and the revised Product Liability Directive seeking to establish a harmonized
civil liability regime for AI in the European Union in order to facilitate civil claims in respect of harm caused by AI and to include
AI-enabled products within the scope of the European Union&#8217;s existing product liability regime. If enacted, this regulatory framework
is expected to have a material impact on the way AI is regulated in the European Union,</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"></p>

<!-- Field: Page; Sequence: 35 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white">and together with developing guidance and/or decisions
in this area, may affect Renovaro Cube&#8217;s or BioSymetrics&#8217; use of AI and its ability to provide and to improve its services,
require additional compliance measures and changes to its operations and processes, result in increased compliance costs and potential
increases in civil claims against Renovaro Cube or BioSymetrics, and could adversely affect either&#8217;s business, operations and financial
condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On October
30, 2023, the Biden administration issued an Executive Order on the Safe, Secure and Trustworthy Development and Use of AI, emphasizing
the need for transparency, accountability, and fairness in the development and use of AI, including in the healthcare industry. The order
seeks to balance fostering innovation with addressing risks associated with AI by providing eight guiding principles and priorities, such
as ensuring that consumers are protected from fraud, discrimination, and privacy risks related to AI. The order also calls for future
regulations from various agencies, such as the Department of Commerce (to draft guidance for detecting and authenticating AI content)
and the Federal Trade Commission (to ensure fair competition and reduce consumer harm). In alignment with the order, other agencies have
published guidance. Other jurisdictions may decide to adopt similar or more restrictive legislation that may render the use of such technologies
challenging.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The FTC
has issued a report expressing a concern regarding AI and bias across industry sectors, including in the healthcare space, and has suggested
that such bias could lead to unfair and deceptive practices, among other concerns. Any changes to our ability to use AI or concerns about
bias could require us to modify our products and services or could have other negative financial impact on our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">These
compliance obligations may make it harder for us to conduct our business using AI, lead to regulatory fines or penalties, require us to
change our product offerings or business practices, or prevent or limit our use of AI. If we cannot use AI, or if our use of AI is restricted,
our business may be less efficient, or we may be at a competitive disadvantage. Though we have taken steps to be thoughtful in our development,
training, and implementation of machine learning, including taking steps to comply with the laws and frameworks discussed above, our machine
learning-related processing could pose certain risks to our end-users, including patients, clinicians, and healthcare institutions, and
it is not guaranteed that regulators will agree with our approach to limiting these risks or to our compliance more generally. Any of
these factors could adversely affect our business, financial condition, and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>The results of pre-clinical
studies or earlier clinical studies are not necessarily predictive of future results, and if we fail to demonstrate efficacy in our pre-clinical
studies and/or clinical trials in the future our future business prospects, financial condition and operating results will be materially
adversely affected.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The success of our therapeutic
research and development efforts will depend upon our ability to demonstrate the efficacy of the treatments in our pipeline in pre-clinical
studies, as well as in clinical trials following IND approval by the FDA. Pre-clinical studies involve testing potential product candidates
in appropriate non-human disease models to demonstrate efficacy and safety.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Success in pre-clinical studies
does not ensure that later clinical studies will generate adequate data to demonstrate the efficacy and safety of an investigational drug.
Currently, several of our product candidates, including RENB-DC-11, our genetically-modified allogeneic dendritic therapeutic vaccination
platform for solid tumors, and BioS_831, our small molecule compound being developed for epilepsy, are in various stages of pre-clinical
development with ongoing and planned pre-clinical studies in conjunction with research institutions and third parties. Despite preliminary
data we believe is positive, this does not guarantee that any of these products will proceed to the clinical stage or to approval for
commercial use. A number of companies in the pharmaceutical and biotechnology industries, including those with greater resources and experience
than us, have suffered significant setbacks in clinical studies, even after seeing promising results in earlier preclinical or clinical
studies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Regulatory agencies evaluate non-clinical
data carefully before they will approve clinical testing in humans. If certain non-clinical data reveals potential safety issues or the
results are inconsistent with an expectation of the potential product candidates&#8217; efficacy in humans, the regulatory agencies may
require additional more rigorous testing before allowing human clinical trials. This additional testing will increase program expenses
and extend timelines. We may decide to suspend further testing on our potential products or abandon the product lines altogether if, in
the judgment of our management and advisors, the pre-clinical test results do not support further development, as we did with our pan-coronavirus
and influenza product lines.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 36 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Our novel gene, cell and
immunotherapy product candidates and new therapeutic approaches could result in heightened regulatory scrutiny, delays in clinical development
or delays in our ability to achieve regulatory approval or commercialization of our product candidates.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Renovaro Biosciences&#8217; future
success is dependent on the successful development of novel gene, cell and immunotherapy product candidates. Because these programs, particularly
our pipeline of allogeneic T-cell product candidates that are bioengineered from healthy donor cells, represent a new approach to immunotherapy
for the treatment of cancer and other diseases, developing and commercializing our product candidates subject us to a number of challenges.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Moreover, actual or perceived
safety issues, including adoption of new therapeutics or novel approaches to treatment, may adversely influence the willingness of subjects
to participate in clinical studies, or if approved by applicable regulatory authorities, of physicians to subscribe to the novel treatment
mechanics. The FDA or other applicable regulatory authorities may ask for specific post-market requirements, and additional information
informing benefits or risks of our products may emerge at any time prior to or after regulatory approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>We face significant competition
in an environment of rapid technological change and there is the possibility that our competitors may achieve regulatory approval before
us or develop therapies that are more advanced or effective than ours, which may adversely affect our financial condition and our ability
to successfully market or commercialize our product candidates. </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The development of treatments
in the fields of cancer and neurology is highly competitive and many pharmaceutical and biotechnology companies, academic institutions,
governmental agencies, and other public and private research organizations may pursue the research and development of technologies, drugs
or other therapeutic products for the treatment of some or all of the diseases we are targeting. Nearly all of our competitors have greater
capital resources, larger overall research and development staffs and facilities, and a longer history in drug discovery and development,
obtaining regulatory approval and pharmaceutical product manufacturing and marketing than we do. Techniques in gene, cell and immunotherapy
are subject to rapid technological change and development and are significantly affected by existing rival products and medical procedures,
new product introductions and the market activities of other participants. With additional resources, our competitors may be able to respond
to rapid and significant technological changes faster than we can. The future success of Renovaro Biosciences and BioSymetrics will depend
in large part on our ability to maintain a competitive position with respect to these technologies. We may also face competition from
products, which have already been approved and accepted by the medical community for the treatment of these same indications. If we are
unable to compete effectively with any existing products, new treatment methods and new technologies, we may be unable to commercialize
therapeutic products that we may develop in the future, which could adversely impact our potential revenues, results of operations and
financial condition or lead to abandonment of product candidates in our pipeline.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Our reliance on third parties,
such as university laboratories, contract manufacturing organizations and contract or clinical research organizations, may result in delays
in completing, or a failure to complete, non-clinical testing or clinical trials if they fail to perform under our agreements with them.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In the course of the development
of our pipeline, we have and expect to continue to engage university laboratories, non-profit organizations, independent contractors,
other biotechnology companies or clinical manufacturing organizations to conduct and manage research and development, pre-clinical and
clinical studies and to manufacture materials for us to be used in pre-clinical and clinical testing. Due to engagements with these organizations,
many important aspects of our research have been and will be out of our direct control. If any of these organizations we may engage in
the future, fail to perform their obligations under our agreements with them or fail to perform non-clinical testing and/or clinical trials
in a satisfactory manner, we may face delays in completing our clinical trials, as well as commercialization of any of our product candidates.
Furthermore, any loss or delay in obtaining contracts with such entities may also delay the completion of our clinical trials, regulatory
filings and the potential market approval of our product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 37 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt"><b><i>Changes in healthcare law
and implementing regulations, including government restrictions on pricing and reimbursement, as well as healthcare policy, may negatively
impact our ability to generate revenues.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt"><span style="background-color: white">In
the United States and some foreign jurisdictions, there have been a number of proposed legislative and regulatory changes related to the
healthcare system that could affect our ability to profitably sell or commercialize our product candidates for which we obtain marketing
approval in the future. The potential pricing and reimbursement environment for our product candidates may change in the future and become
more challenging due to, among other reasons, policies advanced by the current or any new presidential administration, federal agencies,
healthcare legislation passed by Congress, or fiscal challenges faced by all levels of government health administration authorities, or
by similar changes in foreign countries.</span> The implementation of any such changes could have a material adverse effect on our competitive
position, business, financial condition, results of operations, and prospects, including our share price and ability to raise capital.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt"><b><i>We have limited experience
in drug development and may not be able to successfully develop any drugs, which would cause us to cease operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">We have never successfully developed
a new drug and brought it to market. Our management and clinical teams have experience in drug development, but they may not be able to
successfully develop any drugs. Our ability to achieve revenues and profitability in our business will depend on, among other things,
our ability to develop products internally or to obtain rights to them from others on favorable terms; complete laboratory testing and
human studies; obtain and maintain necessary intellectual property rights to our products; successfully complete regulatory review to
obtain requisite governmental agency approvals; enter into arrangements with third parties to manufacture our products on our behalf;
and enter into arrangements with third parties to provide sales and marketing functions. If we are unable to achieve these objectives,
we will be forced to cease operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt"><b><i>Disruptions at the FDA and
other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key
leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely
manner or at all, which could negatively impact our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">The ability of the FDA to review
and approve new products can be affected by a variety of factors, including government budget and funding levels, the ability to hire
and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the
agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and
development activities is subject to the political process, which is inherently fluid and unpredictable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">Our gene therapy product candidates
are still in development and will require extensive clinical testing before we are prepared to submit an application for marketing approval
to regulatory authorities. We cannot predict with any certainty if or when we might submit any such application for regulatory approval
for our product candidates or whether any such application will be approved by the applicable regulatory authority in our target markets.
Human clinical trials are expensive and difficult to design and implement, in part because they are subject to rigorous regulatory requirements.
For instance, regulatory authorities may not agree with our proposed endpoints for any clinical trials of our gene therapy product candidates,
which may delay the commencement of our clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt"><b><i>Clinical trials are expensive,
time-consuming, difficult to design and implement, and involve an uncertain outcome.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">Our therapeutic product candidates
are still in development and will require extensive clinical testing before we are prepared to submit an application for marketing approval
to regulatory authorities. We cannot predict with any certainty if or when we might submit any such application for regulatory approval
of our product candidates or whether any such application will be approved by the applicable regulatory authority in our target markets.
Human clinical trials are expensive and difficult to design and implement, in part because they are subject to rigorous regulatory requirements.
For instance, regulatory authorities may not agree with our proposed endpoints for any clinical trials of our product candidates, which
may delay the commencement of our clinical trials. The clinical trial process is also time-consuming. We estimate that clinical trials
of our product candidates will take at least several years to complete.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt"></p>

<!-- Field: Page; Sequence: 38 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">A number of companies in the biopharmaceutical
industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding
promising results in earlier trials, and in the regulatory approval process. In addition, the design of a clinical trial, such as endpoints,
inclusion and exclusion criteria, statistical analysis plans, data access protocols and trial sizing, can determine whether its results
will support approval of a product and flaws in the design of a clinical trial may not become apparent until the clinical trial is well
advanced. If we experience delays in the commencement or completion of our clinical trials, or if we terminate a clinical trial prior
to completion, the commercial prospects of our product candidates could be harmed, and our ability to generate revenues may be delayed.
In addition, any delays in our clinical trials could increase our costs, cause a drop in our stock price, slow down the approval process
and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may harm our business, financial
condition, and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt"><b><i>Enrollment and retention
of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple
factors outside our control.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">We may encounter delays in enrolling,
or be unable to enroll, a sufficient number of patients to complete any of our clinical trials, and even once enrolled we may be unable
to retain a sufficient number of patients to complete any of our trials. Patient enrollment and retention in clinical trials depends on
many factors, including the size of the patient population, the nature of the trial protocol, the effectiveness of our patient recruitment
efforts, delays in enrollment due to travel or quarantine policies, the existing body of safety and efficacy data with respect to the
study candidate, the perceived risks and benefits of gene therapy approaches for the treatment of certain diseases, the number and nature
of competing existing treatments for our target indications, the number and nature of ongoing trials for other product candidates in development
for our target indications, perceived risk of the delivery procedure, patients with pre-existing conditions that preclude their participation
in any trial, the proximity of patients to clinical sites and the eligibility criteria for the study. Furthermore, the results we have
reported in clinical trials to date and any other results we may report in clinical trials of any of our gene therapy product candidates
in the future may make it difficult or impossible to recruit and retain patients in other clinical trials of those gene therapy product
candidates. Similarly, negative results reported by our competitors about their product candidates may negatively affect patient recruitment
in our clinical trials. Delays or failures in planned patient enrollment or retention may result in increased costs, program delays or
both, which could have a harmful effect on our ability to develop our gene therapy product candidates or could render further development
impossible. In addition, we expect to rely on clinical trial sites to ensure proper and timely conduct of our future clinical trials and,
while we intend to enter into agreements governing their services, we will be limited in our ability to control their actual performance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Risks Related to Our Technology and Intellectual
Property</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>We have licensed a portion
of our intellectual property from our licensors. If we breach any of our license agreements with these licensors, or otherwise experience
disruptions to our business relationships with our licensors, we could lose intellectual property rights that are important to our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We hold rights under license agreements
with our licensors that are important to our business. Our research and development platform is built, in part, around patent rights licensed
from such licensors. Under our existing license agreements, we are subject to various obligations, including diligence obligations with
respect to development and commercialization activities, provision of support with respect to development of licensed intellectual property,
prosecution of intellectual property protection, payment obligations upon achievement of certain milestones and royalties on product sales.
In spite of our efforts, our licensors might conclude that we have materially breached our obligations under such license agreements and
might therefore terminate the license agreements, thereby removing or limiting our ability to develop and commercialize products and technology
covered by these license agreements. If any of these licenses are terminated, or if the underlying patents fail to provide the intended
exclusivity, competitors or other third parties would have the freedom to seek regulatory approval of, and to market, products identical
to ours and we may be required to cease our development and commercialization of product candidates covered by any such licenses. Any
of the foregoing could have a material adverse effect on our competitive position, business, financial condition, results of operations,
and prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Moreover, disputes may arise regarding
intellectual property subject to a licensing agreement, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 39 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr>
    <td style="width: 20px; text-align: justify">&#160;</td>
    <td style="vertical-align: top; width: 20px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">the scope of rights granted under license agreements and other interpretation-related issues;</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">payment obligations due to licensors under license agreements and other disputes related to the obligations for payment related to intellectual property protection;</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">the extent to which our product candidates, technology and processes infringe on intellectual property of a licensor that is not subject to a licensing agreement;</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">the sublicensing of patent and other rights under our collaborative development relationships;</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">our diligence obligations under license agreements and what activities satisfy those diligence obligations; </span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us; and</span></td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">the priority of invention of patented technology.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, the agreements under
which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements
may be susceptible to multiple interpretations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The resolution of any contract
interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property
or technology or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could
have a material adverse effect on our business, financial condition, results of operations, and prospects. Moreover, if disputes over
intellectual property that we have licensed prevent or impair our ability to maintain our licensing arrangements on commercially acceptable
terms, we may be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse
effect on our business, financial condition, results of operations, and prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If we do not obtain required intellectual property
licenses or rights, we could encounter delays in our product development efforts while we attempt to design around other patents or even
be prohibited from developing, manufacturing or selling products requiring these rights or licenses. There is also a risk that legal disputes
may arise as to the rights to technology developed in collaboration with other parties, all with attendant risk, distraction, expense,
and lack of predictability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>If we are unable to obtain
and maintain sufficient intellectual property protection for our product candidates, or if the scope of the intellectual property protection
is not sufficiently broad, our ability to commercialize our product candidates successfully and to compete effectively may be adversely
affected.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We rely upon a combination of
patents, trademarks, trade secrets and confidentiality agreements &#8211; either that we own or possess or that are owned or possessed
by our licensors that are licensed to us &#8211; to protect the intellectual property related to our technology and product candidates.
When we refer to &#8220;our&#8221; technologies, inventions, patents, provisional patents, patent applications or other intellectual property
rights, we are referring to both the rights that we own or possess as well as those that we license, many of which are critical to our
intellectual property protection and our business. For example, the product candidates and platform technology we have licensed from our
licensors are protected primarily by patent or patent applications of our licensors that we have licensed and as confidential know-how
and trade secrets. If the intellectual property that we rely on is not adequately protected, competitors may be able to use our technologies
and erode or negate any competitive advantage we may have.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The patentability of inventions
and the validity, enforceability and scope of patents in the biotechnology field is uncertain because it involves complex legal, scientific
and factual considerations, and it has in recent years been the subject of significant litigation. Moreover, the standards applied by
the U.S. Patent and Trademark Office, or USPTO, and non-U.S. patent offices in granting patents are not always applied uniformly or predictably.
For example, there is no uniform worldwide policy regarding patentable subject matter or the scope of claims allowable in biotechnology
patents.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 40 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">There is no assurance that all
potentially relevant prior art relating to our patents and patent applications is known to us or has been found in the instances where
searching was done. We may be unaware of prior art that could be used to invalidate an issued patent or prevent a pending patent application
from issuing as a patent. There also may be prior art of which we are aware, but which we do not believe affects the validity or enforceability
of a claim of one of our patents or patent applications, which may, nonetheless, ultimately be found to affect the validity or enforceability
of such claim. We also may not be able to obtain full patent protection from provisional patents for which we have sought or will seek
further patent protection. As a consequence of these and other factors, our patent applications may fail to result in issued patents with
claims that cover our product candidates in the U.S. or in other countries.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Even if patents have issued or
do successfully issue from patent applications, and even if these patents cover our product candidates, third parties may challenge the
validity, enforceability or scope thereof, which may result in these patents being narrowed, invalidated or held to be unenforceable.
No assurance can be given that if challenged, our patents would be declared by a court to be valid or enforceable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Even if unchallenged, our patents
and patent applications or other intellectual property rights may not adequately protect our intellectual property, provide exclusivity
for our product candidates or prevent others from designing around our claims. The possibility exists that others will develop products
on an independent basis which have the same effect as our product candidates and which do not infringe our patents or other intellectual
property rights, or that others will design around the claims of patents that we have had issued that cover our product candidates. If
the breadth or strength of protection provided by our patents and patent applications with respect to our product candidates is threatened,
it could jeopardize our ability to commercialize our product candidates and dissuade companies from collaborating with us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We may also desire to seek a license
from a third party who owns intellectual property that may be useful for providing exclusivity for our product candidates, or for providing
the ability to develop and commercialize a product candidate in an unrestricted manner. There is no guarantee that we will be able to
obtain a license from such a third party on commercially reasonable terms, or at all.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, the United States
Patent and Trademark Office (USPTO) and various foreign governmental patent agencies require compliance with a number of procedural, documentary,
fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured
by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result
in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We and our licensors have filed
a number of patent applications covering our product candidates or methods of using or making those product candidates. We cannot offer
any assurances about which, if any, patents will be issued with respect to these pending patent applications, the breadth of any such
patents that are ultimately issued or whether any issued patents will be found invalid and unenforceable or will be threatened by third
parties. Because patent applications in the U.S. and most other countries are confidential for a period of time after filing, and some
remain so until issued, we cannot be certain that we or our licensors were the first to file any patent application related to a product
candidate. We or our licensors may also become involved in proceedings regarding our patents, including patent infringement lawsuits,
interference or derivation proceedings, oppositions, and <i>inter partes </i>and post-grant review proceedings before the USPTO, the European
Patent Office and other non-U.S. patent offices.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Third-party claims of intellectual
property infringement may prevent or delay our development and commercialization efforts.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our success will depend in part
on our ability to commercialize our product candidates without infringing the proprietary rights of others. While some of the intellectual
property utilized in our product candidates is owned, some is licensed from our licensors, who hold patents and provisional patents in
their names. We have not conducted extensive freedom of use patent searches and no assurance can be given that patents do not exist or
could be issued which would have an adverse effect on our ability to market our technology or maintain our competitive position with respect
to our technology. We also cannot be sure that patents or provisional patents filed by others are valid or will be upheld if challenged.
It is possible that there are additional patents that may cover certain other aspects of technology used in our product candidates that
is not covered by our licensed intellectual property. If our licensed technology or other subject matter are claimed under other United
States patents or other international patents or are otherwise protected by third party proprietary rights,</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 41 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">we or our licensors may be
subject to infringement actions. In such event, we may challenge the validity of such patents or other proprietary rights or we may be
required to obtain licenses from such companies in order to develop, manufacture or market our technology. There can be no assurances
that we would be successful in a challenge or be able to obtain such licenses or that such licenses, if available, could be obtained on
commercially reasonable terms. Furthermore, the failure to succeed in a challenge, develop a commercially viable alternative or obtain
needed licenses could have significant adverse consequences to the development of our pipeline. Adverse consequences include delays in
marketing some or all of our product candidates based on our technology or the inability to proceed with the development, manufacture
or sale of products requiring such licenses. If we defend ourselves against charges of patent infringement or to protect our proprietary
rights against third parties, substantial costs will be incurred regardless of whether we are successful. Such proceedings are typically
protracted with no certainty of success. An adverse outcome could subject us to significant liabilities to third parties and force us
to curtail or cease the research and development of our technology.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Parties making claims against
us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our
product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial
diversion of resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial
damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties, redesign our infringing products
or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure. Additionally,
parties making claims against us may be able to sustain the costs of complex patent litigation more effectively than we can because they
have substantially greater resources. Furthermore, because of the substantial amount of discovery required in connection with intellectual
property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure.
In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on
our ability to raise additional funds or otherwise have a material adverse effect on our business, results of operations, financial condition
and prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Issues in the development
and use of&#160;AI, including machine learning and computer vision, in Renovaro Cube&#8217;s AI platform may result in reputational harm
or liability.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">AI is
integrated into Renovaro Cube&#8217;s and BioSymetrics&#8217; platforms and is a significant element of each of their business offerings
going forward. As with many developing technologies, AI presents risks, challenges and unintended consequences that could affect its further
development, adoption, and use, and therefore Renovaro Cube&#8217;s and BioSymetrics&#8217; business. AI algorithms and training methodologies
may be flawed. Data sets may be insufficient, of poor quality, or contain biased information. Inappropriate or controversial data practices
by data scientists, engineers, and end-users&#160;of Renovaro Cube&#8217;s or BioSymetrics&#8217; systems could impair the acceptance
of AI solutions. If the analyses that AI applications assist in producing are deficient or inaccurate, Renovaro Cube or BioSymetrics could
be subjected to competitive harm, potential legal liability, and brand or reputational harm. Some uses of AI present ethical issues, and
Renovaro Cube&#8217;s or BioSymetrics&#8217; judgment as to the ethical concerns may not be perceived as accurate. While Renovaro Cube
and BioSymetrics aim to develop and use AI responsibly and attempt to identify and mitigate ethical and legal issues presented by its
use, Renovaro Cube and BioSymetrics may be unsuccessful in identifying or resolving issues before they arise. If Renovaro Cube or BioSymetrics
use AI as part of their platform in a manner that is controversial or perceived as unethical, this may lead to adverse results for Renovaro
Cube&#8217;s or BioSymetrics&#8217; financial condition and operations or the financial condition and operations of their collaborators
or vendors, which may further lead to Renovaro Cube or BioSymetrics experiencing competitive harm, legal liability and brand or reputational
harm. In addition, AI-related issues, deficiencies and/or failures could give rise to legal and/or regulatory action, including with respect
to proposed legislation regulating AI in jurisdictions such as the European Union and others, and as a result of new applications of existing
data protection, privacy, intellectual property, and other laws.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>Failure
of, or defects in, Renovaro Cube&#8217;s or BioSymetrics&#8217; machine learning and&#160;cloud-based&#160;computing infrastructure, or
increased regulation in the machine learning space, could impair their ability to process data, develop products, or provide test results,
and harm their business and results of operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The design,
development, maintenance and operation of Renovaro Cube&#8217;s and BioSymetrics&#8217; technologies over time is expensive and complex,
and may involve unforeseen difficulties including material performance problems, undetected defects or errors. Overcoming technical obstacles
and correcting defects or errors could prove to be impossible or impracticable, and the costs incurred may be substantial and adversely
affect either&#8217;s results of operations. Additionally, regulation in the machine learning space is constantly evolving and may make
it difficult for Renovaro Cube or BioSymetrics to continue using its machine learning approach. If Renovaro Cube&#8217;s or BioSymetrics&#8217;
technology does not function reliably, fails to meet expectations in terms of performance, or cannot be fully utilized due to increasing
regulation, we may be unable to provide, or its customers may stop using, our products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"></p>

<!-- Field: Page; Sequence: 42 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Renovaro
Cube currently hosts all of its data on, and conducts its data analysis through, local&#160;hosting facilities. Any technical problems
or outages that may arise in connection with these hosting facilities could result in the loss of Renovaro Cube&#8217;s data or delayed
or ineffective data processing. A variety of factors, including infrastructure changes, human or software errors, viruses, malware, security
attacks, fraud, spikes in customer usage, or denial of service issues could cause interruptions in Renovaro Cube&#8217;s service. Such
service interruptions may reduce or inhibit Renovaro Cube&#8217;s ability to provide its products, delay any further clinical validation
and any future clinical studies, and damage its relationships with its customers. Renovaro Cube could also be exposed to potential lawsuits,
liability claims or regulatory actions, if, for example, Renovaro Cube&#8217;s local servers experienced a data privacy breach. If Renovaro
Cube was required to transfer its data to an alternative hosting provider, the transfer and acclimation to the new provider could result
in significant business delays and require additional resources.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Real or perceived errors,
failures, or bugs in Renovaro Cube&#8217;s or BioSymetrics&#8217; platform and future products could adversely affect their business,
results of operations, financial condition, and growth prospects.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Renovaro Cube&#8217;s and BioSymetrics&#8217;
platforms are, and their future products will be, complex, and therefore, undetected errors, failures, bugs, or defects may be present
in such platform or products or occur in the future in their platform or products, their technology or software or the technology or software
they license from third parties, including open source software, especially when updates or new products are released. Such software and
technology is used in information technology (&#8220;IT&#8221;) environments with different operating systems, system management software,
devices, databases, servers, storage, middleware, custom and third-party applications, and equipment and networking configurations, which
may cause errors, failures, bugs, or defects in the IT environment into which such software and technology is deployed. This diversity
increases the likelihood of errors, failures, bugs, or defects in those IT environments. Some of the features in Renovaro Cube&#8217;s
and BioSymetrics&#8217; platforms are powered by machine learning and&#160;AI, which depend on datasets and algorithms that could be flawed,
including through inaccurate, insufficient, outdated, or biased data. Despite testing by Renovaro Cube and BioSymetrics, real or perceived
errors, failures, bugs, or defects may not be found until customers use their products. Real or perceived errors, failures, bugs, or defects
in Renovaro Cube&#8217;s or BioSymetrics&#8217; products could result in negative publicity, loss of or delay in market acceptance of
their platforms or future products and harm to their brand, loss of investor confidence, weakening of our competitive position, claims
by customers for losses sustained by them, or failure to meet the stated service level commitments in customer agreements. In such an
event, Renovaro Cube or BioSymetrics may be required, or may choose, for customer relations or other reasons, to expend significant additional
resources in order to help correct the problem. Any real or perceived errors, failures, bugs, or defects in Renovaro Cube&#8217;s or BioSymetrics&#8217;
products could also impair their ability to attract new customers, retain existing customers, or expand their use of its products, which
would adversely affect Renovaro Cube&#8217;s or BioSymetrics&#8217; business, results of operations and financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Renovaro Cube and BioSymetrics
may also be subject to liability claims for damages related to real or perceived errors, failures, bugs, or defects in its platform or
future products. A material liability claim or other occurrence that harms Renovaro Cube&#8217;s or BioSymetrics&#8217; reputation or
decreases market acceptance of its platform or future products may harm its business and results of operations. Finally, since some of
Renovaro Cube&#8217;s or BioSymetrics&#8217; customers use its products for compliance reasons, any errors, failures, bugs, defects, disruptions
in service or other performance problems with Renovaro Cube&#8217;s or BioSymetrics&#8217; products may damage its customers&#8217; businesses
and could hurt its reputation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>Renovaro
Cube&#8217;s or BioSymetrics&#8217; internal computer systems, or those expected to be used by its third-party research institution collaborators
or other contractors or consultants, may fail or suffer security breaches.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Despite
the implementation of security and&#160;back-up&#160;measures, Renovaro Cube&#8217;s or BioSymetrics&#8217; internal computer, server
and other information technology systems as well as those of its&#160;third-party&#160;collaborators, consultants, contractors, suppliers
and service providers, may be vulnerable to damage from physical or electronic&#160;break-ins,&#160;computer viruses, malware, ransomware,
denial of service and other&#160;cyber-attacks&#160;or disruptive incidents that could result in unauthorized access to, use or disclosure
of, corruption of, or loss of sensitive and/or proprietary data, including personal and health information, and could subject Renovaro
Cube or BioSymetrics to significant liabilities, regulatory and enforcement actions and reputational damage. For example, the loss of
clinical study data from future clinical studies could result in delays in any regulatory clearance or approval efforts and significantly
increase Renovaro Cube&#8217;s or BioSymetrics&#8217; costs to recover or reproduce the data, and subsequently commercialize its future
products. If Renovaro Cube, BioSymetrics&#8217; or either&#8217;s&#160;third-party&#160;collaborators, consultants, contractors, suppliers
or service providers were to suffer an attack or breach, for example, that resulted in the unauthorized access to or use or disclosure
of personal or health information, Renovaro Cube or BioSymetrics may have to notify physicians, patients, partners,</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"></p>

<!-- Field: Page; Sequence: 43 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white">collaborators, government
authorities and the media, and may be subject to investigations, civil penalties, administrative and enforcement actions and litigation,
any of which could harm their business and reputation. Likewise, Renovaro Cube and BioSymetrics rely on third-party&#160;research institution
collaborators and other third parties to conduct clinical validation, and similar events relating to their computer systems could also
have a material adverse effect on Renovaro Cube&#8217;s or BioSymetrics&#8217; business. To the extent that any disruption or security
breach were to result in a loss of, or damage to, Renovaro Cube&#8217;s or BioSymetrics&#8217; data or systems, or inappropriate or unauthorized
access to or disclosure or use of confidential, proprietary, or other sensitive, personal, or health information, Renovaro Cube or BioSymetrics
could incur liability and suffer reputational harm, and the development and commercialization of its products could be delayed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Renovaro
Cube&#8217;s or BioSymetrics&#8217; insurance policies may not be adequate to compensate it for the potential losses arising from such
disruptions, failure, or security breach. In addition, such insurance may not be available to Renovaro Cube or BioSymetrics in the future
on economically reasonable terms, or at all. Further, Renovaro Cube&#8217;s or BioSymetrics&#8217; insurance may not cover all claims
made against it and defending a suit, regardless of its merit, could be costly, divert management attention and harm Renovaro Cube&#8217;s
or BioSymetrics&#8217; reputation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>If
Renovaro Cube or BioSymetrics is unable to protect the confidentiality of its trade secrets, Renovaro Cube&#8217;s or BioSymetrics&#8217;
business and competitive position would be harmed.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Renovaro
Cube and BioSymetrics rely on trade secrets and confidentiality agreements to protect their know-how,&#160;technology, data and other
proprietary information and to maintain a competitive position. Trade secrets and&#160;know-how&#160;can be difficult to protect. Renovaro
Cube and BioSymetrics expect trade secrets and&#160;know-how&#160;to, over time, be disseminated within the industry through independent
development, the publication of journal articles describing the methodology and the movement of personnel from academic to industry scientific
positions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Renovaro
Cube and BioSymetrics each seeks to protect these trade secrets and other proprietary technology, in part, by entering into&#160;non-disclosure&#160;and
confidentiality agreements with parties who have access to them, such as Renovaro Cube&#8217;s and BioSymetrics&#8217; employees, directors,
corporate collaborators, outside scientific collaborators, contract research organizations (&#8220;CROs&#8221;), contract manufacturers,
suppliers, service providers, consultants, advisors and other third parties. Renovaro Cube and BioSymetrics also enter into confidentiality
and invention or patent assignment agreements with its employees and consultants, and reminds departing employees when they leave their
employment of their continuing confidentiality obligations. Renovaro Cube and BioSymetrics cannot guarantee that they have entered into
such agreements with each party that may have, or have had, access to trade secrets or proprietary technology and processes. Despite Renovaro
Cube&#8217;s and BioSymetrics&#8217; efforts, any of these parties may breach the agreements and disclose our proprietary information,
including trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally
disclosed or misappropriated a trade secret is difficult, expensive, and&#160;time-consuming,&#160;and the outcome is unpredictable. Some
courts outside the respective jurisdictions of BioSymetrics and Renovaro Cube are less willing or unwilling to protect trade secrets.
For example, in China, claims regarding infringement or misappropriation of trade secrets are difficult to prove, and consequently plaintiffs
are rarely successful in bringing these claims. If any of Renovaro Cube&#8217;s or BioSymetrics&#8217; trade secrets were to be lawfully
obtained or independently developed by a competitor or other third party, Renovaro Cube and BioSymetrics would have no right to prevent
them from using that technology or information to compete with us. If any of Renovaro Cube&#8217;s or BioSymetrics&#8217; trade secrets
were to be misappropriated by, disclosed to, or independently developed by a competitor or other third party, Renovaro Cube&#8217;s or
BioSymetrics&#8217; competitive position could be materially and adversely harmed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Renovaro
Cube and BioSymetrics have and may enter into collaboration, license, contract research and/or manufacturing relationships with contract
organizations that operate in certain countries that are at heightened risk of <span style="background-color: white">theft of technology,
data and intellectual property through direct intrusion by private parties or foreign actors, including those affiliated with or controlled
by state actors. Accordingly, Renovaro Cube&#8217;s and BioSymetrics&#8217; efforts to protect and enforce their intellectual property
rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that Renovaro Cube
and BioSymetrics develops or licenses, and we may be at heightened risk of losing proprietary intellectual property rights around the
world, including outside of such countries, to the extent such theft or intrusion destroys the proprietary nature of its intellectual
property.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"></p>

<!-- Field: Page; Sequence: 44 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>We
depend on our information technology and telecommunications systems and those of third parties, the failure or disruption of which could
harm our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">We depend
on information technology and telecommunications systems, including those provided by third parties and their vendors, for significant
elements of our operations, such as our information management systems, research and development, scientific and medical data analysis
and general administrative activities. In addition, our&#160;third-party&#160;service providers depend upon technology and telecommunications
systems provided by outside vendors. We expect to expand and strengthen a number of enterprise software systems that affect a broad range
of business processes and functions, including, for example, systems handling human resources, financial controls and reporting, customer
relationship management, regulatory compliance, security controls and other infrastructure operations. These expansions may prove more
difficult than we expect and could cause disruptions in our operations or additional expense.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Information technology and telecommunications
systems are vulnerable to damage from a variety of sources, including telecommunications or network failures, malicious human acts and
natural disasters. Moreover, despite network security and&#160;back-up&#160;measures, some of our servers are potentially vulnerable to
physical or electronic&#160;break-ins,&#160;computer viruses and similar disruptive events. Despite the precautionary measures we have
taken to detect and prevent or solve problems that could affect our information technology and telecommunications systems, failures or
significant downtime of these systems or those used by its&#160;third-party&#160;service providers and their vendors could prevent us
from conducting tests, preparing and providing our orts to future customers, billing payors, conducting research and development activities,
maintaining our financial controls and other reporting functions, and managing the administrative aspects of our business. In addition,
the loss of formulas or data from completed, ongoing or planned pre-clinical studies could result in delays in our regulatory approval
efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were
to result in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information,
we could incur liability and further development of our product candidates could be delayed. Any disruption or loss of information technology
or telecommunications systems on which critical aspects of our operations depend could have an adverse effect on our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>Intellectual
property litigation may lead to unfavorable publicity that harms our reputation.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">During
the course of any intellectual property litigation, there could be public announcements of the initiation of the litigation as well as
results of hearings, rulings on motions and other interim proceedings in the litigation. Such announcements could harm our reputation,
the perceived value of our intellectual property or the potential market for our products, which could have a material adverse effect
on our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>Renovaro
Cube&#8217;s and BioSymetrics&#8217; success depends on our ability to develop and commercialize our technology without infringing, misappropriating,
or otherwise violating the intellectual property of third parties. Third parties may initiate legal proceedings alleging that Renovaro
Cube or BioSymetrics is infringing their intellectual property rights, and if they prevail, could block sales of Renovaro Cube&#8217;s
or BioSymetrics&#8217; products and force us to make large damages and/or royalty payments, which could have a material adverse effect
on the success of our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Renovaro
Cube&#8217;s and BioSymetrics&#8217; commercial success in part depends upon our ability, and the ability of our collaborators, to market,
sell and distribute our products and use our proprietary technologies without infringing, misappropriating or otherwise violating the
proprietary rights of third parties. There is considerable intellectual property litigation in the medical technology, biotechnology,
diagnostic and pharmaceutical industries. Renovaro Cube or BioSymetrics may become party to, or threatened with, future adversarial proceedings
or litigation regarding intellectual property rights with respect to its products, including interference proceedings before the United
Kingdom <span style="background-color: white">Intellectual Property&#160;Office, the European Patent Office</span>, the United States
Patent and Trademark Office and similar bodies in other jurisdictions. Third parties may assert infringement claims against Renovaro Cube
or BioSymetrics based on existing patents or patents that may be issued in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">If Renovaro
Cube or BioSymetrics is found to infringe, misappropriate, or otherwise violate a third party&#8217;s intellectual property rights, it
could be required to obtain a license from such third party to continue developing, marketing, selling and distributing our products,
or to cease using the infringing technology. However, we may not be able to obtain any required license on commercially reasonable terms
or at all. Even if we were able to obtain a license, it could be&#160;non-exclusive,&#160;thereby giving our competitors access to the
same technologies licensed to us. In addition, We could be found liable for monetary damages, including treble damages if it is found
to have willfully infringed a patent and attorneys&#8217; fees if the court finds the case to be exceptional. A finding of infringement,
misappropriation, or other violation could prevent us from commercializing our products or force us to cease some of our operations, which
could materially harm our business. Claims that Renovaro Cube or BioSymetrics has misappropriated the confidential information or trade
secrets of third parties could have a similar negative impact on our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"></p>

<!-- Field: Page; Sequence: 45 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Even
if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant
expenses and could distract our personnel from their normal responsibilities. Such litigation or proceedings could substantially increase
our operating losses and reduce the resources available for development activities or any future sales, marketing, or distribution activities.
We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors
may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources
and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent
litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>Renovaro
Cube&#8217;s and BioSymetrics&#8217; use of&#160;open-source&#160;software could subject our proprietary technology to unwanted&#160;open-source&#160;license
conditions that could negatively impact its business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">A portion
of our technology capabilities incorporates&#160;open-source&#160;software, and we may incorporate&#160;open-source&#160;software into
other offerings or products in the future. If an author or other third party that distributed such&#160;open-source&#160;software to Renovaro
Cube or BioSymetrics were to allege that we had not complied with the conditions of one or more of these licenses, we could be required
to incur significant legal expenses defending against such allegations. Further, the outcome of such litigation may be particularly uncertain
in some cases, because there is little legal precedent governing the interpretation of certain terms of common open-source licenses. In
addition, if Renovaro Cube or BioSymetrics combines its proprietary software with&#160;open-source&#160;software in a certain manner and
makes it available to others, under some&#160;open-source&#160;licenses, it could be required to license or make available the source
code of its proprietary software, which could substantially help its competitors develop products that are similar to or better than ours
and harm our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>The
success and growth of Renovaro Cube&#8217;s or BioSymetrics&#8217; business depends upon their ability to continuously innovate and develop
new products and technologies.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Renovaro
Cube&#8217;s and BioSymetrics&#8217; solutions are technology-driven platforms that rely on innovation to remain competitive. The process
of developing new technologies and products is complex, and we have built and seek to further develop our own technology using the latest
in&#160;AI&#160;and machine learning, cloud-based technologies and other tools to differentiate our products and technologies. In addition,
our dedication to incorporating technological advancements into our AI platforms requires significant financial and personnel resources
and talent. Our development efforts with respect to these initiatives could distract management from current operations and could divert
capital and other resources from other growth initiatives important to our business. We operate in an industry experiencing rapid technological
change and frequent product introductions. We may not be able to make technological improvements as quickly as demanded by our customers,
or we may not be able to accurately predict the demand or growth of its technological investments, which could harm its ability to attract
customers and have a material and adverse effect on its business, results of operations, financial condition and future prospects. In
addition, we may not be able to effectively implement new technology-driven products and services as quickly as our competitors or be
successful in marketing these products and services to potential customers. If we are unable to successfully and timely innovate, we could
experience reputational damage and decreased demand for our AI platforms and other products and technologies and our growth, business,
results of operations, financial condition and future prospects could be materially and adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>Renovaro
Cube&#8217;s and BioSymetrics&#8217; AI platform and other related products may become obsolete due to fast growing technological innovations
or the entry of competitors with more financial and brand power.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">AI is a fast-growing industry
and Renovaro Cube and BioSymetrics must successfully adapt and manage technological advancements in AI and&#160;AI-related&#160;markets,
as well as effectively compete with the emergence of additional competitors in the AI industry in order to maintain and grow AI business
and products. Thus, the success of Renovaro Cube&#8217;s or BioSymetrics&#8217; AI platform, other products and business depends in large
part on their ability to keep pace with rapid technological changes in the development and implementation of AI products. For example,
the development of groundbreaking technological innovations in AI, or innovations that would render AI obsolete, would harm Renovaro Cube&#8217;s
or BioSymetrics&#8217; business and make its platform or other products less durable. Further, the entry of competitors into the AI market
that have more financial and brand power could cause Renovaro Cube&#8217;s or BioSymetrics&#8217; share of the market to be significantly
reduced thereby negatively affecting their business, operating results and financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 46 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>We may not be able to protect
our intellectual property rights throughout the world.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Filing, prosecuting and defending
patents on our product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property
rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some
foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently,
we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling
or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies
in jurisdictions where we have not obtained patent protection to develop their own products and may also export infringing products to
territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete
with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Risks Related to Employee
Matters and Managing Growth </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Our success depends on our ability to attract and retain highly skilled employees in artificial intelligence,
data science, and biomedical research, and competition for such talent is intense.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">We have limited corporate infrastructure and may face challenges in managing growth, which could strain
our resources and delay development.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Periods of uncertainty or rapid growth may make it difficult to maintain company culture and employee
engagement, which could negatively affect execution of our business objectives.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">The loss of key members of our management or technical teams could disrupt our operations and harm our
business prospects.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">We rely on consultants and contractors for certain specialized functions, which may create challenges
in retaining institutional knowledge and ensuring continuity.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Recruiting, training, and retaining qualified personnel may require significant costs, and failure to
manage these costs could adversely affect our business and financial results.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>We have limited corporate
infrastructure and may experience difficulties in managing growth. </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of June 30, 2025, we had 29
full-time employees. We rely on third-party contractors for the provision of professional, scientific, regulatory, and other services.
As our development and commercialization plans and strategies develop, we may need additional managerial, scientific, operational, financial,
and other resources. Our management may need to divert a disproportionate amount of its attention away from our day-to-day operations
and devote a substantial amount of time to managing these growth activities. We might not be able to effectively manage the expansion
of our operations, which may result in weaknesses in our infrastructure, operational inefficiencies, loss of business opportunities, loss
of employees and reduced productivity among remaining employees. Our expected growth could require significant capital expenditures and
may divert financial resources from other projects, such as the development of our current and potential future product candidates. If
our management is unable to effectively manage our growth, our expenses may increase more than expected and our ability to generate and
grow revenue could be reduced and we might not be able to implement our business strategy. Our future financial performance, our ability
to commercialize product candidates, develop a scalable infrastructure and compete effectively will depend, in part, on our ability to
effectively manage any future growth.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>Management
and employee turnover creates uncertainties and could harm our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">We have
experienced significant turnover in our executive leadership and management in recent years. Changes to strategic or operating goals,
which oftentimes occur with the appointment of new executives and board members, can create uncertainty, may negatively impact our ability
to execute quickly and effectively, and may ultimately be unsuccessful. In addition, executive leadership transition periods are often
difficult as the new executives gain detailed knowledge of our operations, and friction can result from changes in strategy and management
style. Management turnover inherently causes some loss of institutional knowledge, which can negatively affect strategy and execution.
Until we integrate new personnel, and unless they are able to succeed in their positions, we may be unable to successfully manage and
grow our business, and our financial condition and ability to become profitable may suffer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"></p>

<!-- Field: Page; Sequence: 47 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">As we
continue our exploration of strategic alternatives, we may experience additional turnover in our board and senior management. Departures
of our management team and board members have created, and will create if they continue, significant continuity risks and challenges to
our ability to operate our business, assess and manage risks and comply with applicable laws. If key members of our senior management
team depart, it will be important that we attract and retain qualified managers promptly and develop and implement an effective succession
plan. We expect to face significant competition in attracting experienced executives and other key personnel, and there can be no assurance
that we will be able to do so. Further, to the extent we experience additional management turnover, competition for top management is
high and it may take months to find a candidate that meets our requirements. If we are unable to attract and retain qualified management
personnel, our business could suffer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">We also
experience competition for the hiring of scientific and clinical personnel from universities and research institutions. Further, inflationary
pressure may increase our costs, including employee compensation costs or result in employee attrition to the extent our compensation
does not keep up with inflation, particularly if our competitors&#8217; compensation does.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>Renovaro
Cube and BioSymetrics are highly dependent on their key personnel. If Renovaro Cube or BioSymetrics is not successful in attracting, motivating
and retaining highly qualified personnel, they may not be able to successfully implement their business strategy.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Renovaro
Cube&#8217;s and BioSymetrics&#8217; ability to compete in the highly competitive AI-driven healthcare technology industry depends upon
its ability to attract, motivate and retain highly qualified personnel. We are highly dependent on our executive management team and its
scientific, medical, technological and engineering personnel, all of whom have been working together as a group for only a limited period
of time. The loss of the services provided by any of our executive officers, other key employees and other scientific and medical advisors,
and our inability to find suitable replacements as needed, could result in delays in commercialization of its products and harm our business.
Renovaro Cube and BioSymetrics do not maintain &#8220;key person&#8221; insurance policies on the lives of these individuals or the lives
of any of their other employees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt; background-color: white">Renovaro
Cube is headquartered in Amsterdam, the Netherlands, a region in which many other healthcare companies, technology companies and academic
and research institutions are headquartered. Competition for personnel is intense and the turnover rate can be high, which may limit Renovaro
Cube&#8217;s ability to hire and retain highly qualified personnel on acceptable terms or at all. Renovaro Cube expects that it may need
to recruit talent from outside of its region, and doing so may be costly and difficult. If Renovaro Cube is unable to attract and retain
highly qualified personnel, its ability to develop and commercialize its products may be limited.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt; background-color: white"><b><i>If
Renovaro Cube or BioSymetrics is unable to scale its operations successfully to support demand for its products following the launch of
its platform, its business could suffer.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">As and
to the extent demand increases beyond Renovaro Cube&#8217;s or BioSymetrics&#8217; expectations following the launch of each&#8217;s platform,
Renovaro Cube and BioSymetrics will likely need to start to ramp up operating capacity. We will need to implement new infrastructure,
data processing capabilities, customer service, billing and systems processes, and expand internal quality assurance program and technology
to support operations on a larger scale. We will also need collaboration arrangements with third-party laboratories to process its physical
tests or, if processing of such tests is not fully outsourced to support demand, will need to obtain equipment and certified and licensed
laboratory personnel to process these physical tests internally. We may face difficulties increasing the scale of operations, including
implementing changes in infrastructure or programs or acquiring additional equipment or personnel. As we refine our products and develop
additional products, Renovaro Cube and BioSymetrics may need to introduce new equipment,&#160;implement new systems, technology, controls
and procedures, and hire personnel with different qualifications, licenses or certifications.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The value
of Renovaro Cube&#8217;s and BioSymetrics&#8217; products will depend, in part, on our ability to perform tests, whether through a licensed
provider or internally, and return results to providers on a timely basis and at an appropriate quality standard, and on our reputation
for such timeliness and quality. Failure to establish necessary arrangements with licensed providers, to implement necessary procedures,
to transition to new equipment or processes, or to hire the appropriately qualified personnel could result in higher costs of processing,
longer turnaround times or an inability to meet market demand. There can be no assurance that Renovaro Cube, BioSymetrics, or any such
licensed provider will be able to perform tests on a timely basis at a level consistent with demand, that we will be able to maintain
the quality of our test results as we scale our commercial operations, or that we will be successful in responding to the potential growing
complexity of its operations, including the related data analysis requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"></p>

<!-- Field: Page; Sequence: 48 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">In addition,
Renovaro Cube&#8217;s and BioSymetrics&#8217; growth may place a significant strain on its management, operating and financial systems,
research and development, and its sales, marketing, and administrative resources. As a result of growth, our operating costs may escalate
even faster than planned, and some of its internal systems may need to be enhanced or replaced. If Renovaro Cube or BioSymetrics cannot
effectively manage expanding operations and costs, Renovaro Cube or BioSymetrics may not be able to grow successfully or it may grow at
a slower pace, and its business could be adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>Renovaro
Cube and BioSymetrics will need to grow the size and capabilities of their organizations, and may experience difficulties in managing
this growth.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">As of
June 30, 2025, Renovaro Cube had 14 full-time employees, and BioSymetrics had 6. As our growth plan and strategies develop, it must add
a significant number of additional managerial, operational, financial and other personnel. Future growth will impose significant added
responsibilities on members of management, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr>
    <td style="width: 48px">&#160;</td>
    <td style="vertical-align: top; width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">identifying, recruiting, integrating, retaining and motivating additional employees;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">managing its internal development efforts effectively, including creating compliant programs and processes, and managing the regulatory requirements for its products, while complying with its contractual obligations to contractors and other third parties;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">expanding its operational, financial and management controls, reporting systems and procedures; and</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">managing the increasing complexity associated with a larger organization and expanded operations.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt; background-color: white">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Renovaro
Cube&#8217;s and BioSymetrics&#8217; future financial performance and their ability to commercialize their respective products will depend,
in part, on their ability to effectively manage any future growth. Renovaro Cube&#8217;s and BioSymetrics&#8217; management may also have
to divert a disproportionate amount of their attention away from&#160;day-to-day&#160;activities in order to manage these growth activities.
Renovaro Cube&#8217;s and BioSymetrics&#8217; ability to successfully manage expected growth is uncertain given the fact that Renovaro
Cube has been in full operation as an independent company focusing on cancer diagnostics AI only since 2018, and BioSymetrics similarly
since 2017. Renovaro Cube&#8217;s and BioSymetrics&#8217; executive management team&#8217;s lack of&#160;long-term&#160;experience working
together may adversely impact their ability to effectively manage its business and growth.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">If Renovaro
Cube or BioSymetrics is not able to effectively expand its organization by hiring new employees, each may not be able to successfully
implement the tasks necessary to commercialize its products, which would have a negative impact on Renovaro Cube&#8217;s or BioSymetrics&#8217;
business and result of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>Renovaro
Cube&#8217;s or BioSymetrics&#8217; employees, independent contractors, consultants, commercial partners and vendors may engage in misconduct
or other improper activities, including noncompliance with regulatory standards and requirements.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Renovaro
Cube and BioSymetrics are exposed to the risk of fraud, misconduct, or other illegal activity by its employees, independent contractors,
consultants, commercial partners and vendors. Misconduct by these parties could include intentional, reckless and negligent conduct that
fails to comply with the rules and regulations of the Centers for Medicare &amp; Medicaid Services (the &#8220;CMS&#8221;), the FDA, the
EMA, the MRHA and other comparable regulatory authorities; provide true, complete and accurate information to such regulatory authorities;
comply with manufacturing and clinical laboratory standards; comply with healthcare fraud and abuse laws in the United Kingdom, Europe,
Canada, and, in the future, the United States and similar fraudulent misconduct laws; or report financial information or data accurately
or to disclose unauthorized activities to Renovaro Cube or BioSymetrics. When Renovaro Cube begins commercializing its products in the
United Kingdom and Europe and, in the future, the United States, its potential exposure under such laws will increase significantly, and
its costs associated with compliance with such laws are also likely to increase. In particular, research, sales, marketing, education
and other business arrangements in the healthcare industry are subject to extensive laws designed to prevent fraud, kickbacks,&#160;self-dealing&#160;and
other abusive practices,</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"></p>

<!-- Field: Page; Sequence: 49 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt; background-color: white">as well as&#160;off-label&#160;product promotion. These laws and regulations may restrict or prohibit a wide
range of pricing, discounting, educating, marketing and promotion, sales and commission, certain customer incentive programs and other
business arrangements generally. Activities subject to these laws also involve the improper use of information obtained in the course
of clinical validation, which could result in regulatory sanctions and cause serious harm to Renovaro Cube&#8217;s reputation. Renovaro
Cube and BioSymetrics have each adopted a code of business conduct and ethics, but it is not always possible to identify and deter misconduct
by employees and third parties, and the precautions taken to detect and prevent this activity may not be effective in controlling unknown
or unmanaged risks or losses or in protecting each entity from governmental investigations or other actions or lawsuits stemming from
a failure to be in compliance with such laws. If any such actions are instituted against Renovaro Cube or BioSymetrics, and either is
not successful in defending itself or asserting its rights, those actions could have a significant impact on each&#8217;s business, including
the imposition of significant fines or other sanctions. Even if it is later determined after an action is instituted against Renovaro
Cube or BioSymetrics that either was not in violation of these laws, Renovaro Cube or BioSymetrics may be faced with negative publicity,
incur significant expenses defending its actions and have to divert significant management resources from other matters.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Risks Related To Our Business Operations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Our business plan may lead
to the initiation of one or more product development programs, the discontinuation of one or more development programs, or the execution
of one or more transactions that investors do not agree with or that investors do not perceive as favorable to their investment in our
Common Stock.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are pursuing a strategy to,
dependent upon raising sufficient funding to do so, leverage our clinical experience and expertise for the clinical development and regulatory
approval of our gene therapy product candidates and advance our AI-driven healthcare technology. As part of our ongoing business strategy,
we continue to explore potential opportunities to acquire or license new product candidates and to collaborate on our existing products
in development. We cannot be certain that our product candidates will be successfully developed, or that the early clinical trial results
of our therapeutic product candidates will be predictive of future clinical trial results. During 2022, we decided to abandon our pan-coronavirus
and influenza pipelines as the results did not support further development. We again may determine at any time that one or more of our
in-licensed product candidates is not suitable for continued development due to cost, feasibility of obtaining regulatory approvals or
any other reason, and may terminate the related license.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our business plan requires us
to be successful in a number of challenging, uncertain and risky activities, including pursuing development of our gene therapy product
candidates in indications for which we have limited or no human clinical data, designing and executing a nonclinical and/or clinical development
program for our product candidates, building internal or outsourced gene therapy capabilities, converting early stage gene therapy research
efforts into clinical development opportunities, identifying additional promising new assets for development that are available for acquisition
or in-license and that fit our strategic focus and identifying potential partners to collaborate on our products. We may not be successful
at one or more of the activities required for us to execute this business plan. In addition, we may consider other strategic alternatives,
such as mergers, acquisitions, divestitures, joint ventures, partnerships and collaborations. We cannot be sure when or if any type of
transaction will result. Even if we pursue a transaction, such transaction may not be consistent with our stockholders&#8217; expectations
or may not ultimately be favorable for our stockholders, either in the shorter or longer term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our growth prospects and the future
value of our Company are primarily dependent on the progress of our ongoing and planned development programs for our product candidates
as well as the outcome of our ongoing business development efforts and pipeline progression, together with the amount of our remaining
available cash. The development of our product candidates and the outcome of our ongoing business development efforts and pipeline are
highly uncertain. We expect to continue to reassess and make changes to our existing development programs and pipeline strategy. Our plans
for our development programs may be affected by the results of competitors&#8217; clinical trials of product candidates addressing our
current target indications, and our business development efforts and pipeline progression may also be affected by the results of competitors&#8217;
ongoing research and development efforts. We may modify, expand or terminate some or all our development programs, clinical trials or
collaborative research programs at any time as a result of new competitive information or as the result of changes to our product pipeline
or business development strategy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 50 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>If serious adverse events
or other undesirable side effects or safety concerns attributable to our product candidates occur, they may adversely affect or delay
our clinical development and commercialization of some or all of our product candidates. </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Undesirable side effects or safety
concerns caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt our clinical trials and
could result in a more restrictive label or the delay or denial of regulatory approval. If treatment-related serious adverse events (&#8220;SAEs&#8221;)
or other undesirable side effects or safety concerns, or unexpected characteristics attributable to our product candidates are observed
in any future clinical trials, they may adversely affect or delay our clinical development and commercialization of the effected product
candidate, and the occurrence of these events could have a material adverse effect on our business and financial prospects. Results of
our future clinical trials could reveal a high and unacceptable severity and prevalence of adverse side effects. In such an event, our
trials could be suspended or terminated, and the FDA or other regulatory agency could order us to cease further development of or deny
approval of our product candidates for any or all targeted indications. The drug-related side effects could affect patient recruitment
or the ability of enrolled patients to complete the trial or result in potential product liability claims.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Additionally, if any of our product
candidates receives marketing approval and we or others later identify undesirable or unacceptable side effects or safety concerns caused
by these product candidates, a number of potentially significant negative consequences could result, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 20px">&#160;</td>
    <td style="width: 20px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">regulatory authorities may withdraw, suspend, or limit approvals of such products and require us to take them off the market;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">regulatory authorities may require the addition of labeling statements, specific warnings, a contraindication or field alerts to physicians and pharmacies;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">regulatory authorities may require a medication guide outlining the risks of such side effects for distribution to patients, or that we implement a REMS or REMS-like plan to ensure that the benefits of the product outweigh its risks;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 20px">&#160;</td>
    <td style="width: 20px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">we may be required to change the way a product is distributed or administered, conduct additional clinical trials, or change the labeling of a product;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">we may be required to conduct additional post-marketing studies or surveillance;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">we may be subject to limitations on how we may promote the product;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">sales of the product may decrease significantly;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">we may be subject to regulatory investigations,</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">we may be subject to government enforcement actions, litigation, or product liability claims; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td><span style="font-size: 10pt">our products may become less competitive, or our reputation may suffer.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Any of these events could prevent
us or any collaborators from achieving or maintaining market acceptance of our product candidates or could substantially increase commercialization
costs and expenses, which in turn could delay or prevent us from generating revenue from the sale of our product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>Renovaro
Cube&#8217;s and BioSymetrics&#8217; business is subject to economic, political, regulatory and other risks associated with international
operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Renovaro
Cube&#8217;s and BioSymetrics&#8217; business is subject to risks associated with conducting business internationally. For example, some
of Renovaro Cube&#8217;s and BioSymetrics&#8217; suppliers and parties with whom they have collaborative relationships are located outside
of the United States, including in Canada, the United Kingdom, and Israel. Accordingly, Renovaro Cube&#8217;s and BioSymetrics&#8217;
future results could be harmed by a variety of factors, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"></p>

<!-- Field: Page; Sequence: 51 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr>
    <td style="width: 20px">&#160;</td>
    <td style="vertical-align: top; width: 20px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">economic weakness, including inflation, or political instability in particular&#160;foreign economies and markets;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">challenges enforcing its contractual and intellectual property rights, especially in those foreign jurisdictions that do not respect and protect intellectual property rights to the same extent as the Netherlands;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">changes in&#160;foreign&#160;laws,&#160;regulations and customs, tariffs and trade barriers;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">changes in foreign currency exchange rates;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">changes in a specific countries or region&#8217;s political or economic environment;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">negative consequences from changes in tax laws;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">trade protection measures, import or export licensing requirements or other restrictive actions by the Netherlands or foreign governments;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">workforce uncertainty in countries where labor unrest is more common than in the Netherlands;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">difficulties associated with staffing and managing international operations, including differing labor relations; and</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">business interruptions resulting from&#160;geo-political&#160;actions, including war and terrorism, pandemics, or natural disasters, including earthquakes, typhoons, floods and fires.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>&#160;</i></b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><b><i>If
we are sued for product or professional liability, we could face substantial liabilities that exceed our resources.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Renovaro
Cube&#8217;s business depends upon its ability to obtain reliable and accurate test results that incorporate rapidly evolving understanding
of how to interpret minute signals detected by Renovaro Cube&#8217;s assays as indications of potential presence of disease. Actual or
perceived errors resulting from laboratory or reporting errors, false positive or false negative test results, or the manufacture, design,
or labelling of Renovaro Cube&#8217;s products, could subject Renovaro Cube to product liability or professional liability claims. A product
liability or professional liability claim against Renovaro Cube could result in substantial damage and be costly and&#160;time-consuming&#160;to
defend. Any liability claim brought against Renovaro Cube, with or without merit, could increase its insurance rates or prevent it from
securing insurance coverage in the future. Additionally, any liability lawsuit could damage Renovaro Cube&#8217;s reputation or force
it to delay or suspend sales of its products. The occurrence of any of these events could have a material adverse effect on Renovaro Cube&#8217;s
business, results of operations, financial condition and prospects. The same would apply to products of BioSymetrics.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Risks Related to our Common Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Our stock price has been and will likely continue to be volatile
and may decline regardless of our operating performance.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our stock price has fluctuated in the past and can be expected to be volatile
in the future. From September 26, 2024, through September 26, 2025, the reported sale price of our Common Stock has fluctuated between
$1.91 and $0.13 per share. The stock market in general and the market for biotechnology and technology companies in particular have experienced
extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility,
investors may experience losses on their investment in our Common Stock. The market price of our Common Stock may be influenced by many
factors, including the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 20px; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; width: 20px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">negative publicity;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our compliance with Nasdaq rules and regulations;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the success of competitive products or technologies;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">regulatory actions with respect to our product candidates or products or our competitors&#8217; product candidates or products;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 52 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 20px; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; width: 20px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">actual or anticipated changes in our growth rate relative to our competitors;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations, or capital commitments;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">results of clinical studies of our product candidates or those of our competitors;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">regulatory or legal developments in the U.S. and other countries;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">developments or disputes concerning patent applications, issued patents or other proprietary rights;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">the recruitment or departure of key personnel;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the level of expenses related to any of our product candidates or clinical development programs;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the results of our efforts to in-license or acquire additional product candidates or products;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">variations in our financial results or those of companies that are perceived to be similar to us;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">fluctuations in the valuation of companies perceived by investors to be comparable to us;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">inconsistent trading volume levels of our shares;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">announcement or expectation of additional financing efforts;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">sales of our Common Stock by us, our insiders or our other stockholders;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr>
    <td style="width: 20px">&#160;</td>
    <td style="vertical-align: top; width: 20px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">market conditions in the pharmaceutical and biotechnology sectors;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">general economic, industry and market conditions; and</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">the other risks described in this &#8220;Risk Factors&#8221; section.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, the stock markets
in general, and the markets for biotechnology, pharmaceutical and technology stocks in particular, have experienced significant volatility
that has often been unrelated to the operating performance of particular companies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><b><i>Sales of a substantial number of shares of our
Common Stock in the public market could cause our stock price to fall.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The market price of our Common
Stock could decline as a result of substantial sales of our Common Stock in the public market, or the perception that such sales could
occur. Because the majority of our outstanding shares of Common Stock are registered and unrestricted, they may be sold in the public
market at any time. Any such sales, or the availability of those shares for sale, could adversely affect the trading price of our Common
Stock and make it more difficult for us to raise capital through future equity offerings. In addition, a decline in the trading price
of our Common Stock could impair our ability to retain and recruit employees, many of whom are granted stock-based awards that vest over
time and are influenced by the market value of our Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 53 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>We have incurred and will
continue to incur increased costs as a result of being a public company and our management expects to devote substantial time to public
company compliance programs.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As a public company, we have incurred
and will continue to incur significant legal, accounting and other expenses. We are subject to the reporting requirements of the Exchange
Act, which require, among other things, that we file with the SEC annual, quarterly, and current reports with respect to our business
and financial condition. In addition, the Sarbanes-Oxley Act, as well as rules subsequently adopted by the SEC and The Nasdaq Stock Market
to implement provisions of the Sarbanes-Oxley Act, impose significant requirements on public companies, including requiring establishment
and maintenance of effective disclosure and financial controls and changes in corporate governance practices. As a Smaller Reporting Company
and Non-accelerated Filer, we are able to take advantage of certain accommodations afforded to such companies, including being exempt
from the requirement to conduct an audit of our internal controls. In the event we no longer qualify as a Smaller Reporting Company and
Non-accelerated Filer, we will lose such accommodations, which could involve significant costs that could affect our operations. Changes
in reporting requirements, the current political environment and the potential for future regulatory reform may lead to substantial new
regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business
in ways we cannot currently anticipate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The rules and regulations applicable
to public companies have substantially increased our legal and financial compliance costs and make some activities more time-consuming
and costly. To the extent these requirements divert the attention of our management and personnel from other business concerns, they could
have a material adverse effect on our business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Because we do not anticipate
paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be the sole source of potential
gain for our stockholders.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have never declared or paid
cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development
of our business. As a result, capital appreciation, if any, of our Common Stock will be the sole source of gain for our stockholders for
the foreseeable future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Future sales and issuances
of our Common Stock or rights to purchase Common Stock, including pursuant to our equity incentive plans, could result in additional dilution
of the percentage ownership of our stockholders and could cause our stock price to fall.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We expect that significant additional
capital will be needed in the future to continue our planned operations. To raise capital, we may sell substantial amounts of Common Stock
or securities convertible into or exchangeable for Common Stock in one or more transactions at prices and in a manner, we determine from
time to time. These future issuances of Common Stock or Common Stock-related securities, together with the exercise of outstanding options
or warrants, and any additional shares that may be issued in connection with acquisitions or licenses, if any, may result in material
dilution to our investors. Such sales may also result in material dilution to our existing stockholders, and new investors could gain
rights, preferences, and privileges senior to those of holders of our Common Stock. Pursuant to our equity incentive plans, our Compensation
Committee is authorized to grant equity-based incentive awards to our employees, non-employee directors and consultants. Future grants
of RSUs, options and other equity awards and issuances of Common Stock under our equity incentive plans will result in dilution and may
have an adverse effect on the market price of our Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Some terms of our charter
documents and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition
would be beneficial to our stockholders and may prevent attempts by our stockholders to replace or remove our current management.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our Certificate of Incorporation,
and our Bylaws, as well as Delaware law, could make it more difficult for a third party to acquire us or increase the cost of acquiring
us, even if doing so would benefit our stockholders, or remove our current management. These include terms that:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 54 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 20px; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; width: 20px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">permit our Board of Directors to issue up to 10,000,000 shares of preferred stock, with any rights, preferences, and privileges as they may designate;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">provide that all vacancies on our Board of Directors, including as a result of newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide advance notice in writing, and also specify requirements as to the form and content of a stockholder&#8217;s notice; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">do not provide for cumulative voting rights, thereby allowing the holders of a majority of the shares of Common Stock entitled to vote in any election of directors to elect all of the directors standing for election. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Any of the factors listed above
may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for
stockholders to replace members of our Board of Directors, who are responsible for appointing the members of our management.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, because we are incorporated
in Delaware, we are governed by Section 203 of the Delaware General Corporation Law, which may discourage, delay or prevent someone from
acquiring us or merging with us whether or not it is desired by or beneficial to our stockholders. Under Delaware law, a corporation may
not, in general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock
for three years or, among other things, the Board of Directors has approved the transaction. Any term of our Certificate of Incorporation
or Bylaws or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders
to receive a premium for their shares of our Common Stock and could also affect the price that some investors are willing to pay for our
Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_004"></span>1B. Unresolved Staff Comments</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Not applicable.</p>

<div id="xdx_982_ecyd--CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_iB_c20240701__20250630_z8tui5vslgDg" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000051" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_005"></span>1C. Cybersecurity Risk Management and Strategy</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Lunai has established a comprehensive cybersecurity
risk management program aimed at safeguarding the confidentiality, integrity, and availability of our essential systems and information.
Central to our cybersecurity efforts is a robust incident response plan designed to address potential cyber incidents swiftly and effectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In designing and evaluating our cybersecurity initiatives,
we have adopted the National Institute of Standards and Technology Cybersecurity Framework (NIST CSF 2.0) as a guiding principle. It&#8217;s
important to clarify that our use of the NIST CSF 2.0 is for guidance purposes to frame our risk identification, assessment, and management
processes and does not equate to compliance with any specific technical standards or requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span id="xdx_909_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_c20240701__20250630_zDLga0DalTY2" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000052" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock">Our cybersecurity framework is seamlessly <span id="xdx_902_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240701__20250630_zNhQtaEQyyN4" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" format="ixt:booleantrue" id="Fact000053" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag">integrated</ix:nonNumeric>
</span>broader enterprise risk management strategy, sharing methodologies, reporting mechanisms, and <span id="xdx_901_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20240701__20250630_zMZIGsSwP4Lj" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><span id="xdx_909_ecyd--CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_dbT_c20240701__20250630_zW0Q3zUCKb87" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><span id="xdx_90D_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbT_c20240701__20250630_zFeXpLgHgOM3" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" format="ixt:booleantrue" id="Fact000054" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" format="ixt:booleantrue" id="Fact000055" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" format="ixt:booleantrue" id="Fact000056" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">governance structures</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></span></span></span> with other risk domains
including legal, compliance, strategic, operational, and financial risks.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Key components of our cybersecurity risk management program include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_ecyd--CybersecurityRiskRoleOfManagementTextBlock_c20240701__20250630_zVmUDpMuvk8l" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000057" name="cyd:CybersecurityRiskRoleOfManagementTextBlock">Conducting risk assessments to pinpoint <span id="xdx_90C_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_dbT_c20240701__20250630_zkWS6UoQT297" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" format="ixt:booleantrue" id="Fact000058" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">material</ix:nonNumeric></span> cybersecurity
    threats to our critical systems, data, products, services, and overall IT infrastructure.</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#9679;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A dedicated security team overseeing the risk assessment
    processes, maintenance of security controls, and coordination of responses to cybersecurity incidents.</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 55 -->
    <div id="xdx_238_zFFy9Yd9vfT" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div>
    <div id="xdx_233_zL2qmvAynuzg" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_238_zVFP6uOtqbJe" style="margin: 0">&#160;</p></ix:exclude>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Engagement with external service providers to evaluate,
    enhance, or support our security measures.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive cybersecurity training programs for employees,
    incident responders, and senior management to foster a culture of security awareness.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An incident response plan outlining specific procedures
    for managing cybersecurity incidents.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A thorough third-party risk management process to evaluate
    and manage risks associated with service providers, suppliers, and vendors.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">To date, we have not identified any cybersecurity
threats or past incidents that have had, or are likely to have, a material impact on our company&#8217;s operations, business strategy,
financial performance, or results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&#160;</p>

<div id="xdx_98F_ecyd--CybersecurityRiskBoardOfDirectorsOversightTextBlock_c20240701__20250630_zrWKq2PZKUOj" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000060" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Cybersecurity Governance:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The governance of cybersecurity risks is a critical
function of our Board of Directors, with the Audit Committee (the &#8220;Committee&#8221;) playing a key role in the oversight of cybersecurity
and related technology risks. The Committee is tasked with monitoring the effectiveness of our cybersecurity risk management program as
implemented by management.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The Committee receives regular updates from management
on the state of cybersecurity risks facing the company. This includes briefings on any significant cyber incidents and ongoing risk management
efforts. These updates enable the Committee to provide informed reports on cybersecurity matters to the full Board.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span id="xdx_90B_ecyd--CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20240701__20250630_zBbYgFic1Y3l" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000061" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">Our Board is actively involved in our cybersecurity
oversight, receiving detailed briefings from internal technology teams or external cybersecurity experts. These sessions are part of the
Board&#8217;s commitment to continuous learning and staying informed about issues critical to public companies, including cybersecurity.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The responsibility for day-to-day management of cybersecurity
risks lies with our management team, including the Chief Financial Officer. <span id="xdx_909_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_c20240701__20250630_zftgl5LXRPv4" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000062" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">This team is at the forefront of our cybersecurity initiatives,
coordinating both internal and external resources to anticipate, identify, and mitigate cyber <span id="xdx_900_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_dbT_c20240701__20250630_zs0rj4wsEPZa" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" format="ixt:booleantrue" id="Fact000063" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">threats</ix:nonNumeric></span>.</ix:nonNumeric></span> Our approach includes regular updates
from internal security teams, leveraging intelligence from various sources, and utilizing advanced security tools to protect our digital
environment.</p>

</ix:nonNumeric></div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

</ix:nonNumeric></div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_006"></span>Item 2. Properties</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company currently leases the following properties:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: white">
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt">Location</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: justify"><span style="font-size: 10pt">Use</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 71%; text-align: justify"><span style="font-size: 10pt">Terms</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">2080 Century Park East, Suite 906 <br/>
Los Angeles, CA 90067</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Headquarters</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">The Company entered into a Lease Agreement on June 19, 2018 for our corporate headquarters located at Century City Medical Plaza. We have a ten-year lease that was for approximately 2,453 square feet at this location. In February 2019, we extended our corporate headquarters to encompass the adjoining suite for approximately 1,101 square feet, bringing the total workspace to 3,554 square feet. The new base rent for this leased premises increases by 3% each year over the term, and ranges from $17,770 per month as of the date of the amendment until the end of the first year to $23,186 per month for the tenth year. The additional suite was in the form of an amendment to the original lease and will expire on the same date as the original lease. The Company was entitled to a total of $148,168 in contributions toward tenant improvements for both spaces.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><p style="margin-top: 0; margin-bottom: 0">101 Plaza Real South, Suite 202,</p>
                    <p style="margin-top: 0; margin-bottom: 0"></p>
                    <p style="margin-top: 0; margin-bottom: 0">Boca Raton, FL 33432</p></td>
    <td><p style="margin-top: 0; margin-bottom: 0">&#160;</p></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Lunai Bioworks Inc.</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">Lunai leases an office lease in Boca Raton, Florida, under a
    36-month operating lease agreement commencing on November 1, 2024, with a maturity date of October 31, 2027. In determining lease asset
    values, the Company considers fixed and variable payment terms, prepayments, incentives, and options to extend, terminate or purchase.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 56 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_007"></span>Item 3. Legal Proceedings </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i>Securities Class Action Litigation</i>.
On July 26, 2022 and July 28, 2022, securities class action complaints (the former, the &#8220;Chow Action&#8221; and the latter, the
Manici Action&#8221;) were filed by purported stockholders of the Company in the United States District Court for the Central District
of California against the Company and certain of the Company&#8217;s current and former officers and directors. The complaints allege,
among other things, that the defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule
10b-5 thereunder, by making false and misleading statements and omissions of material fact in connection with the Company&#8217;s relationship
with Serhat G&#252;mr&#252;kc&#252; and its commercial prospects. The complaints seek unspecified damages, interest, fees, and costs.
On November 22, 2022, the Manici Action was voluntarily dismissed without prejudice. The Chow Action (also referred to as the &#8220;Securities
Class Action Litigation&#8221;) remains pending. On October 22, 2023, the Court appointed a lead plaintiff in the Chow Action. The lead
plaintiff filed an amended complaint on December 15, 2023. The Company filed a motion to dismiss the amended complaint on March 15, 2024.
The Court denied the Company&#8217;s motion to dismiss on June 28, 2024. A mediation was held on September 17, 2024, after which the parties
signed a stipulation of settlement. The court granted the lead plaintiff&#8217;s motion for preliminary approval of the settlement on
August 18, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i>Federal Derivative Litigation</i>.
On September 22, 2022, Samuel E. Koenig filed a shareholder derivative action in the United States District Court for the Central District
of California (the &#8220;Koenig Matter&#8221;). The Koenig Matter, filed on behalf of the Company, names Serhat G&#252;mr&#252;kc&#252;
and certain of the Company&#8217;s current and former directors as defendants, and also names the Company as a nominal defendant. The
Koenig Matter alleges violations of Sections 14(a) and 20(a) of the Securities Exchange Act of 1934, and also sets out claims for breach
of fiduciary duty, contribution and indemnification, aiding and abetting, and gross mismanagement. Plaintiff does not quantify any alleged
injury, but seeks damages, disgorgement, restitution, and other costs and expenses. On January 24, 2023, the United States District Court
for the Central District of California stayed the Koenig Matter pending resolution of the defendants&#8217; anticipated motion to dismiss
in the Securities Class Action Litigation. On June 28, 2024, the United States District Court for the Central District of California denied
defendants&#8217; motion to dismiss the Securities Class Action Litigation. On July 14, 2025, the Court stayed the Koenig Matter until
October 17, 2025. The defendants have not yet responded to the complaint.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On January 19, 2023, John Solak
filed a shareholder derivative action in the United States District Court for the District of Delaware (the &#8220;Solak Matter&#8221;).
The Solak Matter, filed on behalf of the Company, names Serhat G&#252;mr&#252;kc&#252; and certain of the Company&#8217;s current and
former directors as defendants, and also names the Company as a nominal defendant. The Solak Matter alleges violations of Section 14(a)
of the Securities Exchange Act of 1934 and SEC Rule 14a-9 promulgated thereunder, and also sets out claims for breach of fiduciary duty
and contribution and indemnification. Plaintiff does not quantify any alleged injury, but seeks damages, disgorgement, restitution, and
other costs and expenses. On April 6, 2023, the United States District Court for the District of Delaware stayed the Solak Matter pending
resolution of the defendants&#8217; anticipated motion to dismiss in the Securities Class Action Litigation. On June 28, 2024, the United
States District Court for the Central District of California denied defendants&#8217; motion to dismiss the Securities Class Action Litigation.
On July 29, 2025, the court stayed the Solak Matter for 90 days. The defendants have not yet responded to the complaint.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company intends to contest
these matters but expresses no opinion as to the likelihood of favorable outcomes. Management is unable to determine the likelihood of
a loss, including a possible range of losses, if any, arising from this matter as of the reporting date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i>State Derivative Litigation</i>.
On October 20, 2022, Susan Midler filed a shareholder derivative action in the Superior Court of California, Los Angeles County (the &#8220;Midler
Matter&#8221;). The Midler Matter, filed on behalf of the Company, names Serhat G&#252;mr&#252;kc&#252; and certain of the Company&#8217;s
current and former directors as defendants. The Midler Matter also names the Company as a nominal defendant. The Midler Matter sets out
claims for breaches of fiduciary duty, contribution and indemnification, aiding and abetting, and gross mismanagement. Plaintiff does
not quantify any alleged injury, but seeks damages, disgorgement, restitution, and other costs and expenses. On January 20, 2023, the
Court stayed the Midler Matter pending resolution of the defendants&#8217; anticipated motion to dismiss in the Securities Class Action
Litigation. On June 28, 2024, the United States District Court for the Central District of California denied defendants&#8217; motion
to dismiss the Securities Class Action Litigation. On July 31, 2025, the court stayed the Midler Matter for 120 days. The defendants have
not yet responded to the complaint. The Company intends to contest this matter but expresses no opinion as to the likelihood of a favorable
outcome. Management is unable to determine the likelihood of a loss, including a possible range of losses, if any, arising from this matter
as of the reporting date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 57 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On October
21, 2022, the Company filed a Complaint in the Superior Court of the State of California for the County of Los Angeles against Serhat
G&#252;mr&#252;kc&#252; (&#8220;Gumrukcu&#8221;), William Anderson Wittekind (&#8220;Wittekind&#8221;), G Tech Bio, SG &amp; AW Holdings,
LLC, and SRI (collectively, the &#8220;Defendants&#8221;). The Complaint alleges that the Defendants engaged in a &#8220;concerted, deliberate
scheme to alter, falsify, and misrepresent to the Company the results of multiple studies supporting its Hepatitis B and SARS-CoV-2/influenza
pipelines.&#8221; Specifically, &#8220;Defendants manipulated negative results to reflect positive outcomes from various studies, and
even fabricated studies out of whole cloth.&#8221; As a result of the Defendants&#8217; conduct, the Company claims that it &#8220;paid
approximately $25 million to Defendants and third-parties that it would not otherwise have paid.&#8221; On April 21, 2023, defendants
Wittekind, G Tech, SG &amp; AW Holdings, LLC, and SRI filed a demurrer with respect to some, but not all, of the Company&#8217;s claims,
as well as a motion to strike. On September 6, 2023, the court denied in part and granted in part the pending motions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On December
4, 2023, the Defendants answered the Company&#8217;s First Amended Complaint and G Tech and SRI filed a Cross-Complaint. In the Cross-Complaint,
G Tech and SRI seek declaratory and injunctive relief related to certain agreements between G Tech, SRI, and the Company, including, <i>inter
alia</i>, a declaration that the Framework Agreement, effective as of November 15, 2019, the Statement of Work &amp; License Agreement,
effective as of January 31, 2020, and the Statement of Work and License Agreement for Influenza and Coronavirus Indications, effective
as of April 18, 2021, have been terminated and the Company has no rights to any license under such agreements. Trial was scheduled to
begin on March 3, 2025. On November 14, 2024, the court vacated the March 3, 2025, trial date and set a trial setting conference for May
1, 2025. At the May 1, 2025, trial setting conference, the court reset the trial to begin on November 30, 2026. Discovery remains ongoing.
The Company denies the allegations in Defendants&#8217; cross claims and intends to vigorously defend against them while pursuing its
claims against the Defendants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On June
7, 2023, Weird Science LLC (&#8220;Weird Science&#8221;), Wittekind, the William Anderson Wittekind 2020 Annuity Trust, the William Anderson
Wittekind 2021 Annuity Trust, the Dybul 2020 Angel Annuity Trust, and the Ty Mabry 2021 Annuity Trust (collectively, the &#8220;Trusts&#8221;)
(collectively, &#8220;Plaintiffs&#8221;) filed a Verified Complaint against the Company in the Court of Chancery of Delaware. In the Verified
Complaint, Plaintiffs alleged that the Company breached the February 16, 2018 Investor Rights Agreement between the Company, Weird Science,
and RS Group ApS (the &#8220;Investor Rights Agreement&#8221;). According to the Verified Complaint, the Investor Rights Agreement required
the Company to (i) notify all &#8220;Holders&#8221; of &#8220;Registrable Securities&#8221; at least 30 days prior to filing a registration
statement and (ii) afford such Holders an opportunity to have their Registrable Securities included in such registration statement. Plaintiffs
alleged that the Company breached these registration rights by failing to provide the required notice in connection with S-3 registration
statements filed by the Company on July 13, 2020 and February 11, 2022. The Company moved to dismiss the Verified Complaint on September
15, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On December
4, 2023, in lieu of opposing the motion to dismiss, Plaintiffs filed a Verified First Amended Complaint (&#8220;FAC&#8221;). In the FAC,
Plaintiffs assert claims against the Company and others for purported breaches of the Investor Rights Agreement, fraud, tortious interference
with a contract, and several other torts. Plaintiffs seek compensatory, exemplary, and punitive damages, as well as certain declaratory
relief, specific performance, and pre- and post-judgment interest, costs, and attorneys&#8217; fees. The Company filed a motion to dismiss
the FAC on December 18, 2023 and the court held a hearing on November 15, 2024. At the hearing, the court dismissed (1) all claims brought
on behalf of Wittekind and the Trusts, (2) the fraudulent concealment claim against the Company and others (without prejudice), and (3)
the breach of contract claim against the Company related to a registration statement that was not filed in 2023. At the hearing, the court
also found that punitive damages were not available to Plaintiffs. The court took the remaining issues briefed on the Company&#8217;s
motion to dismiss under advisement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On February
26, 2025, the Court ruled on the balance of the claims against the Company and (1) denied the Company&#8217;s motion to dismiss Weird
Science&#8217;s breach of contract claims related to registration statements filed in 2020 and 2022; (2) dismissed the fraudulent inducement
claim as time barred; and (3) dismissed the declaratory judgment claim. The Company denies Plaintiffs&#8217; allegations and remaining
claims and intends to vigorously defend against these claims.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"></p>

<!-- Field: Page; Sequence: 58 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On August
24, 2023, counsel on behalf of Weird Science, Wittekind, individually, and Wittekind, as trustee of the Trusts served a demand to inspect
the Company&#8217;s books and records (the &#8220;Demand&#8221;) pursuant to Delaware General Corporation Law, &#167; 220 (&#8220;Section
220&#8221;). The Demand seeks the Company&#8217;s books and records in connection with various issues identified in the Demand. The Company
takes its obligations under Section 220 seriously and, to the extent that the requests are proper under Section 220, intends to comply
with those obligations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On January 19, 2024, Weird Science
and Wittekind sent the Board of Directors a letter demanding it take corrective actions with respect to twenty-one issues identified therein.
On February 27, 2024, Weird Science and Wittekind sent the Board of Directors a supplemental letter that expanded their demand for corrective
actions to twenty-six issues. In response to these demand letters, the Board of Directors initially formed a Special Committee (&#8220;Special
Committee&#8221;) of independent directors on February 29, 2024. The Special Committee retained Stradling Yocca Carlson &amp; Rauth LLP
as its counsel to investigate the issues identified in the demand letters.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On January 23, 2024, Weird Science
and Wittekind filed a shareholder derivative action in the United States District Court for the Central District of California against
certain officers, directors, and investors of the Company, as well as other defendants, in connection with, <i>inter alia</i>, Weird Science
and Wittekind&#8217;s demand for corrective action. Plaintiffs filed an amended complaint on June 21, 2024. The First Amended Verified
Stockholder Derivative Complaint (&#8220;Derivative Complaint&#8221;) alleges, among other claims, violations of Section 13(d) and 14(a)
and Rules 10b-5(a), 10b-5(c) and 14a-9 of the Exchange Act of 1934. The Derivative Complaint also includes claims of breach of fiduciary
duty, corporate waste, unjust enrichment, and contribution/indemnification. Weird Science and Wittekind seek unspecified compensatory,
exemplary, and punitive damages and certain injunctive relief. The Derivative Complaint names the Company as a nominal defendant. On July
19, 2024, certain of the director defendants, who had agreed to waive service of the summons and Derivative Complaint, filed a motion
to dismiss the Derivative Complaint on a variety of procedural and substantive grounds. A hearing on the motion dismiss was held on October
3, 2024 and the court subsequently took the motion under submission. On October 22, 2024, the plaintiffs filed a notice of certain subsequent
events that they allege relate to their pending motion to dismiss. On October 29, 2024, the court granted the director defendants&#8217;
motion to dismiss and dismissed the Derivative Complaint without prejudice, but also without leave to amend.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On November 27, 2024, Weird Science
and Wittekind filed a notice of appeal of the court&#8217;s decision granting the director defendants&#8217; motion to dismiss. The appeal
remains pending.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On June 21, 2024, the Company
filed suit against Weird Science, Gumrukcu, Wittekind, and certain trusts in connection with the February 16, 2018 merger involving the
Company and two companies closely associated with Gumrukcu. In the complaint, the Company alleges that G&#252;mr&#252;kc&#252;and others
deliberately and fraudulently concealed a murder-for-hire scheme from the Company in order to induce the Company to enter into the merger
agreement, which resulted in the defendants receiving shares and compensation. The Company asserts claims for fraudulent concealment,
equitable fraud, unjust enrichment, and civil conspiracy and seeks, <i>inter alia</i>, equitable relief, including, but not limited to,
return to the Company any shares received in connection with the merger, and damages. On October 1, 2024, the defendants moved to dismiss
the complaint. A hearing took place on June 25, 2025 and the Court took defendants&#8217; motion under advisement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Renovaro, Inc. (&#8220;Renovaro&#8221;)
commenced an action against Predictive Oncology, Inc. (&#8220;POAI&#8221;) in the Delaware Court of Chancery claiming that POAI breached
a &#8220;definitive&#8221; January 2025 Letter Agreement pursuant to which Renovaro was going to acquire POAI. As a result of its breach,
POAI made that acquisition impossible and dramatically devalued the share price of stock Renovaro had already acquired as well as the
value of the company it was contractually entitled to acquire. Renovaro sought specific perfo1mance or, in the alternative, money damages.
The parties have exchanged paper discovery and noticed depositions. The action has been held in abeyance while the parties attempt to
negotiate a settlement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_008"></span>Item 4. Mine Safety Disclosures.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 59 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_009"></span>PART II</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="a_010"></span>Item 5. Market for Registrant&#8217;s Common Equity,
Related Stockholder Matters and Issuer Purchases of Equity Securities </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Market Information and Holders of our Common Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our Common Stock trades on the
Nasdaq Capital Market under the symbol &#8220;RENB&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of September 26, 2025, the
Company had 231,802,470 shares of Common Stock issued and approximately 233 stockholders of record. The actual number of stockholders
is greater than this number of record holders and includes stockholders who are beneficial owners but whose shares are held in street
name by brokers and other nominees.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Recent Sales of Unregistered Securities</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Company Purchases of Equity Securities</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Dividends</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company has not declared or
paid any cash dividends on its Common Stock and does not intend to declare or pay any cash dividends in the foreseeable future. The payment
of dividends, if any, is within the discretion of the Board and will depend on the Company&#8217;s earnings, if any, its capital requirements
and financial condition and such other factors as the Board may consider.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_011"></span>Item 6. [Reserved]</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_012"></span>Item 7. Management&#8217;s Discussion and Analysis of Financial Condition
and Results of Operations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i>The following discussion of
our financial condition and results of operations should be read in conjunction with our financial statements, and the related notes to
those statements included elsewhere in this report. In addition to the historical financial information, the following discussion and
analysis contains forward-looking statements that involve risks and uncertainties. Our actual results may differ materially from those
anticipated in these forward-looking statements.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Our Business</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Lunai
Bioworks Inc. operates through three subsidiaries, Renovaro Biosciences,
Renovaro Cube and BioSymetrics Inc. Renovaro Cube refers to GediCube Intl. Ltd. and its wholly owned subsidiaries GediCube, B.V. and Grace
Systems B.V., which were acquired on February 13, 2024. BioSymetrics Inc. refers to BioSymetrics Inc. and its wholly owned subsidiary
BioSymetrics Corp., which were acquired on April 8, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Renovaro
Biosciences is a biotechnology company intending, if the necessary funding is obtained, to develop advanced allogeneic cell and gene therapies
to promote stronger immune system responses potentially for long-term or life-long cancer remission in some of the deadliest cancers.
As a result of our acquisition of GEDi Cube Intl on February 13, 2024 and BioSymetrics Inc. on April 8, 2025, we have shifted the Company&#8217;s
primary focus and resources to the development of the GEDi Cube Intl and BioSymetrics Inc. technologies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">To date, our operations have been
funded by sales of our securities and debt financing. We have never generated any sales revenue and we expect this to continue until our
products are approved for marketing in the United States and/or Europe. Even if we are successful in having our products approved for
sale in the United States and/or Europe, we cannot guarantee that a market for the products will develop. We may never be profitable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 60 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Recent Developments</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On September 2, 2025, the Court
of Amsterdam (the &#8220;Court&#8221;) declared bankrupt Gedi Cube B.V. (&#8220;Gedi&#8221;), an indirect subsidiary of Lunai Bioworks,
Inc. (&#8220;Lunai&#8221;), and appointed Mr. M.M. Dellebeke as the receiver in the bankruptcy. Gedi filed a voluntary petition seeking
a declaration of bankruptcy due to its inability to make payments as they became due. As a result of this, the Company determined that
a material impairment of Gedi had occurred (see Note 6 to the financial statements).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On August 18, 2025, the Company
issued Promissory Notes in the aggregate principal amount of $1,000,000. The Notes bear an interest rate of&#160;18%&#160;per annum and
mature on&#160;the 6-month anniversary of the Issue Date.,&#160;(the &#8220;Maturity Date&#8221;). The Company is required to pay principal
and interest on the Maturity Date.<b>	</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">From July 3, 2025, to August 19,
2025, the Company issued Promissory Notes in the aggregate principal amount of $695,000. The Notes bear an interest rate of&#160;10%&#160;per
annum and mature on&#160;June 30, 2026,&#160;(the &#8220;Maturity Date&#8221;). The Company is required to pay principal and interest
on the Maturity Date.<b>	</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On July 7, 2025, Renovaro Inc.
(&#8220;Renovaro&#8221;) entered into an Exchange Agreement (the &#8220;Exchange Agreement&#8221;) with certain accredited investors (the
&#8220;Investors&#8221;), all of whom are existing shareholders of the Company. Pursuant to the Exchange Agreement, the Investors agreed
to exchange an aggregate of $9.7 million in outstanding secured promissory notes (the &#8220;Secured Notes&#8221;) for $16.1 million in
new convertible promissory notes (the &#8220;Convertible Notes&#8221;), representing a 65% premium to the principal and interest amount
of the Secured Notes. The Convertible Notes mature on July 31, 2025, and do not bear any interest. The exchange was completed to restructure
the Company&#8217;s debt obligations and provide additional flexibility to support strategic initiatives.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Immediately following the issuance
of the Convertible Notes on July 7, 2025, the Investors elected to convert the entire $16.1 million principal amount into an aggregate
of 53.6 million shares of common stock (the &#8220;Conversion Shares&#8221;), based on the stated $0.30 per share conversion price. The
$0.30 per share conversion price of the Convertible Notes represented a premium to the closing price of the Company&#8217;s common stock
on July 7, 2025, the date of execution and conversion. As a result, the issuance of the 53.6 million shares of common stock upon conversion
of the Convertible Notes did not constitute a &#8220;below market&#8221; issuance under applicable Nasdaq listing rules and did not trigger
stockholder approval requirements under Nasdaq Listing Rule 5635(d). The shares were issued without any additional consideration from
the Investors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As a result of the foregoing transactions,
the Company (i) eliminated $9.7 million of secured indebtedness, (ii) issued $16.1 million in Convertible Notes to the same holders, and
(iii) issued 53.6 million shares of common stock upon full conversion of such Convertible Notes. The shares of common stock will be issued
on or before July 11, 2025, and no cash will be issued for any fractional shares. The transactions did not involve any cash proceeds to
the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Known Trends</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Going Concern and Management&#8217;s Plans</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The financial statements included
elsewhere herein for the year ended June 30, 2025, were prepared under the assumption that we would continue our operations as a going
concern, which contemplates the realization of assets and the satisfaction of liabilities during the normal course of business. As of
June 30, 2025, we had cash and cash equivalents of $92,700, an accumulated deficit of $510,462,570 and total liabilities of $29,580,681.
We have incurred losses from continuing operations, have used cash in our continuing operations, and are dependent on additional financing
to fund operations. These conditions raise substantial doubt about our ability to continue as a going concern for one year after the date
the financial statements are issued. The financial statements included elsewhere herein do not include any adjustments to reflect the
possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result
from the outcome of this uncertainty.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 61 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Management has reduced overhead
and administrative costs by streamlining the organization to focus around the development and validation of its AI driven cancer diagnostics
platform. The Company has tailored its workforce to focus on these activities. In addition, the Company intends to attempt to secure additional
required funding through equity or debt financing. However, there can be no assurance that the Company will be able to obtain any sources
of funding. Such additional funding may not be available or may not be available on reasonable terms, and, in the case of equity financing
transactions, could result in significant additional dilution to our stockholders. If we do not obtain required additional equity or debt
funding, our cash resources will be depleted and we could be required to materially reduce or suspend operations, which would likely have
a material adverse effect on our business, stock price and our relationships with third parties with whom we have business relationships,
at least until additional funding is obtained. If we do not have sufficient funds to continue operations, we could be required to seek
bankruptcy protection or other alternatives that could result in our stockholders losing some or all of their investment in us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Funding that we may receive during
fiscal 2026 is expected to be used to satisfy existing and future obligations and liabilities and working capital needs, to support commercialization
of our products and conduct the clinical and regulatory work to develop our product candidates, and to begin building working capital
reserves.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>RESULTS OF OPERATIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Year ended June 30, 2025 compared to the year ended June 30, 2024.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table sets forth
our revenues, expenses and net loss for the years ended June 30, 2025 and 2024. The financial information below is derived from our audited
consolidated financial statements included elsewhere in this Annual Report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="7" style="font-weight: bold; text-align: center">For the Years Ended</td><td>&#160;</td>
    <td colspan="7" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Increase/(Decrease)</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Operating Expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt">General and administrative</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">17,880,050</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">24,557,608</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">6,677,558</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">(27</td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">537,428</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,708,829</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,171,401</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(80</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Intangible asset impairment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,611,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(42,611,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(100</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Goodwill impairment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">170,419,429</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,640,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">158,779,429</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,364</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Depreciation and amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">129,095</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">121,859</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">7,236</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">6</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total Operating Expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">188,966,002</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">81,639,296</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">107,326,706</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">131</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">LOSS FROM OPERATIONS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(188,966,002</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(81,639,296</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(107,326,706</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">131</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Other Income (Expense)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Change in fair value of contingent consideration</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,680,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,048,183</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,728,183</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(483</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Loss on extinguishment of debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,303,578</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,303,578</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(100</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Change in fair value of equity securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(112,149</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(112,149</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(725,684</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,011,322</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">285,638</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(28</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Interest and other income (expense)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">116,346</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,423,449</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,539,795</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(108</td><td style="padding-bottom: 1pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total Other Income (Expense)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">10,958,513</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(6,786,532</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">17.745,045</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(261</td><td style="padding-bottom: 1pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">NET LOSS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(178,007,489</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(88,425,828</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(89,581,661</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">101</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="7" style="font-weight: bold; text-align: center">For the Years Ended</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Increase/(Decrease)</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 40%; font-weight: bold; text-align: left; text-indent: -10pt">Net Loss</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(178,007,489</td><td style="width: 1%; text-align: left">)</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(88,425,828</td><td style="width: 1%; text-align: left">)</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(89,581,661</td><td style="width: 1%; text-align: left">)</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">101</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Other Comprehensive Income (Loss)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;Foreign Currency Translation, net of taxes</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">10,985,688</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(140,964</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">11,126,652</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(7,893</td><td style="padding-bottom: 1pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Comprehensive Loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(167,0021,801</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(88,566,792</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(78,455,009</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">89</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 62 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Revenues</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are a pre-revenue, pre-clinical
biotechnology and artificial intelligence driven healthcare technology company. We have never generated revenues and have incurred losses
since inception. We do not anticipate earning any revenues until our therapies or products are approved for marketing and sale.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Operating Expenses</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our operating expenses for the
years ended June 30, 2025 and 2024 were $188,966,002 and $81,639,296, respectively, representing an increase of $107,326,706 or 131%.
The largest contributors to the increase in operating expenses for the year ended June 30, 2025, were the increase in the non-cash goodwill
impairment of $158,779,429 partially offset by the decreases in the non-cash intangible asset impairment of $42,611,000, general and administrative
expenses of $6,677,558 and in research and development expenses of $2,171,401 compared to the year ended June 30, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">General and administrative expenses
for the years ended June 30, 2025 and 2024, were $17,880,050 and $24,557,608, respectively, representing a decrease of $6,677,558, or
27%. The decrease in general and administrative expenses is primarily related to decreases in consulting expenses of $2,783,367, legal
expenses of $2,260,485, stock based compensation expense of $1,359,838, sales tax expense of $717,744, investor relations expenses of
$526,229, advertising expenses of $247,491, board member compensation of $238,855, partially offset by an increase in compensation related
expenses of $986,127, rent expenses of $174,590, information technology expenses of $145,199 and subscription related expenses of $112,738.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Research and development expenses
for the years ended June 30, 2025, and 2024, were $537,428 and $2,708,829, respectively, representing a decrease of $2,171,401 or 80%.
The decrease in research and development expenses is primarily related to decreases in collaborating partner expenses of $1,351,135&#160;with
CDMO and CROs related to discontinued product candidates, decreases in consulting expenses of $534,564, and decreases in consumables of
$241,982.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Other Income (Expenses)</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Net other income (expenses) for
the years ended June 30, 2025 and 2024 was $10,958,513 and $(6,786,532), respectively, representing a change of $17,745,045 or 261%. The
increase in other income was due primarily to the change in the fair value of the contingent consideration in the amount of $11,680,000,
which resulted from the mark to market adjustment on the remaining contingent consideration liability in the year ended June 30, 2025,
offset by interest expense of $725,684.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Net Loss</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Net loss for the years ended June
30, 2025 and June 30, 2024 was $178,007,489 and $88,425,828, respectively, representing an increase in net loss of $89,581,661 or 101%.
The increase in net loss was primarily due to the increase of non-cash goodwill impairment of $158,779,429, offset by the decrease in
non-cash intangible asset impairment of $42,611,000, decrease in general and administrative expenses of $6,677,558, decrease in research
and development expenses of $2,171,401 and by the change in fair value of contingent consideration of $14,728,183.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Liquidity and Capital Resources</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have historically satisfied
our capital and liquidity requirements through funding from stockholders, the sale of our Common Stock and warrants, and debt financing.
We have never generated any sales revenue to support our operations, and we expect this to continue until our therapies or products are
approved for marketing in the United States and/or Europe. Even if we are successful in having our therapies or products approved for
sale in the United States and/or Europe, we cannot guarantee that a market for the therapies or products will develop. We may never be
profitable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As noted above under the heading
&#8220;Going Concern and Management&#8217;s Plans,&#8221; through June 30, 2025, we have incurred substantial losses. We will need additional
funds both in the next twelve months and beyond for (a) research and development, (b) increases in personnel, (c) the purchase of equipment,
and investment in the development and validation of our technology. The availability of any required additional funding cannot be assured.
In addition, an adverse outcome in legal or regulatory proceedings in which we are currently involved or in the future may be involved
could adversely affect our liquidity and financial position. We may raise such funds from time to time through public or private sales
of our equity or debt securities. Such financing may not be available on acceptable terms, or at all, and our failure to raise capital
when needed could materially adversely affect our growth plans and our financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 63 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of June 30, 2025, the Company
had $92,700 in cash and working capital of $(28,109,502) as compared to $220,467 in cash and working capital of $(28,312,274) as of June
30, 2024. The decrease in cash of $127,767 is primarily due to the cost of operations of $7,874,647, investment in equity securities of
$500,000 and repayments of finance agreement of $971,231, partially <span style="background-color: white">offset by funding totaling $9,354,003
related to private placements and proceeds from note payables during the</span> period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Equity </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">On
April 8, 2025, the Company issued 15,000,000 shares of Common Stock valued at $6,058,500 pursuant to the Stock Purchase Agreement of Biosymetrics,
Inc. (see Note 10 to the Financial Statements).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On January 21, 2025, the Company
issued&#160;250,000&#160;shares of Common Stock to its Chief Executive Officer of Renovaro Cube valued at $177,500 <span style="background-color: white">(see
Note 10 to the Financial Statements).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On October 17, 2024, the Company
issued&#160;160,000&#160;shares of Common Stock for consulting services valued at $118,400 <span style="background-color: white">(see
Note 10 to the Financial Statements).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On October 14, 2024, the Company
issued&#160;500,000&#160;shares of Common Stock for consulting services valued at $275,000 <span style="background-color: white">(see
Note 10 to the Financial Statements).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On October 14, 2024, the Company
issued&#160;250,000&#160;shares of Common Stock to its Chief Executive Officer valued at $137,500 <span style="background-color: white">(see
Note 10 to the Financial Statements).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On August 1, 2024, the Company
issued&#160;2,000,000&#160;shares of Common Stock for consulting services valued at $1,400,000 <span style="background-color: white">(see
Note 10 to the Financial Statements).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Debt</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Convertible Notes Payable &#8212;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>The January 2024 Note &#8212;</i></b>
On January 12, 2024, the Company entered into Subscription Agreements with an investor to issue a Convertible Promissory Note for an aggregate
principal amount of $125,000 (the &#8220;January 2024 Note&#8221;). The Company received a total of $125,000 in gross proceeds.&#160;The
January 2024 Note bears an interest rate of 12% per annum and matured on December 29, 2024. The Company is required to pay interest quarterly,
in arrears, in cash, on the first day of each quarter of each year following the issue date prior to the maturity of the January 2024
Note. The January 2024 Note is convertible either at the option of the holder or automatically upon maturity into shares of the Company&#8217;s
Common Stock at the Note Conversion Price of $3.38.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>December 2023 Notes &#8212;
</i></b>On December 20, 2023, the Company entered into Subscription Agreements to purchase Convertible Promissory Notes for an aggregate
principal amount of $120,000 (the &#8220;December 2023 Notes&#8221;). The Company received a total of $120,000 from the private placement
between December 2023 and January 2024.&#160;The December 2023 Notes bear an interest rate of 12% per annum and matured one year after
their respective dates of issuance (the &#8220;Maturity Date&#8221;). The Company is required to pay interest quarterly, in arrears, in
cash, on the first day of each quarter of each year following the issue date prior to the maturity of the December 2023 Notes. Notwithstanding
the immediately foregoing, at the option of the holder, interest may accrue on the December Notes on a quarterly basis. The December 2023
Notes are convertible into shares of the Company&#8217;s Common Stock in whole or in part at any time and from time to time, after the
original issue date and prior to the Maturity Date, at a conversion price of $3.38 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The January 2024 Note and December
2023 Notes balance at June 30, 2025 was $245,000 (see Note 8 to the Financial Statements).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 64 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Notes Payable </b>&#8212;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Bridge Loans &#8212; </i></b>From
June 4, 2025 to June 14, 2025, the Company entered into agreements with Paseco ApS, a Danish entity controlled by a shareholder (&#8220;Paseco
ApS&#8221;) and Laksya Ventures Inc. to issue Promissory Notes for the principal amount of $1,725,000 to each note holder. The Company
received $3,450,000 in gross proceeds. The notes bear an interest rate of 10% per annum and mature on December 31, 2025. The notes balance
at June 30, 2025, was $3,450,000 with Paseco ApS and Laksya Ventures Inc. each holding $1,725,000 (see Note 8 to the Financial Statements).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">From October 21, 2024 to January
24, 2025, the Company entered into agreements with Paseco ApS, a Danish entity controlled by a shareholder (&#8220;Paseco ApS&#8221;),
to issue Promissory Notes for the principal amount of $2,650,000. The Company received $2,650,000 in gross proceeds. The notes bear an
interest rate of 10% per annum and mature from December 31, 2024 to December 31, 2025. Approximately $700,000 matured on December 31,
2024, $900,000 matured on December 31, 2025 and $1,050,000 matured on January 31, 2025. On February 24, 2025, Paseco ApS assigned 50%
of its ownership rights to Laksya Ventures Inc. with all terms remaining unchanged. The note balance at June 30, 2025, was $2,650,000
with Paseco ApS and Laksya Ventures Inc. each holding $1,325,000 (see Note 8 to the Financial Statements).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">From November 12, 2024 to December
3, 2024, Renovaro Cube entered into an agreement with Paseco ApS, a Danish entity controlled by a shareholder (&#8220;Paseco ApS&#8221;),
to issue Promissory Notes for the principal amount of &#8364;450,000. The note bears an interest rate of 10% per annum and matures on December
1, 2025. On February 24, 2025 Paseco ApS assigned 50% of its ownership rights to Laksya Ventures Inc. with all terms remaining unchanged.
The note balance at June 30, 2025 was approximately $530,000 with Paseco ApS and Laksya Ventures Inc. each holding approximately $265,000
(see Note 8 to the Financial Statements).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On November 1, 2024, Renovaro
Cube entered into an agreement with Yalla Yalla Limited, an investor to issue a Promissory Note for the amount of approximately &#8364;225,000.
The note bears an interest rate of 10% per annum and matured on February 24, 2025. The note balance at June 30, 2025 was approximately
$238,000 (see Note 8 to the 	Financial Statements).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On September 16, 2024, the Company
entered into an agreement with RS Bio ApS, a Danish entity controlled by a shareholder (&#8220;RS Bio&#8221;), to issue a Promissory Note
for the principal amount of $100,000 (the &#8220;September 2024 Note&#8221;). The Company received $100,000 in gross proceeds. The note
bears an interest rate of 12% per annum and matured on December 31, 2024. On February 24, 2025 RS Bio assigned its ownership rights to
Rene Sindlev with all terms remaining unchanged. The note balance at June 30, 2025 was $100,000 (see Note 8 to the Financial Statements).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On September 6, 2024, Renovaro
Cube entered into an agreement with Paseco ApS, a Danish entity controlled by a shareholder (&#8220;Paseco ApS&#8221;), to issue a Promissory
Note for the principal amount of &#8364;50,000. The note bears an interest rate of 12% per annum and matures on September 9, 2025. On February
24, 2025 Paseco ApS assigned 50% of its ownership rights to Laksya Ventures Inc. with all terms remaining unchanged. The note balance
at June 30, 2025 was approximately $59,000 with Paseco ApS and Laksya Ventures Inc. each holding approximately $30,000 (see Note 8 to
the Financial Statements).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On February 5, 2024, the Company
entered into an agreement with RS Bio to issue a 5% Original Issue Discount Secured Promissory Note for the principal amount of $105,263
(the &#8220;February 2024 Note&#8221;). The Company received $100,000 in gross proceeds after taking into account the 5% original issue
discount. The note bears an interest rate of 12% per annum and matured on December 31, 2024. On February 24, 2025 RS Bio assigned its
ownership rights to Rene Sindlev with all terms remaining unchanged. The note balance, net of discount at June 30, 2025 was $105,263 (see
Note 8 to the Financial Statements).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On January 2, 2024, the Company
entered into an agreement with RS Bio to issue a 5% Original Issue Discount Secured Promissory Note for the principal amount of $526,315.
The Company received a total of $500,000 in gross proceeds after taking into account the 5% original issue discount.&#160;The note bears
an interest rate of 12% per annum and matured on December 31, 2024. On February 24, 2025 RS Bio assigned its ownership rights to Rene
Sindlev with all terms remaining unchanged. The note balance, net of discount at June 30, 2025 was $526,315 (see Note 8 to the Financial
Statements).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 65 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On November 3, 2023, the Company
entered into an agreement with RS Bio to issue a 5% Original Issue Discount Promissory Note for the principal amount of $1,000,000. The
Company received a total of $950,000 in gross proceeds after taking into account the 5% original issue discount.&#160;The discount of
$50,000 will be accreted over the life of the note. The note bears an interest rate of 12% per annum and matured on December 31, 2024.
On February 24, 2025 RS Bio assigned its ownership rights to Rene Sindlev with all terms remaining unchanged. The note balance, net of
discount at June 30, 2025 was $750,000 (see Note 8 to the Financial Statements).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Promissory Note &#8212; </b>On
March 30, 2020 (the &#8220;Issuance Date&#8221;), the Company issued a Promissory Note in the principal amount of $5,000,000 (the &#8220;Promissory
Note&#8221;) to Paseco ApS. There have been eight amendments to the Promissory Note since the issuance date, the most recent of which
is dated August 1, 2024. The principal amount of the Promissory Note, as amended, was payable and matured on November 1, 2024 (the &#8220;Maturity
Date&#8221;). The Promissory Note, as amended, bears interest at a fixed rate of 12% per annum. On February 24, 2025 Paseco ApS assigned
its ownership rights to Rene Sindlev with all terms remaining unchanged. The Promissory Note balance at June 30, 2025 is $831,497.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s obligations
under the referenced Promissory and Bridge Notes, except for those originally entered into by Renovaro Cube, are secured by a Security
Agreement. To secure the Company&#8217;s obligations under the Promissory Note, the Company entered into a Security Agreement with the
Holder, pursuant to which the Company granted a lien on all assets of the Company (the &#8220;Collateral&#8221;) for the benefit of Paseco
ApS, Rene Sindlev and Laksya Ventures. Upon an Event of Default (as defined in the notes, respectively) Paseco ApS, Rene Sindlev and Laksya
Ventures may, among other things, collect or take possession of the Collateral, proceed with the foreclosure of the security interest
in the Collateral or sell, lease, or dispose of the Collateral (see Note 8 to the Financial Statements).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Cash Flows</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Year ended June 30, 2025 compared to the year ended June 30, 2024</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Following is a summary of the
Company&#8217;s cash flows provided by (used in) operating, investing, and financing activities:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="7" style="font-weight: bold; text-align: center">For the Years Ended</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Net Cash Used in Operating Activities</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(7,874,647</td><td style="width: 1%; text-align: left">)</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(10,971,430</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net Cash Used in Investing Activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(500,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,260,179</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net Cash Provided by Financing Activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,382,772</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,517,455</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Effect of exchange rates on cash</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(135,892</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">60,141</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net (Decrease) in Cash</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(127,767</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,654,013</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">At June 30, 2025, we had cash
and cash equivalents of $92,700, a decrease of $127,767, when compared to the June 30, 2024 balance of $220,467. This decrease was primarily
due to cash used in operating activities, partially offset by cash provided by financing activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We plan to use our cash and cash
equivalents to fund research and development, specifically to increase investment in the development and validation of our AI driven cancer
diagnostics platform. These activities will require an increase in selling, general and administrative costs, and research and development
costs to support the expected growth. As additional funds are required, we may raise such funds from time to time through public or private
sales of our equity or debt securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">Cash
used in operating activities represents the cash receipts and disbursements related to all of our activities other than investing and
financing activities. Operating cash flow is derived by adjusting our net loss for non-cash items and changes in operating assets and
liabilities. </span>Net cash used in operating activities for the years ended June 30, 2025 and 2024 was $7,874,647 and $10,971,430, respectively,
representing a decrease of $3,096,783. The decrease is primarily related to the changes in our operating assets and liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Net cash used in investing activities
for the years ended June 30, 2025 and 2024 was $500,000 and $1,260,179, respectively, representing an decrease of $760,179. The decrease
in cash used is primarily due to notes receivable prior to acquisition of Renovaro Cube of $1,255,600 in the prior period compared to
$500,000 used for investment in equity securities in year ended June 30, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 66 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Net cash provided by financing
activities for the years ended June 30, 2025 and 2024 was $8,382,772 and $10,517,455, respectively, representing a decrease of $2,134,683.
The net cash provided by financing activities in the current year consists primarily of $2,376,181 of proceeds from private placements,
$6,977,822 from the issuance of notes, and partially offset by repayments of $971,231 under a finance agreement. <span style="background-color: white">The
prior year net cash from financing activities primarily consisted of </span>3,000,000 of proceeds from private placements, $8,045,663
from the issuance of notes, and $341,865 of proceeds from the exercise of warrants, partially offset by repayments of $870,073 under a
finance agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Off-Balance Sheet Arrangements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of June 30, 2025, and 2024,
we had no off-balance sheet arrangements. We are not aware of any material transactions which are not disclosed in our consolidated financial
statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Significant Accounting Policies and Critical Accounting Estimates</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our management&#8217;s discussion
and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared
in accordance with accounting principles generally accepted in the U.S. The preparation of these financial statements requires us to make
estimates and assumptions that affect the reported amounts of assets, liabilities, and expenses. On an ongoing basis, we evaluate our
critical accounting policies and estimates. We base our estimates on historical experience and on various other assumptions that we believe
to be reasonable in the circumstances, the results of which form the basis for making judgments about the carrying values of assets and
liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions
and conditions. Our most critical accounting estimates are detailed below, and our significant accounting policies are more fully described
in Note 1 of the accompanying consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Intangible Assets - </b>The
Company has both definite and indefinite life intangible assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Definite life intangible assets
relate to patents. The Company accounts for definite life intangible assets in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;)
Accounting Standards Codification (&#8220;ASC&#8221;) Topic 350, <i>Goodwill and Other Intangible Assets</i>. Intangible assets are recorded
at cost. Patent costs capitalized consist of costs incurred to acquire the underlying patent. If it is determined that a patent will not
be issued, the related remaining capitalized patent costs are charged to expense. Definite life intangible assets are amortized on a straight-line
basis over their estimated useful life. The estimated useful life of patents is twenty years from the date of application.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Indefinite life intangible assets
include license agreements and goodwill acquired in a business combination. The Company accounts for indefinite life intangible assets
in accordance with ASC 350. License agreement costs represent the fair value of the license agreement on the date acquired and are tested
annually for impairment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Goodwill </b>- Goodwill is
not amortized but is evaluated for impairment annually as of June 30, 2025 or whenever events or changes in circumstances indicate the
carrying value may not be recoverable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Impairment of Goodwill and
Indefinite Lived Intangible Assets</b> &#8211; We test for goodwill impairment at the reporting unit level, which is one
level below the operating segment level. Our detailed impairment testing involves comparing the fair value of each reporting unit to its
carrying value, including goodwill. Fair value reflects the price a market participant would be willing to pay in a potential sale of
the reporting unit and is based on discounted cash flows or relative market-based approaches. If the carrying value of the reporting unit
exceeds its fair value, we record an impairment loss for such excess. The annual fair value analysis performed on goodwill supported that
goodwill was impaired as of June 30, 2025. The Company recorded an impairment loss of $47,614,729 for the period ended September 30, 2024
and $122,804,700 for the period ended June 30, 2025, related to goodwill during the year ended June 30, 2025 (see Note 6 to the financial
statements).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For indefinite-lived intangible
assets, such as licenses acquired as an In-Process Research and Development (&#8220;IPR&amp;D&#8221;) asset, on an annual basis we determine
the fair value of the asset and record an impairment loss, if any, for the excess of the carrying value of the asset over its fair value.
For the year ended June 30, 2025, the carrying value of IPR&amp;D was zero. For the year ended June 30, 2024, the carrying value of the
licenses acquired as an IPR&amp;D asset exceeded its fair value, due to changes in the projected economic benefits to be realized from
these assets. The Company recorded impairment losses of zero and $42,611,000 during the years ended June 30, 2025 and 2024, respectively
(see Note 6 to the financial statements).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 67 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The carrying values of IPR&amp;D
and goodwill at June 30, 2025, were&#160;zero and $5,963,000, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;<b>Fair Value of Financial
Instruments </b>&#8211; The Company accounts for fair value measurements for financial assets and financial liabilities in accordance
with FASB ASC Topic 820, &#8220;Fair Value Measurements&#8221;. The authoritative guidance, among other things, defines fair value, establishes
a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value
on either a recurring or nonrecurring basis. Fair value is defined as the exit price, representing the amount that would either be received
to sell an asset or be paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based
measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. There
were no Level 2, or 3 assets, nor any Level 1, or 2 liabilities measured at fair value on a recurring basis as of June 30, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Level 1 assets held as of June
30, 2025, consisted of an investment in equity securities related to an extension agreement entered on February 28, 2024<span style="background-color: white">.
The Company purchased 467,290 shares of common stock at a purchase price of $1.07 per share. The investment in equity securities was recorded
at a fair value of $500,000 at the time of purchase and is subsequently remeasured to fair value at the end of each reporting period.
As of June 30, 2025, the Company held 467,290 shares of common stock in connection with the investment in equity securities. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Level 3 liabilities held as of June 30, 2025,
consisted of a contingent consideration liability related to the February 13, 2024, acquisition of Renovaro Cube (see Note 3).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Stock-Based Compensation -
</b>The Company has granted stock options, restricted share units (&#8220;RSUs&#8221;) and warrants to certain employees, officers, directors,
and consultants. The Company accounts for options in accordance with the provisions of <b><i>FASB ASC Topic 718, Compensation &#8211;
Stock Compensation</i></b>. Stock based compensation costs for the vesting of options and RSUs granted to certain employees, officers,
directors, and consultants for the years ended June 30, 2025 and 2024 were $3,313,291 and $4,673,129, respectively (see Note 10 to the
Financial Statements).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.2pt">The Company recognizes compensation
costs for stock option awards to employees, officers and directors based on their grant-date fair value. The value of each stock option
is estimated on the date of grant using the Black-Scholes option-pricing model. The weighted-average assumptions used to estimate the
fair value of the stock options granted using the Black-Scholes option-pricing model are the expected term of the award, the underlying
stock price volatility, the risk-free interest rate, and the expected dividend yield. The Company accounts for forfeitures as they occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.2pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company records stock-based
compensation for services received from non-employees in accordance with <b><i>ASC 718, Compensation&#8212;Stock Compensation Non-Employees</i></b>.
All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based
on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable.
Equity instruments issued to consultants and the cost of the services received as consideration are measured and recognized based on the
fair value of the equity instruments issued and are recognized over the consultants&#8217; required service period, which is generally
the vesting period (see Note 10 to the Financial Statements).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company does not have sufficient
historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior.
Accordingly, the Company has elected to use the &#8220;simplified method&#8221; to estimate the expected term of its share-based awards.
The simplified method computes the expected term as the sum of the award&#8217;s vesting term plus the original contractual term divided
by two.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Recently Enacted Accounting Standards</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For a description of recent accounting
standards, including the expected dates of adoption and estimated effects, if any, on our consolidated financial statements, see &#8220;Note
1: Recent Accounting Pronouncements&#8221; in the financial statements included elsewhere in this Annual Report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_013"></span>Item 7A. Quantitative and Qualitative Disclosures about Market Risk</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The Company is a smaller reporting company and is not
required to provide this information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="a_014"></span>Item 8. Financial Statements and Supplementary
Data</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 68 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Lunai Bioworks Inc. AND SUBSIDIARIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Index to Consolidated Financial Statements </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr>
<td style="vertical-align: top; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page </b></span></td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#b_001">Report of Independent Registered Public Accounting Firm (PCAOB ID:<span id="xdx_908_edei--AuditorFirmId_c20240701__20250630_z5ENbWZmSvtk"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" id="Fact000064" name="dei:AuditorFirmId">3627</ix:nonNumeric></span>)</a></span></td>
<td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr>
<tr style="background-color: white">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#b_002">Consolidated Balance Sheets at June 30, 2025 and 2024</a></span></td>
<td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#b_003">Consolidated Statements of Operations for the Years Ended June 30, 2025 and 2024</a></span></td>
<td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr>
<tr style="background-color: white">
<td style="vertical-align: top; padding-left: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#b_004">Consolidated Statements of Comprehensive Loss for the Years Ended June 30, 2025 and 2024</a></span></td>
<td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#b_005">Consolidated Statement of Stockholders&#8217; Equity (Deficit) for the Years Ended June 30, 2025 and 2024</a></span></td>
<td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</span></td></tr>
<tr style="background-color: white">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#b_006">Consolidated Statements of Cash Flows for the Years Ended June 30, 2025 and 2024</a></span></td>
<td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-8</span></td></tr>
<tr style="background-color: #CCEEFF">
<td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#b_007">Notes to the Consolidated Financial Statements</a></span></td>
<td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-9</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 69; Options: NewSection -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span style="text-decoration: underline"><span id="b_001"></span>REPORT OF INDEPENDENT REGISTERED
PUBLIC ACCOUNTING FIRM</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b>&#160;</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">To the Board of Directors and Shareholders of Lunai Bioworks, Inc. (fka:
Renovaro, Inc.):</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Opinion
on the Financial Statements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have audited the accompanying consolidated balance
sheets of Lunai Bioworks, Inc. (fka: Renovaro, Inc.) (&#8220;the Company&#8221;) as of June 30, 2025 and 2024, the related consolidated
statements of operations, comprehensive loss, stockholders&#8217; equity(deficit), and cash flows for each of the years in the two-year
period ended June 30, 2025 and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion,
the financial statements referred to above present fairly, in all material respects, the financial position of the Company as of June
30, 2025 and 2024, and the results of its operations and its cash flows for each of the years in the two-year period ended June 30, 2025,
in conformity with accounting principles generally accepted in the United States of America.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Explanatory
Paragraph Regarding Going Concern</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note
2 to the financial statements, the Company has incurred substantial recurring losses from operations, has used cash in the Company&#8217;s
continuing operations, and is dependent on additional financing to fund operations, which raises substantial doubt about its ability
to continue as a going concern. Management's plans in regard to these matters are also described in Note 2. The financial statements
do not include any adjustments that might result from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Basis
for Opinion</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits,
we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion
on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits
provide a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Critical
Audit Matters</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated
or required to be communicated to the audit committee and that: (1) related to accounts or disclosures that are material to the financial
statements and (2) involved our especially challenging, subjective, or complex judgements. The communication of critical audit matters
does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical matters
below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 70 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Goodwill
Impairment Assessment</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Critical
Audit Matter Description</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended June 30, 2025, the Company fully impaired previously recorded goodwill of approximately $170 million, exchange rate adjusted,
related to the Company&#8217;s RenC reporting unit. As described in notes 1 and 5 to the consolidated financial statements, the Company
tests goodwill for impairment annually on June 30 at the reporting unit level, or more frequently if events or circumstances indicate
it is more likely than not that the fair value of a reporting unit is less than it&#8217;s carrying amount. The Company recognized an
impairment loss of approximately $48 million during the three months ended September 30, 2024 with the remaining goodwill amount being
impaired at June 30, 2025. The determination of the fair value of the reporting unit on September 30, 2024, and June 30, 2025, required
management to make significant estimates and assumptions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>How
the Critical Audit Matter was Addressed in the Audit</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
identified the evaluation of the impairment analysis for goodwill as a critical audit matter because of the significant estimates and
assumptions management makes in performing impairment tests for the RenC reporting unit. These required a high degree of auditor judgment
and an increased extent of effort when performing audit procedures to evaluate the reasonableness of such estimates and assumptions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audit procedures related to the following:</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 54pt"/><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            tested management&#8217;s processes for estimating the fair value of the reporting unit at
                                            each respective date</span></td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
                                                                                 </table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 54pt"/><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            evaluated whether the valuation techniques used were appropriate and reasonable and</span></td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
                                                                                                                                                </table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 54pt"/><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            evaluated the significant assumptions and underlying data used in developing the fair value
                                            of goodwill</span></td></tr>
                                                                        </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, professionals with specialized skill and knowledge were utilized by the Firm to assist in the performance of these procedures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
<span id="xdx_90D_edei--AuditorName_c20240701__20250630_znaV1zUUJWCj"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" id="Fact000065" name="dei:AuditorName">Sadler, Gibb &amp; Associates, LLC</ix:nonNumeric></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&#8217;s auditor since 2018.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--AuditorLocation_c20240701__20250630_zFiWRBZTQR9e"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" id="Fact000066" name="dei:AuditorLocation">Draper,
UT</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
29, 2025</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 71 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>LUNAI BIOWORKS INC. FKA: RENOVARO INC. AND SUBSIDIARIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="b_002"></span>CONSOLIDATED BALANCE SHEETS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_30F_111_z8KJ2I4fI58f" summary="xdx: Statement - CONSOLIDATED BALANCE SHEETS" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; font-size: 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_490_20250630_z2NN56DHhTg" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_495_20240630_zqZz1Ijykimb" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    30,</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--AssetsAbstract_iB_zecnJbsl2EKa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; font-weight: bold; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASSETS</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--AssetsCurrentAbstract_i01B_zcbc8AnLsND6" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CURRENT
    ASSETS:</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maCzUeu_zKCUp7E1yQu3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 30pt; width: 56%; font-size: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash</span></td><td style="width: 8%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 12%; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2025-06-30" id="Fact000074" format="ixt:numdotdecimal" decimals="0" unitRef="USD">92,700</ix:nonFraction></span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 8%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 12%; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-06-30" id="Fact000075" format="ixt:numdotdecimal" decimals="0" unitRef="USD">220,467</ix:nonFraction></span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--InsuranceSettlementsReceivableCurrent_i02I_d0_maCzUeu_zXqRAHBrgcuj" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 30pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insurance
    receivable</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:InsuranceSettlementsReceivableCurrent" contextRef="AsOf2025-06-30" id="Fact000077" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:InsuranceSettlementsReceivableCurrent" contextRef="AsOf2024-06-30" id="Fact000078" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,108,247</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--EquitySecuritiesFvNi_i02I_maCzUeu_zf6TnoKusxr5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 30pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment
    in equity securities</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:EquitySecuritiesFvNi" contextRef="AsOf2025-06-30" id="Fact000080" format="ixt:numdotdecimal" decimals="0" unitRef="USD">387,851</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0081">&#8212;</span></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--OtherPrepaidExpenseCurrent_i02I_maCzUeu_zpQDHqM8yY2i" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 30pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaids
    and other assets</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2025-06-30" id="Fact000083" format="ixt:numdotdecimal" decimals="0" unitRef="USD">566,081</ix:nonFraction></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2024-06-30" id="Fact000084" format="ixt:numdotdecimal" decimals="0" unitRef="USD">668,929</ix:nonFraction></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--AssetsCurrent_i02TI_mtCzUeu_maCzXZc_zKT30Z03s5q6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Current Assets</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2025-06-30" id="Fact000086" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,046,632</ix:nonFraction></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2024-06-30" id="Fact000087" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,997,643</ix:nonFraction></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_i01I_maCzXZc_zVS7YbXIIgy8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
    and equipment, net</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2025-06-30" id="Fact000089" format="ixt:numdotdecimal" decimals="0" unitRef="USD">367,843</ix:nonFraction></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-06-30" id="Fact000090" format="ixt:numdotdecimal" decimals="0" unitRef="USD">482,121</ix:nonFraction></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--AssetsNoncurrentAbstract_i01B_z6MlGOExirn1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OTHER
    ASSETS</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_ecustom--DefiniteLifeIntangibleAssetsNet_i02I_maCzmfR_z2xrQwH12vG8" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 30pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definite
    life intangible assets, net</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="RENB:DefiniteLifeIntangibleAssetsNet" contextRef="AsOf2025-06-30" id="Fact000095" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,994</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="RENB:DefiniteLifeIntangibleAssetsNet" contextRef="AsOf2024-06-30" id="Fact000096" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,043</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--CapitalizedComputerSoftwareGross_i02I_maCzmfR_z75LzU09hmg1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 30pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Software
    platform</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CapitalizedComputerSoftwareGross" contextRef="AsOf2025-06-30" id="Fact000098" format="ixt:numdotdecimal" decimals="0" unitRef="USD">143,000</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0099">&#8212;</span></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--FiniteLivedTrademarksGross_i02I_maCzmfR_zklnELS95TJf" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 30pt; font-size: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trademarks</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:FiniteLivedTrademarksGross" contextRef="AsOf2025-06-30" id="Fact000101" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,000</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0102">&#8212;</span></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--Goodwill_i02I_maCzmfR_zrbqJ1dluEee" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 30pt; font-size: 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2025-06-30" id="Fact000104" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,963,000</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2024-06-30" id="Fact000105" format="ixt:numdotdecimal" decimals="0" unitRef="USD">159,330,161</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--DepositsAssetsNoncurrent_i02I_maCzmfR_zLddMGGVa6gl" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 30pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deposits
    and other assets</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0107">&#8212;</span></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DepositsAssetsNoncurrent" contextRef="AsOf2024-06-30" id="Fact000108" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,849</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeaseRightOfUseAsset_i02I_maCzmfR_zmYrid8o8Q79" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 30pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    lease right-of-use assets</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2025-06-30" id="Fact000110" format="ixt:numdotdecimal" decimals="0" unitRef="USD">687,371</ix:nonFraction></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-06-30" id="Fact000111" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,269,633</ix:nonFraction></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--OtherAssetsNoncurrent_i02TI_mtCzmfR_maCzXZc_zwzNvEUE6kAi" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 30pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Other Assets</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2025-06-30" id="Fact000113" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,816,365</ix:nonFraction></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2024-06-30" id="Fact000114" format="ixt:numdotdecimal" decimals="0" unitRef="USD">160,649,686</ix:nonFraction></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--Assets_iTI_mtCzXZc_zdPM19LkP2y" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; font-weight: bold; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TOTAL
    ASSETS</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2025-06-30" id="Fact000116" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,230,840</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-06-30" id="Fact000117" format="ixt:numdotdecimal" decimals="0" unitRef="USD">163,129,450</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zC4I844rGORe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; font-weight: bold; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LIABILITIES</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--LiabilitiesCurrentAbstract_i01B_zshyjigTW11e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CURRENT
    LIABILITIES:</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--AccountsPayableTradeCurrent_i02I_maCzN78_zEVEshVGANX3" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 30pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
    payable &#8211; trade</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="AsOf2025-06-30" id="Fact000125" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,555,839</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="AsOf2024-06-30" id="Fact000126" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,448,683</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--AccruedLiabilitiesCurrent_i02I_maCzN78_zYbaoOnwP8V2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 30pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
    expenses</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2025-06-30" id="Fact000128" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,843,069</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2024-06-30" id="Fact000129" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,311,324</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--OtherLiabilitiesCurrent_i02I_maCzN78_zpOISdoPHpx" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 30pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    current liabilities</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2025-06-30" id="Fact000131" format="ixt:numdotdecimal" decimals="0" unitRef="USD">378,282</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2024-06-30" id="Fact000132" format="ixt:numdotdecimal" decimals="0" unitRef="USD">295,361</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_ecustom--ContingentConsiderationLiabilityCurrent_i02I_pp0p0_d0_maCzN78_zGqnQFyoG6Bg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 30pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contingent
    consideration liability</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="RENB:ContingentConsiderationLiabilityCurrent" contextRef="AsOf2025-06-30" id="Fact000134" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">630,000</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="RENB:ContingentConsiderationLiabilityCurrent" contextRef="AsOf2024-06-30" id="Fact000135" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">12,310,000</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--ConvertibleNotesPayable_i02I_d0_maCzN78_z5nW0piofBK1" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 30pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible
    notes payable</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ConvertibleNotesPayable" contextRef="AsOf2025-06-30" id="Fact000137" format="ixt:numdotdecimal" decimals="0" unitRef="USD">245,000</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ConvertibleNotesPayable" contextRef="AsOf2024-06-30" id="Fact000138" format="ixt:numdotdecimal" decimals="0" unitRef="USD">245,000</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_maCzN78_zpTrUJU9mau9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 30pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
    portion of operating lease liabilities</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2025-06-30" id="Fact000140" format="ixt:numdotdecimal" decimals="0" unitRef="USD">313,047</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2024-06-30" id="Fact000141" format="ixt:numdotdecimal" decimals="0" unitRef="USD">493,553</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--NotesPayable_i02I_maCzN78_zEP2QI1JicW5" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 30pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
    payable</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2025-06-30" id="Fact000143" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,580,525</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0144">&#8212;</span></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_ecustom--NotesPayableRelatedPartiesNetCurrent_i02I_maCzN78_zfsheoRwsdfd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 30pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
    payable &#8211; related parties, net</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="RENB:NotesPayableRelatedPartiesNetCurrent" contextRef="AsOf2025-06-30" id="Fact000146" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,610,372</ix:nonFraction></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="RENB:NotesPayableRelatedPartiesNetCurrent" contextRef="AsOf2024-06-30" id="Fact000147" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,205,996</ix:nonFraction></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesCurrent_i02TI_mtCzN78_maCzBiT_zYlkoofP59r9" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Current Liabilities</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2025-06-30" id="Fact000149" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,156,134</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2024-06-30" id="Fact000150" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,309,917</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--LiabilitiesNoncurrentAbstract_i01B_z5vRpuV674Dg" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NON-CURRENT
    LIABILITIES:</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLeaseLiabilityNoncurrent_i02I_maCzm6m_zHXEIoHARCyh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    lease liabilities, net of current portion</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2025-06-30" id="Fact000155" format="ixt:numdotdecimal" decimals="0" unitRef="USD">424,547</ix:nonFraction></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2024-06-30" id="Fact000156" format="ixt:numdotdecimal" decimals="0" unitRef="USD">842,389</ix:nonFraction></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--LiabilitiesNoncurrent_i02TI_pp0p0_mtCzm6m_maCzBiT_zkffQjPmY3U7" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Non-Current Liabilities</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="AsOf2025-06-30" id="Fact000158" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">424,547</ix:nonFraction></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="AsOf2024-06-30" id="Fact000159" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">842,389</ix:nonFraction></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--Liabilities_i02TI_mtCzBiT_maLASEzxaF_zN7JdFWxRqY3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Liabilities</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2025-06-30" id="Fact000161" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,580,681</ix:nonFraction></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2024-06-30" id="Fact000162" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,152,306</ix:nonFraction></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--StockholdersEquityAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; font-weight: bold; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">STOCKHOLDERS&#8217;
    EQUITY (DEFICIT)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--PreferredStockValue_i02I_pp0p0_d0_maCz7Aa_zydx7VtWCNAk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred
    stock, $<span id="xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20250630_z81MHUUhxLk6" title="Preferred stock, par value"><span id="xdx_906_eus-gaap--PreferredStockParOrStatedValuePerShare_c20240630_zL8XlyO5K2L2" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2025-06-30" id="Fact000170" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-06-30" id="Fact000172" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> par value; <span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_c20250630_zoWKJHYDMIh5" title="Preferred stock, shares authorized"><span id="xdx_908_eus-gaap--PreferredStockSharesAuthorized_c20240630_zGXOFgy7bvu7" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2025-06-30" id="Fact000174" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-06-30" id="Fact000176" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_904_eus-gaap--PreferredStockSharesIssued_iI_do_c20250630_zxccmifAfjz6" title="Preferred stock, shares issued"><span id="xdx_904_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20250630_z6az0cwU1EXk" title="Preferred stock, shares outstanding"><span id="xdx_906_eus-gaap--PreferredStockSharesIssued_iI_do_c20240630_zA6AIYxq6nv8" title="Preferred stock, shares issued"><span id="xdx_90D_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20240630_zulko3BSdtoj" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2025-06-30" id="Fact000178" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2025-06-30" id="Fact000180" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-06-30" id="Fact000182" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-06-30" id="Fact000184" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares issued and outstanding</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2025-06-30" id="Fact000167" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-06-30" id="Fact000168" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--CommonStockValue_i02I_maCz7Aa_z7tY8cL2Tfsa" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    stock, par value $<span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20250630_zlHBjNCdDfqf" title="Common stock, par value"><span id="xdx_907_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240630_zOrjcdGERyV5" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-06-30" id="Fact000189" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-06-30" id="Fact000191" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span>, <span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_iI_c20250630_zVCZUaiIbatf" title="Common stock, shares authorized"><span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_iI_c20240630_za6B2o2Fvve6" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2025-06-30" id="Fact000193" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-06-30" id="Fact000195" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized, <span id="xdx_908_eus-gaap--CommonStockSharesIssued_iI_c20250630_zzwIsG9bvAoh" title="Common stock, shares issued"><span id="xdx_90D_eus-gaap--CommonStockSharesOutstanding_iI_c20250630_zBJfTNmk8kl" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2025-06-30" id="Fact000197" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2025-06-30" id="Fact000199" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">177,392,907</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding at June 30, 2025; <span id="xdx_90D_eus-gaap--CommonStockSharesIssued_iI_c20240630_zVXtS8dEcy77" title="Common stock, shares issued"><span id="xdx_902_eus-gaap--CommonStockSharesOutstanding_c20240630_z8mNBuA9cV5f" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-06-30" id="Fact000201" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-06-30" id="Fact000203" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">158,452,644</ix:nonFraction></ix:nonFraction></span></span>
    shares issued and outstanding at June 30, 2024</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2025-06-30" id="Fact000186" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,741</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2024-06-30" id="Fact000187" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,847</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--AdditionalPaidInCapital_i02I_maCz7Aa_ztxaHRQLtA8f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
    paid-in capital</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2025-06-30" id="Fact000205" format="ixt:numdotdecimal" decimals="0" unitRef="USD">478,280,146</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2024-06-30" id="Fact000206" format="ixt:numdotdecimal" decimals="0" unitRef="USD">464,587,224</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maCz7Aa_zevmHnTrDDPh" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated
    deficit</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2025-06-30" id="Fact000208" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">510,462,570</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-06-30" id="Fact000209" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">332,455,081</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_402_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_i02I_maCz7Aa_z5ERaWVf89b7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated
    other comprehensive (loss)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2025-06-30" id="Fact000211" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,814,842</ix:nonFraction></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2024-06-30" id="Fact000212" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">170,846</ix:nonFraction></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40F_eus-gaap--StockholdersEquity_i02TI_pp0p0_mtCz7Aa_maLASEzxaF_zLNiNQsXSmJ6" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Stockholders&#8217; Equity (Deficit)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30" id="Fact000214" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">21,349,841</ix:nonFraction></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30" id="Fact000215" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">131,977,144</ix:nonFraction></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_pp0p0_mtLASEzxaF_z7CWZtpAMZO7" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; font-weight: bold; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TOTAL
    LIABILITIES AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2025-06-30" id="Fact000217" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,230,840</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-06-30" id="Fact000218" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">163,129,450</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>The accompanying notes are an integral part of these
consolidated financial statements.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Page; Sequence: 72 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>LUNAI BIOWORKS INC. FKA: RENOVARO INC. AND SUBSIDIARIES</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="b_003"></span>CONSOLIDATED STATEMENTS OF OPERATIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_309_113_z3ktZJjSQOUi" summary="xdx: Statement - CONSOLIDATED STATEMENTS OF OPERATIONS" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_490_20240701__20250630_zufGEw2XSAK6" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_499_20230701__20240630_zRN1MHEM3Ywc" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="7" style="font-weight: bold; text-align: center">For the Years Ended</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingExpensesAbstract_iB_zhOgKip5D8P3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Operating Expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--GeneralAndAdministrativeExpense_i01_maCzuO2_zqZ3aBm0WGz8" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; width: 56%; text-align: left; text-indent: -10pt">General and administrative</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-07-01to2025-06-30" id="Fact000223" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,880,050</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-07-012024-06-30" id="Fact000224" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,557,608</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--ResearchAndDevelopmentExpense_i01_maCzuO2_zxJ9Ij3zKFTa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-07-01to2025-06-30" id="Fact000226" format="ixt:numdotdecimal" decimals="0" unitRef="USD">537,428</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-07-012024-06-30" id="Fact000227" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,708,829</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_i01_pp0p0_maCzuO2_zhj7KH8G3Y72" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Intangible asset impairment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0229">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="From2023-07-012024-06-30" id="Fact000230" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">42,611,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--GoodwillImpairmentLoss_i01_pp0p0_d0_maCzuO2_zX5gaTRehh4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Goodwill impairment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="From2024-07-01to2025-06-30" id="Fact000232" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">170,419,429</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="From2023-07-012024-06-30" id="Fact000233" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">11,640,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DepreciationDepletionAndAmortization_i01_maCzuO2_zKBVBY0XKbgf" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Depreciation and amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2024-07-01to2025-06-30" id="Fact000235" format="ixt:numdotdecimal" decimals="0" unitRef="USD">129,095</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2023-07-012024-06-30" id="Fact000236" format="ixt:numdotdecimal" decimals="0" unitRef="USD">121,859</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingExpenses_i01T_mtCzuO2_msCzHGi_zsFyUKFicJ08" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Total Operating Expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-07-01to2025-06-30" id="Fact000238" format="ixt:numdotdecimal" decimals="0" unitRef="USD">188,966,002</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2023-07-012024-06-30" id="Fact000239" format="ixt:numdotdecimal" decimals="0" unitRef="USD">81,639,296</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingIncomeLoss_iT_mtCzHGi_maCz4nz_zPNMk0bApyZb" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">LOSS FROM OPERATIONS</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-07-01to2025-06-30" id="Fact000241" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">188,966,002</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-07-012024-06-30" id="Fact000242" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">81,639,296</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_z0wnPu03jWK" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Other Income (Expense)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--ChangeInFairValueOfContingentConsideration_i01_pp0p0_d0_maCzGcn_zY9HgKvp68Jk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Change in fair value of contingent consideration</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="RENB:ChangeInFairValueOfContingentConsideration" contextRef="From2024-07-01to2025-06-30" id="Fact000247" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">11,680,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="RENB:ChangeInFairValueOfContingentConsideration" contextRef="From2023-07-012024-06-30" id="Fact000248" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">3,048,183</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i01_d0_maCzGcn_z79ViKBkb1Zh" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Loss on extinguishment of debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2024-07-01to2025-06-30" id="Fact000250" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2023-07-012024-06-30" id="Fact000251" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,303,578</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--EquitySecuritiesFvNiRealizedLoss_i01N_di_msCzGcn_zKMLHub7Xb16" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Change in fair value of equity securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EquitySecuritiesFvNiRealizedLoss" contextRef="From2024-07-01to2025-06-30" id="Fact000253" format="ixt:numdotdecimal" decimals="0" unitRef="USD">112,149</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0254">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--InterestExpenseNonoperating_i01N_di_msCzGcn_zH5HG6wdr0lc" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2024-07-01to2025-06-30" id="Fact000256" format="ixt:numdotdecimal" decimals="0" unitRef="USD">725,684</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2023-07-012024-06-30" id="Fact000257" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,011,322</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_ecustom--InterestIncomeAndOtherIncomeExpense_i01_maCzGcn_zXTgJgyfHIFg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Interest income and other income (expense)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="RENB:InterestIncomeAndOtherIncomeExpense" contextRef="From2024-07-01to2025-06-30" id="Fact000259" format="ixt:numdotdecimal" decimals="0" unitRef="USD">116,346</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="RENB:InterestIncomeAndOtherIncomeExpense" contextRef="From2023-07-012024-06-30" id="Fact000260" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,423,449</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--NonoperatingIncomeExpense_iT_mtCzGcn_maCz4nz_z9QgGibaXdnk" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total Other Income (Expense)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2024-07-01to2025-06-30" id="Fact000262" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,958,513</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2023-07-012024-06-30" id="Fact000263" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,786,532</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--NetIncomeLoss_iT_mtCz4nz_zPZzTOip9821" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">NET LOSS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-07-01to2025-06-30" id="Fact000265" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">178,007,489</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012024-06-30" id="Fact000266" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">88,425,828</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">BASIC AND DILUTED NET LOSS PER COMMON SHARE</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--EarningsPerShareBasic_c20240701__20250630_zmVGbCjlVyib" title="BASIC NET LOSS PER COMMON SHARE" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OU09MSURBVEVEIFNUQVRFTUVOVFMgT0YgT1BFUkFUSU9OUwA_"><span id="xdx_905_eus-gaap--EarningsPerShareDiluted_c20240701__20250630_z8Dr7C8JlJl1" title="DILUTED NET LOSS PER COMMON SHARE" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OU09MSURBVEVEIFNUQVRFTUVOVFMgT0YgT1BFUkFUSU9OUwA_">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-07-01to2025-06-30" id="Fact000268" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-07-01to2025-06-30" id="Fact000270" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.08</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--EarningsPerShareBasic_c20230701__20240630_zhAIg2JPaY34" title="BASIC NET LOSS PER COMMON SHARE" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OU09MSURBVEVEIFNUQVRFTUVOVFMgT0YgT1BFUkFUSU9OUwA_"><span id="xdx_90C_eus-gaap--EarningsPerShareDiluted_c20230701__20240630_z8aBb773PhO2" title="DILUTED NET LOSS PER COMMON SHARE" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OU09MSURBVEVEIFNUQVRFTUVOVFMgT0YgT1BFUkFUSU9OUwA_">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-07-012024-06-30" id="Fact000272" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-07-012024-06-30" id="Fact000274" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.91</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING - BASIC AND DILUTED</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240701__20250630_zp6wyb2BQbw4" title="WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING - BASIC" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OU09MSURBVEVEIFNUQVRFTUVOVFMgT0YgT1BFUkFUSU9OUwA_"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240701__20250630_z8LWN7FbHlf5" title="WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING - DILUTED" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OU09MSURBVEVEIFNUQVRFTUVOVFMgT0YgT1BFUkFUSU9OUwA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-07-01to2025-06-30" id="Fact000276" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-07-01to2025-06-30" id="Fact000278" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">165,061,967</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230701__20240630_z3KNCTDbe5Lf" title="WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING - BASIC" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OU09MSURBVEVEIFNUQVRFTUVOVFMgT0YgT1BFUkFUSU9OUwA_"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230701__20240630_zusEfh0dcpCh" title="WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING - DILUTED" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OU09MSURBVEVEIFNUQVRFTUVOVFMgT0YgT1BFUkFUSU9OUwA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-07-012024-06-30" id="Fact000280" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-07-012024-06-30" id="Fact000282" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">97,511,557</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>The accompanying notes are an integral part of these
consolidated financial statements.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Page; Sequence: 73 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>LUNAI BIOWORKS INC. FKA: RENOVARO INC. AND SUBSIDIARIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="b_004"></span>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_303_113_zea4XaPIJjIa" summary="xdx: Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49A_20240701__20250630_z5Pm6lamk38f" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_490_20230701__20240630_z3sd0tu87qJ6" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="7" style="font-weight: bold; text-align: center">For the Years Ended</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ProfitLoss_maCzFTz_z2udLRMYsXG2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; font-weight: bold; text-align: left; text-indent: -10pt">Net Loss</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-07-01to2025-06-30" id="Fact000284" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">178,007,489</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-07-012024-06-30" id="Fact000285" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">88,425,828</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--ComprehensiveIncomeNetOfTaxAbstract_iB_znFJeh6CWCz1" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Other Comprehensive Income (Loss)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_iN_di_msCzFTz_zETMZC4YDlkj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">Foreign currency translation, net of taxes</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" contextRef="From2024-07-01to2025-06-30" id="Fact000290" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">109,985,688</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" contextRef="From2023-07-012024-06-30" id="Fact000291" format="ixt:numdotdecimal" decimals="0" unitRef="USD">140,964</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ComprehensiveIncomeNetOfTax_iT_mtCzFTz_zqmszGkwx418" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Comprehensive Loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2024-07-01to2025-06-30" id="Fact000293" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">167,021,801</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2023-07-012024-06-30" id="Fact000294" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">88,566,792</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>The accompanying notes are an integral part of these
consolidated financial statements.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Page; Sequence: 74 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>LUNAI BIOWORKS INC. FKA: RENOVARO INC. AND SUBSIDIARIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="b_005"></span>CONSOLIDATED STATEMENT OF STOCKHOLDERS&#8217; EQUITY (DEFICIT)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the Years Ended June 30, 2025 and June 30, 2024</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_30E_114_zkWXOdXx00e2" summary="xdx: Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B9_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_zcgbaNDM3N4" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4BD_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_z8VjMwFSuzJ6" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B5_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zveAqwdR8TXc" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4BC_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_z4W7T2lgrGCk" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4BA_us-gaap--StatementEquityComponentsAxis_us-gaap--AccumulatedOtherComprehensiveIncomeMember_zFrawURnbWha" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B3_zcnpF2wLjb91" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"># of Preferred Shares</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Preferred Shares Amount</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"># of Common Shares</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock Amount</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Additional Paid-In Capital</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accumulated Deficit</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accumulated Other Comprehensive Income (Loss)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td></tr>
  <tr id="xdx_43A_c20230701__20240630_eus-gaap--StockholdersEquity_iS_zK8UrwnndfOj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; font-weight: bold; text-indent: -10pt; padding-left: 10pt">Balance June 30, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharesOutstanding_iS_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zYhvAcQX9jQg" title="Beginning balance, shares" style="width: 5%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0303">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0296">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharesOutstanding_iS_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKZmG1Z2ZTk4" title="Beginning balance, shares" style="width: 5%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" id="Fact000305" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">63,698,144</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 5%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" id="Fact000297" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,371</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 5%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000298" format="ixt:numdotdecimal" decimals="0" unitRef="USD">290,554,875</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 5%; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember" id="Fact000299" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">244,029,253</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 5%; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000300" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">29,882</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30" id="Fact000301" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,502,111</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--IssuanceOfPreferredStockAndWarrantsInPrivatePlacement_iP3us-gaap--SharesOutstanding_zrNmUVEgABV9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Issuance of preferred stock and warrants in private placement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--IssuanceOfPreferredStockAndWarrantsInPrivatePlacementShares_c20240701__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zXNXAjfc9Iqj" title="Issuance of preferred stock and warrants in private placement, shares" style="text-align: right"><ix:nonFraction name="RENB:IssuanceOfPreferredStockAndWarrantsInPrivatePlacementShares" contextRef="From2024-07-012025-06-30_us-gaap_PreferredStockMember" id="Fact000314" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">280,505</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="RENB:IssuanceOfPreferredStockAndWarrantsInPrivatePlacement" contextRef="From2023-07-012024-06-30_us-gaap_PreferredStockMember" id="Fact000307" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0308">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="RENB:IssuanceOfPreferredStockAndWarrantsInPrivatePlacement" contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000309" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,999,972</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0310">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0311">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="RENB:IssuanceOfPreferredStockAndWarrantsInPrivatePlacement" contextRef="From2023-07-012024-06-30" id="Fact000312" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable_iP3custom--IssuanceOfPreferredStockAndWarrantsInPrivatePlacement_zVlrITXH717d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Issuance of preferred stock and warrants for conversion of Note Payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayableShares_c20240701__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z6JkM6dSiu2h" title="Issuance of preferred stock and warrants for conversion of Note Payable, shares" style="text-align: right"><ix:nonFraction name="RENB:IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayableShares" contextRef="From2024-07-012025-06-30_us-gaap_PreferredStockMember" id="Fact000323" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">280,505</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="RENB:IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable" contextRef="From2023-07-012024-06-30_us-gaap_PreferredStockMember" id="Fact000316" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0317">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="RENB:IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable" contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000318" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,999,973</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0319">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0320">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="RENB:IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable" contextRef="From2023-07-012024-06-30" id="Fact000321" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000,001</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--RestrictedSharesIssuedForServicesRenderedValue_zItgOwDrTbS9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Restricted shares issued for services rendered</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0325">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--RestrictedSharesIssuedForServicesRenderedShares_c20240701__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zYlyC6e4Qfkj" title="Restricted shares issued for services rendered, shares" style="text-align: right"><ix:nonFraction name="RENB:RestrictedSharesIssuedForServicesRenderedShares" contextRef="From2024-07-012025-06-30_us-gaap_CommonStockMember" id="Fact000332" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,083,760</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="RENB:RestrictedSharesIssuedForServicesRenderedValue" contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember" id="Fact000326" format="ixt:numdotdecimal" decimals="0" unitRef="USD">308</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="RENB:RestrictedSharesIssuedForServicesRenderedValue" contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000327" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,663,882</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0328">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0329">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="RENB:RestrictedSharesIssuedForServicesRenderedValue" contextRef="From2023-07-012024-06-30" id="Fact000330" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,664,190</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--StockIssuedDuringPeriodValueExerciseOfWarrants_zewwW2DtPUu6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">Exercise of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0334">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--StockIssuedDuringPeriodSharesExerciseOfWarrants_c20240701__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztPjyY3J3bTh" title="Exercise of warrants, shares" style="text-align: right"><ix:nonFraction name="RENB:StockIssuedDuringPeriodSharesExerciseOfWarrants" contextRef="From2024-07-012025-06-30_us-gaap_CommonStockMember" id="Fact000341" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,951,344</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="RENB:StockIssuedDuringPeriodValueExerciseOfWarrants" contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember" id="Fact000335" format="ixt:numdotdecimal" decimals="0" unitRef="USD">396</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="RENB:StockIssuedDuringPeriodValueExerciseOfWarrants" contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000336" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,341,470</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0337">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0338">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="RENB:StockIssuedDuringPeriodValueExerciseOfWarrants" contextRef="From2023-07-012024-06-30" id="Fact000339" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,341,866</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue_zyonBD5XB3W" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Issuance of common stock and warrants under private placement offering in settlement of debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0343">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtShares_c20240701__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zeLXKwekvoYj" title="Issuance of common stock and warrants under private placement offering in settlement of debt, shares" style="text-align: right"><ix:nonFraction name="RENB:IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtShares" contextRef="From2024-07-012025-06-30_us-gaap_CommonStockMember" id="Fact000350" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,660,042</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="RENB:IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue" contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember" id="Fact000344" format="ixt:numdotdecimal" decimals="0" unitRef="USD">566</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="RENB:IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue" contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000345" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,575,759</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0346">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0347">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="RENB:IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue" contextRef="From2023-07-012024-06-30" id="Fact000348" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,576,106</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--SharesIssuableForSettlementOfContingentConsiderationValue_z6GP58ow81wc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Shares issuable for settlement of contingent consideration</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0352">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--SharesIssuableForSettlementOfContingentConsideration_c20240701__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbfCkVeG2403" title="Shares issuable for settlement of contingent consideration, shares" style="text-align: right"><ix:nonFraction name="RENB:SharesIssuableForSettlementOfContingentConsideration" contextRef="From2024-07-012025-06-30_us-gaap_CommonStockMember" id="Fact000359" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,615,071</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="RENB:SharesIssuableForSettlementOfContingentConsiderationValue" contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember" id="Fact000353" format="ixt:numdotdecimal" decimals="0" unitRef="USD">562</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="RENB:SharesIssuableForSettlementOfContingentConsiderationValue" contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000354" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,295,121</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0355">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0356">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="RENB:SharesIssuableForSettlementOfContingentConsiderationValue" contextRef="From2023-07-012024-06-30" id="Fact000357" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,295,783</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--IssuanceOfCommonStockPursuantToAcquisitionOfGediCube_zlrIxzF0Ayj9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Issuance of common stock pursuant to acquisition of GEDi Cube</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0361">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--IssuanceOfCommonStockPursuantAcquisitionOfGediCubeShares_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z68Sxj2ktcMb" title="Issuance of common stock pursuant to acquisition of GEDi Cube, shares" style="text-align: right"><ix:nonFraction name="RENB:IssuanceOfCommonStockPursuantAcquisitionOfGediCubeShares" contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember" id="Fact000368" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">70,834,183</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="RENB:IssuanceOfCommonStockPursuantToAcquisitionOfGediCube" contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember" id="Fact000362" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,083</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="RENB:IssuanceOfCommonStockPursuantToAcquisitionOfGediCube" contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000363" format="ixt:numdotdecimal" decimals="0" unitRef="USD">135,994,548</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0364">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0365">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="RENB:IssuanceOfCommonStockPursuantToAcquisitionOfGediCube" contextRef="From2023-07-012024-06-30" id="Fact000366" format="ixt:numdotdecimal" decimals="0" unitRef="USD">136,001,631</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube_zWFPRXPfzJl7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Preferred stock converted to common stock pursuant to acquisition of GEDi Cube</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCubeShares_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zcp3zE2BRXXi" title="Preferred stock converted to common stock pursuant to acquisition of GEDi Cube, shares" style="text-align: right">(<ix:nonFraction name="RENB:PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCubeShares" contextRef="From2023-07-012024-06-30_us-gaap_PreferredStockMember" id="Fact000377" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">561,010</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="RENB:PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube" contextRef="From2023-07-012024-06-30_us-gaap_PreferredStockMember" id="Fact000370" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">56</ix:nonFraction></td><td style="text-align: left">)&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCubeShares_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zoiXZw7i034a" title="Preferred stock converted to common stock pursuant to acquisition of GEDi Cube, shares" style="text-align: right"><ix:nonFraction name="RENB:PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCubeShares" contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember" id="Fact000379" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,610,100</ix:nonFraction></td><td style="text-align: left"/><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="RENB:PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube" contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember" id="Fact000371" format="ixt:numdotdecimal" decimals="0" unitRef="USD">561</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="RENB:PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube" contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000372" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">505</ix:nonFraction></td><td style="text-align: left">)&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0373">&#8212;</span></td><td style="text-align: left"/><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0374">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0375">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--StockIssuedDuringPeriodValueOther_iP3custom--PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCubeShares_zEgGS2jKs5lk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Issuance of options for services rendered</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;<span style="-sec-ix-hidden: xdx2ixbrl0381">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0382">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000383" format="ixt:numdotdecimal" decimals="0" unitRef="USD">489,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0384">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0385">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-07-012024-06-30" id="Fact000386" format="ixt:numdotdecimal" decimals="0" unitRef="USD">489,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ShareBasedCompensation_zCNqzpnquZG9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;<span style="-sec-ix-hidden: xdx2ixbrl0388">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0389">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000390" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,673,129</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0391">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0392">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-07-012024-06-30" id="Fact000393" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,673,129</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLoss_zR9IBN4ITO5j" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;<span style="-sec-ix-hidden: xdx2ixbrl0395">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0396">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0397">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember" id="Fact000398" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">88,425,828</ix:nonFraction></td><td style="text-align: left">)&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0399">&#8212;</span></td><td style="text-align: left"/><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012024-06-30" id="Fact000400" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">88,425,828</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--ForeignCurrencyTransactionGainLossBeforeTax_zQ1547f0MNv" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Foreign currency translation adjustment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0402">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0403">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0404">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0405">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000406" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">140,964</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2023-07-012024-06-30" id="Fact000407" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">140,964</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_435_c20240701__20250630_eus-gaap--StockholdersEquity_iS_zqq3gIlSDsS1" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-indent: -10pt; padding-left: 10pt">Balance June 30, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharesOutstanding_iS_c20240701__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zrlq9lt9pSDc" title="Beginning balance, shares" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0416">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0409">&#8212;</span></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharesOutstanding_iS_c20240701__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zs5IlP9guZde" title="Beginning balance, shares" style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-06-30_us-gaap_CommonStockMember" id="Fact000418" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">158,452,644</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_CommonStockMember" id="Fact000410" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,847</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000411" format="ixt:numdotdecimal" decimals="0" unitRef="USD">464,587,224</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_RetainedEarningsMember" id="Fact000412" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">332,455,081</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000413" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">170,846</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30" id="Fact000414" format="ixt:numdotdecimal" decimals="0" unitRef="USD">131,977,144</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--IssuanceOfCommonStockUnderPrivatePlacementOfferingValue_iP3us-gaap--SharesOutstanding_zfChpB0YEYrc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Issuance of common stock under private placement offering</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0420">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--IssuanceOfCommonStockUnderPrivatePlacementOfferingShares_iP3custom--IssuanceOfCommonStockUnderPrivatePlacementOfferingValue_c20240701__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQdnpho3D3Ei" title="Issuance of common stock under private placement offering, shares" style="text-align: right"><ix:nonFraction name="RENB:IssuanceOfCommonStockUnderPrivatePlacementOfferingShares" contextRef="From2024-07-012025-06-30_us-gaap_CommonStockMember" id="Fact000427" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,613,596</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="RENB:IssuanceOfCommonStockUnderPrivatePlacementOfferingValue" contextRef="From2024-07-012025-06-30_us-gaap_CommonStockMember" id="Fact000421" format="ixt:numdotdecimal" decimals="0" unitRef="USD">161</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="RENB:IssuanceOfCommonStockUnderPrivatePlacementOfferingValue" contextRef="From2024-07-012025-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000422" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,376,020</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0423">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0424">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="RENB:IssuanceOfCommonStockUnderPrivatePlacementOfferingValue" contextRef="From2024-07-01to2025-06-30" id="Fact000425" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,376,181</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationValue_iP3custom--IssuanceOfCommonStockUnderPrivatePlacementOfferingShares_zlIMYzZ1Anre" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Restricted shares issued for services rendered and executive compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0429">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationShares_iP3custom--RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationValue_c20240701__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z1hbEhui9Dzj" title="Restricted shares issued for services rendered and executive compensation, shares" style="text-align: right"><ix:nonFraction name="RENB:RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationShares" contextRef="From2024-07-012025-06-30_us-gaap_CommonStockMember" id="Fact000436" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,160,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="RENB:RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationValue" contextRef="From2024-07-012025-06-30_us-gaap_CommonStockMember" id="Fact000430" format="ixt:numdotdecimal" decimals="0" unitRef="USD">316</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="RENB:RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationValue" contextRef="From2024-07-012025-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000431" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,946,529</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0432">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0433">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="RENB:RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationValue" contextRef="From2024-07-01to2025-06-30" id="Fact000434" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,946,845</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensationForfeited_iP3custom--RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationShares_zT47yCRY5WR" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">Forfeited shares of common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0438">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_iP3us-gaap--StockIssuedDuringPeriodValueShareBasedCompensationForfeited_c20240701__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBhvMRVm77Z1" title="Forfeited shares of common stock, shares" style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" contextRef="From2024-07-012025-06-30_us-gaap_CommonStockMember" id="Fact000445" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">833,333</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" contextRef="From2024-07-012025-06-30_us-gaap_CommonStockMember" id="Fact000439" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">83</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" contextRef="From2024-07-012025-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000440" format="ixt:numdotdecimal" decimals="0" unitRef="USD">83</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0441">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0442">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0443">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--IssuanceOfCommonStockPursuantToAcquisitionValue_iP3us-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_zSdp9Gyk5rrl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Issuance of common stock pursuant to acquisition</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0447">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--IssuanceOfCommonStockPursuantToAcquisitionShares_iP3custom--IssuanceOfCommonStockPursuantToAcquisitionValue_c20240701__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zn4hsd7MXpQ" title="Issuance of common stock pursuant to acquisition, shares" style="text-align: right"><ix:nonFraction name="RENB:IssuanceOfCommonStockPursuantToAcquisitionShares" contextRef="From2024-07-012025-06-30_us-gaap_CommonStockMember" id="Fact000454" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="RENB:IssuanceOfCommonStockPursuantToAcquisitionValue" contextRef="From2024-07-012025-06-30_us-gaap_CommonStockMember" id="Fact000448" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="RENB:IssuanceOfCommonStockPursuantToAcquisitionValue" contextRef="From2024-07-012025-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000449" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,057,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0450">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0451">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="RENB:IssuanceOfCommonStockPursuantToAcquisitionValue" contextRef="From2024-07-01to2025-06-30" id="Fact000452" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,058,500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ShareBasedCompensation_zYvGstC00tvl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0456">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0457">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-07-012025-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000458" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,313,291</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0459">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0460">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-07-01to2025-06-30" id="Fact000461" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,313,291</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLoss_zTQp2FRq3Gm3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0463">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0464">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0465">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-07-012025-06-30_us-gaap_RetainedEarningsMember" id="Fact000466" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">178,007,489</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0467">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-07-01to2025-06-30" id="Fact000468" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">178,007,489</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--ForeignCurrencyTransactionGainLossBeforeTax_zUZ9a2nmmkY1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Foreign currency translation adjustment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0470">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0471">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0472">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0473">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2024-07-012025-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000474" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,985,688</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2024-07-01to2025-06-30" id="Fact000475" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,985,688</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_439_c20240701__20250630_eus-gaap--StockholdersEquity_iE_zejIBJBrQiM9" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Balance June 30, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharesOutstanding_iE_c20240701__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zpay8Lqf9Pya" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0484">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0477">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharesOutstanding_iE_c20240701__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zumyTXns00za" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-06-30_us-gaap_CommonStockMember" id="Fact000486" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">177,392,907</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30_us-gaap_CommonStockMember" id="Fact000478" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,741</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000479" format="ixt:numdotdecimal" decimals="0" unitRef="USD">478,280,146</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30_us-gaap_RetainedEarningsMember" id="Fact000480" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">510,462,570</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000481" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,814,842</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-06-30" id="Fact000482" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">21,349,841</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr>
  </table>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;&#160;&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&#160;<b>The accompanying notes
are an integral part of these consolidated financial statements.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 75 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>LUNAI BIOWORKS INC. FKA: RENOVARO INC. AND SUBSIDIARIES</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="b_006"></span>CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_308_112_zJ6cys1npP99" summary="xdx: Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_492_20240701__20250630_zdvEJ46hZOP8" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_492_20230701__20240630_zEKktB14qKtc" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="7" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    the Years Ended</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    30,</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td></tr>
  <tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_iB_zgLM22CVuuga" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CASH
    FLOWS FROM OPERATING ACTIVITIES:</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLoss_i01_maCzjUq_zeaa3bJXVhy9" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-07-01to2025-06-30" id="Fact000491" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">178,007,489</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012024-06-30" id="Fact000492" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">88,425,828</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_z7bvlJqZOmIl" style="vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ADJUSTMENTS
    TO RECONCILE NET LOSS TO NET CASH USED IN OPERATING ACTIVITIES:</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--DepreciationAndAmortization_i02_maCzjUq_zxyFBxTiN5Y6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
    and amortization</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2024-07-01to2025-06-30" id="Fact000497" format="ixt:numdotdecimal" decimals="0" unitRef="USD">129,095</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2023-07-012024-06-30" id="Fact000498" format="ixt:numdotdecimal" decimals="0" unitRef="USD">121,859</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_ecustom--ChangeInFairValueOfContingentConsideration_i02N_di0_msCzjUq_zXDkSIdtVIYk" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
    in fair value of contingent consideration</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="RENB:ChangeInFairValueOfContingentConsideration" contextRef="From2024-07-01to2025-06-30" id="Fact000500" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,680,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="RENB:ChangeInFairValueOfContingentConsideration" contextRef="From2023-07-012024-06-30" id="Fact000501" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,048,183</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--EquitySecuritiesFvNiRealizedLoss_i02_maCzjUq_zkGx71BNxTHf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
    in value of equity securities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:EquitySecuritiesFvNiRealizedLoss" contextRef="From2024-07-01to2025-06-30" id="Fact000503" format="ixt:numdotdecimal" decimals="0" unitRef="USD">112,149</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0504">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_ecustom--LossOnExtinguishmentOfDebt_i02N_di_msCzjUq_zEnQwlRKwmCl" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
    on extinguishment of debt</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0506">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="RENB:LossOnExtinguishmentOfDebt" contextRef="From2023-07-012024-06-30" id="Fact000507" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,303,578</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_401_ecustom--NoncashStockbasedCompensationExpense_i02_maCzjUq_zAselRPyfq9l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-cash
    stock-based compensation expense</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><ix:nonFraction name="RENB:NoncashStockbasedCompensationExpense" contextRef="From2024-07-01to2025-06-30" id="Fact000509" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,313,291</ix:nonFraction></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="RENB:NoncashStockbasedCompensationExpense" contextRef="From2023-07-012024-06-30" id="Fact000510" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,673,129</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_ecustom--NoncashRestrictedSharesIssuedForServicesRendered_i02_maCzjUq_zaHRCXrdYIa6" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-cash
    restricted shares issued for services rendered</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><ix:nonFraction name="RENB:NoncashRestrictedSharesIssuedForServicesRendered" contextRef="From2024-07-01to2025-06-30" id="Fact000512" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,946,845</ix:nonFraction></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="RENB:NoncashRestrictedSharesIssuedForServicesRendered" contextRef="From2023-07-012024-06-30" id="Fact000513" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,664,190</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_i02_maCzjUq_ziCfwHM2mEb7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
    asset impairment</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0515">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="From2023-07-012024-06-30" id="Fact000516" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,611,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--GoodwillImpairmentLoss_i02_d0_maCzjUq_zntSBAfzkYYg" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill
    impairment</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="From2024-07-01to2025-06-30" id="Fact000518" format="ixt:numdotdecimal" decimals="0" unitRef="USD">170,419,429</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="From2023-07-012024-06-30" id="Fact000519" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,640,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_ecustom--AmortizationOfDiscountOnNotePayable_i02_maCzjUq_zBSM20AlNw19" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
    of discount on note payable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="RENB:AmortizationOfDiscountOnNotePayable" contextRef="From2024-07-01to2025-06-30" id="Fact000521" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,024</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="RENB:AmortizationOfDiscountOnNotePayable" contextRef="From2023-07-012024-06-30" id="Fact000522" format="ixt:numdotdecimal" decimals="0" unitRef="USD">580,605</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_zsAhC69UMk14" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
    in assets and liabilities:</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--IncreaseDecreaseInAccountsAndOtherReceivables_i03N_di_msCzjUq_z98M8qmwDcjk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    receivables</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" contextRef="From2024-07-01to2025-06-30" id="Fact000527" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,153,768</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" contextRef="From2023-07-012024-06-30" id="Fact000528" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,108,247</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40E_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i03N_di_msCzjUq_z6oG14FfZeWl" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
    expenses/deposits</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2024-07-01to2025-06-30" id="Fact000530" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,143,293</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2023-07-012024-06-30" id="Fact000531" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,082,267</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--IncreaseDecreaseInAccountsPayable_i03_maCzjUq_zLsJfcShbSQb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
    payable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2024-07-01to2025-06-30" id="Fact000533" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,106,181</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2023-07-012024-06-30" id="Fact000534" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,057,282</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--IncreaseDecreaseInOtherCurrentLiabilities_i03_d0_maCzjUq_z09yDyIwM4y9" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    current liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="From2024-07-01to2025-06-30" id="Fact000536" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">26,477</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="From2023-07-012024-06-30" id="Fact000537" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_i03_maCzjUq_zDuA5pPgvFq6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    leases, net</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2024-07-01to2025-06-30" id="Fact000539" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">16,086</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2023-07-012024-06-30" id="Fact000540" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,284</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInOtherAccruedLiabilities_i03_maCzjUq_zs9ZPTgEvlkd" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
    expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" contextRef="From2024-07-01to2025-06-30" id="Fact000542" format="ixt:numdotdecimal" decimals="0" unitRef="USD">499,330</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" contextRef="From2023-07-012024-06-30" id="Fact000543" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,769,268</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iT_mtCzjUq_maCzFSa_zJD5mKzw4rC5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NET
    CASH USED IN OPERATING ACTIVITIES</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-07-01to2025-06-30" id="Fact000545" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,874,647</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-07-012024-06-30" id="Fact000546" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,971,430</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_iB_zgQ4hUNARkCa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CASH
    FLOWS FROM INVESTING ACTIVITIES:</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--PaymentsToAcquireEquitySecuritiesFvNi_i01N_di0_msCzdZK_zVmoAGovPBEd" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment
    in equity securities</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:PaymentsToAcquireEquitySecuritiesFvNi" contextRef="From2024-07-01to2025-06-30" id="Fact000551" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:PaymentsToAcquireEquitySecuritiesFvNi" contextRef="From2023-07-012024-06-30" id="Fact000552" format="ixt:zerodash" decimals="0" sign="-" unitRef="USD">&#8212;</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--PaymentsToAcquireNotesReceivable_i01N_di0_msCzdZK_zpSk8dzicS9f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
    receivable prior to acquisition</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:PaymentsToAcquireNotesReceivable" contextRef="From2024-07-01to2025-06-30" id="Fact000554" format="ixt:zerodash" decimals="0" sign="-" unitRef="USD">&#8212;</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:PaymentsToAcquireNotesReceivable" contextRef="From2023-07-012024-06-30" id="Fact000555" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,255,600</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40D_eus-gaap--CashAcquiredFromAcquisition_i01_d0_maCzdZK_zk1G9LoxWE41" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    received from acquisition, net</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CashAcquiredFromAcquisition" contextRef="From2024-07-01to2025-06-30" id="Fact000557" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CashAcquiredFromAcquisition" contextRef="From2023-07-012024-06-30" id="Fact000558" format="ixt:numdotdecimal" decimals="0" unitRef="USD">65,851</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_msCzdZK_zSk6l4f7CxW6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchase
    of property and equipment</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0560">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2023-07-012024-06-30" id="Fact000561" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70,430</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_403_eus-gaap--NetCashProvidedByUsedInInvestingActivities_iT_mtCzdZK_maCzFSa_z5R5T0uYGVY1" style="vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NET
    CASH USED IN INVESTING ACTIVITIES</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2024-07-01to2025-06-30" id="Fact000563" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">500,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2023-07-012024-06-30" id="Fact000564" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,260,179</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_iB_zv6F0s7yA7Md" style="vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CASH
    FLOWS FROM FINANCING ACTIVITIES:</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_ecustom--RepaymentsOfFinanceAgreement_i01N_di_msCz8o0_zTmUEXqCohMe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Repayments
    of finance agreement</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="RENB:RepaymentsOfFinanceAgreement" contextRef="From2024-07-01to2025-06-30" id="Fact000569" format="ixt:numdotdecimal" decimals="0" unitRef="USD">971,231</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="RENB:RepaymentsOfFinanceAgreement" contextRef="From2023-07-012024-06-30" id="Fact000570" format="ixt:numdotdecimal" decimals="0" unitRef="USD">870,073</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_400_eus-gaap--ProceedsFromWarrantExercises_i01_maCz8o0_zK9v4jCVX5x1" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
    from exercise of warrants</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0572">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2023-07-012024-06-30" id="Fact000573" format="ixt:numdotdecimal" decimals="0" unitRef="USD">341,865</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_i01_pp0p0_maCz8o0_zJLNkhsXU6Sg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
    from private placements</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2024-07-01to2025-06-30" id="Fact000575" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,376,181</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2023-07-012024-06-30" id="Fact000576" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,000,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--ProceedsFromIssuanceOfDebt_i01_d0_maCz8o0_zNW1tJEApjkf" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
    from issuance of promissory notes</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="From2024-07-01to2025-06-30" id="Fact000578" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="From2023-07-012024-06-30" id="Fact000579" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,770,512</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--ProceedsFromNotesPayable_i01_d0_maCz8o0_zcphkBqotp02" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
    from notes payable</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2024-07-01to2025-06-30" id="Fact000581" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,977,822</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2023-07-012024-06-30" id="Fact000582" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,275,151</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInFinancingActivities_iT_mtCz8o0_maCzFSa_z3gOtZcUCxHh" style="vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NET
    CASH PROVIDED BY FINANCING ACTIVITIES</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2024-07-01to2025-06-30" id="Fact000584" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,382,772</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-07-012024-06-30" id="Fact000585" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,517,455</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_maCzFSa_z4SgEVXYAMg8" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Effect
    of exchange rates on cash</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="From2024-07-01to2025-06-30" id="Fact000587" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">135,892</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="From2023-07-012024-06-30" id="Fact000588" format="ixt:numdotdecimal" decimals="0" unitRef="USD">60,141</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_mtCzFSa_zfqCdU7qRGi7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NET
    INCREASE (DECREASE) IN CASH</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2024-07-01to2025-06-30" id="Fact000590" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">127,767</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2023-07-012024-06-30" id="Fact000591" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,654,013</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iS_zQVFsJrjU4u6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CASH,
    BEGINNING OF PERIOD</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-06-30" id="Fact000593" format="ixt:numdotdecimal" decimals="0" unitRef="USD">220,467</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-06-30" id="Fact000594" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,874,480</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iE_z0Ny9C45YPZ4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CASH,
    END OF PERIOD</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2025-06-30" id="Fact000596" format="ixt:numdotdecimal" decimals="0" unitRef="USD">92,700</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-06-30" id="Fact000597" format="ixt:numdotdecimal" decimals="0" unitRef="USD">220,467</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zR03YbkPRS3j" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SUPPLEMENTAL
    DISCLOSURES OF CASH FLOW INFORMATION</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_ecustom--CashPaidDuringYearForAbstract_i01B_zqZnQ1HFkU6a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    Paid during the year for:</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--InterestPaidNet_i02_zLoqQ505Xsc6" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2024-07-01to2025-06-30" id="Fact000605" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,555</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2023-07-012024-06-30" id="Fact000606" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,128</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxesPaidNet_i02_d0_zGbsZ5tdDTme" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
    Taxes</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2024-07-01to2025-06-30" id="Fact000608" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2023-07-012024-06-30" id="Fact000609" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SUPPLEMENTAL
    DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_ecustom--ContingentSharesIssuedPursuantToAcquisitionAgreement_i01_d0_zWndjfJ6yB0c" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contingent
    Shares issued pursuant to Acquisition Agreement</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="RENB:ContingentSharesIssuedPursuantToAcquisitionAgreement" contextRef="From2024-07-01to2025-06-30" id="Fact000614" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="RENB:ContingentSharesIssuedPursuantToAcquisitionAgreement" contextRef="From2023-07-012024-06-30" id="Fact000615" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_ecustom--CancellationOfRestrictedStockAwards_i01_zsCJHH3L7P17" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cancellation
    of restricted stock awards</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="RENB:CancellationOfRestrictedStockAwards" contextRef="From2024-07-01to2025-06-30" id="Fact000617" format="ixt:numdotdecimal" decimals="0" unitRef="USD">83</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0618">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_ecustom--FinanceAgreementEnteredIntoInExchangeForPrepaidAssets_i01_zQt0NMqK0mn9" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance
    agreement entered into in exchange for prepaid assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="RENB:FinanceAgreementEnteredIntoInExchangeForPrepaidAssets" contextRef="From2024-07-01to2025-06-30" id="Fact000620" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,018,930</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="RENB:FinanceAgreementEnteredIntoInExchangeForPrepaidAssets" contextRef="From2023-07-012024-06-30" id="Fact000621" format="ixt:numdotdecimal" decimals="0" unitRef="USD">906,834</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_ecustom--ConversionOfNotePayableForIssuanceOfPreferredStock_i01_d0_zGkibJ2Ua4eg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conversion
    of note payable for issuance of preferred stock</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="RENB:ConversionOfNotePayableForIssuanceOfPreferredStock" contextRef="From2024-07-01to2025-06-30" id="Fact000623" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="RENB:ConversionOfNotePayableForIssuanceOfPreferredStock" contextRef="From2023-07-012024-06-30" id="Fact000624" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000,001</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_401_ecustom--NotePayableSettledThroughNoncashExerciseOfWarrants_i01_d0_zasGx1EShgNj" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
    payable settled through non-cash exercise of warrants</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="RENB:NotePayableSettledThroughNoncashExerciseOfWarrants" contextRef="From2024-07-01to2025-06-30" id="Fact000626" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="RENB:NotePayableSettledThroughNoncashExerciseOfWarrants" contextRef="From2023-07-012024-06-30" id="Fact000627" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_ecustom--DebtDiscountRelatedToConvertiblePromissoryNotes_i01_d0_z4cKj0g3f6Q" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt
    discount related to notes payable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="RENB:DebtDiscountRelatedToConvertiblePromissoryNotes" contextRef="From2024-07-01to2025-06-30" id="Fact000629" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,954</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="RENB:DebtDiscountRelatedToConvertiblePromissoryNotes" contextRef="From2023-07-012024-06-30" id="Fact000630" format="ixt:numdotdecimal" decimals="0" unitRef="USD">339,342</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_ecustom--CommonSharesIssuedUponAcquisition_i01_d0_zENCa9Bgvw" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    shares issued upon acquisition</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="RENB:CommonSharesIssuedUponAcquisition" contextRef="From2024-07-01to2025-06-30" id="Fact000632" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,058,500</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="RENB:CommonSharesIssuedUponAcquisition" contextRef="From2023-07-012024-06-30" id="Fact000633" format="ixt:numdotdecimal" decimals="0" unitRef="USD">136,001,631</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_408_ecustom--ContingentConsiderationIssuedUponAcquisition_i01_d0_zqOBAi8gvOg3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contingent
    consideration issued upon acquisition</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="RENB:ContingentConsiderationIssuedUponAcquisition" contextRef="From2024-07-01to2025-06-30" id="Fact000635" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="RENB:ContingentConsiderationIssuedUponAcquisition" contextRef="From2023-07-012024-06-30" id="Fact000636" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,557,500</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_ecustom--CommonSharesIssuedUponSettlementOfDebt_i01_d0_zz3DEMbMOIj9" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    shares issued upon settlement of debt</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="RENB:CommonSharesIssuedUponSettlementOfDebt" contextRef="From2024-07-01to2025-06-30" id="Fact000638" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="RENB:CommonSharesIssuedUponSettlementOfDebt" contextRef="From2023-07-012024-06-30" id="Fact000639" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,582,912</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_ecustom--EarnOutSharesIssuedInSettlementOfContingentLiability_i01_d0_zehgNzTx2rDg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Earn
    out shares issued in settlement of contingent liability</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="RENB:EarnOutSharesIssuedInSettlementOfContingentLiability" contextRef="From2024-07-01to2025-06-30" id="Fact000641" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="RENB:EarnOutSharesIssuedInSettlementOfContingentLiability" contextRef="From2023-07-012024-06-30" id="Fact000642" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,295,683</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_ecustom--OptionsIssuedInSettlementOfDebt_i01_d0_zideV1MgQ702" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    issued in settlement of debt</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="RENB:OptionsIssuedInSettlementOfDebt" contextRef="From2024-07-01to2025-06-30" id="Fact000644" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="RENB:OptionsIssuedInSettlementOfDebt" contextRef="From2023-07-012024-06-30" id="Fact000645" format="ixt:numdotdecimal" decimals="0" unitRef="USD">489,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_ecustom--SettlementOfNotesPayable_i01_d0_z6gAlrGuxLY9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Settlement
    of notes payable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="RENB:SettlementOfNotesPayable" contextRef="From2024-07-01to2025-06-30" id="Fact000647" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="RENB:SettlementOfNotesPayable" contextRef="From2023-07-012024-06-30" id="Fact000648" format="ixt:numdotdecimal" decimals="0" unitRef="USD">418,503</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>The accompanying notes are an integral part of these
consolidated financial statements.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Page; Sequence: 76 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>LUNAI BIOWORKS INC. FKA: RENOVARO INC. AND SUBSIDIARIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b></b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="b_007"></span>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000650" name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"><p id="xdx_800_eus-gaap--OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_zXBRMONLJ7el" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 1 &#8212; <span id="xdx_824_zC5Om9BGvJmf">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000652" name="RENB:BusinessPolicyTextBlock"><p id="xdx_845_ecustom--BusinessPolicyTextBlock_zYUaib2yJrql" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_86F_zWx8dfvOISIj">Business</span> &#8211; </b>On August 20, 2025, the Company changed its corporate name from Renovaro Inc.
to Lunai Bioworks Inc. (&#8220;Lunai&#8221;) On April 8, 2025, Lunai Bioworks Inc. acquired BioSymetrics, Inc. and its subsidiary (&#8220;BioSymetrics,
Corp.&#8221;), as a wholly owned subsidiary pursuant to a stock purchase agreement. On February 13, 2024, the Company changed its corporate
name from Renovaro Biosciences Inc. to Renovaro Inc. (&#8220;Renovaro&#8221;, and together with its subsidiaries, the &#8220;Company&#8221;,
&#8220;we&#8221; or &#8220;us&#8221;) and acquired GEDi Cube Intl Ltd and its subsidiaries (&#8220;Renovaro Cube&#8221;), as a wholly
owned subsidiary pursuant to a stock purchase agreement. In August 2023, the Company changed its corporate name from Enochian Biosciences
Inc. to Renovaro Biosciences Inc. The Company is an AI-driven platform for precision medicine, diagnostics, and biodefense. Its proprietary
technologies transform complex biomedical data into predictive insights, enabling faster discovery, greater accuracy, and strategic partnerships
across the life sciences and government sectors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000654" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_84E_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zkcuu00BbdI8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_86F_zEXXiiFIMlJ7">Basis of Presentation</span> &#8211;
</b>The Company prepares consolidated financial statements in accordance with accounting principles generally accepted in the United States
of America (&#8220;U.S. GAAP&#8221;) and follows the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000656" name="us-gaap:ConsolidationPolicyTextBlock"><p id="xdx_84C_eus-gaap--ConsolidationPolicyTextBlock_zrqS0OafGlp6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_865_z1KoBG5SEgYe">Principles of Consolidation</span>
&#8211; </b>For the years ended June 30, 2025 and 2024, the consolidated financial statements include the accounts and operations of Lunai,
and its wholly owned subsidiaries. All material inter-company transactions and accounts have been eliminated in the consolidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000658" name="us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy"><p id="xdx_84E_eus-gaap--ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_zpuJAViAAP6d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_862_zydL5jMJeb8k">Subsidiaries</span> &#8211; </b>Renovaro
Biosciences Inc. (&#8220;Renovaro Biosciences&#8221;), formerly Renovaro
Biopharma Inc., was incorporated on May 19, 2017 in Delaware and is a 100% owned subsidiary of Lunai. Renovaro Biosciences owns a perpetual,
fully paid-up, royalty-free, sublicensable, and sole and exclusive worldwide license to research, develop, use, sell, have sold, make,
have made, offer for sale, import and otherwise commercialize certain intellectual property in cellular therapies for the prevention,
treatment, amelioration of and/or therapy exclusively for HIV in humans, and research and development exclusively relating to HIV in humans.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Renovaro Biosciences Denmark ApS
(&#8220;Renovaro Denmark&#8221;), formerly Enochian Biosciences Denmark ApS a Danish corporation was incorporated on April 1, 2001. On
February 12, 2014, in accordance with the terms and conditions of a Share Exchange Agreement, the Company acquired Renovaro Denmark and
it became a 100% owned subsidiary of Lunai subject to 185,053 shares of Common Stock of Lunai held in escrow according to Danish law (the
&#8220;Escrow Shares&#8221;). As of June 30, 2025, there are 17,414 Escrow Shares remaining (see Note 10).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On February 13, 2024, the Company
acquired <span id="xdx_90F_ecustom--BusinessAcquisitionPercentage_iI_dp_c20240213__us-gaap--BusinessAcquisitionAxis__custom--RenovaroCubeMember_zzu7S4nWvqHk" title="Acquisition percentage"><ix:nonFraction name="RENB:BusinessAcquisitionPercentage" contextRef="AsOf2024-02-13_custom_RenovaroCubeMember" id="Fact000660" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">100</ix:nonFraction></span>% of Renovaro Cube. As a result of the acquisition, Renovaro Cube became a wholly-owned subsidiary of the Company (see Note
13).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On April 8, 2025, the Company acquired
100% of Biosymetrics, Corp. As a result of the acquisition, Biosymetrics, Corp. became a wholly-owned subsidiary of the Company (see Note
13).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000662" name="us-gaap:UseOfEstimates"><p id="xdx_844_eus-gaap--UseOfEstimates_z1PAWZOr1WM8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_860_z7ZmMRXloNK5">Use of Accounting Estimates</span>
</b>- The preparation of financial statements in conformity with generally accepted accounting principles requires management to make
estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities
at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could
differ from those estimated. Significant estimates include the fair value and potential impairment of intangible assets, the fair value
of the contingent consideration liability, and the fair value of equity instruments issued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 77 -->
    <div id="xdx_23C_zz1WIMwwYTrh" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div>
    <div id="xdx_230_zojK2e6tYd0d" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_233_zNOiJdMNx4cj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000665" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"><p id="xdx_845_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zyeZrTS2kLa6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_860_zM6CXfrzgW3j">Functional Currency and Foreign
Currency Translation</span> </b>&#8211; The functional currency of Renovaro Denmark is the Danish Kroner (&#8220;DKK&#8221;) and the functional
currency of Renovaro Cube is the Euro (&#8220;EUR&#8221;) and the functional currency of BioSymetrics Corp. is Canadian Dollar (&#8220;CAD&#8221;).
The Company&#8217;s reporting currency is the U.S. Dollar for the purpose of these financial statements. The Company&#8217;s balance sheet
accounts are translated into U.S. dollars at the period-end exchange rates and all revenue and expenses are translated into U.S. dollars
at the average exchange rates prevailing during the years ended June 30, 2025, and 2024. Translation gains and losses are deferred and
accumulated as a component of other comprehensive income in stockholders&#8217; equity. Transaction gains and losses that arise from exchange
rate fluctuations from transactions denominated in a currency other than the functional currency are included in the statement of operations
as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000667" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_84B_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z1pBNr7bNr16" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_864_zKkxoHpQUD82">Cash and Cash Equivalents</span> </b>&#8211;
The Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000669" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_84B_eus-gaap--ConcentrationRiskCreditRisk_zSp4CzxxGON3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_869_zG0cDF1nI7Df">Concentration of Credit Risk</span>
&#8211;</b> Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in financial
institutions, which, at times, exceed the amount of deposit insurance provided within the relevant jurisdiction where the deposits are
held. As of June 30, 2025, and June 30, 2024, the Company has not experienced losses on these accounts and management believes the Company
is not exposed to significant risks on such accounts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000671" name="RENB:InvestmentinEquitySecuritiesPolicyTextBlock"><p id="xdx_848_ecustom--InvestmentinEquitySecuritiesPolicyTextBlock_zPhvPJ0FpCb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_86D_z4PxeoMQXEja">Investment in Equity Securities</span>
</b>&#8211; The Company accounts for investments in equity securities in accordance with ASC 321, Investments&#8212;Equity Securities.
Equity securities with readily determinable fair values are measured at fair value, with changes in fair value recognized in net income
or loss. Equity securities without readily determinable fair values are measured at cost, less impairment, if any, and adjusted for observable
price changes in orderly transactions for the identical or a similar investment of the same issuer. The Company evaluates such investments
at each reporting period for impairment or other observable transactions that would require adjustment. On February 28, 2025, the Company
purchased $<span id="xdx_90D_ecustom--PurchaseEquitySecuritiesValue_iI_c20250630_zdDehCdNLaYh" title="Purchase equity securities value"><ix:nonFraction name="RENB:PurchaseEquitySecuritiesValue" contextRef="AsOf2025-06-30" id="Fact000673" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,000</ix:nonFraction></span> of equity securities. During the year ended June 30, 2025, the Company recorded a change in fair value of equity securities
for $<span id="xdx_904_eus-gaap--DebtSecuritiesTradingAndEquitySecuritiesFvNiCost_iI_c20250630_zAnM259h5M4b" title="Fair value of equity securities"><ix:nonFraction name="us-gaap:DebtSecuritiesTradingAndEquitySecuritiesFvNiCost" contextRef="AsOf2025-06-30" id="Fact000675" format="ixt:numdotdecimal" decimals="0" unitRef="USD">112,149</ix:nonFraction></span> (see Note 3). The investment in equity securities balance at June 30, 2025, was $<span id="xdx_903_eus-gaap--DebtAndEquitySecuritiesGainLoss_c20240701__20250630_z4DS7NglA2n7" title="Investment in equity securities"><ix:nonFraction name="us-gaap:DebtAndEquitySecuritiesGainLoss" contextRef="From2024-07-01to2025-06-30" id="Fact000677" format="ixt:numdotdecimal" decimals="0" unitRef="USD">387,851</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000679" name="RENB:InsuranceReceivablePolicy"><p id="xdx_843_ecustom--InsuranceReceivablePolicy_z318v78IRBx3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_860_zSQo35l8z6Xh">Insurance Receivable</span> &#8211;</b>
The Company recognizes insurance receivables associated with expected recoveries of costs incurred for litigation which is probable of
incurring a loss and for which it is probable the Company will receive coverage under its existing insurance policies. The Company records
any such recoveries on a gross basis and does not net such amounts against any related loss contingency accruals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000681" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_846_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zPkradVek9Nk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_865_zZ0FLRKdTa8k">Property and Equipment</span> </b>-
Property and equipment are stated at cost. Expenditures for major renewals and betterments that extend the useful lives of property and
equipment are capitalized and depreciated upon being placed in service. Expenditures for maintenance and repairs are charged to expense
as incurred. Depreciation is computed for financial statement purposes on a straight-line basis over the estimated useful lives of the
assets, which range from four to ten years (see Note 5).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000683" name="us-gaap:IntangibleAssetsFiniteLivedPolicy"><p id="xdx_84A_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zlQ0lARpwWP2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_862_zduFUJqHNupk">Intangible Assets</span> - </b>The
Company has both definite and indefinite life intangible assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Definite life intangible assets
relate to patents. The Company accounts for definite life intangible assets in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;)
Accounting Standards Codification (&#8220;ASC&#8221;) Topic 350, <i>Goodwill and Other Intangible Assets</i>. Intangible assets are recorded
at cost. Patent costs capitalized consist of costs incurred to acquire the underlying patent. If it is determined that a patent will not
be issued, the related remaining capitalized patent costs are charged to expense. Definite life intangible assets are amortized on a straight-line
basis over their estimated useful life. The estimated useful life of patents is twenty years from the date of application.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Indefinite life intangible assets
include license agreements and goodwill acquired in a business combination. The Company accounts for indefinite life intangible assets
in accordance with ASC 350. License agreement costs represent the fair value of the license agreement on the date acquired and are tested
annually for impairment on June 30 or whenever events or changes in circumstances indicate the fair value of the license is less than
the carrying amount.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000685" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock"><p id="xdx_84E_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zppE3uZ4rs8l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_86A_zY6jWxzGpd27">Goodwill</span></b> - Goodwill is
not amortized but is evaluated for impairment annually as of June 30 or whenever events or changes in circumstances indicate the carrying
value of the reporting unit may be less than the fair value of the reporting unit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 78 -->
    <div id="xdx_236_zLtZJPMyksLc" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div>
    <div id="xdx_234_zfFEazaJaZra" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23E_zcKDPXjSA0X5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000688" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock"><p id="xdx_846_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_zUHEWWKhdzql" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_86A_zYdnNWAi0jOc">Impairment of Goodwill and
Indefinite Lived Intangible Assets</span></b> &#8211; We test for goodwill impairment at the reporting unit level, which is one level below the
operating segment level. Our detailed impairment testing involves comparing the fair value of each reporting unit to its carrying value,
including goodwill. Fair value reflects the price a market participant would be willing to pay in a potential sale of the reporting unit
and is based on discounted cash flows or relative market-based approaches. If the carrying value of the reporting unit exceeds its fair
value, we record an impairment loss for such excess.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the year ended June 30, 2025, the results of the assessment indicated that
the carrying value of the RENC reporting unit exceeded its fair value, due to the decline in the estimated fair value of the reporting
unit based on the Company&#8217;s market capitalization. Management concluded the significant driver for the change in the economic benefits
was due to the Company&#8217;s continued inability to raise capital for the further development of the technologies within this reporting
unit. The Company recorded an impairment loss of $<span id="xdx_900_ecustom--ImpairmentLoss_iI_c20240930_zvTM8vzNPVO1" title="Impairment loss"><ix:nonFraction name="RENB:ImpairmentLoss" contextRef="AsOf2024-09-30" id="Fact000690" format="ixt:numdotdecimal" decimals="0" unitRef="USD">47,614,729</ix:nonFraction></span> for the period ended September 30, 2024 and $<span id="xdx_90A_ecustom--ImpairmentLoss_iI_c20250630_zWUNhMmystdk" title="Impairment loss"><ix:nonFraction name="RENB:ImpairmentLoss" contextRef="AsOf2025-06-30" id="Fact000692" format="ixt:numdotdecimal" decimals="0" unitRef="USD">122,804,700</ix:nonFraction></span> for the period ended
June 30, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For indefinite life intangible
assets, such as IPR&amp;D, on an annual basis on June 30th we determine the fair value of the asset and record an impairment loss, if
any, for the excess of the carrying value of the asset over its fair value. For the year ended June 30, 2024, the carrying value of the
IPR&amp;D exceeded its fair value. Therefore, the Company recorded an impairment loss of $<span id="xdx_90C_ecustom--ImpairmentLoss_iI_c20240630_zS5WUF3ShNad" title="Impairment loss"><ix:nonFraction name="RENB:ImpairmentLoss" contextRef="AsOf2024-06-30" id="Fact000694" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,611,000</ix:nonFraction></span> during the year ended June 30, 2024.
During the year ended June 30, 2025, the Company recorded no impairment loss related to IPR&amp;D.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The carrying value of
IPR&amp;D and goodwill at June 30, 2025, were&#160;<span id="xdx_908_ecustom--InProcessResearchAndDevelopment_iI_c20250630_zj3R8xMjC70l" title="In-process research and development" style="display: none"><ix:nonFraction name="RENB:InProcessResearchAndDevelopment" contextRef="AsOf2025-06-30" id="Fact000696" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span>
zero and $<span id="xdx_90B_eus-gaap--Goodwill_iI_c20250630_zsA8QKJf2cWd" title="Goodwill"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2025-06-30" id="Fact000698" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,963,000</ix:nonFraction></span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000700" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><p id="xdx_84D_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zKn0gA0Hulw" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;<b><span id="xdx_862_zpCMsJFbXpTj">Impairment of Long-Lived
Assets</span> - </b>Long-lived assets, such as property and equipment and definite life intangible assets are reviewed for impairment whenever
events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Circumstances which could trigger
a review include, but are not limited to: significant decreases in the market price of the asset; significant adverse changes in the business
climate or legal factors; current period cash flow or operating losses combined with a history of losses or a forecast of continuing losses
associated with the use of the asset; and current expectations that the asset will more likely than not be sold or disposed of significantly
before the end of its estimated useful life.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Recoverability of assets to be
held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected
to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge
is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of would
be separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell and would
no longer be depreciated. The depreciable basis of assets that are impaired and continue in use are their respective fair values. <span id="xdx_901_eus-gaap--AssetImpairmentCharges_do_c20240701__20250630_z0oVRYKbcl5l" title="Impairment of assets"><span id="xdx_909_eus-gaap--AssetImpairmentCharges_do_c20230701__20240630_zMHxZhPQePZj" title="Impairment of assets"><ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="From2024-07-01to2025-06-30" id="Fact000702" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="From2023-07-012024-06-30" id="Fact000704" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">No</ix:nonFraction></ix:nonFraction></span></span> impairment
of these assets was recorded during the year ended June 30, 2025 or 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000706" name="us-gaap:LesseeLeasesPolicyTextBlock"><p id="xdx_84F_eus-gaap--LesseeLeasesPolicyTextBlock_zLsY70deoHF7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;<b><span id="xdx_86B_z3Yxf2ZBGssk">Leases</span> -</b> In accordance
with ASC Topic 842, the Company determined the initial classification and measurement of its right-of-use assets and lease liabilities
at the lease commencement date and thereafter. The lease terms include any renewal options and termination options that the Company is
reasonably assured to exercise, if applicable. The present value of lease payments is determined by using the implicit interest rate in
the lease, if that rate is readily determinable; otherwise, the Company develops an incremental borrowing rate based on the information
available at the commencement date in determining the present value of the future payments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Rent expense for operating leases
is recognized on a straight-line basis, unless the operating lease right-of-use assets have been impaired, over the reasonably assured
lease term based on the total lease payments and is included in general and administrative expenses in the consolidated statements of
operations. For operating leases that reflect impairment, the Company will recognize the amortization of the operating lease right-of-use
assets on a straight-line basis over the remaining lease term with rent expense still included in general and administrative expenses
in the consolidated statements of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 79 -->
    <div id="xdx_234_zh4EsuvL69vh" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div>
    <div id="xdx_23E_z7TOOWmoz845" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_230_zeCd5KBHe7fa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000709" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_842_eus-gaap--ResearchAndDevelopmentExpensePolicy_zYLdwUrdqhD9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_869_zaRzb8gbnWt8">Research and Development Expenses</span>
&#8211; </b>The Company expenses research and development costs incurred in formulating, improving, validating, and creating alternative
or modified processes related to and expanding the use of the Company&#8217;s technologies. Research and development expenses for the
years ended June 30, 2025 and 2024 amounted to $<span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20240701__20250630_zZJeJ1XukUpc" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-07-01to2025-06-30" id="Fact000711" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">537,428</ix:nonFraction></span>, and $<span id="xdx_900_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230701__20240630_zkydk6f0dDki" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-07-012024-06-30" id="Fact000713" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,708,829</ix:nonFraction></span> respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000715" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_zfMXOt5X8KO5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_862_z48fhTLPouia">Income Taxes</span> </b>- The Company
accounts for income taxes in accordance with FASB ASC Topic 740 Accounting for Income Taxes, which requires an asset and liability approach
for accounting for income taxes (see Note 9).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000717" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_845_eus-gaap--EarningsPerSharePolicyTextBlock_zFEfdTf7feMe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_86A_ziMuA0HBi456">Loss Per Share</span></b> - The Company
calculates earnings (loss) per share in accordance with FASB ASC 260 Earnings Per Share. Basic earnings per common share (EPS) are based
on the weighted average number of shares of Common Stock outstanding during each period. Diluted earnings per common share are based on
shares outstanding (computed as for basic EPS) and potentially dilutive common shares. Potential shares of Common Stock included in the
diluted earnings per share calculation include in-the-money stock options that have been granted but have not been exercised. The shares
of Common Stock outstanding at June 30, 2025 and 2024 were <span id="xdx_905_eus-gaap--CommonStockOtherSharesOutstanding_iI_c20250630_zMapRAqnrkA9" title="Common stock outstanding"><ix:nonFraction name="us-gaap:CommonStockOtherSharesOutstanding" contextRef="AsOf2025-06-30" id="Fact000719" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">177,392,907</ix:nonFraction></span> and <span id="xdx_903_eus-gaap--CommonStockOtherSharesOutstanding_iI_c20240630_zaQnmzBUSFij" title="Common stock outstanding"><ix:nonFraction name="us-gaap:CommonStockOtherSharesOutstanding" contextRef="AsOf2024-06-30" id="Fact000721" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">158,452,644</ix:nonFraction></span>, respectively. Because of the net loss for each
of the years ended June 30, 2025 and June 30, 2024, dilutive shares for both periods were excluded from the diluted EPS calculation, as
the effect of these potential shares of Common Stock is anti-dilutive. The Company had <span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240701__20250630_zScZFt79wZuh" title="Anti-dilutive shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-07-01to2025-06-30" id="Fact000723" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,669,140</ix:nonFraction></span> and <span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20240630_zhSvmErRFtTi" title="Anti-dilutive shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-07-012024-06-30" id="Fact000725" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">17,146,315</ix:nonFraction></span> potential shares of Common
Stock excluded from the diluted EPS calculation for the years ended June 30, 2025 and 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000727" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_84A_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zakJ3iM7cBMi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_86F_zNE5vRN0nSkg">Fair Value of Financial Instruments</span>
</b>&#8211; The Company accounts for fair value measurements for financial assets and financial liabilities in accordance with FASB ASC
Topic 820, &#8220;Fair Value Measurements&#8221;. The authoritative guidance, among other things, defines fair value, establishes a consistent
framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either
a recurring or nonrecurring basis. Fair value is defined as the exit price, representing the amount that would either be received to
sell an asset or be paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based
measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000729" name="us-gaap:CompensationRelatedCostsPolicyTextBlock"><p id="xdx_84C_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zBv2wJW9shTb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;<b><span id="xdx_869_zLzKFsYnd3xa">Stock-Based Compensation</span>
- </b>The Company has granted stock options, restricted share units (&#8220;RSUs&#8221;) and warrants to certain employees, officers,
directors, and consultants. The Company accounts for options in accordance with the provisions of <b><i>FASB ASC Topic 718, Compensation
&#8211; Stock Compensation</i></b>. Stock based compensation costs for the vesting of options and RSUs granted to certain employees, officers,
directors, and consultants for the years ended June 30, 2025 and 2024 were $<span id="xdx_900_eus-gaap--ShareBasedCompensation_c20240701__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesOfficersDirectorsAndConsultantsMember_zzOV5taph179" title="Stock based compensation costs"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-07-012025-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_EmployeesOfficersDirectorsAndConsultantsMember" id="Fact000731" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,313,291</ix:nonFraction></span> and $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_c20230701__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesOfficersDirectorsAndConsultantsMember_z0Xu23kdrakh" title="Stock based compensation costs"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-07-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_EmployeesOfficersDirectorsAndConsultantsMember" id="Fact000733" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,673,129</ix:nonFraction></span>, respectively<b>.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.2pt">The Company recognizes compensation
costs for stock option awards to employees, officers and directors based on their grant-date fair value. The value of each stock option
is estimated on the date of grant using the Black-Scholes option-pricing model. The weighted-average assumptions used to estimate the
fair value of the stock options granted using the Black-Scholes option-pricing model are the expected term of the award, the underlying
stock price volatility, the risk-free interest rate, and the expected dividend yield. The Company accounts for forfeitures as they occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.2pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company records stock-based
compensation for services received from non-employees in accordance with <b><i>ASC 718, Compensation&#8212;Stock Compensation Non-Employees</i></b>.
All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based
on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable.
Equity instruments issued to consultants and the cost of the services received as consideration are measured and recognized based on
the fair value of the equity instruments issued and are recognized over the consultants&#8217; required service period, which is generally
the vesting period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company does not have sufficient
historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior.
Accordingly, the Company has elected to use the &#8220;simplified method&#8221; to estimate the expected term of its share-based awards.
The simplified method computes the expected term as the sum of the award&#8217;s vesting term plus the original contractual term divided
by two.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000735" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zIzlraGROM96" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_86C_zlgwLRK4maNc">New Accounting Pronouncements
Not Yet Adopte</span>d</b> - Recent accounting pronouncements issued by the FASB that have not yet been adopted by the Company are not expected
to have a material impact on the Company&#8217;s present or future consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 80 -->
    <div id="xdx_231_zRqOJ9MwSj13" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div>
    <div id="xdx_233_zSB49cq2L583" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_234_zRBWSC0qbLkh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:exclude>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000738" name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock"><p id="xdx_806_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zORVQ1TBu9Fk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 2 &#8211; <span id="xdx_82F_zGKnBM1iu628">GOING CONCERN</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s consolidated
financial statements are prepared using the generally accepted accounting principles applicable to a going concern, which contemplates
the realization of assets and liquidation of liabilities in the normal course of business. However, the Company has incurred substantial
recurring losses from continuing operations, has used cash in the Company&#8217;s continuing operations, and is dependent on additional
financing to fund operations. The Company incurred a net loss of $<span id="xdx_904_eus-gaap--NetIncomeLoss_iN_pp0p0_di_c20240701__20250630_zQ7AP2eX5xAk" title="Net loss"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-07-01to2025-06-30" id="Fact000740" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">178,007,489</ix:nonFraction></span> and $<span id="xdx_908_eus-gaap--NetIncomeLoss_iN_pp0p0_di_c20230701__20240630_z9VhM10puope" title="Net loss"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012024-06-30" id="Fact000742" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">88,425,828</ix:nonFraction></span> for the years ended June 30, 2025 and 2024,
respectively. As of June 30, 2025, the Company had cash and cash equivalents of $<span id="xdx_909_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_c20250630_zLM5AcFUOiEg" title="Cash and cash equivalents"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2025-06-30" id="Fact000744" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">92,700</ix:nonFraction></span> and an accumulated deficit of $<span id="xdx_906_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pp0p0_di_c20250630_zlXWnIcMzoPl" title="Accumulated deficit"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2025-06-30" id="Fact000746" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">510,462,570</ix:nonFraction></span> and
a working capital deficit of $<span id="xdx_900_ecustom--WorkingCapitalDeficit_iI_pp0p0_c20250630_zEsDJ9rWAdm4" title="Working capital deficit"><ix:nonFraction name="RENB:WorkingCapitalDeficit" contextRef="AsOf2025-06-30" id="Fact000748" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">28,109,502</ix:nonFraction></span>. These conditions raise substantial doubt about the Company&#8217;s ability to continue as a
going concern for one year after the date the financial statements are issued. The consolidated financial statements do not include any
adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be
necessary should the Company be unable to continue in existence.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Management has reduced overhead
and administrative costs by streamlining the organization to focus on the development and validation of its AI-driven cancer diagnostics
platform. The Company has tailored its workforce to focus on these activities. In addition, the Company intends to secure additional required
funding through equity or debt financing. However, there can be no assurance that the Company will be able to obtain any sources of funding.
Such additional funding may not be available or may not be available on reasonable terms, and, in the case of equity financing transactions,
could result in significant additional dilution to our stockholders. If we do not obtain required additional equity or debt funding, our
cash resources will be depleted and we could be required to materially reduce or suspend operations, which would likely have a material
adverse effect on our business, stock price and our relationships with third parties with whom we have business relationships, at least
until additional funding is obtained. If we do not have sufficient funds to continue operations, we could be required to seek bankruptcy
protection or other alternatives that could result in our stockholders losing some or all of their investment in us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Funding that we may receive during
the fiscal year 2026 is expected to be used to satisfy existing and future obligations and liabilities and working capital needs, to support
commercialization of our products, to conduct the clinical and regulatory work to develop our product candidates, and to begin building
working capital reserves.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000750" name="us-gaap:FairValueMeasurementInputsDisclosureTextBlock"><p id="xdx_803_eus-gaap--FairValueMeasurementInputsDisclosureTextBlock_zutd0oyZKMol" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 3 &#8212; <span id="xdx_82F_zWDsZ5OpVgE6">FAIR VALUE MEASUREMENTS</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company accounts for fair
value measurements for financial assets and financial liabilities in accordance with FASB ASC Topic 820, &#8220;Fair Value Measurements&#8221;.
The authoritative guidance among other things, defines fair value, establishes a consistent framework for measuring fair value and expands
disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value
is defined as the exit price, representing the amount that would either be received to sell an asset or be paid to transfer a liability
in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based
on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the guidance
establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Level 1. Observable inputs such as quoted prices in active markets for identical assets or liabilities; </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="vertical-align: top; width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Level 2. Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="vertical-align: top; width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 81 -->
    <div id="xdx_232_zMt2lFvswIKj" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div>
    <div id="xdx_23B_zUpli9DS5NJf" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23F_zFWnARLmyNY3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">There were no Level 2 and 3 assets,
or any Level 1 or 2 liabilities as of June 30, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Unless otherwise disclosed, the
fair value of the Company&#8217;s financial instruments including cash, accounts receivable, prepaid expenses, accounts payable, accrued
expenses, lease obligations and notes payable approximate their recorded values due to their short-term maturities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Level 1 assets held as of June
30, 2025, consisted of an investment in equity securities related to an extension agreement entered on February 28, 2024<span style="background-color: white">.
The Company purchased <span id="xdx_909_eus-gaap--StockRepurchasedDuringPeriodShares_c20240701__20250630__us-gaap--StatementClassOfStockAxis__custom--CommonStocksMember_zA3ftsTJhGwa" title="Purchased shares of common stock"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="From2024-07-012025-06-30_custom_CommonStocksMember" id="Fact000753" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">467,290</ix:nonFraction></span> shares of common stock at a purchase price of $<span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_c20250630__us-gaap--StatementClassOfStockAxis__custom--CommonStocksMember_zERKJoEbLkmi" title="Purchase price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2025-06-30_custom_CommonStocksMember" id="Fact000755" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.07</ix:nonFraction></span> per share. The investment in equity securities was recorded
at a fair value of $<span id="xdx_90F_eus-gaap--EquitySecuritiesFvNiCost_iI_c20250630__us-gaap--StatementClassOfStockAxis__custom--CommonStocksMember_zZz0ZTkeuXN9" title="Fair value of equity securities"><ix:nonFraction name="us-gaap:EquitySecuritiesFvNiCost" contextRef="AsOf2025-06-30_custom_CommonStocksMember" id="Fact000757" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,000</ix:nonFraction></span> at the time of purchase and is subsequently remeasured to fair value at the end of each reporting period.
As of June 30, 2025, the Company held <span id="xdx_90F_ecustom--InvestmentEquitySecuritiesShares_iI_c20250630__us-gaap--StatementClassOfStockAxis__custom--CommonStocksMember_zdPwRGfDhOT1" title="investment  equity securities shares"><ix:nonFraction name="RENB:InvestmentEquitySecuritiesShares" contextRef="AsOf2025-06-30_custom_CommonStocksMember" id="Fact000759" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">467,290</ix:nonFraction></span> shares of common stock in connection with the investment in equity securities. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Level 3 liabilities held as of
June 30, 2025, consisted of a contingent consideration liability related to the February 13, 2024 acquisition of <span style="background-color: white">Renovaro
Cube, (the &#8220;Acquisition&#8221;). As consideration for the Acquisition, the stockholders of Renovaro Cube received (i) <span id="xdx_90C_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c20250212__20250213__us-gaap--BusinessAcquisitionAxis__custom--RenovaroCubeMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zcUTErZOEbRi" title="Contingent shares issuable in connection with the acquisition"><ix:nonFraction name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" contextRef="From2025-02-122025-02-13_custom_RenovaroCubeMember_us-gaap_CommonStockMember" id="Fact000761" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">70,834,183</ix:nonFraction></span>
shares of Common Stock, and (ii) the right to receive up to <span id="xdx_90D_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c20250212__20250213__us-gaap--BusinessAcquisitionAxis__custom--RenovaroCubeMember__us-gaap--StatementClassOfStockAxis__custom--ConvertibleNotesMember_zbl4B3pUVHdd" title="Contingent shares issuable in connection with the acquisition"><ix:nonFraction name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" contextRef="From2025-02-122025-02-13_custom_RenovaroCubeMember_custom_ConvertibleNotesMember" id="Fact000763" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,899,545</ix:nonFraction></span> contingent shares pro rata upon the exercise of convertible notes,
options, and warrants, which were outstanding at closing. The contingent consideration liability was recorded at fair value of $<span id="xdx_90E_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_c20250213__us-gaap--BusinessAcquisitionAxis__custom--RenovaroCubeMember_zyzRa4uGa3t8" title="Contingent consideration liability was recorded at fair value"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="AsOf2025-02-13_custom_RenovaroCubeMember" id="Fact000765" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,557,500</ix:nonFraction></span>
at the time of the Acquisition and is subsequently remeasured to fair value at the end of each reporting period. As of June 30, 2025,
there were <span id="xdx_90E_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c20240701__20250630__us-gaap--BusinessAcquisitionAxis__custom--RenovaroCubeMember_zb9LuVVHfoIc" title="Contingent shares issuable in connection with the acquisition"><ix:nonFraction name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" contextRef="From2024-07-012025-06-30_custom_RenovaroCubeMember" id="Fact000767" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,775,650</ix:nonFraction></span> contingent shares issuable in connection with the Acquisition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s assets and
liabilities measured at fair value on recurring bases as of June 30, 2025 were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000769" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_z2jvxTefkOie" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt"><span id="xdx_8B7_zTaUZdgmxFHb" style="display: none">Schedule of assets and
liabilities measured at fair value on recurring bases</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_499_20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zQzvXgkEBbQ" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49A_20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zEsjnT6mDvcc" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49D_20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zuh9bP385oC4" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value Measurements at<br/> Reporting Date Using</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-indent: -10pt; padding-left: 10pt">Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--EquitySecuritiesFvNi_iI_zcG3r0N1i5Ia" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Investment in equity securities</td><td style="width: 5%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"><ix:nonFraction name="us-gaap:EquitySecuritiesFvNi" contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel1Member" id="Fact000771" format="ixt:numdotdecimal" decimals="0" unitRef="USD">387,851</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 5%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0772">&#8212;</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 5%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0773">&#8212;</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AccruedLiabilitiesFairValueDisclosure_iI_zFAPaLuCkqGc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Total assets at fair value</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesFairValueDisclosure" contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel1Member" id="Fact000775" format="ixt:numdotdecimal" decimals="0" unitRef="USD">387,851</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0776">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0777">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-indent: -10pt; padding-left: 10pt">Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ContingentConsiderationClassifiedAsEquityFairValueDisclosure_iI_zByKpBBRISY2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Contingent consideration</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0779">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0780">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure" contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel3Member" id="Fact000781" format="ixt:numdotdecimal" decimals="0" unitRef="USD">630,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DerivativeFairValueOfDerivativeLiability_iI_zeFlGaeTvPDg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Total liabilities at fair value</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0783">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0784">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel3Member" id="Fact000785" format="ixt:numdotdecimal" decimals="0" unitRef="USD">630,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A2_zESIYL92M3dg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The fair value of the contingent
consideration liability is estimated using a Black-Scholes option-pricing model and a Monte-Carlo option pricing model. The key inputs
to the model are all contractual or observable with the exception being volatility, which is computed based on the volatility of the Company&#8217;s
underlying stock. The key inputs to valuing the contingent consideration liability as of June 30, 2025, were:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000787" name="us-gaap:FairValueConcentrationOfRiskTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--FairValueConcentrationOfRiskTextBlock_z9h8AL4mIza1" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details 1)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B0_zvM5tZevQ8A6" style="display: none">Schedule of key input to valuing the
contingent consideration liability</span> </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-indent: -10pt">Stock Price</td><td style="width: 10%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 18%; text-align: right"><span id="xdx_901_eus-gaap--SharePrice_iI_pip0_c20250630__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_z7AWelG40Uq8" title="Stock Price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2025-06-30_custom_BlackScholesOptionPricingModelMember" id="Fact000789" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">0.29</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Exercise Price</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">$<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pip0_c20250630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zvLRxaPuJjx5" title="Exercise Price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2025-06-30_srt_MinimumMember_custom_BlackScholesOptionPricingModelMember" id="Fact000791" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">0.53</ix:nonFraction></span> - $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pip0_c20250630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zdEwZKSKFTF6" title="Exercise Price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2025-06-30_srt_MaximumMember_custom_BlackScholesOptionPricingModelMember" id="Fact000793" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">1.92</ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Volatility</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20240701__20250630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zB66ZpszDMN4" title="Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2024-07-012025-06-30_srt_MinimumMember_custom_BlackScholesOptionPricingModelMember" id="Fact000795" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">116</ix:nonFraction></span>% - <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20240701__20250630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_znPOfT17uTp5" title="Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2024-07-012025-06-30_srt_MaximumMember_custom_BlackScholesOptionPricingModelMember" id="Fact000797" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">141</ix:nonFraction></span>%</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Risk Free Rate</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20240701__20250630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zbcy1swkb2H9" title="Risk Free Rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2024-07-012025-06-30_srt_MinimumMember_custom_BlackScholesOptionPricingModelMember" id="Fact000799" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">3.61</ix:nonFraction></span>% - <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20240701__20250630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zTIaRnl1D08k" title="Risk Free Rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2024-07-012025-06-30_srt_MaximumMember_custom_BlackScholesOptionPricingModelMember" id="Fact000801" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">4.02</ix:nonFraction></span>%</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Expected Dividends</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20240701__20250630__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_ze9cCHjxT9Ya" title="Expected Dividends"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2024-07-012025-06-30_custom_BlackScholesOptionPricingModelMember" id="Fact000803" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">0</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Discount Rate (Monte-Carlo model only)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate_pip0_dp_c20240701__20250630__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_z66eiy3IqZqb" title="Discount Rate (Monte-Carlo model only)"><ix:nonFraction name="RENB:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate" contextRef="From2024-07-012025-06-30_custom_BlackScholesOptionPricingModelMember" id="Fact000805" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">0</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Expected Term (years)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240701__20250630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zL8pzYmdMZq" title="Expected Term (years)"><ix:nonNumeric contextRef="From2024-07-012025-06-30_srt_MinimumMember_custom_BlackScholesOptionPricingModelMember" format="ixt-sec:duryear" id="Fact000807" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">2.70</ix:nonNumeric></span> &#8211;<span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240701__20250630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zKGilmjz5Yhb" title="Expected Term (years)"> <ix:nonNumeric contextRef="From2024-07-012025-06-30_srt_MaximumMember_custom_BlackScholesOptionPricingModelMember" format="ixt-sec:duryear" id="Fact000809" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">8.38</ix:nonNumeric></span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At initial recognition of the contingent consideration,
the inputs were:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-indent: -10pt">Stock Price</td><td style="width: 10%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 18%; text-align: right"><span id="xdx_909_eus-gaap--SharePrice_iI_pip0_c20250630__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_z2wyC1dnZCZ7" title="Stock Price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2025-06-30_custom_InitialRecognitionMember" id="Fact000811" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">1.92</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Exercise Price</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">$<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pip0_c20250630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zsR9QLQztrJ4" title="Exercise Price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2025-06-30_srt_MinimumMember_custom_InitialRecognitionMember" id="Fact000813" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">0.46</ix:nonFraction></span> - $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pip0_c20250630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zTkAmBRGujaa" title="Exercise Price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2025-06-30_srt_MaximumMember_custom_InitialRecognitionMember" id="Fact000815" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">4.50</ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Volatility</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20240701__20250630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zyTHaNhBnsTd" title="Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2024-07-012025-06-30_srt_MinimumMember_custom_InitialRecognitionMember" id="Fact000817" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">107</ix:nonFraction></span>% - <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20240701__20250630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_z7TkkYwypWI7" title="Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2024-07-012025-06-30_srt_MaximumMember_custom_InitialRecognitionMember" id="Fact000819" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">133</ix:nonFraction></span>% </span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Risk Free Rate</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20240701__20250630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zO5IUsIsnpgi" title="Risk Free Rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2024-07-012025-06-30_srt_MinimumMember_custom_InitialRecognitionMember" id="Fact000821" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">4.22</ix:nonFraction></span>% - <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20240701__20250630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zYhvR1yEwEdl" title="Risk Free Rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2024-07-012025-06-30_srt_MaximumMember_custom_InitialRecognitionMember" id="Fact000823" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">5.14</ix:nonFraction></span>%</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Expected Dividends</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20240701__20250630__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zKNk75opeJU4" title="Expected Dividends"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2024-07-012025-06-30_custom_InitialRecognitionMember" id="Fact000825" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">0</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Discount Rate (Monte-Carlo model only)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate_pip0_dp_c20240701__20250630__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zd2uyHoAiima" title="Discount Rate (Monte-Carlo model only)"><ix:nonFraction name="RENB:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate" contextRef="From2024-07-012025-06-30_custom_InitialRecognitionMember" id="Fact000827" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">12</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Expected Term (years)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240701__20250630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_z4tNQ2OULmz6" title="Expected Term (years)"><ix:nonNumeric contextRef="From2024-07-012025-06-30_srt_MinimumMember_custom_InitialRecognitionMember" format="ixt-sec:duryear" id="Fact000829" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">0.56</ix:nonNumeric></span> &#8211; <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240701__20250630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zNmm9snjaAQ7" title="Expected Term (years)"><ix:nonNumeric contextRef="From2024-07-012025-06-30_srt_MaximumMember_custom_InitialRecognitionMember" format="ixt-sec:duryear" id="Fact000831" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">9.88</ix:nonNumeric></span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zXrFA4k8MP92" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 82 -->
    <div id="xdx_232_zflR2UXOGDi5" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div>
    <div id="xdx_234_z53Usm2BJx6g" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23B_zgC0BjupuSY3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The following table sets forth the Level 3 liability
at June 30, 2025, which is recorded on the consolidated balance sheet at fair value on a recurring basis. As required, this liability
is classified based on the lowest level of input that is significant to the fair value measurement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><b>The roll forward of contingent consideration liability
is as follows:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000834" name="RENB:ScheduleOfContingentConsiderationLiabilityTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_894_ecustom--ScheduleOfContingentConsiderationLiabilityTableTextBlock_z6kiE8CH7ob2" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details 2)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt"><span id="xdx_8BF_z7Ro7lNVSB5i" style="display: none">Schedule of fair value measurement on recurring basis</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49F_20240701__20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zbcmlYNu04xa" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49C_20240701__20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zTHGQ9VNTKx1" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_496_20240701__20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zV3BlZEzgj34" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value Measurements at<br/> Reporting Date Using</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Quoted Prices in <br/> Active Markets for Identical Assets Inputs</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Significant Other <br/> Observable Inputs</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Significant Other Unobservable Inputs</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 1)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 2)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 3)</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">The roll forward of the contingent consideration liability is as follows:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--BusinessCombinationContingentConsiderationLiability_iS_d0_zbQGZBKugltc" style="vertical-align: bottom; background-color: White">
    <td style="width: 46%; text-indent: -10pt; padding-left: 10pt">Balance June 30, 2024</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member" id="Fact000836" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member" id="Fact000837" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member" id="Fact000838" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,310,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LiabilitiesFairValueAdjustment_d0_zFUffL1kEte5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Fair value adjustment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueAdjustment" contextRef="From2024-07-012025-06-30_us-gaap_FairValueInputsLevel1Member" id="Fact000840" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueAdjustment" contextRef="From2024-07-012025-06-30_us-gaap_FairValueInputsLevel2Member" id="Fact000841" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:LiabilitiesFairValueAdjustment" contextRef="From2024-07-012025-06-30_us-gaap_FairValueInputsLevel3Member" id="Fact000842" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,680,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--BusinessCombinationContingentConsiderationLiability_iE_d0_z9kYfPmHC4L" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Contingent Consideration Liability at June 30, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel1Member" id="Fact000844" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel2Member" id="Fact000845" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel3Member" id="Fact000846" format="ixt:numdotdecimal" decimals="0" unitRef="USD">630,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>



</ix:nonNumeric><p id="xdx_8AA_zXxFcBipTzd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000848" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p id="xdx_805_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zxl19FJXkld9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 4 - <span id="xdx_823_zKpHywtfHgRl">PROPERTY AND EQUIPMENT</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Property and equipment consisted of the following at
June 30, 2025 and 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000850" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_886_eus-gaap--PropertyPlantAndEquipmentTextBlock_zdkXhz1M3JWc" summary="xdx: Disclosure - PROPERTY AND EQUIPMENT (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B1_zRY6zMpgJIYd" style="display: none">Schedule of Property and equipment</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Useful Life</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2025</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2024</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt">Lab equipment and instruments</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: center"><span style="font-size: 10pt"><span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20250630__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentAndInstrumentsMember_z1cwyeI9Mxdl" title="Useful Life"><ix:nonNumeric contextRef="AsOf2025-06-30_srt_MinimumMember_custom_LabEquipmentAndInstrumentsMember" format="ixt-sec:duryear" id="Fact000852" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">4</ix:nonNumeric></span>-<span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20250630__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentAndInstrumentsMember_zfHQFKzYqhD3" title="Useful Life"><ix:nonNumeric contextRef="AsOf2025-06-30_srt_MaximumMember_custom_LabEquipmentAndInstrumentsMember" format="ixt-sec:duryear" id="Fact000854" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">7</ix:nonNumeric></span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentGross_pp0p0_c20250630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentAndInstrumentsMember_zsQiSUjKqOX5" title="Total" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2025-06-30_custom_LabEquipmentAndInstrumentsMember" id="Fact000856" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">639,998</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_pp0p0_c20240630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentAndInstrumentsMember_zEnrdRZwSEQ8" title="Total" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-06-30_custom_LabEquipmentAndInstrumentsMember" id="Fact000858" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">639,998</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20250630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zxFk7F40U1A1" title="Useful Life"><ix:nonNumeric contextRef="AsOf2025-06-30_us-gaap_LeaseholdImprovementsMember" format="ixt-sec:duryear" id="Fact000860" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">10</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_pp0p0_c20250630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zwMVpHRLeBY7" title="Total" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2025-06-30_us-gaap_LeaseholdImprovementsMember" id="Fact000862" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">224,629</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_pp0p0_c20240630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zQI2prmRptC1" title="Total" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-06-30_us-gaap_LeaseholdImprovementsMember" id="Fact000864" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">224,629</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Furniture, fixtures, and equipment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt"><span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20250630__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_z9j8Mw96hsWl" title="Useful Life"><ix:nonNumeric contextRef="AsOf2025-06-30_srt_MinimumMember_us-gaap_FurnitureAndFixturesMember" format="ixt-sec:duryear" id="Fact000866" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">4</ix:nonNumeric></span>-<span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20250630__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_z7GXQciyftgg" title="Useful Life"><ix:nonNumeric contextRef="AsOf2025-06-30_srt_MaximumMember_us-gaap_FurnitureAndFixturesMember" format="ixt-sec:duryear" id="Fact000868" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">7</ix:nonNumeric></span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_pp0p0_c20250630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zCYF512hkL1f" title="Total" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2025-06-30_us-gaap_FurnitureAndFixturesMember" id="Fact000870" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">205,396</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_pp0p0_c20240630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zXDEbVL2Eqfe" title="Total" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-06-30_us-gaap_FurnitureAndFixturesMember" id="Fact000872" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">195,834</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_pp0p0_c20250630_zyhEYxV1OOD6" title="Total" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2025-06-30" id="Fact000874" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,070,023</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_pp0p0_c20240630_zKSQ8OYf06tg" title="Total" style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-06-30" id="Fact000876" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,060,461</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Less accumulated depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20250630_zBuzJe4yqVb" title="Less Accumulated Depreciation" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2025-06-30" id="Fact000878" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">702,180</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20240630_znx8NEzgYOa5" title="Less Accumulated Depreciation" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2024-06-30" id="Fact000880" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">578,340</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net Property and Equipment</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: center">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentNet_pp0p0_c20250630_zb0XkweEblt5" title="Net Property and Equipment" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2025-06-30" id="Fact000882" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">367,843</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentNet_pp0p0_c20240630_zgqY1LLvXHw2" title="Net Property and Equipment" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-06-30" id="Fact000884" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">482,121</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Depreciation expense amounted
to $<span id="xdx_905_eus-gaap--Depreciation_pp0p0_c20240701__20250630_zQV36t4Ync48" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2024-07-01to2025-06-30" id="Fact000886" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">119,193</ix:nonFraction></span> and $<span id="xdx_905_eus-gaap--Depreciation_pp0p0_c20230701__20240630_zvoiiJw49Xve" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2023-07-012024-06-30" id="Fact000888" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">113,563</ix:nonFraction></span> for the years ended June 30, 2025 and 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000890" name="us-gaap:IntangibleAssetsDisclosureTextBlock"><p id="xdx_80A_eus-gaap--IntangibleAssetsDisclosureTextBlock_z83twAFzGaPi" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 5 &#8212; <span id="xdx_824_zwtUXnKln0Ad">INTANGIBLE ASSETS AND GOODWILL</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">At June 30, 2025, definite-life
intangible assets, net of accumulated amortization, consisted of patents, software platform and trademarks on the Company&#8217;s products
and processes of $<span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20250630__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zWoKJkZq8fcj" title="Definite-life intangible assets"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2025-06-30_us-gaap_PatentsMember" id="Fact000892" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">14,994</ix:nonFraction></span>, $<span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20250630__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_zat8g1b9D78h" title="Definite-life intangible assets"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2025-06-30_custom_SoftwarePlatformMember" id="Fact000894" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">143,000</ix:nonFraction></span> and $<span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_zYrDsOvImAKd" title="Definite-life intangible assets"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2025-06-30_custom_TrademarkMember" id="Fact000896" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,000</ix:nonFraction></span>. At June 30, 2024, definite-life intangible assets, net of accumulated amortization, consisted
of patents on the Company&#8217;s products and processes of $<span id="xdx_902_eus-gaap--AccumulatedAmortizationOfCurrentDeferredFinanceCosts_iI_c20240630_zOk7N08mioSl" title="Accumulated amortization cost"><ix:nonFraction name="us-gaap:AccumulatedAmortizationOfCurrentDeferredFinanceCosts" contextRef="AsOf2024-06-30" id="Fact000898" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,043</ix:nonFraction></span>. The patents are recorded at cost and amortized over twenty years
from the date of application. Amortization expense for the years ended June 30, 2025 and 2024 was $<span id="xdx_90E_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20240701__20250630_z2DcqlhMhexi" title="Amortization expense"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2024-07-01to2025-06-30" id="Fact000900" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,902</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20230701__20240630_zx5sRbE5vp4d" title="Amortization expense"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2023-07-012024-06-30" id="Fact000902" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,296</ix:nonFraction></span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">At June 30, 2025 and 2024, indefinite
life intangible assets consisted of a license agreement classified as In-Process Research and Development (&#8220;IPR&amp;D&#8221;) intangible
assets, which are not amortizable until the intangible assets provide economic benefit, and goodwill.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 83 -->
    <div id="xdx_236_zKmrdEw7RIc" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div>
    <div id="xdx_23B_zOcEqtp9e8Ub" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_239_zUOMhewuJ6Ca" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">At June 30, 2025 and 2024, definite-life
and indefinite-life intangible assets consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact000905" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zxS1O5kteR7" summary="xdx: Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B3_zFdrFns2PjV7" style="display: none">Schedule of definite-life
and indefinite-life intangible assets</span></td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Useful Life</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2024</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">&#160;<b>Additions</b></span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">&#160;<b>Amortization</b></span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">&#160;<b>Impairment</b></span></td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Translation Adjustment</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2025</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 18%; font-weight: bold; text-align: left; text-indent: -10pt">Definite Life Intangible Assets</td><td style="width: 2%">&#160;</td>
    <td style="text-align: center; width: 8%; padding-left: 5.4pt">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"/><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"/><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"/><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"/><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"/><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"/><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Software platform</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_zKDgw0CvNEa1" title="Useful life"><ix:nonNumeric contextRef="AsOf2025-06-30_custom_SoftwarePlatformMember1126485421" format="ixt-sec:duryear" id="Fact000907" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">5</ix:nonNumeric></span> Years</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_zJGoDYDERBOk" title="Net definite-life intangible assets at beginning" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0909">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_zLTbAOW8wDei" title="Net definite-life intangible assets, Additions" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" contextRef="From2024-07-012025-06-30_custom_SoftwarePlatformMember" id="Fact000911" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">143,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_d0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_zFKC0eOjohHl" title="Net definite-life intangible assets, Amortization" style="text-align: right"><ix:nonFraction name="RENB:NetDefinitelifeIntangibleAssetsAmortization" contextRef="From2024-07-012025-06-30_custom_SoftwarePlatformMember" id="Fact000913" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_zuln89l3Uto1" title="Net definite-life intangible assets, Impairment" style="text-align: right"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="From2024-07-012025-06-30_custom_SoftwarePlatformMember" id="Fact000915" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_zFoqaOz3XOr3" title="Net definite-life intangible assets, Translation adjustment" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0917">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_zxO255rBSjQ8" title="Net definite-life intangible assets at ending" style="text-align: right"><ix:nonFraction name="RENB:NetDefinitelifeIntangibleAssets" contextRef="AsOf2025-06-30_custom_SoftwarePlatformMember1126485421" id="Fact000919" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">143,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Trademark</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_z02VLJxSHsb9" title="Useful life"><ix:nonNumeric contextRef="AsOf2025-06-30_custom_TrademarkMember" format="ixt-sec:duryear" id="Fact000921" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">2</ix:nonNumeric></span> Years</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_zgQbP6Vi2M4g" title="Net definite-life intangible assets at beginning" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0923">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_zofiC2jNydfc" title="Net definite-life intangible assets, Additions" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" contextRef="From2024-07-012025-06-30_custom_TrademarkMember" id="Fact000925" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_d0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_zlfmDMvRsokk" title="Net definite-life intangible assets, Amortization" style="text-align: right"><ix:nonFraction name="RENB:NetDefinitelifeIntangibleAssetsAmortization" contextRef="From2024-07-012025-06-30_custom_TrademarkMember" id="Fact000927" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_zXapNlDBbgzi" title="Net definite-life intangible assets, Impairment" style="text-align: right"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="From2024-07-012025-06-30_custom_TrademarkMember" id="Fact000929" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_zVQeZjfLLNS7" title="Net definite-life intangible assets, Translation adjustment" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0931">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_zR1tYG7DguW5" title="Net definite-life intangible assets at ending" style="text-align: right"><ix:nonFraction name="RENB:NetDefinitelifeIntangibleAssets" contextRef="AsOf2025-06-30_custom_TrademarkMember" id="Fact000933" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Patents</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zIabVC9iVBwe" title="Useful life"><ix:nonNumeric contextRef="AsOf2025-06-30_us-gaap_PatentsMember1126485515" format="ixt-sec:duryear" id="Fact000935" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">20</ix:nonNumeric></span> Years</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zI94aHMbOyM" title="Net definite-life intangible assets at beginning" style="text-align: right"><ix:nonFraction name="RENB:NetDefinitelifeIntangibleAssets" contextRef="AsOf2024-06-30_us-gaap_PatentsMember" id="Fact000937" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">284,977</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zOLRsLLVq87h" title="Net definite-life intangible assets, Additions" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" contextRef="From2024-07-012025-06-30_us-gaap_PatentsMember" id="Fact000939" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_d0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zz7N5EZrcuii" title="Net definite-life intangible assets, Amortization" style="text-align: right"><ix:nonFraction name="RENB:NetDefinitelifeIntangibleAssetsAmortization" contextRef="From2024-07-012025-06-30_us-gaap_PatentsMember" id="Fact000941" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zvaP3kU1OSU6" title="Net definite-life intangible assets, Impairment" style="text-align: right"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="From2024-07-012025-06-30_us-gaap_PatentsMember" id="Fact000943" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zYwTZH1bJS6e" title="Net definite-life intangible assets, Translation adjustment" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" contextRef="From2024-07-012025-06-30_us-gaap_PatentsMember" id="Fact000945" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">28,033</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zGx1XQ5ijRC3" title="Net definite-life intangible assets at ending" style="text-align: right"><ix:nonFraction name="RENB:NetDefinitelifeIntangibleAssets" contextRef="AsOf2025-06-30_us-gaap_PatentsMember1126485515" id="Fact000947" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">313,010</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Less Accumulated Amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt; padding-left: 5.4pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zvRV4WPb7Xpb" title="Net definite-life intangible assets at beginning" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="RENB:NetDefinitelifeIntangibleAssets" contextRef="AsOf2024-06-30_custom_LessAccumulatedAmortizationMember" id="Fact000949" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">254,934</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_z5CgLFnFELmi" title="Net definite-life intangible assets, Additions" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" contextRef="From2024-07-012025-06-30_custom_LessAccumulatedAmortizationMember" id="Fact000951" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_z4kzqeRSI9y1" title="Net definite-life intangible assets, Amortization" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="RENB:NetDefinitelifeIntangibleAssetsAmortization" contextRef="From2024-07-012025-06-30_custom_LessAccumulatedAmortizationMember" id="Fact000953" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">9,902</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_z2gDFxhwFlNf" title="Net definite-life intangible assets, Impairment" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="From2024-07-012025-06-30_custom_LessAccumulatedAmortizationMember" id="Fact000955" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zgrxQKogzR7h" title="Net definite-life intangible assets, Translation adjustment" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" contextRef="From2024-07-012025-06-30_custom_LessAccumulatedAmortizationMember" id="Fact000957" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">33,180</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zvlmX4hnJiV3" title="Net definite-life intangible assets at ending" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="RENB:NetDefinitelifeIntangibleAssets" contextRef="AsOf2025-06-30_custom_LessAccumulatedAmortizationMember" id="Fact000959" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">298,016</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Net Definite-Life Intangible Assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt; padding-left: 5.4pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20240701__20250630_zrPSE28IG2M3" title="Net definite-life intangible assets at beginning" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="RENB:NetDefinitelifeIntangibleAssets" contextRef="AsOf2024-06-30" id="Fact000961" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">30,043</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20240701__20250630_z3QafijyuGbf" title="Net definite-life intangible assets, Additions" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" contextRef="From2024-07-01to2025-06-30" id="Fact000963" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">151,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_c20240701__20250630_zv5BPUhvgFa8" title="Net definite-life intangible assets, Amortization" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="RENB:NetDefinitelifeIntangibleAssetsAmortization" contextRef="From2024-07-01to2025-06-30" id="Fact000965" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">9,902</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20240701__20250630_zauppiG9kKOh" title="Net definite-life intangible assets, Impairment" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="From2024-07-01to2025-06-30" id="Fact000967" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20240701__20250630_z0ED7xf0gSJ8" title="Net definite-life intangible assets, Translation adjustment" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" contextRef="From2024-07-01to2025-06-30" id="Fact000969" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">5,147</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20240701__20250630_z7NHUSlScmS4" title="Net definite-life intangible assets at ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="RENB:NetDefinitelifeIntangibleAssets" contextRef="AsOf2025-06-30" id="Fact000971" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">165,994</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-indent: -10pt">Goodwill</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Goodwill</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zYQ7stsJmGeg" title="Total indefinite life intangible assets and goodwill at beginning" style="text-align: right"><ix:nonFraction name="us-gaap:OtherIndefiniteLivedIntangibleAssets" contextRef="AsOf2024-06-30_us-gaap_GoodwillMember" id="Fact000973" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">159,330,161</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zjcbBxKVEHjd" title="Total indefinite life intangible assets and goodwill, Additions" style="text-align: right"><ix:nonFraction name="us-gaap:IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease" contextRef="From2024-07-012025-06-30_us-gaap_GoodwillMember" id="Fact000975" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,963,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillAmortization_pp0p0_d0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zZWCBJDFqvye" title="Total indefinite life intangible assets and goodwill, Amortization" style="text-align: right"><ix:nonFraction name="RENB:IndefiniteLifeIntangibleAssetsAndGoodwillAmortization" contextRef="From2024-07-012025-06-30_us-gaap_GoodwillMember" id="Fact000977" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillImpairment_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zp9sqSLEORah" title="Total indefinite life intangible assets and goodwill, Impairment" style="text-align: right">(<ix:nonFraction name="RENB:IndefiniteLifeIntangibleAssetsAndGoodwillImpairment" contextRef="From2024-07-012025-06-30_us-gaap_GoodwillMember" id="Fact000979" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">170,419,429</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zwdneV1Ax3zb" title="Total indefinite life intangible assets and goodwill, Translation adjustment" style="text-align: right"><ix:nonFraction name="us-gaap:IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" contextRef="From2024-07-012025-06-30_us-gaap_GoodwillMember" id="Fact000981" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">11,089,268</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iE_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_z9lzaKaMF8b7" title="Total indefinite life intangible assets and goodwill at ending" style="text-align: right"><ix:nonFraction name="us-gaap:OtherIndefiniteLivedIntangibleAssets" contextRef="AsOf2025-06-30_us-gaap_GoodwillMember" id="Fact000983" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,963,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Total Goodwill</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt; padding-left: 5.4pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20240701__20250630_zckWwmOVPp4" title="Total indefinite life intangible assets and goodwill at beginning" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OtherIndefiniteLivedIntangibleAssets" contextRef="AsOf2024-06-30" id="Fact000985" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">159,330,161</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_c20240701__20250630_zcmJwXWeGib5" title="Total indefinite life intangible assets and goodwill, Additions" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease" contextRef="From2024-07-01to2025-06-30" id="Fact000987" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,963,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillAmortization_pp0p0_d0_c20240701__20250630_zR5l2f7KZ3d4" title="Total indefinite life intangible assets and goodwill, Amortization" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="RENB:IndefiniteLifeIntangibleAssetsAndGoodwillAmortization" contextRef="From2024-07-01to2025-06-30" id="Fact000989" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillImpairment_pp0p0_c20240701__20250630_z5CmQQHJHznb" title="Total indefinite life intangible assets and goodwill, Impairment" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="RENB:IndefiniteLifeIntangibleAssetsAndGoodwillImpairment" contextRef="From2024-07-01to2025-06-30" id="Fact000991" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">170,419,429</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20240701__20250630_zKwEnw7E9pOd" title="Total indefinite life intangible assets and goodwill, Translation adjustment" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" contextRef="From2024-07-01to2025-06-30" id="Fact000993" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">11,089,268</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iE_pp0p0_c20240701__20250630_z6SB979hjI9f" title="Total indefinite life intangible assets and goodwill at ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OtherIndefiniteLivedIntangibleAssets" contextRef="AsOf2025-06-30" id="Fact000995" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,963,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Useful Life</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">&#160;<b>Additions</b></span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">&#160;<b>Amortization</b></span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">&#160;<b>Impairment</b></span></td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Translation Adjustment</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2024</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Definite Life Intangible Assets</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 18%; text-indent: -10pt">Patents</td><td style="width: 2%">&#160;</td>
    <td style="width: 8%; text-align: center; padding-left: 5.4pt"><span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zwcPlFDYIuZf" title="Useful life"><ix:nonNumeric contextRef="AsOf2025-06-30_us-gaap_PatentsMember1126485515" format="ixt-sec:duryear" id="Fact000997" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">20</ix:nonNumeric></span> Years</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zfEb16zeTnj2" title="Net definite-life intangible assets at beginning" style="width: 8%; text-align: right"><ix:nonFraction name="RENB:NetDefinitelifeIntangibleAssets" contextRef="AsOf2023-06-30_us-gaap_PatentsMember" id="Fact000999" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">290,936</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zJ7fAgtfGv37" title="Net definite-life intangible assets, Additions" style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" contextRef="From2023-07-012024-06-30_us-gaap_PatentsMember" id="Fact001001" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zjPYMFp1vs98" title="Net definite-life intangible assets, Amortization" style="width: 8%; text-align: right"><ix:nonFraction name="RENB:NetDefinitelifeIntangibleAssetsAmortization" contextRef="From2023-07-012024-06-30_us-gaap_PatentsMember" id="Fact001003" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zAiLki89dtH6" title="Net definite-life intangible assets, Impairment" style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="From2023-07-012024-06-30_us-gaap_PatentsMember" id="Fact001005" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z5AiMHi03suf" title="Net definite-life intangible assets, Translation adjustment" style="width: 8%; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" contextRef="From2023-07-012024-06-30_us-gaap_PatentsMember" id="Fact001007" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">5,959</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zLGY4yuJEExi" title="Net definite-life intangible assets at ending" style="width: 8%; text-align: right"><ix:nonFraction name="RENB:NetDefinitelifeIntangibleAssets" contextRef="AsOf2024-06-30_us-gaap_PatentsMember" id="Fact001009" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">284,977</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Less Accumulated Amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt; padding-left: 5.4pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zJol2J4hyr3l" title="Net definite-life intangible assets at beginning" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="RENB:NetDefinitelifeIntangibleAssets" contextRef="AsOf2023-06-30_custom_LessAccumulatedAmortizationMember" id="Fact001011" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">251,260</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zrnuJuLKfwki" title="Net definite-life intangible assets, Additions" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" contextRef="From2023-07-012024-06-30_custom_LessAccumulatedAmortizationMember" id="Fact001013" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zEibEadINif8" title="Net definite-life intangible assets, Amortization" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="RENB:NetDefinitelifeIntangibleAssetsAmortization" contextRef="From2023-07-012024-06-30_custom_LessAccumulatedAmortizationMember" id="Fact001015" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">8,296</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zdE5db2anRIe" title="Net definite-life intangible assets, Impairment" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="From2023-07-012024-06-30_custom_LessAccumulatedAmortizationMember" id="Fact001017" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zggvI2ANGL5e" title="Net definite-life intangible assets, Translation adjustment" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" contextRef="From2023-07-012024-06-30_custom_LessAccumulatedAmortizationMember" id="Fact001019" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,622</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zrB8QScOP5k1" title="Net definite-life intangible assets at ending" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="RENB:NetDefinitelifeIntangibleAssets" contextRef="AsOf2024-06-30_custom_LessAccumulatedAmortizationMember" id="Fact001021" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">254,934</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Net Definite-Life Intangible Assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt; padding-left: 5.4pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20230701__20240630_z5Arwfkpf5yb" title="Net definite-life intangible assets at beginning" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="RENB:NetDefinitelifeIntangibleAssets" contextRef="AsOf2023-06-30" id="Fact001023" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">39,676</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20230701__20240630_zW3vXIX6Agq7" title="Net definite-life intangible assets, Additions" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" contextRef="From2023-07-012024-06-30" id="Fact001025" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_c20230701__20240630_ztF926anJYla" title="Net definite-life intangible assets, Amortization" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="RENB:NetDefinitelifeIntangibleAssetsAmortization" contextRef="From2023-07-012024-06-30" id="Fact001027" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">8,296</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20230701__20240630_zfzCmbhysTHb" title="Net definite-life intangible assets, Impairment" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="From2023-07-012024-06-30" id="Fact001029" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20230701__20240630_zc0TlrPaLLg8" title="Net definite-life intangible assets, Translation adjustment" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" contextRef="From2023-07-012024-06-30" id="Fact001031" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,337</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20230701__20240630_zGu7SYVAdEBj" title="Net definite-life intangible assets at ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="RENB:NetDefinitelifeIntangibleAssets" contextRef="AsOf2024-06-30" id="Fact001033" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">30,043</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Indefinite Life Intangible Assets and Goodwill</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Goodwill</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zB2jSfWy2ld2" title="Total indefinite life intangible assets and goodwill at beginning" style="text-align: right"><ix:nonFraction name="us-gaap:OtherIndefiniteLivedIntangibleAssets" contextRef="AsOf2023-06-30_us-gaap_GoodwillMember" id="Fact001035" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">11,640,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zDU1gbDrif4j" title="Total indefinite life intangible assets and goodwill, Additions" style="text-align: right"><ix:nonFraction name="us-gaap:IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease" contextRef="From2023-07-012024-06-30_us-gaap_GoodwillMember" id="Fact001037" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">159,464,039</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillAmortization_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zUBT57FkhyX" title="Total indefinite life intangible assets and goodwill, Amortization" style="text-align: right"><ix:nonFraction name="RENB:IndefiniteLifeIntangibleAssetsAndGoodwillAmortization" contextRef="From2023-07-012024-06-30_us-gaap_GoodwillMember" id="Fact001039" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillImpairment_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zd4CqzoBjYFl" title="Total indefinite life intangible assets and goodwill, Impairment" style="text-align: right">(<ix:nonFraction name="RENB:IndefiniteLifeIntangibleAssetsAndGoodwillImpairment" contextRef="From2023-07-012024-06-30_us-gaap_GoodwillMember" id="Fact001041" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">11,640,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zNeFETdRY1ia" title="Total indefinite life intangible assets and goodwill, Translation adjustment" style="text-align: right">(<ix:nonFraction name="us-gaap:IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" contextRef="From2023-07-012024-06-30_us-gaap_GoodwillMember" id="Fact001043" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">133,878</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iE_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zrlt65boy9Aj" title="Total indefinite life intangible assets and goodwill at ending" style="text-align: right"><ix:nonFraction name="us-gaap:OtherIndefiniteLivedIntangibleAssets" contextRef="AsOf2024-06-30_us-gaap_GoodwillMember" id="Fact001045" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">159,330,161</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">IPR&amp;D</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt; padding-left: 5.4pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zjsS956KFFuk" title="Total indefinite life intangible assets and goodwill at beginning" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherIndefiniteLivedIntangibleAssets" contextRef="AsOf2023-06-30_us-gaap_InProcessResearchAndDevelopmentMember" id="Fact001047" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">42,611,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_z0Ss2Apml1J1" title="Total indefinite life intangible assets and goodwill, Additions" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease" contextRef="From2023-07-012024-06-30_us-gaap_InProcessResearchAndDevelopmentMember" id="Fact001049" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillAmortization_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zGJ8NJgKfiX1" title="Total indefinite life intangible assets and goodwill, Amortization" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="RENB:IndefiniteLifeIntangibleAssetsAndGoodwillAmortization" contextRef="From2023-07-012024-06-30_us-gaap_InProcessResearchAndDevelopmentMember" id="Fact001051" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillImpairment_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zgMLOlPFRta3" title="Total indefinite life intangible assets and goodwill, Impairment" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="RENB:IndefiniteLifeIntangibleAssetsAndGoodwillImpairment" contextRef="From2023-07-012024-06-30_us-gaap_InProcessResearchAndDevelopmentMember" id="Fact001053" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">42,611,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zASnIycpGfsf" title="Total indefinite life intangible assets and goodwill, Translation adjustment" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" contextRef="From2023-07-012024-06-30_us-gaap_InProcessResearchAndDevelopmentMember" id="Fact001055" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iE_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zoHKP38JxOtc" title="Total indefinite life intangible assets and goodwill at ending" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherIndefiniteLivedIntangibleAssets" contextRef="AsOf2024-06-30_us-gaap_InProcessResearchAndDevelopmentMember" id="Fact001057" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Total Indefinite Life Intangible Assets and Goodwill</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt; padding-left: 5.4pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20230701__20240630_z2LoUc1O8Cjl" title="Total indefinite life intangible assets and goodwill at beginning" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OtherIndefiniteLivedIntangibleAssets" contextRef="AsOf2023-06-30" id="Fact001059" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">54,251,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_c20230701__20240630_z2L7zbO8iEne" title="Total indefinite life intangible assets and goodwill, Additions" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease" contextRef="From2023-07-012024-06-30" id="Fact001061" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">159,464,039</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillAmortization_pp0p0_d0_c20230701__20240630_zV0JSbNWMYhe" title="Total indefinite life intangible assets and goodwill, Amortization" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="RENB:IndefiniteLifeIntangibleAssetsAndGoodwillAmortization" contextRef="From2023-07-012024-06-30" id="Fact001063" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillImpairment_pp0p0_c20230701__20240630_zSI9EOJ7LZ3i" title="Total indefinite life intangible assets and goodwill, Impairment" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="RENB:IndefiniteLifeIntangibleAssetsAndGoodwillImpairment" contextRef="From2023-07-012024-06-30" id="Fact001065" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">54,251,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20230701__20240630_zFwhJXemLzF4" title="Total indefinite life intangible assets and goodwill, Translation adjustment" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" contextRef="From2023-07-012024-06-30" id="Fact001067" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">133,878</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iE_pp0p0_c20230701__20240630_zczZFCtZTPe1" title="Total indefinite life intangible assets and goodwill at ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OtherIndefiniteLivedIntangibleAssets" contextRef="AsOf2024-06-30" id="Fact001069" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">159,330,161</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_z64nXS896v6l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Expected future amortization expense is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact001071" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zrffr1Kb1ul7" summary="xdx: Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details 1)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B9_zucCgOr290Jb" style="display: none">Schedule of future amortization expense</span></td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Years
    ended&#160;June 30,</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 73%; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2026</span></td><td style="width: 10%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pp0p0_c20250630_zgWunGgaLwWc" title="2026" style="width: 15%; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="AsOf2025-06-30" id="Fact001073" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">36,350</ix:nonFraction></span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2027</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pp0p0_c20250630_zujEcm2NjZHc" title="2027" style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="AsOf2025-06-30" id="Fact001075" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">36,348</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2028</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pp0p0_c20250630_zI2kCElHpZG6" title="2028" style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="AsOf2025-06-30" id="Fact001077" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">32,348</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2029</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pp0p0_c20250630_z9rB87fMI4L" title="2029" style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="AsOf2025-06-30" id="Fact001079" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">32,348</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thereafter</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pp0p0_c20250630_zQPwDE569wN" title="Thereafter" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" contextRef="AsOf2025-06-30" id="Fact001081" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">28,600</ix:nonFraction></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20250630_zC5XSMIb2DUd" title="Total" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2025-06-30" id="Fact001083" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">165,994</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>



</ix:nonNumeric><p id="xdx_8AF_zsVcX84tJLHe" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 84 -->
    <div id="xdx_231_zspCJV9wH3s3" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div>
    <div id="xdx_23E_z9gPNSldtUo2" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_233_zjgix5Ax3u0j" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On February 13, 2024, the Company
acquired Renovaro Cube as a wholly owned subsidiary pursuant to a stock purchase agreement.&#160;As part of the acquisition of Renovaro
Cube, the Company acquired goodwill valued at $<span id="xdx_903_eus-gaap--Goodwill_iI_c20240213__srt--StatementGeographicalAxis__custom--RenovaroCubeMember_zSOtQhaxworj" title="Goodwill"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2024-02-13_custom_RenovaroCubeMember1126484703" id="Fact001086" format="ixt:numdotdecimal" decimals="0" unitRef="USD">159,464,039</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On April 8, 2025, the Company
acquired Biosymetrics, Inc. as a wholly owned subsidiary pursuant to a stock purchase agreement.&#160;As part of the acquisition of Biosymetrics,
Inc., the Company acquired goodwill valued at $<span id="xdx_90E_eus-gaap--Goodwill_iI_c20250408__srt--StatementGeographicalAxis__custom--BioSymetricsMember_zrllylrMlMb3" title="Goodwill"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2025-04-08_custom_BioSymetricsMember" id="Fact001088" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,963,500</ix:nonFraction></span>, software valued at $<span id="xdx_905_ecustom--Software_iI_c20250408_zXCei7nuteth" title="Software"><ix:nonFraction name="RENB:Software" contextRef="AsOf2025-04-08" id="Fact001090" format="ixt:numdotdecimal" decimals="0" unitRef="USD">143,000</ix:nonFraction></span> and Trademark valued at $<span id="xdx_90F_ecustom--Trademark_iI_c20250408_znfXQM7Ma7m2" title="Trademark"><ix:nonFraction name="RENB:Trademark" contextRef="AsOf2025-04-08" id="Fact001092" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,000</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><b><i>Impairment</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Following the fourth quarter of
each year, management performs its annual test of impairment of intangible assets by performing an assessment and determines if it is
more likely than not that the fair value of the asset is greater than or equal to the carrying value of the asset.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the quarter ended September
30, 2024, the results of the assessment indicated that the carrying value of the RENC reporting unit exceeded its fair value, due to the
decline in the estimated fair value of the reporting unit based on the Company&#8217;s market capitalization. Management concluded the
significant driver for the change in the economic benefits was due to the Company&#8217;s continued inability to raise capital for the
further development of the technologies within this reporting unit. Therefore, an impairment adjustment of $<span id="xdx_907_ecustom--ImpairmentAdjustment_iI_c20240930_zSPlKB6P7xjc" title="Impairment adjustment"><ix:nonFraction name="RENB:ImpairmentAdjustment" contextRef="AsOf2024-09-30" id="Fact001094" format="ixt:numdotdecimal" decimals="0" unitRef="USD">47,614,729</ix:nonFraction></span>&#160;was recorded
for the period ended September 30, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the quarter ended June
30, 2025, the results of the assessment indicated that the carrying value of the RENC reporting unit exceeded its fair value, due to the
decline in the estimated fair value of the reporting unit based on the Company&#8217;s market capitalization. Management concluded the
significant driver for the change in the economic benefits was due to the Company&#8217;s continued inability to raise capital for the
further development of the technologies within this reporting unit. Therefore, an impairment adjustment of $<span id="xdx_909_ecustom--ImpairmentAdjustment_iI_c20250630_zuuqqIPS9Oue" title="Impairment adjustment"><ix:nonFraction name="RENB:ImpairmentAdjustment" contextRef="AsOf2025-06-30" id="Fact001096" format="ixt:numdotdecimal" decimals="0" unitRef="USD">122,804,700</ix:nonFraction></span> was recorded for
the period ended June 30, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact001098" name="us-gaap:LesseeOperatingLeasesTextBlock"><p id="xdx_800_eus-gaap--LesseeOperatingLeasesTextBlock_zYAeab0Otljd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 7 &#8212; <span id="xdx_823_zrGmbdSqhADb">LEASES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><b>Operating
Leases </b>&#8212; O<span id="xdx_90B_eus-gaap--LesseeOperatingLeaseDescription_c20180618__20180619_zfvuwx7i60O4" title="Lease premises, description"><ix:nonNumeric contextRef="From2018-06-182018-06-19" id="Fact001100" name="us-gaap:LesseeOperatingLeaseDescription">n June 19, 2018, Lunai entered into a Lease Agreement for a term of ten years from September 1, 2018, with Century
City Medical Plaza Land Co., Inc., pursuant to which the Company agreed to lease approximately 2,453 rentable square feet. On February
20, 2019, Lunai entered into an Addendum to the original Lease Agreement with an effective date of December 1, 2019, where it expanded
the lease area to include another 1,101 square feet for a total rentable 3,554 square feet. The base rent increases by 3% each year, and
ranges from $17,770 per month for the first year to $23,186 per month for the tenth year. The equalized monthly lease payment for the
term of the lease is $20,050.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Renovaro Cube leases an office
facility in Amsterdam, Netherlands, under a 30-month operating lease agreement commencing on September 1, 2023, with a maturity date of
February 28, 2026. In determining lease asset values, the Company considers fixed and variable payment terms, prepayments, incentives,
and options to extend, terminate or purchase. The Company mutually terminated this lease on April 29, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Lunai entered an office lease
in Boca Raton, Florida, under a 36-month operating lease agreement commencing on November 1, 2024, with a maturity date of October 31,
2027. In determining lease asset values, the Company considers fixed and variable payment terms, prepayments, incentives, and options
to extend, terminate or purchase.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company identified and assessed
the following significant assumptions in recognizing the right-of-use assets and corresponding liabilities:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Expected lease term </i></b>&#8212;
The expected lease term includes both contractual lease periods and, when applicable, cancelable option periods when it is reasonably
certain that the Company would exercise such options. The Company&#8217;s leases have a remaining lease term of 26 and 28 months. As of
June 30, 2025, the weighted-average remaining term is <span id="xdx_906_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20250630_znvPKHru2HUc" title="Weighted-average remaining term"><ix:nonNumeric contextRef="AsOf2025-06-30" format="ixt-sec:duryear" id="Fact001102" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">1.95</ix:nonNumeric></span> years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Incremental borrowing rate</i></b>
&#8212; The Company&#8217;s lease agreements do not provide an implicit rate. As the Company does not have any external borrowings for
comparable terms of its leases, the Company estimated the incremental borrowing rate based on the U.S. Treasury Yield Curve rate that
corresponds to the length of each lease. This rate is an estimate of what the Company would have to pay if borrowing on a collateralized
basis over a similar term in an amount equal to the lease payments in a similar economic environment. As of June 30, 2025, the weighted-average
discount rate is <span id="xdx_90C_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20250630_zfJxniLs6XVk" title="Weighted-average discount rate"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2025-06-30" id="Fact001104" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">4.66</ix:nonFraction></span>%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 85 -->
    <div id="xdx_23F_zs6QS45N7BNi" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div>
    <div id="xdx_23F_zogKvLvRofjk" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23E_zL3PGTpS2Zlc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Lease and non-lease components</i></b>
&#8212; In certain cases the Company is required to pay for certain additional charges for operating costs, including insurance, maintenance,
taxes, and other costs incurred, which are billed based on both usage and as a percentage of the Company&#8217;s share of total square
footage. The Company determined that these costs are non-lease components, and they are not included in the calculation of the lease liabilities
because they are variable. Payments for these variable, non-lease components are considered variable lease costs and are recognized in
the period in which the costs are incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Below are the lease commitments for the next 5 years:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact001107" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zu0MeaLfUyJh" summary="xdx: Disclosure - LEASES (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B4_zXboek72wFhi" style="display: none">Schedule of lease commitments</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Years Ending June 30</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Lease Expense</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 73%; text-align: left; text-indent: -10pt">2026</td><td style="width: 10%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_c20250630_za8Be45kf0tj" title="2026" style="width: 15%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2025-06-30" id="Fact001109" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">363,999</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_c20250630_zxvdZcBLzsO9" title="2027" style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2025-06-30" id="Fact001111" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">358,326</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Thereafter</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo_iI_pp0p0_c20250630_zuMJ9yxeEnV" title="Thereafter" style="text-align: right"><ix:nonFraction name="RENB:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" contextRef="AsOf2025-06-30" id="Fact001113" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">56,621</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Less imputed interest</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_c20250630_zSfGZNFdyBfc" title="Less imputed interest" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2025-06-30" id="Fact001115" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">41,353</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"><span style="font-size: 10pt"><b>Total</b></span></td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_986_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pp0p0_c20250630_z4G5CPVvqkf9" title="Total" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2025-06-30" id="Fact001117" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">737,593</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A1_zaCkZ7Wcd1Jh" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact001119" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_800_eus-gaap--DebtDisclosureTextBlock_z1GsRvs682Zb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 8 &#8212; <span id="xdx_822_zcld5SgGorO4">DEBT</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Convertible Notes Payable &#8212;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>The January 2024 Note &#8212;</i></b>
On January 12, 2024, the Company entered into Subscription Agreements with an investor to issue a Convertible Promissory Note for an aggregate
principal amount of $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_c20240112__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zDWRPdIZCbef" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-01-12_custom_JanuaryNote2024Member" id="Fact001121" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,000</ix:nonFraction></span> (the &#8220;January 2024 Note&#8221;). The Company received a total of $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfDebt_c20240109__20240112__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zH6tpqJWmByc" title="Gross proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="From2024-01-092024-01-12_custom_JanuaryNote2024Member" id="Fact001123" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,000</ix:nonFraction></span> in gross proceeds.&#160;The
January 2024 Note bears an interest rate of <span id="xdx_90A_eus-gaap--LongTermDebtPercentageBearingFixedInterestRate_iI_dp_c20240112__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zDBgGdoWVAJi" title="Bear interest percentage"><ix:nonFraction name="us-gaap:LongTermDebtPercentageBearingFixedInterestRate" contextRef="AsOf2024-01-12_custom_JanuaryNote2024Member" id="Fact001125" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">12</ix:nonFraction></span>% per annum and matured on <span id="xdx_904_eus-gaap--DebtInstrumentMaturityDate_dd_c20240109__20240112__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zL15lKdhrY99" title="Debt maturity period"><ix:nonNumeric contextRef="From2024-01-092024-01-12_custom_JanuaryNote2024Member" format="ixt:datemonthdayyearen" id="Fact001127" name="us-gaap:DebtInstrumentMaturityDate">December 29, 2024</ix:nonNumeric></span>. The Company is required to pay interest quarterly,
in arrears, in cash, on the first day of each quarter of each year following the issue date prior to the maturity of the January 2024
Note. The January 2024 Note is convertible either at the option of the holder or automatically upon maturity into shares of the Company&#8217;s
Common Stock at the Note Conversion Price of $<span id="xdx_901_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20240112__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zYCoUmBOPcv2" title="Conversion price"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2024-01-12_custom_JanuaryNote2024Member" id="Fact001129" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.38</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>December 2023 Notes &#8212;
</i></b>On December 20, 2023, the Company entered into Subscription Agreements to purchase Convertible Promissory Notes for an aggregate
principal amount of $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_c20231220__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_zKnh24zNbM7a" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2023-12-20_custom_DecemberNote2023Member" id="Fact001131" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120,000</ix:nonFraction></span> (the &#8220;December 2023 Notes&#8221;). The Company received a total of $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfDebt_c20231219__20231220__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_ze5n0o3Uc7Pg" title="Gross proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="From2023-12-192023-12-20_us-gaap_PrivatePlacementMember_custom_DecemberNote2023Member" id="Fact001133" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120,000</ix:nonFraction></span> from the private placement
between December 2023 and January 2024.&#160;The December 2023 Notes bear an interest rate of <span id="xdx_90C_eus-gaap--LongTermDebtPercentageBearingFixedInterestRate_iI_dp_c20231220__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_z292Q4HR4224" title="Bear interest percentage"><ix:nonFraction name="us-gaap:LongTermDebtPercentageBearingFixedInterestRate" contextRef="AsOf2023-12-20_custom_DecemberNote2023Member" id="Fact001135" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">12</ix:nonFraction></span>% per annum and matured one year after
their respective dates of issuance (the &#8220;Maturity Date&#8221;). The Company is required to pay interest quarterly, in arrears, in
cash, on the first day of each quarter of each year following the issue date prior to the maturity of the December 2023 Notes. Notwithstanding
the immediately foregoing, at the option of the holder, interest may accrue on the December Notes on a quarterly basis. The December 2023
Notes are convertible into shares of the Company&#8217;s Common Stock in whole or in part at any time and from time to time, after the
original issue date and prior to the Maturity Date, at a conversion price of $<span id="xdx_90D_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20231220__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_zOeGXobaPxki" title="Conversion price"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2023-12-20_custom_DecemberNote2023Member" id="Fact001137" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.38</ix:nonFraction></span> per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The January 2024 Note and December
2023 Notes balance at June 30, 2025 was $<span id="xdx_905_ecustom--NotesBalance_iI_c20250630_zaqzXyAJXqJf" title="Notes balance"><ix:nonFraction name="RENB:NotesBalance" contextRef="AsOf2025-06-30" id="Fact001139" format="ixt:numdotdecimal" decimals="0" unitRef="USD">245,000</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Notes Payable </b>&#8212;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Bridge Loans &#8212; </i></b>From
June 4, 2025 to June 14, 2025, the Company entered into agreements with Paseco ApS, a Danish entity controlled by a shareholder (&#8220;Paseco
ApS&#8221;) and Laksya Ventures Inc. to issue Promissory Notes for the principal amount of $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_c20250604__us-gaap--RelatedPartyTransactionAxis__custom--PasecoApSMember_zZiKmDfr3R68" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2025-06-04_custom_PasecoApSMember" id="Fact001141" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,725,000</ix:nonFraction></span> to each note holder. The Company
received $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfDebt_c20240701__20250630__us-gaap--RelatedPartyTransactionAxis__custom--PasecoApSMember_zdoh1Od0qyw7" title="Gross proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="From2024-07-012025-06-30_custom_PasecoApSMember" id="Fact001143" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,450,000</ix:nonFraction></span> in gross proceeds. The notes bear an interest rate of <span id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20250604__us-gaap--LongtermDebtTypeAxis__custom--TheNotesMember_zOeaTD0v9Loh" title="Note interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2025-06-04_custom_TheNotesMember" id="Fact001145" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">10</ix:nonFraction></span>% per annum and mature on December 31, 2025. The notes balance
at June 30, 2025, was $<span id="xdx_90E_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20240701__20250630__us-gaap--LongtermDebtTypeAxis__custom--TheNotesMember_zMy6aCUNzW61" title="Sale of stock, value"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2024-07-012025-06-30_custom_TheNotesMember" id="Fact001147" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,450,000</ix:nonFraction></span> with Paseco ApS and Laksya Ventures Inc. each holding $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20250630__us-gaap--RelatedPartyTransactionAxis__custom--PasecoApSMember_zkHMOckvwuN6" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2025-06-30_custom_PasecoApSMember" id="Fact001149" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,725,000</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">From October 21, 2024 to January
24, 2025, the Company entered into agreements with Paseco ApS, a Danish entity controlled by a shareholder (&#8220;Paseco ApS&#8221;),
to issue Promissory Notes for the principal amount of $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_c20241021__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member__us-gaap--RelatedPartyTransactionAxis__custom--PasecoApSMember_zqJtN10uzz3k" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-10-21_custom_JanuaryNote2024Member_custom_PasecoApSMember" id="Fact001151" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,650,000</ix:nonFraction></span>. The Company received $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfDebt_c20240101__20240124__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member__us-gaap--RelatedPartyTransactionAxis__custom--PasecoApSMember_zD4KBeRS7Ku7" title="Gross proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="From2024-01-012024-01-24_custom_JanuaryNote2024Member_custom_PasecoApSMember" id="Fact001153" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,650,000</ix:nonFraction></span> in gross proceeds. The notes bear an
interest rate of <span id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20241021__us-gaap--LongtermDebtTypeAxis__custom--TheNotesMember_zDL9ipEmzOB7" title="Note interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2024-10-21_custom_TheNotesMember" id="Fact001155" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">10</ix:nonFraction></span>% per annum and mature from December 31, 2024 to December 31, 2025. <span id="xdx_90D_eus-gaap--MaturitiesOfTimeDepositsDescription_c20240701__20250630_z2GskIECLgIl" title="Maturity description"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" id="Fact001157" name="us-gaap:MaturitiesOfTimeDepositsDescription">Approximately $700,000 matured on December 31,
2024, $900,000 matured on December 31, 2025 and $1,050,000 matured on January 31, 2025. On February 24, 2025, Paseco ApS assigned 50%
of its ownership rights to Laksya Ventures Inc. with all terms remaining unchanged. The note balance at June 30, 2025, was $2,650,000
with Paseco ApS and Laksya Ventures Inc. each holding $1,325,000</ix:nonNumeric></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 86 -->
    <div id="xdx_238_zNlrITAKbOk" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div>
    <div id="xdx_23B_zDE9LQ4o9tm6" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_237_zih0gCO3Ewa6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_90F_ecustom--AgreementDescription_c20241112__20241203__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNotesMember_zHtxUzOyEVQ3" title="Agreement description"><ix:nonNumeric contextRef="From2024-11-122024-12-03_custom_PromissoryNotesMember" id="Fact001160" name="RENB:AgreementDescription">From November 12, 2024 to December
3, 2024, Renovaro Cube entered into an agreement with Paseco ApS, a Danish entity controlled by a shareholder (&#8220;Paseco ApS&#8221;),
to issue Promissory Notes for the principal amount of &#8364;450,000. The note bears an interest rate of 10% per annum and matures on December
1, 2025. On February 24, 2025 Paseco ApS assigned 50% of its ownership rights to Laksya Ventures Inc. with all terms remaining unchanged.
The note balance at June 30, 2025 was approximately $490,000 with Paseco ApS and Laksya Ventures Inc. each holding $245,000.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_90B_ecustom--AgreementDescription_c20250223__20250224__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNotesMember_z2ZOwfVKVt7h" title="Agreement description"><ix:nonNumeric contextRef="From2025-02-232025-02-24_custom_PromissoryNotesMember" id="Fact001162" name="RENB:AgreementDescription">On November 1, 2024, Renovaro
Cube entered into an agreement with Yalla Yalla Limited, an investor to issue a Promissory Note for the amount of approximately &#8364;225,000.
The note bears an interest rate of 10% per annum and matured on February 24, 2025. The note balance at June 30, 2025 was approximately
$238,000.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_905_ecustom--AgreementDescription_c20240915__20240916__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNotesMember_zZod2qlMyZc1" title="Agreement description"><ix:nonNumeric contextRef="From2024-09-152024-09-16_custom_PromissoryNotesMember" id="Fact001164" name="RENB:AgreementDescription">On September 16, 2024, the Company
entered into an agreement with RS Bio ApS, a Danish entity controlled by a shareholder (&#8220;RS Bio&#8221;), to issue a Promissory Note
for the principal amount of $100,000 (the &#8220;September 2024 Note&#8221;). The Company received $100,000 in gross proceeds. The note
bears an interest rate of 12% per annum and matured on December 31, 2024. On February 24, 2025 RS Bio assigned its ownership rights to
Rene Sindlev with all terms remaining unchanged. The note balance at June 30, 2025 was $100,000</ix:nonNumeric></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">O<span id="xdx_904_ecustom--AgreementDescription_c20240905__20240906__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNotesMember_zm2x4YXN4lH8" title="Agreement description"><ix:nonNumeric contextRef="From2024-09-052024-09-06_custom_PromissoryNotesMember" id="Fact001166" name="RENB:AgreementDescription">n September 6, 2024, Renovaro
Cube entered into an agreement with Paseco ApS, a Danish entity controlled by a shareholder (&#8220;Paseco ApS&#8221;), to issue a Promissory
Note for the principal amount of &#8364;50,000. The note bears an interest rate of 12% per annum and matures on September 9, 2025. On February
24, 2025 Paseco ApS assigned 50% of its ownership rights to Laksya Ventures Inc. with all terms remaining unchanged. The note balance
at June 30, 2025 was approximately $59,000 with Paseco ApS and Laksya Ventures Inc. each holding approximately $30,000 (see Note 8 to
the Financial Statements)</ix:nonNumeric></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_909_ecustom--AgreementDescription_c20240204__20240205__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNotesMember_zFhCUFu7dVv1" title="Agreement description"><ix:nonNumeric contextRef="From2024-02-042024-02-05_custom_PromissoryNotesMember" id="Fact001168" name="RENB:AgreementDescription">On February 5, 2024, the Company
entered into an agreement with RS Bio to issue a 5% Original Issue Discount Secured Promissory Note for the principal amount of $105,263
(the &#8220;February 2024 Note&#8221;). The Company received $100,000 in gross proceeds after taking into account the 5% original issue
discount. The note bears an interest rate of 12% per annum and matured on December 31, 2024. On February 24, 2025 RS Bio assigned its
ownership rights to Rene Sindlev with all terms remaining unchanged. The note balance, net of discount at June 30, 2025 was $105,263</ix:nonNumeric></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_907_ecustom--AgreementDescription_c20240101__20240102__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNotesMember_z645ny91519i" title="Agreement description"><ix:nonNumeric contextRef="From2024-01-012024-01-02_custom_PromissoryNotesMember" id="Fact001170" name="RENB:AgreementDescription">On January 2, 2024, the Company
entered into an agreement with RS Bio to issue a 5% Original Issue Discount Secured Promissory Note for the principal amount of $526,315.
The Company received a total of $500,000 in gross proceeds after taking into account the 5% original issue discount.&#160;The note bears
an interest rate of 12% per annum and matured on December 31, 2024. On February 24, 2025 RS Bio assigned its ownership rights to Rene
Sindlev with all terms remaining unchanged. The note balance, net of discount at June 30, 2025 was $526,315</ix:nonNumeric></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_902_ecustom--AgreementDescription_c20241102__20241103__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNotesMember_z4bHB0FPjdEa" title="Agreement description"><ix:nonNumeric contextRef="From2024-11-022024-11-03_custom_PromissoryNotesMember" id="Fact001172" name="RENB:AgreementDescription">On November 3, 2023, the Company
entered into an agreement with RS Bio to issue a 5% Original Issue Discount Promissory Note for the principal amount of $1,000,000. The
Company received a total of $950,000 in gross proceeds after taking into account the 5% original issue discount.&#160;The discount of
$50,000 will be accreted over the life of the note. The note bears an interest rate of 12% per annum and matured on December 31, 2024.
On February 24, 2025 RS Bio assigned its ownership rights to Rene Sindlev with all terms remaining unchanged. The note balance, net of
discount at June 30, 2025 was $750,000.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Promissory Note &#8212; </b>On
March 30, 2020 (the &#8220;Issuance Date&#8221;), the Company issued a Promissory Note in the principal amount of $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20200330__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zTgvK82DPgE8" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2020-03-30_custom_PromissoryNoteMember" id="Fact001174" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000,000</ix:nonFraction></span> (the &#8220;Promissory
Note&#8221;) to Paseco ApS. There have been eight amendments to the Promissory Note since the issuance date, the most recent of which
is dated August 1, 2024. The principal amount of the Promissory Note, as amended, was payable on <span id="xdx_908_eus-gaap--DebtInstrumentMaturityDate_dd_c20200329__20200330__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zHhIXAjGUWh1" title="Maturity date"><ix:nonNumeric contextRef="From2020-03-292020-03-30_custom_PromissoryNoteMember" format="ixt:datemonthdayyearen" id="Fact001176" name="us-gaap:DebtInstrumentMaturityDate">November 1, 2024</ix:nonNumeric></span> (the &#8220;Maturity
Date&#8221;). The Promissory Note, as amended, bears interest at a fixed rate of <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_dp_c20200329__20200330__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zEwKclneWNGf" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" contextRef="From2020-03-292020-03-30_custom_PromissoryNoteMember" id="Fact001178" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">12</ix:nonFraction></span>% per annum. On February 24, 2025 Paseco ApS assigned
its ownership rights to Rene Sindlev with all terms remaining unchanged. The Promissory Note balance at June 30, 2025 is $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_c20250101__20250630__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_z97MRh2cZ809" title="Issuance of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2025-01-012025-06-30_custom_PromissoryNoteMember" id="Fact001180" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">831,497</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s obligations
under the referenced Promissory and Bridge Notes, except for those originally entered into by Renovaro Cube, are secured by a Security
Agreement. To secure the Company&#8217;s obligations under the Promissory Note, the Company entered into a Security Agreement with the
Holder, pursuant to which the Company granted a lien on all assets of the Company (the &#8220;Collateral&#8221;) for the benefit of Paseco
ApS, Rene Sindlev and Laksya Ventures. Upon an Event of Default (as defined in the notes, respectively) Paseco ApS, Rene Sindlev and Laksya
Ventures may, among other things, collect or take possession of the Collateral, proceed with the foreclosure of the security interest
in the Collateral or sell, lease, or dispose of the Collateral (see Note 8 to the Financial Statements).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 87 -->
    <div id="xdx_234_zaDBkcFeHcbk" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div>
    <div id="xdx_23B_zgWylV8p4jPl" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_238_zcLJ2AWerxV8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Finance Agreement </b>&#8212;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On November 30, 2024, the Company
entered into a premium finance agreement (the &#8220;Agreement&#8221;) related to insurance,&#160;<span style="background-color: white">which
resulted in the recognition of a liability and prepaid exp</span>ense with a principal amount of $<span id="xdx_903_eus-gaap--DebtInstrumentAnnualPrincipalPayment_iI_c20241130__us-gaap--BalanceSheetLocationAxis__us-gaap--OtherCurrentLiabilitiesMember__us-gaap--TypeOfArrangementAxis__custom--FinanceAgreementMember_zOfHqmcl5AX8" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentAnnualPrincipalPayment" contextRef="AsOf2024-11-30_us-gaap_OtherCurrentLiabilitiesMember_custom_FinanceAgreementMember" id="Fact001183" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,018,930</ix:nonFraction></span> at&#160;<span id="xdx_906_eus-gaap--DerivativeFixedInterestRate_iI_dp_c20241130__us-gaap--BalanceSheetLocationAxis__us-gaap--OtherCurrentLiabilitiesMember__us-gaap--TypeOfArrangementAxis__custom--FinanceAgreementMember_zo3mPZ897sw1" title="Rate of interest"><ix:nonFraction name="us-gaap:DerivativeFixedInterestRate" contextRef="AsOf2024-11-30_us-gaap_OtherCurrentLiabilitiesMember_custom_FinanceAgreementMember" id="Fact001185" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">7.50</ix:nonFraction></span>% interest per
annum, which is reflected on the consolidated balance sheet under &#8220;other current liabilities&#8221; and &#8220;prepaid assets and
other assets&#8221;, respectively. The repayment of the Agreement will be made in nine equal monthly installments of $<span id="xdx_90C_ecustom--MonthlyInstallments_pp0p0_c20241129__20241130__us-gaap--TypeOfArrangementAxis__custom--FinanceAgreementMember_zjLV9XrLOAb2" title="Monthly instalments amount"><ix:nonFraction name="RENB:MonthlyInstallments" contextRef="From2024-11-292024-11-30_custom_FinanceAgreementMember" id="Fact001187" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">93,401</ix:nonFraction></span>&#160;after
a down payment of $<span id="xdx_903_ecustom--RepaymentOnFinanceAgreement_pp0p0_c20241129__20241130__us-gaap--TypeOfArrangementAxis__custom--FinanceAgreementMember_zTyIeEMKVMIl" title="Down payment amount"><ix:nonFraction name="RENB:RepaymentOnFinanceAgreement" contextRef="From2024-11-292024-11-30_custom_FinanceAgreementMember" id="Fact001189" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">204,000</ix:nonFraction></span>.&#160;For the years ended June 30, 2025 and 2024 the Company made payments of $<span id="xdx_900_ecustom--RepaymentOnFinanceAgreement_pp0p0_c20240701__20250630__us-gaap--TypeOfArrangementAxis__custom--FinanceAgreementMember_zDtkx2Vagz0j" title="Down payment amount"><ix:nonFraction name="RENB:RepaymentOnFinanceAgreement" contextRef="From2024-07-012025-06-30_custom_FinanceAgreementMember" id="Fact001191" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">971,231</ix:nonFraction></span>&#160;and $<span id="xdx_90F_ecustom--RepaymentOnFinanceAgreement_pp0p0_c20230701__20240630__us-gaap--TypeOfArrangementAxis__custom--FinanceAgreementMember_zXOG5pko0Nlh" title="Down payment amount"><ix:nonFraction name="RENB:RepaymentOnFinanceAgreement" contextRef="From2023-07-012024-06-30_custom_FinanceAgreementMember" id="Fact001193" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">870,073</ix:nonFraction></span>, respectively.
The remaining balance at June 30, 2025 is $<span id="xdx_90A_eus-gaap--OtherLiabilitiesNoncurrent_iI_c20250630_zOvTMAbygdja" title="Other current liabilities"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="AsOf2025-06-30" id="Fact001195" format="ixt:numdotdecimal" decimals="0" unitRef="USD">271,643</ix:nonFraction></span>; the amount is reflected in other current liabilities. <span style="background-color: white">For
the years ended June 30, 2025 and 2024 the Company recorded total interest expense in the amount of $<span id="xdx_907_eus-gaap--InterestAndDebtExpense_c20240701__20250630__us-gaap--TypeOfArrangementAxis__custom--FinanceAgreementMember_zHyESXXVSmig" title="Accrued interest expense"><ix:nonFraction name="us-gaap:InterestAndDebtExpense" contextRef="From2024-07-012025-06-30_custom_FinanceAgreementMember" id="Fact001197" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,555</ix:nonFraction></span> and $<span id="xdx_907_eus-gaap--InterestAndDebtExpense_c20230701__20240630__us-gaap--TypeOfArrangementAxis__custom--FinanceAgreementMember_z7UJAqzEgSac" title="Accrued interest expense"><ix:nonFraction name="us-gaap:InterestAndDebtExpense" contextRef="From2023-07-012024-06-30_custom_FinanceAgreementMember" id="Fact001199" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,128</ix:nonFraction></span>&#160;related to
the Agreement. This amount is reflected in other income and expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Total
interest expense recorded for the years ended June 30, 2025 and 2024, was $<span id="xdx_907_eus-gaap--InterestExpenseNonoperating_c20240701__20250630_zBwkCPNq1Af2" title="Total interest expense"><ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2024-07-01to2025-06-30" id="Fact001201" format="ixt:numdotdecimal" decimals="0" unitRef="USD">725,684</ix:nonFraction></span> and $<span id="xdx_90A_eus-gaap--InterestExpenseNonoperating_c20230701__20240630_zZnN5KnHq0j9" title="Total interest expense"><ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="From2023-07-012024-06-30" id="Fact001203" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,011,322</ix:nonFraction></span> respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact001205" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_80D_eus-gaap--IncomeTaxDisclosureTextBlock_z8Ea9I1PCun8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 9 &#8212; <span id="xdx_821_zC4Mx3WBYbO6">INCOME TAXES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company accounts for income
taxes in accordance with FASB ASC Topic 740, Accounting for Income Taxes; which requires the Company to provide a net deferred tax asset
or liability equal to the expected future tax benefit or expense of temporary reporting differences between book and tax accounting and
any available operating loss or tax credit carryforwards. The amount of and ultimate realization of the benefits from the deferred tax
assets for income tax purposes is dependent, in part, upon the tax laws in effect, the Company&#8217;s future earnings, and other future
events, the effects of which cannot be determined.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of June 30, 2025 and 2024,
the Company had net operating loss carryforwards of approximately $<span id="xdx_900_eus-gaap--OperatingLossCarryforwards_iI_c20250630__us-gaap--IncomeTaxAuthorityAxis__custom--UnitedStatesTaxMember_zsaoSjHpHZW8" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2025-06-30_custom_UnitedStatesTaxMember" id="Fact001207" format="ixt:numdotdecimal" decimals="0" unitRef="USD">541,603,425</ix:nonFraction></span> and $<span id="xdx_907_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20240630__us-gaap--IncomeTaxAuthorityAxis__custom--UnitedStatesTaxMember_znNFFosXZBU2" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2024-06-30_custom_UnitedStatesTaxMember" id="Fact001209" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">489,177,759</ix:nonFraction></span> respectively, giving rise to deferred
tax assets of $<span id="xdx_90A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsForeign_iI_pp0p0_c20250630__us-gaap--IncomeTaxAuthorityAxis__custom--UnitedStatesTaxMember_zHZBf4U995Ci" title="Deferred tax assets"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" contextRef="AsOf2025-06-30_custom_UnitedStatesTaxMember" id="Fact001211" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">76,296,814</ix:nonFraction></span> and $<span id="xdx_906_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsForeign_iI_pp0p0_c20240630__us-gaap--IncomeTaxAuthorityAxis__custom--UnitedStatesTaxMember_z1axxMxqB38j" title="Deferred tax assets"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" contextRef="AsOf2024-06-30_custom_UnitedStatesTaxMember" id="Fact001213" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">144,191,530</ix:nonFraction></span>, respectively. The net operating loss carryforwards generated prior to January 1, 2018 expire
over various dates from 2031 to 2038. All subsequent net operating loss carryforwards are indefinite.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company files Danish and U.S.
income tax returns and these returns are generally no longer subject to tax examinations for years prior to 2021 for the Danish tax returns
and 2022 for the U.S. tax returns.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The temporary differences, tax
credits and carry forwards gave rise to the following deferred tax assets (liabilities) at June 30, 2025 and 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact001215" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zG7ef07kCjig" summary="xdx: Disclosure - INCOME TAXES (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8BE_zWb6LjrOJUod" style="display: none">Schedule of deferred tax assets and liabilities</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_491_20250630_z2pzuoOnf8yk" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49E_20240630_zpnAVDgg77Sb" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td></tr>
  <tr id="xdx_407_ecustom--Depreciations_iI_z8O0Jizr4Ah3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-indent: -10pt">Depreciation</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(<ix:nonFraction name="RENB:Depreciations" contextRef="AsOf2025-06-30" id="Fact001217" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">24,619</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="RENB:Depreciations" contextRef="AsOf2024-06-30" id="Fact001218" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,258</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--DeferredTaxAssetExcessTaxOverDepreciationPatents_iI_pp0p0_maDTALNzwuT_z05qOfiHebK9" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Excess of tax over book depreciation of patents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1220">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="RENB:DeferredTaxAssetExcessTaxOverDepreciationPatents" contextRef="AsOf2024-06-30" id="Fact001221" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,415</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--StockoptionsCompensation_iI_pp0p0_maDTALNzwuT_z0eQx4ABu7Gc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Stock/options compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="RENB:StockoptionsCompensation" contextRef="AsOf2025-06-30" id="Fact001223" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">463,099</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="RENB:StockoptionsCompensation" contextRef="AsOf2024-06-30" id="Fact001224" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,672,252</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--DepreciationAndAmortizations_iI_pp0p0_maDTALNzwuT_z3xluljzTyLe" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1226">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="RENB:DepreciationAndAmortizations" contextRef="AsOf2024-06-30" id="Fact001227" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">188,422</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_maDTALNzwuT_za5kAs7Fzbnl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net operating loss carryforwards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2025-06-30" id="Fact001229" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">76,296,814</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2024-06-30" id="Fact001230" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">148,832,041</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--ImpairmentExpense_iI_pp0p0_d0_maDTALNzwuT_zPLauX3Dg9Xf" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;Impairment expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="RENB:ImpairmentExpense" contextRef="AsOf2025-06-30" id="Fact001232" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="RENB:ImpairmentExpense" contextRef="AsOf2024-06-30" id="Fact001233" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">16,188,497</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--ContingentConsiderationFairValue_iI_pp0p0_d0_maDTALNzwuT_zapO6NPIqsz" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Contingent consideration fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="RENB:ContingentConsiderationFairValue" contextRef="AsOf2025-06-30" id="Fact001235" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="RENB:ContingentConsiderationFairValue" contextRef="AsOf2024-06-30" id="Fact001236" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">909,577</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--AccumulatedAmortizationOfOtherDeferredCosts_iI_pp0p0_zdsvvMK0hJ28" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccumulatedAmortizationOfOtherDeferredCosts" contextRef="AsOf2025-06-30" id="Fact001238" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,961,747</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1239">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--Section174ReCapitalization_iI_pp0p0_zsRiglMBn91h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Section 174 R&amp;E Capitalization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="RENB:Section174ReCapitalization" contextRef="AsOf2025-06-30" id="Fact001241" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,292,075</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1242">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--OperatingLeaseRightOfUseAssets_iI_pp0p0_zasdyD3kGSyk" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">ROU Assets and Lease Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="RENB:OperatingLeaseRightOfUseAssets" contextRef="AsOf2025-06-30" id="Fact001244" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">14,227</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1245">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--Section481aAdjustment_iI_pp0p0_zSm9CwUyzF5c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Section 481(a) Adjustment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="RENB:Section481aAdjustment" contextRef="AsOf2025-06-30" id="Fact001247" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">40,895</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1248">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pp0p0_zwOcJj92EMD4" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">R&amp;D Tax Credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2025-06-30" id="Fact001250" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,718,415</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1251">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--ChangeInTaxRate_iI_pp0p0_d0_maDTALNzwuT_zbDREXQcEyMh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Change in tax rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="RENB:ChangeInTaxRate" contextRef="AsOf2025-06-30" id="Fact001253" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="RENB:ChangeInTaxRate" contextRef="AsOf2024-06-30" id="Fact001254" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_msDTALNzwuT_z6J1A7OH0Kjg" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2025-06-30" id="Fact001256" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">83,680,863</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2024-06-30" id="Fact001257" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">170,988,308</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_iI_pp0p0_zcd39fI1vKZk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total Deferred Tax Assets (Liabilities)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1259">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1260">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A7_zoAvNePKcrtj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 88 -->
    <div id="xdx_230_zxN2NK6uf5mc" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div>
    <div id="xdx_234_zDPLfKdQFHTf" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23F_z3qA36HoqaJf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In accordance with prevailing
accounting guidance, the Company is required to recognize and disclose any income tax uncertainties. The guidance provides a two-step
approach to recognizing and measuring tax benefits and liabilities when realization of the tax position is uncertain. The first step is
to determine whether the tax position meets the more-likely-than-not condition for recognition, and the second step is to determine the
amount to be recognized based on the cumulative probability that exceeds 50%. The amount of and ultimate realization of the benefits from
the deferred tax assets for income tax purposes is dependent, in part, upon the tax laws in effect, the Company&#8217;s future earnings,
and other future events, the effects of which can be difficult to determine and can only be estimated. Management estimates that it is
more likely than not that the Company will not generate adequate net profits to use the deferred tax assets; and consequently, a valuation
allowance was recorded for all deferred tax assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A reconciliation of income tax
expense at the federal statutory rate to income tax expense at the Company&#8217;s effective rate is as follows for the years ended June
30, 2025 and 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact001263" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zlDfgmV18te" summary="xdx: Disclosure - INCOME TAXES (Details 1)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_495_20240701__20250630_zFeO7GtMwKsf" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_490_20230701__20240630_zHDY7JCSDrbe" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years ended June 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationChangeInEnactedTaxRate_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Computed tax at expected statutory rate</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" contextRef="From2024-07-01to2025-06-30" id="Fact001265" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">951,542</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" contextRef="From2023-07-012024-06-30" id="Fact001266" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">24,066,011</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--IncomeTaxReconciliationRepatriationOfForeignEarnings_iN_pp0p0_d0_zKIUKpKrDoYf" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Non-US income taxed at different rates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings" contextRef="From2024-07-01to2025-06-30" id="Fact001268" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings" contextRef="From2023-07-012024-06-30" id="Fact001269" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncomeTaxReconciliationNondeductibleExpense_d0_zMIO6nQnezl6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Non-deductible expenses / other items</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" contextRef="From2024-07-01to2025-06-30" id="Fact001271" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,046,364</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" contextRef="From2023-07-012024-06-30" id="Fact001272" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2024-07-01to2025-06-30" id="Fact001274" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,999,380</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2023-07-012024-06-30" id="Fact001275" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,066,011</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OtherTaxExpenseBenefit_d0_zo2a8bR4x85k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Income Tax Expense (Benefit)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OtherTaxExpenseBenefit" contextRef="From2024-07-01to2025-06-30" id="Fact001277" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,474</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OtherTaxExpenseBenefit" contextRef="From2023-07-012024-06-30" id="Fact001278" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A6_ztLRpc0LQb7d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
components of income tax expense (benefit) from continuing operations for the years ended June 30, 2025 and 2024 consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact001280" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zysVPktt2Tdj" summary="xdx: Disclosure - INCOME TAXES (Details 2)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-top: 0pt; padding-right: 0pt; padding-left: 20pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B7_zPjqVwYUCxq2" style="display: none">Schedule
    of components of income tax expense (benefit) from continuing operations</span></td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_49B_20240701__20250630_zw3QhO3HHRB3" style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_495_20230701__20240630_zyuACp3VqK58" style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Years
    ended June 30,</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td></tr>
  <tr id="xdx_400_eus-gaap--CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; font-size: 10pt; font-weight: bold; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
    Income Tax Expense</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--CurrentFederalTaxExpenseBenefit_i01_pp0p0_d0_maCITEBzr8l_zuuOhRzfy6Ng" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal
    income tax (benefit)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="From2024-07-01to2025-06-30" id="Fact001285" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="From2023-07-012024-06-30" id="Fact001286" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i01_pp0p0_d0_maCITEBzr8l_zKtOaFUWvZ5d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; width: 56%; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State
    income tax (benefit)</span></td><td style="width: 8%; font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; width: 12%; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="From2024-07-01to2025-06-30" id="Fact001288" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,474</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 8%; font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; width: 12%; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="From2023-07-012024-06-30" id="Fact001289" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--CurrentForeignTaxExpenseBenefit_i01_pp0p0_d0_maCITEBzr8l_z2ediuyAkH21" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
    income tax (benefit)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CurrentForeignTaxExpenseBenefit" contextRef="From2024-07-01to2025-06-30" id="Fact001291" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CurrentForeignTaxExpenseBenefit" contextRef="From2023-07-012024-06-30" id="Fact001292" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--CurrentIncomeTaxExpenseBenefit_i01T_pp0p0_d0_mtCITEBzr8l_maITEBzLgX_ztyyjCR5lrL5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Current Tax Expense (Benefit)</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2024-07-01to2025-06-30" id="Fact001294" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,474</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2023-07-012024-06-30" id="Fact001295" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_zpTGFHzNm6E" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; font-weight: bold; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
    Income Tax Expense Federal income tax (benefit)</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="From2024-07-01to2025-06-30" id="Fact001297" format="ixt:numdotdecimal" decimals="0" unitRef="USD">101,609,457</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="From2023-07-012024-06-30" id="Fact001298" format="ixt:numdotdecimal" decimals="0" unitRef="USD">165,458,980</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefit_zwgRvZRgyeG1" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State
    income tax (benefit)</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit" contextRef="From2024-07-01to2025-06-30" id="Fact001300" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,302,006</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit" contextRef="From2023-07-012024-06-30" id="Fact001301" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,529,328</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_zaArW39NQWz3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
    income tax (benefit)</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1303">&#8212;</span></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1304">&#8212;</span></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_ziMMCuaxDi1d" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
    Change in valuation allowance</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2024-07-01to2025-06-30" id="Fact001306" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">87,307,451</ix:nonFraction></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2023-07-012024-06-30" id="Fact001307" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">170,988,308</ix:nonFraction></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_408_eus-gaap--DeferredIncomeTaxExpenseBenefit_i01T_pp0p0_d0_mtDITEBzk3M_maITEBzLgX_zMuyJTSzElsj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Deferred Tax Expense</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2024-07-01to2025-06-30" id="Fact001309" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2023-07-012024-06-30" id="Fact001310" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxExpenseBenefit_i01T_pp0p0_d0_mtITEBzLgX_zfLHiVBg5I98" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; font-size: 10pt; font-weight: bold; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Tax Expense</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2024-07-01to2025-06-30" id="Fact001312" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,474</ix:nonFraction></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-07-012024-06-30" id="Fact001313" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>



</ix:nonNumeric><p id="xdx_8A0_zqdlppKeJgil" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
income tax expense (benefit) results primarily from the reversal of temporary timing differences between tax and financial statement
income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact001315" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_809_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zaC8WTAZ9VA8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 10 &#8212; <span id="xdx_825_zVe4vLcVRFy1">STOCKHOLDERS&#8217; EQUITY</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Preferred Stock </b>&#8212;
The Company has <span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_c20250630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zBSZG3asjI0k" title="Preferred stock shares authorized"><span id="xdx_906_eus-gaap--PreferredStockSharesAuthorized_iI_c20240630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zWVUegqqL3u8" title="Preferred stock shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2025-06-30_custom_SeriesAConvertiblePreferredStockMember" id="Fact001317" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-06-30_custom_SeriesAConvertiblePreferredStockMember" id="Fact001319" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000,000</ix:nonFraction></ix:nonFraction></span></span>
authorized shares of Preferred Stock, par value $<span id="xdx_90F_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20250630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zboOgxgtnlDf" title="Preferred stock, par value"><span id="xdx_900_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20240630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zrtHwbqcdaY6" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2025-06-30_custom_SeriesAConvertiblePreferredStockMember" id="Fact001321" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-06-30_custom_SeriesAConvertiblePreferredStockMember" id="Fact001323" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span>
per share, <span id="xdx_90B_ecustom--PreferredStockDesignatedShares_iI_c20250630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zJYeBrcJjm5f" title="Preferred stock designated shares"><span id="xdx_90A_ecustom--PreferredStockDesignatedShares_iI_c20240630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zLEUxE1WBQp6" title="Preferred stock designated shares"><ix:nonFraction name="RENB:PreferredStockDesignatedShares" contextRef="AsOf2025-06-30_custom_SeriesAConvertiblePreferredStockMember" id="Fact001325" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="RENB:PreferredStockDesignatedShares" contextRef="AsOf2024-06-30_custom_SeriesAConvertiblePreferredStockMember" id="Fact001327" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></ix:nonFraction></span></span>
of which have been designated as Series A Convertible Preferred Stock. At June 30, 2025 and 2024, there were <span id="xdx_901_eus-gaap--PreferredStockSharesIssued_iI_c20250630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zeGwrZVntiOe" title="Preferred stock, shares issued"><span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_c20250630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zwbMMhoKqCOh" title="Preferred stock, shares outstanding"><span id="xdx_905_eus-gaap--PreferredStockSharesIssued_iI_c20240630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_znRVqMI74Sc1" title="Preferred stock, shares issued"><span id="xdx_901_eus-gaap--PreferredStockSharesOutstanding_iI_c20240630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zfLHOI5Eewj8" title="Preferred stock, shares outstanding" style="display: none"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2025-06-30_custom_SeriesAConvertiblePreferredStockMember" id="Fact001329" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2025-06-30_custom_SeriesAConvertiblePreferredStockMember" id="Fact001331" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-06-30_custom_SeriesAConvertiblePreferredStockMember" id="Fact001333" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-06-30_custom_SeriesAConvertiblePreferredStockMember" id="Fact001335" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> zero shares of
Preferred Stock issued and outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Voting &#8212; </b>Holders
of Series A Preferred Stock shall be permitted to vote on all matters required or permitted to be voted on by the holders of Common Stock
of the Company and shall be entitled to that number of votes equal to ten votes for the number of shares of Common Stock into which such
holder&#8217;s shares of Preferred Stock could then be converted in accordance with conversion rights.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 89 -->
    <div id="xdx_23D_z73FV444ksXi" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div>
    <div id="xdx_235_zGGa7aqyhLV6" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_232_zEv7FDqHO1qf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"><b>Dividends &#8212; </b>The
Company shall pay dividends on shares of Series A Preferred Stock equal (on an as-if-converted-to-Common-Stock basis) to and in the same
form as dividends actually paid on shares of the Common Stock when, as and if such dividends are paid on shares of the Common Stock. No
other dividends shall be paid on shares of Preferred Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Liquidation Rights &#8212;</b>
In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, the holders of shares of Series A
Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Company available for distribution to its stockholders,
before any payment shall be made to the holders of Common Stock by reason of their ownership thereof, an amount in cash equal to the aggregate
liquidation value of all shares held by such holder. The Series A Preferred Stock is not participating preferred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Conversion Rights &#8212; </b>On
or after the date of issuance, any holder of Series A Preferred Stock shall have the right by written election (a &#8220;Series A Election
Notice&#8221;) to the Company to convert all or any portion of the outstanding Shares of Series A Preferred Stock held by such holder
into an aggregate number of shares of Common Stock as is determined by multiplying the number of Shares to be converted by ten (10) (the
&#8220;Conversion Ratio&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Common Stock </b>&#8212; The
Company has <span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_iI_c20250630_zBN2SghKHYl9" title="Common stock, shares authorized"><span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_c20240630_zl9ZgqQYK9e5" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2025-06-30" id="Fact001338" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-06-30" id="Fact001340" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000,000</ix:nonFraction></ix:nonFraction></span></span> authorized shares of Common Stock, par value $<span id="xdx_902_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20250630_zf734HAwMVTi" title="Common stock, par value"><span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240630_zQI2ZeNWSHXl" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-06-30" id="Fact001342" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-06-30" id="Fact001344" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> per share. At June 30, 2025 and 2024, there were <span id="xdx_906_ecustom--CommonStockShareIssued_iI_c20250630_z19u5s4itUNg" title="Common stock, shares issued"><span id="xdx_90C_eus-gaap--CommonStockSharesOutstanding_iI_c20250630_zYkVqKMkh3aj" title="Common stock, shares outstanding"><ix:nonFraction name="RENB:CommonStockShareIssued" contextRef="AsOf2025-06-30" id="Fact001346" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2025-06-30" id="Fact001348" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">177,392,907</ix:nonFraction></ix:nonFraction></span></span>
and <span id="xdx_900_ecustom--CommonStockShareIssued_iI_c20240630_zgc7FaGPdxj5" title="Common stock, shares issued"><span id="xdx_907_eus-gaap--CommonStockSharesOutstanding_iI_c20240630_zIU1OLpUmXW6" title="Common stock, shares outstanding"><ix:nonFraction name="RENB:CommonStockShareIssued" contextRef="AsOf2024-06-30" id="Fact001350" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-06-30" id="Fact001352" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">158,452,644</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Voting &#8212; </b>Holders
of Common Stock are entitled to one vote for each share held of record on each matter submitted to a vote of stockholders, including the
election of directors, and do not have any right to cumulate votes in the election of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Dividends &#8212; </b>Holders
of Common Stock are entitled to receive ratably such dividends as the Company&#8217;s Board of Directors from time to time may declare
out of funds legally available.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Liquidation Rights &#8212;</b>
In the event of any liquidation, dissolution or winding-up of the affairs of the Company, after payment of all debts and liabilities,
the holders of Common Stock will be entitled to share ratably in the distribution of any remaining assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Purchase Agreement with
Lincoln Park Capital</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On June
20, 2023, the Company entered into a purchase agreement (the &#8220;2023 Purchase Agreement&#8221;) with Lincoln Park, pursuant to which
the Company may sell and issue to Lincoln Park, and Lincoln Park is obligated to purchase, up to $<span id="xdx_907_eus-gaap--PurchaseObligation_iI_pp0p0_c20230620_zp4gtWcI7fJ2" title="Obligation to purchase"><ix:nonFraction name="us-gaap:PurchaseObligation" contextRef="AsOf2023-06-20" id="Fact001354" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">20,000,000</ix:nonFraction></span> of shares of Common Stock
over the 36-month term of the 2023 Purchase Agreement. Concurrently with entering into the 2023 Purchase Agreement, the Company also entered
into a registration rights agreement with Lincoln Park, pursuant to which it agreed to provide Lincoln Park with certain registration
rights related to the shares issued under the 2023 Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In consideration for entering
into the 2023 Purchase Agreement, the Company issued <span id="xdx_906_eus-gaap--SharesIssued_iI_c20230620__us-gaap--SubsidiarySaleOfStockAxis__custom--PurchaseAgreementMember_zqhShCpZj6xe" title="Number of shares issued"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2023-06-20_custom_PurchaseAgreementMember" id="Fact001356" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">696,021</ix:nonFraction></span> shares of Common Stock to Lincoln Park as a commitment fee on June 20, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the years ended June 30,
2025 and June 30, 2024 <span id="xdx_90A_eus-gaap--SharesIssued_iI_do_c20250630__us-gaap--SubsidiarySaleOfStockAxis__custom--PurchaseAgreementMember_z294MvXDPYq7" title="Number of shares issued"><span id="xdx_90D_eus-gaap--SharesIssued_iI_do_c20240630__us-gaap--SubsidiarySaleOfStockAxis__custom--PurchaseAgreementMember_zRGChiczFYYb" title="Number of shares issued"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2025-06-30_custom_PurchaseAgreementMember" id="Fact001358" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2024-06-30_custom_PurchaseAgreementMember" id="Fact001360" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></span></span> shares of Common Stock to Lincoln Park were sold under the Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Common Stock Issuances </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">On
April 8, 2025, the Company issued <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20250407__20250408__us-gaap--StatementClassOfStockAxis__custom--CommonStockIssuancesMember_z2bDB1c5gOn8" title="Issuance of common stock shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2025-04-072025-04-08_custom_CommonStockIssuancesMember" id="Fact001362" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,000,000</ix:nonFraction></span> shares of Common Stock valued at $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20250407__20250408__us-gaap--StatementClassOfStockAxis__custom--CommonStockIssuancesMember_zjmA12x5Klq5" title="Issuance of common stock value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-04-072025-04-08_custom_CommonStockIssuancesMember" id="Fact001364" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,058,500</ix:nonFraction></span> (see Note 13) pursuant to the Stock Purchase
Agreement of Biosymetrics, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On January 21, 2025, the Company
issued&#160;<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20250112__20250121__us-gaap--StatementClassOfStockAxis__srt--ChiefExecutiveOfficerMember_zhvGteContIk" title="Issuance of common stock shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2025-01-122025-01-21_srt_ChiefExecutiveOfficerMember" id="Fact001366" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250,000</ix:nonFraction></span>&#160;shares of Common Stock to its Chief Executive Officer of Renovaro Cube valued at $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20250112__20250122__us-gaap--StatementClassOfStockAxis__srt--ChiefExecutiveOfficerMember_zgLRtLQiV1bf" title="Issuance of common stock shares, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2025-01-122025-01-22_srt_ChiefExecutiveOfficerMember" id="Fact001368" format="ixt:numdotdecimal" decimals="0" unitRef="USD">177,500</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On October 17, 2024, the Company
issued&#160;<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20241016__20241017_zST4lPfrBI59" title="Issuance of common stock shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2024-10-162024-10-17" id="Fact001370" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">160,000</ix:nonFraction></span>&#160;shares of Common Stock for consulting services valued at $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20241016__20241017__us-gaap--StatementClassOfStockAxis__custom--CommonStockIssuancesMember_zpW7Vn9ykmre" title="Common stock for consulting services value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-10-162024-10-17_custom_CommonStockIssuancesMember" id="Fact001372" format="ixt:numdotdecimal" decimals="0" unitRef="USD">119,400</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 90 -->
    <div id="xdx_230_ze08gWWeHKFj" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div>
    <div id="xdx_231_zxeJ8wpcneXi" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_234_zXKZB0VZ8Qkj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On October 14, 2024, the Company
issued&#160;<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20241013__20241014_zTSOGzQB1NCd" title="Issuance of common stock shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2024-10-132024-10-14" id="Fact001375" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500,000</ix:nonFraction></span>&#160;shares of Common Stock for consulting services valued at $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20241013__20241014__us-gaap--StatementClassOfStockAxis__custom--CommonStockIssuancesMember_z9locy8x2Wu" title="Common stock for consulting services value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-10-132024-10-14_custom_CommonStockIssuancesMember" id="Fact001377" format="ixt:numdotdecimal" decimals="0" unitRef="USD">275,000</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On October 14, 2024, the Company
issued&#160;<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20241013__20241014__us-gaap--StatementClassOfStockAxis__srt--ChiefExecutiveOfficerMember_z8yPsDncQIlg" title="Issuance of common stock shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2024-10-132024-10-14_srt_ChiefExecutiveOfficerMember" id="Fact001379" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250,000</ix:nonFraction></span>&#160;shares of Common Stock to its Chief Executive Officer valued at $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20241013__20241014__us-gaap--StatementClassOfStockAxis__srt--ChiefExecutiveOfficerMember_zfrxf1whlF7b" title="Issuance of common stock shares, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-10-132024-10-14_srt_ChiefExecutiveOfficerMember" id="Fact001381" format="ixt:numdotdecimal" decimals="0" unitRef="USD">137,750</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On August 23, 2024, Avram Miller,
a former member of the Company&#8217;s board of directors (the &#8220;Board of Directors&#8221;), forfeited&#160;<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20240802__20240823__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zohmeImWSOfc" title="Number of share warrant purchase forfeited"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="From2024-08-022024-08-23_us-gaap_CommonStockMember" id="Fact001383" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">833,333</ix:nonFraction></span>&#160;shares of
Common Stock from the original&#160;<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240802__20240823__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zZ6MOvje5Yje" title="Granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2024-08-022024-08-23_us-gaap_CommonStockMember" id="Fact001385" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span>&#160;shares of Common Stock for advisory services originally granted to him on October 11,
2023. As consideration for such forfeiture, the Company granted to Mr. Miller, an option to purchase&#160;<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20240802__20240823__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__custom--MrMillerMember_zNYtmbJTRhgj" title="Number of share warrant purchase forfeited"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="From2024-08-022024-08-23_us-gaap_CommonStockMember_custom_MrMillerMember" id="Fact001387" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">978,261</ix:nonFraction></span>&#160;shares of Common
Stock of the Company with a per-share exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240823__us-gaap--StatementClassOfStockAxis__custom--BoardOfDirectorsMember_zfxghSMgqmUi" title="Warrants exercised"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-08-23_custom_BoardOfDirectorsMember" id="Fact001389" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.69</ix:nonFraction></span>. The Company determined that this transaction represented a modification
of the original award. The Company measured the fair value of the options issued as compared to the fair value of the original issuance
and determined that there was no incremental compensation to recognize as the fair value of the options was less than the fair value of
the Common Stock. Therefore, the Company will recognize the remaining fair value of the original award over the remaining vesting period,
which is one year. The Company recognized stock-based compensation expense of $<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630_zUWXTJOzcLPk" title="Stock-based compensation expense vested"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2025-06-30" id="Fact001391" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,159,470</ix:nonFraction></span>&#160;related to the vesting of the stocks options
during the year ended June 30, 2025. At June 30, 2025, the Company had $<span id="xdx_902_ecustom--UnrecognizedCompensationCostandVest_iI_c20250630_zVxgTdXHBayk" title="Unrecognized compensation cost and vest"><ix:nonFraction name="RENB:UnrecognizedCompensationCostandVest" contextRef="AsOf2025-06-30" id="Fact001393" format="ixt:numdotdecimal" decimals="0" unitRef="USD">185,373</ix:nonFraction></span>&#160;of unrecognized compensation cost related to the
options which vest at August 23, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On August 1, 2024, the Company
issued&#160;<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240719__20240801_z72Luo4ZBDp5" title="Issuance of common stock shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2024-07-192024-08-01" id="Fact001395" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,000,000</ix:nonFraction></span>&#160;shares of Common Stock for consulting services valued at $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20240729__20240801__us-gaap--StatementClassOfStockAxis__custom--CommonStockConsultingServicesMember_zOfZOFDpsBol" title="Common stock for consulting services value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-07-292024-08-01_custom_CommonStockConsultingServicesMember" id="Fact001397" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,400,000</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 14, 2024, Lunai a Delaware corporation (the &#8220;<span style="text-decoration: underline">Company</span>&#8221;) closed a private placement of&#160;<span id="xdx_908_ecustom--IssuanceOfCommonStockUnderPrivatePlacementOffering_c20240613__20240614_zl48YP3f1NKd" title="Issuance of common stock under private placement"><ix:nonFraction name="RENB:IssuanceOfCommonStockUnderPrivatePlacementOffering" contextRef="From2024-06-132024-06-14" id="Fact001399" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,315,215</ix:nonFraction></span>&#160;of the
Company&#8217;s units, each such Unit consisting of (i) one share of the Company&#8217;s common stock, $<span id="xdx_903_ecustom--CommonStockParValuePrivatePlacement_c20240613__20240614_z5ZSxeLqDvf7" title="Common stock par value under private placement"><ix:nonFraction name="RENB:CommonStockParValuePrivatePlacement" contextRef="From2024-06-132024-06-14" id="Fact001401" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span>&#160;par value per share
and (ii) one common stock purchase warrant to purchase one-tenth of a share of Common Stock, with certain investors (the &#8220;Private
Placement&#8221;). The Warrants are exercisable for five years from the date of issuance and have an exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240614__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zQKTisHAyfRi" title="Warrants exercised"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-06-14_srt_MinimumMember_us-gaap_WarrantMember" id="Fact001403" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.4726</ix:nonFraction></span> and $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240614__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_znVl8uFIhjxk" title="Warrants exercised"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-06-14_srt_MaximumMember_us-gaap_WarrantMember" id="Fact001405" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.4765</ix:nonFraction></span>&#160;per
share, payable in cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the Private Placement, the Company sold&#160;<span style="background-color: white"><span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230701__20240630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zw2s7MhoWxx7" title="Shares sold"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2023-07-012024-06-30_us-gaap_PrivatePlacementMember" id="Fact001407" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,325,869</ix:nonFraction></span></span>&#160;Units at a price per Unit equal
to $<span id="xdx_904_eus-gaap--SaleOfStockPricePerShare_iI_c20240630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_ztiSFbK2bUj9" title="Price per unit"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2024-06-30_us-gaap_PrivatePlacementMember" id="Fact001409" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.4726</ix:nonFraction></span>&#160;to a certain investor who paid in cash and settlement of debt an aggregate amount of $<span style="background-color: white"><span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230701__20240630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zZ8i6Xt9C20d" title="Paid in cash and settlement of debt"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2023-07-012024-06-30_us-gaap_PrivatePlacementMember" id="Fact001411" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,425,075</ix:nonFraction></span></span>&#160;in
consideration for the Units.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
the Company sold&#160;<span style="background-color: white"><span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230701__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zntgYuNqyKDd" title="Shares sold"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2023-07-012024-06-30_us-gaap_InvestorMember" id="Fact001413" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,671,631</ix:nonFraction></span></span>&#160;Units to certain investors who surrendered and terminated&#160;<span style="background-color: white">$<span id="xdx_90F_ecustom--PrincipalAmountAndInterestAccrued_c20230701__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zRmE4LZ7njR9" title="Principal amount and interest accrued"><ix:nonFraction name="RENB:PrincipalAmountAndInterestAccrued" contextRef="From2023-07-012024-06-30_us-gaap_InvestorMember" id="Fact001415" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,955,033</ix:nonFraction></span></span>&#160;in
aggregate principal amount and interest accrued thereon of certain convertible promissory notes issued by the Company in 2023 and 2024
and paid in cash an aggregate amount of $<span id="xdx_906_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20220701__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zUfykS9Y7x6j" title="Paid in cash and settlement of debt"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2022-07-012023-06-30_us-gaap_InvestorMember" id="Fact001417" format="ixt:numdotdecimal" decimals="0" unitRef="USD">478,060</ix:nonFraction></span>&#160;to the Company in consideration for the Units.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
the Company sold&#160;<span id="xdx_905_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220701__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--Investor1Member_zRMV7lJM3A67" title="Shares sold"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2022-07-012023-06-30_custom_Investor1Member" id="Fact001419" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">317,715</ix:nonFraction></span>&#160;Units to an investor who surrendered and terminated $<span style="background-color: white"><span id="xdx_90B_ecustom--PrincipalAmountAndInterestAccrued_c20220701__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--Investor1Member_zeO71y79asE3" title="Principal amount and interest accrued"><ix:nonFraction name="RENB:PrincipalAmountAndInterestAccrued" contextRef="From2022-07-012023-06-30_custom_Investor1Member" id="Fact001421" format="ixt:numdotdecimal" decimals="0" unitRef="USD">468,453</ix:nonFraction></span></span>&#160;in
aggregate principal amount and interest accrued thereon of a convertible promissory note issued in 2023 and paid in cash an aggregate
amount of $<span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20220701__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--Investor1Member_zHj8Yy5N7Lp1" title="Paid in cash and settlement of debt"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2022-07-012023-06-30_custom_Investor1Member" id="Fact001423" format="ixt:numdotdecimal" decimals="0" unitRef="USD">66,000</ix:nonFraction></span>&#160;to the Company in consideration for the Units.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
relation to the June 14, 2024 Private Placement the Company recognized a loss on the settlement of debt for $<span id="xdx_90E_eus-gaap--OtherNonrecurringIncomeExpense_c20240701__20250630_zqUhlpp8Vxl2" title="Other income (expense)"><ix:nonFraction name="us-gaap:OtherNonrecurringIncomeExpense" contextRef="From2024-07-01to2025-06-30" id="Fact001425" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,183,560</ix:nonFraction>&#160;</span>which was
recorded in other income (expense) in the statement of operations for the year ended June 30, 2024.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related
to the June 14, 2024 Private Placement, ranging from July 3, 2024, to October 10, 2024, the Company sold <span id="xdx_902_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240703__20241002_zDqkQ1NrDVWf" title="Sale of stock issued"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2024-07-032024-10-02" id="Fact001427" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,613,596</ix:nonFraction></span> Units at a price per
Unit equal to $<span id="xdx_904_eus-gaap--SaleOfStockPricePerShare_iI_c20241002_zIV28vdoDwRa" title="Sale of stock price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2024-10-02" id="Fact001429" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.4726</ix:nonFraction></span> to a certain investor who paid in cash an aggregate amount of $<span id="xdx_905_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_c20240703__20241002_znPHNyyahFgg" title="Sale of stock issued cash consideration"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" contextRef="From2024-07-032024-10-02" id="Fact001431" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,376,181</ix:nonFraction></span> in consideration of the Units.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On April 5, 2024, the Company
issued&#160;<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240404__20240405__us-gaap--StatementClassOfStockAxis__custom--CommonStockIssuancesMember_zpojgP2U6bcf" title="Issuance of common stock shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2024-04-042024-04-05_custom_CommonStockIssuancesMember" id="Fact001433" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">33,760</ix:nonFraction></span>&#160;shares of common stock for consulting services valued at $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20240404__20240405__us-gaap--StatementClassOfStockAxis__custom--CommonStockIssuancesMember_zGAfK59mWIN1" title="Common stock for consulting services value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-04-042024-04-05_custom_CommonStockIssuancesMember" id="Fact001435" format="ixt:numdotdecimal" decimals="0" unitRef="USD">94,190</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On February 20, 2024, <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240220__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zun1qtNZllhg" title="Warrants outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-02-20_us-gaap_WarrantMember" id="Fact001437" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,953,700</ix:nonFraction></span>
warrants outstanding were exercised at prices ranging from $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240220__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zhiA02vxoA81" title="Warrants exercised"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-02-20_srt_MinimumMember_us-gaap_WarrantMember" id="Fact001439" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.53</ix:nonFraction></span> to $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240220__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zdSznezIgyUf" title="Warrants exercised"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-02-20_srt_MaximumMember_us-gaap_WarrantMember" id="Fact001441" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.65</ix:nonFraction></span> per share and the aggregate $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExpenseOrRevenueRecognized_c20240219__20240220__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zvMD2LHqCouh" title="Warrants aggregate amount"><ix:nonNumeric contextRef="From2024-02-192024-02-20_us-gaap_WarrantMember" id="Fact001443" name="us-gaap:ClassOfWarrantOrRightExpenseOrRevenueRecognized">1,750,000</ix:nonNumeric></span> of a promissory note
held by the holder was applied to the exercise price of the warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On February 20, 2024, <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240220__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--SingleRangeMember_zbAtdy2zll2h" title="Warrants outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-02-20_us-gaap_WarrantMember_custom_SingleRangeMember" id="Fact001445" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">471,699</ix:nonFraction></span>
warrants outstanding were exercised at $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240220__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--SingleRangeMember_zdJjr26EG1Rb" title="Warrants exercised"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-02-20_us-gaap_WarrantMember_custom_SingleRangeMember" id="Fact001447" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.53</ix:nonFraction></span> per share valued at $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExpenseOrRevenueRecognized_c20240219__20240220__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--SingleRangeMember_zNgo4Z0hFuq4" title="Warrants aggregate amount"><ix:nonNumeric contextRef="From2024-02-192024-02-20_us-gaap_WarrantMember_custom_SingleRangeMember" id="Fact001449" name="us-gaap:ClassOfWarrantOrRightExpenseOrRevenueRecognized">250,000</ix:nonNumeric></span>. A promissory note held by the holder was applied to the exercise
price of the warrants in lieu of cash proceeds.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On February 15, 2024, the Company
issued <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240214__20240215_ztDhI08h5Bkj" title="Issuance of common stock shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2024-02-142024-02-15" id="Fact001451" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></span> shares of Common Stock for consulting services valued at $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20240214__20240215__us-gaap--StatementClassOfStockAxis__custom--CommonStockIssuancesMember_zu4fTPPG5qrd" title="Common stock for consulting services value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-02-142024-02-15_custom_CommonStockIssuancesMember" id="Fact001453" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 91 -->
    <div id="xdx_23A_zVWVkBj1iTxi" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div>
    <div id="xdx_238_zy821QDkeIB1" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_238_zGSY65yUrw67" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">On
February 15, 2024, the Company closed a private placement of <span id="xdx_906_ecustom--IssuanceOfCommonStockUnderPrivatePlacementOffering_c20240214__20240215_zE0QuYFoeZFa" title="Issuance of common stock under private placement"><ix:nonFraction name="RENB:IssuanceOfCommonStockUnderPrivatePlacementOffering" contextRef="From2024-02-142024-02-15" id="Fact001456" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">344,827</ix:nonFraction></span> shares of Common Stock, $<span id="xdx_90C_ecustom--CommonStockParValuePrivatePlacement_c20240214__20240215_zd1ESw1hvJPj" title="Common stock par value under private placement"><ix:nonFraction name="RENB:CommonStockParValuePrivatePlacement" contextRef="From2024-02-142024-02-15" id="Fact001458" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> par value, at $2.90 per share for
aggregate proceeds to the Company of $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20240214__20240215_zdhKeSQBb5d" title="Proceeds from issuance of private placement"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2024-02-142024-02-15" id="Fact001460" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000,000</ix:nonFraction></span> in cash. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On February 16, 2024, the Company
recognized <span id="xdx_90F_eus-gaap--SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares_iI_c20240216__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GEDiCubeIntlLtdMember_zZwCh50qz7Q8" title="Common Stock to be issued in settlement"><ix:nonFraction name="us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares" contextRef="AsOf2024-02-16_custom_GEDiCubeIntlLtdMember" id="Fact001462" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,425,399</ix:nonFraction></span> shares of Common Stock to be issued in settlement of the contingent consideration as a result of the Company&#8217;s
acquisition of GEDi Cube Intl Ltd.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">On
February 13, 2024, the Company issued <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240212__20240213__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementOfRenovaroCubeMember_zGOxd5vhrrP7" title="Issuance of common stock shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2024-02-122024-02-13_custom_StockPurchaseAgreementOfRenovaroCubeMember" id="Fact001464" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">70,834,183</ix:nonFraction></span> shares of Common Stock valued at $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20240212__20240213__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementOfRenovaroCubeMember_zRgTmcN3kXM" title="Issuance of common stock shares, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2024-02-122024-02-13_custom_StockPurchaseAgreementOfRenovaroCubeMember" id="Fact001466" format="ixt:numdotdecimal" decimals="0" unitRef="USD">136,001,631</ix:nonFraction></span> (see Note 13) pursuant to the Stock Purchase
Agreement of Renovaro Cube.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On December 4, 2023, the Company
issued <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20231203__20231204_z58zP4SIBOFb" title="Issuance of common stock shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2023-12-032023-12-04" id="Fact001468" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">525,945</ix:nonFraction></span> shares of Common Stock pursuant to warrants exercised for cash proceeds of $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20231203__20231204_zfPgWL1K4ck9" title="Issuance of common stock shares, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2023-12-032023-12-04" id="Fact001470" format="ixt:numdotdecimal" decimals="0" unitRef="USD">341,865</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On October 23, 2023, the Company
issued <span id="xdx_90E_eus-gaap--SharesIssued_iI_c20231023__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AvramMillerMember_zuQYzlLrTdj5" title="Shares issued"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2023-10-23_us-gaap_CommonStockMember_custom_AvramMillerMember" id="Fact001472" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span> shares of Common Stock valued at $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20231022__20231023__us-gaap--StatementClassOfStockAxis__custom--CommonStockIssuancesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AvramMillerMember_zXvJbVF8dEX2" title="Issuance of common stock shares, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2023-10-222023-10-23_custom_CommonStockIssuancesMember_custom_AvramMillerMember" id="Fact001474" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,760,000</ix:nonFraction></span> for advisory services to Avram Miller, a member of the Company&#8217;s board
of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Between July 28, 2023, and September
28, 2023, the Company issued <span id="xdx_90E_ecustom--PurchaseSharesOfCommonStock_iI_c20230728__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zZg7Sl0Tz1lc" title="Purchase shares of common stock"><ix:nonFraction name="RENB:PurchaseSharesOfCommonStock" contextRef="AsOf2023-07-28_us-gaap_CommonStockMember" id="Fact001476" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,000,000</ix:nonFraction></span> shares of Common Stock for consulting services valued at $<span id="xdx_909_eus-gaap--ConversionOfStockAmountConverted1_c20230727__20230728__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z2PLBpr7s3Vk" title="Converted shares of common stock, value"><ix:nonFraction name="us-gaap:ConversionOfStockAmountConverted1" contextRef="From2023-07-272023-07-28_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001478" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,470,000</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><b>2017
Warrants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On July
14, 2022, certain of our warrant holders exercised warrants to purchase&#160;<span id="xdx_909_eus-gaap--StockRepurchasedDuringPeriodShares_c20220713__20220714__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zWpCkUoKrUOk" title="Shares purchased"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="From2022-07-132022-07-14_us-gaap_WarrantMember" id="Fact001480" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,250,000</ix:nonFraction></span>&#160;shares of Common Stock for total proceeds
to the Company of $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_c20220713__20220714__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zNCy0STHof72" title="Proceeds from common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2022-07-132022-07-14_us-gaap_WarrantMember" id="Fact001482" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,625,000</ix:nonFraction></span>, with corresponding earn-out distribution of the same number of shares in connection with the acquisition
of Renovaro Biosciences. This non-cash earn-out distribution impacted stockholders&#8217; equity in the amount of $<span id="xdx_90C_eus-gaap--NoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1_pp0p0_c20220713__20220714__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zzrVgkt6TA62" title="Non cash earn out distribution"><ix:nonFraction name="us-gaap:NoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1" contextRef="From2022-07-132022-07-14_us-gaap_WarrantMember" id="Fact001484" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,762,500</ix:nonFraction></span>&#160;based
on the share price on July 14, 2022 of $<span id="xdx_907_eus-gaap--SharePrice_iI_c20220714__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zwaif8RRWnZ3" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-07-14_us-gaap_WarrantMember" id="Fact001486" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.21</ix:nonFraction></span>. The Company recorded a loss on extinguishment of contingent consideration liability of $<span id="xdx_90D_ecustom--ExtinguishmentOfContingentConsiderationLiability_c20230701__20240630_zBn1tEcE51qe" title="Extinguishment of contingent consideration liability"><ix:nonFraction name="RENB:ExtinguishmentOfContingentConsiderationLiability" contextRef="From2023-07-012024-06-30" id="Fact001488" format="ixt:numdotdecimal" decimals="0" unitRef="USD">419,182</ix:nonFraction></span>&#160;during
the year ended June 30, 2024 which reflected the difference between the fair value of the shares and the contingent consideration liability
at the time of extinguishment. As of June 30, 2023, all outstanding warrants as of the date of acquisition of Renovaro Biosciences (the
&#8220;2017 Warrants&#8221;) were exercised and there is no further contingent consideration liability related to the 2017 Warrants remaining
as of June 30, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Acquisition of Renovaro Biopharma
/ Contingently issuable shares</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On February 16, 2018, the acquisition
of Renovaro Biosciences was completed. As part of the acquisition, the stockholders of Renovaro Biosciences received (i) 18,081,962 shares
of Common Stock, and (ii) the right to receive Contingent Shares of Common Stock pro rata upon the exercise or conversion of warrants,
which were outstanding at closing. As of June 30, 2025, <span id="xdx_909_ecustom--BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuable_iI_do_c20250630__us-gaap--BusinessAcquisitionAxis__custom--EBIAndWeirdScienceLLCMember__us-gaap--TypeOfArrangementAxis__custom--AgreementAndPlanOfMergerAgreementAxisMember_zMN6mqjNfpp8" title="Common shares contingently issuable"><ix:nonFraction name="RENB:BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuable" contextRef="AsOf2025-06-30_custom_EBIAndWeirdScienceLLCMember_custom_AgreementAndPlanOfMergerAgreementAxisMember" id="Fact001490" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></span> further Contingent Shares are issuable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Acquisition of Renovaro Denmark
</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">At June 30, 2025 and 2024, the
Company maintained a reserve of <span id="xdx_901_ecustom--ReserveEscrowShares_iI_c20250630_z9Y2hOzNgtQb" title="Reserve escrow shares"><ix:nonFraction name="RENB:ReserveEscrowShares" contextRef="AsOf2025-06-30" id="Fact001492" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">17,414</ix:nonFraction></span> Escrow Shares, all of which are reflected as issued and outstanding in the accompanying financial
statements. The Escrow Shares are reserved to acquire the shares of Renovaro Denmark held by non-consenting shareholders of Renovaro Denmark
on both June 30, 2025 and 2024, in accordance with Section 70 of the Danish Companies Act and the Articles of Association of Renovaro
Denmark. There have been <span id="xdx_90E_ecustom--StockIssuedToNonconsentingShareholders_iI_c20250630_zTtjQONp4gK7" title="Stock issued to non-consenting shareholders"><ix:nonFraction name="RENB:StockIssuedToNonconsentingShareholders" contextRef="AsOf2025-06-30" id="Fact001494" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">167,639</ix:nonFraction></span> shares of Common Stock issued to non-consenting shareholders of Renovaro Denmark as of June 30, 2025.
During the years ended June 30, 2025 and 2024, the Company did not issue any shares of Common Stock to such non-consenting shareholders
of Renovaro Denmark.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><b>Stock-based Compensation </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company recognizes compensation
costs for stock option awards to employees based on their grant-date fair value. The value of each stock option is estimated on the date
of grant using the Black-Scholes option-pricing model. In the year ended June 30, 2025, the weighted-average assumptions used to estimate
the grant date fair values of the stock options granted using the Black-Scholes option-pricing model are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact001496" name="RENB:ScheduleOfShareBasedPaymentAwardStockOptionValuationAssumptionsTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--ScheduleOfShareBasedPaymentAwardStockOptionValuationAssumptionsTableTextBlock_zI6lhXrzJhJg" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span id="xdx_8BA_zwawgDZ0RtLk" style="display: none">Schedule of weighted-average assumptions used to estimate the fair values of the stock options granted</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Lunai Bioworks Inc.</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Expected term (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240701__20250630__dei--LegalEntityAxis__custom--RenovaroMember_zuGOzNmRhLCb" style="font-size: 10pt"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_RenovaroMember" format="ixt-sec:duryear" id="Fact001497" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.5</ix:nonNumeric></span>
<span style="font-size: 10pt"></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20240701__20250630__srt--RangeAxis__srt--MinimumMember__dei--LegalEntityAxis__custom--RenovaroMember_zvvQSHEtbPH" title="Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2024-07-012025-06-30_srt_MinimumMember_custom_RenovaroMember" id="Fact001499" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">109.45</ix:nonFraction></span>% &#8211; <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20240701__20250630__srt--RangeAxis__srt--MaximumMember__dei--LegalEntityAxis__custom--RenovaroMember_zU8NWSv9gxX6" title="Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2024-07-012025-06-30_srt_MaximumMember_custom_RenovaroMember" id="Fact001501" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">118.99</ix:nonFraction></span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20240701__20250630__srt--RangeAxis__srt--MinimumMember__dei--LegalEntityAxis__custom--RenovaroMember_zNXl7K6POpVh" title="Risk free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2024-07-012025-06-30_srt_MinimumMember_custom_RenovaroMember" id="Fact001503" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">3.86</ix:nonFraction></span>%- <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20240701__20250630__srt--RangeAxis__srt--MaximumMember__dei--LegalEntityAxis__custom--RenovaroMember_z48dYHM6ppXb" title="Risk free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2024-07-012025-06-30_srt_MaximumMember_custom_RenovaroMember" id="Fact001505" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">4.40</ix:nonFraction></span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-align: left; text-indent: -10pt">Dividend yield</td><td style="width: 10%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20240701__20250630__dei--LegalEntityAxis__custom--RenovaroMember_zg0rIcCdEzod" title="Dividend yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2024-07-012025-06-30_custom_RenovaroMember" id="Fact001507" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">0</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A3_zXCgDyz3xIU2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 92 -->
    <div id="xdx_236_zIIrVjKcs1ej" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div>
    <div id="xdx_237_z5aGyCsK9uR8" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23D_zXdTtuyTtePh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company recognized stock-based
compensation expense related to all equity instruments of $<span id="xdx_909_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20240701__20250630_z8A7WYjgNOg4" title="Stock-based compensation expense"><ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="From2024-07-01to2025-06-30" id="Fact001510" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,313,291</ix:nonFraction></span> and $<span id="xdx_907_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20230701__20240630_z0LDxbn4h2rh" title="Stock-based compensation expense"><ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="From2023-07-012024-06-30" id="Fact001512" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,673,129</ix:nonFraction></span> for the years ended June 30, 2025 and 2024, respectively.
At June 30, 2025, the Company had approximately $<span id="xdx_90E_ecustom--UnrecognizedCompensationCostNonVested_iI_c20250630_z1Uz85GML2Z3" title="Unrecognized compensation cost non vested"><ix:nonFraction name="RENB:UnrecognizedCompensationCostNonVested" contextRef="AsOf2025-06-30" id="Fact001514" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,009,277</ix:nonFraction></span> of unrecognized compensation cost related to non-vested options.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Plan Options</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On February 6, 2014, the Company&#8217;s
Board of Directors adopted the Company&#8217;s 2014 Equity Incentive Plan (the &#8220;2014 Plan&#8221;), and the Company had reserved
<span id="xdx_906_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20140206__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2014Member_zJ6PzdgXQpTb" title="Common stock reserved for issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2014-02-06_custom_EquityIncentivePlan2014Member" id="Fact001516" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,206,000</ix:nonFraction></span> shares of Common Stock for issuance in accordance with the terms of the 2014 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On October 30, 2019, the Board
approved and on October 31, 2019, the Company&#8217;s stockholders adopted its 2019 Equity Incentive Plan (the &#8220;2019 Plan&#8221;),
which replaced the 2014 Plan. The 2019 Plan provided that the maximum aggregate number of shares of the Company&#8217;s Common Stock reserved
and available for issuance under the 2019 Plan was the sum of (1) 6,000,000 new shares, and (2) the number of shares available for the
grant of awards as of the effective date under the 2014 Plan plus any options related to awards that expire, are terminated, surrendered,
or forfeited for any reason without issuance of shares under the 2014 Plan after the effective date of the 2019 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Effective July 21, 2023, the Company
adopted the Renovaro Biosciences Inc. 2023 Equity Incentive Plan (the &#8220;2023 Plan&#8221;). The 2023 Plan replaced the 2019 Plan.
The 2023 Plan provides that the maximum aggregate number of shares of the Company&#8217;s Common Stock reserved and available for issuance
under the 2023 Plan was the sum of (1) 4,000,000 new shares, and (2) the number of shares available for the grant of awards as of the
effective date under the 2019 Plan. Any awards outstanding under the 2019 Plan as of the date of adoption of the 2023 Plan remain subject
to and will be available under the 2019 Plan, and any shares subject to outstanding awards under the 2019 Plan that subsequently expire,
terminate, or are surrendered or forfeited for any reason without issuance of shares automatically become available for issuance under
the 2023 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;The Company granted options
to purchase <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230701__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmployeesMember_z3t46SDLWZU5" title="Option granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2023-07-012024-06-30_custom_EmployeesMember" id="Fact001518" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span> shares of Common Stock to employees with a five-year vesting period during the year end June 30, 2025 under the
2019 and 2023 Plan. For the year ended June 30, 2024, the Company granted options to purchase zero shares of Common Stock to employees
with a five-year vesting period under the 2019 and 2023 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;The Company granted options
to purchase zero shares of Common Stock to employees with a three-year vesting period during the year end June 30, 2025 under the 2019
and 2023 Plan. For the year ended June 30, 2024, the Company granted options to purchase <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240701__20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmployeesThreeYearMember_zr3OG910x5pg" title="Option granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2024-07-012025-06-30_custom_EmployeesThreeYearMember" id="Fact001520" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">369,500</ix:nonFraction></span> shares to employees with a three-year
vesting period under the 2019 and 2023 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;The Company granted options
to purchase <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240701__20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmployeesMember_zE3SdXuQmmab" title="Option granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2024-07-012025-06-30_custom_EmployeesMember" id="Fact001522" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,850,000</ix:nonFraction></span> shares of Common Stock to employees with a two-year vesting period during the year end June 30, 2025 under the 2019
and 2023 Plan. For the year ended June 30, 2024, the Company granted options to purchase zero shares of Common Stock to employees with
a two-year vesting period under the 2019 and 2023 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the years ended June 30,
2025 and 2024, the Company granted options to purchase <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240701__20250630__us-gaap--VestingAxis__custom--ShareBasedCompensationAwardAdvisoryBoardMember_zF9PK6UZOzHh" title="Option granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2024-07-012025-06-30_custom_ShareBasedCompensationAwardAdvisoryBoardMember" id="Fact001524" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">362,904</ix:nonFraction></span> and <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230701__20240630__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zS0wu7AV4mGh" title="Option granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2023-07-012024-06-30_us-gaap_ShareBasedCompensationAwardTrancheOneMember" id="Fact001526" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">424,412</ix:nonFraction></span> shares, respectively, to the Board of Directors and Scientific
Advisory Board Members with a one-year vesting period, under the 2019 and 2023 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the years ended June
30, 2025 and 2024, the Company granted options to purchase <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240701__20250630__us-gaap--VestingAxis__custom--ShareBasedCompensationAwardBoardofDirectorsMember_zLa4xBQPOl57" title="Option granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2024-07-012025-06-30_custom_ShareBasedCompensationAwardBoardofDirectorsMember" id="Fact001528" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></span> zero and <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230701__20240630__us-gaap--VestingAxis__custom--ShareBasedCompensationAwardBoardofDirectorsMember_zXpM7RGZ03if" title="Option granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2023-07-012024-06-30_custom_ShareBasedCompensationAwardBoardofDirectorsMember" id="Fact001530" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">329,729</ix:nonFraction></span>
shares, respectively, to the Board of Directors and Scientific Advisory Board Members with immediate vesting, under the 2019 and
2023 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the years ended June 30,
2025, and 2024, the Company granted options to purchase zero and <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240701__20250630__us-gaap--VestingAxis__custom--ShareBasedCompensationAwardConsultingServicesMember_z7K2HKYVrxs4" title="Option granted"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230701__20240630__us-gaap--VestingAxis__custom--ShareBasedCompensationAwardConsultingServicesMember_zeHYMP0XqRDe" title="Option granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2024-07-012025-06-30_custom_ShareBasedCompensationAwardConsultingServicesMember" id="Fact001532" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2023-07-012024-06-30_custom_ShareBasedCompensationAwardConsultingServicesMember" id="Fact001534" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000</ix:nonFraction></ix:nonFraction></span></span> shares, respectively, for consulting services with a one-year
vesting period, under the 2019 and 2023 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On November 4, 2024, the Company
issued&#160;<span id="xdx_908_ecustom--DebtConversionConvertedInstrumentWarrantsOptionsIssued1_iI_c20241104__us-gaap--PlanNameAxis__custom--PlanOptionsMember_zqChV9EgDXg6" title="Options available to be issued"><ix:nonFraction name="RENB:DebtConversionConvertedInstrumentWarrantsOptionsIssued1" contextRef="AsOf2024-11-04_custom_PlanOptionsMember" id="Fact001536" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">58,500</ix:nonFraction></span>&#160;stock options to its former interim Chief Financial Officer. The options had a fair value of $<span id="xdx_905_eus-gaap--FairValueOptionChangesInFairValueGainLoss1_c20241101__20241104_zElPdxsGBtH1" title="Option fair value"><ix:nonFraction name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" contextRef="From2024-11-012024-11-04" id="Fact001538" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,005</ix:nonFraction></span>&#160;on the
grant date, fully vest on&#160;January 6, 2025&#160;and expire on November 4, 2034. Subsequently, during the period ended March 31, 2025,
pursuant to the Company&#8217;s executive officer compensation claw back policy, the board of directors directed the Company to claw back
and cancel the&#160;<span id="xdx_909_ecustom--StockOptionIssued_iI_c20241104_znSpmhndaDkb" title="Stock option issued"><ix:nonFraction name="RENB:StockOptionIssued" contextRef="AsOf2024-11-04" id="Fact001540" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">58,500</ix:nonFraction></span>&#160;options which were issued on November 4, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 93 -->
    <div id="xdx_237_zfd5So0V5tnf" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div>
    <div id="xdx_23E_zJwDaNiyLMx7" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23D_zMGY38H9w9vh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On August 23, 2024, Avram Miller,
a former member of the Company&#8217;s board of directors (the &#8220;Board of Directors&#8221;), forfeited&#160;833,333&#160;shares of
Common Stock from the original&#160;1,000,000&#160;shares of Common Stock for advisory services originally granted to him on October 11,
2023. As consideration for such forfeiture, the Company granted to Mr. Miller, an option to purchase&#160;978,261&#160;shares of Common
Stock of the Company with a per-share exercise price of $0.69. The Company determined that this transaction represented a modification
of the original award. The Company measured the fair value of the options issued as compared to the fair value of the original issuance
and determined that there was no incremental compensation to recognize as the fair value of the options was less than the fair value of
the Common Stock. Therefore, the Company will recognize the remaining fair value of the original award over the remaining vesting period,
which is one year. The Company recognized stock-based compensation expense of $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_c20250630_zMoQKEKwLq1h" title="stock option vested"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" contextRef="AsOf2025-06-30" id="Fact001543" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,159,470</ix:nonFraction></span>&#160;related to the vesting of the stocks options
during the year ended June 30, 2025. At June 30, 2025, the Company had $<span id="xdx_90E_ecustom--UnrecognizedCompensationCost_iI_c20250630_zFlEIf6Lk8R" title="Unrecognized compensation cost"><ix:nonFraction name="RENB:UnrecognizedCompensationCost" contextRef="AsOf2025-06-30" id="Fact001545" format="ixt:numdotdecimal" decimals="0" unitRef="USD">185,373</ix:nonFraction></span>&#160;of unrecognized compensation cost related to the
options which vest at August 23, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">All of the above options are exercisable
at the market price of the Company&#8217;s Common Stock on the date of the grant. On February 13, 2024, the Company repriced 3,849,931
eligible employee and consultant options from the original issued exercise price to a new exercise price of $1.92 per share, the closing
price of the Company&#8217;s Common Stock on February 13, 2024. The Company recognized stock-based compensation expense related to the
repricing of options of $921,254 during the year ended June 30, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;To date the Company has
granted options under the 2014, 2019 and 2023 Plans (&#8220;Plan Options&#8221;) to purchase <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240701__20250630__us-gaap--PlanNameAxis__custom--PlanOptionsMember_zjvJ4JKiiiAi" title="Option granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2024-07-012025-06-30_custom_PlanOptionsMember" id="Fact001547" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,088,250</ix:nonFraction></span> shares of Common Stock. At June
30, 2025, the Company has <span id="xdx_901_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_c20240701__20250630__us-gaap--PlanNameAxis__custom--PlanOptionsMember_zSRI2QBeS0ad" title="Options available to be issued"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" contextRef="From2024-07-012025-06-30_custom_PlanOptionsMember" id="Fact001549" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,093,444</ix:nonFraction></span> options available to be issued under the 2023 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">A summary of the Plan Options outstanding at June 30,
2025 is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact001551" name="RENB:ScheduleOfStockBasedCompensationActivityTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_896_ecustom--ScheduleOfStockBasedCompensationActivityTableTextBlock_zzUDy1OZibYe" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details 1)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B0_zxwLmvygJApl" style="display: none">Schedule of stock options outstanding</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    Outstanding</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="7" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    Exercisable</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise
    Price Ranges</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
    Outstanding</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    Average Remaining Contractual Life (years)</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    Average Exercise Price</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
    Exercisable</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    Average Remaining Contractual Life (years)</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    Average Exercise Price</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 11%; text-align: left; text-indent: -10pt"/><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zUI9fWUQjxyb" title="Exercise Prices, Lower"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2024-07-012025-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange1Member" id="Fact001553" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.45</ix:nonFraction></span>&#8211;<span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zDbsOAVwv6ej" title="Exercise Prices, Upper"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2024-07-012025-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange1Member" id="Fact001555" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.50</ix:nonFraction></span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zTDfxYZcrRCd" title="Number share option outstanding" style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange1Member" id="Fact001557" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,623,614</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtYp_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zlRCO83FiHfi" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)"><ix:nonNumeric contextRef="From2024-07-012025-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange1Member" format="ixt-sec:duryear" id="Fact001559" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">8.97</ix:nonNumeric></span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zjnlcPtUsJkl" title="Options Outstanding, Weighted Average Exercise Price" style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange1Member" id="Fact001561" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.75</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><p id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zQDTcPmHmPY3" title="Options Exercisable" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2025-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange1Member" id="Fact001563" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">567,233</ix:nonFraction></p></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zhvX39G5OXP8" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)"><ix:nonNumeric contextRef="From2024-07-012025-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange1Member" format="ixt-sec:duryear" id="Fact001565" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">8.71</ix:nonNumeric></span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zDv7lyXUxepa" title="Options Exercisable, Weighted Average Exercise Price" style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2025-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange1Member" id="Fact001567" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.96</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"/><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zc1x7zTr4Tgi" title="Exercise Prices, Lower"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2024-07-012025-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange2Member" id="Fact001569" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.51</ix:nonFraction></span>&#8211;<span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_z3GBkhz0mLX7" title="Exercise Prices, Upper"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2024-07-012025-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange2Member" id="Fact001571" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.50</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zrTjt887m7n7" title="Number share option outstanding" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1573">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zk1QH7XpIgwf" title="Options Outstanding, Weighted Average Exercise Price" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1575">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zuLeTzWytcp" title="Options Exercisable" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1577">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zbV2PosiIG1" title="Options Exercisable, Weighted Average Exercise Price" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1579">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"/><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_z5xKfWKRu2y4" title="Exercise Prices, Lower"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2024-07-012025-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange3Member" id="Fact001581" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.51</ix:nonFraction></span>&#8211;<span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_znrPyRCIviei" title="Exercise Prices, Upper"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2024-07-012025-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange3Member" id="Fact001583" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.00</ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zMKFlfOEYKMh" title="Number share option outstanding" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1585">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zeVPVvRIQwf6" title="Options Outstanding, Weighted Average Exercise Price" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1587">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zCb448HV19ke" title="Options Exercisable" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1589">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zuOQs31b4cL2" title="Options Exercisable, Weighted Average Exercise Price" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1591">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"/><td style="text-align: right"/><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zy8D829558B2" title="Number share option outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-06-30_us-gaap_EmployeeStockOptionMember" id="Fact001593" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,623,614</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zDqsZMhn89h1" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)"><ix:nonNumeric contextRef="From2024-07-012025-06-30_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" id="Fact001595" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">8.97</ix:nonNumeric></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zQ44h6xUyaAj" title="Options Outstanding, Weighted Average Exercise Price" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-06-30_us-gaap_EmployeeStockOptionMember" id="Fact001597" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.75</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><p id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zsCPYUXgu5M" title="Options Exercisable" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2025-06-30_us-gaap_EmployeeStockOptionMember" id="Fact001599" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">567,233</ix:nonFraction></p></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zvxA8dTfWuo3" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)"><ix:nonNumeric contextRef="From2024-07-012025-06-30_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" id="Fact001601" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">8.71</ix:nonNumeric></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zHKzMsbH294g" title="Options Exercisable, Weighted Average Exercise Price" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2025-06-30_us-gaap_EmployeeStockOptionMember" id="Fact001603" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.96</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>



</ix:nonNumeric><p id="xdx_8A8_zcS9TpCyIEue" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A summary of changes are presented
below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact001605" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zvSnzBGHPz0g" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details 2)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B3_z0CmkDDSPxKi" style="display: none">Schedule of Stock option activity</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise<br/> Price</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Average Remaining Life</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Intrinsic<br/> Value</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 44%; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Outstanding at June 30, 2024</span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zzpK6WLrjZSb" title="Options Outstanding at beginning of period" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-06-30_custom_EmployeeStockOptionsMember" id="Fact001607" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,527,852</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zOLIRWzP8ibk" title="Weighted Average Exercise Price, Outstanding at beginning of period" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-06-30_custom_EmployeeStockOptionsMember" id="Fact001609" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.11</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zhw6GsP3381i" title="Weighted Average remaining life"><ix:nonNumeric contextRef="From2023-07-012024-06-30_custom_EmployeeStockOptionsMember" format="ixt-sec:duryear" id="Fact001611" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">7.30</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_d0_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zvWP6K5tBpij" title="Weighted Average Intrinsic Value, Outstanding at beginning of period" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2024-06-30_custom_EmployeeStockOptionsMember" id="Fact001613" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Granted</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zplZ5PVWrrJc" title="Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-07-012025-06-30_custom_EmployeeStockOptionsMember" id="Fact001615" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,249,665</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zkdWeeXIJJre" title="Weighted average exercise price, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2024-07-012025-06-30_custom_EmployeeStockOptionsMember" id="Fact001617" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.64</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Exercised</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_d0_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zURyob3CXWw5" title="Exercised" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2024-07-012025-06-30_custom_EmployeeStockOptionsMember" id="Fact001619" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8212;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d0_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zKKmDwjg2LFj" title="Weighted average exercise price, Exercised" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2024-07-012025-06-30_custom_EmployeeStockOptionsMember" id="Fact001621" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">&#8212;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Forfeited</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di0_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zjc88dpn6Jz5" title="Forfeited" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2024-07-012025-06-30_custom_EmployeeStockOptionsMember" id="Fact001623" format="ixt:zerodash" decimals="INF" sign="-" unitRef="Shares">&#8212;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d0_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zxICJY7Nerkj" title="Weighted Average Exercise Price, Forfeited" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2024-07-012025-06-30_custom_EmployeeStockOptionsMember" id="Fact001625" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">&#8212;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Expired/Canceled </span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zwN2ajgNYL67" title="Cancelled/Expired" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2024-07-012025-06-30_custom_EmployeeStockOptionsMember" id="Fact001627" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,153,903</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zWkV5FsImWG" title="Weighted Average Exercise Price, Expired" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2024-07-012025-06-30_custom_EmployeeStockOptionsMember" id="Fact001629" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.12</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Outstanding at June 30, 2025</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zwAUx66zJX0b" title="Options Outstanding at end of period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-06-30_custom_EmployeeStockOptionsMember" id="Fact001631" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,623,614</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zHvVQZ2Em65h" title="Weighted Average Exercise Price, Outstanding at ending of period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-06-30_custom_EmployeeStockOptionsMember" id="Fact001633" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.75</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zN2elfknGk5e" title="Weighted Average remaining life"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_EmployeeStockOptionsMember" format="ixt-sec:duryear" id="Fact001635" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">8.97</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_d0_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zhUKVHVYnXd7" title="Weighted Average Intrinsic Value, Outstanding at end of period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2025-06-30_custom_EmployeeStockOptionsMember" id="Fact001637" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Exercisable at June 30, 2025</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zK5TNBKjTdta" title="Options Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2025-06-30_custom_EmployeeStockOptionsMember" id="Fact001639" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">567,233</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zzvYeoMsMiuh" title="Weighted Average Exercise Price, Exercisable at ending of period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2025-06-30_custom_EmployeeStockOptionsMember" id="Fact001641" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.96</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisablesWeightedAverageRemainingContractualTerm1_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zjlgEU9sn9i3" title="Weighted Average Remaining Life, Exercisable"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_EmployeeStockOptionsMember" format="ixt-sec:duryear" id="Fact001643" name="RENB:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisablesWeightedAverageRemainingContractualTerm1">8.71</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zKsb74I44fKf" title="Weighted Average Intrinsic Value, Exercisable end of period" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1645">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zBJeEfMU4Kvb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">At June 30, 2025, the Company
had Plan Options to purchase <span id="xdx_906_ecustom--PurchaseExercisableWarrantsOutstandingShares_iI_c20250630__us-gaap--VestingAxis__custom--PlanOptionMember_zcQ5SVLMi5Jk" title="Purchase exercisable warrants outstanding shares"><ix:nonFraction name="RENB:PurchaseExercisableWarrantsOutstandingShares" contextRef="AsOf2025-06-30_custom_PlanOptionMember" id="Fact001647" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">567,233</ix:nonFraction></span> shares of common stock that were exercisable. The total intrinsic value of options exercisable
at June 30, 2025, was zero. Intrinsic value is measured using the fair value at the date of exercise (for shares exercised) and at June
30, 2025 (for outstanding options), less the applicable exercise price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 94 -->
    <div id="xdx_231_zi6I7FU8Cji6" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div>
    <div id="xdx_23A_zFg2bpRt0mFf" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23A_zqrFthwczSC6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Common Stock Purchase Warrants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A summary of the status of the
Common Stock Purchase Warrants outstanding at June 30, 2025, is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact001650" name="RENB:ScheduleOfCommonStockPurchaseWarrantsOutstandingTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--ScheduleOfCommonStockPurchaseWarrantsOutstandingTableTextBlock_znnvu9Do9Rh7" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details 3)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center"><span id="xdx_8BA_zLcFsXMryOo1" style="display: none">Schedule of common stock purchase warrants outstanding</span></td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="15" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants Exercisable</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Weighted</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Weighted</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Weighted</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Weighted</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Average</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Average</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Number</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Contractual</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Number</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Contractual</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Exercise</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Price</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Outstanding</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Life (years)</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Price</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Exercisable</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Life (years)</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Price</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 10%; text-align: left; text-indent: -10pt"/><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_ecustom--ExercisePrices_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zErerTL2NLEd" title="Exercise Prices" style="width: 9%; text-align: right"><ix:nonFraction name="RENB:ExercisePrices" contextRef="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange1Member" id="Fact001652" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.53</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zqsTt1jq56j3" title="Number share option outstanding" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange1Member" id="Fact001654" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">471,698</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zoQoCKU7jjyb" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange1Member" format="ixt-sec:duryear" id="Fact001656" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">2.99</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zzschGzn2H2k" title="Options Exercisable" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange1Member" id="Fact001658" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">471,698</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zqa4oBkNShb7" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange1Member" format="ixt-sec:duryear" id="Fact001660" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">2.99</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"/><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"/><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_ecustom--ExercisePrices_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zogcE8auYHQ" title="Exercise Prices" style="text-align: right"><ix:nonFraction name="RENB:ExercisePrices" contextRef="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange2Member" id="Fact001662" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.65</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_z7BBCyXyUPij" title="Number share option outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange2Member" id="Fact001664" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">741,274</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zRhcrEUsTeGa" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange2Member" format="ixt-sec:duryear" id="Fact001666" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">3.09</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zVbKbyFkw2v" title="Options Exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange2Member" id="Fact001668" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">741,274</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zVZOlilTGUfk" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange2Member" format="ixt-sec:duryear" id="Fact001670" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">3.09</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"/><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"/><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_ecustom--ExercisePrices_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zh2EYdUTccQ1" title="Exercise Prices" style="text-align: right"><ix:nonFraction name="RENB:ExercisePrices" contextRef="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange3Member" id="Fact001672" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.14</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zwiNVo2M901i" title="Number share option outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange3Member" id="Fact001674" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,189,036</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zyGfDsmGybBl" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange3Member" format="ixt-sec:duryear" id="Fact001676" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">2.73</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_z2Nkcp1NNoh4" title="Options Exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange3Member" id="Fact001678" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,189,036</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_z8pAXF5C9THb" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange3Member" format="ixt-sec:duryear" id="Fact001680" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">2.73</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"/><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"/><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_ecustom--ExercisePrices_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange4Member_zLoXfHYiP6O2" title="Exercise Prices" style="text-align: right"><ix:nonFraction name="RENB:ExercisePrices" contextRef="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange4Member" id="Fact001682" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.47</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange4Member_z1PFmtDD0SB1" title="Number share option outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange4Member" id="Fact001684" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">642,128</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange4Member_zyj7XFqt9AGa" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange4Member" format="ixt-sec:duryear" id="Fact001686" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">3.96</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange4Member_zNTz6scTFOKa" title="Options Exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange4Member" id="Fact001688" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">642,128</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange4Member_z5XXprFMgA61" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange4Member" format="ixt-sec:duryear" id="Fact001690" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">3.96</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"/><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"/><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_ecustom--ExercisePrices_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange5Member_zY5K85JnGc7h" title="Exercise Prices" style="text-align: right"><ix:nonFraction name="RENB:ExercisePrices" contextRef="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange5Member" id="Fact001692" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.48</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange5Member_zq2pUtkY1pGg" title="Number share option outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange5Member" id="Fact001694" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,740</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange5Member_zNf7PImUdK4g" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange5Member" format="ixt-sec:duryear" id="Fact001696" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">3.99</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange5Member_zrmaHjTboG87" title="Options Exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange5Member" id="Fact001698" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,740</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange5Member_z2oOP9dWTSX8" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange5Member" format="ixt-sec:duryear" id="Fact001700" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">3.99</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"/><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"/><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_980_ecustom--ExercisePrice_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange6Member_zm39b6tcAYeb" title="Exercise Prices" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange6Member" id="Fact001702" name="RENB:ExercisePrice">0.50-1.68</ix:nonNumeric></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-size: 11pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 11pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 11pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; font-size: 11pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange6Member_zpSuPsupMBbl" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange6Member" id="Fact001704" format="ixt:numunitdecimalin" decimals="INF" unitRef="Shares">3,175,00</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange5Member_zI6jp7nrJhAi" title="Options Outstanding, Weighted Average Exercise Price" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange5Member" id="Fact001706" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.65</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange6Member_zg2s0pLbgVjc" title="Options Exercisable" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange6Member" id="Fact001708" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,175,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange6Member_zabxc8i6t6W3" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange6Member" format="ixt-sec:duryear" id="Fact001710" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">0.65</ix:nonNumeric></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"/><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"/><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"/><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zm4kDZ2xvYzh" title="Number share option outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-06-30_custom_CommonStockPurchaseWarrantsMember" id="Fact001712" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,269,876</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left"/><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zoSkyrPouaLl" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantsMember" format="ixt-sec:duryear" id="Fact001714" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">1.88</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_z4i7amudu6w" title="Options Outstanding, Weighted Average Exercise Price" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-06-30_custom_CommonStockPurchaseWarrantsMember" id="Fact001716" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.91</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zxYsnD7qnQFh" title="Options Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2025-06-30_custom_CommonStockPurchaseWarrantsMember" id="Fact001718" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,269,876</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left"/><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zBUsqskJmcL5" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantsMember" format="ixt-sec:duryear" id="Fact001720" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">1.88</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><p id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zOnYsPKkZJI" title="Options Exercisable, Weighted Average Exercise Price" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2025-06-30_custom_CommonStockPurchaseWarrantsMember" id="Fact001722" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.91</ix:nonFraction></p></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>



</ix:nonNumeric><p id="xdx_8AF_zUlyDqlRuEL8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A summary of the warrant activity
is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact001724" name="RENB:ScheduleOfWarrantsOutstandingTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfWarrantsOutstandingTableTextBlock_zqlAtTNSi9Zb" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details 4)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span id="xdx_8B6_z46HeFRRSjh3" style="display: none">Schedule of warrants outstanding</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">&#160;<b>Shares</b></span></td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise<br/> Price</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Remaining<br/> Life</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-indent: -10pt">Outstanding at June 30, 2024</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_ecustom--CommonStockPurchaseWarrant_iS_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zBgOqd18AEHd" title="Outstanding at beginning of period" style="width: 11%; text-align: right"><ix:nonFraction name="RENB:CommonStockPurchaseWarrant" contextRef="AsOf2024-06-30_custom_CommonStockPurchaseWarrantMember" id="Fact001726" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,094,876</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_ecustom--CommonStockPurchaseWarrantsWeightedAverageExercisePrice_iS_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zEWM0Odm6RQ5" title="Weighted average exercise price, Outstanding at beginning of period" style="width: 11%; text-align: right"><ix:nonFraction name="RENB:CommonStockPurchaseWarrantsWeightedAverageExercisePrice" contextRef="AsOf2024-06-30_custom_CommonStockPurchaseWarrantMember" id="Fact001728" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zNqfsW65LQy" title="Weighted Average remaining life, Outstanding"><ix:nonNumeric contextRef="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantMember" format="ixt-sec:duryear" id="Fact001730" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">3.48</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zXoWIGJN6QYe" title="Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantMember" id="Fact001732" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,175,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zYR1iPI6QKbi" title="Weighted average exercise price, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantMember" id="Fact001734" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.82</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zVm37PF83K2" title="Weighted Average remaining life, Granted"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantMember" format="ixt-sec:duryear" id="Fact001736" name="RENB:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2">0.65</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zT71R1ozEGnl" title="Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1738">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zPdw0hYmN7uf" title="Weighted average exercise price, Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1740">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Cancelled/Expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_d0_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zkHisiUAIiQf" title="Cancelled/Expired" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantMember" id="Fact001742" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8212;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_d0_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zIBoQIjac9n5" title="Weighted average exercise price, Expired" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantMember" id="Fact001744" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">&#8212;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Outstanding and exercisable at June 30, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_ecustom--CommonStockPurchaseWarrant_iE_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zlg69IGA1S8d" title="Outstanding at end of period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="RENB:CommonStockPurchaseWarrant" contextRef="AsOf2025-06-30_custom_CommonStockPurchaseWarrantMember" id="Fact001746" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,269,876</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_ecustom--CommonStockPurchaseWarrantsWeightedAverageExercisePrice_iE_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zN82cjnupID9" title="Weighted average exercise price, Outstanding at ending of period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="RENB:CommonStockPurchaseWarrantsWeightedAverageExercisePrice" contextRef="AsOf2025-06-30_custom_CommonStockPurchaseWarrantMember" id="Fact001748" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.91</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zUvqf2AuS4H9" title="Weighted Average remaining life, Outstanding"><ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantMember" format="ixt-sec:duryear" id="Fact001750" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">1.88</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_zBIZOmiDe8tl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">At June 30, 2025, the
Company had <span id="xdx_903_ecustom--PurchaseExercisableWarrantsOutstandingShares_iI_c20250630__us-gaap--VestingAxis__us-gaap--WarrantMember_zhi72n91c6n" title="Purchase exercisable warrants outstanding shares"><ix:nonFraction name="RENB:PurchaseExercisableWarrantsOutstandingShares" contextRef="AsOf2025-06-30_us-gaap_WarrantMember" id="Fact001752" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,269,876</ix:nonFraction></span>
exercisable Common Stock Purchase Warrants outstanding. The total intrinsic value of warrants exercisable at June 30, 2025, was <span id="xdx_900_ecustom--WarrantsExercisablePurchaseValue_iI_c20250630_zFcMrSXoXj0i" title="Warrants exercisable purchase value" style="display: none"><ix:nonFraction name="RENB:WarrantsExercisablePurchaseValue" contextRef="AsOf2025-06-30" id="Fact001754" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span>
zero. Intrinsic value is measured using the fair market value at the date of exercise (for shares exercised) and at June 30, 2025
(for outstanding warrants), less the applicable exercise price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Restricted Stock Awards (RSA)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company recognized stock-based
compensation expense related to RSAs of $<span id="xdx_908_ecustom--StockbasedCompensationExpense_iI_c20250630__us-gaap--SubsidiarySaleOfStockAxis__custom--RestrictedStockAwardsMember_zjRTC7Pp3nr4" title="Stock-based compensation expense"><ix:nonFraction name="RENB:StockbasedCompensationExpense" contextRef="AsOf2025-06-30_custom_RestrictedStockAwardsMember" id="Fact001756" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,972</ix:nonFraction></span> for the year ended June 30, 2025. The restricted stock awards are related to&#160;a grant
of<span id="xdx_906_ecustom--StockbasedCompensationExpenseGrantShares_iI_c20250630__us-gaap--SubsidiarySaleOfStockAxis__custom--RestrictedStockAwardsMember_zicIW7tePhW8" title="Stock-based compensation expense grant shares">&#160;<ix:nonFraction name="RENB:StockbasedCompensationExpenseGrantShares" contextRef="AsOf2025-06-30_custom_RestrictedStockAwardsMember" id="Fact001758" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250,000</ix:nonFraction></span>&#160;shares of restricted stock with a 5-year vesting period made to the Chief Executive Officer of Renovaro Cube with
a total value of $<span id="xdx_905_ecustom--StockbasedCompensationExpense_iI_c20250630__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zZTGFTfswg72" title="Stock-based compensation expense"><ix:nonFraction name="RENB:StockbasedCompensationExpense" contextRef="AsOf2025-06-30_srt_ChiefExecutiveOfficerMember" id="Fact001760" format="ixt:numdotdecimal" decimals="0" unitRef="USD">177,500</ix:nonFraction></span>. At June 30, 2025, the Company had $<span id="xdx_90A_ecustom--UnrecognizedStockbasedCompensationExpense_iI_c20250630__us-gaap--SubsidiarySaleOfStockAxis__custom--RestrictedStockAwardsMember_zzBeeSMoIvVf" title="Unrecognized stock-based compensation expense"><ix:nonFraction name="RENB:UnrecognizedStockbasedCompensationExpense" contextRef="AsOf2025-06-30_custom_RestrictedStockAwardsMember" id="Fact001762" format="ixt:numdotdecimal" decimals="0" unitRef="USD">140,527</ix:nonFraction></span> of unrecognized stock-based compensation expense remaining to be
amortized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company recognized stock-based
compensation expense related to RSAs of $<span id="xdx_90E_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20230701__20240630__us-gaap--SubsidiarySaleOfStockAxis__custom--RestrictedStockAwardsMember_z7SvccEoAHa7" title="Stock-based compensation expense"><ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="From2023-07-012024-06-30_custom_RestrictedStockAwardsMember" id="Fact001764" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,415,157</ix:nonFraction></span>&#160;for the year ended June 30, 2024. The restricted stock awards are related to&#160;a
grant of&#160;<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230701__20240630__us-gaap--SubsidiarySaleOfStockAxis__custom--RestrictedStockAwardsMember_zAdGzo5J0c9g" title="Stock-based compensation expense grant shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-07-012024-06-30_custom_RestrictedStockAwardsMember" id="Fact001766" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span>&#160;shares of restricted stock with a 3-year vesting period made to a former director as consideration for advisory
services, with a total value of $<span id="xdx_90A_ecustom--AdvisoryServices_iI_c20240630__us-gaap--SubsidiarySaleOfStockAxis__custom--AdvisoryServicesMember_znhvIfxxAgIc" title="Advisory services"><ix:nonFraction name="RENB:AdvisoryServices" contextRef="AsOf2024-06-30_custom_AdvisoryServicesMember" id="Fact001768" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,760,000</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 95 -->
    <div id="xdx_235_zxe0oWaTE9x3" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div>
    <div id="xdx_23D_zKWAiTiNtBv6" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_234_z1VrpL1y6zFl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact001771" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_80D_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zqjOelFGCAp6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 11 &#8212; <span id="xdx_826_zYWqMpeYjux">COMMITMENTS AND CONTINGENCIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Commitments</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On January 31, 2020, the Company
entered into a Statement of Work and License Agreement (the &#8220;HBV License Agreement&#8221;) by and among the Company, G Tech Bio,
LLC, a California limited liability company (&#8220;G Tech&#8221;), and G Health Research Foundation, a not-for-profit entity organized
under the laws of California doing business as Seraph Research Institute (&#8220;SRI&#8221;) (collectively the &#8220;Licensors&#8221;),
whereby the Company acquired a perpetual, sublicensable, exclusive license (the &#8220;HBV License&#8221;) for a treatment under development
(the &#8220;Treatment&#8221;) aimed to treat Hepatitis B Virus (HBV) infections.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The HBV License Agreement states
that in consideration for the HBV License, the Company shall provide cash funding for research costs and equipment and certain other in-kind
funding related to the Treatment over a 24-month period, and provides for an up-front payment of $<span id="xdx_90A_eus-gaap--PaymentsForFees_pn3n6_c20210130__20210131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GTechMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_z6ZAq11kOxr9" title="Payment for license"><ix:nonFraction name="us-gaap:PaymentsForFees" contextRef="From2021-01-302021-01-31_custom_GTechMember_custom_LicenseAgreementMember" id="Fact001773" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">1.2</ix:nonFraction></span> million within 7 days of January
31, 2020, along with additional payments upon the occurrence of certain benchmarks in the development of the technology set forth in the
HBV License Agreement, in each case subject to the terms of the HBV License Agreement. Additionally, the HBV License Agreement provides
for cooperation related to the development of intellectual property related to the Treatment and for a <span id="xdx_901_ecustom--RoyaltyPercentage_dp_c20200130__20200131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GTechMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zKkCk4Qnv2nc" title="Royalty percentage"><ix:nonFraction name="RENB:RoyaltyPercentage" contextRef="From2020-01-302020-01-31_custom_GTechMember_custom_LicenseAgreementMember" id="Fact001775" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">2</ix:nonFraction></span>% royalty to G Tech on any net
sales that may occur under the HBV License. On February 6, 2020, the Company paid the $<span id="xdx_907_eus-gaap--PaymentsForFees_pn5n6_c20200205__20200206__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GTechMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_ztcdTq2xUFA4" title="Payment for license"><ix:nonFraction name="us-gaap:PaymentsForFees" contextRef="From2020-02-052020-02-06_custom_GTechMember_custom_LicenseAgreementMember" id="Fact001777" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.2</ix:nonFraction></span> million up-front payment. The HBV License Agreement
contains customary representations, warranties, and covenants of the parties with respect to the development of the Treatment and the
HBV License.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The cash funding for research
costs pursuant to the HBV License Agreement consisted of monthly payments amounting to $144,500 that covered scientific staffing resources
to complete the project as well as periodic payments for materials and equipment needed to complete the project. There were no payments
made after January 31, 2022. The Company paid zero under the HBV License Agreement in years ended June 30, 2025, and 2024. The Company
has filed a claim against the Licensors, which includes certain payments it made related to this license (see Contingencies sub-section
below).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On April 18, 2021, the Company
entered into a Statement of Work and License Agreement (the &#8220;License Development Agreement&#8221;), by and among the Company, G
Tech and SRI (collectively, the &#8220;Licensors&#8221;), whereby the Company acquired a perpetual sublicensable, exclusive license (the
&#8220;Development License&#8221;) to research, develop, and commercialize certain formulations which were aimed at preventing and treating
pan-coronavirus or the potential combination of the pan-coronavirus and pan-influenza, including the SARS-coronavirus that causes COVID-19
and pan-influenza (the &#8220;Prevention and Treatment&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Development License Agreement
was entered into pursuant to the existing Framework Agreement between the parties dated November 15, 2019. The Development License Agreement
states that in consideration for the Development License, the Company shall provide cash funding for research costs and equipment and
certain other in-kind funding related to the Prevention and Treatment over a 24-month period. Additionally, the Development License Agreement
provides for an up-front payment of $<span id="xdx_908_ecustom--UpfrontPayment_c20191114__20191115_zGPdt4xSUA5g" title="Up-front payment"><ix:nonFraction name="RENB:UpfrontPayment" contextRef="From2019-11-142019-11-15" id="Fact001779" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000,000</ix:nonFraction></span> and a $<span id="xdx_908_ecustom--PaymentForExpenditures_c20191114__20191115_zxSlRWotlc3a" title="Payment for expenditures"><ix:nonFraction name="RENB:PaymentForExpenditures" contextRef="From2019-11-142019-11-15" id="Fact001781" format="ixt:numdotdecimal" decimals="0" unitRef="USD">760,000</ix:nonFraction></span> payment for expenditures to date prior to the effective date related to
research towards the Prevention and Treatment within 60 days of April 18, 2021. The Development License Agreement provides for additional
payments upon the occurrence of certain benchmarks in the development of the technology set forth in the Development License Agreement,
in each case subject to the terms of the Development License Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Development License Agreement
provides for (i) cooperation related to the development of intellectual property related to the Prevention and Treatment and (ii) a 3%
royalty to G Tech on any net sales that may occur under the Development License Agreement. The Company is no longer pursuing any product
candidates that relate to this license. The Company has filed a claim against the Licensors to recover all monies it paid related to this
license (see Contingencies below).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On August 25, 2021, the Company
entered into an ALC Patent License and Research Funding Agreement in the HIV Field (the &#8220;ALC License Agreement&#8221;) with Serhat
G&#252;mr&#252;kc&#252; and SRI (collectively, the &#8220;Licensors&#8221;) whereby the Licensors granted the Company an exclusive, worldwide,
perpetual, fully paid-up, royalty-free license, with the right to sublicense, proprietary technology subject to a U.S. patent application,
to make, use, offer to sell, sell or import products for use solely for the prevention, treatment, amelioration of or therapy exclusively
for HIV in humans, and research and development exclusively relating to HIV in humans; provided the Licensors retained the right to conduct
HIV research in the field. Pursuant to the ALC License Agreement, the Company granted a non-exclusive license back to the Licensors, under
any patents or other intellectual property owned or controlled by the Company, to the extent arising from the ALC License, to make, use,
offer to sell, sell or import products for use in the diagnosis, prevention, treatment, amelioration or therapy of any (i) HIV Comorbidities
and (ii) any other diseases or conditions outside the HIV Field. The Company made an initial payment to SRI of $<span id="xdx_902_ecustom--InitialPayment_c20220824__20220825_z6dfIkTJBa28" title="Initial payment"><ix:nonFraction name="RENB:InitialPayment" contextRef="From2022-08-242022-08-25" id="Fact001783" format="ixt:numdotdecimal" decimals="0" unitRef="USD">600,000</ix:nonFraction></span> and agreed to
fund future HIV research conducted by the Licensors, as mutually agreed to by the parties. On September 10, 2021, pursuant to the ALC
License Agreement, the Company paid the initial payment of $<span id="xdx_903_ecustom--InitialPayment_c20220909__20220910_zMG1PlJZJcxj" title="Initial payment"><ix:nonFraction name="RENB:InitialPayment" contextRef="From2022-09-092022-09-10" id="Fact001785" format="ixt:numdotdecimal" decimals="0" unitRef="USD">600,000</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 96 -->
    <div id="xdx_23B_zNl1VRK4IOLk" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div>
    <div id="xdx_231_zbJeUxlx4917" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_233_zNjt34AfYPD3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">G Tech and SRI are controlled
by Anderson Wittekind, a stockholder of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Shares held for non-consenting
shareholders</b> &#8211; The <span id="xdx_901_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20250630_z6DAam1N4LZ5" title="Remaining shares"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2025-06-30" id="Fact001788" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">17,414</ix:nonFraction></span> remaining shares of Common Stock related to the Acquisition of Renovaro Denmark have been reflected
as issued and outstanding in the accompanying financial statements.&#160;There were zero shares of Common Stock issued to such&#160;non-consenting
stockholders during the years ended June 30, 2025 and 2024 (see Note 10.)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Service Agreements</b> <i>&#8211;</i>The
Company maintains employment agreements with certain senior staff in the ordinary course of business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Contingencies</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i>Securities Class Action Litigation</i>.
On July 26, 2022 and July 28, 2022, securities class action complaints (the former, the &#8220;Chow Action&#8221; and the latter, the
Manici Action&#8221;) were filed by purported stockholders of the Company in the United States District Court for the Central District
of California against the Company and certain of the Company&#8217;s current and former officers and directors. The complaints allege,
among other things, that the defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule
10b-5 thereunder, by making false and misleading statements and omissions of material fact in connection with the Company&#8217;s relationship
with Serhat G&#252;mr&#252;kc&#252; and its commercial prospects. The complaints seek unspecified damages, interest, fees, and costs.
On November 22, 2022, the Manici Action was voluntarily dismissed without prejudice. The Chow Action (also referred to as the &#8220;Securities
Class Action Litigation&#8221;) remains pending. On October 22, 2023, the Court appointed a lead plaintiff in the Chow Action. The lead
plaintiff filed an amended complaint on December 15, 2023. The Company filed a motion to dismiss the amended complaint on March 15, 2024.
The Court denied the Company&#8217;s motion to dismiss on June 28, 2024. A mediation was held on September 17, 2024, after which the parties
signed a stipulation of settlement. The court granted the lead plaintiff&#8217;s motion for preliminary approval of the settlement on
August 18, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i>Federal Derivative Litigation</i>.
On September 22, 2022, Samuel E. Koenig filed a shareholder derivative action in the United States District Court for the Central District
of California (the &#8220;Koenig Matter&#8221;). The Koenig Matter, filed on behalf of the Company, names Serhat G&#252;mr&#252;kc&#252;
and certain of the Company&#8217;s current and former directors as defendants, and also names the Company as a nominal defendant. The
Koenig Matter alleges violations of Sections 14(a) and 20(a) of the Securities Exchange Act of 1934, and also sets out claims for breach
of fiduciary duty, contribution and indemnification, aiding and abetting, and gross mismanagement. Plaintiff does not quantify any alleged
injury, but seeks damages, disgorgement, restitution, and other costs and expenses. On January 24, 2023, the United States District Court
for the Central District of California stayed the Koenig Matter pending resolution of the defendants&#8217; anticipated motion to dismiss
in the Securities Class Action Litigation. On June 28, 2024, the United States District Court for the Central District of California denied
defendants&#8217; motion to dismiss the Securities Class Action Litigation. On July 14, 2025, the Court stayed the Koenig Matter until
October 17, 2025. The defendants have not yet responded to the complaint.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On January 19, 2023, John Solak
filed a shareholder derivative action in the United States District Court for the District of Delaware (the &#8220;Solak Matter&#8221;).
The Solak Matter, filed on behalf of the Company, names Serhat G&#252;mr&#252;kc&#252; and certain of the Company&#8217;s current and
former directors as defendants, and also names the Company as a nominal defendant. The Solak Matter alleges violations of Section 14(a)
of the Securities Exchange Act of 1934 and SEC Rule 14a-9 promulgated thereunder, and also sets out claims for breach of fiduciary duty
and contribution and indemnification. Plaintiff does not quantify any alleged injury, but seeks damages, disgorgement, restitution, and
other costs and expenses. On April 6, 2023, the United States District Court for the District of Delaware stayed the Solak Matter pending
resolution of the defendants&#8217; anticipated motion to dismiss in the Securities Class Action Litigation. On June 28, 2024, the United
States District Court for the Central District of California denied defendants&#8217; motion to dismiss the Securities Class Action Litigation.
On July 29, 2025, the court stayed the Solak Matter for 90 days. The defendants have not yet responded to the complaint.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company intends to contest
these matters but expresses no opinion as to the likelihood of favorable outcomes. Management is unable to determine the likelihood of
a loss, including a possible range of losses, if any, arising from this matter as of the reporting date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 97 -->
    <div id="xdx_231_zc5yMpqqX8Jg" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div>
    <div id="xdx_23E_zJNYLujI6Rh3" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23D_zWoOrArlumU6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i>State Derivative Litigation</i>.
On October 20, 2022, Susan Midler filed a shareholder derivative action in the Superior Court of California, Los Angeles County (the &#8220;Midler
Matter&#8221;). The Midler Matter, filed on behalf of the Company, names Serhat G&#252;mr&#252;kc&#252; and certain of the Company&#8217;s
current and former directors as defendants. The Midler Matter also names the Company as a nominal defendant. The Midler Matter sets out
claims for breaches of fiduciary duty, contribution and indemnification, aiding and abetting, and gross mismanagement. Plaintiff does
not quantify any alleged injury, but seeks damages, disgorgement, restitution, and other costs and expenses. On January 20, 2023, the
Court stayed the Midler Matter pending resolution of the defendants&#8217; anticipated motion to dismiss in the Securities Class Action
Litigation. On June 28, 2024, the United States District Court for the Central District of California denied defendants&#8217; motion
to dismiss the Securities Class Action Litigation. On July 31, 2025, the court stayed the Midler Matter for 120 days. The defendants have
not yet responded to the complaint. The Company intends to contest this matter but expresses no opinion as to the likelihood of a favorable
outcome. Management is unable to determine the likelihood of a loss, including a possible range of losses, if any, arising from this matter
as of the reporting date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On October
21, 2022, the Company filed a Complaint in the Superior Court of the State of California for the County of Los Angeles against Serhat
G&#252;mr&#252;kc&#252; (&#8220;Gumrukcu&#8221;), William Anderson Wittekind (&#8220;Wittekind&#8221;), G Tech Bio, SG &amp; AW Holdings,
LLC, and SRI (collectively, the &#8220;Defendants&#8221;). The Complaint alleges that the Defendants engaged in a &#8220;concerted, deliberate
scheme to alter, falsify, and misrepresent to the Company the results of multiple studies supporting its Hepatitis B and SARS-CoV-2/influenza
pipelines.&#8221; Specifically, &#8220;Defendants manipulated negative results to reflect positive outcomes from various studies, and
even fabricated studies out of whole cloth.&#8221; As a result of the Defendants&#8217; conduct, the Company claims that it &#8220;paid
approximately $25 million to Defendants and third-parties that it would not otherwise have paid.&#8221; On April 21, 2023, defendants
Wittekind, G Tech, SG &amp; AW Holdings, LLC, and SRI filed a demurrer with respect to some, but not all, of the Company&#8217;s claims,
as well as a motion to strike. On September 6, 2023, the court denied in part and granted in part the pending motions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On December
4, 2023, the Defendants answered the Company&#8217;s First Amended Complaint and G Tech and SRI filed a Cross-Complaint. In the Cross-Complaint,
G Tech and SRI seek declaratory and injunctive relief related to certain agreements between G Tech, SRI, and the Company, including, <i>inter
alia</i>, a declaration that the Framework Agreement, effective as of November 15, 2019, the Statement of Work &amp; License Agreement,
effective as of January 31, 2020, and the Statement of Work and License Agreement for Influenza and Coronavirus Indications, effective
as of April 18, 2021, have been terminated and the Company has no rights to any license under such agreements. Trial was scheduled to
begin on March 3, 2025. On November 14, 2024, the court vacated the March 3, 2025, trial date and set a trial setting conference for May
1, 2025. At the May 1, 2025, trial setting conference, the court reset the trial to begin on November 30, 2026. Discovery remains ongoing.
The Company denies the allegations in Defendants&#8217; cross claims and intends to vigorously defend against them while pursuing its
claims against the Defendants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On June
7, 2023, Weird Science LLC (&#8220;Weird Science&#8221;), Wittekind, the William Anderson Wittekind 2020 Annuity Trust, the William Anderson
Wittekind 2021 Annuity Trust, the Dybul 2020 Angel Annuity Trust, and the Ty Mabry 2021 Annuity Trust (collectively, the &#8220;Trusts&#8221;)
(collectively, &#8220;Plaintiffs&#8221;) filed a Verified Complaint against the Company in the Court of Chancery of Delaware. In the Verified
Complaint, Plaintiffs alleged that the Company breached the February 16, 2018 Investor Rights Agreement between the Company, Weird Science,
and RS Group ApS (the &#8220;Investor Rights Agreement&#8221;). According to the Verified Complaint, the Investor Rights Agreement required
the Company to (i) notify all &#8220;Holders&#8221; of &#8220;Registrable Securities&#8221; at least 30 days prior to filing a registration
statement and (ii) afford such Holders an opportunity to have their Registrable Securities included in such registration statement. Plaintiffs
alleged that the Company breached these registration rights by failing to provide the required notice in connection with S-3 registration
statements filed by the Company on July 13, 2020 and February 11, 2022. The Company moved to dismiss the Verified Complaint on September
15, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On December
4, 2023, in lieu of opposing the motion to dismiss, Plaintiffs filed a Verified First Amended Complaint (&#8220;FAC&#8221;). In the FAC,
Plaintiffs assert claims against the Company and others for purported breaches of the Investor Rights Agreement, fraud, tortious interference
with a contract, and several other torts. Plaintiffs seek compensatory, exemplary, and punitive damages, as well as certain declaratory
relief, specific performance, and pre- and post-judgment interest, costs, and attorneys&#8217; fees. The Company filed a motion to dismiss
the FAC on December 18, 2023 and the court held a hearing on November 15, 2024. At the hearing, the court dismissed (1) all claims brought
on behalf of Wittekind and the Trusts, (2) the fraudulent concealment claim against the Company and others (without prejudice), and (3)
the breach of contract claim against the Company related to a registration statement that was not filed in 2023. At the hearing, the court
also found that punitive damages were not available to Plaintiffs. The court took the remaining issues briefed on the Company&#8217;s
motion to dismiss under advisement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"></p>

<ix:exclude><!-- Field: Page; Sequence: 98 -->
    <div id="xdx_238_zUoHjltvsgWf" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div>
    <div id="xdx_233_znaMgUhtja21" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_235_zENd2SWDxDV7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On February
26, 2025, the Court ruled on the balance of the claims against the Company and (1) denied the Company&#8217;s motion to dismiss Weird
Science&#8217;s breach of contract claims related to registration statements filed in 2020 and 2022; (2) dismissed the fraudulent inducement
claim as time barred; and (3) dismissed the declaratory judgment claim. The Company denies Plaintiffs&#8217; allegations and remaining
claims and intends to vigorously defend against these claims.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On August
24, 2023, counsel on behalf of Weird Science, Wittekind, individually, and Wittekind, as trustee of the Trusts served a demand to inspect
the Company&#8217;s books and records (the &#8220;Demand&#8221;) pursuant to Delaware General Corporation Law, &#167; 220 (&#8220;Section
220&#8221;). The Demand seeks the Company&#8217;s books and records in connection with various issues identified in the Demand. The Company
takes its obligations under Section 220 seriously and, to the extent that the requests are proper under Section 220, intends to comply
with those obligations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On January 19, 2024, Weird Science
and Wittekind sent the Board of Directors a letter demanding it take corrective actions with respect to twenty-one issues identified therein.
On February 27, 2024, Weird Science and Wittekind sent the Board of Directors a supplemental letter that expanded their demand for corrective
actions to twenty-six issues. In response to these demand letters, the Board of Directors initially formed a Special Committee (&#8220;Special
Committee&#8221;) of independent directors on February 29, 2024. The Special Committee retained Stradling Yocca Carlson &amp; Rauth LLP
as its counsel to investigate the issues identified in the demand letters.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On January 23, 2024, Weird Science
and Wittekind filed a shareholder derivative action in the United States District Court for the Central District of California against
certain officers, directors, and investors of the Company, as well as other defendants, in connection with, <i>inter alia</i>, Weird Science
and Wittekind&#8217;s demand for corrective action. Plaintiffs filed an amended complaint on June 21, 2024. The First Amended Verified
Stockholder Derivative Complaint (&#8220;Derivative Complaint&#8221;) alleges, among other claims, violations of Section 13(d) and 14(a)
and Rules 10b-5(a), 10b-5(c) and 14a-9 of the Exchange Act of 1934. The Derivative Complaint also includes claims of breach of fiduciary
duty, corporate waste, unjust enrichment, and contribution/indemnification. Weird Science and Wittekind seek unspecified compensatory,
exemplary, and punitive damages and certain injunctive relief. The Derivative Complaint names the Company as a nominal defendant. On July
19, 2024, certain of the director defendants, who had agreed to waive service of the summons and Derivative Complaint, filed a motion
to dismiss the Derivative Complaint on a variety of procedural and substantive grounds. A hearing on the motion dismiss was held on October
3, 2024 and the court subsequently took the motion under submission. On October 22, 2024, the plaintiffs filed a notice of certain subsequent
events that they allege relate to their pending motion to dismiss. On October 29, 2024, the court granted the director defendants&#8217;
motion to dismiss and dismissed the Derivative Complaint without prejudice, but also without leave to amend.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On November 27, 2024, Weird Science
and Wittekind filed a notice of appeal of the court&#8217;s decision granting the director defendants&#8217; motion to dismiss. The appeal
remains pending.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On June 21, 2024, the Company
filed suit against Weird Science, Gumrukcu, Wittekind, and certain trusts in connection with the February 16, 2018 merger involving the
Company and two companies closely associated with Gumrukcu. In the complaint, the Company alleges that G&#252;mr&#252;kc&#252;and others
deliberately and fraudulently concealed a murder-for-hire scheme from the Company in order to induce the Company to enter into the merger
agreement, which resulted in the defendants receiving shares and compensation. The Company asserts claims for fraudulent concealment,
equitable fraud, unjust enrichment, and civil conspiracy and seeks, <i>inter alia</i>, equitable relief, including, but not limited to,
return to the Company any shares received in connection with the merger, and damages. On October 1, 2024, the defendants moved to dismiss
the complaint. A hearing took place on June 25, 2025 and the Court took defendants&#8217; motion under advisement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Lunai commenced an action against
Predictive Oncology, Inc. (&#8220;POAI&#8221;) in the Delaware Court of Chancery claiming that POAI breached a &#8220;definitive&#8221;
January 2025 Letter Agreement pursuant to which Lunai was going to acquire POAI. As a result of its breach, POAI made that acquisition
impossible and dramatically devalued the share price of stock Lunai had already acquired as well as the value of the company it was contractually
entitled to acquire. Lunai sought specific performance or, in the alternative, money damages. The parties have exchanged paper discovery
and noticed depositions. The action has been held in abeyance while the parties attempt to negotiate a settlement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact001792" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_802_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zntZKDnOBTzg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 12 &#8212; <span id="xdx_823_zNGLGMjaoHqd">RELATED PARTY TRANSACTIONS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of June 30, 2025, the Company
has accrued $<span id="xdx_90F_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20240701__20250630__us-gaap--RelatedPartyTransactionAxis__custom--MarkDybulMember_zO0CghFWmOp8" title="Accrued balance"><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2024-07-012025-06-30_custom_MarkDybulMember" id="Fact001794" format="ixt:numdotdecimal" decimals="0" unitRef="USD">384,949</ix:nonFraction></span> of compensation related expenses for the Company&#8217;s former Chief Executive Officer, Mark Dybul, related to budget
constraints.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 99 -->
    <div id="xdx_238_zqbtiiUr4gZ4" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div>
    <div id="xdx_23C_zXeeQ3e0avS7" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23F_zgWXTtdoLqmi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On August 23, 2024, Avram Miller,
a former member of the Company&#8217;s board of directors (the &#8220;Board of Directors&#8221;), forfeited&#160;<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_c20240802__20240823_zc9KYGpvYfN1" title="Common stock forfeited shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" contextRef="From2024-08-022024-08-23" id="Fact001797" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">833,333</ix:nonFraction></span>&#160;shares of
Common Stock from the original&#160;<span id="xdx_90D_ecustom--SharesOfCommonStockGranted_iI_c20240823_zVhLqixksHz7" title="Shares of common stock  granted"><ix:nonFraction name="RENB:SharesOfCommonStockGranted" contextRef="AsOf2024-08-23" id="Fact001799" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span>&#160;shares of Common Stock for advisory services originally granted to him on October 11,
2023. As consideration for such forfeiture, the Company granted to Mr. Miller, an option to purchase&#160;<span id="xdx_900_eus-gaap--StockRepurchasedDuringPeriodShares_c20240822__20250823_zNp1pogyFMKc" title="Purchase shares"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="From2024-08-222025-08-23" id="Fact001801" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">978,261</ix:nonFraction></span>&#160;shares of Common
Stock of the Company with a per-share exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250216__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zEAowP0qjJTj" title="Warrant exercise price per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-02-16_custom_RSBioMember" id="Fact001803" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.69</ix:nonFraction></span>. The Company determined that this transaction represented a modification
of the original award. The Company measured the fair value of the options issued as compared to the fair value of the original issuance
and determined that there was no incremental compensation to recognize as the fair value of the options was less than the fair value of
the Common Stock. Therefore, the Company will recognize the remaining fair value of the original award over the remaining vesting period,
which is one year. The Company recognized stock-based compensation expense of $<span id="xdx_901_eus-gaap--ProceedsFromStockOptionsExercised_c20240701__20250630_zcZfzMMTIiaj" title="Stock-based compensation expense stock option vesting"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2024-07-01to2025-06-30" id="Fact001805" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,159,470</ix:nonFraction></span>&#160;related to the vesting of the stocks options
during the year ended June 30, 2025. At June 30, 2025, the Company had $<span id="xdx_907_ecustom--UnrecognizedCompensationExpense_c20240701__20250630_zQgDmpzUZP5b" title="Unrecognized compensation expense"><ix:nonFraction name="RENB:UnrecognizedCompensationExpense" contextRef="From2024-07-01to2025-06-30" id="Fact001807" format="ixt:numdotdecimal" decimals="0" unitRef="USD">185,373</ix:nonFraction></span>&#160;of unrecognized compensation cost related to the
options which vest at August 23, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact001809" name="us-gaap:BusinessCombinationDisclosureTextBlock"><p id="xdx_80C_eus-gaap--BusinessCombinationDisclosureTextBlock_zUSNEpfwWoca" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 13 &#8212; <span id="xdx_824_zKidpMCOiJpg">ACQUISITIONS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><i><span style="text-decoration: underline">BioSymetrics Inc. Acquisition:</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">On February 26, 2025, Lunai Bioworks Inc., a Delaware
corporation (&#8220;<span style="text-decoration: underline">Lunai</span>&#8221;), entered into an Agreement and Plan of Merger (the &#8220;<span style="text-decoration: underline">Merger Agreement</span>&#8221;) with
Renovaro Acquisition Sub, a Delaware corporation and wholly owned subsidiary of Lunai (&#8220;<span style="text-decoration: underline">Merger Sub</span>&#8221;), and Biosymetrics,
Inc., a Delaware corporation (&#8220;<span style="text-decoration: underline">Biosymetrics</span>&#8221;), pursuant to which Lunai agreed to acquire Biosymetrics pursuant to the
merger of Merger Sub with and into Biosymetrics, with Biosymetrics as the surviving corporation and a wholly owned subsidiary of Lunai
(the &#8220;<span style="text-decoration: underline">Transaction</span>&#8221;). On April 8, 2025, Lunai consummated the Transaction and issued <span id="xdx_90A_ecustom--TransactionIssuedShares_iI_pn3n3_dm_c20250408_z14JRduEqDef" title="Transaction issued shares"><ix:nonFraction name="RENB:TransactionIssuedShares" contextRef="AsOf2025-04-08" id="Fact001811" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="Shares">15.0</ix:nonFraction></span> million shares of Lunai&#8217;s
common stock, par value $<span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20250408_z59MeWvqqdc7" title="Common stock per value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-04-08" id="Fact001813" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per share (the &#8220;<span style="text-decoration: underline">Shares</span>&#8221;), to the former stockholders of Biosymetrics in accordance
with the terms of the Merger Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The
offer and sale of the Shares have not been registered under the Securities Act of 1933, as amended (the &#8220;<span style="text-decoration: underline">Securities Act</span>&#8221;),
in reliance on the exemption from registration requirements thereunder provided by Section 4(a)(2) thereof. Lunai relied in part upon
representations contained in the Merger Agreement that all those receiving Shares in connection with the Transaction are &#8220;accredited
investors&#8221; as defined in Rule 501(a) under the Securities Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">The
transaction was accounted for in accordance with ASC 805-10 -&#160;<i>Business Combinations</i>. </span>The assets acquired and liabilities
assumed are initially recognized in the accompanying consolidated balance sheets at their estimated fair values as of the acquisition
date. The fair values as of the acquisition date are based on information that existed as of the acquisition date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The acquisition-date
fair value of the consideration transferred totaled approximately $<span id="xdx_900_eus-gaap--BusinessCombinationConsiderationTransferredOther1_pn5n6_c20240701__20250630__us-gaap--BusinessAcquisitionAxis__custom--BioSymetricsMember_zxPFPfGodem2" title="Fair value of consideration transferred amount"><ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferredOther1" contextRef="From2024-07-012025-06-30_custom_BioSymetricsMember" id="Fact001815" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">6</ix:nonFraction></span> million, which consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_BioSymetricsncAcquisitionMember" escape="true" id="Fact001817" name="RENB:ScheduleOfAcquistionFairValueOfConsiderationTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89A_ecustom--ScheduleOfAcquistionFairValueOfConsiderationTableTextBlock_hsrt--CounterpartyNameAxis__custom--BioSymetricsncAcquisitionMember_zAl9SmiIjYt3" summary="xdx: Disclosure - ACQUISITION (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B0_zAaE5SSH5Q6b" style="display: none">Schedule of acquisition
date fair value</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-align: left; text-indent: -10pt">Common stock</td><td style="width: 10%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--BusinessCombinationContingentConsiderationCommonStock_iI_c20250226__us-gaap--BusinessAcquisitionAxis__custom--BioSymetricsncAcquisitionMember_zwtePe5aQoNe" title="Common stock" style="border-bottom: Black 1pt solid; width: 18%; text-align: right"><ix:nonFraction name="RENB:BusinessCombinationContingentConsiderationCommonStock" contextRef="AsOf2025-02-26_custom_BioSymetricsncAcquisitionMember" id="Fact001819" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,058,500</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total consideration transferred</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--BusinessCombinationConsiderationTransferred1_c20250212__20250226__us-gaap--BusinessAcquisitionAxis__custom--BioSymetricsncAcquisitionMember_zhrSYeUXaz88" title="Total consideration transferred" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="From2025-02-122025-02-26_custom_BioSymetricsncAcquisitionMember" id="Fact001821" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,058,500</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_zSkxWy4Nvem2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">The
fair value of the Company&#8217;s common shares issued as consideration was based on the closing price of the Company&#8217;s common stock
as of the Acquisition Date. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">The
following table details the fair values of the assets acquired and liabilities assumed at the acquisition date:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_BioSymetricsncAcquisitionMember" escape="true" id="Fact001823" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_hsrt--CounterpartyNameAxis__custom--BioSymetricsncAcquisitionMember_zPoXSZHQBGMg" summary="xdx: Disclosure - ACQUISITION (Details 1)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8BA_z32iterXKz8f" style="display: none">Schedule of fair value of assets acquired and
liabilities assumed</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49B_20250226__us-gaap--BusinessAcquisitionAxis__custom--BioSymetricsncAcquisitionMember_z2TTACyafD7f" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iNI_di_zoDfgVvesNhc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-indent: -10pt">Cash</td><td style="width: 10%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">(<ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" contextRef="AsOf2025-02-26_custom_BioSymetricsncAcquisitionMember" id="Fact001825" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,822</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_iI_zGuAiTHzuQO4" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Prepaid &amp; Other Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" contextRef="AsOf2025-02-26_custom_BioSymetricsncAcquisitionMember" id="Fact001827" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,405</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets_iI_zEIivZWq8YOd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Fixed Assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="RENB:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets" contextRef="AsOf2025-02-26_custom_BioSymetricsncAcquisitionMember" id="Fact001829" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,365</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_iI_zIu0KyNSDl4a" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total Assets Acquired:</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" contextRef="AsOf2025-02-26_custom_BioSymetricsncAcquisitionMember" id="Fact001831" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,948</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_iI_zUlScKTen1dk" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Accounts Payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" contextRef="AsOf2025-02-26_custom_BioSymetricsncAcquisitionMember" id="Fact001833" format="ixt:numdotdecimal" decimals="0" unitRef="USD">975</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_iI_zlFuO4SDEVje" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Accrued Expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="RENB:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" contextRef="AsOf2025-02-26_custom_BioSymetricsncAcquisitionMember" id="Fact001835" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,594</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities_iI_zEuGctgBrD98" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Other Current Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="RENB:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities" contextRef="AsOf2025-02-26_custom_BioSymetricsncAcquisitionMember" id="Fact001837" format="ixt:numdotdecimal" decimals="0" unitRef="USD">73,879</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_iI_zbHlNEqiQkeb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total Liabilities Assumed</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" contextRef="AsOf2025-02-26_custom_BioSymetricsncAcquisitionMember" id="Fact001839" format="ixt:numdotdecimal" decimals="0" unitRef="USD">82,448</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_zJ9gkdRrmkS8" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net Assets Acquired</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" contextRef="AsOf2025-02-26_custom_BioSymetricsncAcquisitionMember" id="Fact001841" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">55,500</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_404_ecustom--Software_iI_zYuBoHYY5pJd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Software</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="RENB:Software" contextRef="AsOf2025-02-26_custom_BioSymetricsncAcquisitionMember" id="Fact001843" format="ixt:numdotdecimal" decimals="0" unitRef="USD">143,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--TradeName_iI_zbjIakIOHa1a" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Trade Name</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="RENB:TradeName" contextRef="AsOf2025-02-26_custom_BioSymetricsncAcquisitionMember" id="Fact001845" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_iI_z0JeEKq8Wzb7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Goodwill</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" contextRef="AsOf2025-02-26_custom_BioSymetricsncAcquisitionMember" id="Fact001847" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,963,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_iI_zr73hkD7clp9" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total Consideration</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" contextRef="AsOf2025-02-26_custom_BioSymetricsncAcquisitionMember" id="Fact001849" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,058,500</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zVppS1OX6XYf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"></p>

<ix:exclude><!-- Field: Page; Sequence: 100 -->
    <div id="xdx_23A_zXzfPtssZnRe" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div>
    <div id="xdx_237_zZFxGTr0ygi7" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23B_zbbMuUvJHBpf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
goodwill recognized is attributable primarily to expected synergies and the assembled workforce of BioSymetrics. None of the
goodwill is expected to be deductible for income tax purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The fair
values of the acquired tangible and intangible assets were determined using variations of the income approach. The income approach valuation
methodology used for the intangible assets acquired makes use of Level 3 inputs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Consolidated unaudited pro forma information: </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following consolidated pro
forma information assumes that the acquisition of BioSymetrics Inc. took place on July 1, 2024 for the statement of operations for the
twelve-month period ended June 30, 2025. These amounts have been estimated after applying the Company&#8217;s accounting policies:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--ScheduleOfConsolidatedStatementsOfOperationsTableTextBlock_hsrt--CounterpartyNameAxis__custom--BioSymetricsncAcquisitionMember_znkTNcWBnRG" summary="xdx: Disclosure - ACQUISITION (Details 2)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B1_ziqFm9TRWEY2" style="display: none">Schedule of consolidated
statements of operations</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_493_20240701__20250630__us-gaap--BusinessAcquisitionAxis__custom--BioSymetricsncAcquisitionMember_zFVaF7KKfc59" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_ecustom--BusinessAcquisitionsRevenue_d0_zOZF3Ef0iEd9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-indent: -10pt">Revenues</td><td style="width: 10%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 18%; text-align: right"><ix:nonFraction name="RENB:BusinessAcquisitionsRevenue" contextRef="From2024-07-012025-06-30_custom_BioSymetricsncAcquisitionMember1126504281" id="Fact001854" format="ixt:numdotdecimal" decimals="0" unitRef="USD">663,660</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--BusinessAcquisitionsNetIncomeLoss_zf5Rj2q3Pt01" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="RENB:BusinessAcquisitionsNetIncomeLoss" contextRef="From2024-07-012025-06-30_custom_BioSymetricsncAcquisitionMember1126504281" id="Fact001856" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">179,698,700</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  </table>

<p id="xdx_8A8_z89EKECiWZH6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The unaudited pro forma results
are presented for informational purposes only and are not necessarily indicative of what the actual results of operations would have been
if the acquisition had occurred at the beginning of the period presented, nor are they indicative of future results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><i><span style="text-decoration: underline">GEDi Cube Intl Ltd. Acquisition:</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On September
28, 2023, the Company, entered into a Stock Purchase Agreement (the &#8220;<span style="text-decoration: underline">Purchase Agreement</span>&#8221;) with GEDi Cube Intl Ltd.,
a private company formed under the laws of England and Wales (&#8220;<span style="text-decoration: underline">GEDi Cube</span>&#8221;) to acquire 100% of the equity interests
of GEDi Cube from its equity holders (the &#8220;<span style="text-decoration: underline">Sellers</span>&#8221;). On September 28, 2023, the Board of Directors of the Company,
and the board of managers of GEDi Cube unanimously approved the Purchase Agreement and on January 25, 2024, the shareholders of the Company
approved the issuance of the shares of Common Stock pursuant to the Purchase Agreement. On February 13, 2024 (the &#8220;Closing Date&#8221;),
the Company consummated the acquisition of GEDi Cube and the other transactions contemplated by the Stock Purchase Agreement (collectively,
the &#8220;Transaction&#8221;). As a result of the Transaction, GEDi Cube became a wholly-owned subsidiary of the Company. The Company
believes the acquisition will provide it with access to the nascent field of artificial intelligence and machine learning driven diagnostics,
which was the primary purpose for the acquisition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Pursuant
to the Stock Purchase Agreement, as of the Closing Date, the Company acquired all the issued and outstanding equity interests of GEDi
Cube owned by the Sellers as of the Closing Date (each, a &#8220;GEDi Cube Share&#8221; and, collectively, the &#8220;GEDi Cube Shares&#8221;)
in exchange for which each Seller was entitled to receive (i) as of the Closing Date, such Seller&#8217;s pro rata percentage of an aggregate
of 70,834,183 shares of common stock, par value $0.0001 per share, of the Company (&#8220;Common Stock&#8221;), which represents the 67,224,089
shares of Common Stock issued and outstanding as of the Closing Date (minus (a) 1 million shares of Common Stock previously issued to
a consultant assisting with the Transaction and (b) 1 million shares of Common Stock previously issued to Avram Miller, a director of
the Company, pursuant to his Advisory Agreement, dated October 11, 2023, by and between Mr. Miller and the Company) (the &#8220;Closing
Consideration&#8221;) plus 5,610,100 shares of Common Stock representing the Seller&#8217;s Earnout Shares (defined below) resulting from
the automatic conversion of the Company&#8217;s Series A Convertible Preferred and, (ii) following the Closing Date, such Seller&#8217;s
pro rata percentage of the shares of Common Stock (the &#8220;Earnout Shares&#8221; and, together with the Closing Consideration, the
&#8220;Exchange Consideration&#8221;) to be issued to the Sellers upon the exercise or conversion of any of the Company&#8217;s derivative
securities (subject to certain exceptions) that are outstanding at the Closing Date (the &#8220;Closing Derivative Securities&#8221;).
Each Seller&#8217;s pro rata percentage of the Exchange Consideration is equal to the ratio of the aggregate number of GEDi Cube Shares
owned by such Seller divided by the aggregate number of GEDi Cube Shares issued and outstanding, in each case, as of the Closing Date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">The
transaction was accounted for in accordance with the provisions of ASC 805-10 -&#160;<i>Business Combinations</i>. </span>As a result
of the issuance of the Closing Consideration on the Closing Date and based on the number of shares of Common Stock outstanding as of the
Closing Date, the Sellers held approximately 49% of the issued and outstanding shares of Common Stock immediately following the closing
of the Transaction and the conversion of the Series A Convertible Preferred Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"></p>

<ix:exclude><!-- Field: Page; Sequence: 101 -->
    <div id="xdx_237_zNm2Pku13aW4" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div>
    <div id="xdx_233_zeDRPbQEtzLe" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_233_zqPqkWlWR5M" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The assets
acquired and liabilities assumed were initially recognized provisionally in the accompanying consolidated balance sheets at their estimated
fair values as of the acquisition date. The fair values as of the acquisition date are based on information that existed as of the acquisition
date. The Company completed its accounting for this acquisition during the period ended June 30, 2024. As a result of the completion of
the Company&#8217;s analysis, the amount of in-process research and development was determined to have a value of nil. Accordingly, the
amount of goodwill recognized was increased to include the previously recognized amount of in-process research and development. There
was no impact to the Company&#8217;s consolidated statement of operations as a result of this change to the allocation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The acquisition-date
fair value of the consideration transferred totaled approximately $<span id="xdx_90C_eus-gaap--BusinessCombinationConsiderationTransferredOther1_pn5n6_c20240701__20250603__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zx20bFH8Rutf" title="Fair value of consideration transferred amount"><ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferredOther1" contextRef="From2024-07-012025-06-03_custom_GEDiCubeMember" id="Fact001859" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">156.6</ix:nonFraction></span> million, which consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<ix:nonNumeric contextRef="From2024-07-012025-06-30_custom_GEDiCubeIntlLtdAcquisitionMember" escape="true" id="Fact001861" name="RENB:ScheduleOfAcquistionFairValueOfConsiderationTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfAcquistionFairValueOfConsiderationTableTextBlock_hsrt--CounterpartyNameAxis__custom--GEDiCubeIntlLtdAcquisitionMember_zbLc9sRUqKSk" summary="xdx: Disclosure - ACQUISITION (Details 5)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B6_zEeSLO08dL32" style="display: none">Schedule of acquisition
date fair value</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-align: left; text-indent: -10pt">Common stock</td><td style="width: 10%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_ecustom--BusinessCombinationContingentConsiderationCommonStock_iI_c20250226__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zaxIB00nYcQb" title="Common stock" style="width: 18%; text-align: right"><ix:nonFraction name="RENB:BusinessCombinationContingentConsiderationCommonStock" contextRef="AsOf2025-02-26_custom_GEDiCubeMember" id="Fact001863" format="ixt:numdotdecimal" decimals="0" unitRef="USD">136,001,631</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Contingent consideration</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--BusinessCombinationContingentConsiderationAsset_iI_c20250226__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zriLj2VJ8p0i" title="Contingent consideration" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationAsset" contextRef="AsOf2025-02-26_custom_GEDiCubeMember" id="Fact001865" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,557,500</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total consideration transferred</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--BusinessCombinationConsiderationTransferred1_c20250212__20250226__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zP2MJDibj9K8" title="Total consideration transferred" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="From2025-02-122025-02-26_custom_GEDiCubeMember" id="Fact001867" format="ixt:numdotdecimal" decimals="0" unitRef="USD">156,559,131</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_zKBo6QVtLnP6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">The
fair value of the Company&#8217;s common shares issued as consideration was based on the closing price of the Company&#8217;s common stock
as of the Acquisition Date. The fair value of the contingent consideration was based on the Sellers&#8217; right to receive additional
shares of common, pro rata, upon the exercise or conversion of warrants, options and convertible notes payables outstanding as of the
Closing Date. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">The
following table details the fair values of the assets acquired and liabilities assumed at the acquisition date:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact001869" name="RENB:ScheduleOfRecognizedIdentifiedAssetsAndLiabilitiesAssumedTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_898_ecustom--ScheduleOfRecognizedIdentifiedAssetsAndLiabilitiesAssumedTableTextBlock_zVmaEFICs4S2" summary="xdx: Disclosure - ACQUISITION (Details 4)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B0_znxHeYyjvRB2" style="display: none">Schedule of fair value of assets acquired and
liabilities assumed</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49F_20250226__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zQph1CtNtkS6" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_z6tSoIkmltI3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-indent: -10pt">Cash</td><td style="width: 10%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" contextRef="AsOf2025-02-26_custom_GEDiCubeMember" id="Fact001871" format="ixt:numdotdecimal" decimals="0" unitRef="USD">65,851</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_iI_zGDtqFoBR44b" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Prepaid &amp; Other Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" contextRef="AsOf2025-02-26_custom_GEDiCubeMember" id="Fact001873" format="ixt:numdotdecimal" decimals="0" unitRef="USD">151,544</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets_iI_zkTa9G4qylS3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Fixed Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="RENB:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets" contextRef="AsOf2025-02-26_custom_GEDiCubeMember" id="Fact001875" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,243</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseRightOfUseAssets_iI_zLa2H5VBx0Pk" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Operating lease ROU</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="RENB:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseRightOfUseAssets" contextRef="AsOf2025-02-26_custom_GEDiCubeMember" id="Fact001877" format="ixt:numdotdecimal" decimals="0" unitRef="USD">624,366</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_iI_ziRcp96fGfof" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total Assets Acquired:</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" contextRef="AsOf2025-02-26_custom_GEDiCubeMember" id="Fact001879" format="ixt:numdotdecimal" decimals="0" unitRef="USD">858,004</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_iI_zfWvrHdXf6M1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Accounts Payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" contextRef="AsOf2025-02-26_custom_GEDiCubeMember" id="Fact001881" format="ixt:numdotdecimal" decimals="0" unitRef="USD">583,577</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_iI_zIYxlh3dLwCd" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Accrued Expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="RENB:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" contextRef="AsOf2025-02-26_custom_GEDiCubeMember" id="Fact001883" format="ixt:numdotdecimal" decimals="0" unitRef="USD">722,508</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities_iI_zUFJjLa0R0T8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Operating Lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="RENB:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities" contextRef="AsOf2025-02-26_custom_GEDiCubeMember" id="Fact001885" format="ixt:numdotdecimal" decimals="0" unitRef="USD">624,367</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable_iI_zQmWfInPkEQj" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Notes Payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="RENB:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable" contextRef="AsOf2025-02-26_custom_GEDiCubeMember" id="Fact001887" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,832,460</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_iI_zKqbaXpnCKcc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total Liabilities Assumed</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" contextRef="AsOf2025-02-26_custom_GEDiCubeMember" id="Fact001889" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,762,913</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_zCEVoVBIByZi" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net Assets Acquired</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" contextRef="AsOf2025-02-26_custom_GEDiCubeMember" id="Fact001891" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,904,909</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_iI_zM2LzSTjVeUb" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Goodwill</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" contextRef="AsOf2025-02-26_custom_GEDiCubeMember" id="Fact001893" format="ixt:numdotdecimal" decimals="0" unitRef="USD">159,464,040</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_iI_zCMPUeGT5kcd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total Consideration</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" contextRef="AsOf2025-02-26_custom_GEDiCubeMember" id="Fact001895" format="ixt:numdotdecimal" decimals="0" unitRef="USD">156,559,131</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The
goodwill recognized is attributable primarily to expected synergies and the assembled workforce of GEDi. None of the goodwill is expected
to be deductible for income tax purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The fair
values of the acquired tangible and intangible assets were determined using variations of the income approach. The income approach valuation
methodology used for the intangible assets acquired makes use of Level 3 inputs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The Company
recognized approximately $<span id="xdx_903_eus-gaap--BusinessCombinationAcquisitionRelatedCosts_pn5n6_c20230701__20240630__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zM59CyDtHqCl" title="Acquisition related costs"><ix:nonFraction name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" contextRef="From2023-07-012024-06-30_custom_GEDiCubeMember" id="Fact001897" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.2</ix:nonFraction></span> million of acquisition related costs that were expensed during the period ended June 30, 2024. These costs
are included in &#8220;selling, general and administrative expenses&#8221; in the accompanying condensed consolidated statements of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Consolidated unaudited pro forma information: </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following consolidated pro forma information assumes that the acquisition
of GEDi took place on July 1, 2023 for the statement of operations for the twelve-month period ended June 30, 2024. These amounts have
been estimated after applying the Company&#8217;s accounting policies:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 102 -->
    <div id="xdx_23E_za5oCYyA7k8e" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div>
    <div id="xdx_23C_zTvTnmw7RG38" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23B_zf4Wtbc5SgYg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:exclude>

<table cellpadding="0" cellspacing="0" id="xdx_89C_ecustom--custom--ScheduleOfConsolidatedStatementsOfOperationsTableTextBlock_hsrt--CounterpartyNameAxis__custom--GEDiCubeIntlLtdAcquisitionMember_zOpINOOxtCmk" summary="xdx: Disclosure - ACQUISITION (Details 3)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_492_20240701__20250630__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zSRDllRMIJN7" style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_404_ecustom--BusinessAcquisitionsRevenue_d0_zgHWOo15vUoe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Revenues</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="RENB:BusinessAcquisitionsRevenue" contextRef="From2024-07-012025-06-30_custom_GEDiCubeMember" id="Fact001902" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--BusinessAcquisitionsNetIncomeLoss_zalIi4AWeGz2" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-align: left; text-indent: -10pt">Net loss</td><td style="width: 10%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 18%; text-align: right">(<ix:nonFraction name="RENB:BusinessAcquisitionsNetIncomeLoss" contextRef="From2024-07-012025-06-30_custom_GEDiCubeMember" id="Fact001904" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">83,571,822</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_z1q3TSJBrgoc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The unaudited pro forma results
are presented for informational purposes only and are not necessarily indicative of what the actual results of operations would have been
if the acquisition had occurred at the beginning of the period presented, nor are they indicative of future results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact001906" name="us-gaap:SegmentReportingDisclosureTextBlock"><p id="xdx_80B_eus-gaap--SegmentReportingDisclosureTextBlock_zz2CxbAImxtg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 14 &#8212; <span id="xdx_824_zxhHHSpDe9c5">SEGMENT REPORTING</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For the year ended June 30, 2025,
the Company had three reportable segments. These segments have different strategic and economic goals and are managed separately because
they require different technology and marketing strategies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
<td style="border-bottom: black 1pt solid; white-space: nowrap; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reportable
Segment</b></span></td>
<td style="white-space: nowrap; width: 2%; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: black 1pt solid; white-space: nowrap; width: 80%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description
</b></span></td></tr>
<tr style="vertical-align: bottom">
<td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RENB</b></span></td>
<td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Developing new immunotherapies
to combat cancer </span></td></tr>
<tr style="vertical-align: bottom">
<td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BioSymetrics</b></span></td>
<td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Integrating multimodal data
sources, including genomics, imaging, electronic health records, and other real-world evidence, to advance biomarker discovery, therapeutic
development, and precision medicine.</span></td></tr>
<tr style="vertical-align: bottom">
<td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RENC</b></span></td>
<td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Developing a predicative artificial intelligence based
diagnostic methodology for the use of earlier cancer detection </span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The Company&#8217;s
chief executive officer is the chief operating decision maker and reviews the internal management reports for each segment at least quarterly.
During the year ended June 30, 2025, there were no significant inter-company revenues or expenses. The chief operating decision maker
assesses performance for each segment and decides how to allocate resources based on segment operating losses that also is reported on
the consolidated statement of operations. The measure of segment assets is reported on the balance sheet as total consolidated assets.
The accounting policies of each segment are the same as those described in the summary of significant accounting policies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact001908" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zdUDi4exyaWb" summary="xdx: Disclosure - SEGMENT REPORTING (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"><span id="xdx_8B2_z6gLeveQNbOf" style="display: none">Schedule of segment operating loss and
    asset information</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Operating loss</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Assets</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; font-weight: bold; text-align: left; text-indent: -10pt">United States (RENB)</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--SegmentOperatingLoss_c20240701__20250630__srt--StatementGeographicalAxis__country--US_zTqkzEFiBbkk" title="Operating income loss" style="width: 12%; text-align: right"><ix:nonFraction name="RENB:SegmentOperatingLoss" contextRef="From2024-07-012025-06-30_country_US" id="Fact001910" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,530,056</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--SegmentAsset_iI_c20250630__srt--StatementGeographicalAxis__country--US_z1Dxzi7xZxc7" title="Assets" style="width: 12%; text-align: right"><ix:nonFraction name="RENB:SegmentAsset" contextRef="AsOf2025-06-30_country_US" id="Fact001912" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,907,647</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">United States (BioSymetrics)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--SegmentOperatingLoss_c20240701__20250630__srt--StatementGeographicalAxis__custom--BioSymetricsMember_z3IMPpLY3Z4i" title="Operating income loss" style="text-align: right"><ix:nonFraction name="RENB:SegmentOperatingLoss" contextRef="From2024-07-012025-06-30_custom_BioSymetricsMember1126506984" id="Fact001914" format="ixt:numdotdecimal" decimals="0" unitRef="USD">237,880</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--SegmentAsset_iI_c20250630__srt--StatementGeographicalAxis__custom--BioSymetricsMember_zQx2JOs8qNi3" title="Assets" style="text-align: right"><ix:nonFraction name="RENB:SegmentAsset" contextRef="AsOf2025-06-30_custom_BioSymetricsMember" id="Fact001916" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,109,643</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Netherlands (RENC)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_ecustom--SegmentOperatingLoss_c20240701__20250630__srt--StatementGeographicalAxis__country--NL_zLymUYaPzfqj" title="Operating income loss" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="RENB:SegmentOperatingLoss" contextRef="From2024-07-012025-06-30_country_NL" id="Fact001918" format="ixt:numdotdecimal" decimals="0" unitRef="USD">173,198,066</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_ecustom--SegmentAsset_iI_c20250630__srt--StatementGeographicalAxis__country--NL_zkTPpSNyISdj" title="Assets" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="RENB:SegmentAsset" contextRef="AsOf2025-06-30_country_NL" id="Fact001920" format="ixt:numdotdecimal" decimals="0" unitRef="USD">213,550</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_988_ecustom--SegmentOperatingLoss_c20240701__20250630_zEwvC8oPeMQb" title="Operating income loss" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="RENB:SegmentOperatingLoss" contextRef="From2024-07-01to2025-06-30" id="Fact001922" format="ixt:numdotdecimal" decimals="0" unitRef="USD">188,966,002</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_981_ecustom--SegmentAsset_iI_c20250630_zLf8FAxU9A23" title="Assets" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="RENB:SegmentAsset" contextRef="AsOf2025-06-30" id="Fact001924" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,230,840</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_zY8Yw0fcgMZ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The chief
operating decision maker uses loss from operations to evaluate the performance of each segment&#8217;s assets in deciding how to allocate
available capital between segments. The chief operating decision maker also uses loss from operations in their competitive analysis by
benchmarking the Company&#8217;s competitors. The competitive analysis along with the monitoring of budgeted versus actual results are
used in assessing the performance of the segment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Information
regarding each reportable segment for the year ended June 30, 2025 is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact001926" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_zBaCQ2PFb6W6" summary="xdx: Disclosure - SEGMENT REPORTING (Details 1)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B8_zGCMTWRXTdPf" style="display: none">Schedule of information regarding segment reporting</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_490_20240701__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--RENBMember_zKUWfCht6Nvd" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_497_20240701__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--BioSymetricsMember_zixUeXPh5Ud9" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_496_20240701__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--RENCMember_zbZDpF18LPS7" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49F_20240701__20250630_zGqqSm4HTlD1" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">RENB</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">BioSymetrics</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">RENC</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td></tr>
  <tr id="xdx_405_eus-gaap--OtherGeneralAndAdministrativeExpense_zm8VctnRFQ5k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt">General and administrative</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="From2024-07-012025-06-30_custom_RENBMember" id="Fact001928" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,904,855</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="From2024-07-012025-06-30_custom_BioSymetricsMember1126507484" id="Fact001929" format="ixt:numdotdecimal" decimals="0" unitRef="USD">211,401</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="From2024-07-012025-06-30_custom_RENCMember" id="Fact001930" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,763,794</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="From2024-07-01to2025-06-30" id="Fact001931" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,880,050</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--ResearchAndDevelopmentExpense_zNfZ1RwN4MBl" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-07-012025-06-30_custom_RENBMember" id="Fact001933" format="ixt:numdotdecimal" decimals="0" unitRef="USD">502,896</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-07-012025-06-30_custom_BioSymetricsMember1126507484" id="Fact001934" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,029</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-07-012025-06-30_custom_RENCMember" id="Fact001935" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,503</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-07-01to2025-06-30" id="Fact001936" format="ixt:numdotdecimal" decimals="0" unitRef="USD">537,428</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--GoodwillAndIntangibleAssetImpairment_d0_zJWFVuCpvcrh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Goodwill impairment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GoodwillAndIntangibleAssetImpairment" contextRef="From2024-07-012025-06-30_custom_RENBMember" id="Fact001938" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GoodwillAndIntangibleAssetImpairment" contextRef="From2024-07-012025-06-30_custom_BioSymetricsMember1126507484" id="Fact001939" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GoodwillAndIntangibleAssetImpairment" contextRef="From2024-07-012025-06-30_custom_RENCMember" id="Fact001940" format="ixt:numdotdecimal" decimals="0" unitRef="USD">170,419,429</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GoodwillAndIntangibleAssetImpairment" contextRef="From2024-07-01to2025-06-30" id="Fact001941" format="ixt:numdotdecimal" decimals="0" unitRef="USD">170,419,429</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DepreciationDepletionAndAmortization_zygwY7gL8pY5" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2024-07-012025-06-30_custom_RENBMember" id="Fact001943" format="ixt:numdotdecimal" decimals="0" unitRef="USD">122,305</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2024-07-012025-06-30_custom_BioSymetricsMember1126507484" id="Fact001944" format="ixt:numdotdecimal" decimals="0" unitRef="USD">450</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2024-07-012025-06-30_custom_RENCMember" id="Fact001945" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,340</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2024-07-01to2025-06-30" id="Fact001946" format="ixt:numdotdecimal" decimals="0" unitRef="USD">129,095</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--SegmentOperatingLoss_zQ1J1j7Y6Pq9" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Segment operating loss</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="RENB:SegmentOperatingLoss" contextRef="From2024-07-012025-06-30_custom_RENBMember" id="Fact001948" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,530,056</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="RENB:SegmentOperatingLoss" contextRef="From2024-07-012025-06-30_custom_BioSymetricsMember1126507484" id="Fact001949" format="ixt:numdotdecimal" decimals="0" unitRef="USD">237,880</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="RENB:SegmentOperatingLoss" contextRef="From2024-07-012025-06-30_custom_RENCMember" id="Fact001950" format="ixt:numdotdecimal" decimals="0" unitRef="USD">173,198,066</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="RENB:SegmentOperatingLoss" contextRef="From2024-07-01to2025-06-30" id="Fact001951" format="ixt:numdotdecimal" decimals="0" unitRef="USD">188,966,002</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white"><b><span style="text-decoration: underline">Geographic information:</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">RENB,
BioSymetrics and RENC are managed on a worldwide basis but operate in offices located in the United States and the Netherlands, respectively.
The geographic information analyses the Company&#8217;s operations and assets based on the country in which each segment operates. In
presenting this geographic information, segment operating results have been based on the geographic location in which the services were
provided to the segment and segment assets were based on the geographic location of the assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"></p>

<ix:exclude><!-- Field: Page; Sequence: 103 -->
    <div id="xdx_231_zsWDMZiiBRx3" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div>
    <div id="xdx_233_zhfyvsG8GW37" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_239_zBQy0kGNVjq2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p></ix:exclude>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact001954" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_80C_eus-gaap--SubsequentEventsTextBlock_z9ePr0vhNaW3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 15 &#8212; <span id="xdx_826_z6AHyLeMjOd8">SUBSEQUENT EVENTS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="background-color: white">On
September 18, 2025, the Company filed a Certificate of Amendment to the Certificate of Incorporation of the Company (the &#8220;</span><b>Certificate
of Amendment</b><span style="background-color: white">&#8221;) with the Secretary of State of the State of Delaware to effect a 1-for-10
reverse stock split of the shares of the Company&#8217;s common stock, par value $0.0001 per share (the &#8220;</span><b>Common Stock</b><span style="background-color: white">&#8221;),
either issued and outstanding or held by the Company as treasury stock, effective as of 12:01 a.m. (New York time) on September 29, 2025
(the &#8220;</span><b>Reverse Stock Split</b><span style="background-color: white">&#8221;). The Common Stock will begin trading on a
reverse stock split-adjusted basis on The Nasdaq Capital Market on September 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="background-color: white">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">On September 18, 2025, the Company entered into the
First Amendment to Convertible Promissory Note whereby the January 2024 Note (see Note 8 to the Financial Statements) that matured on
December 29, 2024, was amended extending the Maturity Date in the second paragraph of the Note from December 29, 2024 to December 29,
2025. Accordingly, the Note unless otherwise amended, replaced, or otherwise altered by this First Amendment, any and all terms contained
in the Note continue in full force and effect.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On September 2, 2025, the Court
of Amsterdam (the &#8220;Court&#8221;) declared bankrupt Gedi Cube B.V. (&#8220;Gedi&#8221;), an indirect subsidiary of Lunai Bioworks,
Inc. (&#8220;Lunai&#8221;), and appointed Mr. M.M. Dellebeke as the receiver in the bankruptcy. Gedi filed a voluntary petition seeking
a declaration of bankruptcy due to its inability to make payments as they became due. As a result of this, the Company determined that
a material impairment of Gedi had occurred (see Note 6 to the financial statements).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On August 18, 2025, the Company
issued Promissory Notes in the aggregate principal amount of $<span id="xdx_904_ecustom--SaleOfStockConsiderationReceivedCashTransaction_iI_c20250818__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zPiswzPzObP8" title="Sale of stock issued cash consideration"><ix:nonFraction name="RENB:SaleOfStockConsiderationReceivedCashTransaction" contextRef="AsOf2025-08-18_us-gaap_SubsequentEventMember" id="Fact001956" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000,000</ix:nonFraction></span>. The Notes bear an interest rate of&#160;<span id="xdx_90B_ecustom--InterestRate_iI_dp_c20250818__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z3dKOLvfiFhh" title="Interest rate"><ix:nonFraction name="RENB:InterestRate" contextRef="AsOf2025-08-18_us-gaap_SubsequentEventMember" id="Fact001958" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">18</ix:nonFraction></span>%&#160;per annum and
mature on&#160;the 6-month anniversary of the Issue Date.,&#160;(the &#8220;Maturity Date&#8221;). The Company is required to pay principal
and interest on the Maturity Date.<b>	</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">From July 3, 2025, to August 19, 2025, the Company
issued Promissory Notes in the aggregate principal amount of $<span id="xdx_90C_ecustom--SaleOfStockConsiderationReceivedCashTransaction_iI_c20250703__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zJE7kzm4cEei" title="Sale of stock issued cash consideration"><ix:nonFraction name="RENB:SaleOfStockConsiderationReceivedCashTransaction" contextRef="AsOf2025-07-03_us-gaap_SubsequentEventMember" id="Fact001960" format="ixt:numdotdecimal" decimals="0" unitRef="USD">695,000</ix:nonFraction></span>. The Notes bear an interest rate of&#160;<span id="xdx_902_ecustom--InterestRate_iI_dp_c20250819__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zwtv7Un1ychg" title="Interest rate"><ix:nonFraction name="RENB:InterestRate" contextRef="AsOf2025-08-19_us-gaap_SubsequentEventMember" id="Fact001962" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Ratio">10</ix:nonFraction></span>%&#160;per annum and
mature on&#160;June 30, 2026,&#160;(the &#8220;Maturity Date&#8221;). The Company is required to pay principal and interest on the Maturity
Date<b>.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">On July 7, 2025, Lunai Bioworks Inc. (&#8220;Lunai&#8221;)
entered into an Exchange Agreement (the &#8220;Exchange Agreement&#8221;) with certain accredited investors (the &#8220;Investors&#8221;),
all of whom are existing shareholders of the Company. Pursuant to the Exchange Agreement, the Investors agreed to exchange an aggregate
of $<span id="xdx_90A_ecustom--SaleOfStockConsiderationReceivedCashTransaction_iI_pn3n3_dm_c20250707__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__custom--ExchangeAgreementMember_zC1Ugg8ChPf" title="Sale of stock issued cash consideration"><ix:nonFraction name="RENB:SaleOfStockConsiderationReceivedCashTransaction" contextRef="AsOf2025-07-07_us-gaap_SubsequentEventMember_custom_ExchangeAgreementMember" id="Fact001964" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">9.7</ix:nonFraction></span> million in outstanding secured promissory notes (the &#8220;Secured Notes&#8221;) for $<span id="xdx_904_ecustom--SaleOfStockConsiderationReceivedCashTransaction_iI_pn3n3_dm_c20250707__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__custom--ConvertiblePromissoryNoteMember_zNyTHkDAEULl" title="Sale of stock issued cash consideration"><ix:nonFraction name="RENB:SaleOfStockConsiderationReceivedCashTransaction" contextRef="AsOf2025-07-07_us-gaap_SubsequentEventMember_custom_ConvertiblePromissoryNoteMember" id="Fact001966" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">16.1</ix:nonFraction></span> million in new convertible promissory
notes (the &#8220;Convertible Notes&#8221;), representing a 65% premium to the principal and interest amount of the Secured Notes. The
Convertible Notes mature on July 31, 2025, and do not bear any interest. The exchange was completed to restructure the Company&#8217;s
debt obligations and provide additional flexibility to support strategic initiatives.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Immediately following the issuance of the Convertible
Noes on July 7, 2025, the Investors elected to convert the entire $<span id="xdx_908_ecustom--SaleOfStockConsiderationReceivedCashTransaction_iI_pn3n3_dm_c20250707__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__custom--ConvertibleNotesMember_zqPN5J1hUSX" title="Sale of stock issued cash consideration"><ix:nonFraction name="RENB:SaleOfStockConsiderationReceivedCashTransaction" contextRef="AsOf2025-07-07_us-gaap_SubsequentEventMember_custom_ConvertibleNotesMember" id="Fact001968" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">16.1</ix:nonFraction></span>million principal amount into an aggregate of <span id="xdx_90C_ecustom--SaleOfStockConsiderationReceivedCashTransaction_iI_pn3n3_dm_c20250707__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_ztITHVJPi7y6" title="Sale of stock issued cash consideration"><ix:nonFraction name="RENB:SaleOfStockConsiderationReceivedCashTransaction" contextRef="AsOf2025-07-07_us-gaap_SubsequentEventMember" id="Fact001970" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">53.6</ix:nonFraction></span> million shares
of common stock (the &#8220;Conversion Shares&#8221;), based on the stated $<span id="xdx_90D_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20250707__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zd6Yl6a8MPt3" title="Conversion price"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2025-07-07_us-gaap_SubsequentEventMember" id="Fact001972" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.30</ix:nonFraction></span> per share conversion price. The $0.30 per share conversion
price of the Convertible Notes represented a premium to the closing price of the Company&#8217;s common stock on July 7, 2025, the date
of execution and conversion. As a result, the issuance of the <span id="xdx_90F_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pn3n3_dm_c20250707__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zTit72dvmJ26" title="Issuance of common stock shares"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2025-07-07_us-gaap_SubsequentEventMember" id="Fact001974" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="Shares">53.6</ix:nonFraction></span> million shares of common stock upon conversion of the Convertible Notes
did not constitute a &#8220;below market&#8221; issuance under applicable Nasdaq listing rules and did not trigger stockholder approval
requirements under Nasdaq Listing Rule 5635(d). The shares were issued without any additional consideration from the Investors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As a result of the foregoing transactions,
the Company (i) eliminated $<span id="xdx_90A_ecustom--SaleOfStockConsiderationReceivedCashTransaction_iI_pn3n3_dm_c20250707__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__custom--ExchangeAgreementMember_ziyZl1aytO44" title="Sale of stock issued cash consideration"><ix:nonFraction name="RENB:SaleOfStockConsiderationReceivedCashTransaction" contextRef="AsOf2025-07-07_us-gaap_SubsequentEventMember_custom_ExchangeAgreementMember" id="Fact001976" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">9.7</ix:nonFraction></span> million of secured indebtedness, (ii) issued $<span id="xdx_908_ecustom--SaleOfStockConsiderationReceivedCashTransaction_iI_pn3n3_dm_c20250707__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__custom--ConvertibleNotesMember_zwqZTDaEUKx5" title="Sale of stock issued cash consideration"><ix:nonFraction name="RENB:SaleOfStockConsiderationReceivedCashTransaction" contextRef="AsOf2025-07-07_us-gaap_SubsequentEventMember_custom_ConvertibleNotesMember" id="Fact001978" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">16.1</ix:nonFraction></span> million in Convertible Notes to the same holders, and
(iii) issued <span id="xdx_902_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pn3n3_dm_c20250707__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z3WeddEHVXK5" title="Issuance of common stock shares"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2025-07-07_us-gaap_SubsequentEventMember" id="Fact001980" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="Shares">53.6</ix:nonFraction></span> million shares of common stock upon full conversion of such Convertible Notes without any cash proceeds to the Company.</p>

</ix:nonNumeric><p id="xdx_81E_z9q7avahvDk4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 104 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_015"></span>Item 9. Changes in and Disagreements with Accountants on Accounting
and Financial Disclosure</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_016"></span>Item 9A. Controls and Procedures</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Evaluation of Disclosure Controls and Procedures</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our Principal Executive Officer
and Principal Financial Officer (the &#8220;Certifying Officers&#8221;) are responsible for establishing and maintaining disclosure controls
and procedures for the Company. The Certifying Officers have designed such disclosure controls and procedures to ensure that material
information is made known to the Certifying Officers, particularly during the period in which this Report was prepared.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Certifying Officers conducted
a review of the Company&#8217;s &#8220;disclosure controls and procedures&#8221; (as defined in the Exchange Act, Rules 13a-15(e) and
15-d-15(e)) as of the end of the period covered by this Annual Report (the &#8220;Evaluation Date&#8221;). Based upon that evaluation,
the Certifying Officers concluded that, as of June 30, 2025, our disclosure controls and procedures were not effective in ensuring that
the information we were required to disclose in reports that we file or submit under the Securities Exchange Act of 1934, as amended,
is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Management Annual Report on Internal Control over Financial Reporting</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Management is responsible for
establishing and maintaining adequate internal control over financial reporting for the Company. Management used the &#8220;Internal Control
over Financial Reporting Integrated Framework&#8221; issued by the Committee of Sponsoring Organizations (&#8220;COSO-2013&#8221;) to
conduct a review of the Company&#8217;s internal controls over financial reporting. As of June 30, 2025, Management concluded that internal
controls over financial reporting were not effective, based on COSO&#8217;s framework. The deficiency is attributed to the Company not
having adequate resources to address complex accounting matters. This control deficiency will be monitored, and attention will be given
to this matter as the Company grows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This Annual Report does not include
an attestation report from the Company&#8217;s registered public accounting firm regarding internal controls over financial reporting.
Management&#8217;s report was not subject to attestation by the Company&#8217;s registered public accounting firm pursuant to the rules
of the SEC that permit the Company to provide only management&#8217;s report in this Annual Report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Changes in Internal Control over Financial Reporting</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">There were no changes in our internal
control over financial reporting that occurred during the period covered by this report that have materially affected, or are reasonably
likely to materially affect, our internal control over financial reporting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_017"></span>Item 9B. Other Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_904_eecd--MtrlTermsOfTrdArrTextBlock_c20240701__20250630_zwwR1frA0rib"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" escape="true" id="Fact001981" name="ecd:MtrlTermsOfTrdArrTextBlock">During the Company&#8217;s fourth quarter, no director or officer&#160;<span id="xdx_90D_eecd--Rule10b51ArrAdoptedFlag_dbT_c20240701__20250630_zNMZNHlaqbMe"><span id="xdx_907_eecd--NonRule10b51ArrAdoptedFlag_dbT_c20240701__20250630_zXC75o3wEEg3"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" format="ixt:booleantrue" id="Fact001982" name="ecd:Rule10b51ArrAdoptedFlag"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" format="ixt:booleantrue" id="Fact001983" name="ecd:NonRule10b51ArrAdoptedFlag">adopted&#160;</ix:nonNumeric></ix:nonNumeric></span></span>or&#160;<span id="xdx_907_eecd--Rule10b51ArrTrmntdFlag_dbT_c20240701__20250630_zu759zLP3aFh"><span id="xdx_90D_eecd--NonRule10b51ArrTrmntdFlag_dbT_c20240701__20250630_zYPLz5wyhTkd"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" format="ixt:booleantrue" id="Fact001984" name="ecd:Rule10b51ArrTrmntdFlag"><ix:nonNumeric contextRef="From2024-07-01to2025-06-30" format="ixt:booleantrue" id="Fact001985" name="ecd:NonRule10b51ArrTrmntdFlag">terminated&#160;</ix:nonNumeric></ix:nonNumeric></span></span>a
Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 105; Options: NewSection; Value: 64 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_018"></span>PART III</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><b><span id="a_019"></span>Item 10. Directors, Executive Officers and
Corporate Governance</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The information
required by this Item 10 will be included under the captions &#8220;Directors and Executive Officers&#8221;, &#8220;Information as to
Nominees and Other Directors&#8221;, &#8220;Information Regarding Meetings and Committees of the Board&#8221;, &#8220;Compliance with
Section 16(a) of the Exchange Act&#8221;, &#8220;Code of Ethics&#8221;, &#8220;Corporate Governance&#8221; and as otherwise set forth
in the Company&#8217;s Definitive Proxy Statement and is incorporated herein by reference or, alternatively will be included, by amendment
to this Form 10-K under cover of Form 10-K/A no later than 120-days after the end of our fiscal year covered by this report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><b><span id="a_020"></span>Item 11. Executive Compensation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The information
required by this Item 11 will be included in the Definitive Proxy Statement referenced above in Item 10 and is incorporated herein by
reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><b><span id="a_021"></span>Item 12. Security Ownership of Certain Beneficial
Owners and Management and Related Stockholder Matters</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white; color: #212529">The
information required by this Item 12 will be included in the Definitive Proxy Statement referenced above in Item 10 and is incorporated
herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white; color: #212529">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><b><span id="a_022"></span>Item 13. Certain Relationships and Related
Transactions and Director Independence</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white; color: #212529">The
information required by this Item 13 will be included in the Definitive Proxy Statement referenced above in Item 10 and is incorporated
herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white; color: #212529">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><b><span id="a_023"></span>Item 14. Principal Accounting Fees and Services</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #212529">The information required by this Item
14 will be included in the Definitive Proxy Statement referenced above in Item 10 and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #212529">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #212529"></p>

<!-- Field: Page; Sequence: 106; Value: 64 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #212529">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_024"></span>PART IV</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_025"></span>Item 15. Exhibits and Financial Statement Schedules</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr>
<td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 6%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit No.</b></span></td>
<td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 45%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td>
<td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 47%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Incorporated by Reference</b></span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112225000312/e6390_ex2-1.htm">Agreement and Plan of Merger, dated February 26, 2025, by and among Renovaro, Inc., Renovaro Acquisition Sub and Biosymetrics, Inc.</a></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112225000312/e6390_ex2-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to Exhibit 2.1 to the Company&#8217;s Form 8-K filed with the SEC on February 28, 2025. </span></a></td></tr>
<tr style="vertical-align: top; background-color: White">
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: justify">&#160;</td>
<td>&#160;</td>
<td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td>2.2&#160;</td>
<td>&#160;</td>
<td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112224000246/e5418_ex2-1.htm">Second&#160;Amendment&#160;to&#160;Stock&#160;Purchase&#160;Agreement, dated February 13, 2024, by and among LUNAI BIOWORKS INC.., GEDi Cube Intl Ltd., the sellers party thereto and Yalla Yalla Ltd&#160;</a></td>
<td>&#160;</td>
<td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112224000246/e5418_ex2-1.htm">Incorporated by reference to Exhibit 2.1 to the Company&#8217;s Form 8-K filed with the SEC on February 14, 2024</a></td></tr>
<tr style="vertical-align: top; background-color: White">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112223001770/e5061_ex3-1.htm">Certificate of Incorporation, as amended</a></span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/0001527728/000173112224000248/e5415_ex3-1.htm">Incorporated by reference to Exhibit 3.1 to the Company&#8217;s Form 10-Q filed with the SEC on February 14, 2024</a></span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2 </span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112219000259/e1349_ex3-1.htm">Amended and Restated Bylaws</a></span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1527728/000173112224000883/e5703_8k.htm">Incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on May 21, 2024.</a></span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112225001173/e6800_ex3-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to the Restated Certificate of Incorporation of Renovaro Inc., dated August 18, 2025 (Name Change).</span></a></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1527728/000173112225001173/e6800_ex3-1.htm">Incorporated by reference to Exhibit 3.1 to the Company&#8217;s Form 8-K filed with the SEC on August 26, 2025.</a></span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112224000246/e5418_ex4-1.htm">Registration Rights Agreement, dated February 13, 2024, by and among Lunai Bioworks Inc.&#160;Gedi Cube Intl Ltd, and the shareholders of Gedi Cube Intl Ltd named the Sellers named thereto</a></span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1527728/000173112224000246/e5418_8-k.htm">Incorporated herein by reference to exhibit to the Company&#8217;s Form 8-K filed with the SEC on February 14, 2024</a></span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112220000335/e1841_10-2.htm">Promissory Note dated March 30, 2020 issued to Paseco ApS</a></span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112220000335/e1841_10-2.htm">Incorporated herein by reference to Exhibit 10.2 to the Company&#8217;s Form 8-K filed with the SEC on March 31, 2020.</a></span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112223000271/e4443_ex4-3.htm">Amendment No.2 to Promissory Note, dated May 17, 2022</a></span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112223000271/e4443_ex4-3.htm">Incorporated herein by reference to Exhibit 4.3 to the Company&#8217;s Form 10-K filed with the SEC on February 27, 2023.</a></span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112220000335/e1841_10-2.htm">Amendment No.3 to Promissory Note, effective December 30, 2022</a></span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112220000335/e1841_10-2.htm">Incorporated herein by reference to Exhibit 10.2 to the Company&#8217;s Form 8-K filed with the SEC on February 23, 2023.</a></span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112223001396/e4889_ex10-2.htm">Amendment No. 4 to Promissory Note, effective July 31, 2023</a></span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112223001396/e4889_ex10-2.htm">Incorporated by reference to Exhibit 10.2 to the Company&#8217;s Form 8-K filed with the SEC on August 7, 2023</a></span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112220000975/e2119_4-1.htm">Description of Securities</a></span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112220000975/e2119_4-1.htm">Incorporated herein by reference to Exhibit 4.1 to the Company&#8217;s Form 10-K filed with the SEC on September 30, 2020.</a></span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112223000552/e4510_ex4-1.htm">Form of Warrant</a></span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112223000552/e4510_ex4-1.htm">Incorporated by reference to Exhibit 4.1 to the Company&#8217;s Form 8-K filed with the SEC on April 3, 2023</a></span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112223000552/e4510_ex4-1.htm">Form of Warrant</a></span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112223001396/e4889_ex4-1.htm">Incorporated by reference to Exhibit 4.1 to the Company&#8217;s Form 8-K filed with the SEC on August 7, 2023</a></span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112224001001/e5764_ex4-1.htm">Form of Warrant</a></span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/0001527728/000173112224001001/e5764_ex4-1.htm">Incorporated herein by reference to Exhibit 4.1 to the Company&#8217;s Form 8-K filed with the SEC on June 21, 2024</a></span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/0001527728/000173112223001841/e5116_ex4-1.htm">Form of 5% Original Issue Discount Convertible Promissory Note</a></span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/0001527728/000173112223001841/e5116_ex4-1.htm">Incorporated herein by reference to Exhibit 4.1 to the Company&#8217;s Form 8-K filed with the SEC on October 10, 2023</a></span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112225000948/e6687_ex99-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Convertible Note</span></a></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1527728/000173112225000948/e6687_ex99-2.htm">Incorporated herein by reference to Exhibit 99.2 to the Company&#8217;s Form 8-K filed with the SEC on July 9, 2024</a></span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 107; Value: 64 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 6%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 45%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112220000112/e1702_ex10-1.htm">2019
    Equity Incentive Plan</a></span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 47%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112220000112/e1702_ex10-1.htm">Incorporated
    herein by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the SEC on February 10, 2020.</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112223002120/e5207_ex10-3.htm">2023
    Equity Incentive Plan</a></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112223001993/e5171_ex10-12.htm">Incorporated
    herein by reference to Exhibit 10.12 to the Company&#8217;s Form 10-K/A filed with the SEC on October 30, 2023</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112220000085/e1694_10-1.htm">Statement
    of Work and License Agreement by and among G-Tech Bio, LLC, the Company and G Health Research Foundation</a></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112220000085/e1694_10-1.htm">Incorporated
    herein by reference to Exhibit 10.1 to the Company&#8217;s Form 8-K filed with the SEC on February 3, 2020.</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112220000335/e1841_10-1.htm">Note
    Purchase Agreement</a></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112220000335/e1841_10-1.htm">Incorporated
    herein by reference to Exhibit 10.1 to the Company&#8217;s Form 8-K filed with the SEC on March 31, 2020.</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112218000021/e1105_10-1.htm">General
    Office Lease by and between the Registrant and Century City Medical Plaza Land Co., Inc. dated June 19, 2018</a></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112218000021/e1105_10-1.htm">Incorporated
    herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on June 25, 2018.</a></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="width: 6%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 45%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112221001378/e3028_ex10-1.htm">Employment
    Agreement, dated August 11, 2021, by and between the Company and Dr. Mark Dybul</a></span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 47%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112221001378/e3028_ex10-1.htm">Incorporated
    herein by reference to Exhibit to 10.1 the Company&#8217;s Current Report on Form 8-K/A, filed with the SEC on August 16, 2021.</a></span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112221001378/e3028_ex10-1.htm">Amendment
    to Employment Agreement between Mark Dybul, M.D. and the Company, dated December 12, 2022</a></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112221001378/e3028_ex10-1.htm">Incorporated
    herein by reference to Exhibit to 10.1 the Company&#8217;s Current Report on Form 8-K, filed with the SEC on December 16, 2022.</a></span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10 </span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112223000258/e4441_ex10-2.htm">Security
    Agreement, effective December 30, 2022, by and between the Company and Paseco ApS</a></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112223000258/e4441_ex10-2.htm">Incorporated
    herein by reference to Exhibit 10.2 to the Company&#8217;s Form 8-K filed with the SEC on February 23, 2023.</a></span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112223001210/e4828_ex10-1.htm">Purchase
    Agreement, dated June 20, 2023, by and between the Company and Lincoln Park Capital Fund, LLC</a></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112223001210/e4828_ex10-1.htm">Incorporated
    herein by reference to Exhibit 10.1 to the Company&#8217;s Form 8-K filed with the SEC on June 27, 2023</a></span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112223001210/e4828_ex10-2.htm">Registration
    Rights Agreement, dated June 20, 2023, by and between the Company and Lincoln Park Capital Fund, LLC</a></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112223001210/e4828_ex10-2.htm">Incorporated
    herein by reference to Exhibit 10.2 to the Company&#8217;s Form 8-K filed with the SEC on June 27, 2023</a></span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112224000419/e5493_ex10-1.htm">Consulting
    Agreement, dated March 11, 2024, by and between Lunai Bioworks Inc. and Tarsh PB Advisors LLC.</a></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/0001527728/000173112224000419/e5493_ex10-1.htm">Incorporated
    herein by reference to Exhibit 10.1 to the Company&#8217;s Form 8-K filed with the SEC on March 13, 2024</a></span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112223001396/e4889_ex10-1.htm">Form
    of Subscription Agreement</a></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/0001527728/000173112223001396/e4889_ex10-1.htm">Incorporated
    herein by reference to Exhibit 10.1 to the Company&#8217;s Form 8-K filed with the SEC on August 7, 2023</a></span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112223001841/e5116_ex10-1.htm">Form
    of Subscription Agreement</a></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/0001527728/000173112223001841/e5116_ex10-1.htm">Incorporated
    herein by reference to Exhibit 10.1 to the Company&#8217;s Form 8-K filed with the SEC on October 10, 2023</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112224001001/e5764_ex10-1.htm">Form
    of Subscription Agreement</a></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/0001527728/000173112224001001/e5764_ex10-1.htm">Incorporated
    herein by reference to Exhibit 10.1 to the Company&#8217;s Form 8-K filed with the SEC on June 21, 2024</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112225000948/e6687_ex99-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Exchange Agreement</span></a></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1527728/000173112225000948/e6687_ex99-1.htm">Incorporated
    herein by reference to Exhibit 99.1 to the Company&#8217;s Form 8-K filed with the SEC on July 9, 2024</a></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 108; Value: 64 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="width: 6%"><span style="font-size: 10pt">21.1*</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 45%; text-align: justify"><a href="e6882_ex21-1.htm"><span style="font-size: 10pt">Subsidiaries of the Registrant</span></a></td>
    <td style="width: 1%; text-align: justify">&#160;</td>
    <td style="width: 47%; text-align: justify"><a href="e6882_ex21-1.htm"><span style="font-size: 10pt">Incorporated Incorporated herein by reference to as Exhibit 21.1 to the Company&#8217;s Form 10-K filed with the SEC on September
29, 2025</span></a></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">23.1*&#160;</span></td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: justify"><a href="e6882_ex23-1.htm"><span style="font-size: 10pt">Consent of Sadler, Gibb &amp; Associates&#160;</span></a></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">31.1* </span></td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: justify"><a href="e6882_ex31-1.htm"><span style="font-size: 10pt">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934</span></a></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">31.2* </span></td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: justify"><a href="e6882_ex31-2.htm"><span style="font-size: 10pt">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934</span></a></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">32.1** </span></td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: justify"><a href="e6882_ex32-1.htm"><span style="font-size: 10pt">Certification of Principal Executive Officer pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350</span></a></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">32.2**</span></td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: justify"><a href="e6882_ex32-2.htm"><span style="font-size: 10pt">Certification of Chief Financial Officer pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350</span></a></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">97.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112224001664/e6062_ex97-1.htm"><span style="font-size: 10pt">Clawback Policy</span></a></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1527728/000173112224001664/e6062_ex97-1.htm"><span style="font-size: 10pt">Incorporated herein by reference to as Exhibit 97.1 to the Company&#8217;s Form 10-K filed with the SEC on October 10, 2024</span></a></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">101.INS </span></td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: justify"><span style="font-size: 10pt">XBRL Instance Document* </span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">101.SCH </span></td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: justify"><span style="font-size: 10pt">XBRL Taxonomy Extension Schema* </span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: justify">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt">101.CAL </span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="3" style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">XBRL Taxonomy Extension Calculation Linkbase* </span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="3" style="vertical-align: bottom; text-align: justify">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt">101.DEF </span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="3" style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">XBRL Taxonomy Extension Definition Linkbase* </span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="3" style="vertical-align: bottom; text-align: justify">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt">101.LAB </span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="3" style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">XBRL Taxonomy Extension Label Linkbase* </span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="3" style="vertical-align: bottom; text-align: justify">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt">101.PRE </span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="3" style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">XBRL Taxonomy Extension Presentation Linkbase* </span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="3" style="vertical-align: bottom; text-align: justify">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt">104</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="3" style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) *</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 10pt">*</span></td>
    <td style="width: 24px">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Provided herewith.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">**</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Furnished herewith.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Page; Sequence: 109; Value: 64 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_026"></span>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements of
Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Date: September 29, 2025</span></td>
    <td colspan="2"><span style="font-size: 10pt"><b>LUNAI BIOWORKS INC.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 50%">&#160;</td>
    <td style="width: 5%">&#160;</td>
    <td style="width: 45%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">By: </span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt">/s/ David Weinstein</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">David Weinstein</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chief Executive Officer </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">(Principal Executive Officer) </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">By: </span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt">/s/ Nathen Fuentes</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Nathen Fuentes</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#160;Chief Financial Officer </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">(Principal Financial and Accounting Officer) </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements of
the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the
capacities and on the dates indicated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="width: 28%; text-align: center"><span style="font-size: 10pt"><b>Signature</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 42%; text-align: center"><span style="font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 28%; text-align: center"><span style="font-size: 10pt"><b>Date</b></span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="border-bottom: black 1pt solid; vertical-align: bottom"><span style="font-size: 10pt">/s/&#160;David Weinstein</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Chief Executive Officer </span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">September 29, 2025</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-size: 10pt">David Weinstein</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td><span style="font-size: 10pt">(Principal Executive Officer) </span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="border-bottom: black 1pt solid; vertical-align: top"><span style="font-size: 10pt">/s/&#160;Nathen Fuentes</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Chief Financial Officer</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">September 29, 2025</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">Nathen Fuentes</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">(Principal Financial and Accounting Officer)</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: White">
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt">/s/&#160;Douglas W. Calder</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Director </span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">September 29, 2025</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-size: 10pt">Douglas W. Calder</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="border-bottom: black 1pt solid; vertical-align: bottom"><span style="font-size: 10pt">/s/ James A. McNulty </span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Director </span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">September 29, 2025</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">James A. McNulty</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="border-bottom: black 1pt solid; vertical-align: bottom"><span style="font-size: 10pt">/s/&#160;Mark Collins, PhD. </span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Director </span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">September 29, 2025</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-size: 10pt">Mark Collins, PhD.</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</span></p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="margin: 0">&#160;</p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- 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 -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>2
<FILENAME>e6882_ex21-1.htm
<DESCRIPTION>EXHIBIT 21.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 10pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; font: bold 10pt Times New Roman, Times, Serif; margin: 0">Exhibit 21.1</P>

<P STYLE="color: #365F91; font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">LIST OF SUBSIDIARIEs</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The following is a list of subsidiaries of the Company as of June 30, 2025:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Cambria, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; width: 50%; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Subsidiary Legal Name</U></FONT></TD>
    <TD STYLE="padding: 0pt; width: 50%; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>State or Other Jurisdiction of Incorporation or Organization</U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Renovaro Biosciences, Inc.</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Renovaro Biosciences Denmark ApS</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Denmark</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GEDi Cube Intl Ltd.</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">England and Wales</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GEDi Cube B.V.</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Netherlands</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grace Systems B.V.</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Netherlands</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioSymetrics Inc.</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioSymetrics Corp.</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nova Scotia</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>e6882_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We hereby consent to the incorporation by reference in the Registration Statements
on Forms S-8 (No. 333-261628 and 333-275132) and Form S-3 (Registration Statement No 333-282898) of our report dated September 29, 2025,
relating to the consolidated financial statements of Lunai Bioworks, Inc., which appears in this Form 10-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt"><I>/s/ Sadler, Gibb &amp; Associates, LLC</I></FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Draper, UT</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>September 29, 2025</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>e6882_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT
OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>I, David Weinstein, certify that: </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">1. </FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">I have reviewed this Annual Report on Form 10-K of Lunai Bioworks Inc.; </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">2. </FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">3. </FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">4. </FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15-d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">a) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">b) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">c) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">d) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">5. </FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions): </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">a) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">b) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Date: September 29, 2025</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s / David Weinstein</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">David Weinstein</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">(Principal Executive Officer)</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>e6882_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER<BR>
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>I, Nathen Fuentes, certify that: </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">1. </FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">I have reviewed this Annual Report on Form 10-K of Lunai Bioworks Inc.; </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">2. </FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">3. </FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">4. </FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15-d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">a) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">b) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">c) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">d) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">5. </FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions): </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">a) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">b) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">Date: September 29, 2025</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Nathen Fuentes</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Nathen Fuentes</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Chief Financial Officer <BR>
(Principal Financial and Accounting Officer)</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>e6882_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION PURSUANT TO<BR>
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO<BR>
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Annual Report of Lunai Bioworks
Inc. (the &ldquo;Company&rdquo;) on Form 10-K for the year ending June 30, 2025 as filed with the Securities and Exchange Commission (the
&ldquo;Report&rdquo;), the undersigned, David Weinstein, as Chief Executive Officer (Principal Executive Officer) of the Company, hereby
certifies as of the date hereof, solely for purposes of Title 18, Chapter 63, Section 1350 of the United States Code, that to the best
of my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">(1) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, and </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">(2) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Date: September 29, 2025</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ David Weinstein</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">David Weinstein</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">(Principal Executive Officer)</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>e6882_ex32-2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 32.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION PURSUANT TO<BR>
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO<BR>
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Annual Report of Lunai Bioworks
Inc. (the &ldquo;Company&rdquo;) on Form 10-K for the year ending June 30, 2025 as filed with the Securities and Exchange Commission (the
&ldquo;Report&rdquo;), the undersigned, Nathen Fuentes, as Chief Financial Officer (Principal Financial Officer) of the Company, hereby
certifies as of the date hereof, solely for purposes of Title 18, Chapter 63, Section 1350 of the United States Code, that to the best
of my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">(1) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, and </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">(2) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">Date: September 29, 2025</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Nathen Fuentes</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Nathen Fuentes</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Chief Financial Officer<BR>
(Principal Financial and Accounting Officer)</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /U U?5+
M/0=+NM0O[F.ST^VC:>:XE;:D4:C<S,WIBO+U_:Z^"LBJP^*'A<JW3_B91?XU
MM_M&?\F__$;YMG_%/7_S?]N[U_/5']U:Z:-&-4\W%8B5"7NG[^_\-<?!?_HJ
M'AG_ ,&,7^-'_#77P5_Z*AX7_P#!C'_C7X"?)]VE\L[=WE-M_P!VM_JT3D_M
M&7\I^_7_  UQ\%?^BH>%_P#P8Q?XT?\ #7'P7_Z*CX9_\&,7^-?@+L%''I3^
MIQ#^TI?RG[]?\-=?!3_HJ'A?_P &4?\ C1_PUQ\%?^BH>%__  8Q?XU^ O'I
M1QZ4?4XA_:,OY3]^O^&N/@O_ -%1\,_^#&+_ !H_X:Z^"G_14/"__@RC_P :
M_ 7Y/]FG^2WE>;Y;>5NV[]OR[J/J<1_VC+^4_??_ (:X^"O_ $5#PO\ ^#&+
M_&C_ (:X^"__ $5'PS_X,8O\:_ 3Y:78*/J<1?VC+^4_?K_AKKX*_P#14/"_
M_@QC_P :/^&N/@K_ -%0\+_^#&+_ !K\!>*-@I?5HA_:,OY3]^O^&N/@O_T5
M'PS_ .#&+_&C_AKKX*?]%0\+_P#@RC_QK\!/EI=@=OE3?_NK3^IQ#^T9?RG[
M]?\ #7'P5_Z*AX7_ /!C%_C1_P -<?!?_HJ/AG_P8Q?XU^ O'I1\G^S1]3B'
M]HR_E/WZ_P"&NO@I_P!%0\+_ /@RC_QH_P"&N/@K_P!%0\+_ /@QB_QK\!>/
M2D^6CZG$/[1E_*?OW_PUQ\%_^BH>&?\ P8Q?XT?\-=?!7_HJ'A?_ ,&,?^-?
M@+L%'%+ZM$/[2E_*?OU_PUQ\%O\ HI_A?_P91_XU+>?M5?!_3OL_VGXC>';<
M7$*7$7FWR+YD3?==>>5K\ "E=G\3E&[P?\B_\BS8_P#L]'U:(?7Y<OPG[C_\
M-=?!3_HJ'A?_ ,&4?^-'_#7'P5_Z*AX7_P#!C%_C7X$0VTEU*L4$332O]U47
M<S4S8=VU4;?_ '=OS4_JD1_VC+^4_?K_ (:X^"__ $5#PS_X,8O\:/\ AKKX
M*_\ 14/"_P#X,8_\:_ B:SDMI?*G@:%]OW98]E,XI?5HA_:,OY3]^O\ AKCX
M*_\ 14/"_P#X,8O\:/\ AKCX+_\ 14?#/_@QB_QK\!=@HX]*?U.(O[1E_*?O
MU_PUU\%/^BH>%_\ P91_XT?\-<?!7_HJ'A?_ ,&,7^-?@+QZ4<>E'U.(_P"T
M9?RG[]?\-<?!?_HJ/AG_ ,&,7^-'_#77P4_Z*AX7_P#!E'_C7X"_)_LTZ2%H
M=NZ)DW+N7<OWEH^IQ%_:,OY3]^/^&N/@K_T5#PO_ .#&+_&C_AKCX+_]%1\,
M_P#@QB_QK\!?+']VC8*/J<1_VC+^4_?K_AKKX*?]%0\+_P#@RC_QH_X:X^"O
M_14/"_\ X,8O\:_ 7C/W?FHV"CZG$/[1E_*?OU_PUQ\%_P#HJ/AG_P &,7^-
M'_#77P4_Z*AX7_\ !E'_ (U^ GRTO'I1]3B+^TI?RG[]?\-<?!7_ **AX7_\
M&,7^-'_#7'P7_P"BH^&?_!C%_C7X"\>E'R?[-'U.(?VE+^4_?K_AKKX*?]%0
M\+_^#*/_ !H_X:X^"O\ T5#PO_X,8O\ &OP%X]*3Y:/J<0_M*7\I^_7_  UQ
M\%_^BH>&?_!C%_C3E_:N^#[Z?<7J?$?PZUG;NB2S+?(RHSYV!L?WMK5^ >U:
M[;PQC_A5OCO[O^OT[_T;+1]6B+^T)?RG[??\-D?!#_HJ/AO_ ,#DJ?\ X:[^
M"G_14/#'_@RB_P :_ 7BEVCYVV_=^9J/JD1?VC4_E/WY_P"&N/@K_P!%0\+_
M /@QB_QH_P"&N/@O_P!%1\,_^#&+_&OP%V#^%-S?[M)\M'U.)7]HR_E/W[_X
M:Z^"G_14/"__ (,H_P#&C_AKCX*_]%0\+_\ @QB_QK\!/EI=@H^IQ#^T9?RG
M[]?\-<?!?_HJ'AG_ ,&,7^-'_#77P5_Z*AX7_P#!C'_C7X"[!1Q_=I?5HA_:
M,OY3]^O^&N/@K_T5#PO_ .#&+_&C_AKCX+_]%1\,_P#@QB_QK\!=@I\,+32I
M%%$TTK?=1%WO3^J1'_:,OY3]]_\ AKKX*_\ 14/"_P#X,8_\:/\ AKCX*_\
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M9-T2[\_WON-_M4>TE_,'L*?\IYS_ ,.]_@!_T(K?^#.X_P#BZ/\ AWO\ /\
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MIK.'1Y]4U6\O+A8K>RL;%Y96W)YJOM7_ )9;?FWO_<:CVD@]A3_E.+_X=Y_
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M(XY9[R*'3WE-C%$T2RRS[-RHO[V+_OK_ &7H]I+^8/84_P"4Y#_AWG\ ]O\
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MMJ.\Z2OYJHGS/]QUV-\JT =;H7P&\.^']3TK4A=ZMJ-]I+V_V";4+OS?L]O
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MS%KK<MV\$6EW"7[N\JK_ !2[/[OS?\!>@#W1])L?L_E-I]E]GW?<>VBV;O\
M=KD=0\ ^$-#\12>*;K2I7U*XO/\ IK/$D\_[KS?(^94=_NL^W[M>+:]^S/KE
MQH.@"'S9+K[5J,NKV]GJJQ//+++_ *)<>;*CK^ZB^55_@W_+71P_"'Q/#<:J
MC:?;RZK)K]KJ7_"4RZH[3WMFEZDOV=UV;EV1+L_X"O\ >H*/;KF\L8=<TRUE
MBWZA+YOV:;R-_E;?O_-_RR_]FJIJO@_0M<BLSJ&E64T5K=+?0)Y2JGVC8R([
M;?E;_6M][^_7SQ'\!OB FGWUC82PZ-;@ZC]F:74B]W+Y\,2_OY8OO[F1EW_>
M56W-5RY_9[U_7EU)I--M-$T>6VU3^S/#BZJ\L6G74MK;I;ON7Y?];%++_L;Z
M />?$'B;P]X+BN+[4Y[2PEM;%KM_W:^:MK$R;_N_-L1F2I=!\*Z1X;L'@TS3
M[:VMVE:X;:F]Y69WE=W?^)M[.]>,?&#X'ZWX\GTZ]CTRRU756\%W7AZ?4+B[
M\J6UNI?*;S5;^)&VRK\G]ZL#QM^SCXBOM<N(M(9T\))J4LEGH^GZDMJ\'FV]
MNOVI'E1MK)+%+\OWOGW+0!],M;1)=?:6BB2XV[?M#(GF[?[F[^[_ +%#V<3H
MD7D0NFUD5?*79M;[Z;?[M?.'B[]G_P 1WG@_7K?3;'3KS7-:UJ]ENM0O;MWF
M6S;S7M=C,VU=C,FY/X?G9/FKG=/^"_C_ ,23^(8EW:#KL5W=12^+)M0E\VZ5
M]*@B^SI%_P \GEW-N^[\F]?FH ^KO[/LY(HE^QVGE(_FQ)Y"[%?^!T_NM_M5
MFP:[HL%\EA9M#]HGO&LI5LH-Z+<>5YKI+M3:OR?WZ^>;3X)>-]#\.RQ:+93B
M>_TK5M,ET^_UV,)9RW26ZI<(T2(NS=$WRK\WS[OXJNM\ O%%OJ6O?V'%9>'K
MB^U:ZO\ ^W+2\V/+YNE- FY5^;Y)_F_X'N6@#WB;PCH=YJ>FZA+IED]UIR2P
MV?[M=D7FNC2[%^[OW1)_WQ6M';11W#SK%']HW;VFV_.S;/[U>"6WPCUQ-:\"
M:AIOA"R\-OI-Q_IENVKK=6BKN3S9=NS=Y[[/E=/F_O5F?$3X,_$'Q=X\\6ZE
M8_8+"ROM-O\ 38)K>\,;W44J1?9WE_C5T>)_[JK_  T >^ZI>:9X5T*^U.Z2
MULM+L(I;J=TB54B3;^]?;_G=5RP2S>**\MH($^T1*_G0Q;'9?X*^:/'O[.OB
M74)_%ECI6EV&J>%;Z/48M'T>XU5[>*PGGM;=4NO^ RI<?+_TUW?Q5]+Z3:M9
MZ3I]K)_K;>UBB;_?5=O_ ++0 [[%!NMV6"#S8/\ 4-Y2_NO]W^[_ , J9(XH
M518E5$7[J(NQ*/N?_9T__>:@D9_#1]_[M%'WJ '_ ,5"?>6A/O?>H3[RT =1
M1114&I%-_J7_ -VN9KIIO]2_^[7,U1$@_AHV>W_C]%%,D/X?X?[]/^[3*/XT
MH /^^:?3/X:?0 ;F?93/O4__ &6IGW__ +"@ ^6A_P"]13Z #_@'\5-^7_9I
MWETS_>_]"H /N?P_^.T4/\M% !L_V&H^6C[_ -ZGT ,_\?>C_/W:?3/_ !^@
M ^__ +='_?-/_P!BC9_LT %'_H'_ *%3/]U:?0!R/Q"^(4'P]M_#[SZ?J&JM
MK.JV^D1)I\7FNK2H[[WV_P /R5R^I?M,^ -*M9;RYOKY+=;JXM8IOL,J).T&
M_P"T>5_>6+8^YOX*[3QIX-MO&EKIT,]W=Z=-INH0:I:W=H5W13Q[MOWDV[=C
M,K?[U<KJGP#\/ZEIFCVBW5]9RZ3<WEQ:WBI%+*BW4KRW$6V6)UV[ON_+N78E
M $'CS]H?PQX&L]8;R-2U*ZL+-=0BM[>Q?_3(F>)-]N_\>SS4^Y4^L?M">#M!
MU&XL;M=8^UV_RRVZZ/*[^:MNEP\7R+]]8GW,O]W?63J7[,'A34M<UO5;J^U4
MW6J07%NS^;%O@67RG;:VS=\C6Z,JO\JUT+?!?1Y;YKNYO=0N+J2\GO9)6E1/
M-EELOL4K_(G\47S?[U &==?M+?#FSOM0L?\ A(E>2RLWNY)8XF=&5(EG94_O
M,L3HVVGQ_'S0[WQ5X<T.ST[6KF[U>]N=/E\S3Y4:P:"!)?WJM\RJZ2HV[^Z^
MZJ=K^S-X8T_3]6T^VO-0MM-U2Q^Q75NB0?,WE)$TOF[?-WOM3Y=^S_8K;OO@
MSIESXFE\0VVJZII6L-?-J'VBTEB^\UK%:NGS(_R[(D_X%04=[\OW6HIEM"UG
M:Q12SR7+Q*J---]^7Y/O_P"]3_\ OJ@D/E2CY?\ OGY/O4__ '?GIE #T=E^
M969&_O+1_GYZ9_']VB@ ^7_<H^^]'^S_ '?O4?-_G^*@ _S\]/\ ]W=13/X]
MOR_[E !_%1L;;]VC[Z44 /\ XJ9]]?\ ;:BG_P#?5 #'^=G_ -ZC_@2T^B@!
ME<5KGQ4L]!^(*>$Y]*U:Y=M%EUIKZTLWEB55EV;/E_BKM:X+X@?"'2_B%?37
M5SJ>K:<\VFRZ1/\ 8)UB2:!I?,7=\GWE9/X/]UJ .;U[]H;3UCTFZT 6]]#>
M2K ]G=++;W$<O]I6]E*G]U-GF_<:M6X_:,\"VEO<3RWM]Y2NGV9OL,O^G*\O
MD*UK\G[]6EV+N3^^E4M/_9G\(:=;VD$3:@Z6\LMPOS*B,SWL5T_R*FW_ %MN
MGW?X=]6+']G?P[9W=B_]HZM<PZ;)!_95O-(NW3HHKA+CRHOE^9&9%^_N^5=M
M!1T.O?%?PYX;TVTNKN>Y>6ZG6W33[>V>6]65HGE\J6W7YE;8C_*]8D'[17@J
M\T&]UR"?4IM/M4BN)7BTR??]EE1Y8KC;_P \-BO\_P#L/75ZUX#T?7=4TS4I
M+5;:]LK[^TOM%G$D33R^5+%^];9N;Y)7KSG6OV5?".O:?8V=WJ&L1P6NG6NE
M'RY5?S8((I8EW*Z,N[;*_P _\+?=H O>*/VC?#6@^)=*L8I-^E-/=1:GK,T4
MJ6-JL5D]T^R79M9MB)\G^W5C4/VAO#2?#R]\7Z1;:AKUI97\&FSV-I9M]HBE
MEE1$W)_=_>JW_?%5KC]F3PK>%[>ZN]6FTAVEE_L=IT^S^9+:_999?N;]S)\W
MW_OUM_\ "F=/?X?WOA.75M0>WNIXKC^T$2WBN(I8GB>)UVQ*OR/$GWD:@DKZ
MI\?_  =HYU474]^BZ=>+ILK/8R[6O&_Y=4;[K2[?FV4VY_: \(?8[2YM9[Z\
M2\TRXU73GALW\J\6*)Y7BB?[OF[$?Y/]AZGU;X):'K&A7=A<W5YOEUIO$*WK
M^4\L5YLV,^QUV,OWUVLFWYJRH?V;/#"^++?Q#-?:I>7MO T2J[1*GS6KVK_=
MB^171W;8GR[_ )_XJ"@L?VD_"=SI^E2W-GKMG=ZE!:RK8_V9*[JUTCO;Q?*G
MWGV/M7^+95N']I/X>7.HZ?:1ZYOFO[5+J)DB;8N]'E1'_NRNB/\ )4F@_ G1
M=$73I'U#5-1N+*33I8I[IUW/]A65;='VI_=E?=_NK6=HG[-/A7PW<;M/NM0M
MHFM?LMRG^CR_:OD=$=Y6BW*^V7^!U^XE!(Y_VD/#4SZ$NFV6LZE+JFIVNGK"
MFG2I*JW44MQ%<;&^]$Z1/\_^Q7JW_?/^_7G$GP)T..ZT^[MM0U2QO;'^R_(N
M(I4^7["LL47WDV_.DLJM_O?+7>:58-I6FV]M+>7.I2Q?\O=WM\UO]_:E %SY
M?]FDCI^__:^=:9_WU0 4_P"^W_Q%,_X%_P".T?>_SOH -^_^+_OBC^&G_P#H
M%,H /,IZ?>6C?_M4)]Y&V[Z .HHHHJ#4BF_U+_[M<S733?ZE_P#=KF4_\?\
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MY^2C_>_W*/O_ 'JU ?\ [/\ [/3/X?FH^_\ +MW_ .PE/_S\E #*?_Z'3/\
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M7Y-W_C__ -C5&$I#III+F7S69II?O_>_W/\ ["F_]]/_ )WT/_XY_N_^.?\
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MOG@9-Z2KY3M\O^]\U;GB3_D7-8^]_P @Z?\ ]%/7*? 3_DA/P\^7Y/[ L_\
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M(OD^]_%_'09RD8CNTS.S,SNW\?\ '_G_ -FH?^/_ ,>=/D_S_G_;H_\ '/\
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M_HI*ZKQ+_P BWK;?<_T&Z_\ 135ROP%_Y(7\//\ L 67_HI*K[)'VCNZ*?\
M[_\ X]6?K&J_V5:HVWSI6;8J;JDLYSQ/>7-MJGRRR(FWY=C5U=@[7-G%*R_.
MR+NKYL\0_M+13:EKMS!IZWB:2T44#[ODG9G='_W5KR+]H3XV:]KWC"WNI?$_
MBWP;X4;PS]M\-_\ "+6WF_;]6W_/%+\_S,CHB+$_RM\]:^SD<OM(Q/O6N/\
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M_P!>[UTM<U\5/E^%_C7^#;H5_P#P_P#3O+3B;2^$/A6FSX7^"E^5/^)%8?\
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M_P"!T_\ X$O_ 'U1O7^%E_[ZH$9GB3_D7-8_Z\;C_P!%/7*? /\ Y(5\//\
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MJ_Z;:JUU _\ N_?3_@?_ +)7CQ.BI'F/E+Q._P!FTE)8E;?;RJ\2(W]W_/\
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M._YO_'_O51TK_CPB7^ZS[?E_VWK'FES?$3RQ_E//?^&:/AA_T)]I_P"!,_\
M\=K)UK]G'X:0W$2Q^$;1/EW_ .OG_P#CM>S5S^O?\?D3_-LV_?K;FD5[./\
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MGYZL84?YV4]/[JT?W: #RZ9_Z'_MT4__ - H R_$W_(LZQ_V#[K_ -%-7*_
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M,T/Q-+%+JNE07\L2[%>9?NUZQK&CKJMOM^Y*OW7KA+FWEMKAX)5V2K\G^?\
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M_P#'O\[*BG1ITO>C$.2!P]G\$_!UGJ45Y%I7SJRNN^5]BM\G\%=PGS[/X_\
M<7_/^=E&S?O^3Y_]W?\ [_\ G_\ 9KJ/#WAY=R7EXO\ MJE;<Q<8EWPWH_\
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M4LWB9WWZNLKI^Z@_NJOW=WWM]?3G@7QTOBWX;^&O%ES9R:5_:VG6^H?87^_
MS)OV5XU\+?@AH>O:)X?L_'_A#2]5U/2VE^R_VA EP\2[]Z?\!_V/N5[5XS3R
M=-MUBB7Y6_=(B_['R)_Z!1+E+I\WQ2/-_&'QR\+IJVJK+*SIHRQ?:D1=^[<^
MS8G^W\]>:?&;]J/Q'8^-E\.^ M7\+^'M/L/#+>)&U/Q3]R_7Y]EO%_=5=OSM
M_#NK"\*_!_7KFW\5RZ]8LDMY:_Z+^_\ G\_?O2N[^%'P6T7Q/X9T?2OB)X0T
M_5;C39[A[:'4X$E\I-^_Y/\ 9W_P5?+&)ES2D>Q?"?XD?\+&^$/A7QK?6/\
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MFVO0H?"5\S/N:--U,B,92,7Y=W^Q_"__  /_ ,>^^]2V=A/>2I%%$SNW\?\
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MB_\ L: &?=I_S)_MTS^&G_\ LU #**?3* '_ /CE,_@^]3Z.?_'J &?[E/\
MO?\ [-,W_P#?=&S_ (!_O4 5YO\ D*6GR_(L4K_^@?\ V=,N?GO]/5ON;F?9
M_>;91-\^J6G^S%*__H%37ELTT7[K:DL7SQ?W*YN7XB"'?_Q-(OX]L#_^AU>3
MY/FW5GVURMS>)+M9-T#;D_X'\]7?XMWRI5T_>*B9]YX=T^\TW4+-K2"%;R!K
M>?[/$BNR,FS[VRLK5;"S\/> TL;Z>2_TRU@BBGN+O]Z[1*Z;]_\ P"NE^?\
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M8FT[8_E,J;G=_G6O3?+@=ONP?>_V*\Q^(5QX CMO#5OXS^Q);^?++:RW"O\
M>_C^[]Q7^7=N^6N"I\1U%74/VFO L/A=+NYO98;VXM8)GTIHF^T(L_\ $_\
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M,_AHH /^^:/]S_QVC^&B@!/X?_BZD^__  KLH^[OIE #_NTS^';1]Q*?_%0
MS_;I_P!S_P"SH_X#3* !/\_-13_^!-1_G?0 S^+_ .QH3[E'^S\WW?NT_P#V
MZ &?P_\ V5%/^[10 ?,E,_N;/^ TO\7_ ,12?]\T 5/^8MM_Z=?E_P"^Z?-?
MQVUQ%$RL[LZ_<_AW/]]Z9>?Z,T5S_!%\DO\ NM5?4H7^U/M^^T2^5_M-$^[9
M7-*4H\Q 6'R:S+M_Z:_^AI_\6]:?^ZU95F[/JCR+N2*7S=N_Y-WW/_LZV/\
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M]?G_ +]%=/M7^Z/RIODQ_P#/-?R% '-??_NT?]\_WJZ7R4_N+^5'DI_<7\J
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MH\E/[B_E0!S7_ EH^3_ONNE\E/[B_E1Y*?W%_*@#FOX:*Z7R4_N+^5'DQ_\
M/-?R% '-?+1_GY*Z3:O]T?E3O*3^XOY4KL#F7=7H_P"!?\ KI]J_W1^5-\E/
M[B_E3 YK_P ?I_S?WZZ':O\ ='Y4ODQ_\\U_(4 <[]ZM+3M.:-O-E7YOX5K1
1A55Z*!]!4M05'8****"S_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0'X:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X])^^[OR<@:60])U<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"<_/@T*/'@Z>&UP;65T82!X;6QN<SIX/2)A9&]B93IN
M<SIM971A+R(^/')D9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R
M9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M;G,C(CX\<F1F.D1E<V-R:7!T:6]N
M(')D9CIA8F]U=#TB=75I9#IF868U8F1D-2UB83-D+3$Q9&$M860S,2UD,S-D
M-S4Q.#)F,6(B('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N
M=',O,2XQ+R(^/&1C.G)I9VAT<SX\<F1F.D%L="!X;6QN<SIR9&8](FAT=' Z
M+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/CQR9&8Z
M;&D@>&UL.FQA;F<](G@M9&5F875L="(^/"]R9&8Z;&D^/"]R9&8Z06QT/@T*
M"0D)/"]D8SIR:6=H=',^/"]R9&8Z1&5S8W)I<'1I;VX^/"]R9&8Z4D1&/CPO
M>#IX;7!M971A/@T*/#]X<&%C:V5T(&5N9#TG=R<_/O_A ")%>&EF  !-30 J
M    "  !@I@  @    $          /_; $,  P(" P(" P,# P0# P0%" 4%
M! 0%"@<'!@@,"@P,"PH+"PT.$A -#A$."PL0%A 1$Q05%14,#Q<8%A08$A05
M%/_; $,! P0$!00%"04%"10-"PT4%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!04%/_  !$( 7 ".0,!(@ "$0$#$0'_
MQ  ?   !!0$! 0$! 0           0(#! 4&!P@)"@O_Q "U$  " 0,# @0#
M!04$!    7T! @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*"
M"0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS
M='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$
MQ<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$!
M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M.TS_ +YI] !L_P!G_P =H_S]VF?+MI__  %: #9_L_\ CM&S_9_\=HIGR[:
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MW:FJ"S_X]HO]VIZ@U/!OVN<?\(GX+W?=_P"$MT_/Y2UQO\7_  +?79_M=?\
M(J>"?^QML/\ T&6N,?[VW=6T?A.&I\18TK_D*6O_ %U3_P!#J*;_ %LJKM^=
MO^^O\[*L:.K/JUI\O_+7?_NU4?YY7^?[S?WJHR#^^WS?WZ]-^&GB'[3:OI4[
M+YMO\\7^TM>7_P"U_P #JW87T^E7\5S;-LN(F^6@<9<I] ;/O_[U7+?3&E^:
M7Y%;^'^*H_#K+J&FVU^8V0SHLBH_\"XK;K%G?'8JPV,$8X3_ +ZYI_V6!O\
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M=M/_ ,_Y_P#'J/\ /^?_ !Z@ _BIUON\Y=OWOEVTW^^M";?-^;Y$W?-0 /\
M>:FO]RG?Q?\  J90 _\ Y:?Y_OT?=IGF4_\ C_VZ &?PT_\ C>F4^@!F_P";
M=3_]S_QVC^&B@!G\-/\ N[_^!4?[/^?XZ:_W* '?Q4?=H_B_X%3/[_\ G^"@
M!_\ =IE/_C2F?W/\_P % #_XMW^?OT)_!1_%10!N6?\ Q[1?[M3U!9_\>T7^
M[4]0:G@_[77_ "*G@G_L;;#_ -!EKC)'^_\ -7:_M:;/^$9\#^:':+_A+;#=
ML^]]V6N:_M**VE_T.V5'^;9-<?O7_P#B:VC\)PU/B"VMFL+=[F5=CLK) CML
MW,WR;_\ =_\ BZS_ /=_[[I\TS7,OFRLSNW_ "V?[],CJC(/\K_?K:\%Z+_P
MD'B>RM)5WQ,WFR_[JUA?[7WZ]$^"<2-X@OY#MW1VV/\ Q^ID:1]Z1[0J!%"C
MI3J*2L3O/&/%5U=_%;QGJ7A6'4Y=)\':)M76KNTF,$]_=,NY;))5^Y&J%7E9
M3N^=$^7YZ[S0OAGX3\.Z:MGI?AS2;.UVX*06<0#_ .]\OS5X39^']4U3_A*(
M[:":_>U\4:C]LBA^9]S.CQ/M_P"N7E?]\U:^*7[1UM^RWX%T"VUO3[C6]>U"
M1UMM/AEVE8U?[SNW^]6O)?2)R>TC'WI',ZQ\,O'?PB^)&J^)? .E[;)[EKJZ
MTFUD6&PU&'[S(T7W8I53?ME1>6V[]]?4/A7Q%8>,O#.FZYILGG6&HVZ7,#^J
M,N17GOP.^-VE?M"?#^/Q)I=O-ICVUSY%W:7#?ZATPQ&_^)=K?>J?]FQ6;X.Z
M,X.()YKJ>U7T@>ZE>+_QPBO*PN#E@XRBZDI>]]KH%&,8ZQE[LCTZ^M_M%LR[
M?F7[M8WWJZ*O//'_ (M3P%X-U7Q"UFU^NG1>;]G27:\OSJNS>W_ :])'1(Z'
M[_\ OT?>KQG7OVD(O#,^H:;J'A?4(=:TY)7O+&WG6=(MOV=T?<OWE=+A&W;/
MDV/5N'X_6]SHNJZ];:#)>>&M)14OM3M+Z*5//9$=8HD_Y:_ZU%W?+]^F!ZWO
M_B_]GH_SO_S_ +E>0:A^T1;>%]8OM(\3>'+O0M3L[9IY4%S%<(W[KS8HE9?X
MI=KJO^TE8&H?M71Z;I>IZE<^&OLT5AJJZ1*MWJL43I<?.[[OD^5?DVT!RGOU
M'^ZG_ *\U\-?&1/$OBJQ\/Q^&M5MKRZMDOW^T(JI!9O%N25_]IG?RMOWMR5Z
M/_G[M!(__=_[[_S_ , HH_X#_P".T;/[R?\ CM !_P !_P" ?Y_X#1_G?1L_
MSMH_X#_X[0 ?Y_S_ ..TRG[/[R?^.T?W/[_^W0 _YMLOR_Y_SLIE";=K_P!_
MY=J4S^]0 _[NRBC_ ):?Y_OT?W: "F?^.4^B@ _] H_Y9_Y_N4?W:* #T_S_
M 'Z*/OI3/^6?^?[E #_]G^*C_;HIE #_ .Y_O4;-G\-&_P#[[H\N@!G\/S4_
M^+=3/]NG_P 6Z@!G\-/'\?\ P*F?P_\  :?_ !;?]J@ _O?Y_OT?/M_S_<IG
M]ZC^-Z '_P#+3_/]^C_;H^X]'W: &)_X_3_\_=H_V?\ /\%,3;MH ?L_V?\
MQVC9_L_^.T;/]FF?[O\ Z#0 ?P)4L6[SEV_.RM_X]45/AV^8FYMB[E_BH /[
MW^?[]'_+/_/]RA]S_P!YZ/XMU  W\?WJ/[U,I_\ L4 '_H='^S_P"F?\L_\
M/]RG_P!Z@ _B_BIG]VG[/FV_P?\ V='^W0 S[M'\-/H_NT %,_AH^]0_SJ]
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M?_'Z/,_O??6GS)LV?=_W_N4R@ _V?^ 4?W/]ZBF?P_\ CE !_#13_O4?^.4
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M )YM_P!]4)]Y_P"#[W_ :=O7_GNU "[U3YO*;_@;4-_KG_WJ=O\ OMYLC_\
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M )%/P7_V-UA_[5KCN?\ QZMH_"<-3XA/]W_@%,_\?W?Q_P"?]RG_ ,*;MO\
MOT?^A;:HR,_Q%_R+FK?]><O_ * ]/T3_ ) FF?=_X]8O_0*9X@_Y .J_]>LO
M_H#T_07_ .)'IC?P?98O_0$H)^V7?^^J*9_#MI_^Q04'^]_Z%1_<W4?^.?[J
MTS^'Y: +TWSZ3:?W/-E1G_[XH3Y]&N-[?=G67_=^1TI[_/HR,O\ #=,G_CE,
ML/GM=0B_@\AG_P"^72H J4S^'YOGI_\ %1_%5@7=-WS6NH1;F?\ =>;L_P!W
M_P"PJE_M??JWH_[RZV_P-$WS[O\ 8>J/W_O?[*4 /_OK_P!]4?[E,I_^SO\
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M_P!1$K?(J_\ LU:WA[XBWVF[(+[_ $^T^YO=OWJ_\#K;E.;VAZVFW;]YM_\
ML41UGZ)KUCXALWELY5?Y?F1_OK_P#_?K0_O5!H/AA:9MJ_?K3M+%;?YF^:3U
MKQKQ-_;6@_'70]9M['Q5JVC+H=U#<VUFH>Q67>C1;4^7][]_YFJ+XD_\)"WC
M!FC6_=?E^R);;]FW_@/\5'Q!*7+[Q[IG'M17Y_?\%!F^)4=]X-^S2ZLGAW["
MOF?V7YNQK[^+S=G\7]ROHW]F3_A-/^&??#/_  F7VE]9\EO^/O?]H\CGRO-W
M_-OV_P!ZJE3]WF,XUG*I[/E/=6;%5[BW2Z7[VP_=W+7@?[7G_">?\,R^-/\
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MQKX%U#0KNWT;3M1N=-UJ]N;B9]0@A:Z@G$JI\Z1;_DW_ '9=U07OP#\9>*/
MNA>'-2M;"PBTN"]L'N+?579[A9[B*7S4=4_=-L1_^!4!RGTL\T2?ZV>%/FV?
M/*GWO[E2['_RU?,O_"A?']CJFN7MW-H?C*^NI9TL9M75?+M3NB,5Z\3(R^8R
MIL?;\W\2U]-P[O*A5MN_ROGV+0 S9_NT/#_WQ3ON1K_O-_#_ +M/^XTK?Q__
M &=!(UW_ +K[/F;[E,\YO[W^?DHWL^SYFHH -^]J9_#\S?\  Z?1_=_S_<H
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M\_[=6*"1GWJ?L;Y_EH_B^;_Q^IIYA!#-.4:01*S;%^=FV_-_WU\O_H- $/\
M%1L;;]UJ\[U#]H?P5I5G:WLM_<"WN+:TN@\5JS82>7RDW?W&_=ON3^%4W?PU
MK:E\8_#6CV%U?3W4WV>SU-M(=UB?_7JGFO\ [R[4^_05RG7;7_NT;'W?=_\
M':\WC_:,\'0Z&=4NY=1TI%>U'V:^LG2X=)_]5,J?Q1MM/S?P[&J>3X_>'+'6
M=0T[4+;6-'-A>16$]U?6>RW665-\7S[O[B[J Y3T39LB?_:9:97F\O[1G@JW
M^Q1:C<7^B2:C<6\-G_:5B]OYZ3[EBE7_ *9;OEW?P_+NK2O/C!X>L-+TW59%
MU!M/O[I[5;B&S9T@=9?*_>LOW5W[5H [9'5%?=_=_P#B*/W?]YO^^?\ [.C9
ML;:U&_Y?_LO\_P!^@D'38SK3W2)&9=S?W/NT3(SR2_*WWJ)O]<_W?O4 'R[4
M5?[W]W_<J'_/^?\ OBGTS^';_G^.@#?L_P#CVB_W:GJ&U_X]H_\ =J:H-3P?
M]KK_ )%/P7_V-UA_*6N,=/O_ ,==G^UY_P BKX*_[&VP_P#09:XSY-S_ .]7
M3'X3AJ?$'_C]'^?DH^_\O]ZCS*1D9_B'_D ZK_?^QR_^@4_0?^0'IFW_ )]8
MMG_?%,\0_P#(OZKM^Y]EE_\ 0*?HG_(#T_\ CW6L6[>O^Q027?N?P_[M,_\
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M_?KS3Q5\(O%VN3Z[_9^A^%]%M=>T!=(GM[2^94LG2665714M_P![OWK_ ':
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MBU_GY%I__?6S_P"SH_S_ +:T?[6WYZ"@_P!K_P#8IFW^'_T*G_<_] IO^?\
M[.@!WW_^!5=T3_D*1*WW&W(W_ DV52\NK>C_ /(4LO\ KJO\- %%/N_-M^;^
MY]QJT+_<]OIDK-O?RO*_[Y=ZJNC_ &AUBW.^[8J?[7W*M:EMAEM[9=KO;KL;
M9_$WSO0!%IKLFI6C;6=O-7_8IEXFR\EB7_EDS)_N_?I^E)_Q-+)?E_UJU7F?
MYGW?WM] &%K'_(V^'/[FVZ^__N)6U]S[WS_WO\_]\5BZJG_%6^&O[_\ I7^Q
M_!6[_P".4$A]S[U'S?>V_P"]1_K/XME-^_\ W4^7YJ"AWW%_^(^2C9\_^W1_
M>H_W* "C_P! IG\'^S_<H^7^]_P.@ I^S^]_P*BF?+0!>L]SZ;J'[]43;%YJ
M/L_>_/\ ^R54^Y_]G5B';]@O=\#3/\NV9%_U3;ZK_<9Z #^__P#$T;__ !ZC
M^*B@!>?_ !ZD_P!7\W]U:*$1=VW;_P  H /N?+_ O\%'\7WO_LJ8G^?EI_\
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M[:__ 'TG_P!G69J<IJOS^+?#G]S_ $K^/_8K=K"UC_D;O#/][_2O_0*VN_\
MG^_02/\ ]K_Q]*/]W_@/ST?[G^[]^C?\V[^!FH*&/\_^W3V_C_\ 'J/][;3/
MG_X'_P"S4 /^_P#+O^]]Y:/_ $.C_@6]*90 ]/\ OM/_ &6C^YNH_N?[U-^7
MYU5OGH OV'F_V;J#+*J1?NO-_P!KY_DV5GU;A\A[6[9HF>7Y?*F3^'Y_XZK_
M /?+_P"Y0 S_ &*?_P!]5%>3?9K.XEB^^L3.O_ :^%/"/[7GQR\?W6I0>&O"
M.DZPU@NZZ\FSE_=)]Q-[^;6D8\YE*IRGWA_=IGWU^[\E? 'A[]N3XP>+=9_L
MK1O#FC:EJ&V67[);V<N_9$CN_P#RU^78BO6A_P -A?')]>ET;_A$])_MB"Q_
MM*6T>SEWK:^5YOF_ZW[GE;&J_9R)]M$^\OO_ 'J/XWK\\KK]O+XKV=G97<^A
MZ##:WBLUM</8RHDZK\C[?WOS54_X>%_$A=O_ !+/#_\ P&UE^[_W]I>QD1]8
M1^BO_H?_ *%3WV_Q?.E?G0?^"AWQ(^3=I^@?[7[B7Y__ !^O7/V7?VM/&?QF
M^*2>'-<MM)ALFL9;C?8P.C[E_P!YWIRIR*C6C(^N_P"+;_[-3/X=W^S_ !UP
MOQ:\<WW@:PT^?3_LS_:)627SEW[=E<3-\4?B##=/!+I%LEQ%9KJ#(\#_ "V[
M)_K?O_=_BJ.4N52,3W-W_P"^*/\ 8KYT3]H'Q*^S]UI__?IZT[;XM>.II='@
M73+1WU;_ (\42+_CZ^?9\GS_ -^CED/VD3WA$_AV['_V*/OM_O?P5X)<_&#Q
MQ8::E]/IEI#:-=-9;W@^3[0OWT^_]^HM5^-/C'0;^73[ZVT^SO8'V2PO$_RM
M1RR#VD3Z 3^!O_']M,_A_P!ZOG?_ (:!\1_(S+INS[_SQ/3_ /A?WBC=_J+'
M_OP]'+(/:1/HC[G_  &O6_@MK226%UI3M^]B;S(_]I#7C]L[S6MO*WWVB5_N
M_P 7\=:6@ZU/H.K6][;-^]B;YT_O+_M5C(Z(RY9'T]161X<\16GB;38KVS?<
MC?>0GYHV_NM6M6)WA2T44 8_B?PSIGC#P_J&B:S9Q:CI>H0/;7-K-RDL;##*
M?PKXR7_@E'\.YO$5K+=^*O%%]X5LY&EM?#DUTAABWON=$EV[U1O]G#?[=?<8
M)KFO&GB^W\)Z6TCLKWDORP6_]]O_ (FJC*4?A,:E.,OB*#ZAX?\ "\-GX>LY
M;33H-.A6"*T7Y4B39M1/^^:T+.YBN98O(GC?_<;?7S_>7D]_=2W,[--<2MN9
MW_O5-I4RVVI6[,LCQ++\R6_WV7^-$K3E,?:'OK_QT?-\_P!ZO#T\6ZK9ROY%
M].B?-M1VW_+OK5L_B=J\.U6:"YV_QNO_ ,31RA[0]WM6\RUB;_9K@-8\(^#=
M!UE-7U2^MM.=FW+'>7:11%MV[.&]Z\._:*_;$;X&_!G4]8M[2#_A)[AEM='A
MD^>+SFX9W7Y?E3EMM?CIXR\;^(_B7X@GUGQ/K-_XAUBZ;YIKN5I6^;^!%_@_
MW5K6G1E(RK8B,3]NO$'[&GPH^(/C[_A.YK:>:XNIENIX+*]_T*Z;^^RK_>_V
M6KW5M)M&=7\K:$7:JK\J_I7XJ>#_ !S\3_\ @GY\1_#T-UJD=Q:ZC8P:EJ?A
M=;EY8D@D/W94_P"64^VOVC\*^)+'QEX:TK7--<36&I6T5W WJCJ&4_K45(RB
M:X>I&7-RQY9'A'QR_81^%OQ_\;0^*_$MIJ4.L[$BN9--N_)2\5?N"5=K=OEW
M+M->0_\ !2;X)1P_L_\ AV\\-:+,ND>&+JUBOK'2Q\_]G*-FT>R\?-7W;Z"H
M9H5FA>.15=&&UE8?>KF]V?+S^]RFE2C&46?A-XTM?"NM-X*^&OP4:Y\4W&HZ
MBNKRZFUGLO?M4OR6]K_>VVZ?>;[F[YJ_;ZWAN+72=+M[V3SKV.!4G=?XVVKN
M?_OK^=5?#OPL\&^$M2GU/0_"FBZ/J%Q_K;JQL(H96^K*N:T+NX^T3[OX?NK7
M3*ISF=&C[(B?[J?[M'\?W:>W\/\ NTS^&LC<$3>O^?\ 8IG\-'W_ /;I_P!]
MOFH ?#_Q\)_O4S^'YJX_P9XP^V:I+I5XW^D+._D3/_%_L5UO\- &_9_+:Q?[
MM3U#:_\ 'M'_ +M35!J>#?M<?\BGX+_[&ZP_E+7&_P!S_P =V5V7[7/_ "*7
M@O\ [&VP_E+7&_?9_P".MH_"<-3XAG^L_P"^:/O[_P#:I_\ O?Q?)1_WU5&1
MG^(?^1?U5O\ ISE_W/N/3]$_Y >F?Q_Z+%_P+Y$IGB'_ )%_56_Z=9?_ $!Z
M?HG_ " =,;_IUB_] 2@G[1XO^VQ_R;CXC^9?];:_^C4KY/\ AG^TEX3\&_#7
MP[H/B/PU<^.9=)OHKJSM-6L[7[/IW^D;Y?L\_P#K6WI_RR?Y=U?HAXG\*Z1X
MVT:71=>T^/4M,N&7S;2;?L;;\Z5P*?LN_"3Y/^*"TO\ W-K_ /Q=;QE&,>61
MC4IRE+FB?+'_  V%X.AOOE\/ZM?KYMA+/J%W!:Q7%_Y#W#[Y8D^3Y?M"*O\
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M+=?^BDK=^7=_X_02%'S?)_NT1_>_VZ8G^W_L_?H*).?_ !VD_P K\U,^XO\
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MR=XFENHI4?[G\$22I_VUKZ>_X9=^$G_0B:7_ -\M_P#%T[_AEGX3?]"%I?\
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M &UKZ469&52K+\WW:/.7^\/O;:/:A[&)\SQ_ _XO),C/K_@J9%_A>QO/F_\
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M%_\ Z&+P5_N_V==?_':^FO-16V[E_O4N]/[P_O4>T#V,3YD_X49\7MV?[?\
M!7_@NO/_ (]1_P *)^+NW9_PD'@K9_=_LZZ_^.U]->=&VW#J=WW?F^]09$_O
M+\WRT>T#V,3YE_X49\7_ .+Q!X*?_N'77_QVL'3_ (+?%63QMK4*Z_X-\^.V
MM6E_XEUULV_O=G_+7_?KZW\Z+:S;UVKP>:Y#2F6/XG>)&;Y%^P6?S?\  I:O
MVC#V,#QV'X*_%^WM;J!=>\#^5<(BM_Q++K^'_MK5?_A1?Q>_Z#_@K_P7WG_Q
MVOIK>G]Y?[U'FHS;=R[OO5'M ]C$^9?^%%_%_P#B\0^"7_[AMU_\=I?^%&?%
M_P#Z&#P5_P""ZZ_^.U],K-&P7:ZG=]WGK1YZ_P!Y?O8ZT>T#V,#YE_X43\7?
M^A@\%?\ @NNO_CM'_"B?B[_T'_!7_@OO/_CU?37GK_>7[V.M'G1KNRZC;][Y
MONT>T#V,3YF_X47\7?\ H8?!/_@NNO\ X[1_PHSXN_\ 0=\#_P#@NO/_ (]7
MT[D5%-(RQNR+O;'RKZT>T#V,3YG_ .%&?%__ *&#P5_X+KK_ ..T?\*,^+__
M $,'@K_P777_ ,=KZ%T_6&DTF:]O(UA\MWRL1W?*K4ZZ\36-I(R-(SNOWO*7
M=1[0/8P/GC_A1?Q@_P"AC\%?^"VZ_P#CM-_X45\7=FW^W_!7_@OO/_CU?0D_
MB?3[9I2\C;8U=RZQ-M^7[W_H5:\4GG1JVUDW?PL*/:![&)\S?\*+^+I^]X@\
M$O\ ]PZZ_P#CM'_"C/B__P!#!X*_\%UU_P#':^G&D"KDTS>F[;N&_P"]BCV@
M>QB?,W_"C/C!_P!#'X*_\%MU_P#':P/%GP6^*MO_ &+YVO>#/FU6W6+9IUU]
M[Y_O?O:^M_-3Y/F7Y_N\]:Y7X@,&7PUM/_,:MOXO]ZK]HPE1B>(+\"OB\O\
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M:/-16V[E_O4>T#V,3Y-^('P?^*:^'4-SK7@X1K/:P+Y5G=?\_";?X_[U;;_
MSXL/_P QSP9_P*PNO_CM>S_%1E;P?C*MNO+/Y?[W^D15V'FK\OS#YJOVC%[&
M/,?-'_"C/BUM;_B?>#/_   NO_CM._X4;\6MW_(>\&?[WV"Z_P#CM?2GG1;5
M;>NUN.M'G1_WE^]MZ_Q>E1[0?L8GQ5]@^*FFZL\46H>"YIHI]B_Z#=;&9?\
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M^ /ACY/LYO[29/NW%O=NKJN9=R]?XEGE7\:/=)_>%:]_:$T"Q\.VFHSVM_\
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M+)MVQIMW,O7Y_N_*U+JG[//A/6-32\G2\++.ER(?M)\KS$\K:^W_ +8)5O\
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M;^\M','LY?S'SLOQ&^+%Y;&Z.G16$BQ2?Z.^D2O\T5JL^_[_ /RU;Y-O\/\
MO5-I/Q.^*&L:A-;2:=::7)/J$%J8WLY9WL8VE=-Y3Y-Z[=C;]U?1G-'-*X_9
MR_F/&O@WXB\5ZYXJU=_$]Q-"DNGVLL&F-8O%$K_,DLJNW]YE^[_M5[+MH!IU
'*YI&/*?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,M!:8# 2(  A$! Q$!_\0
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M?WC^=)10%Q^X^I_.C<?4_G245)0NX^I_.C<?4_G244 .W-ZG\Z-S>I_.DHH
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M_P \L'N!W(]146B^)=/\0&4V(D#+C_6;>^?0GT-8'Q1R/#J#@GG..WSI6/\
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M1W_VO:L'3OA9;[5%[<R-*V<^4X('7U3TQ7!>(]-31=9:WM;C<JXPZ/G^$'J
M/6N=UYQ?O'=#"T*CM%GOQ&1G.Y3[YHW!B_'I6=H,\EQH-M/+DN=V0<Y^\16D
MP QA2,^U=J9Y#5G83-&:**!!FC-%% AM%%% @HHHI@)FC-%% #:***!!1110
M F:,T44P&T444 %%%% A,T9HHH ;1110 F:,T44 -HHHIDA1110 &FFG&FD4
M )1110 F:,T450AM%%% "9HS1102-HHHH 3-&:**8!FC-%% #:***!"9HS11
M0(;1110-O08%(X)H&6Y/2EY^8D]*QO$6L?V;:"./'GMT3^(\CMG/0U$G9:ET
M*;JNR,_7M:EDD_LW2F:2<_>D4DD]&ZJ<],]JSY_#VH:%"E_93.\G/F*&8^PZ
M >IK2T+2ETVSDO;EA)?ICY<Y89)'0C/0UNRQ2V\$#S7,%Q%=;ODC<N1M/H:Y
ME%RU/4YO9>Y!>ZM_,KZ/J]MK%H94*JW_ #RX!ZGMD^F:OY^7&,&N(U"(^'-7
M%_9-NLF_Y9H<@?*!R!@=6-=E;W4=[ DT;*1)G&#Z'']*VH3YG9G'BL,J7[R&
MS):;3J;72<(9HS110 E-IU-H ,T9HHH W_"'_(6E_P"N!_\ 0EHH\(_\A:7_
M *X'_P!"6BN#$_Q#VL!_!^;*'B'_ )&/4_\ K[E_]#-9_:M#Q#_R,>I_]?<O
M_H9K/[5VP^%>B/)J_P 27J_S8M%%%49CLT9HHH6P+5 <_=]*X_Q]9F6TAN0,
M[-V?Q*BNPW9<D\5G>(+3[7HL\>W+?+M&.3\PKGQ"O2L=6"J^SKIG,>$]3$.@
MWB%@##LQSZLWO6!X>TTZQ?NK#(&/Y'V/I69:7\MK!<1)G$NW/7L<UW7P^LMM
MM+=%>6Q@XZX+"O/A>JTNQ]%77L(SJ+K8PO",[6.NK"QVALYSQT5C_6JWBB9K
M[Q!-@[@-N._\"_X4[75;1_$DC1Y&S&,>Z#Z>M0Z#$VJ^((1)SYF[=^"'Z^E0
MKRM3-$E_'\CTDVZVGA?R-F"/;_;S7DUA9&^OD@4\G/\ (G^E>RZMC^RIP,<;
M?_0A7E?A(!O$ELK#KN_] :NG$1YIQB<6 J/V=229U.L^#;.TT8O;R,9XOO<C
MNPQT7/2L+P/.\6O1B-CM;.X$]?E:O1-=;&C73A5W'9GC_:%>;^"ACQ%"3D#G
MC_@#5+A[.NFA8>K*MAY\[/2-<LK2_LG@O9TAC&-CLX7N">3]!7,6UAX4MXO*
MFNHY&[MYD1_4BJ'C[4KE=16S$CK&F?NDC.0I]:L>'/"FG7UD+RZO %;JIE7(
MY(Z$>U.=12DW85.DZ-%2<G9]CC9Q#;:A_HLK,HZ-N![>WXUZ[?:=!K.EQ"Y!
MP,_/Q_>'<@^E>27T=O!J<B6[!X>,-D'^$>G'6O:8 5TT(X4IV Z]:G#6G%JQ
M>8R<73:W/%]-M4N-3CA<DJV<_D37K%GX6L--N!/%G<O^[Z8]/>O*M)D$.LQ%
MV4 9Y)X^Z:]K^T6\C*%N(6+] '!Z4\)&+;N1FDZD;<NQ(>U9/B?_ ) %S_P'
M_P!"6M?' K(\3\^'[DCI\O/_  -:ZZWP'D8=IUE<\QT73AJ%A?\ RYD3R]G'
MJ3GM[5T/PYU$QW4MD[91\;1GT#D]ZA^':+-/=HP!'R<?@]8D<TGAGQ$3R?*[
M<\Y3\/[U>?"3I14SZ.HO;.=)^1I>*KAM9\3&WCRP7[N.>J*3Z^E9/B6S6PUV
M>UC^Y'MVX]U!_K6UX*MSJGB-;J89"]2>GW&'?/I69XQ)_P"$HNL\[=G/_ %J
M;.REW+I-*?LET1ZUI8!TJ$ML,2[LCM]XUR-QH_A>*_DFN;Y,G'[L2Q>F.A%:
M&KWDEAX'WVSNDGJ3C_EH/3ZUP7A_3DU_55BNKDH6ZN\F!]T]R#Z5TUY^_:US
MS\-1DHRJ.5EY%OQ1!HBM#)I4H(?=N4,G&-N.%_&NE^&US)):7$+L2D6W8I/J
M7)XK!\9:/I.CQ0Q6=QYDYW;@'0X^Z>< 'H36S\,@/(O3R679SV/+UG0=JFQO
M7L\+??U.=\= KXEG&<XV\C_<6K6M>+6?1;73[)FC W^8RG!/S!AR&^M5/'9_
MXJ>XV]/EX/\ N+5>[\*ZA;Z-%J!VO')GA-Q(PVWTK&7,K\IT0C2Y(.?R.G\%
M^$A.!?:@H\ION@CTW#NOKBM'XA:E)8Z7#;Q.\9FS@J2.C(?7WJCX#\3J%-A>
MR?*/]7N;_>)ZGZ4_XF6TK06;$;E3?R 3C)2MWI0M$XGS?6TJGR.;\(VVCR,\
MNK7"!1C:C.G^UV;\*B\4P:3!>H^DS*\;9W*K(<<+CA?QJQX2T/2]:WI=W1@=
M,8S(J[L[NF0?05TDOP_T&%=TNI2(S=WG0 ?^.UE"+DDCMG6A"H^9LGT^\N=0
M\ S$22&=-N>3SF4_CT%>=Z3/9PZDCZ@CO;\[E0 GH<<'CKBO8-&L=/T;1BRS
MI-:2?>:5U8<,>_ ZFL'5/ NDZH//TN\@B_V?-1<]!T53Z&M:U-W3.7#XB"E)
M-.S(;?P]X;U69);&[56Y_=-)&/;H ?0FO0-BQJ4P%"= O'6O!6^V:!J9C6?Y
MD[QN<'*_AZU[CI\QGL(WD!,KYR3[$UKA9QE=(Y\SI2BXMNZ++\(V.,XKP$+Y
MVJ*).C=<_P"[7T!@2#&0#[UX1KMI)I>MRIM90N-I(QG*CZ>M9XM\KC<O+'\2
M1[G:Q+'"BJ0%7.U,^_/%5-:B270IS,%*G;N4C_:'8UG^'?$NGZIIR;[A([E,
M\,Z@G)/N3T%9_C/Q+9VFD26T%Q')/)C(1P<893V.>E:U)QY-&<E.C5=9)H\]
M\&L4\3VF/]O_ - :NM^*0)-ID]=__LE<_P##[3WO/$<,I4^7'NW-C@91NIQ7
M1?%)&(LSZ;__ &2N-IQHW/6J-/%12W-'X;@#0F)/Z_[3UC_%48GT]=QVCS._
MLE7_ (;:A:?V?);S31HPQPS 'JY[FL+XE:I;WNH0Q02)((]W*,#C(3T/M6E5
MIT4KF5.$EC&['5?#+']@@'_/S/7G7BLE/$ESM/\ =_\ 0%KT;X9KNT'/^?O/
M7G'BOCQ+<9_V?_0%J*[;C%7-,.V\1.YU&A_#M]0M1=7]PT;/VWX/!([K["O1
M]/LDT^TCLXW)6//+'U)/]:=9[5T^)2,[<_SJ<C<Y)PH/IQ7?"FHQ/)Q-:=;=
M["_+D+C@?=_K7E/Q-U437L5C&WRQ9W8/J$/K7J$\R6UL9G8 1=23ZG%> W]Q
M-KFKM+\S/+C@9/11]?2N;$R=N1'5EE)N7M)=#T3PWI]K-X#F1Y[9)IMN07 /
M$I]O2N/\(ZC_ &3XFBS(!&<[B#Q]QL=QZU=B\'^*8(@J2S(G]P-*!^6VN=U/
M2[W1;X1W =)1T/(SP/4#UKGDW%IV/2C&G+FCS7N?0-WQ;2X/RG'\Z\(T4Y\1
M0XZ_-_Z :]ATC4O[3\*BYR&8]<<_QD>OM7CNBC;XFB_'_P! -=%3WJBU.+!*
MT:D>Q[^:!00?2DW!4+D@*.I/05UR7+[USRG&[2/,_BCJPWP:>C$%=VX ^NQO
M6I_ 6F61\.W$D\]N!<;<K(X_A=NQ%</X@OY-:\12SQ;Y ^-JGGH@!XY]*V8?
M!_BB&W"P2S)%_=1I0!SZ!:\Z[;<K'T/LX0I*#=C*T&^?0/$<;LXVKG=@_P"P
M?IZU[RQ#0,R/O3^'G/?FOGS5](OM&N$%^&WR9P3NSP!Z@>HKV3PGJ@U3PXC[
MP7CSN!/(R[8SR?2KP\FTX,Y<?!2Y:D3Q06[76J>0I.YOZ+FO3KWX9VBZ&[I,
M!<+CC<,\L/\ 8STKS6WNEM-<$Y&0/_B<5[EJ>NZ9#I,EW]LA8/C"B53T8#IF
MLZ48N#N;XJ56$XJ!X_X*U">Q\0PB-RJ/NSR1T1O?WKKOB\H T_';S/\ VG7$
M>&()+C7H%C!R-W3/]UJ[?XO'"::O7/FY/_?NJN_9-#G98J+1D> _"$.OK+<7
MDFV),8 8#KN'=3W K.\:^'(_#^H@0OE).BD^@7T ]:ZSX7:I9K97%C--'%*=
MN"[!<\N>YK&^)^IVM]J4,=O(CO'NR8V!'(3T/M2G"*IKE%&=5XEQ^R=GX&OW
MU#PJPG8L8\=3GJ[>OTKQI(YI[[9 6WMT SZ>U>N?#N!H?"4DK@C?C&>^)'KS
M/0!GQ-"N./FZ_P"X:JI=M)BH+DE4:.^TGX916\<<U[<L)^?E5QCN.A3/3%9_
MQ2U.:*ZCTU&Q ,_=)YX1O7'7VKU=BBR LN\'H2,UXY\4K62+70^&9#T8Y(^Z
ME56CR1T.7"5G6KISZ%WP5X'M=5TIK^[+$M]Q1C'#,#P5/H*YKQ9H+^&=9V0R
M-Y9^XZMS]U<\@#^]7H_PZU6S;PS#:?:8HYH=VX22 $Y=R.^>E<3\2=4M+_64
M2SE,J19RVX,#E4]#[&HJ*/*K(ZZ4ZCKN+V/2O!^J/J?AV&ZFPY&[=NY_C8=S
M[5S-[X>\(PZF\][J*?-C,23Q?W0.A'T-,L)[G2/A5]ICW1RMT/(_Y;D>WK7%
M^&],/B76%@N[PJ6S\\LN/X2>I!_NBJG4NUH9TZ-I2DG9%[QE;^'8Q%)HLP.,
MY16C_P!GLOXUU'PEN));>\@=R4BV;4)]2Y/%8/CC0=%T.VMXK*<R7+[MP+H=
MN"N,X (X)K9^$&&&HGG>OE?^U*FDWSM&M:TL-=:G&^+-2GU7Q!-))(SH-NQ"
M2<?(N<#)]*]!L/AEIJZ:JWDDWG-G+HR_+@GN4STQ7F>M*;;7Y0ZE2N,\8_A%
M>\:?K6FW]A%+'>0D-G>&E7*\G'?CI548IW<F98J=2$8*GL5?#'AFW\-Q2I&V
MYY<<Y!Z9]A_>KQ'Q$N?$%PF<-\O_ * *^@;#4;+4Y"MI<1RE.K(X;&<^A]C7
M@&M(9/$LP=NNWG/^P*6(2=@P4FY2<GJ>BZ=\-+)M#4SMFZ;W']X^JYZ5YMI@
MDT[7(]K'>F<8/JI_QKZ'B79"@ZD9KY[7=_PD63C/O_N45H<DXCPM:=534F?1
M .10@YI$Z<TX=:ZY-V=CQUI)W/GWQJ/^*LO#Z[/_ $!:]QT4K_8MN N,[N<?
M[1KQGQ[;M!XMNF9"%.S!(Z_NUZ5ZCX4\06&H:-! US!',N[*LZ@_>8^OH*Y<
M*TF[GK8U.I3A9&7\4B!X>4C^+/\ Z&E9'PF(\VZP,GY.W^_1\4-?L[J.*RM9
MHI<9W>6P;'W#S@U-\);:017<^TA3LPQ''\8IPY76<D#BXX.ST,3XIC_B?)Z\
M]/\ =2K_ (+\"VNJZ>+Z]D;:>@R/5AW4^@JG\40/[?3J1SS_ ,!2O1/!<?E^
M%K5 %(;?V_VVI4XQE)W*J591H1MH>,>)=(_L'79K1'SY>WOZJ#Z#UKVS1)FN
M/#,#.<YW?^AFO)OB-@^,+ILGG9_Z+2O5/#F#X4@]MW_H9J:/VD+%-2C"3/'/
M"63XIM<CIO\ _0&KO?BOJ,UO:P6J2$"7=P">Q0^M<)X27'BRU!(YW_\ HMJ[
M'XOP.SV$JJVU?,R<<#/ET-WHFT[/$0N9'@+P;#XA$US>OL@3;@@@==P[J1U
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MK8\QF\":K=6K7$\YEG.,;G9CUQW7/2NB\#Z)=Z+#=+=J5W[,<$=-WJ!ZBNL
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MXZX(SQD'H:R&\0^(EB6=],Q&V<*+>3/IZU<JL;$0P4W&[9V)'0[L9]Z7A02
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MVNJ7ML0/G_=[)/E^7;R"#C.!WKU%B&=1R!WQ6E*ZYC+$I<L%?8XWXE@GPPY
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M+%/[1J_\)%?>J?\ CW^-._X2.^_V?_'O\:Q@&]13@&]11_9V%_D#^T,5_.;
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M10 M%%%(H=FC-%% "T444 %%%% #LT9HHI#%HHHH =FC-%%!0M%%% !1110
M[-&:** %HHHH*"BBB@!V:,T45(!FC-%% "T444#"BBB@ HHHH =FC-%% !FC
M-%% !FC-%% !FC-%% !FC-%% !FC-%% !FC-%% !FC-%% #:*** "BBB@ HH
MHH 3-&:**!!FC-%% #:*** "BBB@!,T9HHJ@&T444""BBB@0F:,T44 -HHHH
M)"BBB@!,T9HHI@-HHHH 3-&:**!#:*** $S1FBBF(;1110(****8A,T9HHH
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M 44450"9HS110 9HS110(;1110 4444 )FC-%% !FC-%% AM%%% "9HS115
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M4470"9HS1Q1Q3)&T444 )FC-%'7I3N+7N-HHHH 3-&:**!#:*** $S1FBBJ
M8:::>::10(Z#PG_R%9?^N!_]"6BCPG_R%9?^N!_]"6BN#$?&>U@/X/S90\0_
M\C-J?_7S)_Z$:SQ_#6AXA_Y&;4_^OF3_ -"-9X_AKMA\*/)J_P 27J_S84ZF
MTZJ(%S1FBBI *=3:=0 "G"FBG"FQH7HO;%!=-GR.F?K3)4\V(J&93['%9?\
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M_P (]/\ ]!.[_P"_Y_PHYI!RT^YN>8G]Y?SH\Q/[R_G6)_PCT_\ T$[O_O\
MG_"C_A'I_P#H)W?_ '_/^%3S2#EI]S<\Q/[R_G1YB?WE_.L3_A'YO^@G=_\
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MRSW]3]/SK:7(^8,"OKGBBY#B&:,T 9Z<T4Q"T444 .S1FC'M1C/04#%HHHH
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M?_H)WG_@0?\ "C_A')_^@G>?^!!_PHYI!RP[FYE/^>J_]]493_GJO_?58?\
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M_02O/^_Y_P *.:0N6GW-G?'_ ,]%_P"^J-\?_/1?^^JQ/^$>E_Z"5Y_W_/\
MA1_PCTO_ $$KS_O^?\*.:0N6GW-KS$_O+^='F)_>7\ZP_P#A'I_^@G=_]_S_
M (4?\(]/_P!!.[_[_G_"JYI!RT^YM;D_YZ+_ -]4;D_YZ+_WU6+_ ,(])_T$
MKS_O^?\ "C_A'I/^@G>?]_\ _P"M1S2#EI]S8W1_\]%_[ZHW1_\ /1?^^JQ?
M^$>D_P"@E>?]_P _X4?\(])_T$KS_O\ G_"ES2#EI]S9W)_>7\Z-R?WE_.L7
M_A'Y_P#H)W?_ '_/^%'_  C\_P#T$[O_ +_G_"CFD+EI]S7WK_>7\Z-Z_P!Y
M?SK'_L";_H)7?_?\_P"%']@3?]!*[_[_ )_PI\TA<M/N:^]?[R_G1O7^\OYU
MC_V!/_T$KO\ [_G_  I/[!F_Z"5W_P!_S_A1S2#EI]S9W+_>7\Z-R_WE_.L;
M^P9O^@E=_P#?\_X4?V#-_P!!*[_[_G_"GS2%R4^YL;E_O+^=&Y?[R_G6-_8,
M_P#T$KO_ +_G_"C^P9_^@E=_]_S_ (4<T@Y:?<V"R_WE_.FEE_O+^=9!T*;_
M *"5W_W_ #_A2?V%-_T$KO\ [_G_  I<T@Y:?<U]R_WA^=&Y?[P_.LC^PIO^
M@E=_]_S_ (4?V%-_T$KO_O\ G_"CFD')3[FMN7^]'^=&Y?[T?YUC_P!@S?\
M01N?^_Y_PH_L*;_H(W/_ '_/^%5S2)Y:?<UMR_WX_P Z-R_WX_SK(_L&;_H(
MW/\ W^/^%']A3?\ 01N?^_Y_PI<TA\M/N:PDCSRR_G3 Z^9\K+^=99T.;/\
MQ_W'_?X_X4L>C3*_-]/_ -_3_A0F0Z<%U-6FTZFUJC)Z;"FFFE-(:!"4444
M)FC-%%4 VBBB@1O>$_\ D*R_]<#_ .A+11X3_P"0K+_UP/\ Z$M%<&(^,]K
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M5S3Q2CL>A3P$G\6ASBZ=?M_RZR#ZQM_A4RZ)J#?\L@/JK?X5MF_N#V4?3/\
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MH^J'_"NA$UG#_J+5,_[<8_I0=0F;HB(/]@$?UK)XE]CMCEW=F"NC7[]82/\
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MF3J,E-Q(W4G]:C)9NIHQ[TF#ZTS,,48IU% #<48IU%,!N*,4ZBD W%&*=10
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MD"N<4@%CCBNVEJCRL4VI6#%&*=16QR:C<48IU%%QW#%&*=BC% QN*,4[%&*
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M$_\ H2T5Q8CXSV<!_!^;,_Q#_P C+J?_ %\O_P"A&L_^[^-:'B'_ )&74_\
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MG4 OBL!W':.N.II7V\L"H3N6/%*N2,#OU]J\Y\6:UJ6JZ\OA[0961N=\J,P
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MD;,OB*YD&(DBB_W05_K6=-<W-P<RRR-]&)J#@]0?PIX]BWXU:I*)C*M.6[$
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M2.<$^AIDN!<---.---42(:::<::: "FTZFT$B4VG4V@!*;3J;0 IIIIQIIH
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MAU]+JZES9W6?+C+' VH0>"<=:[7.T@$#(^^OKZ<5QE]X5DL=*66*YN99K?\
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M,T=.M%,S4@IU-IU!:'4444 %%%% #Z***!BBG"F"G T +1112*%%.%,%.!H
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M:***"1,T9HHH ;1113$!III32&@!****"0)II-!-)0 44450A.E(>:5J:*
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M;Z]IMS<&'> 3T;*\\9]:A7Q):KJ[V+(W&.<#^[GUI.214:,V;)RJ J5/K2@
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MH#[&M*3Q)IB3E!+NV_Q*RD<CUS2N6Z31JTZFCGD=*=TIF;T%S1FBB@!:***
M'9HS110,6BBB@!V:,T44BA:*** 'T444%#LT9HXHH 6BBBI 44X4P4X4 *I
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MO.NHJL-J1F5KI(,T9HHKK/+&T444 )FC-%%4 VBBB@0F:,T44"%---*3330
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M4P[]X6BBBNO5.QR:6NAN*7-+BFT$B4444 -IM.I,'TH  *"* :0M0(W?"?\
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MI+RW:W7&Z595*#G')SCKQ1?6PK/>Q=R%XP32'*<E2WX9K!/C70=P!U&W /\
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MFDJ@$S1FBB@!!3A3!3@: &&FFG&FF@1O^$_^0K+_ -<#_P"A+11X3_Y"DO\
MUP/_ *$M%<6(^,]K _P?FS.\0_\ (S:I_P!?,G_H1K._N_C6CXA_Y&;5/^OF
M3_T(UG?W?QKKA\*/)J_Q)>K_ #8"G"D%**H04ZFTZ@!:=3:=0 N:,T44T^H-
M7T"G4VG5&SN4]58!3A312BK8HJVX4ZFTZIYKA9]!<T9HHI7"P_-&:.*.*"DA
M:***'L-;CLT9HXHH>XEL%.IM.I%H7-&:** <K!3J;3J 6X"G"FBE%*PD] IU
M-IU!0M.IM.J1@*<*8*<*+@+1111<8[-&:.*.*0"T444 **<*8*<*!BT444 .
MS1FCBCBD4+1110 [-&:.*.*!A3J;3J  4X4P4X5(Q:*,T4 .S1FCBCBG:X6]
MX[OP[*)=,09^[G_T(UK \US/A.;]Q)&3R,<9YZM73C@YKS*RM-GTN&GS4T'M
M7)ZY&5U!F[-C^0KK <C-8/B&+]W'*%.><G'TJ8;E5%='/BG"FT[%=!PK<AN4
MW6V/\]:S5K88 @@UD8PY!&*TB85$ IPI@IPK1F+"G4VG4@%IU-IU #E(PG'K
M7 _$2XN[F:QTBSD\O[5YF[YB/N[&[?CVKO01@/CIVKA?B-IEZQM-2TU)))[?
M?A8@2?FV+T49Z9[UG(VH_%J;<7@G08;)(OL2M(F<EHD/4Y_NUS?C2*75?$^G
M:%%</#:-YN8T<J/N*_3D=1Z5J0_$G2YX%7[+>).>JM&H/7_>STK/\9QW5KK.
MG^)+"VEG">9NB$98C*K'T'XGK4*YI'^)J;.M^"-&ET:6*WM$@E3&UTC16Y8=
MPOI6=X&U2YU'P;+'?2R/(F-LCL2W,C9Y)]@*;JGQ'L9])D%C:WTE_)C">6I
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M!T.2RF_X2729$CGM?];M.TONVQC[HR< GJ:M:;XH\-7VIQ6NG:'B3G,OV2/
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M_M&Q_P"?R#_OZO\ C4']C6'_ #R'_?*_X4?V+8_\\1_WRO\ A2O,.6GW+/\
M:%C_ ,_D'_?U?\:/[0L?^?R#_OZO^-0?V+8?\\A_WRO^%']BV'_/+_QU?\*?
MOART^Y.-1L?^?R#_ +^K_C3AJ-C_ ,_D'_?U?\:K?V+8?\\?_'5_PIPT6P_Y
MY#_OE?\ "I]\?+3[D_\ :5C_ ,_D'_?U?\:/[2L?^?R#_OZO^-0_V)8?\\A_
MWRO^%']B6'_/(?\ ?*_X4>^%J?<L?VE8_P#/[!_W]7_&C^TK'_G]@_[^K_C4
M']B6'_/(?]\K_A1_8EA_SR'_ 'RO^%'OCM3[EC^TK'_G\@_[^K_C1_:5C_S^
M0?\ ?U?\:A_L2P_YY#_OE?\ "C^Q+#_GD/\ OE?\*+S#EI]RQ_:5E_S^VW_?
MU?\ &C^TK+_G]MO^_J_XU!_8EA_SQ7_OE?\ "C^Q+#_GBO\ WRO^%+WPY8%C
M^U+#_G\M?^_J_P"-']J6'_/Y:_\ ?U?\:A_L73_^?=/^^%_PH_L73_\ GW3_
M +X7_"E>8<M/N6/[3L/^?RV_[^K_ (T?VG8?\_EM_P!_5_QJ'^Q=/_Y]U_[X
M7_"C^Q=/_P"?=?\ OA?\*=Y=BN6'<F&J:?\ \_EK_P!_5_QIPU33_P#G\M?^
M_J_XU7&A:=_SP3_OA?\ "G?V%IW_ #P3_OA?\*+R[!RT^Y-_:FG_ //Y:_\
M?U?\:<-4T_\ Y_+7_OZO^-5QH6G?\\$_[X7_  I?["T[_G@G_?"_X4KR[#Y8
M=R8:II__ #^6O_?U?\:<-4T__G\M?^_J_P"-5QH6G?\ /!/^^%_PIW]A:=_S
MP3_OA?\ "B\NP<L.Y/\ VKI__/Y:_P#?U?\ &C^U=/\ ^?RU_P"_J_XU!_86
MG_\ /!?^^%_PH_L+3_\ G@O_ 'PO^%+4KEI]RS_:NG_\_EK_ -_5_P :/[5T
M_P#Y_+7_ +^K_C5?^P]/_P">"_\ ?"_X4?V'I_\ SP7_ +X7_"C4.6GW+/\
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MXUNS@*>@)]F-8XF-X7.W!3Y:EF=G0:,T9S7F=3W3G/$%J$(G4<G_ .L*Q5Z
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M#_%<1?\ ?8_PK%S1V*@TC(.>C*,_2M[0K3&9V7![9'U%5VT7]X&^TQ'Z2?\
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ML<,W^UR*5\GY3^G2MXQMJ<,I:V J>]  [TK/FF<U:1G?N)1115 Q,T9I*3-
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MS?=)'L"?YUW4:G.K'B8[#.F[K8@S1FFY'K1WQWKK/-#-&:** &DT**"* <4
M)FC--S1F@!Q--)H)III-W$HW8#. I5@?4BN5^(>\^&7X#GCCK_&E=622%^8D
M\]Z@N[2VO(&M[J-94..JAN^>_P!*56/-$THSY*ESR:72FO?AY'=*A$EMG QS
M\TN/3VJ;P)!<:UKSW]YN<0XX;)'*L.^?05ZA#IMG';&S6WB%J_5-@['/3&.M
M,L=,L=-B86-K'"9/O9C5>F?0>YK&-'W[G:\<G!JQYKX' 'B^=G8K'\O)./\
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MZFDA>6( ]ZF:VG2$3/#(L1_C*D+UQUIR]UV'R-O1$:@@[LNR^_- ^]N3YO\
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M&_[ZHZ<8&?3%- W'G%%A3DW;4?N:EWF@GG'<=J;NJMR7OH'G.@VQR,!_O5&
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MW.T8%/;&_)/%)"AFGV@$^P^E*_<?,NII_83=:8(E.P_7'>L2YTBYLU!1#)]
M3_3WKK40*,9P/:G;0PPPS]:TC*VQC*"EL<*?E['_ ($*0L!U_P#':ZVYT>WN
M!PH3_= ']*R;K0)(AF$E_KS_ "%:JI<YW2DC)S1FI&@E3[\3K]5(J/BK3(:L
M&:,T4<4B;#LT9IM%,+(49)ILKI&.2*2258DR2 ?K65-<-,W7 ^M4D95)J(Z:
M<S/DU&3SBFY &>WK5FUMS*VY@0OJ>E:IV,5'GV);2VYRPJ\3@86D("\+^E*.
M.>M8MLZ8Q2%S1FFY]Z,^]3=C89HS32<=:4 MT&?I3;&FV.R.WS?K2$9[[?TJ
M>*QGN#B.&1?JI%:MOH!(S,WZ_P"(J'4L6H29BHC/\L<9<^N,UH6FAW$O,V5'
MIR/YBN@MM.M[<?(BD^I _P *M#/?%0ZC-X4>Y4M=.@M<[%QGV'^%8EQ$4N3G
MC_\ 573=ZQ-7A;>)$'R]R.G:LG(W2C$I*:E4U O6IE.>*!DX-3*:K U*#[T
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MH-.!J/-.%  #3@:9S2B@!P-.!J,4Z@ [C/0UKZ!?"SU$)(<1GU^A_P :R,Y
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M/)S28H7WI33*'9IN* :<!0 E%%%(!Q%.4T-CUIH- #\T9HXHXH&(M.--6E-
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M'9HS11BE>Q2:'(\J-OA<H1Z$C^5;]CXD*KLO5\T>XW>OJ?I7.DD'O^%..&'
MY]ZSE34MS:EB)TG[K.V465YS;7<8/H9%_I]*1K.X'!0D>J UQBR/ <QNZGU0
MXJ_#KVI0#!FWCW9C_6N6>&_E/3AF:_Y>'0X<=8G'_ :3=CJ)!6>/%DW\5K ?
M^V9_QIX\5(?O647_ 'Z_^O6?U>H=/U^@7"9>RY^@-/6.=O\ EB__ 'R:S_\
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MIVZJL2GW#-&:;13$.S1FFY]Z,^] !FC--S1F@0[-&:;FC- "YHS3<^]&?>J
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M,^H4444"8X4C&G<4QJ"1"::303335 (*<*04HH$)3:=3: #-&:**!'0>$?\
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M&E44,!V(IH.* '&E4TTFF@T /S1FFYHS3 7-&:;10(,T9I.:.: N+FC-'%%
M7&T444!<**** N%%%%! F:,T44 &:,T8]J*!#:*,44 %%&**H!,T9HQ10 VB
MC%%!(4444 )FC-%% AM%%% "9HS1BBF VBC%% !FC-&!1@4"&XHQ3L48H CQ
M1BG44P&XHQ3J* $-(12;N,^O2FEL9S00D^K'DTTFD)--SD9[>M4AN+6PXFFD
MT'T]::>*+(-0S1FFY''/7I1WQW]*+(+,4TTTN<G YI.V>U(5GM<2BCL3V'6@
M\=>]%@NUJ**<*8*=D9QGFJ$]]@)II-!--SGI0*.FEAN:,T<8SVI.,@=STI7;
M6HY.VPE%%%#U8W9;A12X/I252=M$0U?<"::3033<T[+J&KV#-&:**!AFC-%%
M!+&DTTF@TG- #LT9HHXH$;_A$_\ $VE_ZX'_ -"6BD\(?\A:7_K@?_0EHKAQ
M'QGLX'^#\V9WB#_D:-4_Z^Y?_0C6>.AK0\0_\C1JG_7W+_Z$:S^QKLA\*/+J
M_P 27J_S89HS115&8_-&:.** '9HS3:* '=:4<4BTI-24%.IM.H 7-&:*,>U
M#8UN9.KSWJ75O;VLBIYF[YF)'0 ]1^-16=Q?6>KK97CJZ\_,I8_PYZGZBKMS
M://J=M*I_=IN^_VRM$MH\^KPSR<)\V=O4?+BLFF=:E&R1SC:Y>RQRW<<R*HQ
M^ZW,/;IG\:FN)-0O-4LG2=H?,\S@NRCA?_K4^+2;VP:6%+2TG1L?,\;-[]<>
M]7]0T^\,EK<VBQ^;'O\ E8':,X'0#ZUC:9T<U)/0C75;JR>]CNRN^'9M!)^;
M/7&3SU%58/$%T='D,N!=QXW*V<MEN.,Y/%6M1T>ZOKZUNB5 ^?SEY^;@!<\<
M].])<>')IM<6Z0H+<YWQC.#\N!QC'6BTP3I6'M/J>I7[6-I*D)BQ\Q9ESD9Z
MCZ&F0ZS=BRO5F$8N+?9@#/.X^YSTJU>6=[::NUWI^W:^,!MV>%QSC\:9%HMQ
M)I]U+<^6+F?9_J\_PGW&>E5:1'-3:N5C%J<GAZ:[OY%,<NW"[FW+A\=^G:GZ
M1JEUJDZ6]DZ?9XL[F8G<<@D<@D=0:U[BVN)="^R_NVE/;DJ/FS6<FAW&GS0S
MZ>5B'S>;&,J&[#@#W/6BTA<].2:-;5[O^S]->ZA&YAC!'/<#M]:Q)+G6=/MS
MJ$L\<D/9-[GOMZ=.IK<U.U.HV<D!*QYQ@)PO4'^E8+VFLZA"EE.MO';\\J'!
M]><\=11-3N304;:E^TUAXM1N(+P[8TVXSP#D9[GZ5DS:YJ,>EK(S('GSY>"V
M1M;GO6AK^C37?DR6;JI&[S,DAFZ8Z#GO4FIZ)Y]E$ML$WQ9VANG)&>@I34[&
MB=),IZ;J]W#?_9I)#<+_ ,]8V+@\$]<_A5C17U;45BNY)XQ#S^Z#OD]1T^HS
M4^GVMZTA^T6-A H^[Y$14]_6KNE64EAIZP.1Y@SADSQR3_6FD[$S=.+T,C39
MQ#X?#+/#;2'[IG?83\YS3-(U6Z&M1VEQ*LRMG<%8L#A21U-)<Z%=MI$,(\IY
M8=W7)#9;/IS4EEI5Z=7BU"XBMX4&<I;J5;[I7H125S2]-HCMVU[4;>6XAN8E
M08PN^0$<X[?2M[1[N2_TV.0A0RYWL>C9)Q_*N8TDZPMK,EEY+03;<;]Y9<$^
MG YS6FD5WI4%E96FYY#O\TODKUR.F/4]:(29%50>QLZC>C3-.FO,&4C;C^(=
M0/ZUR"Z]J,:Q7HN$FC?/[@.S8QQ]W/XUV-]9I?V,ML3AFQQ_!U!_I7/6>GZC
M;[(&TS361,X;R&)YYZXHFV*A[-+49:QZ@_BBY(NBT2;<J)&(Y3TJ6UN-7UN6
M>6VN88H8]N0KNIYX[9'45:DL[ZRUN2ZM5A>*;&0P8XPN.WU-5;?3M7T:\GCM
M/L\D,NW/WRO ]@.Y-)7-.:+N2:K')9:S97$9Q(_F;SZX4 ?SKIN0<G[I^Z/2
MN;U+S=0URQME1L0>9O?!P=R@CG\*Z1N9&8'Y>,#TK1'-5MI8!3@M-Z4H;%69
M"T444 /#4C&F*32FD,<*>#3,CUHS0 [-&:;10 _-&:.*.* %HHHS04%%%&*0
M#LT9IM+S2 7-&:2CF@!U%%% QV:,TG-% "YHS244 /S1FFT9H =FC--HH*'Y
MHS3<T9H =FC--S1FD [-&:;FC- $F:,TVB@8[-&:;10 [-&:;10,?FC--S1F
M@!V:,TW-&: '9HS3<T9H =FC--S1F@!<T9IM% #LT9IM% "T444 %%%% "YH
MS3<T4 &:,TG-'- A<T9HHH ,T9HHI@&:,T44 &:,T<4<4$W$ IV*9FG;J N+
MBC%,W4;J N+BC%-R:,F@+CB: ::30#0(": :0T"@!S&F@T,::#0(>332:"::
M: )"::303[TTFJ <332:":2@!Q--)H)]Z:302.)II-!-)0 [-&:;FC- AQ%-
M(HW4W)H D(II%&ZF[J8#C2$4FZFEJ '$4 4TM0&H$.S32:;FDS0 N:,TSFCF
MF H.&)IC2;4)I?6H[@8M_?T_&@%N<XGB74'M_M<NGXMU[QPMCKCUQUK=74+9
MH([N2>%8Y,_(S@'@XZ9KEM-MM8U#0Q;H\"VS=22X/WB?IU%7-0%O;O;Z;!$T
MTB[L[U##LW;_  K#F9VU*46]$;\=W;R1&2*XC:)>I9P:1;RT=BL=U"X'99 :
MXNP>4Z3JT1DVK'Y."K$=6)K8L[2RTG1?MC^=)(W7=M./FQ[>M4ILB>'BEN;2
M7]G-(-MW"S#H$D!I9KNTMG99KJ%6_NO(!_.N(G\RWN;2Y6,0B3?\BC;T&.E;
M3:?#J/BJX69I&1=OR9!ZIZ$>U'M9=A_5H]S9.IV"JN;FV /0-(N1^M.EN;>.
M(3-,J9Z,[ !NWXUS&DZ-;W4-ZLKR,1LV.Y!V]<\XXJ.*SNM1T2TD68N8=^49
MB2^6].^,4>UEV#ZO#N=;#<PW )MY89"O7RV!_E22SQ0@332)"G]QV"Y[=#65
MX?FMY2\<4302+C<K*$/?'%0:DBW?B."WN)62V;=PS8!^0'OQUI\YA["U1IFY
M'>6TJ,\<L3J,;MC CVK&TC5;C5KEBDML4&-JJQST/;)]*K1V\,'B":T@ED\A
MMN55A@?)GMQUJ7PG9PQZ>LT:A&7.YL $Y+"CG9M[.FJ;-V:X@ME62>:.('/W
MF"_SJ..[AN$:6.2)D7'*L"?2N=\0O,^LP1JJO;G=A6!/\([=.M1V<=WI+W,]
MT%%F-OR)GZ=#@=2*/;"6&3I\U]3HOM]J\OE1W$,C=MC@_P!:=<75O:-Y<L\2
M-WWN!7%7)EAN;6:-4@+[^,%>@Q6K:PPZEJ]VM_(QV[-H+#G*\]?H*/;#EAER
MWN:%WJL=K?P1O)']FDW8?=Z#USCK5Z*>"=CY%Q%(1T^<$_I6%J>GP76L6%OD
M_9QYG(Q_=!],=:EBM4L/$2) SB(YRC'_ &/0?6FI2<M2'1IJFFGJ;8STIZXS
MC%*,9K4T/3%U"YVG_/!]O:G6K0HPYF8TJ$ZU7EB9A*[\%B/J:C<$-][(^M=K
MJGANT_LXW$6 1]/4#TKB,_*1G.*QP>-IXKX33%X*IA7[PAIIIQI#79JG8YE9
MJXN:,T44Q 332:#32:"6+FC-%% "4VG4V@1T/A _\3:7_K@?_0EHI/"!_P")
MM+_UP/\ Z$M%<.(^,]G _P 'YLS_ !%_R,VI_P#7W+_Z$:SCUK1\1?\ (S:G
M_P!?<O\ Z$:SCUKLA\*/+J_Q)>K_ #8@IPI!2U1F%.IM.H ":513:>M !111
M4@.Q29HR:7 H&.!Q2EJ& [$4@!H*N.HHI<'TH"XF6IP+4[BE!% A4&12JVTT
MT-@=:1>3S0 YSDT;\C%*0,5&HYYI%#T.*>7S3=N**  5(%S48.*>'H 1A0#0
M3F@ 4 /$E!;- 2D88J1BYHQ30:D&* (;>SBLHQ% .!Z8_I]:EVQF42L,D4H(
M SWIO .#R*"B1#4FZH5.*4F@!<T9IM% !''$)3<! '/L/I3^-IP<,?>FANV.
M*!C=NP?I0 ^BBBD,=FC-%% !3J;3J $Q3J4@4TT +2XI!3QCUI#&F@4&@4 2
M$4TBE+4F: %!IP-1BG T  -.!J,9IPH*)"HIA-&XFD/- #U%.(J-213BU P#
M9IPJ,4NZD XF@&FF@4@)#2$4FZFDT 2@4$4T-06H* "G 4W-+NH 0"G 4W-+
MNH #0*#0* '&@4AH% "L*0&G-CUIE #L4F:<2*8:"AV:,T<4<4 &:,T<4<4
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MHS3<T9H$/Q1BF9HW4"' 4HJ,-3M_O3 "* *:6H#4 *PIH%*S4T&@0&@4&@4
M!III3330 M-I<BDH 3%&*=BC%,0A%-Q3Z3% #2*:14AQ33B@D;BC%+QZT<>M
M !BC%)FC-.Q+0$4TBE+4A:BP) 332:0D>M(318I(?FFDTW/O3<T6!Q'$TTF@
MFDHL)"YHS3<^]&?>BPEN&:,T<4<56@[#<4X"C%+QZT:$B"D8T[CU%1L:-@C%
MR FFDT$TTTW'6Z#6UA<T9HHI*S!MK1AFC-%%/U#EZC:***9(F*=F@TTF@!I-
M-)H-)0 AIIIQI#0!T/@[_D+R_P#7 _\ H2T4O@[_ )"\O_7 _P#H2T5PXCXS
MV<#_  ?FRAXA_P"1HU3_ *^Y?_0C6;V-:7B'_D:-4_Z^Y?\ T(UF]C7;#X5Z
M'DU?XDO5_FPS2[J4C%-(Q5$#E&ZG$;:8"13LEJ07#%+DBG@"G!0: N,).:>>
ME*RKGJ*1NG% #P033F<$8J-5&.HINTYH E+T#FF,"*0$BI E)S2JN:BR:>KX
MH &%-%.)S3E4&@H0'%*6I6 %- H 514@J($T[<:0D.- I":!04@6G$TX**1E
MH&-IU-IU $H%-84H--8T  -.!J,4X4 29I*:#3JD$ -.!J,&G"@H=FC-%% Q
M:*** '9HS110 @IPIHI10 [%+FCBDI# 4X4T4X4 &*,TIQZTPF@!XIPI@IP-
M !FC-'%'% Q0*"* :": $IU-IU(H=BFD4N:;F@!5%.(IBFG$T (:5:0TJT .
MIM+D4E QXH-(*#0 9I<4T4\$4 )FC-'%'%( Q29IQQ3#2*'XI*><>M,- !G-
M&<4Y%H=: $HHHH **** $IU-IU "9HQ31FI!B@ S1FCBCB@!%%.(IBFG%J %
M H(I@:@M0 [-&:;FB@!V:,TW-+SZ4 +UHZ4B^]#>U "YHS1Q1Q0  T$T@H-!
M(H-!-(*0F@!V:,TW-&: "BBB@ HHHJ@"BBB@!,T9HHH$!H%(:!0 XTTTIIIH
M 6FTZFT **#0*#02)FC-'%'% #:***8[@:::<::: N%-IU-H$+1110 W-&:7
M%&* &YHS1BC%  6INZE(II%,D7-&:3FCF@ W4;J3%&* '%Z:7I#3: 'DTTF@
MGWII- "YHS24F: #=1NI,48JB12::30324 )FC-%% 7&T444!<**** N-Q1B
MG8HQ0%QN*,4ZDXID 332:"::: %)II-!--H'<7-&:** N&*,4ZCBJ)&FFFG&
MFF@!:;3J;0("::30::30 I--)H)IIH 7-&:.*.* .@\'?\A>7_K@?_0EHH\'
M?\A>7_K@?_0EHK@Q'QGLX'^#\V4/$1_XJC5/^ON7_P!"-9HY!K5\1J/^$FU/
M!&?M4O\ Z$:RU!P>#7=#X5Z(\FK_ !)>K_-@22>:D*@CFHB3GH:<2<51F."F
MG!33?,]J42TA#L&C+4[>*,CVH&,!)I=V*>J"D=,4#&[J=NIN*6@"1C2"FDTY
M2*D!:;3J;0 [.:>K8I M!&*"A6-(*:<TY: ) M!6E##UH)I"0RG4VG4%(>K8
MH9LTSD49H&+3J;3J #-&:7;1B@ IU-IU "@4$4X4&I!#!3A312B@H?FC--S1
M0,4&G TRE!H ?FC--HH =FC--HH ?FC-)S12&.!IP-1BG T +FC--HYH ?FC
M-)S24 .S1FFTO- Q^:,TWFB@!^:,TW-%(H=FC-)S24 .S1FFTO- #\T9IM%
M#LT9IM% Q^:,TW-&: '9HS3<T9H =FC--S2T@'YHS3:*10NZC=28HQ0!(KXH
M9\TRB@!VZC=3>*.* '9HS3<T9H 4&G TRE!H 7-&:;FC- #LT9IN:,T .S1F
MCBB@ S1FCBC&>U !3J;3J $I<TE-.: 'YHS3:* %HHP?2B@ HHHR/6@D6FTN
M1ZTF: %-(12%J3)H =FC--HS0 [-&:3FDJ@#=1NI,48H  :<#3<4[ H$(:!0
M:!0 M-IU-H 4TTTII#0 N:,T44"&T444""BBBF*XM-I<BDH"XVBBB@04444
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M(9_U$/\ R#_]E2CP9_T__P#D'_[*I]O3[D_4ZW\OY',XII%=7_PAW_3_ /\
MD'_[*D_X0W_I_P#_ "#_ /94>WI]P^IUOY?R.5Q1BNK_ .$-_P"G_P#\@_\
MV5'_  AO_3__ .0?_LJ/;T^X_J=;^7\CE:=73_\ "&_]/_\ Y!_^RI?^$._Z
M?_\ R#_]E1[>GW#ZG6_E_(YP"@BNF'A _P#/_P#^0?\ [*@^$#_S_P#_ )!_
M^RI>WI]P^IUNWY'*TN*Z<>#O^G__ ,@__94\>#_^G[_R#_\ 94>WAW#ZG6[?
MD<MFE#5U!\'_ /3]_P"0?_LJ3_A#O^G_ /\ (/\ ]E1[>'<?U.MV_(Y<5(*Z
M0>#_ /I__P#(/_V5/_X1#_I^_P#(7_V5'MX=P^IUNWY',D4TBNI_X1'_ *?O
M_(7_ ->D/A'_ *?O_(7_ -E2]M#N'U.MV_(Y<4X5TH\(?]/W_D'_ .RI1X0_
MZ?O_ "%_]E1[:'<:PE;M^1SH-(U=(/"7_3]_Y"_^RI3X2_Z?O_(7_P!E1[:'
M<?U2MV_(YG-&:Z7_ (1'_I]_\A?_ %Z/^$1_Z??_ "%_]>CVT.X?5*W;\CG=
MU&ZND_X1+_I^_P#(7_UZ/^$2_P"G[_R%_P#7H]M#N/ZI6['-YHS72?\ ")_]
M/O\ Y"_^O1_PB?\ T^_^0O\ Z]'MH=P^J5NQS=.KH_\ A$_^GW_R%_\ 7I?^
M$3_Z??\ R%_]>E[:'</JE;L<U172_P#")_\ 3[_Y"_\ KT?\(G_T^_\ D+_Z
M]'MH=P^J5NQS>:7%=$/"?_3[_P"0O_KT\>%/^GW_ ,A?_7H]M#N'U2MV.;Q2
M5TW_  BO_3Y_Y"_^O33X4_Z??_(7_P!>CVT.X?5*W8YW-+BNA'A7_I]_\A?_
M %Z</"W_ $^?^0O_ *]'MH=Q_5*W8YW%)72GPM_T^?\ D+_Z]-/A7_I]_P#(
M7_UZ/;0[A]4K=CG*=70_\(K_ -/O_D+_ .O2_P#"+?\ 3Y_Y"_\ KTO;0[C^
MJU>QSYIIKH_^$6_Z?/\ R%_]>D_X1;_I\_\ (7_UZ/;0[A]5J]CG13A70?\
M"+?]/G_D+_Z]+_PBW_3Y_P"0O_KT>VAW#ZK5['/TVNC_ .$7_P"GS_R%_P#7
MI/\ A%O^GS_R%_\ 7H]M#N'U6KV.>%. K?'A;_I\_P#(7_UZD'AC_I[_ /(7
M_P!>CVT.XWA:O8YQJ05T1\+Y_P"7S_R%_P#7I/\ A%_^GS_R%_\ 7H]M#N"P
MM7L<\HIQ%= /#&/^7S_R%_\ 7IW_  C'_3Y_Y"_^O4^VAW#ZK6['.9HS70_\
M(O\ ]/G_ )"_^O2?\(O_ -/G_D+_ .O1[6'<?U6KV,#%)71_\(Q_T]_^0_\
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M/YHS6]_PBW_3[_Y"_P#KT?\ "+?]/O\ Y"_^O1[:'</JM7L<_FC-=!_PBO\
MT^_^0O\ Z]'_  BO_3[_ .0O_KT>VAW)^J5>QS^:,UT'_"*_]/O_ )"_^O1_
MPBO_ $^_^0O_ *]'MH=P^J5>QSV:,UO_ /"*_P#3[_Y"_P#KT?\ "*_]/O\
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4W]J*XZ]2+G=,]7!T*D:5FNY__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %[ 4<# 2(  A$! Q$!_\0
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M12+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB@G R:
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M17*'Q/=?\\HOR/\ C2'Q1=_\\XOR/^-'UB _J%;R^\ZRBL;1M:;4)'BF55D
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MHKLP5= 1@JPS]179AL1]8@T]&92BZ$U)'G9I8T,DJ1KC+L%&?>KFKV9L;YT
M^1OF3Z54@)CGCE*,51@QP.P-8M6=F>Y&2E#FCU+<>F;I2&GC*#>K,A^ZP!.#
MQ[5&FES2.=KH4VAA(,D$'IVSV--EU*=W8KL526.%0#.X8)/OBHH]0GB  *E0
MH7:RY& <C^=.\"5&M:]R5],F13ODC63Y\1Y.3MZ^U$>ER/*B-+&#N02*#ED#
M="?SJNU].75BP)4, <?WNO\ .E.IW.U0&4$%26"C<VWID]\5-X%<M:VZ%;3Y
M.621&B <[QG V]<^_(_.E?2)_-,4<D4LBN$=58_*3TSQ3&U!C930XPTTH=PH
MPN!Z?C_*ENM8GDN7DAVQJ9 X(0!CCIN/>CW"DJU]""]LI;(IYA!60$J0",XZ
M\$9JF34UU=R714R! %&%5%P!58G)Q64FKZ'334N7WMS;\-6,EYJ)=9'C2)26
M=.#SP!176:!IW]G:7&C#$K_._P!3VHKT:-)1@K[GSV,Q3G6?*]%H:E%%%;G
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MS9CW&I7,L[N)G4,<@!B,5";ZZ_Y^)?\ OLU 332:]%178^:=2;=VV3F_NO\
MGXE_[[---_=_\_,O_?9JN33":?*NP<\N[^\L'4+O_GYE_P"^S3#J-Y_S\S?]
M]FJ[&HR:.5=@YY=W]YIZ?K-Q;7T4DL\CQ9PX9B>*[TA)8L<,CC\P:\K9J[CP
MKJ7VO3S;NV98./JO:N;$TU;F1Z>6XA\SIR>^QEWMN;6Z>(]CP?456-=+K=D9
MX5FC4ETX( Y(K*:PAALFEN)2LP_Y9 @G)Z5\K7P\H5&EMN?4TZJ<4WN3SSPP
MW&'="%:,J@3!3&"3FH8[R!F#S;?,^<!MN,=,=OK6822<DY/O32:QEB97ND4J
M2L:C7L"RGR]@5I5W?)U7'/:HVN+<6Y567;L($>SG?GALUG$TTFLI8F12IHV'
MN8IC<3L1((L21G;CDC&T_CS^%,GF@CB5961E,*?NA'@[N#G/TK(+'&,G'I36
M8GJ<U,L4[/34:I(T=3N;:9$$.TG<2"!C"]AT%9A-!-+#$\\R1(,LY  KEJU'
M5G>VK-(Q458W_#-COD:\<<+\J?6MW4;K[+:,X/SGA?K4EI;+:6L<"=$&"?4]
MS6!K%WY]UL4_)'P/KWKZ.,5A,*H]7^;_ ,CSK^VJWZ%7[9<9_P!=)_WT:3[9
M<?\ /:3_ +Z-045YW/+N=?*NQ/\ :[DG FE)/0!C5O4Y[F*Z&'D52BXY(YQS
M69D@@@X(Z5->7<EY*)).H4*!5*I[C3;OH)Q]Y:"?;+G_ )[R?]]&D-[<_P#/
M>3_OHU 329K!U)=R^5=C;T34'-R8)G+!_NECG!KHJX)',;JZG!!R#7:V5RMW
M:),.I'(]#7JY=7YDZ<MT<>)IV?,BQ1117IG*%%%% !1110 4444 %%%% !11
M10 R6588GE<X51DUPMW<M=7,DS]6.?I6_P"([W9&MJAY;YG^G:N8)KMP\++F
M?4\/,:W-/V:V7Y@33":":3:YVX5CN.%P.I]!72><-)J,FE8XXJ(M[T"%8U&S
M4C-4;-0 Y5>618XU+.QPJCJ36QHBSZ7=I?W4BVMO@@B3[T@] O7\:R[#4I--
MN?M$,<;R 84R#.WW%5[^^EO[M[F8CS'ZXS@?2IDG+3H;4Y1A:?VD>MY62/(.
M58<$'J*XR^MVM;N2(Y.#D$]Q6CX.U7[;IIM9&S+;X'U7M_A^57-?L_-MQ<(/
MFCX;Z5\_F6';@WUC^1]9@:ZFE);,Y@FD)H)II-?.-GJ@332:":TKM;4:':-&
M&\TLWS$=?7/]*48\ZD[[*XF[-+N99--)H)IA-<TI&B0$UT7A>QWRO>..$^5/
MKW/^?6N?AB>>=(HQEG( %>A6=LMG:1P)T08)]3W->CE.']K6]H]H_G_6IS8J
MIRPY5NR/4;K[+:,X/SGA?K7)DY)-:.L7?GW913\D? ^O>LVNW&5O:5++9$4(
M<L?4*2BDKC;-@II-!-)FH;&!I*"::34-C FMGP]>^7<&V<_+)]WZUB$T)(T;
MJZG#*<@TZ59TJBFN@IP4XN+/0J*K6-TMY9QS#J1\P]#WHKZJ,E**DMF>2TT[
M,LT4450@HK!U37);:[,-N$(488D9YJC_ ,)'>^D?_?-9.M!.QUPP5645)=3K
M**Y/_A)+WTC_ .^:3_A)+WTC_P"^:7UB!7U"MY?>=;17(_\ "2WOI%_WS2?\
M)->^D7_?-+ZQ /[/K>7WG7TR65887E<X5!DUR8\3WN1E8L?[M=1%)%?60<<Q
MRIR/YBM*=6,WH8U\-4HQN^IP]Y<M=7,DS]6.?I58FK%_;-9WDD+?PG@^HJH3
M7L*UM#XV?-S/FW FK]I?6\$=HLB*Q2<LQ;/R#CD8^E9C&KMO81R*K33JK/$\
MJQ@') !YSTZBE.UM2J7-S>Z2&:S,#2&5 _D&/RRAR6W9SG&.E.EU6+S9"IBV
M_:%V?NA_JN=W;Z5!/I1\N:5)% C ^3EC]T'D]NM-GT*>)E4RI]XJY((V8!)/
MN, ]*CW.K-_WRVB3I>6*(P6:)(@LH,3199V.=I!Q]/IBJ5[?P36T\0*8"1>3
MB/!W #=SCZT)HXG>+RKR-DEC,BL$.3AMN,=<U$VB3_8FN?-3A6<+@\JI(//8
M\'BA<B>XFZK5N4RF:H6:AFJ%VK8Y#3T+53I.KPW!)\O.V0>JGK_C^%>MG9-%
MV9'7\"#7D?AO2SK&M10L"84.^4_[([?CTKU[Y8T[*JC\A7#BK.21[>6<R@V]
MNGZG/-X98L2+D =OEIO_  B[_P#/RO\ WS5AO$D*L0(&(!X.[_ZU)_PDT7_/
MNW_?7_UJ\W^R*3^Q^)Z']K0_G_#_ (!7_P"$6?\ Y^E_[YJ>7P\\EC!;_: #
M$S'=MZYH_P"$HA_Y]V_[Z_\ K5+)X@BCLX;CR6(E+ #=TQ0LII*ZY=]-_P"N
MP?VI"6O/MY?\ H_\(I)_S]+_ -\4G_")2?\ /VO_ 'Q4Y\5PC_EV;_OK_P"M
M2'Q;"/\ EV;_ +Z_^M4_V)1_D_$/[7A_/^'_  ";2O#PT^[^T22B5@,*-N,'
MUK1U&Z^RV;.#\[?*OUJGIFOP:E<F 1F-\9&3G-7K^V%U:/'CYNJ_6K^JK#4G
M3I*QI3Q$:[4[W1R!.3DTE*P*L0>HIM> V>J6;=(3!+),C%4'#!L9/88J=--"
MR1;Y V60.OU].:I)<S11F-)"$)R11]JN,(OFOA""HST(Z5HJE-)<RN0XROHR
M<64;?.)SY8WY)3D%?;-)]ACVMF8[UC$A79Q@X[YZ\U!)<W$A^>5V.".?0]:;
M]KN/)\OS7\O&,=L5#G2_E_K[Q\L^Y>EL8'F9(V\M0[+D]3@#CDX[U$]C%Y:)
MYC+,3(!E>&V^OI507=PC;Q*P)).?4GK3#<S%@QE8L,D'/KUJ95J3^R-0GW(L
MTTF@FFDUPMFUC<\.Z@MO.\$KXC<9!/8BBG>&K 32O=2J"B?*H/<_Y_G17T66
M^V^KK:W2]]CSL3R>T9U55KZZ%G9R3'J!A1ZGM5FN6\0WOFW(MU/RQ]?K7H5)
M\L;D8:E[6HET,=W,CL['))R33**0FN ^@2 FDHII-(8$TTF@FD)I#2 FNE\+
MW_+V3G_:3^HKF":?:SR6]U%+%DNK @#O50GR23(KT55IN)U?B>Q\VW6[0?-'
MP_T_S_.N8L[.:_G\F  OC/)P*]!&VZM<21D+(GS(PY&1T-<3J=U<Z==O:6X%
MM'&V5$?5O0D]37O4*C<>5'P6/H1A4]I+9[V[F;=P/:7#P2,A=.&V'(!]*$U*
MYAA\I) %VE1E02 >H!ZXJL[EF+$DDG))[U$S5U6NM3RN:S;CH6VU2[V.GFC#
MC!.T9Q@#@]N *CDU:\9D?SL,C;@0H!)QC)XYX]:ILU1,U'*NP_:3[EYM9O1(
MKB1,HNU1Y:X SGIC'7FJTFJW;0O$TVY7SDE06P3D@'J 351FJ%FI\J[![2?<
ML6EI/J%R+>V4/*P)"E@,X^M0W]I<:?<M;74?ES  E<@XSTZ5%'<26\\<T3E9
M(V#*P[$5TV@7$WBC51:ZG;QW2+F0SD;7C'ID=1GC!J92<=>A=.$:GN+XG]QU
M'@K2/[.T<7$BXGNL.?9>P_K^-7]?O?L]IY*GYY?Y5K?*B=@JC\A7$:E>&\O7
ME_ASA?I7'23J5.9GK8J2P^'5..[T_P RH332:"::37<>(!-:%W<VCZ):11K^
M_5FR,_=]3^/%9A-,)J7&]BHS<4TNH$U&30QJ-FJB":VNGM+J.>,X9&R*])M;
ME+NUCN(S\KKD>U>6,U=7X.U+)DT^0_[<?]1_GWKGQ$+QYET/1RZOR5.1[/\
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MFDU=.E7W_/O)_P!\FFG2K[_GVD_[Y-?,.E4_E?W/_(]GGCW*1--)JZ=)O_\
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M  >N:Y=SU6TE=D--)J\^F2^;M0G9MW%I%*8YQ@BF?V9<<AO+5@Q4*SX+$#)
MI\LNPE5AW*1-(35F2PN([;SV4;<!B,\@'H350FH::W-(M2V#.#FNZT._^W:<
MI8YDC^5_Z&N#)K3T#4/L6HJ'.(I?E;V]#6E&IRR\F88RA[6D[;K4[RBBBO1/
MG0H(!&#T-%% ' :S8FQU&2-5_=M\R?0UFD-Z&O3VC1_OHK?49IOV>'_GC'_W
MR*Y)86[NF>M3S/EBE*-WZGF!!]#3"#Z&O4OL\/\ SQC_ .^11]G@_P">,?\
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M?GCZ?2O1RVO:3I/KL<V)IW7,C8HHHKVCA"BBB@ HHHH **** "BBB@ HHHH
MH:O>?8[!V!Q(_P J_P"-<43DYK3UR^^U7Q53^[C^5??U-9)->A1ARQ]3YW&U
M_:U=-EH!-$;[)D;.-K YQG'/I3[>$W,XB#JF03N;H,#/]*DDL,1[TN8Y"8_,
M50""R]">G%:-K9G/&$FN9(N7%[ OF2+*DDOE-M&"RABPQC=T.,U%)>V<DK"5
M8C"#$P"1XYXW_P!:B32\W*H\R.%?9*J9RA()[CGI4;Z+=")&!4LQ7Y>1C=TY
MZ'K6=H=SH;K/7E+,MY;+"0T\#RE9ANBCV\%<*.@K)U.=)M0FDC;<C$8/X"G2
MV:A)7BNHI5C0NVW(Z$#'/UJ5='DE5$5QYI;D\X"[ W3KGFJ7+'6Y$O:5%RV,
MZ!X1<QFY#F$'+A.I'I6CJ6OAY1_9B&SB."X4 %F'J1V]JS=0M)+"X$4C!LJ&
M4@$9!]CTJBS57*I:F?/.FG#;\_O/6])U!-3TV&Y4C<PPX'9AUKG?$UCY%V+E
M!\DO7V:LOP5JWV;46L9&_=W'W<]G'^/^%=QJ5F+^PD@/WB,J?0]J\O%4=X_<
M?4Y5C/AF_1_U^)YX332:>\4B,5*,"#@\5&4?^Z?RKR#ZU#2:833RC_W3^5,*
M/_</Y4BTAI-,)IQ1_P"Z?RIA1_[C?E4FB&DUZ'X8TW[!I:NXQ-/\[>P[#_/K
M7(>']+;4-5C61#Y,?SOD=AVKT>2188F=N%49KLPL-ZC/'S6OHJ,?5_H9.N7A
M15MT8AC\S$?I5&*_A>W=+N,R.PP) !D#ZU3N9VN+AY6ZL<U#7!5Q,I5');')
M"DE%)@:3-!K3WV[-!;NH;<J9X "\<\]>:PC'FZV+D[&732:T4AMY(/,\L!2&
M+MO_ -61T&.__P!>IEM[:9]S1H/D3:JMUXY/7M35"3V8G42,>D)K3=+9+=FP
M)1&&V*6Q_'CM[50NT2*ZD2/[@/'.:PJ4W!7N7&5R$FK&GW9L[R.4=,X8>HJJ
M332:P51QDI+=%N*:LST16#J&4Y4C(-%8WAV^\^T-NY^>+I[K17UE"LJU-374
M\F<'"3BS:HHHK4@**** "BBB@ HHHH *BN5D>UE6(XD*D*?>I:*%H)JZL>=/
ME7(;@@\U$36UXCLOLUYYZ#]W+S]&[UA$UZD)*2NCY:K3=.;@^@])FA?>APV"
M,_48I/M<H"@-]V,QCC^$]1^M6]*G@AGD,[(H*@ LN<<\XX/\J62YMOLH6.6)
M4 PT;0_,S;NN>W'O[4F];6+C#W;\Q5?5;HE#YBY5MV0H&XXQD^IJ%]3NC&J>
M8!M*D,%&[Y>F3U.*UXM1L&GN&E\H S$C*8#1]@!M/].O6JZWNFC3T0A 0%!0
MK\P;=DMT]/?VQ4W_ +IIRO\ Y^&>-2O)9LQA&(1@46)=I'5LC&#TS4+ZQ>-+
MYOFKNSNX48/R[>GICC%7Y=1M)FD:0Q9$DPCVQX^0H=O0>M*+^SNK_P MHXY(
MQ<1^0B1 $KM(;MSSC@]:=_[HK-[3,*ZNY+J7S)2I. H"@  #L *J,U;FOJT=
ME8^:T;3EI=S)#Y>1D8XP/Y5SKO5Q=T8U(N,K,L6:SS7\$=MGSF<!,>N>*]J0
M,(U#D%\#<1W-<!X TGS9Y-4E7Y8_DBSW;N?P'\Z]!KCQ,[RMV/9RVDXTW-]1
M-J^@_*C:O]T?E2T5S'HB;5_NC\J-J_W1^5+10%Q-J_W1^5&U?[H_*EHH"X@
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FG:39P6L<AAC"EB,\DUHU[N6X7V%+7=[G#B:OM)^2"BBBO0.<_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &G C<# 2(  A$! Q$!_\0
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MZ+XGT+7?"MY,TUG-BY34+IGWP]-JG''!88Z<UTWB2.Z.N*T4B>4$!9&7GO\
M=-.'BF[('[L'_MF:S=7U:XN )8X&>=B "%P !S_]:@"Y:2)-I321D%6.13@
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MBMK/4;V:RDFB5[IX0'4E7+J,KTX4].":[2HKEITMV:VB2688VH[[0>?7![4
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MNM\)C):[1<"3[YS@7;3>G]TC\:KP?#O68[6*-I;3<D2(<.>H@FC/;UD7\,T
M<K<_\>EQ_P!<9O\ TFM:N-_R%6_Z_#_Z<5KH)OAYK,D$J"6UR\<BCYSU:&%!
MV]8V_2K!\!ZL;XS>9;;3<&3[YSC[6)O3^Z/SH 9X;_Y ^D?[D/\ Z.FJP/\
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ML!A <JB-U('\1^M #@I"H?+ )4 KGI4-U<QV<?G31A5R%W=>2<"K,KB./<2
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M:=K,MQ:QRK&\:L.$<8(KG_%T,+PV\S!6F1B$0N$R".?F/ _&M>ZO#I^G0RB
M.-T:,N\#:&(&<]\9H OUFV/_ "&-5_WX_P#T 41ZLKZPUAY) &0)-W5@ 2,>
MF".:9ILJ2ZOJQ0Y"RQJ>,<A!0!JT444 8WB!/.CAA]=[_P#?*FM6!_,MXW'\
M2@_I5*Z7SM3CC/(6"0_G@5-I;;]+MC_TS _+BM)?"CGA_%D^_P"A;HHHK,Z
MHHHH **AN;J*SB$DS;5+*@/N3@5-185U>P4444#"BBB@ HHHH **** "BBB@
M HHHH *0TM(: *%O_P AV]_ZXQ?^S446_P#R';W_ *XQ?^S44 :%<3XD@BGD
M"3('1\JRGH1N-=M7!>+YYH%+P1M(Z L /9^?TS0!-%$(U"*,J.F>U*EI$LYN
M-H,Q&-YZ@>@]!4-GJ5I>1*\$Z,&'0'D?A4\UW!;Q%Y7*H.IVDXH MJ/]%:D
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M*B9Y550W<=2/R!JTNJ6;6*W@G40-@!CV/H?>L6_NH=1U)^1]FL[:20D\?.>
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M!,_,/QJW,;GSUV-"L)')8$MGT Z5)@@#]YGZU#);&6^CF:4A8@=J#H2>Y]Z
M+)W*AQ\S=LU22ZD@N(+:YECEFE#$^6,8QST],<9J[C'5S52YL[2<J\J1,R,&
M5F'*GV/6@"U(W[EN<<8S5=8%MXH9[C;)+!&5,N,<=S27=J;JR$*7!C4L"S@9
M) .<5:.&4@G@]: *]IJ5I?P^=:S++'NV97U],5;JJMG ETMP@PZJ5 ' YZG'
MK[U8!Z].* *L1CNW62>U>*:%CL$HY';(QQR*-3TNRUG3Y+'4+=9[>3JIX(/9
ME/4,.Q%2PP)$6;S)&+$DEFSCZ5+C/<T <K!JM[X4N(]/\03M<:7(PCM-7?JI
M[1W'H>P?H>^#74&>(3"$R*)2NX)GDCUK.U*&5LHYBN;*562>UG0$,"/7TKF[
M>:Y\'1I)(LMYX:)XR#)/IH_F\7ZK]* .W=%DC:-P&1@5(/<&JMI8)9+#%#-*
M8XH]FV1MQ8=LD^E3PS17,$=Q;S++#*H=)(V!5@>A!IEU")8Q^]:-T.Y7!Q@^
M_M[4 4?$<4<VBS)(Q /0@XYKDX?^/6+_ '!77ZL770I]V'D\KG' )]JXR(OY
M$( XV+4?;^7ZF_\ RX_[>_0T%Z4$ CV%9L4VHS2,OE11HKXW-GD>U7-ASAW+
M'T'%68$S%2.IS[4PRLOH_P!.M2*H48P!2/$DG44 53>VXEVM*JLHY#<&F[U9
ML@Y!.1535M.GE@8PMNP/N,.?P-20QNJQA@ 0!P* .J\*LJ:?<Y(&;E_Z5LRR
M* C C&[%87AH!M/NE+ #[2_!'TJP=&MA,CPR"-@^[ <X;/J*BG\*_KN;XG^+
M+^NB)]0U.*RN[:-V&Z5MBKZDU:MI9R"EVB)*#U0Y5AVQ6=JNBVM]J%O=7*0E
MH2&B9\[E/M5]$;_GNN#V%68$LSA4Y.,G S2Y!C0U6N;3S_+#S_<<.O..13C&
M4MD0SJ&!/S4 27,2W$9A<9B;[X]1Z5'=7,-C:EW98T&%4=!GH *@:Q2:=;AI
M5:0+M#9[475@EU;-#*Z,A[,* -'PXW[R13U#9_/-=)7.Z# 8;E\R*Y..AZ<&
MNBH ***S]6MKRYAC2SF,1!)8JVTG@XY],XS0!H5YCXHG6+Q9J ?;M"PMQ]X$
M+P:[6W34CKIDE\T6Q3G+#9T& !_>W;OPKG->\"ZAK6O7&HB_MHDD"!8_+8G"
MC')S4R3>Q=.3B[Q=F<DU[,+>79-&4F.9#N(_!AWJ*UU":WDCN$=_,#%5WC>
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M_P!*XZ]BKR32;&[3Q2CM:SA/M,YW&,XP;J,C] 37K=6(**** "BBB@ HHHH
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MIW<_(H( (]<]A0!:!I>:HPSW'G&VF,?G[=XV$XVYP*EM;>2)I'GG,TCGKC
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MLO[UMQW.2!]/04<B_IL/;S[+[E_D5M(TQ],M'A>42L\AD9MN.3[5?96.T#
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MD)"]2!GCFFRRQPQF25U1%ZLQP!5'6+274+!8[<0LXECD4R$X&U@<@@'GC]:
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MJ*0."S=.@[DT 7:SK+_D+ZI_OQ_^@"K*WMLUXUF)E-PJ[C'W JM9?\A?5/\
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M!+(\J(6*AL#A5R2:IZ4VH31">_587=,^2AR$.?7UQ6E2"@#+L;Z:XNYUW+)
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M:/SB/.VY?:.,]\5C:E=ZA;WD=P2@LXY]N%0E]A7&3[;JU?M)%W]G\M]^S?\
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M3:5B09WD<$],"K1FCV_>H CM1,EK%]ID\R7)).,=3P*9?W_V-X@8)75VVET
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M&C:IN+-%II8GD[I/\*Z>B@#G#IVM!E BTXKSD^8_'Z4O]FZQ_P \]._[[?\
MPKHJ* .=_LW6/[FG^GWW_P *:VF:RB$QPZ<6[#S'&?TKI** .>_L[6/[NG_]
M]O\ X4Q])U5U*M'IQ4G)!=_\*Z2B@#G$TK5D&%CTX#V9_P#"A=.UH@[H].!R
M<8D<\>O2NCHH YI=(U1&++#IH)ZD,_\ A3ETK5D!VQZ</HS_ .%='10!S?\
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M!\1=0_L>+6OL6R+9]D$OEYV#.-O'6OIS/M29]J /BW[/\0/^>?B7\IZ/L_Q
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M*^A4U.[Y;&5)'HI;Y?#4#9/+.V*NP:LMC#Y=GI5O$O\ =23&?KQS4KZ-"/\
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M;#RF?+_NGUJ7;-ZI_P!\FHLGT*C*2TN5_L(SS*<?[HH^P#O*?^^:L;9O5/\
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M7W"]JCS0:-K3.)XM');.3R"*BGT_5X")[G3V3G+^7P2/I7JBQLHPIB ] /\
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M*MN?];SU_>M_C7R^_P ?/%TBE3#IH!()Q$XSCI_'4G_#07C'C]QI?'3]P_\
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M6PO+XHID>1,GH, _A6#=^(&B\5!H&!2Y'EXZXW<G\>*==ZNO]G2W%O*'3S%
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M3'?R*_V1/^>MQ_W]-'V1/^>MQ_W]-6.:,4>TF%_(K_9$_P">MQ_W^-'V1/\
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M;QFT]OI\[6WFQ'>B?+@8S0!Z5N3U7\Z9,D<T+1E]H88)4X-'V:W_ .>$?_?
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MZ'.?PZTEKX3UV1GC>UEC1EQGICD>M;3G3Y'J*G=2U1SUE9SSW_EIC[P);+8
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MY[\7/%5_X5NO"LUMJ,EI:2W^+TJH.^(;2<C![9Z5W%Q]D_M2Z^U\I]G3<6/
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M!QTKK^*JQ70:[O(W("0;3GT!7-)*XV['$_\ "DO /_0%/_@3)_\ %4?\*2\
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M,RKOP]9021.K+%%"A<J<Y;'4_J*@L?#EJL5K=-(2MR%>4.<EC@8'\ZVWLY)
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MHH%IJ!(!+;;AMXS^ Z=ZEOLBTGU9OI(LB!US@]*P;7Q!'%,;:X+%S<O'O8\
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++!N<Y HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>13
<FILENAME>renb-20250630.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +KIpo7xRiXgen8uAZHZcOaKJCbPtxZ976ekhsmR6bRnqvycuoHOOACl5G7uGEe8H -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:RENB="http://renovarobio.com/20250630" elementFormDefault="qualified" targetNamespace="http://renovarobio.com/20250630">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://renovarobio.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
          <link:definition>00000002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/ConsolidatedStatementsOfOperations" id="ConsolidatedStatementsOfOperations">
          <link:definition>00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/ConsolidatedStatementsOfComprehensiveLoss" id="ConsolidatedStatementsOfComprehensiveLoss">
          <link:definition>00000005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit" id="ConsolidatedStatementOfStockholdersEquityDeficit">
          <link:definition>00000006 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
          <link:definition>00000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" id="OrganizationAndSummaryOfSignificantAccountingPolicies">
          <link:definition>999015 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/GoingConcern" id="GoingConcern">
          <link:definition>999016 - Disclosure - GOING CONCERN</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/FairValueMeasurements" id="FairValueMeasurements">
          <link:definition>999017 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
          <link:definition>999018 - Disclosure - PROPERTY AND EQUIPMENT</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/IntangibleAssetsAndGoodwill" id="IntangibleAssetsAndGoodwill">
          <link:definition>999019 - Disclosure - INTANGIBLE ASSETS AND GOODWILL</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/Leases" id="Leases">
          <link:definition>999020 - Disclosure - LEASES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/Debt" id="Debt">
          <link:definition>999021 - Disclosure - DEBT</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/IncomeTaxes" id="IncomeTaxes">
          <link:definition>999022 - Disclosure - INCOME TAXES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/StockholdersEquity" id="StockholdersEquity">
          <link:definition>999023 - Disclosure - STOCKHOLDERS&#8217; EQUITY</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
          <link:definition>999024 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
          <link:definition>999025 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/Acquisitions" id="Acquisitions">
          <link:definition>999026 - Disclosure - ACQUISITIONS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/SegmentReporting" id="SegmentReporting">
          <link:definition>999027 - Disclosure - SEGMENT REPORTING</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>999028 - Disclosure - SUBSEQUENT EVENTS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" id="OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies">
          <link:definition>999029 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
          <link:definition>999030 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/PropertyAndEquipmentTables" id="PropertyAndEquipmentTables">
          <link:definition>999031 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/IntangibleAssetsAndGoodwillTables" id="IntangibleAssetsAndGoodwillTables">
          <link:definition>999032 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/LeasesTables" id="LeasesTables">
          <link:definition>999033 - Disclosure - LEASES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
          <link:definition>999034 - Disclosure - INCOME TAXES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
          <link:definition>999035 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/AcquisitionsTables" id="AcquisitionsTables">
          <link:definition>999036 - Disclosure - ACQUISITIONS (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/SegmentReportingTables" id="SegmentReportingTables">
          <link:definition>999037 - Disclosure - SEGMENT REPORTING (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" id="OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative">
          <link:definition>999038 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/GoingConcernDetailsNarrative" id="GoingConcernDetailsNarrative">
          <link:definition>999039 - Disclosure - GOING CONCERN (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/FairValueMeasurementsDetails" id="FairValueMeasurementsDetails">
          <link:definition>999040 - Disclosure - FAIR VALUE MEASUREMENTS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/FairValueMeasurementsDetails1" id="FairValueMeasurementsDetails1">
          <link:definition>999041 - Disclosure - FAIR VALUE MEASUREMENTS (Details 1)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/FairValueMeasurementsDetails2" id="FairValueMeasurementsDetails2">
          <link:definition>999042 - Disclosure - FAIR VALUE MEASUREMENTS (Details 2)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/FairValueMeasurementsDetailsNarrative" id="FairValueMeasurementsDetailsNarrative">
          <link:definition>999043 - Disclosure - FAIR VALUE MEASUREMENTS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/PropertyAndEquipmentDetails" id="PropertyAndEquipmentDetails">
          <link:definition>999044 - Disclosure - PROPERTY AND EQUIPMENT (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/PropertyAndEquipmentDetailsNarrative" id="PropertyAndEquipmentDetailsNarrative">
          <link:definition>999045 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails" id="IntangibleAssetsAndGoodwillDetails">
          <link:definition>999046 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails1" id="IntangibleAssetsAndGoodwillDetails1">
          <link:definition>999047 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details 1)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetailsNarrative" id="IntangibleAssetsAndGoodwillDetailsNarrative">
          <link:definition>999048 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/LeasesDetails" id="LeasesDetails">
          <link:definition>999049 - Disclosure - LEASES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/LeasesDetailsNarrative" id="LeasesDetailsNarrative">
          <link:definition>999050 - Disclosure - LEASES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/DebtDetailsNarrative" id="DebtDetailsNarrative">
          <link:definition>999051 - Disclosure - DEBT (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/IncomeTaxesDetails" id="IncomeTaxesDetails">
          <link:definition>999052 - Disclosure - INCOME TAXES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/IncomeTaxesDetails1" id="IncomeTaxesDetails1">
          <link:definition>999053 - Disclosure - INCOME TAXES (Details 1)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/IncomeTaxesDetails2" id="IncomeTaxesDetails2">
          <link:definition>999054 - Disclosure - INCOME TAXES (Details 2)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
          <link:definition>999055 - Disclosure - INCOME TAXES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/StockholdersEquityDetails" id="StockholdersEquityDetails">
          <link:definition>999056 - Disclosure - STOCKHOLDERS' EQUITY (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/StockholdersEquityDetails1" id="StockholdersEquityDetails1">
          <link:definition>999057 - Disclosure - STOCKHOLDERS' EQUITY (Details 1)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/StockholdersEquityDetails2" id="StockholdersEquityDetails2">
          <link:definition>999058 - Disclosure - STOCKHOLDERS' EQUITY (Details 2)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/StockholdersEquityDetails3" id="StockholdersEquityDetails3">
          <link:definition>999059 - Disclosure - STOCKHOLDERS' EQUITY (Details 3)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/StockholdersEquityDetails4" id="StockholdersEquityDetails4">
          <link:definition>999060 - Disclosure - STOCKHOLDERS' EQUITY (Details 4)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
          <link:definition>999061 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
          <link:definition>999062 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
          <link:definition>999063 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/AcquisitionDetails" id="AcquisitionDetails">
          <link:definition>999064 - Disclosure - ACQUISITION (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/AcquisitionDetails1" id="AcquisitionDetails1">
          <link:definition>999065 - Disclosure - ACQUISITION (Details 1)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/AcquisitionDetails2" id="AcquisitionDetails2">
          <link:definition>999066 - Disclosure - ACQUISITION (Details 2)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/AcquisitionDetails5" id="AcquisitionDetails5">
          <link:definition>999067 - Disclosure - ACQUISITION (Details 5)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/AcquisitionDetails4" id="AcquisitionDetails4">
          <link:definition>999068 - Disclosure - ACQUISITION (Details 4)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/AcquisitionDetails3" id="AcquisitionDetails3">
          <link:definition>999069 - Disclosure - ACQUISITION (Details 3)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/AcquisitionsDetailsNarrative" id="AcquisitionsDetailsNarrative">
          <link:definition>999070 - Disclosure - ACQUISITIONS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/SegmentReportingDetails" id="SegmentReportingDetails">
          <link:definition>999071 - Disclosure - SEGMENT REPORTING (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/SegmentReportingDetails1" id="SegmentReportingDetails1">
          <link:definition>999072 - Disclosure - SEGMENT REPORTING (Details 1)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://renovarobio.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
          <link:definition>999073 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="renb-20250630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="renb-20250630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="renb-20250630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="renb-20250630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://xbrl.sec.gov/cyd/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd" />
    <element id="RENB_RenovaroCubeMember" name="RenovaroCubeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_EmployeesOfficersDirectorsAndConsultantsMember" name="EmployeesOfficersDirectorsAndConsultantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_CommonStocksMember" name="CommonStocksMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ConvertibleNotesMember" name="ConvertibleNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_BlackScholesOptionPricingModelMember" name="BlackScholesOptionPricingModelMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_InitialRecognitionMember" name="InitialRecognitionMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_LabEquipmentAndInstrumentsMember" name="LabEquipmentAndInstrumentsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_SoftwarePlatformMember" name="SoftwarePlatformMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_TrademarkMember" name="TrademarkMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_BioSymetricsMember" name="BioSymetricsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_LessAccumulatedAmortizationMember" name="LessAccumulatedAmortizationMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_JanuaryNote2024Member" name="JanuaryNote2024Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_DecemberNote2023Member" name="DecemberNote2023Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_PasecoApSMember" name="PasecoApSMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_TheNotesMember" name="TheNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_PromissoryNotesMember" name="PromissoryNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_PromissoryNoteMember" name="PromissoryNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_FinanceAgreementMember" name="FinanceAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_UnitedStatesTaxMember" name="UnitedStatesTaxMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_SeriesAConvertiblePreferredStockMember" name="SeriesAConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_PurchaseAgreementMember" name="PurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_CommonStockIssuancesMember" name="CommonStockIssuancesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_MrMillerMember" name="MrMillerMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_BoardOfDirectorsMember" name="BoardOfDirectorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_CommonStockConsultingServicesMember" name="CommonStockConsultingServicesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_Investor1Member" name="Investor1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_SingleRangeMember" name="SingleRangeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_GEDiCubeIntlLtdMember" name="GEDiCubeIntlLtdMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_StockPurchaseAgreementOfRenovaroCubeMember" name="StockPurchaseAgreementOfRenovaroCubeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_AvramMillerMember" name="AvramMillerMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_EBIAndWeirdScienceLLCMember" name="EBIAndWeirdScienceLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_AgreementAndPlanOfMergerAgreementAxisMember" name="AgreementAndPlanOfMergerAgreementAxisMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_EquityIncentivePlan2014Member" name="EquityIncentivePlan2014Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_EmployeesMember" name="EmployeesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_EmployeesThreeYearMember" name="EmployeesThreeYearMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ShareBasedCompensationAwardAdvisoryBoardMember" name="ShareBasedCompensationAwardAdvisoryBoardMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ShareBasedCompensationAwardBoardofDirectorsMember" name="ShareBasedCompensationAwardBoardofDirectorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ShareBasedCompensationAwardConsultingServicesMember" name="ShareBasedCompensationAwardConsultingServicesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_PlanOptionsMember" name="PlanOptionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_PlanOptionMember" name="PlanOptionMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_RestrictedStockAwardsMember" name="RestrictedStockAwardsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_AdvisoryServicesMember" name="AdvisoryServicesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_RenovaroMember" name="RenovaroMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ExercisePriceRange1Member" name="ExercisePriceRange1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ExercisePriceRange2Member" name="ExercisePriceRange2Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ExercisePriceRange3Member" name="ExercisePriceRange3Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_EmployeeStockOptionsMember" name="EmployeeStockOptionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_CommonStockPurchaseWarrantsMember" name="CommonStockPurchaseWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ExercisePriceRange4Member" name="ExercisePriceRange4Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ExercisePriceRange5Member" name="ExercisePriceRange5Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ExercisePriceRange6Member" name="ExercisePriceRange6Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_CommonStockPurchaseWarrantMember" name="CommonStockPurchaseWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_GTechMember" name="GTechMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_LicenseAgreementMember" name="LicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_MarkDybulMember" name="MarkDybulMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_RSBioMember" name="RSBioMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_GEDiCubeMember" name="GEDiCubeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_BioSymetricsncAcquisitionMember" name="BioSymetricsncAcquisitionMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_GEDiCubeIntlLtdAcquisitionMember" name="GEDiCubeIntlLtdAcquisitionMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_RENBMember" name="RENBMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_RENCMember" name="RENCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ExchangeAgreementMember" name="ExchangeAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ConvertiblePromissoryNoteMember" name="ConvertiblePromissoryNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_DefiniteLifeIntangibleAssetsNet" name="DefiniteLifeIntangibleAssetsNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ContingentConsiderationLiabilityCurrent" name="ContingentConsiderationLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_NotesPayableRelatedPartiesNetCurrent" name="NotesPayableRelatedPartiesNetCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ChangeInFairValueOfContingentConsideration" name="ChangeInFairValueOfContingentConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_InterestIncomeAndOtherIncomeExpense" name="InterestIncomeAndOtherIncomeExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_IssuanceOfCommonStockUnderPrivatePlacementOfferingValue" name="IssuanceOfCommonStockUnderPrivatePlacementOfferingValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_IssuanceOfCommonStockUnderPrivatePlacementOfferingShares" name="IssuanceOfCommonStockUnderPrivatePlacementOfferingShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationValue" name="RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationShares" name="RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_IssuanceOfCommonStockPursuantToAcquisitionValue" name="IssuanceOfCommonStockPursuantToAcquisitionValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_IssuanceOfCommonStockPursuantToAcquisitionShares" name="IssuanceOfCommonStockPursuantToAcquisitionShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable" name="IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_IssuanceOfPreferredStockAndWarrantsInPrivatePlacement" name="IssuanceOfPreferredStockAndWarrantsInPrivatePlacement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayableShares" name="IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayableShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_IssuanceOfPreferredStockAndWarrantsInPrivatePlacementShares" name="IssuanceOfPreferredStockAndWarrantsInPrivatePlacementShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_RestrictedSharesIssuedForServicesRenderedValue" name="RestrictedSharesIssuedForServicesRenderedValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_RestrictedSharesIssuedForServicesRenderedShares" name="RestrictedSharesIssuedForServicesRenderedShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_StockIssuedDuringPeriodValueExerciseOfWarrants" name="StockIssuedDuringPeriodValueExerciseOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_StockIssuedDuringPeriodSharesExerciseOfWarrants" name="StockIssuedDuringPeriodSharesExerciseOfWarrants" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue" name="IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtShares" name="IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_SharesIssuableForSettlementOfContingentConsiderationValue" name="SharesIssuableForSettlementOfContingentConsiderationValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_SharesIssuableForSettlementOfContingentConsideration" name="SharesIssuableForSettlementOfContingentConsideration" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_IssuanceOfCommonStockPursuantToAcquisitionOfGediCube" name="IssuanceOfCommonStockPursuantToAcquisitionOfGediCube" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_IssuanceOfCommonStockPursuantAcquisitionOfGediCubeShares" name="IssuanceOfCommonStockPursuantAcquisitionOfGediCubeShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube" name="PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCubeShares" name="PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCubeShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_LossOnExtinguishmentOfDebt" name="LossOnExtinguishmentOfDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_NoncashStockbasedCompensationExpense" name="NoncashStockbasedCompensationExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_NoncashRestrictedSharesIssuedForServicesRendered" name="NoncashRestrictedSharesIssuedForServicesRendered" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_AmortizationOfDiscountOnNotePayable" name="AmortizationOfDiscountOnNotePayable" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_RepaymentsOfFinanceAgreement" name="RepaymentsOfFinanceAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_CashPaidDuringYearForAbstract" name="CashPaidDuringYearForAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ContingentSharesIssuedPursuantToAcquisitionAgreement" name="ContingentSharesIssuedPursuantToAcquisitionAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_CancellationOfRestrictedStockAwards" name="CancellationOfRestrictedStockAwards" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_FinanceAgreementEnteredIntoInExchangeForPrepaidAssets" name="FinanceAgreementEnteredIntoInExchangeForPrepaidAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ConversionOfNotePayableForIssuanceOfPreferredStock" name="ConversionOfNotePayableForIssuanceOfPreferredStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_NotePayableSettledThroughNoncashExerciseOfWarrants" name="NotePayableSettledThroughNoncashExerciseOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_DebtDiscountRelatedToConvertiblePromissoryNotes" name="DebtDiscountRelatedToConvertiblePromissoryNotes" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_CommonSharesIssuedUponAcquisition" name="CommonSharesIssuedUponAcquisition" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ContingentConsiderationIssuedUponAcquisition" name="ContingentConsiderationIssuedUponAcquisition" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_CommonSharesIssuedUponSettlementOfDebt" name="CommonSharesIssuedUponSettlementOfDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_EarnOutSharesIssuedInSettlementOfContingentLiability" name="EarnOutSharesIssuedInSettlementOfContingentLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_OptionsIssuedInSettlementOfDebt" name="OptionsIssuedInSettlementOfDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_SettlementOfNotesPayable" name="SettlementOfNotesPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_DisclosureLeasesAbstract" name="DisclosureLeasesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_BusinessPolicyTextBlock" name="BusinessPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_InvestmentinEquitySecuritiesPolicyTextBlock" name="InvestmentinEquitySecuritiesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_InsuranceReceivablePolicy" name="InsuranceReceivablePolicy" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ScheduleOfContingentConsiderationLiabilityTableTextBlock" name="ScheduleOfContingentConsiderationLiabilityTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ScheduleOfShareBasedPaymentAwardStockOptionValuationAssumptionsTableTextBlock" name="ScheduleOfShareBasedPaymentAwardStockOptionValuationAssumptionsTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ScheduleOfStockBasedCompensationActivityTableTextBlock" name="ScheduleOfStockBasedCompensationActivityTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ScheduleOfCommonStockPurchaseWarrantsOutstandingTableTextBlock" name="ScheduleOfCommonStockPurchaseWarrantsOutstandingTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ScheduleOfWarrantsOutstandingTableTextBlock" name="ScheduleOfWarrantsOutstandingTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ScheduleOfAcquistionFairValueOfConsiderationTableTextBlock" name="ScheduleOfAcquistionFairValueOfConsiderationTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ScheduleOfRecognizedIdentifiedAssetsAndLiabilitiesAssumedTableTextBlock" name="ScheduleOfRecognizedIdentifiedAssetsAndLiabilitiesAssumedTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_BusinessAcquisitionPercentage" name="BusinessAcquisitionPercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_PurchaseEquitySecuritiesValue" name="PurchaseEquitySecuritiesValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ImpairmentLoss" name="ImpairmentLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_InProcessResearchAndDevelopment" name="InProcessResearchAndDevelopment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_WorkingCapitalDeficit" name="WorkingCapitalDeficit" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_InvestmentEquitySecuritiesShares" name="InvestmentEquitySecuritiesShares" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_NetDefinitelifeIntangibleAssets" name="NetDefinitelifeIntangibleAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_NetDefinitelifeIntangibleAssetsAmortization" name="NetDefinitelifeIntangibleAssetsAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_IndefiniteLifeIntangibleAssetsAndGoodwillAmortization" name="IndefiniteLifeIntangibleAssetsAndGoodwillAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_IndefiniteLifeIntangibleAssetsAndGoodwillImpairment" name="IndefiniteLifeIntangibleAssetsAndGoodwillImpairment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_Software" name="Software" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_Trademark" name="Trademark" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ImpairmentAdjustment" name="ImpairmentAdjustment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_NotesBalance" name="NotesBalance" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_AgreementDescription" name="AgreementDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_MonthlyInstallments" name="MonthlyInstallments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_RepaymentOnFinanceAgreement" name="RepaymentOnFinanceAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_Depreciations" name="Depreciations" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_DeferredTaxAssetExcessTaxOverDepreciationPatents" name="DeferredTaxAssetExcessTaxOverDepreciationPatents" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_StockoptionsCompensation" name="StockoptionsCompensation" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_DepreciationAndAmortizations" name="DepreciationAndAmortizations" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ImpairmentExpense" name="ImpairmentExpense" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ContingentConsiderationFairValue" name="ContingentConsiderationFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_Section174ReCapitalization" name="Section174ReCapitalization" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_OperatingLeaseRightOfUseAssets" name="OperatingLeaseRightOfUseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_Section481aAdjustment" name="Section481aAdjustment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ChangeInTaxRate" name="ChangeInTaxRate" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisablesWeightedAverageRemainingContractualTerm1" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisablesWeightedAverageRemainingContractualTerm1" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ExercisePrices" name="ExercisePrices" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ExercisePrice" name="ExercisePrice" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_CommonStockPurchaseWarrant" name="CommonStockPurchaseWarrant" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_CommonStockPurchaseWarrantsWeightedAverageExercisePrice" name="CommonStockPurchaseWarrantsWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_PreferredStockDesignatedShares" name="PreferredStockDesignatedShares" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_CommonStockShareIssued" name="CommonStockShareIssued" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_UnrecognizedCompensationCostandVest" name="UnrecognizedCompensationCostandVest" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_IssuanceOfCommonStockUnderPrivatePlacementOffering" name="IssuanceOfCommonStockUnderPrivatePlacementOffering" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_CommonStockParValuePrivatePlacement" name="CommonStockParValuePrivatePlacement" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_PrincipalAmountAndInterestAccrued" name="PrincipalAmountAndInterestAccrued" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_PurchaseSharesOfCommonStock" name="PurchaseSharesOfCommonStock" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ExtinguishmentOfContingentConsiderationLiability" name="ExtinguishmentOfContingentConsiderationLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuable" name="BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuable" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_ReserveEscrowShares" name="ReserveEscrowShares" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_StockIssuedToNonconsentingShareholders" name="StockIssuedToNonconsentingShareholders" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_UnrecognizedCompensationCostNonVested" name="UnrecognizedCompensationCostNonVested" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_DebtConversionConvertedInstrumentWarrantsOptionsIssued1" name="DebtConversionConvertedInstrumentWarrantsOptionsIssued1" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_StockOptionIssued" name="StockOptionIssued" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_UnrecognizedCompensationCost" name="UnrecognizedCompensationCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_PurchaseExercisableWarrantsOutstandingShares" name="PurchaseExercisableWarrantsOutstandingShares" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_WarrantsExercisablePurchaseValue" name="WarrantsExercisablePurchaseValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_StockbasedCompensationExpense" name="StockbasedCompensationExpense" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_StockbasedCompensationExpenseGrantShares" name="StockbasedCompensationExpenseGrantShares" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_UnrecognizedStockbasedCompensationExpense" name="UnrecognizedStockbasedCompensationExpense" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_AdvisoryServices" name="AdvisoryServices" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_RoyaltyPercentage" name="RoyaltyPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_UpfrontPayment" name="UpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_PaymentForExpenditures" name="PaymentForExpenditures" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_InitialPayment" name="InitialPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_SharesOfCommonStockGranted" name="SharesOfCommonStockGranted" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_UnrecognizedCompensationExpense" name="UnrecognizedCompensationExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_BusinessCombinationContingentConsiderationCommonStock" name="BusinessCombinationContingentConsiderationCommonStock" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_TradeName" name="TradeName" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_BusinessAcquisitionsRevenue" name="BusinessAcquisitionsRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_BusinessAcquisitionsNetIncomeLoss" name="BusinessAcquisitionsNetIncomeLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseRightOfUseAssets" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseRightOfUseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_TransactionIssuedShares" name="TransactionIssuedShares" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_SegmentOperatingLoss" name="SegmentOperatingLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_SegmentAsset" name="SegmentAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_SaleOfStockConsiderationReceivedCashTransaction" name="SaleOfStockConsiderationReceivedCashTransaction" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="RENB_InterestRate" name="InterestRate" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>14
<FILENAME>renb-20250630_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#Cover" roleURI="http://renovarobio.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#ConsolidatedBalanceSheets" roleURI="http://renovarobio.com/role/ConsolidatedBalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://renovarobio.com/role/ConsolidatedBalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#ConsolidatedStatementsOfOperations" roleURI="http://renovarobio.com/role/ConsolidatedStatementsOfOperations" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#ConsolidatedStatementsOfComprehensiveLoss" roleURI="http://renovarobio.com/role/ConsolidatedStatementsOfComprehensiveLoss" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#ConsolidatedStatementOfStockholdersEquityDeficit" roleURI="http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#MaterialCybersecurityIncidentDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" roleURI="http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#GoingConcern" roleURI="http://renovarobio.com/role/GoingConcern" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#FairValueMeasurements" roleURI="http://renovarobio.com/role/FairValueMeasurements" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#PropertyAndEquipment" roleURI="http://renovarobio.com/role/PropertyAndEquipment" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#IntangibleAssetsAndGoodwill" roleURI="http://renovarobio.com/role/IntangibleAssetsAndGoodwill" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#Leases" roleURI="http://renovarobio.com/role/Leases" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#Debt" roleURI="http://renovarobio.com/role/Debt" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#IncomeTaxes" roleURI="http://renovarobio.com/role/IncomeTaxes" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#StockholdersEquity" roleURI="http://renovarobio.com/role/StockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#CommitmentsAndContingencies" roleURI="http://renovarobio.com/role/CommitmentsAndContingencies" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#RelatedPartyTransactions" roleURI="http://renovarobio.com/role/RelatedPartyTransactions" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#Acquisitions" roleURI="http://renovarobio.com/role/Acquisitions" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#SegmentReporting" roleURI="http://renovarobio.com/role/SegmentReporting" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#SubsequentEvents" roleURI="http://renovarobio.com/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#FairValueMeasurementsTables" roleURI="http://renovarobio.com/role/FairValueMeasurementsTables" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#PropertyAndEquipmentTables" roleURI="http://renovarobio.com/role/PropertyAndEquipmentTables" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#IntangibleAssetsAndGoodwillTables" roleURI="http://renovarobio.com/role/IntangibleAssetsAndGoodwillTables" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#LeasesTables" roleURI="http://renovarobio.com/role/LeasesTables" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#IncomeTaxesTables" roleURI="http://renovarobio.com/role/IncomeTaxesTables" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#StockholdersEquityTables" roleURI="http://renovarobio.com/role/StockholdersEquityTables" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#AcquisitionsTables" roleURI="http://renovarobio.com/role/AcquisitionsTables" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#SegmentReportingTables" roleURI="http://renovarobio.com/role/SegmentReportingTables" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" roleURI="http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#GoingConcernDetailsNarrative" roleURI="http://renovarobio.com/role/GoingConcernDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#FairValueMeasurementsDetails" roleURI="http://renovarobio.com/role/FairValueMeasurementsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#FairValueMeasurementsDetails1" roleURI="http://renovarobio.com/role/FairValueMeasurementsDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#FairValueMeasurementsDetails2" roleURI="http://renovarobio.com/role/FairValueMeasurementsDetails2" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#FairValueMeasurementsDetailsNarrative" roleURI="http://renovarobio.com/role/FairValueMeasurementsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#PropertyAndEquipmentDetails" roleURI="http://renovarobio.com/role/PropertyAndEquipmentDetails" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#PropertyAndEquipmentDetailsNarrative" roleURI="http://renovarobio.com/role/PropertyAndEquipmentDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#IntangibleAssetsAndGoodwillDetails" roleURI="http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#IntangibleAssetsAndGoodwillDetails1" roleURI="http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#IntangibleAssetsAndGoodwillDetailsNarrative" roleURI="http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#LeasesDetails" roleURI="http://renovarobio.com/role/LeasesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#LeasesDetailsNarrative" roleURI="http://renovarobio.com/role/LeasesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#DebtDetailsNarrative" roleURI="http://renovarobio.com/role/DebtDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#IncomeTaxesDetails" roleURI="http://renovarobio.com/role/IncomeTaxesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#IncomeTaxesDetails1" roleURI="http://renovarobio.com/role/IncomeTaxesDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#IncomeTaxesDetails2" roleURI="http://renovarobio.com/role/IncomeTaxesDetails2" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#IncomeTaxesDetailsNarrative" roleURI="http://renovarobio.com/role/IncomeTaxesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#StockholdersEquityDetails" roleURI="http://renovarobio.com/role/StockholdersEquityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#StockholdersEquityDetails1" roleURI="http://renovarobio.com/role/StockholdersEquityDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#StockholdersEquityDetails2" roleURI="http://renovarobio.com/role/StockholdersEquityDetails2" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#StockholdersEquityDetails3" roleURI="http://renovarobio.com/role/StockholdersEquityDetails3" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#StockholdersEquityDetails4" roleURI="http://renovarobio.com/role/StockholdersEquityDetails4" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#StockholdersEquityDetailsNarrative" roleURI="http://renovarobio.com/role/StockholdersEquityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#CommitmentsAndContingenciesDetailsNarrative" roleURI="http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#RelatedPartyTransactionsDetailsNarrative" roleURI="http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#AcquisitionDetails" roleURI="http://renovarobio.com/role/AcquisitionDetails" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#AcquisitionDetails1" roleURI="http://renovarobio.com/role/AcquisitionDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#AcquisitionDetails2" roleURI="http://renovarobio.com/role/AcquisitionDetails2" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#AcquisitionDetails5" roleURI="http://renovarobio.com/role/AcquisitionDetails5" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#AcquisitionDetails4" roleURI="http://renovarobio.com/role/AcquisitionDetails4" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#AcquisitionDetails3" roleURI="http://renovarobio.com/role/AcquisitionDetails3" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#AcquisitionsDetailsNarrative" roleURI="http://renovarobio.com/role/AcquisitionsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#SegmentReportingDetails" roleURI="http://renovarobio.com/role/SegmentReportingDetails" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#SegmentReportingDetails1" roleURI="http://renovarobio.com/role/SegmentReportingDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#SubsequentEventsDetailsNarrative" roleURI="http://renovarobio.com/role/SubsequentEventsDetailsNarrative" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InsuranceSettlementsReceivableCurrent" xlink:label="loc_us-gaapInsuranceSettlementsReceivableCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInsuranceSettlementsReceivableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="loc_us-gaapEquitySecuritiesFvNi" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapEquitySecuritiesFvNi" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_DefiniteLifeIntangibleAssetsNet" xlink:label="loc_RENBDefiniteLifeIntangibleAssetsNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssetsNoncurrent" xlink:to="loc_RENBDefiniteLifeIntangibleAssetsNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedComputerSoftwareGross" xlink:label="loc_us-gaapCapitalizedComputerSoftwareGross" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssetsNoncurrent" xlink:to="loc_us-gaapCapitalizedComputerSoftwareGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedTrademarksGross" xlink:label="loc_us-gaapFiniteLivedTrademarksGross" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssetsNoncurrent" xlink:to="loc_us-gaapFiniteLivedTrademarksGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssetsNoncurrent" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaapDepositsAssetsNoncurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssetsNoncurrent" xlink:to="loc_us-gaapDepositsAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssetsNoncurrent" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaapAccountsPayableTradeCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableTradeCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ContingentConsiderationLiabilityCurrent" xlink:label="loc_RENBContingentConsiderationLiabilityCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_RENBContingentConsiderationLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapConvertibleNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_NotesPayableRelatedPartiesNetCurrent" xlink:label="loc_RENBNotesPayableRelatedPartiesNetCurrent" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_RENBNotesPayableRelatedPartiesNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/ConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsExcludingGoodwill" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairmentLoss" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGoodwillImpairmentLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ChangeInFairValueOfContingentConsideration" xlink:label="loc_RENBChangeInFairValueOfContingentConsideration" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_RENBChangeInFairValueOfContingentConsideration" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiRealizedLoss" xlink:label="loc_us-gaapEquitySecuritiesFvNiRealizedLoss" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapEquitySecuritiesFvNiRealizedLoss" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="loc_us-gaapInterestExpenseNonoperating" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpenseNonoperating" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_InterestIncomeAndOtherIncomeExpense" xlink:label="loc_RENBInterestIncomeAndOtherIncomeExpense" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_RENBInterestIncomeAndOtherIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS&apos; EQUITY (DEFICIT)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ChangeInFairValueOfContingentConsideration" xlink:label="loc_RENBChangeInFairValueOfContingentConsideration" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_RENBChangeInFairValueOfContingentConsideration" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiRealizedLoss" xlink:label="loc_us-gaapEquitySecuritiesFvNiRealizedLoss" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapEquitySecuritiesFvNiRealizedLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_LossOnExtinguishmentOfDebt" xlink:label="loc_RENBLossOnExtinguishmentOfDebt" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_RENBLossOnExtinguishmentOfDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_NoncashStockbasedCompensationExpense" xlink:label="loc_RENBNoncashStockbasedCompensationExpense" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_RENBNoncashStockbasedCompensationExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_NoncashRestrictedSharesIssuedForServicesRendered" xlink:label="loc_RENBNoncashRestrictedSharesIssuedForServicesRendered" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_RENBNoncashRestrictedSharesIssuedForServicesRendered" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsExcludingGoodwill" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairmentLoss" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGoodwillImpairmentLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_AmortizationOfDiscountOnNotePayable" xlink:label="loc_RENBAmortizationOfDiscountOnNotePayable" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_RENBAmortizationOfDiscountOnNotePayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsAndOtherReceivables" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsAndOtherReceivables" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccruedLiabilities" />
      <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:label="loc_us-gaapPaymentsToAcquireEquitySecuritiesFvNi" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireEquitySecuritiesFvNi" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireNotesReceivable" xlink:label="loc_us-gaapPaymentsToAcquireNotesReceivable" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireNotesReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_us-gaapCashAcquiredFromAcquisition" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapCashAcquiredFromAcquisition" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_RepaymentsOfFinanceAgreement" xlink:label="loc_RENBRepaymentsOfFinanceAgreement" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_RENBRepaymentsOfFinanceAgreement" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfDebt" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000013 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" />
    <link:calculationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000014 - Disclosure - Material Cybersecurity Incident Disclosure" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:title="999015 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/GoingConcern" xlink:title="999016 - Disclosure - GOING CONCERN" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/FairValueMeasurements" xlink:title="999017 - Disclosure - FAIR VALUE MEASUREMENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/PropertyAndEquipment" xlink:title="999018 - Disclosure - PROPERTY AND EQUIPMENT" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IntangibleAssetsAndGoodwill" xlink:title="999019 - Disclosure - INTANGIBLE ASSETS AND GOODWILL" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/Leases" xlink:title="999020 - Disclosure - LEASES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/Debt" xlink:title="999021 - Disclosure - DEBT" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IncomeTaxes" xlink:title="999022 - Disclosure - INCOME TAXES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/StockholdersEquity" xlink:title="999023 - Disclosure - STOCKHOLDERS&#8217; EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/CommitmentsAndContingencies" xlink:title="999024 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/RelatedPartyTransactions" xlink:title="999025 - Disclosure - RELATED PARTY TRANSACTIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/Acquisitions" xlink:title="999026 - Disclosure - ACQUISITIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/SegmentReporting" xlink:title="999027 - Disclosure - SEGMENT REPORTING" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/SubsequentEvents" xlink:title="999028 - Disclosure - SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999029 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/FairValueMeasurementsTables" xlink:title="999030 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/PropertyAndEquipmentTables" xlink:title="999031 - Disclosure - PROPERTY AND EQUIPMENT (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IntangibleAssetsAndGoodwillTables" xlink:title="999032 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/LeasesTables" xlink:title="999033 - Disclosure - LEASES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IncomeTaxesTables" xlink:title="999034 - Disclosure - INCOME TAXES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/StockholdersEquityTables" xlink:title="999035 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/AcquisitionsTables" xlink:title="999036 - Disclosure - ACQUISITIONS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/SegmentReportingTables" xlink:title="999037 - Disclosure - SEGMENT REPORTING (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999038 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/GoingConcernDetailsNarrative" xlink:title="999039 - Disclosure - GOING CONCERN (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/FairValueMeasurementsDetails" xlink:title="999040 - Disclosure - FAIR VALUE MEASUREMENTS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/FairValueMeasurementsDetails1" xlink:title="999041 - Disclosure - FAIR VALUE MEASUREMENTS (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/FairValueMeasurementsDetails2" xlink:title="999042 - Disclosure - FAIR VALUE MEASUREMENTS (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/FairValueMeasurementsDetailsNarrative" xlink:title="999043 - Disclosure - FAIR VALUE MEASUREMENTS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/PropertyAndEquipmentDetails" xlink:title="999044 - Disclosure - PROPERTY AND EQUIPMENT (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="999045 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails" xlink:title="999046 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:title="999047 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetailsNarrative" xlink:title="999048 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/LeasesDetails" xlink:title="999049 - Disclosure - LEASES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/LeasesDetailsNarrative" xlink:title="999050 - Disclosure - LEASES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/DebtDetailsNarrative" xlink:title="999051 - Disclosure - DEBT (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IncomeTaxesDetails" xlink:title="999052 - Disclosure - INCOME TAXES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IncomeTaxesDetails1" xlink:title="999053 - Disclosure - INCOME TAXES (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IncomeTaxesDetails2" xlink:title="999054 - Disclosure - INCOME TAXES (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentFederalTaxExpenseBenefit" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapCurrentFederalTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentForeignTaxExpenseBenefit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapCurrentForeignTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IncomeTaxesDetailsNarrative" xlink:title="999055 - Disclosure - INCOME TAXES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/StockholdersEquityDetails" xlink:title="999056 - Disclosure - STOCKHOLDERS&apos; EQUITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/StockholdersEquityDetails1" xlink:title="999057 - Disclosure - STOCKHOLDERS&apos; EQUITY (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/StockholdersEquityDetails2" xlink:title="999058 - Disclosure - STOCKHOLDERS&apos; EQUITY (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/StockholdersEquityDetails3" xlink:title="999059 - Disclosure - STOCKHOLDERS&apos; EQUITY (Details 3)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/StockholdersEquityDetails4" xlink:title="999060 - Disclosure - STOCKHOLDERS&apos; EQUITY (Details 4)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/StockholdersEquityDetailsNarrative" xlink:title="999061 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999062 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="999063 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/AcquisitionDetails" xlink:title="999064 - Disclosure - ACQUISITION (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/AcquisitionDetails1" xlink:title="999065 - Disclosure - ACQUISITION (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/AcquisitionDetails2" xlink:title="999066 - Disclosure - ACQUISITION (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/AcquisitionDetails5" xlink:title="999067 - Disclosure - ACQUISITION (Details 5)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/AcquisitionDetails4" xlink:title="999068 - Disclosure - ACQUISITION (Details 4)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/AcquisitionDetails3" xlink:title="999069 - Disclosure - ACQUISITION (Details 3)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/AcquisitionsDetailsNarrative" xlink:title="999070 - Disclosure - ACQUISITIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/SegmentReportingDetails" xlink:title="999071 - Disclosure - SEGMENT REPORTING (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/SegmentReportingDetails1" xlink:title="999072 - Disclosure - SEGMENT REPORTING (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/SubsequentEventsDetailsNarrative" xlink:title="999073 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>15
<FILENAME>renb-20250630_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#Cover" roleURI="http://renovarobio.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#ConsolidatedBalanceSheets" roleURI="http://renovarobio.com/role/ConsolidatedBalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://renovarobio.com/role/ConsolidatedBalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#ConsolidatedStatementsOfOperations" roleURI="http://renovarobio.com/role/ConsolidatedStatementsOfOperations" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#ConsolidatedStatementsOfComprehensiveLoss" roleURI="http://renovarobio.com/role/ConsolidatedStatementsOfComprehensiveLoss" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#ConsolidatedStatementOfStockholdersEquityDeficit" roleURI="http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#MaterialCybersecurityIncidentDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" roleURI="http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#GoingConcern" roleURI="http://renovarobio.com/role/GoingConcern" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#FairValueMeasurements" roleURI="http://renovarobio.com/role/FairValueMeasurements" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#PropertyAndEquipment" roleURI="http://renovarobio.com/role/PropertyAndEquipment" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#IntangibleAssetsAndGoodwill" roleURI="http://renovarobio.com/role/IntangibleAssetsAndGoodwill" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#Leases" roleURI="http://renovarobio.com/role/Leases" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#Debt" roleURI="http://renovarobio.com/role/Debt" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#IncomeTaxes" roleURI="http://renovarobio.com/role/IncomeTaxes" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#StockholdersEquity" roleURI="http://renovarobio.com/role/StockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#CommitmentsAndContingencies" roleURI="http://renovarobio.com/role/CommitmentsAndContingencies" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#RelatedPartyTransactions" roleURI="http://renovarobio.com/role/RelatedPartyTransactions" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#Acquisitions" roleURI="http://renovarobio.com/role/Acquisitions" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#SegmentReporting" roleURI="http://renovarobio.com/role/SegmentReporting" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#SubsequentEvents" roleURI="http://renovarobio.com/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#FairValueMeasurementsTables" roleURI="http://renovarobio.com/role/FairValueMeasurementsTables" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#PropertyAndEquipmentTables" roleURI="http://renovarobio.com/role/PropertyAndEquipmentTables" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#IntangibleAssetsAndGoodwillTables" roleURI="http://renovarobio.com/role/IntangibleAssetsAndGoodwillTables" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#LeasesTables" roleURI="http://renovarobio.com/role/LeasesTables" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#IncomeTaxesTables" roleURI="http://renovarobio.com/role/IncomeTaxesTables" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#StockholdersEquityTables" roleURI="http://renovarobio.com/role/StockholdersEquityTables" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#AcquisitionsTables" roleURI="http://renovarobio.com/role/AcquisitionsTables" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#SegmentReportingTables" roleURI="http://renovarobio.com/role/SegmentReportingTables" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" roleURI="http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#GoingConcernDetailsNarrative" roleURI="http://renovarobio.com/role/GoingConcernDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#FairValueMeasurementsDetails" roleURI="http://renovarobio.com/role/FairValueMeasurementsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#FairValueMeasurementsDetails1" roleURI="http://renovarobio.com/role/FairValueMeasurementsDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#FairValueMeasurementsDetails2" roleURI="http://renovarobio.com/role/FairValueMeasurementsDetails2" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#FairValueMeasurementsDetailsNarrative" roleURI="http://renovarobio.com/role/FairValueMeasurementsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#PropertyAndEquipmentDetails" roleURI="http://renovarobio.com/role/PropertyAndEquipmentDetails" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#PropertyAndEquipmentDetailsNarrative" roleURI="http://renovarobio.com/role/PropertyAndEquipmentDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#IntangibleAssetsAndGoodwillDetails" roleURI="http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#IntangibleAssetsAndGoodwillDetails1" roleURI="http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#IntangibleAssetsAndGoodwillDetailsNarrative" roleURI="http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#LeasesDetails" roleURI="http://renovarobio.com/role/LeasesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#LeasesDetailsNarrative" roleURI="http://renovarobio.com/role/LeasesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#DebtDetailsNarrative" roleURI="http://renovarobio.com/role/DebtDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#IncomeTaxesDetails" roleURI="http://renovarobio.com/role/IncomeTaxesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#IncomeTaxesDetails1" roleURI="http://renovarobio.com/role/IncomeTaxesDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#IncomeTaxesDetails2" roleURI="http://renovarobio.com/role/IncomeTaxesDetails2" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#IncomeTaxesDetailsNarrative" roleURI="http://renovarobio.com/role/IncomeTaxesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#StockholdersEquityDetails" roleURI="http://renovarobio.com/role/StockholdersEquityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#StockholdersEquityDetails1" roleURI="http://renovarobio.com/role/StockholdersEquityDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#StockholdersEquityDetails2" roleURI="http://renovarobio.com/role/StockholdersEquityDetails2" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#StockholdersEquityDetails3" roleURI="http://renovarobio.com/role/StockholdersEquityDetails3" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#StockholdersEquityDetails4" roleURI="http://renovarobio.com/role/StockholdersEquityDetails4" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#StockholdersEquityDetailsNarrative" roleURI="http://renovarobio.com/role/StockholdersEquityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#CommitmentsAndContingenciesDetailsNarrative" roleURI="http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#RelatedPartyTransactionsDetailsNarrative" roleURI="http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#AcquisitionDetails" roleURI="http://renovarobio.com/role/AcquisitionDetails" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#AcquisitionDetails1" roleURI="http://renovarobio.com/role/AcquisitionDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#AcquisitionDetails2" roleURI="http://renovarobio.com/role/AcquisitionDetails2" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#AcquisitionDetails5" roleURI="http://renovarobio.com/role/AcquisitionDetails5" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#AcquisitionDetails4" roleURI="http://renovarobio.com/role/AcquisitionDetails4" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#AcquisitionDetails3" roleURI="http://renovarobio.com/role/AcquisitionDetails3" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#AcquisitionsDetailsNarrative" roleURI="http://renovarobio.com/role/AcquisitionsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#SegmentReportingDetails" roleURI="http://renovarobio.com/role/SegmentReportingDetails" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#SegmentReportingDetails1" roleURI="http://renovarobio.com/role/SegmentReportingDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#SubsequentEventsDetailsNarrative" roleURI="http://renovarobio.com/role/SubsequentEventsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosureWithAdditionalMeasures" roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosureWithAdditionalMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpTable" roleURI="http://xbrl.sec.gov/ecd/role/PvpTable" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsToCompensation" roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsToCompensation" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListsByExecutiveCategory" roleURI="http://xbrl.sec.gov/ecd/role/TabularListsByExecutiveCategory" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListMeasures" roleURI="http://xbrl.sec.gov/ecd/role/TabularListMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpMeasures" roleURI="http://xbrl.sec.gov/ecd/role/PvpMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpExecutiveCategoriesOnly" roleURI="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsOnly" roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly" roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTypeOnly" roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TradingArrangmentsOnly" roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ForgoneRecoveries" roleURI="http://xbrl.sec.gov/ecd/role/ForgoneRecoveries" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#OutstandingRecoveries" roleURI="http://xbrl.sec.gov/ecd/role/OutstandingRecoveries" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardsCloseToMnpiDisc" roleURI="http://xbrl.sec.gov/ecd/role/AwardsCloseToMnpiDisc" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangemenstByInd" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsByInd" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#Defaults" roleURI="http://xbrl.sec.gov/ecd/role/Defaults" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/ConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS&apos; EQUITY (DEFICIT)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_IssuanceOfCommonStockUnderPrivatePlacementOfferingValue" xlink:label="loc_RENBIssuanceOfCommonStockUnderPrivatePlacementOfferingValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBIssuanceOfCommonStockUnderPrivatePlacementOfferingValue_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_IssuanceOfCommonStockUnderPrivatePlacementOfferingShares" xlink:label="loc_RENBIssuanceOfCommonStockUnderPrivatePlacementOfferingShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBIssuanceOfCommonStockUnderPrivatePlacementOfferingShares_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationValue" xlink:label="loc_RENBRestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBRestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationValue_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationShares" xlink:label="loc_RENBRestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBRestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationShares_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensationForfeited_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensationForfeited_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensationForfeited_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensationForfeited_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_IssuanceOfCommonStockPursuantToAcquisitionValue" xlink:label="loc_RENBIssuanceOfCommonStockPursuantToAcquisitionValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBIssuanceOfCommonStockPursuantToAcquisitionValue_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_IssuanceOfCommonStockPursuantToAcquisitionShares" xlink:label="loc_RENBIssuanceOfCommonStockPursuantToAcquisitionShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBIssuanceOfCommonStockPursuantToAcquisitionShares_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable" xlink:label="loc_RENBIssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBIssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_IssuanceOfPreferredStockAndWarrantsInPrivatePlacement" xlink:label="loc_RENBIssuanceOfPreferredStockAndWarrantsInPrivatePlacement_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBIssuanceOfPreferredStockAndWarrantsInPrivatePlacement_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayableShares" xlink:label="loc_RENBIssuanceOfPreferredStockAndWarrantsForConversionOfNotePayableShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBIssuanceOfPreferredStockAndWarrantsForConversionOfNotePayableShares_70" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_IssuanceOfPreferredStockAndWarrantsInPrivatePlacementShares" xlink:label="loc_RENBIssuanceOfPreferredStockAndWarrantsInPrivatePlacementShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBIssuanceOfPreferredStockAndWarrantsInPrivatePlacementShares_70" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_RestrictedSharesIssuedForServicesRenderedValue" xlink:label="loc_RENBRestrictedSharesIssuedForServicesRenderedValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBRestrictedSharesIssuedForServicesRenderedValue_70" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_RestrictedSharesIssuedForServicesRenderedShares" xlink:label="loc_RENBRestrictedSharesIssuedForServicesRenderedShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBRestrictedSharesIssuedForServicesRenderedShares_70" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:label="loc_RENBStockIssuedDuringPeriodValueExerciseOfWarrants_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBStockIssuedDuringPeriodValueExerciseOfWarrants_70" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="loc_RENBStockIssuedDuringPeriodSharesExerciseOfWarrants_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBStockIssuedDuringPeriodSharesExerciseOfWarrants_70" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue" xlink:label="loc_RENBIssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBIssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue_70" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtShares" xlink:label="loc_RENBIssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBIssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtShares_70" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_SharesIssuableForSettlementOfContingentConsiderationValue" xlink:label="loc_RENBSharesIssuableForSettlementOfContingentConsiderationValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBSharesIssuableForSettlementOfContingentConsiderationValue_70" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_SharesIssuableForSettlementOfContingentConsideration" xlink:label="loc_RENBSharesIssuableForSettlementOfContingentConsideration_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBSharesIssuableForSettlementOfContingentConsideration_70" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_IssuanceOfCommonStockPursuantToAcquisitionOfGediCube" xlink:label="loc_RENBIssuanceOfCommonStockPursuantToAcquisitionOfGediCube_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBIssuanceOfCommonStockPursuantToAcquisitionOfGediCube_70" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_IssuanceOfCommonStockPursuantAcquisitionOfGediCubeShares" xlink:label="loc_RENBIssuanceOfCommonStockPursuantAcquisitionOfGediCubeShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBIssuanceOfCommonStockPursuantAcquisitionOfGediCubeShares_70" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube" xlink:label="loc_RENBPreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBPreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube_70" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCubeShares" xlink:label="loc_RENBPreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCubeShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBPreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCubeShares_70" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_70" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation_70" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_70" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax_70" xlink:type="arc" order="30" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000013 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000014 - Disclosure - Material Cybersecurity Incident Disclosure" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:title="999015 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/GoingConcern" xlink:title="999016 - Disclosure - GOING CONCERN" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/FairValueMeasurements" xlink:title="999017 - Disclosure - FAIR VALUE MEASUREMENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/PropertyAndEquipment" xlink:title="999018 - Disclosure - PROPERTY AND EQUIPMENT" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IntangibleAssetsAndGoodwill" xlink:title="999019 - Disclosure - INTANGIBLE ASSETS AND GOODWILL" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/Leases" xlink:title="999020 - Disclosure - LEASES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/Debt" xlink:title="999021 - Disclosure - DEBT" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IncomeTaxes" xlink:title="999022 - Disclosure - INCOME TAXES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/StockholdersEquity" xlink:title="999023 - Disclosure - STOCKHOLDERS&#8217; EQUITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/CommitmentsAndContingencies" xlink:title="999024 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/RelatedPartyTransactions" xlink:title="999025 - Disclosure - RELATED PARTY TRANSACTIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/Acquisitions" xlink:title="999026 - Disclosure - ACQUISITIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/SegmentReporting" xlink:title="999027 - Disclosure - SEGMENT REPORTING" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/SubsequentEvents" xlink:title="999028 - Disclosure - SUBSEQUENT EVENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999029 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/FairValueMeasurementsTables" xlink:title="999030 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/PropertyAndEquipmentTables" xlink:title="999031 - Disclosure - PROPERTY AND EQUIPMENT (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IntangibleAssetsAndGoodwillTables" xlink:title="999032 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/LeasesTables" xlink:title="999033 - Disclosure - LEASES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IncomeTaxesTables" xlink:title="999034 - Disclosure - INCOME TAXES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/StockholdersEquityTables" xlink:title="999035 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/AcquisitionsTables" xlink:title="999036 - Disclosure - ACQUISITIONS (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_srtCounterpartyNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BioSymetricsncAcquisitionMember" xlink:label="loc_RENBBioSymetricsncAcquisitionMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_RENBBioSymetricsncAcquisitionMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_GEDiCubeIntlLtdAcquisitionMember" xlink:label="loc_RENBGEDiCubeIntlLtdAcquisitionMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_RENBGEDiCubeIntlLtdAcquisitionMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ScheduleOfAcquistionFairValueOfConsiderationTableTextBlock" xlink:label="loc_RENBScheduleOfAcquistionFairValueOfConsiderationTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_RENBScheduleOfAcquistionFairValueOfConsiderationTableTextBlock_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaapScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ScheduleOfRecognizedIdentifiedAssetsAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_RENBScheduleOfRecognizedIdentifiedAssetsAndLiabilitiesAssumedTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_RENBScheduleOfRecognizedIdentifiedAssetsAndLiabilitiesAssumedTableTextBlock_40" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/SegmentReportingTables" xlink:title="999037 - Disclosure - SEGMENT REPORTING (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999038 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaapRestructuringCostAndReserveLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_RenovaroCubeMember" xlink:label="loc_RENBRenovaroCubeMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_RENBRenovaroCubeMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_EmployeesOfficersDirectorsAndConsultantsMember" xlink:label="loc_RENBEmployeesOfficersDirectorsAndConsultantsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_RENBEmployeesOfficersDirectorsAndConsultantsMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BusinessAcquisitionPercentage" xlink:label="loc_RENBBusinessAcquisitionPercentage_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_RENBBusinessAcquisitionPercentage_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_PurchaseEquitySecuritiesValue" xlink:label="loc_RENBPurchaseEquitySecuritiesValue_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_RENBPurchaseEquitySecuritiesValue_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCost" xlink:label="loc_us-gaapDebtSecuritiesTradingAndEquitySecuritiesFvNiCost_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapDebtSecuritiesTradingAndEquitySecuritiesFvNiCost_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtAndEquitySecuritiesGainLoss" xlink:label="loc_us-gaapDebtAndEquitySecuritiesGainLoss_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapDebtAndEquitySecuritiesGainLoss_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ImpairmentLoss" xlink:label="loc_RENBImpairmentLoss_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_RENBImpairmentLoss_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_InProcessResearchAndDevelopment" xlink:label="loc_RENBInProcessResearchAndDevelopment_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_RENBInProcessResearchAndDevelopment_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapGoodwill_90" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaapAssetImpairmentCharges_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapAssetImpairmentCharges_90" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_90" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockOtherSharesOutstanding" xlink:label="loc_us-gaapCommonStockOtherSharesOutstanding_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapCommonStockOtherSharesOutstanding_90" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_90" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapShareBasedCompensation_90" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/GoingConcernDetailsNarrative" xlink:title="999039 - Disclosure - GOING CONCERN (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/FairValueMeasurementsDetails" xlink:title="999040 - Disclosure - FAIR VALUE MEASUREMENTS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="loc_us-gaapEquitySecuritiesFvNi_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapEquitySecuritiesFvNi_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapAccruedLiabilitiesFairValueDisclosure_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesFairValueDisclosure_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="loc_us-gaapContingentConsiderationClassifiedAsEquityFairValueDisclosure_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapContingentConsiderationClassifiedAsEquityFairValueDisclosure_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaapDerivativeFairValueOfDerivativeLiability_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapDerivativeFairValueOfDerivativeLiability_40" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/FairValueMeasurementsDetails1" xlink:title="999041 - Disclosure - FAIR VALUE MEASUREMENTS (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BlackScholesOptionPricingModelMember" xlink:label="loc_RENBBlackScholesOptionPricingModelMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_RENBBlackScholesOptionPricingModelMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_InitialRecognitionMember" xlink:label="loc_RENBInitialRecognitionMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_RENBInitialRecognitionMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapSharePrice_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_130" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate" xlink:label="loc_RENBShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_RENBShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate_130" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_130" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/FairValueMeasurementsDetails2" xlink:title="999042 - Disclosure - FAIR VALUE MEASUREMENTS (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationLiability_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationLiability_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="loc_us-gaapLiabilitiesFairValueAdjustment_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapLiabilitiesFairValueAdjustment_100" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/FairValueMeasurementsDetailsNarrative" xlink:title="999043 - Disclosure - FAIR VALUE MEASUREMENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_CommonStocksMember" xlink:label="loc_RENBCommonStocksMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_RENBCommonStocksMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ConvertibleNotesMember" xlink:label="loc_RENBConvertibleNotesMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_RENBConvertibleNotesMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_RenovaroCubeMember" xlink:label="loc_RENBRenovaroCubeMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_RENBRenovaroCubeMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodShares_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiCost" xlink:label="loc_us-gaapEquitySecuritiesFvNiCost_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquitySecuritiesFvNiCost_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_InvestmentEquitySecuritiesShares" xlink:label="loc_RENBInvestmentEquitySecuritiesShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBInvestmentEquitySecuritiesShares_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaapBusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationLiability_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationLiability_70" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/PropertyAndEquipmentDetails" xlink:title="999044 - Disclosure - PROPERTY AND EQUIPMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_LabEquipmentAndInstrumentsMember" xlink:label="loc_RENBLabEquipmentAndInstrumentsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_RENBLabEquipmentAndInstrumentsMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_130" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="999045 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails" xlink:title="999046 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_SoftwarePlatformMember" xlink:label="loc_RENBSoftwarePlatformMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_RENBSoftwarePlatformMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_TrademarkMember" xlink:label="loc_RENBTrademarkMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_RENBTrademarkMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaapPatentsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapPatentsMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_LessAccumulatedAmortizationMember" xlink:label="loc_RENBLessAccumulatedAmortizationMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_RENBLessAccumulatedAmortizationMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillMember" xlink:label="loc_us-gaapGoodwillMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapGoodwillMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaapInProcessResearchAndDevelopmentMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapInProcessResearchAndDevelopmentMember_260" xlink:type="arc" order="261" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_300" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_NetDefinitelifeIntangibleAssets" xlink:label="loc_RENBNetDefinitelifeIntangibleAssets_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_RENBNetDefinitelifeIntangibleAssets_300" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsPeriodIncreaseDecrease_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsPeriodIncreaseDecrease_300" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_NetDefinitelifeIntangibleAssetsAmortization" xlink:label="loc_RENBNetDefinitelifeIntangibleAssetsAmortization_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_RENBNetDefinitelifeIntangibleAssetsAmortization_300" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived_300" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_300" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaapOtherIndefiniteLivedIntangibleAssets_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapOtherIndefiniteLivedIntangibleAssets_300" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_300" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_IndefiniteLifeIntangibleAssetsAndGoodwillAmortization" xlink:label="loc_RENBIndefiniteLifeIntangibleAssetsAndGoodwillAmortization_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_RENBIndefiniteLifeIntangibleAssetsAndGoodwillAmortization_300" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_IndefiniteLifeIntangibleAssetsAndGoodwillImpairment" xlink:label="loc_RENBIndefiniteLifeIntangibleAssetsAndGoodwillImpairment_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_RENBIndefiniteLifeIntangibleAssetsAndGoodwillImpairment_300" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_300" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:title="999047 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetailsNarrative" xlink:title="999048 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfIndefiniteLivedIntangibleAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaapPatentsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapPatentsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_SoftwarePlatformMember" xlink:label="loc_RENBSoftwarePlatformMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_RENBSoftwarePlatformMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_TrademarkMember" xlink:label="loc_RENBTrademarkMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_RENBTrademarkMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_RenovaroCubeMember" xlink:label="loc_RENBRenovaroCubeMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_RENBRenovaroCubeMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BioSymetricsMember" xlink:label="loc_RENBBioSymetricsMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_RENBBioSymetricsMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet_120" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedAmortizationOfCurrentDeferredFinanceCosts" xlink:label="loc_us-gaapAccumulatedAmortizationOfCurrentDeferredFinanceCosts_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapAccumulatedAmortizationOfCurrentDeferredFinanceCosts_120" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets_120" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapGoodwill_120" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_Software" xlink:label="loc_RENBSoftware_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_RENBSoftware_120" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_Trademark" xlink:label="loc_RENBTrademark_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_RENBTrademark_120" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ImpairmentAdjustment" xlink:label="loc_RENBImpairmentAdjustment_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_RENBImpairmentAdjustment_120" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/LeasesDetails" xlink:title="999049 - Disclosure - LEASES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/LeasesDetailsNarrative" xlink:title="999050 - Disclosure - LEASES (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/DebtDetailsNarrative" xlink:title="999051 - Disclosure - DEBT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapAwardDateAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_JanuaryNote2024Member" xlink:label="loc_RENBJanuaryNote2024Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_RENBJanuaryNote2024Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_DecemberNote2023Member" xlink:label="loc_RENBDecemberNote2023Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_RENBDecemberNote2023Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_PasecoApSMember" xlink:label="loc_RENBPasecoApSMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_RENBPasecoApSMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_TheNotesMember" xlink:label="loc_RENBTheNotesMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_RENBTheNotesMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_PromissoryNotesMember" xlink:label="loc_RENBPromissoryNotesMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_RENBPromissoryNotesMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_PromissoryNoteMember" xlink:label="loc_RENBPromissoryNoteMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_RENBPromissoryNoteMember_210" xlink:type="arc" order="211" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaapBalanceSheetLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapBalanceSheetLocationAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaapBalanceSheetLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBalanceSheetLocationAxis" xlink:to="loc_us-gaapBalanceSheetLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaapBalanceSheetLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBalanceSheetLocationAxis" xlink:to="loc_us-gaapBalanceSheetLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaapOtherCurrentLiabilitiesMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBalanceSheetLocationDomain" xlink:to="loc_us-gaapOtherCurrentLiabilitiesMember_240" xlink:type="arc" order="241" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_FinanceAgreementMember" xlink:label="loc_RENBFinanceAgreementMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_RENBFinanceAgreementMember_240" xlink:type="arc" order="242" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_300" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfDebt_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfDebt_300" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:label="loc_us-gaapLongTermDebtPercentageBearingFixedInterestRate_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLongTermDebtPercentageBearingFixedInterestRate_300" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate_300" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_300" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_NotesBalance" xlink:label="loc_RENBNotesBalance_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_RENBNotesBalance_300" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_300" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_300" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MaturitiesOfTimeDepositsDescription" xlink:label="loc_us-gaapMaturitiesOfTimeDepositsDescription_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapMaturitiesOfTimeDepositsDescription_300" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_AgreementDescription" xlink:label="loc_RENBAgreementDescription_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_RENBAgreementDescription_300" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="loc_us-gaapDebtInstrumentInterestRateIncreaseDecrease_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateIncreaseDecrease_300" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_300" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:label="loc_us-gaapDebtInstrumentAnnualPrincipalPayment_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentAnnualPrincipalPayment_300" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFixedInterestRate" xlink:label="loc_us-gaapDerivativeFixedInterestRate_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDerivativeFixedInterestRate_300" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_MonthlyInstallments" xlink:label="loc_RENBMonthlyInstallments_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_RENBMonthlyInstallments_300" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_RepaymentOnFinanceAgreement" xlink:label="loc_RENBRepaymentOnFinanceAgreement_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_RENBRepaymentOnFinanceAgreement_300" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent_300" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestAndDebtExpense" xlink:label="loc_us-gaapInterestAndDebtExpense_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestAndDebtExpense_300" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="loc_us-gaapInterestExpenseNonoperating_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestExpenseNonoperating_300" xlink:type="arc" order="18" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IncomeTaxesDetails" xlink:title="999052 - Disclosure - INCOME TAXES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IncomeTaxesDetails1" xlink:title="999053 - Disclosure - INCOME TAXES (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IncomeTaxesDetails2" xlink:title="999054 - Disclosure - INCOME TAXES (Details 2)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IncomeTaxesDetailsNarrative" xlink:title="999055 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_UnitedStatesTaxMember" xlink:label="loc_RENBUnitedStatesTaxMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_RENBUnitedStatesTaxMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsForeign_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsForeign_30" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/StockholdersEquityDetails" xlink:title="999056 - Disclosure - STOCKHOLDERS&apos; EQUITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_RenovaroMember" xlink:label="loc_RENBRenovaroMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_RENBRenovaroMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_40" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/StockholdersEquityDetails1" xlink:title="999057 - Disclosure - STOCKHOLDERS&apos; EQUITY (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityEquityTable" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ExercisePriceRange1Member" xlink:label="loc_RENBExercisePriceRange1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_RENBExercisePriceRange1Member_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ExercisePriceRange2Member" xlink:label="loc_RENBExercisePriceRange2Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_RENBExercisePriceRange2Member_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ExercisePriceRange3Member" xlink:label="loc_RENBExercisePriceRange3Member_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_RENBExercisePriceRange3Member_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_90" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_90" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/StockholdersEquityDetails2" xlink:title="999058 - Disclosure - STOCKHOLDERS&apos; EQUITY (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityEquityTable" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_EmployeeStockOptionsMember" xlink:label="loc_RENBEmployeeStockOptionsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_RENBEmployeeStockOptionsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_50" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_50" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisablesWeightedAverageRemainingContractualTerm1" xlink:label="loc_RENBSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisablesWeightedAverageRemainingContractualTerm1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_RENBSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisablesWeightedAverageRemainingContractualTerm1_50" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_50" xlink:type="arc" order="18" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/StockholdersEquityDetails3" xlink:title="999059 - Disclosure - STOCKHOLDERS&apos; EQUITY (Details 3)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityEquityTable" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_CommonStockPurchaseWarrantsMember" xlink:label="loc_RENBCommonStockPurchaseWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_RENBCommonStockPurchaseWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ExercisePriceRange1Member" xlink:label="loc_RENBExercisePriceRange1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_RENBExercisePriceRange1Member_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ExercisePriceRange2Member" xlink:label="loc_RENBExercisePriceRange2Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_RENBExercisePriceRange2Member_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ExercisePriceRange3Member" xlink:label="loc_RENBExercisePriceRange3Member_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_RENBExercisePriceRange3Member_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ExercisePriceRange4Member" xlink:label="loc_RENBExercisePriceRange4Member_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_RENBExercisePriceRange4Member_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ExercisePriceRange5Member" xlink:label="loc_RENBExercisePriceRange5Member_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_RENBExercisePriceRange5Member_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ExercisePriceRange6Member" xlink:label="loc_RENBExercisePriceRange6Member_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_RENBExercisePriceRange6Member_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ExercisePrices" xlink:label="loc_RENBExercisePrices_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_RENBExercisePrices_150" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_150" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_150" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_150" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_150" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ExercisePrice" xlink:label="loc_RENBExercisePrice_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_RENBExercisePrice_150" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_150" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_150" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/StockholdersEquityDetails4" xlink:title="999060 - Disclosure - STOCKHOLDERS&apos; EQUITY (Details 4)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityEquityTable" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_CommonStockPurchaseWarrantMember" xlink:label="loc_RENBCommonStockPurchaseWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_RENBCommonStockPurchaseWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_CommonStockPurchaseWarrant" xlink:label="loc_RENBCommonStockPurchaseWarrant_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_RENBCommonStockPurchaseWarrant_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_CommonStockPurchaseWarrantsWeightedAverageExercisePrice" xlink:label="loc_RENBCommonStockPurchaseWarrantsWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_RENBCommonStockPurchaseWarrantsWeightedAverageExercisePrice_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" xlink:label="loc_RENBSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_RENBSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_50" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/StockholdersEquityDetailsNarrative" xlink:title="999061 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapScheduleOfStockByClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_SeriesAConvertiblePreferredStockMember" xlink:label="loc_RENBSeriesAConvertiblePreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_RENBSeriesAConvertiblePreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_CommonStockIssuancesMember" xlink:label="loc_RENBCommonStockIssuancesMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_RENBCommonStockIssuancesMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_srtChiefExecutiveOfficerMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BoardOfDirectorsMember" xlink:label="loc_RENBBoardOfDirectorsMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_RENBBoardOfDirectorsMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_CommonStockConsultingServicesMember" xlink:label="loc_RENBCommonStockConsultingServicesMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_RENBCommonStockConsultingServicesMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapWarrantMember_220" xlink:type="arc" order="222" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_PurchaseAgreementMember" xlink:label="loc_RENBPurchaseAgreementMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_RENBPurchaseAgreementMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember_240" xlink:type="arc" order="241" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_RestrictedStockAwardsMember" xlink:label="loc_RENBRestrictedStockAwardsMember_680" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_RENBRestrictedStockAwardsMember_680" xlink:type="arc" order="681" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_AdvisoryServicesMember" xlink:label="loc_RENBAdvisoryServicesMember_710" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_RENBAdvisoryServicesMember_710" xlink:type="arc" order="711" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_MrMillerMember" xlink:label="loc_RENBMrMillerMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_RENBMrMillerMember_170" xlink:type="arc" order="172" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_470" xlink:type="arc" order="471" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_220" xlink:type="arc" order="221" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_230" xlink:type="arc" order="231" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapInvestorMember_260" xlink:type="arc" order="261" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_Investor1Member" xlink:label="loc_RENBInvestor1Member_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_RENBInvestor1Member_280" xlink:type="arc" order="281" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_GEDiCubeIntlLtdMember" xlink:label="loc_RENBGEDiCubeIntlLtdMember_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_RENBGEDiCubeIntlLtdMember_410" xlink:type="arc" order="411" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_AvramMillerMember" xlink:label="loc_RENBAvramMillerMember_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_RENBAvramMillerMember_440" xlink:type="arc" order="442" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_EmployeesMember" xlink:label="loc_RENBEmployeesMember_530" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_RENBEmployeesMember_530" xlink:type="arc" order="531" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_EmployeesThreeYearMember" xlink:label="loc_RENBEmployeesThreeYearMember_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_RENBEmployeesThreeYearMember_540" xlink:type="arc" order="541" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_SingleRangeMember" xlink:label="loc_RENBSingleRangeMember_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_RENBSingleRangeMember_370" xlink:type="arc" order="372" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_StockPurchaseAgreementOfRenovaroCubeMember" xlink:label="loc_RENBStockPurchaseAgreementOfRenovaroCubeMember_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_RENBStockPurchaseAgreementOfRenovaroCubeMember_420" xlink:type="arc" order="421" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_AgreementAndPlanOfMergerAgreementAxisMember" xlink:label="loc_RENBAgreementAndPlanOfMergerAgreementAxisMember_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_RENBAgreementAndPlanOfMergerAgreementAxisMember_510" xlink:type="arc" order="512" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_EBIAndWeirdScienceLLCMember" xlink:label="loc_RENBEBIAndWeirdScienceLLCMember_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_RENBEBIAndWeirdScienceLLCMember_510" xlink:type="arc" order="511" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_EquityIncentivePlan2014Member" xlink:label="loc_RENBEquityIncentivePlan2014Member_520" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_RENBEquityIncentivePlan2014Member_520" xlink:type="arc" order="521" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_PlanOptionsMember" xlink:label="loc_RENBPlanOptionsMember_620" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_RENBPlanOptionsMember_620" xlink:type="arc" order="621" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapVestingAxis" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ShareBasedCompensationAwardAdvisoryBoardMember" xlink:label="loc_RENBShareBasedCompensationAwardAdvisoryBoardMember_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_RENBShareBasedCompensationAwardAdvisoryBoardMember_560" xlink:type="arc" order="561" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheOneMember_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheOneMember_570" xlink:type="arc" order="571" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ShareBasedCompensationAwardBoardofDirectorsMember" xlink:label="loc_RENBShareBasedCompensationAwardBoardofDirectorsMember_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_RENBShareBasedCompensationAwardBoardofDirectorsMember_580" xlink:type="arc" order="581" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ShareBasedCompensationAwardConsultingServicesMember" xlink:label="loc_RENBShareBasedCompensationAwardConsultingServicesMember_600" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_RENBShareBasedCompensationAwardConsultingServicesMember_600" xlink:type="arc" order="601" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_PlanOptionMember" xlink:label="loc_RENBPlanOptionMember_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_RENBPlanOptionMember_660" xlink:type="arc" order="661" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_670" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapWarrantMember_670" xlink:type="arc" order="671" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefExecutiveOfficerMember_690" xlink:type="arc" order="691" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_730" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_730" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_730" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_730" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_PreferredStockDesignatedShares" xlink:label="loc_RENBPreferredStockDesignatedShares_730" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBPreferredStockDesignatedShares_730" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_730" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_730" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_730" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_730" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_730" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_730" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_730" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_730" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_CommonStockShareIssued" xlink:label="loc_RENBCommonStockShareIssued_730" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBCommonStockShareIssued_730" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_730" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_730" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligation" xlink:label="loc_us-gaapPurchaseObligation_730" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPurchaseObligation_730" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_730" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharesIssued_730" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_730" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_730" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_730" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_730" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_730" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_730" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_730" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_730" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_730" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_730" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_730" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_730" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_UnrecognizedCompensationCostandVest" xlink:label="loc_RENBUnrecognizedCompensationCostandVest_730" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBUnrecognizedCompensationCostandVest_730" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_IssuanceOfCommonStockUnderPrivatePlacementOffering" xlink:label="loc_RENBIssuanceOfCommonStockUnderPrivatePlacementOffering_730" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBIssuanceOfCommonStockUnderPrivatePlacementOffering_730" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_CommonStockParValuePrivatePlacement" xlink:label="loc_RENBCommonStockParValuePrivatePlacement_730" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBCommonStockParValuePrivatePlacement_730" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_730" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_730" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_730" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_730" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_730" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_730" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_PrincipalAmountAndInterestAccrued" xlink:label="loc_RENBPrincipalAmountAndInterestAccrued_730" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBPrincipalAmountAndInterestAccrued_730" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonrecurringIncomeExpense" xlink:label="loc_us-gaapOtherNonrecurringIncomeExpense_730" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapOtherNonrecurringIncomeExpense_730" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedPerTransaction_730" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedPerTransaction_730" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_730" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_730" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExpenseOrRevenueRecognized" xlink:label="loc_us-gaapClassOfWarrantOrRightExpenseOrRevenueRecognized_730" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExpenseOrRevenueRecognized_730" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement_730" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement_730" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares" xlink:label="loc_us-gaapSharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares_730" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares_730" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_PurchaseSharesOfCommonStock" xlink:label="loc_RENBPurchaseSharesOfCommonStock_730" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBPurchaseSharesOfCommonStock_730" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaapConversionOfStockAmountConverted1_730" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockAmountConverted1_730" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodShares_730" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodShares_730" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_730" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_730" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1" xlink:label="loc_us-gaapNoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1_730" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapNoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1_730" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_730" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharePrice_730" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ExtinguishmentOfContingentConsiderationLiability" xlink:label="loc_RENBExtinguishmentOfContingentConsiderationLiability_730" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBExtinguishmentOfContingentConsiderationLiability_730" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuable" xlink:label="loc_RENBBusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuable_730" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBBusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuable_730" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ReserveEscrowShares" xlink:label="loc_RENBReserveEscrowShares_730" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBReserveEscrowShares_730" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_StockIssuedToNonconsentingShareholders" xlink:label="loc_RENBStockIssuedToNonconsentingShareholders_730" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBStockIssuedToNonconsentingShareholders_730" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation_730" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation_730" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_UnrecognizedCompensationCostNonVested" xlink:label="loc_RENBUnrecognizedCompensationCostNonVested_730" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBUnrecognizedCompensationCostNonVested_730" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_730" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_730" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_DebtConversionConvertedInstrumentWarrantsOptionsIssued1" xlink:label="loc_RENBDebtConversionConvertedInstrumentWarrantsOptionsIssued1_730" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBDebtConversionConvertedInstrumentWarrantsOptionsIssued1_730" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:label="loc_us-gaapFairValueOptionChangesInFairValueGainLoss1_730" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapFairValueOptionChangesInFairValueGainLoss1_730" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_StockOptionIssued" xlink:label="loc_RENBStockOptionIssued_730" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBStockOptionIssued_730" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_730" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_730" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_UnrecognizedCompensationCost" xlink:label="loc_RENBUnrecognizedCompensationCost_730" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBUnrecognizedCompensationCost_730" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_730" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_730" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_PurchaseExercisableWarrantsOutstandingShares" xlink:label="loc_RENBPurchaseExercisableWarrantsOutstandingShares_730" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBPurchaseExercisableWarrantsOutstandingShares_730" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_WarrantsExercisablePurchaseValue" xlink:label="loc_RENBWarrantsExercisablePurchaseValue_730" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBWarrantsExercisablePurchaseValue_730" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_StockbasedCompensationExpense" xlink:label="loc_RENBStockbasedCompensationExpense_730" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBStockbasedCompensationExpense_730" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_StockbasedCompensationExpenseGrantShares" xlink:label="loc_RENBStockbasedCompensationExpenseGrantShares_730" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBStockbasedCompensationExpenseGrantShares_730" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_UnrecognizedStockbasedCompensationExpense" xlink:label="loc_RENBUnrecognizedStockbasedCompensationExpense_730" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBUnrecognizedStockbasedCompensationExpense_730" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_730" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_730" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_AdvisoryServices" xlink:label="loc_RENBAdvisoryServices_730" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBAdvisoryServices_730" xlink:type="arc" order="55" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999062 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_GTechMember" xlink:label="loc_RENBGTechMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_RENBGTechMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_LicenseAgreementMember" xlink:label="loc_RENBLicenseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_RENBLicenseAgreementMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForFees" xlink:label="loc_us-gaapPaymentsForFees_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapPaymentsForFees_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_RoyaltyPercentage" xlink:label="loc_RENBRoyaltyPercentage_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_RENBRoyaltyPercentage_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_UpfrontPayment" xlink:label="loc_RENBUpfrontPayment_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_RENBUpfrontPayment_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_PaymentForExpenditures" xlink:label="loc_RENBPaymentForExpenditures_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_RENBPaymentForExpenditures_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_InitialPayment" xlink:label="loc_RENBInitialPayment_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_RENBInitialPayment_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_80" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="999063 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_MarkDybulMember" xlink:label="loc_RENBMarkDybulMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_RENBMarkDybulMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_RSBioMember" xlink:label="loc_RENBRSBioMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_RENBRSBioMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensationForfeited_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensationForfeited_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_SharesOfCommonStockGranted" xlink:label="loc_RENBSharesOfCommonStockGranted_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_RENBSharesOfCommonStockGranted_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodShares_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_UnrecognizedCompensationExpense" xlink:label="loc_RENBUnrecognizedCompensationExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_RENBUnrecognizedCompensationExpense_70" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/AcquisitionDetails" xlink:title="999064 - Disclosure - ACQUISITION (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BioSymetricsncAcquisitionMember" xlink:label="loc_RENBBioSymetricsncAcquisitionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_RENBBioSymetricsncAcquisitionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BusinessCombinationContingentConsiderationCommonStock" xlink:label="loc_RENBBusinessCombinationContingentConsiderationCommonStock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_RENBBusinessCombinationContingentConsiderationCommonStock_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferred1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferred1_30" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/AcquisitionDetails1" xlink:title="999065 - Disclosure - ACQUISITION (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BioSymetricsncAcquisitionMember" xlink:label="loc_RENBBioSymetricsncAcquisitionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_RENBBioSymetricsncAcquisitionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_20" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_20" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets" xlink:label="loc_RENBBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_RENBBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets_20" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_20" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_20" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xlink:label="loc_RENBBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_RENBBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_20" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities" xlink:label="loc_RENBBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_RENBBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities_20" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_20" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_20" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_Software" xlink:label="loc_RENBSoftware_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_RENBSoftware_20" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_TradeName" xlink:label="loc_RENBTradeName_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_RENBTradeName_20" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_20" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_20" xlink:type="arc" order="12" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/AcquisitionDetails2" xlink:title="999066 - Disclosure - ACQUISITION (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BioSymetricsncAcquisitionMember" xlink:label="loc_RENBBioSymetricsncAcquisitionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_RENBBioSymetricsncAcquisitionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BusinessAcquisitionsRevenue" xlink:label="loc_RENBBusinessAcquisitionsRevenue_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_RENBBusinessAcquisitionsRevenue_20" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BusinessAcquisitionsNetIncomeLoss" xlink:label="loc_RENBBusinessAcquisitionsNetIncomeLoss_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_RENBBusinessAcquisitionsNetIncomeLoss_20" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/AcquisitionDetails5" xlink:title="999067 - Disclosure - ACQUISITION (Details 5)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_GEDiCubeMember" xlink:label="loc_RENBGEDiCubeMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_RENBGEDiCubeMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BusinessCombinationContingentConsiderationCommonStock" xlink:label="loc_RENBBusinessCombinationContingentConsiderationCommonStock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_RENBBusinessCombinationContingentConsiderationCommonStock_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationAsset" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationAsset_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationAsset_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferred1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferred1_30" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/AcquisitionDetails4" xlink:title="999068 - Disclosure - ACQUISITION (Details 4)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_GEDiCubeMember" xlink:label="loc_RENBGEDiCubeMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_RENBGEDiCubeMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_20" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_20" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets" xlink:label="loc_RENBBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_RENBBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets_20" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseRightOfUseAssets" xlink:label="loc_RENBBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseRightOfUseAssets_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_RENBBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseRightOfUseAssets_20" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_20" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_20" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xlink:label="loc_RENBBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_RENBBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_20" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities" xlink:label="loc_RENBBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_RENBBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities_20" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable" xlink:label="loc_RENBBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_RENBBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable_20" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_20" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_20" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_20" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_20" xlink:type="arc" order="12" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/AcquisitionDetails3" xlink:title="999069 - Disclosure - ACQUISITION (Details 3)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_GEDiCubeMember" xlink:label="loc_RENBGEDiCubeMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_RENBGEDiCubeMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BusinessAcquisitionsRevenue" xlink:label="loc_RENBBusinessAcquisitionsRevenue_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_RENBBusinessAcquisitionsRevenue_20" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BusinessAcquisitionsNetIncomeLoss" xlink:label="loc_RENBBusinessAcquisitionsNetIncomeLoss_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_RENBBusinessAcquisitionsNetIncomeLoss_20" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/AcquisitionsDetailsNarrative" xlink:title="999070 - Disclosure - ACQUISITIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BioSymetricsMember" xlink:label="loc_RENBBioSymetricsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_RENBBioSymetricsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_GEDiCubeMember" xlink:label="loc_RENBGEDiCubeMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_RENBGEDiCubeMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_TransactionIssuedShares" xlink:label="loc_RENBTransactionIssuedShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_RENBTransactionIssuedShares_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferredOther1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferredOther1_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="loc_us-gaapBusinessCombinationAcquisitionRelatedCosts_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationAcquisitionRelatedCosts_50" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/SegmentReportingDetails" xlink:title="999071 - Disclosure - SEGMENT REPORTING (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="loc_countryUS_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryUS_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BioSymetricsMember" xlink:label="loc_RENBBioSymetricsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_RENBBioSymetricsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_NL" xlink:label="loc_countryNL_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryNL_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_SegmentOperatingLoss" xlink:label="loc_RENBSegmentOperatingLoss_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="loc_RENBSegmentOperatingLoss_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_SegmentAsset" xlink:label="loc_RENBSegmentAsset_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="loc_RENBSegmentAsset_90" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/SegmentReportingDetails1" xlink:title="999072 - Disclosure - SEGMENT REPORTING (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaapSegmentReportingInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_RENBMember" xlink:label="loc_RENBRENBMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_RENBRENBMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BioSymetricsMember" xlink:label="loc_RENBBioSymetricsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_RENBBioSymetricsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_RENCMember" xlink:label="loc_RENBRENCMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_RENBRENCMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapOtherGeneralAndAdministrativeExpense_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapOtherGeneralAndAdministrativeExpense_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetImpairment_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetImpairment_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_SegmentOperatingLoss" xlink:label="loc_RENBSegmentOperatingLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_RENBSegmentOperatingLoss_50" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://renovarobio.com/role/SubsequentEventsDetailsNarrative" xlink:title="999073 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ExchangeAgreementMember" xlink:label="loc_RENBExchangeAgreementMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_RENBExchangeAgreementMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ConvertiblePromissoryNoteMember" xlink:label="loc_RENBConvertiblePromissoryNoteMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_RENBConvertiblePromissoryNoteMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ConvertibleNotesMember" xlink:label="loc_RENBConvertibleNotesMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_RENBConvertibleNotesMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_SaleOfStockConsiderationReceivedCashTransaction" xlink:label="loc_RENBSaleOfStockConsiderationReceivedCashTransaction_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_RENBSaleOfStockConsiderationReceivedCashTransaction_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_InterestRate" xlink:label="loc_RENBInterestRate_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_RENBInterestRate_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_80" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_MrMillerMember" xlink:label="loc_RENBMrMillerMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_RENBMrMillerMember" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ExchangeAgreementMember" xlink:label="loc_RENBExchangeAgreementMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_RENBExchangeAgreementMember" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ConvertiblePromissoryNoteMember" xlink:label="loc_RENBConvertiblePromissoryNoteMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_RENBConvertiblePromissoryNoteMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ConvertibleNotesMember" xlink:label="loc_RENBConvertibleNotesMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_RENBConvertibleNotesMember" xlink:type="arc" order="30" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>16
<FILENAME>renb-20250630_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US">Business Acquisition [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_RenovaroCubeMember" xlink:label="RENB_RenovaroCubeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_RenovaroCubeMember" xlink:to="RENB_RenovaroCubeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_RenovaroCubeMember_lbl" xml:lang="en-US">Renovaro Cube [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_EmployeesOfficersDirectorsAndConsultantsMember" xlink:label="RENB_EmployeesOfficersDirectorsAndConsultantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_EmployeesOfficersDirectorsAndConsultantsMember" xlink:to="RENB_EmployeesOfficersDirectorsAndConsultantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_EmployeesOfficersDirectorsAndConsultantsMember_lbl" xml:lang="en-US">Employees, Officers, Directors and Consultants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_CommonStocksMember" xlink:label="RENB_CommonStocksMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_CommonStocksMember" xlink:to="RENB_CommonStocksMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_CommonStocksMember_lbl" xml:lang="en-US">Common Stocks [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ConvertibleNotesMember" xlink:label="RENB_ConvertibleNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ConvertibleNotesMember" xlink:to="RENB_ConvertibleNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ConvertibleNotesMember_lbl" xml:lang="en-US">Convertible Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BlackScholesOptionPricingModelMember" xlink:label="RENB_BlackScholesOptionPricingModelMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_BlackScholesOptionPricingModelMember" xlink:to="RENB_BlackScholesOptionPricingModelMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_BlackScholesOptionPricingModelMember_lbl" xml:lang="en-US">Black Scholes Option Pricing Model [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_InitialRecognitionMember" xlink:label="RENB_InitialRecognitionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_InitialRecognitionMember" xlink:to="RENB_InitialRecognitionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_InitialRecognitionMember_lbl" xml:lang="en-US">Initial Recognition [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_LabEquipmentAndInstrumentsMember" xlink:label="RENB_LabEquipmentAndInstrumentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_LabEquipmentAndInstrumentsMember" xlink:to="RENB_LabEquipmentAndInstrumentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_LabEquipmentAndInstrumentsMember_lbl" xml:lang="en-US">Lab Equipment And Instruments [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PatentsMember_lbl" xml:lang="en-US">Patents [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_SoftwarePlatformMember" xlink:label="RENB_SoftwarePlatformMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_SoftwarePlatformMember" xlink:to="RENB_SoftwarePlatformMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_SoftwarePlatformMember_lbl" xml:lang="en-US">Software Platform [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_TrademarkMember" xlink:label="RENB_TrademarkMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_TrademarkMember" xlink:to="RENB_TrademarkMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_TrademarkMember_lbl" xml:lang="en-US">Trademark [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BioSymetricsMember" xlink:label="RENB_BioSymetricsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_BioSymetricsMember" xlink:to="RENB_BioSymetricsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_BioSymetricsMember_lbl" xml:lang="en-US">Bio Symetrics [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_LessAccumulatedAmortizationMember" xlink:label="RENB_LessAccumulatedAmortizationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_LessAccumulatedAmortizationMember" xlink:to="RENB_LessAccumulatedAmortizationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_LessAccumulatedAmortizationMember_lbl" xml:lang="en-US">Less Accumulated Amortization [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillMember" xlink:label="us-gaap_GoodwillMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillMember" xlink:to="us-gaap_GoodwillMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillMember_lbl" xml:lang="en-US">Goodwill [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember_lbl" xml:lang="en-US">In Process Research and Development [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateAxis_lbl" xml:lang="en-US">Award Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_JanuaryNote2024Member" xlink:label="RENB_JanuaryNote2024Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_JanuaryNote2024Member" xlink:to="RENB_JanuaryNote2024Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_JanuaryNote2024Member_lbl" xml:lang="en-US">January Note 2024 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_DecemberNote2023Member" xlink:label="RENB_DecemberNote2023Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_DecemberNote2023Member" xlink:to="RENB_DecemberNote2023Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_DecemberNote2023Member_lbl" xml:lang="en-US">December Note 2023 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_PasecoApSMember" xlink:label="RENB_PasecoApSMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_PasecoApSMember" xlink:to="RENB_PasecoApSMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_PasecoApSMember_lbl" xml:lang="en-US">Paseco Ap S [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_TheNotesMember" xlink:label="RENB_TheNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_TheNotesMember" xlink:to="RENB_TheNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_TheNotesMember_lbl" xml:lang="en-US">The Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_PromissoryNotesMember" xlink:label="RENB_PromissoryNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_PromissoryNotesMember" xlink:to="RENB_PromissoryNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_PromissoryNotesMember_lbl" xml:lang="en-US">Promissory Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_PromissoryNoteMember" xlink:label="RENB_PromissoryNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_PromissoryNoteMember" xlink:to="RENB_PromissoryNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_PromissoryNoteMember_lbl" xml:lang="en-US">Promissory Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xml:lang="en-US">Statement of Financial Position Location, Balance [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="us-gaap_OtherCurrentLiabilitiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentLiabilitiesMember" xlink:to="us-gaap_OtherCurrentLiabilitiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentLiabilitiesMember_lbl" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_FinanceAgreementMember" xlink:label="RENB_FinanceAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_FinanceAgreementMember" xlink:to="RENB_FinanceAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_FinanceAgreementMember_lbl" xml:lang="en-US">Finance Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_UnitedStatesTaxMember" xlink:label="RENB_UnitedStatesTaxMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_UnitedStatesTaxMember" xlink:to="RENB_UnitedStatesTaxMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_UnitedStatesTaxMember_lbl" xml:lang="en-US">United States Tax [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_SeriesAConvertiblePreferredStockMember" xlink:label="RENB_SeriesAConvertiblePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_SeriesAConvertiblePreferredStockMember" xlink:to="RENB_SeriesAConvertiblePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_SeriesAConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_PurchaseAgreementMember" xlink:label="RENB_PurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_PurchaseAgreementMember" xlink:to="RENB_PurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_PurchaseAgreementMember_lbl" xml:lang="en-US">Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_CommonStockIssuancesMember" xlink:label="RENB_CommonStockIssuancesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_CommonStockIssuancesMember" xlink:to="RENB_CommonStockIssuancesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_CommonStockIssuancesMember_lbl" xml:lang="en-US">Common Stock Issuances [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_MrMillerMember" xlink:label="RENB_MrMillerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_MrMillerMember" xlink:to="RENB_MrMillerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_MrMillerMember_lbl" xml:lang="en-US">Mr Miller [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BoardOfDirectorsMember" xlink:label="RENB_BoardOfDirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_BoardOfDirectorsMember" xlink:to="RENB_BoardOfDirectorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_BoardOfDirectorsMember_lbl" xml:lang="en-US">Board Of Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_CommonStockConsultingServicesMember" xlink:label="RENB_CommonStockConsultingServicesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_CommonStockConsultingServicesMember" xlink:to="RENB_CommonStockConsultingServicesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_CommonStockConsultingServicesMember_lbl" xml:lang="en-US">Common Stock Consulting Services [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember" xlink:label="us-gaap_InvestorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestorMember" xlink:to="us-gaap_InvestorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestorMember_lbl" xml:lang="en-US">Investor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_Investor1Member" xlink:label="RENB_Investor1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_Investor1Member" xlink:to="RENB_Investor1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_Investor1Member_lbl" xml:lang="en-US">Investor 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_SingleRangeMember" xlink:label="RENB_SingleRangeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_SingleRangeMember" xlink:to="RENB_SingleRangeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_SingleRangeMember_lbl" xml:lang="en-US">Single Range [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_GEDiCubeIntlLtdMember" xlink:label="RENB_GEDiCubeIntlLtdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_GEDiCubeIntlLtdMember" xlink:to="RENB_GEDiCubeIntlLtdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_GEDiCubeIntlLtdMember_lbl" xml:lang="en-US">G E Di Cube Intl Ltd [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_StockPurchaseAgreementOfRenovaroCubeMember" xlink:label="RENB_StockPurchaseAgreementOfRenovaroCubeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_StockPurchaseAgreementOfRenovaroCubeMember" xlink:to="RENB_StockPurchaseAgreementOfRenovaroCubeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_StockPurchaseAgreementOfRenovaroCubeMember_lbl" xml:lang="en-US">Stock Purchase Agreement Of Renovaro Cube [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_AvramMillerMember" xlink:label="RENB_AvramMillerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_AvramMillerMember" xlink:to="RENB_AvramMillerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_AvramMillerMember_lbl" xml:lang="en-US">Avram Miller [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_EBIAndWeirdScienceLLCMember" xlink:label="RENB_EBIAndWeirdScienceLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_EBIAndWeirdScienceLLCMember" xlink:to="RENB_EBIAndWeirdScienceLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_EBIAndWeirdScienceLLCMember_lbl" xml:lang="en-US">EBI And Weird Science LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_AgreementAndPlanOfMergerAgreementAxisMember" xlink:label="RENB_AgreementAndPlanOfMergerAgreementAxisMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_AgreementAndPlanOfMergerAgreementAxisMember" xlink:to="RENB_AgreementAndPlanOfMergerAgreementAxisMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_AgreementAndPlanOfMergerAgreementAxisMember_lbl" xml:lang="en-US">Agreement And Plan Of Merger Agreement Axis [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_EquityIncentivePlan2014Member" xlink:label="RENB_EquityIncentivePlan2014Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_EquityIncentivePlan2014Member" xlink:to="RENB_EquityIncentivePlan2014Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_EquityIncentivePlan2014Member_lbl" xml:lang="en-US">Equity Incentive Plan 2014 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_EmployeesMember" xlink:label="RENB_EmployeesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_EmployeesMember" xlink:to="RENB_EmployeesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_EmployeesMember_lbl" xml:lang="en-US">Employees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_EmployeesThreeYearMember" xlink:label="RENB_EmployeesThreeYearMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_EmployeesThreeYearMember" xlink:to="RENB_EmployeesThreeYearMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_EmployeesThreeYearMember_lbl" xml:lang="en-US">Employees Three Year [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US">Vesting [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ShareBasedCompensationAwardAdvisoryBoardMember" xlink:label="RENB_ShareBasedCompensationAwardAdvisoryBoardMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ShareBasedCompensationAwardAdvisoryBoardMember" xlink:to="RENB_ShareBasedCompensationAwardAdvisoryBoardMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ShareBasedCompensationAwardAdvisoryBoardMember_lbl" xml:lang="en-US">Share Based Compensation Award Advisory Board [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ShareBasedCompensationAwardBoardofDirectorsMember" xlink:label="RENB_ShareBasedCompensationAwardBoardofDirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ShareBasedCompensationAwardBoardofDirectorsMember" xlink:to="RENB_ShareBasedCompensationAwardBoardofDirectorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ShareBasedCompensationAwardBoardofDirectorsMember_lbl" xml:lang="en-US">Share Based Compensation Award Boardof Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ShareBasedCompensationAwardConsultingServicesMember" xlink:label="RENB_ShareBasedCompensationAwardConsultingServicesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ShareBasedCompensationAwardConsultingServicesMember" xlink:to="RENB_ShareBasedCompensationAwardConsultingServicesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ShareBasedCompensationAwardConsultingServicesMember_lbl" xml:lang="en-US">Share Based Compensation Award Consulting Services [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_PlanOptionsMember" xlink:label="RENB_PlanOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_PlanOptionsMember" xlink:to="RENB_PlanOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_PlanOptionsMember_lbl" xml:lang="en-US">Plan Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_PlanOptionMember" xlink:label="RENB_PlanOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_PlanOptionMember" xlink:to="RENB_PlanOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_PlanOptionMember_lbl" xml:lang="en-US">Plan Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_RestrictedStockAwardsMember" xlink:label="RENB_RestrictedStockAwardsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_RestrictedStockAwardsMember" xlink:to="RENB_RestrictedStockAwardsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_RestrictedStockAwardsMember_lbl" xml:lang="en-US">Restricted Stock Awards [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_AdvisoryServicesMember" xlink:label="RENB_AdvisoryServicesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_AdvisoryServicesMember" xlink:to="RENB_AdvisoryServicesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_AdvisoryServicesMember_lbl" xml:lang="en-US">Advisory Services [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_RenovaroMember" xlink:label="RENB_RenovaroMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_RenovaroMember" xlink:to="RENB_RenovaroMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_RenovaroMember_lbl" xml:lang="en-US">Renovaro [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityEquityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityAxis_lbl" xml:lang="en-US">Option Indexed to Issuer's Equity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ExercisePriceRange1Member" xlink:label="RENB_ExercisePriceRange1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ExercisePriceRange1Member" xlink:to="RENB_ExercisePriceRange1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ExercisePriceRange1Member_lbl" xml:lang="en-US">Exercise Price Range 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ExercisePriceRange2Member" xlink:label="RENB_ExercisePriceRange2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ExercisePriceRange2Member" xlink:to="RENB_ExercisePriceRange2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ExercisePriceRange2Member_lbl" xml:lang="en-US">Exercise Price Range 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ExercisePriceRange3Member" xlink:label="RENB_ExercisePriceRange3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ExercisePriceRange3Member" xlink:to="RENB_ExercisePriceRange3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ExercisePriceRange3Member_lbl" xml:lang="en-US">Exercise Price Range 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_EmployeeStockOptionsMember" xlink:label="RENB_EmployeeStockOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_EmployeeStockOptionsMember" xlink:to="RENB_EmployeeStockOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_EmployeeStockOptionsMember_lbl" xml:lang="en-US">Employee Stock Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_CommonStockPurchaseWarrantsMember" xlink:label="RENB_CommonStockPurchaseWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_CommonStockPurchaseWarrantsMember" xlink:to="RENB_CommonStockPurchaseWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_CommonStockPurchaseWarrantsMember_lbl" xml:lang="en-US">Common Stock Purchase Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ExercisePriceRange4Member" xlink:label="RENB_ExercisePriceRange4Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ExercisePriceRange4Member" xlink:to="RENB_ExercisePriceRange4Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ExercisePriceRange4Member_lbl" xml:lang="en-US">Exercise Price Range 4 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ExercisePriceRange5Member" xlink:label="RENB_ExercisePriceRange5Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ExercisePriceRange5Member" xlink:to="RENB_ExercisePriceRange5Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ExercisePriceRange5Member_lbl" xml:lang="en-US">Exercise Price Range 5 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ExercisePriceRange6Member" xlink:label="RENB_ExercisePriceRange6Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ExercisePriceRange6Member" xlink:to="RENB_ExercisePriceRange6Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ExercisePriceRange6Member_lbl" xml:lang="en-US">Exercise Price Range 6 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_CommonStockPurchaseWarrantMember" xlink:label="RENB_CommonStockPurchaseWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_CommonStockPurchaseWarrantMember" xlink:to="RENB_CommonStockPurchaseWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_CommonStockPurchaseWarrantMember_lbl" xml:lang="en-US">Common Stock Purchase Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_GTechMember" xlink:label="RENB_GTechMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_GTechMember" xlink:to="RENB_GTechMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_GTechMember_lbl" xml:lang="en-US">G Tech [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_LicenseAgreementMember" xlink:label="RENB_LicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_LicenseAgreementMember" xlink:to="RENB_LicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_LicenseAgreementMember_lbl" xml:lang="en-US">License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_MarkDybulMember" xlink:label="RENB_MarkDybulMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_MarkDybulMember" xlink:to="RENB_MarkDybulMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_MarkDybulMember_lbl" xml:lang="en-US">Mark Dybul [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_RSBioMember" xlink:label="RENB_RSBioMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_RSBioMember" xlink:to="RENB_RSBioMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_RSBioMember_lbl" xml:lang="en-US">RS Bio [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_GEDiCubeMember" xlink:label="RENB_GEDiCubeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_GEDiCubeMember" xlink:to="RENB_GEDiCubeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_GEDiCubeMember_lbl" xml:lang="en-US">GEDi Cube [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US">Counterparty Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BioSymetricsncAcquisitionMember" xlink:label="RENB_BioSymetricsncAcquisitionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_BioSymetricsncAcquisitionMember" xlink:to="RENB_BioSymetricsncAcquisitionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_BioSymetricsncAcquisitionMember_lbl" xml:lang="en-US">Bio Symetricsnc Acquisition [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_GEDiCubeIntlLtdAcquisitionMember" xlink:label="RENB_GEDiCubeIntlLtdAcquisitionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_GEDiCubeIntlLtdAcquisitionMember" xlink:to="RENB_GEDiCubeIntlLtdAcquisitionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_GEDiCubeIntlLtdAcquisitionMember_lbl" xml:lang="en-US">G E Di Cube Intl Ltd Acquisition [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="country_US" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl" xml:lang="en-US">UNITED STATES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_NL" xlink:label="country_NL" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_NL" xlink:to="country_NL_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_NL_lbl" xml:lang="en-US">NETHERLANDS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xml:lang="en-US">Segments [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_RENBMember" xlink:label="RENB_RENBMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_RENBMember" xlink:to="RENB_RENBMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_RENBMember_lbl" xml:lang="en-US">RENB [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_RENCMember" xlink:label="RENB_RENCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_RENCMember" xlink:to="RENB_RENCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_RENCMember_lbl" xml:lang="en-US">RENC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ExchangeAgreementMember" xlink:label="RENB_ExchangeAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ExchangeAgreementMember" xlink:to="RENB_ExchangeAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ExchangeAgreementMember_lbl" xml:lang="en-US">Exchange Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ConvertiblePromissoryNoteMember" xlink:label="RENB_ConvertiblePromissoryNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ConvertiblePromissoryNoteMember" xlink:to="RENB_ConvertiblePromissoryNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ConvertiblePromissoryNoteMember_lbl" xml:lang="en-US">Convertible Promissory Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InsuranceSettlementsReceivableCurrent" xlink:label="us-gaap_InsuranceSettlementsReceivableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InsuranceSettlementsReceivableCurrent" xlink:to="us-gaap_InsuranceSettlementsReceivableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InsuranceSettlementsReceivableCurrent_lbl" xml:lang="en-US">Insurance receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNi" xlink:to="us-gaap_EquitySecuritiesFvNi_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquitySecuritiesFvNi_lbl" xml:lang="en-US">Investment in equity securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaids and other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">OTHER ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_DefiniteLifeIntangibleAssetsNet" xlink:label="RENB_DefiniteLifeIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_DefiniteLifeIntangibleAssetsNet" xlink:to="RENB_DefiniteLifeIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_DefiniteLifeIntangibleAssetsNet_lbl" xml:lang="en-US">Definite life intangible assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedComputerSoftwareGross" xlink:label="us-gaap_CapitalizedComputerSoftwareGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedComputerSoftwareGross" xlink:to="us-gaap_CapitalizedComputerSoftwareGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalizedComputerSoftwareGross_lbl" xml:lang="en-US">Software platform</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedTrademarksGross" xlink:label="us-gaap_FiniteLivedTrademarksGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedTrademarksGross" xlink:to="us-gaap_FiniteLivedTrademarksGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedTrademarksGross_lbl" xml:lang="en-US">Trademarks</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US">Goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl" xml:lang="en-US">Deposits and other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Total Other Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Accounts payable &#8211; trade</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ContingentConsiderationLiabilityCurrent" xlink:label="RENB_ContingentConsiderationLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ContingentConsiderationLiabilityCurrent" xlink:to="RENB_ContingentConsiderationLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ContingentConsiderationLiabilityCurrent_lbl" xml:lang="en-US">Contingent consideration liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayable_lbl" xml:lang="en-US">Convertible notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Current portion of operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayable_lbl" xml:lang="en-US">Notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_NotesPayableRelatedPartiesNetCurrent" xlink:label="RENB_NotesPayableRelatedPartiesNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_NotesPayableRelatedPartiesNetCurrent" xlink:to="RENB_NotesPayableRelatedPartiesNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_NotesPayableRelatedPartiesNetCurrent_lbl" xml:lang="en-US">Notes payable &#8211; related parties, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">NON-CURRENT LIABILITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liabilities, net of current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total Non-Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY (DEFICIT)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, par value $0.0001, 350,000,000 shares authorized, 177,392,907 shares issued and outstanding at June 30, 2025; 158,452,644 shares issued and outstanding at June 30, 2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive (loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders&#8217; Equity (Deficit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl" xml:lang="en-US">Intangible asset impairment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xml:lang="en-US">Goodwill impairment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total Operating Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">LOSS FROM OPERATIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other Income (Expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ChangeInFairValueOfContingentConsideration" xlink:label="RENB_ChangeInFairValueOfContingentConsideration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ChangeInFairValueOfContingentConsideration" xlink:to="RENB_ChangeInFairValueOfContingentConsideration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ChangeInFairValueOfContingentConsideration_lbl" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Loss on extinguishment of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiRealizedLoss" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiRealizedLoss" xlink:to="us-gaap_EquitySecuritiesFvNiRealizedLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedLoss_lbl" xml:lang="en-US">Change in fair value of equity securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_InterestIncomeAndOtherIncomeExpense" xlink:label="RENB_InterestIncomeAndOtherIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_InterestIncomeAndOtherIncomeExpense" xlink:to="RENB_InterestIncomeAndOtherIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_InterestIncomeAndOtherIncomeExpense_lbl" xml:lang="en-US">Interest income and other income (expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total Other Income (Expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">NET LOSS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">BASIC NET LOSS PER COMMON SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">DILUTED NET LOSS PER COMMON SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING - BASIC</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING - DILUTED</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xml:lang="en-US">Other Comprehensive Income (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_lbl" xml:lang="en-US">Foreign currency translation, net of taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_IssuanceOfCommonStockUnderPrivatePlacementOfferingValue" xlink:label="RENB_IssuanceOfCommonStockUnderPrivatePlacementOfferingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_IssuanceOfCommonStockUnderPrivatePlacementOfferingValue" xlink:to="RENB_IssuanceOfCommonStockUnderPrivatePlacementOfferingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_IssuanceOfCommonStockUnderPrivatePlacementOfferingValue_lbl" xml:lang="en-US">Issuance of common stock under private placement offering</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_IssuanceOfCommonStockUnderPrivatePlacementOfferingShares" xlink:label="RENB_IssuanceOfCommonStockUnderPrivatePlacementOfferingShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_IssuanceOfCommonStockUnderPrivatePlacementOfferingShares" xlink:to="RENB_IssuanceOfCommonStockUnderPrivatePlacementOfferingShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_IssuanceOfCommonStockUnderPrivatePlacementOfferingShares_lbl" xml:lang="en-US">Issuance of common stock under private placement offering, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationValue" xlink:label="RENB_RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationValue" xlink:to="RENB_RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationValue_lbl" xml:lang="en-US">Restricted shares issued for services rendered and executive compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationShares" xlink:label="RENB_RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationShares" xlink:to="RENB_RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationShares_lbl" xml:lang="en-US">Restricted shares issued for services rendered and executive compensation, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_lbl" xml:lang="en-US">Forfeited shares of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_lbl" xml:lang="en-US">Forfeited shares of common stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_IssuanceOfCommonStockPursuantToAcquisitionValue" xlink:label="RENB_IssuanceOfCommonStockPursuantToAcquisitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_IssuanceOfCommonStockPursuantToAcquisitionValue" xlink:to="RENB_IssuanceOfCommonStockPursuantToAcquisitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_IssuanceOfCommonStockPursuantToAcquisitionValue_lbl" xml:lang="en-US">Issuance of common stock pursuant to acquisition</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_IssuanceOfCommonStockPursuantToAcquisitionShares" xlink:label="RENB_IssuanceOfCommonStockPursuantToAcquisitionShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_IssuanceOfCommonStockPursuantToAcquisitionShares" xlink:to="RENB_IssuanceOfCommonStockPursuantToAcquisitionShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_IssuanceOfCommonStockPursuantToAcquisitionShares_lbl" xml:lang="en-US">Issuance of common stock pursuant to acquisition, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable" xlink:label="RENB_IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable" xlink:to="RENB_IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable_lbl" xml:lang="en-US">Issuance of preferred stock and warrants for conversion of Note Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_IssuanceOfPreferredStockAndWarrantsInPrivatePlacement" xlink:label="RENB_IssuanceOfPreferredStockAndWarrantsInPrivatePlacement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_IssuanceOfPreferredStockAndWarrantsInPrivatePlacement" xlink:to="RENB_IssuanceOfPreferredStockAndWarrantsInPrivatePlacement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_IssuanceOfPreferredStockAndWarrantsInPrivatePlacement_lbl" xml:lang="en-US">Issuance of preferred stock and warrants in private placement</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayableShares" xlink:label="RENB_IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayableShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayableShares" xlink:to="RENB_IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayableShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayableShares_lbl" xml:lang="en-US">Issuance of preferred stock and warrants for conversion of Note Payable, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_IssuanceOfPreferredStockAndWarrantsInPrivatePlacementShares" xlink:label="RENB_IssuanceOfPreferredStockAndWarrantsInPrivatePlacementShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_IssuanceOfPreferredStockAndWarrantsInPrivatePlacementShares" xlink:to="RENB_IssuanceOfPreferredStockAndWarrantsInPrivatePlacementShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_IssuanceOfPreferredStockAndWarrantsInPrivatePlacementShares_lbl" xml:lang="en-US">Issuance of preferred stock and warrants in private placement, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_RestrictedSharesIssuedForServicesRenderedValue" xlink:label="RENB_RestrictedSharesIssuedForServicesRenderedValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_RestrictedSharesIssuedForServicesRenderedValue" xlink:to="RENB_RestrictedSharesIssuedForServicesRenderedValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_RestrictedSharesIssuedForServicesRenderedValue_lbl" xml:lang="en-US">Restricted shares issued for services rendered</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_RestrictedSharesIssuedForServicesRenderedShares" xlink:label="RENB_RestrictedSharesIssuedForServicesRenderedShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_RestrictedSharesIssuedForServicesRenderedShares" xlink:to="RENB_RestrictedSharesIssuedForServicesRenderedShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_RestrictedSharesIssuedForServicesRenderedShares_lbl" xml:lang="en-US">Restricted shares issued for services rendered, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:label="RENB_StockIssuedDuringPeriodValueExerciseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:to="RENB_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl" xml:lang="en-US">Exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="RENB_StockIssuedDuringPeriodSharesExerciseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:to="RENB_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl" xml:lang="en-US">Exercise of warrants, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue" xlink:label="RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue" xlink:to="RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue_lbl" xml:lang="en-US">Issuance of common stock and warrants under private placement offering in settlement of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtShares" xlink:label="RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtShares" xlink:to="RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtShares_lbl" xml:lang="en-US">Issuance of common stock and warrants under private placement offering in settlement of debt, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_SharesIssuableForSettlementOfContingentConsiderationValue" xlink:label="RENB_SharesIssuableForSettlementOfContingentConsiderationValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_SharesIssuableForSettlementOfContingentConsiderationValue" xlink:to="RENB_SharesIssuableForSettlementOfContingentConsiderationValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_SharesIssuableForSettlementOfContingentConsiderationValue_lbl" xml:lang="en-US">Shares issuable for settlement of contingent consideration</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_SharesIssuableForSettlementOfContingentConsideration" xlink:label="RENB_SharesIssuableForSettlementOfContingentConsideration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_SharesIssuableForSettlementOfContingentConsideration" xlink:to="RENB_SharesIssuableForSettlementOfContingentConsideration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_SharesIssuableForSettlementOfContingentConsideration_lbl" xml:lang="en-US">Shares issuable for settlement of contingent consideration, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_IssuanceOfCommonStockPursuantToAcquisitionOfGediCube" xlink:label="RENB_IssuanceOfCommonStockPursuantToAcquisitionOfGediCube" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_IssuanceOfCommonStockPursuantToAcquisitionOfGediCube" xlink:to="RENB_IssuanceOfCommonStockPursuantToAcquisitionOfGediCube_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_IssuanceOfCommonStockPursuantToAcquisitionOfGediCube_lbl" xml:lang="en-US">Issuance of common stock pursuant to acquisition of GEDi Cube</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_IssuanceOfCommonStockPursuantAcquisitionOfGediCubeShares" xlink:label="RENB_IssuanceOfCommonStockPursuantAcquisitionOfGediCubeShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_IssuanceOfCommonStockPursuantAcquisitionOfGediCubeShares" xlink:to="RENB_IssuanceOfCommonStockPursuantAcquisitionOfGediCubeShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_IssuanceOfCommonStockPursuantAcquisitionOfGediCubeShares_lbl" xml:lang="en-US">Issuance of common stock pursuant to acquisition of GEDi Cube, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube" xlink:label="RENB_PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube" xlink:to="RENB_PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube_lbl" xml:lang="en-US">Preferred stock converted to common stock pursuant to acquisition of GEDi Cube</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCubeShares" xlink:label="RENB_PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCubeShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCubeShares" xlink:to="RENB_PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCubeShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCubeShares_lbl" xml:lang="en-US">Preferred stock converted to common stock pursuant to acquisition of GEDi Cube, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Issuance of options for services rendered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Foreign currency translation adjustment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Ending balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">ADJUSTMENTS TO RECONCILE NET LOSS TO NET CASH USED IN OPERATING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ChangeInFairValueOfContingentConsideration" xlink:to="RENB_ChangeInFairValueOfContingentConsideration_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="RENB_ChangeInFairValueOfContingentConsideration_2_lbl" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiRealizedLoss" xlink:to="us-gaap_EquitySecuritiesFvNiRealizedLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedLoss_2_lbl" xml:lang="en-US">Change in value of equity securities</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_LossOnExtinguishmentOfDebt" xlink:label="RENB_LossOnExtinguishmentOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_LossOnExtinguishmentOfDebt" xlink:to="RENB_LossOnExtinguishmentOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="RENB_LossOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Loss on extinguishment of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_NoncashStockbasedCompensationExpense" xlink:label="RENB_NoncashStockbasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_NoncashStockbasedCompensationExpense" xlink:to="RENB_NoncashStockbasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_NoncashStockbasedCompensationExpense_lbl" xml:lang="en-US">Non-cash stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_NoncashRestrictedSharesIssuedForServicesRendered" xlink:label="RENB_NoncashRestrictedSharesIssuedForServicesRendered" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_NoncashRestrictedSharesIssuedForServicesRendered" xlink:to="RENB_NoncashRestrictedSharesIssuedForServicesRendered_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_NoncashRestrictedSharesIssuedForServicesRendered_lbl" xml:lang="en-US">Non-cash restricted shares issued for services rendered</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_AmortizationOfDiscountOnNotePayable" xlink:label="RENB_AmortizationOfDiscountOnNotePayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_AmortizationOfDiscountOnNotePayable" xlink:to="RENB_AmortizationOfDiscountOnNotePayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_AmortizationOfDiscountOnNotePayable_lbl" xml:lang="en-US">Amortization of discount on note payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl" xml:lang="en-US">Other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses/deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xml:lang="en-US">Other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Operating leases, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">NET CASH USED IN OPERATING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:label="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:to="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_lbl" xml:lang="en-US">Investment in equity securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireNotesReceivable" xlink:label="us-gaap_PaymentsToAcquireNotesReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireNotesReceivable" xlink:to="us-gaap_PaymentsToAcquireNotesReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireNotesReceivable_lbl" xml:lang="en-US">Notes receivable prior to acquisition</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAcquiredFromAcquisition" xlink:to="us-gaap_CashAcquiredFromAcquisition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAcquiredFromAcquisition_lbl" xml:lang="en-US">Cash received from acquisition, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">NET CASH USED IN INVESTING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_RepaymentsOfFinanceAgreement" xlink:label="RENB_RepaymentsOfFinanceAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_RepaymentsOfFinanceAgreement" xlink:to="RENB_RepaymentsOfFinanceAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="RENB_RepaymentsOfFinanceAgreement_lbl" xml:lang="en-US">Repayments of finance agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Proceeds from private placements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US">Proceeds from issuance of promissory notes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xml:lang="en-US">Proceeds from notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">NET CASH PROVIDED BY FINANCING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">&#160;Effect of exchange rates on cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">NET INCREASE (DECREASE) IN CASH</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">CASH, BEGINNING OF PERIOD</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">CASH, END OF PERIOD</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_CashPaidDuringYearForAbstract" xlink:label="RENB_CashPaidDuringYearForAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_CashPaidDuringYearForAbstract" xlink:to="RENB_CashPaidDuringYearForAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_CashPaidDuringYearForAbstract_lbl" xml:lang="en-US">Cash Paid during the year for:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ContingentSharesIssuedPursuantToAcquisitionAgreement" xlink:label="RENB_ContingentSharesIssuedPursuantToAcquisitionAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ContingentSharesIssuedPursuantToAcquisitionAgreement" xlink:to="RENB_ContingentSharesIssuedPursuantToAcquisitionAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ContingentSharesIssuedPursuantToAcquisitionAgreement_lbl" xml:lang="en-US">Contingent Shares issued pursuant to Acquisition Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_CancellationOfRestrictedStockAwards" xlink:label="RENB_CancellationOfRestrictedStockAwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_CancellationOfRestrictedStockAwards" xlink:to="RENB_CancellationOfRestrictedStockAwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_CancellationOfRestrictedStockAwards_lbl" xml:lang="en-US">Cancellation of restricted stock awards</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_FinanceAgreementEnteredIntoInExchangeForPrepaidAssets" xlink:label="RENB_FinanceAgreementEnteredIntoInExchangeForPrepaidAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_FinanceAgreementEnteredIntoInExchangeForPrepaidAssets" xlink:to="RENB_FinanceAgreementEnteredIntoInExchangeForPrepaidAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_FinanceAgreementEnteredIntoInExchangeForPrepaidAssets_lbl" xml:lang="en-US">Finance agreement entered into in exchange for prepaid assets</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ConversionOfNotePayableForIssuanceOfPreferredStock" xlink:label="RENB_ConversionOfNotePayableForIssuanceOfPreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ConversionOfNotePayableForIssuanceOfPreferredStock" xlink:to="RENB_ConversionOfNotePayableForIssuanceOfPreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ConversionOfNotePayableForIssuanceOfPreferredStock_lbl" xml:lang="en-US">Conversion of note payable for issuance of preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_NotePayableSettledThroughNoncashExerciseOfWarrants" xlink:label="RENB_NotePayableSettledThroughNoncashExerciseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_NotePayableSettledThroughNoncashExerciseOfWarrants" xlink:to="RENB_NotePayableSettledThroughNoncashExerciseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_NotePayableSettledThroughNoncashExerciseOfWarrants_lbl" xml:lang="en-US">Note payable settled through non-cash exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_DebtDiscountRelatedToConvertiblePromissoryNotes" xlink:label="RENB_DebtDiscountRelatedToConvertiblePromissoryNotes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_DebtDiscountRelatedToConvertiblePromissoryNotes" xlink:to="RENB_DebtDiscountRelatedToConvertiblePromissoryNotes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_DebtDiscountRelatedToConvertiblePromissoryNotes_lbl" xml:lang="en-US">Debt discount related to notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_CommonSharesIssuedUponAcquisition" xlink:label="RENB_CommonSharesIssuedUponAcquisition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_CommonSharesIssuedUponAcquisition" xlink:to="RENB_CommonSharesIssuedUponAcquisition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_CommonSharesIssuedUponAcquisition_lbl" xml:lang="en-US">Common shares issued upon acquisition</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ContingentConsiderationIssuedUponAcquisition" xlink:label="RENB_ContingentConsiderationIssuedUponAcquisition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ContingentConsiderationIssuedUponAcquisition" xlink:to="RENB_ContingentConsiderationIssuedUponAcquisition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ContingentConsiderationIssuedUponAcquisition_lbl" xml:lang="en-US">Contingent consideration issued upon acquisition</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_CommonSharesIssuedUponSettlementOfDebt" xlink:label="RENB_CommonSharesIssuedUponSettlementOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_CommonSharesIssuedUponSettlementOfDebt" xlink:to="RENB_CommonSharesIssuedUponSettlementOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_CommonSharesIssuedUponSettlementOfDebt_lbl" xml:lang="en-US">Common shares issued upon settlement of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_EarnOutSharesIssuedInSettlementOfContingentLiability" xlink:label="RENB_EarnOutSharesIssuedInSettlementOfContingentLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_EarnOutSharesIssuedInSettlementOfContingentLiability" xlink:to="RENB_EarnOutSharesIssuedInSettlementOfContingentLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_EarnOutSharesIssuedInSettlementOfContingentLiability_lbl" xml:lang="en-US">Earn out shares issued in settlement of contingent liability</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_OptionsIssuedInSettlementOfDebt" xlink:label="RENB_OptionsIssuedInSettlementOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_OptionsIssuedInSettlementOfDebt" xlink:to="RENB_OptionsIssuedInSettlementOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_OptionsIssuedInSettlementOfDebt_lbl" xml:lang="en-US">Options issued in settlement of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_SettlementOfNotesPayable" xlink:label="RENB_SettlementOfNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_SettlementOfNotesPayable" xlink:to="RENB_SettlementOfNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_SettlementOfNotesPayable_lbl" xml:lang="en-US">Settlement of notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable" xlink:label="ecd_PvpTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTable" xlink:to="ecd_PvpTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTable_lbl" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis" xlink:label="ecd_ExecutiveCategoryAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ExecutiveCategoryAxis" xlink:to="ecd_ExecutiveCategoryAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ExecutiveCategoryAxis_lbl" xml:lang="en-US">Executive Category [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="ecd_IndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_IndividualAxis" xlink:to="ecd_IndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_IndividualAxis_lbl" xml:lang="en-US">Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis" xlink:label="ecd_AdjToCompAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAxis" xlink:to="ecd_AdjToCompAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAxis_lbl" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis" xlink:label="ecd_MeasureAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureAxis" xlink:to="ecd_MeasureAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureAxis_lbl" xml:lang="en-US">Measure [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock" xlink:label="ecd_PvpTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTableTextBlock" xlink:to="ecd_PvpTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTableTextBlock_lbl" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName" xlink:label="ecd_CoSelectedMeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureName" xlink:to="ecd_CoSelectedMeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureName_lbl" xml:lang="en-US">Company Selected Measure Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="ecd_PeerGroupIssuersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupIssuersFnTextBlock" xlink:to="ecd_PeerGroupIssuersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupIssuersFnTextBlock_lbl" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="ecd_ChangedPeerGroupFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ChangedPeerGroupFnTextBlock" xlink:to="ecd_ChangedPeerGroupFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ChangedPeerGroupFnTextBlock_lbl" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt" xlink:label="ecd_PeoTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoTotalCompAmt" xlink:to="ecd_PeoTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoTotalCompAmt_lbl" xml:lang="en-US">PEO Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="ecd_PeoActuallyPaidCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoActuallyPaidCompAmt" xlink:to="ecd_PeoActuallyPaidCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoActuallyPaidCompAmt_lbl" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="ecd_AdjToPeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToPeoCompFnTextBlock" xlink:to="ecd_AdjToPeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToPeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock" xlink:label="ecd_TabularListTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TabularListTableTextBlock" xlink:to="ecd_TabularListTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TabularListTableTextBlock_lbl" xml:lang="en-US">Tabular List, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt" xlink:label="ecd_TotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnAmt" xlink:to="ecd_TotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnAmt_lbl" xml:lang="en-US">Total Shareholder Return Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net Income (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt" xlink:label="ecd_CoSelectedMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureAmt" xlink:to="ecd_CoSelectedMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureAmt_lbl" xml:lang="en-US">Company Selected Measure Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt" xlink:label="ecd_OtherPerfMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OtherPerfMeasureAmt" xlink:to="ecd_OtherPerfMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OtherPerfMeasureAmt_lbl" xml:lang="en-US">Other Performance Measure, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt" xlink:label="ecd_AdjToCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAmt" xlink:to="ecd_AdjToCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAmt_lbl" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName" xlink:label="ecd_PeoName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoName" xlink:to="ecd_PeoName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoName_lbl" xml:lang="en-US">PEO Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName" xlink:label="ecd_MeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureName" xlink:to="ecd_MeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xml:lang="en-US">Non-GAAP Measure Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="ecd_Additional402vDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Additional402vDisclosureTextBlock" xlink:to="ecd_Additional402vDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Additional402vDisclosureTextBlock_lbl" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="ecd_PnsnBnftsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PnsnBnftsAdjFnTextBlock" xlink:to="ecd_PnsnBnftsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PnsnBnftsAdjFnTextBlock_lbl" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock" xlink:label="ecd_EqtyAwrdsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="ecd_EqtyAwrdsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EqtyAwrdsAdjFnTextBlock_lbl" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable" xlink:label="ecd_ErrCompRecoveryTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompRecoveryTable" xlink:to="ecd_ErrCompRecoveryTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompRecoveryTable_lbl" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis" xlink:label="ecd_RestatementDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDateAxis" xlink:to="ecd_RestatementDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDateAxis_lbl" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate" xlink:label="ecd_RestatementDeterminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDeterminationDate" xlink:to="ecd_RestatementDeterminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDeterminationDate_lbl" xml:lang="en-US">Restatement Determination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt" xlink:label="ecd_AggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompAmt" xlink:to="ecd_AggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompAmt_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="ecd_ErrCompAnalysisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompAnalysisTextBlock" xlink:to="ecd_ErrCompAnalysisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompAnalysisTextBlock_lbl" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="ecd_OutstandingAggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingAggtErrCompAmt" xlink:to="ecd_OutstandingAggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingAggtErrCompAmt_lbl" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName" xlink:label="ecd_ForgoneRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_ForgoneRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName" xlink:label="ecd_OutstandingRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_OutstandingRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="ecd_OutstandingRecoveryCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryCompAmt" xlink:to="ecd_OutstandingRecoveryCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryCompAmt_lbl" xml:lang="en-US">Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xml:lang="en-US">Restatement does not require Recovery</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="ecd_AwardsCloseToMnpiDiscTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTable" xlink:to="ecd_AwardsCloseToMnpiDiscTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTable_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="ecd_AwardTmgMnpiDiscTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiDiscTextBlock" xlink:to="ecd_AwardTmgMnpiDiscTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiDiscTextBlock_lbl" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="ecd_AwardTmgMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMethodTextBlock" xlink:to="ecd_AwardTmgMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMethodTextBlock_lbl" xml:lang="en-US">Award Timing Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="ecd_AwardTmgPredtrmndFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgPredtrmndFlag" xlink:to="ecd_AwardTmgPredtrmndFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgPredtrmndFlag_lbl" xml:lang="en-US">Award Timing Predetermined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xml:lang="en-US">Award Timing MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="ecd_MnpiDiscTimedForCompValFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MnpiDiscTimedForCompValFlag" xlink:to="ecd_MnpiDiscTimedForCompValFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MnpiDiscTimedForCompValFlag_lbl" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="ecd_AwardsCloseToMnpiDiscIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="ecd_AwardUndrlygSecuritiesAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardUndrlygSecuritiesAmt" xlink:to="ecd_AwardUndrlygSecuritiesAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardUndrlygSecuritiesAmt_lbl" xml:lang="en-US">Underlying Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice" xlink:label="ecd_AwardExrcPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardExrcPrice" xlink:to="ecd_AwardExrcPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardExrcPrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue" xlink:label="ecd_AwardGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardGrantDateFairValue" xlink:to="ecd_AwardGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardGrantDateFairValue_lbl" xml:lang="en-US">Fair Value as of Grant Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="ecd_UndrlygSecurityMktPriceChngPct" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_UndrlygSecurityMktPriceChngPct" xlink:to="ecd_UndrlygSecurityMktPriceChngPct_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_UndrlygSecurityMktPriceChngPct_lbl" xml:lang="en-US">Underlying Security Market Price Change</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable" xlink:label="ecd_TradingArrByIndTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TradingArrByIndTable" xlink:to="ecd_TradingArrByIndTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TradingArrByIndTable_lbl" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis" xlink:label="ecd_TradingArrAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TradingArrAxis" xlink:to="ecd_TradingArrAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TradingArrAxis_lbl" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName" xlink:label="ecd_TrdArrIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_TrdArrIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle" xlink:label="ecd_TrdArrIndTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndTitle" xlink:to="ecd_TrdArrIndTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndTitle_lbl" xml:lang="en-US">Title</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate" xlink:label="ecd_TrdArrAdoptionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrAdoptionDate" xlink:to="ecd_TrdArrAdoptionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrAdoptionDate_lbl" xml:lang="en-US">Adoption Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate" xlink:label="ecd_TrdArrTerminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrTerminationDate" xlink:to="ecd_TrdArrTerminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrTerminationDate_lbl" xml:lang="en-US">Termination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate" xlink:label="ecd_TrdArrExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrExpirationDate" xlink:to="ecd_TrdArrExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrExpirationDate_lbl" xml:lang="en-US">Expiration Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration" xlink:label="ecd_TrdArrDuration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrDuration" xlink:to="ecd_TrdArrDuration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrDuration_lbl" xml:lang="en-US">Arrangement Duration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt" xlink:label="ecd_TrdArrSecuritiesAggAvailAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="ecd_TrdArrSecuritiesAggAvailAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrSecuritiesAggAvailAmt_lbl" xml:lang="en-US">Aggregate Available</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="ecd_InsiderTradingPoliciesProcLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingPoliciesProcLineItems" xlink:to="ecd_InsiderTradingPoliciesProcLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingPoliciesProcLineItems_lbl" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Third Party Engaged [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xml:lang="en-US">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board of Directors Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Role of Management [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentAbstract" xlink:label="cyd_MaterialCybersecurityIncidentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentAbstract" xlink:to="cyd_MaterialCybersecurityIncidentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentAbstract_lbl" xml:lang="en-US">Material Cybersecurity Incident [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentNatureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentNatureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentNatureTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Nature [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentScopeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentScopeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentScopeTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Scope [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentTimingTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentTimingTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentTimingTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Timing [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xml:lang="en-US">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xml:lang="en-US">GOING CONCERN</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:to="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">INTANGIBLE ASSETS AND GOODWILL</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_DisclosureLeasesAbstract" xlink:label="RENB_DisclosureLeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_DisclosureLeasesAbstract" xlink:to="RENB_DisclosureLeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_DisclosureLeasesAbstract_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">LEASES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">DEBT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_lbl" xml:lang="en-US">Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xml:lang="en-US">ACQUISITIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">SEGMENT REPORTING</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BusinessPolicyTextBlock" xlink:label="RENB_BusinessPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_BusinessPolicyTextBlock" xlink:to="RENB_BusinessPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_BusinessPolicyTextBlock_lbl" xml:lang="en-US">Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:label="us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:to="us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_lbl" xml:lang="en-US">Subsidiaries</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Accounting Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Functional Currency and Foreign Currency Translation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of Credit Risk</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_InvestmentinEquitySecuritiesPolicyTextBlock" xlink:label="RENB_InvestmentinEquitySecuritiesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_InvestmentinEquitySecuritiesPolicyTextBlock" xlink:to="RENB_InvestmentinEquitySecuritiesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_InvestmentinEquitySecuritiesPolicyTextBlock_lbl" xml:lang="en-US">Investment in Equity Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_InsuranceReceivablePolicy" xlink:label="RENB_InsuranceReceivablePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_InsuranceReceivablePolicy" xlink:to="RENB_InsuranceReceivablePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_InsuranceReceivablePolicy_lbl" xml:lang="en-US">Insurance Receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xml:lang="en-US">Goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Goodwill and Indefinite Lived Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Loss Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New Accounting Pronouncements Not Yet Adopte</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US">Schedule of assets and liabilities measured at fair value on recurring bases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueConcentrationOfRiskTextBlock" xlink:label="us-gaap_FairValueConcentrationOfRiskTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueConcentrationOfRiskTextBlock" xlink:to="us-gaap_FairValueConcentrationOfRiskTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueConcentrationOfRiskTextBlock_lbl" xml:lang="en-US">Schedule of key input to valuing the contingent consideration liability</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ScheduleOfContingentConsiderationLiabilityTableTextBlock" xlink:label="RENB_ScheduleOfContingentConsiderationLiabilityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ScheduleOfContingentConsiderationLiabilityTableTextBlock" xlink:to="RENB_ScheduleOfContingentConsiderationLiabilityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ScheduleOfContingentConsiderationLiabilityTableTextBlock_lbl" xml:lang="en-US">Schedule of fair value measurement on recurring basis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of Property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of definite-life and indefinite-life intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of future amortization expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of lease commitments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of deferred tax assets and liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of components of income tax expense (benefit) from continuing operations</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ScheduleOfShareBasedPaymentAwardStockOptionValuationAssumptionsTableTextBlock" xlink:label="RENB_ScheduleOfShareBasedPaymentAwardStockOptionValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ScheduleOfShareBasedPaymentAwardStockOptionValuationAssumptionsTableTextBlock" xlink:to="RENB_ScheduleOfShareBasedPaymentAwardStockOptionValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ScheduleOfShareBasedPaymentAwardStockOptionValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of weighted-average assumptions used to estimate the fair values of the stock options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ScheduleOfStockBasedCompensationActivityTableTextBlock" xlink:label="RENB_ScheduleOfStockBasedCompensationActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ScheduleOfStockBasedCompensationActivityTableTextBlock" xlink:to="RENB_ScheduleOfStockBasedCompensationActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ScheduleOfStockBasedCompensationActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of stock options outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Stock option activity</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ScheduleOfCommonStockPurchaseWarrantsOutstandingTableTextBlock" xlink:label="RENB_ScheduleOfCommonStockPurchaseWarrantsOutstandingTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ScheduleOfCommonStockPurchaseWarrantsOutstandingTableTextBlock" xlink:to="RENB_ScheduleOfCommonStockPurchaseWarrantsOutstandingTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ScheduleOfCommonStockPurchaseWarrantsOutstandingTableTextBlock_lbl" xml:lang="en-US">Schedule of common stock purchase warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ScheduleOfWarrantsOutstandingTableTextBlock" xlink:label="RENB_ScheduleOfWarrantsOutstandingTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ScheduleOfWarrantsOutstandingTableTextBlock" xlink:to="RENB_ScheduleOfWarrantsOutstandingTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ScheduleOfWarrantsOutstandingTableTextBlock_lbl" xml:lang="en-US">Schedule of warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ScheduleOfAcquistionFairValueOfConsiderationTableTextBlock" xlink:label="RENB_ScheduleOfAcquistionFairValueOfConsiderationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ScheduleOfAcquistionFairValueOfConsiderationTableTextBlock" xlink:to="RENB_ScheduleOfAcquistionFairValueOfConsiderationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ScheduleOfAcquistionFairValueOfConsiderationTableTextBlock_lbl" xml:lang="en-US">Schedule of acquisition date fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xml:lang="en-US">Schedule of fair value of assets acquired and liabilities assumed</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ScheduleOfRecognizedIdentifiedAssetsAndLiabilitiesAssumedTableTextBlock" xlink:label="RENB_ScheduleOfRecognizedIdentifiedAssetsAndLiabilitiesAssumedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ScheduleOfRecognizedIdentifiedAssetsAndLiabilitiesAssumedTableTextBlock" xlink:to="RENB_ScheduleOfRecognizedIdentifiedAssetsAndLiabilitiesAssumedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="RENB_ScheduleOfRecognizedIdentifiedAssetsAndLiabilitiesAssumedTableTextBlock_lbl" xml:lang="en-US">Schedule of fair value of assets acquired and liabilities assumed</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US">Schedule of segment operating loss and asset information</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl" xml:lang="en-US">Schedule of information regarding segment reporting</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xml:lang="en-US">Restructuring Cost [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCostAndReserveLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_lbl" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BusinessAcquisitionPercentage" xlink:label="RENB_BusinessAcquisitionPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_BusinessAcquisitionPercentage" xlink:to="RENB_BusinessAcquisitionPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_BusinessAcquisitionPercentage_lbl" xml:lang="en-US">Acquisition percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_PurchaseEquitySecuritiesValue" xlink:label="RENB_PurchaseEquitySecuritiesValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_PurchaseEquitySecuritiesValue" xlink:to="RENB_PurchaseEquitySecuritiesValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_PurchaseEquitySecuritiesValue_lbl" xml:lang="en-US">Purchase equity securities value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCost" xlink:label="us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCost" xlink:to="us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCost_lbl" xml:lang="en-US">Fair value of equity securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtAndEquitySecuritiesGainLoss" xlink:label="us-gaap_DebtAndEquitySecuritiesGainLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtAndEquitySecuritiesGainLoss" xlink:to="us-gaap_DebtAndEquitySecuritiesGainLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtAndEquitySecuritiesGainLoss_lbl" xml:lang="en-US">Investment in equity securities</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ImpairmentLoss" xlink:label="RENB_ImpairmentLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ImpairmentLoss" xlink:to="RENB_ImpairmentLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ImpairmentLoss_lbl" xml:lang="en-US">Impairment loss</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_InProcessResearchAndDevelopment" xlink:label="RENB_InProcessResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_InProcessResearchAndDevelopment" xlink:to="RENB_InProcessResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_InProcessResearchAndDevelopment_lbl" xml:lang="en-US">In-process research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xml:lang="en-US">Impairment of assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Research and development expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockOtherSharesOutstanding" xlink:label="us-gaap_CommonStockOtherSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockOtherSharesOutstanding" xlink:to="us-gaap_CommonStockOtherSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockOtherSharesOutstanding_lbl" xml:lang="en-US">Common stock outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Anti-dilutive shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Stock based compensation costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLoss_4_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_WorkingCapitalDeficit" xlink:label="RENB_WorkingCapitalDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_WorkingCapitalDeficit" xlink:to="RENB_WorkingCapitalDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_WorkingCapitalDeficit_lbl" xml:lang="en-US">Working capital deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesFairValueDisclosure" xlink:label="us-gaap_AccruedLiabilitiesFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesFairValueDisclosure" xlink:to="us-gaap_AccruedLiabilitiesFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesFairValueDisclosure_lbl" xml:lang="en-US">Total assets at fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:to="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_lbl" xml:lang="en-US">Contingent consideration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xml:lang="en-US">Total liabilities at fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Stock Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk Free Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected Dividends</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate" xlink:label="RENB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate" xlink:to="RENB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate_lbl" xml:lang="en-US">Discount Rate (Monte-Carlo model only)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected Term (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xml:lang="en-US">Balance June 30, 2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="us-gaap_LiabilitiesFairValueAdjustment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueAdjustment" xlink:to="us-gaap_LiabilitiesFairValueAdjustment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueAdjustment_lbl" xml:lang="en-US">Fair value adjustment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_2_lbl" xml:lang="en-US">Contingent Consideration Liability at June 30, 2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xml:lang="en-US">Purchased shares of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Purchase price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiCost" xlink:label="us-gaap_EquitySecuritiesFvNiCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiCost" xlink:to="us-gaap_EquitySecuritiesFvNiCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EquitySecuritiesFvNiCost_lbl" xml:lang="en-US">Fair value of equity securities</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_InvestmentEquitySecuritiesShares" xlink:label="RENB_InvestmentEquitySecuritiesShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_InvestmentEquitySecuritiesShares" xlink:to="RENB_InvestmentEquitySecuritiesShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_InvestmentEquitySecuritiesShares_lbl" xml:lang="en-US">investment equity securities shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xml:lang="en-US">Contingent shares issuable in connection with the acquisition</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_3_lbl" xml:lang="en-US">Contingent consideration liability was recorded at fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Useful Life</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less Accumulated Depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">Net Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US">Intangible Asset, Finite-Lived [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Useful life</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_NetDefinitelifeIntangibleAssets" xlink:label="RENB_NetDefinitelifeIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_NetDefinitelifeIntangibleAssets" xlink:to="RENB_NetDefinitelifeIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="RENB_NetDefinitelifeIntangibleAssets_lbl" xml:lang="en-US">Net definite-life intangible assets at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:to="us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Net definite-life intangible assets, Additions</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_NetDefinitelifeIntangibleAssetsAmortization" xlink:label="RENB_NetDefinitelifeIntangibleAssetsAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_NetDefinitelifeIntangibleAssetsAmortization" xlink:to="RENB_NetDefinitelifeIntangibleAssetsAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_NetDefinitelifeIntangibleAssetsAmortization_lbl" xml:lang="en-US">Net definite-life intangible assets, Amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xml:lang="en-US">Net definite-life intangible assets, Impairment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" xlink:label="us-gaap_FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" xlink:to="us-gaap_FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_lbl" xml:lang="en-US">Net definite-life intangible assets, Translation adjustment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_NetDefinitelifeIntangibleAssets" xlink:to="RENB_NetDefinitelifeIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="RENB_NetDefinitelifeIntangibleAssets_2_lbl" xml:lang="en-US">Net definite-life intangible assets at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIndefiniteLivedIntangibleAssets" xlink:label="us-gaap_OtherIndefiniteLivedIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIndefiniteLivedIntangibleAssets" xlink:to="us-gaap_OtherIndefiniteLivedIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_OtherIndefiniteLivedIntangibleAssets_lbl" xml:lang="en-US">Total indefinite life intangible assets and goodwill at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Total indefinite life intangible assets and goodwill, Additions</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_IndefiniteLifeIntangibleAssetsAndGoodwillAmortization" xlink:label="RENB_IndefiniteLifeIntangibleAssetsAndGoodwillAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_IndefiniteLifeIntangibleAssetsAndGoodwillAmortization" xlink:to="RENB_IndefiniteLifeIntangibleAssetsAndGoodwillAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_IndefiniteLifeIntangibleAssetsAndGoodwillAmortization_lbl" xml:lang="en-US">Total indefinite life intangible assets and goodwill, Amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_IndefiniteLifeIntangibleAssetsAndGoodwillImpairment" xlink:label="RENB_IndefiniteLifeIntangibleAssetsAndGoodwillImpairment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_IndefiniteLifeIntangibleAssetsAndGoodwillImpairment" xlink:to="RENB_IndefiniteLifeIntangibleAssetsAndGoodwillImpairment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_IndefiniteLifeIntangibleAssetsAndGoodwillImpairment_lbl" xml:lang="en-US">Total indefinite life intangible assets and goodwill, Impairment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_lbl" xml:lang="en-US">Total indefinite life intangible assets and goodwill, Translation adjustment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIndefiniteLivedIntangibleAssets" xlink:to="us-gaap_OtherIndefiniteLivedIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_OtherIndefiniteLivedIntangibleAssets_2_lbl" xml:lang="en-US">Total indefinite life intangible assets and goodwill at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">2027</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">2028</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US">2029</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US">Intangible Asset, Indefinite-Lived [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_lbl" xml:lang="en-US">Indefinite-Lived Intangible Assets [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xml:lang="en-US">Definite-life intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedAmortizationOfCurrentDeferredFinanceCosts" xlink:label="us-gaap_AccumulatedAmortizationOfCurrentDeferredFinanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedAmortizationOfCurrentDeferredFinanceCosts" xlink:to="us-gaap_AccumulatedAmortizationOfCurrentDeferredFinanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedAmortizationOfCurrentDeferredFinanceCosts_lbl" xml:lang="en-US">Accumulated amortization cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization expense</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_Software" xlink:label="RENB_Software" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_Software" xlink:to="RENB_Software_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_Software_lbl" xml:lang="en-US">Software</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_Trademark" xlink:label="RENB_Trademark" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_Trademark" xlink:to="RENB_Trademark_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_Trademark_lbl" xml:lang="en-US">Trademark</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ImpairmentAdjustment" xlink:label="RENB_ImpairmentAdjustment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ImpairmentAdjustment" xlink:to="RENB_ImpairmentAdjustment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ImpairmentAdjustment_lbl" xml:lang="en-US">Impairment adjustment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2027</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" xlink:label="RENB_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" xlink:to="RENB_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="RENB_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less imputed interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xml:lang="en-US">Lease premises, description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted-average remaining term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted-average discount rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Principal amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_2_lbl" xml:lang="en-US">Gross proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:label="us-gaap_LongTermDebtPercentageBearingFixedInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:to="us-gaap_LongTermDebtPercentageBearingFixedInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtPercentageBearingFixedInterestRate_lbl" xml:lang="en-US">Bear interest percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Maturity date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US">Conversion price</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_NotesBalance" xlink:label="RENB_NotesBalance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_NotesBalance" xlink:to="RENB_NotesBalance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_NotesBalance_lbl" xml:lang="en-US">Notes balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Note interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Sale of stock, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MaturitiesOfTimeDepositsDescription" xlink:label="us-gaap_MaturitiesOfTimeDepositsDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaturitiesOfTimeDepositsDescription" xlink:to="us-gaap_MaturitiesOfTimeDepositsDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MaturitiesOfTimeDepositsDescription_lbl" xml:lang="en-US">Maturity description</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_AgreementDescription" xlink:label="RENB_AgreementDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_AgreementDescription" xlink:to="RENB_AgreementDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_AgreementDescription_lbl" xml:lang="en-US">Agreement description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:to="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl" xml:lang="en-US">Interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Issuance of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl" xml:lang="en-US">Principal amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFixedInterestRate" xlink:label="us-gaap_DerivativeFixedInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFixedInterestRate" xlink:to="us-gaap_DerivativeFixedInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeFixedInterestRate_lbl" xml:lang="en-US">Rate of interest</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_MonthlyInstallments" xlink:label="RENB_MonthlyInstallments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_MonthlyInstallments" xlink:to="RENB_MonthlyInstallments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_MonthlyInstallments_lbl" xml:lang="en-US">Monthly instalments amount</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_RepaymentOnFinanceAgreement" xlink:label="RENB_RepaymentOnFinanceAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_RepaymentOnFinanceAgreement" xlink:to="RENB_RepaymentOnFinanceAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_RepaymentOnFinanceAgreement_lbl" xml:lang="en-US">Down payment amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestAndDebtExpense" xlink:label="us-gaap_InterestAndDebtExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndDebtExpense" xlink:to="us-gaap_InterestAndDebtExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestAndDebtExpense_lbl" xml:lang="en-US">Accrued interest expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseNonoperating_2_lbl" xml:lang="en-US">Total interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_Depreciations" xlink:label="RENB_Depreciations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_Depreciations" xlink:to="RENB_Depreciations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_Depreciations_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_DeferredTaxAssetExcessTaxOverDepreciationPatents" xlink:label="RENB_DeferredTaxAssetExcessTaxOverDepreciationPatents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_DeferredTaxAssetExcessTaxOverDepreciationPatents" xlink:to="RENB_DeferredTaxAssetExcessTaxOverDepreciationPatents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_DeferredTaxAssetExcessTaxOverDepreciationPatents_lbl" xml:lang="en-US">Excess of tax over book depreciation of patents</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_StockoptionsCompensation" xlink:label="RENB_StockoptionsCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_StockoptionsCompensation" xlink:to="RENB_StockoptionsCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_StockoptionsCompensation_lbl" xml:lang="en-US">Stock/options compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_DepreciationAndAmortizations" xlink:label="RENB_DepreciationAndAmortizations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_DepreciationAndAmortizations" xlink:to="RENB_DepreciationAndAmortizations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="RENB_DepreciationAndAmortizations_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ImpairmentExpense" xlink:label="RENB_ImpairmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ImpairmentExpense" xlink:to="RENB_ImpairmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ImpairmentExpense_lbl" xml:lang="en-US">&#160;Impairment expense</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ContingentConsiderationFairValue" xlink:label="RENB_ContingentConsiderationFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ContingentConsiderationFairValue" xlink:to="RENB_ContingentConsiderationFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ContingentConsiderationFairValue_lbl" xml:lang="en-US">Contingent consideration fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedAmortizationOfOtherDeferredCosts" xlink:label="us-gaap_AccumulatedAmortizationOfOtherDeferredCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedAmortizationOfOtherDeferredCosts" xlink:to="us-gaap_AccumulatedAmortizationOfOtherDeferredCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedAmortizationOfOtherDeferredCosts_lbl" xml:lang="en-US">Amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_Section174ReCapitalization" xlink:label="RENB_Section174ReCapitalization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_Section174ReCapitalization" xlink:to="RENB_Section174ReCapitalization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_Section174ReCapitalization_lbl" xml:lang="en-US">Section 174 R&amp;E Capitalization</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_OperatingLeaseRightOfUseAssets" xlink:label="RENB_OperatingLeaseRightOfUseAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_OperatingLeaseRightOfUseAssets" xlink:to="RENB_OperatingLeaseRightOfUseAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_OperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">ROU Assets and Lease Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_Section481aAdjustment" xlink:label="RENB_Section481aAdjustment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_Section481aAdjustment" xlink:to="RENB_Section481aAdjustment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_Section481aAdjustment_lbl" xml:lang="en-US">Section 481(a) Adjustment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">R&amp;D Tax Credits</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ChangeInTaxRate" xlink:label="RENB_ChangeInTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ChangeInTaxRate" xlink:to="RENB_ChangeInTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ChangeInTaxRate_lbl" xml:lang="en-US">Change in tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_lbl" xml:lang="en-US">Total Deferred Tax Assets (Liabilities)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US">Computed tax at expected statutory rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings" xlink:label="us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings" xlink:to="us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_lbl" xml:lang="en-US">Non-US income taxed at different rates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl" xml:lang="en-US">Non-deductible expenses / other items</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherTaxExpenseBenefit" xlink:label="us-gaap_OtherTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherTaxExpenseBenefit" xlink:to="us-gaap_OtherTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherTaxExpenseBenefit_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US">Current Income Tax Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US">Federal income tax (benefit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US">State income tax (benefit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xml:lang="en-US">Foreign income tax (benefit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total Current Tax Expense (Benefit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred Income Tax Expense Federal income tax (benefit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US">State income tax (benefit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Foreign income tax (benefit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total Deferred Tax Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total Tax Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_lbl" xml:lang="en-US">Deferred tax assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2_lbl" xml:lang="en-US">Risk free interest rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2_lbl" xml:lang="en-US">Dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityEquityTable" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityEquityTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityEquityTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityTable_lbl" xml:lang="en-US">Option Indexed to Issuer's Equity, Equity [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:label="us-gaap_OptionIndexedToIssuersEquityLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:to="us-gaap_OptionIndexedToIssuersEquityLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityLineItems_lbl" xml:lang="en-US">Option Indexed to Issuer's Equity [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xml:lang="en-US">Exercise Prices, Lower</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US">Exercise Prices, Upper</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number share option outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Options Outstanding, Weighted Average Remaining Contractual Life (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options Outstanding, Weighted Average Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Options Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Options Exercisable, Weighted Average Remaining Contractual Life (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options Exercisable, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Options Outstanding at beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding at beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2_lbl" xml:lang="en-US">Weighted Average remaining life</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Weighted Average Intrinsic Value, Outstanding at beginning of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Cancelled/Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Options Outstanding at end of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding at ending of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Weighted Average Intrinsic Value, Outstanding at end of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercisable at ending of period</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisablesWeightedAverageRemainingContractualTerm1" xlink:label="RENB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisablesWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisablesWeightedAverageRemainingContractualTerm1" xlink:to="RENB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisablesWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisablesWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Life, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Weighted Average Intrinsic Value, Exercisable end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ExercisePrices" xlink:label="RENB_ExercisePrices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ExercisePrices" xlink:to="RENB_ExercisePrices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ExercisePrices_lbl" xml:lang="en-US">Exercise Prices</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ExercisePrice" xlink:label="RENB_ExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ExercisePrice" xlink:to="RENB_ExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="RENB_ExercisePrice_lbl" xml:lang="en-US">Exercise Prices</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_CommonStockPurchaseWarrant" xlink:label="RENB_CommonStockPurchaseWarrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_CommonStockPurchaseWarrant" xlink:to="RENB_CommonStockPurchaseWarrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="RENB_CommonStockPurchaseWarrant_lbl" xml:lang="en-US">Outstanding at beginning of period</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_CommonStockPurchaseWarrantsWeightedAverageExercisePrice" xlink:label="RENB_CommonStockPurchaseWarrantsWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_CommonStockPurchaseWarrantsWeightedAverageExercisePrice" xlink:to="RENB_CommonStockPurchaseWarrantsWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="RENB_CommonStockPurchaseWarrantsWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Outstanding at beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_3_lbl" xml:lang="en-US">Weighted Average remaining life, Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" xlink:label="RENB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" xlink:to="RENB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average remaining life, Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2_lbl" xml:lang="en-US">Cancelled/Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_CommonStockPurchaseWarrant" xlink:to="RENB_CommonStockPurchaseWarrant_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="RENB_CommonStockPurchaseWarrant_2_lbl" xml:lang="en-US">Outstanding at end of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_CommonStockPurchaseWarrantsWeightedAverageExercisePrice" xlink:to="RENB_CommonStockPurchaseWarrantsWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="RENB_CommonStockPurchaseWarrantsWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price, Outstanding at ending of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_2_lbl" xml:lang="en-US">Preferred stock shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_PreferredStockDesignatedShares" xlink:label="RENB_PreferredStockDesignatedShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_PreferredStockDesignatedShares" xlink:to="RENB_PreferredStockDesignatedShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_PreferredStockDesignatedShares_lbl" xml:lang="en-US">Preferred stock designated shares</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_CommonStockShareIssued" xlink:label="RENB_CommonStockShareIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_CommonStockShareIssued" xlink:to="RENB_CommonStockShareIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="RENB_CommonStockShareIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligation" xlink:label="us-gaap_PurchaseObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligation" xlink:to="us-gaap_PurchaseObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PurchaseObligation_lbl" xml:lang="en-US">Obligation to purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Issuance of common stock shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Issuance of common stock shares, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US">Number of share warrant purchase forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Option granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Warrants exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xml:lang="en-US">Stock-based compensation expense vested</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_UnrecognizedCompensationCostandVest" xlink:label="RENB_UnrecognizedCompensationCostandVest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_UnrecognizedCompensationCostandVest" xlink:to="RENB_UnrecognizedCompensationCostandVest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_UnrecognizedCompensationCostandVest_lbl" xml:lang="en-US">Unrecognized compensation cost and vest</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_IssuanceOfCommonStockUnderPrivatePlacementOffering" xlink:label="RENB_IssuanceOfCommonStockUnderPrivatePlacementOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_IssuanceOfCommonStockUnderPrivatePlacementOffering" xlink:to="RENB_IssuanceOfCommonStockUnderPrivatePlacementOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_IssuanceOfCommonStockUnderPrivatePlacementOffering_lbl" xml:lang="en-US">Issuance of common stock under private placement</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_CommonStockParValuePrivatePlacement" xlink:label="RENB_CommonStockParValuePrivatePlacement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_CommonStockParValuePrivatePlacement" xlink:to="RENB_CommonStockParValuePrivatePlacement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_CommonStockParValuePrivatePlacement_lbl" xml:lang="en-US">Common stock par value under private placement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Sale of stock issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Sale of stock price per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2_lbl" xml:lang="en-US">Paid in cash and settlement of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_PrincipalAmountAndInterestAccrued" xlink:label="RENB_PrincipalAmountAndInterestAccrued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_PrincipalAmountAndInterestAccrued" xlink:to="RENB_PrincipalAmountAndInterestAccrued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_PrincipalAmountAndInterestAccrued_lbl" xml:lang="en-US">Principal amount and interest accrued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonrecurringIncomeExpense" xlink:label="us-gaap_OtherNonrecurringIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonrecurringIncomeExpense" xlink:to="us-gaap_OtherNonrecurringIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonrecurringIncomeExpense_lbl" xml:lang="en-US">Other income (expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xml:lang="en-US">Sale of stock issued cash consideration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExpenseOrRevenueRecognized" xlink:label="us-gaap_ClassOfWarrantOrRightExpenseOrRevenueRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExpenseOrRevenueRecognized" xlink:to="us-gaap_ClassOfWarrantOrRightExpenseOrRevenueRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExpenseOrRevenueRecognized_lbl" xml:lang="en-US">Warrants aggregate amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_2_lbl" xml:lang="en-US">Proceeds from issuance of private placement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares" xlink:to="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares_lbl" xml:lang="en-US">Common Stock to be issued in settlement</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_PurchaseSharesOfCommonStock" xlink:label="RENB_PurchaseSharesOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_PurchaseSharesOfCommonStock" xlink:to="RENB_PurchaseSharesOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_PurchaseSharesOfCommonStock_lbl" xml:lang="en-US">Purchase shares of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xml:lang="en-US">Converted shares of common stock, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_2_lbl" xml:lang="en-US">Shares purchased</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xml:lang="en-US">Proceeds from common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1_lbl" xml:lang="en-US">Non cash earn out distribution</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_2_lbl" xml:lang="en-US">Share price</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ExtinguishmentOfContingentConsiderationLiability" xlink:label="RENB_ExtinguishmentOfContingentConsiderationLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ExtinguishmentOfContingentConsiderationLiability" xlink:to="RENB_ExtinguishmentOfContingentConsiderationLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ExtinguishmentOfContingentConsiderationLiability_lbl" xml:lang="en-US">Extinguishment of contingent consideration liability</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuable" xlink:label="RENB_BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuable" xlink:to="RENB_BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuable_lbl" xml:lang="en-US">Common shares contingently issuable</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ReserveEscrowShares" xlink:label="RENB_ReserveEscrowShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ReserveEscrowShares" xlink:to="RENB_ReserveEscrowShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ReserveEscrowShares_lbl" xml:lang="en-US">Reserve escrow shares</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_StockIssuedToNonconsentingShareholders" xlink:label="RENB_StockIssuedToNonconsentingShareholders" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_StockIssuedToNonconsentingShareholders" xlink:to="RENB_StockIssuedToNonconsentingShareholders_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_StockIssuedToNonconsentingShareholders_lbl" xml:lang="en-US">Stock issued to non-consenting shareholders</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_UnrecognizedCompensationCostNonVested" xlink:label="RENB_UnrecognizedCompensationCostNonVested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_UnrecognizedCompensationCostNonVested" xlink:to="RENB_UnrecognizedCompensationCostNonVested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_UnrecognizedCompensationCostNonVested_lbl" xml:lang="en-US">Unrecognized compensation cost non vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Common stock reserved for issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_DebtConversionConvertedInstrumentWarrantsOptionsIssued1" xlink:label="RENB_DebtConversionConvertedInstrumentWarrantsOptionsIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_DebtConversionConvertedInstrumentWarrantsOptionsIssued1" xlink:to="RENB_DebtConversionConvertedInstrumentWarrantsOptionsIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_DebtConversionConvertedInstrumentWarrantsOptionsIssued1_lbl" xml:lang="en-US">Options available to be issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:label="us-gaap_FairValueOptionChangesInFairValueGainLoss1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:to="us-gaap_FairValueOptionChangesInFairValueGainLoss1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOptionChangesInFairValueGainLoss1_lbl" xml:lang="en-US">Option fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_StockOptionIssued" xlink:label="RENB_StockOptionIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_StockOptionIssued" xlink:to="RENB_StockOptionIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_StockOptionIssued_lbl" xml:lang="en-US">Stock option issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US">stock option vested</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_UnrecognizedCompensationCost" xlink:label="RENB_UnrecognizedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_UnrecognizedCompensationCost" xlink:to="RENB_UnrecognizedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_UnrecognizedCompensationCost_lbl" xml:lang="en-US">Unrecognized compensation cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_lbl" xml:lang="en-US">Options available to be issued</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_PurchaseExercisableWarrantsOutstandingShares" xlink:label="RENB_PurchaseExercisableWarrantsOutstandingShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_PurchaseExercisableWarrantsOutstandingShares" xlink:to="RENB_PurchaseExercisableWarrantsOutstandingShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_PurchaseExercisableWarrantsOutstandingShares_lbl" xml:lang="en-US">Purchase exercisable warrants outstanding shares</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_WarrantsExercisablePurchaseValue" xlink:label="RENB_WarrantsExercisablePurchaseValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_WarrantsExercisablePurchaseValue" xlink:to="RENB_WarrantsExercisablePurchaseValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_WarrantsExercisablePurchaseValue_lbl" xml:lang="en-US">Warrants exercisable purchase value</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_StockbasedCompensationExpense" xlink:label="RENB_StockbasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_StockbasedCompensationExpense" xlink:to="RENB_StockbasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="RENB_StockbasedCompensationExpense_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_StockbasedCompensationExpenseGrantShares" xlink:label="RENB_StockbasedCompensationExpenseGrantShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_StockbasedCompensationExpenseGrantShares" xlink:to="RENB_StockbasedCompensationExpenseGrantShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_StockbasedCompensationExpenseGrantShares_lbl" xml:lang="en-US">Stock-based compensation expense grant shares</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_UnrecognizedStockbasedCompensationExpense" xlink:label="RENB_UnrecognizedStockbasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_UnrecognizedStockbasedCompensationExpense" xlink:to="RENB_UnrecognizedStockbasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_UnrecognizedStockbasedCompensationExpense_lbl" xml:lang="en-US">Unrecognized stock-based compensation expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xml:lang="en-US">Stock-based compensation expense grant shares</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_AdvisoryServices" xlink:label="RENB_AdvisoryServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_AdvisoryServices" xlink:to="RENB_AdvisoryServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_AdvisoryServices_lbl" xml:lang="en-US">Advisory services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xml:lang="en-US">Defined Benefit Plan [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForFees" xlink:label="us-gaap_PaymentsForFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForFees" xlink:to="us-gaap_PaymentsForFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForFees_lbl" xml:lang="en-US">Payment for license</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_RoyaltyPercentage" xlink:label="RENB_RoyaltyPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_RoyaltyPercentage" xlink:to="RENB_RoyaltyPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_RoyaltyPercentage_lbl" xml:lang="en-US">Royalty percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_UpfrontPayment" xlink:label="RENB_UpfrontPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_UpfrontPayment" xlink:to="RENB_UpfrontPayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_UpfrontPayment_lbl" xml:lang="en-US">Up-front payment</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_PaymentForExpenditures" xlink:label="RENB_PaymentForExpenditures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_PaymentForExpenditures" xlink:to="RENB_PaymentForExpenditures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_PaymentForExpenditures_lbl" xml:lang="en-US">Payment for expenditures</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_InitialPayment" xlink:label="RENB_InitialPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_InitialPayment" xlink:to="RENB_InitialPayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_InitialPayment_lbl" xml:lang="en-US">Initial payment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2_lbl" xml:lang="en-US">Remaining shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Related Party Transaction [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xml:lang="en-US">Accrued balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_2_lbl" xml:lang="en-US">Common stock forfeited shares</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_SharesOfCommonStockGranted" xlink:label="RENB_SharesOfCommonStockGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_SharesOfCommonStockGranted" xlink:to="RENB_SharesOfCommonStockGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_SharesOfCommonStockGranted_lbl" xml:lang="en-US">Shares of common stock granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_3_lbl" xml:lang="en-US">Purchase shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Warrant exercise price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Stock-based compensation expense stock option vesting</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_UnrecognizedCompensationExpense" xlink:label="RENB_UnrecognizedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_UnrecognizedCompensationExpense" xlink:to="RENB_UnrecognizedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_UnrecognizedCompensationExpense_lbl" xml:lang="en-US">Unrecognized compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BusinessCombinationContingentConsiderationCommonStock" xlink:label="RENB_BusinessCombinationContingentConsiderationCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_BusinessCombinationContingentConsiderationCommonStock" xlink:to="RENB_BusinessCombinationContingentConsiderationCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_BusinessCombinationContingentConsiderationCommonStock_lbl" xml:lang="en-US">Common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xml:lang="en-US">Total consideration transferred</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid &amp; Other Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets" xlink:label="RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets" xlink:to="RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets_lbl" xml:lang="en-US">Fixed Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl" xml:lang="en-US">Total Assets Acquired:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl" xml:lang="en-US">Accounts Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xlink:label="RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xlink:to="RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_lbl" xml:lang="en-US">Accrued Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities" xlink:label="RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities" xlink:to="RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities_lbl" xml:lang="en-US">Other Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_lbl" xml:lang="en-US">Total Liabilities Assumed</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xml:lang="en-US">Net Assets Acquired</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_TradeName" xlink:label="RENB_TradeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_TradeName" xlink:to="RENB_TradeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_TradeName_lbl" xml:lang="en-US">Trade Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_lbl" xml:lang="en-US">Goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_lbl" xml:lang="en-US">Total Consideration</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BusinessAcquisitionsRevenue" xlink:label="RENB_BusinessAcquisitionsRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_BusinessAcquisitionsRevenue" xlink:to="RENB_BusinessAcquisitionsRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_BusinessAcquisitionsRevenue_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BusinessAcquisitionsNetIncomeLoss" xlink:label="RENB_BusinessAcquisitionsNetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_BusinessAcquisitionsNetIncomeLoss" xlink:to="RENB_BusinessAcquisitionsNetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="RENB_BusinessAcquisitionsNetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationAsset" xlink:label="us-gaap_BusinessCombinationContingentConsiderationAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationAsset" xlink:to="us-gaap_BusinessCombinationContingentConsiderationAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessCombinationContingentConsiderationAsset_lbl" xml:lang="en-US">Contingent consideration</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_2_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseRightOfUseAssets" xlink:label="RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseRightOfUseAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseRightOfUseAssets" xlink:to="RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseRightOfUseAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Operating lease ROU</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities" xlink:to="RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities_2_lbl" xml:lang="en-US">Operating Lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable" xlink:label="RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable" xlink:to="RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable_lbl" xml:lang="en-US">Notes Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_TransactionIssuedShares" xlink:label="RENB_TransactionIssuedShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_TransactionIssuedShares" xlink:to="RENB_TransactionIssuedShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_TransactionIssuedShares_lbl" xml:lang="en-US">Transaction issued shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_2_lbl" xml:lang="en-US">Common stock per value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredOther1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredOther1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredOther1_lbl" xml:lang="en-US">Fair value of consideration transferred amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl" xml:lang="en-US">Acquisition related costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_lbl" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_lbl" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_SegmentOperatingLoss" xlink:label="RENB_SegmentOperatingLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_SegmentOperatingLoss" xlink:to="RENB_SegmentOperatingLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_SegmentOperatingLoss_lbl" xml:lang="en-US">Operating income loss</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_SegmentAsset" xlink:label="RENB_SegmentAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_SegmentAsset" xlink:to="RENB_SegmentAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_SegmentAsset_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:to="us-gaap_GoodwillAndIntangibleAssetImpairment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment_lbl" xml:lang="en-US">Goodwill impairment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_SegmentOperatingLoss" xlink:to="RENB_SegmentOperatingLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="RENB_SegmentOperatingLoss_2_lbl" xml:lang="en-US">Segment operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_SaleOfStockConsiderationReceivedCashTransaction" xlink:label="RENB_SaleOfStockConsiderationReceivedCashTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_SaleOfStockConsiderationReceivedCashTransaction" xlink:to="RENB_SaleOfStockConsiderationReceivedCashTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="RENB_SaleOfStockConsiderationReceivedCashTransaction_lbl" xml:lang="en-US">Sale of stock issued cash consideration</link:label>
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_InterestRate" xlink:label="RENB_InterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_InterestRate" xlink:to="RENB_InterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="RENB_InterestRate_lbl" xml:lang="en-US">Interest rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_3_lbl" xml:lang="en-US">Issuance of common stock shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_2_lbl" xml:lang="en-US">Other Assets, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_2_lbl" xml:lang="en-US">Liabilities, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_2_lbl" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_2_lbl" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_LossOnExtinguishmentOfDebt" xlink:to="RENB_LossOnExtinguishmentOfDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_LossOnExtinguishmentOfDebt_2_lbl" xml:lang="en-US">LossOnExtinguishmentOfDebt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts and Other Receivables</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Current Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:to="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_2_lbl" xml:lang="en-US">Payments to Acquire Equity Securities, FV-NI</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireNotesReceivable" xlink:to="us-gaap_PaymentsToAcquireNotesReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireNotesReceivable_2_lbl" xml:lang="en-US">Payments to Acquire Notes Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_RepaymentsOfFinanceAgreement" xlink:to="RENB_RepaymentsOfFinanceAgreement_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_RepaymentsOfFinanceAgreement_2_lbl" xml:lang="en-US">RepaymentsOfFinanceAgreement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryIndName_2_lbl" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryIndName_2_lbl" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndName_2_lbl" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_2_lbl" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_2_lbl" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ScheduleOfRecognizedIdentifiedAssetsAndLiabilitiesAssumedTableTextBlock" xlink:to="RENB_ScheduleOfRecognizedIdentifiedAssetsAndLiabilitiesAssumedTableTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ScheduleOfRecognizedIdentifiedAssetsAndLiabilitiesAssumedTableTextBlock_2_lbl" xml:lang="en-US">ScheduleOfRecognizedIdentifiedAssetsAndLiabilitiesAssumedTableTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtAndEquitySecuritiesGainLoss" xlink:to="us-gaap_DebtAndEquitySecuritiesGainLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtAndEquitySecuritiesGainLoss_2_lbl" xml:lang="en-US">Debt and Equity Securities, Gain (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiCost" xlink:to="us-gaap_EquitySecuritiesFvNiCost_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquitySecuritiesFvNiCost_2_lbl" xml:lang="en-US">Equity Securities, FV-NI, Cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_NetDefinitelifeIntangibleAssets" xlink:to="RENB_NetDefinitelifeIntangibleAssets_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_NetDefinitelifeIntangibleAssets_3_lbl" xml:lang="en-US">NetDefinitelifeIntangibleAssets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIndefiniteLivedIntangibleAssets" xlink:to="us-gaap_OtherIndefiniteLivedIntangibleAssets_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIndefiniteLivedIntangibleAssets_3_lbl" xml:lang="en-US">Other Indefinite-Lived Intangible Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" xlink:to="RENB_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo_2_lbl" xml:lang="en-US">LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment_2_lbl" xml:lang="en-US">Debt Instrument, Annual Principal Payment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_2_lbl" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_DepreciationAndAmortizations" xlink:to="RENB_DepreciationAndAmortizations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_DepreciationAndAmortizations_2_lbl" xml:lang="en-US">DepreciationAndAmortizations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings" xlink:to="us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred Federal, State and Local, Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Income Tax Expense (Benefit) [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_ExercisePrice" xlink:to="RENB_ExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_ExercisePrice_2_lbl" xml:lang="en-US">ExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_CommonStockPurchaseWarrant" xlink:to="RENB_CommonStockPurchaseWarrant_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_CommonStockPurchaseWarrant_3_lbl" xml:lang="en-US">CommonStockPurchaseWarrant</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_CommonStockPurchaseWarrantsWeightedAverageExercisePrice" xlink:to="RENB_CommonStockPurchaseWarrantsWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_CommonStockPurchaseWarrantsWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">CommonStockPurchaseWarrantsWeightedAverageExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_CommonStockShareIssued" xlink:to="RENB_CommonStockShareIssued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_CommonStockShareIssued_2_lbl" xml:lang="en-US">CommonStockShareIssued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_2_lbl" xml:lang="en-US">Debt Conversion, Converted Instrument, Warrants or Options Issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_StockbasedCompensationExpense" xlink:to="RENB_StockbasedCompensationExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_StockbasedCompensationExpense_2_lbl" xml:lang="en-US">StockbasedCompensationExpense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_3_lbl" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_2_lbl" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_BusinessAcquisitionsNetIncomeLoss" xlink:to="RENB_BusinessAcquisitionsNetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_BusinessAcquisitionsNetIncomeLoss_2_lbl" xml:lang="en-US">BusinessAcquisitionsNetIncomeLoss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationAsset" xlink:to="us-gaap_BusinessCombinationContingentConsiderationAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationAsset_2_lbl" xml:lang="en-US">Business Combination, Contingent Consideration, Asset</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_2_lbl" xml:lang="en-US">Other General and Administrative Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:to="us-gaap_GoodwillAndIntangibleAssetImpairment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment_2_lbl" xml:lang="en-US">Goodwill and Intangible Asset Impairment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_SaleOfStockConsiderationReceivedCashTransaction" xlink:to="RENB_SaleOfStockConsiderationReceivedCashTransaction_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_SaleOfStockConsiderationReceivedCashTransaction_2_lbl" xml:lang="en-US">SaleOfStockConsiderationReceivedCashTransaction</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RENB_InterestRate" xlink:to="RENB_InterestRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="RENB_InterestRate_2_lbl" xml:lang="en-US">InterestRate</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>17
<FILENAME>renb-20250630_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#Cover" roleURI="http://renovarobio.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#ConsolidatedBalanceSheets" roleURI="http://renovarobio.com/role/ConsolidatedBalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://renovarobio.com/role/ConsolidatedBalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#ConsolidatedStatementsOfOperations" roleURI="http://renovarobio.com/role/ConsolidatedStatementsOfOperations" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#ConsolidatedStatementsOfComprehensiveLoss" roleURI="http://renovarobio.com/role/ConsolidatedStatementsOfComprehensiveLoss" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#ConsolidatedStatementOfStockholdersEquityDeficit" roleURI="http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#MaterialCybersecurityIncidentDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" roleURI="http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#GoingConcern" roleURI="http://renovarobio.com/role/GoingConcern" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#FairValueMeasurements" roleURI="http://renovarobio.com/role/FairValueMeasurements" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#PropertyAndEquipment" roleURI="http://renovarobio.com/role/PropertyAndEquipment" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#IntangibleAssetsAndGoodwill" roleURI="http://renovarobio.com/role/IntangibleAssetsAndGoodwill" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#Leases" roleURI="http://renovarobio.com/role/Leases" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#Debt" roleURI="http://renovarobio.com/role/Debt" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#IncomeTaxes" roleURI="http://renovarobio.com/role/IncomeTaxes" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#StockholdersEquity" roleURI="http://renovarobio.com/role/StockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#CommitmentsAndContingencies" roleURI="http://renovarobio.com/role/CommitmentsAndContingencies" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#RelatedPartyTransactions" roleURI="http://renovarobio.com/role/RelatedPartyTransactions" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#Acquisitions" roleURI="http://renovarobio.com/role/Acquisitions" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#SegmentReporting" roleURI="http://renovarobio.com/role/SegmentReporting" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#SubsequentEvents" roleURI="http://renovarobio.com/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#FairValueMeasurementsTables" roleURI="http://renovarobio.com/role/FairValueMeasurementsTables" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#PropertyAndEquipmentTables" roleURI="http://renovarobio.com/role/PropertyAndEquipmentTables" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#IntangibleAssetsAndGoodwillTables" roleURI="http://renovarobio.com/role/IntangibleAssetsAndGoodwillTables" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#LeasesTables" roleURI="http://renovarobio.com/role/LeasesTables" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#IncomeTaxesTables" roleURI="http://renovarobio.com/role/IncomeTaxesTables" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#StockholdersEquityTables" roleURI="http://renovarobio.com/role/StockholdersEquityTables" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#AcquisitionsTables" roleURI="http://renovarobio.com/role/AcquisitionsTables" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#SegmentReportingTables" roleURI="http://renovarobio.com/role/SegmentReportingTables" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" roleURI="http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#GoingConcernDetailsNarrative" roleURI="http://renovarobio.com/role/GoingConcernDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#FairValueMeasurementsDetails" roleURI="http://renovarobio.com/role/FairValueMeasurementsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#FairValueMeasurementsDetails1" roleURI="http://renovarobio.com/role/FairValueMeasurementsDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#FairValueMeasurementsDetails2" roleURI="http://renovarobio.com/role/FairValueMeasurementsDetails2" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#FairValueMeasurementsDetailsNarrative" roleURI="http://renovarobio.com/role/FairValueMeasurementsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#PropertyAndEquipmentDetails" roleURI="http://renovarobio.com/role/PropertyAndEquipmentDetails" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#PropertyAndEquipmentDetailsNarrative" roleURI="http://renovarobio.com/role/PropertyAndEquipmentDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#IntangibleAssetsAndGoodwillDetails" roleURI="http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#IntangibleAssetsAndGoodwillDetails1" roleURI="http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#IntangibleAssetsAndGoodwillDetailsNarrative" roleURI="http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#LeasesDetails" roleURI="http://renovarobio.com/role/LeasesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#LeasesDetailsNarrative" roleURI="http://renovarobio.com/role/LeasesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#DebtDetailsNarrative" roleURI="http://renovarobio.com/role/DebtDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#IncomeTaxesDetails" roleURI="http://renovarobio.com/role/IncomeTaxesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#IncomeTaxesDetails1" roleURI="http://renovarobio.com/role/IncomeTaxesDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#IncomeTaxesDetails2" roleURI="http://renovarobio.com/role/IncomeTaxesDetails2" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#IncomeTaxesDetailsNarrative" roleURI="http://renovarobio.com/role/IncomeTaxesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#StockholdersEquityDetails" roleURI="http://renovarobio.com/role/StockholdersEquityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#StockholdersEquityDetails1" roleURI="http://renovarobio.com/role/StockholdersEquityDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#StockholdersEquityDetails2" roleURI="http://renovarobio.com/role/StockholdersEquityDetails2" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#StockholdersEquityDetails3" roleURI="http://renovarobio.com/role/StockholdersEquityDetails3" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#StockholdersEquityDetails4" roleURI="http://renovarobio.com/role/StockholdersEquityDetails4" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#StockholdersEquityDetailsNarrative" roleURI="http://renovarobio.com/role/StockholdersEquityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#CommitmentsAndContingenciesDetailsNarrative" roleURI="http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#RelatedPartyTransactionsDetailsNarrative" roleURI="http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#AcquisitionDetails" roleURI="http://renovarobio.com/role/AcquisitionDetails" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#AcquisitionDetails1" roleURI="http://renovarobio.com/role/AcquisitionDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#AcquisitionDetails2" roleURI="http://renovarobio.com/role/AcquisitionDetails2" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#AcquisitionDetails5" roleURI="http://renovarobio.com/role/AcquisitionDetails5" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#AcquisitionDetails4" roleURI="http://renovarobio.com/role/AcquisitionDetails4" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#AcquisitionDetails3" roleURI="http://renovarobio.com/role/AcquisitionDetails3" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#AcquisitionsDetailsNarrative" roleURI="http://renovarobio.com/role/AcquisitionsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#SegmentReportingDetails" roleURI="http://renovarobio.com/role/SegmentReportingDetails" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#SegmentReportingDetails1" roleURI="http://renovarobio.com/role/SegmentReportingDetails1" />
    <link:roleRef xlink:type="simple" xlink:href="renb-20250630.xsd#SubsequentEventsDetailsNarrative" roleURI="http://renovarobio.com/role/SubsequentEventsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" />
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiIcfrAuditorAttestationFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_deiDocumentFinStmtErrorCorrectionFlag" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFinStmtErrorCorrectionFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InsuranceSettlementsReceivableCurrent" xlink:label="loc_us-gaapInsuranceSettlementsReceivableCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapInsuranceSettlementsReceivableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="loc_us-gaapEquitySecuritiesFvNi" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapEquitySecuritiesFvNi" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaapAssetsNoncurrentAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_DefiniteLifeIntangibleAssetsNet" xlink:label="loc_RENBDefiniteLifeIntangibleAssetsNet" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_RENBDefiniteLifeIntangibleAssetsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedComputerSoftwareGross" xlink:label="loc_us-gaapCapitalizedComputerSoftwareGross" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapCapitalizedComputerSoftwareGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedTrademarksGross" xlink:label="loc_us-gaapFiniteLivedTrademarksGross" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapFiniteLivedTrademarksGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaapDepositsAssetsNoncurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapDepositsAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaapAccountsPayableTradeCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableTradeCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ContingentConsiderationLiabilityCurrent" xlink:label="loc_RENBContingentConsiderationLiabilityCurrent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_RENBContingentConsiderationLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapConvertibleNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_NotesPayableRelatedPartiesNetCurrent" xlink:label="loc_RENBNotesPayableRelatedPartiesNetCurrent" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_RENBNotesPayableRelatedPartiesNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/ConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsExcludingGoodwill" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairmentLoss" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGoodwillImpairmentLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ChangeInFairValueOfContingentConsideration" xlink:label="loc_RENBChangeInFairValueOfContingentConsideration" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_RENBChangeInFairValueOfContingentConsideration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiRealizedLoss" xlink:label="loc_us-gaapEquitySecuritiesFvNiRealizedLoss" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapEquitySecuritiesFvNiRealizedLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="loc_us-gaapInterestExpenseNonoperating" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestExpenseNonoperating" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_InterestIncomeAndOtherIncomeExpense" xlink:label="loc_RENBInterestIncomeAndOtherIncomeExpense" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_RENBInterestIncomeAndOtherIncomeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTaxAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS&apos; EQUITY (DEFICIT)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_IssuanceOfCommonStockUnderPrivatePlacementOfferingValue" xlink:label="loc_RENBIssuanceOfCommonStockUnderPrivatePlacementOfferingValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBIssuanceOfCommonStockUnderPrivatePlacementOfferingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_IssuanceOfCommonStockUnderPrivatePlacementOfferingShares" xlink:label="loc_RENBIssuanceOfCommonStockUnderPrivatePlacementOfferingShares" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBIssuanceOfCommonStockUnderPrivatePlacementOfferingShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationValue" xlink:label="loc_RENBRestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBRestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationShares" xlink:label="loc_RENBRestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationShares" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBRestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensationForfeited" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensationForfeited" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_IssuanceOfCommonStockPursuantToAcquisitionValue" xlink:label="loc_RENBIssuanceOfCommonStockPursuantToAcquisitionValue" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBIssuanceOfCommonStockPursuantToAcquisitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_IssuanceOfCommonStockPursuantToAcquisitionShares" xlink:label="loc_RENBIssuanceOfCommonStockPursuantToAcquisitionShares" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBIssuanceOfCommonStockPursuantToAcquisitionShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable" xlink:label="loc_RENBIssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBIssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_IssuanceOfPreferredStockAndWarrantsInPrivatePlacement" xlink:label="loc_RENBIssuanceOfPreferredStockAndWarrantsInPrivatePlacement" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBIssuanceOfPreferredStockAndWarrantsInPrivatePlacement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayableShares" xlink:label="loc_RENBIssuanceOfPreferredStockAndWarrantsForConversionOfNotePayableShares" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBIssuanceOfPreferredStockAndWarrantsForConversionOfNotePayableShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_IssuanceOfPreferredStockAndWarrantsInPrivatePlacementShares" xlink:label="loc_RENBIssuanceOfPreferredStockAndWarrantsInPrivatePlacementShares" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBIssuanceOfPreferredStockAndWarrantsInPrivatePlacementShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_RestrictedSharesIssuedForServicesRenderedValue" xlink:label="loc_RENBRestrictedSharesIssuedForServicesRenderedValue" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBRestrictedSharesIssuedForServicesRenderedValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_RestrictedSharesIssuedForServicesRenderedShares" xlink:label="loc_RENBRestrictedSharesIssuedForServicesRenderedShares" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBRestrictedSharesIssuedForServicesRenderedShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:label="loc_RENBStockIssuedDuringPeriodValueExerciseOfWarrants" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBStockIssuedDuringPeriodValueExerciseOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="loc_RENBStockIssuedDuringPeriodSharesExerciseOfWarrants" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBStockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue" xlink:label="loc_RENBIssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBIssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtShares" xlink:label="loc_RENBIssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtShares" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBIssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_SharesIssuableForSettlementOfContingentConsiderationValue" xlink:label="loc_RENBSharesIssuableForSettlementOfContingentConsiderationValue" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBSharesIssuableForSettlementOfContingentConsiderationValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_SharesIssuableForSettlementOfContingentConsideration" xlink:label="loc_RENBSharesIssuableForSettlementOfContingentConsideration" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBSharesIssuableForSettlementOfContingentConsideration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_IssuanceOfCommonStockPursuantToAcquisitionOfGediCube" xlink:label="loc_RENBIssuanceOfCommonStockPursuantToAcquisitionOfGediCube" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBIssuanceOfCommonStockPursuantToAcquisitionOfGediCube" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_IssuanceOfCommonStockPursuantAcquisitionOfGediCubeShares" xlink:label="loc_RENBIssuanceOfCommonStockPursuantAcquisitionOfGediCubeShares" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBIssuanceOfCommonStockPursuantAcquisitionOfGediCubeShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube" xlink:label="loc_RENBPreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBPreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCubeShares" xlink:label="loc_RENBPreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCubeShares" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBPreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCubeShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ChangeInFairValueOfContingentConsideration" xlink:label="loc_RENBChangeInFairValueOfContingentConsideration" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_RENBChangeInFairValueOfContingentConsideration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiRealizedLoss" xlink:label="loc_us-gaapEquitySecuritiesFvNiRealizedLoss" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapEquitySecuritiesFvNiRealizedLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_LossOnExtinguishmentOfDebt" xlink:label="loc_RENBLossOnExtinguishmentOfDebt" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_RENBLossOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_NoncashStockbasedCompensationExpense" xlink:label="loc_RENBNoncashStockbasedCompensationExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_RENBNoncashStockbasedCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_NoncashRestrictedSharesIssuedForServicesRendered" xlink:label="loc_RENBNoncashRestrictedSharesIssuedForServicesRendered" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_RENBNoncashRestrictedSharesIssuedForServicesRendered" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsExcludingGoodwill" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairmentLoss" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGoodwillImpairmentLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_AmortizationOfDiscountOnNotePayable" xlink:label="loc_RENBAmortizationOfDiscountOnNotePayable" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_RENBAmortizationOfDiscountOnNotePayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsAndOtherReceivables" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsAndOtherReceivables" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccruedLiabilities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:label="loc_us-gaapPaymentsToAcquireEquitySecuritiesFvNi" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapPaymentsToAcquireEquitySecuritiesFvNi" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireNotesReceivable" xlink:label="loc_us-gaapPaymentsToAcquireNotesReceivable" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapPaymentsToAcquireNotesReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_us-gaapCashAcquiredFromAcquisition" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapCashAcquiredFromAcquisition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_RepaymentsOfFinanceAgreement" xlink:label="loc_RENBRepaymentsOfFinanceAgreement" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_RENBRepaymentsOfFinanceAgreement" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfDebt" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_CashPaidDuringYearForAbstract" xlink:label="loc_RENBCashPaidDuringYearForAbstract" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_RENBCashPaidDuringYearForAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_RENBCashPaidDuringYearForAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_RENBCashPaidDuringYearForAbstract" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ContingentSharesIssuedPursuantToAcquisitionAgreement" xlink:label="loc_RENBContingentSharesIssuedPursuantToAcquisitionAgreement" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_RENBContingentSharesIssuedPursuantToAcquisitionAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_CancellationOfRestrictedStockAwards" xlink:label="loc_RENBCancellationOfRestrictedStockAwards" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_RENBCancellationOfRestrictedStockAwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_FinanceAgreementEnteredIntoInExchangeForPrepaidAssets" xlink:label="loc_RENBFinanceAgreementEnteredIntoInExchangeForPrepaidAssets" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_RENBFinanceAgreementEnteredIntoInExchangeForPrepaidAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ConversionOfNotePayableForIssuanceOfPreferredStock" xlink:label="loc_RENBConversionOfNotePayableForIssuanceOfPreferredStock" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_RENBConversionOfNotePayableForIssuanceOfPreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_NotePayableSettledThroughNoncashExerciseOfWarrants" xlink:label="loc_RENBNotePayableSettledThroughNoncashExerciseOfWarrants" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_RENBNotePayableSettledThroughNoncashExerciseOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_DebtDiscountRelatedToConvertiblePromissoryNotes" xlink:label="loc_RENBDebtDiscountRelatedToConvertiblePromissoryNotes" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_RENBDebtDiscountRelatedToConvertiblePromissoryNotes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_CommonSharesIssuedUponAcquisition" xlink:label="loc_RENBCommonSharesIssuedUponAcquisition" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_RENBCommonSharesIssuedUponAcquisition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ContingentConsiderationIssuedUponAcquisition" xlink:label="loc_RENBContingentConsiderationIssuedUponAcquisition" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_RENBContingentConsiderationIssuedUponAcquisition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_CommonSharesIssuedUponSettlementOfDebt" xlink:label="loc_RENBCommonSharesIssuedUponSettlementOfDebt" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_RENBCommonSharesIssuedUponSettlementOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_EarnOutSharesIssuedInSettlementOfContingentLiability" xlink:label="loc_RENBEarnOutSharesIssuedInSettlementOfContingentLiability" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_RENBEarnOutSharesIssuedInSettlementOfContingentLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_OptionsIssuedInSettlementOfDebt" xlink:label="loc_RENBOptionsIssuedInSettlementOfDebt" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_RENBOptionsIssuedInSettlementOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_SettlementOfNotesPayable" xlink:label="loc_RENBSettlementOfNotesPayable" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_RENBSettlementOfNotesPayable" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:title="995410 - Disclosure - Pay vs Performance Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems" xlink:label="loc_ecdPayVsPerformanceDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable" xlink:label="loc_ecdPvpTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis" xlink:label="loc_ecdExecutiveCategoryAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdExecutiveCategoryAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember" xlink:label="loc_ecdAllExecutiveCategoriesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdExecutiveCategoryAxis" xlink:to="loc_ecdAllExecutiveCategoriesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis" xlink:label="loc_ecdAdjToCompAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdAdjToCompAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember" xlink:label="loc_ecdAllAdjToCompMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAdjToCompAxis" xlink:to="loc_ecdAllAdjToCompMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis" xlink:label="loc_ecdMeasureAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdMeasureAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock" xlink:label="loc_ecdPvpTableTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName" xlink:label="loc_ecdCoSelectedMeasureName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdCoSelectedMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="loc_ecdNamedExecutiveOfficersFnTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdNamedExecutiveOfficersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="loc_ecdPeerGroupIssuersFnTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeerGroupIssuersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="loc_ecdChangedPeerGroupFnTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdChangedPeerGroupFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt" xlink:label="loc_ecdPeoTotalCompAmt" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="loc_ecdPeoActuallyPaidCompAmt" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoActuallyPaidCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="loc_ecdAdjToPeoCompFnTextBlock" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdAdjToPeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="loc_ecdNonPeoNeoAvgTotalCompAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="loc_ecdAdjToNonPeoNeoCompFnTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdAdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:presentationArc order="2140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" />
      <link:presentationArc order="2150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" />
      <link:presentationArc order="2160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock" xlink:label="loc_ecdTabularListTableTextBlock" />
      <link:presentationArc order="2170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTabularListTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt" xlink:label="loc_ecdTotalShareholderRtnAmt" />
      <link:presentationArc order="2180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="loc_ecdPeerGroupTotalShareholderRtnAmt" />
      <link:presentationArc order="2190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdPeerGroupTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="2200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt" xlink:label="loc_ecdCoSelectedMeasureAmt" />
      <link:presentationArc order="2210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdCoSelectedMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt" xlink:label="loc_ecdOtherPerfMeasureAmt" />
      <link:presentationArc order="2220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdOtherPerfMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt" xlink:label="loc_ecdAdjToCompAmt" />
      <link:presentationArc order="2230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdAdjToCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName" xlink:label="loc_ecdPeoName" />
      <link:presentationArc order="2240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdPeoName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName" xlink:label="loc_ecdMeasureName" />
      <link:presentationArc order="2250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="loc_ecdNonGaapMeasureDescriptionTextBlock" />
      <link:presentationArc order="2260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdMeasureName" xlink:to="loc_ecdNonGaapMeasureDescriptionTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="loc_ecdAdditional402vDisclosureTextBlock" />
      <link:presentationArc order="2270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdAdditional402vDisclosureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="loc_ecdPnsnBnftsAdjFnTextBlock" />
      <link:presentationArc order="2280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPnsnBnftsAdjFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock" xlink:label="loc_ecdEqtyAwrdsAdjFnTextBlock" />
      <link:presentationArc order="2290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdEqtyAwrdsAdjFnTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:title="995440 - Disclosure - Recovery of Erroneously Awarded Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems" xlink:label="loc_ecdRecoveryOfErrCompDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable" xlink:label="loc_ecdErrCompRecoveryTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdErrCompRecoveryTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis" xlink:label="loc_ecdRestatementDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdRestatementDateAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate" xlink:label="loc_ecdRestatementDeterminationDate" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdRestatementDeterminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt" xlink:label="loc_ecdAggtErrCompAmt" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="loc_ecdErrCompAnalysisTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdErrCompAnalysisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="loc_ecdOutstandingAggtErrCompAmt" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdOutstandingAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="loc_ecdAggtErrCompNotYetDeterminedTextBlock" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdAggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName" xlink:label="loc_ecdForgoneRecoveryIndName" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName" xlink:label="loc_ecdOutstandingRecoveryIndName" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="loc_ecdOutstandingRecoveryCompAmt" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:title="995443 - Disclosure - Award Timing Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems" xlink:label="loc_ecdAwardTmgDiscLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="loc_ecdAwardsCloseToMnpiDiscTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_ecdIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="loc_ecdAwardTmgMnpiDiscTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiDiscTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="loc_ecdAwardTmgMethodTextBlock" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="loc_ecdAwardTmgPredtrmndFlag" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgPredtrmndFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="loc_ecdAwardTmgMnpiCnsdrdFlag" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiCnsdrdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="loc_ecdMnpiDiscTimedForCompValFlag" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdMnpiDiscTimedForCompValFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="loc_ecdAwardsCloseToMnpiDiscIndName" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="loc_ecdAwardUndrlygSecuritiesAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardUndrlygSecuritiesAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice" xlink:label="loc_ecdAwardExrcPrice" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardExrcPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue" xlink:label="loc_ecdAwardGrantDateFairValue" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="loc_ecdUndrlygSecurityMktPriceChngPct" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdUndrlygSecurityMktPriceChngPct" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="995445 - Disclosure - Insider Trading Arrangements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="loc_ecdInsiderTradingArrLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable" xlink:label="loc_ecdTradingArrByIndTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTradingArrByIndTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis" xlink:label="loc_ecdTradingArrAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdTradingArrByIndTable" xlink:to="loc_ecdTradingArrAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember" xlink:label="loc_ecdAllTradingArrangementsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdTradingArrAxis" xlink:to="loc_ecdAllTradingArrangementsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdTradingArrByIndTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="loc_ecdMtrlTermsOfTrdArrTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdMtrlTermsOfTrdArrTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName" xlink:label="loc_ecdTrdArrIndName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle" xlink:label="loc_ecdTrdArrIndTitle" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="loc_ecdRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="loc_ecdNonRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate" xlink:label="loc_ecdTrdArrAdoptionDate" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrAdoptionDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="loc_ecdRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="loc_ecdNonRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate" xlink:label="loc_ecdTrdArrTerminationDate" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrTerminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate" xlink:label="loc_ecdTrdArrExpirationDate" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration" xlink:label="loc_ecdTrdArrDuration" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrDuration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt" xlink:label="loc_ecdTrdArrSecuritiesAggAvailAmt" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrSecuritiesAggAvailAmt" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:title="995447 - Disclosure - Insider Trading Policies and Procedures">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="loc_ecdInsiderTradingPoliciesProcLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000013 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="loc_cydCybersecurityRiskManagementProcessesIntegratedFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementProcessesIntegratedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="loc_cydCybersecurityRiskManagementProcessesIntegratedTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="loc_cydCybersecurityRiskManagementThirdPartyEngagedFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementThirdPartyEngagedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="loc_cydCybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="loc_cydCybersecurityRiskBoardOfDirectorsOversightTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="loc_cydCybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="loc_cydCybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="loc_cydCybersecurityRiskRoleOfManagementTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskRoleOfManagementTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="loc_cydCybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="loc_cydCybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000014 - Disclosure - Material Cybersecurity Incident Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentAbstract" xlink:label="loc_cydMaterialCybersecurityIncidentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentNatureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentNatureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentScopeTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentScopeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentTimingTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentTimingTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:title="999015 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapOrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/GoingConcern" xlink:title="999016 - Disclosure - GOING CONCERN">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/FairValueMeasurements" xlink:title="999017 - Disclosure - FAIR VALUE MEASUREMENTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:label="loc_us-gaapFairValueMeasurementInputsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueMeasurementInputsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/PropertyAndEquipment" xlink:title="999018 - Disclosure - PROPERTY AND EQUIPMENT">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IntangibleAssetsAndGoodwill" xlink:title="999019 - Disclosure - INTANGIBLE ASSETS AND GOODWILL">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapIntangibleAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapIntangibleAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/Leases" xlink:title="999020 - Disclosure - LEASES">
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_DisclosureLeasesAbstract" xlink:label="loc_RENBDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeasesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_RENBDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeasesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/Debt" xlink:title="999021 - Disclosure - DEBT">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IncomeTaxes" xlink:title="999022 - Disclosure - INCOME TAXES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/StockholdersEquity" xlink:title="999023 - Disclosure - STOCKHOLDERS&#8217; EQUITY">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/CommitmentsAndContingencies" xlink:title="999024 - Disclosure - COMMITMENTS AND CONTINGENCIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/RelatedPartyTransactions" xlink:title="999025 - Disclosure - RELATED PARTY TRANSACTIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/Acquisitions" xlink:title="999026 - Disclosure - ACQUISITIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaapBusinessCombinationDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapBusinessCombinationDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/SegmentReporting" xlink:title="999027 - Disclosure - SEGMENT REPORTING">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaapSegmentReportingDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapSegmentReportingDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/SubsequentEvents" xlink:title="999028 - Disclosure - SUBSEQUENT EVENTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999029 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BusinessPolicyTextBlock" xlink:label="loc_RENBBusinessPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_RENBBusinessPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:label="loc_us-gaapConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_InvestmentinEquitySecuritiesPolicyTextBlock" xlink:label="loc_RENBInvestmentinEquitySecuritiesPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_RENBInvestmentinEquitySecuritiesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_InsuranceReceivablePolicy" xlink:label="loc_RENBInsuranceReceivablePolicy" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_RENBInsuranceReceivablePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/FairValueMeasurementsTables" xlink:title="999030 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueConcentrationOfRiskTextBlock" xlink:label="loc_us-gaapFairValueConcentrationOfRiskTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueConcentrationOfRiskTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ScheduleOfContingentConsiderationLiabilityTableTextBlock" xlink:label="loc_RENBScheduleOfContingentConsiderationLiabilityTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_RENBScheduleOfContingentConsiderationLiabilityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/PropertyAndEquipmentTables" xlink:title="999031 - Disclosure - PROPERTY AND EQUIPMENT (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IntangibleAssetsAndGoodwillTables" xlink:title="999032 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/LeasesTables" xlink:title="999033 - Disclosure - LEASES (Tables)">
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_DisclosureLeasesAbstract" xlink:label="loc_RENBDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_RENBDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IncomeTaxesTables" xlink:title="999034 - Disclosure - INCOME TAXES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/StockholdersEquityTables" xlink:title="999035 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ScheduleOfShareBasedPaymentAwardStockOptionValuationAssumptionsTableTextBlock" xlink:label="loc_RENBScheduleOfShareBasedPaymentAwardStockOptionValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_RENBScheduleOfShareBasedPaymentAwardStockOptionValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ScheduleOfStockBasedCompensationActivityTableTextBlock" xlink:label="loc_RENBScheduleOfStockBasedCompensationActivityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_RENBScheduleOfStockBasedCompensationActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ScheduleOfCommonStockPurchaseWarrantsOutstandingTableTextBlock" xlink:label="loc_RENBScheduleOfCommonStockPurchaseWarrantsOutstandingTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_RENBScheduleOfCommonStockPurchaseWarrantsOutstandingTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ScheduleOfWarrantsOutstandingTableTextBlock" xlink:label="loc_RENBScheduleOfWarrantsOutstandingTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_RENBScheduleOfWarrantsOutstandingTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/AcquisitionsTables" xlink:title="999036 - Disclosure - ACQUISITIONS (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_srtCounterpartyNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BioSymetricsncAcquisitionMember" xlink:label="loc_RENBBioSymetricsncAcquisitionMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_RENBBioSymetricsncAcquisitionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_GEDiCubeIntlLtdAcquisitionMember" xlink:label="loc_RENBGEDiCubeIntlLtdAcquisitionMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_RENBGEDiCubeIntlLtdAcquisitionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ScheduleOfAcquistionFairValueOfConsiderationTableTextBlock" xlink:label="loc_RENBScheduleOfAcquistionFairValueOfConsiderationTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_RENBScheduleOfAcquistionFairValueOfConsiderationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaapScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ScheduleOfRecognizedIdentifiedAssetsAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_RENBScheduleOfRecognizedIdentifiedAssetsAndLiabilitiesAssumedTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_RENBScheduleOfRecognizedIdentifiedAssetsAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/SegmentReportingTables" xlink:title="999037 - Disclosure - SEGMENT REPORTING (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:label="loc_us-gaapReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999038 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaapRestructuringCostAndReserveLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_us-gaapRestructuringCostAndReserveLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_RenovaroCubeMember" xlink:label="loc_RENBRenovaroCubeMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_RENBRenovaroCubeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTable" xlink:to="loc_srtTitleOfIndividualAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_EmployeesOfficersDirectorsAndConsultantsMember" xlink:label="loc_RENBEmployeesOfficersDirectorsAndConsultantsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_RENBEmployeesOfficersDirectorsAndConsultantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BusinessAcquisitionPercentage" xlink:label="loc_RENBBusinessAcquisitionPercentage" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_RENBBusinessAcquisitionPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_PurchaseEquitySecuritiesValue" xlink:label="loc_RENBPurchaseEquitySecuritiesValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_RENBPurchaseEquitySecuritiesValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCost" xlink:label="loc_us-gaapDebtSecuritiesTradingAndEquitySecuritiesFvNiCost" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapDebtSecuritiesTradingAndEquitySecuritiesFvNiCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtAndEquitySecuritiesGainLoss" xlink:label="loc_us-gaapDebtAndEquitySecuritiesGainLoss" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapDebtAndEquitySecuritiesGainLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ImpairmentLoss" xlink:label="loc_RENBImpairmentLoss" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_RENBImpairmentLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_InProcessResearchAndDevelopment" xlink:label="loc_RENBInProcessResearchAndDevelopment" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_RENBInProcessResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaapAssetImpairmentCharges" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapAssetImpairmentCharges" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockOtherSharesOutstanding" xlink:label="loc_us-gaapCommonStockOtherSharesOutstanding" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapCommonStockOtherSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestructuringCostAndReserveLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/GoingConcernDetailsNarrative" xlink:title="999039 - Disclosure - GOING CONCERN (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_WorkingCapitalDeficit" xlink:label="loc_RENBWorkingCapitalDeficit" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_RENBWorkingCapitalDeficit" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/FairValueMeasurementsDetails" xlink:title="999040 - Disclosure - FAIR VALUE MEASUREMENTS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="loc_us-gaapEquitySecuritiesFvNi" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapEquitySecuritiesFvNi" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapAccruedLiabilitiesFairValueDisclosure" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesFairValueDisclosure" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="loc_us-gaapContingentConsiderationClassifiedAsEquityFairValueDisclosure" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaapDerivativeFairValueOfDerivativeLiability" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapDerivativeFairValueOfDerivativeLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/FairValueMeasurementsDetails1" xlink:title="999041 - Disclosure - FAIR VALUE MEASUREMENTS (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BlackScholesOptionPricingModelMember" xlink:label="loc_RENBBlackScholesOptionPricingModelMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_RENBBlackScholesOptionPricingModelMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_InitialRecognitionMember" xlink:label="loc_RENBInitialRecognitionMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_RENBInitialRecognitionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate" xlink:label="loc_RENBShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_RENBShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/FairValueMeasurementsDetails2" xlink:title="999042 - Disclosure - FAIR VALUE MEASUREMENTS (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationLiability" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="loc_us-gaapLiabilitiesFairValueAdjustment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapLiabilitiesFairValueAdjustment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationLiability_2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationLiability_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/FairValueMeasurementsDetailsNarrative" xlink:title="999043 - Disclosure - FAIR VALUE MEASUREMENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_CommonStocksMember" xlink:label="loc_RENBCommonStocksMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_RENBCommonStocksMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ConvertibleNotesMember" xlink:label="loc_RENBConvertibleNotesMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_RENBConvertibleNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_RenovaroCubeMember" xlink:label="loc_RENBRenovaroCubeMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_RENBRenovaroCubeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodShares" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiCost" xlink:label="loc_us-gaapEquitySecuritiesFvNiCost" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquitySecuritiesFvNiCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_InvestmentEquitySecuritiesShares" xlink:label="loc_RENBInvestmentEquitySecuritiesShares" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_RENBInvestmentEquitySecuritiesShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaapBusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationLiability" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/PropertyAndEquipmentDetails" xlink:title="999044 - Disclosure - PROPERTY AND EQUIPMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_LabEquipmentAndInstrumentsMember" xlink:label="loc_RENBLabEquipmentAndInstrumentsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_RENBLabEquipmentAndInstrumentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="999045 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails" xlink:title="999046 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_SoftwarePlatformMember" xlink:label="loc_RENBSoftwarePlatformMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_RENBSoftwarePlatformMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_TrademarkMember" xlink:label="loc_RENBTrademarkMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_RENBTrademarkMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaapPatentsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapPatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_LessAccumulatedAmortizationMember" xlink:label="loc_RENBLessAccumulatedAmortizationMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_RENBLessAccumulatedAmortizationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillMember" xlink:label="loc_us-gaapGoodwillMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapGoodwillMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaapInProcessResearchAndDevelopmentMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapInProcessResearchAndDevelopmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_NetDefinitelifeIntangibleAssets" xlink:label="loc_RENBNetDefinitelifeIntangibleAssets" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_RENBNetDefinitelifeIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsPeriodIncreaseDecrease" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_NetDefinitelifeIntangibleAssetsAmortization" xlink:label="loc_RENBNetDefinitelifeIntangibleAssetsAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_RENBNetDefinitelifeIntangibleAssetsAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_NetDefinitelifeIntangibleAssets" xlink:label="loc_RENBNetDefinitelifeIntangibleAssets_2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_RENBNetDefinitelifeIntangibleAssets_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaapOtherIndefiniteLivedIntangibleAssets" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapOtherIndefiniteLivedIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_IndefiniteLifeIntangibleAssetsAndGoodwillAmortization" xlink:label="loc_RENBIndefiniteLifeIntangibleAssetsAndGoodwillAmortization" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_RENBIndefiniteLifeIntangibleAssetsAndGoodwillAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_IndefiniteLifeIntangibleAssetsAndGoodwillImpairment" xlink:label="loc_RENBIndefiniteLifeIntangibleAssetsAndGoodwillImpairment" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_RENBIndefiniteLifeIntangibleAssetsAndGoodwillImpairment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaapOtherIndefiniteLivedIntangibleAssets_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapOtherIndefiniteLivedIntangibleAssets_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:title="999047 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetailsNarrative" xlink:title="999048 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfIndefiniteLivedIntangibleAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfIndefiniteLivedIntangibleAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaapPatentsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapPatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_SoftwarePlatformMember" xlink:label="loc_RENBSoftwarePlatformMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_RENBSoftwarePlatformMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_TrademarkMember" xlink:label="loc_RENBTrademarkMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_RENBTrademarkMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="loc_srtStatementGeographicalAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_RenovaroCubeMember" xlink:label="loc_RENBRenovaroCubeMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_RENBRenovaroCubeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BioSymetricsMember" xlink:label="loc_RENBBioSymetricsMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_RENBBioSymetricsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedAmortizationOfCurrentDeferredFinanceCosts" xlink:label="loc_us-gaapAccumulatedAmortizationOfCurrentDeferredFinanceCosts" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapAccumulatedAmortizationOfCurrentDeferredFinanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_Software" xlink:label="loc_RENBSoftware" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_RENBSoftware" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_Trademark" xlink:label="loc_RENBTrademark" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_RENBTrademark" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ImpairmentAdjustment" xlink:label="loc_RENBImpairmentAdjustment" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_RENBImpairmentAdjustment" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/LeasesDetails" xlink:title="999049 - Disclosure - LEASES (Details)">
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_DisclosureLeasesAbstract" xlink:label="loc_RENBDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_RENBDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_RENBDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" xlink:label="loc_RENBLesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_RENBDisclosureLeasesAbstract" xlink:to="loc_RENBLesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_RENBDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_RENBDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/LeasesDetailsNarrative" xlink:title="999050 - Disclosure - LEASES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_DisclosureLeasesAbstract" xlink:label="loc_RENBDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="loc_us-gaapLesseeOperatingLeaseDescription" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_RENBDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_RENBDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_RENBDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/DebtDetailsNarrative" xlink:title="999051 - Disclosure - DEBT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapAwardDateAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_JanuaryNote2024Member" xlink:label="loc_RENBJanuaryNote2024Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_RENBJanuaryNote2024Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_DecemberNote2023Member" xlink:label="loc_RENBDecemberNote2023Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_RENBDecemberNote2023Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_PasecoApSMember" xlink:label="loc_RENBPasecoApSMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_RENBPasecoApSMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_TheNotesMember" xlink:label="loc_RENBTheNotesMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_RENBTheNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_PromissoryNotesMember" xlink:label="loc_RENBPromissoryNotesMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_RENBPromissoryNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_PromissoryNoteMember" xlink:label="loc_RENBPromissoryNoteMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_RENBPromissoryNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaapBalanceSheetLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapBalanceSheetLocationAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaapBalanceSheetLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBalanceSheetLocationAxis" xlink:to="loc_us-gaapBalanceSheetLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaapOtherCurrentLiabilitiesMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBalanceSheetLocationDomain" xlink:to="loc_us-gaapOtherCurrentLiabilitiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_FinanceAgreementMember" xlink:label="loc_RENBFinanceAgreementMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_RENBFinanceAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfDebt" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:label="loc_us-gaapLongTermDebtPercentageBearingFixedInterestRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLongTermDebtPercentageBearingFixedInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_NotesBalance" xlink:label="loc_RENBNotesBalance" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_RENBNotesBalance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MaturitiesOfTimeDepositsDescription" xlink:label="loc_us-gaapMaturitiesOfTimeDepositsDescription" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapMaturitiesOfTimeDepositsDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_AgreementDescription" xlink:label="loc_RENBAgreementDescription" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_RENBAgreementDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="loc_us-gaapDebtInstrumentInterestRateIncreaseDecrease" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateIncreaseDecrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:label="loc_us-gaapDebtInstrumentAnnualPrincipalPayment" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentAnnualPrincipalPayment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFixedInterestRate" xlink:label="loc_us-gaapDerivativeFixedInterestRate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDerivativeFixedInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_MonthlyInstallments" xlink:label="loc_RENBMonthlyInstallments" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_RENBMonthlyInstallments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_RepaymentOnFinanceAgreement" xlink:label="loc_RENBRepaymentOnFinanceAgreement" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_RENBRepaymentOnFinanceAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestAndDebtExpense" xlink:label="loc_us-gaapInterestAndDebtExpense" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestAndDebtExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="loc_us-gaapInterestExpenseNonoperating" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestExpenseNonoperating" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IncomeTaxesDetails" xlink:title="999052 - Disclosure - INCOME TAXES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_Depreciations" xlink:label="loc_RENBDepreciations" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_RENBDepreciations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_DeferredTaxAssetExcessTaxOverDepreciationPatents" xlink:label="loc_RENBDeferredTaxAssetExcessTaxOverDepreciationPatents" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_RENBDeferredTaxAssetExcessTaxOverDepreciationPatents" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_StockoptionsCompensation" xlink:label="loc_RENBStockoptionsCompensation" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_RENBStockoptionsCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_DepreciationAndAmortizations" xlink:label="loc_RENBDepreciationAndAmortizations" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_RENBDepreciationAndAmortizations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ImpairmentExpense" xlink:label="loc_RENBImpairmentExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_RENBImpairmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ContingentConsiderationFairValue" xlink:label="loc_RENBContingentConsiderationFairValue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_RENBContingentConsiderationFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedAmortizationOfOtherDeferredCosts" xlink:label="loc_us-gaapAccumulatedAmortizationOfOtherDeferredCosts" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapAccumulatedAmortizationOfOtherDeferredCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_Section174ReCapitalization" xlink:label="loc_RENBSection174ReCapitalization" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_RENBSection174ReCapitalization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_OperatingLeaseRightOfUseAssets" xlink:label="loc_RENBOperatingLeaseRightOfUseAssets" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_RENBOperatingLeaseRightOfUseAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_Section481aAdjustment" xlink:label="loc_RENBSection481aAdjustment" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_RENBSection481aAdjustment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ChangeInTaxRate" xlink:label="loc_RENBChangeInTaxRate" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_RENBChangeInTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:label="loc_us-gaapDeferredTaxLiabilitiesGoodwillAndIntangibleAssets" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IncomeTaxesDetails1" xlink:title="999053 - Disclosure - INCOME TAXES (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInEnactedTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings" xlink:label="loc_us-gaapIncomeTaxReconciliationRepatriationOfForeignEarnings" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationRepatriationOfForeignEarnings" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherTaxExpenseBenefit" xlink:label="loc_us-gaapOtherTaxExpenseBenefit" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapOtherTaxExpenseBenefit" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IncomeTaxesDetails2" xlink:title="999054 - Disclosure - INCOME TAXES (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentFederalTaxExpenseBenefit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="loc_us-gaapCurrentFederalTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentForeignTaxExpenseBenefit" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="loc_us-gaapCurrentForeignTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredFederalStateAndLocalTaxExpenseBenefit" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredFederalStateAndLocalTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredForeignIncomeTaxExpenseBenefit" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredIncomeTaxExpenseBenefit" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/IncomeTaxesDetailsNarrative" xlink:title="999055 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_UnitedStatesTaxMember" xlink:label="loc_RENBUnitedStatesTaxMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_RENBUnitedStatesTaxMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsForeign" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/StockholdersEquityDetails" xlink:title="999056 - Disclosure - STOCKHOLDERS&apos; EQUITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_RenovaroMember" xlink:label="loc_RENBRenovaroMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_RENBRenovaroMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/StockholdersEquityDetails1" xlink:title="999057 - Disclosure - STOCKHOLDERS&apos; EQUITY (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityEquityTable" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ExercisePriceRange1Member" xlink:label="loc_RENBExercisePriceRange1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_RENBExercisePriceRange1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ExercisePriceRange2Member" xlink:label="loc_RENBExercisePriceRange2Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_RENBExercisePriceRange2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ExercisePriceRange3Member" xlink:label="loc_RENBExercisePriceRange3Member" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_RENBExercisePriceRange3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/StockholdersEquityDetails2" xlink:title="999058 - Disclosure - STOCKHOLDERS&apos; EQUITY (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityEquityTable" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_EmployeeStockOptionsMember" xlink:label="loc_RENBEmployeeStockOptionsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_RENBEmployeeStockOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisablesWeightedAverageRemainingContractualTerm1" xlink:label="loc_RENBSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisablesWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_RENBSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisablesWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/StockholdersEquityDetails3" xlink:title="999059 - Disclosure - STOCKHOLDERS&apos; EQUITY (Details 3)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityEquityTable" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_CommonStockPurchaseWarrantsMember" xlink:label="loc_RENBCommonStockPurchaseWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_RENBCommonStockPurchaseWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ExercisePriceRange1Member" xlink:label="loc_RENBExercisePriceRange1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_RENBExercisePriceRange1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ExercisePriceRange2Member" xlink:label="loc_RENBExercisePriceRange2Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_RENBExercisePriceRange2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ExercisePriceRange3Member" xlink:label="loc_RENBExercisePriceRange3Member" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_RENBExercisePriceRange3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ExercisePriceRange4Member" xlink:label="loc_RENBExercisePriceRange4Member" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_RENBExercisePriceRange4Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ExercisePriceRange5Member" xlink:label="loc_RENBExercisePriceRange5Member" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_RENBExercisePriceRange5Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ExercisePriceRange6Member" xlink:label="loc_RENBExercisePriceRange6Member" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_RENBExercisePriceRange6Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ExercisePrices" xlink:label="loc_RENBExercisePrices" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_RENBExercisePrices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ExercisePrice" xlink:label="loc_RENBExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_RENBExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/StockholdersEquityDetails4" xlink:title="999060 - Disclosure - STOCKHOLDERS&apos; EQUITY (Details 4)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityEquityTable" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_CommonStockPurchaseWarrantMember" xlink:label="loc_RENBCommonStockPurchaseWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_RENBCommonStockPurchaseWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_CommonStockPurchaseWarrant" xlink:label="loc_RENBCommonStockPurchaseWarrant" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_RENBCommonStockPurchaseWarrant" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_CommonStockPurchaseWarrantsWeightedAverageExercisePrice" xlink:label="loc_RENBCommonStockPurchaseWarrantsWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_RENBCommonStockPurchaseWarrantsWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" xlink:label="loc_RENBSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_RENBSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_CommonStockPurchaseWarrant" xlink:label="loc_RENBCommonStockPurchaseWarrant_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_RENBCommonStockPurchaseWarrant_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_CommonStockPurchaseWarrantsWeightedAverageExercisePrice" xlink:label="loc_RENBCommonStockPurchaseWarrantsWeightedAverageExercisePrice_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_RENBCommonStockPurchaseWarrantsWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/StockholdersEquityDetailsNarrative" xlink:title="999061 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockByClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_SeriesAConvertiblePreferredStockMember" xlink:label="loc_RENBSeriesAConvertiblePreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_RENBSeriesAConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_CommonStockIssuancesMember" xlink:label="loc_RENBCommonStockIssuancesMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_RENBCommonStockIssuancesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_srtChiefExecutiveOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BoardOfDirectorsMember" xlink:label="loc_RENBBoardOfDirectorsMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_RENBBoardOfDirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_CommonStockConsultingServicesMember" xlink:label="loc_RENBCommonStockConsultingServicesMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_RENBCommonStockConsultingServicesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_PurchaseAgreementMember" xlink:label="loc_RENBPurchaseAgreementMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_RENBPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_RestrictedStockAwardsMember" xlink:label="loc_RENBRestrictedStockAwardsMember" />
      <link:presentationArc order="690" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_RENBRestrictedStockAwardsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_AdvisoryServicesMember" xlink:label="loc_RENBAdvisoryServicesMember" />
      <link:presentationArc order="720" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_RENBAdvisoryServicesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapAwardTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_MrMillerMember" xlink:label="loc_RENBMrMillerMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_RENBMrMillerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtRangeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapInvestorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_Investor1Member" xlink:label="loc_RENBInvestor1Member" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_RENBInvestor1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_GEDiCubeIntlLtdMember" xlink:label="loc_RENBGEDiCubeIntlLtdMember" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_RENBGEDiCubeIntlLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_AvramMillerMember" xlink:label="loc_RENBAvramMillerMember" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_RENBAvramMillerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_EmployeesMember" xlink:label="loc_RENBEmployeesMember" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_RENBEmployeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_EmployeesThreeYearMember" xlink:label="loc_RENBEmployeesThreeYearMember" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_RENBEmployeesThreeYearMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_SingleRangeMember" xlink:label="loc_RENBSingleRangeMember" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_RENBSingleRangeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_StockPurchaseAgreementOfRenovaroCubeMember" xlink:label="loc_RENBStockPurchaseAgreementOfRenovaroCubeMember" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_RENBStockPurchaseAgreementOfRenovaroCubeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_AgreementAndPlanOfMergerAgreementAxisMember" xlink:label="loc_RENBAgreementAndPlanOfMergerAgreementAxisMember" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_RENBAgreementAndPlanOfMergerAgreementAxisMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_EBIAndWeirdScienceLLCMember" xlink:label="loc_RENBEBIAndWeirdScienceLLCMember" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_RENBEBIAndWeirdScienceLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapPlanNameAxis" order="80" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_EquityIncentivePlan2014Member" xlink:label="loc_RENBEquityIncentivePlan2014Member" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_RENBEquityIncentivePlan2014Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_PlanOptionsMember" xlink:label="loc_RENBPlanOptionsMember" />
      <link:presentationArc order="630" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_RENBPlanOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapVestingAxis" order="90" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ShareBasedCompensationAwardAdvisoryBoardMember" xlink:label="loc_RENBShareBasedCompensationAwardAdvisoryBoardMember" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_RENBShareBasedCompensationAwardAdvisoryBoardMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheOneMember" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ShareBasedCompensationAwardBoardofDirectorsMember" xlink:label="loc_RENBShareBasedCompensationAwardBoardofDirectorsMember" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_RENBShareBasedCompensationAwardBoardofDirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ShareBasedCompensationAwardConsultingServicesMember" xlink:label="loc_RENBShareBasedCompensationAwardConsultingServicesMember" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_RENBShareBasedCompensationAwardConsultingServicesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_PlanOptionMember" xlink:label="loc_RENBPlanOptionMember" />
      <link:presentationArc order="670" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_RENBPlanOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_2" />
      <link:presentationArc order="680" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapWarrantMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtTitleOfIndividualAxis" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember_2" />
      <link:presentationArc order="700" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefExecutiveOfficerMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_PreferredStockDesignatedShares" xlink:label="loc_RENBPreferredStockDesignatedShares" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBPreferredStockDesignatedShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_CommonStockShareIssued" xlink:label="loc_RENBCommonStockShareIssued" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBCommonStockShareIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligation" xlink:label="loc_us-gaapPurchaseObligation" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPurchaseObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_UnrecognizedCompensationCostandVest" xlink:label="loc_RENBUnrecognizedCompensationCostandVest" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBUnrecognizedCompensationCostandVest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_IssuanceOfCommonStockUnderPrivatePlacementOffering" xlink:label="loc_RENBIssuanceOfCommonStockUnderPrivatePlacementOffering" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBIssuanceOfCommonStockUnderPrivatePlacementOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_CommonStockParValuePrivatePlacement" xlink:label="loc_RENBCommonStockParValuePrivatePlacement" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBCommonStockParValuePrivatePlacement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_PrincipalAmountAndInterestAccrued" xlink:label="loc_RENBPrincipalAmountAndInterestAccrued" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBPrincipalAmountAndInterestAccrued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonrecurringIncomeExpense" xlink:label="loc_us-gaapOtherNonrecurringIncomeExpense" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapOtherNonrecurringIncomeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedPerTransaction" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedPerTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExpenseOrRevenueRecognized" xlink:label="loc_us-gaapClassOfWarrantOrRightExpenseOrRevenueRecognized" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExpenseOrRevenueRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares" xlink:label="loc_us-gaapSharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_PurchaseSharesOfCommonStock" xlink:label="loc_RENBPurchaseSharesOfCommonStock" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBPurchaseSharesOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaapConversionOfStockAmountConverted1" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockAmountConverted1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodShares" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1" xlink:label="loc_us-gaapNoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapNoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ExtinguishmentOfContingentConsiderationLiability" xlink:label="loc_RENBExtinguishmentOfContingentConsiderationLiability" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBExtinguishmentOfContingentConsiderationLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuable" xlink:label="loc_RENBBusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuable" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBBusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ReserveEscrowShares" xlink:label="loc_RENBReserveEscrowShares" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBReserveEscrowShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_StockIssuedToNonconsentingShareholders" xlink:label="loc_RENBStockIssuedToNonconsentingShareholders" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBStockIssuedToNonconsentingShareholders" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_UnrecognizedCompensationCostNonVested" xlink:label="loc_RENBUnrecognizedCompensationCostNonVested" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBUnrecognizedCompensationCostNonVested" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_DebtConversionConvertedInstrumentWarrantsOptionsIssued1" xlink:label="loc_RENBDebtConversionConvertedInstrumentWarrantsOptionsIssued1" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBDebtConversionConvertedInstrumentWarrantsOptionsIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:label="loc_us-gaapFairValueOptionChangesInFairValueGainLoss1" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapFairValueOptionChangesInFairValueGainLoss1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_StockOptionIssued" xlink:label="loc_RENBStockOptionIssued" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBStockOptionIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_UnrecognizedCompensationCost" xlink:label="loc_RENBUnrecognizedCompensationCost" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBUnrecognizedCompensationCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_PurchaseExercisableWarrantsOutstandingShares" xlink:label="loc_RENBPurchaseExercisableWarrantsOutstandingShares" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBPurchaseExercisableWarrantsOutstandingShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_WarrantsExercisablePurchaseValue" xlink:label="loc_RENBWarrantsExercisablePurchaseValue" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBWarrantsExercisablePurchaseValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_StockbasedCompensationExpense" xlink:label="loc_RENBStockbasedCompensationExpense" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBStockbasedCompensationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_StockbasedCompensationExpenseGrantShares" xlink:label="loc_RENBStockbasedCompensationExpenseGrantShares" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBStockbasedCompensationExpenseGrantShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_UnrecognizedStockbasedCompensationExpense" xlink:label="loc_RENBUnrecognizedStockbasedCompensationExpense" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBUnrecognizedStockbasedCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_AdvisoryServices" xlink:label="loc_RENBAdvisoryServices" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_RENBAdvisoryServices" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999062 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_GTechMember" xlink:label="loc_RENBGTechMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_RENBGTechMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_LicenseAgreementMember" xlink:label="loc_RENBLicenseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_RENBLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForFees" xlink:label="loc_us-gaapPaymentsForFees" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapPaymentsForFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_RoyaltyPercentage" xlink:label="loc_RENBRoyaltyPercentage" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_RENBRoyaltyPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_UpfrontPayment" xlink:label="loc_RENBUpfrontPayment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_RENBUpfrontPayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_PaymentForExpenditures" xlink:label="loc_RENBPaymentForExpenditures" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_RENBPaymentForExpenditures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_InitialPayment" xlink:label="loc_RENBInitialPayment" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_RENBInitialPayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="999063 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_MarkDybulMember" xlink:label="loc_RENBMarkDybulMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_RENBMarkDybulMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_RSBioMember" xlink:label="loc_RENBRSBioMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_RENBRSBioMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensationForfeited" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_SharesOfCommonStockGranted" xlink:label="loc_RENBSharesOfCommonStockGranted" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_RENBSharesOfCommonStockGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodShares" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_UnrecognizedCompensationExpense" xlink:label="loc_RENBUnrecognizedCompensationExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_RENBUnrecognizedCompensationExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/AcquisitionDetails" xlink:title="999064 - Disclosure - ACQUISITION (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BioSymetricsncAcquisitionMember" xlink:label="loc_RENBBioSymetricsncAcquisitionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_RENBBioSymetricsncAcquisitionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BusinessCombinationContingentConsiderationCommonStock" xlink:label="loc_RENBBusinessCombinationContingentConsiderationCommonStock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_RENBBusinessCombinationContingentConsiderationCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferred1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferred1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/AcquisitionDetails1" xlink:title="999065 - Disclosure - ACQUISITION (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BioSymetricsncAcquisitionMember" xlink:label="loc_RENBBioSymetricsncAcquisitionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_RENBBioSymetricsncAcquisitionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets" xlink:label="loc_RENBBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_RENBBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xlink:label="loc_RENBBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_RENBBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities" xlink:label="loc_RENBBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_RENBBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_Software" xlink:label="loc_RENBSoftware" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_RENBSoftware" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_TradeName" xlink:label="loc_RENBTradeName" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_RENBTradeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/AcquisitionDetails2" xlink:title="999066 - Disclosure - ACQUISITION (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BioSymetricsncAcquisitionMember" xlink:label="loc_RENBBioSymetricsncAcquisitionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_RENBBioSymetricsncAcquisitionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BusinessAcquisitionsRevenue" xlink:label="loc_RENBBusinessAcquisitionsRevenue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_RENBBusinessAcquisitionsRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BusinessAcquisitionsNetIncomeLoss" xlink:label="loc_RENBBusinessAcquisitionsNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_RENBBusinessAcquisitionsNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/AcquisitionDetails5" xlink:title="999067 - Disclosure - ACQUISITION (Details 5)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_GEDiCubeMember" xlink:label="loc_RENBGEDiCubeMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_RENBGEDiCubeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BusinessCombinationContingentConsiderationCommonStock" xlink:label="loc_RENBBusinessCombinationContingentConsiderationCommonStock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_RENBBusinessCombinationContingentConsiderationCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationAsset" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationAsset" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferred1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferred1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/AcquisitionDetails4" xlink:title="999068 - Disclosure - ACQUISITION (Details 4)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_GEDiCubeMember" xlink:label="loc_RENBGEDiCubeMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_RENBGEDiCubeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets" xlink:label="loc_RENBBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_RENBBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseRightOfUseAssets" xlink:label="loc_RENBBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseRightOfUseAssets" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_RENBBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseRightOfUseAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xlink:label="loc_RENBBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_RENBBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities" xlink:label="loc_RENBBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_RENBBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable" xlink:label="loc_RENBBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_RENBBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/AcquisitionDetails3" xlink:title="999069 - Disclosure - ACQUISITION (Details 3)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_GEDiCubeMember" xlink:label="loc_RENBGEDiCubeMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_RENBGEDiCubeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BusinessAcquisitionsRevenue" xlink:label="loc_RENBBusinessAcquisitionsRevenue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_RENBBusinessAcquisitionsRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BusinessAcquisitionsNetIncomeLoss" xlink:label="loc_RENBBusinessAcquisitionsNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_RENBBusinessAcquisitionsNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/AcquisitionsDetailsNarrative" xlink:title="999070 - Disclosure - ACQUISITIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaapBusinessAcquisitionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BioSymetricsMember" xlink:label="loc_RENBBioSymetricsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_RENBBioSymetricsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_GEDiCubeMember" xlink:label="loc_RENBGEDiCubeMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_RENBGEDiCubeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_TransactionIssuedShares" xlink:label="loc_RENBTransactionIssuedShares" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_RENBTransactionIssuedShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredOther1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferredOther1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferredOther1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="loc_us-gaapBusinessCombinationAcquisitionRelatedCosts" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionLineItems" xlink:to="loc_us-gaapBusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/SegmentReportingDetails" xlink:title="999071 - Disclosure - SEGMENT REPORTING (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="loc_srtStatementGeographicalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="loc_countryUS" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryUS" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BioSymetricsMember" xlink:label="loc_RENBBioSymetricsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_RENBBioSymetricsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_NL" xlink:label="loc_countryNL" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryNL" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_SegmentOperatingLoss" xlink:label="loc_RENBSegmentOperatingLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="loc_RENBSegmentOperatingLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_SegmentAsset" xlink:label="loc_RENBSegmentAsset" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="loc_RENBSegmentAsset" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/SegmentReportingDetails1" xlink:title="999072 - Disclosure - SEGMENT REPORTING (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaapSegmentReportingInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapSegmentReportingInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_RENBMember" xlink:label="loc_RENBRENBMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_RENBRENBMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_BioSymetricsMember" xlink:label="loc_RENBBioSymetricsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_RENBBioSymetricsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_RENCMember" xlink:label="loc_RENBRENCMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_RENBRENCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapOtherGeneralAndAdministrativeExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapOtherGeneralAndAdministrativeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetImpairment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetImpairment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_SegmentOperatingLoss" xlink:label="loc_RENBSegmentOperatingLoss" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_RENBSegmentOperatingLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://renovarobio.com/role/SubsequentEventsDetailsNarrative" xlink:title="999073 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ExchangeAgreementMember" xlink:label="loc_RENBExchangeAgreementMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_RENBExchangeAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ConvertiblePromissoryNoteMember" xlink:label="loc_RENBConvertiblePromissoryNoteMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_RENBConvertiblePromissoryNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_ConvertibleNotesMember" xlink:label="loc_RENBConvertibleNotesMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_RENBConvertibleNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_SaleOfStockConsiderationReceivedCashTransaction" xlink:label="loc_RENBSaleOfStockConsiderationReceivedCashTransaction" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_RENBSaleOfStockConsiderationReceivedCashTransaction" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="renb-20250630.xsd#RENB_InterestRate" xlink:label="loc_RENBInterestRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_RENBInterestRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Sep. 26, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--06-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">LUNAI BIOWORKS INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001527728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">45-2259340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2080 Century Park East<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Los Angeles<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">90067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(305)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">918-1980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RENB<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 111,903,627<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">231,802,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">3627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Sadler, Gibb & Associates, LLC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Draper,
UT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash</a></td>
<td class="nump">$ 92,700<span></span>
</td>
<td class="nump">$ 220,467<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceSettlementsReceivableCurrent', window );">Insurance receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,108,247<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investment in equity securities</a></td>
<td class="nump">387,851<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Prepaids and other assets</a></td>
<td class="nump">566,081<span></span>
</td>
<td class="nump">668,929<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">1,046,632<span></span>
</td>
<td class="nump">1,997,643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">367,843<span></span>
</td>
<td class="nump">482,121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>OTHER ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_DefiniteLifeIntangibleAssetsNet', window );">Definite life intangible assets, net</a></td>
<td class="nump">14,994<span></span>
</td>
<td class="nump">30,043<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareGross', window );">Software platform</a></td>
<td class="nump">143,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedTrademarksGross', window );">Trademarks</a></td>
<td class="nump">8,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">5,963,000<span></span>
</td>
<td class="nump">159,330,161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Deposits and other assets</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">19,849<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">687,371<span></span>
</td>
<td class="nump">1,269,633<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Total Other Assets</a></td>
<td class="nump">6,816,365<span></span>
</td>
<td class="nump">160,649,686<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">8,230,840<span></span>
</td>
<td class="nump">163,129,450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Accounts payable &#8211; trade</a></td>
<td class="nump">12,555,839<span></span>
</td>
<td class="nump">9,448,683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">5,843,069<span></span>
</td>
<td class="nump">5,311,324<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">378,282<span></span>
</td>
<td class="nump">295,361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_ContingentConsiderationLiabilityCurrent', window );">Contingent consideration liability</a></td>
<td class="nump">630,000<span></span>
</td>
<td class="nump">12,310,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible notes payable</a></td>
<td class="nump">245,000<span></span>
</td>
<td class="nump">245,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">313,047<span></span>
</td>
<td class="nump">493,553<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable</a></td>
<td class="nump">3,580,525<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_NotesPayableRelatedPartiesNetCurrent', window );">Notes payable &#8211; related parties, net</a></td>
<td class="nump">5,610,372<span></span>
</td>
<td class="nump">2,205,996<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">29,156,134<span></span>
</td>
<td class="nump">30,309,917<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>NON-CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">424,547<span></span>
</td>
<td class="nump">842,389<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total Non-Current Liabilities</a></td>
<td class="nump">424,547<span></span>
</td>
<td class="nump">842,389<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">29,580,681<span></span>
</td>
<td class="nump">31,152,306<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS&#8217; EQUITY (DEFICIT)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.0001, 350,000,000 shares authorized, 177,392,907 shares issued and outstanding at June 30, 2025; 158,452,644 shares issued and outstanding at June 30, 2024</a></td>
<td class="nump">17,741<span></span>
</td>
<td class="nump">15,847<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">478,280,146<span></span>
</td>
<td class="nump">464,587,224<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(510,462,570)<span></span>
</td>
<td class="num">(332,455,081)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive (loss)</a></td>
<td class="nump">10,814,842<span></span>
</td>
<td class="num">(170,846)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders&#8217; Equity (Deficit)</a></td>
<td class="num">(21,349,841)<span></span>
</td>
<td class="nump">131,977,144<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</a></td>
<td class="nump">$ 8,230,840<span></span>
</td>
<td class="nump">$ 163,129,450<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_ContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_ContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_DefiniteLifeIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_DefiniteLifeIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_NotesPayableRelatedPartiesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_NotesPayableRelatedPartiesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedTrademarksGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross carrying amount before accumulated amortization as of the balance sheet date for the rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style for a specified period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedTrademarksGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceSettlementsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due in settlement of a claim for reimbursement from an insurance company when the Company has suffered a loss covered under an insurance policy. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceSettlementsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">177,392,907<span></span>
</td>
<td class="nump">158,452,644<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">177,392,907<span></span>
</td>
<td class="nump">158,452,644<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 17,880,050<span></span>
</td>
<td class="nump">$ 24,557,608<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">537,428<span></span>
</td>
<td class="nump">2,708,829<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangible asset impairment</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">42,611,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">170,419,429<span></span>
</td>
<td class="nump">11,640,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">129,095<span></span>
</td>
<td class="nump">121,859<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total Operating Expenses</a></td>
<td class="nump">188,966,002<span></span>
</td>
<td class="nump">81,639,296<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">LOSS FROM OPERATIONS</a></td>
<td class="num">(188,966,002)<span></span>
</td>
<td class="num">(81,639,296)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other Income (Expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_ChangeInFairValueOfContingentConsideration', window );">Change in fair value of contingent consideration</a></td>
<td class="nump">11,680,000<span></span>
</td>
<td class="num">(3,048,183)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,303,578)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedLoss', window );">Change in fair value of equity securities</a></td>
<td class="num">(112,149)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(725,684)<span></span>
</td>
<td class="num">(1,011,322)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_InterestIncomeAndOtherIncomeExpense', window );">Interest income and other income (expense)</a></td>
<td class="nump">116,346<span></span>
</td>
<td class="num">(1,423,449)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total Other Income (Expense)</a></td>
<td class="nump">10,958,513<span></span>
</td>
<td class="num">(6,786,532)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
<td class="num">$ (178,007,489)<span></span>
</td>
<td class="num">$ (88,425,828)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">BASIC NET LOSS PER COMMON SHARE</a></td>
<td class="num">$ (1.08)<span></span>
</td>
<td class="num">$ (0.91)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">DILUTED NET LOSS PER COMMON SHARE</a></td>
<td class="num">$ (1.08)<span></span>
</td>
<td class="num">$ (0.91)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING - BASIC</a></td>
<td class="nump">165,061,967<span></span>
</td>
<td class="nump">97,511,557<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING - DILUTED</a></td>
<td class="nump">165,061,967<span></span>
</td>
<td class="nump">97,511,557<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_ChangeInFairValueOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_ChangeInFairValueOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_InterestIncomeAndOtherIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_InterestIncomeAndOtherIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized loss from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Loss</a></td>
<td class="num">$ (178,007,489)<span></span>
</td>
<td class="num">$ (88,425,828)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Other Comprehensive Income (Loss)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation, net of taxes</a></td>
<td class="nump">109,985,688<span></span>
</td>
<td class="num">(140,964)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive Loss</a></td>
<td class="num">$ (167,021,801)<span></span>
</td>
<td class="num">$ (88,566,792)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)<br></strong></div></th>
<th class="th"><div>Preferred Stock [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Jun. 30, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 6,371<span></span>
</td>
<td class="nump">$ 290,554,875<span></span>
</td>
<td class="num">$ (244,029,253)<span></span>
</td>
<td class="num">$ (29,882)<span></span>
</td>
<td class="nump">$ 46,502,111<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Jun. 30, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">63,698,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable', window );">Issuance of preferred stock and warrants for conversion of Note Payable</a></td>
<td class="nump">$ 28<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,999,973<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,000,001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_IssuanceOfPreferredStockAndWarrantsInPrivatePlacement', window );">Issuance of preferred stock and warrants in private placement</a></td>
<td class="nump">28<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,999,972<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_RestrictedSharesIssuedForServicesRenderedValue', window );">Restricted shares issued for services rendered</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">308<span></span>
</td>
<td class="nump">4,663,882<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,664,190<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_StockIssuedDuringPeriodValueExerciseOfWarrants', window );">Exercise of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">396<span></span>
</td>
<td class="nump">2,341,470<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,341,866<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue', window );">Issuance of common stock and warrants under private placement offering in settlement of debt</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">566<span></span>
</td>
<td class="nump">10,575,759<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">10,576,106<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_SharesIssuableForSettlementOfContingentConsiderationValue', window );">Shares issuable for settlement of contingent consideration</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">562<span></span>
</td>
<td class="nump">11,295,121<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">11,295,783<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_IssuanceOfCommonStockPursuantToAcquisitionOfGediCube', window );">Issuance of common stock pursuant to acquisition of GEDi Cube</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 7,083<span></span>
</td>
<td class="nump">135,994,548<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">136,001,631<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_IssuanceOfCommonStockPursuantAcquisitionOfGediCubeShares', window );">Issuance of common stock pursuant to acquisition of GEDi Cube, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,834,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube', window );">Preferred stock converted to common stock pursuant to acquisition of GEDi Cube</a></td>
<td class="num">$ (56)<span></span>
</td>
<td class="nump">$ 561<span></span>
</td>
<td class="num">(505)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCubeShares', window );">Preferred stock converted to common stock pursuant to acquisition of GEDi Cube, shares</a></td>
<td class="num">(561,010)<span></span>
</td>
<td class="nump">5,610,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of options for services rendered</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">489,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">489,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,673,129<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,673,129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(88,425,828)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(88,425,828)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(140,964)<span></span>
</td>
<td class="num">(140,964)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jun. 30, 2024</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 15,847<span></span>
</td>
<td class="nump">464,587,224<span></span>
</td>
<td class="num">(332,455,081)<span></span>
</td>
<td class="num">(170,846)<span></span>
</td>
<td class="nump">131,977,144<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Jun. 30, 2024</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">158,452,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_IssuanceOfCommonStockUnderPrivatePlacementOfferingValue', window );">Issuance of common stock under private placement offering</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 161<span></span>
</td>
<td class="nump">2,376,020<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,376,181<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_IssuanceOfCommonStockUnderPrivatePlacementOfferingShares', window );">Issuance of common stock under private placement offering, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,613,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationValue', window );">Restricted shares issued for services rendered and executive compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 316<span></span>
</td>
<td class="nump">1,946,529<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,946,845<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationShares', window );">Restricted shares issued for services rendered and executive compensation, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited', window );">Forfeited shares of common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="num">$ (83)<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited', window );">Forfeited shares of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(833,333)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_IssuanceOfCommonStockPursuantToAcquisitionValue', window );">Issuance of common stock pursuant to acquisition</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="nump">6,057,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,058,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_IssuanceOfCommonStockPursuantToAcquisitionShares', window );">Issuance of common stock pursuant to acquisition, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayableShares', window );">Issuance of preferred stock and warrants for conversion of Note Payable, shares</a></td>
<td class="nump">280,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_IssuanceOfPreferredStockAndWarrantsInPrivatePlacementShares', window );">Issuance of preferred stock and warrants in private placement, shares</a></td>
<td class="nump">280,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_RestrictedSharesIssuedForServicesRenderedShares', window );">Restricted shares issued for services rendered, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,083,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Exercise of warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,951,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtShares', window );">Issuance of common stock and warrants under private placement offering in settlement of debt, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,660,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_SharesIssuableForSettlementOfContingentConsideration', window );">Shares issuable for settlement of contingent consideration, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,615,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,313,291<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,313,291<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(178,007,489)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(178,007,489)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">10,985,688<span></span>
</td>
<td class="nump">10,985,688<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jun. 30, 2025</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 17,741<span></span>
</td>
<td class="nump">$ 478,280,146<span></span>
</td>
<td class="num">$ (510,462,570)<span></span>
</td>
<td class="nump">$ 10,814,842<span></span>
</td>
<td class="num">$ (21,349,841)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Jun. 30, 2025</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">177,392,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_IssuanceOfCommonStockPursuantAcquisitionOfGediCubeShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_IssuanceOfCommonStockPursuantAcquisitionOfGediCubeShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_IssuanceOfCommonStockPursuantToAcquisitionOfGediCube">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_IssuanceOfCommonStockPursuantToAcquisitionOfGediCube</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_IssuanceOfCommonStockPursuantToAcquisitionShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_IssuanceOfCommonStockPursuantToAcquisitionShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_IssuanceOfCommonStockPursuantToAcquisitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_IssuanceOfCommonStockPursuantToAcquisitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_IssuanceOfCommonStockUnderPrivatePlacementOfferingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_IssuanceOfCommonStockUnderPrivatePlacementOfferingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_IssuanceOfCommonStockUnderPrivatePlacementOfferingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_IssuanceOfCommonStockUnderPrivatePlacementOfferingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayableShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayableShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_IssuanceOfPreferredStockAndWarrantsInPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_IssuanceOfPreferredStockAndWarrantsInPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_IssuanceOfPreferredStockAndWarrantsInPrivatePlacementShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_IssuanceOfPreferredStockAndWarrantsInPrivatePlacementShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCubeShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCubeShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_RestrictedSharesIssuedForServicesRenderedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_RestrictedSharesIssuedForServicesRenderedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_RestrictedSharesIssuedForServicesRenderedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_RestrictedSharesIssuedForServicesRenderedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_SharesIssuableForSettlementOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_SharesIssuableForSettlementOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_SharesIssuableForSettlementOfContingentConsiderationValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_SharesIssuableForSettlementOfContingentConsiderationValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_StockIssuedDuringPeriodSharesExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_StockIssuedDuringPeriodSharesExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_StockIssuedDuringPeriodValueExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_StockIssuedDuringPeriodValueExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of forfeited shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (178,007,489)<span></span>
</td>
<td class="num">$ (88,425,828)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>ADJUSTMENTS TO RECONCILE NET LOSS TO NET CASH USED IN OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">129,095<span></span>
</td>
<td class="nump">121,859<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_ChangeInFairValueOfContingentConsideration', window );">Change in fair value of contingent consideration</a></td>
<td class="num">(11,680,000)<span></span>
</td>
<td class="nump">3,048,183<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedLoss', window );">Change in value of equity securities</a></td>
<td class="nump">112,149<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_LossOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,303,578<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_NoncashStockbasedCompensationExpense', window );">Non-cash stock-based compensation expense</a></td>
<td class="nump">3,313,291<span></span>
</td>
<td class="nump">4,673,129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_NoncashRestrictedSharesIssuedForServicesRendered', window );">Non-cash restricted shares issued for services rendered</a></td>
<td class="nump">1,946,845<span></span>
</td>
<td class="nump">4,664,190<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangible asset impairment</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">42,611,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">170,419,429<span></span>
</td>
<td class="nump">11,640,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_AmortizationOfDiscountOnNotePayable', window );">Amortization of discount on note payable</a></td>
<td class="nump">32,024<span></span>
</td>
<td class="nump">580,605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables', window );">Other receivables</a></td>
<td class="nump">1,153,768<span></span>
</td>
<td class="num">(1,108,247)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses/deposits</a></td>
<td class="nump">1,143,293<span></span>
</td>
<td class="nump">1,082,267<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">3,106,181<span></span>
</td>
<td class="nump">4,057,282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="num">(26,477)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating leases, net</a></td>
<td class="num">(16,086)<span></span>
</td>
<td class="nump">11,284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">499,330<span></span>
</td>
<td class="nump">4,769,268<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">NET CASH USED IN OPERATING ACTIVITIES</a></td>
<td class="num">(7,874,647)<span></span>
</td>
<td class="num">(10,971,430)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi', window );">Investment in equity securities</a></td>
<td class="num">(500,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireNotesReceivable', window );">Notes receivable prior to acquisition</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,255,600)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash received from acquisition, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">65,851<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(70,430)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">NET CASH USED IN INVESTING ACTIVITIES</a></td>
<td class="num">(500,000)<span></span>
</td>
<td class="num">(1,260,179)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_RepaymentsOfFinanceAgreement', window );">Repayments of finance agreement</a></td>
<td class="num">(971,231)<span></span>
</td>
<td class="num">(870,073)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">341,865<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from private placements</a></td>
<td class="nump">2,376,181<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of promissory notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,770,512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from notes payable</a></td>
<td class="nump">6,977,822<span></span>
</td>
<td class="nump">4,275,151<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">NET CASH PROVIDED BY FINANCING ACTIVITIES</a></td>
<td class="nump">8,382,772<span></span>
</td>
<td class="nump">10,517,455<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">&#160;Effect of exchange rates on cash</a></td>
<td class="num">(135,892)<span></span>
</td>
<td class="nump">60,141<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">NET INCREASE (DECREASE) IN CASH</a></td>
<td class="num">(127,767)<span></span>
</td>
<td class="num">(1,654,013)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH, BEGINNING OF PERIOD</a></td>
<td class="nump">220,467<span></span>
</td>
<td class="nump">1,874,480<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH, END OF PERIOD</a></td>
<td class="nump">92,700<span></span>
</td>
<td class="nump">220,467<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_CashPaidDuringYearForAbstract', window );"><strong>Cash Paid during the year for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="nump">24,555<span></span>
</td>
<td class="nump">20,128<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income Taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_ContingentSharesIssuedPursuantToAcquisitionAgreement', window );">Contingent Shares issued pursuant to Acquisition Agreement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_CancellationOfRestrictedStockAwards', window );">Cancellation of restricted stock awards</a></td>
<td class="nump">83<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_FinanceAgreementEnteredIntoInExchangeForPrepaidAssets', window );">Finance agreement entered into in exchange for prepaid assets</a></td>
<td class="nump">1,018,930<span></span>
</td>
<td class="nump">906,834<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_ConversionOfNotePayableForIssuanceOfPreferredStock', window );">Conversion of note payable for issuance of preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,000,001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_NotePayableSettledThroughNoncashExerciseOfWarrants', window );">Note payable settled through non-cash exercise of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_DebtDiscountRelatedToConvertiblePromissoryNotes', window );">Debt discount related to notes payable</a></td>
<td class="nump">24,954<span></span>
</td>
<td class="nump">339,342<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_CommonSharesIssuedUponAcquisition', window );">Common shares issued upon acquisition</a></td>
<td class="nump">6,058,500<span></span>
</td>
<td class="nump">136,001,631<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_ContingentConsiderationIssuedUponAcquisition', window );">Contingent consideration issued upon acquisition</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">20,557,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_CommonSharesIssuedUponSettlementOfDebt', window );">Common shares issued upon settlement of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,582,912<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_EarnOutSharesIssuedInSettlementOfContingentLiability', window );">Earn out shares issued in settlement of contingent liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,295,683<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_OptionsIssuedInSettlementOfDebt', window );">Options issued in settlement of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">489,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_SettlementOfNotesPayable', window );">Settlement of notes payable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 418,503<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_AmortizationOfDiscountOnNotePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_AmortizationOfDiscountOnNotePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_CancellationOfRestrictedStockAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_CancellationOfRestrictedStockAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_CashPaidDuringYearForAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_CashPaidDuringYearForAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_ChangeInFairValueOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_ChangeInFairValueOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_CommonSharesIssuedUponAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_CommonSharesIssuedUponAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_CommonSharesIssuedUponSettlementOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_CommonSharesIssuedUponSettlementOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_ContingentConsiderationIssuedUponAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_ContingentConsiderationIssuedUponAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_ContingentSharesIssuedPursuantToAcquisitionAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_ContingentSharesIssuedPursuantToAcquisitionAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_ConversionOfNotePayableForIssuanceOfPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_ConversionOfNotePayableForIssuanceOfPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_DebtDiscountRelatedToConvertiblePromissoryNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_DebtDiscountRelatedToConvertiblePromissoryNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_EarnOutSharesIssuedInSettlementOfContingentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_EarnOutSharesIssuedInSettlementOfContingentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_FinanceAgreementEnteredIntoInExchangeForPrepaidAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_FinanceAgreementEnteredIntoInExchangeForPrepaidAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_LossOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_LossOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_NoncashRestrictedSharesIssuedForServicesRendered">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_NoncashRestrictedSharesIssuedForServicesRendered</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_NoncashStockbasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_NoncashStockbasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_NotePayableSettledThroughNoncashExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_NotePayableSettledThroughNoncashExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_OptionsIssuedInSettlementOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_OptionsIssuedInSettlementOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_RepaymentsOfFinanceAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_RepaymentsOfFinanceAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_SettlementOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_SettlementOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized loss from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 321<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479567/321-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireNotesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireNotesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (178,007,489)<span></span>
</td>
<td class="num">$ (88,425,828)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text">During the Company&#8217;s fourth quarter, no director or officer&#160;<span id="xdx_90D_eecd--Rule10b51ArrAdoptedFlag_dbT_c20240701__20250630_zNMZNHlaqbMe"><span id="xdx_907_eecd--NonRule10b51ArrAdoptedFlag_dbT_c20240701__20250630_zXC75o3wEEg3">adopted&#160;</span></span>or&#160;<span id="xdx_907_eecd--Rule10b51ArrTrmntdFlag_dbT_c20240701__20250630_zu759zLP3aFh"><span id="xdx_90D_eecd--NonRule10b51ArrTrmntdFlag_dbT_c20240701__20250630_zYPLz5wyhTkd">terminated&#160;</span></span>a
Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_005"></span>1C. Cybersecurity Risk Management and Strategy</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Lunai has established a comprehensive cybersecurity
risk management program aimed at safeguarding the confidentiality, integrity, and availability of our essential systems and information.
Central to our cybersecurity efforts is a robust incident response plan designed to address potential cyber incidents swiftly and effectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In designing and evaluating our cybersecurity initiatives,
we have adopted the National Institute of Standards and Technology Cybersecurity Framework (NIST CSF 2.0) as a guiding principle. It&#8217;s
important to clarify that our use of the NIST CSF 2.0 is for guidance purposes to frame our risk identification, assessment, and management
processes and does not equate to compliance with any specific technical standards or requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_909_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_c20240701__20250630_zDLga0DalTY2">Our cybersecurity framework is seamlessly <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_902_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240701__20250630_zNhQtaEQyyN4">integrated
</span>broader enterprise risk management strategy, sharing methodologies, reporting mechanisms, and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_901_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20240701__20250630_zMZIGsSwP4Lj"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_909_ecyd--CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_dbT_c20240701__20250630_zW0Q3zUCKb87"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90D_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbT_c20240701__20250630_zFeXpLgHgOM3">governance structures</span></span></span> with other risk domains
including legal, compliance, strategic, operational, and financial risks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Key components of our cybersecurity risk management program include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_908_ecyd--CybersecurityRiskRoleOfManagementTextBlock_c20240701__20250630_zVmUDpMuvk8l">Conducting risk assessments to pinpoint <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90C_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_dbT_c20240701__20250630_zkWS6UoQT297">material</span> cybersecurity
    threats to our critical systems, data, products, services, and overall IT infrastructure.</span></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#9679;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A dedicated security team overseeing the risk assessment
    processes, maintenance of security controls, and coordination of responses to cybersecurity incidents.</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>





<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Engagement with external service providers to evaluate,
    enhance, or support our security measures.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive cybersecurity training programs for employees,
    incident responders, and senior management to foster a culture of security awareness.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An incident response plan outlining specific procedures
    for managing cybersecurity incidents.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A thorough third-party risk management process to evaluate
    and manage risks associated with service providers, suppliers, and vendors.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">To date, we have not identified any cybersecurity
threats or past incidents that have had, or are likely to have, a material impact on our company&#8217;s operations, business strategy,
financial performance, or results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&#160;</p>

<div class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_98F_ecyd--CybersecurityRiskBoardOfDirectorsOversightTextBlock_c20240701__20250630_zrWKq2PZKUOj">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Cybersecurity Governance:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The governance of cybersecurity risks is a critical
function of our Board of Directors, with the Audit Committee (the &#8220;Committee&#8221;) playing a key role in the oversight of cybersecurity
and related technology risks. The Committee is tasked with monitoring the effectiveness of our cybersecurity risk management program as
implemented by management.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The Committee receives regular updates from management
on the state of cybersecurity risks facing the company. This includes briefings on any significant cyber incidents and ongoing risk management
efforts. These updates enable the Committee to provide informed reports on cybersecurity matters to the full Board.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90B_ecyd--CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20240701__20250630_zBbYgFic1Y3l">Our Board is actively involved in our cybersecurity
oversight, receiving detailed briefings from internal technology teams or external cybersecurity experts. These sessions are part of the
Board&#8217;s commitment to continuous learning and staying informed about issues critical to public companies, including cybersecurity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The responsibility for day-to-day management of cybersecurity
risks lies with our management team, including the Chief Financial Officer. <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_909_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_c20240701__20250630_zftgl5LXRPv4">This team is at the forefront of our cybersecurity initiatives,
coordinating both internal and external resources to anticipate, identify, and mitigate cyber <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_900_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_dbT_c20240701__20250630_zs0rj4wsEPZa">threats</span>.</span> Our approach includes regular updates
from internal security teams, leveraging intelligence from various sources, and utilizing advanced security tools to protect our digital
environment.</p>

</div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text">Our cybersecurity framework is seamlessly <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_902_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240701__20250630_zNhQtaEQyyN4">integrated
</span>broader enterprise risk management strategy, sharing methodologies, reporting mechanisms, and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_901_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20240701__20250630_zMZIGsSwP4Lj"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_909_ecyd--CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_dbT_c20240701__20250630_zW0Q3zUCKb87"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90D_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbT_c20240701__20250630_zFeXpLgHgOM3">governance structures</span></span></span> with other risk domains
including legal, compliance, strategic, operational, and financial risks.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Cybersecurity Governance:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The governance of cybersecurity risks is a critical
function of our Board of Directors, with the Audit Committee (the &#8220;Committee&#8221;) playing a key role in the oversight of cybersecurity
and related technology risks. The Committee is tasked with monitoring the effectiveness of our cybersecurity risk management program as
implemented by management.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The Committee receives regular updates from management
on the state of cybersecurity risks facing the company. This includes briefings on any significant cyber incidents and ongoing risk management
efforts. These updates enable the Committee to provide informed reports on cybersecurity matters to the full Board.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90B_ecyd--CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20240701__20250630_zBbYgFic1Y3l">Our Board is actively involved in our cybersecurity
oversight, receiving detailed briefings from internal technology teams or external cybersecurity experts. These sessions are part of the
Board&#8217;s commitment to continuous learning and staying informed about issues critical to public companies, including cybersecurity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The responsibility for day-to-day management of cybersecurity
risks lies with our management team, including the Chief Financial Officer. <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_909_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_c20240701__20250630_zftgl5LXRPv4">This team is at the forefront of our cybersecurity initiatives,
coordinating both internal and external resources to anticipate, identify, and mitigate cyber <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_900_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_dbT_c20240701__20250630_zs0rj4wsEPZa">threats</span>.</span> Our approach includes regular updates
from internal security teams, leveraging intelligence from various sources, and utilizing advanced security tools to protect our digital
environment.</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">Our Board is actively involved in our cybersecurity
oversight, receiving detailed briefings from internal technology teams or external cybersecurity experts. These sessions are part of the
Board&#8217;s commitment to continuous learning and staying informed about issues critical to public companies, including cybersecurity.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text">Conducting risk assessments to pinpoint <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90C_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_dbT_c20240701__20250630_zkWS6UoQT297">material</span> cybersecurity
    threats to our critical systems, data, products, services, and overall IT infrastructure.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text">This team is at the forefront of our cybersecurity initiatives,
coordinating both internal and external resources to anticipate, identify, and mitigate cyber <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_900_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_dbT_c20240701__20250630_zs0rj4wsEPZa">threats</span>.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p id="xdx_800_eus-gaap--OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_zXBRMONLJ7el" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 1 &#8212; <span id="xdx_824_zC5Om9BGvJmf">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_845_ecustom--BusinessPolicyTextBlock_zYUaib2yJrql" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_86F_zWx8dfvOISIj">Business</span> &#8211; </b>On August 20, 2025, the Company changed its corporate name from Renovaro Inc.
to Lunai Bioworks Inc. (&#8220;Lunai&#8221;) On April 8, 2025, Lunai Bioworks Inc. acquired BioSymetrics, Inc. and its subsidiary (&#8220;BioSymetrics,
Corp.&#8221;), as a wholly owned subsidiary pursuant to a stock purchase agreement. On February 13, 2024, the Company changed its corporate
name from Renovaro Biosciences Inc. to Renovaro Inc. (&#8220;Renovaro&#8221;, and together with its subsidiaries, the &#8220;Company&#8221;,
&#8220;we&#8221; or &#8220;us&#8221;) and acquired GEDi Cube Intl Ltd and its subsidiaries (&#8220;Renovaro Cube&#8221;), as a wholly
owned subsidiary pursuant to a stock purchase agreement. In August 2023, the Company changed its corporate name from Enochian Biosciences
Inc. to Renovaro Biosciences Inc. The Company is an AI-driven platform for precision medicine, diagnostics, and biodefense. Its proprietary
technologies transform complex biomedical data into predictive insights, enabling faster discovery, greater accuracy, and strategic partnerships
across the life sciences and government sectors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_84E_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zkcuu00BbdI8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_86F_zEXXiiFIMlJ7">Basis of Presentation</span> &#8211;
</b>The Company prepares consolidated financial statements in accordance with accounting principles generally accepted in the United States
of America (&#8220;U.S. GAAP&#8221;) and follows the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_84C_eus-gaap--ConsolidationPolicyTextBlock_zrqS0OafGlp6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_865_z1KoBG5SEgYe">Principles of Consolidation</span>
&#8211; </b>For the years ended June 30, 2025 and 2024, the consolidated financial statements include the accounts and operations of Lunai,
and its wholly owned subsidiaries. All material inter-company transactions and accounts have been eliminated in the consolidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_84E_eus-gaap--ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_zpuJAViAAP6d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_862_zydL5jMJeb8k">Subsidiaries</span> &#8211; </b>Renovaro
Biosciences Inc. (&#8220;Renovaro Biosciences&#8221;), formerly Renovaro
Biopharma Inc., was incorporated on May 19, 2017 in Delaware and is a 100% owned subsidiary of Lunai. Renovaro Biosciences owns a perpetual,
fully paid-up, royalty-free, sublicensable, and sole and exclusive worldwide license to research, develop, use, sell, have sold, make,
have made, offer for sale, import and otherwise commercialize certain intellectual property in cellular therapies for the prevention,
treatment, amelioration of and/or therapy exclusively for HIV in humans, and research and development exclusively relating to HIV in humans.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Renovaro Biosciences Denmark ApS
(&#8220;Renovaro Denmark&#8221;), formerly Enochian Biosciences Denmark ApS a Danish corporation was incorporated on April 1, 2001. On
February 12, 2014, in accordance with the terms and conditions of a Share Exchange Agreement, the Company acquired Renovaro Denmark and
it became a 100% owned subsidiary of Lunai subject to 185,053 shares of Common Stock of Lunai held in escrow according to Danish law (the
&#8220;Escrow Shares&#8221;). As of June 30, 2025, there are 17,414 Escrow Shares remaining (see Note 10).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On February 13, 2024, the Company
acquired <span id="xdx_90F_ecustom--BusinessAcquisitionPercentage_iI_dp_c20240213__us-gaap--BusinessAcquisitionAxis__custom--RenovaroCubeMember_zzu7S4nWvqHk" title="Acquisition percentage">100</span>% of Renovaro Cube. As a result of the acquisition, Renovaro Cube became a wholly-owned subsidiary of the Company (see Note
13).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On April 8, 2025, the Company acquired
100% of Biosymetrics, Corp. As a result of the acquisition, Biosymetrics, Corp. became a wholly-owned subsidiary of the Company (see Note
13).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_844_eus-gaap--UseOfEstimates_z1PAWZOr1WM8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_860_z7ZmMRXloNK5">Use of Accounting Estimates</span>
</b>- The preparation of financial statements in conformity with generally accepted accounting principles requires management to make
estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities
at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could
differ from those estimated. Significant estimates include the fair value and potential impairment of intangible assets, the fair value
of the contingent consideration liability, and the fair value of equity instruments issued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>





<p id="xdx_845_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zyeZrTS2kLa6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_860_zM6CXfrzgW3j">Functional Currency and Foreign
Currency Translation</span> </b>&#8211; The functional currency of Renovaro Denmark is the Danish Kroner (&#8220;DKK&#8221;) and the functional
currency of Renovaro Cube is the Euro (&#8220;EUR&#8221;) and the functional currency of BioSymetrics Corp. is Canadian Dollar (&#8220;CAD&#8221;).
The Company&#8217;s reporting currency is the U.S. Dollar for the purpose of these financial statements. The Company&#8217;s balance sheet
accounts are translated into U.S. dollars at the period-end exchange rates and all revenue and expenses are translated into U.S. dollars
at the average exchange rates prevailing during the years ended June 30, 2025, and 2024. Translation gains and losses are deferred and
accumulated as a component of other comprehensive income in stockholders&#8217; equity. Transaction gains and losses that arise from exchange
rate fluctuations from transactions denominated in a currency other than the functional currency are included in the statement of operations
as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_84B_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z1pBNr7bNr16" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_864_zKkxoHpQUD82">Cash and Cash Equivalents</span> </b>&#8211;
The Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_84B_eus-gaap--ConcentrationRiskCreditRisk_zSp4CzxxGON3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_869_zG0cDF1nI7Df">Concentration of Credit Risk</span>
&#8211;</b> Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in financial
institutions, which, at times, exceed the amount of deposit insurance provided within the relevant jurisdiction where the deposits are
held. As of June 30, 2025, and June 30, 2024, the Company has not experienced losses on these accounts and management believes the Company
is not exposed to significant risks on such accounts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_848_ecustom--InvestmentinEquitySecuritiesPolicyTextBlock_zPhvPJ0FpCb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_86D_z4PxeoMQXEja">Investment in Equity Securities</span>
</b>&#8211; The Company accounts for investments in equity securities in accordance with ASC 321, Investments&#8212;Equity Securities.
Equity securities with readily determinable fair values are measured at fair value, with changes in fair value recognized in net income
or loss. Equity securities without readily determinable fair values are measured at cost, less impairment, if any, and adjusted for observable
price changes in orderly transactions for the identical or a similar investment of the same issuer. The Company evaluates such investments
at each reporting period for impairment or other observable transactions that would require adjustment. On February 28, 2025, the Company
purchased $<span id="xdx_90D_ecustom--PurchaseEquitySecuritiesValue_iI_c20250630_zdDehCdNLaYh" title="Purchase equity securities value">500,000</span> of equity securities. During the year ended June 30, 2025, the Company recorded a change in fair value of equity securities
for $<span id="xdx_904_eus-gaap--DebtSecuritiesTradingAndEquitySecuritiesFvNiCost_iI_c20250630_zAnM259h5M4b" title="Fair value of equity securities">112,149</span> (see Note 3). The investment in equity securities balance at June 30, 2025, was $<span id="xdx_903_eus-gaap--DebtAndEquitySecuritiesGainLoss_c20240701__20250630_z4DS7NglA2n7" title="Investment in equity securities">387,851</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_843_ecustom--InsuranceReceivablePolicy_z318v78IRBx3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_860_zSQo35l8z6Xh">Insurance Receivable</span> &#8211;</b>
The Company recognizes insurance receivables associated with expected recoveries of costs incurred for litigation which is probable of
incurring a loss and for which it is probable the Company will receive coverage under its existing insurance policies. The Company records
any such recoveries on a gross basis and does not net such amounts against any related loss contingency accruals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_846_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zPkradVek9Nk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_865_zZ0FLRKdTa8k">Property and Equipment</span> </b>-
Property and equipment are stated at cost. Expenditures for major renewals and betterments that extend the useful lives of property and
equipment are capitalized and depreciated upon being placed in service. Expenditures for maintenance and repairs are charged to expense
as incurred. Depreciation is computed for financial statement purposes on a straight-line basis over the estimated useful lives of the
assets, which range from four to ten years (see Note 5).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_84A_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zlQ0lARpwWP2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_862_zduFUJqHNupk">Intangible Assets</span> - </b>The
Company has both definite and indefinite life intangible assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Definite life intangible assets
relate to patents. The Company accounts for definite life intangible assets in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;)
Accounting Standards Codification (&#8220;ASC&#8221;) Topic 350, <i>Goodwill and Other Intangible Assets</i>. Intangible assets are recorded
at cost. Patent costs capitalized consist of costs incurred to acquire the underlying patent. If it is determined that a patent will not
be issued, the related remaining capitalized patent costs are charged to expense. Definite life intangible assets are amortized on a straight-line
basis over their estimated useful life. The estimated useful life of patents is twenty years from the date of application.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Indefinite life intangible assets
include license agreements and goodwill acquired in a business combination. The Company accounts for indefinite life intangible assets
in accordance with ASC 350. License agreement costs represent the fair value of the license agreement on the date acquired and are tested
annually for impairment on June 30 or whenever events or changes in circumstances indicate the fair value of the license is less than
the carrying amount.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_84E_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zppE3uZ4rs8l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_86A_zY6jWxzGpd27">Goodwill</span></b> - Goodwill is
not amortized but is evaluated for impairment annually as of June 30 or whenever events or changes in circumstances indicate the carrying
value of the reporting unit may be less than the fair value of the reporting unit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>





<p id="xdx_846_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_zUHEWWKhdzql" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_86A_zYdnNWAi0jOc">Impairment of Goodwill and
Indefinite Lived Intangible Assets</span></b> &#8211; We test for goodwill impairment at the reporting unit level, which is one level below the
operating segment level. Our detailed impairment testing involves comparing the fair value of each reporting unit to its carrying value,
including goodwill. Fair value reflects the price a market participant would be willing to pay in a potential sale of the reporting unit
and is based on discounted cash flows or relative market-based approaches. If the carrying value of the reporting unit exceeds its fair
value, we record an impairment loss for such excess.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the year ended June 30, 2025, the results of the assessment indicated that
the carrying value of the RENC reporting unit exceeded its fair value, due to the decline in the estimated fair value of the reporting
unit based on the Company&#8217;s market capitalization. Management concluded the significant driver for the change in the economic benefits
was due to the Company&#8217;s continued inability to raise capital for the further development of the technologies within this reporting
unit. The Company recorded an impairment loss of $<span id="xdx_900_ecustom--ImpairmentLoss_iI_c20240930_zvTM8vzNPVO1" title="Impairment loss">47,614,729</span> for the period ended September 30, 2024 and $<span id="xdx_90A_ecustom--ImpairmentLoss_iI_c20250630_zWUNhMmystdk" title="Impairment loss">122,804,700</span> for the period ended
June 30, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For indefinite life intangible
assets, such as IPR&amp;D, on an annual basis on June 30th we determine the fair value of the asset and record an impairment loss, if
any, for the excess of the carrying value of the asset over its fair value. For the year ended June 30, 2024, the carrying value of the
IPR&amp;D exceeded its fair value. Therefore, the Company recorded an impairment loss of $<span id="xdx_90C_ecustom--ImpairmentLoss_iI_c20240630_zS5WUF3ShNad" title="Impairment loss">42,611,000</span> during the year ended June 30, 2024.
During the year ended June 30, 2025, the Company recorded no impairment loss related to IPR&amp;D.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The carrying value of
IPR&amp;D and goodwill at June 30, 2025, were&#160;<span id="xdx_908_ecustom--InProcessResearchAndDevelopment_iI_c20250630_zj3R8xMjC70l" style="display: none" title="In-process research and development">0</span>
zero and $<span id="xdx_90B_eus-gaap--Goodwill_iI_c20250630_zsA8QKJf2cWd" title="Goodwill">5,963,000</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_84D_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zKn0gA0Hulw" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;<b><span id="xdx_862_zpCMsJFbXpTj">Impairment of Long-Lived
Assets</span> - </b>Long-lived assets, such as property and equipment and definite life intangible assets are reviewed for impairment whenever
events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Circumstances which could trigger
a review include, but are not limited to: significant decreases in the market price of the asset; significant adverse changes in the business
climate or legal factors; current period cash flow or operating losses combined with a history of losses or a forecast of continuing losses
associated with the use of the asset; and current expectations that the asset will more likely than not be sold or disposed of significantly
before the end of its estimated useful life.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Recoverability of assets to be
held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected
to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge
is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of would
be separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell and would
no longer be depreciated. The depreciable basis of assets that are impaired and continue in use are their respective fair values. <span id="xdx_901_eus-gaap--AssetImpairmentCharges_do_c20240701__20250630_z0oVRYKbcl5l" title="Impairment of assets"><span id="xdx_909_eus-gaap--AssetImpairmentCharges_do_c20230701__20240630_zMHxZhPQePZj" title="Impairment of assets">No</span></span> impairment
of these assets was recorded during the year ended June 30, 2025 or 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_84F_eus-gaap--LesseeLeasesPolicyTextBlock_zLsY70deoHF7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;<b><span id="xdx_86B_z3Yxf2ZBGssk">Leases</span> -</b> In accordance
with ASC Topic 842, the Company determined the initial classification and measurement of its right-of-use assets and lease liabilities
at the lease commencement date and thereafter. The lease terms include any renewal options and termination options that the Company is
reasonably assured to exercise, if applicable. The present value of lease payments is determined by using the implicit interest rate in
the lease, if that rate is readily determinable; otherwise, the Company develops an incremental borrowing rate based on the information
available at the commencement date in determining the present value of the future payments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Rent expense for operating leases
is recognized on a straight-line basis, unless the operating lease right-of-use assets have been impaired, over the reasonably assured
lease term based on the total lease payments and is included in general and administrative expenses in the consolidated statements of
operations. For operating leases that reflect impairment, the Company will recognize the amortization of the operating lease right-of-use
assets on a straight-line basis over the remaining lease term with rent expense still included in general and administrative expenses
in the consolidated statements of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>





<p id="xdx_842_eus-gaap--ResearchAndDevelopmentExpensePolicy_zYLdwUrdqhD9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_869_zaRzb8gbnWt8">Research and Development Expenses</span>
&#8211; </b>The Company expenses research and development costs incurred in formulating, improving, validating, and creating alternative
or modified processes related to and expanding the use of the Company&#8217;s technologies. Research and development expenses for the
years ended June 30, 2025 and 2024 amounted to $<span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20240701__20250630_zZJeJ1XukUpc" title="Research and development expense">537,428</span>, and $<span id="xdx_900_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230701__20240630_zkydk6f0dDki" title="Research and development expense">2,708,829</span> respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_zfMXOt5X8KO5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_862_z48fhTLPouia">Income Taxes</span> </b>- The Company
accounts for income taxes in accordance with FASB ASC Topic 740 Accounting for Income Taxes, which requires an asset and liability approach
for accounting for income taxes (see Note 9).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_845_eus-gaap--EarningsPerSharePolicyTextBlock_zFEfdTf7feMe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_86A_ziMuA0HBi456">Loss Per Share</span></b> - The Company
calculates earnings (loss) per share in accordance with FASB ASC 260 Earnings Per Share. Basic earnings per common share (EPS) are based
on the weighted average number of shares of Common Stock outstanding during each period. Diluted earnings per common share are based on
shares outstanding (computed as for basic EPS) and potentially dilutive common shares. Potential shares of Common Stock included in the
diluted earnings per share calculation include in-the-money stock options that have been granted but have not been exercised. The shares
of Common Stock outstanding at June 30, 2025 and 2024 were <span id="xdx_905_eus-gaap--CommonStockOtherSharesOutstanding_iI_c20250630_zMapRAqnrkA9" title="Common stock outstanding">177,392,907</span> and <span id="xdx_903_eus-gaap--CommonStockOtherSharesOutstanding_iI_c20240630_zaQnmzBUSFij" title="Common stock outstanding">158,452,644</span>, respectively. Because of the net loss for each
of the years ended June 30, 2025 and June 30, 2024, dilutive shares for both periods were excluded from the diluted EPS calculation, as
the effect of these potential shares of Common Stock is anti-dilutive. The Company had <span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240701__20250630_zScZFt79wZuh" title="Anti-dilutive shares">13,669,140</span> and <span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20240630_zhSvmErRFtTi" title="Anti-dilutive shares">17,146,315</span> potential shares of Common
Stock excluded from the diluted EPS calculation for the years ended June 30, 2025 and 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_84A_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zakJ3iM7cBMi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_86F_zNE5vRN0nSkg">Fair Value of Financial Instruments</span>
</b>&#8211; The Company accounts for fair value measurements for financial assets and financial liabilities in accordance with FASB ASC
Topic 820, &#8220;Fair Value Measurements&#8221;. The authoritative guidance, among other things, defines fair value, establishes a consistent
framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either
a recurring or nonrecurring basis. Fair value is defined as the exit price, representing the amount that would either be received to
sell an asset or be paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based
measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_84C_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zBv2wJW9shTb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;<b><span id="xdx_869_zLzKFsYnd3xa">Stock-Based Compensation</span>
- </b>The Company has granted stock options, restricted share units (&#8220;RSUs&#8221;) and warrants to certain employees, officers,
directors, and consultants. The Company accounts for options in accordance with the provisions of <b><i>FASB ASC Topic 718, Compensation
&#8211; Stock Compensation</i></b>. Stock based compensation costs for the vesting of options and RSUs granted to certain employees, officers,
directors, and consultants for the years ended June 30, 2025 and 2024 were $<span id="xdx_900_eus-gaap--ShareBasedCompensation_c20240701__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesOfficersDirectorsAndConsultantsMember_zzOV5taph179" title="Stock based compensation costs">3,313,291</span> and $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_c20230701__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesOfficersDirectorsAndConsultantsMember_z0Xu23kdrakh" title="Stock based compensation costs">4,673,129</span>, respectively<b>.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.2pt">The Company recognizes compensation
costs for stock option awards to employees, officers and directors based on their grant-date fair value. The value of each stock option
is estimated on the date of grant using the Black-Scholes option-pricing model. The weighted-average assumptions used to estimate the
fair value of the stock options granted using the Black-Scholes option-pricing model are the expected term of the award, the underlying
stock price volatility, the risk-free interest rate, and the expected dividend yield. The Company accounts for forfeitures as they occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.2pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company records stock-based
compensation for services received from non-employees in accordance with <b><i>ASC 718, Compensation&#8212;Stock Compensation Non-Employees</i></b>.
All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based
on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable.
Equity instruments issued to consultants and the cost of the services received as consideration are measured and recognized based on
the fair value of the equity instruments issued and are recognized over the consultants&#8217; required service period, which is generally
the vesting period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company does not have sufficient
historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior.
Accordingly, the Company has elected to use the &#8220;simplified method&#8221; to estimate the expected term of its share-based awards.
The simplified method computes the expected term as the sum of the award&#8217;s vesting term plus the original contractual term divided
by two.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zIzlraGROM96" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_86C_zlgwLRK4maNc">New Accounting Pronouncements
Not Yet Adopte</span>d</b> - Recent accounting pronouncements issued by the FASB that have not yet been adopted by the Company are not expected
to have a material impact on the Company&#8217;s present or future consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>





<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 250<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/250/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOING CONCERN<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">GOING CONCERN</a></td>
<td class="text"><p id="xdx_806_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zORVQ1TBu9Fk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 2 &#8211; <span id="xdx_82F_zGKnBM1iu628">GOING CONCERN</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s consolidated
financial statements are prepared using the generally accepted accounting principles applicable to a going concern, which contemplates
the realization of assets and liquidation of liabilities in the normal course of business. However, the Company has incurred substantial
recurring losses from continuing operations, has used cash in the Company&#8217;s continuing operations, and is dependent on additional
financing to fund operations. The Company incurred a net loss of $<span id="xdx_904_eus-gaap--NetIncomeLoss_iN_pp0p0_di_c20240701__20250630_zQ7AP2eX5xAk" title="Net loss">178,007,489</span> and $<span id="xdx_908_eus-gaap--NetIncomeLoss_iN_pp0p0_di_c20230701__20240630_z9VhM10puope" title="Net loss">88,425,828</span> for the years ended June 30, 2025 and 2024,
respectively. As of June 30, 2025, the Company had cash and cash equivalents of $<span id="xdx_909_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_c20250630_zLM5AcFUOiEg" title="Cash and cash equivalents">92,700</span> and an accumulated deficit of $<span id="xdx_906_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pp0p0_di_c20250630_zlXWnIcMzoPl" title="Accumulated deficit">510,462,570</span> and
a working capital deficit of $<span id="xdx_900_ecustom--WorkingCapitalDeficit_iI_pp0p0_c20250630_zEsDJ9rWAdm4" title="Working capital deficit">28,109,502</span>. These conditions raise substantial doubt about the Company&#8217;s ability to continue as a
going concern for one year after the date the financial statements are issued. The consolidated financial statements do not include any
adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be
necessary should the Company be unable to continue in existence.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Management has reduced overhead
and administrative costs by streamlining the organization to focus on the development and validation of its AI-driven cancer diagnostics
platform. The Company has tailored its workforce to focus on these activities. In addition, the Company intends to secure additional required
funding through equity or debt financing. However, there can be no assurance that the Company will be able to obtain any sources of funding.
Such additional funding may not be available or may not be available on reasonable terms, and, in the case of equity financing transactions,
could result in significant additional dilution to our stockholders. If we do not obtain required additional equity or debt funding, our
cash resources will be depleted and we could be required to materially reduce or suspend operations, which would likely have a material
adverse effect on our business, stock price and our relationships with third parties with whom we have business relationships, at least
until additional funding is obtained. If we do not have sufficient funds to continue operations, we could be required to seek bankruptcy
protection or other alternatives that could result in our stockholders losing some or all of their investment in us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Funding that we may receive during
the fiscal year 2026 is expected to be used to satisfy existing and future obligations and liabilities and working capital needs, to support
commercialization of our products, to conduct the clinical and regulatory work to develop our product candidates, and to begin building
working capital reserves.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205-40/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><p id="xdx_803_eus-gaap--FairValueMeasurementInputsDisclosureTextBlock_zutd0oyZKMol" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 3 &#8212; <span id="xdx_82F_zWDsZ5OpVgE6">FAIR VALUE MEASUREMENTS</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company accounts for fair
value measurements for financial assets and financial liabilities in accordance with FASB ASC Topic 820, &#8220;Fair Value Measurements&#8221;.
The authoritative guidance among other things, defines fair value, establishes a consistent framework for measuring fair value and expands
disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value
is defined as the exit price, representing the amount that would either be received to sell an asset or be paid to transfer a liability
in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based
on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the guidance
establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Level 1. Observable inputs such as quoted prices in active markets for identical assets or liabilities; </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="vertical-align: top; width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Level 2. Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="vertical-align: top; width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">There were no Level 2 and 3 assets,
or any Level 1 or 2 liabilities as of June 30, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Unless otherwise disclosed, the
fair value of the Company&#8217;s financial instruments including cash, accounts receivable, prepaid expenses, accounts payable, accrued
expenses, lease obligations and notes payable approximate their recorded values due to their short-term maturities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Level 1 assets held as of June
30, 2025, consisted of an investment in equity securities related to an extension agreement entered on February 28, 2024<span style="background-color: white">.
The Company purchased <span id="xdx_909_eus-gaap--StockRepurchasedDuringPeriodShares_c20240701__20250630__us-gaap--StatementClassOfStockAxis__custom--CommonStocksMember_zA3ftsTJhGwa" title="Purchased shares of common stock">467,290</span> shares of common stock at a purchase price of $<span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_c20250630__us-gaap--StatementClassOfStockAxis__custom--CommonStocksMember_zERKJoEbLkmi" title="Purchase price">1.07</span> per share. The investment in equity securities was recorded
at a fair value of $<span id="xdx_90F_eus-gaap--EquitySecuritiesFvNiCost_iI_c20250630__us-gaap--StatementClassOfStockAxis__custom--CommonStocksMember_zZz0ZTkeuXN9" title="Fair value of equity securities">500,000</span> at the time of purchase and is subsequently remeasured to fair value at the end of each reporting period.
As of June 30, 2025, the Company held <span id="xdx_90F_ecustom--InvestmentEquitySecuritiesShares_iI_c20250630__us-gaap--StatementClassOfStockAxis__custom--CommonStocksMember_zdPwRGfDhOT1" title="investment  equity securities shares">467,290</span> shares of common stock in connection with the investment in equity securities. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Level 3 liabilities held as of
June 30, 2025, consisted of a contingent consideration liability related to the February 13, 2024 acquisition of <span style="background-color: white">Renovaro
Cube, (the &#8220;Acquisition&#8221;). As consideration for the Acquisition, the stockholders of Renovaro Cube received (i) <span id="xdx_90C_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c20250212__20250213__us-gaap--BusinessAcquisitionAxis__custom--RenovaroCubeMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zcUTErZOEbRi" title="Contingent shares issuable in connection with the acquisition">70,834,183</span>
shares of Common Stock, and (ii) the right to receive up to <span id="xdx_90D_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c20250212__20250213__us-gaap--BusinessAcquisitionAxis__custom--RenovaroCubeMember__us-gaap--StatementClassOfStockAxis__custom--ConvertibleNotesMember_zbl4B3pUVHdd" title="Contingent shares issuable in connection with the acquisition">11,899,545</span> contingent shares pro rata upon the exercise of convertible notes,
options, and warrants, which were outstanding at closing. The contingent consideration liability was recorded at fair value of $<span id="xdx_90E_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_c20250213__us-gaap--BusinessAcquisitionAxis__custom--RenovaroCubeMember_zyzRa4uGa3t8" title="Contingent consideration liability was recorded at fair value">20,557,500</span>
at the time of the Acquisition and is subsequently remeasured to fair value at the end of each reporting period. As of June 30, 2025,
there were <span id="xdx_90E_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c20240701__20250630__us-gaap--BusinessAcquisitionAxis__custom--RenovaroCubeMember_zb9LuVVHfoIc" title="Contingent shares issuable in connection with the acquisition">2,775,650</span> contingent shares issuable in connection with the Acquisition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s assets and
liabilities measured at fair value on recurring bases as of June 30, 2025 were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_z2jvxTefkOie" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt"><span id="xdx_8B7_zTaUZdgmxFHb" style="display: none">Schedule of assets and
liabilities measured at fair value on recurring bases</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_499_20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zQzvXgkEBbQ" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49A_20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zEsjnT6mDvcc" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49D_20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zuh9bP385oC4" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value Measurements at<br/> Reporting Date Using</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-indent: -10pt; padding-left: 10pt">Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--EquitySecuritiesFvNi_iI_zcG3r0N1i5Ia" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Investment in equity securities</td><td style="width: 5%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">387,851</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 5%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0772">&#8212;</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 5%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0773">&#8212;</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AccruedLiabilitiesFairValueDisclosure_iI_zFAPaLuCkqGc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Total assets at fair value</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">387,851</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0776">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0777">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-indent: -10pt; padding-left: 10pt">Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ContingentConsiderationClassifiedAsEquityFairValueDisclosure_iI_zByKpBBRISY2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Contingent consideration</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0779">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0780">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">630,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DerivativeFairValueOfDerivativeLiability_iI_zeFlGaeTvPDg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Total liabilities at fair value</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0783">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0784">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">630,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8A2_zESIYL92M3dg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The fair value of the contingent
consideration liability is estimated using a Black-Scholes option-pricing model and a Monte-Carlo option pricing model. The key inputs
to the model are all contractual or observable with the exception being volatility, which is computed based on the volatility of the Company&#8217;s
underlying stock. The key inputs to valuing the contingent consideration liability as of June 30, 2025, were:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--FairValueConcentrationOfRiskTextBlock_z9h8AL4mIza1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B0_zvM5tZevQ8A6" style="display: none">Schedule of key input to valuing the
contingent consideration liability</span> </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-indent: -10pt">Stock Price</td><td style="width: 10%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 18%; text-align: right"><span id="xdx_901_eus-gaap--SharePrice_iI_pip0_c20250630__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_z7AWelG40Uq8" title="Stock Price">0.29</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Exercise Price</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">$<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pip0_c20250630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zvLRxaPuJjx5" title="Exercise Price">0.53</span> - $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pip0_c20250630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zdEwZKSKFTF6" title="Exercise Price">1.92</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Volatility</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20240701__20250630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zB66ZpszDMN4" title="Volatility">116</span>% - <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20240701__20250630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_znPOfT17uTp5" title="Volatility">141</span>%</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Risk Free Rate</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20240701__20250630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zbcy1swkb2H9" title="Risk Free Rate">3.61</span>% - <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20240701__20250630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zTIaRnl1D08k" title="Risk Free Rate">4.02</span>%</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Expected Dividends</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20240701__20250630__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_ze9cCHjxT9Ya" title="Expected Dividends">0</span></td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Discount Rate (Monte-Carlo model only)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate_pip0_dp_c20240701__20250630__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_z66eiy3IqZqb" title="Discount Rate (Monte-Carlo model only)">0</span></td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Expected Term (years)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240701__20250630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zL8pzYmdMZq" title="Expected Term (years)">2.70</span> &#8211;<span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240701__20250630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zKGilmjz5Yhb" title="Expected Term (years)"> 8.38</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At initial recognition of the contingent consideration,
the inputs were:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-indent: -10pt">Stock Price</td><td style="width: 10%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 18%; text-align: right"><span id="xdx_909_eus-gaap--SharePrice_iI_pip0_c20250630__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_z2wyC1dnZCZ7" title="Stock Price">1.92</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Exercise Price</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">$<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pip0_c20250630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zsR9QLQztrJ4" title="Exercise Price">0.46</span> - $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pip0_c20250630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zTkAmBRGujaa" title="Exercise Price">4.50</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Volatility</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20240701__20250630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zyTHaNhBnsTd" title="Volatility">107</span>% - <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20240701__20250630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_z7TkkYwypWI7" title="Volatility">133</span>% </span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Risk Free Rate</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20240701__20250630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zO5IUsIsnpgi" title="Risk Free Rate">4.22</span>% - <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20240701__20250630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zYhvR1yEwEdl" title="Risk Free Rate">5.14</span>%</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Expected Dividends</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20240701__20250630__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zKNk75opeJU4" title="Expected Dividends">0</span></td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Discount Rate (Monte-Carlo model only)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate_pip0_dp_c20240701__20250630__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zd2uyHoAiima" title="Discount Rate (Monte-Carlo model only)">12</span></td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Expected Term (years)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240701__20250630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_z4tNQ2OULmz6" title="Expected Term (years)">0.56</span> &#8211; <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240701__20250630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zNmm9snjaAQ7" title="Expected Term (years)">9.88</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AE_zXrFA4k8MP92" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The following table sets forth the Level 3 liability
at June 30, 2025, which is recorded on the consolidated balance sheet at fair value on a recurring basis. As required, this liability
is classified based on the lowest level of input that is significant to the fair value measurement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><b>The roll forward of contingent consideration liability
is as follows:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_894_ecustom--ScheduleOfContingentConsiderationLiabilityTableTextBlock_z6kiE8CH7ob2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt"><span id="xdx_8BF_z7Ro7lNVSB5i" style="display: none">Schedule of fair value measurement on recurring basis</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49F_20240701__20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zbcmlYNu04xa" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49C_20240701__20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zTHGQ9VNTKx1" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_496_20240701__20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zV3BlZEzgj34" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value Measurements at<br/> Reporting Date Using</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Quoted Prices in <br/> Active Markets for Identical Assets Inputs</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Significant Other <br/> Observable Inputs</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Significant Other Unobservable Inputs</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 1)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 2)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 3)</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">The roll forward of the contingent consideration liability is as follows:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--BusinessCombinationContingentConsiderationLiability_iS_d0_zbQGZBKugltc" style="vertical-align: bottom; background-color: White">
    <td style="width: 46%; text-indent: -10pt; padding-left: 10pt">Balance June 30, 2024</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">12,310,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LiabilitiesFairValueAdjustment_d0_zFUffL1kEte5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Fair value adjustment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(11,680,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--BusinessCombinationContingentConsiderationLiability_iE_d0_z9kYfPmHC4L" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Contingent Consideration Liability at June 30, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">630,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>



<p id="xdx_8AA_zXxFcBipTzd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/820/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementInputsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text"><p id="xdx_805_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zxl19FJXkld9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 4 - <span id="xdx_823_zKpHywtfHgRl">PROPERTY AND EQUIPMENT</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Property and equipment consisted of the following at
June 30, 2025 and 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_886_eus-gaap--PropertyPlantAndEquipmentTextBlock_zdkXhz1M3JWc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PROPERTY AND EQUIPMENT (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B1_zRY6zMpgJIYd" style="display: none">Schedule of Property and equipment</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Useful Life</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2025</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2024</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt">Lab equipment and instruments</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: center"><span style="font-size: 10pt"><span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20250630__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentAndInstrumentsMember_z1cwyeI9Mxdl" title="Useful Life">4</span>-<span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20250630__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentAndInstrumentsMember_zfHQFKzYqhD3" title="Useful Life">7</span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentGross_pp0p0_c20250630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentAndInstrumentsMember_zsQiSUjKqOX5" style="width: 11%; text-align: right" title="Total">639,998</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_pp0p0_c20240630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentAndInstrumentsMember_zEnrdRZwSEQ8" style="width: 11%; text-align: right" title="Total">639,998</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20250630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zxFk7F40U1A1" title="Useful Life">10</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_pp0p0_c20250630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zwMVpHRLeBY7" style="text-align: right" title="Total">224,629</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_pp0p0_c20240630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zQI2prmRptC1" style="text-align: right" title="Total">224,629</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Furniture, fixtures, and equipment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt"><span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20250630__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_z9j8Mw96hsWl" title="Useful Life">4</span>-<span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20250630__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_z7GXQciyftgg" title="Useful Life">7</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_pp0p0_c20250630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zCYF512hkL1f" style="border-bottom: Black 1pt solid; text-align: right" title="Total">205,396</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_pp0p0_c20240630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zXDEbVL2Eqfe" style="border-bottom: Black 1pt solid; text-align: right" title="Total">195,834</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_pp0p0_c20250630_zyhEYxV1OOD6" style="text-align: right" title="Total">1,070,023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_pp0p0_c20240630_zKSQ8OYf06tg" style="text-align: right" title="Total">1,060,461</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Less accumulated depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20250630_zBuzJe4yqVb" style="border-bottom: Black 1pt solid; text-align: right" title="Less Accumulated Depreciation">(702,180</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20240630_znx8NEzgYOa5" style="border-bottom: Black 1pt solid; text-align: right" title="Less Accumulated Depreciation">(578,340</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net Property and Equipment</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: center">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentNet_pp0p0_c20250630_zb0XkweEblt5" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Property and Equipment">367,843</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentNet_pp0p0_c20240630_zgqY1LLvXHw2" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Property and Equipment">482,121</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Depreciation expense amounted
to $<span id="xdx_905_eus-gaap--Depreciation_pp0p0_c20240701__20250630_zQV36t4Ync48" title="Depreciation expense">119,193</span> and $<span id="xdx_905_eus-gaap--Depreciation_pp0p0_c20230701__20240630_zvoiiJw49Xve" title="Depreciation expense">113,563</span> for the years ended June 30, 2025 and 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS AND GOODWILL</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--IntangibleAssetsDisclosureTextBlock_z83twAFzGaPi" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 5 &#8212; <span id="xdx_824_zwtUXnKln0Ad">INTANGIBLE ASSETS AND GOODWILL</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">At June 30, 2025, definite-life
intangible assets, net of accumulated amortization, consisted of patents, software platform and trademarks on the Company&#8217;s products
and processes of $<span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20250630__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zWoKJkZq8fcj" title="Definite-life intangible assets">14,994</span>, $<span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20250630__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_zat8g1b9D78h" title="Definite-life intangible assets">143,000</span> and $<span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_zYrDsOvImAKd" title="Definite-life intangible assets">8,000</span>. At June 30, 2024, definite-life intangible assets, net of accumulated amortization, consisted
of patents on the Company&#8217;s products and processes of $<span id="xdx_902_eus-gaap--AccumulatedAmortizationOfCurrentDeferredFinanceCosts_iI_c20240630_zOk7N08mioSl" title="Accumulated amortization cost">30,043</span>. The patents are recorded at cost and amortized over twenty years
from the date of application. Amortization expense for the years ended June 30, 2025 and 2024 was $<span id="xdx_90E_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20240701__20250630_z2DcqlhMhexi" title="Amortization expense">9,902</span> and $<span id="xdx_90B_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20230701__20240630_zx5sRbE5vp4d" title="Amortization expense">8,296</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">At June 30, 2025 and 2024, indefinite
life intangible assets consisted of a license agreement classified as In-Process Research and Development (&#8220;IPR&amp;D&#8221;) intangible
assets, which are not amortizable until the intangible assets provide economic benefit, and goodwill.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">At June 30, 2025 and 2024, definite-life
and indefinite-life intangible assets consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zxS1O5kteR7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B3_zFdrFns2PjV7" style="display: none">Schedule of definite-life
and indefinite-life intangible assets</span></td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Useful Life</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2024</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">&#160;<b>Additions</b></span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">&#160;<b>Amortization</b></span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">&#160;<b>Impairment</b></span></td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Translation Adjustment</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2025</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 18%; font-weight: bold; text-align: left; text-indent: -10pt">Definite Life Intangible Assets</td><td style="width: 2%">&#160;</td>
    <td style="text-align: center; width: 8%; padding-left: 5.4pt">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Software platform</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_zKDgw0CvNEa1" title="Useful life">5</span> Years</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_zJGoDYDERBOk" style="text-align: right" title="Net definite-life intangible assets at beginning"><span style="-sec-ix-hidden: xdx2ixbrl0909">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_zLTbAOW8wDei" style="text-align: right" title="Net definite-life intangible assets, Additions">143,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_d0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_zFKC0eOjohHl" style="text-align: right" title="Net definite-life intangible assets, Amortization">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_zuln89l3Uto1" style="text-align: right" title="Net definite-life intangible assets, Impairment">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_zFoqaOz3XOr3" style="text-align: right" title="Net definite-life intangible assets, Translation adjustment"><span style="-sec-ix-hidden: xdx2ixbrl0917">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_zxO255rBSjQ8" style="text-align: right" title="Net definite-life intangible assets at ending">143,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Trademark</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_z02VLJxSHsb9" title="Useful life">2</span> Years</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_zgQbP6Vi2M4g" style="text-align: right" title="Net definite-life intangible assets at beginning"><span style="-sec-ix-hidden: xdx2ixbrl0923">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_zofiC2jNydfc" style="text-align: right" title="Net definite-life intangible assets, Additions">8,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_d0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_zlfmDMvRsokk" style="text-align: right" title="Net definite-life intangible assets, Amortization">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_zXapNlDBbgzi" style="text-align: right" title="Net definite-life intangible assets, Impairment">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_zVQeZjfLLNS7" style="text-align: right" title="Net definite-life intangible assets, Translation adjustment"><span style="-sec-ix-hidden: xdx2ixbrl0931">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_zR1tYG7DguW5" style="text-align: right" title="Net definite-life intangible assets at ending">8,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Patents</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zIabVC9iVBwe" title="Useful life">20</span> Years</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zI94aHMbOyM" style="text-align: right" title="Net definite-life intangible assets at beginning">284,977</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zOLRsLLVq87h" style="text-align: right" title="Net definite-life intangible assets, Additions">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_d0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zz7N5EZrcuii" style="text-align: right" title="Net definite-life intangible assets, Amortization">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zvaP3kU1OSU6" style="text-align: right" title="Net definite-life intangible assets, Impairment">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zYwTZH1bJS6e" style="text-align: right" title="Net definite-life intangible assets, Translation adjustment">28,033</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zGx1XQ5ijRC3" style="text-align: right" title="Net definite-life intangible assets at ending">313,010</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Less Accumulated Amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt; padding-left: 5.4pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zvRV4WPb7Xpb" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets at beginning">(254,934</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_z5CgLFnFELmi" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Additions">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_z4kzqeRSI9y1" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Amortization">(9,902</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_z2gDFxhwFlNf" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Impairment">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zgrxQKogzR7h" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Translation adjustment">(33,180</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zvlmX4hnJiV3" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets at ending">(298,016</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Net Definite-Life Intangible Assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt; padding-left: 5.4pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20240701__20250630_zrPSE28IG2M3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets at beginning">30,043</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20240701__20250630_z3QafijyuGbf" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Additions">151,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_c20240701__20250630_zv5BPUhvgFa8" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Amortization">(9,902</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20240701__20250630_zauppiG9kKOh" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Impairment">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20240701__20250630_z0ED7xf0gSJ8" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Translation adjustment">(5,147</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20240701__20250630_z7NHUSlScmS4" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets at ending">165,994</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-indent: -10pt">Goodwill</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Goodwill</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zYQ7stsJmGeg" style="text-align: right" title="Total indefinite life intangible assets and goodwill at beginning">159,330,161</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zjcbBxKVEHjd" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Additions">5,963,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillAmortization_pp0p0_d0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zZWCBJDFqvye" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Amortization">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillImpairment_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zp9sqSLEORah" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Impairment">(170,419,429</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zwdneV1Ax3zb" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Translation adjustment">11,089,268</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iE_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_z9lzaKaMF8b7" style="text-align: right" title="Total indefinite life intangible assets and goodwill at ending">5,963,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Total Goodwill</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt; padding-left: 5.4pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20240701__20250630_zckWwmOVPp4" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill at beginning">159,330,161</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_c20240701__20250630_zcmJwXWeGib5" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Additions">5,963,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillAmortization_pp0p0_d0_c20240701__20250630_zR5l2f7KZ3d4" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Amortization">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillImpairment_pp0p0_c20240701__20250630_z5CmQQHJHznb" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Impairment">(170,419,429</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20240701__20250630_zKwEnw7E9pOd" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Translation adjustment">11,089,268</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iE_pp0p0_c20240701__20250630_z6SB979hjI9f" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill at ending">5,963,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Useful Life</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">&#160;<b>Additions</b></span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">&#160;<b>Amortization</b></span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">&#160;<b>Impairment</b></span></td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Translation Adjustment</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2024</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Definite Life Intangible Assets</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 18%; text-indent: -10pt">Patents</td><td style="width: 2%">&#160;</td>
    <td style="width: 8%; text-align: center; padding-left: 5.4pt"><span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zwcPlFDYIuZf" title="Useful life">20</span> Years</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zfEb16zeTnj2" style="width: 8%; text-align: right" title="Net definite-life intangible assets at beginning">290,936</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zJ7fAgtfGv37" style="width: 8%; text-align: right" title="Net definite-life intangible assets, Additions">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zjPYMFp1vs98" style="width: 8%; text-align: right" title="Net definite-life intangible assets, Amortization">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zAiLki89dtH6" style="width: 8%; text-align: right" title="Net definite-life intangible assets, Impairment">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z5AiMHi03suf" style="width: 8%; text-align: right" title="Net definite-life intangible assets, Translation adjustment">(5,959</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zLGY4yuJEExi" style="width: 8%; text-align: right" title="Net definite-life intangible assets at ending">284,977</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Less Accumulated Amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt; padding-left: 5.4pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zJol2J4hyr3l" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets at beginning">(251,260</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zrnuJuLKfwki" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Additions">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zEibEadINif8" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Amortization">(8,296</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zdE5db2anRIe" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Impairment">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zggvI2ANGL5e" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Translation adjustment">4,622</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zrB8QScOP5k1" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets at ending">(254,934</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Net Definite-Life Intangible Assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt; padding-left: 5.4pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20230701__20240630_z5Arwfkpf5yb" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets at beginning">39,676</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20230701__20240630_zW3vXIX6Agq7" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Additions">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_c20230701__20240630_ztF926anJYla" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Amortization">(8,296</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20230701__20240630_zfzCmbhysTHb" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Impairment">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20230701__20240630_zc0TlrPaLLg8" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Translation adjustment">(1,337</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20230701__20240630_zGu7SYVAdEBj" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets at ending">30,043</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Indefinite Life Intangible Assets and Goodwill</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Goodwill</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zB2jSfWy2ld2" style="text-align: right" title="Total indefinite life intangible assets and goodwill at beginning">11,640,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zDU1gbDrif4j" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Additions">159,464,039</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillAmortization_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zUBT57FkhyX" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Amortization">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillImpairment_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zd4CqzoBjYFl" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Impairment">(11,640,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zNeFETdRY1ia" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Translation adjustment">(133,878</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iE_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zrlt65boy9Aj" style="text-align: right" title="Total indefinite life intangible assets and goodwill at ending">159,330,161</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">IPR&amp;D</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt; padding-left: 5.4pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zjsS956KFFuk" style="border-bottom: Black 1pt solid; text-align: right" title="Total indefinite life intangible assets and goodwill at beginning">42,611,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_z0Ss2Apml1J1" style="border-bottom: Black 1pt solid; text-align: right" title="Total indefinite life intangible assets and goodwill, Additions">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillAmortization_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zGJ8NJgKfiX1" style="border-bottom: Black 1pt solid; text-align: right" title="Total indefinite life intangible assets and goodwill, Amortization">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillImpairment_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zgMLOlPFRta3" style="border-bottom: Black 1pt solid; text-align: right" title="Total indefinite life intangible assets and goodwill, Impairment">(42,611,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zASnIycpGfsf" style="border-bottom: Black 1pt solid; text-align: right" title="Total indefinite life intangible assets and goodwill, Translation adjustment">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iE_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zoHKP38JxOtc" style="border-bottom: Black 1pt solid; text-align: right" title="Total indefinite life intangible assets and goodwill at ending">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Total Indefinite Life Intangible Assets and Goodwill</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt; padding-left: 5.4pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20230701__20240630_z2LoUc1O8Cjl" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill at beginning">54,251,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_c20230701__20240630_z2L7zbO8iEne" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Additions">159,464,039</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillAmortization_pp0p0_d0_c20230701__20240630_zV0JSbNWMYhe" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Amortization">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillImpairment_pp0p0_c20230701__20240630_zSI9EOJ7LZ3i" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Impairment">(54,251,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20230701__20240630_zFwhJXemLzF4" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Translation adjustment">(133,878</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iE_pp0p0_c20230701__20240630_zczZFCtZTPe1" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill at ending">159,330,161</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AF_z64nXS896v6l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Expected future amortization expense is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zrffr1Kb1ul7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B9_zucCgOr290Jb" style="display: none">Schedule of future amortization expense</span></td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Years
    ended&#160;June 30,</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 73%; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2026</span></td><td style="width: 10%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pp0p0_c20250630_zgWunGgaLwWc" style="width: 15%; font-size: 10pt; text-align: right" title="2026"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36,350</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2027</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pp0p0_c20250630_zujEcm2NjZHc" style="font-size: 10pt; text-align: right" title="2027"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36,348</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2028</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pp0p0_c20250630_zI2kCElHpZG6" style="font-size: 10pt; text-align: right" title="2028"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32,348</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2029</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pp0p0_c20250630_z9rB87fMI4L" style="font-size: 10pt; text-align: right" title="2029"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32,348</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thereafter</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pp0p0_c20250630_zQPwDE569wN" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Thereafter"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28,600</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20250630_zC5XSMIb2DUd" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">165,994</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>



<p id="xdx_8AF_zsVcX84tJLHe" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On February 13, 2024, the Company
acquired Renovaro Cube as a wholly owned subsidiary pursuant to a stock purchase agreement.&#160;As part of the acquisition of Renovaro
Cube, the Company acquired goodwill valued at $<span id="xdx_903_eus-gaap--Goodwill_iI_c20240213__srt--StatementGeographicalAxis__custom--RenovaroCubeMember_zSOtQhaxworj" title="Goodwill">159,464,039</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On April 8, 2025, the Company
acquired Biosymetrics, Inc. as a wholly owned subsidiary pursuant to a stock purchase agreement.&#160;As part of the acquisition of Biosymetrics,
Inc., the Company acquired goodwill valued at $<span id="xdx_90E_eus-gaap--Goodwill_iI_c20250408__srt--StatementGeographicalAxis__custom--BioSymetricsMember_zrllylrMlMb3" title="Goodwill">5,963,500</span>, software valued at $<span id="xdx_905_ecustom--Software_iI_c20250408_zXCei7nuteth" title="Software">143,000</span> and Trademark valued at $<span id="xdx_90F_ecustom--Trademark_iI_c20250408_znfXQM7Ma7m2" title="Trademark">8,000</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><b><i>Impairment</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Following the fourth quarter of
each year, management performs its annual test of impairment of intangible assets by performing an assessment and determines if it is
more likely than not that the fair value of the asset is greater than or equal to the carrying value of the asset.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the quarter ended September
30, 2024, the results of the assessment indicated that the carrying value of the RENC reporting unit exceeded its fair value, due to the
decline in the estimated fair value of the reporting unit based on the Company&#8217;s market capitalization. Management concluded the
significant driver for the change in the economic benefits was due to the Company&#8217;s continued inability to raise capital for the
further development of the technologies within this reporting unit. Therefore, an impairment adjustment of $<span id="xdx_907_ecustom--ImpairmentAdjustment_iI_c20240930_zSPlKB6P7xjc" title="Impairment adjustment">47,614,729</span>&#160;was recorded
for the period ended September 30, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the quarter ended June
30, 2025, the results of the assessment indicated that the carrying value of the RENC reporting unit exceeded its fair value, due to the
decline in the estimated fair value of the reporting unit based on the Company&#8217;s market capitalization. Management concluded the
significant driver for the change in the economic benefits was due to the Company&#8217;s continued inability to raise capital for the
further development of the technologies within this reporting unit. Therefore, an impairment adjustment of $<span id="xdx_909_ecustom--ImpairmentAdjustment_iI_c20250630_zuuqqIPS9Oue" title="Impairment adjustment">122,804,700</span> was recorded for
the period ended June 30, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/985-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text"><p id="xdx_800_eus-gaap--LesseeOperatingLeasesTextBlock_zYAeab0Otljd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 7 &#8212; <span id="xdx_823_zrGmbdSqhADb">LEASES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><b>Operating
Leases </b>&#8212; O<span id="xdx_90B_eus-gaap--LesseeOperatingLeaseDescription_c20180618__20180619_zfvuwx7i60O4" title="Lease premises, description">n June 19, 2018, Lunai entered into a Lease Agreement for a term of ten years from September 1, 2018, with Century
City Medical Plaza Land Co., Inc., pursuant to which the Company agreed to lease approximately 2,453 rentable square feet. On February
20, 2019, Lunai entered into an Addendum to the original Lease Agreement with an effective date of December 1, 2019, where it expanded
the lease area to include another 1,101 square feet for a total rentable 3,554 square feet. The base rent increases by 3% each year, and
ranges from $17,770 per month for the first year to $23,186 per month for the tenth year. The equalized monthly lease payment for the
term of the lease is $20,050.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Renovaro Cube leases an office
facility in Amsterdam, Netherlands, under a 30-month operating lease agreement commencing on September 1, 2023, with a maturity date of
February 28, 2026. In determining lease asset values, the Company considers fixed and variable payment terms, prepayments, incentives,
and options to extend, terminate or purchase. The Company mutually terminated this lease on April 29, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Lunai entered an office lease
in Boca Raton, Florida, under a 36-month operating lease agreement commencing on November 1, 2024, with a maturity date of October 31,
2027. In determining lease asset values, the Company considers fixed and variable payment terms, prepayments, incentives, and options
to extend, terminate or purchase.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company identified and assessed
the following significant assumptions in recognizing the right-of-use assets and corresponding liabilities:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Expected lease term </i></b>&#8212;
The expected lease term includes both contractual lease periods and, when applicable, cancelable option periods when it is reasonably
certain that the Company would exercise such options. The Company&#8217;s leases have a remaining lease term of 26 and 28 months. As of
June 30, 2025, the weighted-average remaining term is <span id="xdx_906_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20250630_znvPKHru2HUc" title="Weighted-average remaining term">1.95</span> years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Incremental borrowing rate</i></b>
&#8212; The Company&#8217;s lease agreements do not provide an implicit rate. As the Company does not have any external borrowings for
comparable terms of its leases, the Company estimated the incremental borrowing rate based on the U.S. Treasury Yield Curve rate that
corresponds to the length of each lease. This rate is an estimate of what the Company would have to pay if borrowing on a collateralized
basis over a similar term in an amount equal to the lease payments in a similar economic environment. As of June 30, 2025, the weighted-average
discount rate is <span id="xdx_90C_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20250630_zfJxniLs6XVk" title="Weighted-average discount rate">4.66</span>%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Lease and non-lease components</i></b>
&#8212; In certain cases the Company is required to pay for certain additional charges for operating costs, including insurance, maintenance,
taxes, and other costs incurred, which are billed based on both usage and as a percentage of the Company&#8217;s share of total square
footage. The Company determined that these costs are non-lease components, and they are not included in the calculation of the lease liabilities
because they are variable. Payments for these variable, non-lease components are considered variable lease costs and are recognized in
the period in which the costs are incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Below are the lease commitments for the next 5 years:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zu0MeaLfUyJh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - LEASES (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B4_zXboek72wFhi" style="display: none">Schedule of lease commitments</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Years Ending June 30</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Lease Expense</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 73%; text-align: left; text-indent: -10pt">2026</td><td style="width: 10%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_c20250630_za8Be45kf0tj" style="width: 15%; text-align: right" title="2026">363,999</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_c20250630_zxvdZcBLzsO9" style="text-align: right" title="2027">358,326</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Thereafter</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo_iI_pp0p0_c20250630_zuMJ9yxeEnV" style="text-align: right" title="Thereafter">56,621</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Less imputed interest</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_c20250630_zSfGZNFdyBfc" style="border-bottom: Black 1pt solid; text-align: right" title="Less imputed interest">(41,353</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"><span style="font-size: 10pt"><b>Total</b></span></td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_986_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pp0p0_c20250630_z4G5CPVvqkf9" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Total">737,593</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8A1_zaCkZ7Wcd1Jh" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">DEBT</a></td>
<td class="text"><p id="xdx_800_eus-gaap--DebtDisclosureTextBlock_z1GsRvs682Zb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 8 &#8212; <span id="xdx_822_zcld5SgGorO4">DEBT</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Convertible Notes Payable &#8212;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>The January 2024 Note &#8212;</i></b>
On January 12, 2024, the Company entered into Subscription Agreements with an investor to issue a Convertible Promissory Note for an aggregate
principal amount of $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_c20240112__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zDWRPdIZCbef" title="Principal amount">125,000</span> (the &#8220;January 2024 Note&#8221;). The Company received a total of $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfDebt_c20240109__20240112__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zH6tpqJWmByc" title="Gross proceeds">125,000</span> in gross proceeds.&#160;The
January 2024 Note bears an interest rate of <span id="xdx_90A_eus-gaap--LongTermDebtPercentageBearingFixedInterestRate_iI_dp_c20240112__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zDBgGdoWVAJi" title="Bear interest percentage">12</span>% per annum and matured on <span id="xdx_904_eus-gaap--DebtInstrumentMaturityDate_dd_c20240109__20240112__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zL15lKdhrY99" title="Debt maturity period">December 29, 2024</span>. The Company is required to pay interest quarterly,
in arrears, in cash, on the first day of each quarter of each year following the issue date prior to the maturity of the January 2024
Note. The January 2024 Note is convertible either at the option of the holder or automatically upon maturity into shares of the Company&#8217;s
Common Stock at the Note Conversion Price of $<span id="xdx_901_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20240112__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zYCoUmBOPcv2" title="Conversion price">3.38</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>December 2023 Notes &#8212;
</i></b>On December 20, 2023, the Company entered into Subscription Agreements to purchase Convertible Promissory Notes for an aggregate
principal amount of $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_c20231220__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_zKnh24zNbM7a" title="Principal amount">120,000</span> (the &#8220;December 2023 Notes&#8221;). The Company received a total of $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfDebt_c20231219__20231220__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_ze5n0o3Uc7Pg" title="Gross proceeds">120,000</span> from the private placement
between December 2023 and January 2024.&#160;The December 2023 Notes bear an interest rate of <span id="xdx_90C_eus-gaap--LongTermDebtPercentageBearingFixedInterestRate_iI_dp_c20231220__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_z292Q4HR4224" title="Bear interest percentage">12</span>% per annum and matured one year after
their respective dates of issuance (the &#8220;Maturity Date&#8221;). The Company is required to pay interest quarterly, in arrears, in
cash, on the first day of each quarter of each year following the issue date prior to the maturity of the December 2023 Notes. Notwithstanding
the immediately foregoing, at the option of the holder, interest may accrue on the December Notes on a quarterly basis. The December 2023
Notes are convertible into shares of the Company&#8217;s Common Stock in whole or in part at any time and from time to time, after the
original issue date and prior to the Maturity Date, at a conversion price of $<span id="xdx_90D_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20231220__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_zOeGXobaPxki" title="Conversion price">3.38</span> per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The January 2024 Note and December
2023 Notes balance at June 30, 2025 was $<span id="xdx_905_ecustom--NotesBalance_iI_c20250630_zaqzXyAJXqJf" title="Notes balance">245,000</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Notes Payable </b>&#8212;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Bridge Loans &#8212; </i></b>From
June 4, 2025 to June 14, 2025, the Company entered into agreements with Paseco ApS, a Danish entity controlled by a shareholder (&#8220;Paseco
ApS&#8221;) and Laksya Ventures Inc. to issue Promissory Notes for the principal amount of $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_c20250604__us-gaap--RelatedPartyTransactionAxis__custom--PasecoApSMember_zZiKmDfr3R68" title="Principal amount">1,725,000</span> to each note holder. The Company
received $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfDebt_c20240701__20250630__us-gaap--RelatedPartyTransactionAxis__custom--PasecoApSMember_zdoh1Od0qyw7" title="Gross proceeds">3,450,000</span> in gross proceeds. The notes bear an interest rate of <span id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20250604__us-gaap--LongtermDebtTypeAxis__custom--TheNotesMember_zOeaTD0v9Loh" title="Note interest rate">10</span>% per annum and mature on December 31, 2025. The notes balance
at June 30, 2025, was $<span id="xdx_90E_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20240701__20250630__us-gaap--LongtermDebtTypeAxis__custom--TheNotesMember_zMy6aCUNzW61" title="Sale of stock, value">3,450,000</span> with Paseco ApS and Laksya Ventures Inc. each holding $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20250630__us-gaap--RelatedPartyTransactionAxis__custom--PasecoApSMember_zkHMOckvwuN6" title="Principal amount">1,725,000</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">From October 21, 2024 to January
24, 2025, the Company entered into agreements with Paseco ApS, a Danish entity controlled by a shareholder (&#8220;Paseco ApS&#8221;),
to issue Promissory Notes for the principal amount of $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_c20241021__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member__us-gaap--RelatedPartyTransactionAxis__custom--PasecoApSMember_zqJtN10uzz3k" title="Principal amount">2,650,000</span>. The Company received $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfDebt_c20240101__20240124__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member__us-gaap--RelatedPartyTransactionAxis__custom--PasecoApSMember_zD4KBeRS7Ku7" title="Gross proceeds">2,650,000</span> in gross proceeds. The notes bear an
interest rate of <span id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20241021__us-gaap--LongtermDebtTypeAxis__custom--TheNotesMember_zDL9ipEmzOB7" title="Note interest rate">10</span>% per annum and mature from December 31, 2024 to December 31, 2025. <span id="xdx_90D_eus-gaap--MaturitiesOfTimeDepositsDescription_c20240701__20250630_z2GskIECLgIl" title="Maturity description">Approximately $700,000 matured on December 31,
2024, $900,000 matured on December 31, 2025 and $1,050,000 matured on January 31, 2025. On February 24, 2025, Paseco ApS assigned 50%
of its ownership rights to Laksya Ventures Inc. with all terms remaining unchanged. The note balance at June 30, 2025, was $2,650,000
with Paseco ApS and Laksya Ventures Inc. each holding $1,325,000</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_90F_ecustom--AgreementDescription_c20241112__20241203__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNotesMember_zHtxUzOyEVQ3" title="Agreement description">From November 12, 2024 to December
3, 2024, Renovaro Cube entered into an agreement with Paseco ApS, a Danish entity controlled by a shareholder (&#8220;Paseco ApS&#8221;),
to issue Promissory Notes for the principal amount of &#8364;450,000. The note bears an interest rate of 10% per annum and matures on December
1, 2025. On February 24, 2025 Paseco ApS assigned 50% of its ownership rights to Laksya Ventures Inc. with all terms remaining unchanged.
The note balance at June 30, 2025 was approximately $490,000 with Paseco ApS and Laksya Ventures Inc. each holding $245,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_90B_ecustom--AgreementDescription_c20250223__20250224__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNotesMember_z2ZOwfVKVt7h" title="Agreement description">On November 1, 2024, Renovaro
Cube entered into an agreement with Yalla Yalla Limited, an investor to issue a Promissory Note for the amount of approximately &#8364;225,000.
The note bears an interest rate of 10% per annum and matured on February 24, 2025. The note balance at June 30, 2025 was approximately
$238,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_905_ecustom--AgreementDescription_c20240915__20240916__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNotesMember_zZod2qlMyZc1" title="Agreement description">On September 16, 2024, the Company
entered into an agreement with RS Bio ApS, a Danish entity controlled by a shareholder (&#8220;RS Bio&#8221;), to issue a Promissory Note
for the principal amount of $100,000 (the &#8220;September 2024 Note&#8221;). The Company received $100,000 in gross proceeds. The note
bears an interest rate of 12% per annum and matured on December 31, 2024. On February 24, 2025 RS Bio assigned its ownership rights to
Rene Sindlev with all terms remaining unchanged. The note balance at June 30, 2025 was $100,000</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">O<span id="xdx_904_ecustom--AgreementDescription_c20240905__20240906__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNotesMember_zm2x4YXN4lH8" title="Agreement description">n September 6, 2024, Renovaro
Cube entered into an agreement with Paseco ApS, a Danish entity controlled by a shareholder (&#8220;Paseco ApS&#8221;), to issue a Promissory
Note for the principal amount of &#8364;50,000. The note bears an interest rate of 12% per annum and matures on September 9, 2025. On February
24, 2025 Paseco ApS assigned 50% of its ownership rights to Laksya Ventures Inc. with all terms remaining unchanged. The note balance
at June 30, 2025 was approximately $59,000 with Paseco ApS and Laksya Ventures Inc. each holding approximately $30,000 (see Note 8 to
the Financial Statements)</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_909_ecustom--AgreementDescription_c20240204__20240205__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNotesMember_zFhCUFu7dVv1" title="Agreement description">On February 5, 2024, the Company
entered into an agreement with RS Bio to issue a 5% Original Issue Discount Secured Promissory Note for the principal amount of $105,263
(the &#8220;February 2024 Note&#8221;). The Company received $100,000 in gross proceeds after taking into account the 5% original issue
discount. The note bears an interest rate of 12% per annum and matured on December 31, 2024. On February 24, 2025 RS Bio assigned its
ownership rights to Rene Sindlev with all terms remaining unchanged. The note balance, net of discount at June 30, 2025 was $105,263</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_907_ecustom--AgreementDescription_c20240101__20240102__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNotesMember_z645ny91519i" title="Agreement description">On January 2, 2024, the Company
entered into an agreement with RS Bio to issue a 5% Original Issue Discount Secured Promissory Note for the principal amount of $526,315.
The Company received a total of $500,000 in gross proceeds after taking into account the 5% original issue discount.&#160;The note bears
an interest rate of 12% per annum and matured on December 31, 2024. On February 24, 2025 RS Bio assigned its ownership rights to Rene
Sindlev with all terms remaining unchanged. The note balance, net of discount at June 30, 2025 was $526,315</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_902_ecustom--AgreementDescription_c20241102__20241103__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNotesMember_z4bHB0FPjdEa" title="Agreement description">On November 3, 2023, the Company
entered into an agreement with RS Bio to issue a 5% Original Issue Discount Promissory Note for the principal amount of $1,000,000. The
Company received a total of $950,000 in gross proceeds after taking into account the 5% original issue discount.&#160;The discount of
$50,000 will be accreted over the life of the note. The note bears an interest rate of 12% per annum and matured on December 31, 2024.
On February 24, 2025 RS Bio assigned its ownership rights to Rene Sindlev with all terms remaining unchanged. The note balance, net of
discount at June 30, 2025 was $750,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Promissory Note &#8212; </b>On
March 30, 2020 (the &#8220;Issuance Date&#8221;), the Company issued a Promissory Note in the principal amount of $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20200330__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zTgvK82DPgE8" title="Principal amount">5,000,000</span> (the &#8220;Promissory
Note&#8221;) to Paseco ApS. There have been eight amendments to the Promissory Note since the issuance date, the most recent of which
is dated August 1, 2024. The principal amount of the Promissory Note, as amended, was payable on <span id="xdx_908_eus-gaap--DebtInstrumentMaturityDate_dd_c20200329__20200330__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zHhIXAjGUWh1" title="Maturity date">November 1, 2024</span> (the &#8220;Maturity
Date&#8221;). The Promissory Note, as amended, bears interest at a fixed rate of <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_dp_c20200329__20200330__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zEwKclneWNGf" title="Interest rate">12</span>% per annum. On February 24, 2025 Paseco ApS assigned
its ownership rights to Rene Sindlev with all terms remaining unchanged. The Promissory Note balance at June 30, 2025 is $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_c20250101__20250630__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_z97MRh2cZ809" title="Issuance of common stock">831,497</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s obligations
under the referenced Promissory and Bridge Notes, except for those originally entered into by Renovaro Cube, are secured by a Security
Agreement. To secure the Company&#8217;s obligations under the Promissory Note, the Company entered into a Security Agreement with the
Holder, pursuant to which the Company granted a lien on all assets of the Company (the &#8220;Collateral&#8221;) for the benefit of Paseco
ApS, Rene Sindlev and Laksya Ventures. Upon an Event of Default (as defined in the notes, respectively) Paseco ApS, Rene Sindlev and Laksya
Ventures may, among other things, collect or take possession of the Collateral, proceed with the foreclosure of the security interest
in the Collateral or sell, lease, or dispose of the Collateral (see Note 8 to the Financial Statements).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Finance Agreement </b>&#8212;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On November 30, 2024, the Company
entered into a premium finance agreement (the &#8220;Agreement&#8221;) related to insurance,&#160;<span style="background-color: white">which
resulted in the recognition of a liability and prepaid exp</span>ense with a principal amount of $<span id="xdx_903_eus-gaap--DebtInstrumentAnnualPrincipalPayment_iI_c20241130__us-gaap--BalanceSheetLocationAxis__us-gaap--OtherCurrentLiabilitiesMember__us-gaap--TypeOfArrangementAxis__custom--FinanceAgreementMember_zOfHqmcl5AX8" title="Principal amount">1,018,930</span> at&#160;<span id="xdx_906_eus-gaap--DerivativeFixedInterestRate_iI_dp_c20241130__us-gaap--BalanceSheetLocationAxis__us-gaap--OtherCurrentLiabilitiesMember__us-gaap--TypeOfArrangementAxis__custom--FinanceAgreementMember_zo3mPZ897sw1" title="Rate of interest">7.50</span>% interest per
annum, which is reflected on the consolidated balance sheet under &#8220;other current liabilities&#8221; and &#8220;prepaid assets and
other assets&#8221;, respectively. The repayment of the Agreement will be made in nine equal monthly installments of $<span id="xdx_90C_ecustom--MonthlyInstallments_pp0p0_c20241129__20241130__us-gaap--TypeOfArrangementAxis__custom--FinanceAgreementMember_zjLV9XrLOAb2" title="Monthly instalments amount">93,401</span>&#160;after
a down payment of $<span id="xdx_903_ecustom--RepaymentOnFinanceAgreement_pp0p0_c20241129__20241130__us-gaap--TypeOfArrangementAxis__custom--FinanceAgreementMember_zTyIeEMKVMIl" title="Down payment amount">204,000</span>.&#160;For the years ended June 30, 2025 and 2024 the Company made payments of $<span id="xdx_900_ecustom--RepaymentOnFinanceAgreement_pp0p0_c20240701__20250630__us-gaap--TypeOfArrangementAxis__custom--FinanceAgreementMember_zDtkx2Vagz0j" title="Down payment amount">971,231</span>&#160;and $<span id="xdx_90F_ecustom--RepaymentOnFinanceAgreement_pp0p0_c20230701__20240630__us-gaap--TypeOfArrangementAxis__custom--FinanceAgreementMember_zXOG5pko0Nlh" title="Down payment amount">870,073</span>, respectively.
The remaining balance at June 30, 2025 is $<span id="xdx_90A_eus-gaap--OtherLiabilitiesNoncurrent_iI_c20250630_zOvTMAbygdja" title="Other current liabilities">271,643</span>; the amount is reflected in other current liabilities. <span style="background-color: white">For
the years ended June 30, 2025 and 2024 the Company recorded total interest expense in the amount of $<span id="xdx_907_eus-gaap--InterestAndDebtExpense_c20240701__20250630__us-gaap--TypeOfArrangementAxis__custom--FinanceAgreementMember_zHyESXXVSmig" title="Accrued interest expense">24,555</span> and $<span id="xdx_907_eus-gaap--InterestAndDebtExpense_c20230701__20240630__us-gaap--TypeOfArrangementAxis__custom--FinanceAgreementMember_z7UJAqzEgSac" title="Accrued interest expense">20,128</span>&#160;related to
the Agreement. This amount is reflected in other income and expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Total
interest expense recorded for the years ended June 30, 2025 and 2024, was $<span id="xdx_907_eus-gaap--InterestExpenseNonoperating_c20240701__20250630_zBwkCPNq1Af2" title="Total interest expense">725,684</span> and $<span id="xdx_90A_eus-gaap--InterestExpenseNonoperating_c20230701__20240630_zZnN5KnHq0j9" title="Total interest expense">1,011,322</span> respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--IncomeTaxDisclosureTextBlock_z8Ea9I1PCun8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 9 &#8212; <span id="xdx_821_zC4Mx3WBYbO6">INCOME TAXES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company accounts for income
taxes in accordance with FASB ASC Topic 740, Accounting for Income Taxes; which requires the Company to provide a net deferred tax asset
or liability equal to the expected future tax benefit or expense of temporary reporting differences between book and tax accounting and
any available operating loss or tax credit carryforwards. The amount of and ultimate realization of the benefits from the deferred tax
assets for income tax purposes is dependent, in part, upon the tax laws in effect, the Company&#8217;s future earnings, and other future
events, the effects of which cannot be determined.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of June 30, 2025 and 2024,
the Company had net operating loss carryforwards of approximately $<span id="xdx_900_eus-gaap--OperatingLossCarryforwards_iI_c20250630__us-gaap--IncomeTaxAuthorityAxis__custom--UnitedStatesTaxMember_zsaoSjHpHZW8" title="Operating loss carryforwards">541,603,425</span> and $<span id="xdx_907_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20240630__us-gaap--IncomeTaxAuthorityAxis__custom--UnitedStatesTaxMember_znNFFosXZBU2" title="Operating loss carryforwards">489,177,759</span> respectively, giving rise to deferred
tax assets of $<span id="xdx_90A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsForeign_iI_pp0p0_c20250630__us-gaap--IncomeTaxAuthorityAxis__custom--UnitedStatesTaxMember_zHZBf4U995Ci" title="Deferred tax assets">76,296,814</span> and $<span id="xdx_906_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsForeign_iI_pp0p0_c20240630__us-gaap--IncomeTaxAuthorityAxis__custom--UnitedStatesTaxMember_z1axxMxqB38j" title="Deferred tax assets">144,191,530</span>, respectively. The net operating loss carryforwards generated prior to January 1, 2018 expire
over various dates from 2031 to 2038. All subsequent net operating loss carryforwards are indefinite.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company files Danish and U.S.
income tax returns and these returns are generally no longer subject to tax examinations for years prior to 2021 for the Danish tax returns
and 2022 for the U.S. tax returns.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The temporary differences, tax
credits and carry forwards gave rise to the following deferred tax assets (liabilities) at June 30, 2025 and 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zG7ef07kCjig" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8BE_zWb6LjrOJUod" style="display: none">Schedule of deferred tax assets and liabilities</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_491_20250630_z2pzuoOnf8yk" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49E_20240630_zpnAVDgg77Sb" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td></tr>
  <tr id="xdx_407_ecustom--Depreciations_iI_z8O0Jizr4Ah3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-indent: -10pt">Depreciation</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(24,619</td><td style="width: 1%; text-align: left">)</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">8,258</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--DeferredTaxAssetExcessTaxOverDepreciationPatents_iI_pp0p0_maDTALNzwuT_z05qOfiHebK9" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Excess of tax over book depreciation of patents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1220">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,415</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--StockoptionsCompensation_iI_pp0p0_maDTALNzwuT_z0eQx4ABu7Gc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Stock/options compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">463,099</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,672,252</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--DepreciationAndAmortizations_iI_pp0p0_maDTALNzwuT_z3xluljzTyLe" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1226">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">188,422</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_maDTALNzwuT_za5kAs7Fzbnl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net operating loss carryforwards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">76,296,814</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">148,832,041</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--ImpairmentExpense_iI_pp0p0_d0_maDTALNzwuT_zPLauX3Dg9Xf" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;Impairment expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,188,497</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--ContingentConsiderationFairValue_iI_pp0p0_d0_maDTALNzwuT_zapO6NPIqsz" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Contingent consideration fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(909,577</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--AccumulatedAmortizationOfOtherDeferredCosts_iI_pp0p0_zdsvvMK0hJ28" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,961,747</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1239">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--Section174ReCapitalization_iI_pp0p0_zsRiglMBn91h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Section 174 R&amp;E Capitalization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,292,075</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1242">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--OperatingLeaseRightOfUseAssets_iI_pp0p0_zasdyD3kGSyk" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">ROU Assets and Lease Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,227</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1245">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--Section481aAdjustment_iI_pp0p0_zSm9CwUyzF5c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Section 481(a) Adjustment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(40,895</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1248">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pp0p0_zwOcJj92EMD4" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">R&amp;D Tax Credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,718,415</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1251">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--ChangeInTaxRate_iI_pp0p0_d0_maDTALNzwuT_zbDREXQcEyMh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Change in tax rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_msDTALNzwuT_z6J1A7OH0Kjg" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(83,680,863</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(170,988,308</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_iI_pp0p0_zcd39fI1vKZk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total Deferred Tax Assets (Liabilities)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1259">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1260">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8A7_zoAvNePKcrtj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In accordance with prevailing
accounting guidance, the Company is required to recognize and disclose any income tax uncertainties. The guidance provides a two-step
approach to recognizing and measuring tax benefits and liabilities when realization of the tax position is uncertain. The first step is
to determine whether the tax position meets the more-likely-than-not condition for recognition, and the second step is to determine the
amount to be recognized based on the cumulative probability that exceeds 50%. The amount of and ultimate realization of the benefits from
the deferred tax assets for income tax purposes is dependent, in part, upon the tax laws in effect, the Company&#8217;s future earnings,
and other future events, the effects of which can be difficult to determine and can only be estimated. Management estimates that it is
more likely than not that the Company will not generate adequate net profits to use the deferred tax assets; and consequently, a valuation
allowance was recorded for all deferred tax assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A reconciliation of income tax
expense at the federal statutory rate to income tax expense at the Company&#8217;s effective rate is as follows for the years ended June
30, 2025 and 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zlDfgmV18te" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_495_20240701__20250630_zFeO7GtMwKsf" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_490_20230701__20240630_zHDY7JCSDrbe" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years ended June 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationChangeInEnactedTaxRate_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Computed tax at expected statutory rate</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(951,542</td><td style="width: 1%; text-align: left">)</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(24,066,011</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--IncomeTaxReconciliationRepatriationOfForeignEarnings_iN_pp0p0_d0_zKIUKpKrDoYf" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Non-US income taxed at different rates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncomeTaxReconciliationNondeductibleExpense_d0_zMIO6nQnezl6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Non-deductible expenses / other items</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,046,364</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,999,380</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">24,066,011</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OtherTaxExpenseBenefit_d0_zo2a8bR4x85k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Income Tax Expense (Benefit)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,474</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8A6_ztLRpc0LQb7d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
components of income tax expense (benefit) from continuing operations for the years ended June 30, 2025 and 2024 consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zysVPktt2Tdj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-top: 0pt; padding-right: 0pt; padding-left: 20pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B7_zPjqVwYUCxq2" style="display: none">Schedule
    of components of income tax expense (benefit) from continuing operations</span></td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_49B_20240701__20250630_zw3QhO3HHRB3" style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_495_20230701__20240630_zyuACp3VqK58" style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Years
    ended June 30,</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td></tr>
  <tr id="xdx_400_eus-gaap--CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; font-size: 10pt; font-weight: bold; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
    Income Tax Expense</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--CurrentFederalTaxExpenseBenefit_i01_pp0p0_d0_maCITEBzr8l_zuuOhRzfy6Ng" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal
    income tax (benefit)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i01_pp0p0_d0_maCITEBzr8l_zKtOaFUWvZ5d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; width: 56%; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State
    income tax (benefit)</span></td><td style="width: 8%; font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; width: 12%; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,474</span></td><td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 8%; font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; width: 12%; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--CurrentForeignTaxExpenseBenefit_i01_pp0p0_d0_maCITEBzr8l_z2ediuyAkH21" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
    income tax (benefit)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--CurrentIncomeTaxExpenseBenefit_i01T_pp0p0_d0_mtCITEBzr8l_maITEBzLgX_ztyyjCR5lrL5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Current Tax Expense (Benefit)</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,474</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_zpTGFHzNm6E" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; font-weight: bold; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
    Income Tax Expense Federal income tax (benefit)</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101,609,457</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">165,458,980</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefit_zwgRvZRgyeG1" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State
    income tax (benefit)</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(14,302,006</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,529,328</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_zaArW39NQWz3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
    income tax (benefit)</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1303">&#8212;</span></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1304">&#8212;</span></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_ziMMCuaxDi1d" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
    Change in valuation allowance</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(87,307,451</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(170,988,308</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_408_eus-gaap--DeferredIncomeTaxExpenseBenefit_i01T_pp0p0_d0_mtDITEBzk3M_maITEBzLgX_zMuyJTSzElsj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Deferred Tax Expense</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxExpenseBenefit_i01T_pp0p0_d0_mtITEBzLgX_zfLHiVBg5I98" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; font-size: 10pt; font-weight: bold; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Tax Expense</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,474</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>



<p id="xdx_8A0_zqdlppKeJgil" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
income tax expense (benefit) results primarily from the reversal of temporary timing differences between tax and financial statement
income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="text"><p id="xdx_809_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zaC8WTAZ9VA8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 10 &#8212; <span id="xdx_825_zVe4vLcVRFy1">STOCKHOLDERS&#8217; EQUITY</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Preferred Stock </b>&#8212;
The Company has <span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_c20250630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zBSZG3asjI0k" title="Preferred stock shares authorized"><span id="xdx_906_eus-gaap--PreferredStockSharesAuthorized_iI_c20240630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zWVUegqqL3u8" title="Preferred stock shares authorized">10,000,000</span></span>
authorized shares of Preferred Stock, par value $<span id="xdx_90F_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20250630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zboOgxgtnlDf" title="Preferred stock, par value"><span id="xdx_900_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20240630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zrtHwbqcdaY6" title="Preferred stock, par value">0.0001</span></span>
per share, <span id="xdx_90B_ecustom--PreferredStockDesignatedShares_iI_c20250630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zJYeBrcJjm5f" title="Preferred stock designated shares"><span id="xdx_90A_ecustom--PreferredStockDesignatedShares_iI_c20240630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zLEUxE1WBQp6" title="Preferred stock designated shares">1,000,000</span></span>
of which have been designated as Series A Convertible Preferred Stock. At June 30, 2025 and 2024, there were <span id="xdx_901_eus-gaap--PreferredStockSharesIssued_iI_c20250630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zeGwrZVntiOe" title="Preferred stock, shares issued"><span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_c20250630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zwbMMhoKqCOh" title="Preferred stock, shares outstanding"><span id="xdx_905_eus-gaap--PreferredStockSharesIssued_iI_c20240630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_znRVqMI74Sc1" title="Preferred stock, shares issued"><span id="xdx_901_eus-gaap--PreferredStockSharesOutstanding_iI_c20240630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zfLHOI5Eewj8" style="display: none" title="Preferred stock, shares outstanding">0</span></span></span></span> zero shares of
Preferred Stock issued and outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Voting &#8212; </b>Holders
of Series A Preferred Stock shall be permitted to vote on all matters required or permitted to be voted on by the holders of Common Stock
of the Company and shall be entitled to that number of votes equal to ten votes for the number of shares of Common Stock into which such
holder&#8217;s shares of Preferred Stock could then be converted in accordance with conversion rights.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"><b>Dividends &#8212; </b>The
Company shall pay dividends on shares of Series A Preferred Stock equal (on an as-if-converted-to-Common-Stock basis) to and in the same
form as dividends actually paid on shares of the Common Stock when, as and if such dividends are paid on shares of the Common Stock. No
other dividends shall be paid on shares of Preferred Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Liquidation Rights &#8212;</b>
In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, the holders of shares of Series A
Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Company available for distribution to its stockholders,
before any payment shall be made to the holders of Common Stock by reason of their ownership thereof, an amount in cash equal to the aggregate
liquidation value of all shares held by such holder. The Series A Preferred Stock is not participating preferred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Conversion Rights &#8212; </b>On
or after the date of issuance, any holder of Series A Preferred Stock shall have the right by written election (a &#8220;Series A Election
Notice&#8221;) to the Company to convert all or any portion of the outstanding Shares of Series A Preferred Stock held by such holder
into an aggregate number of shares of Common Stock as is determined by multiplying the number of Shares to be converted by ten (10) (the
&#8220;Conversion Ratio&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Common Stock </b>&#8212; The
Company has <span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_iI_c20250630_zBN2SghKHYl9" title="Common stock, shares authorized"><span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_c20240630_zl9ZgqQYK9e5" title="Common stock, shares authorized">350,000,000</span></span> authorized shares of Common Stock, par value $<span id="xdx_902_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20250630_zf734HAwMVTi" title="Common stock, par value"><span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240630_zQI2ZeNWSHXl" title="Common stock, par value">0.0001</span></span> per share. At June 30, 2025 and 2024, there were <span id="xdx_906_ecustom--CommonStockShareIssued_iI_c20250630_z19u5s4itUNg" title="Common stock, shares issued"><span id="xdx_90C_eus-gaap--CommonStockSharesOutstanding_iI_c20250630_zYkVqKMkh3aj" title="Common stock, shares outstanding">177,392,907</span></span>
and <span id="xdx_900_ecustom--CommonStockShareIssued_iI_c20240630_zgc7FaGPdxj5" title="Common stock, shares issued"><span id="xdx_907_eus-gaap--CommonStockSharesOutstanding_iI_c20240630_zIU1OLpUmXW6" title="Common stock, shares outstanding">158,452,644</span></span> shares issued and outstanding, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Voting &#8212; </b>Holders
of Common Stock are entitled to one vote for each share held of record on each matter submitted to a vote of stockholders, including the
election of directors, and do not have any right to cumulate votes in the election of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Dividends &#8212; </b>Holders
of Common Stock are entitled to receive ratably such dividends as the Company&#8217;s Board of Directors from time to time may declare
out of funds legally available.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Liquidation Rights &#8212;</b>
In the event of any liquidation, dissolution or winding-up of the affairs of the Company, after payment of all debts and liabilities,
the holders of Common Stock will be entitled to share ratably in the distribution of any remaining assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>Purchase Agreement with
Lincoln Park Capital</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On June
20, 2023, the Company entered into a purchase agreement (the &#8220;2023 Purchase Agreement&#8221;) with Lincoln Park, pursuant to which
the Company may sell and issue to Lincoln Park, and Lincoln Park is obligated to purchase, up to $<span id="xdx_907_eus-gaap--PurchaseObligation_iI_pp0p0_c20230620_zp4gtWcI7fJ2" title="Obligation to purchase">20,000,000</span> of shares of Common Stock
over the 36-month term of the 2023 Purchase Agreement. Concurrently with entering into the 2023 Purchase Agreement, the Company also entered
into a registration rights agreement with Lincoln Park, pursuant to which it agreed to provide Lincoln Park with certain registration
rights related to the shares issued under the 2023 Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In consideration for entering
into the 2023 Purchase Agreement, the Company issued <span id="xdx_906_eus-gaap--SharesIssued_iI_c20230620__us-gaap--SubsidiarySaleOfStockAxis__custom--PurchaseAgreementMember_zqhShCpZj6xe" title="Number of shares issued">696,021</span> shares of Common Stock to Lincoln Park as a commitment fee on June 20, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the years ended June 30,
2025 and June 30, 2024 <span id="xdx_90A_eus-gaap--SharesIssued_iI_do_c20250630__us-gaap--SubsidiarySaleOfStockAxis__custom--PurchaseAgreementMember_z294MvXDPYq7" title="Number of shares issued"><span id="xdx_90D_eus-gaap--SharesIssued_iI_do_c20240630__us-gaap--SubsidiarySaleOfStockAxis__custom--PurchaseAgreementMember_zRGChiczFYYb" title="Number of shares issued">no</span></span> shares of Common Stock to Lincoln Park were sold under the Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Common Stock Issuances </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">On
April 8, 2025, the Company issued <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20250407__20250408__us-gaap--StatementClassOfStockAxis__custom--CommonStockIssuancesMember_z2bDB1c5gOn8" title="Issuance of common stock shares">15,000,000</span> shares of Common Stock valued at $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20250407__20250408__us-gaap--StatementClassOfStockAxis__custom--CommonStockIssuancesMember_zjmA12x5Klq5" title="Issuance of common stock value">6,058,500</span> (see Note 13) pursuant to the Stock Purchase
Agreement of Biosymetrics, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On January 21, 2025, the Company
issued&#160;<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20250112__20250121__us-gaap--StatementClassOfStockAxis__srt--ChiefExecutiveOfficerMember_zhvGteContIk" title="Issuance of common stock shares">250,000</span>&#160;shares of Common Stock to its Chief Executive Officer of Renovaro Cube valued at $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20250112__20250122__us-gaap--StatementClassOfStockAxis__srt--ChiefExecutiveOfficerMember_zgLRtLQiV1bf" title="Issuance of common stock shares, value">177,500</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On October 17, 2024, the Company
issued&#160;<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20241016__20241017_zST4lPfrBI59" title="Issuance of common stock shares">160,000</span>&#160;shares of Common Stock for consulting services valued at $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20241016__20241017__us-gaap--StatementClassOfStockAxis__custom--CommonStockIssuancesMember_zpW7Vn9ykmre" title="Common stock for consulting services value">119,400</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On October 14, 2024, the Company
issued&#160;<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20241013__20241014_zTSOGzQB1NCd" title="Issuance of common stock shares">500,000</span>&#160;shares of Common Stock for consulting services valued at $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20241013__20241014__us-gaap--StatementClassOfStockAxis__custom--CommonStockIssuancesMember_z9locy8x2Wu" title="Common stock for consulting services value">275,000</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On October 14, 2024, the Company
issued&#160;<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20241013__20241014__us-gaap--StatementClassOfStockAxis__srt--ChiefExecutiveOfficerMember_z8yPsDncQIlg" title="Issuance of common stock shares">250,000</span>&#160;shares of Common Stock to its Chief Executive Officer valued at $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20241013__20241014__us-gaap--StatementClassOfStockAxis__srt--ChiefExecutiveOfficerMember_zfrxf1whlF7b" title="Issuance of common stock shares, value">137,750</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On August 23, 2024, Avram Miller,
a former member of the Company&#8217;s board of directors (the &#8220;Board of Directors&#8221;), forfeited&#160;<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20240802__20240823__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zohmeImWSOfc" title="Number of share warrant purchase forfeited">833,333</span>&#160;shares of
Common Stock from the original&#160;<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240802__20240823__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zZ6MOvje5Yje" title="Granted">1,000,000</span>&#160;shares of Common Stock for advisory services originally granted to him on October 11,
2023. As consideration for such forfeiture, the Company granted to Mr. Miller, an option to purchase&#160;<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20240802__20240823__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__custom--MrMillerMember_zNYtmbJTRhgj" title="Number of share warrant purchase forfeited">978,261</span>&#160;shares of Common
Stock of the Company with a per-share exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240823__us-gaap--StatementClassOfStockAxis__custom--BoardOfDirectorsMember_zfxghSMgqmUi" title="Warrants exercised">0.69</span>. The Company determined that this transaction represented a modification
of the original award. The Company measured the fair value of the options issued as compared to the fair value of the original issuance
and determined that there was no incremental compensation to recognize as the fair value of the options was less than the fair value of
the Common Stock. Therefore, the Company will recognize the remaining fair value of the original award over the remaining vesting period,
which is one year. The Company recognized stock-based compensation expense of $<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630_zUWXTJOzcLPk" title="Stock-based compensation expense vested">1,159,470</span>&#160;related to the vesting of the stocks options
during the year ended June 30, 2025. At June 30, 2025, the Company had $<span id="xdx_902_ecustom--UnrecognizedCompensationCostandVest_iI_c20250630_zVxgTdXHBayk" title="Unrecognized compensation cost and vest">185,373</span>&#160;of unrecognized compensation cost related to the
options which vest at August 23, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On August 1, 2024, the Company
issued&#160;<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240719__20240801_z72Luo4ZBDp5" title="Issuance of common stock shares">2,000,000</span>&#160;shares of Common Stock for consulting services valued at $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20240729__20240801__us-gaap--StatementClassOfStockAxis__custom--CommonStockConsultingServicesMember_zOfZOFDpsBol" title="Common stock for consulting services value">1,400,000</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 14, 2024, Lunai a Delaware corporation (the &#8220;<span style="text-decoration: underline">Company</span>&#8221;) closed a private placement of&#160;<span id="xdx_908_ecustom--IssuanceOfCommonStockUnderPrivatePlacementOffering_c20240613__20240614_zl48YP3f1NKd" title="Issuance of common stock under private placement">5,315,215</span>&#160;of the
Company&#8217;s units, each such Unit consisting of (i) one share of the Company&#8217;s common stock, $<span id="xdx_903_ecustom--CommonStockParValuePrivatePlacement_c20240613__20240614_z5ZSxeLqDvf7" title="Common stock par value under private placement">0.0001</span>&#160;par value per share
and (ii) one common stock purchase warrant to purchase one-tenth of a share of Common Stock, with certain investors (the &#8220;Private
Placement&#8221;). The Warrants are exercisable for five years from the date of issuance and have an exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240614__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zQKTisHAyfRi" title="Warrants exercised">1.4726</span> and $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240614__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_znVl8uFIhjxk" title="Warrants exercised">1.4765</span>&#160;per
share, payable in cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the Private Placement, the Company sold&#160;<span style="background-color: white"><span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230701__20240630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zw2s7MhoWxx7" title="Shares sold">2,325,869</span></span>&#160;Units at a price per Unit equal
to $<span id="xdx_904_eus-gaap--SaleOfStockPricePerShare_iI_c20240630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_ztiSFbK2bUj9" title="Price per unit">1.4726</span>&#160;to a certain investor who paid in cash and settlement of debt an aggregate amount of $<span style="background-color: white"><span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230701__20240630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zZ8i6Xt9C20d" title="Paid in cash and settlement of debt">3,425,075</span></span>&#160;in
consideration for the Units.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
the Company sold&#160;<span style="background-color: white"><span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230701__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zntgYuNqyKDd" title="Shares sold">2,671,631</span></span>&#160;Units to certain investors who surrendered and terminated&#160;<span style="background-color: white">$<span id="xdx_90F_ecustom--PrincipalAmountAndInterestAccrued_c20230701__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zRmE4LZ7njR9" title="Principal amount and interest accrued">3,955,033</span></span>&#160;in
aggregate principal amount and interest accrued thereon of certain convertible promissory notes issued by the Company in 2023 and 2024
and paid in cash an aggregate amount of $<span id="xdx_906_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20220701__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zUfykS9Y7x6j" title="Paid in cash and settlement of debt">478,060</span>&#160;to the Company in consideration for the Units.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
the Company sold&#160;<span id="xdx_905_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220701__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--Investor1Member_zRMV7lJM3A67" title="Shares sold">317,715</span>&#160;Units to an investor who surrendered and terminated $<span style="background-color: white"><span id="xdx_90B_ecustom--PrincipalAmountAndInterestAccrued_c20220701__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--Investor1Member_zeO71y79asE3" title="Principal amount and interest accrued">468,453</span></span>&#160;in
aggregate principal amount and interest accrued thereon of a convertible promissory note issued in 2023 and paid in cash an aggregate
amount of $<span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20220701__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--Investor1Member_zHj8Yy5N7Lp1" title="Paid in cash and settlement of debt">66,000</span>&#160;to the Company in consideration for the Units.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
relation to the June 14, 2024 Private Placement the Company recognized a loss on the settlement of debt for $<span id="xdx_90E_eus-gaap--OtherNonrecurringIncomeExpense_c20240701__20250630_zqUhlpp8Vxl2" title="Other income (expense)">1,183,560&#160;</span>which was
recorded in other income (expense) in the statement of operations for the year ended June 30, 2024.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related
to the June 14, 2024 Private Placement, ranging from July 3, 2024, to October 10, 2024, the Company sold <span id="xdx_902_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240703__20241002_zDqkQ1NrDVWf" title="Sale of stock issued">1,613,596</span> Units at a price per
Unit equal to $<span id="xdx_904_eus-gaap--SaleOfStockPricePerShare_iI_c20241002_zIV28vdoDwRa" title="Sale of stock price per share">1.4726</span> to a certain investor who paid in cash an aggregate amount of $<span id="xdx_905_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_c20240703__20241002_znPHNyyahFgg" title="Sale of stock issued cash consideration">2,376,181</span> in consideration of the Units.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On April 5, 2024, the Company
issued&#160;<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240404__20240405__us-gaap--StatementClassOfStockAxis__custom--CommonStockIssuancesMember_zpojgP2U6bcf" title="Issuance of common stock shares">33,760</span>&#160;shares of common stock for consulting services valued at $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20240404__20240405__us-gaap--StatementClassOfStockAxis__custom--CommonStockIssuancesMember_zGAfK59mWIN1" title="Common stock for consulting services value">94,190</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On February 20, 2024, <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240220__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zun1qtNZllhg" title="Warrants outstanding">2,953,700</span>
warrants outstanding were exercised at prices ranging from $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240220__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zhiA02vxoA81" title="Warrants exercised">0.53</span> to $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240220__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zdSznezIgyUf" title="Warrants exercised">0.65</span> per share and the aggregate $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExpenseOrRevenueRecognized_c20240219__20240220__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zvMD2LHqCouh" title="Warrants aggregate amount">1,750,000</span> of a promissory note
held by the holder was applied to the exercise price of the warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On February 20, 2024, <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240220__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--SingleRangeMember_zbAtdy2zll2h" title="Warrants outstanding">471,699</span>
warrants outstanding were exercised at $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240220__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--SingleRangeMember_zdJjr26EG1Rb" title="Warrants exercised">0.53</span> per share valued at $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExpenseOrRevenueRecognized_c20240219__20240220__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--SingleRangeMember_zNgo4Z0hFuq4" title="Warrants aggregate amount">250,000</span>. A promissory note held by the holder was applied to the exercise
price of the warrants in lieu of cash proceeds.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On February 15, 2024, the Company
issued <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240214__20240215_ztDhI08h5Bkj" title="Issuance of common stock shares">50,000</span> shares of Common Stock for consulting services valued at $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20240214__20240215__us-gaap--StatementClassOfStockAxis__custom--CommonStockIssuancesMember_zu4fTPPG5qrd" title="Common stock for consulting services value">100,000</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">On
February 15, 2024, the Company closed a private placement of <span id="xdx_906_ecustom--IssuanceOfCommonStockUnderPrivatePlacementOffering_c20240214__20240215_zE0QuYFoeZFa" title="Issuance of common stock under private placement">344,827</span> shares of Common Stock, $<span id="xdx_90C_ecustom--CommonStockParValuePrivatePlacement_c20240214__20240215_zd1ESw1hvJPj" title="Common stock par value under private placement">0.0001</span> par value, at $2.90 per share for
aggregate proceeds to the Company of $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20240214__20240215_zdhKeSQBb5d" title="Proceeds from issuance of private placement">1,000,000</span> in cash. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On February 16, 2024, the Company
recognized <span id="xdx_90F_eus-gaap--SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares_iI_c20240216__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GEDiCubeIntlLtdMember_zZwCh50qz7Q8" title="Common Stock to be issued in settlement">3,425,399</span> shares of Common Stock to be issued in settlement of the contingent consideration as a result of the Company&#8217;s
acquisition of GEDi Cube Intl Ltd.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">On
February 13, 2024, the Company issued <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240212__20240213__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementOfRenovaroCubeMember_zGOxd5vhrrP7" title="Issuance of common stock shares">70,834,183</span> shares of Common Stock valued at $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20240212__20240213__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementOfRenovaroCubeMember_zRgTmcN3kXM" title="Issuance of common stock shares, value">136,001,631</span> (see Note 13) pursuant to the Stock Purchase
Agreement of Renovaro Cube.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On December 4, 2023, the Company
issued <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20231203__20231204_z58zP4SIBOFb" title="Issuance of common stock shares">525,945</span> shares of Common Stock pursuant to warrants exercised for cash proceeds of $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20231203__20231204_zfPgWL1K4ck9" title="Issuance of common stock shares, value">341,865</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On October 23, 2023, the Company
issued <span id="xdx_90E_eus-gaap--SharesIssued_iI_c20231023__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AvramMillerMember_zuQYzlLrTdj5" title="Shares issued">1,000,000</span> shares of Common Stock valued at $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20231022__20231023__us-gaap--StatementClassOfStockAxis__custom--CommonStockIssuancesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AvramMillerMember_zXvJbVF8dEX2" title="Issuance of common stock shares, value">2,760,000</span> for advisory services to Avram Miller, a member of the Company&#8217;s board
of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Between July 28, 2023, and September
28, 2023, the Company issued <span id="xdx_90E_ecustom--PurchaseSharesOfCommonStock_iI_c20230728__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zZg7Sl0Tz1lc" title="Purchase shares of common stock">2,000,000</span> shares of Common Stock for consulting services valued at $<span id="xdx_909_eus-gaap--ConversionOfStockAmountConverted1_c20230727__20230728__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z2PLBpr7s3Vk" title="Converted shares of common stock, value">4,470,000</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><b>2017
Warrants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On July
14, 2022, certain of our warrant holders exercised warrants to purchase&#160;<span id="xdx_909_eus-gaap--StockRepurchasedDuringPeriodShares_c20220713__20220714__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zWpCkUoKrUOk" title="Shares purchased">1,250,000</span>&#160;shares of Common Stock for total proceeds
to the Company of $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_c20220713__20220714__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zNCy0STHof72" title="Proceeds from common stock">1,625,000</span>, with corresponding earn-out distribution of the same number of shares in connection with the acquisition
of Renovaro Biosciences. This non-cash earn-out distribution impacted stockholders&#8217; equity in the amount of $<span id="xdx_90C_eus-gaap--NoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1_pp0p0_c20220713__20220714__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zzrVgkt6TA62" title="Non cash earn out distribution">2,762,500</span>&#160;based
on the share price on July 14, 2022 of $<span id="xdx_907_eus-gaap--SharePrice_iI_c20220714__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zwaif8RRWnZ3" title="Share price">2.21</span>. The Company recorded a loss on extinguishment of contingent consideration liability of $<span id="xdx_90D_ecustom--ExtinguishmentOfContingentConsiderationLiability_c20230701__20240630_zBn1tEcE51qe" title="Extinguishment of contingent consideration liability">419,182</span>&#160;during
the year ended June 30, 2024 which reflected the difference between the fair value of the shares and the contingent consideration liability
at the time of extinguishment. As of June 30, 2023, all outstanding warrants as of the date of acquisition of Renovaro Biosciences (the
&#8220;2017 Warrants&#8221;) were exercised and there is no further contingent consideration liability related to the 2017 Warrants remaining
as of June 30, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Acquisition of Renovaro Biopharma
/ Contingently issuable shares</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On February 16, 2018, the acquisition
of Renovaro Biosciences was completed. As part of the acquisition, the stockholders of Renovaro Biosciences received (i) 18,081,962 shares
of Common Stock, and (ii) the right to receive Contingent Shares of Common Stock pro rata upon the exercise or conversion of warrants,
which were outstanding at closing. As of June 30, 2025, <span id="xdx_909_ecustom--BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuable_iI_do_c20250630__us-gaap--BusinessAcquisitionAxis__custom--EBIAndWeirdScienceLLCMember__us-gaap--TypeOfArrangementAxis__custom--AgreementAndPlanOfMergerAgreementAxisMember_zMN6mqjNfpp8" title="Common shares contingently issuable">no</span> further Contingent Shares are issuable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Acquisition of Renovaro Denmark
</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">At June 30, 2025 and 2024, the
Company maintained a reserve of <span id="xdx_901_ecustom--ReserveEscrowShares_iI_c20250630_z9Y2hOzNgtQb" title="Reserve escrow shares">17,414</span> Escrow Shares, all of which are reflected as issued and outstanding in the accompanying financial
statements. The Escrow Shares are reserved to acquire the shares of Renovaro Denmark held by non-consenting shareholders of Renovaro Denmark
on both June 30, 2025 and 2024, in accordance with Section 70 of the Danish Companies Act and the Articles of Association of Renovaro
Denmark. There have been <span id="xdx_90E_ecustom--StockIssuedToNonconsentingShareholders_iI_c20250630_zTtjQONp4gK7" title="Stock issued to non-consenting shareholders">167,639</span> shares of Common Stock issued to non-consenting shareholders of Renovaro Denmark as of June 30, 2025.
During the years ended June 30, 2025 and 2024, the Company did not issue any shares of Common Stock to such non-consenting shareholders
of Renovaro Denmark.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><b>Stock-based Compensation </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company recognizes compensation
costs for stock option awards to employees based on their grant-date fair value. The value of each stock option is estimated on the date
of grant using the Black-Scholes option-pricing model. In the year ended June 30, 2025, the weighted-average assumptions used to estimate
the grant date fair values of the stock options granted using the Black-Scholes option-pricing model are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--ScheduleOfShareBasedPaymentAwardStockOptionValuationAssumptionsTableTextBlock_zI6lhXrzJhJg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span id="xdx_8BA_zwawgDZ0RtLk" style="display: none">Schedule of weighted-average assumptions used to estimate the fair values of the stock options granted</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Lunai Bioworks Inc.</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Expected term (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240701__20250630__dei--LegalEntityAxis__custom--RenovaroMember_zuGOzNmRhLCb" style="font-size: 10pt">5.5</span>
<span style="font-size: 10pt"></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20240701__20250630__srt--RangeAxis__srt--MinimumMember__dei--LegalEntityAxis__custom--RenovaroMember_zvvQSHEtbPH" title="Volatility">109.45</span>% &#8211; <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20240701__20250630__srt--RangeAxis__srt--MaximumMember__dei--LegalEntityAxis__custom--RenovaroMember_zU8NWSv9gxX6" title="Volatility">118.99</span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20240701__20250630__srt--RangeAxis__srt--MinimumMember__dei--LegalEntityAxis__custom--RenovaroMember_zNXl7K6POpVh" title="Risk free interest rate">3.86</span>%- <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20240701__20250630__srt--RangeAxis__srt--MaximumMember__dei--LegalEntityAxis__custom--RenovaroMember_z48dYHM6ppXb" title="Risk free interest rate">4.40</span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-align: left; text-indent: -10pt">Dividend yield</td><td style="width: 10%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20240701__20250630__dei--LegalEntityAxis__custom--RenovaroMember_zg0rIcCdEzod" title="Dividend yield">0</span></td><td style="width: 1%; text-align: left">%</td></tr>
  </table>


<p id="xdx_8A3_zXCgDyz3xIU2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company recognized stock-based
compensation expense related to all equity instruments of $<span id="xdx_909_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20240701__20250630_z8A7WYjgNOg4" title="Stock-based compensation expense">3,313,291</span> and $<span id="xdx_907_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20230701__20240630_z0LDxbn4h2rh" title="Stock-based compensation expense">4,673,129</span> for the years ended June 30, 2025 and 2024, respectively.
At June 30, 2025, the Company had approximately $<span id="xdx_90E_ecustom--UnrecognizedCompensationCostNonVested_iI_c20250630_z1Uz85GML2Z3" title="Unrecognized compensation cost non vested">1,009,277</span> of unrecognized compensation cost related to non-vested options.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Plan Options</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On February 6, 2014, the Company&#8217;s
Board of Directors adopted the Company&#8217;s 2014 Equity Incentive Plan (the &#8220;2014 Plan&#8221;), and the Company had reserved
<span id="xdx_906_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20140206__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2014Member_zJ6PzdgXQpTb" title="Common stock reserved for issuance">1,206,000</span> shares of Common Stock for issuance in accordance with the terms of the 2014 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On October 30, 2019, the Board
approved and on October 31, 2019, the Company&#8217;s stockholders adopted its 2019 Equity Incentive Plan (the &#8220;2019 Plan&#8221;),
which replaced the 2014 Plan. The 2019 Plan provided that the maximum aggregate number of shares of the Company&#8217;s Common Stock reserved
and available for issuance under the 2019 Plan was the sum of (1) 6,000,000 new shares, and (2) the number of shares available for the
grant of awards as of the effective date under the 2014 Plan plus any options related to awards that expire, are terminated, surrendered,
or forfeited for any reason without issuance of shares under the 2014 Plan after the effective date of the 2019 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Effective July 21, 2023, the Company
adopted the Renovaro Biosciences Inc. 2023 Equity Incentive Plan (the &#8220;2023 Plan&#8221;). The 2023 Plan replaced the 2019 Plan.
The 2023 Plan provides that the maximum aggregate number of shares of the Company&#8217;s Common Stock reserved and available for issuance
under the 2023 Plan was the sum of (1) 4,000,000 new shares, and (2) the number of shares available for the grant of awards as of the
effective date under the 2019 Plan. Any awards outstanding under the 2019 Plan as of the date of adoption of the 2023 Plan remain subject
to and will be available under the 2019 Plan, and any shares subject to outstanding awards under the 2019 Plan that subsequently expire,
terminate, or are surrendered or forfeited for any reason without issuance of shares automatically become available for issuance under
the 2023 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;The Company granted options
to purchase <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230701__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmployeesMember_z3t46SDLWZU5" title="Option granted">1,000,000</span> shares of Common Stock to employees with a five-year vesting period during the year end June 30, 2025 under the
2019 and 2023 Plan. For the year ended June 30, 2024, the Company granted options to purchase zero shares of Common Stock to employees
with a five-year vesting period under the 2019 and 2023 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;The Company granted options
to purchase zero shares of Common Stock to employees with a three-year vesting period during the year end June 30, 2025 under the 2019
and 2023 Plan. For the year ended June 30, 2024, the Company granted options to purchase <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240701__20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmployeesThreeYearMember_zr3OG910x5pg" title="Option granted">369,500</span> shares to employees with a three-year
vesting period under the 2019 and 2023 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;The Company granted options
to purchase <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240701__20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmployeesMember_zE3SdXuQmmab" title="Option granted">1,850,000</span> shares of Common Stock to employees with a two-year vesting period during the year end June 30, 2025 under the 2019
and 2023 Plan. For the year ended June 30, 2024, the Company granted options to purchase zero shares of Common Stock to employees with
a two-year vesting period under the 2019 and 2023 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the years ended June 30,
2025 and 2024, the Company granted options to purchase <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240701__20250630__us-gaap--VestingAxis__custom--ShareBasedCompensationAwardAdvisoryBoardMember_zF9PK6UZOzHh" title="Option granted">362,904</span> and <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230701__20240630__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zS0wu7AV4mGh" title="Option granted">424,412</span> shares, respectively, to the Board of Directors and Scientific
Advisory Board Members with a one-year vesting period, under the 2019 and 2023 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the years ended June
30, 2025 and 2024, the Company granted options to purchase <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240701__20250630__us-gaap--VestingAxis__custom--ShareBasedCompensationAwardBoardofDirectorsMember_zLa4xBQPOl57" title="Option granted">0</span> zero and <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230701__20240630__us-gaap--VestingAxis__custom--ShareBasedCompensationAwardBoardofDirectorsMember_zXpM7RGZ03if" title="Option granted">329,729</span>
shares, respectively, to the Board of Directors and Scientific Advisory Board Members with immediate vesting, under the 2019 and
2023 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the years ended June 30,
2025, and 2024, the Company granted options to purchase zero and <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240701__20250630__us-gaap--VestingAxis__custom--ShareBasedCompensationAwardConsultingServicesMember_z7K2HKYVrxs4" title="Option granted"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230701__20240630__us-gaap--VestingAxis__custom--ShareBasedCompensationAwardConsultingServicesMember_zeHYMP0XqRDe" title="Option granted">10,000</span></span> shares, respectively, for consulting services with a one-year
vesting period, under the 2019 and 2023 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On November 4, 2024, the Company
issued&#160;<span id="xdx_908_ecustom--DebtConversionConvertedInstrumentWarrantsOptionsIssued1_iI_c20241104__us-gaap--PlanNameAxis__custom--PlanOptionsMember_zqChV9EgDXg6" title="Options available to be issued">58,500</span>&#160;stock options to its former interim Chief Financial Officer. The options had a fair value of $<span id="xdx_905_eus-gaap--FairValueOptionChangesInFairValueGainLoss1_c20241101__20241104_zElPdxsGBtH1" title="Option fair value">31,005</span>&#160;on the
grant date, fully vest on&#160;January 6, 2025&#160;and expire on November 4, 2034. Subsequently, during the period ended March 31, 2025,
pursuant to the Company&#8217;s executive officer compensation claw back policy, the board of directors directed the Company to claw back
and cancel the&#160;<span id="xdx_909_ecustom--StockOptionIssued_iI_c20241104_znSpmhndaDkb" title="Stock option issued">58,500</span>&#160;options which were issued on November 4, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On August 23, 2024, Avram Miller,
a former member of the Company&#8217;s board of directors (the &#8220;Board of Directors&#8221;), forfeited&#160;833,333&#160;shares of
Common Stock from the original&#160;1,000,000&#160;shares of Common Stock for advisory services originally granted to him on October 11,
2023. As consideration for such forfeiture, the Company granted to Mr. Miller, an option to purchase&#160;978,261&#160;shares of Common
Stock of the Company with a per-share exercise price of $0.69. The Company determined that this transaction represented a modification
of the original award. The Company measured the fair value of the options issued as compared to the fair value of the original issuance
and determined that there was no incremental compensation to recognize as the fair value of the options was less than the fair value of
the Common Stock. Therefore, the Company will recognize the remaining fair value of the original award over the remaining vesting period,
which is one year. The Company recognized stock-based compensation expense of $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_c20250630_zMoQKEKwLq1h" title="stock option vested">1,159,470</span>&#160;related to the vesting of the stocks options
during the year ended June 30, 2025. At June 30, 2025, the Company had $<span id="xdx_90E_ecustom--UnrecognizedCompensationCost_iI_c20250630_zFlEIf6Lk8R" title="Unrecognized compensation cost">185,373</span>&#160;of unrecognized compensation cost related to the
options which vest at August 23, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">All of the above options are exercisable
at the market price of the Company&#8217;s Common Stock on the date of the grant. On February 13, 2024, the Company repriced 3,849,931
eligible employee and consultant options from the original issued exercise price to a new exercise price of $1.92 per share, the closing
price of the Company&#8217;s Common Stock on February 13, 2024. The Company recognized stock-based compensation expense related to the
repricing of options of $921,254 during the year ended June 30, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;To date the Company has
granted options under the 2014, 2019 and 2023 Plans (&#8220;Plan Options&#8221;) to purchase <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240701__20250630__us-gaap--PlanNameAxis__custom--PlanOptionsMember_zjvJ4JKiiiAi" title="Option granted">6,088,250</span> shares of Common Stock. At June
30, 2025, the Company has <span id="xdx_901_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_c20240701__20250630__us-gaap--PlanNameAxis__custom--PlanOptionsMember_zSRI2QBeS0ad" title="Options available to be issued">5,093,444</span> options available to be issued under the 2023 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">A summary of the Plan Options outstanding at June 30,
2025 is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_896_ecustom--ScheduleOfStockBasedCompensationActivityTableTextBlock_zzUDy1OZibYe" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B0_zxwLmvygJApl" style="display: none">Schedule of stock options outstanding</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    Outstanding</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="7" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    Exercisable</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise
    Price Ranges</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
    Outstanding</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    Average Remaining Contractual Life (years)</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    Average Exercise Price</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
    Exercisable</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    Average Remaining Contractual Life (years)</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    Average Exercise Price</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 11%; text-align: left; text-indent: -10pt"></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zUI9fWUQjxyb" title="Exercise Prices, Lower">0.45</span>&#8211;<span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zDbsOAVwv6ej" title="Exercise Prices, Upper">4.50</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zTDfxYZcrRCd" style="width: 9%; text-align: right" title="Number share option outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,623,614</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtYp_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zlRCO83FiHfi" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)">8.97</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zjnlcPtUsJkl" style="width: 9%; text-align: right" title="Options Outstanding, Weighted Average Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.75</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><p id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zQDTcPmHmPY3" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Options Exercisable">567,233</p></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zhvX39G5OXP8" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)">8.71</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zDv7lyXUxepa" style="width: 8%; text-align: right" title="Options Exercisable, Weighted Average Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.96</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zc1x7zTr4Tgi" title="Exercise Prices, Lower">4.51</span>&#8211;<span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_z3GBkhz0mLX7" title="Exercise Prices, Upper">6.50</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zrTjt887m7n7" style="text-align: right" title="Number share option outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1573">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zk1QH7XpIgwf" style="text-align: right" title="Options Outstanding, Weighted Average Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1575">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zuLeTzWytcp" style="text-align: right" title="Options Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1577">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zbV2PosiIG1" style="text-align: right" title="Options Exercisable, Weighted Average Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1579">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_z5xKfWKRu2y4" title="Exercise Prices, Lower">6.51</span>&#8211;<span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_znrPyRCIviei" title="Exercise Prices, Upper">12.00</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zMKFlfOEYKMh" style="border-bottom: Black 1pt solid; text-align: right" title="Number share option outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1585">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zeVPVvRIQwf6" style="border-bottom: Black 1pt solid; text-align: right" title="Options Outstanding, Weighted Average Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1587">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zCb448HV19ke" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1589">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zuOQs31b4cL2" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercisable, Weighted Average Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1591">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"></td><td style="text-align: right"></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zy8D829558B2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number share option outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,623,614</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zDqsZMhn89h1" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)">8.97</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zQ44h6xUyaAj" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding, Weighted Average Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.75</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><p id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zsCPYUXgu5M" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Options Exercisable">567,233</p></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zvxA8dTfWuo3" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)">8.71</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zHKzMsbH294g" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable, Weighted Average Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.96</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>



<p id="xdx_8A8_zcS9TpCyIEue" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A summary of changes are presented
below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zvSnzBGHPz0g" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B3_z0CmkDDSPxKi" style="display: none">Schedule of Stock option activity</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise<br/> Price</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Average Remaining Life</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Intrinsic<br/> Value</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 44%; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Outstanding at June 30, 2024</span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zzpK6WLrjZSb" style="width: 10%; text-align: right" title="Options Outstanding at beginning of period">5,527,852</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zOLIRWzP8ibk" style="width: 10%; text-align: right" title="Weighted Average Exercise Price, Outstanding at beginning of period">2.11</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zhw6GsP3381i" title="Weighted Average remaining life">7.30</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_d0_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zvWP6K5tBpij" style="width: 10%; text-align: right" title="Weighted Average Intrinsic Value, Outstanding at beginning of period">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Granted</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zplZ5PVWrrJc" style="text-align: right" title="Granted">4,249,665</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zkdWeeXIJJre" style="text-align: right" title="Weighted average exercise price, Granted">0.64</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Exercised</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_d0_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zURyob3CXWw5" style="text-align: right" title="Exercised">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d0_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zKKmDwjg2LFj" style="text-align: right" title="Weighted average exercise price, Exercised">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Forfeited</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di0_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zjc88dpn6Jz5" style="text-align: right" title="Forfeited">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d0_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zxICJY7Nerkj" style="text-align: right" title="Weighted Average Exercise Price, Forfeited">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Expired/Canceled </span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zwN2ajgNYL67" style="border-bottom: Black 1pt solid; text-align: right" title="Cancelled/Expired">(5,153,903</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zWkV5FsImWG" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Expired">2.12</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Outstanding at June 30, 2025</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zwAUx66zJX0b" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding at end of period">4,623,614</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zHvVQZ2Em65h" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding at ending of period">0.75</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zN2elfknGk5e" title="Weighted Average remaining life">8.97</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_d0_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zhUKVHVYnXd7" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Intrinsic Value, Outstanding at end of period">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Exercisable at June 30, 2025</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zK5TNBKjTdta" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable">567,233</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zzvYeoMsMiuh" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Exercisable at ending of period">0.96</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisablesWeightedAverageRemainingContractualTerm1_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zjlgEU9sn9i3" title="Weighted Average Remaining Life, Exercisable">8.71</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zKsb74I44fKf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Intrinsic Value, Exercisable end of period"><span style="-sec-ix-hidden: xdx2ixbrl1645">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AE_zBJeEfMU4Kvb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">At June 30, 2025, the Company
had Plan Options to purchase <span id="xdx_906_ecustom--PurchaseExercisableWarrantsOutstandingShares_iI_c20250630__us-gaap--VestingAxis__custom--PlanOptionMember_zcQ5SVLMi5Jk" title="Purchase exercisable warrants outstanding shares">567,233</span> shares of common stock that were exercisable. The total intrinsic value of options exercisable
at June 30, 2025, was zero. Intrinsic value is measured using the fair value at the date of exercise (for shares exercised) and at June
30, 2025 (for outstanding options), less the applicable exercise price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Common Stock Purchase Warrants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A summary of the status of the
Common Stock Purchase Warrants outstanding at June 30, 2025, is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--ScheduleOfCommonStockPurchaseWarrantsOutstandingTableTextBlock_znnvu9Do9Rh7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details 3)">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center"><span id="xdx_8BA_zLcFsXMryOo1" style="display: none">Schedule of common stock purchase warrants outstanding</span></td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="15" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants Exercisable</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Weighted</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Weighted</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Weighted</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Weighted</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Average</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Average</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Number</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Contractual</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Number</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Contractual</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Exercise</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Price</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Outstanding</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Life (years)</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Price</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Exercisable</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Life (years)</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Price</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 10%; text-align: left; text-indent: -10pt"></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_ecustom--ExercisePrices_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zErerTL2NLEd" style="width: 9%; text-align: right" title="Exercise Prices">0.53</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zqsTt1jq56j3" style="width: 9%; text-align: right" title="Number share option outstanding">471,698</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zoQoCKU7jjyb" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)">2.99</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zzschGzn2H2k" style="width: 9%; text-align: right" title="Options Exercisable">471,698</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zqa4oBkNShb7" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)">2.99</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_ecustom--ExercisePrices_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zogcE8auYHQ" style="text-align: right" title="Exercise Prices">0.65</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_z7BBCyXyUPij" style="text-align: right" title="Number share option outstanding">741,274</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zRhcrEUsTeGa" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)">3.09</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zVbKbyFkw2v" style="text-align: right" title="Options Exercisable">741,274</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zVZOlilTGUfk" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)">3.09</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_ecustom--ExercisePrices_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zh2EYdUTccQ1" style="text-align: right" title="Exercise Prices">1.14</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zwiNVo2M901i" style="text-align: right" title="Number share option outstanding">1,189,036</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zyGfDsmGybBl" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)">2.73</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_z2Nkcp1NNoh4" style="text-align: right" title="Options Exercisable">1,189,036</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_z8pAXF5C9THb" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)">2.73</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_ecustom--ExercisePrices_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange4Member_zLoXfHYiP6O2" style="text-align: right" title="Exercise Prices">1.47</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange4Member_z1PFmtDD0SB1" style="text-align: right" title="Number share option outstanding">642,128</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange4Member_zyj7XFqt9AGa" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)">3.96</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange4Member_zNTz6scTFOKa" style="text-align: right" title="Options Exercisable">642,128</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange4Member_z5XXprFMgA61" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)">3.96</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_ecustom--ExercisePrices_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange5Member_zY5K85JnGc7h" style="text-align: right" title="Exercise Prices">1.48</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange5Member_zq2pUtkY1pGg" style="text-align: right" title="Number share option outstanding">50,740</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange5Member_zNf7PImUdK4g" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)">3.99</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange5Member_zrmaHjTboG87" style="text-align: right" title="Options Exercisable">50,740</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange5Member_z2oOP9dWTSX8" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)">3.99</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_980_ecustom--ExercisePrice_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange6Member_zm39b6tcAYeb" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise Prices"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.50-1.68</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-size: 11pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 11pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 11pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; font-size: 11pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange6Member_zpSuPsupMBbl" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)">3,175,00</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange5Member_zI6jp7nrJhAi" style="border-bottom: Black 1pt solid; text-align: right" title="Options Outstanding, Weighted Average Exercise Price">0.65</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange6Member_zg2s0pLbgVjc" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercisable">3,175,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange6Member_zabxc8i6t6W3" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)">0.65</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zm4kDZ2xvYzh" style="border-bottom: Black 2.5pt double; text-align: right" title="Number share option outstanding">6,269,876</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left"></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zoSkyrPouaLl" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)">1.88</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_z4i7amudu6w" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding, Weighted Average Exercise Price">0.91</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zxYsnD7qnQFh" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable">6,269,876</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left"></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zBUsqskJmcL5" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)">1.88</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><p id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zOnYsPKkZJI" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0" title="Options Exercisable, Weighted Average Exercise Price">0.91</p></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>



<p id="xdx_8AF_zUlyDqlRuEL8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A summary of the warrant activity
is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfWarrantsOutstandingTableTextBlock_zqlAtTNSi9Zb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details 4)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span id="xdx_8B6_z46HeFRRSjh3" style="display: none">Schedule of warrants outstanding</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">&#160;<b>Shares</b></span></td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise<br/> Price</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Remaining<br/> Life</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-indent: -10pt">Outstanding at June 30, 2024</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_ecustom--CommonStockPurchaseWarrant_iS_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zBgOqd18AEHd" style="width: 11%; text-align: right" title="Outstanding at beginning of period">3,094,876</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_ecustom--CommonStockPurchaseWarrantsWeightedAverageExercisePrice_iS_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zEWM0Odm6RQ5" style="width: 11%; text-align: right" title="Weighted average exercise price, Outstanding at beginning of period">1.00</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zNqfsW65LQy" title="Weighted Average remaining life, Outstanding">3.48</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zXoWIGJN6QYe" style="text-align: right" title="Granted">3,175,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zYR1iPI6QKbi" style="text-align: right" title="Weighted average exercise price, Granted">0.82</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zVm37PF83K2" title="Weighted Average remaining life, Granted">0.65</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zT71R1ozEGnl" style="text-align: right" title="Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1738">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zPdw0hYmN7uf" style="text-align: right" title="Weighted average exercise price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1740">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Cancelled/Expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_d0_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zkHisiUAIiQf" style="border-bottom: Black 1pt solid; text-align: right" title="Cancelled/Expired">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_d0_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zIBoQIjac9n5" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Expired">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Outstanding and exercisable at June 30, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_ecustom--CommonStockPurchaseWarrant_iE_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zlg69IGA1S8d" style="border-bottom: Black 2.5pt double; text-align: right" title="Outstanding at end of period">6,269,876</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_ecustom--CommonStockPurchaseWarrantsWeightedAverageExercisePrice_iE_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zN82cjnupID9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Outstanding at ending of period">0.91</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zUvqf2AuS4H9" title="Weighted Average remaining life, Outstanding">1.88</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AD_zBIZOmiDe8tl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">At June 30, 2025, the
Company had <span id="xdx_903_ecustom--PurchaseExercisableWarrantsOutstandingShares_iI_c20250630__us-gaap--VestingAxis__us-gaap--WarrantMember_zhi72n91c6n" title="Purchase exercisable warrants outstanding shares">6,269,876</span>
exercisable Common Stock Purchase Warrants outstanding. The total intrinsic value of warrants exercisable at June 30, 2025, was <span id="xdx_900_ecustom--WarrantsExercisablePurchaseValue_iI_c20250630_zFcMrSXoXj0i" style="display: none" title="Warrants exercisable purchase value">0</span>
zero. Intrinsic value is measured using the fair market value at the date of exercise (for shares exercised) and at June 30, 2025
(for outstanding warrants), less the applicable exercise price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Restricted Stock Awards (RSA)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company recognized stock-based
compensation expense related to RSAs of $<span id="xdx_908_ecustom--StockbasedCompensationExpense_iI_c20250630__us-gaap--SubsidiarySaleOfStockAxis__custom--RestrictedStockAwardsMember_zjRTC7Pp3nr4" title="Stock-based compensation expense">36,972</span> for the year ended June 30, 2025. The restricted stock awards are related to&#160;a grant
of<span id="xdx_906_ecustom--StockbasedCompensationExpenseGrantShares_iI_c20250630__us-gaap--SubsidiarySaleOfStockAxis__custom--RestrictedStockAwardsMember_zicIW7tePhW8" title="Stock-based compensation expense grant shares">&#160;250,000</span>&#160;shares of restricted stock with a 5-year vesting period made to the Chief Executive Officer of Renovaro Cube with
a total value of $<span id="xdx_905_ecustom--StockbasedCompensationExpense_iI_c20250630__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zZTGFTfswg72" title="Stock-based compensation expense">177,500</span>. At June 30, 2025, the Company had $<span id="xdx_90A_ecustom--UnrecognizedStockbasedCompensationExpense_iI_c20250630__us-gaap--SubsidiarySaleOfStockAxis__custom--RestrictedStockAwardsMember_zzBeeSMoIvVf" title="Unrecognized stock-based compensation expense">140,527</span> of unrecognized stock-based compensation expense remaining to be
amortized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company recognized stock-based
compensation expense related to RSAs of $<span id="xdx_90E_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20230701__20240630__us-gaap--SubsidiarySaleOfStockAxis__custom--RestrictedStockAwardsMember_z7SvccEoAHa7" title="Stock-based compensation expense">1,415,157</span>&#160;for the year ended June 30, 2024. The restricted stock awards are related to&#160;a
grant of&#160;<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230701__20240630__us-gaap--SubsidiarySaleOfStockAxis__custom--RestrictedStockAwardsMember_zAdGzo5J0c9g" title="Stock-based compensation expense grant shares">1,000,000</span>&#160;shares of restricted stock with a 3-year vesting period made to a former director as consideration for advisory
services, with a total value of $<span id="xdx_90A_ecustom--AdvisoryServices_iI_c20240630__us-gaap--SubsidiarySaleOfStockAxis__custom--AdvisoryServicesMember_znhvIfxxAgIc" title="Advisory services">2,760,000</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>





<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zqjOelFGCAp6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 11 &#8212; <span id="xdx_826_zYWqMpeYjux">COMMITMENTS AND CONTINGENCIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Commitments</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On January 31, 2020, the Company
entered into a Statement of Work and License Agreement (the &#8220;HBV License Agreement&#8221;) by and among the Company, G Tech Bio,
LLC, a California limited liability company (&#8220;G Tech&#8221;), and G Health Research Foundation, a not-for-profit entity organized
under the laws of California doing business as Seraph Research Institute (&#8220;SRI&#8221;) (collectively the &#8220;Licensors&#8221;),
whereby the Company acquired a perpetual, sublicensable, exclusive license (the &#8220;HBV License&#8221;) for a treatment under development
(the &#8220;Treatment&#8221;) aimed to treat Hepatitis B Virus (HBV) infections.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The HBV License Agreement states
that in consideration for the HBV License, the Company shall provide cash funding for research costs and equipment and certain other in-kind
funding related to the Treatment over a 24-month period, and provides for an up-front payment of $<span id="xdx_90A_eus-gaap--PaymentsForFees_pn3n6_c20210130__20210131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GTechMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_z6ZAq11kOxr9" title="Payment for license">1.2</span> million within 7 days of January
31, 2020, along with additional payments upon the occurrence of certain benchmarks in the development of the technology set forth in the
HBV License Agreement, in each case subject to the terms of the HBV License Agreement. Additionally, the HBV License Agreement provides
for cooperation related to the development of intellectual property related to the Treatment and for a <span id="xdx_901_ecustom--RoyaltyPercentage_dp_c20200130__20200131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GTechMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zKkCk4Qnv2nc" title="Royalty percentage">2</span>% royalty to G Tech on any net
sales that may occur under the HBV License. On February 6, 2020, the Company paid the $<span id="xdx_907_eus-gaap--PaymentsForFees_pn5n6_c20200205__20200206__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GTechMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_ztcdTq2xUFA4" title="Payment for license">1.2</span> million up-front payment. The HBV License Agreement
contains customary representations, warranties, and covenants of the parties with respect to the development of the Treatment and the
HBV License.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The cash funding for research
costs pursuant to the HBV License Agreement consisted of monthly payments amounting to $144,500 that covered scientific staffing resources
to complete the project as well as periodic payments for materials and equipment needed to complete the project. There were no payments
made after January 31, 2022. The Company paid zero under the HBV License Agreement in years ended June 30, 2025, and 2024. The Company
has filed a claim against the Licensors, which includes certain payments it made related to this license (see Contingencies sub-section
below).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On April 18, 2021, the Company
entered into a Statement of Work and License Agreement (the &#8220;License Development Agreement&#8221;), by and among the Company, G
Tech and SRI (collectively, the &#8220;Licensors&#8221;), whereby the Company acquired a perpetual sublicensable, exclusive license (the
&#8220;Development License&#8221;) to research, develop, and commercialize certain formulations which were aimed at preventing and treating
pan-coronavirus or the potential combination of the pan-coronavirus and pan-influenza, including the SARS-coronavirus that causes COVID-19
and pan-influenza (the &#8220;Prevention and Treatment&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Development License Agreement
was entered into pursuant to the existing Framework Agreement between the parties dated November 15, 2019. The Development License Agreement
states that in consideration for the Development License, the Company shall provide cash funding for research costs and equipment and
certain other in-kind funding related to the Prevention and Treatment over a 24-month period. Additionally, the Development License Agreement
provides for an up-front payment of $<span id="xdx_908_ecustom--UpfrontPayment_c20191114__20191115_zGPdt4xSUA5g" title="Up-front payment">10,000,000</span> and a $<span id="xdx_908_ecustom--PaymentForExpenditures_c20191114__20191115_zxSlRWotlc3a" title="Payment for expenditures">760,000</span> payment for expenditures to date prior to the effective date related to
research towards the Prevention and Treatment within 60 days of April 18, 2021. The Development License Agreement provides for additional
payments upon the occurrence of certain benchmarks in the development of the technology set forth in the Development License Agreement,
in each case subject to the terms of the Development License Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Development License Agreement
provides for (i) cooperation related to the development of intellectual property related to the Prevention and Treatment and (ii) a 3%
royalty to G Tech on any net sales that may occur under the Development License Agreement. The Company is no longer pursuing any product
candidates that relate to this license. The Company has filed a claim against the Licensors to recover all monies it paid related to this
license (see Contingencies below).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On August 25, 2021, the Company
entered into an ALC Patent License and Research Funding Agreement in the HIV Field (the &#8220;ALC License Agreement&#8221;) with Serhat
G&#252;mr&#252;kc&#252; and SRI (collectively, the &#8220;Licensors&#8221;) whereby the Licensors granted the Company an exclusive, worldwide,
perpetual, fully paid-up, royalty-free license, with the right to sublicense, proprietary technology subject to a U.S. patent application,
to make, use, offer to sell, sell or import products for use solely for the prevention, treatment, amelioration of or therapy exclusively
for HIV in humans, and research and development exclusively relating to HIV in humans; provided the Licensors retained the right to conduct
HIV research in the field. Pursuant to the ALC License Agreement, the Company granted a non-exclusive license back to the Licensors, under
any patents or other intellectual property owned or controlled by the Company, to the extent arising from the ALC License, to make, use,
offer to sell, sell or import products for use in the diagnosis, prevention, treatment, amelioration or therapy of any (i) HIV Comorbidities
and (ii) any other diseases or conditions outside the HIV Field. The Company made an initial payment to SRI of $<span id="xdx_902_ecustom--InitialPayment_c20220824__20220825_z6dfIkTJBa28" title="Initial payment">600,000</span> and agreed to
fund future HIV research conducted by the Licensors, as mutually agreed to by the parties. On September 10, 2021, pursuant to the ALC
License Agreement, the Company paid the initial payment of $<span id="xdx_903_ecustom--InitialPayment_c20220909__20220910_zMG1PlJZJcxj" title="Initial payment">600,000</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">G Tech and SRI are controlled
by Anderson Wittekind, a stockholder of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Shares held for non-consenting
shareholders</b> &#8211; The <span id="xdx_901_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20250630_z6DAam1N4LZ5" title="Remaining shares">17,414</span> remaining shares of Common Stock related to the Acquisition of Renovaro Denmark have been reflected
as issued and outstanding in the accompanying financial statements.&#160;There were zero shares of Common Stock issued to such&#160;non-consenting
stockholders during the years ended June 30, 2025 and 2024 (see Note 10.)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Service Agreements</b> <i>&#8211;</i>The
Company maintains employment agreements with certain senior staff in the ordinary course of business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>Contingencies</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i>Securities Class Action Litigation</i>.
On July 26, 2022 and July 28, 2022, securities class action complaints (the former, the &#8220;Chow Action&#8221; and the latter, the
Manici Action&#8221;) were filed by purported stockholders of the Company in the United States District Court for the Central District
of California against the Company and certain of the Company&#8217;s current and former officers and directors. The complaints allege,
among other things, that the defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule
10b-5 thereunder, by making false and misleading statements and omissions of material fact in connection with the Company&#8217;s relationship
with Serhat G&#252;mr&#252;kc&#252; and its commercial prospects. The complaints seek unspecified damages, interest, fees, and costs.
On November 22, 2022, the Manici Action was voluntarily dismissed without prejudice. The Chow Action (also referred to as the &#8220;Securities
Class Action Litigation&#8221;) remains pending. On October 22, 2023, the Court appointed a lead plaintiff in the Chow Action. The lead
plaintiff filed an amended complaint on December 15, 2023. The Company filed a motion to dismiss the amended complaint on March 15, 2024.
The Court denied the Company&#8217;s motion to dismiss on June 28, 2024. A mediation was held on September 17, 2024, after which the parties
signed a stipulation of settlement. The court granted the lead plaintiff&#8217;s motion for preliminary approval of the settlement on
August 18, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i>Federal Derivative Litigation</i>.
On September 22, 2022, Samuel E. Koenig filed a shareholder derivative action in the United States District Court for the Central District
of California (the &#8220;Koenig Matter&#8221;). The Koenig Matter, filed on behalf of the Company, names Serhat G&#252;mr&#252;kc&#252;
and certain of the Company&#8217;s current and former directors as defendants, and also names the Company as a nominal defendant. The
Koenig Matter alleges violations of Sections 14(a) and 20(a) of the Securities Exchange Act of 1934, and also sets out claims for breach
of fiduciary duty, contribution and indemnification, aiding and abetting, and gross mismanagement. Plaintiff does not quantify any alleged
injury, but seeks damages, disgorgement, restitution, and other costs and expenses. On January 24, 2023, the United States District Court
for the Central District of California stayed the Koenig Matter pending resolution of the defendants&#8217; anticipated motion to dismiss
in the Securities Class Action Litigation. On June 28, 2024, the United States District Court for the Central District of California denied
defendants&#8217; motion to dismiss the Securities Class Action Litigation. On July 14, 2025, the Court stayed the Koenig Matter until
October 17, 2025. The defendants have not yet responded to the complaint.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On January 19, 2023, John Solak
filed a shareholder derivative action in the United States District Court for the District of Delaware (the &#8220;Solak Matter&#8221;).
The Solak Matter, filed on behalf of the Company, names Serhat G&#252;mr&#252;kc&#252; and certain of the Company&#8217;s current and
former directors as defendants, and also names the Company as a nominal defendant. The Solak Matter alleges violations of Section 14(a)
of the Securities Exchange Act of 1934 and SEC Rule 14a-9 promulgated thereunder, and also sets out claims for breach of fiduciary duty
and contribution and indemnification. Plaintiff does not quantify any alleged injury, but seeks damages, disgorgement, restitution, and
other costs and expenses. On April 6, 2023, the United States District Court for the District of Delaware stayed the Solak Matter pending
resolution of the defendants&#8217; anticipated motion to dismiss in the Securities Class Action Litigation. On June 28, 2024, the United
States District Court for the Central District of California denied defendants&#8217; motion to dismiss the Securities Class Action Litigation.
On July 29, 2025, the court stayed the Solak Matter for 90 days. The defendants have not yet responded to the complaint.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company intends to contest
these matters but expresses no opinion as to the likelihood of favorable outcomes. Management is unable to determine the likelihood of
a loss, including a possible range of losses, if any, arising from this matter as of the reporting date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i>State Derivative Litigation</i>.
On October 20, 2022, Susan Midler filed a shareholder derivative action in the Superior Court of California, Los Angeles County (the &#8220;Midler
Matter&#8221;). The Midler Matter, filed on behalf of the Company, names Serhat G&#252;mr&#252;kc&#252; and certain of the Company&#8217;s
current and former directors as defendants. The Midler Matter also names the Company as a nominal defendant. The Midler Matter sets out
claims for breaches of fiduciary duty, contribution and indemnification, aiding and abetting, and gross mismanagement. Plaintiff does
not quantify any alleged injury, but seeks damages, disgorgement, restitution, and other costs and expenses. On January 20, 2023, the
Court stayed the Midler Matter pending resolution of the defendants&#8217; anticipated motion to dismiss in the Securities Class Action
Litigation. On June 28, 2024, the United States District Court for the Central District of California denied defendants&#8217; motion
to dismiss the Securities Class Action Litigation. On July 31, 2025, the court stayed the Midler Matter for 120 days. The defendants have
not yet responded to the complaint. The Company intends to contest this matter but expresses no opinion as to the likelihood of a favorable
outcome. Management is unable to determine the likelihood of a loss, including a possible range of losses, if any, arising from this matter
as of the reporting date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On October
21, 2022, the Company filed a Complaint in the Superior Court of the State of California for the County of Los Angeles against Serhat
G&#252;mr&#252;kc&#252; (&#8220;Gumrukcu&#8221;), William Anderson Wittekind (&#8220;Wittekind&#8221;), G Tech Bio, SG &amp; AW Holdings,
LLC, and SRI (collectively, the &#8220;Defendants&#8221;). The Complaint alleges that the Defendants engaged in a &#8220;concerted, deliberate
scheme to alter, falsify, and misrepresent to the Company the results of multiple studies supporting its Hepatitis B and SARS-CoV-2/influenza
pipelines.&#8221; Specifically, &#8220;Defendants manipulated negative results to reflect positive outcomes from various studies, and
even fabricated studies out of whole cloth.&#8221; As a result of the Defendants&#8217; conduct, the Company claims that it &#8220;paid
approximately $25 million to Defendants and third-parties that it would not otherwise have paid.&#8221; On April 21, 2023, defendants
Wittekind, G Tech, SG &amp; AW Holdings, LLC, and SRI filed a demurrer with respect to some, but not all, of the Company&#8217;s claims,
as well as a motion to strike. On September 6, 2023, the court denied in part and granted in part the pending motions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On December
4, 2023, the Defendants answered the Company&#8217;s First Amended Complaint and G Tech and SRI filed a Cross-Complaint. In the Cross-Complaint,
G Tech and SRI seek declaratory and injunctive relief related to certain agreements between G Tech, SRI, and the Company, including, <i>inter
alia</i>, a declaration that the Framework Agreement, effective as of November 15, 2019, the Statement of Work &amp; License Agreement,
effective as of January 31, 2020, and the Statement of Work and License Agreement for Influenza and Coronavirus Indications, effective
as of April 18, 2021, have been terminated and the Company has no rights to any license under such agreements. Trial was scheduled to
begin on March 3, 2025. On November 14, 2024, the court vacated the March 3, 2025, trial date and set a trial setting conference for May
1, 2025. At the May 1, 2025, trial setting conference, the court reset the trial to begin on November 30, 2026. Discovery remains ongoing.
The Company denies the allegations in Defendants&#8217; cross claims and intends to vigorously defend against them while pursuing its
claims against the Defendants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On June
7, 2023, Weird Science LLC (&#8220;Weird Science&#8221;), Wittekind, the William Anderson Wittekind 2020 Annuity Trust, the William Anderson
Wittekind 2021 Annuity Trust, the Dybul 2020 Angel Annuity Trust, and the Ty Mabry 2021 Annuity Trust (collectively, the &#8220;Trusts&#8221;)
(collectively, &#8220;Plaintiffs&#8221;) filed a Verified Complaint against the Company in the Court of Chancery of Delaware. In the Verified
Complaint, Plaintiffs alleged that the Company breached the February 16, 2018 Investor Rights Agreement between the Company, Weird Science,
and RS Group ApS (the &#8220;Investor Rights Agreement&#8221;). According to the Verified Complaint, the Investor Rights Agreement required
the Company to (i) notify all &#8220;Holders&#8221; of &#8220;Registrable Securities&#8221; at least 30 days prior to filing a registration
statement and (ii) afford such Holders an opportunity to have their Registrable Securities included in such registration statement. Plaintiffs
alleged that the Company breached these registration rights by failing to provide the required notice in connection with S-3 registration
statements filed by the Company on July 13, 2020 and February 11, 2022. The Company moved to dismiss the Verified Complaint on September
15, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On December
4, 2023, in lieu of opposing the motion to dismiss, Plaintiffs filed a Verified First Amended Complaint (&#8220;FAC&#8221;). In the FAC,
Plaintiffs assert claims against the Company and others for purported breaches of the Investor Rights Agreement, fraud, tortious interference
with a contract, and several other torts. Plaintiffs seek compensatory, exemplary, and punitive damages, as well as certain declaratory
relief, specific performance, and pre- and post-judgment interest, costs, and attorneys&#8217; fees. The Company filed a motion to dismiss
the FAC on December 18, 2023 and the court held a hearing on November 15, 2024. At the hearing, the court dismissed (1) all claims brought
on behalf of Wittekind and the Trusts, (2) the fraudulent concealment claim against the Company and others (without prejudice), and (3)
the breach of contract claim against the Company related to a registration statement that was not filed in 2023. At the hearing, the court
also found that punitive damages were not available to Plaintiffs. The court took the remaining issues briefed on the Company&#8217;s
motion to dismiss under advisement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On February
26, 2025, the Court ruled on the balance of the claims against the Company and (1) denied the Company&#8217;s motion to dismiss Weird
Science&#8217;s breach of contract claims related to registration statements filed in 2020 and 2022; (2) dismissed the fraudulent inducement
claim as time barred; and (3) dismissed the declaratory judgment claim. The Company denies Plaintiffs&#8217; allegations and remaining
claims and intends to vigorously defend against these claims.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On August
24, 2023, counsel on behalf of Weird Science, Wittekind, individually, and Wittekind, as trustee of the Trusts served a demand to inspect
the Company&#8217;s books and records (the &#8220;Demand&#8221;) pursuant to Delaware General Corporation Law, &#167; 220 (&#8220;Section
220&#8221;). The Demand seeks the Company&#8217;s books and records in connection with various issues identified in the Demand. The Company
takes its obligations under Section 220 seriously and, to the extent that the requests are proper under Section 220, intends to comply
with those obligations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On January 19, 2024, Weird Science
and Wittekind sent the Board of Directors a letter demanding it take corrective actions with respect to twenty-one issues identified therein.
On February 27, 2024, Weird Science and Wittekind sent the Board of Directors a supplemental letter that expanded their demand for corrective
actions to twenty-six issues. In response to these demand letters, the Board of Directors initially formed a Special Committee (&#8220;Special
Committee&#8221;) of independent directors on February 29, 2024. The Special Committee retained Stradling Yocca Carlson &amp; Rauth LLP
as its counsel to investigate the issues identified in the demand letters.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On January 23, 2024, Weird Science
and Wittekind filed a shareholder derivative action in the United States District Court for the Central District of California against
certain officers, directors, and investors of the Company, as well as other defendants, in connection with, <i>inter alia</i>, Weird Science
and Wittekind&#8217;s demand for corrective action. Plaintiffs filed an amended complaint on June 21, 2024. The First Amended Verified
Stockholder Derivative Complaint (&#8220;Derivative Complaint&#8221;) alleges, among other claims, violations of Section 13(d) and 14(a)
and Rules 10b-5(a), 10b-5(c) and 14a-9 of the Exchange Act of 1934. The Derivative Complaint also includes claims of breach of fiduciary
duty, corporate waste, unjust enrichment, and contribution/indemnification. Weird Science and Wittekind seek unspecified compensatory,
exemplary, and punitive damages and certain injunctive relief. The Derivative Complaint names the Company as a nominal defendant. On July
19, 2024, certain of the director defendants, who had agreed to waive service of the summons and Derivative Complaint, filed a motion
to dismiss the Derivative Complaint on a variety of procedural and substantive grounds. A hearing on the motion dismiss was held on October
3, 2024 and the court subsequently took the motion under submission. On October 22, 2024, the plaintiffs filed a notice of certain subsequent
events that they allege relate to their pending motion to dismiss. On October 29, 2024, the court granted the director defendants&#8217;
motion to dismiss and dismissed the Derivative Complaint without prejudice, but also without leave to amend.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On November 27, 2024, Weird Science
and Wittekind filed a notice of appeal of the court&#8217;s decision granting the director defendants&#8217; motion to dismiss. The appeal
remains pending.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On June 21, 2024, the Company
filed suit against Weird Science, Gumrukcu, Wittekind, and certain trusts in connection with the February 16, 2018 merger involving the
Company and two companies closely associated with Gumrukcu. In the complaint, the Company alleges that G&#252;mr&#252;kc&#252;and others
deliberately and fraudulently concealed a murder-for-hire scheme from the Company in order to induce the Company to enter into the merger
agreement, which resulted in the defendants receiving shares and compensation. The Company asserts claims for fraudulent concealment,
equitable fraud, unjust enrichment, and civil conspiracy and seeks, <i>inter alia</i>, equitable relief, including, but not limited to,
return to the Company any shares received in connection with the merger, and damages. On October 1, 2024, the defendants moved to dismiss
the complaint. A hearing took place on June 25, 2025 and the Court took defendants&#8217; motion under advisement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Lunai commenced an action against
Predictive Oncology, Inc. (&#8220;POAI&#8221;) in the Delaware Court of Chancery claiming that POAI breached a &#8220;definitive&#8221;
January 2025 Letter Agreement pursuant to which Lunai was going to acquire POAI. As a result of its breach, POAI made that acquisition
impossible and dramatically devalued the share price of stock Lunai had already acquired as well as the value of the company it was contractually
entitled to acquire. Lunai sought specific performance or, in the alternative, money damages. The parties have exchanged paper discovery
and noticed depositions. The action has been held in abeyance while the parties attempt to negotiate a settlement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p id="xdx_802_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zntZKDnOBTzg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 12 &#8212; <span id="xdx_823_zNGLGMjaoHqd">RELATED PARTY TRANSACTIONS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of June 30, 2025, the Company
has accrued $<span id="xdx_90F_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20240701__20250630__us-gaap--RelatedPartyTransactionAxis__custom--MarkDybulMember_zO0CghFWmOp8" title="Accrued balance">384,949</span> of compensation related expenses for the Company&#8217;s former Chief Executive Officer, Mark Dybul, related to budget
constraints.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On August 23, 2024, Avram Miller,
a former member of the Company&#8217;s board of directors (the &#8220;Board of Directors&#8221;), forfeited&#160;<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_c20240802__20240823_zc9KYGpvYfN1" title="Common stock forfeited shares">833,333</span>&#160;shares of
Common Stock from the original&#160;<span id="xdx_90D_ecustom--SharesOfCommonStockGranted_iI_c20240823_zVhLqixksHz7" title="Shares of common stock  granted">1,000,000</span>&#160;shares of Common Stock for advisory services originally granted to him on October 11,
2023. As consideration for such forfeiture, the Company granted to Mr. Miller, an option to purchase&#160;<span id="xdx_900_eus-gaap--StockRepurchasedDuringPeriodShares_c20240822__20250823_zNp1pogyFMKc" title="Purchase shares">978,261</span>&#160;shares of Common
Stock of the Company with a per-share exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250216__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zEAowP0qjJTj" title="Warrant exercise price per share">0.69</span>. The Company determined that this transaction represented a modification
of the original award. The Company measured the fair value of the options issued as compared to the fair value of the original issuance
and determined that there was no incremental compensation to recognize as the fair value of the options was less than the fair value of
the Common Stock. Therefore, the Company will recognize the remaining fair value of the original award over the remaining vesting period,
which is one year. The Company recognized stock-based compensation expense of $<span id="xdx_901_eus-gaap--ProceedsFromStockOptionsExercised_c20240701__20250630_zcZfzMMTIiaj" title="Stock-based compensation expense stock option vesting">1,159,470</span>&#160;related to the vesting of the stocks options
during the year ended June 30, 2025. At June 30, 2025, the Company had $<span id="xdx_907_ecustom--UnrecognizedCompensationExpense_c20240701__20250630_zQgDmpzUZP5b" title="Unrecognized compensation expense">185,373</span>&#160;of unrecognized compensation cost related to the
options which vest at August 23, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">ACQUISITIONS</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--BusinessCombinationDisclosureTextBlock_zUSNEpfwWoca" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 13 &#8212; <span id="xdx_824_zKidpMCOiJpg">ACQUISITIONS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><i><span style="text-decoration: underline">BioSymetrics Inc. Acquisition:</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">On February 26, 2025, Lunai Bioworks Inc., a Delaware
corporation (&#8220;<span style="text-decoration: underline">Lunai</span>&#8221;), entered into an Agreement and Plan of Merger (the &#8220;<span style="text-decoration: underline">Merger Agreement</span>&#8221;) with
Renovaro Acquisition Sub, a Delaware corporation and wholly owned subsidiary of Lunai (&#8220;<span style="text-decoration: underline">Merger Sub</span>&#8221;), and Biosymetrics,
Inc., a Delaware corporation (&#8220;<span style="text-decoration: underline">Biosymetrics</span>&#8221;), pursuant to which Lunai agreed to acquire Biosymetrics pursuant to the
merger of Merger Sub with and into Biosymetrics, with Biosymetrics as the surviving corporation and a wholly owned subsidiary of Lunai
(the &#8220;<span style="text-decoration: underline">Transaction</span>&#8221;). On April 8, 2025, Lunai consummated the Transaction and issued <span id="xdx_90A_ecustom--TransactionIssuedShares_iI_pn3n3_dm_c20250408_z14JRduEqDef" title="Transaction issued shares">15.0</span> million shares of Lunai&#8217;s
common stock, par value $<span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20250408_z59MeWvqqdc7" title="Common stock per value">0.0001</span> per share (the &#8220;<span style="text-decoration: underline">Shares</span>&#8221;), to the former stockholders of Biosymetrics in accordance
with the terms of the Merger Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The
offer and sale of the Shares have not been registered under the Securities Act of 1933, as amended (the &#8220;<span style="text-decoration: underline">Securities Act</span>&#8221;),
in reliance on the exemption from registration requirements thereunder provided by Section 4(a)(2) thereof. Lunai relied in part upon
representations contained in the Merger Agreement that all those receiving Shares in connection with the Transaction are &#8220;accredited
investors&#8221; as defined in Rule 501(a) under the Securities Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">The
transaction was accounted for in accordance with ASC 805-10 -&#160;<i>Business Combinations</i>. </span>The assets acquired and liabilities
assumed are initially recognized in the accompanying consolidated balance sheets at their estimated fair values as of the acquisition
date. The fair values as of the acquisition date are based on information that existed as of the acquisition date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The acquisition-date
fair value of the consideration transferred totaled approximately $<span id="xdx_900_eus-gaap--BusinessCombinationConsiderationTransferredOther1_pn5n6_c20240701__20250630__us-gaap--BusinessAcquisitionAxis__custom--BioSymetricsMember_zxPFPfGodem2" title="Fair value of consideration transferred amount">6</span> million, which consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89A_ecustom--ScheduleOfAcquistionFairValueOfConsiderationTableTextBlock_hsrt--CounterpartyNameAxis__custom--BioSymetricsncAcquisitionMember_zAl9SmiIjYt3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITION (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B0_zAaE5SSH5Q6b" style="display: none">Schedule of acquisition
date fair value</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-align: left; text-indent: -10pt">Common stock</td><td style="width: 10%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--BusinessCombinationContingentConsiderationCommonStock_iI_c20250226__us-gaap--BusinessAcquisitionAxis__custom--BioSymetricsncAcquisitionMember_zwtePe5aQoNe" style="border-bottom: Black 1pt solid; width: 18%; text-align: right" title="Common stock">6,058,500</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total consideration transferred</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--BusinessCombinationConsiderationTransferred1_c20250212__20250226__us-gaap--BusinessAcquisitionAxis__custom--BioSymetricsncAcquisitionMember_zhrSYeUXaz88" style="border-bottom: Black 2.5pt double; text-align: right" title="Total consideration transferred">6,058,500</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_zSkxWy4Nvem2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">The
fair value of the Company&#8217;s common shares issued as consideration was based on the closing price of the Company&#8217;s common stock
as of the Acquisition Date. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">The
following table details the fair values of the assets acquired and liabilities assumed at the acquisition date:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_hsrt--CounterpartyNameAxis__custom--BioSymetricsncAcquisitionMember_zPoXSZHQBGMg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITION (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8BA_z32iterXKz8f" style="display: none">Schedule of fair value of assets acquired and
liabilities assumed</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49B_20250226__us-gaap--BusinessAcquisitionAxis__custom--BioSymetricsncAcquisitionMember_z2TTACyafD7f" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iNI_di_zoDfgVvesNhc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-indent: -10pt">Cash</td><td style="width: 10%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">(3,822</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_iI_zGuAiTHzuQO4" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Prepaid &amp; Other Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,405</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets_iI_zEIivZWq8YOd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Fixed Assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">13,365</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_iI_zIu0KyNSDl4a" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total Assets Acquired:</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">26,948</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_iI_zUlScKTen1dk" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Accounts Payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">975</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_iI_zlFuO4SDEVje" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Accrued Expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,594</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities_iI_zEuGctgBrD98" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Other Current Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">73,879</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_iI_zbHlNEqiQkeb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total Liabilities Assumed</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">82,448</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_zJ9gkdRrmkS8" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net Assets Acquired</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(55,500</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_404_ecustom--Software_iI_zYuBoHYY5pJd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Software</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">143,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--TradeName_iI_zbjIakIOHa1a" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Trade Name</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_iI_z0JeEKq8Wzb7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Goodwill</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,963,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_iI_zr73hkD7clp9" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total Consideration</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,058,500</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_zVppS1OX6XYf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
goodwill recognized is attributable primarily to expected synergies and the assembled workforce of BioSymetrics. None of the
goodwill is expected to be deductible for income tax purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The fair
values of the acquired tangible and intangible assets were determined using variations of the income approach. The income approach valuation
methodology used for the intangible assets acquired makes use of Level 3 inputs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Consolidated unaudited pro forma information: </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following consolidated pro
forma information assumes that the acquisition of BioSymetrics Inc. took place on July 1, 2024 for the statement of operations for the
twelve-month period ended June 30, 2025. These amounts have been estimated after applying the Company&#8217;s accounting policies:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--ScheduleOfConsolidatedStatementsOfOperationsTableTextBlock_hsrt--CounterpartyNameAxis__custom--BioSymetricsncAcquisitionMember_znkTNcWBnRG" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITION (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B1_ziqFm9TRWEY2" style="display: none">Schedule of consolidated
statements of operations</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_493_20240701__20250630__us-gaap--BusinessAcquisitionAxis__custom--BioSymetricsncAcquisitionMember_zFVaF7KKfc59" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_ecustom--BusinessAcquisitionsRevenue_d0_zOZF3Ef0iEd9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-indent: -10pt">Revenues</td><td style="width: 10%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 18%; text-align: right">663,660</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--BusinessAcquisitionsNetIncomeLoss_zf5Rj2q3Pt01" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(179,698,700</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  </table>

<p id="xdx_8A8_z89EKECiWZH6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The unaudited pro forma results
are presented for informational purposes only and are not necessarily indicative of what the actual results of operations would have been
if the acquisition had occurred at the beginning of the period presented, nor are they indicative of future results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><i><span style="text-decoration: underline">GEDi Cube Intl Ltd. Acquisition:</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On September
28, 2023, the Company, entered into a Stock Purchase Agreement (the &#8220;<span style="text-decoration: underline">Purchase Agreement</span>&#8221;) with GEDi Cube Intl Ltd.,
a private company formed under the laws of England and Wales (&#8220;<span style="text-decoration: underline">GEDi Cube</span>&#8221;) to acquire 100% of the equity interests
of GEDi Cube from its equity holders (the &#8220;<span style="text-decoration: underline">Sellers</span>&#8221;). On September 28, 2023, the Board of Directors of the Company,
and the board of managers of GEDi Cube unanimously approved the Purchase Agreement and on January 25, 2024, the shareholders of the Company
approved the issuance of the shares of Common Stock pursuant to the Purchase Agreement. On February 13, 2024 (the &#8220;Closing Date&#8221;),
the Company consummated the acquisition of GEDi Cube and the other transactions contemplated by the Stock Purchase Agreement (collectively,
the &#8220;Transaction&#8221;). As a result of the Transaction, GEDi Cube became a wholly-owned subsidiary of the Company. The Company
believes the acquisition will provide it with access to the nascent field of artificial intelligence and machine learning driven diagnostics,
which was the primary purpose for the acquisition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Pursuant
to the Stock Purchase Agreement, as of the Closing Date, the Company acquired all the issued and outstanding equity interests of GEDi
Cube owned by the Sellers as of the Closing Date (each, a &#8220;GEDi Cube Share&#8221; and, collectively, the &#8220;GEDi Cube Shares&#8221;)
in exchange for which each Seller was entitled to receive (i) as of the Closing Date, such Seller&#8217;s pro rata percentage of an aggregate
of 70,834,183 shares of common stock, par value $0.0001 per share, of the Company (&#8220;Common Stock&#8221;), which represents the 67,224,089
shares of Common Stock issued and outstanding as of the Closing Date (minus (a) 1 million shares of Common Stock previously issued to
a consultant assisting with the Transaction and (b) 1 million shares of Common Stock previously issued to Avram Miller, a director of
the Company, pursuant to his Advisory Agreement, dated October 11, 2023, by and between Mr. Miller and the Company) (the &#8220;Closing
Consideration&#8221;) plus 5,610,100 shares of Common Stock representing the Seller&#8217;s Earnout Shares (defined below) resulting from
the automatic conversion of the Company&#8217;s Series A Convertible Preferred and, (ii) following the Closing Date, such Seller&#8217;s
pro rata percentage of the shares of Common Stock (the &#8220;Earnout Shares&#8221; and, together with the Closing Consideration, the
&#8220;Exchange Consideration&#8221;) to be issued to the Sellers upon the exercise or conversion of any of the Company&#8217;s derivative
securities (subject to certain exceptions) that are outstanding at the Closing Date (the &#8220;Closing Derivative Securities&#8221;).
Each Seller&#8217;s pro rata percentage of the Exchange Consideration is equal to the ratio of the aggregate number of GEDi Cube Shares
owned by such Seller divided by the aggregate number of GEDi Cube Shares issued and outstanding, in each case, as of the Closing Date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">The
transaction was accounted for in accordance with the provisions of ASC 805-10 -&#160;<i>Business Combinations</i>. </span>As a result
of the issuance of the Closing Consideration on the Closing Date and based on the number of shares of Common Stock outstanding as of the
Closing Date, the Sellers held approximately 49% of the issued and outstanding shares of Common Stock immediately following the closing
of the Transaction and the conversion of the Series A Convertible Preferred Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The assets
acquired and liabilities assumed were initially recognized provisionally in the accompanying consolidated balance sheets at their estimated
fair values as of the acquisition date. The fair values as of the acquisition date are based on information that existed as of the acquisition
date. The Company completed its accounting for this acquisition during the period ended June 30, 2024. As a result of the completion of
the Company&#8217;s analysis, the amount of in-process research and development was determined to have a value of nil. Accordingly, the
amount of goodwill recognized was increased to include the previously recognized amount of in-process research and development. There
was no impact to the Company&#8217;s consolidated statement of operations as a result of this change to the allocation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The acquisition-date
fair value of the consideration transferred totaled approximately $<span id="xdx_90C_eus-gaap--BusinessCombinationConsiderationTransferredOther1_pn5n6_c20240701__20250603__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zx20bFH8Rutf" title="Fair value of consideration transferred amount">156.6</span> million, which consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfAcquistionFairValueOfConsiderationTableTextBlock_hsrt--CounterpartyNameAxis__custom--GEDiCubeIntlLtdAcquisitionMember_zbLc9sRUqKSk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITION (Details 5)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B6_zEeSLO08dL32" style="display: none">Schedule of acquisition
date fair value</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-align: left; text-indent: -10pt">Common stock</td><td style="width: 10%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_ecustom--BusinessCombinationContingentConsiderationCommonStock_iI_c20250226__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zaxIB00nYcQb" style="width: 18%; text-align: right" title="Common stock">136,001,631</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Contingent consideration</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--BusinessCombinationContingentConsiderationAsset_iI_c20250226__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zriLj2VJ8p0i" style="border-bottom: Black 1pt solid; text-align: right" title="Contingent consideration">20,557,500</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total consideration transferred</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--BusinessCombinationConsiderationTransferred1_c20250212__20250226__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zP2MJDibj9K8" style="border-bottom: Black 2.5pt double; text-align: right" title="Total consideration transferred">156,559,131</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A6_zKBo6QVtLnP6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">The
fair value of the Company&#8217;s common shares issued as consideration was based on the closing price of the Company&#8217;s common stock
as of the Acquisition Date. The fair value of the contingent consideration was based on the Sellers&#8217; right to receive additional
shares of common, pro rata, upon the exercise or conversion of warrants, options and convertible notes payables outstanding as of the
Closing Date. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">The
following table details the fair values of the assets acquired and liabilities assumed at the acquisition date:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_898_ecustom--ScheduleOfRecognizedIdentifiedAssetsAndLiabilitiesAssumedTableTextBlock_zVmaEFICs4S2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITION (Details 4)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B0_znxHeYyjvRB2" style="display: none">Schedule of fair value of assets acquired and
liabilities assumed</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49F_20250226__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zQph1CtNtkS6" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_z6tSoIkmltI3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-indent: -10pt">Cash</td><td style="width: 10%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">65,851</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_iI_zGDtqFoBR44b" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Prepaid &amp; Other Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">151,544</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets_iI_zkTa9G4qylS3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Fixed Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,243</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseRightOfUseAssets_iI_zLa2H5VBx0Pk" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Operating lease ROU</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">624,366</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_iI_ziRcp96fGfof" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total Assets Acquired:</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">858,004</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_iI_zfWvrHdXf6M1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Accounts Payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">583,577</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_iI_zIYxlh3dLwCd" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Accrued Expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">722,508</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities_iI_zUFJjLa0R0T8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Operating Lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">624,367</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable_iI_zQmWfInPkEQj" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Notes Payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,832,460</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_iI_zKqbaXpnCKcc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total Liabilities Assumed</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,762,913</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_zCEVoVBIByZi" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net Assets Acquired</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,904,909</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_iI_zM2LzSTjVeUb" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Goodwill</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">159,464,040</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_iI_zCMPUeGT5kcd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total Consideration</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">156,559,131</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The
goodwill recognized is attributable primarily to expected synergies and the assembled workforce of GEDi. None of the goodwill is expected
to be deductible for income tax purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The fair
values of the acquired tangible and intangible assets were determined using variations of the income approach. The income approach valuation
methodology used for the intangible assets acquired makes use of Level 3 inputs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The Company
recognized approximately $<span id="xdx_903_eus-gaap--BusinessCombinationAcquisitionRelatedCosts_pn5n6_c20230701__20240630__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zM59CyDtHqCl" title="Acquisition related costs">1.2</span> million of acquisition related costs that were expensed during the period ended June 30, 2024. These costs
are included in &#8220;selling, general and administrative expenses&#8221; in the accompanying condensed consolidated statements of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Consolidated unaudited pro forma information: </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following consolidated pro forma information assumes that the acquisition
of GEDi took place on July 1, 2023 for the statement of operations for the twelve-month period ended June 30, 2024. These amounts have
been estimated after applying the Company&#8217;s accounting policies:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>





<table cellpadding="0" cellspacing="0" id="xdx_89C_ecustom--custom--ScheduleOfConsolidatedStatementsOfOperationsTableTextBlock_hsrt--CounterpartyNameAxis__custom--GEDiCubeIntlLtdAcquisitionMember_zOpINOOxtCmk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITION (Details 3)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_492_20240701__20250630__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zSRDllRMIJN7" style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_404_ecustom--BusinessAcquisitionsRevenue_d0_zgHWOo15vUoe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Revenues</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--BusinessAcquisitionsNetIncomeLoss_zalIi4AWeGz2" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-align: left; text-indent: -10pt">Net loss</td><td style="width: 10%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 18%; text-align: right">(83,571,822</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">)</td></tr>
  </table>

<p id="xdx_8A2_z1q3TSJBrgoc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The unaudited pro forma results
are presented for informational purposes only and are not necessarily indicative of what the actual results of operations would have been
if the acquisition had occurred at the beginning of the period presented, nor are they indicative of future results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/805/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT REPORTING<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT REPORTING</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--SegmentReportingDisclosureTextBlock_zz2CxbAImxtg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 14 &#8212; <span id="xdx_824_zxhHHSpDe9c5">SEGMENT REPORTING</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For the year ended June 30, 2025,
the Company had three reportable segments. These segments have different strategic and economic goals and are managed separately because
they require different technology and marketing strategies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
<td style="border-bottom: black 1pt solid; white-space: nowrap; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reportable
Segment</b></span></td>
<td style="white-space: nowrap; width: 2%; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="border-bottom: black 1pt solid; white-space: nowrap; width: 80%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description
</b></span></td></tr>
<tr style="vertical-align: bottom">
<td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RENB</b></span></td>
<td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Developing new immunotherapies
to combat cancer </span></td></tr>
<tr style="vertical-align: bottom">
<td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BioSymetrics</b></span></td>
<td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Integrating multimodal data
sources, including genomics, imaging, electronic health records, and other real-world evidence, to advance biomarker discovery, therapeutic
development, and precision medicine.</span></td></tr>
<tr style="vertical-align: bottom">
<td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RENC</b></span></td>
<td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Developing a predicative artificial intelligence based
diagnostic methodology for the use of earlier cancer detection </span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The Company&#8217;s
chief executive officer is the chief operating decision maker and reviews the internal management reports for each segment at least quarterly.
During the year ended June 30, 2025, there were no significant inter-company revenues or expenses. The chief operating decision maker
assesses performance for each segment and decides how to allocate resources based on segment operating losses that also is reported on
the consolidated statement of operations. The measure of segment assets is reported on the balance sheet as total consolidated assets.
The accounting policies of each segment are the same as those described in the summary of significant accounting policies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zdUDi4exyaWb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SEGMENT REPORTING (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"><span id="xdx_8B2_z6gLeveQNbOf" style="display: none">Schedule of segment operating loss and
    asset information</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Operating loss</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Assets</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; font-weight: bold; text-align: left; text-indent: -10pt">United States (RENB)</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--SegmentOperatingLoss_c20240701__20250630__srt--StatementGeographicalAxis__country--US_zTqkzEFiBbkk" style="width: 12%; text-align: right" title="Operating income loss">15,530,056</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--SegmentAsset_iI_c20250630__srt--StatementGeographicalAxis__country--US_z1Dxzi7xZxc7" style="width: 12%; text-align: right" title="Assets">1,907,647</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">United States (BioSymetrics)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--SegmentOperatingLoss_c20240701__20250630__srt--StatementGeographicalAxis__custom--BioSymetricsMember_z3IMPpLY3Z4i" style="text-align: right" title="Operating income loss">237,880</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--SegmentAsset_iI_c20250630__srt--StatementGeographicalAxis__custom--BioSymetricsMember_zQx2JOs8qNi3" style="text-align: right" title="Assets">6,109,643</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Netherlands (RENC)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_ecustom--SegmentOperatingLoss_c20240701__20250630__srt--StatementGeographicalAxis__country--NL_zLymUYaPzfqj" style="border-bottom: Black 1pt solid; text-align: right" title="Operating income loss">173,198,066</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_ecustom--SegmentAsset_iI_c20250630__srt--StatementGeographicalAxis__country--NL_zkTPpSNyISdj" style="border-bottom: Black 1pt solid; text-align: right" title="Assets">213,550</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_988_ecustom--SegmentOperatingLoss_c20240701__20250630_zEwvC8oPeMQb" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Operating income loss">188,966,002</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_981_ecustom--SegmentAsset_iI_c20250630_zLf8FAxU9A23" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Assets">8,230,840</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A6_zY8Yw0fcgMZ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The chief
operating decision maker uses loss from operations to evaluate the performance of each segment&#8217;s assets in deciding how to allocate
available capital between segments. The chief operating decision maker also uses loss from operations in their competitive analysis by
benchmarking the Company&#8217;s competitors. The competitive analysis along with the monitoring of budgeted versus actual results are
used in assessing the performance of the segment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Information
regarding each reportable segment for the year ended June 30, 2025 is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_zBaCQ2PFb6W6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SEGMENT REPORTING (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B8_zGCMTWRXTdPf" style="display: none">Schedule of information regarding segment reporting</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_490_20240701__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--RENBMember_zKUWfCht6Nvd" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_497_20240701__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--BioSymetricsMember_zixUeXPh5Ud9" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_496_20240701__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--RENCMember_zbZDpF18LPS7" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49F_20240701__20250630_zGqqSm4HTlD1" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">RENB</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">BioSymetrics</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">RENC</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td></tr>
  <tr id="xdx_405_eus-gaap--OtherGeneralAndAdministrativeExpense_zm8VctnRFQ5k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt">General and administrative</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">14,904,855</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">211,401</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">2,763,794</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">17,880,050</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--ResearchAndDevelopmentExpense_zNfZ1RwN4MBl" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">502,896</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26,029</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,503</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">537,428</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--GoodwillAndIntangibleAssetImpairment_d0_zJWFVuCpvcrh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Goodwill impairment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">170,419,429</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">170,419,429</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DepreciationDepletionAndAmortization_zygwY7gL8pY5" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">122,305</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">450</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,340</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">129,095</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--SegmentOperatingLoss_zQ1J1j7Y6Pq9" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Segment operating loss</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">15,530,056</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">237,880</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">173,198,066</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">188,966,002</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white"><b><span style="text-decoration: underline">Geographic information:</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">RENB,
BioSymetrics and RENC are managed on a worldwide basis but operate in offices located in the United States and the Netherlands, respectively.
The geographic information analyses the Company&#8217;s operations and assets based on the country in which each segment operates. In
presenting this geographic information, segment operating results have been based on the geographic location in which the services were
provided to the segment and segment assets were based on the geographic location of the assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"></p>





<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--SubsequentEventsTextBlock_z9ePr0vhNaW3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 15 &#8212; <span id="xdx_826_z6AHyLeMjOd8">SUBSEQUENT EVENTS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="background-color: white">On
September 18, 2025, the Company filed a Certificate of Amendment to the Certificate of Incorporation of the Company (the &#8220;</span><b>Certificate
of Amendment</b><span style="background-color: white">&#8221;) with the Secretary of State of the State of Delaware to effect a 1-for-10
reverse stock split of the shares of the Company&#8217;s common stock, par value $0.0001 per share (the &#8220;</span><b>Common Stock</b><span style="background-color: white">&#8221;),
either issued and outstanding or held by the Company as treasury stock, effective as of 12:01 a.m. (New York time) on September 29, 2025
(the &#8220;</span><b>Reverse Stock Split</b><span style="background-color: white">&#8221;). The Common Stock will begin trading on a
reverse stock split-adjusted basis on The Nasdaq Capital Market on September 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="background-color: white">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">On September 18, 2025, the Company entered into the
First Amendment to Convertible Promissory Note whereby the January 2024 Note (see Note 8 to the Financial Statements) that matured on
December 29, 2024, was amended extending the Maturity Date in the second paragraph of the Note from December 29, 2024 to December 29,
2025. Accordingly, the Note unless otherwise amended, replaced, or otherwise altered by this First Amendment, any and all terms contained
in the Note continue in full force and effect.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On September 2, 2025, the Court
of Amsterdam (the &#8220;Court&#8221;) declared bankrupt Gedi Cube B.V. (&#8220;Gedi&#8221;), an indirect subsidiary of Lunai Bioworks,
Inc. (&#8220;Lunai&#8221;), and appointed Mr. M.M. Dellebeke as the receiver in the bankruptcy. Gedi filed a voluntary petition seeking
a declaration of bankruptcy due to its inability to make payments as they became due. As a result of this, the Company determined that
a material impairment of Gedi had occurred (see Note 6 to the financial statements).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On August 18, 2025, the Company
issued Promissory Notes in the aggregate principal amount of $<span id="xdx_904_ecustom--SaleOfStockConsiderationReceivedCashTransaction_iI_c20250818__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zPiswzPzObP8" title="Sale of stock issued cash consideration">1,000,000</span>. The Notes bear an interest rate of&#160;<span id="xdx_90B_ecustom--InterestRate_iI_dp_c20250818__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z3dKOLvfiFhh" title="Interest rate">18</span>%&#160;per annum and
mature on&#160;the 6-month anniversary of the Issue Date.,&#160;(the &#8220;Maturity Date&#8221;). The Company is required to pay principal
and interest on the Maturity Date.<b>	</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">From July 3, 2025, to August 19, 2025, the Company
issued Promissory Notes in the aggregate principal amount of $<span id="xdx_90C_ecustom--SaleOfStockConsiderationReceivedCashTransaction_iI_c20250703__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zJE7kzm4cEei" title="Sale of stock issued cash consideration">695,000</span>. The Notes bear an interest rate of&#160;<span id="xdx_902_ecustom--InterestRate_iI_dp_c20250819__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zwtv7Un1ychg" title="Interest rate">10</span>%&#160;per annum and
mature on&#160;June 30, 2026,&#160;(the &#8220;Maturity Date&#8221;). The Company is required to pay principal and interest on the Maturity
Date<b>.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">On July 7, 2025, Lunai Bioworks Inc. (&#8220;Lunai&#8221;)
entered into an Exchange Agreement (the &#8220;Exchange Agreement&#8221;) with certain accredited investors (the &#8220;Investors&#8221;),
all of whom are existing shareholders of the Company. Pursuant to the Exchange Agreement, the Investors agreed to exchange an aggregate
of $<span id="xdx_90A_ecustom--SaleOfStockConsiderationReceivedCashTransaction_iI_pn3n3_dm_c20250707__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__custom--ExchangeAgreementMember_zC1Ugg8ChPf" title="Sale of stock issued cash consideration">9.7</span> million in outstanding secured promissory notes (the &#8220;Secured Notes&#8221;) for $<span id="xdx_904_ecustom--SaleOfStockConsiderationReceivedCashTransaction_iI_pn3n3_dm_c20250707__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__custom--ConvertiblePromissoryNoteMember_zNyTHkDAEULl" title="Sale of stock issued cash consideration">16.1</span> million in new convertible promissory
notes (the &#8220;Convertible Notes&#8221;), representing a 65% premium to the principal and interest amount of the Secured Notes. The
Convertible Notes mature on July 31, 2025, and do not bear any interest. The exchange was completed to restructure the Company&#8217;s
debt obligations and provide additional flexibility to support strategic initiatives.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Immediately following the issuance of the Convertible
Noes on July 7, 2025, the Investors elected to convert the entire $<span id="xdx_908_ecustom--SaleOfStockConsiderationReceivedCashTransaction_iI_pn3n3_dm_c20250707__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__custom--ConvertibleNotesMember_zqPN5J1hUSX" title="Sale of stock issued cash consideration">16.1</span>million principal amount into an aggregate of <span id="xdx_90C_ecustom--SaleOfStockConsiderationReceivedCashTransaction_iI_pn3n3_dm_c20250707__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_ztITHVJPi7y6" title="Sale of stock issued cash consideration">53.6</span> million shares
of common stock (the &#8220;Conversion Shares&#8221;), based on the stated $<span id="xdx_90D_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20250707__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zd6Yl6a8MPt3" title="Conversion price">0.30</span> per share conversion price. The $0.30 per share conversion
price of the Convertible Notes represented a premium to the closing price of the Company&#8217;s common stock on July 7, 2025, the date
of execution and conversion. As a result, the issuance of the <span id="xdx_90F_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pn3n3_dm_c20250707__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zTit72dvmJ26" title="Issuance of common stock shares">53.6</span> million shares of common stock upon conversion of the Convertible Notes
did not constitute a &#8220;below market&#8221; issuance under applicable Nasdaq listing rules and did not trigger stockholder approval
requirements under Nasdaq Listing Rule 5635(d). The shares were issued without any additional consideration from the Investors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As a result of the foregoing transactions,
the Company (i) eliminated $<span id="xdx_90A_ecustom--SaleOfStockConsiderationReceivedCashTransaction_iI_pn3n3_dm_c20250707__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__custom--ExchangeAgreementMember_ziyZl1aytO44" title="Sale of stock issued cash consideration">9.7</span> million of secured indebtedness, (ii) issued $<span id="xdx_908_ecustom--SaleOfStockConsiderationReceivedCashTransaction_iI_pn3n3_dm_c20250707__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__custom--ConvertibleNotesMember_zwqZTDaEUKx5" title="Sale of stock issued cash consideration">16.1</span> million in Convertible Notes to the same holders, and
(iii) issued <span id="xdx_902_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pn3n3_dm_c20250707__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z3WeddEHVXK5" title="Issuance of common stock shares">53.6</span> million shares of common stock upon full conversion of such Convertible Notes without any cash proceeds to the Company.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_BusinessPolicyTextBlock', window );">Business</a></td>
<td class="text"><p id="xdx_845_ecustom--BusinessPolicyTextBlock_zYUaib2yJrql" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_86F_zWx8dfvOISIj">Business</span> &#8211; </b>On August 20, 2025, the Company changed its corporate name from Renovaro Inc.
to Lunai Bioworks Inc. (&#8220;Lunai&#8221;) On April 8, 2025, Lunai Bioworks Inc. acquired BioSymetrics, Inc. and its subsidiary (&#8220;BioSymetrics,
Corp.&#8221;), as a wholly owned subsidiary pursuant to a stock purchase agreement. On February 13, 2024, the Company changed its corporate
name from Renovaro Biosciences Inc. to Renovaro Inc. (&#8220;Renovaro&#8221;, and together with its subsidiaries, the &#8220;Company&#8221;,
&#8220;we&#8221; or &#8220;us&#8221;) and acquired GEDi Cube Intl Ltd and its subsidiaries (&#8220;Renovaro Cube&#8221;), as a wholly
owned subsidiary pursuant to a stock purchase agreement. In August 2023, the Company changed its corporate name from Enochian Biosciences
Inc. to Renovaro Biosciences Inc. The Company is an AI-driven platform for precision medicine, diagnostics, and biodefense. Its proprietary
technologies transform complex biomedical data into predictive insights, enabling faster discovery, greater accuracy, and strategic partnerships
across the life sciences and government sectors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zkcuu00BbdI8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_86F_zEXXiiFIMlJ7">Basis of Presentation</span> &#8211;
</b>The Company prepares consolidated financial statements in accordance with accounting principles generally accepted in the United States
of America (&#8220;U.S. GAAP&#8221;) and follows the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--ConsolidationPolicyTextBlock_zrqS0OafGlp6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_865_z1KoBG5SEgYe">Principles of Consolidation</span>
&#8211; </b>For the years ended June 30, 2025 and 2024, the consolidated financial statements include the accounts and operations of Lunai,
and its wholly owned subsidiaries. All material inter-company transactions and accounts have been eliminated in the consolidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy', window );">Subsidiaries</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_zpuJAViAAP6d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_862_zydL5jMJeb8k">Subsidiaries</span> &#8211; </b>Renovaro
Biosciences Inc. (&#8220;Renovaro Biosciences&#8221;), formerly Renovaro
Biopharma Inc., was incorporated on May 19, 2017 in Delaware and is a 100% owned subsidiary of Lunai. Renovaro Biosciences owns a perpetual,
fully paid-up, royalty-free, sublicensable, and sole and exclusive worldwide license to research, develop, use, sell, have sold, make,
have made, offer for sale, import and otherwise commercialize certain intellectual property in cellular therapies for the prevention,
treatment, amelioration of and/or therapy exclusively for HIV in humans, and research and development exclusively relating to HIV in humans.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Renovaro Biosciences Denmark ApS
(&#8220;Renovaro Denmark&#8221;), formerly Enochian Biosciences Denmark ApS a Danish corporation was incorporated on April 1, 2001. On
February 12, 2014, in accordance with the terms and conditions of a Share Exchange Agreement, the Company acquired Renovaro Denmark and
it became a 100% owned subsidiary of Lunai subject to 185,053 shares of Common Stock of Lunai held in escrow according to Danish law (the
&#8220;Escrow Shares&#8221;). As of June 30, 2025, there are 17,414 Escrow Shares remaining (see Note 10).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On February 13, 2024, the Company
acquired <span id="xdx_90F_ecustom--BusinessAcquisitionPercentage_iI_dp_c20240213__us-gaap--BusinessAcquisitionAxis__custom--RenovaroCubeMember_zzu7S4nWvqHk" title="Acquisition percentage">100</span>% of Renovaro Cube. As a result of the acquisition, Renovaro Cube became a wholly-owned subsidiary of the Company (see Note
13).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">On April 8, 2025, the Company acquired
100% of Biosymetrics, Corp. As a result of the acquisition, Biosymetrics, Corp. became a wholly-owned subsidiary of the Company (see Note
13).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Accounting Estimates</a></td>
<td class="text"><p id="xdx_844_eus-gaap--UseOfEstimates_z1PAWZOr1WM8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_860_z7ZmMRXloNK5">Use of Accounting Estimates</span>
</b>- The preparation of financial statements in conformity with generally accepted accounting principles requires management to make
estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities
at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could
differ from those estimated. Significant estimates include the fair value and potential impairment of intangible assets, the fair value
of the contingent consideration liability, and the fair value of equity instruments issued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>





<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Functional Currency and Foreign Currency Translation</a></td>
<td class="text"><p id="xdx_845_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zyeZrTS2kLa6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_860_zM6CXfrzgW3j">Functional Currency and Foreign
Currency Translation</span> </b>&#8211; The functional currency of Renovaro Denmark is the Danish Kroner (&#8220;DKK&#8221;) and the functional
currency of Renovaro Cube is the Euro (&#8220;EUR&#8221;) and the functional currency of BioSymetrics Corp. is Canadian Dollar (&#8220;CAD&#8221;).
The Company&#8217;s reporting currency is the U.S. Dollar for the purpose of these financial statements. The Company&#8217;s balance sheet
accounts are translated into U.S. dollars at the period-end exchange rates and all revenue and expenses are translated into U.S. dollars
at the average exchange rates prevailing during the years ended June 30, 2025, and 2024. Translation gains and losses are deferred and
accumulated as a component of other comprehensive income in stockholders&#8217; equity. Transaction gains and losses that arise from exchange
rate fluctuations from transactions denominated in a currency other than the functional currency are included in the statement of operations
as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z1pBNr7bNr16" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_864_zKkxoHpQUD82">Cash and Cash Equivalents</span> </b>&#8211;
The Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--ConcentrationRiskCreditRisk_zSp4CzxxGON3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_869_zG0cDF1nI7Df">Concentration of Credit Risk</span>
&#8211;</b> Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in financial
institutions, which, at times, exceed the amount of deposit insurance provided within the relevant jurisdiction where the deposits are
held. As of June 30, 2025, and June 30, 2024, the Company has not experienced losses on these accounts and management believes the Company
is not exposed to significant risks on such accounts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_InvestmentinEquitySecuritiesPolicyTextBlock', window );">Investment in Equity Securities</a></td>
<td class="text"><p id="xdx_848_ecustom--InvestmentinEquitySecuritiesPolicyTextBlock_zPhvPJ0FpCb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_86D_z4PxeoMQXEja">Investment in Equity Securities</span>
</b>&#8211; The Company accounts for investments in equity securities in accordance with ASC 321, Investments&#8212;Equity Securities.
Equity securities with readily determinable fair values are measured at fair value, with changes in fair value recognized in net income
or loss. Equity securities without readily determinable fair values are measured at cost, less impairment, if any, and adjusted for observable
price changes in orderly transactions for the identical or a similar investment of the same issuer. The Company evaluates such investments
at each reporting period for impairment or other observable transactions that would require adjustment. On February 28, 2025, the Company
purchased $<span id="xdx_90D_ecustom--PurchaseEquitySecuritiesValue_iI_c20250630_zdDehCdNLaYh" title="Purchase equity securities value">500,000</span> of equity securities. During the year ended June 30, 2025, the Company recorded a change in fair value of equity securities
for $<span id="xdx_904_eus-gaap--DebtSecuritiesTradingAndEquitySecuritiesFvNiCost_iI_c20250630_zAnM259h5M4b" title="Fair value of equity securities">112,149</span> (see Note 3). The investment in equity securities balance at June 30, 2025, was $<span id="xdx_903_eus-gaap--DebtAndEquitySecuritiesGainLoss_c20240701__20250630_z4DS7NglA2n7" title="Investment in equity securities">387,851</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_InsuranceReceivablePolicy', window );">Insurance Receivable</a></td>
<td class="text"><p id="xdx_843_ecustom--InsuranceReceivablePolicy_z318v78IRBx3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_860_zSQo35l8z6Xh">Insurance Receivable</span> &#8211;</b>
The Company recognizes insurance receivables associated with expected recoveries of costs incurred for litigation which is probable of
incurring a loss and for which it is probable the Company will receive coverage under its existing insurance policies. The Company records
any such recoveries on a gross basis and does not net such amounts against any related loss contingency accruals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p id="xdx_846_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zPkradVek9Nk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_865_zZ0FLRKdTa8k">Property and Equipment</span> </b>-
Property and equipment are stated at cost. Expenditures for major renewals and betterments that extend the useful lives of property and
equipment are capitalized and depreciated upon being placed in service. Expenditures for maintenance and repairs are charged to expense
as incurred. Depreciation is computed for financial statement purposes on a straight-line basis over the estimated useful lives of the
assets, which range from four to ten years (see Note 5).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zlQ0lARpwWP2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_862_zduFUJqHNupk">Intangible Assets</span> - </b>The
Company has both definite and indefinite life intangible assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Definite life intangible assets
relate to patents. The Company accounts for definite life intangible assets in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;)
Accounting Standards Codification (&#8220;ASC&#8221;) Topic 350, <i>Goodwill and Other Intangible Assets</i>. Intangible assets are recorded
at cost. Patent costs capitalized consist of costs incurred to acquire the underlying patent. If it is determined that a patent will not
be issued, the related remaining capitalized patent costs are charged to expense. Definite life intangible assets are amortized on a straight-line
basis over their estimated useful life. The estimated useful life of patents is twenty years from the date of application.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Indefinite life intangible assets
include license agreements and goodwill acquired in a business combination. The Company accounts for indefinite life intangible assets
in accordance with ASC 350. License agreement costs represent the fair value of the license agreement on the date acquired and are tested
annually for impairment on June 30 or whenever events or changes in circumstances indicate the fair value of the license is less than
the carrying amount.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zppE3uZ4rs8l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_86A_zY6jWxzGpd27">Goodwill</span></b> - Goodwill is
not amortized but is evaluated for impairment annually as of June 30 or whenever events or changes in circumstances indicate the carrying
value of the reporting unit may be less than the fair value of the reporting unit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>





<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock', window );">Impairment of Goodwill and Indefinite Lived Intangible Assets</a></td>
<td class="text"><p id="xdx_846_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_zUHEWWKhdzql" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_86A_zYdnNWAi0jOc">Impairment of Goodwill and
Indefinite Lived Intangible Assets</span></b> &#8211; We test for goodwill impairment at the reporting unit level, which is one level below the
operating segment level. Our detailed impairment testing involves comparing the fair value of each reporting unit to its carrying value,
including goodwill. Fair value reflects the price a market participant would be willing to pay in a potential sale of the reporting unit
and is based on discounted cash flows or relative market-based approaches. If the carrying value of the reporting unit exceeds its fair
value, we record an impairment loss for such excess.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the year ended June 30, 2025, the results of the assessment indicated that
the carrying value of the RENC reporting unit exceeded its fair value, due to the decline in the estimated fair value of the reporting
unit based on the Company&#8217;s market capitalization. Management concluded the significant driver for the change in the economic benefits
was due to the Company&#8217;s continued inability to raise capital for the further development of the technologies within this reporting
unit. The Company recorded an impairment loss of $<span id="xdx_900_ecustom--ImpairmentLoss_iI_c20240930_zvTM8vzNPVO1" title="Impairment loss">47,614,729</span> for the period ended September 30, 2024 and $<span id="xdx_90A_ecustom--ImpairmentLoss_iI_c20250630_zWUNhMmystdk" title="Impairment loss">122,804,700</span> for the period ended
June 30, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For indefinite life intangible
assets, such as IPR&amp;D, on an annual basis on June 30th we determine the fair value of the asset and record an impairment loss, if
any, for the excess of the carrying value of the asset over its fair value. For the year ended June 30, 2024, the carrying value of the
IPR&amp;D exceeded its fair value. Therefore, the Company recorded an impairment loss of $<span id="xdx_90C_ecustom--ImpairmentLoss_iI_c20240630_zS5WUF3ShNad" title="Impairment loss">42,611,000</span> during the year ended June 30, 2024.
During the year ended June 30, 2025, the Company recorded no impairment loss related to IPR&amp;D.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The carrying value of
IPR&amp;D and goodwill at June 30, 2025, were&#160;<span id="xdx_908_ecustom--InProcessResearchAndDevelopment_iI_c20250630_zj3R8xMjC70l" style="display: none" title="In-process research and development">0</span>
zero and $<span id="xdx_90B_eus-gaap--Goodwill_iI_c20250630_zsA8QKJf2cWd" title="Goodwill">5,963,000</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zKn0gA0Hulw" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;<b><span id="xdx_862_zpCMsJFbXpTj">Impairment of Long-Lived
Assets</span> - </b>Long-lived assets, such as property and equipment and definite life intangible assets are reviewed for impairment whenever
events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Circumstances which could trigger
a review include, but are not limited to: significant decreases in the market price of the asset; significant adverse changes in the business
climate or legal factors; current period cash flow or operating losses combined with a history of losses or a forecast of continuing losses
associated with the use of the asset; and current expectations that the asset will more likely than not be sold or disposed of significantly
before the end of its estimated useful life.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Recoverability of assets to be
held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected
to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge
is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of would
be separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell and would
no longer be depreciated. The depreciable basis of assets that are impaired and continue in use are their respective fair values. <span id="xdx_901_eus-gaap--AssetImpairmentCharges_do_c20240701__20250630_z0oVRYKbcl5l" title="Impairment of assets"><span id="xdx_909_eus-gaap--AssetImpairmentCharges_do_c20230701__20240630_zMHxZhPQePZj" title="Impairment of assets">No</span></span> impairment
of these assets was recorded during the year ended June 30, 2025 or 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--LesseeLeasesPolicyTextBlock_zLsY70deoHF7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;<b><span id="xdx_86B_z3Yxf2ZBGssk">Leases</span> -</b> In accordance
with ASC Topic 842, the Company determined the initial classification and measurement of its right-of-use assets and lease liabilities
at the lease commencement date and thereafter. The lease terms include any renewal options and termination options that the Company is
reasonably assured to exercise, if applicable. The present value of lease payments is determined by using the implicit interest rate in
the lease, if that rate is readily determinable; otherwise, the Company develops an incremental borrowing rate based on the information
available at the commencement date in determining the present value of the future payments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Rent expense for operating leases
is recognized on a straight-line basis, unless the operating lease right-of-use assets have been impaired, over the reasonably assured
lease term based on the total lease payments and is included in general and administrative expenses in the consolidated statements of
operations. For operating leases that reflect impairment, the Company will recognize the amortization of the operating lease right-of-use
assets on a straight-line basis over the remaining lease term with rent expense still included in general and administrative expenses
in the consolidated statements of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>





<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p id="xdx_842_eus-gaap--ResearchAndDevelopmentExpensePolicy_zYLdwUrdqhD9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_869_zaRzb8gbnWt8">Research and Development Expenses</span>
&#8211; </b>The Company expenses research and development costs incurred in formulating, improving, validating, and creating alternative
or modified processes related to and expanding the use of the Company&#8217;s technologies. Research and development expenses for the
years ended June 30, 2025 and 2024 amounted to $<span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20240701__20250630_zZJeJ1XukUpc" title="Research and development expense">537,428</span>, and $<span id="xdx_900_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230701__20240630_zkydk6f0dDki" title="Research and development expense">2,708,829</span> respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_zfMXOt5X8KO5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_862_z48fhTLPouia">Income Taxes</span> </b>- The Company
accounts for income taxes in accordance with FASB ASC Topic 740 Accounting for Income Taxes, which requires an asset and liability approach
for accounting for income taxes (see Note 9).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss Per Share</a></td>
<td class="text"><p id="xdx_845_eus-gaap--EarningsPerSharePolicyTextBlock_zFEfdTf7feMe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_86A_ziMuA0HBi456">Loss Per Share</span></b> - The Company
calculates earnings (loss) per share in accordance with FASB ASC 260 Earnings Per Share. Basic earnings per common share (EPS) are based
on the weighted average number of shares of Common Stock outstanding during each period. Diluted earnings per common share are based on
shares outstanding (computed as for basic EPS) and potentially dilutive common shares. Potential shares of Common Stock included in the
diluted earnings per share calculation include in-the-money stock options that have been granted but have not been exercised. The shares
of Common Stock outstanding at June 30, 2025 and 2024 were <span id="xdx_905_eus-gaap--CommonStockOtherSharesOutstanding_iI_c20250630_zMapRAqnrkA9" title="Common stock outstanding">177,392,907</span> and <span id="xdx_903_eus-gaap--CommonStockOtherSharesOutstanding_iI_c20240630_zaQnmzBUSFij" title="Common stock outstanding">158,452,644</span>, respectively. Because of the net loss for each
of the years ended June 30, 2025 and June 30, 2024, dilutive shares for both periods were excluded from the diluted EPS calculation, as
the effect of these potential shares of Common Stock is anti-dilutive. The Company had <span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240701__20250630_zScZFt79wZuh" title="Anti-dilutive shares">13,669,140</span> and <span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20240630_zhSvmErRFtTi" title="Anti-dilutive shares">17,146,315</span> potential shares of Common
Stock excluded from the diluted EPS calculation for the years ended June 30, 2025 and 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zakJ3iM7cBMi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_86F_zNE5vRN0nSkg">Fair Value of Financial Instruments</span>
</b>&#8211; The Company accounts for fair value measurements for financial assets and financial liabilities in accordance with FASB ASC
Topic 820, &#8220;Fair Value Measurements&#8221;. The authoritative guidance, among other things, defines fair value, establishes a consistent
framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either
a recurring or nonrecurring basis. Fair value is defined as the exit price, representing the amount that would either be received to
sell an asset or be paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based
measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zBv2wJW9shTb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;<b><span id="xdx_869_zLzKFsYnd3xa">Stock-Based Compensation</span>
- </b>The Company has granted stock options, restricted share units (&#8220;RSUs&#8221;) and warrants to certain employees, officers,
directors, and consultants. The Company accounts for options in accordance with the provisions of <b><i>FASB ASC Topic 718, Compensation
&#8211; Stock Compensation</i></b>. Stock based compensation costs for the vesting of options and RSUs granted to certain employees, officers,
directors, and consultants for the years ended June 30, 2025 and 2024 were $<span id="xdx_900_eus-gaap--ShareBasedCompensation_c20240701__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesOfficersDirectorsAndConsultantsMember_zzOV5taph179" title="Stock based compensation costs">3,313,291</span> and $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_c20230701__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesOfficersDirectorsAndConsultantsMember_z0Xu23kdrakh" title="Stock based compensation costs">4,673,129</span>, respectively<b>.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.2pt">The Company recognizes compensation
costs for stock option awards to employees, officers and directors based on their grant-date fair value. The value of each stock option
is estimated on the date of grant using the Black-Scholes option-pricing model. The weighted-average assumptions used to estimate the
fair value of the stock options granted using the Black-Scholes option-pricing model are the expected term of the award, the underlying
stock price volatility, the risk-free interest rate, and the expected dividend yield. The Company accounts for forfeitures as they occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.2pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company records stock-based
compensation for services received from non-employees in accordance with <b><i>ASC 718, Compensation&#8212;Stock Compensation Non-Employees</i></b>.
All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based
on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable.
Equity instruments issued to consultants and the cost of the services received as consideration are measured and recognized based on
the fair value of the equity instruments issued and are recognized over the consultants&#8217; required service period, which is generally
the vesting period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company does not have sufficient
historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior.
Accordingly, the Company has elected to use the &#8220;simplified method&#8221; to estimate the expected term of its share-based awards.
The simplified method computes the expected term as the sum of the award&#8217;s vesting term plus the original contractual term divided
by two.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements Not Yet Adopte</a></td>
<td class="text"><p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zIzlraGROM96" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><span id="xdx_86C_zlgwLRK4maNc">New Accounting Pronouncements
Not Yet Adopte</span>d</b> - Recent accounting pronouncements issued by the FASB that have not yet been adopted by the Company are not expected
to have a material impact on the Company&#8217;s present or future consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>





<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_BusinessPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_BusinessPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_InsuranceReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_InsuranceReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_InvestmentinEquitySecuritiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_InvestmentinEquitySecuritiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for subsidiaries or other investments that are consolidated, including the accounting treatment for intercompany accounts or transactions and any noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of assets and liabilities measured at fair value on recurring bases</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_z2jvxTefkOie" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt"><span id="xdx_8B7_zTaUZdgmxFHb" style="display: none">Schedule of assets and
liabilities measured at fair value on recurring bases</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_499_20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zQzvXgkEBbQ" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49A_20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zEsjnT6mDvcc" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49D_20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zuh9bP385oC4" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value Measurements at<br/> Reporting Date Using</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-indent: -10pt; padding-left: 10pt">Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--EquitySecuritiesFvNi_iI_zcG3r0N1i5Ia" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Investment in equity securities</td><td style="width: 5%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">387,851</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 5%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0772">&#8212;</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 5%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0773">&#8212;</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AccruedLiabilitiesFairValueDisclosure_iI_zFAPaLuCkqGc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Total assets at fair value</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">387,851</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0776">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0777">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-indent: -10pt; padding-left: 10pt">Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ContingentConsiderationClassifiedAsEquityFairValueDisclosure_iI_zByKpBBRISY2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Contingent consideration</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0779">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0780">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">630,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DerivativeFairValueOfDerivativeLiability_iI_zeFlGaeTvPDg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Total liabilities at fair value</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0783">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0784">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">630,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueConcentrationOfRiskTextBlock', window );">Schedule of key input to valuing the contingent consideration liability</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--FairValueConcentrationOfRiskTextBlock_z9h8AL4mIza1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B0_zvM5tZevQ8A6" style="display: none">Schedule of key input to valuing the
contingent consideration liability</span> </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-indent: -10pt">Stock Price</td><td style="width: 10%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 18%; text-align: right"><span id="xdx_901_eus-gaap--SharePrice_iI_pip0_c20250630__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_z7AWelG40Uq8" title="Stock Price">0.29</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Exercise Price</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">$<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pip0_c20250630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zvLRxaPuJjx5" title="Exercise Price">0.53</span> - $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pip0_c20250630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zdEwZKSKFTF6" title="Exercise Price">1.92</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Volatility</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20240701__20250630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zB66ZpszDMN4" title="Volatility">116</span>% - <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20240701__20250630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_znPOfT17uTp5" title="Volatility">141</span>%</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Risk Free Rate</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20240701__20250630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zbcy1swkb2H9" title="Risk Free Rate">3.61</span>% - <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20240701__20250630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zTIaRnl1D08k" title="Risk Free Rate">4.02</span>%</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Expected Dividends</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20240701__20250630__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_ze9cCHjxT9Ya" title="Expected Dividends">0</span></td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Discount Rate (Monte-Carlo model only)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate_pip0_dp_c20240701__20250630__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_z66eiy3IqZqb" title="Discount Rate (Monte-Carlo model only)">0</span></td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Expected Term (years)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240701__20250630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zL8pzYmdMZq" title="Expected Term (years)">2.70</span> &#8211;<span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240701__20250630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zKGilmjz5Yhb" title="Expected Term (years)"> 8.38</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At initial recognition of the contingent consideration,
the inputs were:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-indent: -10pt">Stock Price</td><td style="width: 10%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 18%; text-align: right"><span id="xdx_909_eus-gaap--SharePrice_iI_pip0_c20250630__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_z2wyC1dnZCZ7" title="Stock Price">1.92</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Exercise Price</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">$<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pip0_c20250630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zsR9QLQztrJ4" title="Exercise Price">0.46</span> - $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pip0_c20250630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zTkAmBRGujaa" title="Exercise Price">4.50</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Volatility</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20240701__20250630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zyTHaNhBnsTd" title="Volatility">107</span>% - <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20240701__20250630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_z7TkkYwypWI7" title="Volatility">133</span>% </span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Risk Free Rate</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20240701__20250630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zO5IUsIsnpgi" title="Risk Free Rate">4.22</span>% - <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20240701__20250630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zYhvR1yEwEdl" title="Risk Free Rate">5.14</span>%</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Expected Dividends</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20240701__20250630__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zKNk75opeJU4" title="Expected Dividends">0</span></td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Discount Rate (Monte-Carlo model only)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate_pip0_dp_c20240701__20250630__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zd2uyHoAiima" title="Discount Rate (Monte-Carlo model only)">12</span></td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Expected Term (years)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240701__20250630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_z4tNQ2OULmz6" title="Expected Term (years)">0.56</span> &#8211; <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240701__20250630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zNmm9snjaAQ7" title="Expected Term (years)">9.88</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_ScheduleOfContingentConsiderationLiabilityTableTextBlock', window );">Schedule of fair value measurement on recurring basis</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_894_ecustom--ScheduleOfContingentConsiderationLiabilityTableTextBlock_z6kiE8CH7ob2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt"><span id="xdx_8BF_z7Ro7lNVSB5i" style="display: none">Schedule of fair value measurement on recurring basis</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49F_20240701__20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zbcmlYNu04xa" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49C_20240701__20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zTHGQ9VNTKx1" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_496_20240701__20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zV3BlZEzgj34" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value Measurements at<br/> Reporting Date Using</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Quoted Prices in <br/> Active Markets for Identical Assets Inputs</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Significant Other <br/> Observable Inputs</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Significant Other Unobservable Inputs</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 1)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 2)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Level 3)</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">The roll forward of the contingent consideration liability is as follows:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--BusinessCombinationContingentConsiderationLiability_iS_d0_zbQGZBKugltc" style="vertical-align: bottom; background-color: White">
    <td style="width: 46%; text-indent: -10pt; padding-left: 10pt">Balance June 30, 2024</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">12,310,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LiabilitiesFairValueAdjustment_d0_zFUffL1kEte5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Fair value adjustment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(11,680,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--BusinessCombinationContingentConsiderationLiability_iE_d0_z9kYfPmHC4L" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Contingent Consideration Liability at June 30, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">630,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>



<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_ScheduleOfContingentConsiderationLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_ScheduleOfContingentConsiderationLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueConcentrationOfRiskTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of all significant concentrations of risk, including credit risk and market risk, arising from all financial instruments (as defined), whether from an individual counterparty or groups of counterparties. The disclosure concerning concentrations of risk may consist of the following information: (1) for concentrations of credit risk disclosure may include: (a) information about the (shared) activity, region, or economic characteristic that identifies the concentration, (b) the maximum amount of loss due to credit risk that, based on the gross fair value of the financial instrument, the entity would incur if parties to the financial instruments that make up the concentration failed completely to perform according to the terms of the contracts and the collateral or other security, if any, for the amount due proved to be of no value to the entity, (c) the policy of requiring collateral or other security to support financial instruments subject to credit risk, information about the entity's access to that collateral or other security, and the nature and a brief description of the collateral or other security supporting those financial instruments, and (d) the policy of entering into master netting arrangements to mitigate the credit risk of financial instruments, information about the arrangements for which the entity is a party, and a brief description of the terms of those arrangements, including the extent to which they would reduce the entity's maximum amount of loss due to credit risk and (2) for disclosure of quantitative information about the market risks of financial instruments that is consistent with the way the company manages or adjusts those risks, disclosure may include: (a) more details about current positions and perhaps activity during the period, (b) the hypothetical effects on comprehensive income (or net assets), or annual income, of several possible changes in market prices, (c) a gap analysis of interest rate re-pricing or maturity dates, (d) the duration of the financial instruments, (e) the entity's value at risk from derivatives and from other positions at the end of the reporting period and the average value at risk during the year, or (f) other ways of reporting quantitative information as internally developed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-23<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueConcentrationOfRiskTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and equipment</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_886_eus-gaap--PropertyPlantAndEquipmentTextBlock_zdkXhz1M3JWc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PROPERTY AND EQUIPMENT (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B1_zRY6zMpgJIYd" style="display: none">Schedule of Property and equipment</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Useful Life</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2025</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2024</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt">Lab equipment and instruments</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: center"><span style="font-size: 10pt"><span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20250630__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentAndInstrumentsMember_z1cwyeI9Mxdl" title="Useful Life">4</span>-<span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20250630__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentAndInstrumentsMember_zfHQFKzYqhD3" title="Useful Life">7</span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentGross_pp0p0_c20250630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentAndInstrumentsMember_zsQiSUjKqOX5" style="width: 11%; text-align: right" title="Total">639,998</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_pp0p0_c20240630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentAndInstrumentsMember_zEnrdRZwSEQ8" style="width: 11%; text-align: right" title="Total">639,998</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20250630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zxFk7F40U1A1" title="Useful Life">10</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_pp0p0_c20250630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zwMVpHRLeBY7" style="text-align: right" title="Total">224,629</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_pp0p0_c20240630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zQI2prmRptC1" style="text-align: right" title="Total">224,629</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Furniture, fixtures, and equipment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt"><span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20250630__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_z9j8Mw96hsWl" title="Useful Life">4</span>-<span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20250630__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_z7GXQciyftgg" title="Useful Life">7</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_pp0p0_c20250630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zCYF512hkL1f" style="border-bottom: Black 1pt solid; text-align: right" title="Total">205,396</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_pp0p0_c20240630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zXDEbVL2Eqfe" style="border-bottom: Black 1pt solid; text-align: right" title="Total">195,834</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_pp0p0_c20250630_zyhEYxV1OOD6" style="text-align: right" title="Total">1,070,023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_pp0p0_c20240630_zKSQ8OYf06tg" style="text-align: right" title="Total">1,060,461</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Less accumulated depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20250630_zBuzJe4yqVb" style="border-bottom: Black 1pt solid; text-align: right" title="Less Accumulated Depreciation">(702,180</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20240630_znx8NEzgYOa5" style="border-bottom: Black 1pt solid; text-align: right" title="Less Accumulated Depreciation">(578,340</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net Property and Equipment</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: center">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentNet_pp0p0_c20250630_zb0XkweEblt5" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Property and Equipment">367,843</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentNet_pp0p0_c20240630_zgqY1LLvXHw2" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Property and Equipment">482,121</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of definite-life and indefinite-life intangible assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zxS1O5kteR7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B3_zFdrFns2PjV7" style="display: none">Schedule of definite-life
and indefinite-life intangible assets</span></td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Useful Life</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2024</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">&#160;<b>Additions</b></span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">&#160;<b>Amortization</b></span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">&#160;<b>Impairment</b></span></td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Translation Adjustment</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2025</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 18%; font-weight: bold; text-align: left; text-indent: -10pt">Definite Life Intangible Assets</td><td style="width: 2%">&#160;</td>
    <td style="text-align: center; width: 8%; padding-left: 5.4pt">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Software platform</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_zKDgw0CvNEa1" title="Useful life">5</span> Years</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_zJGoDYDERBOk" style="text-align: right" title="Net definite-life intangible assets at beginning"><span style="-sec-ix-hidden: xdx2ixbrl0909">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_zLTbAOW8wDei" style="text-align: right" title="Net definite-life intangible assets, Additions">143,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_d0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_zFKC0eOjohHl" style="text-align: right" title="Net definite-life intangible assets, Amortization">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_zuln89l3Uto1" style="text-align: right" title="Net definite-life intangible assets, Impairment">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_zFoqaOz3XOr3" style="text-align: right" title="Net definite-life intangible assets, Translation adjustment"><span style="-sec-ix-hidden: xdx2ixbrl0917">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_zxO255rBSjQ8" style="text-align: right" title="Net definite-life intangible assets at ending">143,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Trademark</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_z02VLJxSHsb9" title="Useful life">2</span> Years</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_zgQbP6Vi2M4g" style="text-align: right" title="Net definite-life intangible assets at beginning"><span style="-sec-ix-hidden: xdx2ixbrl0923">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_zofiC2jNydfc" style="text-align: right" title="Net definite-life intangible assets, Additions">8,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_d0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_zlfmDMvRsokk" style="text-align: right" title="Net definite-life intangible assets, Amortization">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_zXapNlDBbgzi" style="text-align: right" title="Net definite-life intangible assets, Impairment">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_zVQeZjfLLNS7" style="text-align: right" title="Net definite-life intangible assets, Translation adjustment"><span style="-sec-ix-hidden: xdx2ixbrl0931">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_zR1tYG7DguW5" style="text-align: right" title="Net definite-life intangible assets at ending">8,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Patents</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt"><span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zIabVC9iVBwe" title="Useful life">20</span> Years</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zI94aHMbOyM" style="text-align: right" title="Net definite-life intangible assets at beginning">284,977</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zOLRsLLVq87h" style="text-align: right" title="Net definite-life intangible assets, Additions">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_d0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zz7N5EZrcuii" style="text-align: right" title="Net definite-life intangible assets, Amortization">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zvaP3kU1OSU6" style="text-align: right" title="Net definite-life intangible assets, Impairment">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zYwTZH1bJS6e" style="text-align: right" title="Net definite-life intangible assets, Translation adjustment">28,033</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zGx1XQ5ijRC3" style="text-align: right" title="Net definite-life intangible assets at ending">313,010</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Less Accumulated Amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt; padding-left: 5.4pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zvRV4WPb7Xpb" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets at beginning">(254,934</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_z5CgLFnFELmi" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Additions">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_z4kzqeRSI9y1" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Amortization">(9,902</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_z2gDFxhwFlNf" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Impairment">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zgrxQKogzR7h" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Translation adjustment">(33,180</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zvlmX4hnJiV3" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets at ending">(298,016</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Net Definite-Life Intangible Assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt; padding-left: 5.4pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20240701__20250630_zrPSE28IG2M3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets at beginning">30,043</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20240701__20250630_z3QafijyuGbf" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Additions">151,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_c20240701__20250630_zv5BPUhvgFa8" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Amortization">(9,902</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20240701__20250630_zauppiG9kKOh" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Impairment">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20240701__20250630_z0ED7xf0gSJ8" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Translation adjustment">(5,147</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20240701__20250630_z7NHUSlScmS4" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets at ending">165,994</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-indent: -10pt">Goodwill</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Goodwill</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zYQ7stsJmGeg" style="text-align: right" title="Total indefinite life intangible assets and goodwill at beginning">159,330,161</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zjcbBxKVEHjd" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Additions">5,963,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillAmortization_pp0p0_d0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zZWCBJDFqvye" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Amortization">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillImpairment_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zp9sqSLEORah" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Impairment">(170,419,429</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zwdneV1Ax3zb" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Translation adjustment">11,089,268</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iE_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_z9lzaKaMF8b7" style="text-align: right" title="Total indefinite life intangible assets and goodwill at ending">5,963,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Total Goodwill</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt; padding-left: 5.4pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20240701__20250630_zckWwmOVPp4" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill at beginning">159,330,161</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_c20240701__20250630_zcmJwXWeGib5" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Additions">5,963,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillAmortization_pp0p0_d0_c20240701__20250630_zR5l2f7KZ3d4" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Amortization">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillImpairment_pp0p0_c20240701__20250630_z5CmQQHJHznb" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Impairment">(170,419,429</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20240701__20250630_zKwEnw7E9pOd" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Translation adjustment">11,089,268</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iE_pp0p0_c20240701__20250630_z6SB979hjI9f" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill at ending">5,963,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Useful Life</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">&#160;<b>Additions</b></span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">&#160;<b>Amortization</b></span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">&#160;<b>Impairment</b></span></td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Translation Adjustment</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2024</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Definite Life Intangible Assets</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 18%; text-indent: -10pt">Patents</td><td style="width: 2%">&#160;</td>
    <td style="width: 8%; text-align: center; padding-left: 5.4pt"><span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zwcPlFDYIuZf" title="Useful life">20</span> Years</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zfEb16zeTnj2" style="width: 8%; text-align: right" title="Net definite-life intangible assets at beginning">290,936</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zJ7fAgtfGv37" style="width: 8%; text-align: right" title="Net definite-life intangible assets, Additions">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zjPYMFp1vs98" style="width: 8%; text-align: right" title="Net definite-life intangible assets, Amortization">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zAiLki89dtH6" style="width: 8%; text-align: right" title="Net definite-life intangible assets, Impairment">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z5AiMHi03suf" style="width: 8%; text-align: right" title="Net definite-life intangible assets, Translation adjustment">(5,959</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zLGY4yuJEExi" style="width: 8%; text-align: right" title="Net definite-life intangible assets at ending">284,977</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Less Accumulated Amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt; padding-left: 5.4pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zJol2J4hyr3l" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets at beginning">(251,260</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zrnuJuLKfwki" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Additions">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zEibEadINif8" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Amortization">(8,296</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zdE5db2anRIe" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Impairment">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zggvI2ANGL5e" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Translation adjustment">4,622</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zrB8QScOP5k1" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets at ending">(254,934</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Net Definite-Life Intangible Assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt; padding-left: 5.4pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20230701__20240630_z5Arwfkpf5yb" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets at beginning">39,676</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20230701__20240630_zW3vXIX6Agq7" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Additions">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_c20230701__20240630_ztF926anJYla" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Amortization">(8,296</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20230701__20240630_zfzCmbhysTHb" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Impairment">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20230701__20240630_zc0TlrPaLLg8" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Translation adjustment">(1,337</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20230701__20240630_zGu7SYVAdEBj" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets at ending">30,043</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Indefinite Life Intangible Assets and Goodwill</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Goodwill</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zB2jSfWy2ld2" style="text-align: right" title="Total indefinite life intangible assets and goodwill at beginning">11,640,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zDU1gbDrif4j" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Additions">159,464,039</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillAmortization_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zUBT57FkhyX" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Amortization">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillImpairment_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zd4CqzoBjYFl" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Impairment">(11,640,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zNeFETdRY1ia" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Translation adjustment">(133,878</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iE_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zrlt65boy9Aj" style="text-align: right" title="Total indefinite life intangible assets and goodwill at ending">159,330,161</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">IPR&amp;D</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt; padding-left: 5.4pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zjsS956KFFuk" style="border-bottom: Black 1pt solid; text-align: right" title="Total indefinite life intangible assets and goodwill at beginning">42,611,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_z0Ss2Apml1J1" style="border-bottom: Black 1pt solid; text-align: right" title="Total indefinite life intangible assets and goodwill, Additions">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillAmortization_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zGJ8NJgKfiX1" style="border-bottom: Black 1pt solid; text-align: right" title="Total indefinite life intangible assets and goodwill, Amortization">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillImpairment_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zgMLOlPFRta3" style="border-bottom: Black 1pt solid; text-align: right" title="Total indefinite life intangible assets and goodwill, Impairment">(42,611,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zASnIycpGfsf" style="border-bottom: Black 1pt solid; text-align: right" title="Total indefinite life intangible assets and goodwill, Translation adjustment">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iE_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zoHKP38JxOtc" style="border-bottom: Black 1pt solid; text-align: right" title="Total indefinite life intangible assets and goodwill at ending">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Total Indefinite Life Intangible Assets and Goodwill</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt; padding-left: 5.4pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20230701__20240630_z2LoUc1O8Cjl" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill at beginning">54,251,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_c20230701__20240630_z2L7zbO8iEne" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Additions">159,464,039</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillAmortization_pp0p0_d0_c20230701__20240630_zV0JSbNWMYhe" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Amortization">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillImpairment_pp0p0_c20230701__20240630_zSI9EOJ7LZ3i" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Impairment">(54,251,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20230701__20240630_zFwhJXemLzF4" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Translation adjustment">(133,878</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iE_pp0p0_c20230701__20240630_zczZFCtZTPe1" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill at ending">159,330,161</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of future amortization expense</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zrffr1Kb1ul7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B9_zucCgOr290Jb" style="display: none">Schedule of future amortization expense</span></td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Years
    ended&#160;June 30,</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 73%; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2026</span></td><td style="width: 10%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pp0p0_c20250630_zgWunGgaLwWc" style="width: 15%; font-size: 10pt; text-align: right" title="2026"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36,350</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2027</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pp0p0_c20250630_zujEcm2NjZHc" style="font-size: 10pt; text-align: right" title="2027"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36,348</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2028</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pp0p0_c20250630_zI2kCElHpZG6" style="font-size: 10pt; text-align: right" title="2028"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32,348</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2029</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pp0p0_c20250630_z9rB87fMI4L" style="font-size: 10pt; text-align: right" title="2029"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32,348</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thereafter</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pp0p0_c20250630_zQPwDE569wN" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Thereafter"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28,600</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20250630_zC5XSMIb2DUd" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Total"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">165,994</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>



<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of lease commitments</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zu0MeaLfUyJh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - LEASES (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B4_zXboek72wFhi" style="display: none">Schedule of lease commitments</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Years Ending June 30</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Lease Expense</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 73%; text-align: left; text-indent: -10pt">2026</td><td style="width: 10%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_c20250630_za8Be45kf0tj" style="width: 15%; text-align: right" title="2026">363,999</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_c20250630_zxvdZcBLzsO9" style="text-align: right" title="2027">358,326</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Thereafter</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo_iI_pp0p0_c20250630_zuMJ9yxeEnV" style="text-align: right" title="Thereafter">56,621</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Less imputed interest</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_c20250630_zSfGZNFdyBfc" style="border-bottom: Black 1pt solid; text-align: right" title="Less imputed interest">(41,353</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"><span style="font-size: 10pt"><b>Total</b></span></td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_986_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pp0p0_c20250630_z4G5CPVvqkf9" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Total">737,593</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax assets and liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zG7ef07kCjig" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8BE_zWb6LjrOJUod" style="display: none">Schedule of deferred tax assets and liabilities</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_491_20250630_z2pzuoOnf8yk" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49E_20240630_zpnAVDgg77Sb" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td></tr>
  <tr id="xdx_407_ecustom--Depreciations_iI_z8O0Jizr4Ah3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-indent: -10pt">Depreciation</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(24,619</td><td style="width: 1%; text-align: left">)</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">8,258</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--DeferredTaxAssetExcessTaxOverDepreciationPatents_iI_pp0p0_maDTALNzwuT_z05qOfiHebK9" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Excess of tax over book depreciation of patents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1220">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,415</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--StockoptionsCompensation_iI_pp0p0_maDTALNzwuT_z0eQx4ABu7Gc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Stock/options compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">463,099</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,672,252</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--DepreciationAndAmortizations_iI_pp0p0_maDTALNzwuT_z3xluljzTyLe" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1226">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">188,422</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_maDTALNzwuT_za5kAs7Fzbnl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net operating loss carryforwards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">76,296,814</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">148,832,041</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--ImpairmentExpense_iI_pp0p0_d0_maDTALNzwuT_zPLauX3Dg9Xf" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;Impairment expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,188,497</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--ContingentConsiderationFairValue_iI_pp0p0_d0_maDTALNzwuT_zapO6NPIqsz" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Contingent consideration fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(909,577</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--AccumulatedAmortizationOfOtherDeferredCosts_iI_pp0p0_zdsvvMK0hJ28" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,961,747</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1239">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--Section174ReCapitalization_iI_pp0p0_zsRiglMBn91h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Section 174 R&amp;E Capitalization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,292,075</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1242">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--OperatingLeaseRightOfUseAssets_iI_pp0p0_zasdyD3kGSyk" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">ROU Assets and Lease Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,227</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1245">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--Section481aAdjustment_iI_pp0p0_zSm9CwUyzF5c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Section 481(a) Adjustment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(40,895</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1248">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pp0p0_zwOcJj92EMD4" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">R&amp;D Tax Credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,718,415</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1251">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--ChangeInTaxRate_iI_pp0p0_d0_maDTALNzwuT_zbDREXQcEyMh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Change in tax rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_msDTALNzwuT_z6J1A7OH0Kjg" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(83,680,863</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(170,988,308</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_iI_pp0p0_zcd39fI1vKZk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total Deferred Tax Assets (Liabilities)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1259">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1260">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zlDfgmV18te" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_495_20240701__20250630_zFeO7GtMwKsf" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_490_20230701__20240630_zHDY7JCSDrbe" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Years ended June 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationChangeInEnactedTaxRate_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt">Computed tax at expected statutory rate</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(951,542</td><td style="width: 1%; text-align: left">)</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(24,066,011</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--IncomeTaxReconciliationRepatriationOfForeignEarnings_iN_pp0p0_d0_zKIUKpKrDoYf" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Non-US income taxed at different rates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncomeTaxReconciliationNondeductibleExpense_d0_zMIO6nQnezl6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Non-deductible expenses / other items</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,046,364</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,999,380</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">24,066,011</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OtherTaxExpenseBenefit_d0_zo2a8bR4x85k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Income Tax Expense (Benefit)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,474</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of components of income tax expense (benefit) from continuing operations</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zysVPktt2Tdj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-top: 0pt; padding-right: 0pt; padding-left: 20pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B7_zPjqVwYUCxq2" style="display: none">Schedule
    of components of income tax expense (benefit) from continuing operations</span></td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_49B_20240701__20250630_zw3QhO3HHRB3" style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_495_20230701__20240630_zyuACp3VqK58" style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Years
    ended June 30,</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td></tr>
  <tr id="xdx_400_eus-gaap--CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; font-size: 10pt; font-weight: bold; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
    Income Tax Expense</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--CurrentFederalTaxExpenseBenefit_i01_pp0p0_d0_maCITEBzr8l_zuuOhRzfy6Ng" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal
    income tax (benefit)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i01_pp0p0_d0_maCITEBzr8l_zKtOaFUWvZ5d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; width: 56%; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State
    income tax (benefit)</span></td><td style="width: 8%; font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; width: 12%; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,474</span></td><td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 8%; font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; width: 12%; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--CurrentForeignTaxExpenseBenefit_i01_pp0p0_d0_maCITEBzr8l_z2ediuyAkH21" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
    income tax (benefit)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--CurrentIncomeTaxExpenseBenefit_i01T_pp0p0_d0_mtCITEBzr8l_maITEBzLgX_ztyyjCR5lrL5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Current Tax Expense (Benefit)</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,474</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_zpTGFHzNm6E" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; font-weight: bold; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
    Income Tax Expense Federal income tax (benefit)</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101,609,457</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">165,458,980</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefit_zwgRvZRgyeG1" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State
    income tax (benefit)</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(14,302,006</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,529,328</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_zaArW39NQWz3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
    income tax (benefit)</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1303">&#8212;</span></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1304">&#8212;</span></span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_ziMMCuaxDi1d" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 20pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
    Change in valuation allowance</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(87,307,451</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(170,988,308</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_408_eus-gaap--DeferredIncomeTaxExpenseBenefit_i01T_pp0p0_d0_mtDITEBzk3M_maITEBzLgX_zMuyJTSzElsj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Deferred Tax Expense</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeTaxExpenseBenefit_i01T_pp0p0_d0_mtITEBzLgX_zfLHiVBg5I98" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 20pt; font-size: 10pt; font-weight: bold; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Tax Expense</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,474</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>



<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_ScheduleOfShareBasedPaymentAwardStockOptionValuationAssumptionsTableTextBlock', window );">Schedule of weighted-average assumptions used to estimate the fair values of the stock options granted</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--ScheduleOfShareBasedPaymentAwardStockOptionValuationAssumptionsTableTextBlock_zI6lhXrzJhJg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span id="xdx_8BA_zwawgDZ0RtLk" style="display: none">Schedule of weighted-average assumptions used to estimate the fair values of the stock options granted</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Lunai Bioworks Inc.</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Expected term (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240701__20250630__dei--LegalEntityAxis__custom--RenovaroMember_zuGOzNmRhLCb" style="font-size: 10pt">5.5</span>
<span style="font-size: 10pt"></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20240701__20250630__srt--RangeAxis__srt--MinimumMember__dei--LegalEntityAxis__custom--RenovaroMember_zvvQSHEtbPH" title="Volatility">109.45</span>% &#8211; <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20240701__20250630__srt--RangeAxis__srt--MaximumMember__dei--LegalEntityAxis__custom--RenovaroMember_zU8NWSv9gxX6" title="Volatility">118.99</span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20240701__20250630__srt--RangeAxis__srt--MinimumMember__dei--LegalEntityAxis__custom--RenovaroMember_zNXl7K6POpVh" title="Risk free interest rate">3.86</span>%- <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20240701__20250630__srt--RangeAxis__srt--MaximumMember__dei--LegalEntityAxis__custom--RenovaroMember_z48dYHM6ppXb" title="Risk free interest rate">4.40</span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-align: left; text-indent: -10pt">Dividend yield</td><td style="width: 10%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20240701__20250630__dei--LegalEntityAxis__custom--RenovaroMember_zg0rIcCdEzod" title="Dividend yield">0</span></td><td style="width: 1%; text-align: left">%</td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_ScheduleOfStockBasedCompensationActivityTableTextBlock', window );">Schedule of stock options outstanding</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_896_ecustom--ScheduleOfStockBasedCompensationActivityTableTextBlock_zzUDy1OZibYe" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B0_zxwLmvygJApl" style="display: none">Schedule of stock options outstanding</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    Outstanding</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="7" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    Exercisable</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise
    Price Ranges</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
    Outstanding</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    Average Remaining Contractual Life (years)</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    Average Exercise Price</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
    Exercisable</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    Average Remaining Contractual Life (years)</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    Average Exercise Price</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 11%; text-align: left; text-indent: -10pt"></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zUI9fWUQjxyb" title="Exercise Prices, Lower">0.45</span>&#8211;<span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zDbsOAVwv6ej" title="Exercise Prices, Upper">4.50</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zTDfxYZcrRCd" style="width: 9%; text-align: right" title="Number share option outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,623,614</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtYp_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zlRCO83FiHfi" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)">8.97</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zjnlcPtUsJkl" style="width: 9%; text-align: right" title="Options Outstanding, Weighted Average Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.75</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><p id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zQDTcPmHmPY3" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Options Exercisable">567,233</p></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zhvX39G5OXP8" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)">8.71</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zDv7lyXUxepa" style="width: 8%; text-align: right" title="Options Exercisable, Weighted Average Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.96</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zc1x7zTr4Tgi" title="Exercise Prices, Lower">4.51</span>&#8211;<span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_z3GBkhz0mLX7" title="Exercise Prices, Upper">6.50</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zrTjt887m7n7" style="text-align: right" title="Number share option outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1573">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zk1QH7XpIgwf" style="text-align: right" title="Options Outstanding, Weighted Average Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1575">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zuLeTzWytcp" style="text-align: right" title="Options Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1577">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zbV2PosiIG1" style="text-align: right" title="Options Exercisable, Weighted Average Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1579">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_z5xKfWKRu2y4" title="Exercise Prices, Lower">6.51</span>&#8211;<span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_znrPyRCIviei" title="Exercise Prices, Upper">12.00</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zMKFlfOEYKMh" style="border-bottom: Black 1pt solid; text-align: right" title="Number share option outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1585">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zeVPVvRIQwf6" style="border-bottom: Black 1pt solid; text-align: right" title="Options Outstanding, Weighted Average Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1587">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zCb448HV19ke" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1589">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zuOQs31b4cL2" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercisable, Weighted Average Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1591">&#8212;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"></td><td style="text-align: right"></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zy8D829558B2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number share option outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,623,614</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zDqsZMhn89h1" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)">8.97</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zQ44h6xUyaAj" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding, Weighted Average Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.75</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><p id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zsCPYUXgu5M" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Options Exercisable">567,233</p></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zvxA8dTfWuo3" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)">8.71</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zHKzMsbH294g" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable, Weighted Average Exercise Price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.96</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>



<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock option activity</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zvSnzBGHPz0g" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B3_z0CmkDDSPxKi" style="display: none">Schedule of Stock option activity</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise<br/> Price</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Average Remaining Life</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Intrinsic<br/> Value</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 44%; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Outstanding at June 30, 2024</span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zzpK6WLrjZSb" style="width: 10%; text-align: right" title="Options Outstanding at beginning of period">5,527,852</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zOLIRWzP8ibk" style="width: 10%; text-align: right" title="Weighted Average Exercise Price, Outstanding at beginning of period">2.11</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zhw6GsP3381i" title="Weighted Average remaining life">7.30</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_d0_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zvWP6K5tBpij" style="width: 10%; text-align: right" title="Weighted Average Intrinsic Value, Outstanding at beginning of period">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Granted</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zplZ5PVWrrJc" style="text-align: right" title="Granted">4,249,665</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zkdWeeXIJJre" style="text-align: right" title="Weighted average exercise price, Granted">0.64</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Exercised</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_d0_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zURyob3CXWw5" style="text-align: right" title="Exercised">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d0_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zKKmDwjg2LFj" style="text-align: right" title="Weighted average exercise price, Exercised">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Forfeited</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di0_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zjc88dpn6Jz5" style="text-align: right" title="Forfeited">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d0_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zxICJY7Nerkj" style="text-align: right" title="Weighted Average Exercise Price, Forfeited">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Expired/Canceled </span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zwN2ajgNYL67" style="border-bottom: Black 1pt solid; text-align: right" title="Cancelled/Expired">(5,153,903</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zWkV5FsImWG" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Expired">2.12</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Outstanding at June 30, 2025</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zwAUx66zJX0b" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding at end of period">4,623,614</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zHvVQZ2Em65h" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding at ending of period">0.75</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zN2elfknGk5e" title="Weighted Average remaining life">8.97</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_d0_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zhUKVHVYnXd7" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Intrinsic Value, Outstanding at end of period">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-size: 10pt">Exercisable at June 30, 2025</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zK5TNBKjTdta" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable">567,233</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zzvYeoMsMiuh" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Exercisable at ending of period">0.96</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisablesWeightedAverageRemainingContractualTerm1_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zjlgEU9sn9i3" title="Weighted Average Remaining Life, Exercisable">8.71</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zKsb74I44fKf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Intrinsic Value, Exercisable end of period"><span style="-sec-ix-hidden: xdx2ixbrl1645">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_ScheduleOfCommonStockPurchaseWarrantsOutstandingTableTextBlock', window );">Schedule of common stock purchase warrants outstanding</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--ScheduleOfCommonStockPurchaseWarrantsOutstandingTableTextBlock_znnvu9Do9Rh7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details 3)">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center"><span id="xdx_8BA_zLcFsXMryOo1" style="display: none">Schedule of common stock purchase warrants outstanding</span></td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="15" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants Exercisable</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Weighted</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Weighted</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Weighted</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Weighted</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Average</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Average</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Number</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Contractual</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Number</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Contractual</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Exercise</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Price</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Outstanding</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Life (years)</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Price</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Exercisable</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Life (years)</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Price</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 10%; text-align: left; text-indent: -10pt"></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_ecustom--ExercisePrices_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zErerTL2NLEd" style="width: 9%; text-align: right" title="Exercise Prices">0.53</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zqsTt1jq56j3" style="width: 9%; text-align: right" title="Number share option outstanding">471,698</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zoQoCKU7jjyb" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)">2.99</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zzschGzn2H2k" style="width: 9%; text-align: right" title="Options Exercisable">471,698</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zqa4oBkNShb7" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)">2.99</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_ecustom--ExercisePrices_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zogcE8auYHQ" style="text-align: right" title="Exercise Prices">0.65</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_z7BBCyXyUPij" style="text-align: right" title="Number share option outstanding">741,274</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zRhcrEUsTeGa" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)">3.09</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zVbKbyFkw2v" style="text-align: right" title="Options Exercisable">741,274</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zVZOlilTGUfk" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)">3.09</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_ecustom--ExercisePrices_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zh2EYdUTccQ1" style="text-align: right" title="Exercise Prices">1.14</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zwiNVo2M901i" style="text-align: right" title="Number share option outstanding">1,189,036</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zyGfDsmGybBl" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)">2.73</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_z2Nkcp1NNoh4" style="text-align: right" title="Options Exercisable">1,189,036</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_z8pAXF5C9THb" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)">2.73</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_ecustom--ExercisePrices_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange4Member_zLoXfHYiP6O2" style="text-align: right" title="Exercise Prices">1.47</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange4Member_z1PFmtDD0SB1" style="text-align: right" title="Number share option outstanding">642,128</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange4Member_zyj7XFqt9AGa" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)">3.96</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange4Member_zNTz6scTFOKa" style="text-align: right" title="Options Exercisable">642,128</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange4Member_z5XXprFMgA61" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)">3.96</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_ecustom--ExercisePrices_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange5Member_zY5K85JnGc7h" style="text-align: right" title="Exercise Prices">1.48</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange5Member_zq2pUtkY1pGg" style="text-align: right" title="Number share option outstanding">50,740</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange5Member_zNf7PImUdK4g" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)">3.99</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange5Member_zrmaHjTboG87" style="text-align: right" title="Options Exercisable">50,740</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange5Member_z2oOP9dWTSX8" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)">3.99</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_980_ecustom--ExercisePrice_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange6Member_zm39b6tcAYeb" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise Prices"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.50-1.68</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font-size: 11pt">&#160;</td>
    <td style="padding-bottom: 1pt; font-size: 11pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 11pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; font-size: 11pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange6Member_zpSuPsupMBbl" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)">3,175,00</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange5Member_zI6jp7nrJhAi" style="border-bottom: Black 1pt solid; text-align: right" title="Options Outstanding, Weighted Average Exercise Price">0.65</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange6Member_zg2s0pLbgVjc" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercisable">3,175,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange6Member_zabxc8i6t6W3" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)">0.65</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zm4kDZ2xvYzh" style="border-bottom: Black 2.5pt double; text-align: right" title="Number share option outstanding">6,269,876</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left"></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zoSkyrPouaLl" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)">1.88</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_z4i7amudu6w" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding, Weighted Average Exercise Price">0.91</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zxYsnD7qnQFh" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable">6,269,876</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left"></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zBUsqskJmcL5" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)">1.88</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><p id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zOnYsPKkZJI" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0" title="Options Exercisable, Weighted Average Exercise Price">0.91</p></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>



<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_ScheduleOfWarrantsOutstandingTableTextBlock', window );">Schedule of warrants outstanding</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfWarrantsOutstandingTableTextBlock_zqlAtTNSi9Zb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details 4)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"><span id="xdx_8B6_z46HeFRRSjh3" style="display: none">Schedule of warrants outstanding</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">&#160;<b>Shares</b></span></td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise<br/> Price</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Remaining<br/> Life</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-indent: -10pt">Outstanding at June 30, 2024</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_ecustom--CommonStockPurchaseWarrant_iS_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zBgOqd18AEHd" style="width: 11%; text-align: right" title="Outstanding at beginning of period">3,094,876</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_ecustom--CommonStockPurchaseWarrantsWeightedAverageExercisePrice_iS_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zEWM0Odm6RQ5" style="width: 11%; text-align: right" title="Weighted average exercise price, Outstanding at beginning of period">1.00</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zNqfsW65LQy" title="Weighted Average remaining life, Outstanding">3.48</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zXoWIGJN6QYe" style="text-align: right" title="Granted">3,175,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zYR1iPI6QKbi" style="text-align: right" title="Weighted average exercise price, Granted">0.82</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zVm37PF83K2" title="Weighted Average remaining life, Granted">0.65</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zT71R1ozEGnl" style="text-align: right" title="Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1738">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zPdw0hYmN7uf" style="text-align: right" title="Weighted average exercise price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1740">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Cancelled/Expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_d0_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zkHisiUAIiQf" style="border-bottom: Black 1pt solid; text-align: right" title="Cancelled/Expired">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_d0_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zIBoQIjac9n5" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Expired">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Outstanding and exercisable at June 30, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_ecustom--CommonStockPurchaseWarrant_iE_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zlg69IGA1S8d" style="border-bottom: Black 2.5pt double; text-align: right" title="Outstanding at end of period">6,269,876</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_ecustom--CommonStockPurchaseWarrantsWeightedAverageExercisePrice_iE_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zN82cjnupID9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Outstanding at ending of period">0.91</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zUvqf2AuS4H9" title="Weighted Average remaining life, Outstanding">1.88</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_ScheduleOfCommonStockPurchaseWarrantsOutstandingTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_ScheduleOfCommonStockPurchaseWarrantsOutstandingTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_ScheduleOfShareBasedPaymentAwardStockOptionValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_ScheduleOfShareBasedPaymentAwardStockOptionValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_ScheduleOfStockBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_ScheduleOfStockBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_ScheduleOfWarrantsOutstandingTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_ScheduleOfWarrantsOutstandingTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_ScheduleOfRecognizedIdentifiedAssetsAndLiabilitiesAssumedTableTextBlock', window );">Schedule of fair value of assets acquired and liabilities assumed</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_898_ecustom--ScheduleOfRecognizedIdentifiedAssetsAndLiabilitiesAssumedTableTextBlock_zVmaEFICs4S2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITION (Details 4)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B0_znxHeYyjvRB2" style="display: none">Schedule of fair value of assets acquired and
liabilities assumed</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49F_20250226__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zQph1CtNtkS6" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_z6tSoIkmltI3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-indent: -10pt">Cash</td><td style="width: 10%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">65,851</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_iI_zGDtqFoBR44b" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Prepaid &amp; Other Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">151,544</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets_iI_zkTa9G4qylS3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Fixed Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,243</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseRightOfUseAssets_iI_zLa2H5VBx0Pk" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Operating lease ROU</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">624,366</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_iI_ziRcp96fGfof" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total Assets Acquired:</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">858,004</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_iI_zfWvrHdXf6M1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Accounts Payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">583,577</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_iI_zIYxlh3dLwCd" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Accrued Expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">722,508</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities_iI_zUFJjLa0R0T8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Operating Lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">624,367</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable_iI_zQmWfInPkEQj" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Notes Payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,832,460</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_iI_zKqbaXpnCKcc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total Liabilities Assumed</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,762,913</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_zCEVoVBIByZi" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net Assets Acquired</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,904,909</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_iI_zM2LzSTjVeUb" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Goodwill</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">159,464,040</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_iI_zCMPUeGT5kcd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total Consideration</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">156,559,131</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The
goodwill recognized is attributable primarily to expected synergies and the assembled workforce of GEDi. None of the goodwill is expected
to be deductible for income tax purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The fair
values of the acquired tangible and intangible assets were determined using variations of the income approach. The income approach valuation
methodology used for the intangible assets acquired makes use of Level 3 inputs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The Company
recognized approximately $<span id="xdx_903_eus-gaap--BusinessCombinationAcquisitionRelatedCosts_pn5n6_c20230701__20240630__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zM59CyDtHqCl" title="Acquisition related costs">1.2</span> million of acquisition related costs that were expensed during the period ended June 30, 2024. These costs
are included in &#8220;selling, general and administrative expenses&#8221; in the accompanying condensed consolidated statements of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Consolidated unaudited pro forma information: </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following consolidated pro forma information assumes that the acquisition
of GEDi took place on July 1, 2023 for the statement of operations for the twelve-month period ended June 30, 2024. These amounts have
been estimated after applying the Company&#8217;s accounting policies:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>





<table cellpadding="0" cellspacing="0" id="xdx_89C_ecustom--custom--ScheduleOfConsolidatedStatementsOfOperationsTableTextBlock_hsrt--CounterpartyNameAxis__custom--GEDiCubeIntlLtdAcquisitionMember_zOpINOOxtCmk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITION (Details 3)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_492_20240701__20250630__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zSRDllRMIJN7" style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_404_ecustom--BusinessAcquisitionsRevenue_d0_zgHWOo15vUoe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Revenues</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--BusinessAcquisitionsNetIncomeLoss_zalIi4AWeGz2" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-align: left; text-indent: -10pt">Net loss</td><td style="width: 10%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 18%; text-align: right">(83,571,822</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">)</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=RENB_BioSymetricsncAcquisitionMember', window );">Bio Symetricsnc Acquisition [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_ScheduleOfAcquistionFairValueOfConsiderationTableTextBlock', window );">Schedule of acquisition date fair value</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89A_ecustom--ScheduleOfAcquistionFairValueOfConsiderationTableTextBlock_hsrt--CounterpartyNameAxis__custom--BioSymetricsncAcquisitionMember_zAl9SmiIjYt3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITION (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B0_zAaE5SSH5Q6b" style="display: none">Schedule of acquisition
date fair value</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-align: left; text-indent: -10pt">Common stock</td><td style="width: 10%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--BusinessCombinationContingentConsiderationCommonStock_iI_c20250226__us-gaap--BusinessAcquisitionAxis__custom--BioSymetricsncAcquisitionMember_zwtePe5aQoNe" style="border-bottom: Black 1pt solid; width: 18%; text-align: right" title="Common stock">6,058,500</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total consideration transferred</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--BusinessCombinationConsiderationTransferred1_c20250212__20250226__us-gaap--BusinessAcquisitionAxis__custom--BioSymetricsncAcquisitionMember_zhrSYeUXaz88" style="border-bottom: Black 2.5pt double; text-align: right" title="Total consideration transferred">6,058,500</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of fair value of assets acquired and liabilities assumed</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_hsrt--CounterpartyNameAxis__custom--BioSymetricsncAcquisitionMember_zPoXSZHQBGMg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITION (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8BA_z32iterXKz8f" style="display: none">Schedule of fair value of assets acquired and
liabilities assumed</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49B_20250226__us-gaap--BusinessAcquisitionAxis__custom--BioSymetricsncAcquisitionMember_z2TTACyafD7f" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iNI_di_zoDfgVvesNhc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-indent: -10pt">Cash</td><td style="width: 10%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">(3,822</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_iI_zGuAiTHzuQO4" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Prepaid &amp; Other Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,405</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets_iI_zEIivZWq8YOd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Fixed Assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">13,365</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_iI_zIu0KyNSDl4a" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total Assets Acquired:</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">26,948</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_iI_zUlScKTen1dk" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Accounts Payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">975</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_iI_zlFuO4SDEVje" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Accrued Expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,594</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities_iI_zEuGctgBrD98" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Other Current Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">73,879</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_iI_zbHlNEqiQkeb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total Liabilities Assumed</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">82,448</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_zJ9gkdRrmkS8" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Net Assets Acquired</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(55,500</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_404_ecustom--Software_iI_zYuBoHYY5pJd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Software</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">143,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--TradeName_iI_zbjIakIOHa1a" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Trade Name</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_iI_z0JeEKq8Wzb7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">Goodwill</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,963,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_iI_zr73hkD7clp9" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total Consideration</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,058,500</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=RENB_GEDiCubeIntlLtdAcquisitionMember', window );">G E Di Cube Intl Ltd Acquisition [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_ScheduleOfAcquistionFairValueOfConsiderationTableTextBlock', window );">Schedule of acquisition date fair value</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfAcquistionFairValueOfConsiderationTableTextBlock_hsrt--CounterpartyNameAxis__custom--GEDiCubeIntlLtdAcquisitionMember_zbLc9sRUqKSk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITION (Details 5)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B6_zEeSLO08dL32" style="display: none">Schedule of acquisition
date fair value</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-align: left; text-indent: -10pt">Common stock</td><td style="width: 10%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_ecustom--BusinessCombinationContingentConsiderationCommonStock_iI_c20250226__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zaxIB00nYcQb" style="width: 18%; text-align: right" title="Common stock">136,001,631</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Contingent consideration</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--BusinessCombinationContingentConsiderationAsset_iI_c20250226__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zriLj2VJ8p0i" style="border-bottom: Black 1pt solid; text-align: right" title="Contingent consideration">20,557,500</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Total consideration transferred</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--BusinessCombinationConsiderationTransferred1_c20250212__20250226__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zP2MJDibj9K8" style="border-bottom: Black 2.5pt double; text-align: right" title="Total consideration transferred">156,559,131</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_ScheduleOfAcquistionFairValueOfConsiderationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_ScheduleOfAcquistionFairValueOfConsiderationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_ScheduleOfRecognizedIdentifiedAssetsAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_ScheduleOfRecognizedIdentifiedAssetsAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Paragraph 1<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=RENB_BioSymetricsncAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=RENB_BioSymetricsncAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=RENB_GEDiCubeIntlLtdAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=RENB_GEDiCubeIntlLtdAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT REPORTING (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of segment operating loss and asset information</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zdUDi4exyaWb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SEGMENT REPORTING (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"><span id="xdx_8B2_z6gLeveQNbOf" style="display: none">Schedule of segment operating loss and
    asset information</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Operating loss</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Assets</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 56%; font-weight: bold; text-align: left; text-indent: -10pt">United States (RENB)</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--SegmentOperatingLoss_c20240701__20250630__srt--StatementGeographicalAxis__country--US_zTqkzEFiBbkk" style="width: 12%; text-align: right" title="Operating income loss">15,530,056</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--SegmentAsset_iI_c20250630__srt--StatementGeographicalAxis__country--US_z1Dxzi7xZxc7" style="width: 12%; text-align: right" title="Assets">1,907,647</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">United States (BioSymetrics)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--SegmentOperatingLoss_c20240701__20250630__srt--StatementGeographicalAxis__custom--BioSymetricsMember_z3IMPpLY3Z4i" style="text-align: right" title="Operating income loss">237,880</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--SegmentAsset_iI_c20250630__srt--StatementGeographicalAxis__custom--BioSymetricsMember_zQx2JOs8qNi3" style="text-align: right" title="Assets">6,109,643</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt">Netherlands (RENC)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_ecustom--SegmentOperatingLoss_c20240701__20250630__srt--StatementGeographicalAxis__country--NL_zLymUYaPzfqj" style="border-bottom: Black 1pt solid; text-align: right" title="Operating income loss">173,198,066</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_ecustom--SegmentAsset_iI_c20250630__srt--StatementGeographicalAxis__country--NL_zkTPpSNyISdj" style="border-bottom: Black 1pt solid; text-align: right" title="Assets">213,550</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_988_ecustom--SegmentOperatingLoss_c20240701__20250630_zEwvC8oPeMQb" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Operating income loss">188,966,002</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_981_ecustom--SegmentAsset_iI_c20250630_zLf8FAxU9A23" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Assets">8,230,840</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Schedule of information regarding segment reporting</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_zBaCQ2PFb6W6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SEGMENT REPORTING (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"><span id="xdx_8B8_zGCMTWRXTdPf" style="display: none">Schedule of information regarding segment reporting</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_490_20240701__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--RENBMember_zKUWfCht6Nvd" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_497_20240701__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--BioSymetricsMember_zixUeXPh5Ud9" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_496_20240701__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--RENCMember_zbZDpF18LPS7" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49F_20240701__20250630_zGqqSm4HTlD1" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">RENB</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">BioSymetrics</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">RENC</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td></tr>
  <tr id="xdx_405_eus-gaap--OtherGeneralAndAdministrativeExpense_zm8VctnRFQ5k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt">General and administrative</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">14,904,855</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">211,401</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">2,763,794</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">17,880,050</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--ResearchAndDevelopmentExpense_zNfZ1RwN4MBl" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">502,896</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26,029</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,503</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">537,428</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--GoodwillAndIntangibleAssetImpairment_d0_zJWFVuCpvcrh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Goodwill impairment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">170,419,429</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">170,419,429</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DepreciationDepletionAndAmortization_zygwY7gL8pY5" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">122,305</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">450</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,340</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">129,095</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--SegmentOperatingLoss_zQ1J1j7Y6Pq9" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt">Segment operating loss</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">15,530,056</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">237,880</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">173,198,066</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">188,966,002</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white"><b><span style="text-decoration: underline">Geographic information:</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">RENB,
BioSymetrics and RENC are managed on a worldwide basis but operate in offices located in the United States and the Netherlands, respectively.
The geographic information analyses the Company&#8217;s operations and assets based on the country in which each segment operates. In
presenting this geographic information, segment operating results have been based on the geographic location in which the services were
provided to the segment and segment assets were based on the geographic location of the assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"></p>





<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Feb. 13, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_PurchaseEquitySecuritiesValue', window );">Purchase equity securities value</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCost', window );">Fair value of equity securities</a></td>
<td class="nump">112,149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtAndEquitySecuritiesGainLoss', window );">Investment in equity securities</a></td>
<td class="nump">387,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_ImpairmentLoss', window );">Impairment loss</a></td>
<td class="nump">122,804,700<span></span>
</td>
<td class="nump">$ 42,611,000<span></span>
</td>
<td class="nump">$ 47,614,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_InProcessResearchAndDevelopment', window );">In-process research and development</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">5,963,000<span></span>
</td>
<td class="nump">159,330,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">$ 537,428<span></span>
</td>
<td class="nump">$ 2,708,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Common stock outstanding</a></td>
<td class="nump">177,392,907<span></span>
</td>
<td class="nump">158,452,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares</a></td>
<td class="nump">13,669,140<span></span>
</td>
<td class="nump">17,146,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation costs</a></td>
<td class="nump">$ 3,313,291<span></span>
</td>
<td class="nump">$ 4,673,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Employees, Officers, Directors and Consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation costs</a></td>
<td class="nump">$ 3,313,291<span></span>
</td>
<td class="nump">$ 4,673,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=RENB_RenovaroCubeMember', window );">Renovaro Cube [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_BusinessAcquisitionPercentage', window );">Acquisition percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_BusinessAcquisitionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_BusinessAcquisitionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_ImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_ImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_InProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_InProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_PurchaseEquitySecuritiesValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_PurchaseEquitySecuritiesValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockOtherSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of other common stock instruments held by shareholder, including, but not limited to, exchangeable shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockOtherSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtAndEquitySecuritiesGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtAndEquitySecuritiesGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of investment in debt investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=RENB_EmployeesOfficersDirectorsAndConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=RENB_EmployeesOfficersDirectorsAndConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=RENB_RenovaroCubeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=RENB_RenovaroCubeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOING CONCERN (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 178,007,489<span></span>
</td>
<td class="nump">$ 88,425,828<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">92,700<span></span>
</td>
<td class="nump">220,467<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">510,462,570<span></span>
</td>
<td class="nump">$ 332,455,081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_WorkingCapitalDeficit', window );">Working capital deficit</a></td>
<td class="nump">$ 28,109,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_WorkingCapitalDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_WorkingCapitalDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investment in equity securities</a></td>
<td class="nump">$ 387,851<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investment in equity securities</a></td>
<td class="nump">387,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">387,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure', window );">Contingent consideration</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total liabilities at fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investment in equity securities</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure', window );">Contingent consideration</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total liabilities at fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investment in equity securities</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure', window );">Contingent consideration</a></td>
<td class="nump">630,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total liabilities at fair value</a></td>
<td class="nump">$ 630,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of contingent consideration in a business combination that is classified in shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-7<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -SubTopic 20<br> -Topic 860<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481326/860-20-50-4D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Details 1)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2025 </div>
<div>$ / shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=RENB_BlackScholesOptionPricingModelMember', window );">Black Scholes Option Pricing Model [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock Price</a></td>
<td class="nump">$ 0.29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected Dividends</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate', window );">Discount Rate (Monte-Carlo model only)</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=RENB_BlackScholesOptionPricingModelMember', window );">Black Scholes Option Pricing Model [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 0.53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">116.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk Free Rate</a></td>
<td class="nump">3.61%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected Term (years)</a></td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=RENB_BlackScholesOptionPricingModelMember', window );">Black Scholes Option Pricing Model [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 1.92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">141.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk Free Rate</a></td>
<td class="nump">4.02%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected Term (years)</a></td>
<td class="text">8 years 4 months 17 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=RENB_InitialRecognitionMember', window );">Initial Recognition [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock Price</a></td>
<td class="nump">$ 1.92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected Dividends</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate', window );">Discount Rate (Monte-Carlo model only)</a></td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=RENB_InitialRecognitionMember', window );">Initial Recognition [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 0.46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">107.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk Free Rate</a></td>
<td class="nump">4.22%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected Term (years)</a></td>
<td class="text">6 months 21 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=RENB_InitialRecognitionMember', window );">Initial Recognition [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 4.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">133.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk Free Rate</a></td>
<td class="nump">5.14%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected Term (years)</a></td>
<td class="text">9 years 10 months 17 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=RENB_BlackScholesOptionPricingModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=RENB_BlackScholesOptionPricingModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=RENB_InitialRecognitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=RENB_InitialRecognitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Details 2)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Balance June 30, 2024</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Fair value adjustment</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent Consideration Liability at June 30, 2025</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Balance June 30, 2024</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Fair value adjustment</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent Consideration Liability at June 30, 2025</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Balance June 30, 2024</a></td>
<td class="nump">12,310,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Fair value adjustment</a></td>
<td class="num">(11,680,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent Consideration Liability at June 30, 2025</a></td>
<td class="nump">$ 630,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 13, 2025</div></th>
<th class="th"><div>Aug. 23, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Purchased shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">978,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=RENB_RenovaroCubeMember', window );">Renovaro Cube [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Contingent shares issuable in connection with the acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,775,650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability was recorded at fair value</a></td>
<td class="nump">$ 20,557,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=RENB_CommonStocksMember', window );">Common Stocks [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Purchased shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">467,290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.07<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCost', window );">Fair value of equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_InvestmentEquitySecuritiesShares', window );">investment equity securities shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">467,290<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Renovaro Cube [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Contingent shares issuable in connection with the acquisition</a></td>
<td class="nump">70,834,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=RENB_ConvertibleNotesMember', window );">Convertible Notes [Member] | Renovaro Cube [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Contingent shares issuable in connection with the acquisition</a></td>
<td class="nump">11,899,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_InvestmentEquitySecuritiesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_InvestmentEquitySecuritiesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=RENB_RenovaroCubeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=RENB_RenovaroCubeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=RENB_CommonStocksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=RENB_CommonStocksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=RENB_ConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=RENB_ConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">$ 1,070,023<span></span>
</td>
<td class="nump">$ 1,060,461<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less Accumulated Depreciation</a></td>
<td class="num">(702,180)<span></span>
</td>
<td class="num">(578,340)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net Property and Equipment</a></td>
<td class="nump">367,843<span></span>
</td>
<td class="nump">482,121<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=RENB_LabEquipmentAndInstrumentsMember', window );">Lab Equipment And Instruments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">$ 639,998<span></span>
</td>
<td class="nump">639,998<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">$ 224,629<span></span>
</td>
<td class="nump">224,629<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total</a></td>
<td class="nump">$ 205,396<span></span>
</td>
<td class="nump">$ 195,834<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Lab Equipment And Instruments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Lab Equipment And Instruments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=RENB_LabEquipmentAndInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=RENB_LabEquipmentAndInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 119,193<span></span>
</td>
<td class="nump">$ 113,563<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_NetDefinitelifeIntangibleAssets', window );">Net definite-life intangible assets at beginning</a></td>
<td class="nump">$ 30,043<span></span>
</td>
<td class="nump">$ 39,676<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Net definite-life intangible assets, Additions</a></td>
<td class="nump">151,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_NetDefinitelifeIntangibleAssetsAmortization', window );">Net definite-life intangible assets, Amortization</a></td>
<td class="num">(9,902)<span></span>
</td>
<td class="num">(8,296)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Net definite-life intangible assets, Impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments', window );">Net definite-life intangible assets, Translation adjustment</a></td>
<td class="num">(5,147)<span></span>
</td>
<td class="num">(1,337)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_NetDefinitelifeIntangibleAssets', window );">Net definite-life intangible assets at ending</a></td>
<td class="nump">165,994<span></span>
</td>
<td class="nump">30,043<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIndefiniteLivedIntangibleAssets', window );">Total indefinite life intangible assets and goodwill at beginning</a></td>
<td class="nump">159,330,161<span></span>
</td>
<td class="nump">54,251,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Total indefinite life intangible assets and goodwill, Additions</a></td>
<td class="nump">5,963,000<span></span>
</td>
<td class="nump">159,464,039<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_IndefiniteLifeIntangibleAssetsAndGoodwillAmortization', window );">Total indefinite life intangible assets and goodwill, Amortization</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_IndefiniteLifeIntangibleAssetsAndGoodwillImpairment', window );">Total indefinite life intangible assets and goodwill, Impairment</a></td>
<td class="num">(170,419,429)<span></span>
</td>
<td class="num">(54,251,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments', window );">Total indefinite life intangible assets and goodwill, Translation adjustment</a></td>
<td class="nump">11,089,268<span></span>
</td>
<td class="num">(133,878)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIndefiniteLivedIntangibleAssets', window );">Total indefinite life intangible assets and goodwill at ending</a></td>
<td class="nump">$ 5,963,000<span></span>
</td>
<td class="nump">159,330,161<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=RENB_SoftwarePlatformMember', window );">Software Platform [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_NetDefinitelifeIntangibleAssets', window );">Net definite-life intangible assets at beginning</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Net definite-life intangible assets, Additions</a></td>
<td class="nump">143,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_NetDefinitelifeIntangibleAssetsAmortization', window );">Net definite-life intangible assets, Amortization</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Net definite-life intangible assets, Impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments', window );">Net definite-life intangible assets, Translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_NetDefinitelifeIntangibleAssets', window );">Net definite-life intangible assets at ending</a></td>
<td class="nump">$ 143,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=RENB_TrademarkMember', window );">Trademark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_NetDefinitelifeIntangibleAssets', window );">Net definite-life intangible assets at beginning</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Net definite-life intangible assets, Additions</a></td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_NetDefinitelifeIntangibleAssetsAmortization', window );">Net definite-life intangible assets, Amortization</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Net definite-life intangible assets, Impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments', window );">Net definite-life intangible assets, Translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_NetDefinitelifeIntangibleAssets', window );">Net definite-life intangible assets at ending</a></td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_NetDefinitelifeIntangibleAssets', window );">Net definite-life intangible assets at beginning</a></td>
<td class="nump">$ 284,977<span></span>
</td>
<td class="nump">290,936<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Net definite-life intangible assets, Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_NetDefinitelifeIntangibleAssetsAmortization', window );">Net definite-life intangible assets, Amortization</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Net definite-life intangible assets, Impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments', window );">Net definite-life intangible assets, Translation adjustment</a></td>
<td class="nump">28,033<span></span>
</td>
<td class="num">(5,959)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_NetDefinitelifeIntangibleAssets', window );">Net definite-life intangible assets at ending</a></td>
<td class="nump">313,010<span></span>
</td>
<td class="nump">284,977<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=RENB_LessAccumulatedAmortizationMember', window );">Less Accumulated Amortization [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_NetDefinitelifeIntangibleAssets', window );">Net definite-life intangible assets at beginning</a></td>
<td class="num">(254,934)<span></span>
</td>
<td class="num">(251,260)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Net definite-life intangible assets, Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_NetDefinitelifeIntangibleAssetsAmortization', window );">Net definite-life intangible assets, Amortization</a></td>
<td class="num">(9,902)<span></span>
</td>
<td class="num">(8,296)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Net definite-life intangible assets, Impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments', window );">Net definite-life intangible assets, Translation adjustment</a></td>
<td class="num">(33,180)<span></span>
</td>
<td class="nump">4,622<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_NetDefinitelifeIntangibleAssets', window );">Net definite-life intangible assets at ending</a></td>
<td class="num">(298,016)<span></span>
</td>
<td class="num">(254,934)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_GoodwillMember', window );">Goodwill [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIndefiniteLivedIntangibleAssets', window );">Total indefinite life intangible assets and goodwill at beginning</a></td>
<td class="nump">159,330,161<span></span>
</td>
<td class="nump">11,640,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Total indefinite life intangible assets and goodwill, Additions</a></td>
<td class="nump">5,963,000<span></span>
</td>
<td class="nump">159,464,039<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_IndefiniteLifeIntangibleAssetsAndGoodwillAmortization', window );">Total indefinite life intangible assets and goodwill, Amortization</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_IndefiniteLifeIntangibleAssetsAndGoodwillImpairment', window );">Total indefinite life intangible assets and goodwill, Impairment</a></td>
<td class="num">(170,419,429)<span></span>
</td>
<td class="num">(11,640,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments', window );">Total indefinite life intangible assets and goodwill, Translation adjustment</a></td>
<td class="nump">11,089,268<span></span>
</td>
<td class="num">(133,878)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIndefiniteLivedIntangibleAssets', window );">Total indefinite life intangible assets and goodwill at ending</a></td>
<td class="nump">5,963,000<span></span>
</td>
<td class="nump">159,330,161<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIndefiniteLivedIntangibleAssets', window );">Total indefinite life intangible assets and goodwill at beginning</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">42,611,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Total indefinite life intangible assets and goodwill, Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_IndefiniteLifeIntangibleAssetsAndGoodwillAmortization', window );">Total indefinite life intangible assets and goodwill, Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_IndefiniteLifeIntangibleAssetsAndGoodwillImpairment', window );">Total indefinite life intangible assets and goodwill, Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(42,611,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments', window );">Total indefinite life intangible assets and goodwill, Translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIndefiniteLivedIntangibleAssets', window );">Total indefinite life intangible assets and goodwill at ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_IndefiniteLifeIntangibleAssetsAndGoodwillAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_IndefiniteLifeIntangibleAssetsAndGoodwillAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_IndefiniteLifeIntangibleAssetsAndGoodwillImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_IndefiniteLifeIntangibleAssetsAndGoodwillImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_NetDefinitelifeIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_NetDefinitelifeIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_NetDefinitelifeIntangibleAssetsAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_NetDefinitelifeIntangibleAssetsAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to assets, excluding financial assets and goodwill, lacking physical substance with a finite life for foreign currency translation adjustments and purchase accounting adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit, from foreign currency translation and purchase accounting adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after impairment of indefinite-lived intangible assets classified as other. Excludes financial assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=RENB_SoftwarePlatformMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=RENB_SoftwarePlatformMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=RENB_TrademarkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=RENB_TrademarkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=RENB_LessAccumulatedAmortizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=RENB_LessAccumulatedAmortizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_GoodwillMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_GoodwillMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL (Details 1)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2026</a></td>
<td class="nump">$ 36,350<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2027</a></td>
<td class="nump">36,348<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2028</a></td>
<td class="nump">32,348<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2029</a></td>
<td class="nump">32,348<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Thereafter</a></td>
<td class="nump">28,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 165,994<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Apr. 08, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Feb. 13, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Definite-life intangible assets</a></td>
<td class="nump">$ 165,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedAmortizationOfCurrentDeferredFinanceCosts', window );">Accumulated amortization cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">9,902<span></span>
</td>
<td class="nump">8,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">5,963,000<span></span>
</td>
<td class="nump">$ 159,330,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_Software', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 143,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_Trademark', window );">Trademark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_ImpairmentAdjustment', window );">Impairment adjustment</a></td>
<td class="nump">122,804,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,614,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=RENB_RenovaroCubeMember', window );">Renovaro Cube [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 159,464,039<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=RENB_BioSymetricsMember', window );">Bio Symetrics [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,963,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=RENB_TrademarkMember', window );">Trademark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Definite-life intangible assets</a></td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Definite-life intangible assets</a></td>
<td class="nump">14,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=RENB_SoftwarePlatformMember', window );">Software Platform [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Definite-life intangible assets</a></td>
<td class="nump">$ 143,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_ImpairmentAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_ImpairmentAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_Software">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_Software</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_Trademark">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_Trademark</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedAmortizationOfCurrentDeferredFinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated amortization of debt issuance costs classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedAmortizationOfCurrentDeferredFinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=RENB_RenovaroCubeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=RENB_RenovaroCubeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=RENB_BioSymetricsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=RENB_BioSymetricsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=RENB_TrademarkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=RENB_TrademarkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=RENB_SoftwarePlatformMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=RENB_SoftwarePlatformMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2026</a></td>
<td class="nump">$ 363,999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2027</a></td>
<td class="nump">358,326<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo', window );">Thereafter</a></td>
<td class="nump">56,621<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(41,353)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">$ 737,593<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES (Details Narrative)<br></strong></div></th>
<th class="th"><div>Jun. 19, 2018</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Lease premises, description</a></td>
<td class="text">n June 19, 2018, Lunai entered into a Lease Agreement for a term of ten years from September 1, 2018, with Century
City Medical Plaza Land Co., Inc., pursuant to which the Company agreed to lease approximately 2,453 rentable square feet. On February
20, 2019, Lunai entered into an Addendum to the original Lease Agreement with an effective date of December 1, 2019, where it expanded
the lease area to include another 1,101 square feet for a total rentable 3,554 square feet. The base rent increases by 3% each year, and
ranges from $17,770 per month for the first year to $23,186 per month for the tenth year. The equalized monthly lease payment for the
term of the lease is $20,050.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 11 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.66%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 24, 2025</div></th>
<th class="th"><div>Nov. 30, 2024</div></th>
<th class="th"><div>Nov. 03, 2024</div></th>
<th class="th"><div>Sep. 16, 2024</div></th>
<th class="th"><div>Sep. 06, 2024</div></th>
<th class="th"><div>Feb. 05, 2024</div></th>
<th class="th"><div>Jan. 12, 2024</div></th>
<th class="th"><div>Jan. 02, 2024</div></th>
<th class="th"><div>Dec. 20, 2023</div></th>
<th class="th"><div>Mar. 30, 2020</div></th>
<th class="th"><div>Dec. 03, 2024</div></th>
<th class="th"><div>Jan. 24, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 04, 2025</div></th>
<th class="th"><div>Oct. 21, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,770,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_NotesBalance', window );">Notes balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 245,000<span></span>
</td>
<td class="nump">$ 245,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MaturitiesOfTimeDepositsDescription', window );">Maturity description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Approximately $700,000 matured on December 31,
2024, $900,000 matured on December 31, 2025 and $1,050,000 matured on January 31, 2025. On February 24, 2025, Paseco ApS assigned 50%
of its ownership rights to Laksya Ventures Inc. with all terms remaining unchanged. The note balance at June 30, 2025, was $2,650,000
with Paseco ApS and Laksya Ventures Inc. each holding $1,325,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271,643<span></span>
</td>
<td class="nump">$ 271,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Total interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">725,684<span></span>
</td>
<td class="nump">1,011,322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=RENB_FinanceAgreementMember', window );">Finance Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_MonthlyInstallments', window );">Monthly instalments amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_RepaymentOnFinanceAgreement', window );">Down payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">204,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">971,231<span></span>
</td>
<td class="nump">870,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndDebtExpense', window );">Accrued interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,555<span></span>
</td>
<td class="nump">20,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other Current Liabilities [Member] | Finance Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAnnualPrincipalPayment', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,018,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Rate of interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=RENB_TheNotesMember', window );">The Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Note interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=RENB_PromissoryNotesMember', window );">Promissory Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_AgreementDescription', window );">Agreement description</a></td>
<td class="text">On November 1, 2024, Renovaro
Cube entered into an agreement with Yalla Yalla Limited, an investor to issue a Promissory Note for the amount of approximately &#8364;225,000.
The note bears an interest rate of 10% per annum and matured on February 24, 2025. The note balance at June 30, 2025 was approximately
$238,000.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On November 3, 2023, the Company
entered into an agreement with RS Bio to issue a 5% Original Issue Discount Promissory Note for the principal amount of $1,000,000. The
Company received a total of $950,000 in gross proceeds after taking into account the 5% original issue discount.&#160;The discount of
$50,000 will be accreted over the life of the note. The note bears an interest rate of 12% per annum and matured on December 31, 2024.
On February 24, 2025 RS Bio assigned its ownership rights to Rene Sindlev with all terms remaining unchanged. The note balance, net of
discount at June 30, 2025 was $750,000.<span></span>
</td>
<td class="text">On September 16, 2024, the Company
entered into an agreement with RS Bio ApS, a Danish entity controlled by a shareholder (&#8220;RS Bio&#8221;), to issue a Promissory Note
for the principal amount of $100,000 (the &#8220;September 2024 Note&#8221;). The Company received $100,000 in gross proceeds. The note
bears an interest rate of 12% per annum and matured on December 31, 2024. On February 24, 2025 RS Bio assigned its ownership rights to
Rene Sindlev with all terms remaining unchanged. The note balance at June 30, 2025 was $100,000<span></span>
</td>
<td class="text">n September 6, 2024, Renovaro
Cube entered into an agreement with Paseco ApS, a Danish entity controlled by a shareholder (&#8220;Paseco ApS&#8221;), to issue a Promissory
Note for the principal amount of &#8364;50,000. The note bears an interest rate of 12% per annum and matures on September 9, 2025. On February
24, 2025 Paseco ApS assigned 50% of its ownership rights to Laksya Ventures Inc. with all terms remaining unchanged. The note balance
at June 30, 2025 was approximately $59,000 with Paseco ApS and Laksya Ventures Inc. each holding approximately $30,000 (see Note 8 to
the Financial Statements)<span></span>
</td>
<td class="text">On February 5, 2024, the Company
entered into an agreement with RS Bio to issue a 5% Original Issue Discount Secured Promissory Note for the principal amount of $105,263
(the &#8220;February 2024 Note&#8221;). The Company received $100,000 in gross proceeds after taking into account the 5% original issue
discount. The note bears an interest rate of 12% per annum and matured on December 31, 2024. On February 24, 2025 RS Bio assigned its
ownership rights to Rene Sindlev with all terms remaining unchanged. The note balance, net of discount at June 30, 2025 was $105,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On January 2, 2024, the Company
entered into an agreement with RS Bio to issue a 5% Original Issue Discount Secured Promissory Note for the principal amount of $526,315.
The Company received a total of $500,000 in gross proceeds after taking into account the 5% original issue discount.&#160;The note bears
an interest rate of 12% per annum and matured on December 31, 2024. On February 24, 2025 RS Bio assigned its ownership rights to Rene
Sindlev with all terms remaining unchanged. The note balance, net of discount at June 30, 2025 was $526,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">From November 12, 2024 to December
3, 2024, Renovaro Cube entered into an agreement with Paseco ApS, a Danish entity controlled by a shareholder (&#8220;Paseco ApS&#8221;),
to issue Promissory Notes for the principal amount of &#8364;450,000. The note bears an interest rate of 10% per annum and matures on December
1, 2025. On February 24, 2025 Paseco ApS assigned 50% of its ownership rights to Laksya Ventures Inc. with all terms remaining unchanged.
The note balance at June 30, 2025 was approximately $490,000 with Paseco ApS and Laksya Ventures Inc. each holding $245,000.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=RENB_PromissoryNoteMember', window );">Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov.  01,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">831,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=RENB_PasecoApSMember', window );">Paseco Ap S [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,725,000<span></span>
</td>
<td class="nump">1,725,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,725,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,425,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=RENB_JanuaryNote2024Member', window );">January Note 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate', window );">Bear interest percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 29,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=RENB_JanuaryNote2024Member', window );">January Note 2024 [Member] | Paseco Ap S [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,650,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=RENB_DecemberNote2023Member', window );">December Note 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate', window );">Bear interest percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=RENB_DecemberNote2023Member', window );">December Note 2023 [Member] | Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_AgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_AgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_MonthlyInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_MonthlyInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_NotesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_NotesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_RepaymentOnFinanceAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_RepaymentOnFinanceAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAnnualPrincipalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of annual principal payment for debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAnnualPrincipalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Incremental percentage increase (decrease) in the stated rate on a debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed interest rate related to the interest rate derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndDebtExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest and debt related expenses associated with nonoperating financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndDebtExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtPercentageBearingFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MaturitiesOfTimeDepositsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of time deposit maturities, including certificates of deposit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MaturitiesOfTimeDepositsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=RENB_FinanceAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=RENB_FinanceAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=RENB_TheNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=RENB_TheNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=RENB_PromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=RENB_PromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=RENB_PromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=RENB_PromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=RENB_PasecoApSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=RENB_PasecoApSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=RENB_JanuaryNote2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=RENB_JanuaryNote2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=RENB_DecemberNote2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=RENB_DecemberNote2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_Depreciations', window );">Depreciation</a></td>
<td class="num">$ (24,619)<span></span>
</td>
<td class="nump">$ 8,258<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_DeferredTaxAssetExcessTaxOverDepreciationPatents', window );">Excess of tax over book depreciation of patents</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">8,415<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_StockoptionsCompensation', window );">Stock/options compensation</a></td>
<td class="nump">463,099<span></span>
</td>
<td class="nump">6,672,252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_DepreciationAndAmortizations', window );">Depreciation and amortization</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">188,422<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">76,296,814<span></span>
</td>
<td class="nump">148,832,041<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_ImpairmentExpense', window );">&#160;Impairment expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,188,497<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_ContingentConsiderationFairValue', window );">Contingent consideration fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(909,577)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedAmortizationOfOtherDeferredCosts', window );">Amortization</a></td>
<td class="nump">1,961,747<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_Section174ReCapitalization', window );">Section 174 R&amp;E Capitalization</a></td>
<td class="nump">3,292,075<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_OperatingLeaseRightOfUseAssets', window );">ROU Assets and Lease Liabilities</a></td>
<td class="nump">14,227<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_Section481aAdjustment', window );">Section 481(a) Adjustment</a></td>
<td class="num">(40,895)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">R&amp;D Tax Credits</a></td>
<td class="nump">1,718,415<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_ChangeInTaxRate', window );">Change in tax rate</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(83,680,863)<span></span>
</td>
<td class="num">(170,988,308)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets', window );">Total Deferred Tax Assets (Liabilities)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_ChangeInTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_ChangeInTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_ContingentConsiderationFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_ContingentConsiderationFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_DeferredTaxAssetExcessTaxOverDepreciationPatents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_DeferredTaxAssetExcessTaxOverDepreciationPatents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_DepreciationAndAmortizations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_DepreciationAndAmortizations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_Depreciations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_Depreciations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_ImpairmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_ImpairmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_OperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_OperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_Section174ReCapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_Section174ReCapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_Section481aAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_Section481aAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_StockoptionsCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_StockoptionsCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedAmortizationOfOtherDeferredCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amortization of other deferred costs capitalized at the end of the reporting period. Does not include deferred finance costs, deferred acquisition costs of insurance companies, or deferred leasing costs for real estate operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedAmortizationOfOtherDeferredCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details 1) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Computed tax at expected statutory rate</a></td>
<td class="num">$ (951,542)<span></span>
</td>
<td class="num">$ (24,066,011)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings', window );">Non-US income taxed at different rates</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Non-deductible expenses / other items</a></td>
<td class="num">(2,046,364)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">2,999,380<span></span>
</td>
<td class="nump">24,066,011<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="nump">$ 1,474<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to repatriation of foreign earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details 2) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current Income Tax Expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal income tax (benefit)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State income tax (benefit)</a></td>
<td class="nump">1,474<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign income tax (benefit)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total Current Tax Expense (Benefit)</a></td>
<td class="nump">1,474<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Deferred Income Tax Expense Federal income tax (benefit)</a></td>
<td class="nump">101,609,457<span></span>
</td>
<td class="nump">165,458,980<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit', window );">State income tax (benefit)</a></td>
<td class="num">(14,302,006)<span></span>
</td>
<td class="nump">5,529,328<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign income tax (benefit)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Change in valuation allowance</a></td>
<td class="num">(87,307,451)<span></span>
</td>
<td class="num">(170,988,308)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total Deferred Tax Expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total Tax Expense</a></td>
<td class="nump">$ 1,474<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES (Details Narrative) - United States Tax [Member] - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 541,603,425<span></span>
</td>
<td class="nump">$ 489,177,759<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign', window );">Deferred tax assets</a></td>
<td class="nump">$ 76,296,814<span></span>
</td>
<td class="nump">$ 144,191,530<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=RENB_UnitedStatesTaxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=RENB_UnitedStatesTaxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details) - Renovaro [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</a></td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=RENB_RenovaroMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">109.45%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">3.86%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=RENB_RenovaroMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">118.99%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">4.40%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=RENB_RenovaroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=RENB_RenovaroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details 1)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityLineItems', window );"><strong>Option Indexed to Issuer's Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable | shares</a></td>
<td class="nump">1,159,470<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityLineItems', window );"><strong>Option Indexed to Issuer's Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number share option outstanding | shares</a></td>
<td class="nump">4,623,614<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">8 years 11 months 19 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 0.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable | shares</a></td>
<td class="nump">567,233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options Exercisable, Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">8 years 8 months 15 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 0.96<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | Exercise Price Range 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityLineItems', window );"><strong>Option Indexed to Issuer's Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise Prices, Lower</a></td>
<td class="nump">0.45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices, Upper</a></td>
<td class="nump">$ 4.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number share option outstanding | shares</a></td>
<td class="nump">4,623,614<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">8 years 11 months 19 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 0.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable | shares</a></td>
<td class="nump">567,233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options Exercisable, Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">8 years 8 months 15 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 0.96<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | Exercise Price Range 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityLineItems', window );"><strong>Option Indexed to Issuer's Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise Prices, Lower</a></td>
<td class="nump">4.51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices, Upper</a></td>
<td class="nump">$ 6.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number share option outstanding | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options Outstanding, Weighted Average Exercise Price</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options Exercisable, Weighted Average Exercise Price</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | Exercise Price Range 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityLineItems', window );"><strong>Option Indexed to Issuer's Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise Prices, Lower</a></td>
<td class="nump">6.51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Prices, Upper</a></td>
<td class="nump">$ 12.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number share option outstanding | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options Outstanding, Weighted Average Exercise Price</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options Exercisable, Weighted Average Exercise Price</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=RENB_ExercisePriceRange1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=RENB_ExercisePriceRange1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=RENB_ExercisePriceRange2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=RENB_ExercisePriceRange2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=RENB_ExercisePriceRange3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=RENB_ExercisePriceRange3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details 2) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityLineItems', window );"><strong>Option Indexed to Issuer's Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable</a></td>
<td class="nump">1,159,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=RENB_EmployeeStockOptionsMember', window );">Employee Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityLineItems', window );"><strong>Option Indexed to Issuer's Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding at beginning of period</a></td>
<td class="nump">5,527,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding at beginning of period</a></td>
<td class="nump">$ 2.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average remaining life</a></td>
<td class="text">8 years 11 months 19 days<span></span>
</td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Weighted Average Intrinsic Value, Outstanding at beginning of period</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">4,249,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Granted</a></td>
<td class="nump">$ 0.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercised</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Cancelled/Expired</a></td>
<td class="num">(5,153,903)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Expired</a></td>
<td class="nump">$ 2.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding at end of period</a></td>
<td class="nump">4,623,614<span></span>
</td>
<td class="nump">5,527,852<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding at ending of period</a></td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="nump">$ 2.11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Weighted Average Intrinsic Value, Outstanding at end of period</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable</a></td>
<td class="nump">567,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable at ending of period</a></td>
<td class="nump">$ 0.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisablesWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Life, Exercisable</a></td>
<td class="text">8 years 8 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Weighted Average Intrinsic Value, Exercisable end of period</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisablesWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisablesWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=RENB_EmployeeStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityEquityAxis=RENB_EmployeeStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details 3)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityLineItems', window );"><strong>Option Indexed to Issuer's Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable</a></td>
<td class="nump">1,159,470<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=RENB_CommonStockPurchaseWarrantsMember', window );">Common Stock Purchase Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityLineItems', window );"><strong>Option Indexed to Issuer's Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number share option outstanding</a></td>
<td class="nump">6,269,876<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">1 year 10 months 17 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable</a></td>
<td class="nump">6,269,876<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options Exercisable, Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">1 year 10 months 17 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options Outstanding, Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">$ 0.91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options Exercisable, Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">0.91<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=RENB_CommonStockPurchaseWarrantsMember', window );">Common Stock Purchase Warrants [Member] | Exercise Price Range 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityLineItems', window );"><strong>Option Indexed to Issuer's Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_ExercisePrices', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 0.53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number share option outstanding</a></td>
<td class="nump">471,698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">2 years 11 months 26 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable</a></td>
<td class="nump">471,698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options Exercisable, Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">2 years 11 months 26 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=RENB_CommonStockPurchaseWarrantsMember', window );">Common Stock Purchase Warrants [Member] | Exercise Price Range 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityLineItems', window );"><strong>Option Indexed to Issuer's Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_ExercisePrices', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 0.65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number share option outstanding</a></td>
<td class="nump">741,274<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">3 years 1 month 2 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable</a></td>
<td class="nump">741,274<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options Exercisable, Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">3 years 1 month 2 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=RENB_CommonStockPurchaseWarrantsMember', window );">Common Stock Purchase Warrants [Member] | Exercise Price Range 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityLineItems', window );"><strong>Option Indexed to Issuer's Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_ExercisePrices', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 1.14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number share option outstanding</a></td>
<td class="nump">1,189,036<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">2 years 8 months 23 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable</a></td>
<td class="nump">1,189,036<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options Exercisable, Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">2 years 8 months 23 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=RENB_CommonStockPurchaseWarrantsMember', window );">Common Stock Purchase Warrants [Member] | Exercise Price Range 4 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityLineItems', window );"><strong>Option Indexed to Issuer's Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_ExercisePrices', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 1.47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number share option outstanding</a></td>
<td class="nump">642,128<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">3 years 11 months 15 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable</a></td>
<td class="nump">642,128<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options Exercisable, Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">3 years 11 months 15 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=RENB_CommonStockPurchaseWarrantsMember', window );">Common Stock Purchase Warrants [Member] | Exercise Price Range 5 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityLineItems', window );"><strong>Option Indexed to Issuer's Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_ExercisePrices', window );">Exercise Prices | $ / shares</a></td>
<td class="nump">$ 1.48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number share option outstanding</a></td>
<td class="nump">50,740<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">3 years 11 months 26 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable</a></td>
<td class="nump">50,740<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options Exercisable, Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">3 years 11 months 26 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options Outstanding, Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">$ 0.65<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=RENB_CommonStockPurchaseWarrantsMember', window );">Common Stock Purchase Warrants [Member] | Exercise Price Range 6 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityLineItems', window );"><strong>Option Indexed to Issuer's Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number share option outstanding</a></td>
<td class="nump">3,175.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable</a></td>
<td class="nump">3,175,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options Exercisable, Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">7 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_ExercisePrice', window );">Exercise Prices</a></td>
<td class="text">0.50-1.68<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_ExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_ExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_ExercisePrices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_ExercisePrices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=RENB_CommonStockPurchaseWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityEquityAxis=RENB_CommonStockPurchaseWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=RENB_ExercisePriceRange1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=RENB_ExercisePriceRange1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=RENB_ExercisePriceRange2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=RENB_ExercisePriceRange2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=RENB_ExercisePriceRange3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=RENB_ExercisePriceRange3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=RENB_ExercisePriceRange4Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=RENB_ExercisePriceRange4Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=RENB_ExercisePriceRange5Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=RENB_ExercisePriceRange5Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=RENB_ExercisePriceRange6Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=RENB_ExercisePriceRange6Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details 4) - Common Stock Purchase Warrant [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityLineItems', window );"><strong>Option Indexed to Issuer's Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_CommonStockPurchaseWarrant', window );">Outstanding at beginning of period</a></td>
<td class="nump">3,094,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_CommonStockPurchaseWarrantsWeightedAverageExercisePrice', window );">Weighted average exercise price, Outstanding at beginning of period</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average remaining life, Outstanding</a></td>
<td class="text">1 year 10 months 17 days<span></span>
</td>
<td class="text">3 years 5 months 23 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">3,175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Granted</a></td>
<td class="nump">$ 0.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2', window );">Weighted Average remaining life, Granted</a></td>
<td class="text">7 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Cancelled/Expired</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Expired</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_CommonStockPurchaseWarrant', window );">Outstanding at end of period</a></td>
<td class="nump">6,269,876<span></span>
</td>
<td class="nump">3,094,876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_CommonStockPurchaseWarrantsWeightedAverageExercisePrice', window );">Weighted average exercise price, Outstanding at ending of period</a></td>
<td class="nump">$ 0.91<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_CommonStockPurchaseWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_CommonStockPurchaseWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_CommonStockPurchaseWarrantsWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_CommonStockPurchaseWarrantsWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=RENB_CommonStockPurchaseWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityEquityAxis=RENB_CommonStockPurchaseWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 08, 2025</div></th>
<th class="th"><div>Jan. 22, 2025</div></th>
<th class="th"><div>Jan. 21, 2025</div></th>
<th class="th"><div>Nov. 04, 2024</div></th>
<th class="th"><div>Oct. 17, 2024</div></th>
<th class="th"><div>Oct. 14, 2024</div></th>
<th class="th"><div>Aug. 01, 2024</div></th>
<th class="th"><div>Aug. 01, 2024</div></th>
<th class="th"><div>Jun. 14, 2024</div></th>
<th class="th"><div>Apr. 05, 2024</div></th>
<th class="th"><div>Feb. 20, 2024</div></th>
<th class="th"><div>Feb. 15, 2024</div></th>
<th class="th"><div>Feb. 13, 2024</div></th>
<th class="th"><div>Dec. 04, 2023</div></th>
<th class="th"><div>Oct. 23, 2023</div></th>
<th class="th"><div>Jul. 28, 2023</div></th>
<th class="th"><div>Jul. 14, 2022</div></th>
<th class="th"><div>Aug. 23, 2024</div></th>
<th class="th"><div>Oct. 02, 2024</div></th>
<th class="th"><div>Aug. 23, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Feb. 16, 2024</div></th>
<th class="th"><div>Jun. 20, 2023</div></th>
<th class="th"><div>Feb. 06, 2014</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_CommonStockShareIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177,392,907<span></span>
</td>
<td class="nump">158,452,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177,392,907<span></span>
</td>
<td class="nump">158,452,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Obligation to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">525,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock shares, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 341,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Stock-based compensation expense vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,159,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_UnrecognizedCompensationCostandVest', window );">Unrecognized compensation cost and vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 185,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_IssuanceOfCommonStockUnderPrivatePlacementOffering', window );">Issuance of common stock under private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,315,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">344,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_CommonStockParValuePrivatePlacement', window );">Common stock par value under private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,613,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.4726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonrecurringIncomeExpense', window );">Other income (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,183,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Sale of stock issued cash consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,376,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,376,181<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Shares purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">978,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_ExtinguishmentOfContingentConsiderationLiability', window );">Extinguishment of contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">419,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_ReserveEscrowShares', window );">Reserve escrow shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_StockIssuedToNonconsentingShareholders', window );">Stock issued to non-consenting shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">167,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,313,291<span></span>
</td>
<td class="nump">$ 4,673,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_UnrecognizedCompensationCostNonVested', window );">Unrecognized compensation cost non vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,009,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1', window );">Option fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_StockOptionIssued', window );">Stock option issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">stock option vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,159,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_UnrecognizedCompensationCost', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_WarrantsExercisablePurchaseValue', window );">Warrants exercisable purchase value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_StockbasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 177,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=RENB_ShareBasedCompensationAwardAdvisoryBoardMember', window );">Share Based Compensation Award Advisory Board [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Option granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">362,904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Share-Based Payment Arrangement, Tranche One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Option granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">424,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=RENB_ShareBasedCompensationAwardBoardofDirectorsMember', window );">Share Based Compensation Award Boardof Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Option granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">329,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=RENB_ShareBasedCompensationAwardConsultingServicesMember', window );">Share Based Compensation Award Consulting Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Option granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=RENB_PlanOptionMember', window );">Plan Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_PurchaseExercisableWarrantsOutstandingShares', window );">Purchase exercisable warrants outstanding shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">567,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_PurchaseExercisableWarrantsOutstandingShares', window );">Purchase exercisable warrants outstanding shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,269,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=RENB_EquityIncentivePlan2014Member', window );">Equity Incentive Plan 2014 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,206,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=RENB_PlanOptionsMember', window );">Plan Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Option granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,088,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_DebtConversionConvertedInstrumentWarrantsOptionsIssued1', window );">Options available to be issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1', window );">Options available to be issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,093,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=RENB_StockPurchaseAgreementOfRenovaroCubeMember', window );">Stock Purchase Agreement Of Renovaro Cube [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,834,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock shares, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 136,001,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=RENB_AgreementAndPlanOfMergerAgreementAxisMember', window );">Agreement And Plan Of Merger Agreement Axis [Member] | EBI And Weird Science LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuable', window );">Common shares contingently issuable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,671,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Paid in cash and settlement of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 478,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_PrincipalAmountAndInterestAccrued', window );">Principal amount and interest accrued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,955,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RENB_Investor1Member', window );">Investor 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">317,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Paid in cash and settlement of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_PrincipalAmountAndInterestAccrued', window );">Principal amount and interest accrued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 468,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RENB_GEDiCubeIntlLtdMember', window );">G E Di Cube Intl Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares', window );">Common Stock to be issued in settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,425,399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RENB_EmployeesMember', window );">Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Option granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,850,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RENB_EmployeesThreeYearMember', window );">Employees Three Year [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Option granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">369,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Converted shares of common stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,470,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=RENB_PurchaseAgreementMember', window );">Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">696,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,325,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.4726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Paid in cash and settlement of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,425,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=RENB_RestrictedStockAwardsMember', window );">Restricted Stock Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,415,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_StockbasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_StockbasedCompensationExpenseGrantShares', window );">Stock-based compensation expense grant shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_UnrecognizedStockbasedCompensationExpense', window );">Unrecognized stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock-based compensation expense grant shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=RENB_AdvisoryServicesMember', window );">Advisory Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_AdvisoryServices', window );">Advisory services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,760,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=RENB_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_PreferredStockDesignatedShares', window );">Preferred stock designated shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=RENB_CommonStockIssuancesMember', window );">Common Stock Issuances [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock shares</a></td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock shares, value</a></td>
<td class="nump">$ 6,058,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 119,400<span></span>
</td>
<td class="nump">$ 275,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=RENB_CommonStockIssuancesMember', window );">Common Stock Issuances [Member] | Avram Miller [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock shares, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,760,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock shares, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 177,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 137,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Number of share warrant purchase forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">833,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Option granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_PurchaseSharesOfCommonStock', window );">Purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Avram Miller [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Mr Miller [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Number of share warrant purchase forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">978,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=RENB_BoardOfDirectorsMember', window );">Board Of Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=RENB_CommonStockConsultingServicesMember', window );">Common Stock Consulting Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock shares, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,953,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExpenseOrRevenueRecognized', window );">Warrants aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Shares purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1', window );">Non cash earn out distribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,762,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Single Range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">471,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExpenseOrRevenueRecognized', window );">Warrants aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.4726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.4765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_AdvisoryServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_AdvisoryServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_CommonStockParValuePrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_CommonStockParValuePrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_CommonStockShareIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_CommonStockShareIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_DebtConversionConvertedInstrumentWarrantsOptionsIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_DebtConversionConvertedInstrumentWarrantsOptionsIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_ExtinguishmentOfContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_ExtinguishmentOfContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_IssuanceOfCommonStockUnderPrivatePlacementOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_IssuanceOfCommonStockUnderPrivatePlacementOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_PreferredStockDesignatedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_PreferredStockDesignatedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_PrincipalAmountAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_PrincipalAmountAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_PurchaseExercisableWarrantsOutstandingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_PurchaseExercisableWarrantsOutstandingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_PurchaseSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_PurchaseSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_ReserveEscrowShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_ReserveEscrowShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_StockIssuedToNonconsentingShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_StockIssuedToNonconsentingShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_StockOptionIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_StockOptionIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_StockbasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_StockbasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_StockbasedCompensationExpenseGrantShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_StockbasedCompensationExpenseGrantShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_UnrecognizedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_UnrecognizedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_UnrecognizedCompensationCostNonVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_UnrecognizedCompensationCostNonVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_UnrecognizedCompensationCostandVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_UnrecognizedCompensationCostandVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_UnrecognizedStockbasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_UnrecognizedStockbasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_WarrantsExercisablePurchaseValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_WarrantsExercisablePurchaseValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExpenseOrRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of expense or revenue offset related to the warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExpenseOrRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOptionChangesInFairValueGainLoss1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of accounts receivable that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonrecurringIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense (income) that is infrequent in occurrence or unusual in nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483613/220-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonrecurringIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares that would be issued, determined under the conditions specified in the contract, if the settlement were to occur at the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481648/480-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=RENB_ShareBasedCompensationAwardAdvisoryBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=RENB_ShareBasedCompensationAwardAdvisoryBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=RENB_ShareBasedCompensationAwardBoardofDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=RENB_ShareBasedCompensationAwardBoardofDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=RENB_ShareBasedCompensationAwardConsultingServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=RENB_ShareBasedCompensationAwardConsultingServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=RENB_PlanOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=RENB_PlanOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=RENB_EquityIncentivePlan2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=RENB_EquityIncentivePlan2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=RENB_PlanOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=RENB_PlanOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=RENB_StockPurchaseAgreementOfRenovaroCubeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=RENB_StockPurchaseAgreementOfRenovaroCubeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=RENB_AgreementAndPlanOfMergerAgreementAxisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=RENB_AgreementAndPlanOfMergerAgreementAxisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=RENB_EBIAndWeirdScienceLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=RENB_EBIAndWeirdScienceLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RENB_Investor1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RENB_Investor1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RENB_GEDiCubeIntlLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RENB_GEDiCubeIntlLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RENB_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RENB_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RENB_EmployeesThreeYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RENB_EmployeesThreeYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=RENB_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=RENB_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=RENB_RestrictedStockAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=RENB_RestrictedStockAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=RENB_AdvisoryServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=RENB_AdvisoryServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=RENB_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=RENB_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=RENB_CommonStockIssuancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=RENB_CommonStockIssuancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RENB_AvramMillerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RENB_AvramMillerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=RENB_MrMillerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=RENB_MrMillerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=RENB_BoardOfDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=RENB_BoardOfDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=RENB_CommonStockConsultingServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=RENB_CommonStockConsultingServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=RENB_SingleRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=RENB_SingleRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 10, 2022</div></th>
<th class="th"><div>Aug. 25, 2022</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Feb. 06, 2020</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Nov. 15, 2019</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_UpfrontPayment', window );">Up-front payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_PaymentForExpenditures', window );">Payment for expenditures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 760,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_InitialPayment', window );">Initial payment</a></td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Remaining shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,414<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RENB_GTechMember', window );">G Tech [Member] | License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Payment for license</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_RoyaltyPercentage', window );">Royalty percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_InitialPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_InitialPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_PaymentForExpenditures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_PaymentForExpenditures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_RoyaltyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_RoyaltyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_UpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_UpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for fees classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RENB_GTechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=RENB_GTechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=RENB_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=RENB_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 23, 2024</div></th>
<th class="th"><div>Aug. 23, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Feb. 16, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited', window );">Common stock forfeited shares</a></td>
<td class="nump">833,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_SharesOfCommonStockGranted', window );">Shares of common stock granted</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">978,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Stock-based compensation expense stock option vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,159,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_UnrecognizedCompensationExpense', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=RENB_MarkDybulMember', window );">Mark Dybul [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Accrued balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 384,949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=RENB_RSBioMember', window );">RS Bio [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.69<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_SharesOfCommonStockGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_SharesOfCommonStockGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_UnrecognizedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_UnrecognizedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=RENB_MarkDybulMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=RENB_MarkDybulMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=RENB_RSBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=RENB_RSBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITION (Details) - Bio Symetricsnc Acquisition [Member]<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Feb. 26, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_BusinessCombinationContingentConsiderationCommonStock', window );">Common stock</a></td>
<td class="nump">$ 6,058,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total consideration transferred</a></td>
<td class="nump">$ 6,058,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_BusinessCombinationContingentConsiderationCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_BusinessCombinationContingentConsiderationCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=RENB_BioSymetricsncAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=RENB_BioSymetricsncAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACQUISITION (Details 1) - USD ($)<br></strong></div></th>
<th class="th"><div>Apr. 08, 2025</div></th>
<th class="th"><div>Feb. 26, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_Software', window );">Software</a></td>
<td class="nump">$ 143,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=RENB_BioSymetricsncAcquisitionMember', window );">Bio Symetricsnc Acquisition [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,822)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid &amp; Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,405<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets', window );">Fixed Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,365<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total Assets Acquired:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,948<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">975<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities', window );">Accrued Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,594<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities', window );">Other Current Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,879<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Total Liabilities Assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Net Assets Acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(55,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_Software', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_TradeName', window );">Trade Name</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,963,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Total Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,058,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_Software">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_Software</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_TradeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_TradeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=RENB_BioSymetricsncAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=RENB_BioSymetricsncAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITION (Details 2) - Bio Symetricsnc Acquisition [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_BusinessAcquisitionsRevenue', window );">Revenues</a></td>
<td class="nump">$ 663,660<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_BusinessAcquisitionsNetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (179,698,700)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_BusinessAcquisitionsNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_BusinessAcquisitionsNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_BusinessAcquisitionsRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_BusinessAcquisitionsRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=RENB_BioSymetricsncAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=RENB_BioSymetricsncAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITION (Details 5) - GEDi Cube [Member]<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Feb. 26, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_BusinessCombinationContingentConsiderationCommonStock', window );">Common stock</a></td>
<td class="nump">$ 136,001,631<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationAsset', window );">Contingent consideration</a></td>
<td class="nump">20,557,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total consideration transferred</a></td>
<td class="nump">$ 156,559,131<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_BusinessCombinationContingentConsiderationCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_BusinessCombinationContingentConsiderationCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=RENB_GEDiCubeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=RENB_GEDiCubeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACQUISITION (Details 4) - GEDi Cube [Member]<br></strong></div></th>
<th class="th">
<div>Feb. 26, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash</a></td>
<td class="nump">$ 65,851<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid &amp; Other Assets</a></td>
<td class="nump">151,544<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets', window );">Fixed Assets</a></td>
<td class="nump">16,243<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseRightOfUseAssets', window );">Operating lease ROU</a></td>
<td class="nump">624,366<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total Assets Acquired:</a></td>
<td class="nump">858,004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts Payable</a></td>
<td class="nump">583,577<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities', window );">Accrued Expenses</a></td>
<td class="nump">722,508<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities', window );">Operating Lease liability</a></td>
<td class="nump">624,367<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable', window );">Notes Payable</a></td>
<td class="nump">1,832,460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Total Liabilities Assumed</a></td>
<td class="nump">3,762,913<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Net Assets Acquired</a></td>
<td class="num">(2,904,909)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Goodwill</a></td>
<td class="nump">159,464,040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Total Consideration</a></td>
<td class="nump">$ 156,559,131<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=RENB_GEDiCubeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=RENB_GEDiCubeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITION (Details 3) - GEDi Cube [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_BusinessAcquisitionsRevenue', window );">Revenues</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_BusinessAcquisitionsNetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (83,571,822)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_BusinessAcquisitionsNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_BusinessAcquisitionsNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_BusinessAcquisitionsRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_BusinessAcquisitionsRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=RENB_GEDiCubeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=RENB_GEDiCubeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS (Details Narrative) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 03, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Apr. 08, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_TransactionIssuedShares', window );">Transaction issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock per value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=RENB_BioSymetricsMember', window );">Bio Symetrics [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredOther1', window );">Fair value of consideration transferred amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=RENB_GEDiCubeMember', window );">GEDi Cube [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredOther1', window );">Fair value of consideration transferred amount</a></td>
<td class="nump">$ 156.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_TransactionIssuedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_TransactionIssuedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479405/805-10-25-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredOther1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tangible or intangible assets, including a business or subsidiary of the acquirer transferred by the entity to the former owners of the acquiree. Excludes cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredOther1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=RENB_BioSymetricsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=RENB_BioSymetricsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=RENB_GEDiCubeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=RENB_GEDiCubeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT REPORTING (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_SegmentOperatingLoss', window );">Operating income loss</a></td>
<td class="nump">$ 188,966,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_SegmentAsset', window );">Assets</a></td>
<td class="nump">8,230,840<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_SegmentOperatingLoss', window );">Operating income loss</a></td>
<td class="nump">15,530,056<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_SegmentAsset', window );">Assets</a></td>
<td class="nump">1,907,647<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=RENB_BioSymetricsMember', window );">Bio Symetrics [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_SegmentOperatingLoss', window );">Operating income loss</a></td>
<td class="nump">237,880<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_SegmentAsset', window );">Assets</a></td>
<td class="nump">6,109,643<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_NL', window );">NETHERLANDS</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_SegmentOperatingLoss', window );">Operating income loss</a></td>
<td class="nump">173,198,066<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_SegmentAsset', window );">Assets</a></td>
<td class="nump">$ 213,550<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_SegmentAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_SegmentAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_SegmentOperatingLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_SegmentOperatingLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=RENB_BioSymetricsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=RENB_BioSymetricsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_NL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_NL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT REPORTING (Details 1) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 17,880,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">537,428<span></span>
</td>
<td class="nump">$ 2,708,829<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Goodwill impairment</a></td>
<td class="nump">170,419,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">129,095<span></span>
</td>
<td class="nump">$ 121,859<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_SegmentOperatingLoss', window );">Segment operating loss</a></td>
<td class="nump">188,966,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=RENB_RENBMember', window );">RENB [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">14,904,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">502,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Goodwill impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">122,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_SegmentOperatingLoss', window );">Segment operating loss</a></td>
<td class="nump">15,530,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=RENB_BioSymetricsMember', window );">Bio Symetrics [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">211,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">26,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Goodwill impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_SegmentOperatingLoss', window );">Segment operating loss</a></td>
<td class="nump">237,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=RENB_RENCMember', window );">RENC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">2,763,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">8,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Goodwill impairment</a></td>
<td class="nump">170,419,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">6,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_SegmentOperatingLoss', window );">Segment operating loss</a></td>
<td class="nump">$ 173,198,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_SegmentOperatingLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_SegmentOperatingLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=RENB_RENBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=RENB_RENBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=RENB_BioSymetricsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=RENB_BioSymetricsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=RENB_RENCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=RENB_RENCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Aug. 19, 2025</div></th>
<th class="th"><div>Aug. 18, 2025</div></th>
<th class="th"><div>Jul. 07, 2025</div></th>
<th class="th"><div>Jul. 03, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Issuance of common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,414<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_SaleOfStockConsiderationReceivedCashTransaction', window );">Sale of stock issued cash consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">$ 53,600,000<span></span>
</td>
<td class="nump">$ 695,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_InterestRate', window );">Interest rate</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Issuance of common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Exchange Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_SaleOfStockConsiderationReceivedCashTransaction', window );">Sale of stock issued cash consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Convertible Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_SaleOfStockConsiderationReceivedCashTransaction', window );">Sale of stock issued cash consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_RENB_SaleOfStockConsiderationReceivedCashTransaction', window );">Sale of stock issued cash consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_InterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_InterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_RENB_SaleOfStockConsiderationReceivedCashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">RENB_SaleOfStockConsiderationReceivedCashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>RENB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=RENB_ExchangeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=RENB_ExchangeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=RENB_ConvertiblePromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=RENB_ConvertiblePromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=RENB_ConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=RENB_ConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>270</ContextCount>
  <ElementCount>455</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>99</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/ConsolidatedStatementsOfOperations</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/ConsolidatedStatementsOfComprehensiveLoss</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit</Role>
      <ShortName>CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>999015 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>999016 - Disclosure - GOING CONCERN</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/GoingConcern</Role>
      <ShortName>GOING CONCERN</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>999017 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/FairValueMeasurements</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>999018 - Disclosure - PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/PropertyAndEquipment</Role>
      <ShortName>PROPERTY AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>999019 - Disclosure - INTANGIBLE ASSETS AND GOODWILL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/IntangibleAssetsAndGoodwill</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>999020 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/Leases</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>999021 - Disclosure - DEBT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/Debt</Role>
      <ShortName>DEBT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>999022 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/IncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>999023 - Disclosure - STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/StockholdersEquity</Role>
      <ShortName>STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>999024 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>999025 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/RelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>999026 - Disclosure - ACQUISITIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/Acquisitions</Role>
      <ShortName>ACQUISITIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>999027 - Disclosure - SEGMENT REPORTING</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/SegmentReporting</Role>
      <ShortName>SEGMENT REPORTING</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>999028 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>999029 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>999030 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/FairValueMeasurementsTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://renovarobio.com/role/FairValueMeasurements</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>999031 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://renovarobio.com/role/PropertyAndEquipment</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>999032 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/IntangibleAssetsAndGoodwillTables</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://renovarobio.com/role/IntangibleAssetsAndGoodwill</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>999033 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/LeasesTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://renovarobio.com/role/Leases</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>999034 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/IncomeTaxesTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://renovarobio.com/role/IncomeTaxes</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>999035 - Disclosure - STOCKHOLDERS??? EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/StockholdersEquityTables</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://renovarobio.com/role/StockholdersEquity</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>999036 - Disclosure - ACQUISITIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/AcquisitionsTables</Role>
      <ShortName>ACQUISITIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://renovarobio.com/role/Acquisitions</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>999037 - Disclosure - SEGMENT REPORTING (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/SegmentReportingTables</Role>
      <ShortName>SEGMENT REPORTING (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://renovarobio.com/role/SegmentReporting</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>999038 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>999039 - Disclosure - GOING CONCERN (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/GoingConcernDetailsNarrative</Role>
      <ShortName>GOING CONCERN (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/GoingConcern</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>999040 - Disclosure - FAIR VALUE MEASUREMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>999041 - Disclosure - FAIR VALUE MEASUREMENTS (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/FairValueMeasurementsDetails1</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>999042 - Disclosure - FAIR VALUE MEASUREMENTS (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/FairValueMeasurementsDetails2</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>999043 - Disclosure - FAIR VALUE MEASUREMENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/FairValueMeasurementsDetailsNarrative</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>999044 - Disclosure - PROPERTY AND EQUIPMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/PropertyAndEquipmentDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>999045 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/PropertyAndEquipmentDetailsNarrative</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>999046 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/IntangibleAssetsAndGoodwillTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>999047 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails1</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/IntangibleAssetsAndGoodwillTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>999048 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetailsNarrative</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/IntangibleAssetsAndGoodwillTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>999049 - Disclosure - LEASES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/LeasesDetails</Role>
      <ShortName>LEASES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/LeasesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>999050 - Disclosure - LEASES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/LeasesDetailsNarrative</Role>
      <ShortName>LEASES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/LeasesTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>999051 - Disclosure - DEBT (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/DebtDetailsNarrative</Role>
      <ShortName>DEBT (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/Debt</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>999052 - Disclosure - INCOME TAXES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/IncomeTaxesDetails</Role>
      <ShortName>INCOME TAXES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/IncomeTaxesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>999053 - Disclosure - INCOME TAXES (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/IncomeTaxesDetails1</Role>
      <ShortName>INCOME TAXES (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/IncomeTaxesTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>999054 - Disclosure - INCOME TAXES (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/IncomeTaxesDetails2</Role>
      <ShortName>INCOME TAXES (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/IncomeTaxesTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>999055 - Disclosure - INCOME TAXES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>INCOME TAXES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/IncomeTaxesTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>999056 - Disclosure - STOCKHOLDERS' EQUITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/StockholdersEquityDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>999057 - Disclosure - STOCKHOLDERS' EQUITY (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/StockholdersEquityDetails1</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>999058 - Disclosure - STOCKHOLDERS' EQUITY (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/StockholdersEquityDetails2</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>999059 - Disclosure - STOCKHOLDERS' EQUITY (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/StockholdersEquityDetails3</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>999060 - Disclosure - STOCKHOLDERS' EQUITY (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/StockholdersEquityDetails4</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>999061 - Disclosure - STOCKHOLDERS??? EQUITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/StockholdersEquityTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>999062 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>999063 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/RelatedPartyTransactions</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>999064 - Disclosure - ACQUISITION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/AcquisitionDetails</Role>
      <ShortName>ACQUISITION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/AcquisitionsTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>999065 - Disclosure - ACQUISITION (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/AcquisitionDetails1</Role>
      <ShortName>ACQUISITION (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/AcquisitionsTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>999066 - Disclosure - ACQUISITION (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/AcquisitionDetails2</Role>
      <ShortName>ACQUISITION (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/AcquisitionsTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>999067 - Disclosure - ACQUISITION (Details 5)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/AcquisitionDetails5</Role>
      <ShortName>ACQUISITION (Details 5)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/AcquisitionsTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>999068 - Disclosure - ACQUISITION (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/AcquisitionDetails4</Role>
      <ShortName>ACQUISITION (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/AcquisitionsTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>999069 - Disclosure - ACQUISITION (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/AcquisitionDetails3</Role>
      <ShortName>ACQUISITION (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/AcquisitionsTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>999070 - Disclosure - ACQUISITIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/AcquisitionsDetailsNarrative</Role>
      <ShortName>ACQUISITIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/AcquisitionsTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>999071 - Disclosure - SEGMENT REPORTING (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/SegmentReportingDetails</Role>
      <ShortName>SEGMENT REPORTING (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/SegmentReportingTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>999072 - Disclosure - SEGMENT REPORTING (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/SegmentReportingDetails1</Role>
      <ShortName>SEGMENT REPORTING (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/SegmentReportingTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="e6882_10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>999073 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://renovarobio.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>SUBSEQUENT EVENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://renovarobio.com/role/SubsequentEvents</ParentRole>
      <Position>69</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="e6882_10-k.htm">e6882_10-k.htm</File>
    <File>renb-20250630.xsd</File>
    <File>renb-20250630_cal.xml</File>
    <File>renb-20250630_def.xml</File>
    <File>renb-20250630_lab.xml</File>
    <File>renb-20250630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
    <File>image_002.jpg</File>
    <File>image_003.jpg</File>
    <File>image_004.jpg</File>
    <File>image_006.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="744">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="12">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="5">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>93
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "e6882_10-k.htm": {
   "nsprefix": "RENB",
   "nsuri": "http://renovarobio.com/20250630",
   "dts": {
    "inline": {
     "local": [
      "e6882_10-k.htm"
     ]
    },
    "schema": {
     "local": [
      "renb-20250630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "renb-20250630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "renb-20250630_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "renb-20250630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "renb-20250630_pre.xml"
     ]
    }
   },
   "keyStandard": 325,
   "keyCustom": 130,
   "axisStandard": 28,
   "axisCustom": 0,
   "memberStandard": 26,
   "memberCustom": 63,
   "hidden": {
    "total": 122,
    "http://fasb.org/us-gaap/2024": 76,
    "http://renovarobio.com/20250630": 42,
    "http://xbrl.sec.gov/dei/2024": 4
   },
   "contextCount": 270,
   "entityCount": 1,
   "segmentCount": 99,
   "elementCount": 793,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 744,
    "http://xbrl.sec.gov/dei/2024": 38,
    "http://xbrl.sec.gov/cyd/2024": 12,
    "http://xbrl.sec.gov/ecd/2024": 5
   },
   "report": {
    "R1": {
     "role": "http://renovarobio.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://renovarobio.com/role/ConsolidatedBalanceSheets",
     "longName": "00000002 - Statement - CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:InsuranceSettlementsReceivableCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://renovarobio.com/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://renovarobio.com/role/ConsolidatedStatementsOfOperations",
     "longName": "00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://renovarobio.com/role/ConsolidatedStatementsOfComprehensiveLoss",
     "longName": "00000005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit",
     "longName": "00000006 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT)",
     "shortName": "CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "AsOf2023-06-30_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-06-30_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows",
     "longName": "00000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R9": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies",
     "longName": "999015 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://renovarobio.com/role/GoingConcern",
     "longName": "999016 - Disclosure - GOING CONCERN",
     "shortName": "GOING CONCERN",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://renovarobio.com/role/FairValueMeasurements",
     "longName": "999017 - Disclosure - FAIR VALUE MEASUREMENTS",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://renovarobio.com/role/PropertyAndEquipment",
     "longName": "999018 - Disclosure - PROPERTY AND EQUIPMENT",
     "shortName": "PROPERTY AND EQUIPMENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://renovarobio.com/role/IntangibleAssetsAndGoodwill",
     "longName": "999019 - Disclosure - INTANGIBLE ASSETS AND GOODWILL",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://renovarobio.com/role/Leases",
     "longName": "999020 - Disclosure - LEASES",
     "shortName": "LEASES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://renovarobio.com/role/Debt",
     "longName": "999021 - Disclosure - DEBT",
     "shortName": "DEBT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://renovarobio.com/role/IncomeTaxes",
     "longName": "999022 - Disclosure - INCOME TAXES",
     "shortName": "INCOME TAXES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://renovarobio.com/role/StockholdersEquity",
     "longName": "999023 - Disclosure - STOCKHOLDERS\u2019 EQUITY",
     "shortName": "STOCKHOLDERS\u2019 EQUITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://renovarobio.com/role/CommitmentsAndContingencies",
     "longName": "999024 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://renovarobio.com/role/RelatedPartyTransactions",
     "longName": "999025 - Disclosure - RELATED PARTY TRANSACTIONS",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://renovarobio.com/role/Acquisitions",
     "longName": "999026 - Disclosure - ACQUISITIONS",
     "shortName": "ACQUISITIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://renovarobio.com/role/SegmentReporting",
     "longName": "999027 - Disclosure - SEGMENT REPORTING",
     "shortName": "SEGMENT REPORTING",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://renovarobio.com/role/SubsequentEvents",
     "longName": "999028 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "999029 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "RENB:BusinessPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "RENB:BusinessPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://renovarobio.com/role/FairValueMeasurementsTables",
     "longName": "999030 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)",
     "shortName": "FAIR VALUE MEASUREMENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://renovarobio.com/role/PropertyAndEquipmentTables",
     "longName": "999031 - Disclosure - PROPERTY AND EQUIPMENT (Tables)",
     "shortName": "PROPERTY AND EQUIPMENT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://renovarobio.com/role/IntangibleAssetsAndGoodwillTables",
     "longName": "999032 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://renovarobio.com/role/LeasesTables",
     "longName": "999033 - Disclosure - LEASES (Tables)",
     "shortName": "LEASES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://renovarobio.com/role/IncomeTaxesTables",
     "longName": "999034 - Disclosure - INCOME TAXES (Tables)",
     "shortName": "INCOME TAXES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://renovarobio.com/role/StockholdersEquityTables",
     "longName": "999035 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Tables)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "RENB:ScheduleOfShareBasedPaymentAwardStockOptionValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "RENB:ScheduleOfShareBasedPaymentAwardStockOptionValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://renovarobio.com/role/AcquisitionsTables",
     "longName": "999036 - Disclosure - ACQUISITIONS (Tables)",
     "shortName": "ACQUISITIONS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "RENB:ScheduleOfRecognizedIdentifiedAssetsAndLiabilitiesAssumedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "RENB:ScheduleOfRecognizedIdentifiedAssetsAndLiabilitiesAssumedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://renovarobio.com/role/SegmentReportingTables",
     "longName": "999037 - Disclosure - SEGMENT REPORTING (Tables)",
     "shortName": "SEGMENT REPORTING (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "999038 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "RENB:PurchaseEquitySecuritiesValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "RENB:InvestmentinEquitySecuritiesPolicyTextBlock",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "RENB:PurchaseEquitySecuritiesValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "RENB:InvestmentinEquitySecuritiesPolicyTextBlock",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://renovarobio.com/role/GoingConcernDetailsNarrative",
     "longName": "999039 - Disclosure - GOING CONCERN (Details Narrative)",
     "shortName": "GOING CONCERN (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "RENB:WorkingCapitalDeficit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://renovarobio.com/role/FairValueMeasurementsDetails",
     "longName": "999040 - Disclosure - FAIR VALUE MEASUREMENTS (Details)",
     "shortName": "FAIR VALUE MEASUREMENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:EquitySecuritiesFvNi",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-30_us-gaap_FairValueInputsLevel1Member",
      "name": "us-gaap:EquitySecuritiesFvNi",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://renovarobio.com/role/FairValueMeasurementsDetails1",
     "longName": "999041 - Disclosure - FAIR VALUE MEASUREMENTS (Details 1)",
     "shortName": "FAIR VALUE MEASUREMENTS (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30_custom_BlackScholesOptionPricingModelMember",
      "name": "us-gaap:SharePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueConcentrationOfRiskTextBlock",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-30_custom_BlackScholesOptionPricingModelMember",
      "name": "us-gaap:SharePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueConcentrationOfRiskTextBlock",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://renovarobio.com/role/FairValueMeasurementsDetails2",
     "longName": "999042 - Disclosure - FAIR VALUE MEASUREMENTS (Details 2)",
     "shortName": "FAIR VALUE MEASUREMENTS (Details 2)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "RENB:ScheduleOfContingentConsiderationLiabilityTableTextBlock",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "RENB:ScheduleOfContingentConsiderationLiabilityTableTextBlock",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://renovarobio.com/role/FairValueMeasurementsDetailsNarrative",
     "longName": "999043 - Disclosure - FAIR VALUE MEASUREMENTS (Details Narrative)",
     "shortName": "FAIR VALUE MEASUREMENTS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "From2024-08-222025-08-23",
      "name": "us-gaap:StockRepurchasedDuringPeriodShares",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-012025-06-30_custom_RenovaroCubeMember",
      "name": "us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://renovarobio.com/role/PropertyAndEquipmentDetails",
     "longName": "999044 - Disclosure - PROPERTY AND EQUIPMENT (Details)",
     "shortName": "PROPERTY AND EQUIPMENT (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://renovarobio.com/role/PropertyAndEquipmentDetailsNarrative",
     "longName": "999045 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)",
     "shortName": "PROPERTY AND EQUIPMENT (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "us-gaap:Depreciation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "us-gaap:Depreciation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails",
     "longName": "999046 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details)",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "RENB:NetDefinitelifeIntangibleAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-06-30",
      "name": "RENB:NetDefinitelifeIntangibleAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails1",
     "longName": "999047 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details 1)",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetailsNarrative",
     "longName": "999048 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details Narrative)",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:FiniteLivedIntangibleAssetsNet",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:AccumulatedAmortizationOfCurrentDeferredFinanceCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://renovarobio.com/role/LeasesDetails",
     "longName": "999049 - Disclosure - LEASES (Details)",
     "shortName": "LEASES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://renovarobio.com/role/LeasesDetailsNarrative",
     "longName": "999050 - Disclosure - LEASES (Details Narrative)",
     "shortName": "LEASES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "From2018-06-182018-06-19",
      "name": "us-gaap:LesseeOperatingLeaseDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2018-06-182018-06-19",
      "name": "us-gaap:LesseeOperatingLeaseDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://renovarobio.com/role/DebtDetailsNarrative",
     "longName": "999051 - Disclosure - DEBT (Details Narrative)",
     "shortName": "DEBT (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "us-gaap:ProceedsFromIssuanceOfDebt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "us-gaap:MaturitiesOfTimeDepositsDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://renovarobio.com/role/IncomeTaxesDetails",
     "longName": "999052 - Disclosure - INCOME TAXES (Details)",
     "shortName": "INCOME TAXES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "RENB:Depreciations",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "RENB:Depreciations",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://renovarobio.com/role/IncomeTaxesDetails1",
     "longName": "999053 - Disclosure - INCOME TAXES (Details 1)",
     "shortName": "INCOME TAXES (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://renovarobio.com/role/IncomeTaxesDetails2",
     "longName": "999054 - Disclosure - INCOME TAXES (Details 2)",
     "shortName": "INCOME TAXES (Details 2)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://renovarobio.com/role/IncomeTaxesDetailsNarrative",
     "longName": "999055 - Disclosure - INCOME TAXES (Details Narrative)",
     "shortName": "INCOME TAXES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30_custom_UnitedStatesTaxMember",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-30_custom_UnitedStatesTaxMember",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://renovarobio.com/role/StockholdersEquityDetails",
     "longName": "999056 - Disclosure - STOCKHOLDERS' EQUITY (Details)",
     "shortName": "STOCKHOLDERS' EQUITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "From2024-07-012025-06-30_custom_RenovaroMember",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "RENB:ScheduleOfShareBasedPaymentAwardStockOptionValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-012025-06-30_custom_RenovaroMember",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "RENB:ScheduleOfShareBasedPaymentAwardStockOptionValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://renovarobio.com/role/StockholdersEquityDetails1",
     "longName": "999057 - Disclosure - STOCKHOLDERS' EQUITY (Details 1)",
     "shortName": "STOCKHOLDERS' EQUITY (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-30_us-gaap_EmployeeStockOptionMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "RENB:ScheduleOfStockBasedCompensationActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://renovarobio.com/role/StockholdersEquityDetails2",
     "longName": "999058 - Disclosure - STOCKHOLDERS' EQUITY (Details 2)",
     "shortName": "STOCKHOLDERS' EQUITY (Details 2)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-012025-06-30_custom_EmployeeStockOptionsMember",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://renovarobio.com/role/StockholdersEquityDetails3",
     "longName": "999059 - Disclosure - STOCKHOLDERS' EQUITY (Details 3)",
     "shortName": "STOCKHOLDERS' EQUITY (Details 3)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-30_custom_CommonStockPurchaseWarrantsMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "RENB:ScheduleOfCommonStockPurchaseWarrantsOutstandingTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://renovarobio.com/role/StockholdersEquityDetails4",
     "longName": "999060 - Disclosure - STOCKHOLDERS' EQUITY (Details 4)",
     "shortName": "STOCKHOLDERS' EQUITY (Details 4)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30_custom_CommonStockPurchaseWarrantMember",
      "name": "RENB:CommonStockPurchaseWarrant",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "RENB:ScheduleOfWarrantsOutstandingTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantMember",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "RENB:ScheduleOfWarrantsOutstandingTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://renovarobio.com/role/StockholdersEquityDetailsNarrative",
     "longName": "999061 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Details Narrative)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "RENB:CommonStockShareIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "longName": "999062 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "From2019-11-142019-11-15",
      "name": "RENB:UpfrontPayment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2019-11-142019-11-15",
      "name": "RENB:UpfrontPayment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative",
     "longName": "999063 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)",
     "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "From2024-08-022024-08-23",
      "name": "us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-08-022024-08-23",
      "name": "us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://renovarobio.com/role/AcquisitionDetails",
     "longName": "999064 - Disclosure - ACQUISITION (Details)",
     "shortName": "ACQUISITION (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "AsOf2025-02-26_custom_BioSymetricsncAcquisitionMember",
      "name": "RENB:BusinessCombinationContingentConsiderationCommonStock",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "RENB:ScheduleOfAcquistionFairValueOfConsiderationTableTextBlock",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-02-26_custom_BioSymetricsncAcquisitionMember",
      "name": "RENB:BusinessCombinationContingentConsiderationCommonStock",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "RENB:ScheduleOfAcquistionFairValueOfConsiderationTableTextBlock",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://renovarobio.com/role/AcquisitionDetails1",
     "longName": "999065 - Disclosure - ACQUISITION (Details 1)",
     "shortName": "ACQUISITION (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "AsOf2025-04-08",
      "name": "RENB:Software",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-02-26_custom_BioSymetricsncAcquisitionMember",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://renovarobio.com/role/AcquisitionDetails2",
     "longName": "999066 - Disclosure - ACQUISITION (Details 2)",
     "shortName": "ACQUISITION (Details 2)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "From2024-07-012025-06-30_custom_BioSymetricsncAcquisitionMember1126504281",
      "name": "RENB:BusinessAcquisitionsRevenue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-012025-06-30_custom_BioSymetricsncAcquisitionMember1126504281",
      "name": "RENB:BusinessAcquisitionsRevenue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://renovarobio.com/role/AcquisitionDetails5",
     "longName": "999067 - Disclosure - ACQUISITION (Details 5)",
     "shortName": "ACQUISITION (Details 5)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "AsOf2025-02-26_custom_GEDiCubeMember",
      "name": "RENB:BusinessCombinationContingentConsiderationCommonStock",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "RENB:ScheduleOfAcquistionFairValueOfConsiderationTableTextBlock",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-02-26_custom_GEDiCubeMember",
      "name": "RENB:BusinessCombinationContingentConsiderationCommonStock",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "RENB:ScheduleOfAcquistionFairValueOfConsiderationTableTextBlock",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://renovarobio.com/role/AcquisitionDetails4",
     "longName": "999068 - Disclosure - ACQUISITION (Details 4)",
     "shortName": "ACQUISITION (Details 4)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "AsOf2025-02-26_custom_GEDiCubeMember",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "RENB:ScheduleOfRecognizedIdentifiedAssetsAndLiabilitiesAssumedTableTextBlock",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-02-26_custom_GEDiCubeMember",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "RENB:ScheduleOfRecognizedIdentifiedAssetsAndLiabilitiesAssumedTableTextBlock",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://renovarobio.com/role/AcquisitionDetails3",
     "longName": "999069 - Disclosure - ACQUISITION (Details 3)",
     "shortName": "ACQUISITION (Details 3)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "From2024-07-012025-06-30_custom_GEDiCubeMember",
      "name": "RENB:BusinessAcquisitionsRevenue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "RENB:ScheduleOfRecognizedIdentifiedAssetsAndLiabilitiesAssumedTableTextBlock",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-012025-06-30_custom_GEDiCubeMember",
      "name": "RENB:BusinessAcquisitionsRevenue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "RENB:ScheduleOfRecognizedIdentifiedAssetsAndLiabilitiesAssumedTableTextBlock",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://renovarobio.com/role/AcquisitionsDetailsNarrative",
     "longName": "999070 - Disclosure - ACQUISITIONS (Details Narrative)",
     "shortName": "ACQUISITIONS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "AsOf2025-04-08",
      "name": "RENB:TransactionIssuedShares",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-04-08",
      "name": "RENB:TransactionIssuedShares",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://renovarobio.com/role/SegmentReportingDetails",
     "longName": "999071 - Disclosure - SEGMENT REPORTING (Details)",
     "shortName": "SEGMENT REPORTING (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "RENB:SegmentOperatingLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "RENB:SegmentAsset",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "unique": true
     }
    },
    "R68": {
     "role": "http://renovarobio.com/role/SegmentReportingDetails1",
     "longName": "999072 - Disclosure - SEGMENT REPORTING (Details 1)",
     "shortName": "SEGMENT REPORTING (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "us-gaap:OtherGeneralAndAdministrativeExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-06-30",
      "name": "us-gaap:OtherGeneralAndAdministrativeExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://renovarobio.com/role/SubsequentEventsDetailsNarrative",
     "longName": "999073 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)",
     "shortName": "SUBSEQUENT EVENTS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "AsOf2025-06-30",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-08-18_us-gaap_SubsequentEventMember",
      "name": "RENB:SaleOfStockConsiderationReceivedCashTransaction",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "e6882_10-k.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableTradeCurrent",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable \u2013 trade",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r89"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_AccruedLiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total assets at fair value",
        "documentation": "Fair value portion of accrued expenses."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r1031",
      "r1032",
      "r1035"
     ]
    },
    "us-gaap_AccumulatedAmortizationOfCurrentDeferredFinanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedAmortizationOfCurrentDeferredFinanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated amortization cost",
        "documentation": "Amount of accumulated amortization of debt issuance costs classified as current."
       }
      }
     },
     "auth_ref": [
      "r1037",
      "r1038"
     ]
    },
    "us-gaap_AccumulatedAmortizationOfOtherDeferredCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedAmortizationOfOtherDeferredCosts",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization",
        "documentation": "Accumulated amortization of other deferred costs capitalized at the end of the reporting period. Does not include deferred finance costs, deferred acquisition costs of insurance companies, or deferred leasing costs for real estate operations."
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less Accumulated Depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r178",
      "r599"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated other comprehensive (loss)",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r106",
      "r187",
      "r594",
      "r625",
      "r626"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r17",
      "r26",
      "r481",
      "r484",
      "r529",
      "r621",
      "r622",
      "r941",
      "r942",
      "r943",
      "r954",
      "r955",
      "r956",
      "r957"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r793",
      "r1087"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r640",
      "r954",
      "r955",
      "r956",
      "r957",
      "r1030",
      "r1089"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ADJUSTMENTS TO RECONCILE NET LOSS TO NET CASH USED IN OPERATING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_AdvisoryServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "AdvisoryServices",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advisory services"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_AdvisoryServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "AdvisoryServicesMember",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advisory Services [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r845",
      "r856",
      "r870",
      "r897"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r848",
      "r859",
      "r873",
      "r900"
     ]
    },
    "RENB_AgreementAndPlanOfMergerAgreementAxisMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "AgreementAndPlanOfMergerAgreementAxisMember",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Agreement And Plan Of Merger Agreement Axis [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_AgreementDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "AgreementDescription",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Agreement description"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r885"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r892"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r849",
      "r860",
      "r874",
      "r892",
      "r901",
      "r905",
      "r913"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "auth_ref": [
      "r911"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "RENB_AmortizationOfDiscountOnNotePayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "AmortizationOfDiscountOnNotePayable",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of discount on note payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization expense",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r297",
      "r304",
      "r768"
     ]
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Anti-dilutive shares",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r238"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://renovarobio.com/role/DebtDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r472"
     ]
    },
    "us-gaap_AssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetImpairmentCharges",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of assets",
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r48"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL ASSETS",
        "label": "Assets [Default Label]",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r156",
      "r181",
      "r210",
      "r241",
      "r249",
      "r267",
      "r271",
      "r280",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r474",
      "r478",
      "r500",
      "r590",
      "r676",
      "r761",
      "r762",
      "r793",
      "r815",
      "r991",
      "r992",
      "r1044"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r188",
      "r210",
      "r280",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r474",
      "r478",
      "r500",
      "r793",
      "r991",
      "r992",
      "r1044"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT ASSETS:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OTHER ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r827",
      "r829",
      "r852"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r827",
      "r829",
      "r852"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r827",
      "r829",
      "r852"
     ]
    },
    "RENB_AvramMillerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "AvramMillerMember",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Avram Miller [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AwardDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardDateAxis",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Date [Axis]",
        "documentation": "Information by date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020"
     ]
    },
    "us-gaap_AwardDateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardDateDomain",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r908"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r909"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "auth_ref": [
      "r904"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative",
      "http://renovarobio.com/role/SubsequentEventsDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r907"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r905"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r905"
     ]
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position Location, Balance [Axis]",
        "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported."
       }
      }
     },
     "auth_ref": [
      "r320",
      "r1056",
      "r1057"
     ]
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r78",
      "r320",
      "r1056",
      "r1057"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "RENB_BioSymetricsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "BioSymetricsMember",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionsDetailsNarrative",
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetailsNarrative",
      "http://renovarobio.com/role/SegmentReportingDetails",
      "http://renovarobio.com/role/SegmentReportingDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bio Symetrics [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_BioSymetricsncAcquisitionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "BioSymetricsncAcquisitionMember",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionDetails",
      "http://renovarobio.com/role/AcquisitionDetails1",
      "http://renovarobio.com/role/AcquisitionDetails2",
      "http://renovarobio.com/role/AcquisitionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bio Symetricsnc Acquisition [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_BlackScholesOptionPricingModelMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "BlackScholesOptionPricingModelMember",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Black Scholes Option Pricing Model [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_BoardOfDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "BoardOfDirectorsMember",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Board Of Directors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionDetails",
      "http://renovarobio.com/role/AcquisitionDetails1",
      "http://renovarobio.com/role/AcquisitionDetails2",
      "http://renovarobio.com/role/AcquisitionDetails3",
      "http://renovarobio.com/role/AcquisitionDetails4",
      "http://renovarobio.com/role/AcquisitionDetails5",
      "http://renovarobio.com/role/AcquisitionsDetailsNarrative",
      "http://renovarobio.com/role/FairValueMeasurementsDetailsNarrative",
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r467",
      "r779",
      "r780"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionDetails",
      "http://renovarobio.com/role/AcquisitionDetails1",
      "http://renovarobio.com/role/AcquisitionDetails2",
      "http://renovarobio.com/role/AcquisitionDetails3",
      "http://renovarobio.com/role/AcquisitionDetails4",
      "http://renovarobio.com/role/AcquisitionDetails5",
      "http://renovarobio.com/role/AcquisitionsDetailsNarrative",
      "http://renovarobio.com/role/FairValueMeasurementsDetailsNarrative",
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r71",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r467",
      "r779",
      "r780"
     ]
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent shares issuable in connection with the acquisition",
        "documentation": "Number of shares of equity interests issued or issuable to acquire entity."
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionDetails",
      "http://renovarobio.com/role/AcquisitionDetails1",
      "http://renovarobio.com/role/AcquisitionDetails2",
      "http://renovarobio.com/role/AcquisitionDetails3",
      "http://renovarobio.com/role/AcquisitionDetails4",
      "http://renovarobio.com/role/AcquisitionDetails5",
      "http://renovarobio.com/role/AcquisitionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r467"
     ]
    },
    "RENB_BusinessAcquisitionPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "BusinessAcquisitionPercentage",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisition percentage"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_BusinessAcquisitionsNetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "BusinessAcquisitionsNetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionDetails2",
      "http://renovarobio.com/role/AcquisitionDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net loss",
        "label": "BusinessAcquisitionsNetIncomeLoss"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_BusinessAcquisitionsRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "BusinessAcquisitionsRevenue",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionDetails2",
      "http://renovarobio.com/role/AcquisitionDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisition related costs",
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationConsiderationTransferred1",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionDetails",
      "http://renovarobio.com/role/AcquisitionDetails5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total consideration transferred",
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r2",
      "r15"
     ]
    },
    "us-gaap_BusinessCombinationConsiderationTransferredOther1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationConsiderationTransferredOther1",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of consideration transferred amount",
        "documentation": "Amount of tangible or intangible assets, including a business or subsidiary of the acquirer transferred by the entity to the former owners of the acquiree. Excludes cash."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationContingentConsiderationAsset",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionDetails5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Contingent consideration",
        "label": "Business Combination, Contingent Consideration, Asset",
        "documentation": "Amount of asset recognized arising from contingent consideration in a business combination."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r140",
      "r469"
     ]
    },
    "RENB_BusinessCombinationContingentConsiderationCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "BusinessCombinationContingentConsiderationCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionDetails",
      "http://renovarobio.com/role/AcquisitionDetails5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails2",
      "http://renovarobio.com/role/FairValueMeasurementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance June 30, 2024",
        "periodEndLabel": "Contingent Consideration Liability at June 30, 2025",
        "label": "Contingent consideration liability was recorded at fair value",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r140",
      "r469",
      "r493",
      "r494",
      "r495"
     ]
    },
    "RENB_BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuable",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common shares contingently issuable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationDisclosureTextBlock",
     "presentation": [
      "http://renovarobio.com/role/Acquisitions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ACQUISITIONS",
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r468"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionDetails1",
      "http://renovarobio.com/role/AcquisitionDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Assets Acquired:",
        "documentation": "Amount of assets acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionDetails1",
      "http://renovarobio.com/role/AcquisitionDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cash",
        "verboseLabel": "Cash",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseRightOfUseAssets",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease ROU"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionDetails1",
      "http://renovarobio.com/role/AcquisitionDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid &amp; Other Assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionDetails1",
      "http://renovarobio.com/role/AcquisitionDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fixed Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionDetails1",
      "http://renovarobio.com/role/AcquisitionDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable",
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionDetails1",
      "http://renovarobio.com/role/AcquisitionDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionDetails1",
      "http://renovarobio.com/role/AcquisitionDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Current Liabilities",
        "verboseLabel": "Operating Lease liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionDetails1",
      "http://renovarobio.com/role/AcquisitionDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Goodwill",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets",
        "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionDetails1",
      "http://renovarobio.com/role/AcquisitionDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Liabilities Assumed",
        "documentation": "Amount of liabilities assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionDetails1",
      "http://renovarobio.com/role/AcquisitionDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Assets Acquired",
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r73"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionDetails1",
      "http://renovarobio.com/role/AcquisitionDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Consideration",
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "RENB_BusinessPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "BusinessPolicyTextBlock",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_CancellationOfRestrictedStockAwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "CancellationOfRestrictedStockAwards",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cancellation of restricted stock awards"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalizedComputerSoftwareGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalizedComputerSoftwareGross",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Software platform",
        "documentation": "Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r745"
     ]
    },
    "us-gaap_CashAcquiredFromAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAcquiredFromAcquisition",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash received from acquisition, net",
        "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business)."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets",
      "http://renovarobio.com/role/GoingConcernDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash",
        "verboseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r176",
      "r747"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "CASH, BEGINNING OF PERIOD",
        "periodEndLabel": "CASH, END OF PERIOD",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r115",
      "r207"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET INCREASE (DECREASE) IN CASH",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r115"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_CashPaidDuringYearForAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "CashPaidDuringYearForAbstract",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Paid during the year for:"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_ChangeInFairValueOfContingentConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "ChangeInFairValueOfContingentConsideration",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      },
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows",
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of contingent consideration",
        "negatedLabel": "Change in fair value of contingent consideration"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_ChangeInTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "ChangeInTaxRate",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in tax rate"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "srt_ChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ChiefExecutiveOfficerMember",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]"
       }
      }
     },
     "auth_ref": [
      "r964"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r184",
      "r185",
      "r186",
      "r210",
      "r232",
      "r233",
      "r235",
      "r237",
      "r243",
      "r244",
      "r280",
      "r336",
      "r338",
      "r339",
      "r340",
      "r343",
      "r344",
      "r373",
      "r374",
      "r377",
      "r380",
      "r387",
      "r500",
      "r630",
      "r631",
      "r632",
      "r633",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r664",
      "r685",
      "r708",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r933",
      "r950",
      "r958"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r185",
      "r186",
      "r243",
      "r373",
      "r374",
      "r375",
      "r377",
      "r380",
      "r385",
      "r387",
      "r630",
      "r631",
      "r632",
      "r633",
      "r774",
      "r933",
      "r950"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants exercised",
        "verboseLabel": "Warrant exercise price per share",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExpenseOrRevenueRecognized": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExpenseOrRevenueRecognized",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants aggregate amount",
        "documentation": "Description of expense or revenue offset related to the warrants or rights."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r472"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://renovarobio.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r328",
      "r329",
      "r732",
      "r985",
      "r990"
     ]
    },
    "RENB_CommonSharesIssuedUponAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "CommonSharesIssuedUponAcquisition",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common shares issued upon acquisition"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_CommonSharesIssuedUponSettlementOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "CommonSharesIssuedUponSettlementOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common shares issued upon settlement of debt"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative",
      "http://renovarobio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock reserved for issuance",
        "verboseLabel": "Remaining shares",
        "terseLabel": "Issuance of common stock shares",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "RENB_CommonStockConsultingServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "CommonStockConsultingServicesMember",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Consulting Services [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_CommonStockIssuancesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "CommonStockIssuancesMember",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Issuances [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit",
      "http://renovarobio.com/role/FairValueMeasurementsDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r805",
      "r806",
      "r807",
      "r809",
      "r810",
      "r811",
      "r812",
      "r954",
      "r955",
      "r957",
      "r1030",
      "r1086",
      "r1089"
     ]
    },
    "us-gaap_CommonStockOtherSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockOtherSharesOutstanding",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock outstanding",
        "documentation": "Number of shares of other common stock instruments held by shareholder, including, but not limited to, exchangeable shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionsDetailsNarrative",
      "http://renovarobio.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "verboseLabel": "Common stock per value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "RENB_CommonStockParValuePrivatePlacement": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "CommonStockParValuePrivatePlacement",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock par value under private placement"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_CommonStockPurchaseWarrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "CommonStockPurchaseWarrant",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at beginning of period",
        "periodEndLabel": "Outstanding at end of period",
        "label": "CommonStockPurchaseWarrant"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_CommonStockPurchaseWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "CommonStockPurchaseWarrantMember",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Purchase Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_CommonStockPurchaseWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "CommonStockPurchaseWarrantsMember",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Purchase Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_CommonStockPurchaseWarrantsWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "CommonStockPurchaseWarrantsWeightedAverageExercisePrice",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average exercise price, Outstanding at beginning of period",
        "periodEndLabel": "Weighted average exercise price, Outstanding at ending of period",
        "label": "CommonStockPurchaseWarrantsWeightedAverageExercisePrice"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_CommonStockShareIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "CommonStockShareIssued",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, shares issued",
        "label": "CommonStockShareIssued"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r664"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r99",
      "r664",
      "r682",
      "r1089",
      "r1090"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value $0.0001, 350,000,000 shares authorized, 177,392,907 shares issued and outstanding at June 30, 2025; 158,452,644 shares issued and outstanding at June 30, 2024",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r593",
      "r793"
     ]
    },
    "RENB_CommonStocksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "CommonStocksMember",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stocks [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r888"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r135"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive Loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r191",
      "r193",
      "r198",
      "r584",
      "r604",
      "r605"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration of Credit Risk",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r162"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principles of Consolidation",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r752"
     ]
    },
    "us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiaries",
        "documentation": "Disclosure of accounting policy for subsidiaries or other investments that are consolidated, including the accounting treatment for intercompany accounts or transactions and any noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContingentConsiderationClassifiedAsEquityFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent consideration",
        "documentation": "Fair value of contingent consideration in a business combination that is classified in shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r1031",
      "r1032",
      "r1035"
     ]
    },
    "RENB_ContingentConsiderationFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "ContingentConsiderationFairValue",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent consideration fair value"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_ContingentConsiderationIssuedUponAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "ContingentConsiderationIssuedUponAcquisition",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent consideration issued upon acquisition"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_ContingentConsiderationLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "ContingentConsiderationLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent consideration liability"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_ContingentSharesIssuedPursuantToAcquisitionAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "ContingentSharesIssuedPursuantToAcquisitionAgreement",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Shares issued pursuant to Acquisition Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_ConversionOfNotePayableForIssuanceOfPreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "ConversionOfNotePayableForIssuanceOfPreferredStock",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of note payable for issuance of preferred stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockAmountConverted1",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Converted shares of common stock, value",
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35",
      "r36"
     ]
    },
    "RENB_ConvertibleNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "ConvertibleNotesMember",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetailsNarrative",
      "http://renovarobio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible notes payable",
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r150",
      "r1053"
     ]
    },
    "RENB_ConvertiblePromissoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "ConvertiblePromissoryNoteMember",
     "presentation": [
      "http://renovarobio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Promissory Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r213",
      "r214",
      "r349",
      "r375",
      "r535",
      "r545",
      "r588",
      "r749",
      "r751"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/IncomeTaxesDetails2": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal income tax (benefit)",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r935",
      "r953",
      "r1029"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentForeignTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/IncomeTaxesDetails2": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign income tax (benefit)",
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r935",
      "r953"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/IncomeTaxesDetails2": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Tax Expense (Benefit)",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r454",
      "r953"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/IncomeTaxesDetails2": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State income tax (benefit)",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r935",
      "r953",
      "r1029"
     ]
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r837",
      "r924"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r837",
      "r924"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r839",
      "r926"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r839",
      "r926"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r841",
      "r928"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r839",
      "r926"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r832",
      "r919"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r833",
      "r920"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r833",
      "r920"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r831",
      "r918"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r834",
      "r921"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r836",
      "r923"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r836",
      "r923"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r837",
      "r924"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r840",
      "r927"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r838",
      "r925"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r835",
      "r922"
     ]
    },
    "us-gaap_DebtAndEquitySecuritiesGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtAndEquitySecuritiesGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Investment in equity securities",
        "label": "Debt and Equity Securities, Gain (Loss)",
        "documentation": "Amount of unrealized and realized gain (loss) on investment in debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r112"
     ]
    },
    "RENB_DebtConversionConvertedInstrumentWarrantsOptionsIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "DebtConversionConvertedInstrumentWarrantsOptionsIssued1",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options available to be issued"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Options available to be issued",
        "label": "Debt Conversion, Converted Instrument, Warrants or Options Issued",
        "documentation": "The number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r36"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://renovarobio.com/role/Debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "DEBT",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r208",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r334",
      "r335",
      "r345",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r361",
      "r368",
      "r369",
      "r371",
      "r516"
     ]
    },
    "RENB_DebtDiscountRelatedToConvertiblePromissoryNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "DebtDiscountRelatedToConvertiblePromissoryNotes",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt discount related to notes payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAnnualPrincipalPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAnnualPrincipalPayment",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Principal amount",
        "label": "Debt Instrument, Annual Principal Payment",
        "documentation": "Amount of annual principal payment for debt instrument."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative",
      "http://renovarobio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion price",
        "documentation": "The price per share of the conversion feature embedded in the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r348"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principal amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r516",
      "r517",
      "r770",
      "r771",
      "r791"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateIncreaseDecrease": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateIncreaseDecrease",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest rate",
        "documentation": "Incremental percentage increase (decrease) in the stated rate on a debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note interest rate",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r347"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r352",
      "r357",
      "r358",
      "r359",
      "r360",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r370",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r791",
      "r951",
      "r1037",
      "r1038"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentMaturityDate",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturity date",
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r769",
      "r1033",
      "r1034"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r58",
      "r61",
      "r86",
      "r130",
      "r131",
      "r215",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r352",
      "r357",
      "r358",
      "r359",
      "r360",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r370",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r791",
      "r951",
      "r1037",
      "r1038"
     ]
    },
    "us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesTradingAndEquitySecuritiesFvNiCost",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of equity securities",
        "documentation": "Cost of investment in debt investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value."
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "RENB_DecemberNote2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "DecemberNote2023Member",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "December Note 2023 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense Federal income tax (benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r953",
      "r1028",
      "r1029"
     ]
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "State income tax (benefit)",
        "label": "Deferred Federal, State and Local, Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1021"
     ]
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Foreign income tax (benefit)",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r953",
      "r1028"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/IncomeTaxesDetails2": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Deferred Tax Expense",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r168",
      "r953"
     ]
    },
    "RENB_DeferredTaxAssetExcessTaxOverDepreciationPatents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "DeferredTaxAssetExcessTaxOverDepreciationPatents",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Excess of tax over book depreciation of patents"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "R&amp;D Tax Credits",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r1026"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1026"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsForeign",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1026"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r447"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssets",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Deferred Tax Assets (Liabilities)",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets including goodwill."
       }
      }
     },
     "auth_ref": [
      "r1026"
     ]
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "presentation": [
      "http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "RENB_DefiniteLifeIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "DefiniteLifeIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Definite life intangible assets, net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepositsAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepositsAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deposits and other assets",
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/PropertyAndEquipmentDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation expense",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r49"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r49"
     ]
    },
    "RENB_DepreciationAndAmortizations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "DepreciationAndAmortizations",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Depreciation and amortization",
        "label": "DepreciationAndAmortizations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations",
      "http://renovarobio.com/role/SegmentReportingDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation and amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r241",
      "r254",
      "r271",
      "r761",
      "r762"
     ]
    },
    "RENB_Depreciations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "Depreciations",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total liabilities at fair value",
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r105",
      "r143",
      "r144",
      "r189",
      "r751"
     ]
    },
    "us-gaap_DerivativeFixedInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeFixedInterestRate",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rate of interest",
        "documentation": "Fixed interest rate related to the interest rate derivative."
       }
      }
     },
     "auth_ref": []
    },
    "RENB_DisclosureLeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "DisclosureLeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r827",
      "r829",
      "r852"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r827",
      "r829",
      "r852",
      "r893"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "RENB_EBIAndWeirdScienceLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "EBIAndWeirdScienceLLCMember",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "EBI And Weird Science LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_EarnOutSharesIssuedInSettlementOfContingentLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "EarnOutSharesIssuedInSettlementOfContingentLiability",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earn out shares issued in settlement of contingent liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "BASIC NET LOSS PER COMMON SHARE",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r230",
      "r232",
      "r235",
      "r236",
      "r237",
      "r240",
      "r465",
      "r471",
      "r488",
      "r489",
      "r585",
      "r606",
      "r754"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "DILUTED NET LOSS PER COMMON SHARE",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r232",
      "r235",
      "r236",
      "r237",
      "r240",
      "r465",
      "r471",
      "r488",
      "r489",
      "r585",
      "r606",
      "r754"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r38",
      "r239"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of exchange rates on cash",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r507"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationLineItems",
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r433",
      "r434",
      "r782"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTable",
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Table]",
        "documentation": "Disclosure of information about income tax rate reconciliation between amount of reported income tax expense (benefit) attributable to continuing operation to amount of income tax expense(benefit) that would result from applying statutory federal (national) tax rate to pretax income (loss) from continuing operation."
       }
      }
     },
     "auth_ref": [
      "r433",
      "r434",
      "r782"
     ]
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeBenefitsAndShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation expense",
        "documentation": "Amount of expense for employee benefit and equity-based compensation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "RENB_EmployeeStockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "EmployeeStockOptionsMember",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_EmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "EmployeesMember",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employees [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_EmployeesOfficersDirectorsAndConsultantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "EmployeesOfficersDirectorsAndConsultantsMember",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employees, Officers, Directors and Consultants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_EmployeesThreeYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "EmployeesThreeYearMember",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employees Three Year [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r171",
      "r195",
      "r196",
      "r197",
      "r216",
      "r217",
      "r218",
      "r220",
      "r225",
      "r227",
      "r229",
      "r242",
      "r281",
      "r282",
      "r313",
      "r389",
      "r455",
      "r456",
      "r462",
      "r463",
      "r464",
      "r466",
      "r470",
      "r471",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r487",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r514",
      "r518",
      "r520",
      "r529",
      "r603",
      "r621",
      "r622",
      "r623",
      "r640",
      "r708"
     ]
    },
    "RENB_EquityIncentivePlan2014Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "EquityIncentivePlan2014Member",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Incentive Plan 2014 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesFvNi",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets",
      "http://renovarobio.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in equity securities",
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r499",
      "r748"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesFvNiCost",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair value of equity securities",
        "label": "Equity Securities, FV-NI, Cost",
        "documentation": "Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value."
       }
      }
     },
     "auth_ref": [
      "r589"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiRealizedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesFvNiRealizedLoss",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 3.0
      },
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows",
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in fair value of equity securities",
        "label": "Change in value of equity securities",
        "documentation": "Amount of realized loss from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r965"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r845",
      "r856",
      "r870",
      "r897"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r842",
      "r853",
      "r867",
      "r894"
     ]
    },
    "RENB_ExchangeAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "ExchangeAgreementMember",
     "presentation": [
      "http://renovarobio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "RENB_ExercisePrice": {
     "xbrltype": "stringItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "ExercisePrice",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercise Prices",
        "label": "ExercisePrice"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_ExercisePriceRange1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "ExercisePriceRange1Member",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails1",
      "http://renovarobio.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range 1 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_ExercisePriceRange2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "ExercisePriceRange2Member",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails1",
      "http://renovarobio.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range 2 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_ExercisePriceRange3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "ExercisePriceRange3Member",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails1",
      "http://renovarobio.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range 3 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_ExercisePriceRange4Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "ExercisePriceRange4Member",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range 4 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_ExercisePriceRange5Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "ExercisePriceRange5Member",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range 5 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_ExercisePriceRange6Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "ExercisePriceRange6Member",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range 6 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_ExercisePrices": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "ExercisePrices",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Prices"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "RENB_ExtinguishmentOfContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "ExtinguishmentOfContingentConsiderationLiability",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extinguishment of contingent consideration liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails",
      "http://renovarobio.com/role/FairValueMeasurementsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r491",
      "r492",
      "r497",
      "r785"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails",
      "http://renovarobio.com/role/FairValueMeasurementsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r491",
      "r492",
      "r497",
      "r785"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r493",
      "r494",
      "r495",
      "r787"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r493",
      "r494",
      "r495",
      "r787"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails",
      "http://renovarobio.com/role/FairValueMeasurementsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r490",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r540",
      "r541",
      "r542",
      "r770",
      "r771",
      "r776",
      "r777",
      "r778",
      "r785",
      "r787"
     ]
    },
    "us-gaap_FairValueConcentrationOfRiskTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueConcentrationOfRiskTextBlock",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of key input to valuing the contingent consideration liability",
        "documentation": "Tabular disclosure of all significant concentrations of risk, including credit risk and market risk, arising from all financial instruments (as defined), whether from an individual counterparty or groups of counterparties. The disclosure concerning concentrations of risk may consist of the following information: (1) for concentrations of credit risk disclosure may include: (a) information about the (shared) activity, region, or economic characteristic that identifies the concentration, (b) the maximum amount of loss due to credit risk that, based on the gross fair value of the financial instrument, the entity would incur if parties to the financial instruments that make up the concentration failed completely to perform according to the terms of the contracts and the collateral or other security, if any, for the amount due proved to be of no value to the entity, (c) the policy of requiring collateral or other security to support financial instruments subject to credit risk, information about the entity's access to that collateral or other security, and the nature and a brief description of the collateral or other security supporting those financial instruments, and (d) the policy of entering into master netting arrangements to mitigate the credit risk of financial instruments, information about the arrangements for which the entity is a party, and a brief description of the terms of those arrangements, including the extent to which they would reduce the entity's maximum amount of loss due to credit risk and (2) for disclosure of quantitative information about the market risks of financial instruments that is consistent with the way the company manages or adjusts those risks, disclosure may include: (a) more details about current positions and perhaps activity during the period, (b) the hypothetical effects on comprehensive income (or net assets), or annual income, of several possible changes in market prices, (c) a gap analysis of interest rate re-pricing or maturity dates, (d) the duration of the financial instruments, (e) the entity's value at risk from derivatives and from other positions at the end of the reporting period and the average value at risk during the year, or (f) other ways of reporting quantitative information as internally developed."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r82",
      "r147",
      "r148"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails",
      "http://renovarobio.com/role/FairValueMeasurementsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r391",
      "r396",
      "r492",
      "r497",
      "r540",
      "r776",
      "r777",
      "r778",
      "r785"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails",
      "http://renovarobio.com/role/FairValueMeasurementsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r391",
      "r396",
      "r492",
      "r493",
      "r497",
      "r541",
      "r770",
      "r771",
      "r776",
      "r777",
      "r778",
      "r785"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails",
      "http://renovarobio.com/role/FairValueMeasurementsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r492",
      "r493",
      "r494",
      "r495",
      "r497",
      "r542",
      "r770",
      "r771",
      "r776",
      "r777",
      "r778",
      "r785",
      "r787"
     ]
    },
    "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementInputsDisclosureTextBlock",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "FAIR VALUE MEASUREMENTS",
        "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails",
      "http://renovarobio.com/role/FairValueMeasurementsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r490",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r540",
      "r541",
      "r542",
      "r770",
      "r771",
      "r776",
      "r777",
      "r778",
      "r785",
      "r787"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_FairValueOptionChangesInFairValueGainLoss1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOptionChangesInFairValueGainLoss1",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option fair value",
        "documentation": "For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "RENB_FinanceAgreementEnteredIntoInExchangeForPrepaidAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "FinanceAgreementEnteredIntoInExchangeForPrepaidAssets",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance agreement entered into in exchange for prepaid assets"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_FinanceAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "FinanceAgreementMember",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Useful life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2026",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r745",
      "r768"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Thereafter",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r745",
      "r768"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2029",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r745",
      "r768"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2028",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r745",
      "r768"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2027",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r745",
      "r768"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r296",
      "r298",
      "r299",
      "r300",
      "r302",
      "r303",
      "r307",
      "r308",
      "r551",
      "r552",
      "r745"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r296",
      "r303",
      "r307",
      "r308",
      "r311",
      "r551",
      "r745",
      "r768"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r296",
      "r298",
      "r299",
      "r300",
      "r302",
      "r303",
      "r307",
      "r308",
      "r745"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails1",
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total",
        "label": "Definite-life intangible assets",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r551",
      "r979"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsPeriodIncreaseDecrease",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net definite-life intangible assets, Additions",
        "documentation": "Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net definite-life intangible assets, Translation adjustment",
        "documentation": "Amount of increase (decrease) to assets, excluding financial assets and goodwill, lacking physical substance with a finite life for foreign currency translation adjustments and purchase accounting adjustments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedTrademarksGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedTrademarksGross",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trademarks",
        "documentation": "Gross carrying amount before accumulated amortization as of the balance sheet date for the rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style for a specified period of time."
       }
      }
     },
     "auth_ref": [
      "r936",
      "r979"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign currency translation adjustment",
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r502",
      "r503",
      "r504",
      "r506",
      "r705"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Functional Currency and Foreign Currency Translation",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r501"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r849",
      "r860",
      "r874",
      "r901"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r849",
      "r860",
      "r874",
      "r901"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r849",
      "r860",
      "r874",
      "r901"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r849",
      "r860",
      "r874",
      "r901"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r849",
      "r860",
      "r874",
      "r901"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://renovarobio.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "RENB_GEDiCubeIntlLtdAcquisitionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "GEDiCubeIntlLtdAcquisitionMember",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "G E Di Cube Intl Ltd Acquisition [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_GEDiCubeIntlLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "GEDiCubeIntlLtdMember",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "G E Di Cube Intl Ltd [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_GEDiCubeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "GEDiCubeMember",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionDetails3",
      "http://renovarobio.com/role/AcquisitionDetails4",
      "http://renovarobio.com/role/AcquisitionDetails5",
      "http://renovarobio.com/role/AcquisitionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "GEDi Cube [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_GTechMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "GTechMember",
     "presentation": [
      "http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "G Tech [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss on extinguishment of debt",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r52",
      "r53"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r687"
     ]
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets",
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetailsNarrative",
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill",
        "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r283",
      "r583",
      "r762",
      "r767",
      "r786",
      "r793",
      "r969",
      "r970"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetImpairment",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/SegmentReportingDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Goodwill impairment",
        "label": "Goodwill and Intangible Asset Impairment",
        "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Goodwill",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r968",
      "r971"
     ]
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 4.0
      },
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows",
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill impairment",
        "documentation": "Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r284",
      "r290",
      "r294",
      "r767",
      "r786"
     ]
    },
    "us-gaap_GoodwillMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillMember",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill [Member]",
        "documentation": "Asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r827",
      "r829",
      "r852"
     ]
    },
    "RENB_ImpairmentAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "ImpairmentAdjustment",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment adjustment"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_ImpairmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "ImpairmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment expense"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_ImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "ImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment loss"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      },
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows",
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible asset impairment",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r297",
      "r310"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net definite-life intangible assets, Impairment",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value."
       }
      }
     },
     "auth_ref": [
      "r297",
      "r949",
      "r984"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Goodwill and Indefinite Lived Intangible Assets",
        "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r124"
     ]
    },
    "RENB_InProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "InProcessResearchAndDevelopment",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "In-process research and development"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InProcessResearchAndDevelopmentMember",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "In Process Research and Development [Member]",
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process."
       }
      }
     },
     "auth_ref": [
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r979",
      "r981",
      "r982",
      "r983"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r433",
      "r434",
      "r443",
      "r451",
      "r782",
      "r1025"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r433",
      "r434",
      "r443",
      "r451",
      "r782",
      "r1025"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INCOME TAXES",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r428",
      "r433",
      "r440",
      "r441",
      "r442",
      "r444",
      "r449",
      "r457",
      "r459",
      "r460",
      "r461",
      "r635",
      "r782"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/IncomeTaxesDetails2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Tax Expense",
        "label": "Income Tax Expense (Benefit) [Default Label]",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r169",
      "r228",
      "r229",
      "r241",
      "r257",
      "r271",
      "r432",
      "r433",
      "r458",
      "r607",
      "r782"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r430",
      "r431",
      "r444",
      "r445",
      "r448",
      "r453",
      "r629"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation allowance",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r437",
      "r782",
      "r1022"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computed tax at expected statutory rate",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r429",
      "r433",
      "r436",
      "r782"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationNondeductibleExpense",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-deductible expenses / other items",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r438",
      "r439",
      "r1022"
     ]
    },
    "us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationRepatriationOfForeignEarnings",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Non-US income taxed at different rates",
        "label": "Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to repatriation of foreign earnings."
       }
      }
     },
     "auth_ref": [
      "r1022",
      "r1023"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r206",
      "r450",
      "r451"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsAndOtherReceivables",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other receivables",
        "label": "Increase (Decrease) in Accounts and Other Receivables",
        "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating leases, net",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r934",
      "r948"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued expenses",
        "label": "Increase (Decrease) in Other Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherCurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other current liabilities",
        "label": "Increase (Decrease) in Other Current Liabilities",
        "documentation": "Amount of increase (decrease) in current liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses/deposits",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "RENB_IndefiniteLifeIntangibleAssetsAndGoodwillAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "IndefiniteLifeIntangibleAssetsAndGoodwillAmortization",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total indefinite life intangible assets and goodwill, Amortization"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_IndefiniteLifeIntangibleAssetsAndGoodwillImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "IndefiniteLifeIntangibleAssetsAndGoodwillImpairment",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total indefinite life intangible assets and goodwill, Impairment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r296",
      "r301",
      "r306",
      "r768"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r296",
      "r306",
      "r311",
      "r768"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company."
       }
      }
     },
     "auth_ref": [
      "r296",
      "r301",
      "r306",
      "r768"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total indefinite life intangible assets and goodwill, Additions",
        "documentation": "Amount of increase (decrease) of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r981"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total indefinite life intangible assets and goodwill, Translation adjustment",
        "documentation": "Amount of increase (decrease) of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit, from foreign currency translation and purchase accounting adjustments."
       }
      }
     },
     "auth_ref": [
      "r981"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r849",
      "r860",
      "r874",
      "r892",
      "r901",
      "r905",
      "r913"
     ]
    },
    "RENB_InitialPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "InitialPayment",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial payment"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_InitialRecognitionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "InitialRecognitionMember",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial Recognition [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "auth_ref": [
      "r911"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r830",
      "r917"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r830",
      "r917"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r830",
      "r917"
     ]
    },
    "RENB_InsuranceReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "InsuranceReceivablePolicy",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insurance Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InsuranceSettlementsReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InsuranceSettlementsReceivableCurrent",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insurance receivable",
        "documentation": "Amount due in settlement of a claim for reimbursement from an insurance company when the Company has suffered a loss covered under an insurance policy. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r939"
     ]
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwill"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INTANGIBLE ASSETS AND GOODWILL",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r309",
      "r312",
      "r744",
      "r745"
     ]
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets",
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r547",
      "r548",
      "r549",
      "r551",
      "r753",
      "r971"
     ]
    },
    "us-gaap_InterestAndDebtExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestAndDebtExpense",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued interest expense",
        "documentation": "Interest and debt related expenses associated with nonoperating financing activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations",
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Total interest expense",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r945"
     ]
    },
    "RENB_InterestIncomeAndOtherIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "InterestIncomeAndOtherIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income and other income (expense)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r204",
      "r205"
     ]
    },
    "RENB_InterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "InterestRate",
     "presentation": [
      "http://renovarobio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Interest rate",
        "label": "InterestRate"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_InvestmentEquitySecuritiesShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "InvestmentEquitySecuritiesShares",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "investment equity securities shares"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_InvestmentinEquitySecuritiesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "InvestmentinEquitySecuritiesPolicyTextBlock",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in Equity Securities"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_Investor1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "Investor1Member",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investor 1 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestorMember",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investor [Member]",
        "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value."
       }
      }
     },
     "auth_ref": [
      "r1040",
      "r1041"
     ]
    },
    "RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtShares",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock and warrants under private placement offering in settlement of debt, shares"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock and warrants under private placement offering in settlement of debt"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_IssuanceOfCommonStockPursuantAcquisitionOfGediCubeShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "IssuanceOfCommonStockPursuantAcquisitionOfGediCubeShares",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock pursuant to acquisition of GEDi Cube, shares"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_IssuanceOfCommonStockPursuantToAcquisitionOfGediCube": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "IssuanceOfCommonStockPursuantToAcquisitionOfGediCube",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock pursuant to acquisition of GEDi Cube"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_IssuanceOfCommonStockPursuantToAcquisitionShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "IssuanceOfCommonStockPursuantToAcquisitionShares",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock pursuant to acquisition, shares"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_IssuanceOfCommonStockPursuantToAcquisitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "IssuanceOfCommonStockPursuantToAcquisitionValue",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock pursuant to acquisition"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_IssuanceOfCommonStockUnderPrivatePlacementOffering": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "IssuanceOfCommonStockUnderPrivatePlacementOffering",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock under private placement"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_IssuanceOfCommonStockUnderPrivatePlacementOfferingShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "IssuanceOfCommonStockUnderPrivatePlacementOfferingShares",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock under private placement offering, shares"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_IssuanceOfCommonStockUnderPrivatePlacementOfferingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "IssuanceOfCommonStockUnderPrivatePlacementOfferingValue",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock under private placement offering"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of preferred stock and warrants for conversion of Note Payable"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayableShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayableShares",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of preferred stock and warrants for conversion of Note Payable, shares"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_IssuanceOfPreferredStockAndWarrantsInPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "IssuanceOfPreferredStockAndWarrantsInPrivatePlacement",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of preferred stock and warrants in private placement"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_IssuanceOfPreferredStockAndWarrantsInPrivatePlacementShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "IssuanceOfPreferredStockAndWarrantsInPrivatePlacementShares",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of preferred stock and warrants in private placement, shares"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_JanuaryNote2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "JanuaryNote2024Member",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "January Note 2024 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_LabEquipmentAndInstrumentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "LabEquipmentAndInstrumentsMember",
     "presentation": [
      "http://renovarobio.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lab Equipment And Instruments [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://renovarobio.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r528"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "RENB_LessAccumulatedAmortizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "LessAccumulatedAmortizationMember",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Less Accumulated Amortization [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r523"
     ]
    },
    "us-gaap_LesseeOperatingLeaseDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseDescription",
     "presentation": [
      "http://renovarobio.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease premises, description",
        "documentation": "Description of lessee's operating lease."
       }
      }
     },
     "auth_ref": [
      "r524"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://renovarobio.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of lease commitments",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1039"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r527"
     ]
    },
    "RENB_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Thereafter",
        "label": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r527"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r527"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r527"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://renovarobio.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LEASES",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r90",
      "r91",
      "r92",
      "r94",
      "r95",
      "r96",
      "r97",
      "r210",
      "r280",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r475",
      "r478",
      "r479",
      "r500",
      "r663",
      "r755",
      "r815",
      "r991",
      "r1044",
      "r1045"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY (DEFICIT)",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r151",
      "r596",
      "r793",
      "r952",
      "r966",
      "r1036"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r175",
      "r210",
      "r280",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r475",
      "r478",
      "r479",
      "r500",
      "r793",
      "r991",
      "r1044",
      "r1045"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT LIABILITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesFairValueAdjustment",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value adjustment",
        "documentation": "Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Non-Current Liabilities",
        "label": "Liabilities, Noncurrent",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r94",
      "r95",
      "r96",
      "r97",
      "r210",
      "r280",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r475",
      "r478",
      "r479",
      "r500",
      "r991",
      "r1044",
      "r1045"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NON-CURRENT LIABILITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_LicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "LicenseAgreementMember",
     "presentation": [
      "http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtPercentageBearingFixedInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtPercentageBearingFixedInterestRate",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bear interest percentage",
        "documentation": "The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r986",
      "r987",
      "r988"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r51",
      "r986",
      "r987",
      "r988"
     ]
    },
    "RENB_LossOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "LossOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on extinguishment of debt",
        "label": "LossOnExtinguishmentOfDebt"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_MarkDybulMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "MarkDybulMember",
     "presentation": [
      "http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mark Dybul [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cyd_MaterialCybersecurityIncidentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r863",
      "r864"
     ]
    },
    "cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r863",
      "r865"
     ]
    },
    "cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r863",
      "r866"
     ]
    },
    "cyd_MaterialCybersecurityIncidentNatureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentNatureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Nature [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r863",
      "r866"
     ]
    },
    "cyd_MaterialCybersecurityIncidentScopeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentScopeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Scope [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r863",
      "r866"
     ]
    },
    "cyd_MaterialCybersecurityIncidentTimingTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentTimingTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Timing [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r863",
      "r866"
     ]
    },
    "us-gaap_MaturitiesOfTimeDepositsDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MaturitiesOfTimeDepositsDescription",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturity description",
        "documentation": "Description of time deposit maturities, including certificates of deposit."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails1",
      "http://renovarobio.com/role/PropertyAndEquipmentDetails",
      "http://renovarobio.com/role/StockholdersEquityDetails",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r330",
      "r331",
      "r332",
      "r333",
      "r398",
      "r425",
      "r495",
      "r546",
      "r619",
      "r620",
      "r627",
      "r655",
      "r656",
      "r716",
      "r718",
      "r720",
      "r721",
      "r723",
      "r742",
      "r743",
      "r766",
      "r774",
      "r781",
      "r787",
      "r788",
      "r789",
      "r790",
      "r802",
      "r993",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name"
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r493",
      "r494",
      "r495",
      "r787"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r493",
      "r494",
      "r495",
      "r787"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails1",
      "http://renovarobio.com/role/PropertyAndEquipmentDetails",
      "http://renovarobio.com/role/StockholdersEquityDetails",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r330",
      "r331",
      "r332",
      "r333",
      "r398",
      "r425",
      "r495",
      "r546",
      "r619",
      "r620",
      "r627",
      "r655",
      "r656",
      "r716",
      "r718",
      "r720",
      "r721",
      "r723",
      "r742",
      "r743",
      "r766",
      "r774",
      "r781",
      "r787",
      "r788",
      "r789",
      "r802",
      "r993",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "RENB_MonthlyInstallments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "MonthlyInstallments",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Monthly instalments amount"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_MrMillerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "MrMillerMember",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mr Miller [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "country_NL": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "NL",
     "presentation": [
      "http://renovarobio.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NETHERLANDS"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET CASH PROVIDED BY FINANCING ACTIVITIES",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r203"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET CASH USED IN INVESTING ACTIVITIES",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r203"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET CASH USED IN OPERATING ACTIVITIES",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r116",
      "r117"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_NetDefinitelifeIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "NetDefinitelifeIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Net definite-life intangible assets at beginning",
        "periodEndLabel": "Net definite-life intangible assets at ending",
        "label": "NetDefinitelifeIntangibleAssets"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_NetDefinitelifeIntangibleAssetsAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "NetDefinitelifeIntangibleAssetsAmortization",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net definite-life intangible assets, Amortization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit",
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows",
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations",
      "http://renovarobio.com/role/GoingConcernDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET LOSS",
        "label": "Net loss",
        "verboseLabel": "Net Income (Loss)",
        "negatedLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r117",
      "r152",
      "r173",
      "r190",
      "r192",
      "r197",
      "r210",
      "r219",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r228",
      "r229",
      "r234",
      "r280",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r465",
      "r471",
      "r489",
      "r500",
      "r602",
      "r684",
      "r706",
      "r707",
      "r813",
      "r991"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements Not Yet Adopte",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non cash earn out distribution",
        "documentation": "The amount of accounts receivable that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35",
      "r36"
     ]
    },
    "RENB_NoncashRestrictedSharesIssuedForServicesRendered": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "NoncashRestrictedSharesIssuedForServicesRendered",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash restricted shares issued for services rendered"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_NoncashStockbasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "NoncashStockbasedCompensationExpense",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash stock-based compensation expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Other Income (Expense)",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income (Expense)"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_NotePayableSettledThroughNoncashExerciseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "NotePayableSettledThroughNoncashExerciseOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note payable settled through non-cash exercise of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_NotesBalance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "NotesBalance",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes balance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes payable",
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r150",
      "r1053",
      "r1054"
     ]
    },
    "RENB_NotesPayableRelatedPartiesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "NotesPayableRelatedPartiesNetCurrent",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes payable \u2013 related parties, net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Operating Expenses",
        "label": "Operating Expenses [Default Label]",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "LOSS FROM OPERATIONS",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r756",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current portion of operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r522"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liabilities, net of current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r522"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease right-of-use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r521"
     ]
    },
    "RENB_OperatingLeaseRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "OperatingLeaseRightOfUseAssets",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ROU Assets and Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://renovarobio.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average discount rate",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r526",
      "r792"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://renovarobio.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average remaining term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r525",
      "r792"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating loss carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r452"
     ]
    },
    "us-gaap_OptionIndexedToIssuersEquityEquityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OptionIndexedToIssuersEquityEquityAxis",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails1",
      "http://renovarobio.com/role/StockholdersEquityDetails2",
      "http://renovarobio.com/role/StockholdersEquityDetails3",
      "http://renovarobio.com/role/StockholdersEquityDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Indexed to Issuer's Equity [Axis]",
        "documentation": "Information by type of options indexed to an issuer's equity."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r79",
      "r80",
      "r145"
     ]
    },
    "us-gaap_OptionIndexedToIssuersEquityEquityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OptionIndexedToIssuersEquityEquityTable",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails1",
      "http://renovarobio.com/role/StockholdersEquityDetails2",
      "http://renovarobio.com/role/StockholdersEquityDetails3",
      "http://renovarobio.com/role/StockholdersEquityDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Indexed to Issuer's Equity, Equity [Table]",
        "documentation": "Disclosure of information about option contract issued and indexed to equity, classified as equity. Includes, but is not limited to, strike price, number of shares, indexed share, and settlement date."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r79",
      "r80",
      "r145"
     ]
    },
    "us-gaap_OptionIndexedToIssuersEquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OptionIndexedToIssuersEquityLineItems",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails1",
      "http://renovarobio.com/role/StockholdersEquityDetails2",
      "http://renovarobio.com/role/StockholdersEquityDetails3",
      "http://renovarobio.com/role/StockholdersEquityDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Indexed to Issuer's Equity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OptionIndexedToIssuersEquityTypeDomain",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails1",
      "http://renovarobio.com/role/StockholdersEquityDetails2",
      "http://renovarobio.com/role/StockholdersEquityDetails3",
      "http://renovarobio.com/role/StockholdersEquityDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "RENB_OptionsIssuedInSettlementOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "OptionsIssuedInSettlementOfDebt",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options issued in settlement of debt"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r119",
      "r120",
      "r142"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Other Assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r180"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Foreign currency translation, net of taxes",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax",
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r6",
      "r505",
      "r513"
     ]
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCurrentLiabilitiesMember",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Current Liabilities [Member]",
        "documentation": "Primary financial statement caption encompassing other current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/SegmentReportingDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "General and administrative",
        "label": "Other General and Administrative Expense",
        "documentation": "Amount of general and administrative expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r1088"
     ]
    },
    "us-gaap_OtherIndefiniteLivedIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherIndefiniteLivedIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Total indefinite life intangible assets and goodwill at beginning",
        "periodEndLabel": "Total indefinite life intangible assets and goodwill at ending",
        "label": "Other Indefinite-Lived Intangible Assets",
        "documentation": "Amount after impairment of indefinite-lived intangible assets classified as other. Excludes financial assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r936",
      "r981"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current liabilities",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r793"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other current liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_OtherNonrecurringIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonrecurringIncomeExpense",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income (expense)",
        "documentation": "Amount of other expense (income) that is infrequent in occurrence or unusual in nature."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaids and other assets",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r940",
      "r967"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "us-gaap_OtherTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of other income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r211",
      "r1021",
      "r1027"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r847",
      "r858",
      "r872",
      "r899"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r850",
      "r861",
      "r875",
      "r902"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r850",
      "r861",
      "r875",
      "r902"
     ]
    },
    "RENB_PasecoApSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "PasecoApSMember",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Paseco Ap S [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PatentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PatentsMember",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patents [Member]",
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r972",
      "r973",
      "r974",
      "r975",
      "r977",
      "r979",
      "r982",
      "r983"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "auth_ref": [
      "r879"
     ]
    },
    "RENB_PaymentForExpenditures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "PaymentForExpenditures",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment for expenditures"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForFees",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment for license",
        "documentation": "Amount of cash outflow for fees classified as other."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_PaymentsToAcquireEquitySecuritiesFvNi": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireEquitySecuritiesFvNi",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Investment in equity securities",
        "label": "Payments to Acquire Equity Securities, FV-NI",
        "documentation": "Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r201"
     ]
    },
    "us-gaap_PaymentsToAcquireNotesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireNotesReceivable",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Notes receivable prior to acquisition",
        "label": "Payments to Acquire Notes Receivable",
        "documentation": "The cash outflow to acquire an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020"
     ]
    },
    "RENB_PlanOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "PlanOptionMember",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Option [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_PlanOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "PlanOptionsMember",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "RENB_PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock converted to common stock pursuant to acquisition of GEDi Cube"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCubeShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCubeShares",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock converted to common stock pursuant to acquisition of GEDi Cube, shares"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_PreferredStockDesignatedShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "PreferredStockDesignatedShares",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock designated shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r805",
      "r806",
      "r809",
      "r810",
      "r811",
      "r812",
      "r1086",
      "r1089"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r373"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "verboseLabel": "Preferred stock shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r664"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r373"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r664",
      "r682",
      "r1089",
      "r1090"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r592",
      "r793"
     ]
    },
    "RENB_PrincipalAmountAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "PrincipalAmountAndInterestAccrued",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principal amount and interest accrued"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock",
        "verboseLabel": "Proceeds from common stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfDebt",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows",
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of promissory notes",
        "verboseLabel": "Gross proceeds",
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt."
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from private placements",
        "verboseLabel": "Proceeds from issuance of private placement",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromNotesPayable",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from notes payable",
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation expense stock option vesting",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r21"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of warrants",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r946"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r190",
      "r192",
      "r202",
      "r210",
      "r219",
      "r225",
      "r228",
      "r229",
      "r280",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r465",
      "r471",
      "r473",
      "r476",
      "r477",
      "r489",
      "r500",
      "r586",
      "r601",
      "r639",
      "r684",
      "r706",
      "r707",
      "r783",
      "r784",
      "r814",
      "r943",
      "r991"
     ]
    },
    "RENB_PromissoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "PromissoryNoteMember",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Promissory Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_PromissoryNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "PromissoryNotesMember",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Promissory Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://renovarobio.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r528"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://renovarobio.com/role/PropertyAndEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PROPERTY AND EQUIPMENT",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r163",
      "r166",
      "r167"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r177",
      "r600"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://renovarobio.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r528"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets",
      "http://renovarobio.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "verboseLabel": "Net Property and Equipment",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r528",
      "r587",
      "r600",
      "r793"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r163",
      "r166",
      "r598"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://renovarobio.com/role/PropertyAndEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Property and equipment",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://renovarobio.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r528"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://renovarobio.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "RENB_PurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "PurchaseAgreementMember",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_PurchaseEquitySecuritiesValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "PurchaseEquitySecuritiesValue",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase equity securities value"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_PurchaseExercisableWarrantsOutstandingShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "PurchaseExercisableWarrantsOutstandingShares",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase exercisable warrants outstanding shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PurchaseObligation",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Obligation to purchase",
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier."
       }
      }
     },
     "auth_ref": []
    },
    "RENB_PurchaseSharesOfCommonStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "PurchaseSharesOfCommonStock",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase shares of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "RENB_RENBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "RENBMember",
     "presentation": [
      "http://renovarobio.com/role/SegmentReportingDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RENB [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_RENCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "RENCMember",
     "presentation": [
      "http://renovarobio.com/role/SegmentReportingDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RENC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_RSBioMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "RSBioMember",
     "presentation": [
      "http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RS Bio [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails1",
      "http://renovarobio.com/role/PropertyAndEquipmentDetails",
      "http://renovarobio.com/role/StockholdersEquityDetails",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r330",
      "r331",
      "r332",
      "r333",
      "r390",
      "r398",
      "r421",
      "r422",
      "r423",
      "r425",
      "r495",
      "r543",
      "r544",
      "r546",
      "r619",
      "r620",
      "r627",
      "r655",
      "r656",
      "r716",
      "r718",
      "r720",
      "r721",
      "r723",
      "r742",
      "r743",
      "r766",
      "r774",
      "r781",
      "r787",
      "r788",
      "r789",
      "r790",
      "r802",
      "r807",
      "r989",
      "r993",
      "r1033",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails1",
      "http://renovarobio.com/role/PropertyAndEquipmentDetails",
      "http://renovarobio.com/role/StockholdersEquityDetails",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "auth_ref": [
      "r330",
      "r331",
      "r332",
      "r333",
      "r390",
      "r398",
      "r421",
      "r422",
      "r423",
      "r425",
      "r495",
      "r543",
      "r544",
      "r546",
      "r619",
      "r620",
      "r627",
      "r655",
      "r656",
      "r716",
      "r718",
      "r720",
      "r721",
      "r723",
      "r742",
      "r743",
      "r766",
      "r774",
      "r781",
      "r787",
      "r788",
      "r789",
      "r790",
      "r802",
      "r807",
      "r989",
      "r993",
      "r1033",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051"
     ]
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "presentation": [
      "http://renovarobio.com/role/SegmentReportingTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of information regarding segment reporting",
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r46"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "auth_ref": [
      "r842",
      "r853",
      "r867",
      "r894"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r397",
      "r533",
      "r534",
      "r591",
      "r597",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r681",
      "r683",
      "r715"
     ]
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued balance",
        "documentation": "Amount of transactions with related party during the financial reporting period."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r533"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative",
      "http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r533",
      "r534",
      "r1043"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative",
      "http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r688",
      "r689",
      "r692"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r397",
      "r533",
      "r534",
      "r591",
      "r597",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r681",
      "r683",
      "r715",
      "r1043"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://renovarobio.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RELATED PARTY TRANSACTIONS",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r530",
      "r531",
      "r532",
      "r534",
      "r536",
      "r636",
      "r637",
      "r638",
      "r690",
      "r691",
      "r692",
      "r712",
      "r714"
     ]
    },
    "RENB_RenovaroCubeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "RenovaroCubeMember",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetailsNarrative",
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetailsNarrative",
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Renovaro Cube [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_RenovaroMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "RenovaroMember",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Renovaro [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_RepaymentOnFinanceAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "RepaymentOnFinanceAgreement",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Down payment amount"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_RepaymentsOfFinanceAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "RepaymentsOfFinanceAgreement",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayments of finance agreement",
        "label": "RepaymentsOfFinanceAgreement"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionsTables"
     ],
     "auth_ref": [
      "r213",
      "r214",
      "r349",
      "r375",
      "r535",
      "r545",
      "r588",
      "r750",
      "r751"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations",
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://renovarobio.com/role/SegmentReportingDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "verboseLabel": "Research and development expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r427",
      "r745",
      "r761",
      "r1052"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expenses",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r426"
     ]
    },
    "RENB_ReserveEscrowShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "ReserveEscrowShares",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reserve escrow shares"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r843",
      "r854",
      "r868",
      "r895"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r844",
      "r855",
      "r869",
      "r896"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r851",
      "r862",
      "r876",
      "r903"
     ]
    },
    "RENB_RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationShares",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted shares issued for services rendered and executive compensation, shares"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationValue",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted shares issued for services rendered and executive compensation"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_RestrictedSharesIssuedForServicesRenderedShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "RestrictedSharesIssuedForServicesRenderedShares",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted shares issued for services rendered, shares"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_RestrictedSharesIssuedForServicesRenderedValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "RestrictedSharesIssuedForServicesRenderedValue",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted shares issued for services rendered"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_RestrictedStockAwardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "RestrictedStockAwardsMember",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Awards [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCostAndReserveLineItems",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Cost and Reserve [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets",
      "http://renovarobio.com/role/GoingConcernDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r132",
      "r595",
      "r624",
      "r626",
      "r634",
      "r665",
      "r793"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r216",
      "r217",
      "r218",
      "r220",
      "r225",
      "r227",
      "r229",
      "r281",
      "r282",
      "r313",
      "r455",
      "r456",
      "r462",
      "r463",
      "r464",
      "r466",
      "r470",
      "r471",
      "r480",
      "r482",
      "r483",
      "r485",
      "r487",
      "r518",
      "r520",
      "r621",
      "r623",
      "r640",
      "r1089"
     ]
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "presentation": [
      "http://renovarobio.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "RENB_RoyaltyPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "RoyaltyPercentage",
     "presentation": [
      "http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "RENB_SaleOfStockConsiderationReceivedCashTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "SaleOfStockConsiderationReceivedCashTransaction",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Sale of stock issued cash consideration",
        "label": "SaleOfStockConsiderationReceivedCashTransaction"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of stock, value",
        "verboseLabel": "Paid in cash and settlement of debt",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedPerTransaction",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of stock issued cash consideration",
        "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of stock issued",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of stock price per share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "RENB_ScheduleOfAcquistionFairValueOfConsiderationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "ScheduleOfAcquistionFairValueOfConsiderationTableTextBlock",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of acquisition date fair value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionDetails",
      "http://renovarobio.com/role/AcquisitionDetails1",
      "http://renovarobio.com/role/AcquisitionDetails2",
      "http://renovarobio.com/role/AcquisitionDetails3",
      "http://renovarobio.com/role/AcquisitionDetails4",
      "http://renovarobio.com/role/AcquisitionDetails5",
      "http://renovarobio.com/role/AcquisitionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r71",
      "r467"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r472"
     ]
    },
    "RENB_ScheduleOfCommonStockPurchaseWarrantsOutstandingTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "ScheduleOfCommonStockPurchaseWarrantsOutstandingTableTextBlock",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of common stock purchase warrants outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of components of income tax expense (benefit) from continuing operations",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r1027"
     ]
    },
    "RENB_ScheduleOfContingentConsiderationLiabilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "ScheduleOfContingentConsiderationLiabilityTableTextBlock",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of fair value measurement on recurring basis"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of deferred tax assets and liabilities",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1024"
     ]
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "presentation": [
      "http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan [Table]",
        "documentation": "Disclosure of information about individual defined benefit pension plan or other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r62",
      "r63",
      "r64",
      "r65"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r435",
      "r782",
      "r1022"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of assets and liabilities measured at fair value on recurring bases",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1031",
      "r1032"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Asset, Finite-Lived [Table]",
        "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r296",
      "r303",
      "r307",
      "r308",
      "r311",
      "r551",
      "r745",
      "r768"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of definite-life and indefinite-life intangible assets",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r768",
      "r978"
     ]
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Asset, Indefinite-Lived [Table]",
        "documentation": "Disclosure of information about indefinite-lived intangible asset. Excludes finite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r296",
      "r306",
      "r311",
      "r768"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://renovarobio.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r528"
     ]
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of fair value of assets acquired and liabilities assumed",
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "RENB_ScheduleOfRecognizedIdentifiedAssetsAndLiabilitiesAssumedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAndLiabilitiesAssumedTableTextBlock",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of fair value of assets acquired and liabilities assumed",
        "label": "ScheduleOfRecognizedIdentifiedAssetsAndLiabilitiesAssumedTableTextBlock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r85",
      "r688",
      "r689",
      "r692"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Cost [Table]",
        "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327"
     ]
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "presentation": [
      "http://renovarobio.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "documentation": "Disclosure of information about revenue from external customer and long-lived asset by geographical area. Long-lived asset excludes financial instrument, customer relationship with financial institution, mortgage and other servicing right, deferred policy acquisition cost, and deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r107"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://renovarobio.com/role/SegmentReportingDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r43",
      "r44"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://renovarobio.com/role/SegmentReportingTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of segment operating loss and asset information",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r43",
      "r44"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock option activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r134"
     ]
    },
    "RENB_ScheduleOfShareBasedPaymentAwardStockOptionValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of weighted-average assumptions used to estimate the fair values of the stock options granted"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_ScheduleOfStockBasedCompensationActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "ScheduleOfStockBasedCompensationActivityTableTextBlock",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of stock options outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r57",
      "r58",
      "r59",
      "r60",
      "r61",
      "r128",
      "r130",
      "r131",
      "r132",
      "r184",
      "r185",
      "r186",
      "r243",
      "r373",
      "r374",
      "r375",
      "r377",
      "r380",
      "r385",
      "r387",
      "r630",
      "r631",
      "r632",
      "r633",
      "r774",
      "r933",
      "r950"
     ]
    },
    "RENB_ScheduleOfWarrantsOutstandingTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "ScheduleOfWarrantsOutstandingTableTextBlock",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of warrants outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of future amortization expense",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r768",
      "r980"
     ]
    },
    "RENB_Section174ReCapitalization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "Section174ReCapitalization",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Section 174 R&amp;E Capitalization"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_Section481aAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "Section481aAdjustment",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Section 481(a) Adjustment"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "RENB_SegmentAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "SegmentAsset",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://renovarobio.com/role/SegmentReportingDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r154",
      "r155",
      "r156",
      "r241",
      "r246",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r271",
      "r272",
      "r273",
      "r278",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r311",
      "r324",
      "r327",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r758",
      "r761",
      "r762",
      "r767",
      "r804",
      "r1055",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetailsNarrative",
      "http://renovarobio.com/role/SegmentReportingDetails"
     ],
     "auth_ref": [
      "r276",
      "r277",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r652",
      "r653",
      "r654",
      "r717",
      "r719",
      "r722",
      "r724",
      "r731",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r746",
      "r775",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r803",
      "r807",
      "r994",
      "r1055",
      "r1058",
      "r1059",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085"
     ]
    },
    "RENB_SegmentOperatingLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "SegmentOperatingLoss",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/SegmentReportingDetails",
      "http://renovarobio.com/role/SegmentReportingDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating income loss",
        "verboseLabel": "Segment operating loss"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://renovarobio.com/role/SegmentReporting"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEGMENT REPORTING",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r241",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r261",
      "r263",
      "r264",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r278",
      "r757",
      "r759",
      "r760",
      "r761",
      "r763",
      "r764",
      "r765"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://renovarobio.com/role/SegmentReportingDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "RENB_SeriesAConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "SeriesAConvertiblePreferredStockMember",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Convertible Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_SettlementOfNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "SettlementOfNotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Settlement of notes payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit",
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation",
        "verboseLabel": "Stock based compensation costs",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price",
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award."
       }
      }
     },
     "auth_ref": []
    },
    "RENB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discount Rate (Monte-Carlo model only)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails1",
      "http://renovarobio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected Dividends",
        "verboseLabel": "Dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails1",
      "http://renovarobio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails1",
      "http://renovarobio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk Free Rate",
        "verboseLabel": "Risk free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails1",
      "http://renovarobio.com/role/StockholdersEquityDetails2",
      "http://renovarobio.com/role/StockholdersEquityDetails3",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Exercisable",
        "verboseLabel": "Stock-based compensation expense vested",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r404"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails1",
      "http://renovarobio.com/role/StockholdersEquityDetails2",
      "http://renovarobio.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Exercisable, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price, Exercisable at ending of period",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r404"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails2",
      "http://renovarobio.com/role/StockholdersEquityDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cancelled/Expired",
        "label": "Cancelled/Expired",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Expired",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r1001"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r408"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option granted",
        "documentation": "Net number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r1002"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails2",
      "http://renovarobio.com/role/StockholdersEquityDetails4",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted",
        "verboseLabel": "Stock-based compensation expense grant shares",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r406"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Intrinsic Value, Outstanding at beginning of period",
        "periodEndLabel": "Weighted Average Intrinsic Value, Outstanding at end of period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails1",
      "http://renovarobio.com/role/StockholdersEquityDetails2",
      "http://renovarobio.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number share option outstanding",
        "periodStartLabel": "Options Outstanding at beginning of period",
        "periodEndLabel": "Options Outstanding at end of period",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r403"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails1",
      "http://renovarobio.com/role/StockholdersEquityDetails2",
      "http://renovarobio.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Outstanding, Weighted Average Exercise Price",
        "periodStartLabel": "Weighted Average Exercise Price, Outstanding at beginning of period",
        "periodEndLabel": "Weighted Average Exercise Price, Outstanding at ending of period",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r403"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "stock option vested",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative",
      "http://renovarobio.com/role/SubsequentEventsDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails2",
      "http://renovarobio.com/role/StockholdersEquityDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, Expired",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Forfeited",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r408"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails2",
      "http://renovarobio.com/role/StockholdersEquityDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r406"
     ]
    },
    "RENB_ShareBasedCompensationAwardAdvisoryBoardMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "ShareBasedCompensationAwardAdvisoryBoardMember",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Award Advisory Board [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_ShareBasedCompensationAwardBoardofDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "ShareBasedCompensationAwardBoardofDirectorsMember",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Award Boardof Directors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_ShareBasedCompensationAwardConsultingServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "ShareBasedCompensationAwardConsultingServicesMember",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Award Consulting Services [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails1",
      "http://renovarobio.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Axis]",
        "documentation": "Information by range of option prices pertaining to options granted."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails1",
      "http://renovarobio.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Prices, Lower",
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Prices, Upper",
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharePrice",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails1",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price",
        "verboseLabel": "Share price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetails1",
      "http://renovarobio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected Term (years)",
        "verboseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Intrinsic Value, Exercisable end of period",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails1",
      "http://renovarobio.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Exercisable, Weighted Average Remaining Contractual Life (years)",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "RENB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisablesWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisablesWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Life, Exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average remaining life, Granted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails1",
      "http://renovarobio.com/role/StockholdersEquityDetails2",
      "http://renovarobio.com/role/StockholdersEquityDetails3",
      "http://renovarobio.com/role/StockholdersEquityDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Outstanding, Weighted Average Remaining Contractual Life (years)",
        "verboseLabel": "Weighted Average remaining life",
        "terseLabel": "Weighted Average remaining life, Outstanding",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "RENB_SharesIssuableForSettlementOfContingentConsideration": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "SharesIssuableForSettlementOfContingentConsideration",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issuable for settlement of contingent consideration, shares"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_SharesIssuableForSettlementOfContingentConsiderationValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "SharesIssuableForSettlementOfContingentConsiderationValue",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issuable for settlement of contingent consideration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssued",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase price",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "RENB_SharesOfCommonStockGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "SharesOfCommonStockGranted",
     "presentation": [
      "http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares of common stock granted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance, shares",
        "periodEndLabel": "Ending balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock to be issued in settlement",
        "documentation": "The number of shares that would be issued, determined under the conditions specified in the contract, if the settlement were to occur at the reporting date."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "RENB_SingleRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "SingleRangeMember",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Single Range [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_Software": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "Software",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionDetails1",
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Software"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_SoftwarePlatformMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "SoftwarePlatformMember",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Software Platform [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://renovarobio.com/role/SegmentReportingDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r154",
      "r155",
      "r156",
      "r172",
      "r241",
      "r246",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r271",
      "r272",
      "r273",
      "r278",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r311",
      "r314",
      "r324",
      "r327",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r758",
      "r761",
      "r762",
      "r767",
      "r804",
      "r1055",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r184",
      "r185",
      "r186",
      "r210",
      "r232",
      "r233",
      "r235",
      "r237",
      "r243",
      "r244",
      "r280",
      "r336",
      "r338",
      "r339",
      "r340",
      "r343",
      "r344",
      "r373",
      "r374",
      "r377",
      "r380",
      "r387",
      "r500",
      "r630",
      "r631",
      "r632",
      "r633",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r664",
      "r685",
      "r708",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r933",
      "r950",
      "r958"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r99",
      "r102",
      "r103",
      "r171",
      "r195",
      "r196",
      "r197",
      "r216",
      "r217",
      "r218",
      "r220",
      "r225",
      "r227",
      "r229",
      "r242",
      "r281",
      "r282",
      "r313",
      "r389",
      "r455",
      "r456",
      "r462",
      "r463",
      "r464",
      "r466",
      "r470",
      "r471",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r487",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r514",
      "r518",
      "r520",
      "r529",
      "r603",
      "r621",
      "r622",
      "r623",
      "r640",
      "r708"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetailsNarrative",
      "http://renovarobio.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r276",
      "r277",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r652",
      "r653",
      "r654",
      "r717",
      "r719",
      "r722",
      "r724",
      "r731",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r746",
      "r775",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r803",
      "r807",
      "r994",
      "r1055",
      "r1058",
      "r1059",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit",
      "http://renovarobio.com/role/FairValueMeasurementsDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r217",
      "r218",
      "r242",
      "r520",
      "r550",
      "r628",
      "r651",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r664",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r683",
      "r686",
      "r687",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r708",
      "r808"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit",
      "http://renovarobio.com/role/FairValueMeasurementsDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r217",
      "r218",
      "r242",
      "r279",
      "r520",
      "r550",
      "r628",
      "r651",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r664",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r683",
      "r686",
      "r687",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r708",
      "r808"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r846",
      "r857",
      "r871",
      "r898"
     ]
    },
    "RENB_StockIssuedDuringPeriodSharesExerciseOfWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "StockIssuedDuringPeriodSharesExerciseOfWarrants",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of warrants, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock shares",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of share warrant purchase forfeited",
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r98",
      "r99",
      "r132"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationForfeited",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit",
      "http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forfeited shares of common stock, shares",
        "verboseLabel": "Common stock forfeited shares",
        "documentation": "Number of shares (or other type of equity) forfeited during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetails2",
      "http://renovarobio.com/role/StockholdersEquityDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercised",
        "negatedLabel": "Exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r98",
      "r99",
      "r132",
      "r407"
     ]
    },
    "RENB_StockIssuedDuringPeriodValueExerciseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "StockIssuedDuringPeriodValueExerciseOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock shares, value",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueOther",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of options for services rendered",
        "documentation": "Value of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensationForfeited",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forfeited shares of common stock",
        "documentation": "Value of forfeited shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "RENB_StockIssuedToNonconsentingShareholders": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "StockIssuedToNonconsentingShareholders",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issued to non-consenting shareholders"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_StockOptionIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "StockOptionIssued",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock option issued"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_StockPurchaseAgreementOfRenovaroCubeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "StockPurchaseAgreementOfRenovaroCubeMember",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Purchase Agreement Of Renovaro Cube [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockRepurchasedDuringPeriodShares",
     "presentation": [
      "http://renovarobio.com/role/FairValueMeasurementsDetailsNarrative",
      "http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchased shares of common stock",
        "verboseLabel": "Shares purchased",
        "terseLabel": "Purchase shares",
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r98",
      "r99",
      "r132",
      "r633",
      "r708",
      "r728"
     ]
    },
    "RENB_StockbasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "StockbasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation expense",
        "label": "StockbasedCompensationExpense"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_StockbasedCompensationExpenseGrantShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "StockbasedCompensationExpenseGrantShares",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation expense grant shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://renovarobio.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets",
      "http://renovarobio.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Stockholders\u2019 Equity (Deficit)",
        "periodStartLabel": "Beginning balance, value",
        "periodEndLabel": "Ending balance, value",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r102",
      "r103",
      "r121",
      "r666",
      "r682",
      "r709",
      "r710",
      "r793",
      "r815",
      "r952",
      "r966",
      "r1036",
      "r1089"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS\u2019 EQUITY (DEFICIT)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS\u2019 EQUITY",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r209",
      "r372",
      "r374",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r386",
      "r389",
      "r486",
      "r711",
      "r713",
      "r730"
     ]
    },
    "RENB_StockoptionsCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "StockoptionsCompensation",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock/options compensation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://renovarobio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r515",
      "r538"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://renovarobio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r515",
      "r538"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://renovarobio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r515",
      "r538"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://renovarobio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r515",
      "r538"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://renovarobio.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r515",
      "r538"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://renovarobio.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r537",
      "r539"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubstantialDoubtAboutGoingConcernTextBlock",
     "presentation": [
      "http://renovarobio.com/role/GoingConcern"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "GOING CONCERN",
        "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "RENB_TheNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "TheNotesMember",
     "presentation": [
      "http://renovarobio.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r964",
      "r1042"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "RENB_TradeName": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "TradeName",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade Name"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_Trademark": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "Trademark",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trademark"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_TrademarkMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "TrademarkMember",
     "presentation": [
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetails",
      "http://renovarobio.com/role/IntangibleAssetsAndGoodwillDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trademark [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "RENB_TransactionIssuedShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "TransactionIssuedShares",
     "presentation": [
      "http://renovarobio.com/role/AcquisitionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction issued shares"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r914"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title"
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r914"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://renovarobio.com/role/DebtDetailsNarrative",
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r472"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "US",
     "presentation": [
      "http://renovarobio.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "RENB_UnitedStatesTaxMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "UnitedStatesTaxMember",
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "United States Tax [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_UnrecognizedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "UnrecognizedCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized compensation cost"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_UnrecognizedCompensationCostNonVested": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "UnrecognizedCompensationCostNonVested",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized compensation cost non vested"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_UnrecognizedCompensationCostandVest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "UnrecognizedCompensationCostandVest",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized compensation cost and vest"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_UnrecognizedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "UnrecognizedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized compensation expense"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_UnrecognizedStockbasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "UnrecognizedStockbasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized stock-based compensation expense"
       }
      }
     },
     "auth_ref": []
    },
    "RENB_UpfrontPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "UpfrontPayment",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Up-front payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://renovarobio.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Accounting Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r40",
      "r41",
      "r160",
      "r161",
      "r164",
      "r165"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://renovarobio.com/role/IncomeTaxesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in valuation allowance",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingAxis",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingDomain",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r805",
      "r806",
      "r809",
      "r810",
      "r811",
      "r812"
     ]
    },
    "RENB_WarrantsExercisablePurchaseValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "WarrantsExercisablePurchaseValue",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants exercisable purchase value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING - DILUTED",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r237"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://renovarobio.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING - BASIC",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r237"
     ]
    },
    "RENB_WorkingCapitalDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://renovarobio.com/20250630",
     "localname": "WorkingCapitalDeficit",
     "crdr": "debit",
     "presentation": [
      "http://renovarobio.com/role/GoingConcernDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Working capital deficit"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://renovarobio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "7",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-7"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "8",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-8"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(c)(2)",
   "SubTopic": "20",
   "Topic": "860",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4D"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481648/480-10-50-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "63",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-63"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "25",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-23"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "37",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-37"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-6"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-7"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-4"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-22"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205-40/tableOfContent"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-7"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483613/220-20-50-1"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "250",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/250/tableOfContent"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-5"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/805/tableOfContent"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479613/805-30-35-1"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-3"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/820/tableOfContent"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-23"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r155": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r156": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "321",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479567/321-10-45-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-19"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-2"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-4"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-15"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-5"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-21"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-4"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/985-20/tableOfContent"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 6-K",
   "Section": "General Instruction",
   "Subsection": "B"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05",
   "Subsection": "Instruction",
   "Paragraph": "2"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05",
   "Subsection": "a"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-4"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>94
<FILENAME>0001731122-25-001316-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001731122-25-001316-xbrl.zip
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M+.B%]K#/G4S?\)5I-KCP\1> 3?".0UV1RX/;T8!AV_8UEN^S@'A\I\NC9X3
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M2((2434[[-CPV,;5H\=&Y+A[T]JSOF[?8E^@@_8^9DR]Q8VGNY0!SHX';,;
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M=.X(\5C>JE2&C5Z6O4(0KHBT(M)E$.G)\ZAT07)]9^OXAD??:1GH@@O"U52
M<>Q[1:X5N;XXN7Y8)6K=W3K^ZN.P0^^>N<IN[7;)>;^RMNM>LR+=BG270+JG
MJT2Z>UO'IZ,."V7*V(C6@Z+7^J+3)BGN?!MCH4)OI(Y\!2E:+*VBZXJNET'7
M[952H/>WCJ_#8(AO92LJ?RM+MZ+3)=#ISDK1Z<'6\6?6LSU:!U"LPZA)P(J2
M;+LBV8ID7YYD=U>*9 ^WCK]PGPD[U^ZR>&2=\<CQ@B@)5U76[E:$6Q'N$N.T
M1[DX;16HG4JN>Q6YKCL,UXQ<2<[N/4/.3DH)7@PC:35!^%*!!*T."[8+9C'(
MI/%S*HRHPQ4>]=B@'/!^X&&I[A<L% XC<FV)GJS6=1(Z?3MBE'DO[K72CKBK
M*=<K1E$QBB4PBOU54LA;+>P0+IH]B("QKA+&+G(5X5:$6Q&N)-R#E2+<-@KS
M?',.6A0:U(D80(\2^L0HNDZI^S3P7=&_!:^Y85'BQ9%UU;6NADP,1ZVD=D7\
M%?%KXE^I'*_6SM;Q_V+_ H[-6>Z%/PT)&;[TY'>F8\TZZ01)K(:78(AZ)8E[
M?Z<B[HJX7YZX#U>*MG>WCK6<SA4RB6R29#CTZ&\['*VNFEX1<T7,RR#FHY4B
M9LP1HT:%0C>_$/HVB&:[%S))U-0L\41TJK.I%YBO_E2=2PRS7$OUU:3Z*EI6
M4?TRJ'ZU]/-]')!)?2\CK9M3AHJ[LG'NBG(KRET*Y7Y8*<H]V#J^PBYW4ER+
MOD4\\"N:K6BVHMD\M1SF<U.JY)2I]%IYK]<>AFM&KZ)NJKE2,O9HZ_B,8__@
M((SJM)ASW<;W2K7Q197Y- B' =9.69^P?2_:P"MJ]E:$71'V,@C[F0U"%D/8
M[>;6L:9D6LNIT=6[(MR*<"O"582[4B6/;4H#,ZJ8KQY\D,%]/L2LD5-8C,U]
MZP/S&0AG]$*+WTE&YVJ=IR2,5@R@8@ 5 U ,8*5J*=OMK6-)YK02HF), @,6
M$&7H^@XG?]EJ] ?%LH0F;UWX+AOB>+!*2:](O2)U@]17J@:SO8/M#;CO\*',
M+TE#S]9'QF22"0OOP0ZO9'9%R!4ACY'0;L[M_<_*ZSV-7/<K<EUW&*X9N0JY
MN[=*8G</?6-]WN&Q]'FG.5TZP=.Z=?K,3;Q5E;L5(5>$_/H@F:7C_:WC6WB1
M'6,FET[N0N.9=V$=JULZM7]4"/52IIL73X"B[SAZ!.!YS>T][B]X"E+Q*Y\>
ML;6ST2.VC(VK+?]BW8V&L/'/P0,+Z76_6)?V@(FCN0QPZSPS&TO=B;]L_M"N
M%\%@,B($?>.X/#G*1A+IJ9T@#F*)QV?;[R6XRQO6LT-L<6;EYMWD2T0N?#>)
MXG!4$]4AG>-25KO847C%AWW7YY%UXOL)J$DW>EH];!^3&AJ_UW &H<W]2 U<
M[,J#\>3!I&.)Y?A%RK:7$[4'S/;Q(CGU\3KD]YAKD#:NL#[#OWK$T^'MF M(
M(^CA^M;1T1Z.B13PH$&C0\^6+M&@\Q=RD'O1#F.0!DBPYT8W0<EA!;K.EFZ1
MDTOCD/FN^(8]#N$AXI)M#?#Q?5D.X$^' 0KA/.4N9VZM,Q(#PVT:$V[3K/"1
MY0:6'^ H9'3DP@-"[L3>""<@PQG'08@"R8(%PN9#6BS</OW-..U23&].ACB"
M/$EOMJ,H&0B66J^96Z&]=9C'61>':@)'"0D&\EA<=L^\8)BB,BR=A]8PB'%W
ML$#6[>+T<_FZCAQ'L8V5%5$P8' :$:+<*$CH8.2IC*P<8M2,;:CC"CPO>,"U
M/ "/!TD@46I@C^H*>>173I!X;O[+AZ(OHW[1M^) U+<U^2T'GN./78MHE?\.
M*S_1?Q>S_"]TLO=C7]O#81@\\@'<X8WMA@']#8QGJ?4,0^;R=)EZ06'P%ROX
M6H%(?1^(2=$^CN85 [KQ[X@!G8>#"'\.:)PT#8T.:9X@_L)]T#A[HWK-]F(X
MO%Y?S/CM1"1]]$,(1H#30&.(U3YS  WL$#0C(FN!]W:*K3BF&B_,X<'")H>^
MJ/8S]9U3")C[CI>XK%[K)#%1,YZ0QP<<(SUQ4,^P&4VK[Y=X9HN?.[F5LX4*
M#9R\0B_O;S>'C^F""Q3_S'7CJGW6\CG:/S@J-'V>N/,*&*/=X1XV80+NCB*2
M^PG0$'!4JQ>(\=<$3.*PQJ6AS8&T\"!)]_" A0YY;'M/V8M3SZCH/)[ZKI1W
M//M\U3TS=N?*G[T\\" A B.!*#B7%T38(HO@ ,RUX7C<IRT!F8%ZU^' 0IV^
MX'^"+?HC41WH!W!#X"8@D05GZ]O 46VGC\S>144D :D>@+)(G/[^U8%L/I+H
M,9]16FD(QX>DP;O6 RI,W,.?I1(BE3+B./+T7]FI_B0AI/D J*]%20=GAY,6
M9["8KG"# E."DX^2(>GX8@A[Q.S0Z==-I; .X@F,,]#Z>G74K!/44D%QK!M:
MM%3I)<A0#72Y"] 6"J6BH[I2+T&YC"*ND .)*\&R'W@[\U,U'9EA$%&UK@?K
M#X%15L@P*S+<P2F[W!,9WJD&'Z4Y8I%L860%.O,,U6& 0API^^Q4<D244B3$
MA'""WT+2$V$!3+0>Y&!]8*XX/ .YL2_].<1*I:$AKTRQ#_11^9W+.J -Z?KL
M"LS/IWD$6R13"1",:/B$2'M"\R2J[_,0J-(.R>!&)432/=&G8L4%Q$RPU?0I
M@(LV(1L,O6"D$AD"64]007$^8L5C2SR@!J +/C!9)+%6L@P-NUVI,E8<(G\/
M94,QA("AG 1)#&J-0 4$E=9I<EX$4SDBPK1#,&O#_%L ]E2?B0[-"KQS@!>4
M1$_&*A 4?8:Q!M")LIHDP,[!*60A!2DC)P3^[9/^A# ZN6@(J*4Z:YT4JSJ9
M8T*\\L$@\<G,MX>C%-P]D .^=.WX 5"X)>(I\IT^O)93/E+J]T'7&8IZ@1
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M-5"W]9%UP@0%0;O9WJV;?J2:.$J78D>.GGK@(S(2WMXP/[BWP\#ZP(-;3-1
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M+&ZIG>HL5VG:_PZJE MZ'_PI7U8GU6\T8!BT+!#CIZ88SUR*O^"U/JHT.9B
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M_F-[LLV%L587*\OL2&2.QW"<.KXB%0,N0Y1P58R*R.N(IJEF!GK;D?6&;??
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M%9V&'F#-;ICT:K)1O/.R.=\OB#<_KX*VF\4JJ%6D@M9F4T'OE!T]BS)Z)YC
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M[\""B,A,UY0FF6O'MN*VMM<#F,7] >4D*N^1[7^GA% Q?D%P^A["C;KA62@
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MCM5L)$-Y2NA%HC%H"NRJV:</R"BV3W-'<[!#1-$I7:1@JF7F5 5:'8:9HGY
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M+)-G90?PH1L)@<D0'42M="N)X0.(0,6R^^-#RA\&>VE]+8_5[JU7)2W1=0/
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M]]BQFX8(6JB+TZA_^K5XG+X05].+ .V<.LJ=O"?6$\+KO8<:'&,T>KJ8SRL
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M]-[*325AQ&X0,15[7-G>6ZY7:=?._^MO4*__[P</'A__OEG]+77'SW_]S1=
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ML/D/,DJLLTWLRY[@)&+7S3'^RQ$=WT??(BWYPXM_I?_*YT0.0);P18T&$/H
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MS=!VPV[.P7WC[U'>P1V!5_28O+B2;&&41+H&@]"5M\U&;.')96_+;BRW.9;
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ML)%*N;S:FJ2 +]K3UCOBL-JYD,?\R^]RRJKA,;'VH$@)/^ZB]BAME-2)*:[
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M(6Y.XGK#J)/4X]1 G,: [H T\B(P!Z#*)4(BSF]*:*)HX.F_X];YG8W*R'5
M NL5I6Q8;& ^=)V@B(BTQ0?HHY.6*6E]T!:A&Q-4I=<L.:/V0+1L1PO,\()>
M\;BR4D?D+2RB91^ZTFXO SX(VCT3#\R/H=)-S,_N=@)R%?;2SBFE5B'"03!@
MI1AO%K)E;VIB.A-'12#V";=/97*)ZO]G[TV;(SFN+-'O_BO2:#//)+,HJ$A1
M6[-'9B4NTWPS%&5DR?CQ62 S$@A59D0J%H#H7__\GKOX]8C(!$ 66:A"6EN+
M!2 S%E^NW^7<<T3UV_C/KN6&Q,]$($!PK[D. 7KS$;6<_(Z)&<>(&&BR*+%F
M-6C^)EB@0).87X#)4QKYFJ9MLN+_,B)PRGBHX'[25E8F,6X5JVH>UWS+$P[2
M8R7X2B)YP4C&UM0V%FD8CF$SN'DE-V($G"0I 7K8)#JW3',E?1=S$OL$:F3@
M!O,R_L-EL#Q6FZY"6-H!BY^Z_MKN#8_W:8L,3I85-<8PE+/OX\L:Z ._<\"C
MU#Q6<.O(4H3-W5/4=T?$3:L9<=/T$1R14YB?"0XGFY,2H5T@>6-']Y[SS.?,
M!6E1G(_UGWZLU[USJE)'Y9*#[-6@)U.;L;@M2:5A^JS-X'P^_W2O&>#+MHG>
MCA(<+<U5W6R[,D8TXWHPS?8&!$SQB1FXA]9@P,SN;$^6.[1F.MA@R/1?XT9,
MTI-M-VO-AJD]1#M<=K9SRSG'][U'.%"%Y:'>$%H=.,#@*!<M[TO/O?#V3\L>
MO+/.HZ^X3V1E/E;=7->7]? XA*/STH$DR]WSU'S :E<' 58ZR#.!!ZI?$'UV
M1IJ]QT@SUG5P0,>N6G=C/4C/0DYLSM2"C#\V""_VOS-:Q;3CW=CA! V<6HEB
MN%C6G4\$:][G7%EZ\@E %I%P.%<^"-+9P W3S-^^M(1T763 -@=2$N 25L<2
M=JE0\;YSS>G]6R_H?Z4FR2FS;.FUY/@CA[9N)/L![;K2F21TX'"MFXR1"2S$
M2V[K0>[V;H!MGSYG8-M?SL"V]]F#>8^ ;3,/QM<N!&H[M,6L7EE(KS:H>WZ&
MF-;YQ'FJ)PZD$5)N]HA IB-UDEPB$YAS*[D2ADTB\XF3>RYHO_^K920P5-57
M52.2$D!(D1PJD:M/I6=!N\8I&NHJ1@\8+82%1>"$PW[]ZO4]Z4F=PE\V&XB[
M?0=FFN^(+Y\[56E;?9%W2GX[=JM_"$GJYT37MR&@T"_[:$\W]WAO?V)&>DQI
M8$<>\M47KZPKU]-B.'.W#.MRY?Y UURB_E65.2.LBK$8;0BM(!Q &Z\V4&BO
MO+!@_X"29PDQ')^W7NWJAO/D#1*GO0L=K,/X0<_K'JM0#?59%XYPZX#)1T8V
M($.BC"'4IT.7C6-=2.%$N^5!7M(HH5_T+!J0BKA(-SMLMO [[ID9BK$]UW5@
M3YFG2ZB@E6CM8O4]?72!L5!589C9R.[4.VI+ZO6F9OJ\[E;D>G_\HYROCB11
MQD%/6FZH-[9$QH[:/9,2M.<=2PK0GNNH6"(KX:<P:K*@I()YR=$1P( 66G#M
M;G2V78Q@J/#GIP@AZUYK<LBEIR1XRR@,+ZLMKT/TBU60DC<*_9NQT^M-:FTI
MUP\%HTS'R;.Y*'6B@2RFT@YI] W1&9=ER%?ETG*8=QENC5#@:27RG\C#?&$U
MEY 98!E<8NGJ+<49IQL$",E2J*]XVE(8 [C6M[DX[RR#=7#(-&.C.:I(8>W0
MZQG7++[SAX]?_N;-;\E.OY 0*9IZE,^QTE4XBDVY?B1'_IKA [TA%2:B,8TC
M4K/^6BH&K;XUP2WZ#EXH[JC%U6@2HV:%;"#JYJ;=06@F_G[#K&J,0IHKJTQ9
MW1*KCN+A(<>FM;@^0P_@FGVF5%8L/^NV76+L,Z'>('O=T+"\O^\MOBW@\KAL
MM^)I/M8:G@LA.#Q88#P8BQ>!</Z\L>\C79U"+Q[NC#&)+IL!877^"JI.0B7S
MSWC"?=OLXK+]>\N:/4AB-Y.EM*XVX'(3XF=:TM_]\]N"89@]J2+ MCLQA.(>
M/X=WWW*TVR6_W 6Y/?>M2ZJ$:S-TRN8KC1^"SU@F>/5>0B5 %GR'WO0HW^N1
M JC5"0@K03Y%RXH2@2P!D#U?;\VXFLOK-ZS9U.CU=$."HQTEJ#[R)''\<Y][
M[A4>]=Z.B=P=N=4#G)Y%1K&0%(&74)E/8I^][4W_6 ZWM#"(MZ6ZJOL=?*O@
M?#,CN1?AEE=?RT&TOJ88A&:X8?P:/+[)6#]NKN46V"">IYE@D7#-XN.Q#(S5
M27]!(,][:;I?L66@@^[.C>$:$$":"G'02:V'BDOX/0'PZBO4)5@E@>P@LA1P
MT41ML\JHF[SS+1SY3I 'X5@[=B%!'_^IEG PE ]SM6>6^(JB!-82)#>II?5V
M#-UH;&4PUNTFCE;>R:4WC\X8E<7DDSXH^^?%]Q<"26I>X <FPP2^M1Q$CTC8
MIAG->UF9W"X=;0,KVI!_$>TO-((,:XOAHMB(+NJ)_!/N%_8I#E\UU;O/VL6X
MG2PZA/&/POHY;R'[G9E\&OTX3GDWF>!M2Y(^JID=4!\KX_Z4Z!?>>%P-\F2W
MY GBV[=^^M$XK3;WT<=(G%O=TLQ42-VX9?3^[P9@KT2S^!9.K\S":1#A2-'\
M,1/E<)H).XTPF!39;66$%*YC@%)&PG&8YLS$N!\/C"H&.I9PS9WFM.4S4\F!
MC?$QGSSXCI]['^K9]O,Z#9SH='#MF7$@7\5 ;;?ZY.-B]<E+^M]LNWT>PXH:
M6'H@DTGI!/K)EO?JJ^J-&"HO D(+J:NN-7U$MI2%*R4!23Y1L$P+O-6X:,4
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MU.!QB6R%]1WOG"A].BOH2#,7,KT[QHP-9%O)&%,,&TXR3!APIS%&^!-2H9.
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M=.=-]MOQ[19XNV4N[:NO)VS#A1F*M20J?N=EIMA>74$)BYQ,HJS%_>6#7DI
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MGP/!3:ETJJ0J\YOI23YNV87,2U@F;M1E0\OA':G?OB\3G&=3CCM4C]'(S==
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MA&,9K?E)Q&<35%^;&6ITXQEB.3K$1HS"^U;4N&'9A%GM,NY#\=%13_#RR&I
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MUL0 ;2N\;;"605*L'H2'1NB9S$$@? "0CRU>8/F+JOFN1)1A\BWTI^B"%V%
MLL&4!!0^A?*JJ\2$:LO#[#-Q:M<5[3?2H"QOVD[STUQTX,\KRRJII7P>O9+X
M#M\/[?K-,U))%9J20_1L1GAMB2]T:(N0LFQ$CK+JRAIU*B>-N!VMH02,906:
M83IEQ#9/R;.5<96:CIQH3Y68RCXYY:A/'E1 #])-N=,N&7+]0*U6'NZ6]%L9
MP0V]>GS^'DH8 "59EUUH7YLKT C,.'V@3FH\@XCTB6;0-]1D#.M@$U@S!SKY
M#-QVQ(2KRX^-S*'VSE:)-J;N,R'2@",]B9514RD#O$%Z(.XU]L@1C=MYJ]#.
M],\(E:Y;#+L6_%@V4T/GI#:4[9"GHXJ;>WWJ=M'/@XPIR&&T2KU\Y8O5%YPE
M_.3E)Y^ JG%3K4$W0Z-Z&:^M"KYE$\^8KFW*F[H;N0V42+YB9/O?Y>I0'[CY
M3BF M;TJ/IJP1W%G\):9S&;C"D\"%M2<#VX*O!.= (RRLV4\(G&*7O@^LYG(
ML')7"7\-]'ID:66]"JL-KS7*D!6K+8%$I'9*-[I4>*+/OLI^(;<J)'(22HXI
M3P;(_O R3.N7NKKDF3]X*O6/%HY)J0#U,2P,[+]/J,4<&EJY-A'_)JP 3%?T
M/^Z.%*3,Y"[(%2S9M9#K4A,3T-H(#CJMEDXT7>(?FG9U/>Z)O]L,;#F4A20C
M-5*7\Q@G )7*]+/Q;[]KNT7C')0M ,Q1B\:%HLIZQWZL0BWQ86O(S]YTPG'0
M-C<2EK#=Z0<Z5;)O:$(W*&@3LLN+1\E$\<*!?E=YX_J>SSBRS108"3S37PH;
M'7GGFQCCV::%@>?8!JK1MNTE^"TIQF$[G&AH@?W@KA?W1.D8L<+5\H&@YX"Q
M"8CE3\LUS(T2VGE3JD06.[.?C/W*4;8C"L^VQH2)77AST?J*3FN.W999=H.J
M=.PKPJY1M)J&C+0C:D3; S?M_XLHZJE6)S_K2%S7!TTD.6Z)?G+TH0!Q2V41
MF@H.KX>[ [U_<#XFGT=\$J1 \U8\(HIUW8=%9L1_W0WYM/V7YSFZD]?MCCJT
ME[A)0MO9)7+V^^2TZO;RURHLQN?45'_=$BD4)SJXLSK:]&=BNK6M164.+=?$
M7D4 ,8&:UL\%<P6OMXL#WM4+%)0<L%1]/_4$D:+BAKW% .>$,0PI98M;1"NX
MEFZ_15]S"9..VXL?8\^(E6E0JR3R8# \IB,0P9Z0C-:Z[*^9U6_A##KFE[Z-
M)X^#KTQ:=F!.^)B]<TW^BB.G?E,9S0E1MGBW>'%*LEOGXC=0NPHZ9XO?EER.
M]AP*4,"<1W( %HAB,T=6V0]FX[G9=$I?$_U$%2D:"-D[^!,^B2+\I-61P)N/
M?9&@<WNL?U;O;>?/OMW$S5HHH*SMG'?)S:T=DU,>&>]B/G9Q9)*EYR9<?I8T
MP\X++_.^7#K&/2OHI"*?A0+BS?F59744&58RV(MSX-A>/W2;>W]E]0\OGW-E
M]0_GRNH36JS"'&B5-H$AKU!FZA-^D, J?<TN%T@EN="$BD1?;BO69XR'5=,S
M\?CE.&A2\<AY"=4E1R,]%S#MF(4V9*FR^T4:J7+B;>FQ$_LYZ7#^\][Y"S9_
MJ+WB!#PR<USMXA+M*/3S2Y@VH2VK.E+C+G@RZ=/7Y6[(\Y]RF!&*9UHB+CDP
MTP(\PX4NJYWFRNVJ\7UK3GXNY'A01!RH.9$6S@O-XBPO^]5O!#?X_:LO>P4.
M_J2]@ 3AV%C;1#P_"984[\K-"P_<*E#JNB0VPVH3D#VY6TX*]@_93ZO'[R>D
M-]4UFJ5<4OT:>[J#0;>2H(QI5B*E2 Y)3!MX><3FE&QQDFI??6=^&:S#\F 8
MW."FHENM3,9C;!SK;D\9>72128&=*'3Y!?3I_"PCQ.=0O>%W ZU)R&Z)$+M'
MU)1[>9LT5E]]\2K5<_V2O8JWOY,+<9L/IQW6  8NY%]AXK !YD6 A=6T%8XO
ML8_L4 /(82ZUQ#W=>)6VBE_I(CG-DW:(W^&R*IK#D?V2S5FF%&S5$!2!E@]_
M/,%_*TFM<EH[$[-PF1YYCUVMUUSORGK_Z]9KWY&&LB7@T&MM7.9N>GWZDU01
MP8ONT$:Z*&CMW5:V[!0N8. 5;]I@N?P^N>?8YV,C)*CX0L+39X9M;M&\Y9@T
M% Q *2-Q#_L,.?2NF"Q^=<(*)9\XT5+[T3%BBD]>WD-,D7WN9W?[_H3&WB-.
M YU=E*;9=.5MH6:TX,(@\:^[LHVPVF9\JRJFS#832DUQ/>Y)9 %6AG?%L5;_
M!XWTTJC>][NW<H\G-DLZU+#T8J1H4N"?H1)."'C@$.-$QI,;TA6W94>9-E@#
M[DY)!P_-\I8BL'@R59TPCX(CN%;A]0.! <OU";J&MSJ')T?NF<QO*5(CF*&K
M$9H"X[#C@JKV+:7MF!T4J X111RYN=(&HQY 1LKI=.E6WWWYS??T-_KO"^I<
MX+HCE5X:E"ZLYGY9-=6V'JQ%2 ^=^'RW%;E[C-F+C[>\6MY*F__Y7'BK*S(I
MY%KMC5Q%I!XQR=0G7]I4UWU:8.QM*RTAZ8 4"<Z;ZIBSH(F*N.GZ9K\H!-#[
M/+,3XZ?-T7RH#VT_O$B>:#]$MXV!K'$CWU3U;D?XH_/@+@^NP^G#^5&D=;.Z
M;F^UO,Q]!)6W?^?Q]-_D[HK)"<%(I:5NN_/@W;L8G=.0-P$4Y[&[;^Q2"T7T
M9J)[M!:O9VWB"CJ:A70;+28^3I%6/<_1SJ0W>-Q1B-]Q4X]5.;F9/A,AP,=-
ME.A=TD&]RSR32>1-L[;2=A3&7O4!4LV98.5HHRC7UW5U [>I,_9^^E'4"225
M)*G58T6ASA2B+JF]7?)#UA8]RTX'Z8@6U'0#:D&&^Q'ZAU0L^()6)] >JE&>
MFSOD!J[CQ[^,%?\>R"'5EEDN('WHN<>?2'MRC$')TOIUUH$8=VG3[DG)D_0=
M!];R]&&I=9R+YOJD^UW D^QPAHRNYDQ.\G8HW([,W/)\2!20@9ZR.:)FU*]:
M B:5%/07*-<^7AN'$.F[6FE+E)D$CP!E5U3"4'":(F2DLY>QDAW)MJ[Q^**8
M&,15G/(X&#HY6A9ER5ABTJ#'^;KO2HA#K==M1U^BW/VCWB](44LA2%99H@28
MJ,FNXM7JB@LL6Z4.>MHTS^_Z81Z S_GX.>-S_GC&YSQM%O/[&,GO3?"=9"1_
M^?09R=5?6-W&13?IHD9'DPN>U*% S[,&4+7GO>&!HH4;GT%]D4K1M.2YGGFA
MG^Q2T.ZB.%\<2VM3N"<"+T76,WZ2?\&D%G$A:#,_J&4UTI#6?ET1_QJCEX-F
M/.NYE2Y:8:15+@^0-)RZC[*\]>7>]%P%8>NDL\^+[0DO-E$/S6R&T+T2\0'_
MTW/' %$%^A:"9D5G;;N53H&NW%3Q3.DZ\F#/D_[T)]TL@D#<B!96BD8$;C_/
MX?LPAV7"(8"AJ9-B5-RS<;\FO6OS&RA,57^C:F[JKD7J]CS93W6RE^%CR.BY
M=3"4/S(QY7D>G^@\\@&I7%00M2I[[G4EEJ0.>&8BT^P&:<;G#*X3CG'HV@0>
M5_84:?!RGA? 1V+C4Y'FO$2>[!*94H;%35T(SYH(GNWW]94*#) Z/24!F>N.
M<$F)DFU7:^$B+KL;!G^4EUU;;LZS_U1GGV044#Y-7;(<VZ>#_19"V#SK8T-6
M@!+8Z"=9,Z,1-$:E3?P<A+T'LYZ):$XK#_U0QK^J")UIF?G:PQ'!;KIL!1H=
M7BU6(SAK0SWEU9#7EZC-#&<[ETR4;9)?^:IJ7YA;GQ1U)NO@MNPX/(]7:[NZ
MWQ.S1K.I]J"/),*8<A@[:INJ>Z@49]^NRFZX_O=8OB$O9;@[7+>X_';7MAMM
M9NJJ=ZTX];#2KBX4+J$^K1*.=*T2S1ASB@L]BZ%_\<\M]_<39[YB9T#)PH4T
MHI_T* /[$!H707CYX[JJ-H(4467K<TWYL35E1PA G1P]D^6!N3.)&S%!%YG=
M&@643$5AH(-;RZ#":+ANNP-S_73EH=Z02 _Q%C/5+9' #"P82+5<PDIJ*^JA
MJTB=H"'^'D+]41\)$^QR2?5(B;;OB?"W[#-F*=_$1+"27OL&HW%@AOU7(D79
M!:5<W*Q@6:8VRLLZF%0"3 H^'6U(?% BT.N9J(%"%?S&PET_2$8DF70D*N6T
M*@)<X,MJIQ#GY5=.4D,&R$'9/^=V!5?_%*!V=/MIS][JE36N/?A;1RA^I^W"
M?D=ORCT+O6V8@:@?=D"3\*8A/HP74$39FXS T 8FEXV/V-S-'B%&!./5];#\
M*(61;M)_VW$@(J=ZT/$S"!-+J\90%H%+I[ GA275 U,D]]6:>?W29]>M<$=F
MFA/Q4;,&P3)[<"%@5A 4C\A]/-H2":^K4 _,0"W8*>G&6AFBU@MF<--HW@)<
M'L64W=\)O/B4(5$G.VX6[]2E?F$"HM06_+GNX==:A6']K/)P8&D,0P_&2V82
M(D_$P/[JI,#2DN[I7]\3-F!/\@MN,+#S.PE"M,(2O9DHHWA*I6@M;D!MO:N"
MTD!NJC68@[IH<+O-SK-?'10_Z(0MWZ:C\.[(PZ8CM]V-=*(-B?;_$+U@8>QO
M0$"O5 >389R8K*_HS/N^.@Q0JE]]\L>"^$L_)3P5;.S\;W\HA(N(3L:*39 \
M62(OLU4Z?=K+:KB-LQ[^Q\<7?_D8S_L_7EY\_'N:L55_7=(CP2C@NP)8)4E+
M5D^PGGWY"_F:EW6;N'$E9K ?6;M2I#H3UD#T!XSL=Q/BN%.V4L<)WA Y./3X
M[3;Z%KQ8*7EA.Q)$"TMK#@Y)NID]!)A[/>T3B O3+8EL71FB(267V(A5&$ E
M56?4T-FH\R#*(!V?&\'$"_GLFAVO^ 9W88YAXU73[G;M[;G=>[&MCXZ&%_1(
M,2INVMOH#C\$S7.J ?"G7?%=M K.A0-^5O/.R1%X*\/XV(N\[;;C=_2&[V)M
M@.5F4B'X>]EORG\OJPR>5\Y3?,-WL7( TF**8$_\F$F/@]1'SON?RT5P7CP?
MT.+QC2M2:A8]W5[96X_W/OGEI?9K0IYZ^HO+Z_"78#GXF<'9_2C\3YXS"O]/
MSPJ%?_:TG[RG76HF>T7)U75]*(7/4!%5;>(:Y[0\*J@W1FOH3-GYL'R*;_A.
M5E73M(3>8+S6Y9W0B4[6RU0++]=%2'(*7@-AKI"0"R(PYTMYJ <DBO=[)BY\
MQFOS01B!Q8=Z#X$#GM==R8",F^94=SHWA\A''F#3?HU1?=? D0]G49CK3C72
MZBJGQS5M\W]>?'_ANM(-;W9> ^__&LCFF[GK#B.37H/G%"GWDGNWJ/W<-"CJ
M'C 4_IO#'E,3&/5HEYWV@9V7R?N_3+@497S'3+],_L?((E)OJCNJS/1MTU2[
M#W3"G[)+]*[2AB3O">YM$RMVA;LY;_.4^F:)E%UU7)ZO9_J4W_!=+30/?B&-
M)Q$Y LS-E/54=J^K)BI^C\X@/NU)."^S=Y+R(=Z_/0M48.4EY)7A$#-AR'HO
M$K- .(+*J]F4UH[%B#<&]L=U>M>?%^/3?,-WL1B)Z$B6BB0;9ZLM"\\3 L?T
M2!,$5T1KZWU-.)GXTWBFAWX&:TCQ8+J*Z!PE^4N3N4F+)JV52Z4X;5EF%DCB
M^+%.-7N.K9VG/?YG*_5+K##J2S"=6^I@IG3!3;L;]Q(:F,,&T.%YY3S)-WS7
ME1#I;%<=9%:B,O==SCWJ#6&G_[R(?NH;OL?KQ3HP9NA:5-&@24:M(Z0[;C4U
MU1]/4MF_U-IY4LMD_@!OB2GOETE(WG=5P5=;=XOY,B*-4XU,78.^IPRE'B.L
MGUVK6GS@G_'YMW+_=S$-VAN0Z(OK9A,7HC 6SV;IE^@D?YXCCP8(1PB]J?IU
M5U]J4TK=KT2_DYJ95E]Q3X'H>&(/Q.GXY7NPWSE[]T=__;HQQX&[9WQ_2Q]2
M@TLQZ7#IYRTNQ9)Y\;:%+CWI=REF#2\9CB-UH(1?H.GE_29G7Q1J_EX/_3+K
M<TV:BAQ5B%L0,K= SP@T2B3KE)1\VTF_%R7TRMWN%^AX?P([XW2?4N A4^$
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M@=-(K9^T(T*+)7(*J*A.8.O4V$0<KGKE.];44<-DL_L]$/8XFL:^"6*N-A
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M=P<KF'PK!<.H3_+=#=E.!!/,Z&-*00*+D:M"A<@C9/&LD"3Z\ ><LP&4!QH
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M.=$85KS^*DIZS2YTA@\R;WA%X%PHL,( A =6]0)]$CA@OC(WPX%[B*0[1%!
M)9>D,=$!DN\%) !TD9*3Y82""-N._7% N#D$6$8_W_=[[B@<VEN(2@KW)*4:
M*<V>9J$:7V<BKE,>9ZF 7M\=.RBK$/V,.B^&UXBRY!!(,,']D-GB(_Y1ZJ>I
M42VM7]Z1AH[:=RJU[H9Q2C5+?'TJCTE*'DN\A;X1/BWU$;0H1% /@C$"[3Z(
M4W_RJ2]3H7-S&B*='(;Q[7W!'SYT":*L+/QK"OCLW-,$UAZU]5"U.X#:<NUT
MU.^C6F7JMO+"D2!M>GC0R&(W@<=R=FN4DA!XK>=82,P:[F[0T&48HD?10+@U
M;YZ0$QB>K O<+69O_>=5Z17]/1VX7?GWA=<EHA6$:3Y(P2F7?U*CY<NETH^O
MYAI(N/3P7QFMR&Q"X31-\P4SHPJ+!ZC!RV"K\']>-5]-_6714I#.6 _]1<;>
M 7+28M,9GW(S?K;GGOI:L$-W36Z=<P>EW'G>VU:][VU#<;XV*ZT]\<12(:+J
MC1^S2YP^JA11OTG]?V058.MI4[M*SN?W7SRF]>/,,8U27A:LI6 BI;RZDKO<
MF(7,:&K3?ECXF(EIDT^Q=)PZ@"#<U=(R:W^" <Z+4\V1-!8*J.:!1@EOB;37
MW<.$7S_T2LHT<JC<G!@+^B"'^ET28L'S/3.LQ$-E 3[:&;><:JOB-)L3$W?O
MNN<#K0<XN5YNX@S<QQMA_5 \?"#P=WL8L.&! (DKFI#13YAC[OSB4WJG#+Q?
M>$3OE/LHAJS6G=;=<YK+2XXH7N%71SE4NW-&]Y077XFIZ_-+J*U]@=:*4.8D
MKQ[_X.:;K'T7N3+ [/J0Z_V\M=- K-ER]?O>^V6-TMZ=[+W"/)5'(IN@^2G&
M@U@;-V[H"P1A@;3LY&?$"<*#FR!F>SYHEAWQ(_,EU,+'H,N86,'\E;QE9OZ.
M)1"2:3TBP&3,2=51I.(QA_0S,TA5%(!Z5J'8XF=^(GR8"'=R1),-$HUS36=N
M'C5<A)C.,^8^8&0?9T#3;F-]@YZCM/A$A]TC.3JZBZ216%[@7D4QO$TWQ54/
M<:@D9=]2WS@UKC,0>##YZ4\8KZ>@XXSQ2 BX+2; 3'M3BZXQY\?@*_&P&* G
MGCBP8^^F^4D3#*LBP6J(O;YW/(/%,VWN',_P_(EY/N1#U.36+(FAQX>E#,".
M#$$E- .!3>X%:6>4I*(#VL RQT2<. CC?C)7I5JWQ/QPJU#H&#$2%5"W20XF
M5,.#F4N:K2>' $7F:#4]-VSH]WFU;'ZGN=?E="&N0@[=HX<+M$<T@.X4K5-G
MN4T;D*BB+*)'644N<@/<K%F31ZM.J8V#%:MY3/TITT3I"(TMR P'U]M@F]OP
M_'EEXH -RE0'O, <:%'9:DP9^$'%+>X:SY<YWB;_)GNXEAR8P*LMF)3 3?M<
MZ$:Y&X42Y79!)/(XG$EP<"Z: R_":7 IG"CX0?%*(P5,LT5/4:!E] C8:O;H
M!?APV@C+%T!D<U3U-EYR56]Y4]6[.L2J)&*A6V!]A]I3<4:E]D28;\&!VU70
MG:#VN%=[YFI-)2V$FI@\QN*(YF^B!:OE*#^CVFPXY589_Y8=P#(YI<6Q?FB
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M L$Y^TX5T8,#,(#3?*$$:HQL(3&2<.#7WPZ*(% PF&!MU=FQ,5)W/_WD",;
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MT]@,27<8CG5QJR'#=\CGM^@3647$XB9L\-P!/B1<O#;-\]+PI:Q/-F-"'$?
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M5$;_4"W(:@@06CHZN.!_Z"_G*?07!+K__@5!$@(< TC/9T, >0M\V0Q#-"%
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M[9UCQ2<2(Y+[C9<$5_35!S0[OR[X+12T$"T1\_B_;^*WM4^&$WM#-Y#&0ST
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M$!_I0GZI7PB%R>]VIYCBED.#_1\!2S+%^X !S;N %@B@ZY?/5H45_EQ:HV,
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M0HD)?S*A\66XZD!K("O,8&K:.L%][;G7E*W;YL/SP826]J,($##BHR@:-8;
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M</]D<X/5O045I4+<_G_-5@,J)",)'>2,\X7MNXA/?/O!KL_'^Q?"]8!C"A.
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M1-+^CY82)B$QHF(;++\-' YRA96NV2I'((W!YV$9 E6!*H 9<,(K[OMTDPP
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M7,'MY'!G7KA?$&A7>N9/@<PMU07B1RST2&CU;[E7\?EI1('QEP&C-_@7=5L
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M%#<2;H_=!DI-KSE_9,>O6,]#T?A\P2O7XJARK>Q/E6\,%JUZ_J7;8K3>,Y3
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MBS3+E.@\PZV=D(ZD)^Z?HQ%I:]K-_'UJ "4C)=5VT84)==\D +<'&E0&I%Q
MU2%I(YK=70IWY?&B7]B=O$[[(GX%(N@CS7FX6^Q#\/7WR4DRT@O)G\GP#J)*
M$$4KT$D0,[%@IR*(65Z;;I*4YPS%#OVR7R,CB6,H/(?:$FH U6=+QKN3>N;G
MYT,4&7/41'\O.3SN&QF:7\!3X9MI,<'-R>3YR X53( DYT*ZGY#([A!5(D&E
M>:IZ385TXU'2'"4::8XZY 9NT-57IHS>ZE3;DSM$WMQR\PQ/S] @V2,,IF1%
M>M3@:LK(S"%5'9'G<J4#O'))477#;@&/N!7\V@@LKX]:[R!9C]'D.^ZP9>N[
M02F/9TK+=OO"$7)H>7JQ&R7)(9V8G-K0YX\3)PZ#I\9"TG7UYZ !@,N[D-,<
MM3['G7UP7&RERQ5ND ._Y2"G/L1)4WBJ/+0Q1B0GW=[#]UP/]]#U=NELSM>B
MUFL2A0=GAWVN^6,%N&47-A-HMRV09/I#>#X3P1<NI'.DURV9"8/G=P=ZT;I[
M)+4#!$W0X&L<&)WHJ@P,,LX'32T@C,4^O1NA\KUE&>SDX#1Z8PYK1G ?-L <
MF$*31P66'2![!79O7IQ':[\?[LAQ?JKO-D7@N.?<G(& *>08DR0IU>XRN^0_
MS3D->)T:'PV?U[$0:<H?DD=[0G\E/!.N,%%FII/DIQ@RR86U1[C Q:%Q"(]
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M$X*T/U&6, L G-5]: 4D7C%7V*QK=1'/ER@Z3Y2H,$F7\W>8-=JM&;DJ?XN
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M#?M2NT>$PI;73B\L.Y5;>(<SK8R.F?#I[N'<]@A><X@I[YF,[KHTI*]*SAD
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MA@W^#ZX6E5U)CFK*.B>/1"!^C*ZYZTM0W3.P8MS]M"Q1^KS<6)YQUV**2KN
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M\Y$K2.4)LG@&86@V#[@FF<BNI 'LBF?XSFC=?IUYF]+\K@$;[2L">&0A4LG
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MN&OJY9;H]&X+Q^[1QR&KCY*<$;.-V%X=^C"2>YC?/)X3_8M>0=BZ/Y]6>28
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MZ/*M]=95AL\O1Y3O6W]:MJCKLYMICWR4!IGW:3S0)&!#PQMQ0FAD JEQ8J@
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M["HW JX![X'O%? VM!J4I2YCW @\:L3I0FZJBO) G'*2E2,15(M5]_%44]8
MP\*5 &X5+,/,*O8D"/+IR;Z^/.=4O@9>Y>V?8<( +@K>9+70J/WI7O/-QVI?
M&-K*YMJWQ'5Z(FR%856BQ E8L-E:(W!97L%$)O"H_65>3&0_B;\A&4!Z(?&?
M*X2$OB=^_N,]?E.%@0";Q-FE!T'H(UWH P0!JR U*)2;&BSH& B=(029A3V<
M-8<T;H+'\X(^?;WX,ZDL'&O\3%6 .3XU%[ .B^$+#1SRB?"(L^DPFL#M3(91
M4<9&GEV;/6\ "G.KHJ*/XN.(JPU7Q4@? BCU8]0])ZBER".8R0=!<VT?[5;
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MXE5W3 X>2[C3RM'6YX _!D8S$53[EBZ)W[6+0"IC[#B$OVYJ+965\,T;L9>
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MH-B0^0V FX$[F/ M*P"V\@C.E9SUGV$&,/0(P .$=PZ8FF:B-C21C5"2C6M
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M&5W&9M!!"K"9D >/3G1XU[[@KU-C;YG8(>%&AB<'[$03!B?B^\E8Y,&2?V
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M0R<#GF*'3>+M\C%-Z&0'1H#1D\JNJX;&LAE4^=NUV;643IXR:6@=W8;QR@S
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M)JJ@S21=PZ8J("<5O,@8;P)G"*D"L(XT3D(SA83)5%$Y=8'IX@0./;'F0 _
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M=#O&*@WQ+]=)T=;:V*>![D@DS; 3"PSL(9!GRH:%F V_<Y$9E8X$&EO$X4:
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M*5SB@;&Q6&T[N9SN+Y'D_DC?TPO(UPZM@IW(IT.KZ^K9;>.YUGW]77[_>!4
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MJ[#<C./]5:I8]>O7<GG\\W=^8L:Q:K1C$F=FK#U>@Q3D&1E_8;:QB%E:7V;
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MRHJS.50R-%M[CV2V3$,/R)4C_0)[==IOT'HU4P*8WMV_KME&32LDTVZPZTN
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M29G(=(HY/+!DA_:1<4%8]J%EVJMK2,NIZ+=Y>W3X\ZS\ZTYUR8A![NW:;\4
M9E'M9.,$3&&^)+SLA6>+]8S,G;AC3W4-J9K3JM'V[E+2+H[*OXZ;6G:U:?EX
MO3B(+A7?9VOI&HR_5.7WTEK.U_U[7O'*,&@M,T$Y:=ST"Y6+@VKA6,ZN%W'*
M6$XFP'0Z43D88EGMC4U5,+C.=7(A98CSED6K0X&&R7CU!(';>T,+-D>Y'&49
MONI:V]W,O79VW]963B%7%>E2,L?[AX8>:2&6+AW\WG)$X2WM=:NGM0'4_X@
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MZF@M5(,[':ISVN80N"^HQ"8Q\705S"=RSY9)!"_862\@[_!_J=X)C[MOQ<,
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MS<_06V&&'H J[K9&$STW3#Q3-TBT7(VVS5)Q  $< <!AJ^A^<- !@\0%Y $
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M:2*E)6*?G82)3H#U2A0DX*=K?A]GB9\!CBEMZ-=L6ZF\9:K-F>Q?S_0M6U'
M\SLB]"M-:JSC+=FZ"*4=,@C$((&@"<H(:Q@C.J#_QCA=%.(.,9NRGFZJ.6CW
MO.&?H''!1W*M]'#2ZA0I6T^9D G8-K=7MR?>Q4>6N$F-A>\AG!3^B69<^BKT
M(1",,,/X&8;9I+3PD=AH$KX5- D[LJ)J4A>F ;P/,+$$S,)O+74<H"!I'"2V
MD$?,8VGT\B-IUM>?%B'[6*HVI@7O/" KS+P516OSBSWA1KPIO2]P\P:XD5W@
MS2Y:KR)W8&C?B:3# BTS*:+;A)>7H(*P'44:.-(.L/_"9]89ZQY(XZ@=Q>1R
M8.=[0Q6"IQ:T!TLHX!88*ZP+G&S@^^FB]^F3[NM;$:TO>%P0FP=HTQ;%'L"0
M&JK=>:J0XY<XU.9##KF66U^]^?+1-+8AUU@B3.Z+1NW-$I%0V$\'J<,8 N=>
MW3@)9F<#<+WO<8A!G,&!^;HCUK#F+ZQ !<'!,J5.D]/@B9<TU%B1-)]1AH^P
M_ZB;?]6I)5P0304/=1DJU9BD6NY",JI.R^3H/5M;HN29KW/O!$87T!9W(@\=
MLZ5-Z$/T/=BAZ3\X5NYBAWU!%5?9 7@/98LER(?@1@_"78EI3KNQ.\0D6+=G
M4YNPAWB8^5#!SC!;$U<M\4' H)P;!%/DH-MOUI=RDK8:>\+7?PE?I.-HE+:<
M$.3Q'>MUD@GUY,,8KNY]("@CW/@M*;QF52FM.$\F.'-7D1:B%1S;O$KX-%E$
M.6!.6?^L5;UHBUM$"@U9JW[7-9-EQXM7FRFV[!@1F$!8TJO?0>5!X'_1 !S!
M[\-12@D6*F',I=53L5]MHJ;<MZ$P6R6-Z4_NO/)EF.86!1V*.K3K$J:6=44$
MS\# @G_M+ J%6D;BEE>UNFLM6%6;.L/<\Z[[NW-]V[S^U8#:RB4]&@Z3\E-L
MQ!\([=#@+EPPZX2M"@:X$]WB3)\+8<L+8 OU!VV.":&X\=I!AY9&5UU9<HW3
M[$SBL_$^Y>=N8C!<U%_+;-L^9>>#/(]YJPFV8QE''N:^UN_Z8899/Q/:8?B"
M,QMOW#3LP'.!P/EL@8.N,3QZV(6\ZF)]*E['F0/483+B#E#'3'0R<.9M..4#
MT&=W;#KND%/[/>!M4:\6D\/.M*GRW,G==T>LFMD8JPZ\+7*2,"S$2U)V",1;
M-/Y<SU0S9XA.;UZC==BG?,WZ!%*\<_/!Z#,"K)Q'9_,WSI?"B5Z__@6&4G4^
M$&%YI8[3@PZ8Q+]MHDAG7:U%DS.^9:4\V^Y$PNDV0 ,XZ@?O'XX$LK*@/M[1
MUF"E3?<F+7JX+:VL8 H*#:*D.QJ6X\B%0ENK+'.H#*^ 2SZ<$9J]WVM^UWZP
M:PG($_'9Z)=.5,SJN.W</N'</EP=G+$F6[#UL%)-$M <5#CE#U'R8!J9:P4O
M7B,4?"$X&=WB3K_/?3S$AX['^>RUEV_*2R^K'ZVDM/,Q;FASGUFYLSQ0L%'3
M$U1,%EC9(O[;RB--TQF(T@FN5W$?"K?S6'Q'L9'#+W21QP%S$%Z]23!X,1X,
M['%,CF?@'6-GQ&T+19>VD.,;.$9GAAV (SM4&(5Y$P:F1QL@PV\+*I"M"./D
M*"%V;"O(^5+SA=M#$,CZV?#B3>XFC#NL*E9JWU##/9SAS7-PJ4&O,!3[L-%^
MM4<-+F,.B/#+T<F.P)L?9N1-=V?-_ Q[HQ"7.:VDH:)\H0&_6!8UM*YE( &1
MG8T4Q.9D-!+XD'=0%L8 T)L/0!_>].X#CN 4[CT)GK21_G9LXSC1C-^R)FTL
MAQS'\=UHFROB )9>H.D^G#TN WX5>NAV=X-; 9S0G#US M'S\?O_MP8-_$X'
MUH+!6CI.MOU\"\#; O$P89YA6R_2QKB"#'UR.1-HV8/ .!$[CSSZE>>Z60#B
M:L&Z/ESBHYC=A;",!D6!81Q_=8H0'A(T,"O$+6 =:Y 0&@!D=63 -@QS)(<F
MJAVKR B5$2ZG;(Z'JN*S(U)F7P>\>+C#RBPY<K.666@ERV;WXK*LTJ3XAMK"
M%<6@V=2$E1.B@/!D[)X=>U@4&OQN+09A#+$D!>'G-AW>*?C^RCJ+5]AMXZ?@
M/7 &&J>X* 6698BX"6E%C.!CB5;C1)AD[RF2N#?W+/UKN7:$P[?3$88!8;(P
M*A+3T<S\94T<;)23N+8D8\Q4\/<Q:A741$?_H,-M]P)3A[8$S-DC8\*:#:#W
M1/0FP^Q]@*$;;&XL8WNZ ZS%60*(QG^C8-W.SYHC(S78E*_C"062@C6+/294
MG$'A(6QYP,_MW]VRF-HJH>XAH7SK@=G5-!AB9AN<U\#UY*MSF+>EM3P"%''G
M\VO+QY>@E*2 K<DJP1UU5]93'1[4:@+%Z5M;>919.57NI%5!'-"VY91:V?WF
MG7.HL&J7177P9@^KS5K?E,L&VS=Z>\]ZFL$H]A?<90!;%?Z(6.@:FGS3 :Z0
M.@7RX^\KX?>5R[=O,&\[V17>P7+6&6R.^%&A7RN9=G/F;JF#GX(*'  '(IL;
M)N"=O (;#IPA0-R!P(NR/.0$V'N  K?PW^!X>.O?=L0MXO#LCG_O6T_7#.BF
M0/VE06ME#LNA-E\V#P*]+:)RI#J0,N\M _I?T$O5YFB9?Q/+:"5Q3SB"@L3O
M!.PPE_4_1\0KS4HT..24&^KBWX3UTS] WPI&#SZ%_.L7K(SZCZ%9SY^(&BI+
MMY@.UUIY\5<3\Q<NK#($ZP'FN3B*SJS?H,F3KM_)8L?<SBJOP]^[&/V>0H5=
MKIAJC 24Y9)LM?K$/@?;-IT$21_*W/QO8&TCZ]<\?-2\YM+)#G5LQQL- ?":
M8%\>\*-[G^[5_G)^>,/G$ 7V^>#Z Q\-[5_?4>>D==N_:3+@IYFPGV;9/QN/
M#!V-_?_X3$Q."9%_[7L^3C?<O46;[_Y:<H!5S$<-5W?L7J1G826U+*RTGNVQ
MT%___H^]$EM!AU-+T>"MLF!2#NQL13 XP@6.V@8Z>*Q:]I044T,LBRSWK!9%
MS^C&]F)3#YJ$740Q^7!+-.HHBFPNC:"#>^N1%<VQ;T'56O(NZ"?9L)_UK*7R
MYDEOEO1BIK5K>18!ZG4;][N!-1470VPPX]P$<.^:?F"/N8KH:X2@CH'FW/<*
M)HZSD2F[IL@J COU#>QIU998?^$6X65SP@ZR[J@ WTB=K7?Q")O:VYS&!4KT
M!^\CO6^(^0/WT9,=][V&C\@^]$IC.W+'T>C;HMJ?->>!X@2Y05=DH'^VM[!_
M?&?=95Y#Z#%5EAF(<]2!.:\0C W900[D><MX"+5=EKCMV5#M.+#6G,G$! JW
MV!;=59#W4QI>]C]2RW<EL)LE8.?#50ZW##=MC[H1=M3-\(Q._?T)1[,:TO],
MIQ@6"KL*D&W_M&(')C/V&+ H(G;4I'54$?)+2D<QH3_L+#MK:DZ\FM.XT&7U
MI?KZ]!Q+%[H'N] $]?6<Z.-M0+>7#%0>0X-7:2^Y1;BSCY>\*M\][KK/XZZ?
MTG^V%A^(Q,YCY-&U6C0^YSJ)T)(@I_;6[4V0P>VV[OHM@_=GCWL6Y_0>^$,2
M? 2<%LS'O4G%S)L@O2W41*?;F(AZL<?_^NRX@3M* %:].3JPU?O8T]%W?7J#
M"_S[8+O[A =U<G^9/KIRF?&':?H07WF=]'_6/.(E\X?.Q?P8J1M_LJR)$,#2
M+!<&GT?I!?PW&*Q9I,=1J?:T&#^7 D?<AW.):G/9YJQ0M&8"+_K,8<@+LOZ^
MQW3Z&W%\^7?('R#9G5=B[_#0\C*$MP8>/TKDE#2S[#/$],F,-'EMCL*MDG!I
M); ?_Z,%NSA^4S#@HT'B?6_+(<\Y*IAZPE,^_9TY.NI*,7XFN/O.?"S.NKQ(
MS)FTBN/V9,9D;EZL)N0 =T4J X<B\3():RM_?U)@]X ;=/HHZ ?/^.1WASDZ
M0DH'_9% ^+SAT8NG#[V8=Y5?KBW%ZI8Q]'DM5^<?<(&<7N;F\!E(_-3E*I^K
MB0HE]*](_%@K)<RE?C<[=?.AG%Y>[%LQOB8O(J&S&*?468W35<K"65^.WR".
MEU/C4J":2#;>Q>LT5ZT99:;_\CE.VKG,RJWG<WKF/SI<$?*SD< YV)^Y%/N7
MAB@!IG3S(J>+[EN0'*=YHQO3$I'P%<E]')LP]T(XUOQ=[\#&0SK]53@Z3A%B
M_.&0UT20#]^%U)E,'S>SMY_D8G(D/??%]G6*?.QN.99-1*UTQS<+5YS#J#KK
MM3DZ5!&F_8$CW*UC0Q4[QA4<3=RB:* [E(UT^T)%&_2KUZ0PP.K<48IO$*2X
M8,X($/#D=R9P0(A"!_O^[Z][]^5AV=.6<FU+'04<%?QJQYB:S<"+UCBF/K5:
M[##[.7%M%ZM;:_L\4\A:P>D9YF@?E0HP&^89?M@X":VT[ LBK";!UL1[ANMG
M2D\<=5416[A&-$3W\QC$IM/I.>1H1RY\+OY@SZ1P,XH),0'<@0G\I\$I7<G^
M+F)!,BLF<Z-P<]$.78-H2JNJ ,?2W:S5CY_OZ:_.T8X?ZX\$]Q.OIS)B3U#"
M9/'B5F-6"S&]?B+$R\/(-8EPY 6NE-U_>BO%]27;=AWPZ2_0!7J$+M"3P+XM
M&L-AE2J]!%]:G5M/@K,GX2#$!HHD-T$V1-\6+XM.V=#U5\#+/P^R@3X2LB'T
MMGA-S=(UC9QWI:\$V1 #[D"[,*Y/LD^QX15=JD_!<MBWZP>NX;[##21Y_O>N
M5:#/ZD CX$7C-I*NJ0)6!JP@6"X$:(R:$H8:D,J:)&,TQ1F$NH=CTN:*"+9E
MHB%:/2:#-ARW 2<D D[#+4%.#?% %.$H9-R4LGPY>*/]7(AU ]M9A#&0[P@9
M$8V@X=6!2!C<#([-&ZJZ".%O?G:WT(ZY*; GP.=J K(Z BP[V9HL:/\3Q_^F
M<&:W8Y+W&/5X04QE<]23^3SS5-!P%8[OX7DYKE^BM@0\IQSP0$\5$+H@>*0Y
M7 @_Q[T">Z4#K@_6/\8#L//B1)0)!GQ^.+XP_M&GG?RO_<>SQIU#D,8*-T;#
ML>"8+VQT.<<2_7WN9KO/Z9^K.:>ZK$Z% F3PK9'![(59 F>O=+ZYA!<>>>O&
M(05BT00WM?E9AW,)T<0S\ 1U:#H@-B28SYB*\D2\'P!2],Q9\=ZCPL%V .?C
M43[F0#HTC&XYR8KK(.37X5">6Y/'W>V7YC OU*8)J,$#D7W1>3<N3CBTT2WF
M-17&R>I5B]K /RG9Q#Y'2YO2KQ7Y9DRII _O:*._7D?;Q<;"4&\+:90:1&J5
M9K)%[]/PYKS9/ONZZ:OW[3P-;LS;Z09]>7)9JL&E0KE<AV<C%VAU"ZP7T3C6
MI%> RE7&XIM OBU*KRDFV2&EI'!,J.>L+6KF,M=Z$JY@B,W%QK]X'-OQT]H\
M.).BZ"!+!N@PM1K488_&V P&&7\P>,&Q+YXI*2_Z%44C@^S8O*KK;XL.6WFG
M1TS9@!!15Q/DA!E[H'0^H1'G8.[>/S._D:57CN0RC!W\</*="D7\P4C8'SI=
MY/_/IHBE,T(9?EN$(\E<,BXU7Y^"%\>_O*S![^7J8,QWW8?QV2W@+!Q*L*U_
M3K:C"<"6!X8\&I&OX:G/BL@##L1Q#_!2!+8U0<;'=.DK0'AVZUTN8W^JCF5A
M:;/[I/6YKQ#K1^7Y,1[8B9_9%@$-% ?$D.D?V)OP@]5I:)7@K^ZE=<80]<][
M15\<+_@#N"7I9$(BXN.V"#PX0R;RAO!MD$L^%+DH*>"Q0P,)01^-X1F8%3@J
M-P2)B5]IPS4N9WL?->=\_3E>^".$Q_E!*-NA)DW@2$AS#C0>B>\<SRYS4W0'
MDDI71E<;_'^3DP%]#P8 L9?@7J #W0/Z8M:MA2/7#7@[(?5T((C [Y?;0#/:
M)7!!S8]9 _R/'!8/83S=0 $(=\,^76+U=-<!?%VSF_P^*ZAK0P$#9N2Z)LK
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M^3SL47&C:/2KP0MT1Y]K%+07$&CF;1$TJFJF/Y"-#'-M'=;7 @)Z[1B@VUR
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M4'WBO_[611'_%+8D44I2. 5AL2Q1V/]@Q K@<8PU#%21$/D51@WXB2G@<&Z
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M/7)-/D%L@U6V@1_D*-XQJUX(6#T'?PLVUY&!8EK&Y/3Q$,ZC)=!D)+&+RG+
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M*-1C+Y)^5Y-)['D^ME5A#O^W9PSD?_\?4$L#!!0    (  -_/5MLOE^CWP(
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MQ;SN]8'<#?2"$KV89-]4HA>:_@%02P,$%     @  W\]6U_()\MY!P  3",
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MR?1RN(PV:%G);=?7N$#;A]>E\A_C25?"/X4V30$DQ4O7*8!'*E1^T!J)NA7
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M_>G^G*A43"P&O+BY2I-19<7TY9M[\FPDKG1Q<U5/ 52H7P9_HM5:+?^GU$9
MG0P2,G[0]$_QGR7PH"$I+OQV=.D,PY5<:1_>O=5@](F_Q-=XUJ/^2;CDU;TF
MZ(G7W)Y8'[+?>;;F56X6\A*MIC=:HLG^4]][Y,ZMD[(4^:[AF$"#S7//V)=Z
M.5!9HG/<[G4(J/,V>E832($IJAH#'\F' X[.\J-E.+3L)-<*+4VD_(8W$G4N
MI,M5O"B:[O6B%1CQ'%WM5[$47S-3<PF1BA<\4'.G.(R)%4"CK='-02>H)8(
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M'6ACA"B#V$'5$59L>,&N2[^+)]#NUM^)X-\+=7H=5#BS>H_1K(%J:9*5:5Q
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M9VCXN#E?\'^Q]>9A35UMVW?4JJT354"J5-.JB(*05AE:!=)6$05IB@QA3AT
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MU<EN!]#>^1G@\JL7^GGS0IE:7R.P058$F8X)WV@Q!P%R2M]P-ROW0HVFH7*
M?PG_G$$:0KK]@4ULC 9+FZP[BC.F!?M[-+29;_Y-L19359U$[((=1$F@D:Q
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M"22,^MWQ==QYVFOAEO&4CI3C#S[C=%D\W!/@LNA7@\CP,!Z/7@^@W*#MNN2
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M/\J[8B#YX1]X%28P T+7*^=3C;#AA(S]Y066%X R>Q>R8Y!%GT"S?N()*:>
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MU\'<L$?UKFC 72.'5DQ"O%HX/Y#,Z6W^I-=>\D%(>O^7->TA576\CVC0GVW
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M)ADMM=IW-'A8D,IAC/EV7?>*,3,Z<*)W\]:K"6;95>K!_P%02P,$%     @
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M27X(KV!T$3R]#&9AO?>R.B;@WB'<D3)7#;WCGE)#6<TG?+%I:;<OZ@6_+/C
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M45AR$!)QF"%60A2Q68##DB9CM -ZAB)#6"TL+XB7PQP4D)P!#4YK_66E)0.
M**1_:!9*WP!^,NOH^=FXM@8U9Y_!C$FPV(<J5,+/I6^U9ND0^#U+^[,7,:@U
M.2X('&;U^7EFA%$&WTAR4$M%$<.2L(_\E72K +JV)#<^:V1EZLS5QD\!4FZ?
M9U/\2B&Z,>;GH,+,3CO:#3ERK3Y.43"RWJCI$9=4LY-@[86WW3.^XEA9<V5/
M94?PQK:'CQ/ZVKJ.AC]V\DYAR)'-"QF6R.OR<?BN:0OC!?&Z?6F/PXN<2+I^
M2O$ ZI1R_J?;2L0/&ST7RX);VS_Q57 T._&&0.G@DQUC+WS/CT []&EIA!=$
MPP"/DZS%&[L&I.1*QT"J/A+4]D!:?#R\@L9VM;(OE="F[^?CK?>LV6^G0QG.
M;:JM@S:==>YORIMDP?%F&Y9>Y]9UOV,=KXY50S68N,".V2*OAB_<K:_C3Q=/
MPFO%LF'MH1UG!N(2ZFP&BDU;+.9GI64LO</:7W.94DD^;Q+V.-6(DN+M^*Z%
M75')[]5]OK+6Z^$R?[>TB +J\HUWQ]V7]Q5&';(_^=X2&[Y[MUT4#%C0G-+<
M-A_RP-GL-V<I=7QY)T3C%]+?WK.8Z+M39%N4-U(07D1\=[+]P./0E >/4W6<
M^D;DJH=G@S2;3@GICVCG),*6FXD#_[*.%#Z"JS=6!=GV+: ?<VBN$5D@=?DM
MR.E-XE3VG3Z^0Q<5'?TYG"?/I(O%!W4X#E\KQCXFZ45>'_G)+]J%D?G((J/B
M1+#O9?,VE?19:0WSX;YFQ)>/F[(^)B7U,J[28HO]FFK/=7D$[BY_:-N]G/?0
MQ5^65&59VBQ87YC+E^'3,6]D:#%+$5!_]VK5W4[>ZR^=EO ^%GGM9Y@U-6LT
MMIA6J359G83NBAPZVOXFGVW(S.CM?'#-T_IRZ..ZJ.!-E[:7IJ? G>O/*7%Y
M'UKU0_?'[IM5YO;=E%2.2W7D%)H7 ]MARQBQR R?@04$IQQ=U1V!VDSKI.^1
M@9QHA\(S\R"?2.H1O&]B,+U >!8]^NCP>(91?'<T?)[MK8;"*S_=QS%"X_>;
MA*4SUP':%2XB*62)G\&.VCM$F(A7$"/ @OS,)',$YN>11K V?"^&,$P-K<N[
M#(\'_3$K8;?@,EYG)5WO6MZS8VW()Q/ E[Q<U="N?#!&3],2_EU$7#I9_LAO
ME%/D04.DW3!:=0B/ BC5@HUF?X.C-#Z_U$7A/T"H[&6G !2G3C;B;=U F%<!
M1EP4;M ^XBXYP;5MOIXIR#J?9C(UGX/@TR>8[:LI&91;G@HX(7MBS.)^+I?R
M6\_BX7)3TH2%67"9+RW<M.',W#. Z;-K\K!4D.!3@6&TCCKW-44TKPG;*_0N
MC[1?K T7=6[SZ/OH>G4-J>\PG_CQ1_I(:TO.\_<EGZB4^B,^%8'ARI1P.#9
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MYH@/:N.B)F, UK-4,?SB0E]\*_G!15UL3I+2%X=KG.1^6=KMH#5Z@L.,*TG
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MS3BI(;<6IN]K) 2?MW.),O_VO6&DWJNHS"\6(:$LN08 M9)A ]7">T 5RN5
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M#08DJATZK3N1!PC5#.F&YG"C;"=@J0:H]7"X<DPJ5K)'V\_D-; N! 4Q4'/
M)0\RGCA)7$GOLK1(EQ/@="=>EK;X$-"B[^[3AP /.WU1EP(TI7$28&& <\X
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MFV\.?^PBRE?FY=ML)\CJAIZR%Q"F;=_!PY;=J^2&:$H/WDV1&BN([?ARKJX
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M1JG?N3@7H..;&1(@F6P_*%N!)"2A@[-'%]9*8UQH)=H(D10(+\"7E]>NAW9
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MFG/@Y57OB=UEI ^,O<*3;M/TE.-="XVG,J_-LN[@#\&C'$8GK>V3$M5$;B.
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MV45UJ1V@#4YCA\ER[2% .+L2G.]@^Y[MK"C]$G'3=M$RDA_+_GSC,(:)E&7
MFW$M0]C1)P)[( ;6[<>;PU9(AK^K*0R#Q> PY9\G$#[@^>KTAHSWN(Q)?-9"
M)V^=^("EO5#O)3KIN^EM9<Q1]351-L$&IYU_:>#0+@/=;J3; NO1G@;C'.'<
MD)HHL\^H8)ZPE3&E"*/DR2_-PNI]==7ROD.\8.[2NU+\^A\LM3H%P$27NF)5
M@")/NRKEP")3OH^<E 6,_RIP IH4V8BUM?H#(U9R3R2XQ[_$2HV1S1ZK7>K_
M"S1_#QKI_5FJ<QW3+BD]^D1Q#_=8=:&'ZF7%+4" C_K[UE-$!$X^O?T2_^^M
M0\OPLMZ?9,Q[T)R3QUI;=7-13_6=X-(/D08('>K'R\,+ZZ0&PKC>[(QFRW6R
MU'[X>#^^104=9ZP>;W4HPW1(_!8SH-?\X#Q6?%7"H@6P&L;L><ND2/6OX$=B
M=)B(P^SJYENN)UYL?!@3&?]B1C3O8&L\XZBM( _U=T']4/N92;V.143N8O'-
M^4O$WNN"RZ-+[S;[5T;NW'()*FV('2-RFQ$$3UH^CJ0;@U$^!^8*?F$BU-_W
M\[8$-6"<T)@.FR:7V G9W\](+B=J2\NTDQJ/:@0.J2^.NU,,O._V<9]G24AB
M&HAHP1-&?_=Y@31D@4VTYF]T6H<V>,NZ@Z>0"!N4WL!YIQB9<>9MW?E&[STH
MR&4@$.%C"V((6AQ R,*K3 N8OBC P>LK02DO]F#W+H-#!Y,92U'O%HES(H34
M!AQ]2GJS]CU7D L;([>^5EFA)W(K3FH':BM1TY<$SA XH-(N(W/1SCT$<5+C
M)5@ +^_\>!39.BPBHA>'S$,$!(8;/O_@#[)TO=$%#EGP1Z2!KP2H^?S%IE.G
MV+_-1L1RL_CGK^#XF Y1)V_UIV:50?LB>S0J7'N+#(^HON89XN:WN)I7A'6U
M:G/PAL6QNEI_8-0SK(; #P?:\9*Y.>"P43F[/T 057GBK'?*:$3"5H85M(:,
MZ..+= KK!_$/%N'H6Z VCQ?RQ#/F!>SX:A=-;F,,QL.L7N!?7_O;4U@K@=%
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M\@!XTT<A;FE\7%]./G<N@D[/YX)0!]M<PZ;3A0S\NA D2VR 8-[ITB0>7,&
MF9POER:VY4CY[\LT_.6X?G;FJ.4.8TB+IF2)OF9D(B&?NODR3P6!)I@:.@L!
MD1?)KKY;(^1-#:?+T^*8TPFK0OM_50_3*5$!T(+ZA>Z80>HS/>!T_[.L9U2Q
MS>R92+R!"L[O!5XZ%\:@9TD]VB1/$K>";SFE6ZRMV)/K\"/F^_F&G!EO&6_V
M>WE1;A.+EF&,9D_MB!FE[+ I@U\U21O/);OI+&9;<;$W,++^'K)J[_!+":2H
M(K '](8S:X]V5[V:NQ:\Y/=DY*X_XLZ3@**< _0MKP? *F6JXZ" D%D-V>[^
M[OR3P.<%3XF0LK-0=)[R:OC/Z%M]R.U*.922(WA')58LZTZGWTFN7YB,K4J%
MAC0NT#H85V0=ZY=1G6Y,9Y'!OCZ+/9 (!@+9GC5=E?E%3H -C(OT"K8BY"_
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M]\CA08I=.^E%F"I;!@^+'EGI7X6%R;<Y=_$9Z"-YSK_E#)3.^?*D;IK0"4M
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MF"KW>ML$SSHFHH4C*L2OGQ(&BR/6UYCK9/PG3./_@R#=R\7$JOO"FOPH]VH
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M4M'0,#!QLC \>,Q(0\,J^.@Q%S<?'Q\]BS!0B$>,DY>/!X4$#0<'!Q\/GX*
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M]$<N< >)J.D/]$AN 61(CDE_][B0O+_[U;LSC6S]TT.-\4B'(K48A1A@CV0
M!RFON]+42-+1D%^%!*0,) DR0A^]^]UBO?/_;K'YH\A[SH7$$N;]')U7SJJ=
M#(!<*>'!+RE3HL#P^4;5^$98T3/V@ZX"LF\ 4.P;@+0^ZW]Z['ZD5S+336#L
MM1ZZ_ZD(.O'!C:L68S> [=V7U[<GG+:-OIWI9H@E-K:AWHJH72O@16YB%AR/
M_SYRYQ(H!FV,8X8U%J206Z/F;+"#W+P(G$ZP$M"G9MA[@X^#S(V2%FB5SN[
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M^6Q !?7>O=.O*>1M%517S$4T(=[I[+6-)FHFU@T,!_QI0?@JSK25ZVAO7,)
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M>N(L-X!/F(-7O_1SLO/6=S&UP:!=A<W#HQL NOYVT3Z='&VNGN$1+;DJ54#
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M0M^4AO/I.AL3,3'HE52:GU<SL&ZI21DY&S8<#S[J@#'V(5BW6M]2@;@Q/1P
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M>78PB&-^EC/)F',#0(8H]6?%>?V.MI@%"I+Q'H#4=J*B-ZDDAI[?QTB$%VX
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MCXA"]_O%:KP"'YD_6G.XKX@NRCWR+87S1<K46[-\==G$&P">I!'F1TL:UQN
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MYKNDHG-=)-H;DMIJ\5![VB_/V#N2*2-Z,!%:!RUO,SFD*.P<P#G6;T#RS3<
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M-WYX@V;=AZVNE<AE9,%R0(6EG-*[V\)Y42P-JUO-+7/DC=V*$).B*EZV=SN
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M8)W'U=!!%O4>4+,("6C$6_YV_2E ^,ZD)L58'E861+.E.F5*W[E1H5*& F[
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MHOT/@3@%F$K^[C.&AH\XN[ ;GU*-0M0RBI9P9=!E6.2&&A77&GJE7_;@"-\
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M:#;HNL;@1/>DOYDGL_5N0RV8^=>78:X0+94Y><Q9H?C]\P@MH[.G%&6TNP5
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MO%&E\/A#$S0D^8FPZY6&T_$"".'\K8AM YWEE=U@[.H!V[%1,1H]Q R?"WR
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MD6--WD:<2(N<APQ^[6XUD]W+^LBHI%$PJ=/WU6\^9!DO35\K/1,VKPF<=J5
M\4JQ2VD-5UDN'W8/OIKFPG';IPXBD,?8EPZ>#K):/',UR1NSOOK5=ER>^"^=
MS%=$2)OZS:)LP^M'^D_F<V%/-N;B\U(,+ BP20ZCK$O315[')9EI1E^OE##O
M0TPXW?H>_AU?[1']J.1@B]0KRX&M4\#U)>R&Z)W>IRTSO"TS6KU*&:!)(M$
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M/-'A&[^R+/<B;2<"=U()<RK30=:#7I"PT\=57=$1DPDUXL^TTQ$R@@PX?PB
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M8$2VV4P\=820ZHQEHO6"13M8K1-!:0@.ULH*<4/2U=Z?K]>@6/> F[BQAX%
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M/C@^R>D,IR"^+C-N@VFSRF]U<XDS/9'5L]J<X'Q[7]5LI4[[8'A^OMT'7X:
MDJ@>1G;!R&X*[+C[Z4CTS@S_I<$:; )8;F^F:))J?J,\1]S!7<X+\C8KLL+C
MW-II\N[=Q>R[7^8A-%(S08BWT[LM6\;S>"\#*P(F2WQFZ.8/YI)07:D'!B$6
M]N8AW03\C">%C%/ I'+K,HZ*L2@?;EJ/\B,KX>^E Y>#E@[A01/D)1FJTZ"1
M'E,6=3J[7@!\]L$K)P(E07L0RAF10(#PM+;5H'O&QXD(I5!'6;2%+,E8]D?
MN4POY2HR#:>S^(+3F;$D4M?&M0D[@;YCLT5R_G30 (U\A;<*F8=+$6V5'G*E
M),):@<UE+5;!_= L<E@;Z_'U-TQ6 .K,%I7.B*E.,<O()P^TI4_88'#H7!R[
MBMLL=S^ML'A%Z0@MU$N!7&.I'O#"39O#X^DA Q\!6#:QK=5=A(RWM3/58_L'
M^:.3O(O*@QQZ8(B87.8<?F>=2[QGP)=.#MTQ;LH-O=J^FAZNUXXIV\-]I%[N
MC!3VZBSN&<:+VQ<7>!<)9A],K!\,>*5C6X/Y#DSD;HE&M#V KB$'LZ\8>Z 5
M*K6E:C7:28KW>YR5D<!Z//7"#5<=%0*"-UI:"TN._@8'+O6NR?3TQW-C;'<F
M"DGB*-1]W^J4"P^T^F</D/TLYVJ3G-[.59C.7UE/;FYDB!Z8;803@;Q:J9K7
M"-PY; <]3.SA<.,V- GGB"U1>J )LNMVS#?]=$%@?D>=J4.S$J2#DP<U=2]B
M*A[H<0'/:Z.+DNTC]>ZZ==>9D!\B+3I36%GZR;/*?1_;#00LK^8'A4V#JH<$
ME&AI/Y14O9N\[?U\=]ZR ^X$EJ^\*@#C5<C7U#C%)#'Y[+^[.#YT:%GX-<A9
M9)RW>FN5"7HSM[WS06AADR.P 5=D77=\2M11!^7VZ^DA+9'5&,&]<,7_8^TM
MH]IJNV[A4"C6 BV%%H<6AQ9*<;?B[L4I4MS='8H%ER+!W9V@+1;< L&A>'%W
M^PB]'WG'^,YXSX_S \B^LF$DY-I[S3776G-*N!H_O:%:6&=UM HVX=A?W/R\
M/+^#LU4PF[3VP:%%^%H5[:T[H<F=A6=2%;-':T>JM]*7"LO&JL:JU\64H]/7
ME^3]U)S7\Z)BN-.0S-P ?9>R?:,?WA/%O6!1%TZ\$]8!S1G4FBK#V@G8E5SK
MUTC$H)7%W,_EF5#T:&?N?F['VNJ@.80;W8\DEX7=N!#"RL52^5'L/0PJBA;]
M8_L8"0H/R"0HJ?BW1Z8@X"IY01L3;0]NLOWB/][T6? ;%-Q%F1;G/W[V_\EX
MQ!^]?=M] W$49*R>3XR\/:YE60D8WLIKJ@#<T"<<E#;<[EP,2Y->_U%3VM;Q
M>KM@W.(76#C'?4M7>M-.2.T5'+E.-Z_OXF=9D2.PXF3'3_?+S&'<293HS:0\
M5GSOC8QV\)?>V]MFZU/I>P"SN@%Y0_Y3E&+VW^9&TFL1JC^JS]*8(!(HM\<*
MK-UQ6%>3I >4)3$ X6YZ*KD?0W@K4R,%,8=V8FIG\T3>_1*:6_+C<B6;HYX]
MZFV_Z;Q+[;FQ:FFT'$MQ$:G#HJL9OY<9XH6\"[L=4;N".4RRLZ-\ZB?WQ$OV
M]Q\G;0?QAGFQFL6$A!?+:E8"\D.91$P,3U\_WK/1'X>SGCZ.:TD$:V*%[5,]
M\;-/FUB[P]);?,E*D:*7>JFC>WME<;J1ZV9#EU-MQ;\WF>)2+#1QHOM"K.P/
MV_JR<-IH-W#U)M0_ ''\O"3?R]!:<J[L_4F"L4*+VSW N<6U#7CX$)_78RH"
MYZ]W]NX!95*;&O2'=&P^T5EF>;]/E$PANC+3F^H+!*.UD2\NPLUG;K"0F#Q[
MTH@UXVA<;,3D\TN))0-P& L\Q*"32H? 6$MR7* <-P41";GP'T_ZPDD/XLQY
MDS%-P:](])!XFD#<R76DHS>1LO21%RFVCF]"'< EHSD_>.:+,E+77MB@U)D+
M:UP$VKKG\I8FA!12GC3,M!F24>&]&JWZA%"H1DO+I\G,WX$=H;D4O\I>O"%A
M76T!9&<?9";)Y_-1A73(4'7+H4YK\<:#$V0NXSJ;&J(A6EXX]P",BV_;DA?>
MME_ITNOEZFU^0?II^7Q.6*-_\[_LSS*-,IF<4<VA#',BW-DPIDPI)*\D+LIN
M(CIS^M!?<V,4YJR0>@_XS:NHR7$C<ZBXO*C 2!G?.B<JSN_V_,0"6$0O:VX:
MW)6TISIC !CZQI26OL4TF:]#EU!O7.2B!L$HGYZ1<#9G8R]AJDGJ_(HL\',+
MTF8F>2:0#.L.[F1\OMEV$#'L;6J-FSM?-\="4[EAG[&%[&9\7.0V>-*8^*NW
MS)@[[6PMA2)5"V%Q4^5&:3EL$7=S0WR,)>7B9O\TDK4:,_"+W4-.ZG!6JOO*
MI,IT\9GQV)):@M%L8+C5_(\.6U]0\%A*2Y*]61C)LX.Z2-+ 70IWCCV*=*^S
M! K[HR:#5%4L?WUMYF6=W#R-F(1[0&,[$.4JP<H?F#_65(Y&+K;4)/*#@)WP
MR,? >F@^4G*%Y9E4[46FIQUL+ >E?Y9)".=N-;(%6HXCM1Q"YZS(9 G31;WP
M.Y(Q$#7?=IJN6]G)4SKG9M9SU.-'W_=@Y@]F&),XX2A=B5MQ>]=-L8>"=G&'
M&^^XHHG&KK'5^/1FH 4VJ$[(<P]X93]3U8R2/]\6QN#(49)?4<EM^ZQ3'^7<
MHLT9;WM8YV2E08;Z%12>L9G8M02-BM+DP;W*+0&T\#Z]Y-=^U@TP]%N.PJR6
MQKI[@!H3J1@K%DE0+.)";*B!"D7KJV_\+R72%W\11AI27R;7)7>GD5TN&?+U
M95]-LAZ3I(C!DNWXSK#&JAVB&[M4--/DF\>PD WN 9Z4O,9CJ4M&_.=CD^1K
M#/< L^11/YF>Y6J'B(1/VK(Y\YNCSXN8T\_\D@-/2VR?*V2<:WF3JS>)6?'5
M6"+N [SB1%&ALTVO]<<9"-;9G*G+[3=/R[KD\!$YRYX#[< KN4YN'@N.R1QZ
M$% P[Z"1(AM++MNTA4/!1K@$/BXE2NZWFF]':C+,@U3"SR/Q2>))576[:UFG
M/FNDV 9R0-KZZ.DO MULG,4&5513!$5P5(,>.SX E&QI,D6 ?]O%"_U+F2LC
M^E]>(4HO'OW$,1YNPG.:(35'> ?FV%O4?._K4@N/)ITY3J55IY#BD>YJ@-%-
M"73LF,&X;. <X[ZO.IV:76=6^HS8^Y?MJ][%IT4:)]![@*7(TXZ%#A/FXUGL
MMG8L)8C&%ANME<K'%D)25K8O^FD2)HI:#L=Q3(5G1D+%FJF8*99,_E]NNT:P
M+SE>96X@P<X*G[$'-.<$))!V/"034 'SC)>? U/Z9,K#RT9G$@W=M7!(=/&D
MO25YD[;4K#3(8V &-7-E,G/LQ:D\A@QNSMMCA0O$HL<B=>Y)^::OG!!4*=9:
M[N*G6UJ:Q*OD+'%:?X0SD:9Q9"WAKHAVVP#Z0KT&<#V!ULI.T!O%Y-C9_O>,
MJ;LRLQ]]O9_';LN_C56!65LOUR5PB X@1Q+>:;EO(*DICU+X&Q;$()S7AV]
M<9K(Q9\K=$<';U8*=&.Y:?EL[^F;,-6V!;U3>KG ?+2[L9\\6..G?$ HO)JV
M0<H 33\%EY4*=?:]9EK#6D*\DB_$]O&C/&H#UW@SEIKW8_-63PJGC.\.W[P[
M%*CDEB*QK;2?^%7D%G!\#S"?ASA3WCAM5_<=29"V,T\"&S:UG7[YDB;B*TW:
MY$E8XU3Y'8B0,RJ]>T+(/Y3Y"T/UB,/<W3QZ24+ ;X7'2!W3Z]929S[W>K.J
M V<J<G".V&6#)%WRCY](/149N55E4;CMKK3X5_'1SR\"\:\+/M&<?7TON6.?
M,"F3N7T>X6S)+<8V6"7Z ^79ENT6_8>=/8HQ1^Y82[+CF])*"TYN391(6%.(
M?J@RLKA!_)O\I$Q05  /ZCC"J.1-6SS)P&OJGO;)3%.6+S$<(>2\;VXS-1(5
MI1/>C[S%MATAU36KF+4Q,'S>TC!(SSD',9G=#&V5HL=K3*9R'9SI=\PC(YVQ
MUVEUSEZ+^]JP4BZYN?"1U30MWH^X"21X%)D(JQM#50BC>/T;=(UL1MA$T53#
M-AOZOLWU5T<X$="<T:AOS_*]4*SX4LUQ8Q]KR[5 K?3N_#DG-:_+=NB.:/&K
M+313HD\-%DM]?LW/3P>-TIY<20D:D\^&?9V7LMY.EW8L_?/!H$Y%X+N3,;;!
MQL9"&2A0GZY;/(HT);G6N( W;C;Q ?R=%^6#3%&15)1S":)6?_1*EFS*@:CF
M]T,HP0'MWP6N2,M+]9;:"&S?<^(-$A7,B5./574LF8ZHYIE^[U(NVY>WQ%'0
M?E;%F>X$'Y  TGX7EF')@<K 1TRI6>RED1X0TLNF_^=S6"%PYYYPB,)_NAYI
MLD+?[6>CT9O]/4ZSTDD8IWDT1]6[4E*K:(57FH&B[FYC(V=(39&#^#D]N7 5
M(,R9,!%$4.KHB'$M@C'<EP)3%H4*R 1:J*7- ELVU"B(>2@ZZ9N6!C[ E_U0
M9SOND9FG9%G ?&*(&8W,VQ:1A^4=N:^P5/ZT-R)F=<3)S&* ;\#?SKPTC4^]
MLD9%&+ R<RNTK1A,!HE(XA0:3$X1PO5&7K\_:LO(X36%6'$IXCWB2+BG;^C_
M0I<+_7O(_2]?_H@^:75Z2G> LQT*KFYVZ;J'K+4C*ACO&!EEOQL@&5\FM\U-
M_E!8$!M34,V+:C%/.D3RW8O"G+X3:C1;<>1D7VSC)#(XPA$QHQL\FBIX *E/
M.=3DA",S>F<M#&&20-329]V=PK "A)Z3XI!AA2VX-Z(*,W7#?\,Y@;_8]H<0
MW+9#X -7RK[LKK@ ;7L2[2KN%M-I!OJ*++3#BHTMLT65\AZ 7AM1[->@*X+C
M&\1GI'5+^[/.RT+?=^YX$0]"?[$ACH9FI,M-J1P](*6]_66:HJDKHCZIK;/R
M^1AO;G,U6DY]2&[D7E,&=;2_O])JE+I]\SW /?<I^ _UPN7XQM0X_]=JXV/5
M,7+JPG#ECG(B+$F%#D-KG%<#K(JX4;VKY$QW'WQ&>B+Q@28P$?YV4>\T[HR9
MC)6%0,C"9<AY!N?W[-KJ4&$*5:>#V-L>/^@,QUHXY+W)[WN R[=46U#Z^03]
M:]N?(C=, BEX.( G=%F12]VT?JB_*-]^-E@TP;EM"C-,#7?(B U\[G*6\:H2
M*>&U(MNFA>67>\ D)?]8#AJ>=B6%3>37NC3?25O2?0+AWADQ%HS*. 41I+G'
ML1,H7A!<&L;4Y_&'"<4CC0N/>AF DRSFFC%V#='?MN(O*]/&9\0QE5BRRVOU
M)W[,NF<*_J'/.3A>'\@_]^Z<9.&[*!W&Z+WN'4G?6SDMV;*PEKC>$!'$SXI*
ME_RY4SLDUL7TDD<N4G>U=LC_:%)[.6>PV0K9-C7Z5&,5P"V&W$* ><#G3DBH
M4O&P!2WL'DV#30#_4ZEF O7?YESB_PZXWQ^%,Y$WUK/Y64F[Q [EQ?].%A"&
M.IFP0)7?_F6+T$1P#%*=\]U1,5A&M&UDER Z;DK"V;<PU2NB$;#0F-"H^$!1
M4Y)/:\ZA>%GY^1?VD?6$%=.]0/B%>HK3(L@;K&O&3EEL$I W%L-EG"SZ5I#B
M-V8.M"6PS"_9-$?]9;?"1' !9\;9^:;81\H/K@&#^-DDXS:8W% -]3"9@"Z\
MW.6X0D ,*F)A9N#8BV13%F->SBLE]B=-OCVGN;;J#[F9=$K(HR?G7\&C)Z8Y
M(Z:<>?"*U)-_0Y ,T?/_E=WB_E\-R?Y+E>?KXUVL"PYLT(G@5\W/$;@E6>%E
M<!0)ET/ANR I_SHRB;-!L9\KK$U+D916WFZ]]X GY".3# S5V2)]=#M;[0HJ
MQ32]T_CU!(Z#!1@L%K:+IG=9Q0";+_4/64@KC&3QFO-FD7%@!3'\%/=G'L<\
M= Q<=:-5^:(Y'AC>\>PYS^X;>^YK&:BN%#XYVLNAA8]8_;&+L(1M19=3#@M]
M$6?+V2#F< 8QM]QE([;#V2U4M!BHTU'VOG5[9!E=733]XJ*.65^X\,Y1PZ:/
M\CV H;O1,UNVLTBB(VDQ11G:F4?N#/@Z)]ZV(K^E5J4Q/_N>4DNF:5W'WH<[
M=*/$X9;/$Z&LK.S)7+CQAKS8@!@G_J9B!T6,IJDU.9M82C^IF\?JK0X[5VT,
M+7ZG&JKD"H?M0LI9L2[U$#O3I7#A M/FE^3W%257/@F&<SRM^$%BR)7+UMSM
MQ[Y47ON#3;=M&IP=6UO7:89NK2EO41L#&PP6AW2\-9)GKH9V<.H;@*)W>P?V
M%^BKIQ&O83/:/+-^@3>#\RC2!AG%55.0W(N8Z?=)!9[3BK:IU!F0PIR-MWV!
MG)3?K"6*O@C30SZ<%GAQ8)=?3%1/VK^(KA<S\+V<3)Z:T=DB\  ^39%F.I;$
M:U.Z.,%=W-QF//.PF:^([K;[)$X4NWA0%)[37OL4N:0/=G4:ORU95YV99&#B
M3#IRA:A@RO>V!@Q=3MZZ&J7BG,N3YX[B2I=6E0M^7VKPINK2A.'=M ^.?>H=
M+QTQO5!E;'N$38_T!AZ'%E9JI/1)R?BJR:9B-3<^P^Y2!(%YDCY6^@)SX!#O
M(*LC]QN?P;/O'IDWFI,@VTG6G@4AQV>\V+2Y-E6NUW7LU"CDY6/YAS(-%>;F
MA'ACW-_F$^+T2!O=@%RQPBF47W_O%DX(>IHZXB4LK+\)O[T'+"!&RL9%;34Z
M0"]?ZFKT0/9VX^4LKB9I#7(6GTT+25A;/UNA">\I]G$+U[.7'C/PEV@.>M9O
MDI0V!:) X7EU#N05R 8)7S7CGK);> @"FIN 1^XFGS792H9PCC!=J#<UZ7F>
M/$TSCAC9P&K&W0;6]F]J? #EEIHA[[Z66=!! T0?I2OLT--)Y >W!^HG2S,J
M-2QY>8^E\_@N_3XSMK0LG-*6KCO4%1B8WJ0#39\6N5GELL+*"Z;[HS[<E"<9
M7\2E:W1/[.RP+%8.YGVZS:R_"56S_</%R(M68$6=QE![7J]/R6^\AC8L9T9)
MI6PBV)6B,1GR?I?EDJJFN39&AT\ECN2W$[_&C.^JB:!>J]X.7VV[.8%J+&G@
MYTJI%VF-3(8;F+S58TTIEMVP3W:4%D=<C@\Q[RV5D6HJ.=*H?BA-Z7/X'%07
M7$0P*QI>_5X&/I)%R/\UN"&>:?]/53PC\]]1GD[@<<@#X/4'YY0P%=U:D4[3
MMG$58<C-2^75U!@I@5C6#$,/X![ :^9U,O43_2F#*^ZZE*KG>Y90/%G.8=Q.
MV:4UQM30:=AI37VX&&(QTW;-!C$OAIV-=KQ># F6HKF;C7MU:-U;SFD"945D
MC!'_D]QMC7>:8-G35@MOT(1:'9UYQX][P'"N -]YK98L;9N+QL,K5>X:?W1.
M5OJG>O_D+S[)_*LQ)EE@T.]MXW!3Q.1H=4[U\,V(]*C+$'_S=A&6J_@&&Z#)
MFQ*KE18?$:[##5(>IW#M7CRQ_Y1^:>@=7"YK)F901FZ#3^@MJ=1D8W#,N/'E
MW(MJ]&0[H;ZY-8+(&U':YV18R+-+)1C"13BX*N50@7@N'?-NHXV4E3[SJ#I[
M1I/4@3V7YH_Z]SDN]/4;H^4OS?RY3?3W@)S#&C_.RT2.U8<TND.'H7*BI%1A
MSK-(YG+-_=7=*._33W$L8.CAN-6-R4KA_(6J;/FR)_EG:ZJM-9[%R_6RE":2
M &"GHJD.[>AIXM&'LFSU>\!&BKAO$\@G=D2QD3QZ;A*)-/Z7ZNFFT)*FZ?N%
M6W-V^<F34H8_@@7:D.?!^3_>%?(@SD4JR)O>O1]CE5HR-:6)CQ0*CP"A[<AE
MYML>51NO4Z\-\6X^W(32S7ZU'H(B\N=JJX=;5;I7(T:J5I]\8G>?*"7OU)"M
MZW*X[HH1G$ J$'\L VNCD+/\0K)-O0?4"BQ@#2#S%K.K'F+&9U5H7C=D1YW(
M,0GR<F/SBBA6'.:%%<R%N>SA&_&^3$/@>05UKN6.$$S)27UB ]YR(Y VX$7W
M=FL^6UPFKK[H7IYQ19E2LQH2Q=H[<JOCFG0V=[<N^!D[BVTYRXMZ^@!=0U%H
M6-Z?.YU%(X.3\;)Y";ZA>S,K&AI:&.FY2:1&#H'3B69GM#=1K?861E_QE/A]
MM.O?OO!R+&;(-L@VI64=; \S&B*>M_.R<*3 S(L?L=-JB;XQ(%E.\<%:<#H;
M,G^R M' :,+5C$\34Q6+\+EQ5BW[43AE=H"_PV 0CZ(-+ 6*;R!=$1@VO'D$
M4!/8;Q]9$P <.2&%P'55$6C_0Z8 1FIM1O4(T@%4&(9=S$(N0_1": E6S["&
MJI*YWM+'8**RYF?P]7>3M/TV_^A?$X6A!26TRO A =^)5L>,_/$_'^J_5,+W
M(8DK[=GVU3H#EY2(Z]?;MDW=\F(8H!XS%]6JR++3F%]ES9%6=]IEE_$C;G\A
M9?KC@I/;ZIT>XYXL'$]H#VNA$4M@$QN&%>Z2?E00P16%NV)U$<$KT>$C3_X^
M?OL O.3_XYM%9IH7-T8 D*3)2OJ[*&G)E2+X-IE9]+&#$5?H;P$[ %N39.+I
M[DAM9<(2D&WE<KF$V9+G^7KU:0/!BAB(YM<W;ILW,5Y?%90L48@I"P=K$LV7
M#%QM[3_UW#J)BXE!W!C4:\*N12O&!Q=_M#DH:KDF_5SQC53T1D_P,-/!]J-W
M-/XVWR#*'+E@:$PJ.5EY<!M84SDD+$6W\>-)Q1XO+SWKF\)I=ISPJGJWLV('
MQ2UQB]_3@7Y"3?6,^61']-_Z90F4I&7FQC)G!ZJLIJ^>&[.&F-NR!Y^&Y8#&
MG.L2OW4#/PFT'Z?^=F0U4)N068]^]Z7+SLC#ZM)U*8C)?\>T7?;GBK-194K.
MUF2PKE1QH;VQ8SK#)PBBV0L7:F+SVJ$Q!$3R_?+R?-QN71=5*6):H]#U=?72
M>\!$=]F7B 'F;N81&+Q0K:8P>ZF(#UZ0O,;FWLA5X30S_AZNT2SJ$JJN5Z$:
M) 84O!'\/DP^5K PZ%RT79HOR#S;0;IHT\55\+6G9XMN(P1;G>541&@'?.V3
M>D07#QW.O@@L!\VOUZ00AHMKXDF[8^:%1LS1%LS*#-(3XTUKU82YVQTZ =7M
MI\X@+?;0[42I,M:MGD&]-B=6?;%YB/1*J:6V>1$LMJ7D57-QO5G<D)UK-Q:L
MZNV!1\R?)9T]H]CK0BK^,*BE]&REO.3^#+%S7P?WA542*\;\G*I3E=:04 :$
M&K&5^]:<7A*FW&%I:8_D]WN_+V[5D7?(31E$79V\+91 X\_)T9XG<=U1:\K)
MIXWIHAA: /Y.=LAP.6&U2^5+<0]0U> %_]PHO%+QY.]\4\_5TOE)4WJ4:JX@
M(E*%&E8\-3NE)6=6W5O8N[;?+MDGWL,K6,@RZ2ZC*1]D&,6SH)M(1O2<ECI6
M<?4R>GQ%0DAD=)DJ6?5UPAOL]O2C,1IGQ'0;3WLAN0_Y(:_GTV9F5O@T.*D)
ME:B!:69E@6Z-VFU35J5EV,K;E4QM%*"+(81"Z_1=$HJJ",Z7KC],[H[64)1F
M6:#,-A'S$5</6UXCV[<4[Z4L"@ZZN0HV'(=GK53 ,3D31E8BREB,SQ,F:6J<
M(WMI<A9 #;S#@W !YQX0E=-VVGD/^",E0O(_CFSU^9AG?GJCK _LO[@'] P6
M/J1H ^E7+TL.;_Z6H6OYKRYCX8P#B#_HOPB',!$<%?S'J0KTQX'FAX2=*105
MZYAQ4RYD-4A[M%(7@C-BWX_^"4N6CJ!UC=HR9+VEL8&_-:GB'N"1OJ& D3TW
M1B//V9NA!PI0;D\.ZI*ULEX@!]<'[2V(4P%*DDYV[!=^&'S%3#?Y\)64YLHM
M=G9;]8D5!<D\!N(^)A:O62F)7_A&OU60U(55NRA'PCJ+=\L+(T1@JL%A\7"^
MIL2:3R9Y,+<R (O77:4TW^L@^\/MTE@B/H]=QV1F;C]V2TG3#V>"IZ5=4'&*
MY/G5[B5")!1$X/A%#3U%E?EG3#*\.2\MD/TFL#;'SK;F24>3O"Q. 1Y*F<F:
MSVW)=93,5VN'D>8?MPL[QL1_W#F^-0:=25]&[W7;SNGG]^KA %!WMV77>I:4
M,>>9A2,Z\RD,VX)+7XN:? /7#_$IZ_D?/:F-?=G]4M1[AM>;RVYUIQNV'7,S
M)NK20]BF(!3A.R0]J(T^S\@WB@3-DCI/M"%&YD)0S8!F!/W4$"42X@+!G7E4
MZPV#VG\[J&3'/<=;TZQX>$=I$CB3XC6#%1V[M?/ ]*X+I?V3*59QGS1=.X<>
MXL,MK%SU#4IAFWE9,Z&NU;EF=$Y]])S11,LL,90DOEE7AAN/81H#R))T_<%N
MC=I+"99))5?72T.]CN@]>N75U8,<AV=='#%=P65\^QI:!5YCAJ\37LS(48PR
M#20-DU=TJ6F_'MZI4N?Z1LL$0C%(EQPAI?G]7/X9+J1/KO2UX"Z5D<:%51]L
M51RJI974NA3M?TIT=@_@*);(U1"Q=622#HM("4(Y",><<+#%>W8Q%ADM"["X
M![BG*A_%[W[3XP\H,0S([K>#]9^K_)";##<HM7[W?84.3.FUYZTA__OYRSC^
M#JDA._3C?3&:?$Z)9\G,8K(U2LR*Z ^03-#$$4=!X.G#%]8_A4F_5 S OV:'
MGW(0P">*_?Y22G#9EYQ'27" RJXJRV'*5!OIJEG#KNI).]_L2PK;U#O1N+M7
MDI(3KXRS,+D.][\0P.K(A(F;_*D+^.6$)4K,BY&^X7UA"6Y,7<G<,8_]YBIA
M[-$&+J-33G$V+@SKIK>#8JM]PMA520K"QS4VEXA3H7!'+QFMD?%#)97<LB3"
M6:$N9M#4VETJNHIRU>C2$17LTJP%__IE/0"3I9:F'HUHO =HF;T\-]/T(U 4
M1')7%MZ;2*H<?WC1/@A_VR'_=D4"_E9?$>"HDXPDK7CH9/'R/3OI >DM->N?
MZ)M.A.&QYGN ;'V2ASKH=Q=9P&YGBNSB*9+C)BQ_-\\2Q7#TAVWV[+;NFV^U
MS9=9A#;92-X%PT)8-O3"RTZ^N;,7)O,S,V)(%2<F*RH\C9@9GF;:? L.%Y4\
M=U*7_ Q4CMQR>ZC;T'+<[$,VM&\'J<7/Y>CK^$04(?OY7]5KKVNL\:__9"\W
M++5>V"0>"\7T@6]7R+X]O*_LPBO5_8 33S92K&DYW-1W7]O.08I[USM<*[ST
MC,I0J_([_ _-+WNH\0>^\!]/D?@89PPR__)B!&H^TZ9;D6L*77/>^Q9L]CSA
M:Z_%R5GQM738=<&*0YKBS'D70>!=?=Z"&:%'&QV''G;130 )WN&(PTDA*WZ,
M-<X771=O\?&'O09SS=!TU;OQP0+? YYL;VN\[K?]+?=*6\(Q=] ];[#Z^8>!
M@*^\LA/70_QT?W8\S'-U=80MORYMUW3O]%+&^(^ ,ELB#+,S2_*;/K:^,QW=
M G%!/Q#G/-%EMQW.$??$RG6CS ]VL'QE,*NA*;)F[+#,HC1\+8"EI4:Z'&8>
M=!&;VQ/5'$6= CZ+K?]8]LD-T[P6EI%@^6Y]!IERT8J3<\EW5S6Q\?/,FD:J
M3#=X"6D").7YVE/#"9)T5E<IB_D&*#@LM^I)_^;7L/6;SFF#BCK0&$HW60P3
M"=,S;]25,KD5F8-O309+4F]JQQV>];*^#.=2+\3H)RD1Y*='3V^W]+8_Q"W?
MJYFVS(K%,_:-Q0L,5GJ I;3N79)S$5HQ_=*17=[8Y>E*^F>P!9T>+3_D/ZY+
MOL3*!/N_#Q;"GL[(O$XQBV5P:A3P 7YTA>3:<'T?OR%< ==Z5P[:Y\_MSI&%
MI!/J/QL6G&AQ5U/*N5B?U!A?J:J#EB\;#^\;!="5X8 R@5SZ9>BC[W)/JCEY
M2<6@1A>YA9_/Y)N97#7U7>(*!I! 3,#FR7P1:XQ4*:07$#S\=M$,QG+!TW*F
MYN:&@_K.L$'9K;YU<]HSCY'/7VXJ=O=])UK,1VM:9#]H_&+(#/HR4=W9AP@4
MWY'+Y3 1,6\RLR/%A=PH+FY<;ZIXO8V\J!_UXK]BI=OO0OT&/A@!HH+4^-M#
MO]R>G!3=\=6#K!&Z<&QZCNR/BF*\8>5F79!EEGQZ#H]!.2P7?F%_$1'0$.V"
MUIYS"-X!!*RQ=H=G50L[#</Y=J34.Q/NLJ8%XG(L%QM3L_J!:J.<-E^!,F ^
M?$<ZJR6R[*F]1Q;#RB<+FQ+=CVXT+K6X8Y%C72(?'81C=U@PQU_:\Y%L?(SP
M&4B/O&/>XS*"SXJ_)' TM52*B$_OO& .;W@ D[?K*<U18D;C,0)^E\F7B/J>
M6[=[ +G6W7+)K,NFVOM3Y)"XU!CF.S>87>"@Z43EE+E&N[I(+:;6%6E^6XNM
M#+GXNKJLQ#W@5+F>'<MN-H<R<D-^!;SJI@+U\^.LQ M1<1+T<>&IR'F/Y["J
M>IH0H#J=W_!4$T@(O-BC1WTA%<4$Q;5)FXZ7M$+3LGK(S%5^P+6$ "Q025,,
M>;1_"PS]_[6:_J55$6@>%N$<HPPEG.67#]@4=\TU,\D 0&5H<UC @L5]:]S$
M=!\X\,B[ASOFKMPG6@$<?VCMA.R\#&2Z%Q,K]V7>@NLZ3:)7.HN)VO8CQL.L
MK2J7]$+YS^718Q$Y(&OBFB@ Q-/\O=B!3O)]J]7D?,PT2W.G29ILUS.2I)-B
MGZ-G]MO22&S0*X6]8&8"%:_5L*:#06PZ<9!R)7+D[1PTF/PYG[6&P)>;9G9H
ML@;Z3KCFK-BY91:I>!<W_SS>E5)5<*:9O- Q9$4T8#X.*EMW[::U2]CMCB7M
MIA(UFTU2LX&8B/B'-DT<8E6K2MC\/;"TD>_$[R5UV2]A833/7211.6V_'+JI
MG]U;@DW6'-2P,#*9'::,P!3;(/:H>P A#?5Q4:6IC:;NL$,5<]^L"\5+*$F\
M#2Z>XA?V@DV!(1NGU7/<#_1_%%-"*VKFE (926H5X],&2L;P9%B2F9.%(1JF
MLWKFQ:_A?+7ZAUZ8YL/G0*0@@([!&@$88WW4/K6%$]=P?4"%>\ K">_MD+^"
MZS3>RZ;_S>C:P*TDV?^O&-U_AG+T'_*RSYC_,MIX#,-Z_K&P1#)YR%A>?9U[
M[/?1U"N:06-:FN+>9%$&V=&Y[]C\P2?Y=N[Z95J;;YQ,=$0LL\$HI/T+!<4Q
MS"-NXV.EZ$4'1I)QFY(3+W[G^.7>?84B VUP6W7/(G%#2LT27\P+6UJO?=9T
M,HRE0P&<(I=,EV6;47'%136;UV.6='I97BC91^P$[QCUVTM;#:O.GN9>YW-R
M7,$4+R)E*,I!; _ PVWE$KI[VL)G[HN6Z#^RI^,R7,K=J=.G'2'WPX6#Y"3#
M8O7A0RF5;X%]8+D,9^8P)A8@BUX$GQ=FMM8D3\WE]*]AEC;HV0-K=-[NY$Y5
MH/;@(P2[:>< T)" IRG6Y:;U[,C$OU^-5C4?IFL$>DB8-39-5;'C;2!>@T]S
M5J,5LMDL4HN>Y,J5T@">('R-W)MD-5K&L]QH\MN3KK+X.<<=?LXO"6T>3]"D
M;*@&O2@=;SJ<)(Z$!5*T*^=%*/B!E[PE1<@YE]HTAIIA%B6$O2"58WYP@_%D
M)M\I:VNQ@:/96!==H+2597]@[\_>0?I.2>P=K5YJGZ0SG!6H_W"M 639\F-/
M097GS6X_(\<VT%Q5(H9#.A\]N]"*2609.R#JQL]IJ7I;%,"!M &K4NLB$,;(
M<H3<G"PDW1PK:IK/.)P+30Y=SN8/P-^=QRCC=']EGITFDN^N+ 7P(^"TZ]O"
MMJJ&!TCY".NCXYK+_MSUA*=2IU.C8ZC6OKK*<;TI1NH++&\WSF566<N9[I%+
MY>@8+$&A0D+-V*8+<]"XXU06J&^9,U2S]?9G!:(/2AD7+"VAULB;;8J23^]/
M2B)UN9YGD6O4/%O\X!.U5IPKAUS$2;-(G?A8^^4/;&C-]?%XP)Q/4?P:];8%
M&IKJN0/5^3&7,[/=F)B8G! -SFBF\/)*&^/T1%O>3\P"/V<P=^K-UBD/"72V
MV>2G^Q1TO5;G_=LW,OBZ:W(.J9)BX[#W9F\D^\3()UG*-'-&BV7S@*[$M/.T
M/UJ>_DL<T.>QA/G\WX]"_Y4JP1OC@/]0F0^X[=<#;BL2\#(1^S@(-F5;->89
MP2KEUG*V_CHFN=8,68N@06K%>4T-31; FN\^XN4L2Q$<]24U26,&^0:/.^/&
MK68X*.9M#0N>$;!/EVBODW)"COFR*BE#J!0@K//S#):I-+TKOJ=E%"MDY9*K
M$:+#BKF4Q,]_Z+E<$RD!2#M@M:N"9+](<XU[+492"SZ<X)=".;:4UB9>*HC@
M?A,NA+.73_YBRO_PFN@V&4_29) ?UE9LUIR*W1SROG_HV-=T4&]KJ\":+)>4
M#N*);1HG<!YPH4[7&I,2G,]C$7FB]>,S6L,]X/6O3=D8FIRGU"(_Y ZB""_'
MHFM^KX;*(Q#&OFTA"*JIL.<.#2U*P7M7?J[F>ZFLL'FFP'=Q<OW9>O\]&>DP
M+IL 45&Z'6>N(O-1-:F^2V:II.*(X=F!MBAY0WVH#?]&%O*=PU2)Q0=#;,W-
ML\KHVREE;[I4*X5CRWN S]ASVBTY6(R&?X*/?N"B1]V?8V^/#/YRG7@:ZH*9
MP4U8$MK0B)VGO601\U'E_)8,=45C_*(,=#W%H=&S>( _K%?IEGDLYX60$=;J
MYW#>%^@N>CGQO09S8X E<<\<T EK@>MS$%Z9P4L9'"6:W7=!=XY$JJJOJ] L
M+2SUO\[KJ]SI1GRA;D.<-@7+AA)NB7";L)V\ \&&MM>::H-TG</9CV]H#\6(
M)%:[<!3$_H2^60!)T >I#!>%FA"*&9QF&U([]:S[X8]0C':]BY3'.LX2_QJ'
MP*(@ ;C#SK@+!M8LW2[Y\#>ZC;V:%B,)4+1]2H]6$S##5L1X<+*M(/;\!=CD
MPRCQ584 ER>=#K+@>XF3'#U13!>2H)2+@-R]"GB@1BU"P& 92[;60/X !QS1
M_RFY/H4_G>?#\"6\\A[ 5W,=YLTDP]9I0$VZD5R%]JNG9 X83V)H\-%PJ9#+
MKC;;T0+/$#VC0.7LA9W;<Y5NJ<)A&I:3]UAQOS$&W#'-LT9KL.72', H6157
M<)7_;!/=CZ U5/[YKZ?$J&49@,+VPS]/OVK4?W;\^K%H;DQ$6U!H\\B+=$ M
M#8CA1E7TR^'2]>1.OWF[H*C#3-3(/,?_ 4C0EQQU_TO.6_D_VC?P.FNL# M
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MQ$J)BMKAKT7.F/!+SFP?2W*Y%HEI0;R!'.].Z#NN-FZ'(NZ\8"YR/<="GN>
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M"JH)@N^0%7[]L97E[;):"='W4@3DZ-O^0IK@WPU#;F&3LB6=<6\G=CX9EGZ
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M"C-.41LCRHWO^[1B=OG9^\5P>>Z'\40"_\W!,_5LD^;YU6XQG?2^1AQ"'%I
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MVSSBE9+KGR:!\UQ2QD.B6Q/B;HU90:N4#UG &:;1ET)8/=X@DVO>JL&S;'-
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M\5$I+K&P*CNIC&_8\A(D@75 LZ/SILJQ-//!/67#A95W1N;C.1GXU0V3.VG
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MUKQD/()_)8PLFQK?9U!G442#+537W!:7?SF.,HK2;ORM;]_(V)N0\D=O=_P
M]]-7T&=KMIW;J^.="I]D5BCS+:(2&MX1#F]T8OQF-5<?+G.P2]QI=:E*ET9B
M&/XIY!IP:^PI<_K[?GC9N7(NFRL59GB@XT5"9K >?Q1G<F(+[9:B[G#_:=X&
MD+#0_\?K"/O8MY)[9KE\FW(E^Q*ICFX139]*&?C;ZYG6% M-3W=Z"KGI&X.D
M)'IE\!(9<U0]<J?7E;*99WO:P6&+&L.D<D-/ZZUJ/UH/'+T5EBPT.575K1L-
M:?(0-2)KM:*%DMHI9AJ==FO*?B4<99QC%;GZ1K-3MMCH($)5*<_2ND_^4L6^
M 4ZWRM>GJ#V4=#C=WN\O0%&HP^$AOG@7WB/667YGJ]$^>IRZ9\?"OE5[<%/;
M)GZ!/L(1FWTZ7'5=]W88:V7S?5GAK0&) !I/;QK;L#,XL?NW,:-NK:CV3+&'
MB^36?!K T=+L-[7Y7[EM(XX5F,"AUP"BTUA/PA7&%'%'CX-O23Z>=XZ*XF<F
M=;26(S!9DTC#CI RAT#IJJH?O7IW?ZA,T]WP0UGXKHG9KJ>\C8QF+CUD+/-.
M?[B3T6EQVX,UZ;L^Z%@SW;?<K.!THU4.";'-@ZGQ+^G8ZG="'(R F9!F0ONE
M"9SPQ?5K *"HO%7V&D!X3T36$PEL%KC9OVXH" ?G*K#@DVNU&)!,7P.^*S@L
MXIAR(KH0*[O:&\76*KT]._26S,8AYQ' 0E>?OLMGMR<5A)$B+DM]Q$-L1&-(
MCB224N@K]%; :!KQP^R?/7F&Z=N&9(4# :!]PF/9O:<?B$/KJ#*<3L [E0FY
M!?"@IY4A/2\Z^H-U3KVWMRQ^[,(WI2[9+9QQVZA=YFK1D;SQ0(NX[::9>6JL
M3%$4@ ,SCJYWL88<OB!?.E?)9N(:^=&AY&>4)R% Z8 0&MWJM,A'(_!*F'=<
M/[*!: O8!%=NUM<,P'M**0^7^+8\K\#-;8']DB"_UT 1IQ"H7;T>-3&% \Z
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MA/1C?$GGFKP9M/_Y!/209Z3=P*]X3I0/\6_H96W>@QKKA!ZB;\)?RKPJ_![
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MKXY@VG8G>@&=4P,$.;0[W647AR\OIJ)7K@$FA]JVYIIC%)!FS4"Q]=@C6);
MJ'D'+QO68%24<\DTQ8E_FL_A?2QZ^*UHVRYR2L=LS\!@YW$O\QXL]&(:;;Y>
MP:&Z::<ZHH.4=[FM:#XKA>/K<;SU(>Q</I"H8 6!<WQPJ<U\C\S\/7I+S5+L
M<81Z0I1,3WS'IZ12"?,.?J)@M:2:?%(WS]%$Z.#C2*P+L.0A]1%69RNMG<!
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M!JR77:V&GNF2C=L5W/F5-#)[6M\VVO2@7_]\N9^_H[US=47)+?)JXTQD%M<
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M\0?3-OW!2'DD#.<UCM$Q<GKS46"SU+A"*-,-(,9RONJ\^Z@O2R]6L]*OI;0
MVKI;<T;:;/M] R$_6;3L7=ZY&>$L2@#Y9M].HBO4/='U9:3AC.\T[]S+U\BD
MB(\R+O&##D_* C\J#7,'RXVI!/"G#FM2K3&;XTG;^%QH,EO&#+AFZ12[M,:?
M32IK?3WN8=CLJ'DIY"P#5NR3'W'Z7/&)!^[E4N9/^^/>LND1:?X-X-YH)-$$
M0<(N]?.#J*W3TC\:+)V.A5Q:UP/R_N&=(R9.?#]V3HX+!1.F].(?6CAIJ_!W
M7(CA#%72G%<F (TD:Z!Z$H^E?C=$R;K8.N9ILB;(WI]C. :R12]<O3Z@M'+
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M\L=B3#\0V (^;) 7%(G26S> 5,1F)7%PIS?1,DO4D,SCWU0W (^4IC&]O!M
M^Q9-.VV'%B&+HX>;=4''(Z2N/PKW2@\?C;9VJ;&^KN3LQ\H3>2>^?+R:Z?84
MSB4HT/[0Z:48U?[E)KO8795$9]*U.?+CA(;'S5,?LBP02DN:+(,R%Y^$P0#7
MN9^T5$I+K!82Y@QSQL&[;PKLSM1?^+12D3YO<)G?:RE?J,,9X>93GYU>>A?A
M9?$M'GBU@F7*OM?S<<#DXX=7Z37$[4QA?#IW5_BQ'$0ICHG^O&UD4'>\8$OF
M"K&&*XJDU&=^HYP^["-A$Y)PX&J:&KMJ?@O^2([E2GAG@G_FU'NK(/J@<&<X
M=LS6_L7<1_/?9-?1<Z[RBXU5"S,BU)R]+)JA+MX%6L(3=7S'PGD+OP^BU!97
M17)MOT8R4QF!!1X?6DO0?+]R-Z']E6D*5N&6&R%1QB) +6>8GZ]&8>GX78M7
M$5SO'19("MKK22P//!?NG?:X' G(%A2EF$S@M_KNZHKMCC!IISP&5K_(S0)X
M6EE1]?*R-'PQ.DC4D&5E"#D53;)\X,&[);:V]VX$^G"#GBJ?,$=Z ?Q,VI#%
M*((R+^Q7FA5?0LZUAGZ;8D1"7Z&@R+'CN$D&46^:U2-J+HUNLXVR$M36_5QP
MIE_I96[ I,K$=WK)_H(VLY"A>')"<KDK*::*5KJL9M&?Y_T9;DWY3,;;7(E>
MW$]5/A1&;4DMK7LSUWXCV_36+?E6"D]5@6J\Z;ZW<ZI^K<$\T7$%U7U"+/!J
M0[Y.^"ZS?K#Z!RWY-TH-/8J/::$P$60BH<@.FXD&)0KZ\XH<J7I$6Q-X/K@L
M#S/X/IJ?VK(TF-4/-_WH0"A:" I1:-G0'])-JGA;*VRID1.3I>NGZI2KF:X;
M;7$'M4Q3%;8T:LIE/*0-\B8I_DB<ISLECN7 4'=@@"O$3-,KVF!H4'3IL"^2
MCP$C*M=M\X81<=#F[#*(I!1Z:(4T4D :N1MANP>+CJ[E!_DY5/[4PS< 1RV"
M_.N^1WOW>:*\Z1)*JN,^[%R-7W&)A;'^-O?+W(<C-3T5)[&N>1">!5Z:[<^4
M3JVV"&AE*OJ/O@YMI\LLA?&-I][M>K1]UQWQY]?2A5I+;<BW+GM[<P$3A]8=
M<M3/NCOM:"/\C_"2QW?@AI;S>= KX6_=? Q1-9G".D'KZ15Z#TZ%G^4]S]5-
MM_RJ]M32/\\L1]?GR>U2>S]Y&$/KI_0CYXRK&\!J94^8W'J]H3UUWNG9']1(
M8Y5(Z][P4K3IXXG@GP(N5'JD>:7(HG_+QF:*)/_+4IG\:Q  0_,=4*,!%] X
M";4U 6(OHS<;Y:3R]+:/!9LAI5Y43GFP^+RJ?1'R.7E9F:B12="1POUMSN==
MUIB(/NI#O=CS _T-67.*7Y'0J!#O!R*5GY4L#HAR4\.E. Z]756CN5F[0G4D
MJ^R,3?DAE*)[JGMF9!!*VCTU^ZAD;!8'=D!^&<>JYYL.4;>IPRRBIS> _.C
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M?/FSIP!)E\([>%JZ?A\ F7%Z/CU%"##V7QZ![#W])!:I\*6GGPL#D2A+(<7
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M9.,;(N)AM=1)8GH'NJJA(A4N&^4^9(H&WJ0./LZC2MD,#.*>TSC;$W=W"H\
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MO!C7B\[,L*P0/)9R398X6M<6EBE%$4 2H4Y_<_ ?Q:QW?P-97<ML)Q/4Y+X
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MEZV9[1YR+3'C,G,1WN9NI)O/BE2=YG)=U\FR-OYD+[M184V)U]4[.;W9\*D
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M&'4H([)4GVQ[#3+0_)S1@ILYQ%B8LM!OH49D;-YH0GBG;(K#T^<3061:R3_
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M?+HG?=@9N)>:/D#8.L@<B_@;S3.T,VYN9KTXCQIYWJT$]:XJB9OTT!;]UO9
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MMH3;EGZ@+VFN">*P76_Q!RV+1U<HN&J)M2"TA=2HRF8QBT!0NWE:L[,HIF^
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MU Z[1I,Y(WD45_R^S2OX<81-EC&Y?$RWS$ERD9):^-Q7E6K(,9D1(RH7+5/
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M>L?>>\ZGMG[+_$E ;^QEGO/_)@!02P,$%     @  W\]6\JI7"<<SP  =-(
M  T   !I;6%G95\P,#8N:G!GG+IE4%Y-LRZ\@!NW0'"'&W=W)WAP]^ 6W"%X
M@. 6W-W='8*[NP5W".YP\KS[W7N?777J?-*KYL?4].KIJV?FJNZ:>5]Z_PU\
MD)&0E@ @("" +W\_X'T5$ /@8&!@8:#A8&%AX>'A$) PD)$0$9%PT3^B8A#B
M$1,1XA$0D) S4I&0T8,)"*BY:.B96=C9V8FI> 2X6?D9V=A9_S$" 0\/CX2(
MA(.,C,-*2D#*^O]9WKL!-#B((D@N* @R !(- @H-XKT/( 8 "&B(?PGP;X&
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M?/[\ &O;K9$/V[&P-TJ"V5NR038A(])0>H1_4=JFZH6-SX+^M]0.6K&S6*O
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MCC8Q:I<;%*!6-W2FK//CI;=1W3CBRYQUD38I V&KQ/A<]H!EJTMQ@Q*6+,X
M%\LP.S"J)[BQ(+U,&9NJL78Z)BVX*9-UNO!F&$^WCQ:P?GE;,JU:)>PA4!*O
M8Q?Q(VW49SPB>L0/>@4.4D666OG!'&P_P(=7@M,9YD[Z4V<,86_/("9  +NY
M3(/S<I2A/8K5*-[SU5X<4)^M;]/C7.JQQ9%LKD;JVQ$(5H!:J3Q#X!YZ4I5%
M'M5_G*2M:-8K _2+GON>Y@, &+^/#]!B#.ULXGNC.,[&<?D.F0T\O\UG<@*H
M\]PTUVOEMR.6![RNA1$6+KDA=L0"X(:.;LHS['I'2V4Q7Q.&:Q9L@DDZQ">)
MUV)\\8A^OV%6V%DQ-,&MC]1AT9ZU@6Y[. 0 )UZ4<D87G7 &&:J:12R6_15<
M^# UXJN%CR\R7O>$R,Z04EC&<'$LC*PJ]I.+F$G;>EBKVK-J%#&K:[^VSFQW
M^$S]K^=1;PZM\0:VLA<ETK;==Z*54^)/%P\Y^[]]Y ;> 5!FR68#X*JY7]80
M@>K,2"[NH?H2(4EW4R9PS,GF,5I/E1#8'.=FWD@-L2=REOH90E$6+7769O34
MKEV;DRZ"("P#GI951#"O U!<&,(36#A/HPMDX>O%%4;T,,:][7<5I-'2D1G3
M(%*!.0KX% B[)S3YI]((]>'N^SM0W4!LM_>4]@Z,1C][W9#5Q'0]"8R<MBC%
MP4H0Y59Y0-5QT'VJA8@=.O2:R6/^U:4_N%#>;=@T*<&AO[^@'O122&3&/<Q=
M-MC 2 V5&LE(,3M6^^F\E^315@16\.>)@*"4.7I['+=-LP9_A:U$IVX<-0[H
MO#AZ\\4"RJF7!K>FA=[>9^8=F&E([XYH*^B>)$HIGT1$.KK7!++JFPQ^58SG
ME;=&:,0K@%E-U5GN)3SG5!XT;M<V/[YH^>JA6;GG6OM=D, 20$+TTT21L>V_
M-8"+V4K> 7.,'03F0]@IM60,T=4!W;0(\Y(!6FE&F[P PNLS26X)@<F%O"P%
M-DEZ-W3ZZCH:M24(')[=J ;Z._7KE4&,/X-D4,UTC!(6$,^D_$G#3W,?*5JV
M\K\( !-6H^3,?7J-N=3#9K\A;LLS1"BMT[Q^9#-9(Z3(#KRTO)UO[!!,P6R&
M9#<&'!O4Q4]P(7U!:9A99-EJ^]Z<*A&)0T-:.]K$,^Y\ ZBKM_DZ&-I\7/5/
M_(9E0L^+#@-; IAO-%AD(X7;B.[+N9SEKWRQ$!OX8)+3/;&S&M\O).?XU%BN
MS?E9)A YRD=D$K-$E['&VYE?K%AS=72/QL+4$JUZ]/N;5C][Y2E[I?-*>9P<
M14%"1^^G:]GK=O-]-:7X5R%>[\BYGLJS\V5]664A=QBN$EQ0M'[#D+9U"4HM
M9< 4*B,+T@4X(YR4AZ$M=H)WEJE=G/U>@[%ZU)IP3J;&O+R9W.64AZ.),E.2
M0N:R\/SIZ1W026UB!>O0R5'_8&'4BA(TVT5Z!8@CU>M:6^($-,;$E7CI#V<X
M<1>SP5='NK9E7AZLR29MYF/)".O8$;Z,=%:3*LT+3!5?BUA6AF(?$58==<!1
MJ%^C.F_W*!\/J(4\'N^6#@_NP=A8Y0MOJ:\'A>(DB1@Q!,&*XH(MD4QZ#76S
MJ63[9DTNH;$\I@*#6P$^":8O*I8T[J=HY^9:D#^Z![8B$HFR >O"#,UQ!A>S
M* ;\^?AM0E$;/@7)1EI*#S55+H>YZ"&\^M:"-,V*WQF?D/UP[@1#-FK^)OQS
M+E2[WJD3*]+P_-\._#Q>K.5-"FP[(DHML62WII*FCC5V$MHS N)?NYF%*G3^
M+ LM<1YZ#K:R/;!@QFYYR].AHNKHC'VOY9Q1B;TF[,Y\1?YJX4O2&?CFL=XI
M& +[M!"GWA+)W7S%-2\TG=J@?K#?6J]P-^HC6L=451!;P/"QXJ="W7ADR^8
M//$Z[$Q>FJ9YFY_8![:L=<GV+:UAW*.C<:>%.&FJ^;R:GH(Q:QV?X^-MHKY0
M#&_/M]R*!7Z-.%_+T]9(L@1L:\RO972.<)/-9%4;!F+&-@=CFH6B?H$.Y$\0
M"V$VY(M&^.K-!AL5034IL5G[ *T+SSO 4S*]\$E#%*%Z"-Q<OI<J(*;LG^-
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M\AH;/_0WUK'TH%"0R:K5=,<:]34,B\0,K%,U?5:EUYM+:*&F56M01OJ)R]>
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M;C-'<4;#/OD1/,')B.D?#>E.(J)\\8<D)84DG<3$'.S7SKH5[U8B]R78_8I
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M*I^,Q@'X:GI^.S]$<QU)$E!&13$%DP3?HI(.$S[8(*LW.!+2EE<TX !\ANG
M0XR$/ :135,V:E)"?.:V,'Y4+S^3)-EU7;_<FK*[[:O?^W@P@]&?;ZY""!TK
MPP;]-.1%!F@G_QCN)1M-+2\HWKNX$*4$KW[2>7NPHN@ XH4J\O.,*/AN6(,-
M?!X$\-7>R&NN^6--H].6OGT_$R!"!4G@PD\,&_X%%1#.TP_:<YN8:WM0'E08
M]<FV_\PI&#(AQMAWSEJ+H?>81/31.AEK.^>E)E1 I&&R#,H747WY+KE( 0M+
M;+LQL4[C&'HY[N[VU[^_803*FKN#O)#+?W,X6U])I+ <=ILUY:H_ZOGH9'68
M#OZ0>V#XA=\"U4V6:.@)8*EI_;!3 >G:V7\-,>K#X%>[KF:J?6V?^(:GL3F.
MAY!:KBC)Y[H\N[<-YDI@1"M/[1HZJ(DDFT]4[GBQ!\J;>WB;7XBN)]1Y\@1@
M:U>XN['$5* ![<ATH(C_:EZ>OV3W>1":.8P >C\6.Y..2F-6!06)JG(\4'6/
M0_Q 8ACVZLYX"S_5 :.I7K^.<ZX&G(B-E'MY<HK&">I#L-[@6"@OD//I#_)[
M"]S+CRPW8J1:CMKLC8TJ!'X>('N\6H!__F0Y+3:*^"V\!7+76.+."CBN&N9F
M PK>*MFXM^+?6?\@'VF^.;C!%ITIG5A2EK"2#+[[BF)]7@D?8QD5F&*SS)SX
MHJ/)#$'<;>X;L;(R3J\\GHQM,K!%PG8LC4C-DN1'Y;EP_D3[1,L2OZE=$>V.
MU6AN;)^L13DW6(RL57U,$?=^HXXF[']OUD[7$3JFX.7AGT+AY*T[)79'P-YC
M(]7ZN_1Q?S2@?/@)T-52II:EK?X@5CUVZ*Z9SB4P1SNRL:H>JLGR FT')Z<.
MY6+LC<R$3W7+B!WN8\&4,LB5%@.F0!$M-D?^C7=7L2'G>[Q,:Z@J.QFWQ.T#
M;-9]T<XOX*VONAT#4L W]4*4'#_050IU\=@38+T3LVU+S;6UH,VAS8=KXMS-
M2P*%45Y]63)Y)KY\C]'G"I4PTU*W:+G%X'@5XPGP2P7H-ZHK_+DFJ2.>N6Y+
M=D?\*\ O)YQD^H(TT'(U>V'Z"8!EBV^ITBR/HJ&F4$BK-%JR^E%)MH_O0X8Y
MT\( Y>Y8'%7.W85/S5OXHA&G5KM#,"%$V-1U6Q!$Z!<S%\2SK+\(ZSP)<?-R
ML8B30SBY8/.Y:E[C=W1X)XF]45;,.S3+DAN1/^VSX&OY4<F"B@]*;T T(MHR
MG@"+Z9,]B#Q[9^Z&4*SZT*.N8/JU(()H_R*CI27,B)+0;66]]8C</_'P;W:L
MWVL7J?\LZ,(8Y?\HR$C>8R7)3G^PU_N;-/$JS9%WK:)V8I3;/]ZIL-J0@\"V
M.T2L[V$81,85FW+LS%2?HMT[N>!T[)2P0C%!5)],2<JQM'\LYXEVDF_[0BK@
M1VL^4R/%B>HNR%\KLX.O&IK$;<LR)*!*JP.=8V9L_VO<S[P4E[#=<MLQWX=\
M.YDSY110LY-BK_PFZ3/"T?A.VOZ6 #Z.@KJS5_,C\[O+2GCFR\&_J>M 1ET9
MKX$^"M+'<QURB;GC'TFV5ZW-K'H1N?)W:V1-YO?(_4$N&?L&1>2#8U^? 'M:
MG/'"OG8B@@:%MW!!4COO'9=NV955)M+W(36[G2W3Q;E_EF[$.;&P3-N]"DK.
MM%.!I:+Y-[.#R%R4:JF[@-T?!36XVU&RPBF^>:P0/</.G<@J!6\F*8_9;SGU
MZ)].B$3.!SP)7HY?%R=H>'NB(,7ACU(8/G)IRH\#S0YM"=7>)?11F',BQ3U6
M.!_%&CNMLBE %*U4SJKO[9<,!ECLW;$.!#.*7L>/%-FJ8:,+K*V]L$'.5'JC
M$<.O$$CSZ?&Q??"T%G^]X,!4#L?6Q,_R"=#;AM\:)<V</82*NN5\5IJ9PNKR
M!+CI@6Y' 78U/L_ &6P\9AS<D%LA^_*TB54<VM)36G.%;W?)BSW$;..'N"P[
MZE9-H=LQTV9WL)Q7 9MB!TL/],@8+.1:$:1UMOF@%NLG (;+E&?2&):^BUH,
MZ2ETWZ#@ CF&R\TK/K$-H1D.7U8(W;TQC0XH!6!WEB&_O^?2@=QU"B'N@&?%
MB/$9J.;4$^ 4_&QDR: ,),81T-O590#\]MKS[=!0P'A?$HHBL!A@2BJF_])K
MH!1'1:S#->1P,K5QW&BZ4K84QR_T%$'0?), H91A)?2Z>'9-89XFL5"6>62)
M&,WE38FK.*%\T4%=OE2T,H8@X!2!7ZHT2Z!;Y.?EM^D?DS?2)DB/G/O!JR$D
M9:KG]++[K_IK)FUM9JJI$"HB[.>3;42*CS01RZ6#*O0LQ.^/G[%,]'BT25M^
MEP,0)N>8D*W]O+>7C^W:.&Y:=V$+(XG/?9Y1^(&WO*5!NB2-+KE-Y:P&](PR
M=F[U*]6/4U&7R3MBY,5L<*>Z)X#PU>F_!ML8GSU C,^*M9;>!=X\HV!OFS5"
MR=%7^NY(&$+TR%14$"QP>G1L?M\&?(0_NZ082*?ER?AG?T!^^.7JP[^/^R>;
M+ AUK]9$,I_M?9MJ*L#>NUIS<XTD.3^<_"? +",J31GFG_OYH"*N)\ W 8]J
M/:0ELAS1F/^,</P)8'4H:O,XFQO;[>^_NS^9=2=:,1KR+DM@Z#8O[%9'21K@
MCBPWR[D]I6CVZ!L$_.QNVS92QH"=!:$P:8\38]RWR<=VO*K6EPB/5C0]@2+P
M_Q0=4@#P% $>MT7/ >V7Y6-;[ L.'V19[]+]U22?S]J*PJ1-B=W#^DY>[-FH
MBBI49"M8G'J6M'DO+!5TDT3NNK992_!'34Z7?GA?'%.:=OWP$[N4E0A@./]E
M027$BR;60LZ*L8]BS>/A$,_PO"1[??BCD3)QB]325\?M4&+D'/<3>DS#O<./
M6U^:F^XC=G6E4'>9L9QV\Y= '',\HZ/G\;VJ0W6C-!L-#*:(.!5 R/S]-/"L
MK8-R@NPAQ@+7#C:Y([YHD!L4GEZW,,06L+R$D&!ZY6!BG;@D &FRT\DM':Q%
M;>>\3?]5WC->3MJ@[V?=#WUS^.*3)7P!Q0<6-.$S >Q-YSQ1X72:XZ.]5YM;
M9R#]U:P[ <?"$!!Y!3N/:RWG=FZ,%GBW3Z>C5X2Y^Y-9QW5I2(1#;_4LR]8<
MH;<"7 V3?P*@-Z>(/;_;#UD"F[#"PJK(H+G'5DI<H\!4DYZ^%_4<5T2W<M>G
M6<7/$P<3<\P.J1 966+K_),BK-VGPX4@$8B5[5[!ENW:<M4PE1![G!5LB*MW
MMWNVT3[K"?!U4^ZJ[0G03?L3&F,-!KFC3"G'0:P7/ZZ_!V/&^SWOQSQ18]Q$
MZO^1*='NYWJ$B;J,"(!HDZSS4MVF;KFXJN!H2#XS)LAV%.7H#=UJIQL<(9Q^
MK(89@6\0?QU7U[R)V(.7;9_/]()/Q)F25#*1\:;7L,B5NC.OBJ%DZR/WI' F
M6F#3$\"I/(JA'Q-]]-TK/O/?YL+F-:Z&O3X7@?T9HHIG71IXTY=YIG$,J+&G
M6=X7/_20Y2^H)/OLL#OBBA IMYLP 6/SBM^;TX6-&7897)FP\C<MCB(<OW[!
MJS]O.G98!?T./V%(E3D[2" QCRURSS.<F3V?C<D++#6^*81<%V;B>=@8!I8=
M_CR*6S-@EFH/?TD" BR!T ZSO+Z3;FD[DZXG+E@(4:<\3'0566QVF@V?T_6I
MD<C[C%X;(SJE@NC_JKHX+YW%_).9='4F+R^M5$]X88W!K9IA8*XYK2P6EH/?
M2R90YZ7AYH/>64'"NYWM8?Y;EJ7;:<=S]SY;8KGS XRH]FCB((Z8NS_C9-LR
MGXW1IVR8RHH;*\M?6%[RNRTL'X8DA^SKS_2!!^*QF.AM6<-5'LXG4&N_I#JQ
M18H29JP[ZWJ-4A)P5J(]*%9RF9T>RQHVX0ZXPCTE+3U-U-K_W?Q8PS;M!B>[
M.7?[H_S\8))\NQWV*]&.O,'RGHU.QMU'J1)%N"'YH<9S'A:? &[.]YM/@%HE
M93;-WL%B@I>Y,)W9#1]O!^K:,78W[-<$\JN:%.WLF-9\S._(^-ZZKL;/=F1O
M!A:]7XP/96&E>FL K?!URKP?&4 B3_6SF&/.JMJ/I(UEF<Y(0!YV5C'4EHT-
M0#7=S/"X[NSH;+1GP/K96?G-I!][B\0<N9A=>+,_B'2JB_1!X>P;Y)OW(F^Q
M.]R_DCLU\XMPV02Z< #DG.!X\A-^#%9$E?B@7 U37S?&E1*JH9*=0:>LUG0A
MBK1HH5B6^9V+P.'MG+LX.7. (O@\_H'9R/J>5<3[Z(O=K;'5VUN?^6YO9U)W
MP[P%!,43 "KV%J$QM^@++Q2=1CI/S2$3O??L^OL@#QXS6L#;)*JM2YM=M1E3
MF)HLA381P?/11$>=GPMV\D4-W<9R]7/1C16WQ34,;/ P$!TA'KO?Y%^"*L[Y
M@E3P6^'Y;Z*%XR/$+J']W2E7ON0XP-V\2"##X;'PO5J>'>#L"1#<?'>>;?A\
M!D-%%(A-+X)@U-<!Q\M_K<EFCL4LF@>%4QXJ OZ=&W:4MGHY(,9X6[FQ#(Y&
M[3?Z=$_&8G]D\'$!+L&6GAO&OP31OW,7G<[\9\\@Z#DRPO=O^@4HON%!_ D
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M/6)I]TX]'@>VF6W@ CPL?VXEAN]%>M-U=R+J!(C#L(&X:F)+.#D#Z*8W<JG
M#ZQC9*QMRXA7T ?J]SFXCG;HAY=Y9R7-W67F7QO)(S?JP'@,5J&2O]R#L<7T
MI5MOZTTS"$B"]JZ*O6%Y-=H(<\-#O\1]GOI'*NAU":FY.A6Y8P2YS3>+Z@O?
MF%"!5Z_<3)VWHW0ZOLG(.8 ?.00>;.9: NT:[F4B9WA>^,Z@D455,'+Y^T!V
M9ECEX29B"34^TM;)A&T8Q!492,*:3,[VU.&FKM0.P?G2T4C?:TE5"&H;C(CO
M8XVY@,3WF7]N;YC'##3;+44Z^D)N-:4J-SV7I[S(NYS/JWQH+F@OMWPM(%*X
M)K5D339VQ1DIS3FE-W6S\19W=#=X]$I[K7G#Z;&=K3!].H=KZKSS(AP#U@$#
MD5]70A+(AYI/@*:4A)>-_?<)](@I9L-H]Q#$'/<,NEC]L*YM=SUBRQ@C)/N1
M"!]Y>C/+-Q$OAP(2H"TR,#,E,Q&]G?:+4.!C9<0)B.*4]9H4?,&D:[*T^JF$
M$%V>U=JY935NAR]5]:NE,(X?N=WOJ>JKVTW;=X,+B75_\#>G==ALS7>-6&E_
M:4SX:53]4.*5O;1,7'=!)K2@(EO3]OS)<HANUR4KQ1X$M35<S+H8)X+_#02S
MBC.@#=^Y:CN8@MM#4AUWP5JFJ:ZQS_VJ9*B\IH(U?QHG_PKLD;%X?F92H_F(
M5LXD>^+%->3S9C\CKK8R=&('?],@=]#>7.5>5$[N MXUE4*=:O$@[>%'VUWV
M:]0^())O--4%MCG%,Z _'$A2,Z7<$<.*;O*FA:?!T9.E/RH_XH1J<1SRJM5V
MUB6O[<21G@=O49B#<;Q EO%Q-G'HGZ]4"<B_/O?M:$>$A"]S-A$H-K56>;]B
M9OM/N3?U6^( 5:-.,;AQ2$+Q8JGZX*3U&HP) I4T[!F'D&%$1CDM>+ESG0G_
M"'#I]<+EC<JN;EMJ30'KP$#G^B55\"M%$P&8UQ,@S^X/]4H5L:U-C3-SQ.WB
MB,N \IM/^_+4YWW@,4]U&!:H8_,N:FM.89;*,DU^>3M*@PF"AR7@]/?('3*9
MIH2GW_:MM',F(-+<==O7A%\7,O<W$CEK*@E3AP6KLV@EBG57?Z+\)E/GP-87
M7D.[J31;4\0I']@3&_9^D_^*-'ZD6J,:''$<4 IN![==]#&[OI5L.Q^^&2Y:
M)RCE;)F1%_$UBNO.$J@QS'LKTJ&][;A!A6&HD!9 MI))/E*8KC5[M.9SXK%
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MN#0+DYN+TR(EP7\\OKV;7WI0^.ORLRZ>1!>DGG?).0G%/*7M826-\:I46AX
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M2OZR-1!9PWU-%5.1G:DEHA1)U6VD'%^]AM.&M4_7K"=-[UNOC9J(3?UT*OI
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M]B$)]2#D8_EHA;Y^\Y5]+*TYEX7A>AP\5Y1E-I=:YB7]#/[>.Q3J8HG'4$^
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M5B^:VBX/R8S3V5/.U_2W'02Z447X?>,D[CX?YH0LR^Q^!?<)WE0B@LF,'Q_
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MI^TB_8U)=H2O4&=PU"2Q5JS<Y,0\,H!T56TS4\D^$?%E7];#A=CCM4/"X#8
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M?H?//K _L$<4%2+7EE,ZV6:^OFYR26BT]"AWQ5IGM"8._?HI/M,L"<C&^@1
M _JBKD%$&RE%X7)CP'99*PU4S+1]KCVE<+6O,.(D38U$<< 5+015*T9NA3\N
M1-3G#*B0YSB_[?L*&GS>=T4<NO)]F=FP#([0O2_[@X-\5F;<IR7#U!1FD[!1
MFI#FJ7X=)+99'*]AV+_-TMJ-V=[EHPME6C)'DXC4X;*_O/M\&0[ZG4OYH4Y2
M!8>.R#E:VOB(0+CCZ*<_/)QV)B8/(OKP7KI^$%1NL,PE7I\Q]'@,C-A-&(RS
M';'%'5A/PY(T"?0_?ZBPOK1SX7F[.$FYGT9_:>IE?2'#U_75:$+NTX>OY:8<
MBC&-B;7DZ:*MU!!#,$Y+VLO@,^M\U4U)<FX!@:5O\28\)]-5SR9>R-8>*-WS
M>[DM=U:E7/(J(^SS3H+ !-IEP:;^+!$9JR+IF9?MSD9AL+^R56/T3L1%HC+_
M$6,;_'1<*A?W#$M&.$R87HM68+6ES_P1TTG4SNQ>[[<"L1-S,]OM'W]F,!32
MU8$#O#FI>0+HY<T;NP14M9,Z>P5L\492]NGU%G]]2Y&-/(!V,:CBT^SX_?8
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M5Y?:+BX9QW5H8S2E%;?!N)0+G1&2>5=V[T.Q' I:AP6 Y>577(=4(Z*DL">
MS3)VU5HJMZ%M[RH/V\RMM5"#"9*!1%T=5^B;Y.:I\]M9QR*=1KRN3-$?_-F%
M9ET_K-V^@-#<\F0\S/KU:/E_@4E%L-&.G5AZ#^[LN"M@P1,]&C[)4S@^&XQ_
M^SNG'YJGQ]%93I.ZJ5I1@PY4C?]X>'RJ9X"\@S&]+)HIK78-%O6=OB):"6#$
MF>=LWO+Q2@U?#88C'F>^[B+\CX$G*]ZIS9&.F]:_W EOE7%.D$]VI]L@POT?
MD@I%Y\*/PQ\:/P:#D94UB Z,,]+>/D+$9.5WLY\ @YV#C_=%Q(J[50R"FAEX
M'ZI??;2I6#)Z4Z<83OM6/]CVYS[6_"W%"? .O<I;\W NMO6;MO*N>A%X,/X!
M\PZ#:1H(_PGN?'Q%F%BVMW->;5X/.S7E8LR&Q+C&!*3N=A&+:((W]&LPQD%E
MPS8V[ A.A3+A37+YH9ZCW%28@7_RO=K!D5_IXHRS63=Y"X7K0M9.P#LOX<^G
M6@4;WE5B8U]F'/O[NS/K4D8N2 3_>.5C&ZO?%#I6^\G^38T/O6Q.&K 9,9:J
M(\1)>H^]D6>4>@C=13#]%5TMA:]AV G9\SLMV20UP.);?N)Q!:**OO9!Z@<X
M^83W =%OTHUF'2\-WT^Z3 .,)]PG1X21-=?6N_K^+!(VFF(VS3T!Y-*38YX
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MCN-&@NH,*,&23N$'=)&;53/A0R?W-*2UH]^F-V,8M7- )D0D45E%K#1-BZ-
M;SP[$N @S^5$F6XH_XY:%(K],7R]:E(<]4I%#:L_AN*ODINJC+M]QY &\#B3
M\M0H&N_H(KE/,*6[?3J4TOA@0)4\2%YV(TVAON,&OGC!1+W&2%W.2F%AJA-<
MQ(B=8C^K7CEDWQW5@(I6Q 37B<1Q L:8#&1\_BA="\8D/AJAMYOPD>0%9M@2
MP6FY@;,&!OY6;??X>%,]%],S;, P[5'=#1 ,AFA?OS9?U\_9O3(1=7&VL]?X
M"X[IH8DNICJZ3!XWG]YO!%L51;Z 7+%.T;R#G82$?J6BLL[RA#KOB0C1ZYJ!
MM(AY>FC,NUQN>DUG_BZ(PS6P(Z*@XNEO!^6"FU5AF)(?3.@L"M\+9?N&@=D1
MD%97YMI(WZ'X%R^-0N:49TX\\[)]>).0R# K[4AR4,N9,=@%QU<^Q-A$4ZJR
MQV3+X#3_ .MCJ&D+.%D];5QNKB8.OE<A0P[+KOHN9P+;+#MMC:U1@EM91*WX
MV)0*Z\&O8+Q&I7G]371$K 4M+&3TRV<CD#]4J!J2ZV27&S<BVY"?3FEY^92S
M,"P2:RUGVYT0/G;$GB'#81PQ8_NY/PWPM4@FO.K?;%.T$.WA]H@-\,:W@!^A
M<NWLZH?1&)=?BL*^:7I3;SB#8J5L,]C'W('#NOL9*J+2W V[(IDY*81"-HO$
MN$JYK(_ODJP%5(&E2D%%1?8?TL^(-4:S*'@%D8]S4'RH(21R72FC6/LN 5<\
M'=GH[(L6=J6+@PC%C>>'')53NEA??H7S1%_@3%09N_?+B#>QKW#R\LN/Q UA
MKWA8?LD$FN1^94#7XQXKE9H?T8L_3.A[.R WQG/KFU/BY-AI]#MD?(.(2+'2
M?N_&HFI3=IA; 2>=;,4D(>;H1'Y $D6X)QA1]USFM_,^$3VEZ" M 7-^5'A3
M9WM++1X(ZCP )(TJJIFJ>.#90KEAN/U@=][R@5Z9N.[;HEGX3@_<[+L1YWIH
MFD1;^YB6Q.B83%^$%2%=1'@>F2H,&A Z$Y)*7+YO:Z2=9^LWXGS[=(LC-L^I
M?=)LMZR18U.][,.Y:R]5ONFZRP8I^#ASR181/W\+>: [@V^/+KZ[ZS(<X!Z;
M9G?%^QL;J_?!MS<^J-?N9Q^T)S\7$2\V_E[Y9F/A8ZK06ZO4A^EW1^;%?A.:
MCXVZUE*DYQOX6N2B-TLR"\S-[TQ JG-LA(9$Y+[]<*6Q0%OKX#W_-T9&NLN*
M'1R5%O%DWI56OITEF\=8E$P)IV',8DQH< !<BNQS[K9U^=DUSM!3T_'IFA[3
M:UY25>N#Q,CD)))L_NB<>K2?YP3+K5BE4/^U&WEG:X\[6R#F3D9-7QW2LM)W
M&]Q!CIY%=R0_B7\G,<*^QA#<N^'Z=J193JCW#)_P(/-K4+'/SGE5T\.H8)^9
M-*VB.04D/^.)N##2!^/J!(H -?EFP.XCRSC8EF)@3,KIW4]-JO:N_&ZQ5X([
MVOR7EZV=C_:+,]W,HL9GM)Y;E[)XD4)!ZH%,]]R>-S<E\6K=:7?ZN('7#^FQ
M?[2<-* XN]%75+&FVKP(II\/6!%*;)W8!9W0G"(4*:.D>Z^S?O&P4;@(?A\6
MBBTH[+&VL]/K]&8H#TN08UR@^P82K&][+Q<D&M]2(6;[@+52'1VN\=%O<;O0
MYPE%EC-+>3>>RH9;[%O.&_;YO16B_WZX"E;>J6O,Y0 K\(P1PJ,D,?&AIX E
M>_U+OG"'&$4I#B3/E-L9!^,\W'5QR%ZGA5)3_%9T]12&?)!ZH)AQ>.I]YP@?
M#4 <G!N2;D P+6KHIDQ!FR7K/,3#VZ,QPYE\A_,+=REVD"WB]N4JR!V![E6U
MCE!?R7US Q)2!0]=[=ZMA,[G+]R]"J<!?V#V78?PZ1I?=X>OB1;&'&HK3W_@
M)=6LJJC9YM<K7QW.A&P>8X*+V?<7#\[E23VI]"F>H6=VZH%3%PW/["#V]_A>
MUPV J-N'K!!4Q%% ".ZU1<%Q\>PH-&_?)N]9HL#0C1LW4^O5M,-(W[@HEN#R
M=&AZ YR)$4*T\XAR-__*-;YHL$L).IS_^9(H$2OL7?M=*DZ)WRAF]_K1.OSH
M/C,YY)L3Y>L4-12269158$L#'M* -1+VD3QII;Z&2@.(5XX;IY*BFZ77&G[W
M)MOJC5(&I]2Q;-K2_@;77>< ?DKK!;ZB]_]!E.B5I0%U5.Q/8K/YG!]A9X_O
M VQ;]T(!6;%'Q;!"22^V9D(@U4K^\MZ5<-M '$E$@!$4L!-70*(!P7_Z0+HG
M?827@9)]W]H%#YW4%=F>>_*J"(TM$>'KP:TCTXJV]44.MTH=F'98=_*O9 '1
M:QP1FSK ,)NFL_F/$+87?1TO@HI\HPKW7:U#@E$"@TMGS>K: W/O .?+"(:'
M4J_-$D@QQ[>SSH8,CC!)Y^)LMF04%P>\)/O=N.$=<V((4;674DJQC9MYN"Z;
M=$O%O&[\M0N])5M%2_9L<RL-5;VWW^/KVU9I0.@G\-+DI>^?*7V")7-F3UR#
MY?H\4R8?6RGH/M,[<=Q"=NTOP60<+!Z)(L!1)O#J3BE9N3877!^A^9E3KJ_H
M>\\?L/.H6R/#"@PI;*JNT(.^]N@W?!9S,8B;K,&>^,M$V;STS8O6HXGLKM#D
M6C^;^[G==J16T8M@EE]??X+Z[A99UA(<JX4@VB('YH*SXE6$T[.E'3=!^(1^
MP7XX*JFMH]+$U&UDZ7+)7Z4<[.]2;DJ-N==4&^#^/P3\\C#Q(G N;0&8CX),
M:G,#6Z^J+"'#/!$8KVGQI29$12BIJ>S5<^?4U6<SW=J T9]?,_]/.:6]&CW@
M=_-2JMPJR8>T9$D#)@6P^_N0O58:<$XB\\011S,-R(BC 4&0C5P:$(FNGY_!
MCHM3[V:'LI-U2$<ANH=;-& @YXBCXB\<#=A9^+=QX]B8=\SS_LF#'@;\]/F?
MV'^<_K<Q8^/8:\L_2G8T (KBQ;;_,60?>[!=OQY+H%+QE.-\*CF.!O:SZOC6
M)G0MXZ@6\M\6]>/TWZS\.0SZJ8I_</W\Q-^+4>C^5J"ED#^VNXEMCI:@TPF?
M/G+XJ213&&G /WB&HT;L/AFRUT4#'/#+.C0@??IHGP8L'<=;?E<$V^7]UY&.
MOF#V5W_NY3C 3_.J*B+:9?A39Y@DLD.AM*%_ 5!+ P04    "  #?SU;+0?0
MT#(7   ?)@$ $0   ')E;F(M,C R-3 V,S N>'-D[5UM<]LXDOY^5?<?=+ZJ
MN]FZ<AS);TDFV2U:DAWMR*).DI.9^;(%D9#$#45J0,JV]M=O@V\B"8 $*3E&
M=CD?,C+0 +OQ (WNQMO'OSRO[=8C)I[E.I].VF_>GK2P8[BFY2P_G3Q,3[5I
M=S X:?WES__Y'RWX[^-_G9ZV;BULFQ]:/=<X'3@+]^?6"*WQA]8==C!!ODM^
M;GU!]I:FN+>6C4FKZZXW-O8Q9(1?^M"Z>M-!K=-3B6J_8,=TR<-DD%2[\OV-
M]^'L[.GIZ8WC/J(GEWSSWACN6J["J8_\K9?4]O;Y;?2?7/%[RS.2PO_WRV#C
M7C]/K%^7V'FWU7[__+NAHU_^VIV/_>??WU]?X6\K;SVYFD^</QYWQM;]K.M:
MU[Z\N][>]?&[S^$G/WK&"J]1"[!PO$\G5+Y(O*?S-RY9GG7>OFV?_7H_G 9T
M)R'AAV?;<K[QR-OOW[\_"W)C4H;R>4[LN.KS,YH]1QY.:H9<JX#><CP?.4:&
MWO23 FGBR[,P,T-J<4FO0E(K)C5QCL[#QINE^W@&&4#?N8@)M][I$J%-0KQ
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M,BD2H# AB#"XV31^I1A<=JSDDR5@8&(,Z7A< T:=P%P:$V&N!#1,;$$<I&N
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ME*R6:K6 1UHL1.]5#[K'3XR^!0@"_BO^\%LP48C_@B0 %H*;!# N%(K0(XF
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M7J7F%10#+^>DGMJ5FV+MT&/P;>;,XR2RWJ+&GBXP4+=K>R!L]';"&]1!MA!
MO3)[/>$M9'B_;1TLON(5#?4 .4@:KU;$)]R'H;28(*56:FA42*!"FHWFZ!'%
M_C%C-1>V#KY9*TVL1AJ@RN5B/+9<<_G$NN;RM< UET_--9?FFDMSS:5:^)MK
M+LTUE^::2W/-I;GF4L(U%V(;+G"86D[#9>0^$F/P=R=*4UZXMUV$_6IWZ46*
M(^N667;88YVJTA2Q;XK8VU0,LBEBKT4[FB+V-51$FVV:6BMK4\2^#J6VFR+V
M]<&J*6)?)[1*+6(OC=:%(EI9^^GG-X96GF\(K<^EHW6IB%;6?OKS&T,KSS>$
MUL^EH_59$:VL/3&,WAA<>XS#QQ]E L8*GAP1&T_/ZG2>#-$/2=@R'[$F=6!J
MI1+E2L'.(.M;+KA16^4T(:>:!'%KD@Y=6]73+P4PRE77=1'.N:U)N?;:*J<)
M.8'1B1+M<1ESO%XH N1#PJWM78G:5,^KE?:8D T8YZJK:M;F&L];5$TEV4"J
M:>%3#1>,'/;/'PODL%\T.>Q-#GN3PUXM_$T.>Y/#WN2P6Y%)UN2POYT<]H(I
M[*\N@[V\!'9E2)3!J-7=6PE6=!^;JE_L4'1:!9<C7DTAB5/YM,Y\>?/'EG72
M/L-B>G6'EDWA=OL+M]O[*D!3N-U^9:RH<+OFX\E3%_B4*W3(CLJ&K*-2D2(5
MM=(_4_*Q[PBW>3F@>3F@>3G ;HVK7D(2AZ:6:6M3*-LZ5T&U4'9]7PZHKC2V
M9DI>I5J6(2-(9[_:ET72I\',Q'_>'=7FLDG.N-DD__'S^=F7XW22[8B&TDHZ
M@1/'@UG*\9%V'$\BH+FAM<5]1-XR0!D]5ZN4.D&J"+>3->DA7%@.)ZU8#-:G
M@(P3)TE%DV=<4$T)[F(LT4,&BD.71\"X10<B>1)%Q_RLMH9J"0DEC(64VY>&
M<1H6-J=7G(Y7I=D38V+DH+C=P2&Q;Q*?S/0A:8ZB"'DI2=P<"KG.AC(I.!,!
M%V&A^MP):OLZH8ND:S$>=#!5L4%.\@*Z05=0[_X11TENO2(_[=8J\L.T\^BC
M&;'YW24U<@>S&;'Z(Q .TH/38?K55C@DZ :]''/;^4Y_0$ V$CAL.CTS5'I&
MC 6?9' 1^JQY&;K"U"N>7?L1<DD?_A+$;CP]LWK]X1$-BKGPZB->[<D6%!/#
MPP_G9$]Z]A66?:CG]-Q0#1CE#8#/ 6R^&EM\1!FF6;O]!,QS0[7DI!<=!KF@
M[ O7@#O=V5X^Q+[G.]%J[&Q]58&S#7>ID[,M8MRF!*X=A7UG0?XY(9H5.RX5
MK+  JT1?0\ZX$ &LS(E]SGFYV%GMO&O'MU)G?I.TW)Y'*.68:T$ K4T=_"C,
M%2S'!"3V2V-FPS#RGYT$#0/'Y>.3=6"WGYZ;*G.J#)$$'^#Z=Z'9UAZA.(E\
M-\DB.^FY']_&YO28?C95#K/0-!%R J'P6;?'T_:>_1B3!5;&R6$WGG[1OX64
M*'L>$Y#8OYA[/CG5#7K5C&]2'S2KD1G-9/!5I*?O. L]6E&5*FFQUPY._9H9
M\YR-K*X<$;%TK3+B:Z]%-CL*IC2M4G?B/KKW@X!SWD%;[3>:GGVQJ>RTIFF-
M^>R"T>(OQL(O!_;>-R+]>#3^)O(WN-VF%Z\86WD!0&A??*GT9)+W8!OYNPU/
MK"F89OL4@R*N7,"\H]Z]!A4;/$QY839I%=DF&L5IY<XO+_)R-NE"4K\G(ELL
M%SRY[S6I_HP*T%;,HP\^E*IT";YW7H3"S3>9GK/ -RO<8_I X7XR%I(8H<!)
MZ,X>):M<R(5L^_F_\.,5*F/48<<LP!88#[<!5Y&'R6IK)LI00.0P9O8&$$X#
MQ\HMO#P J]SR%3#LA<_$H<&P!Y\UW&\W/3>4'<>9&%A(+SB#=*?&;3[.?_SS
MH-7TW-!YD5BF(+6@1'6?"=UVK_T.V2%[81+<)1Y7KLRVTPM#)T)RTN70#+JZ
MA0^ H'.WY\A92,3SCMI-+PR=-LO)%J 7E*OVUS 73P%>(<%!YD&KZ675GH"2
M3)G4@M9C8;] )-$):8;^0 Y?8:'FTTNK]99/-BCLPDD1)]L2-(PZF.6BKGQ_
M"VA>(]>*R[!%Y5KR@?!VZ/5QZ.Q^D[=O15:@\D!F_"\^+O@TENSSPTS!:[,'
M5Z(*5'O[T@_G >*'QM-;BH?MII\,G<45G5!8R PH\\*GJ)#0\_5]MWFC@]DH
MJZ5!+74^&M(#3"\,7?G0 9,BEZ#%73@H#WDR&UJR0]W![!Y%<Q3M?D\6 [Z/
M(S_"]-*09ZD!064V0:OSS%@BP]4R]D,4QVWW7TL_7HN<:W>"'6ID>0J8MJCX
M&HM2^D^B8**8L417,_:E2/IBK)@2L,FF+!,VF^U&S=!6:BMVKWID'?\=^9$W
M=GT4NNCNKL./C, ]C&UK\M,%*S ";USFKOIDZ6;\W6J_58VV*!9[%M5ME,U;
MMB-OG2E,MKSMW5.*B=SFW4(9EFKW@[2R8X\LAB$MV4(I.?]X=L'?$7A]II>&
MG%5QUK4$W> 6H-O]3#VI)W[$+;V9>MAN^ME:^0*T@J%NS7EV"JO,;RBF94+X
MN^I>HQIMJ@SFN'5EC8A>M+X?-#.SH[(DR92UO?MI$7';O)LJ0E)M')Y]PR2]
M0I+=WDW+1?'#PDJ#3"\-)5FQ%?_P]1-%/L#=MW#R55D7(-,;09$3DL5Y$,)Q
M?O[5(]8@TTM#1S)<0(OR 0):^):3^M1+M0Q+UJ!3'F=Z:2@C[Y0)R&,%A$QW
MNAZ'/L4B=@5&FGXV5-3N%-CXS(!F=N'Z=D+71=)SV5!IZU;%IA24I[G-J%"]
MP,\6;R@,2D&Q5WLQ=D+?M!C,>J'G/_O>T@G@2[) TSIXC##U$ PLUZ!"%'[W
MD\<T,Y(&&1[]IPGNAHG/N5K"XE T2/6W</D@<,"2DX?I6[LF8+32B2T/:HMN
M"VNM=OZYZG+G)\PRN3KHGWF%T#^;JX2^_V+!^KG)]C)YQ)'_;]ZKG/Q^TR^&
M[BBH/!XDPP*$F+F3LCVBATXTB-)70[S?G&")ABA*^9#%#>I?0_SXK("&C68G
M:8^D:Q3[\Y!2M%8NR&7B=K(;"EGZ08O$CGFT)G7]_*[:FK?N8S=(DN2#=H1-
M& V629PX9(\.YVI Y3K6%JTC'B#(]!8[4H L]RZ#O"W!Z50+J(3T@]%5"V!2
M-R$D.M<-MF+&0]%;>^+W7-*/@]O1P0,HN<9VRUU$-R1G8QGJ1Q-;:O?A];(;
M(&D&(*3,Y6QF=XT&#X$_3SUVCG5PU+86J$!D0U@8R_61,Z9K9S[+&\R:H^4J
MHM^\B(B\ZV5$INOZ'?(\Z3<XVIPC<L!1&J<>\!5@"0387&(*FXO4:#D=7_8P
M=8:7QQ&(KK&@!%='6<]P]%$RF!'&9LA/ENP(DXSZRPQ=9RU0Y1+4#'O?=8"J
M6&>9V;?TP#WNA6MY*.>L%?Q./72F!)9!!3(7F%E+)$N]&$0C?_Z8=%]0Y/HQ
M&I)I@;9_C+._QF<<'Z?(<+50AQ,X U$W%N<Y5;<SOFD227]9*-NU^*=JH2TE
M<0UJDN:0T[<P0BZ>AS14F6>@@U-_GR9S ?$GB9YV ZC$!(A'T= 45!XT>\Q^
M,,O%8+Z%Y%N'K^ -9C,4L<-0:4U.Y8'L1ZLH3R!X1:-5XOCMT(G6<>0#PL3!
M7*BG_?!(,P'B82YBE7N;+UV%R0^YN$ OS-7,X>R "J/8#6=AAL!C?G,1L1T/
MJ?$F/MZ">M0-,@;Q(#SFXED[>ND]!Y^0D^[ (^0B_QEY ^6I)QZF;D#*<@2B
MJ[D&'E&LT/6?G*"]P,NT0%@O3!!9%I*VZT;PD:6PG]W *+  (F$L?C1('E'4
MQ]3>74;4-.J%+EZ@[@NU>3F+(;^?W8 IL  "9BQ>(YK_9&'7LC+NCU,+0(NP
M! )L+@6'%6>2RR\0]*P%B'),@+ 9*Y@-A ?3M83\A)Y1N$2C;51!.8(*#51?
M4$4\@1@;2_L91MA%R(MOB"QV00<)7WZ;NBG3OQ:(JK " FDL*VCMK8Z7#_]$
M;C+!]V1IH5]9C9"'%FD =HR29'U_:X*B1;SOYHJ25PH/7 OHM? (ZD316 _D
MDV3)45F^6CY""'DC< ^[X9$B'I*[N>?$B*GVC")ZD3)C<.U"K7^=((]WV"CJ
M:C=@:ER R)G-.1JAITSG&)D5@K03;M]:8"?+!@B>P7M.K V<OSQR]_[:K)-J
M7(#(&0O9]''H.O'C(**/064_[%4^=NGR$:^]7GJ G-5"YJVDQ<>L!=:GL@<J
M@;DP$%U<TDB^P!A-V]0"I$-R0:$7#<U -6]?:&$:H@N/ZR-BLO'27Z!T"]Y%
MD>Y\Y\$/_&0%V(VJP]B-27&.0-@TIZALBKZ3%?O!#[?I&8/99NZNBS)LJORN
MH_'9"26-S],E/U<#YP!-3:/;#[)61D'L-:?#C%",HF?4C8E(?G#OT#-:VH\)
M2#0H7\T9*[ETZ0FF^R69[RB=_"DUCS@@GX5$+M?9?A14^ "!,9:ZLGD*] J%
M1*;I<T_LG$38?I >PFXLBW$#(<IZ_[6L3$NB=#35$#PXE^IK-SB*;("H& N"
MY!S&CO/D)TZPO51"UW!ZN^AF2:^0;'Q,7CA+<2B[H3V-*Q!IS4DKU^@AV47@
MMD&W7A@GT9+:O=N<_G5B]GI#8+G2=+B"H]D-Y,F,@5@:BZ'<./XZ$W5-;N>1
MIN7'O7#[^ULBO#L<\ZZZR(]A-[P%V0%!+1H3X=FB:YJXA2^.VMDM=0[)H&1K
M>UUHO843BXN>^=.+EA-,?Y6[Y-*>SR,T=Q)$7,S(#V/?375.$-PR09+=:F6'
M=$ -KO":4@&;V6YHY:@'16\L:T;>=(B$-E8V9N$A[498#W>@!F@.$FUR#7*+
MPI:P7;X>O\*EPA!V0U>,&Q JS5DP&S)RE&V(A;99VD_4S7Y(Y#B 8+C4_2(4
MI??A<%>&<^VW-B+4QWX ),@'I:_[A1D>*6FQ!NY:)=N]YI@<<0+"HSD0DS=M
MBDP4Z?[V Z3("HC0*ZE*<QOA6)1SJ_=C=JM(V7R#^J0YLK-Y^(]3EHRV.VQF
M-S@PQ:!8<V&=OWXX8(9\Y_OF;XP_[0V*7A(4>KL V1[O! /\[$3XP<<_N7CQ
M(>6;QN;]A"H&/0[;YG>X/HJO4>+X0=RG!A1]M6)+/WT-X]=W7[]^_?CYO/6^
M=>W';H#C983(#YW!_7UO<M_M3\:M=O^:_-R?]/JWW7ZGUQVW_I2-V=H.^N=W
MACQ2(D/D92>!]+VO'1='P+*\3ZGNAI;>[7-/QV3&.SKW'X!B+*IJPVB=C4X0
MO"OZ(*P2M(<+:A'1L:M\;J@G/9#WZSOBMS.$5(U"I"_5T T@2E:YZX_QU2K_
M%_[;URIC6/#0F0I\N#"C(/XV("UZX9G5MN*'SHJ+',;,WI>W3P/'RN?+R@.P
MTG>Z;R?(?>2^79IK,35C>G)T'(-T6K= 3<C8@UG.0^'O.D#S6F\P7!%8] Q2
MCD+J&O1QZ.Q^DY_EHM=GE0<RLPOQ<<&GL63?;F0*7IOWL1)5H-+][,YW:6RP
M/8]02@YW:V,W-K3+%9U86(8?ZY;8+"07TP1(Q+LK>]!P^K,9=$YQK5DL0(!H
MG@XCO'*"9#4DVSRAP)E#YP='[6HE9Y@#W58@='SS1!@)DPQHZ(QFKU'M!,P@
M7_>J N5:K#])ID]Z\N.!KSJD>0C,QK63-H<-<"O57'69BL8)^#J]WZAV4F:0
M#TG7AL<CJ[]C42= 3V(2/)\R=CP%199DSJ8^'9Y-C;IW[4GWNC5LCR9_M":C
M=G_<[DQZ@[Y%!U, PT=X2T?H[^PYCI(+$TH?2RD-9\WQE"S X,E4 2G6]82J
MT)&4-2'"(D!)G475X/ I1ZW*40>CFU5'4I)'&"#W-@4 RX#+YN">9D@K#>C=
M.]'WZ]7#,N!&\@Y:67!0!4\$S"6[HHC%:'SE8ZY(<RVFK'O_-LKSD&;0F;-M
MIUA7/8P',ZGRY0J#3+]8!9W(UE/E3'<8M=S'2ME)J]E#F]QGH4\8M68:<#*K
M%2V@C"*S:4XQ?$4;[% 7A"2XL.Z<J>PRK?5 3HTAW0'F5_),:ZV@+LZC=0'P
M?*W:7-&(S;5&WKXI[%HS5.7XD8AEEUE_0/ZF&O-25ST D64%PN*SL7.%7.G?
M+/+/.D&X.#Q!:'?^_JTW[M$S@^V1@:&#@DW5SAPG1S@=KP7\7J8/"!C4Q5>K
MW$_29P.R(UES+" #)W@DH"8WZT\#&.SP3P+ #A:< BAB@^48LR[XSZ)T73X8
MB2+*$EW-' *(I"_&BBD!FPX!RH3-YL, S=!6>AAPY>/Q:H$2XK_$H9NCB1O)
M%O0R=%@@/VFP$BL5Q;^8I=.9)?+%KTX5&FMJZ"*\BKER&G/6!;?9K.P82!VG
M&8KXSZVHC%('D(NR)3%1C;N&6QCSON&EC&_8.FN\P\8[;+S#QCMLO,/&.VR\
MP\8[;+S#5^@=EN%3[-Y"[WGTS:&9G];<CF.4Q)N'N=JAMWEZS4<Q^=MR@;P.
M?=DP].AS7<].0*]<*GDA&K\[9:U<M?%;= NB#HYL<9Z7Q*4+DW7+882>'-_+
M3@!)^T'RB*+UWRK215ERWJJ**LG'7##M5 9O_!?2 %(\(#"E\:-U4*^*I !:
MMZ]A^:MR;:N/9I7+/&A0OP:%RB91_@_9"]5#9\4/<U5*QAM50SFY0!JJN8AR
MZ8Q%2Y1O6MU.RB6C#JIG3"Z0ZFG.?BR7M\%3>FH4SN^0$R/3&@A2TRBB6#R0
M/A9]#<RJS9JOF25L/S53O@HD .F7L2?/=#+;1ZS*0R5(E7SHC>K3AG-(CS0_
MG#;&L^2'$X$O/F5_K@,81_1"(M3\H-DD<CS4=Q:0#+=_KXL0]PGF'<;7?T7K
MA1D Q%!XIC\F3CCWMWVK6>T$1-1!;PQ)!53.NAV@W6+L_?"#H+)M5_3!UZ]T
M4A( %2P7+3:>%GC.2@O\+)46>-ZD!39I@4U:8,FJW:0%-FF!VK;1)BVP20ML
MT@*;M$!]AR;YQ7V$GE$(OL+.Z5$'AT&&!4CVNJ<!@PSB=/1"8N>C._8CPQ#Y
M>_WJC,,Q(Q(SP;C[=<ERO[Y(N5^7C?O5N%^-^]6X7XW[U;A?C?O5N%^ENU^W
MW6N_0Y8A_B.S>XWJY%P=4UZQ+]44X'CK!3A8K*0G3TIG>+R!Z@#U"9Q9:YXT
MA5:D$2Y0:,6F$]4+EDO_LY1+?]&X](U+W[CTC4O?N/2-2]^X](U+W[CTMKOT
M5F4D-U533%^I;:JF-%53+%?1IFI*4S6EWE53JE.B=<O]6\'I"TN#V;<8ON=3
MDEQEJ'G#:B<M'M"X?@W;<5/%QYXJ/L8>6FNJ^+P9-3RMBD^M2JDT57SLVW2+
M5_$I6C6EJ>+35/$Y13R0/A:MLF)$'_LX09S]MWP9YPEHM(XI$4C1BI9AL<HJ
M;,I%56[IR2YD16O46*5?3;FHTO5)6*?B51Q/-%5ZK%7 IDI/4Z6G3*5[/55Z
M/K%R2K]*Y91^:G)*FYS2)J>T9-5N<DJ;G%)MVVB34]KDE#8YI6\WI[0IN2//
M B3[IN1.4W+GP)>*,Y>H[T3T>.AY9]3LG*HO'SE.U7CG56W':+RKQKMJO*O&
MNVJ\J\:[:KRKQKNJM :J=-G3S%?1#TDUI4YSY&L_#]+HQ-ICRBM[L=QK&II%
MFU;U<%Q*9R^.E\@;/SH1F$D'M)Y>6B-LKM_$(U^W[WKR?I"KFC1THD$T3IP$
M>;\YP1(-4912#N\($IWK )HB-]::8A(U==++?GJJ#JV'JA&^Q7@#ETB+T,X)
M880"JK4='"LFN@!CU!M?'E.@]68L<#5>V[ C](0CFLN<19Y8,:NSPYC5N'M[
MW^U/6J/N<#":]/JWV\"5H7!5%K&-;PBR72***'2"SC).\ )%,4W/P.$\S0%:
M)W!(A+**CV@ZS*5(N730J]BXUH3 3E41,#QVBKS-!,OB*,FI%/EIIT[DAVEJ
MBE!9WB(\CYRG1]]U B!$1MISFEL0(#L)'2S#9#46F@BSM?;GJ0,C+)0=N'G%
MP3 IV6(9PBL*?U4$A)7A+5U@E1/0VL,K1NY/<_S\(;VJ&JW6D&4_[!#+?C']
M-F; D_WQV[CJ[ $I/<<,(G4O126$"*N.8:G(DD.R]MC5"<K:OX.5M7\WO;!8
MPOM40D*]T*RO&7F[:YMP/@6KZ?2K&:]4E\7*Y4MWC) / 51K/$?BNM;VZQ'Y
MCA^)U=F.&, V9)</ IS+!P%:9X;" (?\],(9CA:.9/:*7&_3[CV'RJM5]D=I
MGUYA,&L<>1600:==68K6I[5L#?--9#+C(N8GMPBZ6>#!JT.%53BT[H E(T^4
M(''0S$P.BYQL,8_PBMSVD@&PTEW7!5*E^2?T/URG<M? 4%8_6X$Q1&$-G')#
M>3M"01K.T2'_Z8A4L6,V-T=&%SN5Q3&*K+;IZ?<M"HEC2B]2M[T%D5F<K+/?
ML\+!\"(LT]O4J?()AJHT6[K==PTGL3$BA- JY=?$F0[P$Y6!$$=NMQH"*.;'
M.KLS5\W@H%)&;_'D^%'>QC@&4*9W#7&49@M<6$W!>8V>(N3ZSKK*PU. 4A&3
MM61!A?#O]/<PG#*]:PBG-%N@M6M79+I&"'!Y $\"S(5&EP\Q^M>2+MK/U%>2
MN=OWZ2A$^NUJW/W[-QHE[?Y&_FO1!;\#_F3"HV /0V[Z/CVBF">SM3U!30$<
MA^XYAW?[(Y4'Q)-/"6*44 =ST4F>_/E0'7!KD0'(H%08 X.[& I("J0MQ,;B
ML*1&>*P.5^J!L((<(PTH@N$E-GMFXY["V<*%QN(W\MH_G,@3[T,'S>JP^S Y
ML\A+32\Z73DQO2NQH,&1]4T*8AN'\W2]B*]6NS9#9Y6F5%"F=IR%WC!PPKZS
M$*^'I7S-S$['1A97P*^%6V/MM<CF#=F4IE5Z[-A]<1\IK>UYA%*"N0<_0.LI
MBZHJ=N8RYSF68QL$2O,K?!T</J,HH7'8(9&#'\<X6M&W$;B "7I5GC1;,7 R
M[(,QN/( 3)^TD,4MU]A8W+-ZN ZYAE"ZU(S2V$ESK^C]]+U[RR/D(IH 2U\B
MSM4>@(+6:J-,?[;"L^''L NPI/N4%L"L1_;U",7)R$F@BHWY)G60]A&]UOF.
MU^@AZ85Q$BWI9,_-W/4_J04VC'P7<>H@2 ]A.V*%^+'.)\V5YN@X3W[B!.N:
M*O1,/R(S_ 9'-\MD&2%:<,4)7;F:)7)#U03A8GQ)'*J6=\JW=]$*N=[ZF&_X
M_-1]0>Z2GL1UR!HSQQ%]X"T,5CF:ROENV_OG,DY2JZ'\[_5"SW_VO:43E/NQ
MK9V3?J4)!F@**9UB%=Q']WX0H(AK9Q\V>L7&-5L>I1MG6@(,KQH8@838Y]K6
MAQ9>-622$M,8*RXOJ/!6@&+(AQ]>K=HF(]ZSYX?SO!!V-DM&#/W/ Q$)^<W_
M!U!+ P04    "  #?SU;/0$1TR2/  "68P@ %0   ')E;F(M,C R-3 V,S!?
M;&%B+GAM;.R];7/C.)(N^OU&W/^ VWMC3T^$:[I>IGMV9G;/"=F6:S3KLKR6
MJOO,Z3C108N0S6F*5).4RYY??P'PG7BG*"!=YV[$3E>5,I-/D@^ !)!(_/O_
M>-[%Z EG>90F__'-N]^__0;A9).&4?+P']]\7KV9K2X6BV]07@1)&,1I@O_C
MFR3]YG_\]__[_T+D__[]_WGS!EU%. [_C"[3S9M%LDW_@FZ"'?XS^H@3G 5%
MFOT%_1C$!_HOZ544XPQ=I+M]C M,?B@?_&?TP^_?!^C-&P.S/^(D3+//=XO&
M[&-1[/,_?_?=ER]??I^D3\&7-/LU__TFW9D97!5!<<@;:V^?WU;_5ZK_>QPE
MO_Z9_L]]D&-$7E>2__DYC_[C&_K<ZK%?/OP^S1Z^>__V[;OO_N>GZ]7F$>^"
M-U%"7]L&?U-K42LBO7=_^M.?OF._UJ*<Y/-]%M?/^/!=#:>Q3'Z-%/(=)'GT
MYYS!NTXW0<&^NO8Q2"I!__:F%GM#_^G-N_=O/KS[_7,>?E._?/8&LS3&=WB+
MF)M_+E[VA$EY1(GP3?5OCQG>BL'$6?8=U?\NP0]!@4/ZH#_1![W[@3[H7ZI_
MO@[N<?P-HI*$'U*__M2S52E]YQKL+<ZB-)PGXU /M3W!)VTG*XYPH*OOW(5U
M6@3Q*/!=3>>P;_"X-][JN7_3I)O'X]YT1_,DL L>LO7K%;_7F/[C-?E3#R)^
M+L@ AL,:)#6AZ('9$]C 4-ENK*>;GMV8]N9IQOM.1T9F<QOD]\SP(7_S$ 1[
M\H#W?_@.QT5>_\L;^B_L)53_\ L=&_$.)\7\MT-4O-"!FX0 29'/GJ.\?A9S
M]#^^,=3Y;N@(U9YEM3=!MM&\DDKBNTU*!K1]\28N7WZIOLW2G3&4ZOVEA@J_
MQ/?-<\J73J!('.J)93A/#]D&6WWSKE<V;[A"N8N)%HWA</+F\^J;_UZ*HE86
M_4RE__>_?]<^P0O%;HD9G&68C 7IYM=/>'>/,XG?8E&7A%*![?)() >&/@IP
M0]8THHC)HI]+:?^L(3S>I8F>,@(YEWR1PNR2A1,"PQ09LB%-2CEH')F%840G
M.$%\&T3A(KD(]A&)VY1\T>BXY(X1_"Z/E I@.&6"<LBO5@=1)3*Q1I4:'+;=
MX2*($AS.@RR)DH=<23.9L$M^J0%WB266!,,H);PAE6IA5$O#8=!LLSGL#C&=
M]BR+1YS16"W#CSC)HR>\2#;I#JO[+G-]I_V8K5N]/LU4&0P;;1%S?=WR8H%F
M19%%]X<BN(\Q*E+2ZV4D9H=#U?-#3AI1GL\V9%J1L[Y9,2.42KNDH09REW02
M43 44^,;$JJ61AWQB29_A)3WE!S?O_WAPUM&D+OYS3GID.DR?)9>'.[%/994
MR@4A-! I$20BW@F@QL4/=:4@HI)P^H[9ER +U^0!BAYC(.-TN!+!ZPU)70'O
ME%"AXH86*H.H$)3%GSN<DX%N4U1K$9^3J,CO5I\UL;-2QVT(;0"_'TDK%,!P
MR00EW]G4.M4R --"WQ*]_'<G[GSRK.B0C?RM)1KYRR_KJ(CQ<KM(PN@I"@]!
M+.AX%'(N"*6%24DD%?).'!VR(5F8+ J2$-VF+@*2^6X?IR\8Y\OM-MK@++^,
M,KPAVODL"2_2)#_$19 4XCG[* O. IEQKC5!CIVZ=Z*-Q\SMA]1&SE!MY@PU
MAA@W.Z;@1$_-WL]%'.3D#;#.UF0WCI?WLA,G@RW<A1L*>^>?*4)N@9R*H71;
M+Y&?LK/K+-HK.C21E+-.2PZQZ9AX$>\?7XU+M2<R7?\A_>;)$\Z*Z#[&-VF!
ME=]=+.GPVZN@=KZ_2 P*!Q38>!XTPHA)PQE+KH(H8UF/YR_-'_\:X8R\T\>7
M:_R$19&RK;++4<;.H>Z08Z;IG7ZCX X9237*;%?4Z+" YV;V(Y2%@<:K1;(_
M%#ESZ9UR64"IX86$<NA"YO'B\.@FQ2CGV!DJE<X04T/O /9_';?>6Y/L/122
MO;<CV?M70++W(TGV'C;)/EB3[ ,4DGVP(]F'5T"R#R-)]@$.R3[A(#]D;$;*
M,&JV5^3B+NFE ]WEEDP6#+$T (>LZHB7K)IR6T8R23R/@\VOJ\TC<25?[NFJ
MZVT6;:+DX5,:8G%:G(6>LPFDC1O-=-)$R3N7;)%R._U4%56ZJ%1&E39BZGXW
M8NX(6%&W-/C-U88+!Z?>9&E^\,X($9KA5Z=KD5%>1)L@1MUNY90S.<V'_A0E
MT>ZP$W8I@M]=?7 AK/JC]WX$\>%%B+AQI)3QVZX_!<_JS]W_W=GG%L%J/G?W
M1QB?6X"(^]RES*F7DQ=)5$1!?(<WZ4/"]F?ET8%<UEE$H(/;1 $R0>_?WP3=
MD N5..K(PYF0W&;I'F?%RRV!7,R2D!X_V]-AZ?Q%,S<QTG1[YLO8E?X1,*V:
M=]K98QV2\#I-'MY<1T\X1&OR[VR78Y;G>*KP0])!70?W#4:"=Y'D17:@?U'L
M?.EUG'58IO";CDNGX)U)-B@Y#@7WJ-%#1!%U-.%T:=<DML9D:A4N=OLL?<)R
MNAEIN.S"#*!WNRZ%N'>BF6/D:%9KH*X*''Y='3(RBI/9&VD!5]$S_9.:7BH%
MI\O$6N"]56*I-!AN:2%R:\2U MM&K57@4&N1A'A+9HH%9D/U(BFJL9H-U?GY
MRZ?@'VG&DI04D9FU%9<D'.EBEYF6)L#0=1QN?CI16ZGBN=9.&='!J1@1%-JA
M=R#C=+X@@M>;&70%P+!(A(HK!U'*G'KY895NBR]!ALETI-BFF7AA22GI+))7
M0VWB=[&8]V^OQ\8M-E?"J):&,\A='3W 65EP&F$=-[!9J'NGY'C,7%"F'LSN
M7Q S@\K<[),N5ZRS(,2[(!/7JA&+..O").":OFOPNW>&*$!QYXQJ*;_[(\UI
M@8\X?<B"_2/=JY/L@RID7>V;:.'6>RA20>\<,4$W)$M7[,2)&%&Z>MEA>EY2
ML5XIDG*79"&%V*94<"+>/[L:%Y<N$:6HD3QU3'O-ZC4TI4%FNS0KHG\&ZKTU
M R5W:]:F#K2+UCH-&'PQA<FO)[*:&HTBZFK""8L_IFGX)8K59<^&0BZ#6S'
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M#B&$59>&Z/WHG0\R1/S'?Z*WN]12KC_T9;HY[*I82>!!_V=7GUD$JO[*W=]
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MK.6;8Y*K9@U50+--?]FLC') MSXL0SHC34\;)#;!G($:&!Z:8S7<68'$/\,
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M$[%25^3/,:9_H"'#CAY2_2?[=XGO9JJ.;UXP=F9P"X-6#PSE+, *;F=H5,L
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M4G=%_U1SF9;,0,O/Z]5Z=G.YN/F(WB#6CT+E=]5L30^/6%L!P'&=BP8LEYF
MSG,-[JF97O7RWKE^FZ7;2)6*UA5P>Q9]"*Q_[+S^%0RO.$C<? (7B/[L_9L+
M"KC5Q=LT&^U&FH[/Q9FZ,C@>IU,#PRMSK.(-]YY^L\AQ#:+:GJJ>X%6:D9XZ
M*>]3V+RLLR#)8[99.PO_<<@+NH,F+R8YB67GEP9/\RJX"X:/,PMM.V(ZEX8-
MIM*N+H'9O-";U&O]YH:8(G@&L%&FZ!7L^Q$P?;9E7PUK35$/5'":N=,U@X@-
MFL.P:\7MGT,AMW5/10#[-4^[$F#&<2$L[IZ/]BPR$_-_$+E!=!TE>$'^*)LH
MB 2]$(,#*B1'(P6/($-H"I)04<1DE4PYZ6L?68?XO=,7O\=9E(;DS66%J@]7
MX.36_/%#E-!U770?D!\V^ Q(02;3!2K/2U!&BTQ^EY%,26.X9B1@3%G!Y%3I
M,7E^H(^AR;--I97/">'V;18]D3[D-@XVN$Q>W!)7DP?1W3G'F7*71G.<LVUJ
MS3@[WD>1"<!S*3B5M3)QNBV\@P[4(MJ7)M&^MDGD2J-@^%RVS&G>5&T+,*/[
M[AY!Z=+0:^5T#_UDI#YQ9WV'\R*+-LT61%EG[2K-5CA[BC8XO\,4( YG23A_
MQIL#+?=!)Y!D]L@6**1]]U26G1%_VE?1-(-IS,)H%)/Z(JC\41D?7*.V33.4
M5P] 6?4$EIF)ZV>P6UWJAT!M*O)A83+3KZ>Q2 :-B>Q^)<U%.:1,UEZF&F*F
MN06I?$F7!SKXW;*9$.LTZF0X''9?$'F76QS)<\J.LNC\7J7C7.<6/L:9\]YT
MIO-!L-%2_MZ4\.P'8U ;0-D-3-H"#$T": )6SANT 2-[T!N!C1.VK<#'\M#M
M(:/_6JS3V>:W0Y1'RJF%M0F_DV>]<^HYLUS?.TV/ &T\0]Y7EE"1HJ"UY9V>
MEJL\2AL "6JSJJ,P\-HH.FX51\)19UUI_YX9,IWX*<@R@H=FIERDR1/.<@)G
MN;U)"WP;O @VV:<PZ('%1S@NH/0(:]#X/=X%%=GW_1N)V&3R2V68S3<WC6DJ
M3HVCRKH_[B^2X5+MR%<G,@2)ZW)';3C.6WDUW)9"'\WI*.'7Y"'VXB9!R!%F
M(;'<]"5,TZ_#C%Z.=>1$?;S_.(?O 8YJ&7)SD%J$SNGC>O]7U@(T#DPZ$D#9
ME#U^\Q7L)NN1FZF ED=&83YNL\<W+R?8Z82[HWGLSB6D?G4<Z./(>>+.4[5M
M-'_&V2;*R3!2CQJBEV)KP1E%Q[G6,-1.'09!1V$>\K,6I&-]/:Z[95_9?(ZB
MG]R$;_[IG-,14*8/FH$:T"84]+'1U@F8E<F,BV2%BR+&;8U9N]VXHY_C=T=D
MHM>DWC4Y\B$PFL<)/3/>?>G-UW0)M71"ES=/G:H8LILV:+GE>/R#7FLKM-F\
M//8I7V4['+<-.D%#//7LH)GFT'5+-M%I'9<4^Y>.?$<8<Q>S'>MP&[V-M02C
M@1P+GSL.V\YTJ<%JKMNE\ZEN?9B0VE.]*."$GH3+KY?&DS,83(K@<OL1A]'%
MX?[(/,&N'8"Y6+R;(_*Q6B,PF'P$\F/SLJC<Q_EEA*A-'R06.C<RH5!I"P:9
M#=PU([3"T"L@M1[]I,0^<2_=WXDMLP\*'*[3XSKM2<PZH_V$+Z%I 1/8A-$8
MIG-DV"YN!SOVF]HV;0]01H )W)</"1,:?TV-13)H3&;YJVDXRF%EVN;S*LZ/
MLO*-@W=MH0?@(!SOANF)3Z;DG=FV2%6Q4+JG+,Q/D_TR32DL[ER>['5(A)T7
MQ9("YBIC<9)PN*6"QQ>T(T1\<T^EC>M'G/ C6%YLY+:0G>JEBW&)ZI#'$&J-
MBHKU!AOZX>D]J]2'<TSZ%2RO:6MEP64['N%:EV 6ZF#(9X_9IOPR"IKZS:^M
MT.4'#S4+YXFRA+8")9<OPRH:6M2X//7H:%\RTD>E4=T'D(+4O7\P$7Y5@W:Y
MO0CRQZLX_9)K+H]0JW@I%:P +RP:+) 'T_\:@)07$B:1/%5"3 O]7.OY+S]-
M@A4*[#9+GZ(0A^<OGTF0N$B6]26?,S+"/+&[J\LMMP/YM^I',BW1,'(JXXYO
MW9SPA0RBV@DL@VD/D[K#5>Z?K?Z*KJZ7/ZW0U=WR$UK>SN]F:WJUT^QBO?AQ
ML5[,5W_VWGC:.R_R=7J'*;NB&/=F">O4\"5IFM)I'N6R89WR976;V2F> Z;1
MG="Y81.<7?[M\VK]:7ZS7J'U$MW-+Y8W%XOK>7MQ)OE7^F?65C^OYI=H<0.T
MH5[B?88W47E131+.=FE61/]4+58I-5PV&P/H7?8KQ)V2^ EG]VF.53&Z'BIW
M=6M'@Z5@!AT=QW,FMGUQ\4C@X45R%419N:QKG)AEKNIJ?J6_(6HL<&YT9R9H
M6NR6&"FGO&/S"$_8],J9^PIO#AGK,*^>;J([',31/\GKD2Q=ZG0 K68:0Y5_
MON;+868+Y8VQ$^TT4US+9/Y,:7*(\L<VCUM$596TL[U@/>2F3Y"+@NH!M#"'
MA*$*B'39N*=RXA,I-^2[D$"(+<7=#S=*YL_TC\*T'#,]9_2Q<:,ADHF2]W[(
M%BFWSY(F;ZANN8$OV-XB?&/ZIR68\<ERA?L6-EP3S]J](0F-#8 BI"UJ*3DS
M"/4LNK$UO8H[WZ0'TF<GFBJ)1FK."&GA1,-! QT8M#,'RLW3.YIL2*UTZ8";
MT-)5^VG*$QX]"5\DFPR33OH2E__M+$I<!/NH"&+-&IB- 9=3='O'NC,&<VWO
M3!T-63R#8"6G@CS'1<YF\W$4W$<QFS[X7S+B?9QM6+O*9TG(LK?N\ 9'3[1I
MR:[LM+3AE[,&[JEIJS  9?IR#'CQ[>]9*P>0LK<9W@=1>%DEP5;Q=.WCC#4]
MXU=D9LPOB6T<5K/9Q!)\6EMX(4B=IJKU)"K_+L3[-(^.+RATPJY9',M:Z,'H
M@@71K+$2X"!!C)2+9RLIR'$K;3QE(EYQW08MYM&23-]SU*IV2Q.TBI6A;3K9
M A>/^F4&9=&-6"'2M [*K^G?:]]>S-^,3!_(Y$KLEN'<JJ\,N-=4(^;X64NC
MF(KG9RC!1Z^PGZH+)5U]=B AS=@N5*0/H N5NV70A?+*KZ0+E0(7#/!4L DL
MO;/3/)/MZ%0XJ+F,Q^4K.F5HD19!K.*G-6YN[=XDJ0DJ:Q?)$\Y/E;EK;1P
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M0J:S>0<\N_BOSXO5 D:7N\(/995=6AZ0A-Z:SE4N[G292@.ZMRHED07#)0U
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MX'Z509&D]X[)")Z@*%=VZ)Q9-*F5Y. CU)>!I$E:I\:KOH1 '% Q0!.4LMN
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M#?U4\SG,,F_?_?$/=_@BV$=%$%</%,Y#%-+NYG1:R.VL3BKJG25F^+B97:F
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M&T- *WX-'!U9^*NR H:WHZ%+U^?9N1!FRE/YX]5CD.'[(*?57-I:B[,LH^L
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MRY)!:49M\TR;&W2C$]'@LRC9)I%EI2+CH=DW\;@2_[G&B38E;AK/J^MF*\;
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M&G#4$4,"-5;"NX6 XLT9I)_RW.Q0O=JU@S #0[; @V.Y]LQ*IFHR3UAM!UE
M["O.R7I/$ZJODO<T3ZN:KOY'K&[4X8;JTRY=A!'MT@8/6K3>@6?I^@G'8OY^
M-, +;HY";O_H+LW]^SY*2T5O<3=4G^;H(HQHCC9XT,S1@6?=;2B4=I A<HGF
M[^[ G.1-LZA;J8H^GPM",OOWPTN%_WD@G-T>IS8!2E"OWI"!V8'WHX"#X^WH
MF9-LI@-%#!:.CSV48=*OUH('M!ZS_ZR!A6I%DWZR9$EG=(UUX::(;49IHL+@
MD/@)QYB&/6G2NK[7]CP2_H)6\X3KES<W?%CKWBS>)9.,>(2!9[(T*4@Q0;6_
M*K/ .(GKA,FWJ9^B6IGC.7SNS:Q4;'4V(SX$91 *QL;:;D$0T6JH%NM"VM67
M:)_64<8SY)YPA4MBMW=%>7>H#R6FZ7.T%?Q$PID=$6A=E><+(.FT 9#:8P=-
M).3!]R8O5J7! 8#G+85I25?SI3Y;V+35]0)]9*'GQ .!UG]L)2"@CV[F3UW8
ML%5!CQ#4U/4V#N@[CQA26S7Z\P;OHD-6(S:!&1W3%3^KD$QOF$9D*$"?V\#<
M^-,+H*%GE<$M!M.LH@2$^?DM9I6!!H)/*A,U.L-=BK/\X#:?.="G94[76Y&1
MO4U%KW77)V7L08+Z^W^ ^= &YL;?FS_>H*NZ+M.70TU#5Z@NT&,$P[JO\L1.
M(5,X,,>!F57#X&"G51P\E'?9QLC;.O%*SW(,!$@->M[T^5\M*! GJ&-,77C(
M  91#PKN])K@P.@3!?\MT.<G;D Q9-YPJJX%!J2*:1[E6ZH]1J>3!BF46M@&
M\$OQOB_Q&^$C/>+>LNZ*$J>O.7>AXQ.+@&;\BDGRCT-5\[2K7]I=\C*R@%1]
M3FDTK05$XL/QND'-*U#[#B2\!/5OV2#RGG"1R/''><#U=J<Q#P,X(+7;<*FX
MS:I7)*WX5NRHFH YD3Q@NCW454U\)3(]*=WX,9#G0+#1B]?R)IW2,,@-$F #
M??0;3"PE3OE<D2=7[S3A[W^C\>F:!3B@,6/#Y5@E(LX&D;\RS*8VZK:+!%@L
M85\6R2$.4'..'0S1@;S-;W_1)?R05F\L769W@U_D1'\]* !UV7(H[:JT*($&
M$9EA2UJAYP;S_][G;5N]MI$T/\2ETZS2WW<B $!SR_B63S$Y-OK4TOD-I<2I
M:%L3TB'(/12!&AA5-VW R?:2W:ZW;N0^CQ)HY3L)8&D%;9?UAIA@#-/W@;S:
M ??/I<)!=JK7((/6]A3/E@J>U=;,OV;-33"=D>%KUL"SDV;;[I3A-4MV/C2)
MZK$LCFF"D^O3CXJVO.A"5%?$HSMJ56N/#4BW,YA650BG-%!+A%Y/^T3I$!W_
MAOH 7T\KD'X?HQ-U!:OGHBGNQL/MWW%\*!E?=\>'5*5:*T1 6G7C=ZS0%IMN
M^!O\YF "]10VZ.Z/SP_W4#3):NOUWI^5$D<XD/6G8]5&=;SL8(\,165DNB!3
M0WUZ)!+43<7MO>[*D#TV9#5.,VVCT);*!C$ZF^[D<!_@:M'$0G*?'W$U>^U4
M8 -2[PRF'=?.CE2XM9/%8)[(%HO;X79WE^8T^_3JM<1X/%HG@0%HSYY'N;Z,
M'@G6J./<S1UU"FP >EO M..HZTB%]U@IE_1_0C>*)S(CE&E<=YTJAC\(D(^X
M3(M$WKW%V2%A21+Q&_DJF%X?N-WM<*Q<>/UR ,C. @FNZC&RX=8JT-^@_M6(
M@U G8/3C$(/SA!1[\0WJ.$,M:XCRACASEVC\9[=E0.>(YY%C+4OS;"TX3OY^
M1Q"*'--R[D=<GN[S9-PG60\%8,JQ8$XJY<O!40M/AW!"UJKD$&63K957TH)P
M6#VA"3TD$&U8,"BER/0HH+1R]3,JD^I+5E3XN?@]WZ<W:15K]&*"!:(9*Q:E
M>RX,"3$L&GA^3M]9.LOO#X_WB!(@#PXLX2*\OI[+Y*HL-0H:/ 2B$35/JJ;O
MS*4N2^I>\%2PL%][NK1+]5AD:7QZQK_JZZR(_T?E5-AC ]#7 J:U56VH.] 3
MZ:[I<3KHS^:_E"!B%(/=+\.$,\PZ)=GHU0 .2)$V7$KI,0QGPYM&58 TQ!,1
MGZ-?%NK1P0+2S22+BF-2FHC),B_!#!]>>T*H93YNF=269U8V2F*5<Y2*/"==
M $I?11Q=B="%](.EDKZTAQ[B6>37*,UU]UPF4 #HW953.:WTI1:N?@U.6"ER
MV/LP+ _YFBP3"4T9QWG%4V9['^[ZU(,T9U7,V::M9EAG)6: >]9N_/87+N.T
MPH]EJB[RL=[; !F*!R&5V>2?&4$DOE1TQEE-80&N>3-BK]X@UCJ(O1T)K]^@
ME@'$. ADI:KL!MI-1F5C.EA %C+)HOK*KYR<L4$4+525C#@^O!]8JQXQ=;Y+
MG!_EW3ME YR+-B"EGUTDN852]P)D?Y<!5*X!\[$><'V#=VF>UCA+=WB\?95<
MS EX &%])S859YDFO) 7-N_SI.&,]5LQ:<H%#X#&9K&KOE/98S==::102M!P
MB;HI]:E-2[HYX >RJWC^B;,C_KW(ZS=U]9*9M #-SXM%T$5A1DV\-UT>-)ES
MZP*]$-<J2HD']M\X*M$V#^5CV<I/V7S^62RQ@H;$!2I_S/E9=$X(!KE$:"GS
MU:[&I4+KLXD T/MRWM6:=R,&<:3_R).T8M?NZ/6MF(!>L6:QSN-=1PB ]L_#
M_YRQ+Q)%G"JZFFS&"V#67S+=7XK&52POF^ #QF'O\ZHN#RRVE.>'*'LLTSQ.
M]^0?7$I=,'8*#Y RG=A5AF5[[ WB^*@CT ;(0FZPK LWZJ$!Z<N"2?46"D8A
M1^8S& I+R)$)$S  O=CS:"J5,48*-N?Q*^?/T2^^JZ:Q;,Y@EA4_=67'+=
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MSI1H/VS$^PWEB-/><)A\Q=O4M'(&^X@T]7<:&)8\^LZS'Z1KIM8V0M0$>H8
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M5?X3"8J)@?M EIW8W2T;J.26G?=6[&PW>/,%VB H:@'F)>TH "OH<^%MKCY
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M-*FC'(E6W\*:O%N1>SH[&$3'X#+03JU&(8.'8R1:NH&@E-M!6QC,DZBG+?4
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M$AY/0L'![,EKH5V>;<H9! 2[F.)KKN_Y#F7"3>@D>2%T%+Z2.#-^'HL2;\B
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M8&%3UK)XCRTD!2182S^.+0E()?ADM\]'H4MY>- =R?[;Z$PL:@K;^VMDR"J
MPQF_Q;U8L[%\V@*V=];0N*Z#"7WM'*TWCD_YHCY9ECM\GXOR*KMI#&[ XB.Z
M:CQJ@H1.JLS>2ITP#IP\BF2:YP1A!RO^0A[/CGM(<MS,&*W5/G94JYDIN@'$
MY[3OTLCYC'%2;3-#&\S9W.\$,$E>"!V%7BYK+5#BX0VK;;&%3S5X=> Y^UVX
M0D[=G7C#YH#:\F<+M:45@(9F]F*?:G::QV@?P-Z\85M 1C_;Q&@+<>V@\[@3
M;4MFL26;_0/=<%G%#7V3KIA6.MFH=_D-J))896XS@(,EZF-^BZ>QT?]@HQ4-
M*J.A';^54;_'9\4+8;]_:ACV>_7A$OB+:<LI;E#XV_%A3,9,:19?2?!*GJ(P
M>6EFPP&UB^P0ZR(RN!MHT5<"/3%^)0Y=?(VZ4HQ#<]C.N/X5HH3D.>H!^W(S
MIYN\06S7&Y(N%-$\0VVXC[:R? <-V\-VYN'H0A'+<U2%P@7+3E0A;0_; XBD
M"L7+JA:K@O0ZM:H>MB?/,+7OZG:U^I0HO63]YZ:G1>S+UG^D4^/Q[I7*] 6]
M,@IKQXZK2-U>&X5)CG]U5-'/XB6LBNE,VW0L:,T._IMIOY[-6   _G53C7[+
MKYQJ-_3')-^2ZZ>*'NM=06W4F!WT-U1_/?Z-7$>U^Z:>,<-="\5%O*W7YR5A
M8W:R#J W?U'XDG\!<R%LDH,!+YWU)0?#.\G!8#8- ,;-$2O3 "@>4SB\P?5
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MAXQ6&CK![39.HC6A,8]-B<)5&CF51:^ [53-VK7CF*7B5VB?:B8TOK5*L]\
M2U;S%BU1@4X&2$E1FH-BR!X6TZ2@'NRGHVJP'WY+MY1\)#R0:$6=S8OO.H'
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M/\]LT6>_^;]02P$"% ,4    "  #?SU;G*7Y7Y%F P!6VQP #@
M    @ $     938X.#)?,3 M:RYH=&U02P$"% ,4    "  #?SU;;+Y?H]\"
M  #1$   $               @ &]9@, 938X.#)?97@R,2TQ+FAT;5!+ 0(4
M Q0    (  -_/5OL/(4I\@(  .$)   0              "  <II P!E-C@X
M,E]E>#(S+3$N:'1M4$L! A0#%     @  W\]6^C+ZA*$!P  UR0  !
M         ( !ZFP# &4V.#@R7V5X,S$M,2YH=&U02P$"% ,4    "  #?SU;
M7\@GRWD'  !,(P  $               @ &<= , 938X.#)?97@S,2TR+FAT
M;5!+ 0(4 Q0    (  -_/5M/'I_L4@0  '40   0              "  4-\
M P!E-C@X,E]E>#,R+3$N:'1M4$L! A0#%     @  W\]6PXHB))%!   P \
M !               ( !PX # &4V.#@R7V5X,S(M,BYH=&U02P$"% ,4
M"  #?SU;9+A@G5:7  "+HP  #0              @ $VA0, :6UA9V5?,# Q
M+FIP9U!+ 0(4 Q0    (  -_/5OVM&5=7)8  !FB   -              "
M ;<<! !I;6%G95\P,#(N:G!G4$L! A0#%     @  W\]6Q9,:U12H0$ ',D!
M  T              ( !/K,$ &EM86=E7S P,RYJ<&=02P$"% ,4    "  #
M?SU;[*Q&@^E#  !V1@  #0              @ &[5 8 :6UA9V5?,# T+FIP
M9U!+ 0(4 Q0    (  -_/5O*J5PG',\  '32   -              "  <^8
M!@!I;6%G95\P,#8N:G!G4$L! A0#%     @  W\]6RT'T- R%P  'R8! !$
M             ( !%F@' ')E;F(M,C R-3 V,S N>'-D4$L! A0#%     @
M W\]6[%ME9,O$P  U?$  !4              ( !=W\' ')E;F(M,C R-3 V
M,S!?8V%L+GAM;%!+ 0(4 Q0    (  -_/5M6NF8L^4(  )/*!  5
M      "  =F2!P!R96YB+3(P,C4P-C,P7V1E9BYX;6Q02P$"% ,4    "  #
M?SU;/0$1TR2/  "68P@ %0              @ $%U@< <F5N8BTR,#(U,#8S
M,%]L86(N>&UL4$L! A0#%     @  W\]6_7<Q;D(;   [GP' !4
M     ( !7&4( ')E;F(M,C R-3 V,S!?<')E+GAM;%!+!08     $0 1 "($
(  "7T0@    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>e6882_10-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:RENB="http://renovarobio.com/20250630"
  xmlns:country="http://xbrl.sec.gov/country/2024"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="renb-20250630.xsd" xlink:type="simple"/>
    <context id="From2024-07-01to2025-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-09-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <instant>2025-09-26</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2023-07-012024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-02-13_custom_RenovaroCubeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">RENB:RenovaroCubeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-13</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_EmployeesOfficersDirectorsAndConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">RENB:EmployeesOfficersDirectorsAndConsultantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_EmployeesOfficersDirectorsAndConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">RENB:EmployeesOfficersDirectorsAndConsultantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_CommonStocksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">RENB:CommonStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_CommonStocksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">RENB:CommonStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2025-02-122025-02-13_custom_RenovaroCubeMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">RENB:RenovaroCubeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-12</startDate>
            <endDate>2025-02-13</endDate>
        </period>
    </context>
    <context id="From2025-02-122025-02-13_custom_RenovaroCubeMember_custom_ConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">RENB:RenovaroCubeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">RENB:ConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-12</startDate>
            <endDate>2025-02-13</endDate>
        </period>
    </context>
    <context id="AsOf2025-02-13_custom_RenovaroCubeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">RENB:RenovaroCubeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-13</instant>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_RenovaroCubeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">RENB:RenovaroCubeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_BlackScholesOptionPricingModelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">RENB:BlackScholesOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_srt_MinimumMember_custom_BlackScholesOptionPricingModelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">RENB:BlackScholesOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_srt_MaximumMember_custom_BlackScholesOptionPricingModelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">RENB:BlackScholesOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_srt_MinimumMember_custom_BlackScholesOptionPricingModelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">RENB:BlackScholesOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_srt_MaximumMember_custom_BlackScholesOptionPricingModelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">RENB:BlackScholesOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_BlackScholesOptionPricingModelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">RENB:BlackScholesOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_InitialRecognitionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">RENB:InitialRecognitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_srt_MinimumMember_custom_InitialRecognitionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">RENB:InitialRecognitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_srt_MaximumMember_custom_InitialRecognitionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">RENB:InitialRecognitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_srt_MinimumMember_custom_InitialRecognitionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">RENB:InitialRecognitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_srt_MaximumMember_custom_InitialRecognitionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">RENB:InitialRecognitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_InitialRecognitionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">RENB:InitialRecognitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_srt_MinimumMember_custom_LabEquipmentAndInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">RENB:LabEquipmentAndInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_srt_MaximumMember_custom_LabEquipmentAndInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">RENB:LabEquipmentAndInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_LabEquipmentAndInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">RENB:LabEquipmentAndInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_LabEquipmentAndInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">RENB:LabEquipmentAndInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_srt_MinimumMember_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_srt_MaximumMember_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_SoftwarePlatformMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">RENB:SoftwarePlatformMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_TrademarkMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">RENB:TrademarkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-02-13_custom_RenovaroCubeMember1126484703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">RENB:RenovaroCubeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-13</instant>
        </period>
    </context>
    <context id="AsOf2025-04-08_custom_BioSymetricsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">RENB:BioSymetricsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-08</instant>
        </period>
    </context>
    <context id="AsOf2025-04-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <instant>2025-04-08</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_SoftwarePlatformMember1126485421">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">RENB:SoftwarePlatformMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_SoftwarePlatformMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">RENB:SoftwarePlatformMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_SoftwarePlatformMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">RENB:SoftwarePlatformMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_TrademarkMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">RENB:TrademarkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_TrademarkMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">RENB:TrademarkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_PatentsMember1126485515">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_LessAccumulatedAmortizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">RENB:LessAccumulatedAmortizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_LessAccumulatedAmortizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">RENB:LessAccumulatedAmortizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_LessAccumulatedAmortizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">RENB:LessAccumulatedAmortizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_GoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_GoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_GoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_LessAccumulatedAmortizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">RENB:LessAccumulatedAmortizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_LessAccumulatedAmortizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">RENB:LessAccumulatedAmortizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_GoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_GoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2018-06-182018-06-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <startDate>2018-06-18</startDate>
            <endDate>2018-06-19</endDate>
        </period>
    </context>
    <context id="AsOf2024-01-12_custom_JanuaryNote2024Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:JanuaryNote2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-12</instant>
        </period>
    </context>
    <context id="From2024-01-092024-01-12_custom_JanuaryNote2024Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:JanuaryNote2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-09</startDate>
            <endDate>2024-01-12</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-20_custom_DecemberNote2023Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:DecemberNote2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-20</instant>
        </period>
    </context>
    <context id="From2023-12-192023-12-20_us-gaap_PrivatePlacementMember_custom_DecemberNote2023Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:DecemberNote2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-19</startDate>
            <endDate>2023-12-20</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-04_custom_PasecoApSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RENB:PasecoApSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-04</instant>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_PasecoApSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RENB:PasecoApSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-04_custom_TheNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:TheNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-04</instant>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_TheNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:TheNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_PasecoApSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RENB:PasecoApSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-10-21_custom_JanuaryNote2024Member_custom_PasecoApSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:JanuaryNote2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RENB:PasecoApSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-21</instant>
        </period>
    </context>
    <context id="From2024-01-012024-01-24_custom_JanuaryNote2024Member_custom_PasecoApSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">RENB:JanuaryNote2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RENB:PasecoApSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-24</endDate>
        </period>
    </context>
    <context id="AsOf2024-10-21_custom_TheNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:TheNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-21</instant>
        </period>
    </context>
    <context id="From2024-11-122024-12-03_custom_PromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:PromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-12</startDate>
            <endDate>2024-12-03</endDate>
        </period>
    </context>
    <context id="From2025-02-232025-02-24_custom_PromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:PromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-23</startDate>
            <endDate>2025-02-24</endDate>
        </period>
    </context>
    <context id="From2024-09-152024-09-16_custom_PromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:PromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-15</startDate>
            <endDate>2024-09-16</endDate>
        </period>
    </context>
    <context id="From2024-09-052024-09-06_custom_PromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:PromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-05</startDate>
            <endDate>2024-09-06</endDate>
        </period>
    </context>
    <context id="From2024-02-042024-02-05_custom_PromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:PromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-04</startDate>
            <endDate>2024-02-05</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-01-02_custom_PromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:PromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-02</endDate>
        </period>
    </context>
    <context id="From2024-11-022024-11-03_custom_PromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:PromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-02</startDate>
            <endDate>2024-11-03</endDate>
        </period>
    </context>
    <context id="AsOf2020-03-30_custom_PromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:PromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-30</instant>
        </period>
    </context>
    <context id="From2020-03-292020-03-30_custom_PromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:PromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-29</startDate>
            <endDate>2020-03-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-06-30_custom_PromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">RENB:PromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-11-30_us-gaap_OtherCurrentLiabilitiesMember_custom_FinanceAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RENB:FinanceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-30</instant>
        </period>
    </context>
    <context id="From2024-11-292024-11-30_custom_FinanceAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RENB:FinanceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-29</startDate>
            <endDate>2024-11-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_FinanceAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RENB:FinanceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_FinanceAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RENB:FinanceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_UnitedStatesTaxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">RENB:UnitedStatesTaxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_UnitedStatesTaxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">RENB:UnitedStatesTaxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">RENB:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">RENB:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <instant>2023-06-20</instant>
        </period>
    </context>
    <context id="AsOf2023-06-20_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">RENB:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-20</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">RENB:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">RENB:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2025-04-072025-04-08_custom_CommonStockIssuancesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">RENB:CommonStockIssuancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-07</startDate>
            <endDate>2025-04-08</endDate>
        </period>
    </context>
    <context id="From2025-01-122025-01-21_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-12</startDate>
            <endDate>2025-01-21</endDate>
        </period>
    </context>
    <context id="From2025-01-122025-01-22_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-12</startDate>
            <endDate>2025-01-22</endDate>
        </period>
    </context>
    <context id="From2024-10-162024-10-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <startDate>2024-10-16</startDate>
            <endDate>2024-10-17</endDate>
        </period>
    </context>
    <context id="From2024-10-162024-10-17_custom_CommonStockIssuancesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">RENB:CommonStockIssuancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-16</startDate>
            <endDate>2024-10-17</endDate>
        </period>
    </context>
    <context id="From2024-10-132024-10-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <startDate>2024-10-13</startDate>
            <endDate>2024-10-14</endDate>
        </period>
    </context>
    <context id="From2024-10-132024-10-14_custom_CommonStockIssuancesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">RENB:CommonStockIssuancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-13</startDate>
            <endDate>2024-10-14</endDate>
        </period>
    </context>
    <context id="From2024-10-132024-10-14_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-13</startDate>
            <endDate>2024-10-14</endDate>
        </period>
    </context>
    <context id="From2024-08-022024-08-23_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-02</startDate>
            <endDate>2024-08-23</endDate>
        </period>
    </context>
    <context id="From2024-08-022024-08-23_us-gaap_CommonStockMember_custom_MrMillerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">RENB:MrMillerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-02</startDate>
            <endDate>2024-08-23</endDate>
        </period>
    </context>
    <context id="AsOf2024-08-23_custom_BoardOfDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">RENB:BoardOfDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-23</instant>
        </period>
    </context>
    <context id="From2024-07-192024-08-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <startDate>2024-07-19</startDate>
            <endDate>2024-08-01</endDate>
        </period>
    </context>
    <context id="From2024-07-292024-08-01_custom_CommonStockConsultingServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">RENB:CommonStockConsultingServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-29</startDate>
            <endDate>2024-08-01</endDate>
        </period>
    </context>
    <context id="From2024-06-132024-06-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <startDate>2024-06-13</startDate>
            <endDate>2024-06-14</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-14_srt_MinimumMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-14</instant>
        </period>
    </context>
    <context id="AsOf2024-06-14_srt_MaximumMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-14</instant>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_InvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012023-06-30_us-gaap_InvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012023-06-30_custom_Investor1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:Investor1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-032024-10-02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <startDate>2024-07-03</startDate>
            <endDate>2024-10-02</endDate>
        </period>
    </context>
    <context id="AsOf2024-10-02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <instant>2024-10-02</instant>
        </period>
    </context>
    <context id="From2024-04-042024-04-05_custom_CommonStockIssuancesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">RENB:CommonStockIssuancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-04</startDate>
            <endDate>2024-04-05</endDate>
        </period>
    </context>
    <context id="AsOf2024-02-20_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-20</instant>
        </period>
    </context>
    <context id="AsOf2024-02-20_srt_MinimumMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-20</instant>
        </period>
    </context>
    <context id="AsOf2024-02-20_srt_MaximumMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-20</instant>
        </period>
    </context>
    <context id="From2024-02-192024-02-20_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-19</startDate>
            <endDate>2024-02-20</endDate>
        </period>
    </context>
    <context id="AsOf2024-02-20_us-gaap_WarrantMember_custom_SingleRangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RENB:SingleRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-20</instant>
        </period>
    </context>
    <context id="From2024-02-192024-02-20_us-gaap_WarrantMember_custom_SingleRangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RENB:SingleRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-19</startDate>
            <endDate>2024-02-20</endDate>
        </period>
    </context>
    <context id="From2024-02-142024-02-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <startDate>2024-02-14</startDate>
            <endDate>2024-02-15</endDate>
        </period>
    </context>
    <context id="From2024-02-142024-02-15_custom_CommonStockIssuancesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">RENB:CommonStockIssuancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-14</startDate>
            <endDate>2024-02-15</endDate>
        </period>
    </context>
    <context id="AsOf2024-02-16_custom_GEDiCubeIntlLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:GEDiCubeIntlLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-16</instant>
        </period>
    </context>
    <context id="From2024-02-122024-02-13_custom_StockPurchaseAgreementOfRenovaroCubeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RENB:StockPurchaseAgreementOfRenovaroCubeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-12</startDate>
            <endDate>2024-02-13</endDate>
        </period>
    </context>
    <context id="From2023-12-032023-12-04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <startDate>2023-12-03</startDate>
            <endDate>2023-12-04</endDate>
        </period>
    </context>
    <context id="AsOf2023-10-23_us-gaap_CommonStockMember_custom_AvramMillerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:AvramMillerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-23</instant>
        </period>
    </context>
    <context id="From2023-10-222023-10-23_custom_CommonStockIssuancesMember_custom_AvramMillerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:AvramMillerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">RENB:CommonStockIssuancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-22</startDate>
            <endDate>2023-10-23</endDate>
        </period>
    </context>
    <context id="AsOf2023-07-28_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-28</instant>
        </period>
    </context>
    <context id="From2023-07-272023-07-28_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-27</startDate>
            <endDate>2023-07-28</endDate>
        </period>
    </context>
    <context id="From2022-07-132022-07-14_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-13</startDate>
            <endDate>2022-07-14</endDate>
        </period>
    </context>
    <context id="AsOf2022-07-14_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-14</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_EBIAndWeirdScienceLLCMember_custom_AgreementAndPlanOfMergerAgreementAxisMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">RENB:EBIAndWeirdScienceLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RENB:AgreementAndPlanOfMergerAgreementAxisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2014-02-06_custom_EquityIncentivePlan2014Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">RENB:EquityIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-02-06</instant>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_EmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:EmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_EmployeesThreeYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:EmployeesThreeYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_EmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:EmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_ShareBasedCompensationAwardAdvisoryBoardMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">RENB:ShareBasedCompensationAwardAdvisoryBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_ShareBasedCompensationAwardBoardofDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">RENB:ShareBasedCompensationAwardBoardofDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_ShareBasedCompensationAwardBoardofDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">RENB:ShareBasedCompensationAwardBoardofDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_ShareBasedCompensationAwardConsultingServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">RENB:ShareBasedCompensationAwardConsultingServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_ShareBasedCompensationAwardConsultingServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">RENB:ShareBasedCompensationAwardConsultingServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-11-04_custom_PlanOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">RENB:PlanOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-04</instant>
        </period>
    </context>
    <context id="From2024-11-012024-11-04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-04</endDate>
        </period>
    </context>
    <context id="AsOf2024-11-04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <instant>2024-11-04</instant>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_PlanOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">RENB:PlanOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_PlanOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">RENB:PlanOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_RestrictedStockAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">RENB:RestrictedStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_RestrictedStockAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">RENB:RestrictedStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_AdvisoryServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">RENB:AdvisoryServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_RenovaroMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">RENB:RenovaroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_srt_MinimumMember_custom_RenovaroMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">RENB:RenovaroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_srt_MaximumMember_custom_RenovaroMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">RENB:RenovaroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_EmployeeStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:EmployeeStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_EmployeeStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:EmployeeStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_EmployeeStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:EmployeeStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_EmployeeStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:EmployeeStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange4Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange4Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange5Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange5Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange6Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange6Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange6Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">RENB:ExercisePriceRange6Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_CommonStockPurchaseWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_CommonStockPurchaseWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_CommonStockPurchaseWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">RENB:CommonStockPurchaseWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2021-01-302021-01-31_custom_GTechMember_custom_LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:GTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RENB:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-30</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="From2020-01-302020-01-31_custom_GTechMember_custom_LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:GTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RENB:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-30</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="From2020-02-052020-02-06_custom_GTechMember_custom_LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">RENB:GTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">RENB:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-05</startDate>
            <endDate>2020-02-06</endDate>
        </period>
    </context>
    <context id="From2019-11-142019-11-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <startDate>2019-11-14</startDate>
            <endDate>2019-11-15</endDate>
        </period>
    </context>
    <context id="From2022-08-242022-08-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <startDate>2022-08-24</startDate>
            <endDate>2022-08-25</endDate>
        </period>
    </context>
    <context id="From2022-09-092022-09-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <startDate>2022-09-09</startDate>
            <endDate>2022-09-10</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_MarkDybulMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RENB:MarkDybulMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-08-022024-08-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <startDate>2024-08-02</startDate>
            <endDate>2024-08-23</endDate>
        </period>
    </context>
    <context id="AsOf2024-08-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <instant>2024-08-23</instant>
        </period>
    </context>
    <context id="From2024-08-222025-08-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
        </entity>
        <period>
            <startDate>2024-08-22</startDate>
            <endDate>2025-08-23</endDate>
        </period>
    </context>
    <context id="AsOf2025-02-16_custom_RSBioMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">RENB:RSBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-16</instant>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_BioSymetricsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">RENB:BioSymetricsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-03_custom_GEDiCubeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">RENB:GEDiCubeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-03</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_GEDiCubeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">RENB:GEDiCubeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_BioSymetricsncAcquisitionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">RENB:BioSymetricsncAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_GEDiCubeIntlLtdAcquisitionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">RENB:GEDiCubeIntlLtdAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-02-26_custom_BioSymetricsncAcquisitionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">RENB:BioSymetricsncAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-26</instant>
        </period>
    </context>
    <context id="From2025-02-122025-02-26_custom_BioSymetricsncAcquisitionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">RENB:BioSymetricsncAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-12</startDate>
            <endDate>2025-02-26</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_BioSymetricsncAcquisitionMember1126504281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">RENB:BioSymetricsncAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-02-26_custom_GEDiCubeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">RENB:GEDiCubeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-26</instant>
        </period>
    </context>
    <context id="From2025-02-122025-02-26_custom_GEDiCubeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">RENB:GEDiCubeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-12</startDate>
            <endDate>2025-02-26</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_GEDiCubeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">RENB:GEDiCubeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_BioSymetricsMember1126506984">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">RENB:BioSymetricsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_BioSymetricsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">RENB:BioSymetricsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_country_NL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:NL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_country_NL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:NL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_RENBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">RENB:RENBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_BioSymetricsMember1126507484">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">RENB:BioSymetricsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_RENCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">RENB:RENCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-08-18_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-18</instant>
        </period>
    </context>
    <context id="AsOf2025-07-03_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-03</instant>
        </period>
    </context>
    <context id="AsOf2025-08-19_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-19</instant>
        </period>
    </context>
    <context id="AsOf2025-07-07_us-gaap_SubsequentEventMember_custom_ExchangeAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">RENB:ExchangeAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-07</instant>
        </period>
    </context>
    <context id="AsOf2025-07-07_us-gaap_SubsequentEventMember_custom_ConvertiblePromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">RENB:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-07</instant>
        </period>
    </context>
    <context id="AsOf2025-07-07_us-gaap_SubsequentEventMember_custom_ConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">RENB:ConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-07</instant>
        </period>
    </context>
    <context id="AsOf2025-07-07_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001527728</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-07</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Ratio">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2024-07-01to2025-06-30" id="Fact000003">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="From2024-07-01to2025-06-30" id="Fact000004">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="From2024-07-01to2025-06-30" id="Fact000005">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2024-07-01to2025-06-30" id="Fact000006">0001527728</dei:EntityCentralIndexKey>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="AsOf2024-06-30"
      id="xdx2ixbrl0081"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CapitalizedComputerSoftwareGross
      contextRef="AsOf2024-06-30"
      id="xdx2ixbrl0099"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedTrademarksGross
      contextRef="AsOf2024-06-30"
      id="xdx2ixbrl0102"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="AsOf2025-06-30"
      id="xdx2ixbrl0107"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NotesPayable
      contextRef="AsOf2024-06-30"
      id="xdx2ixbrl0144"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="From2024-07-01to2025-06-30"
      id="xdx2ixbrl0229"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:EquitySecuritiesFvNiRealizedLoss
      contextRef="From2023-07-012024-06-30"
      id="xdx2ixbrl0254"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0296"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-06-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0303"
      unitRef="Shares"
      xsi:nil="true"/>
    <RENB:IssuanceOfPreferredStockAndWarrantsInPrivatePlacement
      contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0308"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:IssuanceOfPreferredStockAndWarrantsInPrivatePlacement
      contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0310"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:IssuanceOfPreferredStockAndWarrantsInPrivatePlacement
      contextRef="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0311"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable
      contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0317"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable
      contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0319"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable
      contextRef="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0320"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:RestrictedSharesIssuedForServicesRenderedValue
      contextRef="From2023-07-012024-06-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0325"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:RestrictedSharesIssuedForServicesRenderedValue
      contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0328"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:RestrictedSharesIssuedForServicesRenderedValue
      contextRef="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0329"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="From2023-07-012024-06-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0334"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0337"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0338"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue
      contextRef="From2023-07-012024-06-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0343"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue
      contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0346"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue
      contextRef="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0347"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:SharesIssuableForSettlementOfContingentConsiderationValue
      contextRef="From2023-07-012024-06-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0352"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:SharesIssuableForSettlementOfContingentConsiderationValue
      contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0355"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:SharesIssuableForSettlementOfContingentConsiderationValue
      contextRef="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0356"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:IssuanceOfCommonStockPursuantToAcquisitionOfGediCube
      contextRef="From2023-07-012024-06-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0361"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:IssuanceOfCommonStockPursuantToAcquisitionOfGediCube
      contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0364"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:IssuanceOfCommonStockPursuantToAcquisitionOfGediCube
      contextRef="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0365"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube
      contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0373"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube
      contextRef="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0374"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube
      contextRef="From2023-07-012024-06-30"
      id="xdx2ixbrl0375"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-07-012024-06-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0381"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0382"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0384"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0385"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-07-012024-06-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0388"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0389"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0391"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0392"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012024-06-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0395"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0396"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0397"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0399"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2023-07-012024-06-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0402"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0403"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0404"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0405"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0409"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-06-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0416"
      unitRef="Shares"
      xsi:nil="true"/>
    <RENB:IssuanceOfCommonStockUnderPrivatePlacementOfferingValue
      contextRef="From2024-07-012025-06-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0420"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:IssuanceOfCommonStockUnderPrivatePlacementOfferingValue
      contextRef="From2024-07-012025-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0423"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:IssuanceOfCommonStockUnderPrivatePlacementOfferingValue
      contextRef="From2024-07-012025-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0424"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationValue
      contextRef="From2024-07-012025-06-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0429"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationValue
      contextRef="From2024-07-012025-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0432"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationValue
      contextRef="From2024-07-012025-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0433"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="From2024-07-012025-06-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0438"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="From2024-07-012025-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0441"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="From2024-07-012025-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0442"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="From2024-07-01to2025-06-30"
      id="xdx2ixbrl0443"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:IssuanceOfCommonStockPursuantToAcquisitionValue
      contextRef="From2024-07-012025-06-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0447"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:IssuanceOfCommonStockPursuantToAcquisitionValue
      contextRef="From2024-07-012025-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0450"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:IssuanceOfCommonStockPursuantToAcquisitionValue
      contextRef="From2024-07-012025-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0451"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-012025-06-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0456"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-012025-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0457"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-012025-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0459"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-012025-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0460"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012025-06-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0463"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012025-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0464"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0465"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012025-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0467"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2024-07-012025-06-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0470"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2024-07-012025-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0471"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2024-07-012025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0472"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2024-07-012025-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0473"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0477"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-06-30_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0484"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:EquitySecuritiesFvNiRealizedLoss
      contextRef="From2023-07-012024-06-30"
      id="xdx2ixbrl0504"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:LossOnExtinguishmentOfDebt
      contextRef="From2024-07-01to2025-06-30"
      id="xdx2ixbrl0506"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="From2024-07-01to2025-06-30"
      id="xdx2ixbrl0515"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2024-07-01to2025-06-30"
      id="xdx2ixbrl0560"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2024-07-01to2025-06-30"
      id="xdx2ixbrl0572"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:CancellationOfRestrictedStockAwards
      contextRef="From2023-07-012024-06-30"
      id="xdx2ixbrl0618"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0772"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0773"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccruedLiabilitiesFairValueDisclosure
      contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0776"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccruedLiabilitiesFairValueDisclosure
      contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0777"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure
      contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl0779"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure
      contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0780"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl0783"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0784"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:NetDefinitelifeIntangibleAssets
      contextRef="AsOf2024-06-30_custom_SoftwarePlatformMember"
      id="xdx2ixbrl0909"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments
      contextRef="From2024-07-012025-06-30_custom_SoftwarePlatformMember"
      id="xdx2ixbrl0917"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:NetDefinitelifeIntangibleAssets
      contextRef="AsOf2024-06-30_custom_TrademarkMember"
      id="xdx2ixbrl0923"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments
      contextRef="From2024-07-012025-06-30_custom_TrademarkMember"
      id="xdx2ixbrl0931"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:DeferredTaxAssetExcessTaxOverDepreciationPatents
      contextRef="AsOf2025-06-30"
      id="xdx2ixbrl1220"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:DepreciationAndAmortizations
      contextRef="AsOf2025-06-30"
      id="xdx2ixbrl1226"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccumulatedAmortizationOfOtherDeferredCosts
      contextRef="AsOf2024-06-30"
      id="xdx2ixbrl1239"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:Section174ReCapitalization
      contextRef="AsOf2024-06-30"
      id="xdx2ixbrl1242"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:OperatingLeaseRightOfUseAssets
      contextRef="AsOf2024-06-30"
      id="xdx2ixbrl1245"
      unitRef="USD"
      xsi:nil="true"/>
    <RENB:Section481aAdjustment
      contextRef="AsOf2024-06-30"
      id="xdx2ixbrl1248"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2024-06-30"
      id="xdx2ixbrl1251"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets
      contextRef="AsOf2025-06-30"
      id="xdx2ixbrl1259"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets
      contextRef="AsOf2024-06-30"
      id="xdx2ixbrl1260"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="From2024-07-01to2025-06-30"
      id="xdx2ixbrl1303"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="From2023-07-012024-06-30"
      id="xdx2ixbrl1304"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange2Member"
      id="xdx2ixbrl1573"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange2Member"
      id="xdx2ixbrl1575"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2025-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange2Member"
      id="xdx2ixbrl1577"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2025-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange2Member"
      id="xdx2ixbrl1579"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange3Member"
      id="xdx2ixbrl1585"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange3Member"
      id="xdx2ixbrl1587"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2025-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange3Member"
      id="xdx2ixbrl1589"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2025-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange3Member"
      id="xdx2ixbrl1591"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2025-06-30_custom_EmployeeStockOptionsMember"
      id="xdx2ixbrl1645"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantMember"
      id="xdx2ixbrl1738"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantMember"
      id="xdx2ixbrl1740"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2024-07-01to2025-06-30" id="Fact000012">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2024-07-01to2025-06-30" id="Fact000014">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2024-07-01to2025-06-30" id="Fact000015">2025-06-30</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="From2024-07-01to2025-06-30" id="Fact000017">--06-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="From2024-07-01to2025-06-30" id="Fact000019">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2024-07-01to2025-06-30" id="Fact000020">001-38758</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2024-07-01to2025-06-30" id="Fact000022">LUNAI BIOWORKS INC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2024-07-01to2025-06-30" id="Fact000023">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2024-07-01to2025-06-30" id="Fact000024">45-2259340</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2024-07-01to2025-06-30" id="Fact000025">2080 Century Park East</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2024-07-01to2025-06-30" id="Fact000026">Suite 906</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2024-07-01to2025-06-30" id="Fact000027">Los Angeles</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2024-07-01to2025-06-30" id="Fact000028">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2024-07-01to2025-06-30" id="Fact000029">90067</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2024-07-01to2025-06-30" id="Fact000030">(305)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2024-07-01to2025-06-30" id="Fact000031">918-1980</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2024-07-01to2025-06-30" id="Fact000032">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2024-07-01to2025-06-30" id="Fact000033">RENB</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2024-07-01to2025-06-30" id="Fact000034">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2024-07-01to2025-06-30" id="Fact000035">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2024-07-01to2025-06-30" id="Fact000036">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2024-07-01to2025-06-30" id="Fact000037">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2024-07-01to2025-06-30" id="Fact000038">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2024-07-01to2025-06-30" id="Fact000040">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2024-07-01to2025-06-30" id="Fact000042">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2024-07-01to2025-06-30" id="Fact000044">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="From2024-07-01to2025-06-30" id="Fact000045">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="From2024-07-01to2025-06-30" id="Fact000046">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="From2024-07-01to2025-06-30" id="Fact000047">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact000048"
      unitRef="USD">111903627</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2025-09-26"
      decimals="INF"
      id="Fact000050"
      unitRef="Shares">231802470</dei:EntityCommonStockSharesOutstanding>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="From2024-07-01to2025-06-30" id="Fact000051">

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;span id="a_005"&gt;&lt;/span&gt;1C. Cybersecurity Risk Management and Strategy&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;Lunai has established a comprehensive cybersecurity
risk management program aimed at safeguarding the confidentiality, integrity, and availability of our essential systems and information.
Central to our cybersecurity efforts is a robust incident response plan designed to address potential cyber incidents swiftly and effectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;In designing and evaluating our cybersecurity initiatives,
we have adopted the National Institute of Standards and Technology Cybersecurity Framework (NIST CSF 2.0) as a guiding principle. It&#x2019;s
important to clarify that our use of the NIST CSF 2.0 is for guidance purposes to frame our risk identification, assessment, and management
processes and does not equate to compliance with any specific technical standards or requirements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_909_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_c20240701__20250630_zDLga0DalTY2"&gt;Our cybersecurity framework is seamlessly &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_902_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240701__20250630_zNhQtaEQyyN4"&gt;integrated
&lt;/span&gt;broader enterprise risk management strategy, sharing methodologies, reporting mechanisms, and &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_901_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20240701__20250630_zMZIGsSwP4Lj"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_909_ecyd--CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_dbT_c20240701__20250630_zW0Q3zUCKb87"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90D_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbT_c20240701__20250630_zFeXpLgHgOM3"&gt;governance structures&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; with other risk domains
including legal, compliance, strategic, operational, and financial risks.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Key components of our cybersecurity risk management program include:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_908_ecyd--CybersecurityRiskRoleOfManagementTextBlock_c20240701__20250630_zVmUDpMuvk8l"&gt;Conducting risk assessments to pinpoint &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90C_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_dbT_c20240701__20250630_zkWS6UoQT297"&gt;material&lt;/span&gt; cybersecurity
    threats to our critical systems, data, products, services, and overall IT infrastructure.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#x25cf;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A dedicated security team overseeing the risk assessment
    processes, maintenance of security controls, and coordination of responses to cybersecurity incidents.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0"&gt;&lt;/p&gt;





&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Engagement with external service providers to evaluate,
    enhance, or support our security measures.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Comprehensive cybersecurity training programs for employees,
    incident responders, and senior management to foster a culture of security awareness.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;An incident response plan outlining specific procedures
    for managing cybersecurity incidents.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A thorough third-party risk management process to evaluate
    and manage risks associated with service providers, suppliers, and vendors.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"&gt;To date, we have not identified any cybersecurity
threats or past incidents that have had, or are likely to have, a material impact on our company&#x2019;s operations, business strategy,
financial performance, or results of operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;div class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_98F_ecyd--CybersecurityRiskBoardOfDirectorsOversightTextBlock_c20240701__20250630_zrWKq2PZKUOj"&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Cybersecurity Governance:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;The governance of cybersecurity risks is a critical
function of our Board of Directors, with the Audit Committee (the &#x201c;Committee&#x201d;) playing a key role in the oversight of cybersecurity
and related technology risks. The Committee is tasked with monitoring the effectiveness of our cybersecurity risk management program as
implemented by management.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;The Committee receives regular updates from management
on the state of cybersecurity risks facing the company. This includes briefings on any significant cyber incidents and ongoing risk management
efforts. These updates enable the Committee to provide informed reports on cybersecurity matters to the full Board.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90B_ecyd--CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20240701__20250630_zBbYgFic1Y3l"&gt;Our Board is actively involved in our cybersecurity
oversight, receiving detailed briefings from internal technology teams or external cybersecurity experts. These sessions are part of the
Board&#x2019;s commitment to continuous learning and staying informed about issues critical to public companies, including cybersecurity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;The responsibility for day-to-day management of cybersecurity
risks lies with our management team, including the Chief Financial Officer. &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_909_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_c20240701__20250630_zftgl5LXRPv4"&gt;This team is at the forefront of our cybersecurity initiatives,
coordinating both internal and external resources to anticipate, identify, and mitigate cyber &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_900_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_dbT_c20240701__20250630_zs0rj4wsEPZa"&gt;threats&lt;/span&gt;.&lt;/span&gt; Our approach includes regular updates
from internal security teams, leveraging intelligence from various sources, and utilizing advanced security tools to protect our digital
environment.&lt;/p&gt;

&lt;/div&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock contextRef="From2024-07-01to2025-06-30" id="Fact000052">Our cybersecurity framework is seamlessly &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_902_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240701__20250630_zNhQtaEQyyN4"&gt;integrated
&lt;/span&gt;broader enterprise risk management strategy, sharing methodologies, reporting mechanisms, and &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_901_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20240701__20250630_zMZIGsSwP4Lj"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_909_ecyd--CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_dbT_c20240701__20250630_zW0Q3zUCKb87"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90D_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbT_c20240701__20250630_zFeXpLgHgOM3"&gt;governance structures&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; with other risk domains
including legal, compliance, strategic, operational, and financial risks.</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="From2024-07-01to2025-06-30" id="Fact000053">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag contextRef="From2024-07-01to2025-06-30" id="Fact000054">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag contextRef="From2024-07-01to2025-06-30" id="Fact000055">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="From2024-07-01to2025-06-30" id="Fact000056">true</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock contextRef="From2024-07-01to2025-06-30" id="Fact000057">Conducting risk assessments to pinpoint &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90C_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_dbT_c20240701__20250630_zkWS6UoQT297"&gt;material&lt;/span&gt; cybersecurity
    threats to our critical systems, data, products, services, and overall IT infrastructure.</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag contextRef="From2024-07-01to2025-06-30" id="Fact000058">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="From2024-07-01to2025-06-30" id="Fact000060">

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Cybersecurity Governance:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;The governance of cybersecurity risks is a critical
function of our Board of Directors, with the Audit Committee (the &#x201c;Committee&#x201d;) playing a key role in the oversight of cybersecurity
and related technology risks. The Committee is tasked with monitoring the effectiveness of our cybersecurity risk management program as
implemented by management.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;The Committee receives regular updates from management
on the state of cybersecurity risks facing the company. This includes briefings on any significant cyber incidents and ongoing risk management
efforts. These updates enable the Committee to provide informed reports on cybersecurity matters to the full Board.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90B_ecyd--CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20240701__20250630_zBbYgFic1Y3l"&gt;Our Board is actively involved in our cybersecurity
oversight, receiving detailed briefings from internal technology teams or external cybersecurity experts. These sessions are part of the
Board&#x2019;s commitment to continuous learning and staying informed about issues critical to public companies, including cybersecurity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;The responsibility for day-to-day management of cybersecurity
risks lies with our management team, including the Chief Financial Officer. &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_909_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_c20240701__20250630_zftgl5LXRPv4"&gt;This team is at the forefront of our cybersecurity initiatives,
coordinating both internal and external resources to anticipate, identify, and mitigate cyber &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_900_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_dbT_c20240701__20250630_zs0rj4wsEPZa"&gt;threats&lt;/span&gt;.&lt;/span&gt; Our approach includes regular updates
from internal security teams, leveraging intelligence from various sources, and utilizing advanced security tools to protect our digital
environment.&lt;/p&gt;

</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="From2024-07-01to2025-06-30" id="Fact000061">Our Board is actively involved in our cybersecurity
oversight, receiving detailed briefings from internal technology teams or external cybersecurity experts. These sessions are part of the
Board&#x2019;s commitment to continuous learning and staying informed about issues critical to public companies, including cybersecurity.</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock contextRef="From2024-07-01to2025-06-30" id="Fact000062">This team is at the forefront of our cybersecurity initiatives,
coordinating both internal and external resources to anticipate, identify, and mitigate cyber &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_900_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_dbT_c20240701__20250630_zs0rj4wsEPZa"&gt;threats&lt;/span&gt;.</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag contextRef="From2024-07-01to2025-06-30" id="Fact000063">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <dei:AuditorFirmId contextRef="From2024-07-01to2025-06-30" id="Fact000064">3627</dei:AuditorFirmId>
    <dei:AuditorName contextRef="From2024-07-01to2025-06-30" id="Fact000065">Sadler, Gibb &amp; Associates, LLC</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2024-07-01to2025-06-30" id="Fact000066">Draper, UT</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000074"
      unitRef="USD">92700</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000075"
      unitRef="USD">220467</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:InsuranceSettlementsReceivableCurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000077"
      unitRef="USD">0</us-gaap:InsuranceSettlementsReceivableCurrent>
    <us-gaap:InsuranceSettlementsReceivableCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000078"
      unitRef="USD">1108247</us-gaap:InsuranceSettlementsReceivableCurrent>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000080"
      unitRef="USD">387851</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000083"
      unitRef="USD">566081</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000084"
      unitRef="USD">668929</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000086"
      unitRef="USD">1046632</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000087"
      unitRef="USD">1997643</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000089"
      unitRef="USD">367843</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000090"
      unitRef="USD">482121</us-gaap:PropertyPlantAndEquipmentNet>
    <RENB:DefiniteLifeIntangibleAssetsNet
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000095"
      unitRef="USD">14994</RENB:DefiniteLifeIntangibleAssetsNet>
    <RENB:DefiniteLifeIntangibleAssetsNet
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000096"
      unitRef="USD">30043</RENB:DefiniteLifeIntangibleAssetsNet>
    <us-gaap:CapitalizedComputerSoftwareGross
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000098"
      unitRef="USD">143000</us-gaap:CapitalizedComputerSoftwareGross>
    <us-gaap:FiniteLivedTrademarksGross
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000101"
      unitRef="USD">8000</us-gaap:FiniteLivedTrademarksGross>
    <us-gaap:Goodwill
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000104"
      unitRef="USD">5963000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000105"
      unitRef="USD">159330161</us-gaap:Goodwill>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000108"
      unitRef="USD">19849</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000110"
      unitRef="USD">687371</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000111"
      unitRef="USD">1269633</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000113"
      unitRef="USD">6816365</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000114"
      unitRef="USD">160649686</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000116"
      unitRef="USD">8230840</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000117"
      unitRef="USD">163129450</us-gaap:Assets>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000125"
      unitRef="USD">12555839</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000126"
      unitRef="USD">9448683</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000128"
      unitRef="USD">5843069</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000129"
      unitRef="USD">5311324</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000131"
      unitRef="USD">378282</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000132"
      unitRef="USD">295361</us-gaap:OtherLiabilitiesCurrent>
    <RENB:ContingentConsiderationLiabilityCurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000134"
      unitRef="USD">630000</RENB:ContingentConsiderationLiabilityCurrent>
    <RENB:ContingentConsiderationLiabilityCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000135"
      unitRef="USD">12310000</RENB:ContingentConsiderationLiabilityCurrent>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000137"
      unitRef="USD">245000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000138"
      unitRef="USD">245000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000140"
      unitRef="USD">313047</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000141"
      unitRef="USD">493553</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:NotesPayable
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000143"
      unitRef="USD">3580525</us-gaap:NotesPayable>
    <RENB:NotesPayableRelatedPartiesNetCurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000146"
      unitRef="USD">5610372</RENB:NotesPayableRelatedPartiesNetCurrent>
    <RENB:NotesPayableRelatedPartiesNetCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000147"
      unitRef="USD">2205996</RENB:NotesPayableRelatedPartiesNetCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000149"
      unitRef="USD">29156134</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000150"
      unitRef="USD">30309917</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000155"
      unitRef="USD">424547</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000156"
      unitRef="USD">842389</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000158"
      unitRef="USD">424547</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000159"
      unitRef="USD">842389</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000161"
      unitRef="USD">29580681</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000162"
      unitRef="USD">31152306</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact000170"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact000172"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact000174"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact000176"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact000178"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact000180"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact000182"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact000184"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000167"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000168"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact000189"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact000191"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact000193"
      unitRef="Shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact000195"
      unitRef="Shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact000197"
      unitRef="Shares">177392907</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact000199"
      unitRef="Shares">177392907</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact000201"
      unitRef="Shares">158452644</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact000203"
      unitRef="Shares">158452644</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000186"
      unitRef="USD">17741</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000187"
      unitRef="USD">15847</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000205"
      unitRef="USD">478280146</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000206"
      unitRef="USD">464587224</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000208"
      unitRef="USD">-510462570</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000209"
      unitRef="USD">-332455081</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000211"
      unitRef="USD">10814842</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000212"
      unitRef="USD">-170846</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000214"
      unitRef="USD">-21349841</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000215"
      unitRef="USD">131977144</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000217"
      unitRef="USD">8230840</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000218"
      unitRef="USD">163129450</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000223"
      unitRef="USD">17880050</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000224"
      unitRef="USD">24557608</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000226"
      unitRef="USD">537428</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000227"
      unitRef="USD">2708829</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000230"
      unitRef="USD">42611000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000232"
      unitRef="USD">170419429</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000233"
      unitRef="USD">11640000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000235"
      unitRef="USD">129095</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000236"
      unitRef="USD">121859</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:OperatingExpenses
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000238"
      unitRef="USD">188966002</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000239"
      unitRef="USD">81639296</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000241"
      unitRef="USD">-188966002</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000242"
      unitRef="USD">-81639296</us-gaap:OperatingIncomeLoss>
    <RENB:ChangeInFairValueOfContingentConsideration
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000247"
      unitRef="USD">11680000</RENB:ChangeInFairValueOfContingentConsideration>
    <RENB:ChangeInFairValueOfContingentConsideration
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000248"
      unitRef="USD">-3048183</RENB:ChangeInFairValueOfContingentConsideration>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000250"
      unitRef="USD">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000251"
      unitRef="USD">-1303578</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:EquitySecuritiesFvNiRealizedLoss
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000253"
      unitRef="USD">112149</us-gaap:EquitySecuritiesFvNiRealizedLoss>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000256"
      unitRef="USD">725684</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000257"
      unitRef="USD">1011322</us-gaap:InterestExpenseNonoperating>
    <RENB:InterestIncomeAndOtherIncomeExpense
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000259"
      unitRef="USD">116346</RENB:InterestIncomeAndOtherIncomeExpense>
    <RENB:InterestIncomeAndOtherIncomeExpense
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000260"
      unitRef="USD">-1423449</RENB:InterestIncomeAndOtherIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000262"
      unitRef="USD">10958513</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000263"
      unitRef="USD">-6786532</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000265"
      unitRef="USD">-178007489</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000266"
      unitRef="USD">-88425828</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-07-01to2025-06-30"
      decimals="INF"
      id="Fact000268"
      unitRef="USDPShares">-1.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-07-01to2025-06-30"
      decimals="INF"
      id="Fact000270"
      unitRef="USDPShares">-1.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-07-012024-06-30"
      decimals="INF"
      id="Fact000272"
      unitRef="USDPShares">-0.91</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-07-012024-06-30"
      decimals="INF"
      id="Fact000274"
      unitRef="USDPShares">-0.91</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-07-01to2025-06-30"
      decimals="INF"
      id="Fact000276"
      unitRef="Shares">165061967</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-07-01to2025-06-30"
      decimals="INF"
      id="Fact000278"
      unitRef="Shares">165061967</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-07-012024-06-30"
      decimals="INF"
      id="Fact000280"
      unitRef="Shares">97511557</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-07-012024-06-30"
      decimals="INF"
      id="Fact000282"
      unitRef="Shares">97511557</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000284"
      unitRef="USD">-178007489</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000285"
      unitRef="USD">-88425828</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000290"
      unitRef="USD">-109985688</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000291"
      unitRef="USD">140964</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000293"
      unitRef="USD">-167021801</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000294"
      unitRef="USD">-88566792</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000305"
      unitRef="Shares">63698144</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000297"
      unitRef="USD">6371</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000298"
      unitRef="USD">290554875</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000299"
      unitRef="USD">-244029253</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000300"
      unitRef="USD">-29882</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000301"
      unitRef="USD">46502111</us-gaap:StockholdersEquity>
    <RENB:IssuanceOfPreferredStockAndWarrantsInPrivatePlacementShares
      contextRef="From2024-07-012025-06-30_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact000314"
      unitRef="Shares">280505</RENB:IssuanceOfPreferredStockAndWarrantsInPrivatePlacementShares>
    <RENB:IssuanceOfPreferredStockAndWarrantsInPrivatePlacement
      contextRef="From2023-07-012024-06-30_us-gaap_PreferredStockMember"
      decimals="0"
      id="Fact000307"
      unitRef="USD">28</RENB:IssuanceOfPreferredStockAndWarrantsInPrivatePlacement>
    <RENB:IssuanceOfPreferredStockAndWarrantsInPrivatePlacement
      contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000309"
      unitRef="USD">1999972</RENB:IssuanceOfPreferredStockAndWarrantsInPrivatePlacement>
    <RENB:IssuanceOfPreferredStockAndWarrantsInPrivatePlacement
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000312"
      unitRef="USD">2000000</RENB:IssuanceOfPreferredStockAndWarrantsInPrivatePlacement>
    <RENB:IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayableShares
      contextRef="From2024-07-012025-06-30_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact000323"
      unitRef="Shares">280505</RENB:IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayableShares>
    <RENB:IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable
      contextRef="From2023-07-012024-06-30_us-gaap_PreferredStockMember"
      decimals="0"
      id="Fact000316"
      unitRef="USD">28</RENB:IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable>
    <RENB:IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable
      contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000318"
      unitRef="USD">1999973</RENB:IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable>
    <RENB:IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000321"
      unitRef="USD">2000001</RENB:IssuanceOfPreferredStockAndWarrantsForConversionOfNotePayable>
    <RENB:RestrictedSharesIssuedForServicesRenderedShares
      contextRef="From2024-07-012025-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000332"
      unitRef="Shares">3083760</RENB:RestrictedSharesIssuedForServicesRenderedShares>
    <RENB:RestrictedSharesIssuedForServicesRenderedValue
      contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000326"
      unitRef="USD">308</RENB:RestrictedSharesIssuedForServicesRenderedValue>
    <RENB:RestrictedSharesIssuedForServicesRenderedValue
      contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000327"
      unitRef="USD">4663882</RENB:RestrictedSharesIssuedForServicesRenderedValue>
    <RENB:RestrictedSharesIssuedForServicesRenderedValue
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000330"
      unitRef="USD">4664190</RENB:RestrictedSharesIssuedForServicesRenderedValue>
    <RENB:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="From2024-07-012025-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000341"
      unitRef="Shares">3951344</RENB:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <RENB:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000335"
      unitRef="USD">396</RENB:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <RENB:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000336"
      unitRef="USD">2341470</RENB:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <RENB:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000339"
      unitRef="USD">2341866</RENB:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <RENB:IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtShares
      contextRef="From2024-07-012025-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000350"
      unitRef="Shares">5660042</RENB:IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtShares>
    <RENB:IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue
      contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000344"
      unitRef="USD">566</RENB:IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue>
    <RENB:IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue
      contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000345"
      unitRef="USD">10575759</RENB:IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue>
    <RENB:IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000348"
      unitRef="USD">10576106</RENB:IssuanceOfCommonStockAndWarrantsUnderPrivatePlacementOfferingInSettlementOfDebtValue>
    <RENB:SharesIssuableForSettlementOfContingentConsideration
      contextRef="From2024-07-012025-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000359"
      unitRef="Shares">5615071</RENB:SharesIssuableForSettlementOfContingentConsideration>
    <RENB:SharesIssuableForSettlementOfContingentConsiderationValue
      contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000353"
      unitRef="USD">562</RENB:SharesIssuableForSettlementOfContingentConsiderationValue>
    <RENB:SharesIssuableForSettlementOfContingentConsiderationValue
      contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000354"
      unitRef="USD">11295121</RENB:SharesIssuableForSettlementOfContingentConsiderationValue>
    <RENB:SharesIssuableForSettlementOfContingentConsiderationValue
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000357"
      unitRef="USD">11295783</RENB:SharesIssuableForSettlementOfContingentConsiderationValue>
    <RENB:IssuanceOfCommonStockPursuantAcquisitionOfGediCubeShares
      contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000368"
      unitRef="Shares">70834183</RENB:IssuanceOfCommonStockPursuantAcquisitionOfGediCubeShares>
    <RENB:IssuanceOfCommonStockPursuantToAcquisitionOfGediCube
      contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000362"
      unitRef="USD">7083</RENB:IssuanceOfCommonStockPursuantToAcquisitionOfGediCube>
    <RENB:IssuanceOfCommonStockPursuantToAcquisitionOfGediCube
      contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000363"
      unitRef="USD">135994548</RENB:IssuanceOfCommonStockPursuantToAcquisitionOfGediCube>
    <RENB:IssuanceOfCommonStockPursuantToAcquisitionOfGediCube
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000366"
      unitRef="USD">136001631</RENB:IssuanceOfCommonStockPursuantToAcquisitionOfGediCube>
    <RENB:PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCubeShares
      contextRef="From2023-07-012024-06-30_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact000377"
      unitRef="Shares">-561010</RENB:PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCubeShares>
    <RENB:PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube
      contextRef="From2023-07-012024-06-30_us-gaap_PreferredStockMember"
      decimals="0"
      id="Fact000370"
      unitRef="USD">-56</RENB:PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube>
    <RENB:PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCubeShares
      contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000379"
      unitRef="Shares">5610100</RENB:PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCubeShares>
    <RENB:PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube
      contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000371"
      unitRef="USD">561</RENB:PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube>
    <RENB:PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube
      contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000372"
      unitRef="USD">-505</RENB:PreferredStockConvertedToCommonStockPursuantToAcquisitionOfGediCube>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000383"
      unitRef="USD">489000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000386"
      unitRef="USD">489000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000390"
      unitRef="USD">4673129</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000393"
      unitRef="USD">4673129</us-gaap:ShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000398"
      unitRef="USD">-88425828</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000400"
      unitRef="USD">-88425828</us-gaap:NetIncomeLoss>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000406"
      unitRef="USD">-140964</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000407"
      unitRef="USD">-140964</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000418"
      unitRef="Shares">158452644</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000410"
      unitRef="USD">15847</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000411"
      unitRef="USD">464587224</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000412"
      unitRef="USD">-332455081</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000413"
      unitRef="USD">-170846</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000414"
      unitRef="USD">131977144</us-gaap:StockholdersEquity>
    <RENB:IssuanceOfCommonStockUnderPrivatePlacementOfferingShares
      contextRef="From2024-07-012025-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000427"
      unitRef="Shares">1613596</RENB:IssuanceOfCommonStockUnderPrivatePlacementOfferingShares>
    <RENB:IssuanceOfCommonStockUnderPrivatePlacementOfferingValue
      contextRef="From2024-07-012025-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000421"
      unitRef="USD">161</RENB:IssuanceOfCommonStockUnderPrivatePlacementOfferingValue>
    <RENB:IssuanceOfCommonStockUnderPrivatePlacementOfferingValue
      contextRef="From2024-07-012025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000422"
      unitRef="USD">2376020</RENB:IssuanceOfCommonStockUnderPrivatePlacementOfferingValue>
    <RENB:IssuanceOfCommonStockUnderPrivatePlacementOfferingValue
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000425"
      unitRef="USD">2376181</RENB:IssuanceOfCommonStockUnderPrivatePlacementOfferingValue>
    <RENB:RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationShares
      contextRef="From2024-07-012025-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000436"
      unitRef="Shares">3160000</RENB:RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationShares>
    <RENB:RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationValue
      contextRef="From2024-07-012025-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000430"
      unitRef="USD">316</RENB:RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationValue>
    <RENB:RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationValue
      contextRef="From2024-07-012025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000431"
      unitRef="USD">1946529</RENB:RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationValue>
    <RENB:RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationValue
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000434"
      unitRef="USD">1946845</RENB:RestrictedSharesIssuedForServicesRenderedAndExecutiveCompensationValue>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
      contextRef="From2024-07-012025-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000445"
      unitRef="Shares">-833333</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="From2024-07-012025-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000439"
      unitRef="USD">-83</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="From2024-07-012025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000440"
      unitRef="USD">83</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
    <RENB:IssuanceOfCommonStockPursuantToAcquisitionShares
      contextRef="From2024-07-012025-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000454"
      unitRef="Shares">15000000</RENB:IssuanceOfCommonStockPursuantToAcquisitionShares>
    <RENB:IssuanceOfCommonStockPursuantToAcquisitionValue
      contextRef="From2024-07-012025-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000448"
      unitRef="USD">1500</RENB:IssuanceOfCommonStockPursuantToAcquisitionValue>
    <RENB:IssuanceOfCommonStockPursuantToAcquisitionValue
      contextRef="From2024-07-012025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000449"
      unitRef="USD">6057000</RENB:IssuanceOfCommonStockPursuantToAcquisitionValue>
    <RENB:IssuanceOfCommonStockPursuantToAcquisitionValue
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000452"
      unitRef="USD">6058500</RENB:IssuanceOfCommonStockPursuantToAcquisitionValue>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-012025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000458"
      unitRef="USD">3313291</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000461"
      unitRef="USD">3313291</us-gaap:ShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012025-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000466"
      unitRef="USD">-178007489</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000468"
      unitRef="USD">-178007489</us-gaap:NetIncomeLoss>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2024-07-012025-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000474"
      unitRef="USD">10985688</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000475"
      unitRef="USD">10985688</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000486"
      unitRef="Shares">177392907</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000478"
      unitRef="USD">17741</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000479"
      unitRef="USD">478280146</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000480"
      unitRef="USD">-510462570</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000481"
      unitRef="USD">10814842</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000482"
      unitRef="USD">-21349841</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000491"
      unitRef="USD">-178007489</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000492"
      unitRef="USD">-88425828</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000497"
      unitRef="USD">129095</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000498"
      unitRef="USD">121859</us-gaap:DepreciationAndAmortization>
    <RENB:ChangeInFairValueOfContingentConsideration
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000500"
      unitRef="USD">11680000</RENB:ChangeInFairValueOfContingentConsideration>
    <RENB:ChangeInFairValueOfContingentConsideration
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000501"
      unitRef="USD">-3048183</RENB:ChangeInFairValueOfContingentConsideration>
    <us-gaap:EquitySecuritiesFvNiRealizedLoss
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000503"
      unitRef="USD">112149</us-gaap:EquitySecuritiesFvNiRealizedLoss>
    <RENB:LossOnExtinguishmentOfDebt
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000507"
      unitRef="USD">-1303578</RENB:LossOnExtinguishmentOfDebt>
    <RENB:NoncashStockbasedCompensationExpense
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000509"
      unitRef="USD">3313291</RENB:NoncashStockbasedCompensationExpense>
    <RENB:NoncashStockbasedCompensationExpense
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000510"
      unitRef="USD">4673129</RENB:NoncashStockbasedCompensationExpense>
    <RENB:NoncashRestrictedSharesIssuedForServicesRendered
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000512"
      unitRef="USD">1946845</RENB:NoncashRestrictedSharesIssuedForServicesRendered>
    <RENB:NoncashRestrictedSharesIssuedForServicesRendered
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000513"
      unitRef="USD">4664190</RENB:NoncashRestrictedSharesIssuedForServicesRendered>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000516"
      unitRef="USD">42611000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000518"
      unitRef="USD">170419429</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000519"
      unitRef="USD">11640000</us-gaap:GoodwillImpairmentLoss>
    <RENB:AmortizationOfDiscountOnNotePayable
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000521"
      unitRef="USD">32024</RENB:AmortizationOfDiscountOnNotePayable>
    <RENB:AmortizationOfDiscountOnNotePayable
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000522"
      unitRef="USD">580605</RENB:AmortizationOfDiscountOnNotePayable>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000527"
      unitRef="USD">-1153768</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000528"
      unitRef="USD">1108247</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000530"
      unitRef="USD">-1143293</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000531"
      unitRef="USD">-1082267</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000533"
      unitRef="USD">3106181</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000534"
      unitRef="USD">4057282</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000536"
      unitRef="USD">-26477</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000537"
      unitRef="USD">0</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000539"
      unitRef="USD">-16086</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000540"
      unitRef="USD">11284</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000542"
      unitRef="USD">499330</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000543"
      unitRef="USD">4769268</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000545"
      unitRef="USD">-7874647</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000546"
      unitRef="USD">-10971430</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireEquitySecuritiesFvNi
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000551"
      unitRef="USD">500000</us-gaap:PaymentsToAcquireEquitySecuritiesFvNi>
    <us-gaap:PaymentsToAcquireEquitySecuritiesFvNi
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000552"
      unitRef="USD">-0</us-gaap:PaymentsToAcquireEquitySecuritiesFvNi>
    <us-gaap:PaymentsToAcquireNotesReceivable
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000554"
      unitRef="USD">-0</us-gaap:PaymentsToAcquireNotesReceivable>
    <us-gaap:PaymentsToAcquireNotesReceivable
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000555"
      unitRef="USD">1255600</us-gaap:PaymentsToAcquireNotesReceivable>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000557"
      unitRef="USD">0</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000558"
      unitRef="USD">65851</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000561"
      unitRef="USD">70430</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000563"
      unitRef="USD">-500000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000564"
      unitRef="USD">-1260179</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <RENB:RepaymentsOfFinanceAgreement
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000569"
      unitRef="USD">971231</RENB:RepaymentsOfFinanceAgreement>
    <RENB:RepaymentsOfFinanceAgreement
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000570"
      unitRef="USD">870073</RENB:RepaymentsOfFinanceAgreement>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000573"
      unitRef="USD">341865</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000575"
      unitRef="USD">2376181</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000576"
      unitRef="USD">3000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000578"
      unitRef="USD">0</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000579"
      unitRef="USD">3770512</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000581"
      unitRef="USD">6977822</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000582"
      unitRef="USD">4275151</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000584"
      unitRef="USD">8382772</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000585"
      unitRef="USD">10517455</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000587"
      unitRef="USD">-135892</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000588"
      unitRef="USD">60141</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000590"
      unitRef="USD">-127767</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000591"
      unitRef="USD">-1654013</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000593"
      unitRef="USD">220467</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000594"
      unitRef="USD">1874480</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000596"
      unitRef="USD">92700</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000597"
      unitRef="USD">220467</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000605"
      unitRef="USD">24555</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000606"
      unitRef="USD">20128</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000608"
      unitRef="USD">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000609"
      unitRef="USD">0</us-gaap:IncomeTaxesPaidNet>
    <RENB:ContingentSharesIssuedPursuantToAcquisitionAgreement
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000614"
      unitRef="USD">0</RENB:ContingentSharesIssuedPursuantToAcquisitionAgreement>
    <RENB:ContingentSharesIssuedPursuantToAcquisitionAgreement
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000615"
      unitRef="USD">0</RENB:ContingentSharesIssuedPursuantToAcquisitionAgreement>
    <RENB:CancellationOfRestrictedStockAwards
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000617"
      unitRef="USD">83</RENB:CancellationOfRestrictedStockAwards>
    <RENB:FinanceAgreementEnteredIntoInExchangeForPrepaidAssets
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000620"
      unitRef="USD">1018930</RENB:FinanceAgreementEnteredIntoInExchangeForPrepaidAssets>
    <RENB:FinanceAgreementEnteredIntoInExchangeForPrepaidAssets
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000621"
      unitRef="USD">906834</RENB:FinanceAgreementEnteredIntoInExchangeForPrepaidAssets>
    <RENB:ConversionOfNotePayableForIssuanceOfPreferredStock
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000623"
      unitRef="USD">0</RENB:ConversionOfNotePayableForIssuanceOfPreferredStock>
    <RENB:ConversionOfNotePayableForIssuanceOfPreferredStock
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000624"
      unitRef="USD">2000001</RENB:ConversionOfNotePayableForIssuanceOfPreferredStock>
    <RENB:NotePayableSettledThroughNoncashExerciseOfWarrants
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000626"
      unitRef="USD">0</RENB:NotePayableSettledThroughNoncashExerciseOfWarrants>
    <RENB:NotePayableSettledThroughNoncashExerciseOfWarrants
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000627"
      unitRef="USD">2000000</RENB:NotePayableSettledThroughNoncashExerciseOfWarrants>
    <RENB:DebtDiscountRelatedToConvertiblePromissoryNotes
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000629"
      unitRef="USD">24954</RENB:DebtDiscountRelatedToConvertiblePromissoryNotes>
    <RENB:DebtDiscountRelatedToConvertiblePromissoryNotes
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000630"
      unitRef="USD">339342</RENB:DebtDiscountRelatedToConvertiblePromissoryNotes>
    <RENB:CommonSharesIssuedUponAcquisition
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000632"
      unitRef="USD">6058500</RENB:CommonSharesIssuedUponAcquisition>
    <RENB:CommonSharesIssuedUponAcquisition
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000633"
      unitRef="USD">136001631</RENB:CommonSharesIssuedUponAcquisition>
    <RENB:ContingentConsiderationIssuedUponAcquisition
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000635"
      unitRef="USD">0</RENB:ContingentConsiderationIssuedUponAcquisition>
    <RENB:ContingentConsiderationIssuedUponAcquisition
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000636"
      unitRef="USD">20557500</RENB:ContingentConsiderationIssuedUponAcquisition>
    <RENB:CommonSharesIssuedUponSettlementOfDebt
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000638"
      unitRef="USD">0</RENB:CommonSharesIssuedUponSettlementOfDebt>
    <RENB:CommonSharesIssuedUponSettlementOfDebt
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000639"
      unitRef="USD">9582912</RENB:CommonSharesIssuedUponSettlementOfDebt>
    <RENB:EarnOutSharesIssuedInSettlementOfContingentLiability
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000641"
      unitRef="USD">0</RENB:EarnOutSharesIssuedInSettlementOfContingentLiability>
    <RENB:EarnOutSharesIssuedInSettlementOfContingentLiability
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000642"
      unitRef="USD">11295683</RENB:EarnOutSharesIssuedInSettlementOfContingentLiability>
    <RENB:OptionsIssuedInSettlementOfDebt
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000644"
      unitRef="USD">0</RENB:OptionsIssuedInSettlementOfDebt>
    <RENB:OptionsIssuedInSettlementOfDebt
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000645"
      unitRef="USD">489000</RENB:OptionsIssuedInSettlementOfDebt>
    <RENB:SettlementOfNotesPayable
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000647"
      unitRef="USD">0</RENB:SettlementOfNotesPayable>
    <RENB:SettlementOfNotesPayable
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000648"
      unitRef="USD">418503</RENB:SettlementOfNotesPayable>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock contextRef="From2024-07-01to2025-06-30" id="Fact000650">&lt;p id="xdx_800_eus-gaap--OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_zXBRMONLJ7el" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 1 &#x2014; &lt;span id="xdx_824_zC5Om9BGvJmf"&gt;ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_845_ecustom--BusinessPolicyTextBlock_zYUaib2yJrql" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&lt;span id="xdx_86F_zWx8dfvOISIj"&gt;Business&lt;/span&gt; &#x2013; &lt;/b&gt;On August 20, 2025, the Company changed its corporate name from Renovaro Inc.
to Lunai Bioworks Inc. (&#x201c;Lunai&#x201d;) On April 8, 2025, Lunai Bioworks Inc. acquired BioSymetrics, Inc. and its subsidiary (&#x201c;BioSymetrics,
Corp.&#x201d;), as a wholly owned subsidiary pursuant to a stock purchase agreement. On February 13, 2024, the Company changed its corporate
name from Renovaro Biosciences Inc. to Renovaro Inc. (&#x201c;Renovaro&#x201d;, and together with its subsidiaries, the &#x201c;Company&#x201d;,
&#x201c;we&#x201d; or &#x201c;us&#x201d;) and acquired GEDi Cube Intl Ltd and its subsidiaries (&#x201c;Renovaro Cube&#x201d;), as a wholly
owned subsidiary pursuant to a stock purchase agreement. In August 2023, the Company changed its corporate name from Enochian Biosciences
Inc. to Renovaro Biosciences Inc. The Company is an AI-driven platform for precision medicine, diagnostics, and biodefense. Its proprietary
technologies transform complex biomedical data into predictive insights, enabling faster discovery, greater accuracy, and strategic partnerships
across the life sciences and government sectors.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zkcuu00BbdI8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&lt;span id="xdx_86F_zEXXiiFIMlJ7"&gt;Basis of Presentation&lt;/span&gt; &#x2013;
&lt;/b&gt;The Company prepares consolidated financial statements in accordance with accounting principles generally accepted in the United States
of America (&#x201c;U.S. GAAP&#x201d;) and follows the rules and regulations of the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--ConsolidationPolicyTextBlock_zrqS0OafGlp6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&lt;span id="xdx_865_z1KoBG5SEgYe"&gt;Principles of Consolidation&lt;/span&gt;
&#x2013; &lt;/b&gt;For the years ended June 30, 2025 and 2024, the consolidated financial statements include the accounts and operations of Lunai,
and its wholly owned subsidiaries. All material inter-company transactions and accounts have been eliminated in the consolidation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_zpuJAViAAP6d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&lt;span id="xdx_862_zydL5jMJeb8k"&gt;Subsidiaries&lt;/span&gt; &#x2013; &lt;/b&gt;Renovaro
Biosciences Inc. (&#x201c;Renovaro Biosciences&#x201d;), formerly Renovaro
Biopharma Inc., was incorporated on May 19, 2017 in Delaware and is a 100% owned subsidiary of Lunai. Renovaro Biosciences owns a perpetual,
fully paid-up, royalty-free, sublicensable, and sole and exclusive worldwide license to research, develop, use, sell, have sold, make,
have made, offer for sale, import and otherwise commercialize certain intellectual property in cellular therapies for the prevention,
treatment, amelioration of and/or therapy exclusively for HIV in humans, and research and development exclusively relating to HIV in humans.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;Renovaro Biosciences Denmark ApS
(&#x201c;Renovaro Denmark&#x201d;), formerly Enochian Biosciences Denmark ApS a Danish corporation was incorporated on April 1, 2001. On
February 12, 2014, in accordance with the terms and conditions of a Share Exchange Agreement, the Company acquired Renovaro Denmark and
it became a 100% owned subsidiary of Lunai subject to 185,053 shares of Common Stock of Lunai held in escrow according to Danish law (the
&#x201c;Escrow Shares&#x201d;). As of June 30, 2025, there are 17,414 Escrow Shares remaining (see Note 10).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On February 13, 2024, the Company
acquired &lt;span id="xdx_90F_ecustom--BusinessAcquisitionPercentage_iI_dp_c20240213__us-gaap--BusinessAcquisitionAxis__custom--RenovaroCubeMember_zzu7S4nWvqHk" title="Acquisition percentage"&gt;100&lt;/span&gt;% of Renovaro Cube. As a result of the acquisition, Renovaro Cube became a wholly-owned subsidiary of the Company (see Note
13).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On April 8, 2025, the Company acquired
100% of Biosymetrics, Corp. As a result of the acquisition, Biosymetrics, Corp. became a wholly-owned subsidiary of the Company (see Note
13).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--UseOfEstimates_z1PAWZOr1WM8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&lt;span id="xdx_860_z7ZmMRXloNK5"&gt;Use of Accounting Estimates&lt;/span&gt;
&lt;/b&gt;- The preparation of financial statements in conformity with generally accepted accounting principles requires management to make
estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities
at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could
differ from those estimated. Significant estimates include the fair value and potential impairment of intangible assets, the fair value
of the contingent consideration liability, and the fair value of equity instruments issued.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;





&lt;p id="xdx_845_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zyeZrTS2kLa6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&lt;span id="xdx_860_zM6CXfrzgW3j"&gt;Functional Currency and Foreign
Currency Translation&lt;/span&gt; &lt;/b&gt;&#x2013; The functional currency of Renovaro Denmark is the Danish Kroner (&#x201c;DKK&#x201d;) and the functional
currency of Renovaro Cube is the Euro (&#x201c;EUR&#x201d;) and the functional currency of BioSymetrics Corp. is Canadian Dollar (&#x201c;CAD&#x201d;).
The Company&#x2019;s reporting currency is the U.S. Dollar for the purpose of these financial statements. The Company&#x2019;s balance sheet
accounts are translated into U.S. dollars at the period-end exchange rates and all revenue and expenses are translated into U.S. dollars
at the average exchange rates prevailing during the years ended June 30, 2025, and 2024. Translation gains and losses are deferred and
accumulated as a component of other comprehensive income in stockholders&#x2019; equity. Transaction gains and losses that arise from exchange
rate fluctuations from transactions denominated in a currency other than the functional currency are included in the statement of operations
as incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z1pBNr7bNr16" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&lt;span id="xdx_864_zKkxoHpQUD82"&gt;Cash and Cash Equivalents&lt;/span&gt; &lt;/b&gt;&#x2013;
The Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--ConcentrationRiskCreditRisk_zSp4CzxxGON3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&lt;span id="xdx_869_zG0cDF1nI7Df"&gt;Concentration of Credit Risk&lt;/span&gt;
&#x2013;&lt;/b&gt; Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in financial
institutions, which, at times, exceed the amount of deposit insurance provided within the relevant jurisdiction where the deposits are
held. As of June 30, 2025, and June 30, 2024, the Company has not experienced losses on these accounts and management believes the Company
is not exposed to significant risks on such accounts.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_848_ecustom--InvestmentinEquitySecuritiesPolicyTextBlock_zPhvPJ0FpCb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&lt;span id="xdx_86D_z4PxeoMQXEja"&gt;Investment in Equity Securities&lt;/span&gt;
&lt;/b&gt;&#x2013; The Company accounts for investments in equity securities in accordance with ASC 321, Investments&#x2014;Equity Securities.
Equity securities with readily determinable fair values are measured at fair value, with changes in fair value recognized in net income
or loss. Equity securities without readily determinable fair values are measured at cost, less impairment, if any, and adjusted for observable
price changes in orderly transactions for the identical or a similar investment of the same issuer. The Company evaluates such investments
at each reporting period for impairment or other observable transactions that would require adjustment. On February 28, 2025, the Company
purchased $&lt;span id="xdx_90D_ecustom--PurchaseEquitySecuritiesValue_iI_c20250630_zdDehCdNLaYh" title="Purchase equity securities value"&gt;500,000&lt;/span&gt; of equity securities. During the year ended June 30, 2025, the Company recorded a change in fair value of equity securities
for $&lt;span id="xdx_904_eus-gaap--DebtSecuritiesTradingAndEquitySecuritiesFvNiCost_iI_c20250630_zAnM259h5M4b" title="Fair value of equity securities"&gt;112,149&lt;/span&gt; (see Note 3). The investment in equity securities balance at June 30, 2025, was $&lt;span id="xdx_903_eus-gaap--DebtAndEquitySecuritiesGainLoss_c20240701__20250630_z4DS7NglA2n7" title="Investment in equity securities"&gt;387,851&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_843_ecustom--InsuranceReceivablePolicy_z318v78IRBx3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&lt;span id="xdx_860_zSQo35l8z6Xh"&gt;Insurance Receivable&lt;/span&gt; &#x2013;&lt;/b&gt;
The Company recognizes insurance receivables associated with expected recoveries of costs incurred for litigation which is probable of
incurring a loss and for which it is probable the Company will receive coverage under its existing insurance policies. The Company records
any such recoveries on a gross basis and does not net such amounts against any related loss contingency accruals.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zPkradVek9Nk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&lt;span id="xdx_865_zZ0FLRKdTa8k"&gt;Property and Equipment&lt;/span&gt; &lt;/b&gt;-
Property and equipment are stated at cost. Expenditures for major renewals and betterments that extend the useful lives of property and
equipment are capitalized and depreciated upon being placed in service. Expenditures for maintenance and repairs are charged to expense
as incurred. Depreciation is computed for financial statement purposes on a straight-line basis over the estimated useful lives of the
assets, which range from four to ten years (see Note 5).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zlQ0lARpwWP2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&lt;span id="xdx_862_zduFUJqHNupk"&gt;Intangible Assets&lt;/span&gt; - &lt;/b&gt;The
Company has both definite and indefinite life intangible assets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;Definite life intangible assets
relate to patents. The Company accounts for definite life intangible assets in accordance with Financial Accounting Standards Board (&#x201c;FASB&#x201d;)
Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 350, &lt;i&gt;Goodwill and Other Intangible Assets&lt;/i&gt;. Intangible assets are recorded
at cost. Patent costs capitalized consist of costs incurred to acquire the underlying patent. If it is determined that a patent will not
be issued, the related remaining capitalized patent costs are charged to expense. Definite life intangible assets are amortized on a straight-line
basis over their estimated useful life. The estimated useful life of patents is twenty years from the date of application.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;Indefinite life intangible assets
include license agreements and goodwill acquired in a business combination. The Company accounts for indefinite life intangible assets
in accordance with ASC 350. License agreement costs represent the fair value of the license agreement on the date acquired and are tested
annually for impairment on June 30 or whenever events or changes in circumstances indicate the fair value of the license is less than
the carrying amount.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zppE3uZ4rs8l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&lt;span id="xdx_86A_zY6jWxzGpd27"&gt;Goodwill&lt;/span&gt;&lt;/b&gt; - Goodwill is
not amortized but is evaluated for impairment annually as of June 30 or whenever events or changes in circumstances indicate the carrying
value of the reporting unit may be less than the fair value of the reporting unit.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;





&lt;p id="xdx_846_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_zUHEWWKhdzql" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&lt;span id="xdx_86A_zYdnNWAi0jOc"&gt;Impairment of Goodwill and
Indefinite Lived Intangible Assets&lt;/span&gt;&lt;/b&gt; &#x2013; We test for goodwill impairment at the reporting unit level, which is one level below the
operating segment level. Our detailed impairment testing involves comparing the fair value of each reporting unit to its carrying value,
including goodwill. Fair value reflects the price a market participant would be willing to pay in a potential sale of the reporting unit
and is based on discounted cash flows or relative market-based approaches. If the carrying value of the reporting unit exceeds its fair
value, we record an impairment loss for such excess.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;During the year ended June 30, 2025, the results of the assessment indicated that
the carrying value of the RENC reporting unit exceeded its fair value, due to the decline in the estimated fair value of the reporting
unit based on the Company&#x2019;s market capitalization. Management concluded the significant driver for the change in the economic benefits
was due to the Company&#x2019;s continued inability to raise capital for the further development of the technologies within this reporting
unit. The Company recorded an impairment loss of $&lt;span id="xdx_900_ecustom--ImpairmentLoss_iI_c20240930_zvTM8vzNPVO1" title="Impairment loss"&gt;47,614,729&lt;/span&gt; for the period ended September 30, 2024 and $&lt;span id="xdx_90A_ecustom--ImpairmentLoss_iI_c20250630_zWUNhMmystdk" title="Impairment loss"&gt;122,804,700&lt;/span&gt; for the period ended
June 30, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;For indefinite life intangible
assets, such as IPR&amp;amp;D, on an annual basis on June 30th we determine the fair value of the asset and record an impairment loss, if
any, for the excess of the carrying value of the asset over its fair value. For the year ended June 30, 2024, the carrying value of the
IPR&amp;amp;D exceeded its fair value. Therefore, the Company recorded an impairment loss of $&lt;span id="xdx_90C_ecustom--ImpairmentLoss_iI_c20240630_zS5WUF3ShNad" title="Impairment loss"&gt;42,611,000&lt;/span&gt; during the year ended June 30, 2024.
During the year ended June 30, 2025, the Company recorded no impairment loss related to IPR&amp;amp;D.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The carrying value of
IPR&amp;amp;D and goodwill at June 30, 2025, were&#160;&lt;span id="xdx_908_ecustom--InProcessResearchAndDevelopment_iI_c20250630_zj3R8xMjC70l" style="display: none" title="In-process research and development"&gt;0&lt;/span&gt;
zero and $&lt;span id="xdx_90B_eus-gaap--Goodwill_iI_c20250630_zsA8QKJf2cWd" title="Goodwill"&gt;5,963,000&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zKn0gA0Hulw" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;b&gt;&lt;span id="xdx_862_zpCMsJFbXpTj"&gt;Impairment of Long-Lived
Assets&lt;/span&gt; - &lt;/b&gt;Long-lived assets, such as property and equipment and definite life intangible assets are reviewed for impairment whenever
events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Circumstances which could trigger
a review include, but are not limited to: significant decreases in the market price of the asset; significant adverse changes in the business
climate or legal factors; current period cash flow or operating losses combined with a history of losses or a forecast of continuing losses
associated with the use of the asset; and current expectations that the asset will more likely than not be sold or disposed of significantly
before the end of its estimated useful life.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;Recoverability of assets to be
held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected
to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge
is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of would
be separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell and would
no longer be depreciated. The depreciable basis of assets that are impaired and continue in use are their respective fair values. &lt;span id="xdx_901_eus-gaap--AssetImpairmentCharges_do_c20240701__20250630_z0oVRYKbcl5l" title="Impairment of assets"&gt;&lt;span id="xdx_909_eus-gaap--AssetImpairmentCharges_do_c20230701__20240630_zMHxZhPQePZj" title="Impairment of assets"&gt;No&lt;/span&gt;&lt;/span&gt; impairment
of these assets was recorded during the year ended June 30, 2025 or 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--LesseeLeasesPolicyTextBlock_zLsY70deoHF7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;b&gt;&lt;span id="xdx_86B_z3Yxf2ZBGssk"&gt;Leases&lt;/span&gt; -&lt;/b&gt; In accordance
with ASC Topic 842, the Company determined the initial classification and measurement of its right-of-use assets and lease liabilities
at the lease commencement date and thereafter. The lease terms include any renewal options and termination options that the Company is
reasonably assured to exercise, if applicable. The present value of lease payments is determined by using the implicit interest rate in
the lease, if that rate is readily determinable; otherwise, the Company develops an incremental borrowing rate based on the information
available at the commencement date in determining the present value of the future payments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;Rent expense for operating leases
is recognized on a straight-line basis, unless the operating lease right-of-use assets have been impaired, over the reasonably assured
lease term based on the total lease payments and is included in general and administrative expenses in the consolidated statements of
operations. For operating leases that reflect impairment, the Company will recognize the amortization of the operating lease right-of-use
assets on a straight-line basis over the remaining lease term with rent expense still included in general and administrative expenses
in the consolidated statements of operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;





&lt;p id="xdx_842_eus-gaap--ResearchAndDevelopmentExpensePolicy_zYLdwUrdqhD9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&lt;span id="xdx_869_zaRzb8gbnWt8"&gt;Research and Development Expenses&lt;/span&gt;
&#x2013; &lt;/b&gt;The Company expenses research and development costs incurred in formulating, improving, validating, and creating alternative
or modified processes related to and expanding the use of the Company&#x2019;s technologies. Research and development expenses for the
years ended June 30, 2025 and 2024 amounted to $&lt;span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20240701__20250630_zZJeJ1XukUpc" title="Research and development expense"&gt;537,428&lt;/span&gt;, and $&lt;span id="xdx_900_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230701__20240630_zkydk6f0dDki" title="Research and development expense"&gt;2,708,829&lt;/span&gt; respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_zfMXOt5X8KO5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&lt;span id="xdx_862_z48fhTLPouia"&gt;Income Taxes&lt;/span&gt; &lt;/b&gt;- The Company
accounts for income taxes in accordance with FASB ASC Topic 740 Accounting for Income Taxes, which requires an asset and liability approach
for accounting for income taxes (see Note 9).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--EarningsPerSharePolicyTextBlock_zFEfdTf7feMe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&lt;span id="xdx_86A_ziMuA0HBi456"&gt;Loss Per Share&lt;/span&gt;&lt;/b&gt; - The Company
calculates earnings (loss) per share in accordance with FASB ASC 260 Earnings Per Share. Basic earnings per common share (EPS) are based
on the weighted average number of shares of Common Stock outstanding during each period. Diluted earnings per common share are based on
shares outstanding (computed as for basic EPS) and potentially dilutive common shares. Potential shares of Common Stock included in the
diluted earnings per share calculation include in-the-money stock options that have been granted but have not been exercised. The shares
of Common Stock outstanding at June 30, 2025 and 2024 were &lt;span id="xdx_905_eus-gaap--CommonStockOtherSharesOutstanding_iI_c20250630_zMapRAqnrkA9" title="Common stock outstanding"&gt;177,392,907&lt;/span&gt; and &lt;span id="xdx_903_eus-gaap--CommonStockOtherSharesOutstanding_iI_c20240630_zaQnmzBUSFij" title="Common stock outstanding"&gt;158,452,644&lt;/span&gt;, respectively. Because of the net loss for each
of the years ended June 30, 2025 and June 30, 2024, dilutive shares for both periods were excluded from the diluted EPS calculation, as
the effect of these potential shares of Common Stock is anti-dilutive. The Company had &lt;span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240701__20250630_zScZFt79wZuh" title="Anti-dilutive shares"&gt;13,669,140&lt;/span&gt; and &lt;span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20240630_zhSvmErRFtTi" title="Anti-dilutive shares"&gt;17,146,315&lt;/span&gt; potential shares of Common
Stock excluded from the diluted EPS calculation for the years ended June 30, 2025 and 2024, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zakJ3iM7cBMi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&lt;span id="xdx_86F_zNE5vRN0nSkg"&gt;Fair Value of Financial Instruments&lt;/span&gt;
&lt;/b&gt;&#x2013; The Company accounts for fair value measurements for financial assets and financial liabilities in accordance with FASB ASC
Topic 820, &#x201c;Fair Value Measurements&#x201d;. The authoritative guidance, among other things, defines fair value, establishes a consistent
framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either
a recurring or nonrecurring basis. Fair value is defined as the exit price, representing the amount that would either be received to
sell an asset or be paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based
measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zBv2wJW9shTb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;b&gt;&lt;span id="xdx_869_zLzKFsYnd3xa"&gt;Stock-Based Compensation&lt;/span&gt;
- &lt;/b&gt;The Company has granted stock options, restricted share units (&#x201c;RSUs&#x201d;) and warrants to certain employees, officers,
directors, and consultants. The Company accounts for options in accordance with the provisions of &lt;b&gt;&lt;i&gt;FASB ASC Topic 718, Compensation
&#x2013; Stock Compensation&lt;/i&gt;&lt;/b&gt;. Stock based compensation costs for the vesting of options and RSUs granted to certain employees, officers,
directors, and consultants for the years ended June 30, 2025 and 2024 were $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensation_c20240701__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesOfficersDirectorsAndConsultantsMember_zzOV5taph179" title="Stock based compensation costs"&gt;3,313,291&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensation_c20230701__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesOfficersDirectorsAndConsultantsMember_z0Xu23kdrakh" title="Stock based compensation costs"&gt;4,673,129&lt;/span&gt;, respectively&lt;b&gt;.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.2pt"&gt;The Company recognizes compensation
costs for stock option awards to employees, officers and directors based on their grant-date fair value. The value of each stock option
is estimated on the date of grant using the Black-Scholes option-pricing model. The weighted-average assumptions used to estimate the
fair value of the stock options granted using the Black-Scholes option-pricing model are the expected term of the award, the underlying
stock price volatility, the risk-free interest rate, and the expected dividend yield. The Company accounts for forfeitures as they occur.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.2pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The Company records stock-based
compensation for services received from non-employees in accordance with &lt;b&gt;&lt;i&gt;ASC 718, Compensation&#x2014;Stock Compensation Non-Employees&lt;/i&gt;&lt;/b&gt;.
All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based
on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable.
Equity instruments issued to consultants and the cost of the services received as consideration are measured and recognized based on
the fair value of the equity instruments issued and are recognized over the consultants&#x2019; required service period, which is generally
the vesting period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The Company does not have sufficient
historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior.
Accordingly, the Company has elected to use the &#x201c;simplified method&#x201d; to estimate the expected term of its share-based awards.
The simplified method computes the expected term as the sum of the award&#x2019;s vesting term plus the original contractual term divided
by two.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zIzlraGROM96" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&lt;span id="xdx_86C_zlgwLRK4maNc"&gt;New Accounting Pronouncements
Not Yet Adopte&lt;/span&gt;d&lt;/b&gt; - Recent accounting pronouncements issued by the FASB that have not yet been adopted by the Company are not expected
to have a material impact on the Company&#x2019;s present or future consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;





</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <RENB:BusinessPolicyTextBlock contextRef="From2024-07-01to2025-06-30" id="Fact000652">&lt;p id="xdx_845_ecustom--BusinessPolicyTextBlock_zYUaib2yJrql" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&lt;span id="xdx_86F_zWx8dfvOISIj"&gt;Business&lt;/span&gt; &#x2013; &lt;/b&gt;On August 20, 2025, the Company changed its corporate name from Renovaro Inc.
to Lunai Bioworks Inc. (&#x201c;Lunai&#x201d;) On April 8, 2025, Lunai Bioworks Inc. acquired BioSymetrics, Inc. and its subsidiary (&#x201c;BioSymetrics,
Corp.&#x201d;), as a wholly owned subsidiary pursuant to a stock purchase agreement. On February 13, 2024, the Company changed its corporate
name from Renovaro Biosciences Inc. to Renovaro Inc. (&#x201c;Renovaro&#x201d;, and together with its subsidiaries, the &#x201c;Company&#x201d;,
&#x201c;we&#x201d; or &#x201c;us&#x201d;) and acquired GEDi Cube Intl Ltd and its subsidiaries (&#x201c;Renovaro Cube&#x201d;), as a wholly
owned subsidiary pursuant to a stock purchase agreement. In August 2023, the Company changed its corporate name from Enochian Biosciences
Inc. to Renovaro Biosciences Inc. The Company is an AI-driven platform for precision medicine, diagnostics, and biodefense. Its proprietary
technologies transform complex biomedical data into predictive insights, enabling faster discovery, greater accuracy, and strategic partnerships
across the life sciences and government sectors.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</RENB:BusinessPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2024-07-01to2025-06-30" id="Fact000654">&lt;p id="xdx_84E_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zkcuu00BbdI8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&lt;span id="xdx_86F_zEXXiiFIMlJ7"&gt;Basis of Presentation&lt;/span&gt; &#x2013;
&lt;/b&gt;The Company prepares consolidated financial statements in accordance with accounting principles generally accepted in the United States
of America (&#x201c;U.S. GAAP&#x201d;) and follows the rules and regulations of the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2024-07-01to2025-06-30" id="Fact000656">&lt;p id="xdx_84C_eus-gaap--ConsolidationPolicyTextBlock_zrqS0OafGlp6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&lt;span id="xdx_865_z1KoBG5SEgYe"&gt;Principles of Consolidation&lt;/span&gt;
&#x2013; &lt;/b&gt;For the years ended June 30, 2025 and 2024, the consolidated financial statements include the accounts and operations of Lunai,
and its wholly owned subsidiaries. All material inter-company transactions and accounts have been eliminated in the consolidation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy contextRef="From2024-07-01to2025-06-30" id="Fact000658">&lt;p id="xdx_84E_eus-gaap--ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_zpuJAViAAP6d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&lt;span id="xdx_862_zydL5jMJeb8k"&gt;Subsidiaries&lt;/span&gt; &#x2013; &lt;/b&gt;Renovaro
Biosciences Inc. (&#x201c;Renovaro Biosciences&#x201d;), formerly Renovaro
Biopharma Inc., was incorporated on May 19, 2017 in Delaware and is a 100% owned subsidiary of Lunai. Renovaro Biosciences owns a perpetual,
fully paid-up, royalty-free, sublicensable, and sole and exclusive worldwide license to research, develop, use, sell, have sold, make,
have made, offer for sale, import and otherwise commercialize certain intellectual property in cellular therapies for the prevention,
treatment, amelioration of and/or therapy exclusively for HIV in humans, and research and development exclusively relating to HIV in humans.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;Renovaro Biosciences Denmark ApS
(&#x201c;Renovaro Denmark&#x201d;), formerly Enochian Biosciences Denmark ApS a Danish corporation was incorporated on April 1, 2001. On
February 12, 2014, in accordance with the terms and conditions of a Share Exchange Agreement, the Company acquired Renovaro Denmark and
it became a 100% owned subsidiary of Lunai subject to 185,053 shares of Common Stock of Lunai held in escrow according to Danish law (the
&#x201c;Escrow Shares&#x201d;). As of June 30, 2025, there are 17,414 Escrow Shares remaining (see Note 10).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On February 13, 2024, the Company
acquired &lt;span id="xdx_90F_ecustom--BusinessAcquisitionPercentage_iI_dp_c20240213__us-gaap--BusinessAcquisitionAxis__custom--RenovaroCubeMember_zzu7S4nWvqHk" title="Acquisition percentage"&gt;100&lt;/span&gt;% of Renovaro Cube. As a result of the acquisition, Renovaro Cube became a wholly-owned subsidiary of the Company (see Note
13).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On April 8, 2025, the Company acquired
100% of Biosymetrics, Corp. As a result of the acquisition, Biosymetrics, Corp. became a wholly-owned subsidiary of the Company (see Note
13).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy>
    <RENB:BusinessAcquisitionPercentage
      contextRef="AsOf2024-02-13_custom_RenovaroCubeMember"
      decimals="INF"
      id="Fact000660"
      unitRef="Ratio">1</RENB:BusinessAcquisitionPercentage>
    <us-gaap:UseOfEstimates contextRef="From2024-07-01to2025-06-30" id="Fact000662">&lt;p id="xdx_844_eus-gaap--UseOfEstimates_z1PAWZOr1WM8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&lt;span id="xdx_860_z7ZmMRXloNK5"&gt;Use of Accounting Estimates&lt;/span&gt;
&lt;/b&gt;- The preparation of financial statements in conformity with generally accepted accounting principles requires management to make
estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities
at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could
differ from those estimated. Significant estimates include the fair value and potential impairment of intangible assets, the fair value
of the contingent consideration liability, and the fair value of equity instruments issued.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;





</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="From2024-07-01to2025-06-30" id="Fact000665">&lt;p id="xdx_845_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zyeZrTS2kLa6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&lt;span id="xdx_860_zM6CXfrzgW3j"&gt;Functional Currency and Foreign
Currency Translation&lt;/span&gt; &lt;/b&gt;&#x2013; The functional currency of Renovaro Denmark is the Danish Kroner (&#x201c;DKK&#x201d;) and the functional
currency of Renovaro Cube is the Euro (&#x201c;EUR&#x201d;) and the functional currency of BioSymetrics Corp. is Canadian Dollar (&#x201c;CAD&#x201d;).
The Company&#x2019;s reporting currency is the U.S. Dollar for the purpose of these financial statements. The Company&#x2019;s balance sheet
accounts are translated into U.S. dollars at the period-end exchange rates and all revenue and expenses are translated into U.S. dollars
at the average exchange rates prevailing during the years ended June 30, 2025, and 2024. Translation gains and losses are deferred and
accumulated as a component of other comprehensive income in stockholders&#x2019; equity. Transaction gains and losses that arise from exchange
rate fluctuations from transactions denominated in a currency other than the functional currency are included in the statement of operations
as incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2024-07-01to2025-06-30" id="Fact000667">&lt;p id="xdx_84B_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z1pBNr7bNr16" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&lt;span id="xdx_864_zKkxoHpQUD82"&gt;Cash and Cash Equivalents&lt;/span&gt; &lt;/b&gt;&#x2013;
The Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2024-07-01to2025-06-30" id="Fact000669">&lt;p id="xdx_84B_eus-gaap--ConcentrationRiskCreditRisk_zSp4CzxxGON3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&lt;span id="xdx_869_zG0cDF1nI7Df"&gt;Concentration of Credit Risk&lt;/span&gt;
&#x2013;&lt;/b&gt; Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in financial
institutions, which, at times, exceed the amount of deposit insurance provided within the relevant jurisdiction where the deposits are
held. As of June 30, 2025, and June 30, 2024, the Company has not experienced losses on these accounts and management believes the Company
is not exposed to significant risks on such accounts.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <RENB:InvestmentinEquitySecuritiesPolicyTextBlock contextRef="From2024-07-01to2025-06-30" id="Fact000671">&lt;p id="xdx_848_ecustom--InvestmentinEquitySecuritiesPolicyTextBlock_zPhvPJ0FpCb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&lt;span id="xdx_86D_z4PxeoMQXEja"&gt;Investment in Equity Securities&lt;/span&gt;
&lt;/b&gt;&#x2013; The Company accounts for investments in equity securities in accordance with ASC 321, Investments&#x2014;Equity Securities.
Equity securities with readily determinable fair values are measured at fair value, with changes in fair value recognized in net income
or loss. Equity securities without readily determinable fair values are measured at cost, less impairment, if any, and adjusted for observable
price changes in orderly transactions for the identical or a similar investment of the same issuer. The Company evaluates such investments
at each reporting period for impairment or other observable transactions that would require adjustment. On February 28, 2025, the Company
purchased $&lt;span id="xdx_90D_ecustom--PurchaseEquitySecuritiesValue_iI_c20250630_zdDehCdNLaYh" title="Purchase equity securities value"&gt;500,000&lt;/span&gt; of equity securities. During the year ended June 30, 2025, the Company recorded a change in fair value of equity securities
for $&lt;span id="xdx_904_eus-gaap--DebtSecuritiesTradingAndEquitySecuritiesFvNiCost_iI_c20250630_zAnM259h5M4b" title="Fair value of equity securities"&gt;112,149&lt;/span&gt; (see Note 3). The investment in equity securities balance at June 30, 2025, was $&lt;span id="xdx_903_eus-gaap--DebtAndEquitySecuritiesGainLoss_c20240701__20250630_z4DS7NglA2n7" title="Investment in equity securities"&gt;387,851&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</RENB:InvestmentinEquitySecuritiesPolicyTextBlock>
    <RENB:PurchaseEquitySecuritiesValue
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000673"
      unitRef="USD">500000</RENB:PurchaseEquitySecuritiesValue>
    <us-gaap:DebtSecuritiesTradingAndEquitySecuritiesFvNiCost
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000675"
      unitRef="USD">112149</us-gaap:DebtSecuritiesTradingAndEquitySecuritiesFvNiCost>
    <us-gaap:DebtAndEquitySecuritiesGainLoss
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000677"
      unitRef="USD">387851</us-gaap:DebtAndEquitySecuritiesGainLoss>
    <RENB:InsuranceReceivablePolicy contextRef="From2024-07-01to2025-06-30" id="Fact000679">&lt;p id="xdx_843_ecustom--InsuranceReceivablePolicy_z318v78IRBx3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&lt;span id="xdx_860_zSQo35l8z6Xh"&gt;Insurance Receivable&lt;/span&gt; &#x2013;&lt;/b&gt;
The Company recognizes insurance receivables associated with expected recoveries of costs incurred for litigation which is probable of
incurring a loss and for which it is probable the Company will receive coverage under its existing insurance policies. The Company records
any such recoveries on a gross basis and does not net such amounts against any related loss contingency accruals.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</RENB:InsuranceReceivablePolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2024-07-01to2025-06-30" id="Fact000681">&lt;p id="xdx_846_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zPkradVek9Nk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&lt;span id="xdx_865_zZ0FLRKdTa8k"&gt;Property and Equipment&lt;/span&gt; &lt;/b&gt;-
Property and equipment are stated at cost. Expenditures for major renewals and betterments that extend the useful lives of property and
equipment are capitalized and depreciated upon being placed in service. Expenditures for maintenance and repairs are charged to expense
as incurred. Depreciation is computed for financial statement purposes on a straight-line basis over the estimated useful lives of the
assets, which range from four to ten years (see Note 5).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="From2024-07-01to2025-06-30" id="Fact000683">&lt;p id="xdx_84A_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zlQ0lARpwWP2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&lt;span id="xdx_862_zduFUJqHNupk"&gt;Intangible Assets&lt;/span&gt; - &lt;/b&gt;The
Company has both definite and indefinite life intangible assets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;Definite life intangible assets
relate to patents. The Company accounts for definite life intangible assets in accordance with Financial Accounting Standards Board (&#x201c;FASB&#x201d;)
Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 350, &lt;i&gt;Goodwill and Other Intangible Assets&lt;/i&gt;. Intangible assets are recorded
at cost. Patent costs capitalized consist of costs incurred to acquire the underlying patent. If it is determined that a patent will not
be issued, the related remaining capitalized patent costs are charged to expense. Definite life intangible assets are amortized on a straight-line
basis over their estimated useful life. The estimated useful life of patents is twenty years from the date of application.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;Indefinite life intangible assets
include license agreements and goodwill acquired in a business combination. The Company accounts for indefinite life intangible assets
in accordance with ASC 350. License agreement costs represent the fair value of the license agreement on the date acquired and are tested
annually for impairment on June 30 or whenever events or changes in circumstances indicate the fair value of the license is less than
the carrying amount.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="From2024-07-01to2025-06-30" id="Fact000685">&lt;p id="xdx_84E_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zppE3uZ4rs8l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&lt;span id="xdx_86A_zY6jWxzGpd27"&gt;Goodwill&lt;/span&gt;&lt;/b&gt; - Goodwill is
not amortized but is evaluated for impairment annually as of June 30 or whenever events or changes in circumstances indicate the carrying
value of the reporting unit may be less than the fair value of the reporting unit.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;





</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock contextRef="From2024-07-01to2025-06-30" id="Fact000688">&lt;p id="xdx_846_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_zUHEWWKhdzql" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&lt;span id="xdx_86A_zYdnNWAi0jOc"&gt;Impairment of Goodwill and
Indefinite Lived Intangible Assets&lt;/span&gt;&lt;/b&gt; &#x2013; We test for goodwill impairment at the reporting unit level, which is one level below the
operating segment level. Our detailed impairment testing involves comparing the fair value of each reporting unit to its carrying value,
including goodwill. Fair value reflects the price a market participant would be willing to pay in a potential sale of the reporting unit
and is based on discounted cash flows or relative market-based approaches. If the carrying value of the reporting unit exceeds its fair
value, we record an impairment loss for such excess.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;During the year ended June 30, 2025, the results of the assessment indicated that
the carrying value of the RENC reporting unit exceeded its fair value, due to the decline in the estimated fair value of the reporting
unit based on the Company&#x2019;s market capitalization. Management concluded the significant driver for the change in the economic benefits
was due to the Company&#x2019;s continued inability to raise capital for the further development of the technologies within this reporting
unit. The Company recorded an impairment loss of $&lt;span id="xdx_900_ecustom--ImpairmentLoss_iI_c20240930_zvTM8vzNPVO1" title="Impairment loss"&gt;47,614,729&lt;/span&gt; for the period ended September 30, 2024 and $&lt;span id="xdx_90A_ecustom--ImpairmentLoss_iI_c20250630_zWUNhMmystdk" title="Impairment loss"&gt;122,804,700&lt;/span&gt; for the period ended
June 30, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;For indefinite life intangible
assets, such as IPR&amp;amp;D, on an annual basis on June 30th we determine the fair value of the asset and record an impairment loss, if
any, for the excess of the carrying value of the asset over its fair value. For the year ended June 30, 2024, the carrying value of the
IPR&amp;amp;D exceeded its fair value. Therefore, the Company recorded an impairment loss of $&lt;span id="xdx_90C_ecustom--ImpairmentLoss_iI_c20240630_zS5WUF3ShNad" title="Impairment loss"&gt;42,611,000&lt;/span&gt; during the year ended June 30, 2024.
During the year ended June 30, 2025, the Company recorded no impairment loss related to IPR&amp;amp;D.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The carrying value of
IPR&amp;amp;D and goodwill at June 30, 2025, were&#160;&lt;span id="xdx_908_ecustom--InProcessResearchAndDevelopment_iI_c20250630_zj3R8xMjC70l" style="display: none" title="In-process research and development"&gt;0&lt;/span&gt;
zero and $&lt;span id="xdx_90B_eus-gaap--Goodwill_iI_c20250630_zsA8QKJf2cWd" title="Goodwill"&gt;5,963,000&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock>
    <RENB:ImpairmentLoss
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000690"
      unitRef="USD">47614729</RENB:ImpairmentLoss>
    <RENB:ImpairmentLoss
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000692"
      unitRef="USD">122804700</RENB:ImpairmentLoss>
    <RENB:ImpairmentLoss
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000694"
      unitRef="USD">42611000</RENB:ImpairmentLoss>
    <RENB:InProcessResearchAndDevelopment
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000696"
      unitRef="USD">0</RENB:InProcessResearchAndDevelopment>
    <us-gaap:Goodwill
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000698"
      unitRef="USD">5963000</us-gaap:Goodwill>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2024-07-01to2025-06-30" id="Fact000700">&lt;p id="xdx_84D_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zKn0gA0Hulw" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;b&gt;&lt;span id="xdx_862_zpCMsJFbXpTj"&gt;Impairment of Long-Lived
Assets&lt;/span&gt; - &lt;/b&gt;Long-lived assets, such as property and equipment and definite life intangible assets are reviewed for impairment whenever
events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Circumstances which could trigger
a review include, but are not limited to: significant decreases in the market price of the asset; significant adverse changes in the business
climate or legal factors; current period cash flow or operating losses combined with a history of losses or a forecast of continuing losses
associated with the use of the asset; and current expectations that the asset will more likely than not be sold or disposed of significantly
before the end of its estimated useful life.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;Recoverability of assets to be
held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected
to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge
is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of would
be separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell and would
no longer be depreciated. The depreciable basis of assets that are impaired and continue in use are their respective fair values. &lt;span id="xdx_901_eus-gaap--AssetImpairmentCharges_do_c20240701__20250630_z0oVRYKbcl5l" title="Impairment of assets"&gt;&lt;span id="xdx_909_eus-gaap--AssetImpairmentCharges_do_c20230701__20240630_zMHxZhPQePZj" title="Impairment of assets"&gt;No&lt;/span&gt;&lt;/span&gt; impairment
of these assets was recorded during the year ended June 30, 2025 or 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:AssetImpairmentCharges
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000702"
      unitRef="USD">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000704"
      unitRef="USD">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2024-07-01to2025-06-30" id="Fact000706">&lt;p id="xdx_84F_eus-gaap--LesseeLeasesPolicyTextBlock_zLsY70deoHF7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;b&gt;&lt;span id="xdx_86B_z3Yxf2ZBGssk"&gt;Leases&lt;/span&gt; -&lt;/b&gt; In accordance
with ASC Topic 842, the Company determined the initial classification and measurement of its right-of-use assets and lease liabilities
at the lease commencement date and thereafter. The lease terms include any renewal options and termination options that the Company is
reasonably assured to exercise, if applicable. The present value of lease payments is determined by using the implicit interest rate in
the lease, if that rate is readily determinable; otherwise, the Company develops an incremental borrowing rate based on the information
available at the commencement date in determining the present value of the future payments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;Rent expense for operating leases
is recognized on a straight-line basis, unless the operating lease right-of-use assets have been impaired, over the reasonably assured
lease term based on the total lease payments and is included in general and administrative expenses in the consolidated statements of
operations. For operating leases that reflect impairment, the Company will recognize the amortization of the operating lease right-of-use
assets on a straight-line basis over the remaining lease term with rent expense still included in general and administrative expenses
in the consolidated statements of operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;





</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2024-07-01to2025-06-30" id="Fact000709">&lt;p id="xdx_842_eus-gaap--ResearchAndDevelopmentExpensePolicy_zYLdwUrdqhD9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&lt;span id="xdx_869_zaRzb8gbnWt8"&gt;Research and Development Expenses&lt;/span&gt;
&#x2013; &lt;/b&gt;The Company expenses research and development costs incurred in formulating, improving, validating, and creating alternative
or modified processes related to and expanding the use of the Company&#x2019;s technologies. Research and development expenses for the
years ended June 30, 2025 and 2024 amounted to $&lt;span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20240701__20250630_zZJeJ1XukUpc" title="Research and development expense"&gt;537,428&lt;/span&gt;, and $&lt;span id="xdx_900_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230701__20240630_zkydk6f0dDki" title="Research and development expense"&gt;2,708,829&lt;/span&gt; respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000711"
      unitRef="USD">537428</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000713"
      unitRef="USD">2708829</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2024-07-01to2025-06-30" id="Fact000715">&lt;p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_zfMXOt5X8KO5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&lt;span id="xdx_862_z48fhTLPouia"&gt;Income Taxes&lt;/span&gt; &lt;/b&gt;- The Company
accounts for income taxes in accordance with FASB ASC Topic 740 Accounting for Income Taxes, which requires an asset and liability approach
for accounting for income taxes (see Note 9).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2024-07-01to2025-06-30" id="Fact000717">&lt;p id="xdx_845_eus-gaap--EarningsPerSharePolicyTextBlock_zFEfdTf7feMe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&lt;span id="xdx_86A_ziMuA0HBi456"&gt;Loss Per Share&lt;/span&gt;&lt;/b&gt; - The Company
calculates earnings (loss) per share in accordance with FASB ASC 260 Earnings Per Share. Basic earnings per common share (EPS) are based
on the weighted average number of shares of Common Stock outstanding during each period. Diluted earnings per common share are based on
shares outstanding (computed as for basic EPS) and potentially dilutive common shares. Potential shares of Common Stock included in the
diluted earnings per share calculation include in-the-money stock options that have been granted but have not been exercised. The shares
of Common Stock outstanding at June 30, 2025 and 2024 were &lt;span id="xdx_905_eus-gaap--CommonStockOtherSharesOutstanding_iI_c20250630_zMapRAqnrkA9" title="Common stock outstanding"&gt;177,392,907&lt;/span&gt; and &lt;span id="xdx_903_eus-gaap--CommonStockOtherSharesOutstanding_iI_c20240630_zaQnmzBUSFij" title="Common stock outstanding"&gt;158,452,644&lt;/span&gt;, respectively. Because of the net loss for each
of the years ended June 30, 2025 and June 30, 2024, dilutive shares for both periods were excluded from the diluted EPS calculation, as
the effect of these potential shares of Common Stock is anti-dilutive. The Company had &lt;span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240701__20250630_zScZFt79wZuh" title="Anti-dilutive shares"&gt;13,669,140&lt;/span&gt; and &lt;span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20240630_zhSvmErRFtTi" title="Anti-dilutive shares"&gt;17,146,315&lt;/span&gt; potential shares of Common
Stock excluded from the diluted EPS calculation for the years ended June 30, 2025 and 2024, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:CommonStockOtherSharesOutstanding
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact000719"
      unitRef="Shares">177392907</us-gaap:CommonStockOtherSharesOutstanding>
    <us-gaap:CommonStockOtherSharesOutstanding
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact000721"
      unitRef="Shares">158452644</us-gaap:CommonStockOtherSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-07-01to2025-06-30"
      decimals="INF"
      id="Fact000723"
      unitRef="Shares">13669140</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-07-012024-06-30"
      decimals="INF"
      id="Fact000725"
      unitRef="Shares">17146315</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2024-07-01to2025-06-30" id="Fact000727">&lt;p id="xdx_84A_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zakJ3iM7cBMi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&lt;span id="xdx_86F_zNE5vRN0nSkg"&gt;Fair Value of Financial Instruments&lt;/span&gt;
&lt;/b&gt;&#x2013; The Company accounts for fair value measurements for financial assets and financial liabilities in accordance with FASB ASC
Topic 820, &#x201c;Fair Value Measurements&#x201d;. The authoritative guidance, among other things, defines fair value, establishes a consistent
framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either
a recurring or nonrecurring basis. Fair value is defined as the exit price, representing the amount that would either be received to
sell an asset or be paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based
measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="From2024-07-01to2025-06-30" id="Fact000729">&lt;p id="xdx_84C_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zBv2wJW9shTb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;b&gt;&lt;span id="xdx_869_zLzKFsYnd3xa"&gt;Stock-Based Compensation&lt;/span&gt;
- &lt;/b&gt;The Company has granted stock options, restricted share units (&#x201c;RSUs&#x201d;) and warrants to certain employees, officers,
directors, and consultants. The Company accounts for options in accordance with the provisions of &lt;b&gt;&lt;i&gt;FASB ASC Topic 718, Compensation
&#x2013; Stock Compensation&lt;/i&gt;&lt;/b&gt;. Stock based compensation costs for the vesting of options and RSUs granted to certain employees, officers,
directors, and consultants for the years ended June 30, 2025 and 2024 were $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensation_c20240701__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesOfficersDirectorsAndConsultantsMember_zzOV5taph179" title="Stock based compensation costs"&gt;3,313,291&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensation_c20230701__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesOfficersDirectorsAndConsultantsMember_z0Xu23kdrakh" title="Stock based compensation costs"&gt;4,673,129&lt;/span&gt;, respectively&lt;b&gt;.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.2pt"&gt;The Company recognizes compensation
costs for stock option awards to employees, officers and directors based on their grant-date fair value. The value of each stock option
is estimated on the date of grant using the Black-Scholes option-pricing model. The weighted-average assumptions used to estimate the
fair value of the stock options granted using the Black-Scholes option-pricing model are the expected term of the award, the underlying
stock price volatility, the risk-free interest rate, and the expected dividend yield. The Company accounts for forfeitures as they occur.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.2pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The Company records stock-based
compensation for services received from non-employees in accordance with &lt;b&gt;&lt;i&gt;ASC 718, Compensation&#x2014;Stock Compensation Non-Employees&lt;/i&gt;&lt;/b&gt;.
All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based
on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable.
Equity instruments issued to consultants and the cost of the services received as consideration are measured and recognized based on
the fair value of the equity instruments issued and are recognized over the consultants&#x2019; required service period, which is generally
the vesting period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The Company does not have sufficient
historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior.
Accordingly, the Company has elected to use the &#x201c;simplified method&#x201d; to estimate the expected term of its share-based awards.
The simplified method computes the expected term as the sum of the award&#x2019;s vesting term plus the original contractual term divided
by two.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-012025-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_EmployeesOfficersDirectorsAndConsultantsMember"
      decimals="0"
      id="Fact000731"
      unitRef="USD">3313291</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-07-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_EmployeesOfficersDirectorsAndConsultantsMember"
      decimals="0"
      id="Fact000733"
      unitRef="USD">4673129</us-gaap:ShareBasedCompensation>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2024-07-01to2025-06-30" id="Fact000735">&lt;p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zIzlraGROM96" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&lt;span id="xdx_86C_zlgwLRK4maNc"&gt;New Accounting Pronouncements
Not Yet Adopte&lt;/span&gt;d&lt;/b&gt; - Recent accounting pronouncements issued by the FASB that have not yet been adopted by the Company are not expected
to have a material impact on the Company&#x2019;s present or future consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;





</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="From2024-07-01to2025-06-30" id="Fact000738">&lt;p id="xdx_806_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zORVQ1TBu9Fk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 2 &#x2013; &lt;span id="xdx_82F_zGKnBM1iu628"&gt;GOING CONCERN&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The Company&#x2019;s consolidated
financial statements are prepared using the generally accepted accounting principles applicable to a going concern, which contemplates
the realization of assets and liquidation of liabilities in the normal course of business. However, the Company has incurred substantial
recurring losses from continuing operations, has used cash in the Company&#x2019;s continuing operations, and is dependent on additional
financing to fund operations. The Company incurred a net loss of $&lt;span id="xdx_904_eus-gaap--NetIncomeLoss_iN_pp0p0_di_c20240701__20250630_zQ7AP2eX5xAk" title="Net loss"&gt;178,007,489&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--NetIncomeLoss_iN_pp0p0_di_c20230701__20240630_z9VhM10puope" title="Net loss"&gt;88,425,828&lt;/span&gt; for the years ended June 30, 2025 and 2024,
respectively. As of June 30, 2025, the Company had cash and cash equivalents of $&lt;span id="xdx_909_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_c20250630_zLM5AcFUOiEg" title="Cash and cash equivalents"&gt;92,700&lt;/span&gt; and an accumulated deficit of $&lt;span id="xdx_906_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pp0p0_di_c20250630_zlXWnIcMzoPl" title="Accumulated deficit"&gt;510,462,570&lt;/span&gt; and
a working capital deficit of $&lt;span id="xdx_900_ecustom--WorkingCapitalDeficit_iI_pp0p0_c20250630_zEsDJ9rWAdm4" title="Working capital deficit"&gt;28,109,502&lt;/span&gt;. These conditions raise substantial doubt about the Company&#x2019;s ability to continue as a
going concern for one year after the date the financial statements are issued. The consolidated financial statements do not include any
adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be
necessary should the Company be unable to continue in existence.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;Management has reduced overhead
and administrative costs by streamlining the organization to focus on the development and validation of its AI-driven cancer diagnostics
platform. The Company has tailored its workforce to focus on these activities. In addition, the Company intends to secure additional required
funding through equity or debt financing. However, there can be no assurance that the Company will be able to obtain any sources of funding.
Such additional funding may not be available or may not be available on reasonable terms, and, in the case of equity financing transactions,
could result in significant additional dilution to our stockholders. If we do not obtain required additional equity or debt funding, our
cash resources will be depleted and we could be required to materially reduce or suspend operations, which would likely have a material
adverse effect on our business, stock price and our relationships with third parties with whom we have business relationships, at least
until additional funding is obtained. If we do not have sufficient funds to continue operations, we could be required to seek bankruptcy
protection or other alternatives that could result in our stockholders losing some or all of their investment in us.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;Funding that we may receive during
the fiscal year 2026 is expected to be used to satisfy existing and future obligations and liabilities and working capital needs, to support
commercialization of our products, to conduct the clinical and regulatory work to develop our product candidates, and to begin building
working capital reserves.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000740"
      unitRef="USD">-178007489</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000742"
      unitRef="USD">-88425828</us-gaap:NetIncomeLoss>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000744"
      unitRef="USD">92700</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000746"
      unitRef="USD">-510462570</us-gaap:RetainedEarningsAccumulatedDeficit>
    <RENB:WorkingCapitalDeficit
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000748"
      unitRef="USD">28109502</RENB:WorkingCapitalDeficit>
    <us-gaap:FairValueMeasurementInputsDisclosureTextBlock contextRef="From2024-07-01to2025-06-30" id="Fact000750">&lt;p id="xdx_803_eus-gaap--FairValueMeasurementInputsDisclosureTextBlock_zutd0oyZKMol" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 3 &#x2014; &lt;span id="xdx_82F_zWDsZ5OpVgE6"&gt;FAIR VALUE MEASUREMENTS&lt;/span&gt; &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The Company accounts for fair
value measurements for financial assets and financial liabilities in accordance with FASB ASC Topic 820, &#x201c;Fair Value Measurements&#x201d;.
The authoritative guidance among other things, defines fair value, establishes a consistent framework for measuring fair value and expands
disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value
is defined as the exit price, representing the amount that would either be received to sell an asset or be paid to transfer a liability
in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based
on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the guidance
establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Level 1. Observable inputs such as quoted prices in active markets for identical assets or liabilities; &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Level 2. Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr&gt;
    &lt;td style="width: 48px; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;There were no Level 2 and 3 assets,
or any Level 1 or 2 liabilities as of June 30, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;Unless otherwise disclosed, the
fair value of the Company&#x2019;s financial instruments including cash, accounts receivable, prepaid expenses, accounts payable, accrued
expenses, lease obligations and notes payable approximate their recorded values due to their short-term maturities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;Level 1 assets held as of June
30, 2025, consisted of an investment in equity securities related to an extension agreement entered on February 28, 2024&lt;span style="background-color: white"&gt;.
The Company purchased &lt;span id="xdx_909_eus-gaap--StockRepurchasedDuringPeriodShares_c20240701__20250630__us-gaap--StatementClassOfStockAxis__custom--CommonStocksMember_zA3ftsTJhGwa" title="Purchased shares of common stock"&gt;467,290&lt;/span&gt; shares of common stock at a purchase price of $&lt;span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_c20250630__us-gaap--StatementClassOfStockAxis__custom--CommonStocksMember_zERKJoEbLkmi" title="Purchase price"&gt;1.07&lt;/span&gt; per share. The investment in equity securities was recorded
at a fair value of $&lt;span id="xdx_90F_eus-gaap--EquitySecuritiesFvNiCost_iI_c20250630__us-gaap--StatementClassOfStockAxis__custom--CommonStocksMember_zZz0ZTkeuXN9" title="Fair value of equity securities"&gt;500,000&lt;/span&gt; at the time of purchase and is subsequently remeasured to fair value at the end of each reporting period.
As of June 30, 2025, the Company held &lt;span id="xdx_90F_ecustom--InvestmentEquitySecuritiesShares_iI_c20250630__us-gaap--StatementClassOfStockAxis__custom--CommonStocksMember_zdPwRGfDhOT1" title="investment  equity securities shares"&gt;467,290&lt;/span&gt; shares of common stock in connection with the investment in equity securities. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;Level 3 liabilities held as of
June 30, 2025, consisted of a contingent consideration liability related to the February 13, 2024 acquisition of &lt;span style="background-color: white"&gt;Renovaro
Cube, (the &#x201c;Acquisition&#x201d;). As consideration for the Acquisition, the stockholders of Renovaro Cube received (i) &lt;span id="xdx_90C_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c20250212__20250213__us-gaap--BusinessAcquisitionAxis__custom--RenovaroCubeMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zcUTErZOEbRi" title="Contingent shares issuable in connection with the acquisition"&gt;70,834,183&lt;/span&gt;
shares of Common Stock, and (ii) the right to receive up to &lt;span id="xdx_90D_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c20250212__20250213__us-gaap--BusinessAcquisitionAxis__custom--RenovaroCubeMember__us-gaap--StatementClassOfStockAxis__custom--ConvertibleNotesMember_zbl4B3pUVHdd" title="Contingent shares issuable in connection with the acquisition"&gt;11,899,545&lt;/span&gt; contingent shares pro rata upon the exercise of convertible notes,
options, and warrants, which were outstanding at closing. The contingent consideration liability was recorded at fair value of $&lt;span id="xdx_90E_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_c20250213__us-gaap--BusinessAcquisitionAxis__custom--RenovaroCubeMember_zyzRa4uGa3t8" title="Contingent consideration liability was recorded at fair value"&gt;20,557,500&lt;/span&gt;
at the time of the Acquisition and is subsequently remeasured to fair value at the end of each reporting period. As of June 30, 2025,
there were &lt;span id="xdx_90E_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c20240701__20250630__us-gaap--BusinessAcquisitionAxis__custom--RenovaroCubeMember_zb9LuVVHfoIc" title="Contingent shares issuable in connection with the acquisition"&gt;2,775,650&lt;/span&gt; contingent shares issuable in connection with the Acquisition.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The Company&#x2019;s assets and
liabilities measured at fair value on recurring bases as of June 30, 2025 were as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_z2jvxTefkOie" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&lt;span id="xdx_8B7_zTaUZdgmxFHb" style="display: none"&gt;Schedule of assets and
liabilities measured at fair value on recurring bases&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_499_20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zQzvXgkEBbQ" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49A_20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zEsjnT6mDvcc" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49D_20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zuh9bP385oC4" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair Value Measurements at&lt;br/&gt; Reporting Date Using&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-indent: -10pt; padding-left: 10pt"&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--EquitySecuritiesFvNi_iI_zcG3r0N1i5Ia" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt"&gt;Investment in equity securities&lt;/td&gt;&lt;td style="width: 5%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"&gt;387,851&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0772"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0773"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AccruedLiabilitiesFairValueDisclosure_iI_zFAPaLuCkqGc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Total assets at fair value&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;387,851&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0776"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0777"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-indent: -10pt; padding-left: 10pt"&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--ContingentConsiderationClassifiedAsEquityFairValueDisclosure_iI_zByKpBBRISY2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt"&gt;Contingent consideration&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0779"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0780"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;630,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DerivativeFairValueOfDerivativeLiability_iI_zeFlGaeTvPDg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Total liabilities at fair value&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0783"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0784"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;630,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A2_zESIYL92M3dg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The fair value of the contingent
consideration liability is estimated using a Black-Scholes option-pricing model and a Monte-Carlo option pricing model. The key inputs
to the model are all contractual or observable with the exception being volatility, which is computed based on the volatility of the Company&#x2019;s
underlying stock. The key inputs to valuing the contingent consideration liability as of June 30, 2025, were:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--FairValueConcentrationOfRiskTextBlock_z9h8AL4mIza1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B0_zvM5tZevQ8A6" style="display: none"&gt;Schedule of key input to valuing the
contingent consideration liability&lt;/span&gt; &lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-indent: -10pt"&gt;Stock Price&lt;/td&gt;&lt;td style="width: 10%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 18%; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--SharePrice_iI_pip0_c20250630__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_z7AWelG40Uq8" title="Stock Price"&gt;0.29&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pip0_c20250630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zvLRxaPuJjx5" title="Exercise Price"&gt;0.53&lt;/span&gt; - $&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pip0_c20250630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zdEwZKSKFTF6" title="Exercise Price"&gt;1.92&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Volatility&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20240701__20250630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zB66ZpszDMN4" title="Volatility"&gt;116&lt;/span&gt;% - &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20240701__20250630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_znPOfT17uTp5" title="Volatility"&gt;141&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Risk Free Rate&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20240701__20250630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zbcy1swkb2H9" title="Risk Free Rate"&gt;3.61&lt;/span&gt;% - &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20240701__20250630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zTIaRnl1D08k" title="Risk Free Rate"&gt;4.02&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Expected Dividends&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20240701__20250630__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_ze9cCHjxT9Ya" title="Expected Dividends"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Discount Rate (Monte-Carlo model only)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate_pip0_dp_c20240701__20250630__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_z66eiy3IqZqb" title="Discount Rate (Monte-Carlo model only)"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Expected Term (years)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240701__20250630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zL8pzYmdMZq" title="Expected Term (years)"&gt;2.70&lt;/span&gt; &#x2013;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240701__20250630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zKGilmjz5Yhb" title="Expected Term (years)"&gt; 8.38&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At initial recognition of the contingent consideration,
the inputs were:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-indent: -10pt"&gt;Stock Price&lt;/td&gt;&lt;td style="width: 10%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 18%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--SharePrice_iI_pip0_c20250630__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_z2wyC1dnZCZ7" title="Stock Price"&gt;1.92&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pip0_c20250630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zsR9QLQztrJ4" title="Exercise Price"&gt;0.46&lt;/span&gt; - $&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pip0_c20250630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zTkAmBRGujaa" title="Exercise Price"&gt;4.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Volatility&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20240701__20250630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zyTHaNhBnsTd" title="Volatility"&gt;107&lt;/span&gt;% - &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20240701__20250630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_z7TkkYwypWI7" title="Volatility"&gt;133&lt;/span&gt;% &lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Risk Free Rate&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20240701__20250630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zO5IUsIsnpgi" title="Risk Free Rate"&gt;4.22&lt;/span&gt;% - &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20240701__20250630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zYhvR1yEwEdl" title="Risk Free Rate"&gt;5.14&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Expected Dividends&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20240701__20250630__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zKNk75opeJU4" title="Expected Dividends"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Discount Rate (Monte-Carlo model only)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate_pip0_dp_c20240701__20250630__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zd2uyHoAiima" title="Discount Rate (Monte-Carlo model only)"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Expected Term (years)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240701__20250630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_z4tNQ2OULmz6" title="Expected Term (years)"&gt;0.56&lt;/span&gt; &#x2013; &lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240701__20250630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zNmm9snjaAQ7" title="Expected Term (years)"&gt;9.88&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zXrFA4k8MP92" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;The following table sets forth the Level 3 liability
at June 30, 2025, which is recorded on the consolidated balance sheet at fair value on a recurring basis. As required, this liability
is classified based on the lowest level of input that is significant to the fair value measurement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;b&gt;The roll forward of contingent consideration liability
is as follows:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_894_ecustom--ScheduleOfContingentConsiderationLiabilityTableTextBlock_z6kiE8CH7ob2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&lt;span id="xdx_8BF_z7Ro7lNVSB5i" style="display: none"&gt;Schedule of fair value measurement on recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49F_20240701__20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zbcmlYNu04xa" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49C_20240701__20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zTHGQ9VNTKx1" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_496_20240701__20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zV3BlZEzgj34" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair Value Measurements at&lt;br/&gt; Reporting Date Using&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Quoted Prices in &lt;br/&gt; Active Markets for Identical Assets Inputs&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Significant Other &lt;br/&gt; Observable Inputs&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Significant Other Unobservable Inputs&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;(Level 1)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;(Level 2)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;(Level 3)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;The roll forward of the contingent consideration liability is as follows:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--BusinessCombinationContingentConsiderationLiability_iS_d0_zbQGZBKugltc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 46%; text-indent: -10pt; padding-left: 10pt"&gt;Balance June 30, 2024&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;12,310,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LiabilitiesFairValueAdjustment_d0_zFUffL1kEte5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt"&gt;Fair value adjustment&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(11,680,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--BusinessCombinationContingentConsiderationLiability_iE_d0_z9kYfPmHC4L" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Contingent Consideration Liability at June 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;630,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p id="xdx_8AA_zXxFcBipTzd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:FairValueMeasurementInputsDisclosureTextBlock>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="From2024-07-012025-06-30_custom_CommonStocksMember"
      decimals="INF"
      id="Fact000753"
      unitRef="Shares">467290</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2025-06-30_custom_CommonStocksMember"
      decimals="INF"
      id="Fact000755"
      unitRef="USDPShares">1.07</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="AsOf2025-06-30_custom_CommonStocksMember"
      decimals="0"
      id="Fact000757"
      unitRef="USD">500000</us-gaap:EquitySecuritiesFvNiCost>
    <RENB:InvestmentEquitySecuritiesShares
      contextRef="AsOf2025-06-30_custom_CommonStocksMember"
      decimals="INF"
      id="Fact000759"
      unitRef="Shares">467290</RENB:InvestmentEquitySecuritiesShares>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="From2025-02-122025-02-13_custom_RenovaroCubeMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000761"
      unitRef="Shares">70834183</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="From2025-02-122025-02-13_custom_RenovaroCubeMember_custom_ConvertibleNotesMember"
      decimals="INF"
      id="Fact000763"
      unitRef="Shares">11899545</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="AsOf2025-02-13_custom_RenovaroCubeMember"
      decimals="0"
      id="Fact000765"
      unitRef="USD">20557500</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="From2024-07-012025-06-30_custom_RenovaroCubeMember"
      decimals="INF"
      id="Fact000767"
      unitRef="Shares">2775650</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="From2024-07-01to2025-06-30" id="Fact000769">&lt;table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_z2jvxTefkOie" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&lt;span id="xdx_8B7_zTaUZdgmxFHb" style="display: none"&gt;Schedule of assets and
liabilities measured at fair value on recurring bases&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_499_20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zQzvXgkEBbQ" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49A_20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zEsjnT6mDvcc" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49D_20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zuh9bP385oC4" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair Value Measurements at&lt;br/&gt; Reporting Date Using&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-indent: -10pt; padding-left: 10pt"&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--EquitySecuritiesFvNi_iI_zcG3r0N1i5Ia" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt"&gt;Investment in equity securities&lt;/td&gt;&lt;td style="width: 5%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"&gt;387,851&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0772"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0773"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AccruedLiabilitiesFairValueDisclosure_iI_zFAPaLuCkqGc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Total assets at fair value&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;387,851&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0776"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0777"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-indent: -10pt; padding-left: 10pt"&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--ContingentConsiderationClassifiedAsEquityFairValueDisclosure_iI_zByKpBBRISY2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt"&gt;Contingent consideration&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0779"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0780"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;630,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DerivativeFairValueOfDerivativeLiability_iI_zeFlGaeTvPDg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Total liabilities at fair value&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0783"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0784"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;630,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="Fact000771"
      unitRef="USD">387851</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AccruedLiabilitiesFairValueDisclosure
      contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="Fact000775"
      unitRef="USD">387851</us-gaap:AccruedLiabilitiesFairValueDisclosure>
    <us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure
      contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact000781"
      unitRef="USD">630000</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact000785"
      unitRef="USD">630000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:FairValueConcentrationOfRiskTextBlock contextRef="From2024-07-01to2025-06-30" id="Fact000787">&lt;table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--FairValueConcentrationOfRiskTextBlock_z9h8AL4mIza1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B0_zvM5tZevQ8A6" style="display: none"&gt;Schedule of key input to valuing the
contingent consideration liability&lt;/span&gt; &lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-indent: -10pt"&gt;Stock Price&lt;/td&gt;&lt;td style="width: 10%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 18%; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--SharePrice_iI_pip0_c20250630__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_z7AWelG40Uq8" title="Stock Price"&gt;0.29&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pip0_c20250630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zvLRxaPuJjx5" title="Exercise Price"&gt;0.53&lt;/span&gt; - $&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pip0_c20250630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zdEwZKSKFTF6" title="Exercise Price"&gt;1.92&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Volatility&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20240701__20250630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zB66ZpszDMN4" title="Volatility"&gt;116&lt;/span&gt;% - &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20240701__20250630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_znPOfT17uTp5" title="Volatility"&gt;141&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Risk Free Rate&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20240701__20250630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zbcy1swkb2H9" title="Risk Free Rate"&gt;3.61&lt;/span&gt;% - &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20240701__20250630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zTIaRnl1D08k" title="Risk Free Rate"&gt;4.02&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Expected Dividends&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20240701__20250630__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_ze9cCHjxT9Ya" title="Expected Dividends"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Discount Rate (Monte-Carlo model only)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate_pip0_dp_c20240701__20250630__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_z66eiy3IqZqb" title="Discount Rate (Monte-Carlo model only)"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Expected Term (years)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240701__20250630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zL8pzYmdMZq" title="Expected Term (years)"&gt;2.70&lt;/span&gt; &#x2013;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240701__20250630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--BlackScholesOptionPricingModelMember_zKGilmjz5Yhb" title="Expected Term (years)"&gt; 8.38&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At initial recognition of the contingent consideration,
the inputs were:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-indent: -10pt"&gt;Stock Price&lt;/td&gt;&lt;td style="width: 10%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 18%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--SharePrice_iI_pip0_c20250630__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_z2wyC1dnZCZ7" title="Stock Price"&gt;1.92&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pip0_c20250630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zsR9QLQztrJ4" title="Exercise Price"&gt;0.46&lt;/span&gt; - $&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pip0_c20250630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zTkAmBRGujaa" title="Exercise Price"&gt;4.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Volatility&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20240701__20250630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zyTHaNhBnsTd" title="Volatility"&gt;107&lt;/span&gt;% - &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20240701__20250630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_z7TkkYwypWI7" title="Volatility"&gt;133&lt;/span&gt;% &lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Risk Free Rate&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20240701__20250630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zO5IUsIsnpgi" title="Risk Free Rate"&gt;4.22&lt;/span&gt;% - &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20240701__20250630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zYhvR1yEwEdl" title="Risk Free Rate"&gt;5.14&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Expected Dividends&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20240701__20250630__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zKNk75opeJU4" title="Expected Dividends"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Discount Rate (Monte-Carlo model only)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate_pip0_dp_c20240701__20250630__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zd2uyHoAiima" title="Discount Rate (Monte-Carlo model only)"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Expected Term (years)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240701__20250630__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_z4tNQ2OULmz6" title="Expected Term (years)"&gt;0.56&lt;/span&gt; &#x2013; &lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240701__20250630__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__custom--InitialRecognitionMember_zNmm9snjaAQ7" title="Expected Term (years)"&gt;9.88&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueConcentrationOfRiskTextBlock>
    <us-gaap:SharePrice
      contextRef="AsOf2025-06-30_custom_BlackScholesOptionPricingModelMember"
      decimals="INF"
      id="Fact000789"
      unitRef="USDPShares">0.29</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2025-06-30_srt_MinimumMember_custom_BlackScholesOptionPricingModelMember"
      decimals="INF"
      id="Fact000791"
      unitRef="USDPShares">0.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2025-06-30_srt_MaximumMember_custom_BlackScholesOptionPricingModelMember"
      decimals="INF"
      id="Fact000793"
      unitRef="USDPShares">1.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2024-07-012025-06-30_srt_MinimumMember_custom_BlackScholesOptionPricingModelMember"
      decimals="INF"
      id="Fact000795"
      unitRef="Ratio">1.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2024-07-012025-06-30_srt_MaximumMember_custom_BlackScholesOptionPricingModelMember"
      decimals="INF"
      id="Fact000797"
      unitRef="Ratio">1.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-07-012025-06-30_srt_MinimumMember_custom_BlackScholesOptionPricingModelMember"
      decimals="INF"
      id="Fact000799"
      unitRef="Ratio">0.0361</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-07-012025-06-30_srt_MaximumMember_custom_BlackScholesOptionPricingModelMember"
      decimals="INF"
      id="Fact000801"
      unitRef="Ratio">0.0402</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2024-07-012025-06-30_custom_BlackScholesOptionPricingModelMember"
      decimals="INF"
      id="Fact000803"
      unitRef="Ratio">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <RENB:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate
      contextRef="From2024-07-012025-06-30_custom_BlackScholesOptionPricingModelMember"
      decimals="INF"
      id="Fact000805"
      unitRef="Ratio">0</RENB:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-07-012025-06-30_srt_MinimumMember_custom_BlackScholesOptionPricingModelMember"
      id="Fact000807">P2Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-07-012025-06-30_srt_MaximumMember_custom_BlackScholesOptionPricingModelMember"
      id="Fact000809">P8Y4M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharePrice
      contextRef="AsOf2025-06-30_custom_InitialRecognitionMember"
      decimals="INF"
      id="Fact000811"
      unitRef="USDPShares">1.92</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2025-06-30_srt_MinimumMember_custom_InitialRecognitionMember"
      decimals="INF"
      id="Fact000813"
      unitRef="USDPShares">0.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2025-06-30_srt_MaximumMember_custom_InitialRecognitionMember"
      decimals="INF"
      id="Fact000815"
      unitRef="USDPShares">4.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2024-07-012025-06-30_srt_MinimumMember_custom_InitialRecognitionMember"
      decimals="INF"
      id="Fact000817"
      unitRef="Ratio">1.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2024-07-012025-06-30_srt_MaximumMember_custom_InitialRecognitionMember"
      decimals="INF"
      id="Fact000819"
      unitRef="Ratio">1.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-07-012025-06-30_srt_MinimumMember_custom_InitialRecognitionMember"
      decimals="INF"
      id="Fact000821"
      unitRef="Ratio">0.0422</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-07-012025-06-30_srt_MaximumMember_custom_InitialRecognitionMember"
      decimals="INF"
      id="Fact000823"
      unitRef="Ratio">0.0514</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2024-07-012025-06-30_custom_InitialRecognitionMember"
      decimals="INF"
      id="Fact000825"
      unitRef="Ratio">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <RENB:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate
      contextRef="From2024-07-012025-06-30_custom_InitialRecognitionMember"
      decimals="INF"
      id="Fact000827"
      unitRef="Ratio">0.12</RENB:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDiscountRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-07-012025-06-30_srt_MinimumMember_custom_InitialRecognitionMember"
      id="Fact000829">P0Y6M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-07-012025-06-30_srt_MaximumMember_custom_InitialRecognitionMember"
      id="Fact000831">P9Y10M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <RENB:ScheduleOfContingentConsiderationLiabilityTableTextBlock contextRef="From2024-07-01to2025-06-30" id="Fact000834">&lt;table cellpadding="0" cellspacing="0" id="xdx_894_ecustom--ScheduleOfContingentConsiderationLiabilityTableTextBlock_z6kiE8CH7ob2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&lt;span id="xdx_8BF_z7Ro7lNVSB5i" style="display: none"&gt;Schedule of fair value measurement on recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49F_20240701__20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zbcmlYNu04xa" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49C_20240701__20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zTHGQ9VNTKx1" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_496_20240701__20250630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zV3BlZEzgj34" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair Value Measurements at&lt;br/&gt; Reporting Date Using&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Quoted Prices in &lt;br/&gt; Active Markets for Identical Assets Inputs&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Significant Other &lt;br/&gt; Observable Inputs&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Significant Other Unobservable Inputs&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;(Level 1)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;(Level 2)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;(Level 3)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;The roll forward of the contingent consideration liability is as follows:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--BusinessCombinationContingentConsiderationLiability_iS_d0_zbQGZBKugltc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 46%; text-indent: -10pt; padding-left: 10pt"&gt;Balance June 30, 2024&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;12,310,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LiabilitiesFairValueAdjustment_d0_zFUffL1kEte5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt"&gt;Fair value adjustment&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(11,680,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--BusinessCombinationContingentConsiderationLiability_iE_d0_z9kYfPmHC4L" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Contingent Consideration Liability at June 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;630,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



</RENB:ScheduleOfContingentConsiderationLiabilityTableTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="Fact000836"
      unitRef="USD">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member"
      decimals="0"
      id="Fact000837"
      unitRef="USD">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact000838"
      unitRef="USD">12310000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="From2024-07-012025-06-30_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="Fact000840"
      unitRef="USD">0</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="From2024-07-012025-06-30_us-gaap_FairValueInputsLevel2Member"
      decimals="0"
      id="Fact000841"
      unitRef="USD">0</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="From2024-07-012025-06-30_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact000842"
      unitRef="USD">-11680000</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="Fact000844"
      unitRef="USD">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel2Member"
      decimals="0"
      id="Fact000845"
      unitRef="USD">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="AsOf2025-06-30_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact000846"
      unitRef="USD">630000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2024-07-01to2025-06-30" id="Fact000848">&lt;p id="xdx_805_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zxl19FJXkld9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 4 - &lt;span id="xdx_823_zKpHywtfHgRl"&gt;PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;Property and equipment consisted of the following at
June 30, 2025 and 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_886_eus-gaap--PropertyPlantAndEquipmentTextBlock_zdkXhz1M3JWc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PROPERTY AND EQUIPMENT (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B1_zRY6zMpgJIYd" style="display: none"&gt;Schedule of Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Useful Life&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June 30, 2025&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June 30, 2024&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt"&gt;Lab equipment and instruments&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20250630__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentAndInstrumentsMember_z1cwyeI9Mxdl" title="Useful Life"&gt;4&lt;/span&gt;-&lt;span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20250630__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentAndInstrumentsMember_zfHQFKzYqhD3" title="Useful Life"&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentGross_pp0p0_c20250630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentAndInstrumentsMember_zsQiSUjKqOX5" style="width: 11%; text-align: right" title="Total"&gt;639,998&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_pp0p0_c20240630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentAndInstrumentsMember_zEnrdRZwSEQ8" style="width: 11%; text-align: right" title="Total"&gt;639,998&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20250630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zxFk7F40U1A1" title="Useful Life"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_pp0p0_c20250630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zwMVpHRLeBY7" style="text-align: right" title="Total"&gt;224,629&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_pp0p0_c20240630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zQI2prmRptC1" style="text-align: right" title="Total"&gt;224,629&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Furniture, fixtures, and equipment&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20250630__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_z9j8Mw96hsWl" title="Useful Life"&gt;4&lt;/span&gt;-&lt;span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20250630__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_z7GXQciyftgg" title="Useful Life"&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_pp0p0_c20250630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zCYF512hkL1f" style="border-bottom: Black 1pt solid; text-align: right" title="Total"&gt;205,396&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_pp0p0_c20240630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zXDEbVL2Eqfe" style="border-bottom: Black 1pt solid; text-align: right" title="Total"&gt;195,834&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_pp0p0_c20250630_zyhEYxV1OOD6" style="text-align: right" title="Total"&gt;1,070,023&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_pp0p0_c20240630_zKSQ8OYf06tg" style="text-align: right" title="Total"&gt;1,060,461&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Less accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20250630_zBuzJe4yqVb" style="border-bottom: Black 1pt solid; text-align: right" title="Less Accumulated Depreciation"&gt;(702,180&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20240630_znx8NEzgYOa5" style="border-bottom: Black 1pt solid; text-align: right" title="Less Accumulated Depreciation"&gt;(578,340&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Net Property and Equipment&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentNet_pp0p0_c20250630_zb0XkweEblt5" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Property and Equipment"&gt;367,843&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentNet_pp0p0_c20240630_zgqY1LLvXHw2" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Property and Equipment"&gt;482,121&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;Depreciation expense amounted
to $&lt;span id="xdx_905_eus-gaap--Depreciation_pp0p0_c20240701__20250630_zQV36t4Ync48" title="Depreciation expense"&gt;119,193&lt;/span&gt; and $&lt;span id="xdx_905_eus-gaap--Depreciation_pp0p0_c20230701__20240630_zvoiiJw49Xve" title="Depreciation expense"&gt;113,563&lt;/span&gt; for the years ended June 30, 2025 and 2024, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2024-07-01to2025-06-30" id="Fact000850">&lt;table cellpadding="0" cellspacing="0" id="xdx_886_eus-gaap--PropertyPlantAndEquipmentTextBlock_zdkXhz1M3JWc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PROPERTY AND EQUIPMENT (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B1_zRY6zMpgJIYd" style="display: none"&gt;Schedule of Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Useful Life&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June 30, 2025&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June 30, 2024&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt"&gt;Lab equipment and instruments&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20250630__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentAndInstrumentsMember_z1cwyeI9Mxdl" title="Useful Life"&gt;4&lt;/span&gt;-&lt;span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20250630__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentAndInstrumentsMember_zfHQFKzYqhD3" title="Useful Life"&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentGross_pp0p0_c20250630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentAndInstrumentsMember_zsQiSUjKqOX5" style="width: 11%; text-align: right" title="Total"&gt;639,998&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_pp0p0_c20240630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentAndInstrumentsMember_zEnrdRZwSEQ8" style="width: 11%; text-align: right" title="Total"&gt;639,998&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20250630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zxFk7F40U1A1" title="Useful Life"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_pp0p0_c20250630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zwMVpHRLeBY7" style="text-align: right" title="Total"&gt;224,629&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_pp0p0_c20240630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zQI2prmRptC1" style="text-align: right" title="Total"&gt;224,629&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Furniture, fixtures, and equipment&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20250630__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_z9j8Mw96hsWl" title="Useful Life"&gt;4&lt;/span&gt;-&lt;span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20250630__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_z7GXQciyftgg" title="Useful Life"&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_pp0p0_c20250630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zCYF512hkL1f" style="border-bottom: Black 1pt solid; text-align: right" title="Total"&gt;205,396&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_pp0p0_c20240630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zXDEbVL2Eqfe" style="border-bottom: Black 1pt solid; text-align: right" title="Total"&gt;195,834&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_pp0p0_c20250630_zyhEYxV1OOD6" style="text-align: right" title="Total"&gt;1,070,023&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_pp0p0_c20240630_zKSQ8OYf06tg" style="text-align: right" title="Total"&gt;1,060,461&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Less accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20250630_zBuzJe4yqVb" style="border-bottom: Black 1pt solid; text-align: right" title="Less Accumulated Depreciation"&gt;(702,180&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20240630_znx8NEzgYOa5" style="border-bottom: Black 1pt solid; text-align: right" title="Less Accumulated Depreciation"&gt;(578,340&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Net Property and Equipment&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentNet_pp0p0_c20250630_zb0XkweEblt5" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Property and Equipment"&gt;367,843&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentNet_pp0p0_c20240630_zgqY1LLvXHw2" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Property and Equipment"&gt;482,121&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2025-06-30_srt_MinimumMember_custom_LabEquipmentAndInstrumentsMember"
      id="Fact000852">P4Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2025-06-30_srt_MaximumMember_custom_LabEquipmentAndInstrumentsMember"
      id="Fact000854">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2025-06-30_custom_LabEquipmentAndInstrumentsMember"
      decimals="0"
      id="Fact000856"
      unitRef="USD">639998</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-06-30_custom_LabEquipmentAndInstrumentsMember"
      decimals="0"
      id="Fact000858"
      unitRef="USD">639998</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2025-06-30_us-gaap_LeaseholdImprovementsMember"
      id="Fact000860">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2025-06-30_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      id="Fact000862"
      unitRef="USD">224629</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-06-30_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      id="Fact000864"
      unitRef="USD">224629</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2025-06-30_srt_MinimumMember_us-gaap_FurnitureAndFixturesMember"
      id="Fact000866">P4Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2025-06-30_srt_MaximumMember_us-gaap_FurnitureAndFixturesMember"
      id="Fact000868">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2025-06-30_us-gaap_FurnitureAndFixturesMember"
      decimals="0"
      id="Fact000870"
      unitRef="USD">205396</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-06-30_us-gaap_FurnitureAndFixturesMember"
      decimals="0"
      id="Fact000872"
      unitRef="USD">195834</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000874"
      unitRef="USD">1070023</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000876"
      unitRef="USD">1060461</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000878"
      unitRef="USD">702180</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000880"
      unitRef="USD">578340</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000882"
      unitRef="USD">367843</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000884"
      unitRef="USD">482121</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000886"
      unitRef="USD">119193</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000888"
      unitRef="USD">113563</us-gaap:Depreciation>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2024-07-01to2025-06-30" id="Fact000890">&lt;p id="xdx_80A_eus-gaap--IntangibleAssetsDisclosureTextBlock_z83twAFzGaPi" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 5 &#x2014; &lt;span id="xdx_824_zwtUXnKln0Ad"&gt;INTANGIBLE ASSETS AND GOODWILL&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;At June 30, 2025, definite-life
intangible assets, net of accumulated amortization, consisted of patents, software platform and trademarks on the Company&#x2019;s products
and processes of $&lt;span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20250630__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zWoKJkZq8fcj" title="Definite-life intangible assets"&gt;14,994&lt;/span&gt;, $&lt;span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20250630__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_zat8g1b9D78h" title="Definite-life intangible assets"&gt;143,000&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_zYrDsOvImAKd" title="Definite-life intangible assets"&gt;8,000&lt;/span&gt;. At June 30, 2024, definite-life intangible assets, net of accumulated amortization, consisted
of patents on the Company&#x2019;s products and processes of $&lt;span id="xdx_902_eus-gaap--AccumulatedAmortizationOfCurrentDeferredFinanceCosts_iI_c20240630_zOk7N08mioSl" title="Accumulated amortization cost"&gt;30,043&lt;/span&gt;. The patents are recorded at cost and amortized over twenty years
from the date of application. Amortization expense for the years ended June 30, 2025 and 2024 was $&lt;span id="xdx_90E_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20240701__20250630_z2DcqlhMhexi" title="Amortization expense"&gt;9,902&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20230701__20240630_zx5sRbE5vp4d" title="Amortization expense"&gt;8,296&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;At June 30, 2025 and 2024, indefinite
life intangible assets consisted of a license agreement classified as In-Process Research and Development (&#x201c;IPR&amp;amp;D&#x201d;) intangible
assets, which are not amortizable until the intangible assets provide economic benefit, and goodwill.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;At June 30, 2025 and 2024, definite-life
and indefinite-life intangible assets consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zxS1O5kteR7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B3_zFdrFns2PjV7" style="display: none"&gt;Schedule of definite-life
and indefinite-life intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Useful Life&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;b&gt;Additions&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;b&gt;Amortization&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;b&gt;Impairment&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Translation Adjustment&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June 30, 2025&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 18%; font-weight: bold; text-align: left; text-indent: -10pt"&gt;Definite Life Intangible Assets&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 8%; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Software platform&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_zKDgw0CvNEa1" title="Useful life"&gt;5&lt;/span&gt; Years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_zJGoDYDERBOk" style="text-align: right" title="Net definite-life intangible assets at beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0909"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_zLTbAOW8wDei" style="text-align: right" title="Net definite-life intangible assets, Additions"&gt;143,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_d0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_zFKC0eOjohHl" style="text-align: right" title="Net definite-life intangible assets, Amortization"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_zuln89l3Uto1" style="text-align: right" title="Net definite-life intangible assets, Impairment"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_zFoqaOz3XOr3" style="text-align: right" title="Net definite-life intangible assets, Translation adjustment"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0917"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_zxO255rBSjQ8" style="text-align: right" title="Net definite-life intangible assets at ending"&gt;143,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Trademark&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_z02VLJxSHsb9" title="Useful life"&gt;2&lt;/span&gt; Years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_zgQbP6Vi2M4g" style="text-align: right" title="Net definite-life intangible assets at beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0923"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_zofiC2jNydfc" style="text-align: right" title="Net definite-life intangible assets, Additions"&gt;8,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_d0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_zlfmDMvRsokk" style="text-align: right" title="Net definite-life intangible assets, Amortization"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_zXapNlDBbgzi" style="text-align: right" title="Net definite-life intangible assets, Impairment"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_zVQeZjfLLNS7" style="text-align: right" title="Net definite-life intangible assets, Translation adjustment"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0931"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_zR1tYG7DguW5" style="text-align: right" title="Net definite-life intangible assets at ending"&gt;8,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Patents&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zIabVC9iVBwe" title="Useful life"&gt;20&lt;/span&gt; Years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zI94aHMbOyM" style="text-align: right" title="Net definite-life intangible assets at beginning"&gt;284,977&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zOLRsLLVq87h" style="text-align: right" title="Net definite-life intangible assets, Additions"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_d0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zz7N5EZrcuii" style="text-align: right" title="Net definite-life intangible assets, Amortization"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zvaP3kU1OSU6" style="text-align: right" title="Net definite-life intangible assets, Impairment"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zYwTZH1bJS6e" style="text-align: right" title="Net definite-life intangible assets, Translation adjustment"&gt;28,033&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zGx1XQ5ijRC3" style="text-align: right" title="Net definite-life intangible assets at ending"&gt;313,010&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Less Accumulated Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zvRV4WPb7Xpb" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets at beginning"&gt;(254,934&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_z5CgLFnFELmi" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Additions"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_z4kzqeRSI9y1" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Amortization"&gt;(9,902&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_z2gDFxhwFlNf" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Impairment"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zgrxQKogzR7h" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Translation adjustment"&gt;(33,180&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zvlmX4hnJiV3" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets at ending"&gt;(298,016&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;Net Definite-Life Intangible Assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20240701__20250630_zrPSE28IG2M3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets at beginning"&gt;30,043&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20240701__20250630_z3QafijyuGbf" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Additions"&gt;151,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_c20240701__20250630_zv5BPUhvgFa8" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Amortization"&gt;(9,902&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20240701__20250630_zauppiG9kKOh" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Impairment"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20240701__20250630_z0ED7xf0gSJ8" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Translation adjustment"&gt;(5,147&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20240701__20250630_z7NHUSlScmS4" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets at ending"&gt;165,994&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-indent: -10pt"&gt;Goodwill&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Goodwill&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zYQ7stsJmGeg" style="text-align: right" title="Total indefinite life intangible assets and goodwill at beginning"&gt;159,330,161&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zjcbBxKVEHjd" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Additions"&gt;5,963,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillAmortization_pp0p0_d0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zZWCBJDFqvye" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Amortization"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillImpairment_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zp9sqSLEORah" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Impairment"&gt;(170,419,429&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zwdneV1Ax3zb" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Translation adjustment"&gt;11,089,268&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iE_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_z9lzaKaMF8b7" style="text-align: right" title="Total indefinite life intangible assets and goodwill at ending"&gt;5,963,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;Total Goodwill&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20240701__20250630_zckWwmOVPp4" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill at beginning"&gt;159,330,161&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_c20240701__20250630_zcmJwXWeGib5" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Additions"&gt;5,963,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillAmortization_pp0p0_d0_c20240701__20250630_zR5l2f7KZ3d4" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Amortization"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillImpairment_pp0p0_c20240701__20250630_z5CmQQHJHznb" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Impairment"&gt;(170,419,429&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20240701__20250630_zKwEnw7E9pOd" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Translation adjustment"&gt;11,089,268&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iE_pp0p0_c20240701__20250630_z6SB979hjI9f" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill at ending"&gt;5,963,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Useful Life&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;b&gt;Additions&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;b&gt;Amortization&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;b&gt;Impairment&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Translation Adjustment&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June 30, 2024&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;Definite Life Intangible Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 18%; text-indent: -10pt"&gt;Patents&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 8%; text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zwcPlFDYIuZf" title="Useful life"&gt;20&lt;/span&gt; Years&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zfEb16zeTnj2" style="width: 8%; text-align: right" title="Net definite-life intangible assets at beginning"&gt;290,936&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zJ7fAgtfGv37" style="width: 8%; text-align: right" title="Net definite-life intangible assets, Additions"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zjPYMFp1vs98" style="width: 8%; text-align: right" title="Net definite-life intangible assets, Amortization"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zAiLki89dtH6" style="width: 8%; text-align: right" title="Net definite-life intangible assets, Impairment"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z5AiMHi03suf" style="width: 8%; text-align: right" title="Net definite-life intangible assets, Translation adjustment"&gt;(5,959&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zLGY4yuJEExi" style="width: 8%; text-align: right" title="Net definite-life intangible assets at ending"&gt;284,977&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Less Accumulated Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zJol2J4hyr3l" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets at beginning"&gt;(251,260&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zrnuJuLKfwki" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Additions"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zEibEadINif8" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Amortization"&gt;(8,296&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zdE5db2anRIe" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Impairment"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zggvI2ANGL5e" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Translation adjustment"&gt;4,622&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zrB8QScOP5k1" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets at ending"&gt;(254,934&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;Net Definite-Life Intangible Assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20230701__20240630_z5Arwfkpf5yb" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets at beginning"&gt;39,676&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20230701__20240630_zW3vXIX6Agq7" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Additions"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_c20230701__20240630_ztF926anJYla" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Amortization"&gt;(8,296&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20230701__20240630_zfzCmbhysTHb" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Impairment"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20230701__20240630_zc0TlrPaLLg8" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Translation adjustment"&gt;(1,337&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20230701__20240630_zGu7SYVAdEBj" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets at ending"&gt;30,043&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;Indefinite Life Intangible Assets and Goodwill&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Goodwill&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zB2jSfWy2ld2" style="text-align: right" title="Total indefinite life intangible assets and goodwill at beginning"&gt;11,640,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zDU1gbDrif4j" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Additions"&gt;159,464,039&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillAmortization_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zUBT57FkhyX" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Amortization"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillImpairment_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zd4CqzoBjYFl" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Impairment"&gt;(11,640,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zNeFETdRY1ia" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Translation adjustment"&gt;(133,878&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iE_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zrlt65boy9Aj" style="text-align: right" title="Total indefinite life intangible assets and goodwill at ending"&gt;159,330,161&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;IPR&amp;amp;D&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zjsS956KFFuk" style="border-bottom: Black 1pt solid; text-align: right" title="Total indefinite life intangible assets and goodwill at beginning"&gt;42,611,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_z0Ss2Apml1J1" style="border-bottom: Black 1pt solid; text-align: right" title="Total indefinite life intangible assets and goodwill, Additions"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillAmortization_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zGJ8NJgKfiX1" style="border-bottom: Black 1pt solid; text-align: right" title="Total indefinite life intangible assets and goodwill, Amortization"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillImpairment_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zgMLOlPFRta3" style="border-bottom: Black 1pt solid; text-align: right" title="Total indefinite life intangible assets and goodwill, Impairment"&gt;(42,611,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zASnIycpGfsf" style="border-bottom: Black 1pt solid; text-align: right" title="Total indefinite life intangible assets and goodwill, Translation adjustment"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iE_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zoHKP38JxOtc" style="border-bottom: Black 1pt solid; text-align: right" title="Total indefinite life intangible assets and goodwill at ending"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;Total Indefinite Life Intangible Assets and Goodwill&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20230701__20240630_z2LoUc1O8Cjl" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill at beginning"&gt;54,251,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_c20230701__20240630_z2L7zbO8iEne" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Additions"&gt;159,464,039&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillAmortization_pp0p0_d0_c20230701__20240630_zV0JSbNWMYhe" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Amortization"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillImpairment_pp0p0_c20230701__20240630_zSI9EOJ7LZ3i" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Impairment"&gt;(54,251,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20230701__20240630_zFwhJXemLzF4" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Translation adjustment"&gt;(133,878&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iE_pp0p0_c20230701__20240630_zczZFCtZTPe1" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill at ending"&gt;159,330,161&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_z64nXS896v6l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Expected future amortization expense is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zrffr1Kb1ul7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B9_zucCgOr290Jb" style="display: none"&gt;Schedule of future amortization expense&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Years
    ended&#160;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 73%; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pp0p0_c20250630_zgWunGgaLwWc" style="width: 15%; font-size: 10pt; text-align: right" title="2026"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;36,350&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pp0p0_c20250630_zujEcm2NjZHc" style="font-size: 10pt; text-align: right" title="2027"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;36,348&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pp0p0_c20250630_zI2kCElHpZG6" style="font-size: 10pt; text-align: right" title="2028"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;32,348&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pp0p0_c20250630_z9rB87fMI4L" style="font-size: 10pt; text-align: right" title="2029"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;32,348&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pp0p0_c20250630_zQPwDE569wN" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Thereafter"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;28,600&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20250630_zC5XSMIb2DUd" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;165,994&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p id="xdx_8AF_zsVcX84tJLHe" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On February 13, 2024, the Company
acquired Renovaro Cube as a wholly owned subsidiary pursuant to a stock purchase agreement.&#160;As part of the acquisition of Renovaro
Cube, the Company acquired goodwill valued at $&lt;span id="xdx_903_eus-gaap--Goodwill_iI_c20240213__srt--StatementGeographicalAxis__custom--RenovaroCubeMember_zSOtQhaxworj" title="Goodwill"&gt;159,464,039&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On April 8, 2025, the Company
acquired Biosymetrics, Inc. as a wholly owned subsidiary pursuant to a stock purchase agreement.&#160;As part of the acquisition of Biosymetrics,
Inc., the Company acquired goodwill valued at $&lt;span id="xdx_90E_eus-gaap--Goodwill_iI_c20250408__srt--StatementGeographicalAxis__custom--BioSymetricsMember_zrllylrMlMb3" title="Goodwill"&gt;5,963,500&lt;/span&gt;, software valued at $&lt;span id="xdx_905_ecustom--Software_iI_c20250408_zXCei7nuteth" title="Software"&gt;143,000&lt;/span&gt; and Trademark valued at $&lt;span id="xdx_90F_ecustom--Trademark_iI_c20250408_znfXQM7Ma7m2" title="Trademark"&gt;8,000&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Impairment&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;Following the fourth quarter of
each year, management performs its annual test of impairment of intangible assets by performing an assessment and determines if it is
more likely than not that the fair value of the asset is greater than or equal to the carrying value of the asset.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;During the quarter ended September
30, 2024, the results of the assessment indicated that the carrying value of the RENC reporting unit exceeded its fair value, due to the
decline in the estimated fair value of the reporting unit based on the Company&#x2019;s market capitalization. Management concluded the
significant driver for the change in the economic benefits was due to the Company&#x2019;s continued inability to raise capital for the
further development of the technologies within this reporting unit. Therefore, an impairment adjustment of $&lt;span id="xdx_907_ecustom--ImpairmentAdjustment_iI_c20240930_zSPlKB6P7xjc" title="Impairment adjustment"&gt;47,614,729&lt;/span&gt;&#160;was recorded
for the period ended September 30, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;During the quarter ended June
30, 2025, the results of the assessment indicated that the carrying value of the RENC reporting unit exceeded its fair value, due to the
decline in the estimated fair value of the reporting unit based on the Company&#x2019;s market capitalization. Management concluded the
significant driver for the change in the economic benefits was due to the Company&#x2019;s continued inability to raise capital for the
further development of the technologies within this reporting unit. Therefore, an impairment adjustment of $&lt;span id="xdx_909_ecustom--ImpairmentAdjustment_iI_c20250630_zuuqqIPS9Oue" title="Impairment adjustment"&gt;122,804,700&lt;/span&gt; was recorded for
the period ended June 30, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2025-06-30_us-gaap_PatentsMember"
      decimals="0"
      id="Fact000892"
      unitRef="USD">14994</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2025-06-30_custom_SoftwarePlatformMember"
      decimals="0"
      id="Fact000894"
      unitRef="USD">143000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2025-06-30_custom_TrademarkMember"
      decimals="0"
      id="Fact000896"
      unitRef="USD">8000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AccumulatedAmortizationOfCurrentDeferredFinanceCosts
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000898"
      unitRef="USD">30043</us-gaap:AccumulatedAmortizationOfCurrentDeferredFinanceCosts>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000900"
      unitRef="USD">9902</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact000902"
      unitRef="USD">8296</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="From2024-07-01to2025-06-30" id="Fact000905">&lt;table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zxS1O5kteR7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B3_zFdrFns2PjV7" style="display: none"&gt;Schedule of definite-life
and indefinite-life intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Useful Life&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;b&gt;Additions&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;b&gt;Amortization&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;b&gt;Impairment&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Translation Adjustment&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June 30, 2025&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 18%; font-weight: bold; text-align: left; text-indent: -10pt"&gt;Definite Life Intangible Assets&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 8%; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Software platform&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_zKDgw0CvNEa1" title="Useful life"&gt;5&lt;/span&gt; Years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_zJGoDYDERBOk" style="text-align: right" title="Net definite-life intangible assets at beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0909"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_zLTbAOW8wDei" style="text-align: right" title="Net definite-life intangible assets, Additions"&gt;143,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_d0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_zFKC0eOjohHl" style="text-align: right" title="Net definite-life intangible assets, Amortization"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_zuln89l3Uto1" style="text-align: right" title="Net definite-life intangible assets, Impairment"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_zFoqaOz3XOr3" style="text-align: right" title="Net definite-life intangible assets, Translation adjustment"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0917"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwarePlatformMember_zxO255rBSjQ8" style="text-align: right" title="Net definite-life intangible assets at ending"&gt;143,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Trademark&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_z02VLJxSHsb9" title="Useful life"&gt;2&lt;/span&gt; Years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_zgQbP6Vi2M4g" style="text-align: right" title="Net definite-life intangible assets at beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0923"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_zofiC2jNydfc" style="text-align: right" title="Net definite-life intangible assets, Additions"&gt;8,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_d0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_zlfmDMvRsokk" style="text-align: right" title="Net definite-life intangible assets, Amortization"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_zXapNlDBbgzi" style="text-align: right" title="Net definite-life intangible assets, Impairment"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_zVQeZjfLLNS7" style="text-align: right" title="Net definite-life intangible assets, Translation adjustment"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0931"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--TrademarkMember_zR1tYG7DguW5" style="text-align: right" title="Net definite-life intangible assets at ending"&gt;8,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Patents&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zIabVC9iVBwe" title="Useful life"&gt;20&lt;/span&gt; Years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zI94aHMbOyM" style="text-align: right" title="Net definite-life intangible assets at beginning"&gt;284,977&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zOLRsLLVq87h" style="text-align: right" title="Net definite-life intangible assets, Additions"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_d0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zz7N5EZrcuii" style="text-align: right" title="Net definite-life intangible assets, Amortization"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zvaP3kU1OSU6" style="text-align: right" title="Net definite-life intangible assets, Impairment"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zYwTZH1bJS6e" style="text-align: right" title="Net definite-life intangible assets, Translation adjustment"&gt;28,033&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zGx1XQ5ijRC3" style="text-align: right" title="Net definite-life intangible assets at ending"&gt;313,010&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Less Accumulated Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zvRV4WPb7Xpb" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets at beginning"&gt;(254,934&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_z5CgLFnFELmi" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Additions"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_z4kzqeRSI9y1" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Amortization"&gt;(9,902&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_z2gDFxhwFlNf" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Impairment"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zgrxQKogzR7h" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Translation adjustment"&gt;(33,180&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zvlmX4hnJiV3" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets at ending"&gt;(298,016&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;Net Definite-Life Intangible Assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20240701__20250630_zrPSE28IG2M3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets at beginning"&gt;30,043&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20240701__20250630_z3QafijyuGbf" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Additions"&gt;151,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_c20240701__20250630_zv5BPUhvgFa8" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Amortization"&gt;(9,902&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20240701__20250630_zauppiG9kKOh" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Impairment"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20240701__20250630_z0ED7xf0gSJ8" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Translation adjustment"&gt;(5,147&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20240701__20250630_z7NHUSlScmS4" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets at ending"&gt;165,994&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-indent: -10pt"&gt;Goodwill&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Goodwill&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zYQ7stsJmGeg" style="text-align: right" title="Total indefinite life intangible assets and goodwill at beginning"&gt;159,330,161&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zjcbBxKVEHjd" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Additions"&gt;5,963,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillAmortization_pp0p0_d0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zZWCBJDFqvye" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Amortization"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillImpairment_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zp9sqSLEORah" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Impairment"&gt;(170,419,429&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zwdneV1Ax3zb" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Translation adjustment"&gt;11,089,268&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iE_pp0p0_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_z9lzaKaMF8b7" style="text-align: right" title="Total indefinite life intangible assets and goodwill at ending"&gt;5,963,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;Total Goodwill&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20240701__20250630_zckWwmOVPp4" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill at beginning"&gt;159,330,161&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_c20240701__20250630_zcmJwXWeGib5" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Additions"&gt;5,963,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillAmortization_pp0p0_d0_c20240701__20250630_zR5l2f7KZ3d4" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Amortization"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillImpairment_pp0p0_c20240701__20250630_z5CmQQHJHznb" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Impairment"&gt;(170,419,429&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20240701__20250630_zKwEnw7E9pOd" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Translation adjustment"&gt;11,089,268&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iE_pp0p0_c20240701__20250630_z6SB979hjI9f" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill at ending"&gt;5,963,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Useful Life&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;b&gt;Additions&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;b&gt;Amortization&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;b&gt;Impairment&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Translation Adjustment&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June 30, 2024&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;Definite Life Intangible Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 18%; text-indent: -10pt"&gt;Patents&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 8%; text-align: center; padding-left: 5.4pt"&gt;&lt;span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zwcPlFDYIuZf" title="Useful life"&gt;20&lt;/span&gt; Years&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zfEb16zeTnj2" style="width: 8%; text-align: right" title="Net definite-life intangible assets at beginning"&gt;290,936&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zJ7fAgtfGv37" style="width: 8%; text-align: right" title="Net definite-life intangible assets, Additions"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zjPYMFp1vs98" style="width: 8%; text-align: right" title="Net definite-life intangible assets, Amortization"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zAiLki89dtH6" style="width: 8%; text-align: right" title="Net definite-life intangible assets, Impairment"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z5AiMHi03suf" style="width: 8%; text-align: right" title="Net definite-life intangible assets, Translation adjustment"&gt;(5,959&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zLGY4yuJEExi" style="width: 8%; text-align: right" title="Net definite-life intangible assets at ending"&gt;284,977&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Less Accumulated Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zJol2J4hyr3l" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets at beginning"&gt;(251,260&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zrnuJuLKfwki" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Additions"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zEibEadINif8" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Amortization"&gt;(8,296&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zdE5db2anRIe" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Impairment"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zggvI2ANGL5e" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets, Translation adjustment"&gt;4,622&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LessAccumulatedAmortizationMember_zrB8QScOP5k1" style="border-bottom: Black 1pt solid; text-align: right" title="Net definite-life intangible assets at ending"&gt;(254,934&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;Net Definite-Life Intangible Assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--NetDefinitelifeIntangibleAssets_iS_pp0p0_c20230701__20240630_z5Arwfkpf5yb" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets at beginning"&gt;39,676&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20230701__20240630_zW3vXIX6Agq7" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Additions"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--NetDefinitelifeIntangibleAssetsAmortization_pp0p0_c20230701__20240630_ztF926anJYla" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Amortization"&gt;(8,296&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_pp0p0_d0_c20230701__20240630_zfzCmbhysTHb" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Impairment"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20230701__20240630_zc0TlrPaLLg8" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets, Translation adjustment"&gt;(1,337&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--NetDefinitelifeIntangibleAssets_iE_pp0p0_c20230701__20240630_zGu7SYVAdEBj" style="border-bottom: Black 2.5pt double; text-align: right" title="Net definite-life intangible assets at ending"&gt;30,043&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;Indefinite Life Intangible Assets and Goodwill&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Goodwill&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zB2jSfWy2ld2" style="text-align: right" title="Total indefinite life intangible assets and goodwill at beginning"&gt;11,640,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zDU1gbDrif4j" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Additions"&gt;159,464,039&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillAmortization_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zUBT57FkhyX" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Amortization"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillImpairment_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zd4CqzoBjYFl" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Impairment"&gt;(11,640,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zNeFETdRY1ia" style="text-align: right" title="Total indefinite life intangible assets and goodwill, Translation adjustment"&gt;(133,878&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iE_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--GoodwillMember_zrlt65boy9Aj" style="text-align: right" title="Total indefinite life intangible assets and goodwill at ending"&gt;159,330,161&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;IPR&amp;amp;D&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zjsS956KFFuk" style="border-bottom: Black 1pt solid; text-align: right" title="Total indefinite life intangible assets and goodwill at beginning"&gt;42,611,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_z0Ss2Apml1J1" style="border-bottom: Black 1pt solid; text-align: right" title="Total indefinite life intangible assets and goodwill, Additions"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillAmortization_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zGJ8NJgKfiX1" style="border-bottom: Black 1pt solid; text-align: right" title="Total indefinite life intangible assets and goodwill, Amortization"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillImpairment_pp0p0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zgMLOlPFRta3" style="border-bottom: Black 1pt solid; text-align: right" title="Total indefinite life intangible assets and goodwill, Impairment"&gt;(42,611,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zASnIycpGfsf" style="border-bottom: Black 1pt solid; text-align: right" title="Total indefinite life intangible assets and goodwill, Translation adjustment"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iE_pp0p0_d0_c20230701__20240630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zoHKP38JxOtc" style="border-bottom: Black 1pt solid; text-align: right" title="Total indefinite life intangible assets and goodwill at ending"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;Total Indefinite Life Intangible Assets and Goodwill&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iS_pp0p0_c20230701__20240630_z2LoUc1O8Cjl" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill at beginning"&gt;54,251,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_pp0p0_c20230701__20240630_z2L7zbO8iEne" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Additions"&gt;159,464,039&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillAmortization_pp0p0_d0_c20230701__20240630_zV0JSbNWMYhe" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Amortization"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--IndefiniteLifeIntangibleAssetsAndGoodwillImpairment_pp0p0_c20230701__20240630_zSI9EOJ7LZ3i" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Impairment"&gt;(54,251,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments_pp0p0_c20230701__20240630_zFwhJXemLzF4" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill, Translation adjustment"&gt;(133,878&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--OtherIndefiniteLivedIntangibleAssets_iE_pp0p0_c20230701__20240630_zczZFCtZTPe1" style="border-bottom: Black 2.5pt double; text-align: right" title="Total indefinite life intangible assets and goodwill at ending"&gt;159,330,161&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="AsOf2025-06-30_custom_SoftwarePlatformMember1126485421"
      id="Fact000907">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease
      contextRef="From2024-07-012025-06-30_custom_SoftwarePlatformMember"
      decimals="0"
      id="Fact000911"
      unitRef="USD">143000</us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
    <RENB:NetDefinitelifeIntangibleAssetsAmortization
      contextRef="From2024-07-012025-06-30_custom_SoftwarePlatformMember"
      decimals="0"
      id="Fact000913"
      unitRef="USD">0</RENB:NetDefinitelifeIntangibleAssetsAmortization>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="From2024-07-012025-06-30_custom_SoftwarePlatformMember"
      decimals="0"
      id="Fact000915"
      unitRef="USD">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <RENB:NetDefinitelifeIntangibleAssets
      contextRef="AsOf2025-06-30_custom_SoftwarePlatformMember1126485421"
      decimals="0"
      id="Fact000919"
      unitRef="USD">143000</RENB:NetDefinitelifeIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="AsOf2025-06-30_custom_TrademarkMember"
      id="Fact000921">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease
      contextRef="From2024-07-012025-06-30_custom_TrademarkMember"
      decimals="0"
      id="Fact000925"
      unitRef="USD">8000</us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
    <RENB:NetDefinitelifeIntangibleAssetsAmortization
      contextRef="From2024-07-012025-06-30_custom_TrademarkMember"
      decimals="0"
      id="Fact000927"
      unitRef="USD">0</RENB:NetDefinitelifeIntangibleAssetsAmortization>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="From2024-07-012025-06-30_custom_TrademarkMember"
      decimals="0"
      id="Fact000929"
      unitRef="USD">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <RENB:NetDefinitelifeIntangibleAssets
      contextRef="AsOf2025-06-30_custom_TrademarkMember"
      decimals="0"
      id="Fact000933"
      unitRef="USD">8000</RENB:NetDefinitelifeIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="AsOf2025-06-30_us-gaap_PatentsMember1126485515"
      id="Fact000935">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <RENB:NetDefinitelifeIntangibleAssets
      contextRef="AsOf2024-06-30_us-gaap_PatentsMember"
      decimals="0"
      id="Fact000937"
      unitRef="USD">284977</RENB:NetDefinitelifeIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease
      contextRef="From2024-07-012025-06-30_us-gaap_PatentsMember"
      decimals="0"
      id="Fact000939"
      unitRef="USD">0</us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
    <RENB:NetDefinitelifeIntangibleAssetsAmortization
      contextRef="From2024-07-012025-06-30_us-gaap_PatentsMember"
      decimals="0"
      id="Fact000941"
      unitRef="USD">0</RENB:NetDefinitelifeIntangibleAssetsAmortization>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="From2024-07-012025-06-30_us-gaap_PatentsMember"
      decimals="0"
      id="Fact000943"
      unitRef="USD">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments
      contextRef="From2024-07-012025-06-30_us-gaap_PatentsMember"
      decimals="0"
      id="Fact000945"
      unitRef="USD">28033</us-gaap:FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments>
    <RENB:NetDefinitelifeIntangibleAssets
      contextRef="AsOf2025-06-30_us-gaap_PatentsMember1126485515"
      decimals="0"
      id="Fact000947"
      unitRef="USD">313010</RENB:NetDefinitelifeIntangibleAssets>
    <RENB:NetDefinitelifeIntangibleAssets
      contextRef="AsOf2024-06-30_custom_LessAccumulatedAmortizationMember"
      decimals="0"
      id="Fact000949"
      unitRef="USD">-254934</RENB:NetDefinitelifeIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease
      contextRef="From2024-07-012025-06-30_custom_LessAccumulatedAmortizationMember"
      decimals="0"
      id="Fact000951"
      unitRef="USD">0</us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
    <RENB:NetDefinitelifeIntangibleAssetsAmortization
      contextRef="From2024-07-012025-06-30_custom_LessAccumulatedAmortizationMember"
      decimals="0"
      id="Fact000953"
      unitRef="USD">-9902</RENB:NetDefinitelifeIntangibleAssetsAmortization>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="From2024-07-012025-06-30_custom_LessAccumulatedAmortizationMember"
      decimals="0"
      id="Fact000955"
      unitRef="USD">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments
      contextRef="From2024-07-012025-06-30_custom_LessAccumulatedAmortizationMember"
      decimals="0"
      id="Fact000957"
      unitRef="USD">-33180</us-gaap:FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments>
    <RENB:NetDefinitelifeIntangibleAssets
      contextRef="AsOf2025-06-30_custom_LessAccumulatedAmortizationMember"
      decimals="0"
      id="Fact000959"
      unitRef="USD">-298016</RENB:NetDefinitelifeIntangibleAssets>
    <RENB:NetDefinitelifeIntangibleAssets
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000961"
      unitRef="USD">30043</RENB:NetDefinitelifeIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000963"
      unitRef="USD">151000</us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
    <RENB:NetDefinitelifeIntangibleAssetsAmortization
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000965"
      unitRef="USD">-9902</RENB:NetDefinitelifeIntangibleAssetsAmortization>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000967"
      unitRef="USD">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000969"
      unitRef="USD">-5147</us-gaap:FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments>
    <RENB:NetDefinitelifeIntangibleAssets
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000971"
      unitRef="USD">165994</RENB:NetDefinitelifeIntangibleAssets>
    <us-gaap:OtherIndefiniteLivedIntangibleAssets
      contextRef="AsOf2024-06-30_us-gaap_GoodwillMember"
      decimals="0"
      id="Fact000973"
      unitRef="USD">159330161</us-gaap:OtherIndefiniteLivedIntangibleAssets>
    <us-gaap:IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease
      contextRef="From2024-07-012025-06-30_us-gaap_GoodwillMember"
      decimals="0"
      id="Fact000975"
      unitRef="USD">5963000</us-gaap:IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
    <RENB:IndefiniteLifeIntangibleAssetsAndGoodwillAmortization
      contextRef="From2024-07-012025-06-30_us-gaap_GoodwillMember"
      decimals="0"
      id="Fact000977"
      unitRef="USD">0</RENB:IndefiniteLifeIntangibleAssetsAndGoodwillAmortization>
    <RENB:IndefiniteLifeIntangibleAssetsAndGoodwillImpairment
      contextRef="From2024-07-012025-06-30_us-gaap_GoodwillMember"
      decimals="0"
      id="Fact000979"
      unitRef="USD">-170419429</RENB:IndefiniteLifeIntangibleAssetsAndGoodwillImpairment>
    <us-gaap:IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments
      contextRef="From2024-07-012025-06-30_us-gaap_GoodwillMember"
      decimals="0"
      id="Fact000981"
      unitRef="USD">11089268</us-gaap:IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments>
    <us-gaap:OtherIndefiniteLivedIntangibleAssets
      contextRef="AsOf2025-06-30_us-gaap_GoodwillMember"
      decimals="0"
      id="Fact000983"
      unitRef="USD">5963000</us-gaap:OtherIndefiniteLivedIntangibleAssets>
    <us-gaap:OtherIndefiniteLivedIntangibleAssets
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000985"
      unitRef="USD">159330161</us-gaap:OtherIndefiniteLivedIntangibleAssets>
    <us-gaap:IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000987"
      unitRef="USD">5963000</us-gaap:IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
    <RENB:IndefiniteLifeIntangibleAssetsAndGoodwillAmortization
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000989"
      unitRef="USD">0</RENB:IndefiniteLifeIntangibleAssetsAndGoodwillAmortization>
    <RENB:IndefiniteLifeIntangibleAssetsAndGoodwillImpairment
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000991"
      unitRef="USD">-170419429</RENB:IndefiniteLifeIntangibleAssetsAndGoodwillImpairment>
    <us-gaap:IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact000993"
      unitRef="USD">11089268</us-gaap:IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments>
    <us-gaap:OtherIndefiniteLivedIntangibleAssets
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact000995"
      unitRef="USD">5963000</us-gaap:OtherIndefiniteLivedIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="AsOf2025-06-30_us-gaap_PatentsMember1126485515"
      id="Fact000997">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <RENB:NetDefinitelifeIntangibleAssets
      contextRef="AsOf2023-06-30_us-gaap_PatentsMember"
      decimals="0"
      id="Fact000999"
      unitRef="USD">290936</RENB:NetDefinitelifeIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease
      contextRef="From2023-07-012024-06-30_us-gaap_PatentsMember"
      decimals="0"
      id="Fact001001"
      unitRef="USD">0</us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
    <RENB:NetDefinitelifeIntangibleAssetsAmortization
      contextRef="From2023-07-012024-06-30_us-gaap_PatentsMember"
      decimals="0"
      id="Fact001003"
      unitRef="USD">0</RENB:NetDefinitelifeIntangibleAssetsAmortization>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="From2023-07-012024-06-30_us-gaap_PatentsMember"
      decimals="0"
      id="Fact001005"
      unitRef="USD">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments
      contextRef="From2023-07-012024-06-30_us-gaap_PatentsMember"
      decimals="0"
      id="Fact001007"
      unitRef="USD">-5959</us-gaap:FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments>
    <RENB:NetDefinitelifeIntangibleAssets
      contextRef="AsOf2024-06-30_us-gaap_PatentsMember"
      decimals="0"
      id="Fact001009"
      unitRef="USD">284977</RENB:NetDefinitelifeIntangibleAssets>
    <RENB:NetDefinitelifeIntangibleAssets
      contextRef="AsOf2023-06-30_custom_LessAccumulatedAmortizationMember"
      decimals="0"
      id="Fact001011"
      unitRef="USD">-251260</RENB:NetDefinitelifeIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease
      contextRef="From2023-07-012024-06-30_custom_LessAccumulatedAmortizationMember"
      decimals="0"
      id="Fact001013"
      unitRef="USD">0</us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
    <RENB:NetDefinitelifeIntangibleAssetsAmortization
      contextRef="From2023-07-012024-06-30_custom_LessAccumulatedAmortizationMember"
      decimals="0"
      id="Fact001015"
      unitRef="USD">-8296</RENB:NetDefinitelifeIntangibleAssetsAmortization>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="From2023-07-012024-06-30_custom_LessAccumulatedAmortizationMember"
      decimals="0"
      id="Fact001017"
      unitRef="USD">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments
      contextRef="From2023-07-012024-06-30_custom_LessAccumulatedAmortizationMember"
      decimals="0"
      id="Fact001019"
      unitRef="USD">4622</us-gaap:FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments>
    <RENB:NetDefinitelifeIntangibleAssets
      contextRef="AsOf2024-06-30_custom_LessAccumulatedAmortizationMember"
      decimals="0"
      id="Fact001021"
      unitRef="USD">-254934</RENB:NetDefinitelifeIntangibleAssets>
    <RENB:NetDefinitelifeIntangibleAssets
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact001023"
      unitRef="USD">39676</RENB:NetDefinitelifeIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact001025"
      unitRef="USD">0</us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
    <RENB:NetDefinitelifeIntangibleAssetsAmortization
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact001027"
      unitRef="USD">-8296</RENB:NetDefinitelifeIntangibleAssetsAmortization>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact001029"
      unitRef="USD">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact001031"
      unitRef="USD">-1337</us-gaap:FiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments>
    <RENB:NetDefinitelifeIntangibleAssets
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001033"
      unitRef="USD">30043</RENB:NetDefinitelifeIntangibleAssets>
    <us-gaap:OtherIndefiniteLivedIntangibleAssets
      contextRef="AsOf2023-06-30_us-gaap_GoodwillMember"
      decimals="0"
      id="Fact001035"
      unitRef="USD">11640000</us-gaap:OtherIndefiniteLivedIntangibleAssets>
    <us-gaap:IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease
      contextRef="From2023-07-012024-06-30_us-gaap_GoodwillMember"
      decimals="0"
      id="Fact001037"
      unitRef="USD">159464039</us-gaap:IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
    <RENB:IndefiniteLifeIntangibleAssetsAndGoodwillAmortization
      contextRef="From2023-07-012024-06-30_us-gaap_GoodwillMember"
      decimals="0"
      id="Fact001039"
      unitRef="USD">0</RENB:IndefiniteLifeIntangibleAssetsAndGoodwillAmortization>
    <RENB:IndefiniteLifeIntangibleAssetsAndGoodwillImpairment
      contextRef="From2023-07-012024-06-30_us-gaap_GoodwillMember"
      decimals="0"
      id="Fact001041"
      unitRef="USD">-11640000</RENB:IndefiniteLifeIntangibleAssetsAndGoodwillImpairment>
    <us-gaap:IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments
      contextRef="From2023-07-012024-06-30_us-gaap_GoodwillMember"
      decimals="0"
      id="Fact001043"
      unitRef="USD">-133878</us-gaap:IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments>
    <us-gaap:OtherIndefiniteLivedIntangibleAssets
      contextRef="AsOf2024-06-30_us-gaap_GoodwillMember"
      decimals="0"
      id="Fact001045"
      unitRef="USD">159330161</us-gaap:OtherIndefiniteLivedIntangibleAssets>
    <us-gaap:OtherIndefiniteLivedIntangibleAssets
      contextRef="AsOf2023-06-30_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="0"
      id="Fact001047"
      unitRef="USD">42611000</us-gaap:OtherIndefiniteLivedIntangibleAssets>
    <us-gaap:IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease
      contextRef="From2023-07-012024-06-30_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="0"
      id="Fact001049"
      unitRef="USD">0</us-gaap:IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
    <RENB:IndefiniteLifeIntangibleAssetsAndGoodwillAmortization
      contextRef="From2023-07-012024-06-30_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="0"
      id="Fact001051"
      unitRef="USD">0</RENB:IndefiniteLifeIntangibleAssetsAndGoodwillAmortization>
    <RENB:IndefiniteLifeIntangibleAssetsAndGoodwillImpairment
      contextRef="From2023-07-012024-06-30_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="0"
      id="Fact001053"
      unitRef="USD">-42611000</RENB:IndefiniteLifeIntangibleAssetsAndGoodwillImpairment>
    <us-gaap:IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments
      contextRef="From2023-07-012024-06-30_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="0"
      id="Fact001055"
      unitRef="USD">0</us-gaap:IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments>
    <us-gaap:OtherIndefiniteLivedIntangibleAssets
      contextRef="AsOf2024-06-30_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="0"
      id="Fact001057"
      unitRef="USD">0</us-gaap:OtherIndefiniteLivedIntangibleAssets>
    <us-gaap:OtherIndefiniteLivedIntangibleAssets
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact001059"
      unitRef="USD">54251000</us-gaap:OtherIndefiniteLivedIntangibleAssets>
    <us-gaap:IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact001061"
      unitRef="USD">159464039</us-gaap:IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
    <RENB:IndefiniteLifeIntangibleAssetsAndGoodwillAmortization
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact001063"
      unitRef="USD">0</RENB:IndefiniteLifeIntangibleAssetsAndGoodwillAmortization>
    <RENB:IndefiniteLifeIntangibleAssetsAndGoodwillImpairment
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact001065"
      unitRef="USD">-54251000</RENB:IndefiniteLifeIntangibleAssetsAndGoodwillImpairment>
    <us-gaap:IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact001067"
      unitRef="USD">-133878</us-gaap:IndefiniteLivedIntangibleAssetsTranslationAndPurchaseAccountingAdjustments>
    <us-gaap:OtherIndefiniteLivedIntangibleAssets
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001069"
      unitRef="USD">159330161</us-gaap:OtherIndefiniteLivedIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="From2024-07-01to2025-06-30" id="Fact001071">&lt;table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zrffr1Kb1ul7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B9_zucCgOr290Jb" style="display: none"&gt;Schedule of future amortization expense&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Years
    ended&#160;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 73%; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pp0p0_c20250630_zgWunGgaLwWc" style="width: 15%; font-size: 10pt; text-align: right" title="2026"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;36,350&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pp0p0_c20250630_zujEcm2NjZHc" style="font-size: 10pt; text-align: right" title="2027"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;36,348&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pp0p0_c20250630_zI2kCElHpZG6" style="font-size: 10pt; text-align: right" title="2028"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;32,348&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pp0p0_c20250630_z9rB87fMI4L" style="font-size: 10pt; text-align: right" title="2029"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;32,348&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pp0p0_c20250630_zQPwDE569wN" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Thereafter"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;28,600&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0_c20250630_zC5XSMIb2DUd" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Total"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;165,994&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001073"
      unitRef="USD">36350</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001075"
      unitRef="USD">36348</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001077"
      unitRef="USD">32348</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001079"
      unitRef="USD">32348</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001081"
      unitRef="USD">28600</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001083"
      unitRef="USD">165994</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:Goodwill
      contextRef="AsOf2024-02-13_custom_RenovaroCubeMember1126484703"
      decimals="0"
      id="Fact001086"
      unitRef="USD">159464039</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="AsOf2025-04-08_custom_BioSymetricsMember"
      decimals="0"
      id="Fact001088"
      unitRef="USD">5963500</us-gaap:Goodwill>
    <RENB:Software
      contextRef="AsOf2025-04-08"
      decimals="0"
      id="Fact001090"
      unitRef="USD">143000</RENB:Software>
    <RENB:Trademark
      contextRef="AsOf2025-04-08"
      decimals="0"
      id="Fact001092"
      unitRef="USD">8000</RENB:Trademark>
    <RENB:ImpairmentAdjustment
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact001094"
      unitRef="USD">47614729</RENB:ImpairmentAdjustment>
    <RENB:ImpairmentAdjustment
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001096"
      unitRef="USD">122804700</RENB:ImpairmentAdjustment>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2024-07-01to2025-06-30" id="Fact001098">&lt;p id="xdx_800_eus-gaap--LesseeOperatingLeasesTextBlock_zYAeab0Otljd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 7 &#x2014; &lt;span id="xdx_823_zrGmbdSqhADb"&gt;LEASES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;b&gt;Operating
Leases &lt;/b&gt;&#x2014; O&lt;span id="xdx_90B_eus-gaap--LesseeOperatingLeaseDescription_c20180618__20180619_zfvuwx7i60O4" title="Lease premises, description"&gt;n June 19, 2018, Lunai entered into a Lease Agreement for a term of ten years from September 1, 2018, with Century
City Medical Plaza Land Co., Inc., pursuant to which the Company agreed to lease approximately 2,453 rentable square feet. On February
20, 2019, Lunai entered into an Addendum to the original Lease Agreement with an effective date of December 1, 2019, where it expanded
the lease area to include another 1,101 square feet for a total rentable 3,554 square feet. The base rent increases by 3% each year, and
ranges from $17,770 per month for the first year to $23,186 per month for the tenth year. The equalized monthly lease payment for the
term of the lease is $20,050.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;Renovaro Cube leases an office
facility in Amsterdam, Netherlands, under a 30-month operating lease agreement commencing on September 1, 2023, with a maturity date of
February 28, 2026. In determining lease asset values, the Company considers fixed and variable payment terms, prepayments, incentives,
and options to extend, terminate or purchase. The Company mutually terminated this lease on April 29, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;Lunai entered an office lease
in Boca Raton, Florida, under a 36-month operating lease agreement commencing on November 1, 2024, with a maturity date of October 31,
2027. In determining lease asset values, the Company considers fixed and variable payment terms, prepayments, incentives, and options
to extend, terminate or purchase.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The Company identified and assessed
the following significant assumptions in recognizing the right-of-use assets and corresponding liabilities:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Expected lease term &lt;/i&gt;&lt;/b&gt;&#x2014;
The expected lease term includes both contractual lease periods and, when applicable, cancelable option periods when it is reasonably
certain that the Company would exercise such options. The Company&#x2019;s leases have a remaining lease term of 26 and 28 months. As of
June 30, 2025, the weighted-average remaining term is &lt;span id="xdx_906_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20250630_znvPKHru2HUc" title="Weighted-average remaining term"&gt;1.95&lt;/span&gt; years.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Incremental borrowing rate&lt;/i&gt;&lt;/b&gt;
&#x2014; The Company&#x2019;s lease agreements do not provide an implicit rate. As the Company does not have any external borrowings for
comparable terms of its leases, the Company estimated the incremental borrowing rate based on the U.S. Treasury Yield Curve rate that
corresponds to the length of each lease. This rate is an estimate of what the Company would have to pay if borrowing on a collateralized
basis over a similar term in an amount equal to the lease payments in a similar economic environment. As of June 30, 2025, the weighted-average
discount rate is &lt;span id="xdx_90C_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20250630_zfJxniLs6XVk" title="Weighted-average discount rate"&gt;4.66&lt;/span&gt;%.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Lease and non-lease components&lt;/i&gt;&lt;/b&gt;
&#x2014; In certain cases the Company is required to pay for certain additional charges for operating costs, including insurance, maintenance,
taxes, and other costs incurred, which are billed based on both usage and as a percentage of the Company&#x2019;s share of total square
footage. The Company determined that these costs are non-lease components, and they are not included in the calculation of the lease liabilities
because they are variable. Payments for these variable, non-lease components are considered variable lease costs and are recognized in
the period in which the costs are incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;Below are the lease commitments for the next 5 years:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zu0MeaLfUyJh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - LEASES (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B4_zXboek72wFhi" style="display: none"&gt;Schedule of lease commitments&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;Years Ending June 30&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Lease Expense&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 73%; text-align: left; text-indent: -10pt"&gt;2026&lt;/td&gt;&lt;td style="width: 10%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_c20250630_za8Be45kf0tj" style="width: 15%; text-align: right" title="2026"&gt;363,999&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_c20250630_zxvdZcBLzsO9" style="text-align: right" title="2027"&gt;358,326&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo_iI_pp0p0_c20250630_zuMJ9yxeEnV" style="text-align: right" title="Thereafter"&gt;56,621&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_c20250630_zSfGZNFdyBfc" style="border-bottom: Black 1pt solid; text-align: right" title="Less imputed interest"&gt;(41,353&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pp0p0_c20250630_z4G5CPVvqkf9" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Total"&gt;737,593&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A1_zaCkZ7Wcd1Jh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseDescription contextRef="From2018-06-182018-06-19" id="Fact001100">n June 19, 2018, Lunai entered into a Lease Agreement for a term of ten years from September 1, 2018, with Century
City Medical Plaza Land Co., Inc., pursuant to which the Company agreed to lease approximately 2,453 rentable square feet. On February
20, 2019, Lunai entered into an Addendum to the original Lease Agreement with an effective date of December 1, 2019, where it expanded
the lease area to include another 1,101 square feet for a total rentable 3,554 square feet. The base rent increases by 3% each year, and
ranges from $17,770 per month for the first year to $23,186 per month for the tenth year. The equalized monthly lease payment for the
term of the lease is $20,050.</us-gaap:LesseeOperatingLeaseDescription>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2025-06-30" id="Fact001102">P1Y11M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact001104"
      unitRef="Ratio">0.0466</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2024-07-01to2025-06-30" id="Fact001107">&lt;table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zu0MeaLfUyJh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - LEASES (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B4_zXboek72wFhi" style="display: none"&gt;Schedule of lease commitments&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;Years Ending June 30&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Lease Expense&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 73%; text-align: left; text-indent: -10pt"&gt;2026&lt;/td&gt;&lt;td style="width: 10%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_c20250630_za8Be45kf0tj" style="width: 15%; text-align: right" title="2026"&gt;363,999&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_c20250630_zxvdZcBLzsO9" style="text-align: right" title="2027"&gt;358,326&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo_iI_pp0p0_c20250630_zuMJ9yxeEnV" style="text-align: right" title="Thereafter"&gt;56,621&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_c20250630_zSfGZNFdyBfc" style="border-bottom: Black 1pt solid; text-align: right" title="Less imputed interest"&gt;(41,353&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pp0p0_c20250630_z4G5CPVvqkf9" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Total"&gt;737,593&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001109"
      unitRef="USD">363999</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001111"
      unitRef="USD">358326</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <RENB:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001113"
      unitRef="USD">56621</RENB:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001115"
      unitRef="USD">41353</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001117"
      unitRef="USD">737593</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2024-07-01to2025-06-30" id="Fact001119">&lt;p id="xdx_800_eus-gaap--DebtDisclosureTextBlock_z1GsRvs682Zb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 8 &#x2014; &lt;span id="xdx_822_zcld5SgGorO4"&gt;DEBT&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Convertible Notes Payable &#x2014;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;The January 2024 Note &#x2014;&lt;/i&gt;&lt;/b&gt;
On January 12, 2024, the Company entered into Subscription Agreements with an investor to issue a Convertible Promissory Note for an aggregate
principal amount of $&lt;span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_c20240112__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zDWRPdIZCbef" title="Principal amount"&gt;125,000&lt;/span&gt; (the &#x201c;January 2024 Note&#x201d;). The Company received a total of $&lt;span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfDebt_c20240109__20240112__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zH6tpqJWmByc" title="Gross proceeds"&gt;125,000&lt;/span&gt; in gross proceeds.&#160;The
January 2024 Note bears an interest rate of &lt;span id="xdx_90A_eus-gaap--LongTermDebtPercentageBearingFixedInterestRate_iI_dp_c20240112__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zDBgGdoWVAJi" title="Bear interest percentage"&gt;12&lt;/span&gt;% per annum and matured on &lt;span id="xdx_904_eus-gaap--DebtInstrumentMaturityDate_dd_c20240109__20240112__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zL15lKdhrY99" title="Debt maturity period"&gt;December 29, 2024&lt;/span&gt;. The Company is required to pay interest quarterly,
in arrears, in cash, on the first day of each quarter of each year following the issue date prior to the maturity of the January 2024
Note. The January 2024 Note is convertible either at the option of the holder or automatically upon maturity into shares of the Company&#x2019;s
Common Stock at the Note Conversion Price of $&lt;span id="xdx_901_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20240112__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member_zYCoUmBOPcv2" title="Conversion price"&gt;3.38&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;December 2023 Notes &#x2014;
&lt;/i&gt;&lt;/b&gt;On December 20, 2023, the Company entered into Subscription Agreements to purchase Convertible Promissory Notes for an aggregate
principal amount of $&lt;span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_c20231220__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_zKnh24zNbM7a" title="Principal amount"&gt;120,000&lt;/span&gt; (the &#x201c;December 2023 Notes&#x201d;). The Company received a total of $&lt;span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfDebt_c20231219__20231220__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_ze5n0o3Uc7Pg" title="Gross proceeds"&gt;120,000&lt;/span&gt; from the private placement
between December 2023 and January 2024.&#160;The December 2023 Notes bear an interest rate of &lt;span id="xdx_90C_eus-gaap--LongTermDebtPercentageBearingFixedInterestRate_iI_dp_c20231220__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_z292Q4HR4224" title="Bear interest percentage"&gt;12&lt;/span&gt;% per annum and matured one year after
their respective dates of issuance (the &#x201c;Maturity Date&#x201d;). The Company is required to pay interest quarterly, in arrears, in
cash, on the first day of each quarter of each year following the issue date prior to the maturity of the December 2023 Notes. Notwithstanding
the immediately foregoing, at the option of the holder, interest may accrue on the December Notes on a quarterly basis. The December 2023
Notes are convertible into shares of the Company&#x2019;s Common Stock in whole or in part at any time and from time to time, after the
original issue date and prior to the Maturity Date, at a conversion price of $&lt;span id="xdx_90D_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20231220__us-gaap--AwardDateAxis__custom--DecemberNote2023Member_zOeGXobaPxki" title="Conversion price"&gt;3.38&lt;/span&gt; per share.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The January 2024 Note and December
2023 Notes balance at June 30, 2025 was $&lt;span id="xdx_905_ecustom--NotesBalance_iI_c20250630_zaqzXyAJXqJf" title="Notes balance"&gt;245,000&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Notes Payable &lt;/b&gt;&#x2014;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Bridge Loans &#x2014; &lt;/i&gt;&lt;/b&gt;From
June 4, 2025 to June 14, 2025, the Company entered into agreements with Paseco ApS, a Danish entity controlled by a shareholder (&#x201c;Paseco
ApS&#x201d;) and Laksya Ventures Inc. to issue Promissory Notes for the principal amount of $&lt;span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_c20250604__us-gaap--RelatedPartyTransactionAxis__custom--PasecoApSMember_zZiKmDfr3R68" title="Principal amount"&gt;1,725,000&lt;/span&gt; to each note holder. The Company
received $&lt;span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfDebt_c20240701__20250630__us-gaap--RelatedPartyTransactionAxis__custom--PasecoApSMember_zdoh1Od0qyw7" title="Gross proceeds"&gt;3,450,000&lt;/span&gt; in gross proceeds. The notes bear an interest rate of &lt;span id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20250604__us-gaap--LongtermDebtTypeAxis__custom--TheNotesMember_zOeaTD0v9Loh" title="Note interest rate"&gt;10&lt;/span&gt;% per annum and mature on December 31, 2025. The notes balance
at June 30, 2025, was $&lt;span id="xdx_90E_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20240701__20250630__us-gaap--LongtermDebtTypeAxis__custom--TheNotesMember_zMy6aCUNzW61" title="Sale of stock, value"&gt;3,450,000&lt;/span&gt; with Paseco ApS and Laksya Ventures Inc. each holding $&lt;span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20250630__us-gaap--RelatedPartyTransactionAxis__custom--PasecoApSMember_zkHMOckvwuN6" title="Principal amount"&gt;1,725,000&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;From October 21, 2024 to January
24, 2025, the Company entered into agreements with Paseco ApS, a Danish entity controlled by a shareholder (&#x201c;Paseco ApS&#x201d;),
to issue Promissory Notes for the principal amount of $&lt;span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_c20241021__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member__us-gaap--RelatedPartyTransactionAxis__custom--PasecoApSMember_zqJtN10uzz3k" title="Principal amount"&gt;2,650,000&lt;/span&gt;. The Company received $&lt;span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfDebt_c20240101__20240124__us-gaap--AwardDateAxis__custom--JanuaryNote2024Member__us-gaap--RelatedPartyTransactionAxis__custom--PasecoApSMember_zD4KBeRS7Ku7" title="Gross proceeds"&gt;2,650,000&lt;/span&gt; in gross proceeds. The notes bear an
interest rate of &lt;span id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20241021__us-gaap--LongtermDebtTypeAxis__custom--TheNotesMember_zDL9ipEmzOB7" title="Note interest rate"&gt;10&lt;/span&gt;% per annum and mature from December 31, 2024 to December 31, 2025. &lt;span id="xdx_90D_eus-gaap--MaturitiesOfTimeDepositsDescription_c20240701__20250630_z2GskIECLgIl" title="Maturity description"&gt;Approximately $700,000 matured on December 31,
2024, $900,000 matured on December 31, 2025 and $1,050,000 matured on January 31, 2025. On February 24, 2025, Paseco ApS assigned 50%
of its ownership rights to Laksya Ventures Inc. with all terms remaining unchanged. The note balance at June 30, 2025, was $2,650,000
with Paseco ApS and Laksya Ventures Inc. each holding $1,325,000&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_90F_ecustom--AgreementDescription_c20241112__20241203__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNotesMember_zHtxUzOyEVQ3" title="Agreement description"&gt;From November 12, 2024 to December
3, 2024, Renovaro Cube entered into an agreement with Paseco ApS, a Danish entity controlled by a shareholder (&#x201c;Paseco ApS&#x201d;),
to issue Promissory Notes for the principal amount of &#x20ac;450,000. The note bears an interest rate of 10% per annum and matures on December
1, 2025. On February 24, 2025 Paseco ApS assigned 50% of its ownership rights to Laksya Ventures Inc. with all terms remaining unchanged.
The note balance at June 30, 2025 was approximately $490,000 with Paseco ApS and Laksya Ventures Inc. each holding $245,000.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_90B_ecustom--AgreementDescription_c20250223__20250224__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNotesMember_z2ZOwfVKVt7h" title="Agreement description"&gt;On November 1, 2024, Renovaro
Cube entered into an agreement with Yalla Yalla Limited, an investor to issue a Promissory Note for the amount of approximately &#x20ac;225,000.
The note bears an interest rate of 10% per annum and matured on February 24, 2025. The note balance at June 30, 2025 was approximately
$238,000.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_905_ecustom--AgreementDescription_c20240915__20240916__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNotesMember_zZod2qlMyZc1" title="Agreement description"&gt;On September 16, 2024, the Company
entered into an agreement with RS Bio ApS, a Danish entity controlled by a shareholder (&#x201c;RS Bio&#x201d;), to issue a Promissory Note
for the principal amount of $100,000 (the &#x201c;September 2024 Note&#x201d;). The Company received $100,000 in gross proceeds. The note
bears an interest rate of 12% per annum and matured on December 31, 2024. On February 24, 2025 RS Bio assigned its ownership rights to
Rene Sindlev with all terms remaining unchanged. The note balance at June 30, 2025 was $100,000&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;O&lt;span id="xdx_904_ecustom--AgreementDescription_c20240905__20240906__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNotesMember_zm2x4YXN4lH8" title="Agreement description"&gt;n September 6, 2024, Renovaro
Cube entered into an agreement with Paseco ApS, a Danish entity controlled by a shareholder (&#x201c;Paseco ApS&#x201d;), to issue a Promissory
Note for the principal amount of &#x20ac;50,000. The note bears an interest rate of 12% per annum and matures on September 9, 2025. On February
24, 2025 Paseco ApS assigned 50% of its ownership rights to Laksya Ventures Inc. with all terms remaining unchanged. The note balance
at June 30, 2025 was approximately $59,000 with Paseco ApS and Laksya Ventures Inc. each holding approximately $30,000 (see Note 8 to
the Financial Statements)&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_909_ecustom--AgreementDescription_c20240204__20240205__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNotesMember_zFhCUFu7dVv1" title="Agreement description"&gt;On February 5, 2024, the Company
entered into an agreement with RS Bio to issue a 5% Original Issue Discount Secured Promissory Note for the principal amount of $105,263
(the &#x201c;February 2024 Note&#x201d;). The Company received $100,000 in gross proceeds after taking into account the 5% original issue
discount. The note bears an interest rate of 12% per annum and matured on December 31, 2024. On February 24, 2025 RS Bio assigned its
ownership rights to Rene Sindlev with all terms remaining unchanged. The note balance, net of discount at June 30, 2025 was $105,263&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_907_ecustom--AgreementDescription_c20240101__20240102__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNotesMember_z645ny91519i" title="Agreement description"&gt;On January 2, 2024, the Company
entered into an agreement with RS Bio to issue a 5% Original Issue Discount Secured Promissory Note for the principal amount of $526,315.
The Company received a total of $500,000 in gross proceeds after taking into account the 5% original issue discount.&#160;The note bears
an interest rate of 12% per annum and matured on December 31, 2024. On February 24, 2025 RS Bio assigned its ownership rights to Rene
Sindlev with all terms remaining unchanged. The note balance, net of discount at June 30, 2025 was $526,315&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_902_ecustom--AgreementDescription_c20241102__20241103__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNotesMember_z4bHB0FPjdEa" title="Agreement description"&gt;On November 3, 2023, the Company
entered into an agreement with RS Bio to issue a 5% Original Issue Discount Promissory Note for the principal amount of $1,000,000. The
Company received a total of $950,000 in gross proceeds after taking into account the 5% original issue discount.&#160;The discount of
$50,000 will be accreted over the life of the note. The note bears an interest rate of 12% per annum and matured on December 31, 2024.
On February 24, 2025 RS Bio assigned its ownership rights to Rene Sindlev with all terms remaining unchanged. The note balance, net of
discount at June 30, 2025 was $750,000.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Promissory Note &#x2014; &lt;/b&gt;On
March 30, 2020 (the &#x201c;Issuance Date&#x201d;), the Company issued a Promissory Note in the principal amount of $&lt;span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20200330__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zTgvK82DPgE8" title="Principal amount"&gt;5,000,000&lt;/span&gt; (the &#x201c;Promissory
Note&#x201d;) to Paseco ApS. There have been eight amendments to the Promissory Note since the issuance date, the most recent of which
is dated August 1, 2024. The principal amount of the Promissory Note, as amended, was payable on &lt;span id="xdx_908_eus-gaap--DebtInstrumentMaturityDate_dd_c20200329__20200330__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zHhIXAjGUWh1" title="Maturity date"&gt;November 1, 2024&lt;/span&gt; (the &#x201c;Maturity
Date&#x201d;). The Promissory Note, as amended, bears interest at a fixed rate of &lt;span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_dp_c20200329__20200330__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_zEwKclneWNGf" title="Interest rate"&gt;12&lt;/span&gt;% per annum. On February 24, 2025 Paseco ApS assigned
its ownership rights to Rene Sindlev with all terms remaining unchanged. The Promissory Note balance at June 30, 2025 is $&lt;span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_c20250101__20250630__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteMember_z97MRh2cZ809" title="Issuance of common stock"&gt;831,497&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The Company&#x2019;s obligations
under the referenced Promissory and Bridge Notes, except for those originally entered into by Renovaro Cube, are secured by a Security
Agreement. To secure the Company&#x2019;s obligations under the Promissory Note, the Company entered into a Security Agreement with the
Holder, pursuant to which the Company granted a lien on all assets of the Company (the &#x201c;Collateral&#x201d;) for the benefit of Paseco
ApS, Rene Sindlev and Laksya Ventures. Upon an Event of Default (as defined in the notes, respectively) Paseco ApS, Rene Sindlev and Laksya
Ventures may, among other things, collect or take possession of the Collateral, proceed with the foreclosure of the security interest
in the Collateral or sell, lease, or dispose of the Collateral (see Note 8 to the Financial Statements).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Finance Agreement &lt;/b&gt;&#x2014;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On November 30, 2024, the Company
entered into a premium finance agreement (the &#x201c;Agreement&#x201d;) related to insurance,&#160;&lt;span style="background-color: white"&gt;which
resulted in the recognition of a liability and prepaid exp&lt;/span&gt;ense with a principal amount of $&lt;span id="xdx_903_eus-gaap--DebtInstrumentAnnualPrincipalPayment_iI_c20241130__us-gaap--BalanceSheetLocationAxis__us-gaap--OtherCurrentLiabilitiesMember__us-gaap--TypeOfArrangementAxis__custom--FinanceAgreementMember_zOfHqmcl5AX8" title="Principal amount"&gt;1,018,930&lt;/span&gt; at&#160;&lt;span id="xdx_906_eus-gaap--DerivativeFixedInterestRate_iI_dp_c20241130__us-gaap--BalanceSheetLocationAxis__us-gaap--OtherCurrentLiabilitiesMember__us-gaap--TypeOfArrangementAxis__custom--FinanceAgreementMember_zo3mPZ897sw1" title="Rate of interest"&gt;7.50&lt;/span&gt;% interest per
annum, which is reflected on the consolidated balance sheet under &#x201c;other current liabilities&#x201d; and &#x201c;prepaid assets and
other assets&#x201d;, respectively. The repayment of the Agreement will be made in nine equal monthly installments of $&lt;span id="xdx_90C_ecustom--MonthlyInstallments_pp0p0_c20241129__20241130__us-gaap--TypeOfArrangementAxis__custom--FinanceAgreementMember_zjLV9XrLOAb2" title="Monthly instalments amount"&gt;93,401&lt;/span&gt;&#160;after
a down payment of $&lt;span id="xdx_903_ecustom--RepaymentOnFinanceAgreement_pp0p0_c20241129__20241130__us-gaap--TypeOfArrangementAxis__custom--FinanceAgreementMember_zTyIeEMKVMIl" title="Down payment amount"&gt;204,000&lt;/span&gt;.&#160;For the years ended June 30, 2025 and 2024 the Company made payments of $&lt;span id="xdx_900_ecustom--RepaymentOnFinanceAgreement_pp0p0_c20240701__20250630__us-gaap--TypeOfArrangementAxis__custom--FinanceAgreementMember_zDtkx2Vagz0j" title="Down payment amount"&gt;971,231&lt;/span&gt;&#160;and $&lt;span id="xdx_90F_ecustom--RepaymentOnFinanceAgreement_pp0p0_c20230701__20240630__us-gaap--TypeOfArrangementAxis__custom--FinanceAgreementMember_zXOG5pko0Nlh" title="Down payment amount"&gt;870,073&lt;/span&gt;, respectively.
The remaining balance at June 30, 2025 is $&lt;span id="xdx_90A_eus-gaap--OtherLiabilitiesNoncurrent_iI_c20250630_zOvTMAbygdja" title="Other current liabilities"&gt;271,643&lt;/span&gt;; the amount is reflected in other current liabilities. &lt;span style="background-color: white"&gt;For
the years ended June 30, 2025 and 2024 the Company recorded total interest expense in the amount of $&lt;span id="xdx_907_eus-gaap--InterestAndDebtExpense_c20240701__20250630__us-gaap--TypeOfArrangementAxis__custom--FinanceAgreementMember_zHyESXXVSmig" title="Accrued interest expense"&gt;24,555&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--InterestAndDebtExpense_c20230701__20240630__us-gaap--TypeOfArrangementAxis__custom--FinanceAgreementMember_z7UJAqzEgSac" title="Accrued interest expense"&gt;20,128&lt;/span&gt;&#160;related to
the Agreement. This amount is reflected in other income and expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;Total
interest expense recorded for the years ended June 30, 2025 and 2024, was $&lt;span id="xdx_907_eus-gaap--InterestExpenseNonoperating_c20240701__20250630_zBwkCPNq1Af2" title="Total interest expense"&gt;725,684&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--InterestExpenseNonoperating_c20230701__20240630_zZnN5KnHq0j9" title="Total interest expense"&gt;1,011,322&lt;/span&gt; respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-01-12_custom_JanuaryNote2024Member"
      decimals="0"
      id="Fact001121"
      unitRef="USD">125000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2024-01-092024-01-12_custom_JanuaryNote2024Member"
      decimals="0"
      id="Fact001123"
      unitRef="USD">125000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate
      contextRef="AsOf2024-01-12_custom_JanuaryNote2024Member"
      decimals="INF"
      id="Fact001125"
      unitRef="Ratio">0.12</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2024-01-092024-01-12_custom_JanuaryNote2024Member"
      id="Fact001127">2024-12-29</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2024-01-12_custom_JanuaryNote2024Member"
      decimals="INF"
      id="Fact001129"
      unitRef="USDPShares">3.38</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-12-20_custom_DecemberNote2023Member"
      decimals="0"
      id="Fact001131"
      unitRef="USD">120000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2023-12-192023-12-20_us-gaap_PrivatePlacementMember_custom_DecemberNote2023Member"
      decimals="0"
      id="Fact001133"
      unitRef="USD">120000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate
      contextRef="AsOf2023-12-20_custom_DecemberNote2023Member"
      decimals="INF"
      id="Fact001135"
      unitRef="Ratio">0.12</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2023-12-20_custom_DecemberNote2023Member"
      decimals="INF"
      id="Fact001137"
      unitRef="USDPShares">3.38</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <RENB:NotesBalance
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001139"
      unitRef="USD">245000</RENB:NotesBalance>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2025-06-04_custom_PasecoApSMember"
      decimals="0"
      id="Fact001141"
      unitRef="USD">1725000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2024-07-012025-06-30_custom_PasecoApSMember"
      decimals="0"
      id="Fact001143"
      unitRef="USD">3450000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2025-06-04_custom_TheNotesMember"
      decimals="INF"
      id="Fact001145"
      unitRef="Ratio">0.10</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2024-07-012025-06-30_custom_TheNotesMember"
      decimals="0"
      id="Fact001147"
      unitRef="USD">3450000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2025-06-30_custom_PasecoApSMember"
      decimals="0"
      id="Fact001149"
      unitRef="USD">1725000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-10-21_custom_JanuaryNote2024Member_custom_PasecoApSMember"
      decimals="0"
      id="Fact001151"
      unitRef="USD">2650000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2024-01-012024-01-24_custom_JanuaryNote2024Member_custom_PasecoApSMember"
      decimals="0"
      id="Fact001153"
      unitRef="USD">2650000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2024-10-21_custom_TheNotesMember"
      decimals="INF"
      id="Fact001155"
      unitRef="Ratio">0.10</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:MaturitiesOfTimeDepositsDescription contextRef="From2024-07-01to2025-06-30" id="Fact001157">Approximately $700,000 matured on December 31,
2024, $900,000 matured on December 31, 2025 and $1,050,000 matured on January 31, 2025. On February 24, 2025, Paseco ApS assigned 50%
of its ownership rights to Laksya Ventures Inc. with all terms remaining unchanged. The note balance at June 30, 2025, was $2,650,000
with Paseco ApS and Laksya Ventures Inc. each holding $1,325,000</us-gaap:MaturitiesOfTimeDepositsDescription>
    <RENB:AgreementDescription
      contextRef="From2024-11-122024-12-03_custom_PromissoryNotesMember"
      id="Fact001160">From November 12, 2024 to December
3, 2024, Renovaro Cube entered into an agreement with Paseco ApS, a Danish entity controlled by a shareholder (&#x201c;Paseco ApS&#x201d;),
to issue Promissory Notes for the principal amount of &#x20ac;450,000. The note bears an interest rate of 10% per annum and matures on December
1, 2025. On February 24, 2025 Paseco ApS assigned 50% of its ownership rights to Laksya Ventures Inc. with all terms remaining unchanged.
The note balance at June 30, 2025 was approximately $490,000 with Paseco ApS and Laksya Ventures Inc. each holding $245,000.</RENB:AgreementDescription>
    <RENB:AgreementDescription
      contextRef="From2025-02-232025-02-24_custom_PromissoryNotesMember"
      id="Fact001162">On November 1, 2024, Renovaro
Cube entered into an agreement with Yalla Yalla Limited, an investor to issue a Promissory Note for the amount of approximately &#x20ac;225,000.
The note bears an interest rate of 10% per annum and matured on February 24, 2025. The note balance at June 30, 2025 was approximately
$238,000.</RENB:AgreementDescription>
    <RENB:AgreementDescription
      contextRef="From2024-09-152024-09-16_custom_PromissoryNotesMember"
      id="Fact001164">On September 16, 2024, the Company
entered into an agreement with RS Bio ApS, a Danish entity controlled by a shareholder (&#x201c;RS Bio&#x201d;), to issue a Promissory Note
for the principal amount of $100,000 (the &#x201c;September 2024 Note&#x201d;). The Company received $100,000 in gross proceeds. The note
bears an interest rate of 12% per annum and matured on December 31, 2024. On February 24, 2025 RS Bio assigned its ownership rights to
Rene Sindlev with all terms remaining unchanged. The note balance at June 30, 2025 was $100,000</RENB:AgreementDescription>
    <RENB:AgreementDescription
      contextRef="From2024-09-052024-09-06_custom_PromissoryNotesMember"
      id="Fact001166">n September 6, 2024, Renovaro
Cube entered into an agreement with Paseco ApS, a Danish entity controlled by a shareholder (&#x201c;Paseco ApS&#x201d;), to issue a Promissory
Note for the principal amount of &#x20ac;50,000. The note bears an interest rate of 12% per annum and matures on September 9, 2025. On February
24, 2025 Paseco ApS assigned 50% of its ownership rights to Laksya Ventures Inc. with all terms remaining unchanged. The note balance
at June 30, 2025 was approximately $59,000 with Paseco ApS and Laksya Ventures Inc. each holding approximately $30,000 (see Note 8 to
the Financial Statements)</RENB:AgreementDescription>
    <RENB:AgreementDescription
      contextRef="From2024-02-042024-02-05_custom_PromissoryNotesMember"
      id="Fact001168">On February 5, 2024, the Company
entered into an agreement with RS Bio to issue a 5% Original Issue Discount Secured Promissory Note for the principal amount of $105,263
(the &#x201c;February 2024 Note&#x201d;). The Company received $100,000 in gross proceeds after taking into account the 5% original issue
discount. The note bears an interest rate of 12% per annum and matured on December 31, 2024. On February 24, 2025 RS Bio assigned its
ownership rights to Rene Sindlev with all terms remaining unchanged. The note balance, net of discount at June 30, 2025 was $105,263</RENB:AgreementDescription>
    <RENB:AgreementDescription
      contextRef="From2024-01-012024-01-02_custom_PromissoryNotesMember"
      id="Fact001170">On January 2, 2024, the Company
entered into an agreement with RS Bio to issue a 5% Original Issue Discount Secured Promissory Note for the principal amount of $526,315.
The Company received a total of $500,000 in gross proceeds after taking into account the 5% original issue discount.&#160;The note bears
an interest rate of 12% per annum and matured on December 31, 2024. On February 24, 2025 RS Bio assigned its ownership rights to Rene
Sindlev with all terms remaining unchanged. The note balance, net of discount at June 30, 2025 was $526,315</RENB:AgreementDescription>
    <RENB:AgreementDescription
      contextRef="From2024-11-022024-11-03_custom_PromissoryNotesMember"
      id="Fact001172">On November 3, 2023, the Company
entered into an agreement with RS Bio to issue a 5% Original Issue Discount Promissory Note for the principal amount of $1,000,000. The
Company received a total of $950,000 in gross proceeds after taking into account the 5% original issue discount.&#160;The discount of
$50,000 will be accreted over the life of the note. The note bears an interest rate of 12% per annum and matured on December 31, 2024.
On February 24, 2025 RS Bio assigned its ownership rights to Rene Sindlev with all terms remaining unchanged. The note balance, net of
discount at June 30, 2025 was $750,000.</RENB:AgreementDescription>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2020-03-30_custom_PromissoryNoteMember"
      decimals="0"
      id="Fact001174"
      unitRef="USD">5000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2020-03-292020-03-30_custom_PromissoryNoteMember"
      id="Fact001176">2024-11-01</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="From2020-03-292020-03-30_custom_PromissoryNoteMember"
      decimals="INF"
      id="Fact001178"
      unitRef="Ratio">0.12</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2025-01-012025-06-30_custom_PromissoryNoteMember"
      decimals="0"
      id="Fact001180"
      unitRef="USD">831497</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:DebtInstrumentAnnualPrincipalPayment
      contextRef="AsOf2024-11-30_us-gaap_OtherCurrentLiabilitiesMember_custom_FinanceAgreementMember"
      decimals="0"
      id="Fact001183"
      unitRef="USD">1018930</us-gaap:DebtInstrumentAnnualPrincipalPayment>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="AsOf2024-11-30_us-gaap_OtherCurrentLiabilitiesMember_custom_FinanceAgreementMember"
      decimals="INF"
      id="Fact001185"
      unitRef="Ratio">0.0750</us-gaap:DerivativeFixedInterestRate>
    <RENB:MonthlyInstallments
      contextRef="From2024-11-292024-11-30_custom_FinanceAgreementMember"
      decimals="0"
      id="Fact001187"
      unitRef="USD">93401</RENB:MonthlyInstallments>
    <RENB:RepaymentOnFinanceAgreement
      contextRef="From2024-11-292024-11-30_custom_FinanceAgreementMember"
      decimals="0"
      id="Fact001189"
      unitRef="USD">204000</RENB:RepaymentOnFinanceAgreement>
    <RENB:RepaymentOnFinanceAgreement
      contextRef="From2024-07-012025-06-30_custom_FinanceAgreementMember"
      decimals="0"
      id="Fact001191"
      unitRef="USD">971231</RENB:RepaymentOnFinanceAgreement>
    <RENB:RepaymentOnFinanceAgreement
      contextRef="From2023-07-012024-06-30_custom_FinanceAgreementMember"
      decimals="0"
      id="Fact001193"
      unitRef="USD">870073</RENB:RepaymentOnFinanceAgreement>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001195"
      unitRef="USD">271643</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:InterestAndDebtExpense
      contextRef="From2024-07-012025-06-30_custom_FinanceAgreementMember"
      decimals="0"
      id="Fact001197"
      unitRef="USD">24555</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense
      contextRef="From2023-07-012024-06-30_custom_FinanceAgreementMember"
      decimals="0"
      id="Fact001199"
      unitRef="USD">20128</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001201"
      unitRef="USD">725684</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact001203"
      unitRef="USD">1011322</us-gaap:InterestExpenseNonoperating>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2024-07-01to2025-06-30" id="Fact001205">&lt;p id="xdx_80D_eus-gaap--IncomeTaxDisclosureTextBlock_z8Ea9I1PCun8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 9 &#x2014; &lt;span id="xdx_821_zC4Mx3WBYbO6"&gt;INCOME TAXES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The Company accounts for income
taxes in accordance with FASB ASC Topic 740, Accounting for Income Taxes; which requires the Company to provide a net deferred tax asset
or liability equal to the expected future tax benefit or expense of temporary reporting differences between book and tax accounting and
any available operating loss or tax credit carryforwards. The amount of and ultimate realization of the benefits from the deferred tax
assets for income tax purposes is dependent, in part, upon the tax laws in effect, the Company&#x2019;s future earnings, and other future
events, the effects of which cannot be determined.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;As of June 30, 2025 and 2024,
the Company had net operating loss carryforwards of approximately $&lt;span id="xdx_900_eus-gaap--OperatingLossCarryforwards_iI_c20250630__us-gaap--IncomeTaxAuthorityAxis__custom--UnitedStatesTaxMember_zsaoSjHpHZW8" title="Operating loss carryforwards"&gt;541,603,425&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20240630__us-gaap--IncomeTaxAuthorityAxis__custom--UnitedStatesTaxMember_znNFFosXZBU2" title="Operating loss carryforwards"&gt;489,177,759&lt;/span&gt; respectively, giving rise to deferred
tax assets of $&lt;span id="xdx_90A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsForeign_iI_pp0p0_c20250630__us-gaap--IncomeTaxAuthorityAxis__custom--UnitedStatesTaxMember_zHZBf4U995Ci" title="Deferred tax assets"&gt;76,296,814&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsForeign_iI_pp0p0_c20240630__us-gaap--IncomeTaxAuthorityAxis__custom--UnitedStatesTaxMember_z1axxMxqB38j" title="Deferred tax assets"&gt;144,191,530&lt;/span&gt;, respectively. The net operating loss carryforwards generated prior to January 1, 2018 expire
over various dates from 2031 to 2038. All subsequent net operating loss carryforwards are indefinite.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The Company files Danish and U.S.
income tax returns and these returns are generally no longer subject to tax examinations for years prior to 2021 for the Danish tax returns
and 2022 for the U.S. tax returns.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The temporary differences, tax
credits and carry forwards gave rise to the following deferred tax assets (liabilities) at June 30, 2025 and 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zG7ef07kCjig" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8BE_zWb6LjrOJUod" style="display: none"&gt;Schedule of deferred tax assets and liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_491_20250630_z2pzuoOnf8yk" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49E_20240630_zpnAVDgg77Sb" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June 30&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--Depreciations_iI_z8O0Jizr4Ah3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-indent: -10pt"&gt;Depreciation&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;(24,619&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;8,258&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--DeferredTaxAssetExcessTaxOverDepreciationPatents_iI_pp0p0_maDTALNzwuT_z05qOfiHebK9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Excess of tax over book depreciation of patents&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1220"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,415&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--StockoptionsCompensation_iI_pp0p0_maDTALNzwuT_z0eQx4ABu7Gc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Stock/options compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;463,099&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,672,252&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--DepreciationAndAmortizations_iI_pp0p0_maDTALNzwuT_z3xluljzTyLe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Depreciation and amortization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1226"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;188,422&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_maDTALNzwuT_za5kAs7Fzbnl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;76,296,814&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;148,832,041&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--ImpairmentExpense_iI_pp0p0_d0_maDTALNzwuT_zPLauX3Dg9Xf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&#160;Impairment expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,188,497&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--ContingentConsiderationFairValue_iI_pp0p0_d0_maDTALNzwuT_zapO6NPIqsz" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Contingent consideration fair value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(909,577&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AccumulatedAmortizationOfOtherDeferredCosts_iI_pp0p0_zdsvvMK0hJ28" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Amortization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,961,747&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1239"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--Section174ReCapitalization_iI_pp0p0_zsRiglMBn91h" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Section 174 R&amp;amp;E Capitalization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,292,075&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1242"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--OperatingLeaseRightOfUseAssets_iI_pp0p0_zasdyD3kGSyk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;ROU Assets and Lease Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14,227&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1245"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--Section481aAdjustment_iI_pp0p0_zSm9CwUyzF5c" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Section 481(a) Adjustment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(40,895&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1248"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pp0p0_zwOcJj92EMD4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;R&amp;amp;D Tax Credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,718,415&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1251"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--ChangeInTaxRate_iI_pp0p0_d0_maDTALNzwuT_zbDREXQcEyMh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Change in tax rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_msDTALNzwuT_z6J1A7OH0Kjg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(83,680,863&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(170,988,308&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_iI_pp0p0_zcd39fI1vKZk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Total Deferred Tax Assets (Liabilities)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1259"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1260"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A7_zoAvNePKcrtj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;In accordance with prevailing
accounting guidance, the Company is required to recognize and disclose any income tax uncertainties. The guidance provides a two-step
approach to recognizing and measuring tax benefits and liabilities when realization of the tax position is uncertain. The first step is
to determine whether the tax position meets the more-likely-than-not condition for recognition, and the second step is to determine the
amount to be recognized based on the cumulative probability that exceeds 50%. The amount of and ultimate realization of the benefits from
the deferred tax assets for income tax purposes is dependent, in part, upon the tax laws in effect, the Company&#x2019;s future earnings,
and other future events, the effects of which can be difficult to determine and can only be estimated. Management estimates that it is
more likely than not that the Company will not generate adequate net profits to use the deferred tax assets; and consequently, a valuation
allowance was recorded for all deferred tax assets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;A reconciliation of income tax
expense at the federal statutory rate to income tax expense at the Company&#x2019;s effective rate is as follows for the years ended June
30, 2025 and 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zlDfgmV18te" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_495_20240701__20250630_zFeO7GtMwKsf" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_490_20230701__20240630_zHDY7JCSDrbe" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Years ended June 30,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationChangeInEnactedTaxRate_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Computed tax at expected statutory rate&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;(951,542&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;(24,066,011&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--IncomeTaxReconciliationRepatriationOfForeignEarnings_iN_pp0p0_d0_zKIUKpKrDoYf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Non-US income taxed at different rates&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--IncomeTaxReconciliationNondeductibleExpense_d0_zMIO6nQnezl6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Non-deductible expenses / other items&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,046,364&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_i_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,999,380&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;24,066,011&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OtherTaxExpenseBenefit_d0_zo2a8bR4x85k" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Income Tax Expense (Benefit)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,474&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A6_ztLRpc0LQb7d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
components of income tax expense (benefit) from continuing operations for the years ended June 30, 2025 and 2024 consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zysVPktt2Tdj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 20pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B7_zPjqVwYUCxq2" style="display: none"&gt;Schedule
    of components of income tax expense (benefit) from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49B_20240701__20250630_zw3QhO3HHRB3" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_495_20230701__20240630_zyuACp3VqK58" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Years
    ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 20pt; font-size: 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Current
    Income Tax Expense&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--CurrentFederalTaxExpenseBenefit_i01_pp0p0_d0_maCITEBzr8l_zuuOhRzfy6Ng" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 20pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Federal
    income tax (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i01_pp0p0_d0_maCITEBzr8l_zKtOaFUWvZ5d" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 20pt; width: 56%; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;State
    income tax (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 8%; font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; font-size: 10pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,474&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 8%; font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; font-size: 10pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--CurrentForeignTaxExpenseBenefit_i01_pp0p0_d0_maCITEBzr8l_z2ediuyAkH21" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 20pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Foreign
    income tax (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--CurrentIncomeTaxExpenseBenefit_i01T_pp0p0_d0_mtCITEBzr8l_maITEBzLgX_ztyyjCR5lrL5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    Current Tax Expense (Benefit)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,474&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_zpTGFHzNm6E" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 20pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
    Income Tax Expense Federal income tax (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;101,609,457&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;165,458,980&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefit_zwgRvZRgyeG1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 20pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;State
    income tax (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(14,302,006&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,529,328&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_zaArW39NQWz3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 20pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Foreign
    income tax (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1303"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1304"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_ziMMCuaxDi1d" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 20pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;
    Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(87,307,451&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(170,988,308&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredIncomeTaxExpenseBenefit_i01T_pp0p0_d0_mtDITEBzk3M_maITEBzLgX_zMuyJTSzElsj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    Deferred Tax Expense&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--IncomeTaxExpenseBenefit_i01T_pp0p0_d0_mtITEBzLgX_zfLHiVBg5I98" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 20pt; font-size: 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    Tax Expense&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,474&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p id="xdx_8A0_zqdlppKeJgil" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
income tax expense (benefit) results primarily from the reversal of temporary timing differences between tax and financial statement
income.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2025-06-30_custom_UnitedStatesTaxMember"
      decimals="0"
      id="Fact001207"
      unitRef="USD">541603425</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2024-06-30_custom_UnitedStatesTaxMember"
      decimals="0"
      id="Fact001209"
      unitRef="USD">489177759</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign
      contextRef="AsOf2025-06-30_custom_UnitedStatesTaxMember"
      decimals="0"
      id="Fact001211"
      unitRef="USD">76296814</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign
      contextRef="AsOf2024-06-30_custom_UnitedStatesTaxMember"
      decimals="0"
      id="Fact001213"
      unitRef="USD">144191530</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2024-07-01to2025-06-30" id="Fact001215">&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zG7ef07kCjig" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8BE_zWb6LjrOJUod" style="display: none"&gt;Schedule of deferred tax assets and liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_491_20250630_z2pzuoOnf8yk" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49E_20240630_zpnAVDgg77Sb" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;June 30&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--Depreciations_iI_z8O0Jizr4Ah3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-indent: -10pt"&gt;Depreciation&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;(24,619&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;8,258&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--DeferredTaxAssetExcessTaxOverDepreciationPatents_iI_pp0p0_maDTALNzwuT_z05qOfiHebK9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Excess of tax over book depreciation of patents&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1220"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,415&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--StockoptionsCompensation_iI_pp0p0_maDTALNzwuT_z0eQx4ABu7Gc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Stock/options compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;463,099&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,672,252&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--DepreciationAndAmortizations_iI_pp0p0_maDTALNzwuT_z3xluljzTyLe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Depreciation and amortization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1226"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;188,422&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_maDTALNzwuT_za5kAs7Fzbnl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;76,296,814&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;148,832,041&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--ImpairmentExpense_iI_pp0p0_d0_maDTALNzwuT_zPLauX3Dg9Xf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&#160;Impairment expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,188,497&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--ContingentConsiderationFairValue_iI_pp0p0_d0_maDTALNzwuT_zapO6NPIqsz" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Contingent consideration fair value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(909,577&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AccumulatedAmortizationOfOtherDeferredCosts_iI_pp0p0_zdsvvMK0hJ28" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Amortization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,961,747&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1239"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--Section174ReCapitalization_iI_pp0p0_zsRiglMBn91h" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Section 174 R&amp;amp;E Capitalization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,292,075&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1242"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--OperatingLeaseRightOfUseAssets_iI_pp0p0_zasdyD3kGSyk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;ROU Assets and Lease Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14,227&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1245"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--Section481aAdjustment_iI_pp0p0_zSm9CwUyzF5c" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Section 481(a) Adjustment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(40,895&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1248"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pp0p0_zwOcJj92EMD4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;R&amp;amp;D Tax Credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,718,415&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1251"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--ChangeInTaxRate_iI_pp0p0_d0_maDTALNzwuT_zbDREXQcEyMh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Change in tax rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_msDTALNzwuT_z6J1A7OH0Kjg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(83,680,863&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(170,988,308&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_iI_pp0p0_zcd39fI1vKZk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Total Deferred Tax Assets (Liabilities)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1259"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1260"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <RENB:Depreciations
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001217"
      unitRef="USD">-24619</RENB:Depreciations>
    <RENB:Depreciations
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001218"
      unitRef="USD">8258</RENB:Depreciations>
    <RENB:DeferredTaxAssetExcessTaxOverDepreciationPatents
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001221"
      unitRef="USD">8415</RENB:DeferredTaxAssetExcessTaxOverDepreciationPatents>
    <RENB:StockoptionsCompensation
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001223"
      unitRef="USD">463099</RENB:StockoptionsCompensation>
    <RENB:StockoptionsCompensation
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001224"
      unitRef="USD">6672252</RENB:StockoptionsCompensation>
    <RENB:DepreciationAndAmortizations
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001227"
      unitRef="USD">188422</RENB:DepreciationAndAmortizations>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001229"
      unitRef="USD">76296814</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001230"
      unitRef="USD">148832041</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <RENB:ImpairmentExpense
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001232"
      unitRef="USD">0</RENB:ImpairmentExpense>
    <RENB:ImpairmentExpense
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001233"
      unitRef="USD">16188497</RENB:ImpairmentExpense>
    <RENB:ContingentConsiderationFairValue
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001235"
      unitRef="USD">0</RENB:ContingentConsiderationFairValue>
    <RENB:ContingentConsiderationFairValue
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001236"
      unitRef="USD">-909577</RENB:ContingentConsiderationFairValue>
    <us-gaap:AccumulatedAmortizationOfOtherDeferredCosts
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001238"
      unitRef="USD">1961747</us-gaap:AccumulatedAmortizationOfOtherDeferredCosts>
    <RENB:Section174ReCapitalization
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001241"
      unitRef="USD">3292075</RENB:Section174ReCapitalization>
    <RENB:OperatingLeaseRightOfUseAssets
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001244"
      unitRef="USD">14227</RENB:OperatingLeaseRightOfUseAssets>
    <RENB:Section481aAdjustment
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001247"
      unitRef="USD">-40895</RENB:Section481aAdjustment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001250"
      unitRef="USD">1718415</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <RENB:ChangeInTaxRate
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001253"
      unitRef="USD">0</RENB:ChangeInTaxRate>
    <RENB:ChangeInTaxRate
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001254"
      unitRef="USD">0</RENB:ChangeInTaxRate>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001256"
      unitRef="USD">83680863</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001257"
      unitRef="USD">170988308</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2024-07-01to2025-06-30" id="Fact001263">&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zlDfgmV18te" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_495_20240701__20250630_zFeO7GtMwKsf" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_490_20230701__20240630_zHDY7JCSDrbe" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Years ended June 30,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationChangeInEnactedTaxRate_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Computed tax at expected statutory rate&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;(951,542&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;(24,066,011&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--IncomeTaxReconciliationRepatriationOfForeignEarnings_iN_pp0p0_d0_zKIUKpKrDoYf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Non-US income taxed at different rates&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--IncomeTaxReconciliationNondeductibleExpense_d0_zMIO6nQnezl6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Non-deductible expenses / other items&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,046,364&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_i_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,999,380&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;24,066,011&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OtherTaxExpenseBenefit_d0_zo2a8bR4x85k" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Income Tax Expense (Benefit)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,474&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001265"
      unitRef="USD">-951542</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact001266"
      unitRef="USD">-24066011</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001268"
      unitRef="USD">0</us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings>
    <us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact001269"
      unitRef="USD">0</us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001271"
      unitRef="USD">-2046364</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact001272"
      unitRef="USD">0</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001274"
      unitRef="USD">2999380</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact001275"
      unitRef="USD">24066011</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:OtherTaxExpenseBenefit
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001277"
      unitRef="USD">1474</us-gaap:OtherTaxExpenseBenefit>
    <us-gaap:OtherTaxExpenseBenefit
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact001278"
      unitRef="USD">0</us-gaap:OtherTaxExpenseBenefit>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="From2024-07-01to2025-06-30" id="Fact001280">&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zysVPktt2Tdj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 20pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B7_zPjqVwYUCxq2" style="display: none"&gt;Schedule
    of components of income tax expense (benefit) from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49B_20240701__20250630_zw3QhO3HHRB3" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_495_20230701__20240630_zyuACp3VqK58" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Years
    ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 20pt; font-size: 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Current
    Income Tax Expense&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--CurrentFederalTaxExpenseBenefit_i01_pp0p0_d0_maCITEBzr8l_zuuOhRzfy6Ng" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 20pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Federal
    income tax (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i01_pp0p0_d0_maCITEBzr8l_zKtOaFUWvZ5d" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 20pt; width: 56%; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;State
    income tax (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 8%; font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; font-size: 10pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,474&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 8%; font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; font-size: 10pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--CurrentForeignTaxExpenseBenefit_i01_pp0p0_d0_maCITEBzr8l_z2ediuyAkH21" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 20pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Foreign
    income tax (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--CurrentIncomeTaxExpenseBenefit_i01T_pp0p0_d0_mtCITEBzr8l_maITEBzLgX_ztyyjCR5lrL5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    Current Tax Expense (Benefit)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,474&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_zpTGFHzNm6E" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 20pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
    Income Tax Expense Federal income tax (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;101,609,457&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;165,458,980&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefit_zwgRvZRgyeG1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 20pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;State
    income tax (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(14,302,006&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5,529,328&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_zaArW39NQWz3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 20pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Foreign
    income tax (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1303"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1304"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_ziMMCuaxDi1d" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 20pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;
    Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(87,307,451&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(170,988,308&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredIncomeTaxExpenseBenefit_i01T_pp0p0_d0_mtDITEBzk3M_maITEBzLgX_zMuyJTSzElsj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-size: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    Deferred Tax Expense&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--IncomeTaxExpenseBenefit_i01T_pp0p0_d0_mtITEBzLgX_zfLHiVBg5I98" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 20pt; font-size: 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    Tax Expense&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,474&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001285"
      unitRef="USD">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact001286"
      unitRef="USD">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001288"
      unitRef="USD">1474</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact001289"
      unitRef="USD">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001291"
      unitRef="USD">0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact001292"
      unitRef="USD">0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001294"
      unitRef="USD">1474</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact001295"
      unitRef="USD">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001297"
      unitRef="USD">101609457</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact001298"
      unitRef="USD">165458980</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001300"
      unitRef="USD">-14302006</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact001301"
      unitRef="USD">5529328</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001306"
      unitRef="USD">-87307451</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact001307"
      unitRef="USD">-170988308</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001309"
      unitRef="USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact001310"
      unitRef="USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001312"
      unitRef="USD">1474</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact001313"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2024-07-01to2025-06-30" id="Fact001315">&lt;p id="xdx_809_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zaC8WTAZ9VA8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 10 &#x2014; &lt;span id="xdx_825_zVe4vLcVRFy1"&gt;STOCKHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Preferred Stock &lt;/b&gt;&#x2014;
The Company has &lt;span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_c20250630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zBSZG3asjI0k" title="Preferred stock shares authorized"&gt;&lt;span id="xdx_906_eus-gaap--PreferredStockSharesAuthorized_iI_c20240630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zWVUegqqL3u8" title="Preferred stock shares authorized"&gt;10,000,000&lt;/span&gt;&lt;/span&gt;
authorized shares of Preferred Stock, par value $&lt;span id="xdx_90F_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20250630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zboOgxgtnlDf" title="Preferred stock, par value"&gt;&lt;span id="xdx_900_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20240630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zrtHwbqcdaY6" title="Preferred stock, par value"&gt;0.0001&lt;/span&gt;&lt;/span&gt;
per share, &lt;span id="xdx_90B_ecustom--PreferredStockDesignatedShares_iI_c20250630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zJYeBrcJjm5f" title="Preferred stock designated shares"&gt;&lt;span id="xdx_90A_ecustom--PreferredStockDesignatedShares_iI_c20240630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zLEUxE1WBQp6" title="Preferred stock designated shares"&gt;1,000,000&lt;/span&gt;&lt;/span&gt;
of which have been designated as Series A Convertible Preferred Stock. At June 30, 2025 and 2024, there were &lt;span id="xdx_901_eus-gaap--PreferredStockSharesIssued_iI_c20250630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zeGwrZVntiOe" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_c20250630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zwbMMhoKqCOh" title="Preferred stock, shares outstanding"&gt;&lt;span id="xdx_905_eus-gaap--PreferredStockSharesIssued_iI_c20240630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_znRVqMI74Sc1" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_901_eus-gaap--PreferredStockSharesOutstanding_iI_c20240630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zfLHOI5Eewj8" style="display: none" title="Preferred stock, shares outstanding"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; zero shares of
Preferred Stock issued and outstanding.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Voting &#x2014; &lt;/b&gt;Holders
of Series A Preferred Stock shall be permitted to vote on all matters required or permitted to be voted on by the holders of Common Stock
of the Company and shall be entitled to that number of votes equal to ten votes for the number of shares of Common Stock into which such
holder&#x2019;s shares of Preferred Stock could then be converted in accordance with conversion rights.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"&gt;&lt;b&gt;Dividends &#x2014; &lt;/b&gt;The
Company shall pay dividends on shares of Series A Preferred Stock equal (on an as-if-converted-to-Common-Stock basis) to and in the same
form as dividends actually paid on shares of the Common Stock when, as and if such dividends are paid on shares of the Common Stock. No
other dividends shall be paid on shares of Preferred Stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.75pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Liquidation Rights &#x2014;&lt;/b&gt;
In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, the holders of shares of Series A
Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Company available for distribution to its stockholders,
before any payment shall be made to the holders of Common Stock by reason of their ownership thereof, an amount in cash equal to the aggregate
liquidation value of all shares held by such holder. The Series A Preferred Stock is not participating preferred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Conversion Rights &#x2014; &lt;/b&gt;On
or after the date of issuance, any holder of Series A Preferred Stock shall have the right by written election (a &#x201c;Series A Election
Notice&#x201d;) to the Company to convert all or any portion of the outstanding Shares of Series A Preferred Stock held by such holder
into an aggregate number of shares of Common Stock as is determined by multiplying the number of Shares to be converted by ten (10) (the
&#x201c;Conversion Ratio&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Common Stock &lt;/b&gt;&#x2014; The
Company has &lt;span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_iI_c20250630_zBN2SghKHYl9" title="Common stock, shares authorized"&gt;&lt;span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_c20240630_zl9ZgqQYK9e5" title="Common stock, shares authorized"&gt;350,000,000&lt;/span&gt;&lt;/span&gt; authorized shares of Common Stock, par value $&lt;span id="xdx_902_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20250630_zf734HAwMVTi" title="Common stock, par value"&gt;&lt;span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240630_zQI2ZeNWSHXl" title="Common stock, par value"&gt;0.0001&lt;/span&gt;&lt;/span&gt; per share. At June 30, 2025 and 2024, there were &lt;span id="xdx_906_ecustom--CommonStockShareIssued_iI_c20250630_z19u5s4itUNg" title="Common stock, shares issued"&gt;&lt;span id="xdx_90C_eus-gaap--CommonStockSharesOutstanding_iI_c20250630_zYkVqKMkh3aj" title="Common stock, shares outstanding"&gt;177,392,907&lt;/span&gt;&lt;/span&gt;
and &lt;span id="xdx_900_ecustom--CommonStockShareIssued_iI_c20240630_zgc7FaGPdxj5" title="Common stock, shares issued"&gt;&lt;span id="xdx_907_eus-gaap--CommonStockSharesOutstanding_iI_c20240630_zIU1OLpUmXW6" title="Common stock, shares outstanding"&gt;158,452,644&lt;/span&gt;&lt;/span&gt; shares issued and outstanding, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Voting &#x2014; &lt;/b&gt;Holders
of Common Stock are entitled to one vote for each share held of record on each matter submitted to a vote of stockholders, including the
election of directors, and do not have any right to cumulate votes in the election of directors.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Dividends &#x2014; &lt;/b&gt;Holders
of Common Stock are entitled to receive ratably such dividends as the Company&#x2019;s Board of Directors from time to time may declare
out of funds legally available.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Liquidation Rights &#x2014;&lt;/b&gt;
In the event of any liquidation, dissolution or winding-up of the affairs of the Company, after payment of all debts and liabilities,
the holders of Common Stock will be entitled to share ratably in the distribution of any remaining assets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&lt;i&gt;Purchase Agreement with
Lincoln Park Capital&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;On June
20, 2023, the Company entered into a purchase agreement (the &#x201c;2023 Purchase Agreement&#x201d;) with Lincoln Park, pursuant to which
the Company may sell and issue to Lincoln Park, and Lincoln Park is obligated to purchase, up to $&lt;span id="xdx_907_eus-gaap--PurchaseObligation_iI_pp0p0_c20230620_zp4gtWcI7fJ2" title="Obligation to purchase"&gt;20,000,000&lt;/span&gt; of shares of Common Stock
over the 36-month term of the 2023 Purchase Agreement. Concurrently with entering into the 2023 Purchase Agreement, the Company also entered
into a registration rights agreement with Lincoln Park, pursuant to which it agreed to provide Lincoln Park with certain registration
rights related to the shares issued under the 2023 Purchase Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;In consideration for entering
into the 2023 Purchase Agreement, the Company issued &lt;span id="xdx_906_eus-gaap--SharesIssued_iI_c20230620__us-gaap--SubsidiarySaleOfStockAxis__custom--PurchaseAgreementMember_zqhShCpZj6xe" title="Number of shares issued"&gt;696,021&lt;/span&gt; shares of Common Stock to Lincoln Park as a commitment fee on June 20, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;During the years ended June 30,
2025 and June 30, 2024 &lt;span id="xdx_90A_eus-gaap--SharesIssued_iI_do_c20250630__us-gaap--SubsidiarySaleOfStockAxis__custom--PurchaseAgreementMember_z294MvXDPYq7" title="Number of shares issued"&gt;&lt;span id="xdx_90D_eus-gaap--SharesIssued_iI_do_c20240630__us-gaap--SubsidiarySaleOfStockAxis__custom--PurchaseAgreementMember_zRGChiczFYYb" title="Number of shares issued"&gt;no&lt;/span&gt;&lt;/span&gt; shares of Common Stock to Lincoln Park were sold under the Purchase Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Common Stock Issuances &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="background-color: white"&gt;On
April 8, 2025, the Company issued &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20250407__20250408__us-gaap--StatementClassOfStockAxis__custom--CommonStockIssuancesMember_z2bDB1c5gOn8" title="Issuance of common stock shares"&gt;15,000,000&lt;/span&gt; shares of Common Stock valued at $&lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20250407__20250408__us-gaap--StatementClassOfStockAxis__custom--CommonStockIssuancesMember_zjmA12x5Klq5" title="Issuance of common stock value"&gt;6,058,500&lt;/span&gt; (see Note 13) pursuant to the Stock Purchase
Agreement of Biosymetrics, Inc.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On January 21, 2025, the Company
issued&#160;&lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20250112__20250121__us-gaap--StatementClassOfStockAxis__srt--ChiefExecutiveOfficerMember_zhvGteContIk" title="Issuance of common stock shares"&gt;250,000&lt;/span&gt;&#160;shares of Common Stock to its Chief Executive Officer of Renovaro Cube valued at $&lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20250112__20250122__us-gaap--StatementClassOfStockAxis__srt--ChiefExecutiveOfficerMember_zgLRtLQiV1bf" title="Issuance of common stock shares, value"&gt;177,500&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On October 17, 2024, the Company
issued&#160;&lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20241016__20241017_zST4lPfrBI59" title="Issuance of common stock shares"&gt;160,000&lt;/span&gt;&#160;shares of Common Stock for consulting services valued at $&lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20241016__20241017__us-gaap--StatementClassOfStockAxis__custom--CommonStockIssuancesMember_zpW7Vn9ykmre" title="Common stock for consulting services value"&gt;119,400&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On October 14, 2024, the Company
issued&#160;&lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20241013__20241014_zTSOGzQB1NCd" title="Issuance of common stock shares"&gt;500,000&lt;/span&gt;&#160;shares of Common Stock for consulting services valued at $&lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20241013__20241014__us-gaap--StatementClassOfStockAxis__custom--CommonStockIssuancesMember_z9locy8x2Wu" title="Common stock for consulting services value"&gt;275,000&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On October 14, 2024, the Company
issued&#160;&lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20241013__20241014__us-gaap--StatementClassOfStockAxis__srt--ChiefExecutiveOfficerMember_z8yPsDncQIlg" title="Issuance of common stock shares"&gt;250,000&lt;/span&gt;&#160;shares of Common Stock to its Chief Executive Officer valued at $&lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20241013__20241014__us-gaap--StatementClassOfStockAxis__srt--ChiefExecutiveOfficerMember_zfrxf1whlF7b" title="Issuance of common stock shares, value"&gt;137,750&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;On August 23, 2024, Avram Miller,
a former member of the Company&#x2019;s board of directors (the &#x201c;Board of Directors&#x201d;), forfeited&#160;&lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20240802__20240823__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zohmeImWSOfc" title="Number of share warrant purchase forfeited"&gt;833,333&lt;/span&gt;&#160;shares of
Common Stock from the original&#160;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240802__20240823__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zZ6MOvje5Yje" title="Granted"&gt;1,000,000&lt;/span&gt;&#160;shares of Common Stock for advisory services originally granted to him on October 11,
2023. As consideration for such forfeiture, the Company granted to Mr. Miller, an option to purchase&#160;&lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20240802__20240823__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--AwardTypeAxis__custom--MrMillerMember_zNYtmbJTRhgj" title="Number of share warrant purchase forfeited"&gt;978,261&lt;/span&gt;&#160;shares of Common
Stock of the Company with a per-share exercise price of $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240823__us-gaap--StatementClassOfStockAxis__custom--BoardOfDirectorsMember_zfxghSMgqmUi" title="Warrants exercised"&gt;0.69&lt;/span&gt;. The Company determined that this transaction represented a modification
of the original award. The Company measured the fair value of the options issued as compared to the fair value of the original issuance
and determined that there was no incremental compensation to recognize as the fair value of the options was less than the fair value of
the Common Stock. Therefore, the Company will recognize the remaining fair value of the original award over the remaining vesting period,
which is one year. The Company recognized stock-based compensation expense of $&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630_zUWXTJOzcLPk" title="Stock-based compensation expense vested"&gt;1,159,470&lt;/span&gt;&#160;related to the vesting of the stocks options
during the year ended June 30, 2025. At June 30, 2025, the Company had $&lt;span id="xdx_902_ecustom--UnrecognizedCompensationCostandVest_iI_c20250630_zVxgTdXHBayk" title="Unrecognized compensation cost and vest"&gt;185,373&lt;/span&gt;&#160;of unrecognized compensation cost related to the
options which vest at August 23, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On August 1, 2024, the Company
issued&#160;&lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240719__20240801_z72Luo4ZBDp5" title="Issuance of common stock shares"&gt;2,000,000&lt;/span&gt;&#160;shares of Common Stock for consulting services valued at $&lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20240729__20240801__us-gaap--StatementClassOfStockAxis__custom--CommonStockConsultingServicesMember_zOfZOFDpsBol" title="Common stock for consulting services value"&gt;1,400,000&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 14, 2024, Lunai a Delaware corporation (the &#x201c;&lt;span style="text-decoration: underline"&gt;Company&lt;/span&gt;&#x201d;) closed a private placement of&#160;&lt;span id="xdx_908_ecustom--IssuanceOfCommonStockUnderPrivatePlacementOffering_c20240613__20240614_zl48YP3f1NKd" title="Issuance of common stock under private placement"&gt;5,315,215&lt;/span&gt;&#160;of the
Company&#x2019;s units, each such Unit consisting of (i) one share of the Company&#x2019;s common stock, $&lt;span id="xdx_903_ecustom--CommonStockParValuePrivatePlacement_c20240613__20240614_z5ZSxeLqDvf7" title="Common stock par value under private placement"&gt;0.0001&lt;/span&gt;&#160;par value per share
and (ii) one common stock purchase warrant to purchase one-tenth of a share of Common Stock, with certain investors (the &#x201c;Private
Placement&#x201d;). The Warrants are exercisable for five years from the date of issuance and have an exercise price of $&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240614__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zQKTisHAyfRi" title="Warrants exercised"&gt;1.4726&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240614__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_znVl8uFIhjxk" title="Warrants exercised"&gt;1.4765&lt;/span&gt;&#160;per
share, payable in cash.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
the Private Placement, the Company sold&#160;&lt;span style="background-color: white"&gt;&lt;span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230701__20240630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zw2s7MhoWxx7" title="Shares sold"&gt;2,325,869&lt;/span&gt;&lt;/span&gt;&#160;Units at a price per Unit equal
to $&lt;span id="xdx_904_eus-gaap--SaleOfStockPricePerShare_iI_c20240630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_ztiSFbK2bUj9" title="Price per unit"&gt;1.4726&lt;/span&gt;&#160;to a certain investor who paid in cash and settlement of debt an aggregate amount of $&lt;span style="background-color: white"&gt;&lt;span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230701__20240630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zZ8i6Xt9C20d" title="Paid in cash and settlement of debt"&gt;3,425,075&lt;/span&gt;&lt;/span&gt;&#160;in
consideration for the Units.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Additionally,
the Company sold&#160;&lt;span style="background-color: white"&gt;&lt;span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230701__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zntgYuNqyKDd" title="Shares sold"&gt;2,671,631&lt;/span&gt;&lt;/span&gt;&#160;Units to certain investors who surrendered and terminated&#160;&lt;span style="background-color: white"&gt;$&lt;span id="xdx_90F_ecustom--PrincipalAmountAndInterestAccrued_c20230701__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zRmE4LZ7njR9" title="Principal amount and interest accrued"&gt;3,955,033&lt;/span&gt;&lt;/span&gt;&#160;in
aggregate principal amount and interest accrued thereon of certain convertible promissory notes issued by the Company in 2023 and 2024
and paid in cash an aggregate amount of $&lt;span id="xdx_906_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20220701__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zUfykS9Y7x6j" title="Paid in cash and settlement of debt"&gt;478,060&lt;/span&gt;&#160;to the Company in consideration for the Units.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Additionally,
the Company sold&#160;&lt;span id="xdx_905_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220701__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--Investor1Member_zRMV7lJM3A67" title="Shares sold"&gt;317,715&lt;/span&gt;&#160;Units to an investor who surrendered and terminated $&lt;span style="background-color: white"&gt;&lt;span id="xdx_90B_ecustom--PrincipalAmountAndInterestAccrued_c20220701__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--Investor1Member_zeO71y79asE3" title="Principal amount and interest accrued"&gt;468,453&lt;/span&gt;&lt;/span&gt;&#160;in
aggregate principal amount and interest accrued thereon of a convertible promissory note issued in 2023 and paid in cash an aggregate
amount of $&lt;span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20220701__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--Investor1Member_zHj8Yy5N7Lp1" title="Paid in cash and settlement of debt"&gt;66,000&lt;/span&gt;&#160;to the Company in consideration for the Units.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
relation to the June 14, 2024 Private Placement the Company recognized a loss on the settlement of debt for $&lt;span id="xdx_90E_eus-gaap--OtherNonrecurringIncomeExpense_c20240701__20250630_zqUhlpp8Vxl2" title="Other income (expense)"&gt;1,183,560&#160;&lt;/span&gt;which was
recorded in other income (expense) in the statement of operations for the year ended June 30, 2024.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Related
to the June 14, 2024 Private Placement, ranging from July 3, 2024, to October 10, 2024, the Company sold &lt;span id="xdx_902_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240703__20241002_zDqkQ1NrDVWf" title="Sale of stock issued"&gt;1,613,596&lt;/span&gt; Units at a price per
Unit equal to $&lt;span id="xdx_904_eus-gaap--SaleOfStockPricePerShare_iI_c20241002_zIV28vdoDwRa" title="Sale of stock price per share"&gt;1.4726&lt;/span&gt; to a certain investor who paid in cash an aggregate amount of $&lt;span id="xdx_905_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_c20240703__20241002_znPHNyyahFgg" title="Sale of stock issued cash consideration"&gt;2,376,181&lt;/span&gt; in consideration of the Units.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On April 5, 2024, the Company
issued&#160;&lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240404__20240405__us-gaap--StatementClassOfStockAxis__custom--CommonStockIssuancesMember_zpojgP2U6bcf" title="Issuance of common stock shares"&gt;33,760&lt;/span&gt;&#160;shares of common stock for consulting services valued at $&lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20240404__20240405__us-gaap--StatementClassOfStockAxis__custom--CommonStockIssuancesMember_zGAfK59mWIN1" title="Common stock for consulting services value"&gt;94,190&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On February 20, 2024, &lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240220__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zun1qtNZllhg" title="Warrants outstanding"&gt;2,953,700&lt;/span&gt;
warrants outstanding were exercised at prices ranging from $&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240220__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zhiA02vxoA81" title="Warrants exercised"&gt;0.53&lt;/span&gt; to $&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240220__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zdSznezIgyUf" title="Warrants exercised"&gt;0.65&lt;/span&gt; per share and the aggregate $&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExpenseOrRevenueRecognized_c20240219__20240220__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zvMD2LHqCouh" title="Warrants aggregate amount"&gt;1,750,000&lt;/span&gt; of a promissory note
held by the holder was applied to the exercise price of the warrants.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On February 20, 2024, &lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240220__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--SingleRangeMember_zbAtdy2zll2h" title="Warrants outstanding"&gt;471,699&lt;/span&gt;
warrants outstanding were exercised at $&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240220__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--SingleRangeMember_zdJjr26EG1Rb" title="Warrants exercised"&gt;0.53&lt;/span&gt; per share valued at $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExpenseOrRevenueRecognized_c20240219__20240220__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--SingleRangeMember_zNgo4Z0hFuq4" title="Warrants aggregate amount"&gt;250,000&lt;/span&gt;. A promissory note held by the holder was applied to the exercise
price of the warrants in lieu of cash proceeds.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On February 15, 2024, the Company
issued &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240214__20240215_ztDhI08h5Bkj" title="Issuance of common stock shares"&gt;50,000&lt;/span&gt; shares of Common Stock for consulting services valued at $&lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20240214__20240215__us-gaap--StatementClassOfStockAxis__custom--CommonStockIssuancesMember_zu4fTPPG5qrd" title="Common stock for consulting services value"&gt;100,000&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="background-color: white"&gt;On
February 15, 2024, the Company closed a private placement of &lt;span id="xdx_906_ecustom--IssuanceOfCommonStockUnderPrivatePlacementOffering_c20240214__20240215_zE0QuYFoeZFa" title="Issuance of common stock under private placement"&gt;344,827&lt;/span&gt; shares of Common Stock, $&lt;span id="xdx_90C_ecustom--CommonStockParValuePrivatePlacement_c20240214__20240215_zd1ESw1hvJPj" title="Common stock par value under private placement"&gt;0.0001&lt;/span&gt; par value, at $2.90 per share for
aggregate proceeds to the Company of $&lt;span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20240214__20240215_zdhKeSQBb5d" title="Proceeds from issuance of private placement"&gt;1,000,000&lt;/span&gt; in cash. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On February 16, 2024, the Company
recognized &lt;span id="xdx_90F_eus-gaap--SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares_iI_c20240216__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GEDiCubeIntlLtdMember_zZwCh50qz7Q8" title="Common Stock to be issued in settlement"&gt;3,425,399&lt;/span&gt; shares of Common Stock to be issued in settlement of the contingent consideration as a result of the Company&#x2019;s
acquisition of GEDi Cube Intl Ltd.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="background-color: white"&gt;On
February 13, 2024, the Company issued &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240212__20240213__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementOfRenovaroCubeMember_zGOxd5vhrrP7" title="Issuance of common stock shares"&gt;70,834,183&lt;/span&gt; shares of Common Stock valued at $&lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20240212__20240213__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementOfRenovaroCubeMember_zRgTmcN3kXM" title="Issuance of common stock shares, value"&gt;136,001,631&lt;/span&gt; (see Note 13) pursuant to the Stock Purchase
Agreement of Renovaro Cube.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On December 4, 2023, the Company
issued &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20231203__20231204_z58zP4SIBOFb" title="Issuance of common stock shares"&gt;525,945&lt;/span&gt; shares of Common Stock pursuant to warrants exercised for cash proceeds of $&lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20231203__20231204_zfPgWL1K4ck9" title="Issuance of common stock shares, value"&gt;341,865&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On October 23, 2023, the Company
issued &lt;span id="xdx_90E_eus-gaap--SharesIssued_iI_c20231023__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AvramMillerMember_zuQYzlLrTdj5" title="Shares issued"&gt;1,000,000&lt;/span&gt; shares of Common Stock valued at $&lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20231022__20231023__us-gaap--StatementClassOfStockAxis__custom--CommonStockIssuancesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AvramMillerMember_zXvJbVF8dEX2" title="Issuance of common stock shares, value"&gt;2,760,000&lt;/span&gt; for advisory services to Avram Miller, a member of the Company&#x2019;s board
of directors.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;Between July 28, 2023, and September
28, 2023, the Company issued &lt;span id="xdx_90E_ecustom--PurchaseSharesOfCommonStock_iI_c20230728__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zZg7Sl0Tz1lc" title="Purchase shares of common stock"&gt;2,000,000&lt;/span&gt; shares of Common Stock for consulting services valued at $&lt;span id="xdx_909_eus-gaap--ConversionOfStockAmountConverted1_c20230727__20230728__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z2PLBpr7s3Vk" title="Converted shares of common stock, value"&gt;4,470,000&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;b&gt;2017
Warrants&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;On July
14, 2022, certain of our warrant holders exercised warrants to purchase&#160;&lt;span id="xdx_909_eus-gaap--StockRepurchasedDuringPeriodShares_c20220713__20220714__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zWpCkUoKrUOk" title="Shares purchased"&gt;1,250,000&lt;/span&gt;&#160;shares of Common Stock for total proceeds
to the Company of $&lt;span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_c20220713__20220714__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zNCy0STHof72" title="Proceeds from common stock"&gt;1,625,000&lt;/span&gt;, with corresponding earn-out distribution of the same number of shares in connection with the acquisition
of Renovaro Biosciences. This non-cash earn-out distribution impacted stockholders&#x2019; equity in the amount of $&lt;span id="xdx_90C_eus-gaap--NoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1_pp0p0_c20220713__20220714__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zzrVgkt6TA62" title="Non cash earn out distribution"&gt;2,762,500&lt;/span&gt;&#160;based
on the share price on July 14, 2022 of $&lt;span id="xdx_907_eus-gaap--SharePrice_iI_c20220714__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zwaif8RRWnZ3" title="Share price"&gt;2.21&lt;/span&gt;. The Company recorded a loss on extinguishment of contingent consideration liability of $&lt;span id="xdx_90D_ecustom--ExtinguishmentOfContingentConsiderationLiability_c20230701__20240630_zBn1tEcE51qe" title="Extinguishment of contingent consideration liability"&gt;419,182&lt;/span&gt;&#160;during
the year ended June 30, 2024 which reflected the difference between the fair value of the shares and the contingent consideration liability
at the time of extinguishment. As of June 30, 2023, all outstanding warrants as of the date of acquisition of Renovaro Biosciences (the
&#x201c;2017 Warrants&#x201d;) were exercised and there is no further contingent consideration liability related to the 2017 Warrants remaining
as of June 30, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Acquisition of Renovaro Biopharma
/ Contingently issuable shares&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On February 16, 2018, the acquisition
of Renovaro Biosciences was completed. As part of the acquisition, the stockholders of Renovaro Biosciences received (i) 18,081,962 shares
of Common Stock, and (ii) the right to receive Contingent Shares of Common Stock pro rata upon the exercise or conversion of warrants,
which were outstanding at closing. As of June 30, 2025, &lt;span id="xdx_909_ecustom--BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuable_iI_do_c20250630__us-gaap--BusinessAcquisitionAxis__custom--EBIAndWeirdScienceLLCMember__us-gaap--TypeOfArrangementAxis__custom--AgreementAndPlanOfMergerAgreementAxisMember_zMN6mqjNfpp8" title="Common shares contingently issuable"&gt;no&lt;/span&gt; further Contingent Shares are issuable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Acquisition of Renovaro Denmark
&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;At June 30, 2025 and 2024, the
Company maintained a reserve of &lt;span id="xdx_901_ecustom--ReserveEscrowShares_iI_c20250630_z9Y2hOzNgtQb" title="Reserve escrow shares"&gt;17,414&lt;/span&gt; Escrow Shares, all of which are reflected as issued and outstanding in the accompanying financial
statements. The Escrow Shares are reserved to acquire the shares of Renovaro Denmark held by non-consenting shareholders of Renovaro Denmark
on both June 30, 2025 and 2024, in accordance with Section 70 of the Danish Companies Act and the Articles of Association of Renovaro
Denmark. There have been &lt;span id="xdx_90E_ecustom--StockIssuedToNonconsentingShareholders_iI_c20250630_zTtjQONp4gK7" title="Stock issued to non-consenting shareholders"&gt;167,639&lt;/span&gt; shares of Common Stock issued to non-consenting shareholders of Renovaro Denmark as of June 30, 2025.
During the years ended June 30, 2025 and 2024, the Company did not issue any shares of Common Stock to such non-consenting shareholders
of Renovaro Denmark.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;b&gt;Stock-based Compensation &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The Company recognizes compensation
costs for stock option awards to employees based on their grant-date fair value. The value of each stock option is estimated on the date
of grant using the Black-Scholes option-pricing model. In the year ended June 30, 2025, the weighted-average assumptions used to estimate
the grant date fair values of the stock options granted using the Black-Scholes option-pricing model are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--ScheduleOfShareBasedPaymentAwardStockOptionValuationAssumptionsTableTextBlock_zI6lhXrzJhJg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span id="xdx_8BA_zwawgDZ0RtLk" style="display: none"&gt;Schedule of weighted-average assumptions used to estimate the fair values of the stock options granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Lunai Bioworks Inc.&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Expected term (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240701__20250630__dei--LegalEntityAxis__custom--RenovaroMember_zuGOzNmRhLCb" style="font-size: 10pt"&gt;5.5&lt;/span&gt;
&lt;span style="font-size: 10pt"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20240701__20250630__srt--RangeAxis__srt--MinimumMember__dei--LegalEntityAxis__custom--RenovaroMember_zvvQSHEtbPH" title="Volatility"&gt;109.45&lt;/span&gt;% &#x2013; &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20240701__20250630__srt--RangeAxis__srt--MaximumMember__dei--LegalEntityAxis__custom--RenovaroMember_zU8NWSv9gxX6" title="Volatility"&gt;118.99&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20240701__20250630__srt--RangeAxis__srt--MinimumMember__dei--LegalEntityAxis__custom--RenovaroMember_zNXl7K6POpVh" title="Risk free interest rate"&gt;3.86&lt;/span&gt;%- &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20240701__20250630__srt--RangeAxis__srt--MaximumMember__dei--LegalEntityAxis__custom--RenovaroMember_z48dYHM6ppXb" title="Risk free interest rate"&gt;4.40&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-align: left; text-indent: -10pt"&gt;Dividend yield&lt;/td&gt;&lt;td style="width: 10%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20240701__20250630__dei--LegalEntityAxis__custom--RenovaroMember_zg0rIcCdEzod" title="Dividend yield"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A3_zXCgDyz3xIU2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The Company recognized stock-based
compensation expense related to all equity instruments of $&lt;span id="xdx_909_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20240701__20250630_z8A7WYjgNOg4" title="Stock-based compensation expense"&gt;3,313,291&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20230701__20240630_z0LDxbn4h2rh" title="Stock-based compensation expense"&gt;4,673,129&lt;/span&gt; for the years ended June 30, 2025 and 2024, respectively.
At June 30, 2025, the Company had approximately $&lt;span id="xdx_90E_ecustom--UnrecognizedCompensationCostNonVested_iI_c20250630_z1Uz85GML2Z3" title="Unrecognized compensation cost non vested"&gt;1,009,277&lt;/span&gt; of unrecognized compensation cost related to non-vested options.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Plan Options&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On February 6, 2014, the Company&#x2019;s
Board of Directors adopted the Company&#x2019;s 2014 Equity Incentive Plan (the &#x201c;2014 Plan&#x201d;), and the Company had reserved
&lt;span id="xdx_906_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20140206__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2014Member_zJ6PzdgXQpTb" title="Common stock reserved for issuance"&gt;1,206,000&lt;/span&gt; shares of Common Stock for issuance in accordance with the terms of the 2014 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On October 30, 2019, the Board
approved and on October 31, 2019, the Company&#x2019;s stockholders adopted its 2019 Equity Incentive Plan (the &#x201c;2019 Plan&#x201d;),
which replaced the 2014 Plan. The 2019 Plan provided that the maximum aggregate number of shares of the Company&#x2019;s Common Stock reserved
and available for issuance under the 2019 Plan was the sum of (1) 6,000,000 new shares, and (2) the number of shares available for the
grant of awards as of the effective date under the 2014 Plan plus any options related to awards that expire, are terminated, surrendered,
or forfeited for any reason without issuance of shares under the 2014 Plan after the effective date of the 2019 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;Effective July 21, 2023, the Company
adopted the Renovaro Biosciences Inc. 2023 Equity Incentive Plan (the &#x201c;2023 Plan&#x201d;). The 2023 Plan replaced the 2019 Plan.
The 2023 Plan provides that the maximum aggregate number of shares of the Company&#x2019;s Common Stock reserved and available for issuance
under the 2023 Plan was the sum of (1) 4,000,000 new shares, and (2) the number of shares available for the grant of awards as of the
effective date under the 2019 Plan. Any awards outstanding under the 2019 Plan as of the date of adoption of the 2023 Plan remain subject
to and will be available under the 2019 Plan, and any shares subject to outstanding awards under the 2019 Plan that subsequently expire,
terminate, or are surrendered or forfeited for any reason without issuance of shares automatically become available for issuance under
the 2023 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;The Company granted options
to purchase &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230701__20240630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmployeesMember_z3t46SDLWZU5" title="Option granted"&gt;1,000,000&lt;/span&gt; shares of Common Stock to employees with a five-year vesting period during the year end June 30, 2025 under the
2019 and 2023 Plan. For the year ended June 30, 2024, the Company granted options to purchase zero shares of Common Stock to employees
with a five-year vesting period under the 2019 and 2023 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;The Company granted options
to purchase zero shares of Common Stock to employees with a three-year vesting period during the year end June 30, 2025 under the 2019
and 2023 Plan. For the year ended June 30, 2024, the Company granted options to purchase &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240701__20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmployeesThreeYearMember_zr3OG910x5pg" title="Option granted"&gt;369,500&lt;/span&gt; shares to employees with a three-year
vesting period under the 2019 and 2023 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;The Company granted options
to purchase &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240701__20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EmployeesMember_zE3SdXuQmmab" title="Option granted"&gt;1,850,000&lt;/span&gt; shares of Common Stock to employees with a two-year vesting period during the year end June 30, 2025 under the 2019
and 2023 Plan. For the year ended June 30, 2024, the Company granted options to purchase zero shares of Common Stock to employees with
a two-year vesting period under the 2019 and 2023 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;During the years ended June 30,
2025 and 2024, the Company granted options to purchase &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240701__20250630__us-gaap--VestingAxis__custom--ShareBasedCompensationAwardAdvisoryBoardMember_zF9PK6UZOzHh" title="Option granted"&gt;362,904&lt;/span&gt; and &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230701__20240630__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zS0wu7AV4mGh" title="Option granted"&gt;424,412&lt;/span&gt; shares, respectively, to the Board of Directors and Scientific
Advisory Board Members with a one-year vesting period, under the 2019 and 2023 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;During the years ended June
30, 2025 and 2024, the Company granted options to purchase &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240701__20250630__us-gaap--VestingAxis__custom--ShareBasedCompensationAwardBoardofDirectorsMember_zLa4xBQPOl57" title="Option granted"&gt;0&lt;/span&gt; zero and &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230701__20240630__us-gaap--VestingAxis__custom--ShareBasedCompensationAwardBoardofDirectorsMember_zXpM7RGZ03if" title="Option granted"&gt;329,729&lt;/span&gt;
shares, respectively, to the Board of Directors and Scientific Advisory Board Members with immediate vesting, under the 2019 and
2023 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;During the years ended June 30,
2025, and 2024, the Company granted options to purchase zero and &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240701__20250630__us-gaap--VestingAxis__custom--ShareBasedCompensationAwardConsultingServicesMember_z7K2HKYVrxs4" title="Option granted"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230701__20240630__us-gaap--VestingAxis__custom--ShareBasedCompensationAwardConsultingServicesMember_zeHYMP0XqRDe" title="Option granted"&gt;10,000&lt;/span&gt;&lt;/span&gt; shares, respectively, for consulting services with a one-year
vesting period, under the 2019 and 2023 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On November 4, 2024, the Company
issued&#160;&lt;span id="xdx_908_ecustom--DebtConversionConvertedInstrumentWarrantsOptionsIssued1_iI_c20241104__us-gaap--PlanNameAxis__custom--PlanOptionsMember_zqChV9EgDXg6" title="Options available to be issued"&gt;58,500&lt;/span&gt;&#160;stock options to its former interim Chief Financial Officer. The options had a fair value of $&lt;span id="xdx_905_eus-gaap--FairValueOptionChangesInFairValueGainLoss1_c20241101__20241104_zElPdxsGBtH1" title="Option fair value"&gt;31,005&lt;/span&gt;&#160;on the
grant date, fully vest on&#160;January 6, 2025&#160;and expire on November 4, 2034. Subsequently, during the period ended March 31, 2025,
pursuant to the Company&#x2019;s executive officer compensation claw back policy, the board of directors directed the Company to claw back
and cancel the&#160;&lt;span id="xdx_909_ecustom--StockOptionIssued_iI_c20241104_znSpmhndaDkb" title="Stock option issued"&gt;58,500&lt;/span&gt;&#160;options which were issued on November 4, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On August 23, 2024, Avram Miller,
a former member of the Company&#x2019;s board of directors (the &#x201c;Board of Directors&#x201d;), forfeited&#160;833,333&#160;shares of
Common Stock from the original&#160;1,000,000&#160;shares of Common Stock for advisory services originally granted to him on October 11,
2023. As consideration for such forfeiture, the Company granted to Mr. Miller, an option to purchase&#160;978,261&#160;shares of Common
Stock of the Company with a per-share exercise price of $0.69. The Company determined that this transaction represented a modification
of the original award. The Company measured the fair value of the options issued as compared to the fair value of the original issuance
and determined that there was no incremental compensation to recognize as the fair value of the options was less than the fair value of
the Common Stock. Therefore, the Company will recognize the remaining fair value of the original award over the remaining vesting period,
which is one year. The Company recognized stock-based compensation expense of $&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_c20250630_zMoQKEKwLq1h" title="stock option vested"&gt;1,159,470&lt;/span&gt;&#160;related to the vesting of the stocks options
during the year ended June 30, 2025. At June 30, 2025, the Company had $&lt;span id="xdx_90E_ecustom--UnrecognizedCompensationCost_iI_c20250630_zFlEIf6Lk8R" title="Unrecognized compensation cost"&gt;185,373&lt;/span&gt;&#160;of unrecognized compensation cost related to the
options which vest at August 23, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;All of the above options are exercisable
at the market price of the Company&#x2019;s Common Stock on the date of the grant. On February 13, 2024, the Company repriced 3,849,931
eligible employee and consultant options from the original issued exercise price to a new exercise price of $1.92 per share, the closing
price of the Company&#x2019;s Common Stock on February 13, 2024. The Company recognized stock-based compensation expense related to the
repricing of options of $921,254 during the year ended June 30, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;To date the Company has
granted options under the 2014, 2019 and 2023 Plans (&#x201c;Plan Options&#x201d;) to purchase &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20240701__20250630__us-gaap--PlanNameAxis__custom--PlanOptionsMember_zjvJ4JKiiiAi" title="Option granted"&gt;6,088,250&lt;/span&gt; shares of Common Stock. At June
30, 2025, the Company has &lt;span id="xdx_901_eus-gaap--DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_c20240701__20250630__us-gaap--PlanNameAxis__custom--PlanOptionsMember_zSRI2QBeS0ad" title="Options available to be issued"&gt;5,093,444&lt;/span&gt; options available to be issued under the 2023 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;A summary of the Plan Options outstanding at June 30,
2025 is presented below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_896_ecustom--ScheduleOfStockBasedCompensationActivityTableTextBlock_zzUDy1OZibYe" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B0_zxwLmvygJApl" style="display: none"&gt;Schedule of stock options outstanding&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Options
    Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Options
    Exercisable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercise
    Price Ranges&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Number
    Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted
    Average Remaining Contractual Life (years)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted
    Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Number
    Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted
    Average Remaining Contractual Life (years)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted
    Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 11%; text-align: left; text-indent: -10pt"&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zUI9fWUQjxyb" title="Exercise Prices, Lower"&gt;0.45&lt;/span&gt;&#x2013;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zDbsOAVwv6ej" title="Exercise Prices, Upper"&gt;4.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zTDfxYZcrRCd" style="width: 9%; text-align: right" title="Number share option outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,623,614&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtYp_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zlRCO83FiHfi" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)"&gt;8.97&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zjnlcPtUsJkl" style="width: 9%; text-align: right" title="Options Outstanding, Weighted Average Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.75&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;p id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zQDTcPmHmPY3" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Options Exercisable"&gt;567,233&lt;/p&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zhvX39G5OXP8" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)"&gt;8.71&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zDv7lyXUxepa" style="width: 8%; text-align: right" title="Options Exercisable, Weighted Average Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.96&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zc1x7zTr4Tgi" title="Exercise Prices, Lower"&gt;4.51&lt;/span&gt;&#x2013;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_z3GBkhz0mLX7" title="Exercise Prices, Upper"&gt;6.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zrTjt887m7n7" style="text-align: right" title="Number share option outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1573"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zk1QH7XpIgwf" style="text-align: right" title="Options Outstanding, Weighted Average Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1575"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zuLeTzWytcp" style="text-align: right" title="Options Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1577"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zbV2PosiIG1" style="text-align: right" title="Options Exercisable, Weighted Average Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1579"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_z5xKfWKRu2y4" title="Exercise Prices, Lower"&gt;6.51&lt;/span&gt;&#x2013;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_znrPyRCIviei" title="Exercise Prices, Upper"&gt;12.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zMKFlfOEYKMh" style="border-bottom: Black 1pt solid; text-align: right" title="Number share option outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1585"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zeVPVvRIQwf6" style="border-bottom: Black 1pt solid; text-align: right" title="Options Outstanding, Weighted Average Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1587"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zCb448HV19ke" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1589"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zuOQs31b4cL2" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercisable, Weighted Average Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1591"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zy8D829558B2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number share option outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,623,614&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zDqsZMhn89h1" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)"&gt;8.97&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zQ44h6xUyaAj" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding, Weighted Average Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.75&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;p id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zsCPYUXgu5M" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Options Exercisable"&gt;567,233&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zvxA8dTfWuo3" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)"&gt;8.71&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zHKzMsbH294g" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable, Weighted Average Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.96&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p id="xdx_8A8_zcS9TpCyIEue" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;A summary of changes are presented
below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zvSnzBGHPz0g" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B3_z0CmkDDSPxKi" style="display: none"&gt;Schedule of Stock option activity&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Average Remaining Life&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Intrinsic&lt;br/&gt; Value&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 44%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Outstanding at June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zzpK6WLrjZSb" style="width: 10%; text-align: right" title="Options Outstanding at beginning of period"&gt;5,527,852&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zOLIRWzP8ibk" style="width: 10%; text-align: right" title="Weighted Average Exercise Price, Outstanding at beginning of period"&gt;2.11&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zhw6GsP3381i" title="Weighted Average remaining life"&gt;7.30&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_d0_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zvWP6K5tBpij" style="width: 10%; text-align: right" title="Weighted Average Intrinsic Value, Outstanding at beginning of period"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zplZ5PVWrrJc" style="text-align: right" title="Granted"&gt;4,249,665&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zkdWeeXIJJre" style="text-align: right" title="Weighted average exercise price, Granted"&gt;0.64&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_d0_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zURyob3CXWw5" style="text-align: right" title="Exercised"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d0_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zKKmDwjg2LFj" style="text-align: right" title="Weighted average exercise price, Exercised"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di0_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zjc88dpn6Jz5" style="text-align: right" title="Forfeited"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d0_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zxICJY7Nerkj" style="text-align: right" title="Weighted Average Exercise Price, Forfeited"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Expired/Canceled &lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zwN2ajgNYL67" style="border-bottom: Black 1pt solid; text-align: right" title="Cancelled/Expired"&gt;(5,153,903&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zWkV5FsImWG" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Expired"&gt;2.12&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Outstanding at June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zwAUx66zJX0b" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding at end of period"&gt;4,623,614&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zHvVQZ2Em65h" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding at ending of period"&gt;0.75&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zN2elfknGk5e" title="Weighted Average remaining life"&gt;8.97&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_d0_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zhUKVHVYnXd7" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Intrinsic Value, Outstanding at end of period"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Exercisable at June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zK5TNBKjTdta" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable"&gt;567,233&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zzvYeoMsMiuh" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Exercisable at ending of period"&gt;0.96&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisablesWeightedAverageRemainingContractualTerm1_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zjlgEU9sn9i3" title="Weighted Average Remaining Life, Exercisable"&gt;8.71&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zKsb74I44fKf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Intrinsic Value, Exercisable end of period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1645"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zBJeEfMU4Kvb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;At June 30, 2025, the Company
had Plan Options to purchase &lt;span id="xdx_906_ecustom--PurchaseExercisableWarrantsOutstandingShares_iI_c20250630__us-gaap--VestingAxis__custom--PlanOptionMember_zcQ5SVLMi5Jk" title="Purchase exercisable warrants outstanding shares"&gt;567,233&lt;/span&gt; shares of common stock that were exercisable. The total intrinsic value of options exercisable
at June 30, 2025, was zero. Intrinsic value is measured using the fair value at the date of exercise (for shares exercised) and at June
30, 2025 (for outstanding options), less the applicable exercise price.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Common Stock Purchase Warrants&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;A summary of the status of the
Common Stock Purchase Warrants outstanding at June 30, 2025, is presented below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--ScheduleOfCommonStockPurchaseWarrantsOutstandingTableTextBlock_znnvu9Do9Rh7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span id="xdx_8BA_zLcFsXMryOo1" style="display: none"&gt;Schedule of common stock purchase warrants outstanding&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="15" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Warrants Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Warrants Exercisable&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Remaining&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Remaining&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Exercise&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Number&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Contractual&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Exercise&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Number&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Contractual&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Exercise&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Outstanding&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Life (years)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Exercisable&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Life (years)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Price&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 10%; text-align: left; text-indent: -10pt"&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--ExercisePrices_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zErerTL2NLEd" style="width: 9%; text-align: right" title="Exercise Prices"&gt;0.53&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zqsTt1jq56j3" style="width: 9%; text-align: right" title="Number share option outstanding"&gt;471,698&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zoQoCKU7jjyb" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)"&gt;2.99&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zzschGzn2H2k" style="width: 9%; text-align: right" title="Options Exercisable"&gt;471,698&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zqa4oBkNShb7" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)"&gt;2.99&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--ExercisePrices_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zogcE8auYHQ" style="text-align: right" title="Exercise Prices"&gt;0.65&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_z7BBCyXyUPij" style="text-align: right" title="Number share option outstanding"&gt;741,274&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zRhcrEUsTeGa" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)"&gt;3.09&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zVbKbyFkw2v" style="text-align: right" title="Options Exercisable"&gt;741,274&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zVZOlilTGUfk" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)"&gt;3.09&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--ExercisePrices_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zh2EYdUTccQ1" style="text-align: right" title="Exercise Prices"&gt;1.14&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zwiNVo2M901i" style="text-align: right" title="Number share option outstanding"&gt;1,189,036&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zyGfDsmGybBl" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)"&gt;2.73&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_z2Nkcp1NNoh4" style="text-align: right" title="Options Exercisable"&gt;1,189,036&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_z8pAXF5C9THb" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)"&gt;2.73&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--ExercisePrices_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange4Member_zLoXfHYiP6O2" style="text-align: right" title="Exercise Prices"&gt;1.47&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange4Member_z1PFmtDD0SB1" style="text-align: right" title="Number share option outstanding"&gt;642,128&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange4Member_zyj7XFqt9AGa" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)"&gt;3.96&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange4Member_zNTz6scTFOKa" style="text-align: right" title="Options Exercisable"&gt;642,128&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange4Member_z5XXprFMgA61" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)"&gt;3.96&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--ExercisePrices_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange5Member_zY5K85JnGc7h" style="text-align: right" title="Exercise Prices"&gt;1.48&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange5Member_zq2pUtkY1pGg" style="text-align: right" title="Number share option outstanding"&gt;50,740&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange5Member_zNf7PImUdK4g" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)"&gt;3.99&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange5Member_zrmaHjTboG87" style="text-align: right" title="Options Exercisable"&gt;50,740&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange5Member_z2oOP9dWTSX8" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)"&gt;3.99&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--ExercisePrice_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange6Member_zm39b6tcAYeb" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise Prices"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.50-1.68&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange6Member_zpSuPsupMBbl" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)"&gt;3,175,00&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange5Member_zI6jp7nrJhAi" style="border-bottom: Black 1pt solid; text-align: right" title="Options Outstanding, Weighted Average Exercise Price"&gt;0.65&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange6Member_zg2s0pLbgVjc" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercisable"&gt;3,175,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange6Member_zabxc8i6t6W3" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)"&gt;0.65&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zm4kDZ2xvYzh" style="border-bottom: Black 2.5pt double; text-align: right" title="Number share option outstanding"&gt;6,269,876&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zoSkyrPouaLl" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)"&gt;1.88&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_z4i7amudu6w" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding, Weighted Average Exercise Price"&gt;0.91&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zxYsnD7qnQFh" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable"&gt;6,269,876&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zBUsqskJmcL5" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)"&gt;1.88&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;p id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zOnYsPKkZJI" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0" title="Options Exercisable, Weighted Average Exercise Price"&gt;0.91&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p id="xdx_8AF_zUlyDqlRuEL8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;A summary of the warrant activity
is presented below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfWarrantsOutstandingTableTextBlock_zqlAtTNSi9Zb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details 4)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span id="xdx_8B6_z46HeFRRSjh3" style="display: none"&gt;Schedule of warrants outstanding&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;b&gt;Shares&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Remaining&lt;br/&gt; Life&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-indent: -10pt"&gt;Outstanding at June 30, 2024&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--CommonStockPurchaseWarrant_iS_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zBgOqd18AEHd" style="width: 11%; text-align: right" title="Outstanding at beginning of period"&gt;3,094,876&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--CommonStockPurchaseWarrantsWeightedAverageExercisePrice_iS_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zEWM0Odm6RQ5" style="width: 11%; text-align: right" title="Weighted average exercise price, Outstanding at beginning of period"&gt;1.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zNqfsW65LQy" title="Weighted Average remaining life, Outstanding"&gt;3.48&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zXoWIGJN6QYe" style="text-align: right" title="Granted"&gt;3,175,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zYR1iPI6QKbi" style="text-align: right" title="Weighted average exercise price, Granted"&gt;0.82&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zVm37PF83K2" title="Weighted Average remaining life, Granted"&gt;0.65&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zT71R1ozEGnl" style="text-align: right" title="Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1738"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zPdw0hYmN7uf" style="text-align: right" title="Weighted average exercise price, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1740"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Cancelled/Expired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_d0_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zkHisiUAIiQf" style="border-bottom: Black 1pt solid; text-align: right" title="Cancelled/Expired"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_d0_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zIBoQIjac9n5" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Expired"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Outstanding and exercisable at June 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--CommonStockPurchaseWarrant_iE_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zlg69IGA1S8d" style="border-bottom: Black 2.5pt double; text-align: right" title="Outstanding at end of period"&gt;6,269,876&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--CommonStockPurchaseWarrantsWeightedAverageExercisePrice_iE_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zN82cjnupID9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Outstanding at ending of period"&gt;0.91&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zUvqf2AuS4H9" title="Weighted Average remaining life, Outstanding"&gt;1.88&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zBIZOmiDe8tl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;At June 30, 2025, the
Company had &lt;span id="xdx_903_ecustom--PurchaseExercisableWarrantsOutstandingShares_iI_c20250630__us-gaap--VestingAxis__us-gaap--WarrantMember_zhi72n91c6n" title="Purchase exercisable warrants outstanding shares"&gt;6,269,876&lt;/span&gt;
exercisable Common Stock Purchase Warrants outstanding. The total intrinsic value of warrants exercisable at June 30, 2025, was &lt;span id="xdx_900_ecustom--WarrantsExercisablePurchaseValue_iI_c20250630_zFcMrSXoXj0i" style="display: none" title="Warrants exercisable purchase value"&gt;0&lt;/span&gt;
zero. Intrinsic value is measured using the fair market value at the date of exercise (for shares exercised) and at June 30, 2025
(for outstanding warrants), less the applicable exercise price.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Restricted Stock Awards (RSA)&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The Company recognized stock-based
compensation expense related to RSAs of $&lt;span id="xdx_908_ecustom--StockbasedCompensationExpense_iI_c20250630__us-gaap--SubsidiarySaleOfStockAxis__custom--RestrictedStockAwardsMember_zjRTC7Pp3nr4" title="Stock-based compensation expense"&gt;36,972&lt;/span&gt; for the year ended June 30, 2025. The restricted stock awards are related to&#160;a grant
of&lt;span id="xdx_906_ecustom--StockbasedCompensationExpenseGrantShares_iI_c20250630__us-gaap--SubsidiarySaleOfStockAxis__custom--RestrictedStockAwardsMember_zicIW7tePhW8" title="Stock-based compensation expense grant shares"&gt;&#160;250,000&lt;/span&gt;&#160;shares of restricted stock with a 5-year vesting period made to the Chief Executive Officer of Renovaro Cube with
a total value of $&lt;span id="xdx_905_ecustom--StockbasedCompensationExpense_iI_c20250630__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zZTGFTfswg72" title="Stock-based compensation expense"&gt;177,500&lt;/span&gt;. At June 30, 2025, the Company had $&lt;span id="xdx_90A_ecustom--UnrecognizedStockbasedCompensationExpense_iI_c20250630__us-gaap--SubsidiarySaleOfStockAxis__custom--RestrictedStockAwardsMember_zzBeeSMoIvVf" title="Unrecognized stock-based compensation expense"&gt;140,527&lt;/span&gt; of unrecognized stock-based compensation expense remaining to be
amortized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The Company recognized stock-based
compensation expense related to RSAs of $&lt;span id="xdx_90E_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20230701__20240630__us-gaap--SubsidiarySaleOfStockAxis__custom--RestrictedStockAwardsMember_z7SvccEoAHa7" title="Stock-based compensation expense"&gt;1,415,157&lt;/span&gt;&#160;for the year ended June 30, 2024. The restricted stock awards are related to&#160;a
grant of&#160;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230701__20240630__us-gaap--SubsidiarySaleOfStockAxis__custom--RestrictedStockAwardsMember_zAdGzo5J0c9g" title="Stock-based compensation expense grant shares"&gt;1,000,000&lt;/span&gt;&#160;shares of restricted stock with a 3-year vesting period made to a former director as consideration for advisory
services, with a total value of $&lt;span id="xdx_90A_ecustom--AdvisoryServices_iI_c20240630__us-gaap--SubsidiarySaleOfStockAxis__custom--AdvisoryServicesMember_znhvIfxxAgIc" title="Advisory services"&gt;2,760,000&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;





</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-06-30_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact001317"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-06-30_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact001319"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2025-06-30_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact001321"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-06-30_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact001323"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <RENB:PreferredStockDesignatedShares
      contextRef="AsOf2025-06-30_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact001325"
      unitRef="Shares">1000000</RENB:PreferredStockDesignatedShares>
    <RENB:PreferredStockDesignatedShares
      contextRef="AsOf2024-06-30_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact001327"
      unitRef="Shares">1000000</RENB:PreferredStockDesignatedShares>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2025-06-30_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact001329"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-06-30_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact001331"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-06-30_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact001333"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-06-30_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact001335"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact001338"
      unitRef="Shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact001340"
      unitRef="Shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact001342"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact001344"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <RENB:CommonStockShareIssued
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact001346"
      unitRef="Shares">177392907</RENB:CommonStockShareIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact001348"
      unitRef="Shares">177392907</us-gaap:CommonStockSharesOutstanding>
    <RENB:CommonStockShareIssued
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact001350"
      unitRef="Shares">158452644</RENB:CommonStockShareIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact001352"
      unitRef="Shares">158452644</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PurchaseObligation
      contextRef="AsOf2023-06-20"
      decimals="0"
      id="Fact001354"
      unitRef="USD">20000000</us-gaap:PurchaseObligation>
    <us-gaap:SharesIssued
      contextRef="AsOf2023-06-20_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact001356"
      unitRef="Shares">696021</us-gaap:SharesIssued>
    <us-gaap:SharesIssued
      contextRef="AsOf2025-06-30_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact001358"
      unitRef="Shares">0</us-gaap:SharesIssued>
    <us-gaap:SharesIssued
      contextRef="AsOf2024-06-30_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact001360"
      unitRef="Shares">0</us-gaap:SharesIssued>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2025-04-072025-04-08_custom_CommonStockIssuancesMember"
      decimals="INF"
      id="Fact001362"
      unitRef="Shares">15000000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-04-072025-04-08_custom_CommonStockIssuancesMember"
      decimals="0"
      id="Fact001364"
      unitRef="USD">6058500</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2025-01-122025-01-21_srt_ChiefExecutiveOfficerMember"
      decimals="INF"
      id="Fact001366"
      unitRef="Shares">250000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2025-01-122025-01-22_srt_ChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact001368"
      unitRef="USD">177500</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2024-10-162024-10-17"
      decimals="INF"
      id="Fact001370"
      unitRef="Shares">160000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-10-162024-10-17_custom_CommonStockIssuancesMember"
      decimals="0"
      id="Fact001372"
      unitRef="USD">119400</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2024-10-132024-10-14"
      decimals="INF"
      id="Fact001375"
      unitRef="Shares">500000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-10-132024-10-14_custom_CommonStockIssuancesMember"
      decimals="0"
      id="Fact001377"
      unitRef="USD">275000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2024-10-132024-10-14_srt_ChiefExecutiveOfficerMember"
      decimals="INF"
      id="Fact001379"
      unitRef="Shares">250000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-10-132024-10-14_srt_ChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact001381"
      unitRef="USD">137750</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="From2024-08-022024-08-23_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001383"
      unitRef="Shares">833333</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2024-08-022024-08-23_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001385"
      unitRef="Shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="From2024-08-022024-08-23_us-gaap_CommonStockMember_custom_MrMillerMember"
      decimals="INF"
      id="Fact001387"
      unitRef="Shares">978261</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-08-23_custom_BoardOfDirectorsMember"
      decimals="INF"
      id="Fact001389"
      unitRef="USDPShares">0.69</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact001391"
      unitRef="Shares">1159470</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <RENB:UnrecognizedCompensationCostandVest
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001393"
      unitRef="USD">185373</RENB:UnrecognizedCompensationCostandVest>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2024-07-192024-08-01"
      decimals="INF"
      id="Fact001395"
      unitRef="Shares">2000000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-07-292024-08-01_custom_CommonStockConsultingServicesMember"
      decimals="0"
      id="Fact001397"
      unitRef="USD">1400000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <RENB:IssuanceOfCommonStockUnderPrivatePlacementOffering
      contextRef="From2024-06-132024-06-14"
      decimals="INF"
      id="Fact001399"
      unitRef="Shares">5315215</RENB:IssuanceOfCommonStockUnderPrivatePlacementOffering>
    <RENB:CommonStockParValuePrivatePlacement
      contextRef="From2024-06-132024-06-14"
      decimals="INF"
      id="Fact001401"
      unitRef="USDPShares">0.0001</RENB:CommonStockParValuePrivatePlacement>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-06-14_srt_MinimumMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001403"
      unitRef="USDPShares">1.4726</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-06-14_srt_MaximumMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001405"
      unitRef="USDPShares">1.4765</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2023-07-012024-06-30_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact001407"
      unitRef="Shares">2325869</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2024-06-30_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact001409"
      unitRef="USDPShares">1.4726</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2023-07-012024-06-30_us-gaap_PrivatePlacementMember"
      decimals="0"
      id="Fact001411"
      unitRef="USD">3425075</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2023-07-012024-06-30_us-gaap_InvestorMember"
      decimals="INF"
      id="Fact001413"
      unitRef="Shares">2671631</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <RENB:PrincipalAmountAndInterestAccrued
      contextRef="From2023-07-012024-06-30_us-gaap_InvestorMember"
      decimals="0"
      id="Fact001415"
      unitRef="USD">3955033</RENB:PrincipalAmountAndInterestAccrued>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2022-07-012023-06-30_us-gaap_InvestorMember"
      decimals="0"
      id="Fact001417"
      unitRef="USD">478060</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2022-07-012023-06-30_custom_Investor1Member"
      decimals="INF"
      id="Fact001419"
      unitRef="Shares">317715</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <RENB:PrincipalAmountAndInterestAccrued
      contextRef="From2022-07-012023-06-30_custom_Investor1Member"
      decimals="0"
      id="Fact001421"
      unitRef="USD">468453</RENB:PrincipalAmountAndInterestAccrued>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2022-07-012023-06-30_custom_Investor1Member"
      decimals="0"
      id="Fact001423"
      unitRef="USD">66000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:OtherNonrecurringIncomeExpense
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001425"
      unitRef="USD">1183560</us-gaap:OtherNonrecurringIncomeExpense>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2024-07-032024-10-02"
      decimals="INF"
      id="Fact001427"
      unitRef="Shares">1613596</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2024-10-02"
      decimals="INF"
      id="Fact001429"
      unitRef="USDPShares">1.4726</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="From2024-07-032024-10-02"
      decimals="0"
      id="Fact001431"
      unitRef="USD">2376181</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2024-04-042024-04-05_custom_CommonStockIssuancesMember"
      decimals="INF"
      id="Fact001433"
      unitRef="Shares">33760</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-04-042024-04-05_custom_CommonStockIssuancesMember"
      decimals="0"
      id="Fact001435"
      unitRef="USD">94190</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-02-20_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001437"
      unitRef="Shares">2953700</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-02-20_srt_MinimumMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001439"
      unitRef="USDPShares">0.53</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-02-20_srt_MaximumMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001441"
      unitRef="USDPShares">0.65</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExpenseOrRevenueRecognized
      contextRef="From2024-02-192024-02-20_us-gaap_WarrantMember"
      id="Fact001443">1,750,000</us-gaap:ClassOfWarrantOrRightExpenseOrRevenueRecognized>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-02-20_us-gaap_WarrantMember_custom_SingleRangeMember"
      decimals="INF"
      id="Fact001445"
      unitRef="Shares">471699</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-02-20_us-gaap_WarrantMember_custom_SingleRangeMember"
      decimals="INF"
      id="Fact001447"
      unitRef="USDPShares">0.53</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExpenseOrRevenueRecognized
      contextRef="From2024-02-192024-02-20_us-gaap_WarrantMember_custom_SingleRangeMember"
      id="Fact001449">250,000</us-gaap:ClassOfWarrantOrRightExpenseOrRevenueRecognized>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2024-02-142024-02-15"
      decimals="INF"
      id="Fact001451"
      unitRef="Shares">50000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-02-142024-02-15_custom_CommonStockIssuancesMember"
      decimals="0"
      id="Fact001453"
      unitRef="USD">100000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <RENB:IssuanceOfCommonStockUnderPrivatePlacementOffering
      contextRef="From2024-02-142024-02-15"
      decimals="INF"
      id="Fact001456"
      unitRef="Shares">344827</RENB:IssuanceOfCommonStockUnderPrivatePlacementOffering>
    <RENB:CommonStockParValuePrivatePlacement
      contextRef="From2024-02-142024-02-15"
      decimals="INF"
      id="Fact001458"
      unitRef="USDPShares">0.0001</RENB:CommonStockParValuePrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2024-02-142024-02-15"
      decimals="0"
      id="Fact001460"
      unitRef="USD">1000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares
      contextRef="AsOf2024-02-16_custom_GEDiCubeIntlLtdMember"
      decimals="INF"
      id="Fact001462"
      unitRef="Shares">3425399</us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2024-02-122024-02-13_custom_StockPurchaseAgreementOfRenovaroCubeMember"
      decimals="INF"
      id="Fact001464"
      unitRef="Shares">70834183</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-02-122024-02-13_custom_StockPurchaseAgreementOfRenovaroCubeMember"
      decimals="0"
      id="Fact001466"
      unitRef="USD">136001631</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2023-12-032023-12-04"
      decimals="INF"
      id="Fact001468"
      unitRef="Shares">525945</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-12-032023-12-04"
      decimals="0"
      id="Fact001470"
      unitRef="USD">341865</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:SharesIssued
      contextRef="AsOf2023-10-23_us-gaap_CommonStockMember_custom_AvramMillerMember"
      decimals="INF"
      id="Fact001472"
      unitRef="Shares">1000000</us-gaap:SharesIssued>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-10-222023-10-23_custom_CommonStockIssuancesMember_custom_AvramMillerMember"
      decimals="0"
      id="Fact001474"
      unitRef="USD">2760000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <RENB:PurchaseSharesOfCommonStock
      contextRef="AsOf2023-07-28_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001476"
      unitRef="Shares">2000000</RENB:PurchaseSharesOfCommonStock>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="From2023-07-272023-07-28_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact001478"
      unitRef="USD">4470000</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="From2022-07-132022-07-14_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001480"
      unitRef="Shares">1250000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-07-132022-07-14_us-gaap_WarrantMember"
      decimals="0"
      id="Fact001482"
      unitRef="USD">1625000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1
      contextRef="From2022-07-132022-07-14_us-gaap_WarrantMember"
      decimals="0"
      id="Fact001484"
      unitRef="USD">2762500</us-gaap:NoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1>
    <us-gaap:SharePrice
      contextRef="AsOf2022-07-14_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001486"
      unitRef="USDPShares">2.21</us-gaap:SharePrice>
    <RENB:ExtinguishmentOfContingentConsiderationLiability
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact001488"
      unitRef="USD">419182</RENB:ExtinguishmentOfContingentConsiderationLiability>
    <RENB:BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuable
      contextRef="AsOf2025-06-30_custom_EBIAndWeirdScienceLLCMember_custom_AgreementAndPlanOfMergerAgreementAxisMember"
      decimals="INF"
      id="Fact001490"
      unitRef="Shares">0</RENB:BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuable>
    <RENB:ReserveEscrowShares
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact001492"
      unitRef="Shares">17414</RENB:ReserveEscrowShares>
    <RENB:StockIssuedToNonconsentingShareholders
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact001494"
      unitRef="Shares">167639</RENB:StockIssuedToNonconsentingShareholders>
    <RENB:ScheduleOfShareBasedPaymentAwardStockOptionValuationAssumptionsTableTextBlock contextRef="From2024-07-01to2025-06-30" id="Fact001496">&lt;table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--ScheduleOfShareBasedPaymentAwardStockOptionValuationAssumptionsTableTextBlock_zI6lhXrzJhJg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span id="xdx_8BA_zwawgDZ0RtLk" style="display: none"&gt;Schedule of weighted-average assumptions used to estimate the fair values of the stock options granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Lunai Bioworks Inc.&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Expected term (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240701__20250630__dei--LegalEntityAxis__custom--RenovaroMember_zuGOzNmRhLCb" style="font-size: 10pt"&gt;5.5&lt;/span&gt;
&lt;span style="font-size: 10pt"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20240701__20250630__srt--RangeAxis__srt--MinimumMember__dei--LegalEntityAxis__custom--RenovaroMember_zvvQSHEtbPH" title="Volatility"&gt;109.45&lt;/span&gt;% &#x2013; &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20240701__20250630__srt--RangeAxis__srt--MaximumMember__dei--LegalEntityAxis__custom--RenovaroMember_zU8NWSv9gxX6" title="Volatility"&gt;118.99&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20240701__20250630__srt--RangeAxis__srt--MinimumMember__dei--LegalEntityAxis__custom--RenovaroMember_zNXl7K6POpVh" title="Risk free interest rate"&gt;3.86&lt;/span&gt;%- &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20240701__20250630__srt--RangeAxis__srt--MaximumMember__dei--LegalEntityAxis__custom--RenovaroMember_z48dYHM6ppXb" title="Risk free interest rate"&gt;4.40&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-align: left; text-indent: -10pt"&gt;Dividend yield&lt;/td&gt;&lt;td style="width: 10%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20240701__20250630__dei--LegalEntityAxis__custom--RenovaroMember_zg0rIcCdEzod" title="Dividend yield"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</RENB:ScheduleOfShareBasedPaymentAwardStockOptionValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-07-012025-06-30_custom_RenovaroMember"
      id="Fact001497">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2024-07-012025-06-30_srt_MinimumMember_custom_RenovaroMember"
      decimals="INF"
      id="Fact001499"
      unitRef="Ratio">1.0945</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2024-07-012025-06-30_srt_MaximumMember_custom_RenovaroMember"
      decimals="INF"
      id="Fact001501"
      unitRef="Ratio">1.1899</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-07-012025-06-30_srt_MinimumMember_custom_RenovaroMember"
      decimals="INF"
      id="Fact001503"
      unitRef="Ratio">0.0386</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-07-012025-06-30_srt_MaximumMember_custom_RenovaroMember"
      decimals="INF"
      id="Fact001505"
      unitRef="Ratio">0.0440</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2024-07-012025-06-30_custom_RenovaroMember"
      decimals="INF"
      id="Fact001507"
      unitRef="Ratio">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001510"
      unitRef="USD">3313291</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2023-07-012024-06-30"
      decimals="0"
      id="Fact001512"
      unitRef="USD">4673129</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <RENB:UnrecognizedCompensationCostNonVested
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001514"
      unitRef="USD">1009277</RENB:UnrecognizedCompensationCostNonVested>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2014-02-06_custom_EquityIncentivePlan2014Member"
      decimals="INF"
      id="Fact001516"
      unitRef="Shares">1206000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2023-07-012024-06-30_custom_EmployeesMember"
      decimals="INF"
      id="Fact001518"
      unitRef="Shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2024-07-012025-06-30_custom_EmployeesThreeYearMember"
      decimals="INF"
      id="Fact001520"
      unitRef="Shares">369500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2024-07-012025-06-30_custom_EmployeesMember"
      decimals="INF"
      id="Fact001522"
      unitRef="Shares">1850000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2024-07-012025-06-30_custom_ShareBasedCompensationAwardAdvisoryBoardMember"
      decimals="INF"
      id="Fact001524"
      unitRef="Shares">362904</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2023-07-012024-06-30_us-gaap_ShareBasedCompensationAwardTrancheOneMember"
      decimals="INF"
      id="Fact001526"
      unitRef="Shares">424412</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2024-07-012025-06-30_custom_ShareBasedCompensationAwardBoardofDirectorsMember"
      decimals="INF"
      id="Fact001528"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2023-07-012024-06-30_custom_ShareBasedCompensationAwardBoardofDirectorsMember"
      decimals="INF"
      id="Fact001530"
      unitRef="Shares">329729</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2024-07-012025-06-30_custom_ShareBasedCompensationAwardConsultingServicesMember"
      decimals="INF"
      id="Fact001532"
      unitRef="Shares">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2023-07-012024-06-30_custom_ShareBasedCompensationAwardConsultingServicesMember"
      decimals="INF"
      id="Fact001534"
      unitRef="Shares">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <RENB:DebtConversionConvertedInstrumentWarrantsOptionsIssued1
      contextRef="AsOf2024-11-04_custom_PlanOptionsMember"
      decimals="INF"
      id="Fact001536"
      unitRef="Shares">58500</RENB:DebtConversionConvertedInstrumentWarrantsOptionsIssued1>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1
      contextRef="From2024-11-012024-11-04"
      decimals="0"
      id="Fact001538"
      unitRef="USD">31005</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <RENB:StockOptionIssued
      contextRef="AsOf2024-11-04"
      decimals="INF"
      id="Fact001540"
      unitRef="Shares">58500</RENB:StockOptionIssued>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001543"
      unitRef="USD">1159470</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <RENB:UnrecognizedCompensationCost
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001545"
      unitRef="USD">185373</RENB:UnrecognizedCompensationCost>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2024-07-012025-06-30_custom_PlanOptionsMember"
      decimals="INF"
      id="Fact001547"
      unitRef="Shares">6088250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1
      contextRef="From2024-07-012025-06-30_custom_PlanOptionsMember"
      decimals="INF"
      id="Fact001549"
      unitRef="Shares">5093444</us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1>
    <RENB:ScheduleOfStockBasedCompensationActivityTableTextBlock contextRef="From2024-07-01to2025-06-30" id="Fact001551">&lt;table cellpadding="0" cellspacing="0" id="xdx_896_ecustom--ScheduleOfStockBasedCompensationActivityTableTextBlock_zzUDy1OZibYe" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B0_zxwLmvygJApl" style="display: none"&gt;Schedule of stock options outstanding&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Options
    Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Options
    Exercisable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercise
    Price Ranges&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Number
    Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted
    Average Remaining Contractual Life (years)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted
    Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Number
    Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted
    Average Remaining Contractual Life (years)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted
    Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 11%; text-align: left; text-indent: -10pt"&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zUI9fWUQjxyb" title="Exercise Prices, Lower"&gt;0.45&lt;/span&gt;&#x2013;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zDbsOAVwv6ej" title="Exercise Prices, Upper"&gt;4.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zTDfxYZcrRCd" style="width: 9%; text-align: right" title="Number share option outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,623,614&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtYp_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zlRCO83FiHfi" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)"&gt;8.97&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zjnlcPtUsJkl" style="width: 9%; text-align: right" title="Options Outstanding, Weighted Average Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.75&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;p id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zQDTcPmHmPY3" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Options Exercisable"&gt;567,233&lt;/p&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zhvX39G5OXP8" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)"&gt;8.71&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zDv7lyXUxepa" style="width: 8%; text-align: right" title="Options Exercisable, Weighted Average Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.96&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zc1x7zTr4Tgi" title="Exercise Prices, Lower"&gt;4.51&lt;/span&gt;&#x2013;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_z3GBkhz0mLX7" title="Exercise Prices, Upper"&gt;6.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zrTjt887m7n7" style="text-align: right" title="Number share option outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1573"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zk1QH7XpIgwf" style="text-align: right" title="Options Outstanding, Weighted Average Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1575"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zuLeTzWytcp" style="text-align: right" title="Options Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1577"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zbV2PosiIG1" style="text-align: right" title="Options Exercisable, Weighted Average Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1579"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_z5xKfWKRu2y4" title="Exercise Prices, Lower"&gt;6.51&lt;/span&gt;&#x2013;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_znrPyRCIviei" title="Exercise Prices, Upper"&gt;12.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zMKFlfOEYKMh" style="border-bottom: Black 1pt solid; text-align: right" title="Number share option outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1585"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zeVPVvRIQwf6" style="border-bottom: Black 1pt solid; text-align: right" title="Options Outstanding, Weighted Average Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1587"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zCb448HV19ke" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1589"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zuOQs31b4cL2" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercisable, Weighted Average Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1591"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zy8D829558B2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number share option outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,623,614&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zDqsZMhn89h1" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)"&gt;8.97&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zQ44h6xUyaAj" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding, Weighted Average Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.75&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;p id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zsCPYUXgu5M" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Options Exercisable"&gt;567,233&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zvxA8dTfWuo3" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)"&gt;8.71&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_zHKzMsbH294g" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable, Weighted Average Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.96&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



</RENB:ScheduleOfStockBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2024-07-012025-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange1Member"
      decimals="INF"
      id="Fact001553"
      unitRef="USDPShares">0.45</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2024-07-012025-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange1Member"
      decimals="INF"
      id="Fact001555"
      unitRef="USDPShares">4.50</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange1Member"
      decimals="INF"
      id="Fact001557"
      unitRef="Shares">4623614</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-07-012025-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange1Member"
      id="Fact001559">P8Y11M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange1Member"
      decimals="INF"
      id="Fact001561"
      unitRef="USDPShares">0.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2025-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange1Member"
      decimals="INF"
      id="Fact001563"
      unitRef="Shares">567233</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2024-07-012025-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange1Member"
      id="Fact001565">P8Y8M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2025-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange1Member"
      decimals="INF"
      id="Fact001567"
      unitRef="USDPShares">0.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2024-07-012025-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange2Member"
      decimals="INF"
      id="Fact001569"
      unitRef="USDPShares">4.51</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2024-07-012025-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange2Member"
      decimals="INF"
      id="Fact001571"
      unitRef="USDPShares">6.50</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2024-07-012025-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange3Member"
      decimals="INF"
      id="Fact001581"
      unitRef="USDPShares">6.51</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2024-07-012025-06-30_us-gaap_EmployeeStockOptionMember_custom_ExercisePriceRange3Member"
      decimals="INF"
      id="Fact001583"
      unitRef="USDPShares">12.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-06-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001593"
      unitRef="Shares">4623614</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-07-012025-06-30_us-gaap_EmployeeStockOptionMember"
      id="Fact001595">P8Y11M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-06-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001597"
      unitRef="USDPShares">0.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2025-06-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001599"
      unitRef="Shares">567233</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2024-07-012025-06-30_us-gaap_EmployeeStockOptionMember"
      id="Fact001601">P8Y8M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2025-06-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001603"
      unitRef="USDPShares">0.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2024-07-01to2025-06-30" id="Fact001605">&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zvSnzBGHPz0g" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B3_z0CmkDDSPxKi" style="display: none"&gt;Schedule of Stock option activity&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Average Remaining Life&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Intrinsic&lt;br/&gt; Value&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 44%; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Outstanding at June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zzpK6WLrjZSb" style="width: 10%; text-align: right" title="Options Outstanding at beginning of period"&gt;5,527,852&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zOLIRWzP8ibk" style="width: 10%; text-align: right" title="Weighted Average Exercise Price, Outstanding at beginning of period"&gt;2.11&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zhw6GsP3381i" title="Weighted Average remaining life"&gt;7.30&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_d0_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zvWP6K5tBpij" style="width: 10%; text-align: right" title="Weighted Average Intrinsic Value, Outstanding at beginning of period"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zplZ5PVWrrJc" style="text-align: right" title="Granted"&gt;4,249,665&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zkdWeeXIJJre" style="text-align: right" title="Weighted average exercise price, Granted"&gt;0.64&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_d0_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zURyob3CXWw5" style="text-align: right" title="Exercised"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d0_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zKKmDwjg2LFj" style="text-align: right" title="Weighted average exercise price, Exercised"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di0_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zjc88dpn6Jz5" style="text-align: right" title="Forfeited"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d0_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zxICJY7Nerkj" style="text-align: right" title="Weighted Average Exercise Price, Forfeited"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Expired/Canceled &lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zwN2ajgNYL67" style="border-bottom: Black 1pt solid; text-align: right" title="Cancelled/Expired"&gt;(5,153,903&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zWkV5FsImWG" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Expired"&gt;2.12&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Outstanding at June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zwAUx66zJX0b" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding at end of period"&gt;4,623,614&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zHvVQZ2Em65h" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding at ending of period"&gt;0.75&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zN2elfknGk5e" title="Weighted Average remaining life"&gt;8.97&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_d0_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zhUKVHVYnXd7" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Intrinsic Value, Outstanding at end of period"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-size: 10pt"&gt;Exercisable at June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zK5TNBKjTdta" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable"&gt;567,233&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zzvYeoMsMiuh" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Exercisable at ending of period"&gt;0.96&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisablesWeightedAverageRemainingContractualTerm1_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zjlgEU9sn9i3" title="Weighted Average Remaining Life, Exercisable"&gt;8.71&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--EmployeeStockOptionsMember_zKsb74I44fKf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Intrinsic Value, Exercisable end of period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1645"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-06-30_custom_EmployeeStockOptionsMember"
      decimals="INF"
      id="Fact001607"
      unitRef="Shares">5527852</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-06-30_custom_EmployeeStockOptionsMember"
      decimals="INF"
      id="Fact001609"
      unitRef="USDPShares">2.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2023-07-012024-06-30_custom_EmployeeStockOptionsMember"
      id="Fact001611">P7Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2024-06-30_custom_EmployeeStockOptionsMember"
      decimals="0"
      id="Fact001613"
      unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-07-012025-06-30_custom_EmployeeStockOptionsMember"
      decimals="INF"
      id="Fact001615"
      unitRef="Shares">4249665</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-07-012025-06-30_custom_EmployeeStockOptionsMember"
      decimals="INF"
      id="Fact001617"
      unitRef="USDPShares">0.64</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2024-07-012025-06-30_custom_EmployeeStockOptionsMember"
      decimals="INF"
      id="Fact001619"
      unitRef="Shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2024-07-012025-06-30_custom_EmployeeStockOptionsMember"
      decimals="INF"
      id="Fact001621"
      unitRef="USDPShares">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2024-07-012025-06-30_custom_EmployeeStockOptionsMember"
      decimals="INF"
      id="Fact001623"
      unitRef="Shares">-0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2024-07-012025-06-30_custom_EmployeeStockOptionsMember"
      decimals="INF"
      id="Fact001625"
      unitRef="USDPShares">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2024-07-012025-06-30_custom_EmployeeStockOptionsMember"
      decimals="INF"
      id="Fact001627"
      unitRef="Shares">5153903</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-07-012025-06-30_custom_EmployeeStockOptionsMember"
      decimals="INF"
      id="Fact001629"
      unitRef="USDPShares">2.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-06-30_custom_EmployeeStockOptionsMember"
      decimals="INF"
      id="Fact001631"
      unitRef="Shares">4623614</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-06-30_custom_EmployeeStockOptionsMember"
      decimals="INF"
      id="Fact001633"
      unitRef="USDPShares">0.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-07-012025-06-30_custom_EmployeeStockOptionsMember"
      id="Fact001635">P8Y11M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2025-06-30_custom_EmployeeStockOptionsMember"
      decimals="0"
      id="Fact001637"
      unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2025-06-30_custom_EmployeeStockOptionsMember"
      decimals="INF"
      id="Fact001639"
      unitRef="Shares">567233</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2025-06-30_custom_EmployeeStockOptionsMember"
      decimals="INF"
      id="Fact001641"
      unitRef="USDPShares">0.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <RENB:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisablesWeightedAverageRemainingContractualTerm1
      contextRef="From2024-07-012025-06-30_custom_EmployeeStockOptionsMember"
      id="Fact001643">P8Y8M15D</RENB:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisablesWeightedAverageRemainingContractualTerm1>
    <RENB:PurchaseExercisableWarrantsOutstandingShares
      contextRef="AsOf2025-06-30_custom_PlanOptionMember"
      decimals="INF"
      id="Fact001647"
      unitRef="Shares">567233</RENB:PurchaseExercisableWarrantsOutstandingShares>
    <RENB:ScheduleOfCommonStockPurchaseWarrantsOutstandingTableTextBlock contextRef="From2024-07-01to2025-06-30" id="Fact001650">&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--ScheduleOfCommonStockPurchaseWarrantsOutstandingTableTextBlock_znnvu9Do9Rh7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span id="xdx_8BA_zLcFsXMryOo1" style="display: none"&gt;Schedule of common stock purchase warrants outstanding&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="15" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Warrants Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Warrants Exercisable&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Remaining&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Remaining&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Exercise&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Number&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Contractual&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Exercise&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Number&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Contractual&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Exercise&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Outstanding&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Life (years)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Exercisable&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Life (years)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Price&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 10%; text-align: left; text-indent: -10pt"&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--ExercisePrices_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zErerTL2NLEd" style="width: 9%; text-align: right" title="Exercise Prices"&gt;0.53&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zqsTt1jq56j3" style="width: 9%; text-align: right" title="Number share option outstanding"&gt;471,698&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zoQoCKU7jjyb" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)"&gt;2.99&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zzschGzn2H2k" style="width: 9%; text-align: right" title="Options Exercisable"&gt;471,698&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange1Member_zqa4oBkNShb7" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)"&gt;2.99&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--ExercisePrices_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zogcE8auYHQ" style="text-align: right" title="Exercise Prices"&gt;0.65&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_z7BBCyXyUPij" style="text-align: right" title="Number share option outstanding"&gt;741,274&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zRhcrEUsTeGa" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)"&gt;3.09&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zVbKbyFkw2v" style="text-align: right" title="Options Exercisable"&gt;741,274&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange2Member_zVZOlilTGUfk" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)"&gt;3.09&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--ExercisePrices_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zh2EYdUTccQ1" style="text-align: right" title="Exercise Prices"&gt;1.14&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zwiNVo2M901i" style="text-align: right" title="Number share option outstanding"&gt;1,189,036&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_zyGfDsmGybBl" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)"&gt;2.73&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_z2Nkcp1NNoh4" style="text-align: right" title="Options Exercisable"&gt;1,189,036&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange3Member_z8pAXF5C9THb" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)"&gt;2.73&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--ExercisePrices_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange4Member_zLoXfHYiP6O2" style="text-align: right" title="Exercise Prices"&gt;1.47&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange4Member_z1PFmtDD0SB1" style="text-align: right" title="Number share option outstanding"&gt;642,128&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange4Member_zyj7XFqt9AGa" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)"&gt;3.96&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange4Member_zNTz6scTFOKa" style="text-align: right" title="Options Exercisable"&gt;642,128&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange4Member_z5XXprFMgA61" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)"&gt;3.96&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--ExercisePrices_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange5Member_zY5K85JnGc7h" style="text-align: right" title="Exercise Prices"&gt;1.48&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange5Member_zq2pUtkY1pGg" style="text-align: right" title="Number share option outstanding"&gt;50,740&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange5Member_zNf7PImUdK4g" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)"&gt;3.99&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange5Member_zrmaHjTboG87" style="text-align: right" title="Options Exercisable"&gt;50,740&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange5Member_z2oOP9dWTSX8" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)"&gt;3.99&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 1pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--ExercisePrice_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange6Member_zm39b6tcAYeb" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise Prices"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.50-1.68&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange6Member_zpSuPsupMBbl" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)"&gt;3,175,00&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange5Member_zI6jp7nrJhAi" style="border-bottom: Black 1pt solid; text-align: right" title="Options Outstanding, Weighted Average Exercise Price"&gt;0.65&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange6Member_zg2s0pLbgVjc" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercisable"&gt;3,175,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRange6Member_zabxc8i6t6W3" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)"&gt;0.65&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 2.5pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zm4kDZ2xvYzh" style="border-bottom: Black 2.5pt double; text-align: right" title="Number share option outstanding"&gt;6,269,876&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zoSkyrPouaLl" title="Options Outstanding, Weighted Average Remaining Contractual Life (years)"&gt;1.88&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_z4i7amudu6w" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding, Weighted Average Exercise Price"&gt;0.91&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zxYsnD7qnQFh" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable"&gt;6,269,876&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zBUsqskJmcL5" title="Options Exercisable, Weighted Average Remaining Contractual Life (years)"&gt;1.88&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;p id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantsMember_zOnYsPKkZJI" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0" title="Options Exercisable, Weighted Average Exercise Price"&gt;0.91&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



</RENB:ScheduleOfCommonStockPurchaseWarrantsOutstandingTableTextBlock>
    <RENB:ExercisePrices
      contextRef="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange1Member"
      decimals="INF"
      id="Fact001652"
      unitRef="USDPShares">0.53</RENB:ExercisePrices>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange1Member"
      decimals="INF"
      id="Fact001654"
      unitRef="Shares">471698</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange1Member"
      id="Fact001656">P2Y11M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange1Member"
      decimals="INF"
      id="Fact001658"
      unitRef="Shares">471698</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange1Member"
      id="Fact001660">P2Y11M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <RENB:ExercisePrices
      contextRef="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange2Member"
      decimals="INF"
      id="Fact001662"
      unitRef="USDPShares">0.65</RENB:ExercisePrices>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange2Member"
      decimals="INF"
      id="Fact001664"
      unitRef="Shares">741274</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange2Member"
      id="Fact001666">P3Y1M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange2Member"
      decimals="INF"
      id="Fact001668"
      unitRef="Shares">741274</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange2Member"
      id="Fact001670">P3Y1M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <RENB:ExercisePrices
      contextRef="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange3Member"
      decimals="INF"
      id="Fact001672"
      unitRef="USDPShares">1.14</RENB:ExercisePrices>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange3Member"
      decimals="INF"
      id="Fact001674"
      unitRef="Shares">1189036</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange3Member"
      id="Fact001676">P2Y8M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange3Member"
      decimals="INF"
      id="Fact001678"
      unitRef="Shares">1189036</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange3Member"
      id="Fact001680">P2Y8M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <RENB:ExercisePrices
      contextRef="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange4Member"
      decimals="INF"
      id="Fact001682"
      unitRef="USDPShares">1.47</RENB:ExercisePrices>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange4Member"
      decimals="INF"
      id="Fact001684"
      unitRef="Shares">642128</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange4Member"
      id="Fact001686">P3Y11M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange4Member"
      decimals="INF"
      id="Fact001688"
      unitRef="Shares">642128</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange4Member"
      id="Fact001690">P3Y11M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <RENB:ExercisePrices
      contextRef="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange5Member"
      decimals="INF"
      id="Fact001692"
      unitRef="USDPShares">1.48</RENB:ExercisePrices>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange5Member"
      decimals="INF"
      id="Fact001694"
      unitRef="Shares">50740</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange5Member"
      id="Fact001696">P3Y11M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange5Member"
      decimals="INF"
      id="Fact001698"
      unitRef="Shares">50740</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange5Member"
      id="Fact001700">P3Y11M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <RENB:ExercisePrice
      contextRef="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange6Member"
      id="Fact001702">0.50-1.68</RENB:ExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange6Member"
      decimals="INF"
      id="Fact001704"
      unitRef="Shares">3175.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange5Member"
      decimals="INF"
      id="Fact001706"
      unitRef="USDPShares">0.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange6Member"
      decimals="INF"
      id="Fact001708"
      unitRef="Shares">3175000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantsMember_custom_ExercisePriceRange6Member"
      id="Fact001710">P0Y7M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-06-30_custom_CommonStockPurchaseWarrantsMember"
      decimals="INF"
      id="Fact001712"
      unitRef="Shares">6269876</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantsMember"
      id="Fact001714">P1Y10M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-06-30_custom_CommonStockPurchaseWarrantsMember"
      decimals="INF"
      id="Fact001716"
      unitRef="USDPShares">0.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2025-06-30_custom_CommonStockPurchaseWarrantsMember"
      decimals="INF"
      id="Fact001718"
      unitRef="Shares">6269876</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantsMember"
      id="Fact001720">P1Y10M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2025-06-30_custom_CommonStockPurchaseWarrantsMember"
      decimals="INF"
      id="Fact001722"
      unitRef="USDPShares">0.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <RENB:ScheduleOfWarrantsOutstandingTableTextBlock contextRef="From2024-07-01to2025-06-30" id="Fact001724">&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfWarrantsOutstandingTableTextBlock_zqlAtTNSi9Zb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details 4)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span id="xdx_8B6_z46HeFRRSjh3" style="display: none"&gt;Schedule of warrants outstanding&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;b&gt;Shares&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Remaining&lt;br/&gt; Life&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-indent: -10pt"&gt;Outstanding at June 30, 2024&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--CommonStockPurchaseWarrant_iS_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zBgOqd18AEHd" style="width: 11%; text-align: right" title="Outstanding at beginning of period"&gt;3,094,876&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--CommonStockPurchaseWarrantsWeightedAverageExercisePrice_iS_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zEWM0Odm6RQ5" style="width: 11%; text-align: right" title="Weighted average exercise price, Outstanding at beginning of period"&gt;1.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20240630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zNqfsW65LQy" title="Weighted Average remaining life, Outstanding"&gt;3.48&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zXoWIGJN6QYe" style="text-align: right" title="Granted"&gt;3,175,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zYR1iPI6QKbi" style="text-align: right" title="Weighted average exercise price, Granted"&gt;0.82&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zVm37PF83K2" title="Weighted Average remaining life, Granted"&gt;0.65&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zT71R1ozEGnl" style="text-align: right" title="Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1738"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zPdw0hYmN7uf" style="text-align: right" title="Weighted average exercise price, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1740"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Cancelled/Expired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_d0_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zkHisiUAIiQf" style="border-bottom: Black 1pt solid; text-align: right" title="Cancelled/Expired"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_d0_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zIBoQIjac9n5" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Expired"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Outstanding and exercisable at June 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--CommonStockPurchaseWarrant_iE_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zlg69IGA1S8d" style="border-bottom: Black 2.5pt double; text-align: right" title="Outstanding at end of period"&gt;6,269,876&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--CommonStockPurchaseWarrantsWeightedAverageExercisePrice_iE_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zN82cjnupID9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Outstanding at ending of period"&gt;0.91&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240701__20250630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__custom--CommonStockPurchaseWarrantMember_zUvqf2AuS4H9" title="Weighted Average remaining life, Outstanding"&gt;1.88&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</RENB:ScheduleOfWarrantsOutstandingTableTextBlock>
    <RENB:CommonStockPurchaseWarrant
      contextRef="AsOf2024-06-30_custom_CommonStockPurchaseWarrantMember"
      decimals="INF"
      id="Fact001726"
      unitRef="Shares">3094876</RENB:CommonStockPurchaseWarrant>
    <RENB:CommonStockPurchaseWarrantsWeightedAverageExercisePrice
      contextRef="AsOf2024-06-30_custom_CommonStockPurchaseWarrantMember"
      decimals="INF"
      id="Fact001728"
      unitRef="USDPShares">1.00</RENB:CommonStockPurchaseWarrantsWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2023-07-012024-06-30_custom_CommonStockPurchaseWarrantMember"
      id="Fact001730">P3Y5M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantMember"
      decimals="INF"
      id="Fact001732"
      unitRef="Shares">3175000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantMember"
      decimals="INF"
      id="Fact001734"
      unitRef="USDPShares">0.82</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <RENB:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2
      contextRef="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantMember"
      id="Fact001736">P0Y7M24D</RENB:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantMember"
      decimals="INF"
      id="Fact001742"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantMember"
      decimals="INF"
      id="Fact001744"
      unitRef="USDPShares">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <RENB:CommonStockPurchaseWarrant
      contextRef="AsOf2025-06-30_custom_CommonStockPurchaseWarrantMember"
      decimals="INF"
      id="Fact001746"
      unitRef="Shares">6269876</RENB:CommonStockPurchaseWarrant>
    <RENB:CommonStockPurchaseWarrantsWeightedAverageExercisePrice
      contextRef="AsOf2025-06-30_custom_CommonStockPurchaseWarrantMember"
      decimals="INF"
      id="Fact001748"
      unitRef="USDPShares">0.91</RENB:CommonStockPurchaseWarrantsWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-07-012025-06-30_custom_CommonStockPurchaseWarrantMember"
      id="Fact001750">P1Y10M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <RENB:PurchaseExercisableWarrantsOutstandingShares
      contextRef="AsOf2025-06-30_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001752"
      unitRef="Shares">6269876</RENB:PurchaseExercisableWarrantsOutstandingShares>
    <RENB:WarrantsExercisablePurchaseValue
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001754"
      unitRef="USD">0</RENB:WarrantsExercisablePurchaseValue>
    <RENB:StockbasedCompensationExpense
      contextRef="AsOf2025-06-30_custom_RestrictedStockAwardsMember"
      decimals="0"
      id="Fact001756"
      unitRef="USD">36972</RENB:StockbasedCompensationExpense>
    <RENB:StockbasedCompensationExpenseGrantShares
      contextRef="AsOf2025-06-30_custom_RestrictedStockAwardsMember"
      decimals="INF"
      id="Fact001758"
      unitRef="Shares">250000</RENB:StockbasedCompensationExpenseGrantShares>
    <RENB:StockbasedCompensationExpense
      contextRef="AsOf2025-06-30_srt_ChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact001760"
      unitRef="USD">177500</RENB:StockbasedCompensationExpense>
    <RENB:UnrecognizedStockbasedCompensationExpense
      contextRef="AsOf2025-06-30_custom_RestrictedStockAwardsMember"
      decimals="0"
      id="Fact001762"
      unitRef="USD">140527</RENB:UnrecognizedStockbasedCompensationExpense>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2023-07-012024-06-30_custom_RestrictedStockAwardsMember"
      decimals="0"
      id="Fact001764"
      unitRef="USD">1415157</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-07-012024-06-30_custom_RestrictedStockAwardsMember"
      decimals="INF"
      id="Fact001766"
      unitRef="Shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <RENB:AdvisoryServices
      contextRef="AsOf2024-06-30_custom_AdvisoryServicesMember"
      decimals="0"
      id="Fact001768"
      unitRef="USD">2760000</RENB:AdvisoryServices>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2024-07-01to2025-06-30" id="Fact001771">&lt;p id="xdx_80D_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zqjOelFGCAp6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 11 &#x2014; &lt;span id="xdx_826_zYWqMpeYjux"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Commitments&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On January 31, 2020, the Company
entered into a Statement of Work and License Agreement (the &#x201c;HBV License Agreement&#x201d;) by and among the Company, G Tech Bio,
LLC, a California limited liability company (&#x201c;G Tech&#x201d;), and G Health Research Foundation, a not-for-profit entity organized
under the laws of California doing business as Seraph Research Institute (&#x201c;SRI&#x201d;) (collectively the &#x201c;Licensors&#x201d;),
whereby the Company acquired a perpetual, sublicensable, exclusive license (the &#x201c;HBV License&#x201d;) for a treatment under development
(the &#x201c;Treatment&#x201d;) aimed to treat Hepatitis B Virus (HBV) infections.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The HBV License Agreement states
that in consideration for the HBV License, the Company shall provide cash funding for research costs and equipment and certain other in-kind
funding related to the Treatment over a 24-month period, and provides for an up-front payment of $&lt;span id="xdx_90A_eus-gaap--PaymentsForFees_pn3n6_c20210130__20210131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GTechMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_z6ZAq11kOxr9" title="Payment for license"&gt;1.2&lt;/span&gt; million within 7 days of January
31, 2020, along with additional payments upon the occurrence of certain benchmarks in the development of the technology set forth in the
HBV License Agreement, in each case subject to the terms of the HBV License Agreement. Additionally, the HBV License Agreement provides
for cooperation related to the development of intellectual property related to the Treatment and for a &lt;span id="xdx_901_ecustom--RoyaltyPercentage_dp_c20200130__20200131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GTechMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zKkCk4Qnv2nc" title="Royalty percentage"&gt;2&lt;/span&gt;% royalty to G Tech on any net
sales that may occur under the HBV License. On February 6, 2020, the Company paid the $&lt;span id="xdx_907_eus-gaap--PaymentsForFees_pn5n6_c20200205__20200206__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GTechMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_ztcdTq2xUFA4" title="Payment for license"&gt;1.2&lt;/span&gt; million up-front payment. The HBV License Agreement
contains customary representations, warranties, and covenants of the parties with respect to the development of the Treatment and the
HBV License.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The cash funding for research
costs pursuant to the HBV License Agreement consisted of monthly payments amounting to $144,500 that covered scientific staffing resources
to complete the project as well as periodic payments for materials and equipment needed to complete the project. There were no payments
made after January 31, 2022. The Company paid zero under the HBV License Agreement in years ended June 30, 2025, and 2024. The Company
has filed a claim against the Licensors, which includes certain payments it made related to this license (see Contingencies sub-section
below).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On April 18, 2021, the Company
entered into a Statement of Work and License Agreement (the &#x201c;License Development Agreement&#x201d;), by and among the Company, G
Tech and SRI (collectively, the &#x201c;Licensors&#x201d;), whereby the Company acquired a perpetual sublicensable, exclusive license (the
&#x201c;Development License&#x201d;) to research, develop, and commercialize certain formulations which were aimed at preventing and treating
pan-coronavirus or the potential combination of the pan-coronavirus and pan-influenza, including the SARS-coronavirus that causes COVID-19
and pan-influenza (the &#x201c;Prevention and Treatment&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The Development License Agreement
was entered into pursuant to the existing Framework Agreement between the parties dated November 15, 2019. The Development License Agreement
states that in consideration for the Development License, the Company shall provide cash funding for research costs and equipment and
certain other in-kind funding related to the Prevention and Treatment over a 24-month period. Additionally, the Development License Agreement
provides for an up-front payment of $&lt;span id="xdx_908_ecustom--UpfrontPayment_c20191114__20191115_zGPdt4xSUA5g" title="Up-front payment"&gt;10,000,000&lt;/span&gt; and a $&lt;span id="xdx_908_ecustom--PaymentForExpenditures_c20191114__20191115_zxSlRWotlc3a" title="Payment for expenditures"&gt;760,000&lt;/span&gt; payment for expenditures to date prior to the effective date related to
research towards the Prevention and Treatment within 60 days of April 18, 2021. The Development License Agreement provides for additional
payments upon the occurrence of certain benchmarks in the development of the technology set forth in the Development License Agreement,
in each case subject to the terms of the Development License Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The Development License Agreement
provides for (i) cooperation related to the development of intellectual property related to the Prevention and Treatment and (ii) a 3%
royalty to G Tech on any net sales that may occur under the Development License Agreement. The Company is no longer pursuing any product
candidates that relate to this license. The Company has filed a claim against the Licensors to recover all monies it paid related to this
license (see Contingencies below).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On August 25, 2021, the Company
entered into an ALC Patent License and Research Funding Agreement in the HIV Field (the &#x201c;ALC License Agreement&#x201d;) with Serhat
G&#xfc;mr&#xfc;kc&#xfc; and SRI (collectively, the &#x201c;Licensors&#x201d;) whereby the Licensors granted the Company an exclusive, worldwide,
perpetual, fully paid-up, royalty-free license, with the right to sublicense, proprietary technology subject to a U.S. patent application,
to make, use, offer to sell, sell or import products for use solely for the prevention, treatment, amelioration of or therapy exclusively
for HIV in humans, and research and development exclusively relating to HIV in humans; provided the Licensors retained the right to conduct
HIV research in the field. Pursuant to the ALC License Agreement, the Company granted a non-exclusive license back to the Licensors, under
any patents or other intellectual property owned or controlled by the Company, to the extent arising from the ALC License, to make, use,
offer to sell, sell or import products for use in the diagnosis, prevention, treatment, amelioration or therapy of any (i) HIV Comorbidities
and (ii) any other diseases or conditions outside the HIV Field. The Company made an initial payment to SRI of $&lt;span id="xdx_902_ecustom--InitialPayment_c20220824__20220825_z6dfIkTJBa28" title="Initial payment"&gt;600,000&lt;/span&gt; and agreed to
fund future HIV research conducted by the Licensors, as mutually agreed to by the parties. On September 10, 2021, pursuant to the ALC
License Agreement, the Company paid the initial payment of $&lt;span id="xdx_903_ecustom--InitialPayment_c20220909__20220910_zMG1PlJZJcxj" title="Initial payment"&gt;600,000&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;G Tech and SRI are controlled
by Anderson Wittekind, a stockholder of the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Shares held for non-consenting
shareholders&lt;/b&gt; &#x2013; The &lt;span id="xdx_901_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20250630_z6DAam1N4LZ5" title="Remaining shares"&gt;17,414&lt;/span&gt; remaining shares of Common Stock related to the Acquisition of Renovaro Denmark have been reflected
as issued and outstanding in the accompanying financial statements.&#160;There were zero shares of Common Stock issued to such&#160;non-consenting
stockholders during the years ended June 30, 2025 and 2024 (see Note 10.)&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Service Agreements&lt;/b&gt; &lt;i&gt;&#x2013;&lt;/i&gt;The
Company maintains employment agreements with certain senior staff in the ordinary course of business.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;Contingencies&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;Securities Class Action Litigation&lt;/i&gt;.
On July 26, 2022 and July 28, 2022, securities class action complaints (the former, the &#x201c;Chow Action&#x201d; and the latter, the
Manici Action&#x201d;) were filed by purported stockholders of the Company in the United States District Court for the Central District
of California against the Company and certain of the Company&#x2019;s current and former officers and directors. The complaints allege,
among other things, that the defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule
10b-5 thereunder, by making false and misleading statements and omissions of material fact in connection with the Company&#x2019;s relationship
with Serhat G&#xfc;mr&#xfc;kc&#xfc; and its commercial prospects. The complaints seek unspecified damages, interest, fees, and costs.
On November 22, 2022, the Manici Action was voluntarily dismissed without prejudice. The Chow Action (also referred to as the &#x201c;Securities
Class Action Litigation&#x201d;) remains pending. On October 22, 2023, the Court appointed a lead plaintiff in the Chow Action. The lead
plaintiff filed an amended complaint on December 15, 2023. The Company filed a motion to dismiss the amended complaint on March 15, 2024.
The Court denied the Company&#x2019;s motion to dismiss on June 28, 2024. A mediation was held on September 17, 2024, after which the parties
signed a stipulation of settlement. The court granted the lead plaintiff&#x2019;s motion for preliminary approval of the settlement on
August 18, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;Federal Derivative Litigation&lt;/i&gt;.
On September 22, 2022, Samuel E. Koenig filed a shareholder derivative action in the United States District Court for the Central District
of California (the &#x201c;Koenig Matter&#x201d;). The Koenig Matter, filed on behalf of the Company, names Serhat G&#xfc;mr&#xfc;kc&#xfc;
and certain of the Company&#x2019;s current and former directors as defendants, and also names the Company as a nominal defendant. The
Koenig Matter alleges violations of Sections 14(a) and 20(a) of the Securities Exchange Act of 1934, and also sets out claims for breach
of fiduciary duty, contribution and indemnification, aiding and abetting, and gross mismanagement. Plaintiff does not quantify any alleged
injury, but seeks damages, disgorgement, restitution, and other costs and expenses. On January 24, 2023, the United States District Court
for the Central District of California stayed the Koenig Matter pending resolution of the defendants&#x2019; anticipated motion to dismiss
in the Securities Class Action Litigation. On June 28, 2024, the United States District Court for the Central District of California denied
defendants&#x2019; motion to dismiss the Securities Class Action Litigation. On July 14, 2025, the Court stayed the Koenig Matter until
October 17, 2025. The defendants have not yet responded to the complaint.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On January 19, 2023, John Solak
filed a shareholder derivative action in the United States District Court for the District of Delaware (the &#x201c;Solak Matter&#x201d;).
The Solak Matter, filed on behalf of the Company, names Serhat G&#xfc;mr&#xfc;kc&#xfc; and certain of the Company&#x2019;s current and
former directors as defendants, and also names the Company as a nominal defendant. The Solak Matter alleges violations of Section 14(a)
of the Securities Exchange Act of 1934 and SEC Rule 14a-9 promulgated thereunder, and also sets out claims for breach of fiduciary duty
and contribution and indemnification. Plaintiff does not quantify any alleged injury, but seeks damages, disgorgement, restitution, and
other costs and expenses. On April 6, 2023, the United States District Court for the District of Delaware stayed the Solak Matter pending
resolution of the defendants&#x2019; anticipated motion to dismiss in the Securities Class Action Litigation. On June 28, 2024, the United
States District Court for the Central District of California denied defendants&#x2019; motion to dismiss the Securities Class Action Litigation.
On July 29, 2025, the court stayed the Solak Matter for 90 days. The defendants have not yet responded to the complaint.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The Company intends to contest
these matters but expresses no opinion as to the likelihood of favorable outcomes. Management is unable to determine the likelihood of
a loss, including a possible range of losses, if any, arising from this matter as of the reporting date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;State Derivative Litigation&lt;/i&gt;.
On October 20, 2022, Susan Midler filed a shareholder derivative action in the Superior Court of California, Los Angeles County (the &#x201c;Midler
Matter&#x201d;). The Midler Matter, filed on behalf of the Company, names Serhat G&#xfc;mr&#xfc;kc&#xfc; and certain of the Company&#x2019;s
current and former directors as defendants. The Midler Matter also names the Company as a nominal defendant. The Midler Matter sets out
claims for breaches of fiduciary duty, contribution and indemnification, aiding and abetting, and gross mismanagement. Plaintiff does
not quantify any alleged injury, but seeks damages, disgorgement, restitution, and other costs and expenses. On January 20, 2023, the
Court stayed the Midler Matter pending resolution of the defendants&#x2019; anticipated motion to dismiss in the Securities Class Action
Litigation. On June 28, 2024, the United States District Court for the Central District of California denied defendants&#x2019; motion
to dismiss the Securities Class Action Litigation. On July 31, 2025, the court stayed the Midler Matter for 120 days. The defendants have
not yet responded to the complaint. The Company intends to contest this matter but expresses no opinion as to the likelihood of a favorable
outcome. Management is unable to determine the likelihood of a loss, including a possible range of losses, if any, arising from this matter
as of the reporting date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;On October
21, 2022, the Company filed a Complaint in the Superior Court of the State of California for the County of Los Angeles against Serhat
G&#xfc;mr&#xfc;kc&#xfc; (&#x201c;Gumrukcu&#x201d;), William Anderson Wittekind (&#x201c;Wittekind&#x201d;), G Tech Bio, SG &amp;amp; AW Holdings,
LLC, and SRI (collectively, the &#x201c;Defendants&#x201d;). The Complaint alleges that the Defendants engaged in a &#x201c;concerted, deliberate
scheme to alter, falsify, and misrepresent to the Company the results of multiple studies supporting its Hepatitis B and SARS-CoV-2/influenza
pipelines.&#x201d; Specifically, &#x201c;Defendants manipulated negative results to reflect positive outcomes from various studies, and
even fabricated studies out of whole cloth.&#x201d; As a result of the Defendants&#x2019; conduct, the Company claims that it &#x201c;paid
approximately $25 million to Defendants and third-parties that it would not otherwise have paid.&#x201d; On April 21, 2023, defendants
Wittekind, G Tech, SG &amp;amp; AW Holdings, LLC, and SRI filed a demurrer with respect to some, but not all, of the Company&#x2019;s claims,
as well as a motion to strike. On September 6, 2023, the court denied in part and granted in part the pending motions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;On December
4, 2023, the Defendants answered the Company&#x2019;s First Amended Complaint and G Tech and SRI filed a Cross-Complaint. In the Cross-Complaint,
G Tech and SRI seek declaratory and injunctive relief related to certain agreements between G Tech, SRI, and the Company, including, &lt;i&gt;inter
alia&lt;/i&gt;, a declaration that the Framework Agreement, effective as of November 15, 2019, the Statement of Work &amp;amp; License Agreement,
effective as of January 31, 2020, and the Statement of Work and License Agreement for Influenza and Coronavirus Indications, effective
as of April 18, 2021, have been terminated and the Company has no rights to any license under such agreements. Trial was scheduled to
begin on March 3, 2025. On November 14, 2024, the court vacated the March 3, 2025, trial date and set a trial setting conference for May
1, 2025. At the May 1, 2025, trial setting conference, the court reset the trial to begin on November 30, 2026. Discovery remains ongoing.
The Company denies the allegations in Defendants&#x2019; cross claims and intends to vigorously defend against them while pursuing its
claims against the Defendants.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;On June
7, 2023, Weird Science LLC (&#x201c;Weird Science&#x201d;), Wittekind, the William Anderson Wittekind 2020 Annuity Trust, the William Anderson
Wittekind 2021 Annuity Trust, the Dybul 2020 Angel Annuity Trust, and the Ty Mabry 2021 Annuity Trust (collectively, the &#x201c;Trusts&#x201d;)
(collectively, &#x201c;Plaintiffs&#x201d;) filed a Verified Complaint against the Company in the Court of Chancery of Delaware. In the Verified
Complaint, Plaintiffs alleged that the Company breached the February 16, 2018 Investor Rights Agreement between the Company, Weird Science,
and RS Group ApS (the &#x201c;Investor Rights Agreement&#x201d;). According to the Verified Complaint, the Investor Rights Agreement required
the Company to (i) notify all &#x201c;Holders&#x201d; of &#x201c;Registrable Securities&#x201d; at least 30 days prior to filing a registration
statement and (ii) afford such Holders an opportunity to have their Registrable Securities included in such registration statement. Plaintiffs
alleged that the Company breached these registration rights by failing to provide the required notice in connection with S-3 registration
statements filed by the Company on July 13, 2020 and February 11, 2022. The Company moved to dismiss the Verified Complaint on September
15, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;On December
4, 2023, in lieu of opposing the motion to dismiss, Plaintiffs filed a Verified First Amended Complaint (&#x201c;FAC&#x201d;). In the FAC,
Plaintiffs assert claims against the Company and others for purported breaches of the Investor Rights Agreement, fraud, tortious interference
with a contract, and several other torts. Plaintiffs seek compensatory, exemplary, and punitive damages, as well as certain declaratory
relief, specific performance, and pre- and post-judgment interest, costs, and attorneys&#x2019; fees. The Company filed a motion to dismiss
the FAC on December 18, 2023 and the court held a hearing on November 15, 2024. At the hearing, the court dismissed (1) all claims brought
on behalf of Wittekind and the Trusts, (2) the fraudulent concealment claim against the Company and others (without prejudice), and (3)
the breach of contract claim against the Company related to a registration statement that was not filed in 2023. At the hearing, the court
also found that punitive damages were not available to Plaintiffs. The court took the remaining issues briefed on the Company&#x2019;s
motion to dismiss under advisement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;On February
26, 2025, the Court ruled on the balance of the claims against the Company and (1) denied the Company&#x2019;s motion to dismiss Weird
Science&#x2019;s breach of contract claims related to registration statements filed in 2020 and 2022; (2) dismissed the fraudulent inducement
claim as time barred; and (3) dismissed the declaratory judgment claim. The Company denies Plaintiffs&#x2019; allegations and remaining
claims and intends to vigorously defend against these claims.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;On August
24, 2023, counsel on behalf of Weird Science, Wittekind, individually, and Wittekind, as trustee of the Trusts served a demand to inspect
the Company&#x2019;s books and records (the &#x201c;Demand&#x201d;) pursuant to Delaware General Corporation Law, &#xa7; 220 (&#x201c;Section
220&#x201d;). The Demand seeks the Company&#x2019;s books and records in connection with various issues identified in the Demand. The Company
takes its obligations under Section 220 seriously and, to the extent that the requests are proper under Section 220, intends to comply
with those obligations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On January 19, 2024, Weird Science
and Wittekind sent the Board of Directors a letter demanding it take corrective actions with respect to twenty-one issues identified therein.
On February 27, 2024, Weird Science and Wittekind sent the Board of Directors a supplemental letter that expanded their demand for corrective
actions to twenty-six issues. In response to these demand letters, the Board of Directors initially formed a Special Committee (&#x201c;Special
Committee&#x201d;) of independent directors on February 29, 2024. The Special Committee retained Stradling Yocca Carlson &amp;amp; Rauth LLP
as its counsel to investigate the issues identified in the demand letters.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On January 23, 2024, Weird Science
and Wittekind filed a shareholder derivative action in the United States District Court for the Central District of California against
certain officers, directors, and investors of the Company, as well as other defendants, in connection with, &lt;i&gt;inter alia&lt;/i&gt;, Weird Science
and Wittekind&#x2019;s demand for corrective action. Plaintiffs filed an amended complaint on June 21, 2024. The First Amended Verified
Stockholder Derivative Complaint (&#x201c;Derivative Complaint&#x201d;) alleges, among other claims, violations of Section 13(d) and 14(a)
and Rules 10b-5(a), 10b-5(c) and 14a-9 of the Exchange Act of 1934. The Derivative Complaint also includes claims of breach of fiduciary
duty, corporate waste, unjust enrichment, and contribution/indemnification. Weird Science and Wittekind seek unspecified compensatory,
exemplary, and punitive damages and certain injunctive relief. The Derivative Complaint names the Company as a nominal defendant. On July
19, 2024, certain of the director defendants, who had agreed to waive service of the summons and Derivative Complaint, filed a motion
to dismiss the Derivative Complaint on a variety of procedural and substantive grounds. A hearing on the motion dismiss was held on October
3, 2024 and the court subsequently took the motion under submission. On October 22, 2024, the plaintiffs filed a notice of certain subsequent
events that they allege relate to their pending motion to dismiss. On October 29, 2024, the court granted the director defendants&#x2019;
motion to dismiss and dismissed the Derivative Complaint without prejudice, but also without leave to amend.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On November 27, 2024, Weird Science
and Wittekind filed a notice of appeal of the court&#x2019;s decision granting the director defendants&#x2019; motion to dismiss. The appeal
remains pending.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On June 21, 2024, the Company
filed suit against Weird Science, Gumrukcu, Wittekind, and certain trusts in connection with the February 16, 2018 merger involving the
Company and two companies closely associated with Gumrukcu. In the complaint, the Company alleges that G&#xfc;mr&#xfc;kc&#xfc;and others
deliberately and fraudulently concealed a murder-for-hire scheme from the Company in order to induce the Company to enter into the merger
agreement, which resulted in the defendants receiving shares and compensation. The Company asserts claims for fraudulent concealment,
equitable fraud, unjust enrichment, and civil conspiracy and seeks, &lt;i&gt;inter alia&lt;/i&gt;, equitable relief, including, but not limited to,
return to the Company any shares received in connection with the merger, and damages. On October 1, 2024, the defendants moved to dismiss
the complaint. A hearing took place on June 25, 2025 and the Court took defendants&#x2019; motion under advisement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"&gt;Lunai commenced an action against
Predictive Oncology, Inc. (&#x201c;POAI&#x201d;) in the Delaware Court of Chancery claiming that POAI breached a &#x201c;definitive&#x201d;
January 2025 Letter Agreement pursuant to which Lunai was going to acquire POAI. As a result of its breach, POAI made that acquisition
impossible and dramatically devalued the share price of stock Lunai had already acquired as well as the value of the company it was contractually
entitled to acquire. Lunai sought specific performance or, in the alternative, money damages. The parties have exchanged paper discovery
and noticed depositions. The action has been held in abeyance while the parties attempt to negotiate a settlement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:PaymentsForFees
      contextRef="From2021-01-302021-01-31_custom_GTechMember_custom_LicenseAgreementMember"
      decimals="-3"
      id="Fact001773"
      unitRef="USD">1200000</us-gaap:PaymentsForFees>
    <RENB:RoyaltyPercentage
      contextRef="From2020-01-302020-01-31_custom_GTechMember_custom_LicenseAgreementMember"
      decimals="INF"
      id="Fact001775"
      unitRef="Ratio">0.02</RENB:RoyaltyPercentage>
    <us-gaap:PaymentsForFees
      contextRef="From2020-02-052020-02-06_custom_GTechMember_custom_LicenseAgreementMember"
      decimals="-5"
      id="Fact001777"
      unitRef="USD">1200000</us-gaap:PaymentsForFees>
    <RENB:UpfrontPayment
      contextRef="From2019-11-142019-11-15"
      decimals="0"
      id="Fact001779"
      unitRef="USD">10000000</RENB:UpfrontPayment>
    <RENB:PaymentForExpenditures
      contextRef="From2019-11-142019-11-15"
      decimals="0"
      id="Fact001781"
      unitRef="USD">760000</RENB:PaymentForExpenditures>
    <RENB:InitialPayment
      contextRef="From2022-08-242022-08-25"
      decimals="0"
      id="Fact001783"
      unitRef="USD">600000</RENB:InitialPayment>
    <RENB:InitialPayment
      contextRef="From2022-09-092022-09-10"
      decimals="0"
      id="Fact001785"
      unitRef="USD">600000</RENB:InitialPayment>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2025-06-30"
      decimals="INF"
      id="Fact001788"
      unitRef="Shares">17414</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2024-07-01to2025-06-30" id="Fact001792">&lt;p id="xdx_802_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zntZKDnOBTzg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 12 &#x2014; &lt;span id="xdx_823_zNGLGMjaoHqd"&gt;RELATED PARTY TRANSACTIONS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;As of June 30, 2025, the Company
has accrued $&lt;span id="xdx_90F_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20240701__20250630__us-gaap--RelatedPartyTransactionAxis__custom--MarkDybulMember_zO0CghFWmOp8" title="Accrued balance"&gt;384,949&lt;/span&gt; of compensation related expenses for the Company&#x2019;s former Chief Executive Officer, Mark Dybul, related to budget
constraints.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On August 23, 2024, Avram Miller,
a former member of the Company&#x2019;s board of directors (the &#x201c;Board of Directors&#x201d;), forfeited&#160;&lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_c20240802__20240823_zc9KYGpvYfN1" title="Common stock forfeited shares"&gt;833,333&lt;/span&gt;&#160;shares of
Common Stock from the original&#160;&lt;span id="xdx_90D_ecustom--SharesOfCommonStockGranted_iI_c20240823_zVhLqixksHz7" title="Shares of common stock  granted"&gt;1,000,000&lt;/span&gt;&#160;shares of Common Stock for advisory services originally granted to him on October 11,
2023. As consideration for such forfeiture, the Company granted to Mr. Miller, an option to purchase&#160;&lt;span id="xdx_900_eus-gaap--StockRepurchasedDuringPeriodShares_c20240822__20250823_zNp1pogyFMKc" title="Purchase shares"&gt;978,261&lt;/span&gt;&#160;shares of Common
Stock of the Company with a per-share exercise price of $&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250216__us-gaap--RelatedPartyTransactionAxis__custom--RSBioMember_zEAowP0qjJTj" title="Warrant exercise price per share"&gt;0.69&lt;/span&gt;. The Company determined that this transaction represented a modification
of the original award. The Company measured the fair value of the options issued as compared to the fair value of the original issuance
and determined that there was no incremental compensation to recognize as the fair value of the options was less than the fair value of
the Common Stock. Therefore, the Company will recognize the remaining fair value of the original award over the remaining vesting period,
which is one year. The Company recognized stock-based compensation expense of $&lt;span id="xdx_901_eus-gaap--ProceedsFromStockOptionsExercised_c20240701__20250630_zcZfzMMTIiaj" title="Stock-based compensation expense stock option vesting"&gt;1,159,470&lt;/span&gt;&#160;related to the vesting of the stocks options
during the year ended June 30, 2025. At June 30, 2025, the Company had $&lt;span id="xdx_907_ecustom--UnrecognizedCompensationExpense_c20240701__20250630_zQgDmpzUZP5b" title="Unrecognized compensation expense"&gt;185,373&lt;/span&gt;&#160;of unrecognized compensation cost related to the
options which vest at August 23, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2024-07-012025-06-30_custom_MarkDybulMember"
      decimals="0"
      id="Fact001794"
      unitRef="USD">384949</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
      contextRef="From2024-08-022024-08-23"
      decimals="INF"
      id="Fact001797"
      unitRef="Shares">833333</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited>
    <RENB:SharesOfCommonStockGranted
      contextRef="AsOf2024-08-23"
      decimals="INF"
      id="Fact001799"
      unitRef="Shares">1000000</RENB:SharesOfCommonStockGranted>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="From2024-08-222025-08-23"
      decimals="INF"
      id="Fact001801"
      unitRef="Shares">978261</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-02-16_custom_RSBioMember"
      decimals="INF"
      id="Fact001803"
      unitRef="USDPShares">0.69</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001805"
      unitRef="USD">1159470</us-gaap:ProceedsFromStockOptionsExercised>
    <RENB:UnrecognizedCompensationExpense
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001807"
      unitRef="USD">185373</RENB:UnrecognizedCompensationExpense>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="From2024-07-01to2025-06-30" id="Fact001809">&lt;p id="xdx_80C_eus-gaap--BusinessCombinationDisclosureTextBlock_zUSNEpfwWoca" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 13 &#x2014; &lt;span id="xdx_824_zKidpMCOiJpg"&gt;ACQUISITIONS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;BioSymetrics Inc. Acquisition:&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;On February 26, 2025, Lunai Bioworks Inc., a Delaware
corporation (&#x201c;&lt;span style="text-decoration: underline"&gt;Lunai&lt;/span&gt;&#x201d;), entered into an Agreement and Plan of Merger (the &#x201c;&lt;span style="text-decoration: underline"&gt;Merger Agreement&lt;/span&gt;&#x201d;) with
Renovaro Acquisition Sub, a Delaware corporation and wholly owned subsidiary of Lunai (&#x201c;&lt;span style="text-decoration: underline"&gt;Merger Sub&lt;/span&gt;&#x201d;), and Biosymetrics,
Inc., a Delaware corporation (&#x201c;&lt;span style="text-decoration: underline"&gt;Biosymetrics&lt;/span&gt;&#x201d;), pursuant to which Lunai agreed to acquire Biosymetrics pursuant to the
merger of Merger Sub with and into Biosymetrics, with Biosymetrics as the surviving corporation and a wholly owned subsidiary of Lunai
(the &#x201c;&lt;span style="text-decoration: underline"&gt;Transaction&lt;/span&gt;&#x201d;). On April 8, 2025, Lunai consummated the Transaction and issued &lt;span id="xdx_90A_ecustom--TransactionIssuedShares_iI_pn3n3_dm_c20250408_z14JRduEqDef" title="Transaction issued shares"&gt;15.0&lt;/span&gt; million shares of Lunai&#x2019;s
common stock, par value $&lt;span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20250408_z59MeWvqqdc7" title="Common stock per value"&gt;0.0001&lt;/span&gt; per share (the &#x201c;&lt;span style="text-decoration: underline"&gt;Shares&lt;/span&gt;&#x201d;), to the former stockholders of Biosymetrics in accordance
with the terms of the Merger Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The
offer and sale of the Shares have not been registered under the Securities Act of 1933, as amended (the &#x201c;&lt;span style="text-decoration: underline"&gt;Securities Act&lt;/span&gt;&#x201d;),
in reliance on the exemption from registration requirements thereunder provided by Section 4(a)(2) thereof. Lunai relied in part upon
representations contained in the Merger Agreement that all those receiving Shares in connection with the Transaction are &#x201c;accredited
investors&#x201d; as defined in Rule 501(a) under the Securities Act.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="background-color: white"&gt;The
transaction was accounted for in accordance with ASC 805-10 -&#160;&lt;i&gt;Business Combinations&lt;/i&gt;. &lt;/span&gt;The assets acquired and liabilities
assumed are initially recognized in the accompanying consolidated balance sheets at their estimated fair values as of the acquisition
date. The fair values as of the acquisition date are based on information that existed as of the acquisition date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;The acquisition-date
fair value of the consideration transferred totaled approximately $&lt;span id="xdx_900_eus-gaap--BusinessCombinationConsiderationTransferredOther1_pn5n6_c20240701__20250630__us-gaap--BusinessAcquisitionAxis__custom--BioSymetricsMember_zxPFPfGodem2" title="Fair value of consideration transferred amount"&gt;6&lt;/span&gt; million, which consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89A_ecustom--ScheduleOfAcquistionFairValueOfConsiderationTableTextBlock_hsrt--CounterpartyNameAxis__custom--BioSymetricsncAcquisitionMember_zAl9SmiIjYt3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITION (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B0_zAaE5SSH5Q6b" style="display: none"&gt;Schedule of acquisition
date fair value&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-align: left; text-indent: -10pt"&gt;Common stock&lt;/td&gt;&lt;td style="width: 10%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--BusinessCombinationContingentConsiderationCommonStock_iI_c20250226__us-gaap--BusinessAcquisitionAxis__custom--BioSymetricsncAcquisitionMember_zwtePe5aQoNe" style="border-bottom: Black 1pt solid; width: 18%; text-align: right" title="Common stock"&gt;6,058,500&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Total consideration transferred&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--BusinessCombinationConsiderationTransferred1_c20250212__20250226__us-gaap--BusinessAcquisitionAxis__custom--BioSymetricsncAcquisitionMember_zhrSYeUXaz88" style="border-bottom: Black 2.5pt double; text-align: right" title="Total consideration transferred"&gt;6,058,500&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zSkxWy4Nvem2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="background-color: white"&gt;The
fair value of the Company&#x2019;s common shares issued as consideration was based on the closing price of the Company&#x2019;s common stock
as of the Acquisition Date. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="background-color: white"&gt;The
following table details the fair values of the assets acquired and liabilities assumed at the acquisition date:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_hsrt--CounterpartyNameAxis__custom--BioSymetricsncAcquisitionMember_zPoXSZHQBGMg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITION (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8BA_z32iterXKz8f" style="display: none"&gt;Schedule of fair value of assets acquired and
liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49B_20250226__us-gaap--BusinessAcquisitionAxis__custom--BioSymetricsncAcquisitionMember_z2TTACyafD7f" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iNI_di_zoDfgVvesNhc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-indent: -10pt"&gt;Cash&lt;/td&gt;&lt;td style="width: 10%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;(3,822&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_iI_zGuAiTHzuQO4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Prepaid &amp;amp; Other Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,405&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets_iI_zEIivZWq8YOd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Fixed Assets&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;13,365&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_iI_zIu0KyNSDl4a" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Total Assets Acquired:&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;26,948&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_iI_zUlScKTen1dk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Accounts Payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;975&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_iI_zlFuO4SDEVje" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Accrued Expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,594&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities_iI_zEuGctgBrD98" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Other Current Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;73,879&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_iI_zbHlNEqiQkeb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Total Liabilities Assumed&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;82,448&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_zJ9gkdRrmkS8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Net Assets Acquired&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(55,500&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--Software_iI_zYuBoHYY5pJd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Software&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;143,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--TradeName_iI_zbjIakIOHa1a" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Trade Name&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_iI_z0JeEKq8Wzb7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Goodwill&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,963,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_iI_zr73hkD7clp9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Total Consideration&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,058,500&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zVppS1OX6XYf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
goodwill recognized is attributable primarily to expected synergies and the assembled workforce of BioSymetrics. None of the
goodwill is expected to be deductible for income tax purposes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;The fair
values of the acquired tangible and intangible assets were determined using variations of the income approach. The income approach valuation
methodology used for the intangible assets acquired makes use of Level 3 inputs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Consolidated unaudited pro forma information: &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The following consolidated pro
forma information assumes that the acquisition of BioSymetrics Inc. took place on July 1, 2024 for the statement of operations for the
twelve-month period ended June 30, 2025. These amounts have been estimated after applying the Company&#x2019;s accounting policies:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--ScheduleOfConsolidatedStatementsOfOperationsTableTextBlock_hsrt--CounterpartyNameAxis__custom--BioSymetricsncAcquisitionMember_znkTNcWBnRG" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITION (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B1_ziqFm9TRWEY2" style="display: none"&gt;Schedule of consolidated
statements of operations&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_493_20240701__20250630__us-gaap--BusinessAcquisitionAxis__custom--BioSymetricsncAcquisitionMember_zFVaF7KKfc59" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_ecustom--BusinessAcquisitionsRevenue_d0_zOZF3Ef0iEd9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-indent: -10pt"&gt;Revenues&lt;/td&gt;&lt;td style="width: 10%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 18%; text-align: right"&gt;663,660&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--BusinessAcquisitionsNetIncomeLoss_zf5Rj2q3Pt01" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Net loss&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(179,698,700&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_z89EKECiWZH6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The unaudited pro forma results
are presented for informational purposes only and are not necessarily indicative of what the actual results of operations would have been
if the acquisition had occurred at the beginning of the period presented, nor are they indicative of future results of operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;GEDi Cube Intl Ltd. Acquisition:&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;On September
28, 2023, the Company, entered into a Stock Purchase Agreement (the &#x201c;&lt;span style="text-decoration: underline"&gt;Purchase Agreement&lt;/span&gt;&#x201d;) with GEDi Cube Intl Ltd.,
a private company formed under the laws of England and Wales (&#x201c;&lt;span style="text-decoration: underline"&gt;GEDi Cube&lt;/span&gt;&#x201d;) to acquire 100% of the equity interests
of GEDi Cube from its equity holders (the &#x201c;&lt;span style="text-decoration: underline"&gt;Sellers&lt;/span&gt;&#x201d;). On September 28, 2023, the Board of Directors of the Company,
and the board of managers of GEDi Cube unanimously approved the Purchase Agreement and on January 25, 2024, the shareholders of the Company
approved the issuance of the shares of Common Stock pursuant to the Purchase Agreement. On February 13, 2024 (the &#x201c;Closing Date&#x201d;),
the Company consummated the acquisition of GEDi Cube and the other transactions contemplated by the Stock Purchase Agreement (collectively,
the &#x201c;Transaction&#x201d;). As a result of the Transaction, GEDi Cube became a wholly-owned subsidiary of the Company. The Company
believes the acquisition will provide it with access to the nascent field of artificial intelligence and machine learning driven diagnostics,
which was the primary purpose for the acquisition.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;Pursuant
to the Stock Purchase Agreement, as of the Closing Date, the Company acquired all the issued and outstanding equity interests of GEDi
Cube owned by the Sellers as of the Closing Date (each, a &#x201c;GEDi Cube Share&#x201d; and, collectively, the &#x201c;GEDi Cube Shares&#x201d;)
in exchange for which each Seller was entitled to receive (i) as of the Closing Date, such Seller&#x2019;s pro rata percentage of an aggregate
of 70,834,183 shares of common stock, par value $0.0001 per share, of the Company (&#x201c;Common Stock&#x201d;), which represents the 67,224,089
shares of Common Stock issued and outstanding as of the Closing Date (minus (a) 1 million shares of Common Stock previously issued to
a consultant assisting with the Transaction and (b) 1 million shares of Common Stock previously issued to Avram Miller, a director of
the Company, pursuant to his Advisory Agreement, dated October 11, 2023, by and between Mr. Miller and the Company) (the &#x201c;Closing
Consideration&#x201d;) plus 5,610,100 shares of Common Stock representing the Seller&#x2019;s Earnout Shares (defined below) resulting from
the automatic conversion of the Company&#x2019;s Series A Convertible Preferred and, (ii) following the Closing Date, such Seller&#x2019;s
pro rata percentage of the shares of Common Stock (the &#x201c;Earnout Shares&#x201d; and, together with the Closing Consideration, the
&#x201c;Exchange Consideration&#x201d;) to be issued to the Sellers upon the exercise or conversion of any of the Company&#x2019;s derivative
securities (subject to certain exceptions) that are outstanding at the Closing Date (the &#x201c;Closing Derivative Securities&#x201d;).
Each Seller&#x2019;s pro rata percentage of the Exchange Consideration is equal to the ratio of the aggregate number of GEDi Cube Shares
owned by such Seller divided by the aggregate number of GEDi Cube Shares issued and outstanding, in each case, as of the Closing Date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="background-color: white"&gt;The
transaction was accounted for in accordance with the provisions of ASC 805-10 -&#160;&lt;i&gt;Business Combinations&lt;/i&gt;. &lt;/span&gt;As a result
of the issuance of the Closing Consideration on the Closing Date and based on the number of shares of Common Stock outstanding as of the
Closing Date, the Sellers held approximately 49% of the issued and outstanding shares of Common Stock immediately following the closing
of the Transaction and the conversion of the Series A Convertible Preferred Stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;The assets
acquired and liabilities assumed were initially recognized provisionally in the accompanying consolidated balance sheets at their estimated
fair values as of the acquisition date. The fair values as of the acquisition date are based on information that existed as of the acquisition
date. The Company completed its accounting for this acquisition during the period ended June 30, 2024. As a result of the completion of
the Company&#x2019;s analysis, the amount of in-process research and development was determined to have a value of nil. Accordingly, the
amount of goodwill recognized was increased to include the previously recognized amount of in-process research and development. There
was no impact to the Company&#x2019;s consolidated statement of operations as a result of this change to the allocation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;The acquisition-date
fair value of the consideration transferred totaled approximately $&lt;span id="xdx_90C_eus-gaap--BusinessCombinationConsiderationTransferredOther1_pn5n6_c20240701__20250603__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zx20bFH8Rutf" title="Fair value of consideration transferred amount"&gt;156.6&lt;/span&gt; million, which consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfAcquistionFairValueOfConsiderationTableTextBlock_hsrt--CounterpartyNameAxis__custom--GEDiCubeIntlLtdAcquisitionMember_zbLc9sRUqKSk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITION (Details 5)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B6_zEeSLO08dL32" style="display: none"&gt;Schedule of acquisition
date fair value&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-align: left; text-indent: -10pt"&gt;Common stock&lt;/td&gt;&lt;td style="width: 10%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--BusinessCombinationContingentConsiderationCommonStock_iI_c20250226__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zaxIB00nYcQb" style="width: 18%; text-align: right" title="Common stock"&gt;136,001,631&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Contingent consideration&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--BusinessCombinationContingentConsiderationAsset_iI_c20250226__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zriLj2VJ8p0i" style="border-bottom: Black 1pt solid; text-align: right" title="Contingent consideration"&gt;20,557,500&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Total consideration transferred&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--BusinessCombinationConsiderationTransferred1_c20250212__20250226__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zP2MJDibj9K8" style="border-bottom: Black 2.5pt double; text-align: right" title="Total consideration transferred"&gt;156,559,131&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zKBo6QVtLnP6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="background-color: white"&gt;The
fair value of the Company&#x2019;s common shares issued as consideration was based on the closing price of the Company&#x2019;s common stock
as of the Acquisition Date. The fair value of the contingent consideration was based on the Sellers&#x2019; right to receive additional
shares of common, pro rata, upon the exercise or conversion of warrants, options and convertible notes payables outstanding as of the
Closing Date. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="background-color: white"&gt;The
following table details the fair values of the assets acquired and liabilities assumed at the acquisition date:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_898_ecustom--ScheduleOfRecognizedIdentifiedAssetsAndLiabilitiesAssumedTableTextBlock_zVmaEFICs4S2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITION (Details 4)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B0_znxHeYyjvRB2" style="display: none"&gt;Schedule of fair value of assets acquired and
liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49F_20250226__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zQph1CtNtkS6" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_z6tSoIkmltI3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-indent: -10pt"&gt;Cash&lt;/td&gt;&lt;td style="width: 10%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;65,851&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_iI_zGDtqFoBR44b" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Prepaid &amp;amp; Other Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;151,544&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets_iI_zkTa9G4qylS3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Fixed Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,243&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseRightOfUseAssets_iI_zLa2H5VBx0Pk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Operating lease ROU&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;624,366&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_iI_ziRcp96fGfof" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Total Assets Acquired:&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;858,004&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_iI_zfWvrHdXf6M1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Accounts Payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;583,577&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_iI_zIYxlh3dLwCd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Accrued Expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;722,508&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities_iI_zUFJjLa0R0T8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Operating Lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;624,367&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable_iI_zQmWfInPkEQj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Notes Payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,832,460&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_iI_zKqbaXpnCKcc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Total Liabilities Assumed&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,762,913&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_zCEVoVBIByZi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Net Assets Acquired&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(2,904,909&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_iI_zM2LzSTjVeUb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Goodwill&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;159,464,040&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_iI_zCMPUeGT5kcd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Total Consideration&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;156,559,131&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;The
goodwill recognized is attributable primarily to expected synergies and the assembled workforce of GEDi. None of the goodwill is expected
to be deductible for income tax purposes.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;The fair
values of the acquired tangible and intangible assets were determined using variations of the income approach. The income approach valuation
methodology used for the intangible assets acquired makes use of Level 3 inputs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;The Company
recognized approximately $&lt;span id="xdx_903_eus-gaap--BusinessCombinationAcquisitionRelatedCosts_pn5n6_c20230701__20240630__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zM59CyDtHqCl" title="Acquisition related costs"&gt;1.2&lt;/span&gt; million of acquisition related costs that were expensed during the period ended June 30, 2024. These costs
are included in &#x201c;selling, general and administrative expenses&#x201d; in the accompanying condensed consolidated statements of operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Consolidated unaudited pro forma information: &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The following consolidated pro forma information assumes that the acquisition
of GEDi took place on July 1, 2023 for the statement of operations for the twelve-month period ended June 30, 2024. These amounts have
been estimated after applying the Company&#x2019;s accounting policies:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;





&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_ecustom--custom--ScheduleOfConsolidatedStatementsOfOperationsTableTextBlock_hsrt--CounterpartyNameAxis__custom--GEDiCubeIntlLtdAcquisitionMember_zOpINOOxtCmk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITION (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_492_20240701__20250630__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zSRDllRMIJN7" style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_ecustom--BusinessAcquisitionsRevenue_d0_zgHWOo15vUoe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Revenues&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--BusinessAcquisitionsNetIncomeLoss_zalIi4AWeGz2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-align: left; text-indent: -10pt"&gt;Net loss&lt;/td&gt;&lt;td style="width: 10%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 18%; text-align: right"&gt;(83,571,822&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_z1q3TSJBrgoc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The unaudited pro forma results
are presented for informational purposes only and are not necessarily indicative of what the actual results of operations would have been
if the acquisition had occurred at the beginning of the period presented, nor are they indicative of future results of operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:BusinessCombinationDisclosureTextBlock>
    <RENB:TransactionIssuedShares
      contextRef="AsOf2025-04-08"
      decimals="-3"
      id="Fact001811"
      unitRef="Shares">15000000.0</RENB:TransactionIssuedShares>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-04-08"
      decimals="INF"
      id="Fact001813"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:BusinessCombinationConsiderationTransferredOther1
      contextRef="From2024-07-012025-06-30_custom_BioSymetricsMember"
      decimals="-5"
      id="Fact001815"
      unitRef="USD">6000000</us-gaap:BusinessCombinationConsiderationTransferredOther1>
    <RENB:ScheduleOfAcquistionFairValueOfConsiderationTableTextBlock
      contextRef="From2024-07-012025-06-30_custom_BioSymetricsncAcquisitionMember"
      id="Fact001817">&lt;table cellpadding="0" cellspacing="0" id="xdx_89A_ecustom--ScheduleOfAcquistionFairValueOfConsiderationTableTextBlock_hsrt--CounterpartyNameAxis__custom--BioSymetricsncAcquisitionMember_zAl9SmiIjYt3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITION (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B0_zAaE5SSH5Q6b" style="display: none"&gt;Schedule of acquisition
date fair value&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-align: left; text-indent: -10pt"&gt;Common stock&lt;/td&gt;&lt;td style="width: 10%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--BusinessCombinationContingentConsiderationCommonStock_iI_c20250226__us-gaap--BusinessAcquisitionAxis__custom--BioSymetricsncAcquisitionMember_zwtePe5aQoNe" style="border-bottom: Black 1pt solid; width: 18%; text-align: right" title="Common stock"&gt;6,058,500&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Total consideration transferred&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--BusinessCombinationConsiderationTransferred1_c20250212__20250226__us-gaap--BusinessAcquisitionAxis__custom--BioSymetricsncAcquisitionMember_zhrSYeUXaz88" style="border-bottom: Black 2.5pt double; text-align: right" title="Total consideration transferred"&gt;6,058,500&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</RENB:ScheduleOfAcquistionFairValueOfConsiderationTableTextBlock>
    <RENB:BusinessCombinationContingentConsiderationCommonStock
      contextRef="AsOf2025-02-26_custom_BioSymetricsncAcquisitionMember"
      decimals="0"
      id="Fact001819"
      unitRef="USD">6058500</RENB:BusinessCombinationContingentConsiderationCommonStock>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="From2025-02-122025-02-26_custom_BioSymetricsncAcquisitionMember"
      decimals="0"
      id="Fact001821"
      unitRef="USD">6058500</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="From2024-07-012025-06-30_custom_BioSymetricsncAcquisitionMember"
      id="Fact001823">&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_hsrt--CounterpartyNameAxis__custom--BioSymetricsncAcquisitionMember_zPoXSZHQBGMg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITION (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8BA_z32iterXKz8f" style="display: none"&gt;Schedule of fair value of assets acquired and
liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49B_20250226__us-gaap--BusinessAcquisitionAxis__custom--BioSymetricsncAcquisitionMember_z2TTACyafD7f" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iNI_di_zoDfgVvesNhc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-indent: -10pt"&gt;Cash&lt;/td&gt;&lt;td style="width: 10%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;(3,822&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_iI_zGuAiTHzuQO4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Prepaid &amp;amp; Other Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,405&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets_iI_zEIivZWq8YOd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Fixed Assets&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;13,365&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_iI_zIu0KyNSDl4a" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Total Assets Acquired:&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;26,948&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_iI_zUlScKTen1dk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Accounts Payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;975&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_iI_zlFuO4SDEVje" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Accrued Expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,594&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities_iI_zEuGctgBrD98" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Other Current Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;73,879&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_iI_zbHlNEqiQkeb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Total Liabilities Assumed&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;82,448&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_zJ9gkdRrmkS8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Net Assets Acquired&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(55,500&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--Software_iI_zYuBoHYY5pJd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Software&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;143,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--TradeName_iI_zbjIakIOHa1a" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Trade Name&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_iI_z0JeEKq8Wzb7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Goodwill&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,963,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_iI_zr73hkD7clp9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Total Consideration&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,058,500&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="AsOf2025-02-26_custom_BioSymetricsncAcquisitionMember"
      decimals="0"
      id="Fact001825"
      unitRef="USD">3822</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="AsOf2025-02-26_custom_BioSymetricsncAcquisitionMember"
      decimals="0"
      id="Fact001827"
      unitRef="USD">17405</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <RENB:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets
      contextRef="AsOf2025-02-26_custom_BioSymetricsncAcquisitionMember"
      decimals="0"
      id="Fact001829"
      unitRef="USD">13365</RENB:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="AsOf2025-02-26_custom_BioSymetricsncAcquisitionMember"
      decimals="0"
      id="Fact001831"
      unitRef="USD">26948</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="AsOf2025-02-26_custom_BioSymetricsncAcquisitionMember"
      decimals="0"
      id="Fact001833"
      unitRef="USD">975</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <RENB:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities
      contextRef="AsOf2025-02-26_custom_BioSymetricsncAcquisitionMember"
      decimals="0"
      id="Fact001835"
      unitRef="USD">7594</RENB:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities>
    <RENB:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities
      contextRef="AsOf2025-02-26_custom_BioSymetricsncAcquisitionMember"
      decimals="0"
      id="Fact001837"
      unitRef="USD">73879</RENB:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="AsOf2025-02-26_custom_BioSymetricsncAcquisitionMember"
      decimals="0"
      id="Fact001839"
      unitRef="USD">82448</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="AsOf2025-02-26_custom_BioSymetricsncAcquisitionMember"
      decimals="0"
      id="Fact001841"
      unitRef="USD">-55500</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <RENB:Software
      contextRef="AsOf2025-02-26_custom_BioSymetricsncAcquisitionMember"
      decimals="0"
      id="Fact001843"
      unitRef="USD">143000</RENB:Software>
    <RENB:TradeName
      contextRef="AsOf2025-02-26_custom_BioSymetricsncAcquisitionMember"
      decimals="0"
      id="Fact001845"
      unitRef="USD">8000</RENB:TradeName>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="AsOf2025-02-26_custom_BioSymetricsncAcquisitionMember"
      decimals="0"
      id="Fact001847"
      unitRef="USD">5963000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="AsOf2025-02-26_custom_BioSymetricsncAcquisitionMember"
      decimals="0"
      id="Fact001849"
      unitRef="USD">6058500</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <RENB:BusinessAcquisitionsRevenue
      contextRef="From2024-07-012025-06-30_custom_BioSymetricsncAcquisitionMember1126504281"
      decimals="0"
      id="Fact001854"
      unitRef="USD">663660</RENB:BusinessAcquisitionsRevenue>
    <RENB:BusinessAcquisitionsNetIncomeLoss
      contextRef="From2024-07-012025-06-30_custom_BioSymetricsncAcquisitionMember1126504281"
      decimals="0"
      id="Fact001856"
      unitRef="USD">-179698700</RENB:BusinessAcquisitionsNetIncomeLoss>
    <us-gaap:BusinessCombinationConsiderationTransferredOther1
      contextRef="From2024-07-012025-06-03_custom_GEDiCubeMember"
      decimals="-5"
      id="Fact001859"
      unitRef="USD">156600000</us-gaap:BusinessCombinationConsiderationTransferredOther1>
    <RENB:ScheduleOfAcquistionFairValueOfConsiderationTableTextBlock
      contextRef="From2024-07-012025-06-30_custom_GEDiCubeIntlLtdAcquisitionMember"
      id="Fact001861">&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfAcquistionFairValueOfConsiderationTableTextBlock_hsrt--CounterpartyNameAxis__custom--GEDiCubeIntlLtdAcquisitionMember_zbLc9sRUqKSk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITION (Details 5)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B6_zEeSLO08dL32" style="display: none"&gt;Schedule of acquisition
date fair value&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-align: left; text-indent: -10pt"&gt;Common stock&lt;/td&gt;&lt;td style="width: 10%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--BusinessCombinationContingentConsiderationCommonStock_iI_c20250226__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zaxIB00nYcQb" style="width: 18%; text-align: right" title="Common stock"&gt;136,001,631&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Contingent consideration&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--BusinessCombinationContingentConsiderationAsset_iI_c20250226__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zriLj2VJ8p0i" style="border-bottom: Black 1pt solid; text-align: right" title="Contingent consideration"&gt;20,557,500&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Total consideration transferred&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--BusinessCombinationConsiderationTransferred1_c20250212__20250226__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zP2MJDibj9K8" style="border-bottom: Black 2.5pt double; text-align: right" title="Total consideration transferred"&gt;156,559,131&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</RENB:ScheduleOfAcquistionFairValueOfConsiderationTableTextBlock>
    <RENB:BusinessCombinationContingentConsiderationCommonStock
      contextRef="AsOf2025-02-26_custom_GEDiCubeMember"
      decimals="0"
      id="Fact001863"
      unitRef="USD">136001631</RENB:BusinessCombinationContingentConsiderationCommonStock>
    <us-gaap:BusinessCombinationContingentConsiderationAsset
      contextRef="AsOf2025-02-26_custom_GEDiCubeMember"
      decimals="0"
      id="Fact001865"
      unitRef="USD">20557500</us-gaap:BusinessCombinationContingentConsiderationAsset>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="From2025-02-122025-02-26_custom_GEDiCubeMember"
      decimals="0"
      id="Fact001867"
      unitRef="USD">156559131</us-gaap:BusinessCombinationConsiderationTransferred1>
    <RENB:ScheduleOfRecognizedIdentifiedAssetsAndLiabilitiesAssumedTableTextBlock contextRef="From2024-07-01to2025-06-30" id="Fact001869">&lt;table cellpadding="0" cellspacing="0" id="xdx_898_ecustom--ScheduleOfRecognizedIdentifiedAssetsAndLiabilitiesAssumedTableTextBlock_zVmaEFICs4S2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITION (Details 4)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B0_znxHeYyjvRB2" style="display: none"&gt;Schedule of fair value of assets acquired and
liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49F_20250226__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zQph1CtNtkS6" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_z6tSoIkmltI3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-indent: -10pt"&gt;Cash&lt;/td&gt;&lt;td style="width: 10%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;65,851&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_iI_zGDtqFoBR44b" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Prepaid &amp;amp; Other Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;151,544&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets_iI_zkTa9G4qylS3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Fixed Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,243&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseRightOfUseAssets_iI_zLa2H5VBx0Pk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Operating lease ROU&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;624,366&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_iI_ziRcp96fGfof" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Total Assets Acquired:&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;858,004&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_iI_zfWvrHdXf6M1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Accounts Payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;583,577&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_iI_zIYxlh3dLwCd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Accrued Expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;722,508&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities_iI_zUFJjLa0R0T8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Operating Lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;624,367&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable_iI_zQmWfInPkEQj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Notes Payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,832,460&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_iI_zKqbaXpnCKcc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Total Liabilities Assumed&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,762,913&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_zCEVoVBIByZi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Net Assets Acquired&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(2,904,909&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_iI_zM2LzSTjVeUb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Goodwill&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;159,464,040&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_iI_zCMPUeGT5kcd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Total Consideration&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;156,559,131&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;The
goodwill recognized is attributable primarily to expected synergies and the assembled workforce of GEDi. None of the goodwill is expected
to be deductible for income tax purposes.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;The fair
values of the acquired tangible and intangible assets were determined using variations of the income approach. The income approach valuation
methodology used for the intangible assets acquired makes use of Level 3 inputs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;The Company
recognized approximately $&lt;span id="xdx_903_eus-gaap--BusinessCombinationAcquisitionRelatedCosts_pn5n6_c20230701__20240630__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zM59CyDtHqCl" title="Acquisition related costs"&gt;1.2&lt;/span&gt; million of acquisition related costs that were expensed during the period ended June 30, 2024. These costs
are included in &#x201c;selling, general and administrative expenses&#x201d; in the accompanying condensed consolidated statements of operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Consolidated unaudited pro forma information: &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;The following consolidated pro forma information assumes that the acquisition
of GEDi took place on July 1, 2023 for the statement of operations for the twelve-month period ended June 30, 2024. These amounts have
been estimated after applying the Company&#x2019;s accounting policies:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;





&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_ecustom--custom--ScheduleOfConsolidatedStatementsOfOperationsTableTextBlock_hsrt--CounterpartyNameAxis__custom--GEDiCubeIntlLtdAcquisitionMember_zOpINOOxtCmk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITION (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_492_20240701__20250630__us-gaap--BusinessAcquisitionAxis__custom--GEDiCubeMember_zSRDllRMIJN7" style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_ecustom--BusinessAcquisitionsRevenue_d0_zgHWOo15vUoe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Revenues&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--BusinessAcquisitionsNetIncomeLoss_zalIi4AWeGz2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 70%; text-align: left; text-indent: -10pt"&gt;Net loss&lt;/td&gt;&lt;td style="width: 10%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 18%; text-align: right"&gt;(83,571,822&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</RENB:ScheduleOfRecognizedIdentifiedAssetsAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="AsOf2025-02-26_custom_GEDiCubeMember"
      decimals="0"
      id="Fact001871"
      unitRef="USD">65851</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="AsOf2025-02-26_custom_GEDiCubeMember"
      decimals="0"
      id="Fact001873"
      unitRef="USD">151544</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <RENB:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets
      contextRef="AsOf2025-02-26_custom_GEDiCubeMember"
      decimals="0"
      id="Fact001875"
      unitRef="USD">16243</RENB:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentFixedAssets>
    <RENB:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseRightOfUseAssets
      contextRef="AsOf2025-02-26_custom_GEDiCubeMember"
      decimals="0"
      id="Fact001877"
      unitRef="USD">624366</RENB:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseRightOfUseAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="AsOf2025-02-26_custom_GEDiCubeMember"
      decimals="0"
      id="Fact001879"
      unitRef="USD">858004</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="AsOf2025-02-26_custom_GEDiCubeMember"
      decimals="0"
      id="Fact001881"
      unitRef="USD">583577</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <RENB:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities
      contextRef="AsOf2025-02-26_custom_GEDiCubeMember"
      decimals="0"
      id="Fact001883"
      unitRef="USD">722508</RENB:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities>
    <RENB:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities
      contextRef="AsOf2025-02-26_custom_GEDiCubeMember"
      decimals="0"
      id="Fact001885"
      unitRef="USD">624367</RENB:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiabilities>
    <RENB:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable
      contextRef="AsOf2025-02-26_custom_GEDiCubeMember"
      decimals="0"
      id="Fact001887"
      unitRef="USD">1832460</RENB:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="AsOf2025-02-26_custom_GEDiCubeMember"
      decimals="0"
      id="Fact001889"
      unitRef="USD">3762913</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="AsOf2025-02-26_custom_GEDiCubeMember"
      decimals="0"
      id="Fact001891"
      unitRef="USD">-2904909</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="AsOf2025-02-26_custom_GEDiCubeMember"
      decimals="0"
      id="Fact001893"
      unitRef="USD">159464040</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="AsOf2025-02-26_custom_GEDiCubeMember"
      decimals="0"
      id="Fact001895"
      unitRef="USD">156559131</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="From2023-07-012024-06-30_custom_GEDiCubeMember"
      decimals="-5"
      id="Fact001897"
      unitRef="USD">1200000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <RENB:BusinessAcquisitionsRevenue
      contextRef="From2024-07-012025-06-30_custom_GEDiCubeMember"
      decimals="0"
      id="Fact001902"
      unitRef="USD">0</RENB:BusinessAcquisitionsRevenue>
    <RENB:BusinessAcquisitionsNetIncomeLoss
      contextRef="From2024-07-012025-06-30_custom_GEDiCubeMember"
      decimals="0"
      id="Fact001904"
      unitRef="USD">-83571822</RENB:BusinessAcquisitionsNetIncomeLoss>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="From2024-07-01to2025-06-30" id="Fact001906">&lt;p id="xdx_80B_eus-gaap--SegmentReportingDisclosureTextBlock_zz2CxbAImxtg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 14 &#x2014; &lt;span id="xdx_824_zxhHHSpDe9c5"&gt;SEGMENT REPORTING&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;For the year ended June 30, 2025,
the Company had three reportable segments. These segments have different strategic and economic goals and are managed separately because
they require different technology and marketing strategies.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="border-bottom: black 1pt solid; white-space: nowrap; width: 18%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Reportable
Segment&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; width: 2%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; white-space: nowrap; width: 80%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Description
&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="white-space: nowrap"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;RENB&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Developing new immunotherapies
to combat cancer &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="white-space: nowrap"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;BioSymetrics&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Integrating multimodal data
sources, including genomics, imaging, electronic health records, and other real-world evidence, to advance biomarker discovery, therapeutic
development, and precision medicine.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="white-space: nowrap"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;RENC&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Developing a predicative artificial intelligence based
diagnostic methodology for the use of earlier cancer detection &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;The Company&#x2019;s
chief executive officer is the chief operating decision maker and reviews the internal management reports for each segment at least quarterly.
During the year ended June 30, 2025, there were no significant inter-company revenues or expenses. The chief operating decision maker
assesses performance for each segment and decides how to allocate resources based on segment operating losses that also is reported on
the consolidated statement of operations. The measure of segment assets is reported on the balance sheet as total consolidated assets.
The accounting policies of each segment are the same as those described in the summary of significant accounting policies.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zdUDi4exyaWb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SEGMENT REPORTING (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B2_z6gLeveQNbOf" style="display: none"&gt;Schedule of segment operating loss and
    asset information&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Operating loss&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Assets&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; font-weight: bold; text-align: left; text-indent: -10pt"&gt;United States (RENB)&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--SegmentOperatingLoss_c20240701__20250630__srt--StatementGeographicalAxis__country--US_zTqkzEFiBbkk" style="width: 12%; text-align: right" title="Operating income loss"&gt;15,530,056&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--SegmentAsset_iI_c20250630__srt--StatementGeographicalAxis__country--US_z1Dxzi7xZxc7" style="width: 12%; text-align: right" title="Assets"&gt;1,907,647&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;United States (BioSymetrics)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--SegmentOperatingLoss_c20240701__20250630__srt--StatementGeographicalAxis__custom--BioSymetricsMember_z3IMPpLY3Z4i" style="text-align: right" title="Operating income loss"&gt;237,880&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--SegmentAsset_iI_c20250630__srt--StatementGeographicalAxis__custom--BioSymetricsMember_zQx2JOs8qNi3" style="text-align: right" title="Assets"&gt;6,109,643&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;Netherlands (RENC)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--SegmentOperatingLoss_c20240701__20250630__srt--StatementGeographicalAxis__country--NL_zLymUYaPzfqj" style="border-bottom: Black 1pt solid; text-align: right" title="Operating income loss"&gt;173,198,066&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--SegmentAsset_iI_c20250630__srt--StatementGeographicalAxis__country--NL_zkTPpSNyISdj" style="border-bottom: Black 1pt solid; text-align: right" title="Assets"&gt;213,550&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--SegmentOperatingLoss_c20240701__20250630_zEwvC8oPeMQb" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Operating income loss"&gt;188,966,002&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--SegmentAsset_iI_c20250630_zLf8FAxU9A23" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Assets"&gt;8,230,840&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zY8Yw0fcgMZ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;The chief
operating decision maker uses loss from operations to evaluate the performance of each segment&#x2019;s assets in deciding how to allocate
available capital between segments. The chief operating decision maker also uses loss from operations in their competitive analysis by
benchmarking the Company&#x2019;s competitors. The competitive analysis along with the monitoring of budgeted versus actual results are
used in assessing the performance of the segment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;Information
regarding each reportable segment for the year ended June 30, 2025 is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_zBaCQ2PFb6W6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SEGMENT REPORTING (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B8_zGCMTWRXTdPf" style="display: none"&gt;Schedule of information regarding segment reporting&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_490_20240701__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--RENBMember_zKUWfCht6Nvd" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_497_20240701__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--BioSymetricsMember_zixUeXPh5Ud9" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_496_20240701__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--RENCMember_zbZDpF18LPS7" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49F_20240701__20250630_zGqqSm4HTlD1" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;RENB&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;BioSymetrics&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;RENC&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OtherGeneralAndAdministrativeExpense_zm8VctnRFQ5k" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt"&gt;General and administrative&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;14,904,855&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;211,401&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;2,763,794&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;17,880,050&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--ResearchAndDevelopmentExpense_zNfZ1RwN4MBl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;502,896&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;26,029&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,503&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;537,428&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--GoodwillAndIntangibleAssetImpairment_d0_zJWFVuCpvcrh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Goodwill impairment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;170,419,429&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;170,419,429&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DepreciationDepletionAndAmortization_zygwY7gL8pY5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Depreciation and amortization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;122,305&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;450&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,340&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;129,095&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--SegmentOperatingLoss_zQ1J1j7Y6Pq9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Segment operating loss&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;15,530,056&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;237,880&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;173,198,066&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;188,966,002&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Geographic information:&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;RENB,
BioSymetrics and RENC are managed on a worldwide basis but operate in offices located in the United States and the Netherlands, respectively.
The geographic information analyses the Company&#x2019;s operations and assets based on the country in which each segment operates. In
presenting this geographic information, segment operating results have been based on the geographic location in which the services were
provided to the segment and segment assets were based on the geographic location of the assets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;/p&gt;





</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="From2024-07-01to2025-06-30" id="Fact001908">&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zdUDi4exyaWb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SEGMENT REPORTING (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B2_z6gLeveQNbOf" style="display: none"&gt;Schedule of segment operating loss and
    asset information&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Operating loss&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Assets&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; font-weight: bold; text-align: left; text-indent: -10pt"&gt;United States (RENB)&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--SegmentOperatingLoss_c20240701__20250630__srt--StatementGeographicalAxis__country--US_zTqkzEFiBbkk" style="width: 12%; text-align: right" title="Operating income loss"&gt;15,530,056&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--SegmentAsset_iI_c20250630__srt--StatementGeographicalAxis__country--US_z1Dxzi7xZxc7" style="width: 12%; text-align: right" title="Assets"&gt;1,907,647&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;United States (BioSymetrics)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--SegmentOperatingLoss_c20240701__20250630__srt--StatementGeographicalAxis__custom--BioSymetricsMember_z3IMPpLY3Z4i" style="text-align: right" title="Operating income loss"&gt;237,880&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--SegmentAsset_iI_c20250630__srt--StatementGeographicalAxis__custom--BioSymetricsMember_zQx2JOs8qNi3" style="text-align: right" title="Assets"&gt;6,109,643&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; font-weight: bold; text-align: left; text-indent: -10pt"&gt;Netherlands (RENC)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--SegmentOperatingLoss_c20240701__20250630__srt--StatementGeographicalAxis__country--NL_zLymUYaPzfqj" style="border-bottom: Black 1pt solid; text-align: right" title="Operating income loss"&gt;173,198,066&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--SegmentAsset_iI_c20250630__srt--StatementGeographicalAxis__country--NL_zkTPpSNyISdj" style="border-bottom: Black 1pt solid; text-align: right" title="Assets"&gt;213,550&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--SegmentOperatingLoss_c20240701__20250630_zEwvC8oPeMQb" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Operating income loss"&gt;188,966,002&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--SegmentAsset_iI_c20250630_zLf8FAxU9A23" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Assets"&gt;8,230,840&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <RENB:SegmentOperatingLoss
      contextRef="From2024-07-012025-06-30_country_US"
      decimals="0"
      id="Fact001910"
      unitRef="USD">15530056</RENB:SegmentOperatingLoss>
    <RENB:SegmentAsset
      contextRef="AsOf2025-06-30_country_US"
      decimals="0"
      id="Fact001912"
      unitRef="USD">1907647</RENB:SegmentAsset>
    <RENB:SegmentOperatingLoss
      contextRef="From2024-07-012025-06-30_custom_BioSymetricsMember1126506984"
      decimals="0"
      id="Fact001914"
      unitRef="USD">237880</RENB:SegmentOperatingLoss>
    <RENB:SegmentAsset
      contextRef="AsOf2025-06-30_custom_BioSymetricsMember"
      decimals="0"
      id="Fact001916"
      unitRef="USD">6109643</RENB:SegmentAsset>
    <RENB:SegmentOperatingLoss
      contextRef="From2024-07-012025-06-30_country_NL"
      decimals="0"
      id="Fact001918"
      unitRef="USD">173198066</RENB:SegmentOperatingLoss>
    <RENB:SegmentAsset
      contextRef="AsOf2025-06-30_country_NL"
      decimals="0"
      id="Fact001920"
      unitRef="USD">213550</RENB:SegmentAsset>
    <RENB:SegmentOperatingLoss
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001922"
      unitRef="USD">188966002</RENB:SegmentOperatingLoss>
    <RENB:SegmentAsset
      contextRef="AsOf2025-06-30"
      decimals="0"
      id="Fact001924"
      unitRef="USD">8230840</RENB:SegmentAsset>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock contextRef="From2024-07-01to2025-06-30" id="Fact001926">&lt;table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_zBaCQ2PFb6W6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SEGMENT REPORTING (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B8_zGCMTWRXTdPf" style="display: none"&gt;Schedule of information regarding segment reporting&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_490_20240701__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--RENBMember_zKUWfCht6Nvd" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_497_20240701__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--BioSymetricsMember_zixUeXPh5Ud9" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_496_20240701__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--RENCMember_zbZDpF18LPS7" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49F_20240701__20250630_zGqqSm4HTlD1" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;RENB&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;BioSymetrics&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;RENC&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OtherGeneralAndAdministrativeExpense_zm8VctnRFQ5k" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt"&gt;General and administrative&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;14,904,855&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;211,401&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;2,763,794&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;17,880,050&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--ResearchAndDevelopmentExpense_zNfZ1RwN4MBl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;502,896&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;26,029&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,503&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;537,428&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--GoodwillAndIntangibleAssetImpairment_d0_zJWFVuCpvcrh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Goodwill impairment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;170,419,429&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;170,419,429&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DepreciationDepletionAndAmortization_zygwY7gL8pY5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Depreciation and amortization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;122,305&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;450&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,340&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;129,095&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--SegmentOperatingLoss_zQ1J1j7Y6Pq9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Segment operating loss&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;15,530,056&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;237,880&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;173,198,066&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;188,966,002&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Geographic information:&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;RENB,
BioSymetrics and RENC are managed on a worldwide basis but operate in offices located in the United States and the Netherlands, respectively.
The geographic information analyses the Company&#x2019;s operations and assets based on the country in which each segment operates. In
presenting this geographic information, segment operating results have been based on the geographic location in which the services were
provided to the segment and segment assets were based on the geographic location of the assets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;/p&gt;





</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="From2024-07-012025-06-30_custom_RENBMember"
      decimals="0"
      id="Fact001928"
      unitRef="USD">14904855</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="From2024-07-012025-06-30_custom_BioSymetricsMember1126507484"
      decimals="0"
      id="Fact001929"
      unitRef="USD">211401</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="From2024-07-012025-06-30_custom_RENCMember"
      decimals="0"
      id="Fact001930"
      unitRef="USD">2763794</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001931"
      unitRef="USD">17880050</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-07-012025-06-30_custom_RENBMember"
      decimals="0"
      id="Fact001933"
      unitRef="USD">502896</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-07-012025-06-30_custom_BioSymetricsMember1126507484"
      decimals="0"
      id="Fact001934"
      unitRef="USD">26029</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-07-012025-06-30_custom_RENCMember"
      decimals="0"
      id="Fact001935"
      unitRef="USD">8503</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001936"
      unitRef="USD">537428</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="From2024-07-012025-06-30_custom_RENBMember"
      decimals="0"
      id="Fact001938"
      unitRef="USD">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="From2024-07-012025-06-30_custom_BioSymetricsMember1126507484"
      decimals="0"
      id="Fact001939"
      unitRef="USD">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="From2024-07-012025-06-30_custom_RENCMember"
      decimals="0"
      id="Fact001940"
      unitRef="USD">170419429</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001941"
      unitRef="USD">170419429</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2024-07-012025-06-30_custom_RENBMember"
      decimals="0"
      id="Fact001943"
      unitRef="USD">122305</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2024-07-012025-06-30_custom_BioSymetricsMember1126507484"
      decimals="0"
      id="Fact001944"
      unitRef="USD">450</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2024-07-012025-06-30_custom_RENCMember"
      decimals="0"
      id="Fact001945"
      unitRef="USD">6340</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001946"
      unitRef="USD">129095</us-gaap:DepreciationDepletionAndAmortization>
    <RENB:SegmentOperatingLoss
      contextRef="From2024-07-012025-06-30_custom_RENBMember"
      decimals="0"
      id="Fact001948"
      unitRef="USD">15530056</RENB:SegmentOperatingLoss>
    <RENB:SegmentOperatingLoss
      contextRef="From2024-07-012025-06-30_custom_BioSymetricsMember1126507484"
      decimals="0"
      id="Fact001949"
      unitRef="USD">237880</RENB:SegmentOperatingLoss>
    <RENB:SegmentOperatingLoss
      contextRef="From2024-07-012025-06-30_custom_RENCMember"
      decimals="0"
      id="Fact001950"
      unitRef="USD">173198066</RENB:SegmentOperatingLoss>
    <RENB:SegmentOperatingLoss
      contextRef="From2024-07-01to2025-06-30"
      decimals="0"
      id="Fact001951"
      unitRef="USD">188966002</RENB:SegmentOperatingLoss>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2024-07-01to2025-06-30" id="Fact001954">&lt;p id="xdx_80C_eus-gaap--SubsequentEventsTextBlock_z9ePr0vhNaW3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 15 &#x2014; &lt;span id="xdx_826_z6AHyLeMjOd8"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="background-color: white"&gt;On
September 18, 2025, the Company filed a Certificate of Amendment to the Certificate of Incorporation of the Company (the &#x201c;&lt;/span&gt;&lt;b&gt;Certificate
of Amendment&lt;/b&gt;&lt;span style="background-color: white"&gt;&#x201d;) with the Secretary of State of the State of Delaware to effect a 1-for-10
reverse stock split of the shares of the Company&#x2019;s common stock, par value $0.0001 per share (the &#x201c;&lt;/span&gt;&lt;b&gt;Common Stock&lt;/b&gt;&lt;span style="background-color: white"&gt;&#x201d;),
either issued and outstanding or held by the Company as treasury stock, effective as of 12:01 a.m. (New York time) on September 29, 2025
(the &#x201c;&lt;/span&gt;&lt;b&gt;Reverse Stock Split&lt;/b&gt;&lt;span style="background-color: white"&gt;&#x201d;). The Common Stock will begin trading on a
reverse stock split-adjusted basis on The Nasdaq Capital Market on September 30, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;span style="background-color: white"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;On September 18, 2025, the Company entered into the
First Amendment to Convertible Promissory Note whereby the January 2024 Note (see Note 8 to the Financial Statements) that matured on
December 29, 2024, was amended extending the Maturity Date in the second paragraph of the Note from December 29, 2024 to December 29,
2025. Accordingly, the Note unless otherwise amended, replaced, or otherwise altered by this First Amendment, any and all terms contained
in the Note continue in full force and effect.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On September 2, 2025, the Court
of Amsterdam (the &#x201c;Court&#x201d;) declared bankrupt Gedi Cube B.V. (&#x201c;Gedi&#x201d;), an indirect subsidiary of Lunai Bioworks,
Inc. (&#x201c;Lunai&#x201d;), and appointed Mr. M.M. Dellebeke as the receiver in the bankruptcy. Gedi filed a voluntary petition seeking
a declaration of bankruptcy due to its inability to make payments as they became due. As a result of this, the Company determined that
a material impairment of Gedi had occurred (see Note 6 to the financial statements).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;On August 18, 2025, the Company
issued Promissory Notes in the aggregate principal amount of $&lt;span id="xdx_904_ecustom--SaleOfStockConsiderationReceivedCashTransaction_iI_c20250818__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zPiswzPzObP8" title="Sale of stock issued cash consideration"&gt;1,000,000&lt;/span&gt;. The Notes bear an interest rate of&#160;&lt;span id="xdx_90B_ecustom--InterestRate_iI_dp_c20250818__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z3dKOLvfiFhh" title="Interest rate"&gt;18&lt;/span&gt;%&#160;per annum and
mature on&#160;the 6-month anniversary of the Issue Date.,&#160;(the &#x201c;Maturity Date&#x201d;). The Company is required to pay principal
and interest on the Maturity Date.&lt;b&gt;	&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;From July 3, 2025, to August 19, 2025, the Company
issued Promissory Notes in the aggregate principal amount of $&lt;span id="xdx_90C_ecustom--SaleOfStockConsiderationReceivedCashTransaction_iI_c20250703__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zJE7kzm4cEei" title="Sale of stock issued cash consideration"&gt;695,000&lt;/span&gt;. The Notes bear an interest rate of&#160;&lt;span id="xdx_902_ecustom--InterestRate_iI_dp_c20250819__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zwtv7Un1ychg" title="Interest rate"&gt;10&lt;/span&gt;%&#160;per annum and
mature on&#160;June 30, 2026,&#160;(the &#x201c;Maturity Date&#x201d;). The Company is required to pay principal and interest on the Maturity
Date&lt;b&gt;.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;On July 7, 2025, Lunai Bioworks Inc. (&#x201c;Lunai&#x201d;)
entered into an Exchange Agreement (the &#x201c;Exchange Agreement&#x201d;) with certain accredited investors (the &#x201c;Investors&#x201d;),
all of whom are existing shareholders of the Company. Pursuant to the Exchange Agreement, the Investors agreed to exchange an aggregate
of $&lt;span id="xdx_90A_ecustom--SaleOfStockConsiderationReceivedCashTransaction_iI_pn3n3_dm_c20250707__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__custom--ExchangeAgreementMember_zC1Ugg8ChPf" title="Sale of stock issued cash consideration"&gt;9.7&lt;/span&gt; million in outstanding secured promissory notes (the &#x201c;Secured Notes&#x201d;) for $&lt;span id="xdx_904_ecustom--SaleOfStockConsiderationReceivedCashTransaction_iI_pn3n3_dm_c20250707__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__custom--ConvertiblePromissoryNoteMember_zNyTHkDAEULl" title="Sale of stock issued cash consideration"&gt;16.1&lt;/span&gt; million in new convertible promissory
notes (the &#x201c;Convertible Notes&#x201d;), representing a 65% premium to the principal and interest amount of the Secured Notes. The
Convertible Notes mature on July 31, 2025, and do not bear any interest. The exchange was completed to restructure the Company&#x2019;s
debt obligations and provide additional flexibility to support strategic initiatives.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;Immediately following the issuance of the Convertible
Noes on July 7, 2025, the Investors elected to convert the entire $&lt;span id="xdx_908_ecustom--SaleOfStockConsiderationReceivedCashTransaction_iI_pn3n3_dm_c20250707__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__custom--ConvertibleNotesMember_zqPN5J1hUSX" title="Sale of stock issued cash consideration"&gt;16.1&lt;/span&gt;million principal amount into an aggregate of &lt;span id="xdx_90C_ecustom--SaleOfStockConsiderationReceivedCashTransaction_iI_pn3n3_dm_c20250707__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_ztITHVJPi7y6" title="Sale of stock issued cash consideration"&gt;53.6&lt;/span&gt; million shares
of common stock (the &#x201c;Conversion Shares&#x201d;), based on the stated $&lt;span id="xdx_90D_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20250707__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zd6Yl6a8MPt3" title="Conversion price"&gt;0.30&lt;/span&gt; per share conversion price. The $0.30 per share conversion
price of the Convertible Notes represented a premium to the closing price of the Company&#x2019;s common stock on July 7, 2025, the date
of execution and conversion. As a result, the issuance of the &lt;span id="xdx_90F_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pn3n3_dm_c20250707__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zTit72dvmJ26" title="Issuance of common stock shares"&gt;53.6&lt;/span&gt; million shares of common stock upon conversion of the Convertible Notes
did not constitute a &#x201c;below market&#x201d; issuance under applicable Nasdaq listing rules and did not trigger stockholder approval
requirements under Nasdaq Listing Rule 5635(d). The shares were issued without any additional consideration from the Investors.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;As a result of the foregoing transactions,
the Company (i) eliminated $&lt;span id="xdx_90A_ecustom--SaleOfStockConsiderationReceivedCashTransaction_iI_pn3n3_dm_c20250707__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__custom--ExchangeAgreementMember_ziyZl1aytO44" title="Sale of stock issued cash consideration"&gt;9.7&lt;/span&gt; million of secured indebtedness, (ii) issued $&lt;span id="xdx_908_ecustom--SaleOfStockConsiderationReceivedCashTransaction_iI_pn3n3_dm_c20250707__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--AwardTypeAxis__custom--ConvertibleNotesMember_zwqZTDaEUKx5" title="Sale of stock issued cash consideration"&gt;16.1&lt;/span&gt; million in Convertible Notes to the same holders, and
(iii) issued &lt;span id="xdx_902_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pn3n3_dm_c20250707__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z3WeddEHVXK5" title="Issuance of common stock shares"&gt;53.6&lt;/span&gt; million shares of common stock upon full conversion of such Convertible Notes without any cash proceeds to the Company.&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <RENB:SaleOfStockConsiderationReceivedCashTransaction
      contextRef="AsOf2025-08-18_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact001956"
      unitRef="USD">1000000</RENB:SaleOfStockConsiderationReceivedCashTransaction>
    <RENB:InterestRate
      contextRef="AsOf2025-08-18_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001958"
      unitRef="Ratio">0.18</RENB:InterestRate>
    <RENB:SaleOfStockConsiderationReceivedCashTransaction
      contextRef="AsOf2025-07-03_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact001960"
      unitRef="USD">695000</RENB:SaleOfStockConsiderationReceivedCashTransaction>
    <RENB:InterestRate
      contextRef="AsOf2025-08-19_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001962"
      unitRef="Ratio">0.10</RENB:InterestRate>
    <RENB:SaleOfStockConsiderationReceivedCashTransaction
      contextRef="AsOf2025-07-07_us-gaap_SubsequentEventMember_custom_ExchangeAgreementMember"
      decimals="-3"
      id="Fact001964"
      unitRef="USD">9700000</RENB:SaleOfStockConsiderationReceivedCashTransaction>
    <RENB:SaleOfStockConsiderationReceivedCashTransaction
      contextRef="AsOf2025-07-07_us-gaap_SubsequentEventMember_custom_ConvertiblePromissoryNoteMember"
      decimals="-3"
      id="Fact001966"
      unitRef="USD">16100000</RENB:SaleOfStockConsiderationReceivedCashTransaction>
    <RENB:SaleOfStockConsiderationReceivedCashTransaction
      contextRef="AsOf2025-07-07_us-gaap_SubsequentEventMember_custom_ConvertibleNotesMember"
      decimals="-3"
      id="Fact001968"
      unitRef="USD">16100000</RENB:SaleOfStockConsiderationReceivedCashTransaction>
    <RENB:SaleOfStockConsiderationReceivedCashTransaction
      contextRef="AsOf2025-07-07_us-gaap_SubsequentEventMember"
      decimals="-3"
      id="Fact001970"
      unitRef="USD">53600000</RENB:SaleOfStockConsiderationReceivedCashTransaction>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2025-07-07_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001972"
      unitRef="USDPShares">0.30</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2025-07-07_us-gaap_SubsequentEventMember"
      decimals="-3"
      id="Fact001974"
      unitRef="Shares">53600000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <RENB:SaleOfStockConsiderationReceivedCashTransaction
      contextRef="AsOf2025-07-07_us-gaap_SubsequentEventMember_custom_ExchangeAgreementMember"
      decimals="-3"
      id="Fact001976"
      unitRef="USD">9700000</RENB:SaleOfStockConsiderationReceivedCashTransaction>
    <RENB:SaleOfStockConsiderationReceivedCashTransaction
      contextRef="AsOf2025-07-07_us-gaap_SubsequentEventMember_custom_ConvertibleNotesMember"
      decimals="-3"
      id="Fact001978"
      unitRef="USD">16100000</RENB:SaleOfStockConsiderationReceivedCashTransaction>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2025-07-07_us-gaap_SubsequentEventMember"
      decimals="-3"
      id="Fact001980"
      unitRef="Shares">53600000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="From2024-07-01to2025-06-30" id="Fact001981">During the Company&#x2019;s fourth quarter, no director or officer&#160;&lt;span id="xdx_90D_eecd--Rule10b51ArrAdoptedFlag_dbT_c20240701__20250630_zNMZNHlaqbMe"&gt;&lt;span id="xdx_907_eecd--NonRule10b51ArrAdoptedFlag_dbT_c20240701__20250630_zXC75o3wEEg3"&gt;adopted&#160;&lt;/span&gt;&lt;/span&gt;or&#160;&lt;span id="xdx_907_eecd--Rule10b51ArrTrmntdFlag_dbT_c20240701__20250630_zu759zLP3aFh"&gt;&lt;span id="xdx_90D_eecd--NonRule10b51ArrTrmntdFlag_dbT_c20240701__20250630_zYPLz5wyhTkd"&gt;terminated&#160;&lt;/span&gt;&lt;/span&gt;a
Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement.</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="From2024-07-01to2025-06-30" id="Fact001982">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="From2024-07-01to2025-06-30" id="Fact001983">true</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="From2024-07-01to2025-06-30" id="Fact001984">true</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="From2024-07-01to2025-06-30" id="Fact001985">true</ecd:NonRule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
